Tricuspid	B-Disease	NOUN	B
valve	I-Disease	NOUN	I
regurgitation	I-Disease	NOUN	I
and	O	CCONJ	O
lithium	B-Chemical	NOUN	B
carbonate	I-Chemical	NOUN	I
toxicity	B-Disease	NOUN	B
in	O	ADP	O
a	O	DET	O
newborn	O	ADJ	B
infant	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
newborn	O	ADJ	B
with	O	ADP	O
massive	O	ADJ	O
tricuspid	B-Disease	NOUN	B
regurgitation	I-Disease	NOUN	I
,	O	PUNCT	O
atrial	B-Disease	ADJ	B
flutter	I-Disease	NOUN	I
,	O	PUNCT	O
congestive	B-Disease	ADJ	B
heart	I-Disease	NOUN	I
failure	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
high	O	ADJ	O
serum	O	NOUN	B
lithium	B-Chemical	NOUN	O
level	O	NOUN	O
is	O	AUX	O
described	O	VERB	O
.	O	PUNCT	O


This	O	DET	O
is	O	AUX	O
the	O	DET	O
first	O	ADJ	O
patient	O	NOUN	B
to	O	PART	O
initially	O	ADV	O
manifest	O	VERB	O
tricuspid	B-Disease	NOUN	B
regurgitation	I-Disease	NOUN	I
and	O	CCONJ	O
atrial	B-Disease	ADJ	B
flutter	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
11th	O	ADJ	O
described	O	VERB	O
patient	O	NOUN	B
with	O	ADP	O
cardiac	B-Disease	ADJ	B
disease	I-Disease	NOUN	I
among	O	ADP	O
infants	O	NOUN	B
exposed	O	VERB	B
to	O	PART	I
lithium	B-Chemical	NOUN	B
compounds	O	NOUN	I
in	O	ADP	O
the	O	DET	O
first	O	ADJ	O
trimester	O	NOUN	B
of	O	ADP	O
pregnancy	O	NOUN	B
.	O	PUNCT	O


Sixty	O	NUM	B
-	O	PUNCT	O
three	O	NUM	O
percent	O	NOUN	O
of	O	ADP	O
these	O	DET	O
infants	O	NOUN	B
had	O	AUX	O
tricuspid	O	NOUN	B
valve	O	NOUN	I
involvement	O	NOUN	B
.	O	PUNCT	O


Lithium	B-Chemical	NOUN	B
carbonate	I-Chemical	NOUN	I
may	O	AUX	O
be	O	AUX	O
a	O	DET	O
factor	O	NOUN	B
in	O	ADP	O
the	O	DET	O
increasing	O	VERB	B
incidence	O	NOUN	B
of	O	ADP	O
congenital	B-Disease	ADJ	B
heart	I-Disease	NOUN	I
disease	I-Disease	NOUN	I
when	O	SCONJ	O
taken	O	VERB	O
during	O	ADP	O
early	O	ADJ	B
pregnancy	O	NOUN	I
.	O	PUNCT	O


It	O	PRON	O
also	O	ADV	O
causes	O	VERB	O
neurologic	B-Disease	ADJ	B
depression	I-Disease	NOUN	I
,	O	PUNCT	O
cyanosis	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
cardiac	B-Disease	ADJ	B
arrhythmia	I-Disease	NOUN	I


Phenobarbital	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
dyskinesia	B-Disease	NOUN	B
in	O	ADP	O
a	O	DET	O
neurologically-impaired	B-Disease	ADJ	B
child	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
2	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
child	O	NOUN	B
with	O	ADP	O
known	O	ADJ	O
neurologic	B-Disease	ADJ	B
impairment	I-Disease	NOUN	I
developed	O	VERB	O
a	O	DET	O
dyskinesia	B-Disease	NOUN	B
soon	O	ADV	O
after	O	ADP	O
starting	O	VERB	O
phenobarbital	B-Chemical	ADJ	B
therapy	O	NOUN	I
for	O	ADP	O
seizures	B-Disease	NOUN	B
.	O	PUNCT	O


Known	O	PROPN	O
causes	O	NOUN	O
of	O	ADP	O
movement	B-Disease	NOUN	B
disorders	I-Disease	NOUN	I
were	O	AUX	O
eliminated	O	VERB	O
after	O	ADP	O
evaluation	O	NOUN	B
.	O	PUNCT	O


On	O	ADP	O
repeat	O	NOUN	O
challenge	O	NOUN	O
with	O	ADP	O
phenobarbital	B-Chemical	NOUN	B
,	O	PUNCT	O
the	O	DET	O
dyskinesia	B-Disease	NOUN	B
recurred	O	VERB	B
.	O	PUNCT	O


Phenobarbital	B-Chemical	NOUN	B
should	O	AUX	O
be	O	AUX	O
added	O	VERB	O
to	O	ADP	O
the	O	DET	O
list	O	NOUN	O
of	O	ADP	O
anticonvulsant	O	ADJ	B
drugs	O	NOUN	I
that	O	PRON	O
can	O	AUX	O
cause	O	VERB	O
movement	B-Disease	NOUN	B
disorders	I-Disease	NOUN	O


Acute	O	ADJ	B
changes	O	NOUN	B
of	O	ADP	O
blood	O	NOUN	B
ammonia	B-Chemical	NOUN	I
may	O	AUX	O
predict	O	VERB	O
short	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
adverse	O	ADJ	B
effects	O	NOUN	I
of	O	ADP	O
valproic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
.	O	PUNCT	O


Valproic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
(	O	PUNCT	O
VPA	B-Chemical	NOUN	B
)	O	PUNCT	O
was	O	AUX	O
given	O	VERB	O
to	O	PART	O
24	O	NUM	O
epileptic	B-Disease	ADJ	B
patients	O	NOUN	I
who	O	PRON	O
were	O	AUX	O
already	O	ADV	O
being	O	AUX	O
treated	O	VERB	B
with	O	ADP	I
other	O	ADJ	O
antiepileptic	O	ADJ	B
drugs	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
standardized	O	ADJ	B
loading	O	NOUN	O
dose	O	NOUN	O
of	O	ADP	O
VPA	B-Chemical	NOUN	B
was	O	AUX	O
administered	O	VERB	B
,	O	PUNCT	O
and	O	CCONJ	O
venous	O	ADJ	B
blood	O	NOUN	I
was	O	AUX	O
sampled	O	VERB	B
at	O	ADP	O
0	O	NUM	O
,	O	PUNCT	O
1	O	NUM	O
,	O	PUNCT	O
2	O	NUM	O
,	O	PUNCT	O
3	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
4	O	NUM	O
hours	O	NOUN	B
.	O	PUNCT	O


Ammonia	B-Chemical	NOUN	B
(	O	PUNCT	O
NH3	B-Chemical	NOUN	B
)	O	PUNCT	O
was	O	AUX	O
higher	O	ADJ	O
in	O	ADP	O
patients	O	NOUN	B
who	O	PRON	O
,	O	PUNCT	O
during	O	ADP	O
continuous	O	ADJ	B
therapy	O	NOUN	I
,	O	PUNCT	O
complained	O	VERB	B
of	O	ADP	O
drowsiness	B-Disease	NOUN	B
(	O	PUNCT	O
7	O	NUM	O
patients	O	NOUN	B
)	O	PUNCT	O
than	O	ADP	O
in	O	ADP	O
those	O	DET	O
who	O	PRON	O
were	O	AUX	O
symptom	O	NOUN	B
-	O	PUNCT	O
free	O	ADJ	B
(	O	PUNCT	O
17	O	NUM	O
patients	O	NOUN	B
),	O	PUNCT	O
although	O	SCONJ	O
VPA	B-Chemical	NOUN	B
plasma	O	NOUN	B
levels	O	NOUN	O
were	O	AUX	O
similar	O	ADJ	O
in	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
.	O	PUNCT	O


By	O	ADP	O
measuring	O	VERB	B
VPA	B-Chemical	PROPN	B
-	O	PUNCT	O
induced	O	VERB	B
changes	O	NOUN	B
of	O	ADP	O
blood	O	NOUN	B
NH3	B-Chemical	NOUN	B
content	O	NOUN	B
,	O	PUNCT	O
it	O	PRON	O
may	O	AUX	O
be	O	AUX	O
possible	O	ADJ	O
to	O	PART	O
identify	O	VERB	O
patients	O	NOUN	B
at	O	ADP	O
higher	O	ADJ	B
risk	O	NOUN	B
of	O	ADP	O
obtundation	O	NOUN	B
when	O	SCONJ	O
VPA	B-Chemical	NOUN	B


Effects	O	NOUN	B
of	O	ADP	I
calcitonin	O	NOUN	B
on	O	ADP	O
rat	O	NOUN	B
extrapyramidal	O	ADJ	B
motor	O	NOUN	I
system	O	NOUN	I
:	O	PUNCT	O
behavioral	O	ADJ	B
and	O	CCONJ	O
biochemical	O	ADJ	B
data	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
i	O	PRON	O
.	O	PUNCT	O


v	O	NOUN	O
.	O	PUNCT	O


c	O	X	O
.	O	PUNCT	O


injection	O	NOUN	B
of	O	ADP	O
human	O	ADJ	B
and	O	CCONJ	O
salmon	O	NOUN	B
calcitonin	O	NOUN	I
on	O	ADP	O
biochemical	O	ADJ	B
and	O	CCONJ	O
behavioral	O	ADJ	B
parameters	O	NOUN	B
related	O	VERB	O
to	O	PART	O
the	O	DET	O
extrapyramidal	O	ADJ	B
motor	O	NOUN	I
system	O	NOUN	I
,	O	PUNCT	O
were	O	AUX	O
investigated	O	VERB	B
in	O	ADP	O
male	O	NOUN	B
rats	O	NOUN	B
.	O	PUNCT	O


Calcitonin	O	NOUN	B
injection	O	NOUN	B
resulted	O	VERB	O
in	O	ADP	O
a	O	DET	O
potentiation	O	NOUN	B
of	O	ADP	O
haloperidol	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
catalepsy	B-Disease	NOUN	B
and	O	CCONJ	O
a	O	DET	O
partial	O	ADJ	B
prevention	O	NOUN	B
of	O	ADP	O
apomorphine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
hyperactivity	B-Disease	NOUN	B
.	O	PUNCT	O


Moreover	O	ADV	O
calcitonin	O	NOUN	B
induced	O	VERB	B
a	O	DET	O
significant	O	ADJ	O
decrease	O	NOUN	B
in	O	ADP	O
nigral	O	ADJ	B
GAD	O	NOUN	B
activity	O	NOUN	B
but	O	CCONJ	O
no	O	DET	O
change	O	NOUN	O
in	O	ADP	O
striatal	O	ADJ	B
DA	B-Chemical	NOUN	B
and	O	CCONJ	O
DOPAC	B-Chemical	NOUN	B
concentration	O	NOUN	B
or	O	CCONJ	O
GAD	O	NOUN	B
activity	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
results	O	NOUN	B
are	O	AUX	O
discussed	O	VERB	O
in	O	ADP	O
view	O	NOUN	O
of	O	ADP	O
a	O	DET	O
primary	O	ADJ	B
action	O	NOUN	I
of	O	ADP	O
calcitonin	O	NOUN	B
on	O	ADP	O
the	O	DET	O
striatonigral	O	ADJ	B
GABAergic	O	ADJ	B
pathway	O	NOUN	I
mediating	O	VERB	O
the	O	DET	O
DA	B-Chemical	NOUN	B


Development	O	NOUN	B
of	O	ADP	O
isoproterenol	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
cardiac	B-Disease	ADJ	B
hypertrophy	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
development	O	NOUN	B
of	O	ADP	O
cardiac	B-Disease	ADJ	B
hypertrophy	I-Disease	NOUN	I
was	O	AUX	O
studied	O	VERB	O
in	O	ADP	O
adult	O	ADJ	B
female	O	NOUN	B
Wistar	O	PROPN	B
rats	O	NOUN	I
following	O	VERB	O
daily	O	ADJ	B
subcutaneous	O	ADJ	B
injections	O	NOUN	I
of	O	ADP	O
isoproterenol	B-Chemical	NOUN	B
(	O	PUNCT	O
ISO	B-Chemical	NOUN	B
)(	O	NOUN	O
0	O	NUM	O
.	O	PUNCT	O


3	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
body	O	NOUN	B
weight	O	NOUN	I
).	O	PUNCT	B
A	O	DET	I
time	O	NOUN	I
course	O	NOUN	I
was	O	AUX	O
established	O	VERB	O
for	O	ADP	O
the	O	DET	O
change	O	NOUN	B
in	O	ADP	O
tissue	O	NOUN	B
mass	O	NOUN	I
,	O	PUNCT	O
RNA	O	NOUN	B
and	O	CCONJ	O
DNA	O	NOUN	B
content	O	NOUN	I
,	O	PUNCT	O
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
hydroxyproline	B-Chemical	NOUN	B
content	O	NOUN	B
.	O	PUNCT	O


Heart	O	NOUN	B
weight	O	NOUN	I
increased	O	VERB	B
44	O	NUM	O
%	O	NOUN	O
after	O	ADP	O
8	O	NUM	O
days	O	NOUN	B
of	O	ADP	O
treatment	O	NOUN	B
with	O	ADP	O
a	O	DET	O
half	O	ADJ	O
time	O	NOUN	O
of	O	ADP	O
3	O	NUM	O
.	O	PUNCT	O


4	O	NUM	O
days	O	NOUN	B
.	O	PUNCT	O


Ventricular	O	ADJ	B
RNA	O	NOUN	I
content	O	NOUN	B
was	O	AUX	O
elevated	O	VERB	B
26	O	NUM	O
%	O	NOUN	O
after	O	ADP	O
24	O	NUM	O
h	O	NOUN	O
of	O	ADP	O
a	O	DET	O
single	O	ADJ	O
injection	O	NOUN	B
and	O	CCONJ	O
reached	O	VERB	O
a	O	DET	O
maximal	O	ADJ	B
level	O	NOUN	B
following	O	VERB	O
8	O	NUM	O
days	O	NOUN	B
of	O	ADP	O
therapy	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
half	O	ADJ	O
time	O	NOUN	O
for	O	ADP	O
RNA	O	NOUN	B
accumulation	O	NOUN	B
was	O	AUX	O
2	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
days	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
total	O	ADJ	O
content	O	NOUN	B
of	O	ADP	O
hydroxyproline	B-Chemical	NOUN	B
remained	O	VERB	O
stable	O	ADJ	B
during	O	ADP	O
the	O	DET	O
first	O	ADJ	O
2	O	NUM	O
days	O	NOUN	B
of	O	ADP	O
treatment	O	NOUN	B
but	O	CCONJ	O
increased	O	VERB	B
46	O	NUM	O
%	O	NOUN	O
after	O	ADP	O
4	O	NUM	O
days	O	NOUN	B
of	O	ADP	O
therapy	O	NOUN	B
.	O	PUNCT	O


Ventricular	O	ADJ	B
DNA	O	NOUN	I
content	O	NOUN	O
was	O	AUX	O
unchanged	O	ADJ	B
during	O	ADP	O
the	O	DET	O
early	O	ADJ	B
stage	O	NOUN	I
(	O	PUNCT	O
1	O	NUM	O
-	O	SYM	O
4	O	NUM	O
days	O	NOUN	B
)	O	PUNCT	O
of	O	ADP	O
hypertrophic	B-Disease	ADJ	B
growth	O	NOUN	O
but	O	CCONJ	O
increased	O	VERB	B
to	O	ADP	O
a	O	DET	O
new	O	ADJ	O
steady	O	ADJ	B
-	O	PUNCT	O
state	O	NOUN	B
level	O	NOUN	B
19	O	NUM	O
%	O	NOUN	O
above	O	ADP	O
the	O	DET	O
controls	O	NOUN	B
after	O	ADP	O
8	O	NUM	O
days	O	NOUN	B
of	O	ADP	O
treatment	O	NOUN	B
.	O	PUNCT	O


Intraventricular	O	ADJ	B
pressures	O	NOUN	I
and	O	CCONJ	O
coronary	O	ADJ	B
flow	O	NOUN	I
measures	O	NOUN	B
were	O	AUX	O
similar	O	ADJ	O
for	O	ADP	O
control	O	NOUN	B
and	O	CCONJ	O
experimental	O	ADJ	B
animals	O	NOUN	I
following	O	VERB	O
4	O	NUM	O
days	O	NOUN	B
of	O	ADP	O
developed	O	VERB	O
hypertrophy	B-Disease	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
dP	O	NOUN	B
/	O	SYM	O
dt	O	NOUN	B
in	O	ADP	O
the	O	DET	O
ISO	B-Chemical	PROPN	B
-	O	PUNCT	O
treated	O	VERB	B
hearts	O	NOUN	B
was	O	AUX	O
slightly	O	ADV	O
but	O	CCONJ	O
significantly	O	ADV	O
(	O	PUNCT	O
P	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


05	O	NUM	O
)	O	PUNCT	O
elevated	O	ADJ	B
.	O	PUNCT	O


These	O	DET	O
data	O	NOUN	B
indicate	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
adaptive	O	ADJ	B
response	O	NOUN	I
to	O	PART	O
ISO	B-Chemical	NOUN	B
shows	O	VERB	O
an	O	DET	O
early	O	ADJ	O
hypertrophic	B-Disease	ADJ	B
phase	O	NOUN	B
(	O	PUNCT	O
1	O	NUM	O
-	O	SYM	O
4	O	NUM	O
days	O	NOUN	B
)	O	PUNCT	O
characterized	O	VERB	B
by	O	ADP	O
a	O	DET	O
substantial	O	ADJ	O
increase	O	NOUN	B
in	O	ADP	O
RNA	O	NOUN	B
content	O	NOUN	B
and	O	CCONJ	O
cardiac	O	ADJ	B
mass	O	NOUN	I
in	O	ADP	O
the	O	DET	O
absence	O	NOUN	B
of	O	ADP	O
changes	O	NOUN	B
in	O	ADP	O
DNA	O	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
prolonged	O	ADJ	B
stimulation	O	NOUN	I
(	O	PUNCT	O
8	O	NUM	O
-	O	SYM	O
12	O	NUM	O
days	O	NOUN	B
)	O	PUNCT	O
appears	O	VERB	O
to	O	PART	O
represent	O	VERB	O
a	O	DET	O
complex	O	ADJ	B
integration	O	NOUN	B
of	O	ADP	O
both	O	CCONJ	O
cellular	O	ADJ	B
hypertrophy	B-Disease	NOUN	I
and	O	CCONJ	O
hyperplasia	B-Disease	NOUN	B


Co	O	PROPN	B
-	O	PUNCT	O
carcinogenic	B-Disease	ADJ	B
effect	O	NOUN	B
of	O	ADP	O
retinyl	B-Chemical	NOUN	B
acetate	I-Chemical	NOUN	I
on	O	ADP	O
forestomach	B-Disease	ADJ	B
carcinogenesis	I-Disease	NOUN	I
of	O	ADP	O
male	O	ADJ	B
F344	O	NOUN	O
rats	O	NOUN	B
induced	O	VERB	B
with	O	ADP	O
butylated	B-Chemical	VERB	B
hydroxyanisole	I-Chemical	NOUN	I
.	O	PUNCT	O


The	O	DET	O
potential	O	ADJ	B
modifying	O	NOUN	O
effect	O	NOUN	B
of	O	ADP	O
retinyl	B-Chemical	NOUN	B
acetate	I-Chemical	NOUN	I
(	O	PUNCT	O
RA	B-Chemical	NOUN	B
)	O	PUNCT	O
on	O	ADP	O
butylated	B-Chemical	VERB	B
hydroxyanisole	I-Chemical	NOUN	I
(	O	PUNCT	O
BHA	B-Chemical	NOUN	B
)-	O	ADJ	O
induced	O	VERB	B
rat	O	NOUN	B
forestomach	B-Disease	NOUN	B
tumorigenesis	I-Disease	NOUN	B
was	O	AUX	O
examined	O	VERB	O
.	O	PUNCT	O


Male	O	ADJ	B
F344	O	NOUN	O
rats	O	NOUN	B
,	O	PUNCT	O
5	O	NUM	O
weeks	O	NOUN	B
of	O	ADP	O
age	O	NOUN	B
,	O	PUNCT	O
were	O	AUX	O
maintained	O	VERB	B
on	O	ADP	O
diet	O	NOUN	B
containing	O	VERB	O
1	O	NUM	O
%	O	NOUN	O
or	O	CCONJ	O
2	O	NUM	O
%	O	NOUN	O
BHA	B-Chemical	NOUN	B
by	O	ADP	O
weight	O	NOUN	B
and	O	CCONJ	O
simultaneously	O	ADV	B
on	O	ADP	O
drinking	O	NOUN	B
water	O	NOUN	I
supplemented	O	VERB	B
with	O	ADP	O
RA	B-Chemical	NOUN	B
at	O	ADP	O
various	O	ADJ	O
concentrations	O	NOUN	B
(	O	PUNCT	O
w	O	X	O
/	O	SYM	O
v	O	X	O
)	O	PUNCT	O
for	O	ADP	O
52	O	NUM	O
weeks	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
groups	O	NOUN	B
given	O	VERB	O
2	O	NUM	O
%	O	NOUN	O
BHA	B-Chemical	NOUN	B
,	O	PUNCT	O
although	O	SCONJ	O
marked	O	ADJ	O
hyperplastic	O	ADJ	B
changes	O	NOUN	B
of	O	ADP	O
the	O	DET	O
forestomach	O	ADJ	B
epithelium	O	NOUN	I
were	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
all	O	DET	O
animals	O	NOUN	B
,	O	PUNCT	O
co	O	ADJ	B
-	O	PUNCT	O
administration	O	NOUN	B
of	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


25	O	NUM	O
%	O	NOUN	O
RA	B-Chemical	NOUN	B
significantly	O	ADV	O
(	O	PUNCT	O
P	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


05	O	NUM	O
)	O	PUNCT	O
increased	O	VERB	B
the	O	DET	O
incidence	O	NOUN	B
of	O	ADP	O
forestomach	B-Disease	ADJ	B
tumors	I-Disease	NOUN	I
(	O	PUNCT	O
squamous	B-Disease	ADJ	B
cell	I-Disease	NOUN	I
papilloma	I-Disease	NOUN	I
and	O	CCONJ	O
carcinoma	B-Disease	NOUN	B
)	O	PUNCT	O
to	O	PART	O
60	O	NUM	O
%(	O	NOUN	O
9	O	NUM	O
/	O	SYM	O
15	O	NUM	O
,	O	PUNCT	O
2	O	NUM	O
rats	O	NOUN	B
with	O	ADP	O
carcinoma	B-Disease	NOUN	B
)	O	PUNCT	O
from	O	ADP	O
15	O	NUM	O
%(	O	NOUN	O
3	O	NUM	O
/	O	SYM	O
20	O	NUM	O
,	O	PUNCT	O
one	O	NUM	O
rat	O	NOUN	B
with	O	ADP	O
carcinoma	B-Disease	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
group	O	NOUN	B
given	O	VERB	O
RA	B-Chemical	NOUN	B
-	O	PUNCT	O
free	O	ADJ	B
water	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
rats	O	NOUN	B
given	O	VERB	O
1	O	NUM	O
%	O	NOUN	O
BHA	B-Chemical	NOUN	B
,	O	PUNCT	O
RA	B-Chemical	NOUN	B
co	O	X	B
-	O	PUNCT	O
administered	O	VERB	B
at	O	ADP	O
a	O	DET	O
dose	O	NOUN	B
of	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


05	O	NUM	O
,	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
,	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
or	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


25	O	NUM	O
%	O	NOUN	O
showed	O	VERB	O
a	O	DET	O
dose	O	NOUN	B
-	O	PUNCT	O
dependent	O	ADJ	B
enhancing	O	NOUN	B
effect	O	NOUN	B
on	O	ADP	O
the	O	DET	O
development	O	NOUN	B
of	O	ADP	O
the	O	DET	O
BHA	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
epithelial	B-Disease	ADJ	B
hyperplasia	I-Disease	NOUN	I
.	O	PUNCT	O


Tumors	B-Disease	NOUN	B
,	O	PUNCT	O
all	O	DET	O
papillomas	B-Disease	NOUN	B
,	O	PUNCT	O
were	O	AUX	O
induced	O	VERB	B
in	O	ADP	O
3	O	NUM	O
rats	O	NOUN	B
(	O	PUNCT	O
17	O	NUM	O
%)	O	NOUN	O
with	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


25	O	NUM	O
%	O	NOUN	O
RA	B-Chemical	NOUN	B
and	O	CCONJ	O
in	O	ADP	O
one	O	NUM	O
rat	O	NOUN	B
(	O	PUNCT	O
10	O	NUM	O
%)	O	NOUN	O
with	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


05	O	NUM	O
%	O	NOUN	O
RA	B-Chemical	NOUN	B
co	O	X	B
-	O	PUNCT	O
administration	O	NOUN	B
.	O	PUNCT	O


RA	B-Chemical	NOUN	B
alone	O	ADV	O
did	O	AUX	O
not	O	PART	O
induce	O	VERB	O
hyperplastic	O	ADJ	B
changes	O	NOUN	I
in	O	ADP	O
the	O	DET	O
forestomach	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
findings	O	NOUN	B
indicate	O	VERB	O
that	O	SCONJ	O
RA	B-Chemical	NOUN	B
acted	O	VERB	O
as	O	ADP	O
a	O	DET	O
co	O	X	B
-	O	PUNCT	O
carcinogen	O	NOUN	B
in	O	ADP	O
the	O	DET	O
BHA	B-Chemical	NOUN	B
forestomach	B-Disease	NOUN	O
carcinogenesis	I-Disease	NOUN	O


Ketanserin	B-Chemical	NOUN	B
pretreatment	O	NOUN	B
reverses	O	VERB	B
alfentanil	B-Chemical	ADJ	B
-	O	PUNCT	O
induced	O	VERB	B
muscle	B-Disease	NOUN	B
rigidity	I-Disease	NOUN	I
.	O	PUNCT	O


Systemic	O	ADJ	B
pretreatment	O	NOUN	B
with	O	ADP	O
ketanserin	B-Chemical	NOUN	B
,	O	PUNCT	O
a	O	DET	O
relatively	O	ADV	O
specific	O	ADJ	O
type	O	NOUN	B
-	O	PUNCT	O
2	O	NUM	O
serotonin	B-Chemical	NOUN	B
receptor	O	NOUN	I
antagonist	O	NOUN	I
,	O	PUNCT	O
significantly	O	ADV	O
attenuated	O	VERB	B
the	O	DET	O
muscle	B-Disease	NOUN	B
rigidity	I-Disease	NOUN	I
produced	O	VERB	O
in	O	ADP	O
rats	O	NOUN	B
by	O	ADP	O
the	O	DET	O
potent	O	ADJ	O
short	O	ADJ	B
-	O	PUNCT	O
acting	O	VERB	B
opiate	O	ADJ	B
agonist	O	NOUN	I
alfentanil	B-Chemical	NOUN	B
.	O	PUNCT	O


Following	O	VERB	O
placement	O	NOUN	B
of	O	ADP	O
subcutaneous	O	ADJ	B
electrodes	O	NOUN	I
in	O	ADP	O
each	O	DET	O
animal	O	NOUN	B
'	O	PART	O
s	O	NOUN	O
left	O	VERB	B
gastrocnemius	O	NOUN	I
muscle	O	NOUN	I
,	O	PUNCT	O
rigidity	B-Disease	NOUN	B
was	O	AUX	O
assessed	O	VERB	B
by	O	ADP	O
analyzing	O	VERB	O
root	O	NOUN	B
-	O	PUNCT	O
mean	O	NOUN	B
-	O	PUNCT	O
square	O	ADJ	B
electromyographic	O	ADJ	B
activity	O	NOUN	I
.	O	PUNCT	O


Intraperitoneal	O	NOUN	B
ketanserin	B-Chemical	NOUN	B
administration	O	NOUN	B
at	O	ADP	O
doses	O	NOUN	B
of	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


63	O	NUM	O
and	O	CCONJ	O
2	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
mg	O	NOUN	O
/	O	PUNCT	O
kg	O	NOUN	B
prevented	O	VERB	B
the	O	DET	O
alfentanil	B-Chemical	ADJ	B
-	O	PUNCT	O
induced	O	VERB	B
increase	O	NOUN	B
in	O	ADP	O
electromyographic	O	ADJ	B
activity	O	NOUN	I
compared	O	VERB	B
with	O	ADP	O
animals	O	NOUN	B
pretreated	O	VERB	B
with	O	ADP	O
saline	O	NOUN	B
.	O	PUNCT	O


Chlordiazepoxide	B-Chemical	NOUN	B
at	O	ADP	O
doses	O	NOUN	B
up	O	ADV	O
to	O	PART	O
10	O	NUM	O
mg	O	NOUN	O
/	O	PUNCT	O
kg	O	NOUN	O
failed	O	VERB	B
to	O	PART	O
significantly	O	ADV	O
influence	O	VERB	B
the	O	DET	O
rigidity	B-Disease	NOUN	B
produced	O	VERB	O
by	O	ADP	O
alfentanil	B-Chemical	NOUN	B
.	O	PUNCT	O


Despite	O	SCONJ	O
the	O	DET	O
absence	O	NOUN	B
of	O	ADP	O
rigidity	B-Disease	NOUN	B
,	O	PUNCT	O
animals	O	NOUN	B
that	O	PRON	O
received	O	VERB	O
ketanserin	B-Chemical	NOUN	B
(	O	PUNCT	O
greater	O	ADJ	O
than	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


31	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	O
i	O	X	O
.	O	PUNCT	O


p	O	NOUN	O
.)	O	NOUN	O
followed	O	VERB	O
by	O	ADP	O
alfentanil	B-Chemical	NOUN	B
were	O	AUX	O
motionless	O	ADJ	B
,	O	PUNCT	O
flaccid	O	ADJ	B
,	O	PUNCT	O
and	O	CCONJ	O
less	O	ADV	O
responsive	O	ADJ	B
to	O	PART	O
external	O	ADJ	B
stimuli	O	NOUN	B
than	O	ADP	O
were	O	AUX	O
animals	O	NOUN	B
receiving	O	VERB	O
alfentanil	B-Chemical	NOUN	B
alone	O	ADV	O
.	O	PUNCT	O


Rats	O	NOUN	B
that	O	PRON	O
received	O	VERB	O
ketanserin	B-Chemical	NOUN	B
and	O	CCONJ	O
alfentanil	B-Chemical	NOUN	B
exhibited	O	VERB	O
less	O	ADV	O
rearing	O	ADJ	B
and	O	CCONJ	O
exploratory	O	ADJ	B
behavior	O	NOUN	I
at	O	ADP	O
the	O	DET	O
end	O	NOUN	O
of	O	ADP	O
the	O	DET	O
60	O	NUM	O
-	O	PUNCT	O
min	O	NOUN	B
recording	O	NOUN	O
period	O	NOUN	B
than	O	ADP	O
did	O	AUX	O
animals	O	NOUN	B
that	O	PRON	O
received	O	VERB	O
ketanserin	B-Chemical	NOUN	B
alone	O	ADV	O
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	B
,	O	PUNCT	O
in	O	ADP	O
combination	O	NOUN	B
with	O	ADP	O
previous	O	ADJ	O
work	O	NOUN	O
,	O	PUNCT	O
suggest	O	VERB	O
that	O	SCONJ	O
muscle	B-Disease	NOUN	B
rigidity	I-Disease	NOUN	I
,	O	PUNCT	O
a	O	DET	O
clinically	O	ADV	B
relevant	O	ADJ	O
side	O	NOUN	B
-	O	PUNCT	O
effect	O	NOUN	B
of	O	ADP	O
parenteral	O	ADJ	B
narcotic	O	ADJ	I
administration	O	NOUN	I
,	O	PUNCT	O
may	O	AUX	O
be	O	AUX	O
partly	O	ADV	O
mediated	O	VERB	O
via	O	ADP	O
serotonergic	O	NOUN	B
pathways	O	NOUN	I
.	O	PUNCT	O


Pretreatment	O	NOUN	B
with	O	ADP	O
type	O	NOUN	B
-	O	PUNCT	O
2	O	NUM	O
serotonin	B-Chemical	NOUN	B
antagonists	O	NOUN	B
may	O	AUX	O
be	O	AUX	O
clinically	O	ADV	B
useful	O	ADJ	O
in	O	ADP	O
attenuating	O	VERB	B
opiate	O	ADJ	B
-	O	PUNCT	O
induced	O	VERB	B
rigidity	B-Disease	NOUN	B
,	O	PUNCT	O
although	O	SCONJ	O
further	O	ADJ	O
studies	O	NOUN	B
will	O	AUX	O
be	O	AUX	O
necessary	O	ADJ	O
to	O	PART	O
assess	O	VERB	B
the	O	DET	O
interaction	O	NOUN	B
of	O	ADP	O
possibly	O	ADV	O
enhanced	O	VERB	B
CNS	O	NOUN	B
,	O	PUNCT	O
cardiovascular,	B-Disease	NOUN	B
and	I-Disease	CCONJ	O
respiratory	I-Disease	ADJ	B
depression	I-Disease	NOUN	I


Glycopyrronium	B-Chemical	NOUN	B
requirements	O	NOUN	B
for	O	ADP	O
antagonism	O	NOUN	B
of	O	ADP	O
the	O	DET	O
muscarinic	O	ADJ	B
side	O	NOUN	B
effects	O	NOUN	I
of	O	ADP	O
edrophonium	B-Chemical	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
compared	O	VERB	B
,	O	PUNCT	O
in	O	ADP	O
60	O	NUM	O
adult	O	ADJ	B
patients	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
cardiovascular	O	ADJ	B
effects	O	NOUN	B
of	O	ADP	O
glycopyrronium	B-Chemical	NOUN	B
5	O	NUM	O
micrograms	O	NOUN	B
kg	O	NOUN	O
-	O	PUNCT	O
1	O	NUM	O
and	O	CCONJ	O
10	O	NUM	O
micrograms	O	NOUN	O
kg	O	NOUN	O
-	O	PUNCT	O
1	O	NUM	O
given	O	VERB	O
either	O	CCONJ	O
simultaneously	O	ADV	B
or	O	CCONJ	O
1	O	NUM	O
min	O	NOUN	O
before	O	ADP	O
edrophonium	B-Chemical	NOUN	B
1	O	NUM	I
mg	O	NOUN	I
kg	O	NOUN	O
-	O	PUNCT	O
1	O	NUM	O
.	O	PUNCT	O


Significant	O	ADJ	O
differences	O	NOUN	O
between	O	ADP	O
the	O	DET	O
four	O	NUM	O
groups	O	NOUN	B
were	O	AUX	O
detected	O	VERB	B
(	O	PUNCT	O
P	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


001	O	NUM	O
).	O	PUNCT	O
Both	O	DET	O
groups	O	NOUN	B
receiving	O	VERB	O
10	O	NUM	O
micrograms	O	NOUN	B
kg	O	NOUN	O
-	O	PUNCT	O
1	O	NUM	O
showed	O	VERB	O
increases	O	NOUN	B
in	O	ADP	O
heart	O	NOUN	B
rate	O	NOUN	I
of	O	ADP	O
up	O	ADV	O
to	O	PART	O
30	O	NUM	O
beat	O	VERB	B
min	O	NOUN	B
-	O	PUNCT	O
1	O	NUM	O
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
confidence	O	NOUN	B
limits	O	VERB	I
28	O	NUM	O
-	O	SYM	O
32	O	NUM	O
beat	O	VERB	B
min	O	NOUN	B
-	O	PUNCT	O
1	O	NUM	O
).	O	PUNCT	O
Use	O	PROPN	O
of	O	ADP	O
glycopyrronium	B-Chemical	NOUN	B
5	O	NUM	O
micrograms	O	NOUN	B
kg	O	NOUN	O
-	O	PUNCT	O
1	O	NUM	O
provided	O	VERB	O
greater	O	ADJ	O
cardiovascular	O	ADJ	B
stability	O	NOUN	O
and	O	CCONJ	O
,	O	PUNCT	O
given	O	VERB	O
1	O	NUM	O
min	O	NOUN	O
before	O	ADP	O
the	O	DET	O
edrophonium	B-Chemical	NOUN	B
,	O	PUNCT	O
was	O	AUX	O
sufficient	O	ADJ	O
to	O	PART	O
minimize	O	VERB	O
early	O	ADV	B
,	O	PUNCT	O
edrophonium	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
bradycardias	B-Disease	NOUN	B
.	O	PUNCT	O


This	O	DET	O
low	O	ADJ	B
dose	O	NOUN	B
of	O	ADP	O
glycopyrronium	B-Chemical	NOUN	B


Involvement	O	NOUN	B
of	O	ADP	O
locus	O	NOUN	B
coeruleus	O	NOUN	I
and	O	CCONJ	O
noradrenergic	O	ADJ	B
neurotransmission	O	NOUN	B
in	O	ADP	O
fentanyl	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
muscular	B-Disease	ADJ	B
rigidity	I-Disease	NOUN	B
in	O	ADP	O
the	O	DET	O
rat	O	NOUN	B
.	O	PUNCT	O


Whereas	O	SCONJ	O
muscular	B-Disease	ADJ	B
rigidity	I-Disease	NOUN	I
is	O	AUX	O
a	O	DET	O
well	O	ADV	O
-	O	PUNCT	O
known	O	VERB	B
side	O	NOUN	B
effect	O	NOUN	I
that	O	PRON	O
is	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
high	O	ADJ	B
-	O	PUNCT	O
dose	O	NOUN	B
fentanyl	B-Chemical	NOUN	B
anesthesia	O	NOUN	I
,	O	PUNCT	O
a	O	DET	O
paucity	O	NOUN	O
of	O	ADP	O
information	O	NOUN	B
exists	O	VERB	O
with	O	ADP	O
regard	O	NOUN	O
to	O	ADP	O
its	O	PRON	O
underlying	O	ADJ	O
mechanism	O	NOUN	B
(	O	PUNCT	O
s	O	NOUN	O
).	O	PUNCT	O
We	O	PRON	O
investigated	O	VERB	B
in	O	ADP	O
this	O	DET	O
study	O	NOUN	B
the	O	DET	O
possible	O	ADJ	O
engagement	O	NOUN	B
of	O	ADP	O
locus	O	NOUN	B
coeruleus	O	NOUN	I
of	O	ADP	O
the	O	DET	O
pons	O	NOUN	B
in	O	ADP	O
this	O	DET	O
phenomenon	O	NOUN	B
,	O	PUNCT	O
using	O	VERB	O
male	O	ADJ	B
Sprague	O	PROPN	B
-	O	PUNCT	O
Dawley	O	NOUN	B
rats	O	NOUN	B
anesthetized	O	VERB	B
with	O	ADP	O
ketamine	B-Chemical	NOUN	B
.	O	PUNCT	O


Under	O	ADP	O
proper	O	ADJ	O
control	O	NOUN	B
of	O	ADP	O
respiration	O	NOUN	B
,	O	PUNCT	O
body	O	NOUN	B
temperature	O	NOUN	I
and	O	CCONJ	O
end	O	VERB	B
-	O	PUNCT	O
tidal	O	ADJ	B
CO2	B-Chemical	NOUN	B
,	O	PUNCT	O
intravenous	O	ADJ	B
administration	O	NOUN	I
of	O	ADP	O
fentanyl	B-Chemical	NOUN	B
(	O	PUNCT	O
50	O	NUM	O
or	O	CCONJ	O
100	O	NUM	O
micrograms	O	NOUN	B
/	O	SYM	O
kg	O	NOUN	B
)	O	PUNCT	O
consistently	O	ADV	O
promoted	O	VERB	B
an	O	DET	O
increase	O	NOUN	B
in	O	ADP	O
electromyographic	O	ADJ	B
activity	O	NOUN	I
recorded	O	VERB	O
from	O	ADP	O
the	O	DET	O
gastrocnemius	O	NOUN	B
and	O	CCONJ	O
abdominal	O	ADJ	B
rectus	O	NOUN	I
muscles	O	NOUN	I
.	O	PUNCT	O


Such	O	DET	O
an	O	DET	O
induced	O	ADJ	B
muscular	B-Disease	ADJ	B
rigidity	I-Disease	NOUN	B
by	O	ADP	O
the	O	DET	O
narcotic	O	ADJ	B
agent	O	NOUN	I
was	O	AUX	O
significantly	O	ADV	O
antagonized	O	VERB	B
or	O	CCONJ	O
even	O	ADV	O
reduced	O	VERB	B
by	O	ADP	O
prior	O	ADJ	O
electrolytic	O	ADJ	B
lesions	O	NOUN	I
of	O	ADP	O
the	O	DET	O
locus	O	NOUN	B
coeruleus	O	NOUN	I
or	O	CCONJ	O
pretreatment	O	NOUN	B
with	O	ADP	O
the	O	DET	O
alpha	O	NOUN	B
-	O	PUNCT	O
adrenoceptor	O	NOUN	B
blocker	O	NOUN	I
,	O	PUNCT	O
prazosin	B-Chemical	NOUN	B
.	O	PUNCT	O


Microinjection	O	NOUN	B
of	O	ADP	O
fentanyl	B-Chemical	NOUN	B
(	O	PUNCT	O
2	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
micrograms	O	NOUN	B
/	O	SYM	O
50	O	NUM	O
nl	O	NOUN	O
)	O	PUNCT	O
directly	O	ADV	O
into	O	ADP	O
this	O	DET	O
pontine	O	NOUN	B
nucleus	O	NOUN	I
,	O	PUNCT	O
on	O	ADP	O
the	O	DET	O
other	O	ADJ	O
hand	O	NOUN	B
,	O	PUNCT	O
elicited	O	VERB	O
discernible	O	ADJ	O
electromyographic	O	ADJ	B
excitation	O	NOUN	B
.	O	PUNCT	O


It	O	PRON	O
is	O	AUX	O
speculated	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
induction	O	NOUN	B
of	O	ADP	O
muscular	B-Disease	ADJ	B
rigidity	I-Disease	NOUN	I
by	O	ADP	O
fentanyl	B-Chemical	NOUN	B


Cerebral	B-Disease	ADJ	B
sinus	I-Disease	NOUN	I
thrombosis	I-Disease	NOUN	I
as	O	ADP	O
a	O	DET	O
potential	O	ADJ	B
hazard	O	NOUN	B
of	O	ADP	O
antifibrinolytic	O	ADJ	B
treatment	O	NOUN	I
in	O	ADP	O
menorrhagia	B-Disease	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
describe	O	VERB	O
a	O	DET	O
42	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
woman	O	NOUN	B
who	O	PRON	O
developed	O	VERB	O
superior	O	ADJ	B
sagittal	B-Disease	ADJ	B
and	I-Disease	CCONJ	O
left	I-Disease	ADJ	B
transverse	I-Disease	ADJ	I
sinus	I-Disease	NOUN	I
thrombosis	I-Disease	NOUN	I
associated	O	VERB	B
with	O	ADP	I
prolonged	O	ADJ	B
epsilon-aminocaproic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
therapy	O	NOUN	I
for	O	ADP	O
menorrhagia	B-Disease	NOUN	B
.	O	PUNCT	O


This	O	DET	O
antifibrinolytic	O	ADJ	B
agent	O	NOUN	I
has	O	AUX	O
been	O	AUX	O
used	O	VERB	O
in	O	ADP	O
women	O	NOUN	B
with	O	ADP	O
menorrhagia	B-Disease	NOUN	B
to	O	PART	O
promote	O	VERB	B
clotting	O	NOUN	B
and	O	CCONJ	O
reduce	O	VERB	B
blood	B-Disease	NOUN	B
loss	I-Disease	NOUN	I
.	O	PUNCT	O


Although	O	SCONJ	O
increased	O	VERB	B
risk	O	NOUN	B
of	O	ADP	O
thromboembolic	B-Disease	ADJ	B
disease	I-Disease	NOUN	I
has	O	AUX	O
been	O	AUX	O
reported	O	VERB	O
during	O	ADP	O
treatment	O	NOUN	B
with	O	ADP	O
epsilon-aminocaproic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
,	O	PUNCT	O
cerebral	B-Disease	ADJ	B
sinus	I-Disease	NOUN	I
thrombosis	I-Disease	NOUN	I
has	O	AUX	O
not	O	PART	O
been	O	AUX	O
previously	O	ADV	O
described	O	VERB	O
.	O	PUNCT	O


Careful	O	ADJ	O
use	O	NOUN	O
of	O	ADP	O
epsilon-aminocaproic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I


Hemorrhagic	B-Disease	ADJ	B
cystitis	I-Disease	NOUN	I
complicating	O	NOUN	B
bone	O	NOUN	B
marrow	O	NOUN	I
transplantation	O	NOUN	I
.	O	PUNCT	O


Hemorrhagic	B-Disease	ADJ	B
cystitis	I-Disease	NOUN	I
is	O	AUX	O
a	O	DET	O
potentially	O	ADV	O
serious	O	ADJ	O
complication	O	NOUN	B
of	O	ADP	O
high	O	ADJ	B
-	O	PUNCT	O
dose	O	NOUN	B
cyclophosphamide	B-Chemical	NOUN	B
therapy	O	NOUN	I
administered	O	VERB	B
before	O	ADP	O
bone	O	NOUN	B
marrow	O	NOUN	I
transplantation	O	NOUN	I
.	O	PUNCT	O


As	O	ADP	O
standard	O	ADJ	B
practice	O	NOUN	I
at	O	ADP	O
our	O	PRON	O
institution	O	NOUN	B
,	O	PUNCT	O
patients	O	NOUN	B
who	O	PRON	O
are	O	AUX	O
scheduled	O	VERB	B
to	O	PART	O
receive	O	VERB	O
a	O	DET	O
bone	O	NOUN	B
marrow	O	NOUN	I
transplant	O	NOUN	I
are	O	AUX	O
treated	O	VERB	B
prophylactically	O	ADV	B
with	O	ADP	O
forced	O	ADJ	B
hydration	O	NOUN	B
and	O	CCONJ	O
bladder	O	NOUN	B
irrigation	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
an	O	DET	O
attempt	O	NOUN	O
to	O	PART	O
obviate	O	VERB	O
the	O	DET	O
inconvenience	O	NOUN	B
of	O	ADP	O
bladder	O	ADJ	B
irrigation	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
conducted	O	VERB	O
a	O	DET	O
feasibility	O	NOUN	B
trial	O	NOUN	I
of	O	ADP	O
uroprophylaxis	O	NOUN	B
with	O	ADP	O
mesna	B-Chemical	NOUN	B
,	O	PUNCT	O
which	O	DET	O
neutralizes	O	VERB	O
the	O	DET	O
hepatic	O	ADJ	B
metabolite	O	NOUN	I
of	O	ADP	O
cyclophosphamide	B-Chemical	NOUN	B
that	O	PRON	O
causes	O	VERB	O
hemorrhagic	B-Disease	ADJ	B
cystitis	I-Disease	NOUN	I
.	O	PUNCT	O


Of	O	ADP	O
97	O	NUM	O
patients	O	NOUN	B
who	O	PRON	O
received	O	VERB	O
standard	O	ADJ	B
prophylaxis	O	NOUN	B
,	O	PUNCT	O
4	O	NUM	O
had	O	AUX	O
symptomatic	O	ADJ	B
hemorrhagic	B-Disease	ADJ	B
cystitis	I-Disease	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
contrast	O	NOUN	O
,	O	PUNCT	O
two	O	NUM	O
of	O	ADP	O
four	O	NUM	O
consecutive	O	ADJ	B
patients	O	NOUN	B
who	O	PRON	O
received	O	VERB	O
mesna	B-Chemical	NOUN	B
uroprophylaxis	O	NOUN	B
before	O	ADP	O
allogeneic	O	ADJ	B
bone	O	NOUN	I
marrow	O	NOUN	I
transplantation	O	NOUN	I
had	O	AUX	O
severe	O	ADJ	B
hemorrhagic	B-Disease	ADJ	B
cystitis	I-Disease	NOUN	I
for	O	ADP	O
at	O	ADP	O
least	O	ADJ	O
2	O	NUM	O
weeks	O	NOUN	B
.	O	PUNCT	O


Because	O	SCONJ	O
of	O	ADP	O
this	O	DET	O
suboptimal	O	ADJ	B
result	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
resumed	O	VERB	O
the	O	DET	O
use	O	NOUN	O
of	O	ADP	O
bladder	O	ADJ	B
irrigation	O	NOUN	B
and	O	CCONJ	O
forced	O	VERB	B
hydration	O	NOUN	I
to	O	PART	O
minimize	O	VERB	O
the	O	DET	O
risk	O	NOUN	B
of	O	ADP	O
hemorrhagic	B-Disease	ADJ	B
cystitis	I-Disease	NOUN	I


Reversal	O	ADJ	B
of	O	ADP	O
central	O	ADJ	B
benzodiazepine	B-Chemical	NOUN	I
effects	O	NOUN	B
by	O	ADP	O
flumazenil	B-Chemical	NOUN	B
after	O	ADP	O
intravenous	O	ADJ	B
conscious	O	ADJ	O
sedation	O	NOUN	O
with	O	ADP	O
diazepam	B-Chemical	NOUN	B
and	O	CCONJ	O
opioids	O	NOUN	B
:	O	PUNCT	O
report	O	NOUN	B
of	O	ADP	O
a	O	DET	O
double	O	ADJ	B
-	O	PUNCT	O
blind	O	NOUN	B
multicenter	O	NOUN	B
study	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
Flumazenil	B-Chemical	PROPN	B
in	O	ADP	O
Intravenous	O	ADJ	B
Conscious	O	ADJ	O
Sedation	O	NOUN	O
with	O	ADP	O
Diazepam	B-Chemical	NOUN	B
Multicenter	O	PROPN	I
Study	O	PROPN	I
Group	O	PROPN	B
II	O	PROPN	I
.	O	PUNCT	O


The	O	DET	O
efficacy	O	NOUN	B
and	O	CCONJ	O
safety	O	NOUN	B
of	O	ADP	O
a	O	DET	O
new	O	ADJ	O
benzodiazepine	B-Chemical	NOUN	B
antagonist	O	NOUN	B
,	O	PUNCT	O
flumazenil	B-Chemical	NOUN	B
,	O	PUNCT	O
were	O	AUX	O
assessed	O	VERB	B
in	O	ADP	O
a	O	DET	O
double	O	ADJ	B
-	O	PUNCT	O
blind	O	NOUN	B
multicenter	O	NOUN	B
study	O	NOUN	I
.	O	PUNCT	O


Flumazenil	B-Chemical	NOUN	B
(	O	PUNCT	O
mean	O	ADJ	B
dose	O	NOUN	I
,	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


76	O	NUM	O
mg	O	NOUN	O
)	O	PUNCT	O
or	O	CCONJ	O
placebo	O	NOUN	B
(	O	PUNCT	O
mean	O	ADJ	B
dose	O	NOUN	I
,	O	PUNCT	O
8	O	NUM	O
.	O	PUNCT	O


9	O	NUM	O
ml	O	NOUN	O
)	O	PUNCT	O
was	O	AUX	O
administered	O	VERB	B
intravenously	O	ADV	B
to	O	PART	O
130	O	NUM	O
and	O	CCONJ	O
67	O	NUM	O
patients	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
,	O	PUNCT	O
who	O	PRON	O
had	O	AUX	O
been	O	AUX	O
given	O	VERB	O
diazepam	B-Chemical	NOUN	B
in	O	ADP	O
conjunction	O	NOUN	B
with	O	ADP	O
an	O	DET	O
opioid	O	NOUN	B
(	O	PUNCT	O
fentanyl	B-Chemical	NOUN	B
,	O	PUNCT	O
meperidine	B-Chemical	NOUN	B
,	O	PUNCT	O
or	O	CCONJ	O
morphine	B-Chemical	NOUN	B
)	O	PUNCT	O
for	O	ADP	O
the	O	DET	O
induction	O	NOUN	B
and	O	CCONJ	O
maintenance	O	NOUN	B
of	O	ADP	O
intravenous	O	ADJ	B
conscious	O	ADJ	O
sedation	O	NOUN	O
for	O	ADP	O
diagnostic	O	ADJ	B
or	O	CCONJ	O
therapeutic	O	ADJ	B
surgical	O	ADJ	O
procedures	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
group	O	NOUN	B
assessable	O	ADJ	O
for	O	ADP	O
efficacy	O	NOUN	B
comprised	O	VERB	O
122	O	NUM	O
patients	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
flumazenil	B-Chemical	NOUN	B
and	O	CCONJ	O
64	O	NUM	O
patients	O	NOUN	B
given	O	VERB	O
placebo	O	NOUN	B
.	O	PUNCT	O


After	O	ADP	O
5	O	NUM	O
minutes	O	NOUN	B
,	O	PUNCT	O
80	O	NUM	O
/	O	SYM	O
115	O	NUM	O
(	O	PUNCT	O
70	O	NUM	O
%)	O	NOUN	O
flumazenil	B-Chemical	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
patients	O	NOUN	B
,	O	PUNCT	O
compared	O	VERB	B
with	O	ADP	O
21	O	NUM	O
/	O	SYM	O
63	O	NUM	O
(	O	PUNCT	O
33	O	NUM	O
%)	O	NOUN	O
placebo	O	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
patients	O	NOUN	B
,	O	PUNCT	O
were	O	AUX	O
completely	O	ADV	O
awake	O	ADJ	B
and	O	CCONJ	O
alert	O	VERB	B
,	O	PUNCT	O
as	O	ADP	O
indicated	O	VERB	O
by	O	ADP	O
a	O	DET	O
score	O	NOUN	B
of	O	ADP	O
5	O	NUM	O
on	O	ADP	O
the	O	DET	O
Observer	O	PROPN	B
'	O	PART	O
s	O	NOUN	O
Assessment	O	NOUN	B
of	O	ADP	O
Alertness	O	PROPN	B
/	O	SYM	O
Sedation	O	NOUN	B
Scale	O	NOUN	I
.	O	PUNCT	O


Ninety	O	NUM	B
-	O	PUNCT	O
five	O	NUM	O
percent	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
in	O	ADP	O
each	O	DET	O
group	O	NOUN	B
who	O	PRON	O
attained	O	VERB	O
a	O	DET	O
score	O	NOUN	B
of	O	ADP	O
5	O	NUM	O
at	O	ADP	O
the	O	DET	O
5	O	NUM	O
-	O	PUNCT	O
minute	O	NOUN	B
assessment	O	NOUN	B
showed	O	VERB	O
no	O	DET	O
loss	O	NOUN	O
of	O	ADP	O
alertness	O	NOUN	B
throughout	O	ADP	O
the	O	DET	O
180	O	NUM	O
-	O	PUNCT	O
minute	O	NOUN	B
assessment	O	NOUN	B
period	O	NOUN	B
.	O	PUNCT	O


Flumazenil	B-Chemical	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
patients	O	NOUN	B
also	O	ADV	O
performed	O	VERB	O
significantly	O	ADV	O
better	O	ADV	O
on	O	ADP	O
the	O	DET	O
Finger	O	PROPN	B
-	O	PUNCT	O
to	O	ADP	O
-	O	PUNCT	O
Nose	O	PROPN	B
Test	O	PROPN	I
and	O	CCONJ	O
the	O	DET	O
recall	O	NOUN	B
of	O	ADP	O
pictures	O	NOUN	B
shown	O	VERB	O
at	O	ADP	O
the	O	DET	O
5	O	NUM	O
-	O	PUNCT	O
minute	O	NOUN	B
assessment	O	NOUN	B
.	O	PUNCT	O


Flumazenil	B-Chemical	NOUN	B
was	O	AUX	O
well	O	ADV	O
tolerated	O	VERB	B
,	O	PUNCT	O
with	O	ADP	O
no	O	DET	O
serious	O	ADJ	O
adverse	O	ADJ	B
effects	O	NOUN	I
reported	O	VERB	O
.	O	PUNCT	O


Thirty	O	NUM	B
-	O	PUNCT	O
nine	O	NUM	B
(	O	PUNCT	O
30	O	NUM	O
%)	O	NOUN	O
of	O	ADP	O
flumazenil	B-Chemical	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
patients	O	NOUN	B
,	O	PUNCT	O
compared	O	VERB	B
with	O	ADP	O
17	O	NUM	O
(	O	PUNCT	O
25	O	NUM	O
%)	O	NOUN	O
of	O	ADP	O
placebo	O	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
patients	O	NOUN	B
had	O	AUX	O
one	O	NUM	O
or	O	CCONJ	O
more	O	ADJ	O
drug	O	NOUN	B
-	O	PUNCT	O
related	O	VERB	B
adverse	O	ADJ	B
experiences	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
most	O	ADV	O
common	O	ADJ	O
adverse	O	ADJ	B
effects	O	NOUN	I
were	O	AUX	O
nausea	B-Disease	ADJ	B
and	O	CCONJ	O
vomiting	B-Disease	NOUN	B
in	O	ADP	O
the	O	DET	O
flumazenil	B-Chemical	NOUN	B
group	O	NOUN	B
and	O	CCONJ	O
nausea	B-Disease	NOUN	B
and	O	CCONJ	O
injection	O	NOUN	B
-	O	PUNCT	O
site	O	NOUN	B
pain	B-Disease	NOUN	B
in	O	ADP	O
the	O	DET	O
placebo	O	ADJ	B
group	O	NOUN	B
.	O	PUNCT	O


Flumazenil	B-Chemical	NOUN	B
was	O	AUX	O
found	O	VERB	O
to	O	PART	O
promptly	O	ADV	O
reverse	O	VERB	B
sedation	O	NOUN	I
induced	O	VERB	B
by	O	ADP	O
diazepam	B-Chemical	NOUN	B


Hepatic	O	ADJ	B
adenomas	B-Disease	NOUN	I
and	O	CCONJ	O
focal	B-Disease	ADJ	B
nodular	I-Disease	ADJ	I
hyperplasia	I-Disease	NOUN	I
of	O	ADP	O
the	O	DET	O
liver	O	NOUN	B
in	O	ADP	O
young	O	ADJ	B
women	O	NOUN	B
on	O	ADP	O
oral	B-Chemical	ADJ	B
contraceptives	I-Chemical	NOUN	I
:	O	PUNCT	O
case	O	NOUN	B
reports	O	NOUN	I
.	O	PUNCT	O


Two	O	NUM	O
cases	O	NOUN	B
of	O	ADP	O
hepatic	O	ADJ	B
adenoma	B-Disease	NOUN	I
and	O	CCONJ	O
one	O	NUM	O
of	O	ADP	O
focal	B-Disease	ADJ	B
nodular	I-Disease	ADJ	I
hyperplasia	I-Disease	NOUN	I
presumably	O	ADV	O
associated	O	VERB	B
with	O	ADP	I
the	O	DET	O
use	O	NOUN	O
of	O	ADP	O
oral	B-Chemical	ADJ	B
contraceptives	I-Chemical	NOUN	I
,	O	PUNCT	O
are	O	AUX	O
reported	O	VERB	O
.	O	PUNCT	O


Special	O	ADJ	B
reference	O	NOUN	I
is	O	AUX	O
made	O	VERB	O
to	O	PART	O
their	O	PRON	O
clinical	O	ADJ	B
presentation	O	NOUN	I
,	O	PUNCT	O
which	O	DET	O
may	O	AUX	O
be	O	AUX	O
totally	O	ADV	O
asymptomatic	O	ADJ	B
.	O	PUNCT	O


Liver	O	NOUN	B
-	O	PUNCT	O
function	O	NOUN	B
tests	O	NOUN	O
are	O	AUX	O
of	O	ADP	O
little	O	ADJ	O
diagnostic	O	ADJ	B
value	O	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
valuable	O	ADJ	O
information	O	NOUN	B
may	O	AUX	O
be	O	AUX	O
obtained	O	VERB	O
from	O	ADP	O
both	O	CCONJ	O
liver	O	NOUN	B
scanning	O	NOUN	I
and	O	CCONJ	O
hepatic	O	ADJ	B
angiography	O	NOUN	I
.	O	PUNCT	O


Histologic	O	ADJ	B
differences	O	NOUN	B
and	O	CCONJ	O
clinical	O	ADJ	B
similarities	O	NOUN	O
between	O	ADP	O
hepatic	O	ADJ	B
adenoma	B-Disease	NOUN	I
and	O	CCONJ	O
focal	B-Disease	ADJ	B
nodular	I-Disease	ADJ	I
hyperplasia	I-Disease	NOUN	I


Arterial	O	ADJ	B
thromboembolism	B-Disease	NOUN	I
in	O	ADP	O
patients	O	NOUN	B
receiving	O	VERB	O
systemic	O	ADJ	B
heparin	B-Chemical	NOUN	B
therapy	O	NOUN	I
:	O	PUNCT	O
a	O	DET	O
complication	O	NOUN	B
associated	O	VERB	B
with	O	ADP	I
heparin	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
thrombocytopenia	B-Disease	NOUN	B
.	O	PUNCT	O


Arterial	O	ADJ	B
thromboembolism	B-Disease	NOUN	I
is	O	AUX	O
a	O	DET	O
recognized	O	VERB	O
complication	O	NOUN	B
of	O	ADP	O
systemic	O	ADJ	B
heparin	B-Chemical	NOUN	B
therapy	O	NOUN	I
.	O	PUNCT	O


Characteristic	O	ADJ	B
of	O	ADP	O
the	O	DET	O
entity	O	NOUN	B
is	O	AUX	O
arterial	B-Disease	ADJ	B
occlusion	I-Disease	NOUN	I
by	O	ADP	O
platelet	O	NOUN	B
-	O	PUNCT	O
fibrin	O	NOUN	B
thrombi	B-Disease	NOUN	B
with	O	ADP	O
distal	O	ADJ	B
ischemia	B-Disease	NOUN	I
occurring	O	VERB	O
four	O	NUM	O
to	O	PART	O
twenty	O	NUM	O
days	O	NOUN	B
after	O	ADP	O
the	O	DET	O
initiation	O	NOUN	B
of	O	ADP	O
heparin	B-Chemical	NOUN	B
therapy	O	NOUN	I
,	O	PUNCT	O
preceded	O	VERB	O
by	O	ADP	O
profound	O	ADJ	O
thrombocytopenia	B-Disease	NOUN	B
with	O	ADP	O
platelet	O	NOUN	B
counts	O	NOUN	I
in	O	ADP	O
the	O	DET	O
range	O	NOUN	B
of	O	ADP	O
30	O	NUM	O
,	O	PUNCT	O
000	O	NUM	O
to	O	PART	O
40	O	NUM	O
,	O	PUNCT	O
000	O	NUM	O
per	O	ADP	O
cubic	O	ADJ	B
millimeter	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
clinically	O	ADV	B
apparent	O	ADJ	I
occlusion	O	NOUN	B
may	O	AUX	O
be	O	AUX	O
preceded	O	VERB	O
by	O	ADP	O
gastrointestinal	B-Disease	ADJ	B
and	I-Disease	CCONJ	O
musculoskeletal	I-Disease	ADJ	B
symptoms	I-Disease	NOUN	O
that	O	PRON	O
appear	O	VERB	O
to	O	PART	O
be	O	AUX	O
ischemic	B-Disease	ADJ	B
in	O	ADP	O
origin	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
might	O	AUX	O
serve	O	VERB	O
to	O	PART	O
warn	O	VERB	O
the	O	DET	O
clinician	O	NOUN	B
of	O	ADP	O
these	O	DET	O
complications	O	NOUN	B
.	O	PUNCT	O


Previous	O	ADJ	O
reports	O	NOUN	B
of	O	ADP	O
these	O	DET	O
phenomena	O	NOUN	B
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
recent	O	ADJ	O
studies	O	NOUN	B
of	O	ADP	O
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
heparin	B-Chemical	NOUN	B
are	O	AUX	O
reviewed	O	VERB	B
.	O	PUNCT	O


The	O	DET	O
common	O	ADJ	O
factor	O	NOUN	B
relating	O	VERB	O
thromboembolism	B-Disease	NOUN	B
and	O	CCONJ	O
thrombocytopenia	B-Disease	NOUN	B
is	O	AUX	O
heparin	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
platelet	B-Disease	NOUN	B
aggregation	I-Disease	NOUN	I
.	O	PUNCT	O


Appropriate	O	ADJ	B
treatment	O	NOUN	B
consists	O	VERB	O
of	O	ADP	O
discontinuation	O	NOUN	B
of	O	ADP	O
heparin	B-Chemical	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
anticoagulation	O	NOUN	B
with	O	ADP	O
sodium	B-Chemical	NOUN	B
warfarin	I-Chemical	NOUN	I


Long	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
prognosis	O	NOUN	B
for	O	ADP	O
transplant	O	NOUN	B
-	O	PUNCT	O
free	O	ADJ	B
survivors	O	NOUN	B
of	O	ADP	O
paracetamol	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
acute	B-Disease	ADJ	B
liver	I-Disease	NOUN	O
failure	I-Disease	NOUN	O
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
:	O	PUNCT	O
The	O	DET	O
prognosis	O	NOUN	B
for	O	ADP	O
transplant	O	NOUN	B
-	O	PUNCT	O
free	O	ADJ	B
survivors	O	NOUN	B
of	O	ADP	O
paracetamol	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
acute	B-Disease	ADJ	B
liver	I-Disease	NOUN	O
failure	I-Disease	NOUN	O
remains	O	VERB	O
unknown	O	ADJ	O
.	O	PUNCT	O


AIM	O	NOUN	B
:	O	PUNCT	O
To	O	PART	O
examine	O	VERB	O
whether	O	SCONJ	O
paracetamol	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
acute	B-Disease	ADJ	B
liver	I-Disease	NOUN	O
failure	I-Disease	NOUN	O
increases	O	VERB	B
long	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
mortality	O	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
:	O	PUNCT	O
We	O	PRON	O
followed	O	VERB	O
up	O	ADP	O
all	O	DET	O
transplant	O	NOUN	B
-	O	PUNCT	O
free	O	ADJ	B
survivors	O	NOUN	B
of	O	ADP	O
paracetamol	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
acute	B-Disease	ADJ	B
liver	I-Disease	NOUN	I
injury	I-Disease	NOUN	I
,	O	PUNCT	O
hospitalized	O	VERB	B
in	O	ADP	O
a	O	DET	O
Danish	O	ADJ	B
national	O	ADJ	I
referral	O	NOUN	I
centre	O	NOUN	I
during	O	ADP	O
1984	O	NUM	O
-	O	SYM	O
2004	O	NUM	O
.	O	PUNCT	O


We	O	PRON	O
compared	O	VERB	O
age	O	NOUN	B
-	O	PUNCT	O
specific	O	ADJ	B
mortality	O	NOUN	B
rates	O	NOUN	I
from	O	ADP	O
1	O	NUM	O
year	O	NOUN	B
post	O	NOUN	B
-	O	PUNCT	O
discharge	O	NOUN	B
through	O	ADP	O
2008	O	NUM	O
between	O	ADP	O
those	O	DET	O
in	O	ADP	O
whom	O	PRON	O
the	O	DET	O
liver	B-Disease	NOUN	B
injury	I-Disease	NOUN	I
led	O	VERB	O
to	O	PART	O
an	O	DET	O
acute	B-Disease	ADJ	B
liver	I-Disease	NOUN	O
failure	I-Disease	NOUN	O
and	O	CCONJ	O
those	O	DET	O
in	O	ADP	O
whom	O	PRON	O
it	O	PRON	O
did	O	AUX	O
not	O	PART	O
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
We	O	PRON	O
included	O	VERB	O
641	O	NUM	O
patients	O	NOUN	B
.	O	PUNCT	O


On	O	ADP	O
average	O	ADJ	B
,	O	PUNCT	O
age	O	NOUN	B
-	O	PUNCT	O
specific	O	ADJ	B
mortality	O	NOUN	B
rates	O	NOUN	I
were	O	AUX	O
slightly	O	ADV	O
higher	O	ADJ	O
for	O	ADP	O
the	O	DET	O
101	O	NUM	O
patients	O	NOUN	B
whose	O	DET	O
paracetamol	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
liver	B-Disease	NOUN	B
injury	I-Disease	NOUN	I
had	O	AUX	O
caused	O	VERB	O
an	O	DET	O
acute	B-Disease	ADJ	B
liver	I-Disease	NOUN	O
failure	I-Disease	NOUN	O
(	O	PUNCT	O
adjusted	O	VERB	O
mortality	O	NOUN	B
rate	O	NOUN	I
ratio	O	NOUN	O
=	O	ADJ	O
1	O	NUM	O
.	O	PUNCT	O


70	O	NUM	O
,	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
1	O	NUM	O
.	O	PUNCT	O


02	O	NUM	O
-	O	SYM	O
2	O	NUM	O
.	O	PUNCT	O


85	O	NUM	O
),	O	PUNCT	O
but	O	CCONJ	O
the	O	DET	O
association	O	NOUN	B
was	O	AUX	O
age	O	NOUN	B
-	O	PUNCT	O
dependent	O	ADJ	B
,	O	PUNCT	O
and	O	CCONJ	O
no	O	DET	O
survivors	O	NOUN	B
of	O	ADP	O
acute	B-Disease	ADJ	B
liver	I-Disease	NOUN	I
failure	I-Disease	NOUN	I
died	O	VERB	B
of	O	ADP	O
liver	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
,	O	PUNCT	O
whereas	O	SCONJ	O
suicides	O	NOUN	B
were	O	AUX	O
frequent	O	ADJ	B
in	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
observations	O	NOUN	B
speak	O	VERB	O
against	O	ADP	O
long	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
effects	O	NOUN	B
of	O	ADP	I
acute	B-Disease	ADJ	B
liver	I-Disease	NOUN	I
failure	I-Disease	NOUN	I
.	O	PUNCT	O


More	O	ADV	O
likely	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
elevated	O	ADJ	B
mortality	O	NOUN	O
rate	O	NOUN	O
ratio	O	NOUN	O
resulted	O	VERB	O
from	O	ADP	O
incomplete	O	ADJ	B
adjustment	O	NOUN	B
for	O	ADP	O
the	O	DET	O
greater	O	ADJ	O
prevalence	O	NOUN	B
of	O	ADP	O
substance	B-Disease	NOUN	B
abuse	I-Disease	NOUN	I
among	O	ADP	O
survivors	O	NOUN	B
of	O	ADP	O
acute	B-Disease	ADJ	B
liver	I-Disease	NOUN	I
failure	I-Disease	NOUN	I
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
:	O	PUNCT	O
Paracetamol	B-Chemical	PROPN	B
-	O	PUNCT	O
induced	O	VERB	B
acute	B-Disease	ADJ	B
liver	I-Disease	NOUN	O
failure	I-Disease	NOUN	O
did	O	AUX	O
not	O	PART	O
affect	O	VERB	O
long	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
mortality	O	NOUN	B
.	O	PUNCT	O


Clinical	O	ADJ	B
follow	O	NOUN	B
-	O	PUNCT	O
up	O	NOUN	O
may	O	AUX	O
be	O	AUX	O
justified	O	VERB	O
by	O	ADP	O
the	O	DET	O
cause	O	NOUN	O
of	O	ADP	O
the	O	DET	O
liver	B-Disease	NOUN	B
failure	I-Disease	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
not	O	PART	O
by	O	ADP	O
the	O	DET	O
liver	B-Disease	NOUN	B
failure	I-Disease	NOUN	I


Serotonin	B-Chemical	NOUN	B
6	O	NUM	I
receptor	O	NOUN	I
gene	O	NOUN	I
is	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
methamphetamine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
psychosis	B-Disease	NOUN	B
in	O	ADP	O
a	O	DET	O
Japanese	O	ADJ	B
population	O	NOUN	B
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
:	O	PUNCT	O
Altered	O	ADJ	O
serotonergic	O	ADJ	B
neural	O	ADJ	B
transmission	O	NOUN	I
is	O	AUX	O
hypothesized	O	VERB	O
to	O	PART	O
be	O	AUX	O
a	O	DET	O
susceptibility	O	NOUN	B
factor	O	NOUN	I
for	O	ADP	O
psychotic	B-Disease	ADJ	B
disorders	I-Disease	NOUN	I
such	O	ADJ	O
as	O	ADP	O
schizophrenia	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
serotonin	B-Chemical	NOUN	B
6	O	NUM	I
(	O	PUNCT	O
5-HT	B-Chemical	NOUN	B
6	O	NUM	O
)	O	PUNCT	O
receptor	O	NOUN	O
is	O	AUX	O
therapeutically	O	ADV	B
targeted	O	VERB	B
by	O	ADP	O
several	O	ADJ	O
second	O	ADJ	O
generation	O	NOUN	O
antipsychotics	O	NOUN	B
,	O	PUNCT	O
such	O	ADJ	O
as	O	ADP	O
clozapine	B-Chemical	NOUN	B
and	O	CCONJ	O
olanzapine	B-Chemical	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
d-amphetamine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
hyperactivity	B-Disease	NOUN	B
in	O	ADP	O
rats	O	NOUN	B
is	O	AUX	O
corrected	O	VERB	O
with	O	ADP	O
the	O	DET	O
use	O	NOUN	O
of	O	ADP	O
a	O	DET	O
selective	O	ADJ	O
5-HT	B-Chemical	NOUN	O
6	O	NUM	O
receptor	O	NOUN	B
antagonist	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
,	O	PUNCT	O
the	O	DET	O
disrupted	O	ADJ	B
prepulse	O	NOUN	B
inhibition	O	NOUN	I
induced	O	VERB	B
by	O	ADP	O
d-amphetamine	B-Chemical	NOUN	B
or	O	CCONJ	O
phencyclidine	B-Chemical	NOUN	B
was	O	AUX	O
restored	O	VERB	B
by	O	ADP	O
5-HT	B-Chemical	NOUN	B
6	O	NUM	O
receptor	O	NOUN	B
antagonist	O	NOUN	I
in	O	ADP	O
an	O	DET	O
animal	O	NOUN	B
study	O	NOUN	I
using	O	VERB	O
rats	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
animal	O	NOUN	B
models	O	NOUN	I
were	O	AUX	O
considered	O	VERB	O
to	O	PART	O
reflect	O	VERB	O
the	O	DET	O
positive	O	ADJ	B
symptoms	O	NOUN	B
of	O	ADP	O
schizophrenia	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
above	O	ADJ	O
evidence	O	NOUN	B
suggests	O	VERB	O
that	O	SCONJ	O
altered	O	ADJ	O
5-HT	B-Chemical	NOUN	B
6	O	NUM	O
receptors	O	NOUN	B
are	O	AUX	O
involved	O	VERB	O
in	O	ADP	O
the	O	DET	O
pathophysiology	O	NOUN	B
of	O	ADP	O
psychotic	B-Disease	ADJ	B
disorders	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
symptoms	O	NOUN	B
of	O	ADP	O
methamphetamine	B-Chemical	NOUN	B
(	O	PUNCT	O
METH	B-Chemical	NOUN	B
)-	O	ADJ	O
induced	O	VERB	B
psychosis	B-Disease	NOUN	B
are	O	AUX	O
similar	O	ADJ	O
to	O	PART	O
those	O	DET	O
of	O	ADP	O
paranoid	B-Disease	ADJ	B
type	I-Disease	NOUN	O
schizophrenia	I-Disease	NOUN	B
.	O	PUNCT	O


Therefore	O	ADV	O
,	O	PUNCT	O
we	O	PRON	O
conducted	O	VERB	O
an	O	DET	O
analysis	O	NOUN	B
of	O	ADP	O
the	O	DET	O
association	O	NOUN	B
of	O	ADP	O
the	O	DET	O
5-HT	B-Chemical	NOUN	B
6	O	NUM	O
gene	O	NOUN	B
(	O	PUNCT	O
HTR6	O	NOUN	B
)	O	PUNCT	O
with	O	ADP	O
METH	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
psychosis	B-Disease	NOUN	B
.	O	PUNCT	O


METHOD	O	NOUN	B
:	O	PUNCT	O
Using	O	VERB	O
five	O	NUM	O
tagging	O	VERB	B
SNPs	O	NOUN	B
(	O	PUNCT	O
rs6693503	O	NOUN	B
,	O	PUNCT	O
rs1805054	O	NOUN	B
,	O	PUNCT	O
rs4912138	O	PROPN	B
,	O	PUNCT	O
rs3790757	O	NOUN	B
and	O	CCONJ	O
rs9659997	O	PROPN	B
),	O	PUNCT	O
we	O	PRON	O
conducted	O	VERB	O
a	O	DET	O
genetic	O	ADJ	B
association	O	NOUN	O
analysis	O	NOUN	O
of	O	ADP	O
case	O	NOUN	B
-	O	PUNCT	O
control	O	NOUN	B
samples	O	NOUN	O
(	O	PUNCT	O
197	O	NUM	O
METH	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
psychosis	B-Disease	NOUN	B
patients	O	NOUN	B
and	O	CCONJ	O
337	O	NUM	O
controls	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
Japanese	O	ADJ	B
population	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
age	O	NOUN	B
and	O	CCONJ	O
sex	O	NOUN	B
of	O	ADP	O
the	O	DET	O
control	O	ADJ	B
subjects	O	NOUN	I
did	O	AUX	O
not	O	PART	O
differ	O	VERB	O
from	O	ADP	O
those	O	DET	O
of	O	ADP	O
the	O	DET	O
methamphetamine	B-Chemical	NOUN	B
dependence	O	NOUN	O
patients	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
rs6693503	O	NOUN	B
was	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
METH	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
psychosis	B-Disease	NOUN	B
patients	O	NOUN	B
in	O	ADP	O
the	O	DET	O
allele	O	NOUN	B
/	O	SYM	O
genotype	O	NOUN	B
-	O	PUNCT	O
wise	O	ADJ	O
analysis	O	NOUN	B
.	O	PUNCT	O


Moreover	O	ADV	O
,	O	PUNCT	O
this	O	DET	O
association	O	NOUN	B
remained	O	VERB	O
significant	O	ADJ	O
after	O	ADP	O
Bonferroni	O	NOUN	B
correction	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
haplotype	O	NOUN	B
-	O	PUNCT	O
wise	O	ADJ	O
analysis	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
detected	O	VERB	B
an	O	DET	O
association	O	NOUN	B
between	O	ADP	O
two	O	NUM	O
markers	O	NOUN	B
(	O	PUNCT	O
rs6693503	O	NOUN	B
and	O	CCONJ	O
rs1805054	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
three	O	NUM	O
markers	O	NOUN	B
(	O	PUNCT	O
rs6693503	O	NOUN	B
,	O	PUNCT	O
rs1805054	O	NOUN	B
and	O	CCONJ	O
rs4912138	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
HTR6	O	NOUN	B
and	O	CCONJ	O
METH	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
psychosis	B-Disease	NOUN	B
patients	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
:	O	PUNCT	O
HTR6	O	NOUN	B
may	O	AUX	O
play	O	VERB	O
an	O	DET	O
important	O	ADJ	O
role	O	NOUN	O
in	O	ADP	O
the	O	DET	O
pathophysiology	O	NOUN	B
of	O	ADP	O
METH	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
psychosis	B-Disease	NOUN	B


Effect	O	NOUN	B
of	O	ADP	O
increasing	O	VERB	B
intraperitoneal	O	ADJ	B
infusion	O	NOUN	B
rates	O	NOUN	B
on	O	ADP	O
bupropion	B-Chemical	NOUN	B
hydrochloride	I-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
seizures	B-Disease	NOUN	B
in	O	ADP	O
mice	O	NOUN	B
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
:	O	PUNCT	O
It	O	PRON	O
is	O	AUX	O
not	O	PART	O
known	O	VERB	O
if	O	SCONJ	O
there	O	PRON	O
is	O	AUX	O
a	O	DET	O
relationship	O	NOUN	B
between	O	ADP	O
input	O	NOUN	B
rate	O	NOUN	B
and	O	CCONJ	O
incidence	O	NOUN	B
of	O	ADP	O
bupropion	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
seizures	B-Disease	NOUN	B
.	O	PUNCT	O


This	O	DET	O
is	O	AUX	O
important	O	ADJ	O
,	O	PUNCT	O
since	O	SCONJ	O
different	O	ADJ	O
controlled	O	VERB	B
release	O	NOUN	I
formulations	O	NOUN	B
of	O	ADP	O
bupropion	B-Chemical	NOUN	B
release	O	VERB	B
the	O	DET	O
active	O	ADJ	B
drug	O	NOUN	I
at	O	ADP	O
different	O	ADJ	O
rates	O	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
:	O	PUNCT	O
We	O	PRON	O
investigated	O	VERB	B
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
varying	O	VERB	O
the	O	DET	O
intraperitoneal	O	ADJ	B
infusion	O	NOUN	B
rates	O	NOUN	B
of	O	ADP	O
bupropion	B-Chemical	NOUN	B
HCl	I-Chemical	NOUN	B
120	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
known	O	ADJ	O
convulsive	B-Disease	ADJ	B
dose	O	NOUN	I
50	O	NUM	O
(	O	PUNCT	O
CD50	O	NOUN	B
),	O	PUNCT	O
on	O	ADP	O
the	O	DET	O
incidence	O	NOUN	B
and	O	CCONJ	O
severity	O	NOUN	B
of	O	ADP	O
bupropion	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
convulsions	B-Disease	NOUN	B
in	O	ADP	O
the	O	DET	O
Swiss	O	ADJ	B
albino	O	NOUN	I
mice	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
total	O	NOUN	O
of	O	ADP	O
69	O	NUM	O
mice	O	NOUN	B
,	O	PUNCT	O
approximately	O	ADV	O
7	O	NUM	O
weeks	O	NOUN	B
of	O	ADP	O
age	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
weighing	O	VERB	B
21	O	NUM	I
.	O	PUNCT	O


0	O	NUM	O
to	O	PART	O
29	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
g	O	NOUN	O
were	O	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
to	O	PART	O
bupropion	B-Chemical	NOUN	B
HCl	I-Chemical	NOUN	B
120	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
treatment	O	NOUN	B
by	O	ADP	O
intraperitoneal	O	NOUN	B
(	O	PUNCT	O
IP	O	NOUN	B
)	O	PUNCT	O
administration	O	NOUN	B
in	O	ADP	O
7	O	NUM	O
groups	O	NOUN	B
(	O	PUNCT	O
9	O	NUM	O
to	O	PART	O
10	O	NUM	O
animals	O	NOUN	B
per	O	ADP	O
group	O	NOUN	B
).	O	PUNCT	B
Bupropion	B-Chemical	NOUN	B
HCl	I-Chemical	NOUN	B
was	O	AUX	O
infused	O	VERB	B
through	O	ADP	O
a	O	DET	O
surgically	O	ADV	B
implanted	O	VERB	I
IP	O	NOUN	B
dosing	O	NOUN	B
catheter	O	NOUN	B
with	O	ADP	O
infusions	O	NOUN	B
in	O	ADP	O
each	O	DET	O
group	O	NOUN	B
of	O	ADP	O
0	O	NUM	O
min	O	NOUN	B
,	O	PUNCT	O
15	O	NUM	O
min	O	NOUN	O
,	O	PUNCT	O
30	O	NUM	O
min	O	NOUN	O
,	O	PUNCT	O
60	O	NUM	O
min	O	NOUN	O
,	O	PUNCT	O
90	O	NUM	O
min	O	NOUN	O
,	O	PUNCT	O
120	O	NUM	O
min	O	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
240	O	NUM	O
min	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
number	O	NOUN	O
,	O	PUNCT	O
time	O	NOUN	B
of	O	ADP	I
onset	O	NOUN	I
,	O	PUNCT	O
duration	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
intensity	O	NOUN	B
of	O	ADP	O
the	O	DET	O
convulsions	B-Disease	NOUN	B
or	O	CCONJ	O
absence	O	NOUN	B
of	O	ADP	O
convulsions	B-Disease	NOUN	B
were	O	AUX	O
recorded	O	VERB	O
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
The	O	DET	O
results	O	NOUN	B
showed	O	VERB	O
that	O	SCONJ	O
IP	O	NOUN	B
administration	O	NOUN	B
of	O	ADP	O
bupropion	B-Chemical	NOUN	B
HCl	I-Chemical	NOUN	B
120	O	NUM	O
mg	O	NOUN	O
/	O	PUNCT	O
kg	O	NOUN	O
by	O	ADP	O
bolus	O	NOUN	B
injection	O	NOUN	I
induced	O	VERB	B
convulsions	B-Disease	NOUN	B
in	O	ADP	O
6	O	NUM	O
out	O	ADP	O
of	O	ADP	O
10	O	NUM	O
mice	O	NOUN	B
(	O	PUNCT	O
60	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
convulsing	O	VERB	B
mice	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
group	O	NOUN	B
1	O	NUM	I
.	O	PUNCT	O


Logistic	O	ADJ	B
regression	O	NOUN	I
analysis	O	NOUN	I
revealed	O	VERB	O
that	O	SCONJ	O
infusion	O	NOUN	B
time	O	NOUN	B
was	O	AUX	O
significant	O	ADJ	B
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


0004	O	NUM	O
;	O	PUNCT	O
odds	O	NOUN	B
ratio	O	NOUN	I
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


974	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
increasing	O	VERB	B
the	O	DET	O
IP	O	NOUN	B
infusion	O	NOUN	B
time	O	NOUN	B
of	O	ADP	O
bupropion	B-Chemical	NOUN	B
HCl	I-Chemical	NOUN	B
120	O	NUM	O
mg	O	NOUN	O
/	O	PUNCT	O
kg	O	NOUN	B
was	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
a	O	DET	O
91	O	NUM	O
%	O	NOUN	O
reduced	O	VERB	B
odds	O	NOUN	B
of	O	ADP	O
convulsions	B-Disease	NOUN	B
at	O	ADP	O
infusion	O	NOUN	B
times	O	NOUN	O
of	O	ADP	O
15	O	NUM	O
to	O	PART	O
90	O	NUM	O
min	O	NOUN	O
compared	O	VERB	O
to	O	PART	O
bolus	O	NOUN	B
injection	O	NOUN	I
.	O	PUNCT	O


Further	O	ADJ	O
increase	O	NOUN	B
in	O	ADP	O
infusion	O	NOUN	B
time	O	NOUN	B
resulted	O	VERB	O
in	O	ADP	O
further	O	ADJ	O
reduction	O	NOUN	B
in	O	ADP	O
the	O	DET	O
odds	O	NOUN	B
of	O	ADP	O
convulsions	B-Disease	NOUN	B
to	O	ADP	O
99	O	NUM	O
.	O	PUNCT	O


8	O	NUM	O
%	O	NOUN	O
reduction	O	NOUN	B
at	O	ADP	O
240	O	NUM	O
min	O	NOUN	O
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
:	O	PUNCT	O
In	O	ADP	O
conclusion	O	NOUN	O
,	O	PUNCT	O
the	O	DET	O
demonstration	O	NOUN	B
of	O	ADP	O
an	O	DET	O
inverse	O	ADJ	B
relationship	O	NOUN	B
between	O	ADP	O
infusion	O	NOUN	B
time	O	NOUN	B
of	O	ADP	O
a	O	DET	O
fixed	O	ADJ	B
and	O	CCONJ	O
convulsive	B-Disease	ADJ	B
dose	O	NOUN	I
of	O	ADP	O
bupropion	B-Chemical	NOUN	B
and	O	CCONJ	O
the	O	DET	O
risk	O	NOUN	B
of	O	ADP	O
convulsions	B-Disease	NOUN	B


Detailed	O	ADJ	O
spectral	O	ADJ	B
profile	O	NOUN	I
analysis	O	NOUN	I
of	O	ADP	O
penicillin	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
epileptiform	B-Disease	NOUN	B
activity	I-Disease	NOUN	I
in	O	ADP	O
anesthetized	O	ADJ	B
rats	O	NOUN	B
.	O	PUNCT	O


Penicillin	B-Chemical	NOUN	B
model	O	NOUN	B
is	O	AUX	O
a	O	DET	O
widely	O	ADV	O
used	O	VERB	O
experimental	O	ADJ	B
model	O	NOUN	I
for	O	ADP	O
epilepsy	B-Disease	NOUN	B
research	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
we	O	PRON	O
aimed	O	VERB	O
to	O	PART	O
portray	O	VERB	O
a	O	DET	O
detailed	O	ADJ	O
spectral	O	ADJ	B
analysis	O	NOUN	I
of	O	ADP	O
penicillin	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
epileptiform	B-Disease	NOUN	B
activity	I-Disease	NOUN	I
in	O	ADP	O
comparison	O	NOUN	B
with	O	ADP	O
basal	O	ADJ	B
brain	O	NOUN	I
activity	O	NOUN	I
in	O	ADP	O
anesthetized	O	VERB	B
Wistar	O	ADJ	B
rats	O	NOUN	I
.	O	PUNCT	O


Male	O	NOUN	B
Wistar	O	PROPN	B
rats	O	NOUN	I
were	O	AUX	O
anesthetized	O	VERB	B
with	O	ADP	O
i	O	PRON	O
.	O	PUNCT	O


p	O	NOUN	O
.	O	PUNCT	O


urethane	B-Chemical	NOUN	B
and	O	CCONJ	O
connected	O	VERB	O
to	O	ADP	O
an	O	DET	O
electrocorticogram	O	NOUN	B
setup	O	NOUN	B
.	O	PUNCT	O


After	O	ADP	O
a	O	DET	O
short	O	ADJ	O
period	O	NOUN	B
of	O	ADP	O
basal	O	ADJ	B
activity	O	NOUN	I
recording	O	NOUN	O
,	O	PUNCT	O
epileptic	B-Disease	ADJ	B
focus	O	NOUN	I
was	O	AUX	O
induced	O	VERB	B
by	O	ADP	O
injecting	O	VERB	B
400IU	O	PROPN	B
/	O	SYM	O
2	O	NUM	B
microl	O	NOUN	B
penicillin-G	B-Chemical	ADJ	B
potassium	I-Chemical	NOUN	B
into	O	ADP	O
the	O	DET	O
left	O	ADJ	B
lateral	O	ADJ	I
ventricle	O	NOUN	I
while	O	SCONJ	O
the	O	DET	O
cortical	O	ADJ	B
activity	O	NOUN	I
was	O	AUX	O
continuously	O	ADV	O
recorded	O	VERB	O
.	O	PUNCT	O


Basal	O	ADJ	B
activity	O	NOUN	I
,	O	PUNCT	O
latent	O	ADJ	B
period	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
penicillin	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
epileptiform	B-Disease	NOUN	B
activity	I-Disease	NOUN	I
periods	O	NOUN	B
were	O	AUX	O
then	O	ADV	O
analyzed	O	VERB	B
using	O	VERB	O
both	O	CCONJ	O
conventional	O	ADJ	B
methods	O	NOUN	O
and	O	CCONJ	O
spectral	O	ADJ	B
analysis	O	NOUN	I
.	O	PUNCT	O


Spectral	O	ADJ	B
analyses	O	NOUN	I
were	O	AUX	O
conducted	O	VERB	O
by	O	ADP	O
dividing	O	VERB	O
the	O	DET	O
whole	O	ADJ	O
spectrum	O	NOUN	B
into	O	ADP	O
different	O	ADJ	O
frequency	O	NOUN	B
bands	O	NOUN	I
including	O	VERB	O
delta	O	NOUN	B
,	O	PUNCT	O
theta	O	NOUN	B
(	O	PUNCT	O
slow	O	ADJ	B
and	O	CCONJ	O
fast	O	ADJ	B
),	O	PUNCT	O
alpha	O	NOUN	B
-	O	PUNCT	O
sigma	O	NOUN	B
,	O	PUNCT	O
beta	O	NOUN	B
(	O	PUNCT	O
1	O	NUM	O
and	O	CCONJ	O
2	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
gamma	O	NOUN	B
(	O	PUNCT	O
1	O	NUM	O
and	O	CCONJ	O
2	O	NUM	O
)	O	PUNCT	O
bands	O	NOUN	O
.	O	PUNCT	O


Our	O	PRON	O
results	O	NOUN	B
show	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
most	O	ADV	O
affected	O	VERB	B
frequency	O	NOUN	B
bands	O	NOUN	I
were	O	AUX	O
delta	O	NOUN	B
,	O	PUNCT	O
theta	O	NOUN	B
,	O	PUNCT	O
beta	O	NOUN	B
-	O	PUNCT	O
2	O	NUM	O
and	O	CCONJ	O
gamma	O	NOUN	B
-	O	PUNCT	O
2	O	NUM	O
bands	O	NOUN	B
during	O	ADP	O
the	O	DET	O
epileptiform	B-Disease	NOUN	B
activity	I-Disease	NOUN	I
and	O	CCONJ	O
there	O	PRON	O
were	O	AUX	O
marked	O	ADJ	O
differences	O	NOUN	O
in	O	ADP	O
terms	O	NOUN	O
of	O	ADP	O
spectral	O	ADJ	B
densities	O	NOUN	B
between	O	ADP	O
three	O	NUM	O
investigated	O	VERB	B
episodes	O	NOUN	B
(	O	PUNCT	O
basal	O	ADJ	B
activity	O	NOUN	I
,	O	PUNCT	O
latent	O	ADJ	B
period	O	NOUN	B
and	O	CCONJ	O
epileptiform	B-Disease	NOUN	B
activity	I-Disease	NOUN	I
).	O	PUNCT	O
Our	O	PRON	O
results	O	NOUN	B
may	O	AUX	O
help	O	VERB	O
to	O	PART	O
analyze	O	VERB	O
novel	O	ADJ	B
data	O	NOUN	B
obtained	O	VERB	O
using	O	VERB	O
similar	O	ADJ	O
experimental	O	ADJ	B
models	O	NOUN	I
and	O	CCONJ	O
the	O	DET	O
simple	O	ADJ	B
analysis	O	NOUN	I
method	O	NOUN	I
described	O	VERB	O
here	O	ADV	O
can	O	AUX	O
be	O	AUX	O
used	O	VERB	O
in	O	ADP	O
similar	O	ADJ	O
studies	O	NOUN	B
to	O	PART	O
investigate	O	VERB	B
the	O	DET	O
basic	O	ADJ	O
neuronal	O	ADJ	B
mechanism	O	NOUN	B
of	O	ADP	O
this	O	DET	O
or	O	CCONJ	O
other	O	ADJ	O
types	O	NOUN	O
of	O	ADP	O
experimental	O	ADJ	B
epilepsies	B-Disease	NOUN	I


High	O	ADJ	B
dose	O	NOUN	I
dexmedetomidine	B-Chemical	NOUN	B
as	O	ADP	O
the	O	DET	O
sole	O	ADJ	O
sedative	O	ADJ	B
for	O	ADP	O
pediatric	O	ADJ	B
MRI	O	NOUN	B
.	O	PUNCT	O


OBJECTIVE	O	NOUN	O
:	O	PUNCT	O
This	O	DET	O
large	O	ADJ	B
-	O	PUNCT	O
scale	O	NOUN	B
retrospective	O	ADJ	B
review	O	NOUN	I
evaluates	O	VERB	O
the	O	DET	O
sedation	O	NOUN	B
profile	O	NOUN	O
of	O	ADP	O
dexmedetomidine	B-Chemical	NOUN	B
.	O	PUNCT	O


AIM	O	NOUN	B
:	O	PUNCT	O
To	O	PART	O
determine	O	VERB	O
the	O	DET	O
hemodynamic	O	ADJ	B
responses	O	NOUN	O
,	O	PUNCT	O
efficacy	O	NOUN	B
and	O	CCONJ	O
adverse	O	ADJ	B
events	O	NOUN	I
associated	O	VERB	B
with	O	ADP	I
the	O	DET	O
use	O	NOUN	O
of	O	ADP	O
high	O	ADJ	B
dose	O	NOUN	I
dexmedetomidine	B-Chemical	NOUN	B
as	O	ADP	O
the	O	DET	O
sole	O	ADJ	O
sedative	O	ADJ	B
for	O	ADP	O
magnetic	O	ADJ	B
resonance	O	NOUN	I
imaging	O	NOUN	I
(	O	PUNCT	O
MRI	O	NOUN	B
)	O	PUNCT	O
studies	O	NOUN	B
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
:	O	PUNCT	O
Dexmedetomidine	B-Chemical	NOUN	B
has	O	AUX	O
been	O	AUX	O
used	O	VERB	O
at	O	ADP	O
our	O	PRON	O
institution	O	NOUN	B
since	O	SCONJ	O
2005	O	NUM	O
to	O	PART	O
provide	O	VERB	O
sedation	O	NOUN	B
for	O	ADP	O
pediatric	O	ADJ	B
radiological	O	ADJ	O
imaging	O	NOUN	O
studies	O	NOUN	O
.	O	PUNCT	O


Over	O	ADP	O
time	O	NOUN	B
,	O	PUNCT	O
an	O	DET	O
effective	O	ADJ	B
protocol	O	NOUN	B
utilizing	O	VERB	O
high	O	ADJ	B
dose	O	NOUN	I
dexmedetomidine	B-Chemical	NOUN	B
as	O	ADP	O
the	O	DET	O
sole	O	ADJ	O
sedative	O	ADJ	B
agent	O	NOUN	I
has	O	AUX	O
evolved	O	VERB	O
.	O	PUNCT	O


METHODS	O	NOUN	B
/	O	SYM	O
MATERIALS	O	NOUN	B
:	O	PUNCT	O
As	O	ADP	O
part	O	NOUN	O
of	O	ADP	O
the	O	DET	O
ongoing	O	ADJ	O
Quality	O	PROPN	B
Assurance	O	PROPN	I
process	O	NOUN	I
,	O	PUNCT	O
data	O	NOUN	B
on	O	ADP	O
all	O	DET	O
sedations	O	NOUN	B
are	O	AUX	O
reviewed	O	VERB	B
monthly	O	ADV	B
and	O	CCONJ	O
protocols	O	NOUN	B
modified	O	VERB	B
as	O	ADP	O
needed	O	VERB	O
.	O	PUNCT	O


Data	O	NOUN	B
were	O	AUX	O
analyzed	O	VERB	B
from	O	ADP	O
all	O	DET	O
747	O	NUM	O
consecutive	O	ADJ	B
patients	O	NOUN	B
who	O	PRON	O
received	O	VERB	O
dexmedetomidine	B-Chemical	NOUN	B
for	O	ADP	O
MRI	O	NOUN	B
sedation	O	NOUN	B
from	O	ADP	O
April	O	PROPN	O
2005	O	NUM	O
to	O	ADP	O
April	O	PROPN	O
2007	O	NUM	O
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
Since	O	SCONJ	O
2005	O	NUM	O
,	O	PUNCT	O
the	O	DET	O
10	O	NUM	O
-	O	PUNCT	O
min	O	NOUN	B
loading	O	NOUN	B
dose	O	NOUN	I
of	O	ADP	O
our	O	PRON	O
dexmedetomidine	B-Chemical	NOUN	B
protocol	O	NOUN	B
increased	O	VERB	B
from	O	ADP	O
2	O	NUM	O
to	O	PART	O
3	O	NUM	O
microg	O	NOUN	B
.	O	PUNCT	O


kg	O	NOUN	O
(-	O	PUNCT	O
1	O	NUM	O
),	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
infusion	O	NOUN	B
rate	O	NOUN	B
increased	O	VERB	B
from	O	ADP	O
1	O	NUM	O
to	O	PART	O
1	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
to	O	PART	O
2	O	NUM	O
microg	O	NOUN	B
.	O	PUNCT	O


kg	O	NOUN	O
(-	O	PUNCT	O
1	O	NUM	O
).	O	ADJ	O
h	O	NOUN	O
(-	O	PUNCT	O
1	O	NUM	O
).	O	PUNCT	O
The	O	DET	O
current	O	ADJ	O
sedation	O	NOUN	B
protocol	O	NOUN	O
progressively	O	ADV	O
increased	O	VERB	B
the	O	DET	O
rate	O	NOUN	B
of	O	ADP	O
successful	O	ADJ	O
sedation	O	NOUN	B
(	O	PUNCT	O
able	O	ADJ	O
to	O	PART	O
complete	O	VERB	O
the	O	DET	O
imaging	O	NOUN	B
study	O	NOUN	I
)	O	PUNCT	O
when	O	SCONJ	O
using	O	VERB	O
dexmedetomidine	B-Chemical	NOUN	B
alone	O	ADV	O
from	O	ADP	O
91	O	NUM	O
.	O	PUNCT	O


8	O	NUM	O
%	O	NOUN	O
to	O	PART	O
97	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
%(	O	NOUN	O
P	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


009	O	NUM	O
),	O	PUNCT	O
reducing	O	VERB	B
the	O	DET	O
requirement	O	NOUN	B
for	O	ADP	O
adjuvant	O	ADJ	B
pentobarbital	B-Chemical	NOUN	B
in	O	ADP	O
the	O	DET	O
event	O	NOUN	B
of	O	ADP	O
sedation	O	NOUN	B
failure	O	NOUN	O
with	O	ADP	O
dexmedetomidine	B-Chemical	NOUN	B
alone	O	ADV	O
and	O	CCONJ	O
decreased	O	VERB	B
the	O	DET	O
mean	O	ADJ	O
recovery	O	NOUN	B
time	O	NOUN	O
by	O	ADP	O
10	O	NUM	O
min	O	NOUN	O
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


001	O	NUM	O
).	O	PUNCT	O
Although	O	SCONJ	O
dexmedetomidine	B-Chemical	NOUN	B
sedation	O	NOUN	B
was	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
a	O	DET	O
16	O	NUM	O
%	O	NOUN	O
incidence	O	NOUN	B
of	O	ADP	O
bradycardia	B-Disease	NOUN	B
,	O	PUNCT	O
all	O	DET	O
concomitant	O	ADJ	B
mean	O	ADJ	O
arterial	O	ADJ	B
blood	O	NOUN	I
pressures	O	NOUN	I
were	O	AUX	O
within	O	ADP	O
20	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
age	O	NOUN	B
-	O	PUNCT	O
adjusted	O	VERB	B
normal	O	ADJ	O
range	O	NOUN	O
and	O	CCONJ	O
oxygen	B-Chemical	NOUN	B
saturations	O	NOUN	I
were	O	AUX	O
95	O	NUM	O
%	O	NOUN	O
or	O	CCONJ	O
higher	O	ADJ	B
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
:	O	PUNCT	O
Dexmedetomidine	B-Chemical	NOUN	B
in	O	ADP	O
high	O	ADJ	B
doses	O	NOUN	I
provides	O	VERB	O
adequate	O	ADJ	B
sedation	O	NOUN	B
for	O	ADP	O
pediatric	O	ADJ	B
MRI	O	NOUN	B
studies	O	NOUN	O
.	O	PUNCT	O


While	O	SCONJ	O
use	O	NOUN	O
of	O	ADP	O
high	O	ADJ	B
dose	O	NOUN	I
dexmedetomidine	B-Chemical	NOUN	B
is	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
decreases	O	NOUN	B
in	O	ADP	O
heart	O	NOUN	B
rate	O	NOUN	I
and	O	CCONJ	O
blood	O	NOUN	B
pressure	O	NOUN	I
outside	O	ADP	O
the	O	DET	O
established	O	ADJ	B
'	O	PUNCT	O
awake	O	ADJ	B
'	O	PUNCT	O
norms	O	NOUN	B
,	O	PUNCT	O
this	O	DET	O
deviation	O	NOUN	B
is	O	AUX	O
generally	O	ADV	O
within	O	ADP	O
20	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
norms	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
is	O	AUX	O
not	O	PART	O
associated	O	VERB	B
with	O	ADP	I
adverse	O	ADJ	B
sequelae	O	NOUN	I
.	O	PUNCT	O


Dexmedetomidine	B-Chemical	NOUN	B


Methamphetamine	B-Chemical	NOUN	B
causes	O	VERB	O
alterations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
MAP	O	NOUN	B
kinase	O	NOUN	I
-	O	PUNCT	O
related	O	VERB	B
pathways	O	NOUN	B
in	O	ADP	O
the	O	DET	O
brains	O	NOUN	B
of	O	ADP	O
mice	O	NOUN	B
that	O	PRON	O
display	O	VERB	B
increased	O	VERB	B
aggressiveness	B-Disease	NOUN	B
.	O	PUNCT	O


Aggressive	B-Disease	ADJ	B
behaviors	I-Disease	NOUN	I
have	O	AUX	O
been	O	AUX	O
reported	O	VERB	O
in	O	ADP	O
patients	O	NOUN	B
who	O	PRON	O
suffer	O	VERB	O
from	O	ADP	O
some	O	DET	O
psychiatric	B-Disease	ADJ	B
disorders	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
are	O	AUX	O
common	O	ADJ	O
in	O	ADP	O
methamphetamine	B-Chemical	NOUN	B
(	O	PUNCT	O
METH	B-Chemical	NOUN	B
)	O	PUNCT	O
abusers	O	NOUN	B
.	O	PUNCT	O


Herein	O	ADV	O
,	O	PUNCT	O
we	O	PRON	O
report	O	VERB	O
that	O	SCONJ	O
multiple	O	ADJ	B
(	O	PUNCT	O
but	O	CCONJ	O
not	O	PART	O
single	O	ADJ	O
)	O	PUNCT	O
injections	O	NOUN	B
of	O	ADP	O
METH	B-Chemical	NOUN	B
significantly	O	ADV	O
increased	O	VERB	B
aggressiveness	B-Disease	NOUN	B
in	O	ADP	O
male	O	ADJ	B
CD	O	PROPN	B
-	O	PUNCT	O
1	O	NUM	O
mice	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
increase	O	NOUN	B
in	O	ADP	O
aggressiveness	B-Disease	NOUN	B
was	O	AUX	O
not	O	PART	O
secondary	O	ADJ	O
to	O	PART	O
METH	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
hyperactivity	B-Disease	NOUN	B
.	O	PUNCT	O


Analysis	O	NOUN	B
of	O	ADP	O
protein	O	NOUN	B
expression	O	NOUN	I
using	O	VERB	O
antibody	O	NOUN	B
microarrays	O	NOUN	I
and	O	CCONJ	O
Western	O	NOUN	B
blotting	O	NOUN	I
revealed	O	VERB	O
differential	O	ADJ	O
changes	O	NOUN	O
in	O	ADP	O
MAP	O	NOUN	B
kinase	O	NOUN	I
-	O	PUNCT	O
related	O	VERB	B
pathways	O	NOUN	B
after	O	ADP	O
multiple	O	ADJ	B
and	O	CCONJ	O
single	O	ADJ	O
METH	B-Chemical	NOUN	B
injections	O	NOUN	B
.	O	PUNCT	O


There	O	PRON	O
were	O	AUX	O
statistically	O	ADV	B
significant	O	ADJ	I
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


05	O	NUM	O
)	O	PUNCT	O
decreases	O	VERB	B
in	O	ADP	O
MEK1	O	NOUN	B
,	O	PUNCT	O
Erk2p	O	NOUN	B
,	O	PUNCT	O
GSK3alpha	O	NOUN	B
,	O	PUNCT	O
14	O	NUM	O
-	O	PUNCT	O
3	O	NUM	O
-	O	PUNCT	O
3e	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
MEK7	O	NOUN	B
in	O	ADP	O
the	O	DET	O
striata	O	NOUN	B
of	O	ADP	O
mice	O	NOUN	B
after	O	ADP	O
multiple	O	ADJ	O
injections	O	NOUN	B
of	O	ADP	O
METH	B-Chemical	NOUN	B
.	O	PUNCT	O


MEK1	O	NOUN	B
was	O	AUX	O
significantly	O	ADV	O
decreased	O	VERB	B
also	O	ADV	O
after	O	ADP	O
a	O	DET	O
single	O	ADJ	O
injection	O	NOUN	B
of	O	ADP	O
METH	B-Chemical	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
to	O	ADP	O
a	O	DET	O
much	O	ADV	O
lesser	O	ADJ	B
degree	O	NOUN	B
than	O	ADP	O
after	O	ADP	O
multiple	O	ADJ	B
injections	O	NOUN	B
of	O	ADP	O
METH	B-Chemical	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
frontal	O	ADJ	B
cortex	O	NOUN	I
,	O	PUNCT	O
there	O	PRON	O
was	O	AUX	O
a	O	DET	O
statistically	O	ADV	B
significant	O	ADJ	I
decrease	O	NOUN	B
in	O	ADP	O
GSK3alpha	O	NOUN	B
after	O	ADP	O
multiple	O	ADJ	B
(	O	PUNCT	O
but	O	CCONJ	O
not	O	PART	O
single	O	ADJ	O
)	O	PUNCT	O
injections	O	NOUN	B
of	O	ADP	O
METH	B-Chemical	NOUN	B
.	O	PUNCT	O


These	O	DET	O
findings	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
alterations	O	NOUN	B
in	O	ADP	O
MAP	O	NOUN	B
kinase	O	NOUN	I
-	O	PUNCT	O
related	O	VERB	B
pathways	O	NOUN	B
in	O	ADP	O
the	O	DET	O
prefronto	O	NOUN	B
-	O	PUNCT	O
striatal	O	ADJ	B
circuitries	O	NOUN	B
might	O	AUX	O
be	O	AUX	O
involved	O	VERB	O
in	O	ADP	O
the	O	DET	O
manifestation	O	NOUN	B
of	O	ADP	O
aggressive	B-Disease	ADJ	B
behaviors	I-Disease	NOUN	I


Lamotrigine	B-Chemical	NOUN	B
associated	O	VERB	B
with	O	ADP	I
exacerbation	O	NOUN	B
or	O	CCONJ	O
de	O	X	B
novo	O	X	I
myoclonus	B-Disease	NOUN	B
in	O	ADP	O
idiopathic	B-Disease	ADJ	B
generalized	I-Disease	VERB	I
epilepsies	I-Disease	NOUN	I
.	O	PUNCT	O


Five	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
idiopathic	B-Disease	ADJ	B
generalized	I-Disease	VERB	I
epilepsies	I-Disease	NOUN	I
(	O	PUNCT	O
IGE	B-Disease	NOUN	B
)	O	PUNCT	O
treated	O	VERB	B
with	O	ADP	I
lamotrigine	B-Chemical	NOUN	B
(	O	PUNCT	O
LTG	B-Chemical	NOUN	B
)	O	PUNCT	O
experienced	O	VERB	O
exacerbation	O	NOUN	B
or	O	CCONJ	O
de	O	X	B
novo	O	X	I
appearance	O	NOUN	B
of	O	ADP	O
myoclonic	B-Disease	ADJ	B
jerks	I-Disease	NOUN	I
(	O	PUNCT	O
MJ	B-Disease	PROPN	B
).	O	PUNCT	O
In	O	ADP	O
three	O	NUM	O
patients	O	NOUN	B
,	O	PUNCT	O
LTG	B-Chemical	NOUN	B
exacerbated	O	VERB	B
MJ	B-Disease	NOUN	B
in	O	ADP	O
a	O	DET	O
dose	O	NOUN	B
-	O	PUNCT	O
dependent	O	ADJ	B
manner	O	NOUN	O
with	O	ADP	O
early	O	ADJ	O
aggravation	O	NOUN	B
during	O	ADP	O
titration	O	NOUN	B
.	O	PUNCT	O


MJ	B-Disease	NOUN	B
disappeared	O	VERB	O
when	O	SCONJ	O
LTG	B-Chemical	NOUN	B
dose	O	NOUN	B
was	O	AUX	O
decreased	O	VERB	B
by	O	ADP	O
25	O	NUM	O
to	O	PART	O
50	O	NUM	O
%.	O	NOUN	B
In	O	ADP	O
two	O	NUM	O
patients	O	NOUN	B
,	O	PUNCT	O
LTG	B-Chemical	NOUN	B
exacerbated	O	VERB	B
MJ	B-Disease	NOUN	B
in	O	ADP	O
a	O	DET	O
delayed	O	VERB	B
but	O	CCONJ	O
more	O	ADV	O
severe	O	ADJ	B
manner	O	NOUN	O
,	O	PUNCT	O
with	O	ADP	O
myoclonic	B-Disease	ADJ	B
status	I-Disease	NOUN	I
that	O	SCONJ	O
only	O	ADV	O
ceased	O	VERB	O
after	O	ADP	O
LTG	B-Chemical	PROPN	B


rTMS	O	NOUN	B
of	O	ADP	O
supplementary	O	ADJ	O
motor	O	NOUN	B
area	O	NOUN	I
modulates	O	VERB	B
therapy	O	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
dyskinesias	B-Disease	NOUN	B
in	O	ADP	O
Parkinson	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
neural	O	ADJ	B
mechanisms	O	NOUN	I
and	O	CCONJ	O
circuitry	O	NOUN	B
involved	O	VERB	O
in	O	ADP	O
levodopa	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
dyskinesia	B-Disease	NOUN	B
are	O	AUX	O
unclear	O	ADJ	B
.	O	PUNCT	O


Using	O	VERB	O
repetitive	O	ADJ	B
transcranial	O	ADJ	I
magnetic	O	ADJ	I
stimulation	O	NOUN	I
(	O	PUNCT	O
rTMS	O	NOUN	B
)	O	PUNCT	O
over	O	ADP	O
the	O	DET	O
supplementary	O	ADJ	O
motor	O	NOUN	B
area	O	NOUN	I
(	O	PUNCT	O
SMA	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
a	O	DET	O
group	O	NOUN	B
of	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
advanced	O	ADJ	B
Parkinson	B-Disease	NOUN	I
disease	I-Disease	NOUN	I
,	O	PUNCT	O
the	O	DET	O
authors	O	NOUN	B
investigated	O	VERB	B
whether	O	SCONJ	O
modulation	O	NOUN	B
of	O	ADP	O
SMA	O	NOUN	B
excitability	O	NOUN	B
may	O	AUX	O
result	O	VERB	O
in	O	ADP	O
a	O	DET	O
modification	O	NOUN	B
of	O	ADP	O
a	O	DET	O
dyskinetic	B-Disease	ADJ	B
state	O	NOUN	I
induced	O	VERB	B
by	O	ADP	O
continuous	O	ADJ	B
apomorphine	B-Chemical	NOUN	B
infusion	O	NOUN	B
.	O	PUNCT	O


rTMS	O	NOUN	B
at	O	ADP	O
1	O	NUM	O
Hz	O	NOUN	O
was	O	AUX	O
observed	O	VERB	O
to	O	PART	O
markedly	O	ADV	O
reduce	O	VERB	O
drug-induced	B-Disease	ADJ	B
dyskinesias	I-Disease	NOUN	I


Assessment	O	NOUN	B
of	O	ADP	O
the	O	DET	O
onset	O	NOUN	B
and	O	CCONJ	O
persistence	O	NOUN	B
of	O	ADP	O
amnesia	B-Disease	NOUN	B
during	O	ADP	O
procedural	O	ADJ	B
sedation	O	NOUN	B
with	O	ADP	O
propofol	B-Chemical	NOUN	B
.	O	PUNCT	O


OBJECTIVES	O	NOUN	O
:	O	PUNCT	O
To	O	PART	O
assess	O	VERB	O
patients	O	NOUN	B
'	O	PART	O
ability	O	NOUN	O
to	O	PART	O
repeat	O	VERB	O
and	O	CCONJ	O
recall	O	VERB	B
words	O	NOUN	B
presented	O	VERB	O
to	O	ADP	O
them	O	PRON	O
while	O	SCONJ	O
undergoing	O	VERB	O
procedural	O	ADJ	B
sedation	O	NOUN	O
with	O	ADP	O
propofol	B-Chemical	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
correlate	O	VERB	B
their	O	PRON	O
recall	O	NOUN	B
with	O	ADP	O
their	O	PRON	O
level	O	NOUN	B
of	O	ADP	O
awareness	O	NOUN	B
as	O	ADP	O
measured	O	VERB	B
by	O	ADP	O
bispectral	O	ADJ	B
index	O	NOUN	I
(	O	PUNCT	O
BIS	O	NOUN	B
)	O	PUNCT	O
monitoring	O	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
:	O	PUNCT	O
This	O	DET	O
was	O	AUX	O
a	O	DET	O
prospective	O	ADJ	B
,	O	PUNCT	O
single	O	ADJ	B
-	O	PUNCT	O
intervention	O	NOUN	B
study	O	NOUN	O
of	O	ADP	O
consenting	O	VERB	O
adult	O	ADJ	B
patients	O	NOUN	B
undergoing	O	VERB	O
procedural	O	ADJ	B
sedation	O	NOUN	I
with	O	ADP	O
propofol	B-Chemical	NOUN	B
between	O	ADP	O
December	O	PROPN	O
28	O	NUM	O
,	O	PUNCT	O
2002	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
October	O	PROPN	O
31	O	NUM	O
,	O	PUNCT	O
2003	O	NUM	O
.	O	PUNCT	O


BIS	O	NOUN	B
monitoring	O	NOUN	B
was	O	AUX	O
initiated	O	VERB	O
starting	O	VERB	O
3	O	NUM	O
minutes	O	NOUN	B
before	O	ADP	O
the	O	DET	O
procedure	O	NOUN	B
and	O	CCONJ	O
continuing	O	VERB	B
until	O	ADP	O
the	O	DET	O
patient	O	NOUN	B
had	O	AUX	O
regained	O	VERB	B
baseline	O	NOUN	B
mental	O	ADJ	B
status	O	NOUN	I
.	O	PUNCT	O


At	O	ADP	O
1	O	NUM	O
-	O	PUNCT	O
minute	O	NOUN	B
intervals	O	NOUN	B
during	O	ADP	O
the	O	DET	O
procedural	O	ADJ	B
sedation	O	NOUN	B
,	O	PUNCT	O
until	O	ADP	O
the	O	DET	O
patient	O	NOUN	B
regained	O	VERB	B
baseline	O	NOUN	B
mental	O	ADJ	B
status	O	NOUN	I
at	O	ADP	O
the	O	DET	O
end	O	NOUN	O
of	O	ADP	O
the	O	DET	O
procedure	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
word	O	NOUN	B
from	O	ADP	O
a	O	DET	O
standardized	O	ADJ	B
list	O	NOUN	I
was	O	AUX	O
read	O	VERB	O
aloud	O	ADV	O
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
patient	O	NOUN	B
was	O	AUX	O
asked	O	VERB	O
to	O	PART	O
immediately	O	ADV	O
repeat	O	VERB	O
the	O	DET	O
word	O	NOUN	O
to	O	ADP	O
the	O	DET	O
investigator	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
BIS	O	NOUN	B
score	O	NOUN	B
at	O	ADP	O
the	O	DET	O
time	O	NOUN	B
the	O	DET	O
word	O	NOUN	B
was	O	AUX	O
read	O	VERB	B
and	O	CCONJ	O
the	O	DET	O
patient	O	NOUN	B
'	O	PART	O
s	O	NOUN	O
ability	O	NOUN	O
to	O	PART	O
repeat	O	VERB	O
the	O	DET	O
word	O	NOUN	B
were	O	AUX	O
recorded	O	VERB	O
.	O	PUNCT	O


After	O	ADP	O
the	O	DET	O
procedure	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
patient	O	NOUN	B
was	O	AUX	O
asked	O	VERB	O
to	O	PART	O
state	O	NOUN	O
all	O	DET	O
of	O	ADP	O
the	O	DET	O
words	O	NOUN	B
from	O	ADP	O
the	O	DET	O
list	O	NOUN	O
that	O	SCONJ	O
he	O	PRON	O
or	O	CCONJ	O
she	O	PRON	O
could	O	AUX	O
recall	O	VERB	B
,	O	PUNCT	O
and	O	CCONJ	O
to	O	PART	O
identify	O	VERB	O
the	O	DET	O
last	O	ADJ	O
word	O	NOUN	B
recalled	O	VERB	O
from	O	ADP	O
prior	O	ADJ	O
to	O	PART	O
the	O	DET	O
start	O	NOUN	O
of	O	ADP	O
the	O	DET	O
procedure	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
first	O	ADJ	O
word	O	NOUN	O
recalled	O	VERB	O
from	O	ADP	O
after	O	ADP	O
the	O	DET	O
procedure	O	NOUN	B
was	O	AUX	O
completed	O	VERB	O
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
Seventy	O	NUM	B
-	O	PUNCT	O
five	O	NUM	O
consenting	O	VERB	O
patients	O	NOUN	B
were	O	AUX	O
enrolled	O	VERB	O
;	O	PUNCT	O
one	O	NUM	O
patient	O	NOUN	B
was	O	AUX	O
excluded	O	VERB	O
from	O	ADP	O
data	O	NOUN	B
analysis	O	NOUN	I
for	O	ADP	O
a	O	DET	O
protocol	O	NOUN	B
violation	O	NOUN	B
.	O	PUNCT	O


No	O	DET	O
serious	O	ADJ	O
adverse	O	ADJ	B
events	O	NOUN	I
were	O	AUX	O
noted	O	VERB	O
during	O	ADP	O
the	O	DET	O
procedural	O	ADJ	B
sedations	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
mean	O	NOUN	O
(+/-	O	PUNCT	O
standard	O	ADJ	B
deviation	O	NOUN	I
)	O	PUNCT	O
time	O	NOUN	O
of	O	ADP	O
data	O	NOUN	B
collection	O	NOUN	I
was	O	AUX	O
16	O	NUM	O
.	O	PUNCT	O


4	O	NUM	O
minutes	O	NOUN	B
(+/-	O	PUNCT	O
7	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
;	O	PUNCT	O
range	O	VERB	O
5	O	NUM	O
to	O	PART	O
34	O	NUM	O
minutes	O	NOUN	B
).	O	PUNCT	O
The	O	DET	O
mean	O	ADJ	O
initial	O	ADJ	O
(	O	PUNCT	O
preprocedure	O	NOUN	B
)	O	PUNCT	O
BIS	O	NOUN	B
score	O	NOUN	B
was	O	AUX	O
97	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
(+/-	O	SYM	O
2	O	NUM	O
.	O	PUNCT	O


3	O	NUM	O
;	O	PUNCT	O
range	O	VERB	O
92	O	NUM	O
to	O	PART	O
99	O	NUM	O
).	O	PUNCT	O
The	O	DET	O
mean	O	ADJ	O
lowest	O	ADJ	O
BIS	O	NOUN	B
score	O	NOUN	B
occurring	O	VERB	O
during	O	ADP	O
these	O	DET	O
procedural	O	ADJ	B
sedations	O	NOUN	B
was	O	AUX	O
66	O	NUM	O
.	O	PUNCT	O


9	O	NUM	O
(+/-	O	PUNCT	O
14	O	NUM	O
.	O	PUNCT	O


4	O	NUM	O
;	O	PUNCT	O
range	O	VERB	O
33	O	NUM	O
to	O	PART	O
91	O	NUM	O
).	O	PUNCT	O
The	O	DET	O
mean	O	ADJ	O
lowest	O	ADJ	O
BIS	O	NOUN	B
score	O	NOUN	B
corresponding	O	VERB	O
to	O	PART	O
the	O	DET	O
ability	O	NOUN	O
of	O	ADP	O
the	O	DET	O
patient	O	NOUN	B
to	O	PART	O
immediately	O	ADV	O
repeat	O	NOUN	O
words	O	NOUN	O
read	O	VERB	O
from	O	ADP	O
the	O	DET	O
list	O	NOUN	B
was	O	AUX	O
77	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
=	O	ADJ	O
74	O	NUM	O
.	O	PUNCT	O


3	O	NUM	O
to	O	PART	O
80	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
).	O	PUNCT	O
The	O	DET	O
mean	O	ADJ	O
highest	O	ADJ	O
BIS	O	NOUN	B
score	O	NOUN	B
corresponding	O	VERB	O
to	O	PART	O
the	O	DET	O
inability	B-Disease	NOUN	B
to	I-Disease	PART	O
repeat	I-Disease	NOUN	O
words	I-Disease	NOUN	B
was	O	AUX	O
81	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
=	O	ADJ	O
78	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
to	O	PART	O
84	O	NUM	O
.	O	PUNCT	O


8	O	NUM	O
).	O	PUNCT	O
The	O	DET	O
mean	O	ADJ	O
BIS	O	NOUN	B
score	O	NOUN	B
corresponding	O	VERB	O
to	O	PART	O
the	O	DET	O
last	O	ADJ	O
word	O	NOUN	B
recalled	O	VERB	O
from	O	ADP	O
prior	O	ADJ	O
to	O	PART	O
the	O	DET	O
initiation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
sedation	O	NOUN	B
was	O	AUX	O
96	O	NUM	O
.	O	PUNCT	O


7	O	NUM	O
(+/-	O	SYM	O
2	O	NUM	O
.	O	PUNCT	O


4	O	NUM	O
;	O	PUNCT	O
range	O	VERB	O
84	O	NUM	O
to	O	PART	O
98	O	NUM	O
).	O	PUNCT	O
The	O	DET	O
mean	O	ADJ	O
BIS	O	NOUN	B
score	O	NOUN	B
corresponding	O	VERB	O
to	O	PART	O
the	O	DET	O
first	O	ADJ	O
word	O	NOUN	O
recalled	O	VERB	O
after	O	ADP	O
the	O	DET	O
procedure	O	NOUN	B
was	O	AUX	O
completed	O	VERB	B
was	O	AUX	O
91	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
=	O	ADJ	O
88	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
to	O	PART	O
94	O	NUM	O
.	O	PUNCT	O


3	O	NUM	O
).	O	PUNCT	O
All	O	DET	O
patients	O	NOUN	B
recalled	O	VERB	B
at	O	ADP	O
least	O	ADJ	O
one	O	NUM	O
word	O	NOUN	B
that	O	PRON	O
had	O	AUX	O
been	O	AUX	O
read	O	VERB	O
to	O	ADP	O
them	O	PRON	O
during	O	ADP	O
the	O	DET	O
protocol	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
mean	O	ADJ	O
lowest	O	ADJ	O
BIS	O	NOUN	B
score	O	NOUN	B
for	O	ADP	O
any	O	DET	O
recalled	O	ADJ	B
word	O	NOUN	B
was	O	AUX	O
91	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
(+/-	O	PUNCT	O
11	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
;	O	PUNCT	O
range	O	VERB	O
79	O	NUM	O
to	O	PART	O
98	O	NUM	O
),	O	PUNCT	O
and	O	CCONJ	O
no	O	DET	O
words	O	NOUN	O
were	O	AUX	O
recalled	O	VERB	O
when	O	SCONJ	O
the	O	DET	O
corresponding	O	ADJ	O
BIS	O	NOUN	B
score	O	NOUN	B
was	O	AUX	O
less	O	ADJ	O
than	O	ADP	O
90	O	NUM	O
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
:	O	PUNCT	O
There	O	PRON	O
is	O	AUX	O
a	O	DET	O
range	O	NOUN	O
of	O	ADP	O
BIS	O	NOUN	B
scores	O	NOUN	B
during	O	ADP	O
which	O	DET	O
sedated	O	ADJ	B
patients	O	NOUN	B
are	O	AUX	O
able	O	ADJ	O
to	O	PART	O
repeat	O	VERB	O
words	O	NOUN	B
read	O	VERB	I
to	O	ADP	O
them	O	PRON	O
but	O	CCONJ	O
are	O	AUX	O
not	O	PART	O
able	O	ADJ	O
to	O	PART	O
subsequently	O	ADV	O
recall	O	VERB	B
these	O	DET	O
words	O	NOUN	B
.	O	PUNCT	O


Furthermore	O	ADV	O
,	O	PUNCT	O
patients	O	NOUN	B
had	O	AUX	O
no	O	DET	O
recall	O	NOUN	O
of	O	ADP	O
words	O	NOUN	B
repeated	O	VERB	O
prior	O	ADJ	O
to	O	PART	O
procedural	O	ADJ	B
sedation	O	NOUN	B
in	O	ADP	O
BIS	O	NOUN	B
ranges	O	NOUN	B
associated	O	VERB	B
with	O	ADP	I
recall	O	NOUN	B
after	O	ADP	O
procedural	O	ADJ	B
sedation	O	NOUN	B
,	O	PUNCT	O
suggestive	O	ADJ	O
of	O	ADP	O
retrograde	B-Disease	NOUN	B
amnesia	I-Disease	NOUN	B


Assessment	O	NOUN	B
of	O	ADP	O
perinatal	O	ADJ	B
hepatitis	B-Disease	NOUN	I
B	I-Disease	NOUN	I
and	O	CCONJ	O
rubella	B-Disease	NOUN	B
prevention	O	NOUN	I
in	O	ADP	O
New	O	PROPN	B
Hampshire	O	PROPN	I
delivery	O	NOUN	O
hospitals	O	NOUN	O
.	O	PUNCT	O


OBJECTIVE	O	NOUN	B
:	O	PUNCT	O
To	O	PART	O
evaluate	O	VERB	B
current	O	ADJ	B
performance	O	NOUN	B
on	O	ADP	O
recommended	O	VERB	B
perinatal	O	ADJ	B
hepatitis	B-Disease	NOUN	B
B	I-Disease	NOUN	I
and	O	CCONJ	O
rubella	B-Disease	ADJ	B
prevention	O	NOUN	I
practices	O	NOUN	O
in	O	ADP	O
New	O	PROPN	B
Hampshire	O	PROPN	I
.	O	PUNCT	O


METHODS	O	NOUN	O
:	O	PUNCT	O
Data	O	PROPN	B
were	O	AUX	O
extracted	O	VERB	O
from	O	ADP	O
2021	O	NUM	O
paired	O	ADJ	O
mother	O	NOUN	B
-	O	PUNCT	O
infant	O	NOUN	B
records	O	NOUN	O
for	O	ADP	O
the	O	DET	O
year	O	NOUN	B
2000	O	NUM	O
birth	O	NOUN	B
cohort	O	NOUN	I
in	O	ADP	O
New	O	PROPN	B
Hampshire	O	PROPN	I
'	O	PART	O
s	O	NOUN	O
25	O	NUM	O
delivery	O	NOUN	B
hospitals	O	NOUN	I
.	O	PUNCT	O


Assessment	O	NOUN	B
was	O	AUX	O
done	O	VERB	O
on	O	ADP	O
the	O	DET	O
following	O	VERB	O
:	O	PUNCT	O
prenatal	O	ADJ	B
screening	O	NOUN	I
for	O	ADP	O
hepatitis	B-Disease	NOUN	B
B	I-Disease	NOUN	I
and	O	CCONJ	O
rubella	B-Disease	NOUN	B
,	O	PUNCT	O
administration	O	NOUN	B
of	O	ADP	O
the	O	DET	O
hepatitis	B-Disease	NOUN	B
B	I-Disease	NOUN	I
vaccine	O	NOUN	I
birth	O	NOUN	O
dose	O	NOUN	O
to	O	ADP	O
all	O	DET	O
infants	O	NOUN	B
,	O	PUNCT	O
administration	O	NOUN	B
of	O	ADP	O
hepatitis	B-Disease	NOUN	B
B	I-Disease	NOUN	I
immune	O	ADJ	I
globulin	O	NOUN	I
to	O	ADP	O
infants	O	NOUN	B
who	O	PRON	O
were	O	AUX	O
born	O	VERB	B
to	O	PART	O
hepatitis	B-Chemical	NOUN	B
B	I-Chemical	NOUN	I
surface	I-Chemical	NOUN	I
antigen	I-Chemical	NOUN	I
-	O	PUNCT	O
positive	O	ADJ	B
mothers	O	NOUN	B
,	O	PUNCT	O
rubella	B-Disease	ADJ	B
immunity	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
administration	O	NOUN	B
of	O	ADP	O
in	O	ADP	O
-	O	PUNCT	O
hospital	O	NOUN	B
postpartum	O	NOUN	B
rubella	B-Disease	NOUN	I
vaccine	O	NOUN	I
to	O	ADP	O
rubella	B-Disease	ADJ	B
nonimmune	O	ADJ	I
women	O	NOUN	I
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
Prenatal	O	ADJ	B
screening	O	NOUN	I
rates	O	NOUN	I
for	O	ADP	O
hepatitis	B-Disease	NOUN	B
B	I-Disease	NOUN	I
(	O	PUNCT	O
98	O	NUM	O
.	O	PUNCT	O


8	O	NUM	O
%)	O	NOUN	B
and	O	CCONJ	O
rubella	B-Disease	NOUN	B
(	O	PUNCT	O
99	O	NUM	O
.	O	PUNCT	O


4	O	NUM	O
%)	O	NOUN	O
were	O	AUX	O
high	O	ADJ	O
.	O	PUNCT	O


Hepatitis	B-Disease	NOUN	B
B	I-Disease	NOUN	I
vaccine	O	NOUN	I
birth	O	NOUN	O
dose	O	NOUN	O
was	O	AUX	O
administered	O	VERB	B
to	O	ADP	O
76	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
all	O	DET	O
infants	O	NOUN	B
.	O	PUNCT	O


All	O	DET	O
infants	O	NOUN	B
who	O	PRON	O
were	O	AUX	O
born	O	VERB	B
to	O	PART	O
hepatitis	B-Chemical	NOUN	B
B	I-Chemical	NOUN	I
surface	I-Chemical	NOUN	I
antigen	I-Chemical	NOUN	I
-	O	PUNCT	O
positive	O	ADJ	B
mothers	O	NOUN	B
also	O	ADV	O
received	O	VERB	O
hepatitis	B-Disease	NOUN	B
B	I-Disease	NOUN	I
immune	O	ADJ	B
globulin	O	NOUN	I
.	O	PUNCT	O


Multivariate	O	ADJ	B
logistic	O	ADJ	I
regression	O	NOUN	I
showed	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
month	O	NOUN	B
of	O	ADP	O
delivery	O	NOUN	B
and	O	CCONJ	O
infant	O	ADJ	B
birth	O	NOUN	O
weight	O	NOUN	O
were	O	AUX	O
independent	O	ADJ	O
predictors	O	NOUN	B
of	O	ADP	O
hepatitis	B-Disease	NOUN	B
B	I-Disease	NOUN	I
vaccination	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
proportion	O	NOUN	B
of	O	ADP	O
infants	O	NOUN	B
who	O	PRON	O
were	O	AUX	O
vaccinated	O	VERB	B
in	O	ADP	O
January	O	PROPN	B
and	O	CCONJ	O
February	O	PROPN	O
2000	O	NUM	O
(	O	PUNCT	O
48	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
67	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
%,	O	NOUN	O
respectively	O	ADV	O
)	O	PUNCT	O
was	O	AUX	O
less	O	ADJ	O
than	O	ADP	O
any	O	DET	O
other	O	ADJ	O
months	O	NOUN	B
,	O	PUNCT	O
whereas	O	SCONJ	O
the	O	DET	O
proportion	O	NOUN	B
who	O	PRON	O
were	O	AUX	O
vaccinated	O	VERB	B
in	O	ADP	O
December	O	PROPN	O
2000	O	NUM	O
(	O	PUNCT	O
88	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
%)	O	NOUN	O
was	O	AUX	O
the	O	DET	O
highest	O	ADJ	B
.	O	PUNCT	O


Women	O	NOUN	B
who	O	PRON	O
were	O	AUX	O
born	O	VERB	B
between	O	ADP	O
1971	O	NUM	O
and	O	CCONJ	O
1975	O	NUM	O
had	O	AUX	O
the	O	DET	O
highest	O	ADJ	O
rate	O	NOUN	B
of	O	ADP	O
rubella	B-Disease	ADJ	B
nonimmunity	O	NOUN	I
(	O	PUNCT	O
9	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
%).	O	NOUN	O
In	O	ADP	O
-	O	PUNCT	O
hospital	O	NOUN	B
postpartum	O	NOUN	B
rubella	B-Disease	NOUN	I
vaccine	O	NOUN	I
administration	O	NOUN	B
was	O	AUX	O
documented	O	VERB	B
for	O	ADP	O
75	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
nonimmune	O	ADJ	B
women	O	NOUN	I
.	O	PUNCT	O


CONCLUSION	O	NOUN	B
:	O	PUNCT	O
This	O	DET	O
study	O	NOUN	B
documents	O	VERB	B
good	O	ADJ	O
compliance	O	NOUN	B
in	O	ADP	O
New	O	PROPN	B
Hampshire	O	PROPN	I
'	O	PART	O
s	O	NOUN	O
birthing	O	NOUN	B
hospitals	O	NOUN	O
with	O	ADP	O
national	O	ADJ	B
guidelines	O	NOUN	I
for	O	ADP	O
perinatal	O	ADJ	B
hepatitis	B-Disease	NOUN	I
B	I-Disease	NOUN	I
and	O	CCONJ	O
rubella	B-Disease	NOUN	B


Expression	O	NOUN	B
of	O	ADP	O
p300	O	NOUN	B
protects	O	VERB	B
cardiac	O	ADJ	B
myocytes	O	NOUN	I
from	O	ADP	O
apoptosis	O	NOUN	B
in	O	X	B
vivo	O	X	I
.	O	PUNCT	O


Doxorubicin	B-Chemical	NOUN	B
is	O	AUX	O
an	O	DET	O
anti	O	ADJ	B
-	O	PUNCT	O
tumor	B-Disease	NOUN	B
agent	O	NOUN	I
that	O	PRON	O
represses	O	VERB	B
cardiac	O	ADJ	B
-	O	PUNCT	O
specific	O	ADJ	B
gene	O	NOUN	B
expression	O	NOUN	I
and	O	CCONJ	O
induces	O	VERB	O
myocardial	O	ADJ	B
cell	O	NOUN	I
apoptosis	O	NOUN	B
.	O	PUNCT	O


Doxorubicin	B-Chemical	NOUN	B
depletes	O	VERB	B
cardiac	O	ADJ	B
p300	O	NOUN	I
,	O	PUNCT	O
a	O	DET	O
transcriptional	O	ADJ	B
coactivator	O	NOUN	I
that	O	PRON	O
is	O	AUX	O
required	O	VERB	O
for	O	ADP	O
the	O	DET	O
maintenance	O	NOUN	B
of	O	ADP	O
the	O	DET	O
differentiated	O	VERB	B
phenotype	O	NOUN	B
of	O	ADP	O
cardiac	O	ADJ	B
myocytes	O	NOUN	I
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
role	O	NOUN	O
of	O	ADP	O
p300	O	NOUN	B
in	O	ADP	O
protection	O	NOUN	B
against	O	ADP	O
doxorubicin	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
apoptosis	O	NOUN	B
is	O	AUX	O
unknown	O	ADJ	O
.	O	PUNCT	O


Transgenic	O	ADJ	B
mice	O	NOUN	I
overexpressing	O	VERB	B
p300	O	NOUN	B
in	O	ADP	O
the	O	DET	O
heart	O	NOUN	B
and	O	CCONJ	O
wild	O	ADJ	B
-	O	PUNCT	O
type	O	NOUN	B
mice	O	NOUN	B
were	O	AUX	O
subjected	O	VERB	O
to	O	PART	O
doxorubicin	B-Chemical	NOUN	B
treatment	O	NOUN	B
.	O	PUNCT	O


Compared	O	VERB	B
with	O	ADP	O
wild	O	ADJ	B
-	O	PUNCT	O
type	O	NOUN	B
mice	O	NOUN	B
,	O	PUNCT	O
transgenic	O	ADJ	B
mice	O	NOUN	I
exhibited	O	VERB	O
higher	O	ADJ	B
survival	O	NOUN	B
rate	O	NOUN	I
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
more	O	ADV	O
preserved	O	VERB	O
left	O	VERB	B
ventricular	O	ADJ	I
function	O	NOUN	I
and	O	CCONJ	O
cardiac	O	ADJ	B
expression	O	NOUN	I
of	O	ADP	O
alpha	O	NOUN	B
-	O	PUNCT	O
sarcomeric	O	ADJ	B
actin	O	NOUN	I
.	O	PUNCT	O


Doxorubicin	B-Chemical	NOUN	B
induced	O	VERB	B
myocardial	O	ADJ	B
cell	O	NOUN	I
apoptosis	O	NOUN	B
in	O	ADP	O
wild	O	ADJ	B
-	O	PUNCT	O
type	O	NOUN	B
mice	O	NOUN	B
but	O	CCONJ	O
not	O	PART	O
in	O	ADP	O
transgenic	O	ADJ	B
mice	O	NOUN	I
.	O	PUNCT	O


Expression	O	NOUN	B
of	O	ADP	O
p300	O	NOUN	B
increased	O	VERB	B
the	O	DET	O
cardiac	O	ADJ	B
level	O	NOUN	O
of	O	ADP	O
bcl	O	NOUN	B
-	O	PUNCT	O
2	O	NUM	B
and	O	CCONJ	O
mdm	O	NOUN	B
-	O	PUNCT	O
2	O	NUM	O
,	O	PUNCT	O
but	O	CCONJ	O
not	O	PART	O
that	O	DET	O
of	O	ADP	O
p53	O	NOUN	B
or	O	CCONJ	O
other	O	ADJ	O
members	O	NOUN	B
of	O	ADP	O
the	O	DET	O
bcl	O	NOUN	B
-	O	PUNCT	O
2	O	NUM	O
family	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
findings	O	NOUN	B
demonstrate	O	VERB	O
that	O	SCONJ	O
overexpression	O	NOUN	B
of	O	ADP	O
p300	O	NOUN	B
protects	O	VERB	B
cardiac	O	ADJ	B
myocytes	O	NOUN	I
from	O	ADP	O
doxorubicin	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
apoptosis	O	NOUN	B
and	O	CCONJ	O
reduces	O	VERB	B
the	O	DET	O
extent	O	NOUN	O
of	O	ADP	O
acute	O	ADJ	B
heart	B-Disease	NOUN	I
failure	I-Disease	NOUN	I


Mitochondrial	O	ADJ	B
DNA	O	NOUN	I
and	O	CCONJ	O
its	O	PRON	O
respiratory	O	ADJ	B
chain	O	NOUN	I
products	O	NOUN	I
are	O	AUX	O
defective	O	ADJ	B
in	O	ADP	O
doxorubicin	B-Chemical	NOUN	B
nephrosis	B-Disease	NOUN	I
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
:	O	PUNCT	O
Doxorubicin	B-Chemical	NOUN	B
induces	O	VERB	B
a	O	DET	O
self	O	NOUN	B
-	O	PUNCT	O
perpetuating	O	VERB	B
nephropathy	B-Disease	NOUN	B
characterized	O	VERB	B
by	O	ADP	O
early	O	ADJ	B
glomerular	B-Disease	ADJ	I
and	I-Disease	CCONJ	O
late-onset	I-Disease	ADJ	B
tubular	I-Disease	ADJ	B
lesions	I-Disease	NOUN	I
in	O	ADP	O
rats	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
investigated	O	VERB	B
the	O	DET	O
potential	O	ADJ	O
role	O	NOUN	O
of	O	ADP	O
mitochondrial	B-Disease	ADJ	B
injury	I-Disease	NOUN	I
in	O	ADP	O
the	O	DET	O
onset	O	NOUN	O
of	O	ADP	O
these	O	DET	O
lesions	O	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
:	O	PUNCT	O
Rats	O	NOUN	B
were	O	AUX	O
treated	O	VERB	B
with	O	ADP	I
intravenous	O	ADJ	B
doxorubicin	B-Chemical	NOUN	I
(	O	PUNCT	O
1	O	NUM	O
mg	O	NOUN	O
kg	O	NOUN	O
(-	O	PUNCT	O
1	O	NUM	O
)	O	PUNCT	O
week	O	NOUN	B
(-	O	PUNCT	O
1	O	NUM	O
))	O	PUNCT	O
for	O	ADP	O
7	O	NUM	O
weeks	O	NOUN	B
and	O	CCONJ	O
were	O	AUX	O
sacrificed	O	VERB	B
either	O	CCONJ	O
1	O	NUM	O
week	O	NOUN	B
('	O	PUNCT	B
short	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
')	O	PROPN	O
or	O	CCONJ	O
30	O	NUM	O
weeks	O	NOUN	B
('	O	PROPN	B
long	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
')	O	PROPN	O
following	O	VERB	O
the	O	DET	O
last	O	ADJ	O
dose	O	NOUN	B
.	O	PUNCT	O


Additional	O	ADJ	O
rats	O	NOUN	B
received	O	VERB	O
a	O	DET	O
single	O	ADJ	B
dose	O	NOUN	I
either	O	CCONJ	O
6	O	NUM	O
days	O	NOUN	B
or	O	CCONJ	O
2	O	NUM	O
h	O	NOUN	O
prior	O	ADJ	O
to	O	ADP	O
euthanasia	O	NOUN	B
.	O	PUNCT	O


All	O	DET	O
rats	O	NOUN	B
were	O	AUX	O
killed	O	VERB	B
at	O	ADP	O
48	O	NUM	O
weeks	O	NOUN	B
of	O	ADP	O
age	O	NOUN	B
.	O	PUNCT	O


Glomerular	B-Disease	ADJ	B
and	I-Disease	CCONJ	O
tubular	I-Disease	ADJ	B
injury	I-Disease	NOUN	I
was	O	AUX	O
monitored	O	VERB	B
and	O	CCONJ	O
correlated	O	VERB	B
to	O	PART	O
the	O	DET	O
activity	O	NOUN	B
or	O	CCONJ	O
expression	O	NOUN	B
of	O	ADP	O
respiratory	O	ADJ	B
chain	O	NOUN	I
components	O	NOUN	I
.	O	PUNCT	O


Finally	O	ADV	O
,	O	PUNCT	O
we	O	PRON	O
quantified	O	VERB	B
both	O	CCONJ	O
nuclear	O	ADJ	B
and	O	CCONJ	O
mitochondrial	O	ADJ	O
DNA	O	NOUN	O
(	O	PUNCT	O
mtDNA	O	NOUN	B
)	O	PUNCT	O
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
superoxide	B-Chemical	NOUN	B
production	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
4834	O	NUM	O
base	O	NOUN	B
pair	O	NOUN	I
'	O	PUNCT	O
common	O	ADJ	O
'	O	PUNCT	O
mtDNA	O	NOUN	B
deletion	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
The	O	DET	O
'	O	PUNCT	O
long	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
'	O	PART	O
group	O	NOUN	B
had	O	AUX	O
significant	O	ADJ	O
glomerular	B-Disease	ADJ	B
and	I-Disease	CCONJ	O
tubular	I-Disease	ADJ	B
lesions	I-Disease	NOUN	I
,	O	PUNCT	O
depressed	O	ADJ	B
activities	O	NOUN	I
of	O	ADP	O
mtDNA	O	NOUN	B
-	O	PUNCT	O
encoded	O	VERB	B
NADH	O	NOUN	B
dehydrogenase	O	NOUN	I
and	O	CCONJ	O
cytochrome	O	NOUN	B
-	O	PUNCT	O
c	O	NOUN	B
oxidase	O	NOUN	I
(	O	PUNCT	O
COX	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
increased	O	VERB	B
citrate	B-Chemical	NOUN	B
synthase	O	NOUN	I
activity	O	NOUN	O
.	O	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
,	O	PUNCT	O
expression	O	NOUN	B
of	O	ADP	O
the	O	DET	O
mtDNA	O	NOUN	B
-	O	PUNCT	O
encoded	O	VERB	B
COX	O	NOUN	B
subunit	O	NOUN	I
I	O	NUM	I
was	O	AUX	O
reduced	O	VERB	B
and	O	CCONJ	O
mtDNA	O	NOUN	B
levels	O	NOUN	B
were	O	AUX	O
decreased	O	VERB	B
.	O	PUNCT	O


In	O	ADP	O
'	O	PUNCT	O
short	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
'	O	PART	O
rats	O	NOUN	B
,	O	PUNCT	O
there	O	PRON	O
were	O	AUX	O
fewer	O	ADJ	O
tubular	B-Disease	ADJ	B
lesions	I-Disease	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
similar	O	ADJ	O
numbers	O	NOUN	O
of	O	ADP	O
glomerular	B-Disease	ADJ	B
lesions	I-Disease	NOUN	I
activity	O	NOUN	B
.	O	PUNCT	O


Among	O	ADP	O
all	O	DET	O
animals	O	NOUN	B
,	O	PUNCT	O
glomerular	B-Disease	ADJ	B
and	I-Disease	CCONJ	O
tubular	I-Disease	ADJ	B
injury	I-Disease	NOUN	I
were	O	AUX	O
inversely	O	ADV	O
correlated	O	VERB	B
with	O	ADP	O
mtDNA	O	NOUN	B
levels	O	NOUN	O
,	O	PUNCT	O
mtDNA	O	NOUN	B
-	O	PUNCT	O
encoded	O	VERB	B
respiratory	O	ADJ	B
chain	O	NOUN	I
activities	O	NOUN	I
and	O	CCONJ	O
with	O	ADP	O
the	O	DET	O
expression	O	NOUN	B
of	O	ADP	O
the	O	DET	O
mtDNA	O	NOUN	B
-	O	PUNCT	O
encoded	O	VERB	B
respiratory	O	ADJ	B
chain	O	NOUN	I
subunit	O	NOUN	I
COX	O	NOUN	B
-	O	PUNCT	O
I	O	PRON	B
.	O	PUNCT	O


Injury	O	NOUN	B
was	O	AUX	O
positively	O	ADV	O
correlated	O	VERB	B
with	O	ADP	O
superoxide	B-Chemical	NOUN	B
production	O	NOUN	O
and	O	CCONJ	O
the	O	DET	O
activities	O	NOUN	B
of	O	ADP	O
nucleus	O	NOUN	B
-	O	PUNCT	O
encoded	O	VERB	B
mitochondrial	O	ADJ	B
or	O	CCONJ	O
cytoplasmic	O	ADJ	B
enzymes	O	NOUN	O
.	O	PUNCT	O


Kidneys	O	NOUN	B
from	O	ADP	O
the	O	DET	O
'	O	PUNCT	O
long	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
'	O	PART	O
group	O	NOUN	B
showed	O	VERB	O
more	O	ADJ	O
mtDNA	O	NOUN	B
deletions	O	NOUN	B
than	O	ADP	O
in	O	ADP	O
'	O	PUNCT	O
short	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
'	O	PART	O
animals	O	NOUN	B
and	O	CCONJ	O
these	O	DET	O
were	O	AUX	O
not	O	PART	O
observed	O	VERB	O
in	O	ADP	O
the	O	DET	O
other	O	ADJ	O
groups	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
:	O	PUNCT	O
These	O	DET	O
results	O	NOUN	B
suggest	O	VERB	O
an	O	DET	O
important	O	ADJ	O
role	O	NOUN	O
for	O	ADP	O
quantitative	O	ADJ	B
and	O	CCONJ	O
qualitative	O	ADJ	B
mtDNA	O	NOUN	B
alterations	O	NOUN	B
through	O	ADP	O
the	O	DET	O
reduction	O	NOUN	B
of	O	ADP	O
mtDNA	O	NOUN	B
-	O	PUNCT	O
encoded	O	VERB	B
respiratory	O	ADJ	B
chain	O	NOUN	I
function	O	NOUN	I
and	O	CCONJ	O
induction	O	NOUN	B
of	O	ADP	O
superoxide	B-Chemical	NOUN	B
in	O	ADP	O
doxorubicin	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
renal	B-Disease	ADJ	B
lesions	I-Disease	NOUN	I


Amphotericin	B-Chemical	NOUN	B
B	I-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
seizures	B-Disease	NOUN	B
in	O	ADP	O
a	O	DET	O
patient	O	NOUN	B
with	O	ADP	O
AIDS	B-Disease	NOUN	B
.	O	PUNCT	O


OBJECTIVE	O	NOUN	O
:	O	PUNCT	O
To	O	PART	O
report	O	VERB	O
a	O	DET	O
case	O	NOUN	B
of	O	ADP	O
multiple	O	ADJ	B
episodes	O	NOUN	B
of	O	ADP	O
seizure	B-Disease	NOUN	B
activity	O	NOUN	B
in	O	ADP	O
an	O	DET	O
AIDS	B-Disease	NOUN	B
patent	O	NOUN	B
following	O	VERB	O
amphotericin	B-Chemical	NOUN	B
B	I-Chemical	NOUN	O
infusion	O	NOUN	B
.	O	PUNCT	O


CASE	O	ADJ	B
SUMMARY	O	NOUN	I
:	O	PUNCT	O
A	O	DET	O
46	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
African	O	ADJ	B
-	O	PUNCT	O
American	O	ADJ	B
man	O	NOUN	B
experienced	O	VERB	O
recurrent	O	ADJ	B
grand	B-Disease	ADJ	O
mal	I-Disease	ADJ	B
seizures	I-Disease	NOUN	I
during	O	ADP	O
intravenous	O	ADJ	B
infusion	O	NOUN	B
of	O	ADP	O
amphotericin	B-Chemical	NOUN	B
B	I-Chemical	NOUN	I
,	O	PUNCT	O
then	O	ADV	O
petit	O	ADJ	B
mal	O	ADJ	I
seizures	B-Disease	NOUN	I
as	O	ADP	O
the	O	DET	O
infusion	O	NOUN	B
was	O	AUX	O
stopped	O	VERB	B
and	O	CCONJ	O
the	O	DET	O
drug	O	NOUN	B
concentrations	O	NOUN	I
decreased	O	VERB	B
with	O	ADP	O
time	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
patients	O	NOUN	B
concurrent	O	ADJ	B
medications	O	NOUN	B
included	O	VERB	O
didanosine	B-Chemical	NOUN	B
,	O	PUNCT	O
hydroxyzine	B-Chemical	NOUN	B
,	O	PUNCT	O
promethazine	B-Chemical	NOUN	B
,	O	PUNCT	O
hydrocortisone	B-Chemical	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
prochlorperazine	B-Chemical	NOUN	B
.	O	PUNCT	O


Despite	O	SCONJ	O
administration	O	NOUN	B
of	O	ADP	O
phenytoin	B-Chemical	NOUN	B
and	O	CCONJ	O
lorazepam	B-Chemical	NOUN	B
,	O	PUNCT	O
the	O	DET	O
seizures	B-Disease	NOUN	B
persisted	O	VERB	B
and	O	CCONJ	O
occurred	O	VERB	O
only	O	ADV	O
during	O	ADP	O
amphotercin	B-Chemical	NOUN	B
B	I-Chemical	NOUN	O
administration	O	NOUN	B
.	O	PUNCT	O


DISCUSSION	O	NOUN	O
:	O	PUNCT	O
AIDS	B-Disease	NOUN	B
and	O	CCONJ	O
cryptococcal	B-Disease	ADJ	B
meningitis	I-Disease	NOUN	I
,	O	PUNCT	O
both	O	DET	O
of	O	ADP	O
which	O	DET	O
the	O	DET	O
patient	O	NOUN	B
had	O	AUX	O
,	O	PUNCT	O
can	O	AUX	O
potentially	O	ADV	O
cause	O	VERB	O
seizures	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
patient	O	NOUN	B
had	O	AUX	O
a	O	DET	O
history	O	NOUN	B
of	O	ADP	O
alcohol	B-Disease	NOUN	B
abuse	I-Disease	NOUN	I
;	O	PUNCT	O
alcohol	B-Chemical	NOUN	B
intake	O	NOUN	I
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
withdrawal	O	NOUN	B
can	O	AUX	O
also	O	ADV	O
cause	O	VERB	O
seizures	B-Disease	NOUN	B
.	O	PUNCT	O


Didanosine	B-Chemical	NOUN	B
also	O	ADV	O
has	O	AUX	O
a	O	DET	O
potential	O	NOUN	B
for	O	ADP	O
inducing	O	VERB	B
seizures	B-Disease	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
these	O	DET	O
other	O	ADJ	O
potential	O	ADJ	O
causes	O	NOUN	O
of	O	ADP	O
seizure	B-Disease	NOUN	B
were	O	AUX	O
ruled	O	VERB	O
out	O	ADP	O
.	O	PUNCT	O


The	O	DET	O
time	O	NOUN	B
course	O	NOUN	I
of	O	ADP	O
events	O	NOUN	B
suggested	O	VERB	O
that	O	SCONJ	O
amphotericin	B-Chemical	NOUN	B
B	I-Chemical	NOUN	I
was	O	AUX	O
the	O	DET	O
cause	O	NOUN	O
of	O	ADP	O
the	O	DET	O
seizures	B-Disease	NOUN	B
in	O	ADP	O
this	O	DET	O
AIDS	B-Disease	NOUN	B
patient	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
:	O	PUNCT	O
Amphotericin	B-Chemical	NOUN	B
B	I-Chemical	NOUN	O
seems	O	VERB	O
to	O	PART	O
be	O	AUX	O
the	O	DET	O
probable	O	ADJ	O
cause	O	NOUN	B
of	O	ADP	O
the	O	DET	O
seizures	B-Disease	NOUN	B
.	O	PUNCT	O


To	O	ADP	O
date	O	NOUN	O
,	O	PUNCT	O
only	O	ADV	O
three	O	NUM	O
cases	O	NOUN	B
of	O	ADP	O
seizures	B-Disease	NOUN	B
associated	O	VERB	B
with	O	ADP	I
amphotericin	B-Chemical	NOUN	B
B	I-Chemical	NOUN	I


Therapeutic	O	ADJ	B
drug	O	NOUN	I
monitoring	O	NOUN	O
of	O	ADP	O
tobramycin	B-Chemical	NOUN	B
:	O	PUNCT	O
once	O	ADV	B
-	O	PUNCT	O
daily	O	ADV	B
versus	O	CCONJ	O
twice	O	ADV	B
-	O	PUNCT	O
daily	O	ADJ	B
dosage	O	NOUN	B
schedules	O	NOUN	I
.	O	PUNCT	O


OBJECTIVE	O	NOUN	B
:	O	PUNCT	O
To	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
dosage	O	NOUN	B
regimen	O	NOUN	I
(	O	PUNCT	O
once	O	ADV	B
-	O	PUNCT	O
daily	O	ADJ	B
vs	O	ADV	O
.	O	PUNCT	O


twice	O	ADV	B
-	O	PUNCT	O
daily	O	ADV	B
)	O	PUNCT	O
of	O	ADP	O
tobramicyn	B-Chemical	NOUN	B
on	O	ADP	O
steady	O	ADJ	B
-	O	PUNCT	O
state	O	NOUN	B
serum	O	NOUN	B
concentrations	O	NOUN	B
and	O	CCONJ	O
toxicity	B-Disease	NOUN	B
.	O	PUNCT	O


MATERIALS	O	NOUN	O
AND	O	CCONJ	O
METHODS	O	NOUN	O
:	O	PUNCT	O
Patients	O	NOUN	B
undergoing	O	VERB	O
treatment	O	NOUN	B
with	O	ADP	O
i	O	PRON	O
.	O	PUNCT	O


v	O	NOUN	O
.	O	PUNCT	O


tobramycin	B-Chemical	NOUN	B
(	O	PUNCT	O
4	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
/	O	PUNCT	O
day	O	NOUN	B
)	O	PUNCT	O
were	O	AUX	O
randomised	O	VERB	B
to	O	ADP	O
two	O	NUM	O
groups	O	NOUN	B
.	O	PUNCT	O


Group	O	NOUN	B
OD	O	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
22	O	NUM	O
)	O	PUNCT	O
received	O	VERB	O
a	O	DET	O
once	O	ADV	B
-	O	PUNCT	O
daily	O	ADJ	B
dose	O	NOUN	B
of	O	ADP	O
tobramycin	B-Chemical	NOUN	B
and	O	CCONJ	O
group	O	NOUN	B
TD	O	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
21	O	NUM	O
)	O	PUNCT	O
received	O	VERB	O
the	O	DET	O
same	O	ADJ	O
dose	O	NOUN	B
divided	O	VERB	B
into	O	ADP	O
two	O	NUM	O
doses	O	NOUN	B
daily	O	ADV	B
.	O	PUNCT	O


Tobramycin	B-Chemical	NOUN	B
serum	O	NOUN	O
concentrations	O	NOUN	O
(	O	PUNCT	O
peak	O	NOUN	B
and	O	CCONJ	O
trough	O	NOUN	B
)	O	PUNCT	O
were	O	AUX	O
measured	O	VERB	B
by	O	ADP	O
enzyme	O	NOUN	B
multiplied	O	VERB	O
immunoassay	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
renal	O	ADJ	B
and	O	CCONJ	O
auditory	O	ADJ	B
functions	O	NOUN	I
of	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
were	O	AUX	O
monitored	O	VERB	B
before	O	ADP	O
,	O	PUNCT	O
during	O	ADP	O
and	O	CCONJ	O
immediately	O	ADV	O
after	O	ADP	O
treatment	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
The	O	DET	O
two	O	NUM	O
groups	O	NOUN	B
were	O	AUX	O
comparable	O	ADJ	O
with	O	ADP	O
respect	O	NOUN	O
to	O	PART	O
sex	O	NOUN	B
,	O	PUNCT	O
age	O	NOUN	B
,	O	PUNCT	O
body	O	NOUN	B
weight	O	NOUN	I
and	O	CCONJ	O
renal	O	ADJ	B
function	O	NOUN	I
.	O	PUNCT	O


No	O	DET	O
statistically	O	ADV	B
significant	O	ADJ	I
differences	O	NOUN	O
were	O	AUX	O
found	O	VERB	O
in	O	ADP	O
mean	O	ADJ	O
daily	O	ADJ	B
dose	O	NOUN	I
,	O	PUNCT	O
duration	O	NOUN	B
of	O	ADP	O
treatment	O	NOUN	B
,	O	PUNCT	O
or	O	CCONJ	O
cumulative	O	ADJ	B
dose	O	NOUN	B
.	O	PUNCT	O


Trough	O	NOUN	B
concentrations	O	NOUN	B
were	O	AUX	O
<	O	X	O
2	O	NUM	O
g	O	NOUN	O
/	O	PUNCT	O
ml	O	NOUN	O
in	O	ADP	O
the	O	DET	O
two	O	NUM	O
groups	O	NOUN	B
(	O	PUNCT	O
100	O	NUM	O
%).	O	ADJ	O
Peak	O	ADJ	B
concentrations	O	NOUN	I
were	O	AUX	O
>	O	X	O
6	O	NUM	O
microg	O	NOUN	B
/	O	PUNCT	O
ml	O	NOUN	O
in	O	ADP	O
100	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
OD	O	NOUN	B
group	O	NOUN	B
and	O	CCONJ	O
in	O	ADP	O
67	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
TD	O	ADJ	B
group	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


01	O	NUM	O
).	O	PUNCT	O
Mean	O	NOUN	O
peak	O	NOUN	O
concentrations	O	NOUN	O
were	O	AUX	O
markedly	O	ADV	O
different	O	ADJ	O
:	O	PUNCT	O
11	O	NUM	O
.	O	PUNCT	O


00	O	NUM	O
+/-	O	CCONJ	O
2	O	NUM	O
.	O	PUNCT	O


89	O	NUM	O
microg	O	NOUN	B
/	O	PUNCT	O
ml	O	NOUN	O
in	O	ADP	O
OD	O	NOUN	B
vs	O	CCONJ	O
.	O	PUNCT	O


6	O	NUM	O
.	O	PUNCT	O


53	O	NUM	O
+/-	O	CCONJ	O
1	O	NUM	O
.	O	PUNCT	O


45	O	NUM	O
microg	O	NOUN	B
/	O	PUNCT	O
ml	O	NOUN	O
in	O	ADP	O
TD	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


01	O	NUM	O
).	O	PUNCT	O
The	O	DET	O
pharmacokinetics	O	NOUN	B
parameters	O	NOUN	B
were	O	AUX	O
:	O	PUNCT	O
Ke	O	PROPN	O
,(	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


15	O	NUM	O
+/-	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


03	O	NUM	O
/	O	SYM	O
h	O	NOUN	O
in	O	ADP	O
OD	O	NOUN	B
vs	O	CCONJ	O
.	O	PUNCT	O


0	O	NUM	O
.	O	PUNCT	O


24	O	NUM	O
+/-	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


06	O	NUM	O
/	O	SYM	O
h	O	NOUN	O
in	O	ADP	O
TD	O	NOUN	B
),	O	PROPN	O
t1	O	NOUN	B
/	O	SYM	O
2	O	NUM	O
,(	O	PUNCT	O
4	O	NUM	O
.	O	PUNCT	O


95	O	NUM	O
+/-	O	CCONJ	O
1	O	NUM	O
.	O	PUNCT	O


41	O	NUM	O
h	O	NOUN	O
in	O	ADP	O
OD	O	NOUN	B
vs	O	CCONJ	O
.	O	PUNCT	O


3	O	X	O
.	O	PUNCT	O


07	O	NUM	O
+/-	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


71	O	NUM	O
h	O	NOUN	O
in	O	ADP	O
TD	O	NOUN	B
),	O	PUNCT	O
Vd	O	NOUN	B
(	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


35	O	NUM	O
+/-	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


11	O	NUM	O
l	O	X	O
/	O	SYM	O
kg	O	NOUN	B
in	O	ADP	O
OD	O	NOUN	B
vs	O	CCONJ	O
.	O	PUNCT	O


0	O	NUM	O
.	O	PUNCT	O


33	O	NUM	O
+/-	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


09	O	NUM	O
l	O	X	O
/	O	SYM	O
kg	O	NOUN	B
in	O	ADP	O
TD	O	NOUN	B
),	O	PUNCT	O
Cl	O	NOUN	B
(	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


86	O	NUM	O
+/-	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


29	O	NUM	O
ml	O	NOUN	O
/	O	SYM	O
min	O	NOUN	B
/	O	SYM	O
kg	O	NOUN	B
in	O	ADP	O
OD	O	NOUN	B
vs	O	CCONJ	O
.	O	PUNCT	O


1	O	X	O
.	O	PUNCT	O


28	O	NUM	O
+/-	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


33	O	NUM	O
ml	O	NOUN	O
/	O	SYM	O
min	O	NOUN	B
/	O	SYM	O
kg	O	NOUN	B
in	O	ADP	O
TD	O	NOUN	B
).	O	PUNCT	O
Increased	O	VERB	B
serum	O	NOUN	B
creatinine	B-Chemical	NOUN	I
was	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
73	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
in	O	ADP	O
OD	O	NOUN	B
versus	O	CCONJ	O
57	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
in	O	ADP	O
TD	O	NOUN	B
,	O	PUNCT	O
without	O	ADP	O
evidence	O	NOUN	B
of	O	ADP	O
nephrotoxicity	B-Disease	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
TD	O	ADJ	B
group	O	NOUN	B
,	O	PUNCT	O
three	O	NUM	O
patients	O	NOUN	B
developed	O	VERB	O
decreased	B-Disease	VERB	B
auditory	I-Disease	ADJ	B
function	I-Disease	NOUN	I
,	O	PUNCT	O
of	O	ADP	O
which	O	DET	O
one	O	NUM	O
presented	O	VERB	O
with	O	ADP	O
an	O	DET	O
auditory	B-Disease	ADJ	B
loss	I-Disease	NOUN	I
of	O	ADP	O
-	O	PUNCT	O
30	O	NUM	O
dB	O	NOUN	B
,	O	PUNCT	O
whereas	O	SCONJ	O
in	O	ADP	O
the	O	DET	O
OD	O	NOUN	B
group	O	NOUN	B
only	O	ADV	O
one	O	NUM	O
patient	O	NOUN	B
presented	O	VERB	O
decreased	B-Disease	VERB	B
auditory	I-Disease	ADJ	B
function	I-Disease	NOUN	I
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
:	O	PUNCT	O
This	O	DET	O
small	O	ADJ	B
study	O	NOUN	I
suggests	O	VERB	O
that	O	SCONJ	O
a	O	DET	O
once	O	ADV	B
-	O	PUNCT	O
daily	O	ADJ	B
dosing	O	NOUN	B
regimen	O	NOUN	B
of	O	ADP	O
tobramycin	B-Chemical	NOUN	B


Chronic	O	ADJ	B
effects	O	NOUN	I
of	O	ADP	O
a	O	DET	O
novel	O	ADJ	O
synthetic	O	ADJ	B
anthracycline	B-Chemical	NOUN	I
derivative	O	NOUN	I
(	O	PUNCT	O
SM-5887	B-Chemical	PROPN	B
)	O	PUNCT	O
on	O	ADP	O
normal	O	ADJ	B
heart	O	NOUN	I
and	O	CCONJ	O
doxorubicin	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
cardiomyopathy	B-Disease	NOUN	B
in	O	ADP	O
beagle	O	ADJ	B
dogs	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
study	O	NOUN	B
was	O	AUX	O
designed	O	VERB	O
to	O	PART	O
investigate	O	VERB	B
the	O	DET	O
chronic	O	ADJ	B
cardiotoxic	B-Disease	ADJ	O
potential	O	NOUN	O
of	O	ADP	O
SM-5887	B-Chemical	ADJ	B
and	O	CCONJ	O
a	O	DET	O
possible	O	ADJ	O
deteriorating	O	ADJ	B
effect	O	NOUN	B
of	O	ADP	O
SM-5887	B-Chemical	NOUN	B
on	O	ADP	O
low	O	ADJ	B
-	O	PUNCT	O
grade	O	NOUN	B
cardiotoxicity	B-Disease	NOUN	B
pre	O	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
by	O	ADP	O
doxorubicin	B-Chemical	NOUN	B
in	O	ADP	O
beagle	O	ADJ	B
dogs	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
chronic	O	ADJ	B
treatment	O	NOUN	I
,	O	PUNCT	O
beagle	O	ADJ	B
dogs	O	NOUN	I
of	O	ADP	O
each	O	DET	O
sex	O	NOUN	B
were	O	AUX	O
given	O	VERB	O
intravenously	O	ADV	B
once	O	ADV	O
every	O	DET	O
3	O	NUM	O
weeks	O	NOUN	B
,	O	PUNCT	O
either	O	CCONJ	O
a	O	DET	O
sublethal	O	ADJ	B
dose	O	NOUN	B
of	O	ADP	O
doxorubicin	B-Chemical	NOUN	B
(	O	PUNCT	O
1	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
)	O	PUNCT	O
or	O	CCONJ	O
SM-5887	B-Chemical	X	B
(	O	PUNCT	O
2	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
).	O	PUNCT	O
The	O	DET	O
experiment	O	NOUN	B
was	O	AUX	O
terminated	O	VERB	O
3	O	NUM	O
weeks	O	NOUN	B
after	O	ADP	O
the	O	DET	O
ninth	O	ADJ	O
dosing	O	NOUN	B
.	O	PUNCT	O


Animals	O	NOUN	B
which	O	DET	O
received	O	VERB	O
over	O	ADP	O
six	O	NUM	O
courses	O	NOUN	B
of	O	ADP	O
doxorubicin	B-Chemical	NOUN	B
demonstrated	O	VERB	O
the	O	DET	O
electrocardiogram	O	NOUN	B
(	O	PUNCT	O
ECG	O	NOUN	B
)	O	PUNCT	O
changes	O	NOUN	B
,	O	PUNCT	O
decrease	O	NOUN	B
of	O	ADP	O
blood	O	NOUN	B
pressure	O	NOUN	I
and	O	CCONJ	O
high	O	ADJ	B
-	O	PUNCT	O
grade	O	NOUN	B
histopathological	O	ADJ	B
cardiomyopathy	B-Disease	NOUN	O
,	O	PUNCT	O
while	O	SCONJ	O
animals	O	NOUN	B
which	O	DET	O
were	O	AUX	O
terminally	O	ADV	O
sacrificed	O	VERB	B
after	O	ADP	O
the	O	DET	O
SM-5887	B-Chemical	ADJ	B
administration	O	NOUN	B
did	O	AUX	O
not	O	PART	O
show	O	VERB	O
any	O	DET	O
changes	O	NOUN	B
in	O	ADP	O
ECG	O	PROPN	B
,	O	PUNCT	O
blood	O	NOUN	B
pressure	O	NOUN	I
and	O	CCONJ	O
histopathological	O	ADJ	B
examinations	O	NOUN	B
.	O	PUNCT	O


To	O	PART	O
examine	O	VERB	O
a	O	DET	O
possibly	O	ADV	O
deteriorating	O	VERB	B
cardiotoxic	B-Disease	ADJ	B
effect	O	NOUN	I
of	O	ADP	O
SM-5887	B-Chemical	ADJ	B
,	O	PUNCT	O
low	O	ADJ	B
-	O	PUNCT	O
grade	O	NOUN	B
cardiomyopathy	B-Disease	NOUN	B
was	O	AUX	O
induced	O	VERB	B
in	O	ADP	O
dogs	O	NOUN	B
by	O	ADP	O
four	O	NUM	O
courses	O	NOUN	B
of	O	ADP	O
doxorubicin	B-Chemical	NOUN	B
(	O	PUNCT	O
1	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
).	O	PUNCT	O
Nine	O	NUM	O
weeks	O	NOUN	B
after	O	ADP	O
pre	O	ADJ	B
-	O	PUNCT	O
treatment	O	NOUN	B
,	O	PUNCT	O
dogs	O	NOUN	B
were	O	AUX	O
given	O	VERB	O
four	O	NUM	O
courses	O	NOUN	B
of	O	ADP	O
either	O	CCONJ	O
doxorubicin	B-Chemical	NOUN	B
(	O	PUNCT	O
1	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
)	O	PUNCT	O
or	O	CCONJ	O
SM-5887	B-Chemical	X	B
(	O	PUNCT	O
2	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
)	O	PUNCT	O
once	O	ADV	O
every	O	DET	O
3	O	NUM	O
weeks	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
low	O	ADJ	B
-	O	PUNCT	O
grade	O	NOUN	B
cardiotoxic	B-Disease	ADJ	B
changes	O	NOUN	B
were	O	AUX	O
enhanced	O	VERB	B
by	O	ADP	O
the	O	DET	O
additional	O	ADJ	O
doxorubicin	B-Chemical	NOUN	B
treatment	O	NOUN	B
.	O	PUNCT	O


On	O	ADP	O
the	O	DET	O
contrary	O	NOUN	O
,	O	PUNCT	O
the	O	DET	O
SM-5887	B-Chemical	ADJ	B
treatment	O	NOUN	B
did	O	AUX	O
not	O	PART	O
progress	O	VERB	B
the	O	DET	O
grade	O	NOUN	B
of	O	ADP	I
cardiomyopathy	B-Disease	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
conclusion	O	NOUN	O
,	O	PUNCT	O
SM-5887	B-Chemical	PROPN	B
does	O	AUX	O
not	O	PART	O
have	O	AUX	O
any	O	DET	O
potential	O	NOUN	B
of	O	ADP	O
chronic	O	ADJ	B
cardiotoxicity	B-Disease	NOUN	B
and	O	CCONJ	O
deteriorating	O	VERB	B
effect	O	NOUN	O
on	O	ADP	O
doxorubicin	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
cardiotoxicity	B-Disease	NOUN	B


Posteroventral	O	ADJ	B
medial	O	ADJ	O
pallidotomy	O	NOUN	B
in	O	ADP	O
advanced	O	ADJ	B
Parkinson's	B-Disease	ADJ	O
disease	I-Disease	NOUN	O
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
:	O	PUNCT	O
Posteroventral	O	ADJ	B
medial	O	ADJ	B
pallidotomy	O	NOUN	B
sometimes	O	ADV	O
produces	O	VERB	O
striking	O	ADJ	O
improvement	O	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
advanced	O	ADJ	B
Parkinson's	B-Disease	ADJ	O
disease	I-Disease	NOUN	O
,	O	PUNCT	O
but	O	CCONJ	O
the	O	DET	O
studies	O	NOUN	B
to	O	ADP	O
date	O	NOUN	O
have	O	AUX	O
involved	O	VERB	O
small	O	ADJ	O
numbers	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
and	O	CCONJ	O
short	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
follow	O	VERB	B
-	O	PUNCT	O
up	O	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
:	O	PUNCT	O
Forty	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
Parkinson's	B-Disease	ADJ	B
disease	I-Disease	NOUN	I
underwent	O	VERB	O
serial	O	ADJ	B
,	O	PUNCT	O
detailed	O	ADJ	O
assessments	O	NOUN	B
both	O	CCONJ	O
after	O	ADP	O
drug	O	NOUN	B
withdrawal	O	NOUN	I
("	O	NOUN	I
off	O	ADP	O
"	O	PUNCT	O
period	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
while	O	SCONJ	O
taking	O	VERB	O
their	O	PRON	O
optimal	O	ADJ	B
medical	O	ADJ	B
regimens	O	NOUN	I
("	O	NOUN	O
on	O	ADP	O
"	O	PUNCT	O
period	O	NOUN	B
).	O	PUNCT	O
All	O	DET	O
patients	O	NOUN	B
were	O	AUX	O
examined	O	VERB	B
preoperatively	O	ADV	B
and	O	CCONJ	O
39	O	NUM	O
were	O	AUX	O
examined	O	VERB	B
at	O	ADP	O
six	O	NUM	O
months	O	NOUN	B
;	O	PUNCT	O
27	O	NUM	O
of	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
were	O	AUX	O
also	O	ADV	O
examined	O	VERB	O
at	O	ADP	O
one	O	NUM	O
year	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
11	O	NUM	O
at	O	ADP	O
two	O	NUM	O
years	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
The	O	DET	O
percent	O	NOUN	O
improvements	O	NOUN	B
at	O	ADP	O
six	O	NUM	O
months	O	NOUN	B
were	O	AUX	O
as	O	ADP	O
follows	O	VERB	O
:	O	PUNCT	O
off	O	ADV	B
-	O	PUNCT	O
period	O	NOUN	B
score	O	NOUN	B
for	O	ADP	O
overall	O	ADJ	O
motor	O	NOUN	B
function	O	NOUN	I
,	O	PUNCT	O
28	O	NUM	O
percent	O	NOUN	O
(	O	PUNCT	O
95	O	NUM	O
percent	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
,	O	PUNCT	O
19	O	NUM	O
to	O	PART	O
38	O	NUM	O
percent	O	NOUN	O
),	O	PUNCT	O
with	O	ADP	O
most	O	ADJ	O
of	O	ADP	O
the	O	DET	O
improvement	O	NOUN	B
in	O	ADP	O
the	O	DET	O
contralateral	O	ADJ	B
limbs	O	NOUN	I
;	O	PUNCT	O
off	O	ADV	B
-	O	PUNCT	O
period	O	NOUN	B
score	O	NOUN	B
for	O	ADP	O
activities	O	NOUN	B
of	O	ADP	O
daily	O	ADJ	B
living	O	NOUN	O
,	O	PUNCT	O
29	O	NUM	O
percent	O	NOUN	O
(	O	PUNCT	O
95	O	NUM	O
percent	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
,	O	PUNCT	O
19	O	NUM	O
to	O	PART	O
39	O	NUM	O
percent	O	NOUN	O
);	O	ADJ	B
on	O	ADP	O
-	O	PUNCT	O
period	O	NOUN	B
score	O	NOUN	B
for	O	ADP	O
contralateral	O	ADJ	B
dyskinesias	B-Disease	NOUN	I
,	O	PUNCT	O
82	O	NUM	O
percent	O	NOUN	O
(	O	PUNCT	O
95	O	NUM	O
percent	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
,	O	PUNCT	O
72	O	NUM	O
to	O	PART	O
91	O	NUM	O
percent	O	NOUN	O
);	O	ADJ	B
and	O	CCONJ	O
on	O	ADP	B
-	O	PUNCT	O
period	O	NOUN	B
score	O	NOUN	B
for	O	ADP	O
ipsilateral	O	ADJ	B
dyskinesias	B-Disease	NOUN	I
,	O	PUNCT	O
44	O	NUM	O
percent	O	NOUN	O
(	O	PUNCT	O
95	O	NUM	O
percent	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
,	O	PUNCT	O
29	O	NUM	O
to	O	PART	O
59	O	NUM	O
percent	O	NOUN	O
).	O	PUNCT	O
The	O	DET	O
improvements	O	NOUN	B
in	O	ADP	O
dyskinesias	B-Disease	NOUN	B
and	O	CCONJ	O
the	O	DET	O
total	O	NOUN	O
scores	O	NOUN	B
for	O	ADP	O
off	O	ADJ	B
-	O	PUNCT	O
period	O	NOUN	B
parkinsonism	B-Disease	NOUN	B
,	O	PUNCT	O
contralateral	O	ADJ	B
bradykinesia	B-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
rigidity	B-Disease	NOUN	B
were	O	AUX	O
sustained	O	ADJ	B
in	O	ADP	O
the	O	DET	O
11	O	NUM	O
patients	O	NOUN	B
examined	O	VERB	B
at	O	ADP	O
two	O	NUM	O
years	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
improvement	O	NOUN	B
in	O	ADP	O
ipsilateral	O	ADJ	B
dyskinesias	B-Disease	NOUN	I
was	O	AUX	O
lost	O	VERB	B
after	O	ADP	O
one	O	NUM	O
year	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
improvements	O	NOUN	B
in	O	ADP	O
postural	O	ADJ	B
stability	O	NOUN	I
and	O	CCONJ	O
gait	O	NOUN	B
lasted	O	VERB	O
only	O	ADV	O
three	O	NUM	O
to	O	PART	O
six	O	NUM	O
months	O	NOUN	B
.	O	PUNCT	O


Approximately	O	ADV	O
half	O	DET	O
the	O	DET	O
patients	O	NOUN	B
who	O	PRON	O
had	O	AUX	O
been	O	AUX	O
dependent	O	ADJ	O
on	O	ADP	O
assistance	O	NOUN	B
in	O	ADP	O
activities	O	NOUN	B
of	O	ADP	O
daily	O	ADV	B
living	O	NOUN	O
in	O	ADP	O
the	O	DET	O
off	O	ADJ	O
period	O	NOUN	B
before	O	ADP	O
surgery	O	NOUN	B
became	O	VERB	O
independent	O	ADJ	B
after	O	ADP	O
surgery	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
complications	O	NOUN	B
of	O	ADP	O
surgery	O	NOUN	B
were	O	AUX	O
generally	O	ADV	O
well	O	ADV	O
tolerated	O	ADJ	B
,	O	PUNCT	O
and	O	CCONJ	O
there	O	PRON	O
were	O	AUX	O
no	O	DET	O
significant	O	ADJ	O
changes	O	NOUN	B
in	O	ADP	O
the	O	DET	O
use	O	NOUN	O
of	O	ADP	O
medication	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
:	O	PUNCT	O
In	O	ADP	O
late	O	ADJ	B
-	O	PUNCT	O
stage	O	NOUN	B
Parkinson's	B-Disease	ADJ	O
disease	I-Disease	NOUN	O
,	O	PUNCT	O
pallidotomy	O	NOUN	B
significantly	O	ADV	O
reduces	O	VERB	B
levodopa	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
dyskinesias	B-Disease	NOUN	B


Neuropeptide	O	NOUN	B
-	O	PUNCT	O
Y	O	NOUN	B
immunoreactivity	O	NOUN	B
in	O	ADP	O
the	O	DET	O
pilocarpine	B-Chemical	NOUN	B
model	O	NOUN	B
of	O	ADP	O
temporal	B-Disease	ADJ	B
lobe	I-Disease	NOUN	I
epilepsy	I-Disease	NOUN	I
.	O	PUNCT	O


Neuropeptide	O	NOUN	B
-	O	PUNCT	O
Y	O	NOUN	B
(	O	PUNCT	O
NPY	O	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
expressed	O	VERB	B
by	O	ADP	O
granule	O	NOUN	B
cells	O	NOUN	I
and	O	CCONJ	O
mossy	O	NOUN	B
fibres	O	NOUN	I
of	O	ADP	O
the	O	DET	O
hippocampal	O	ADJ	B
dentate	O	NOUN	B
gyrus	O	NOUN	I
during	O	ADP	O
experimental	O	ADJ	B
temporal	B-Disease	ADJ	O
lobe	I-Disease	NOUN	O
epilepsy	I-Disease	NOUN	O
(	O	PUNCT	O
TLE	B-Disease	PROPN	B
).	O	PUNCT	O
This	O	DET	O
expression	O	NOUN	B
may	O	AUX	O
represent	O	VERB	O
an	O	DET	O
endogenous	O	ADJ	B
damping	O	NOUN	B
mechanism	O	NOUN	O
since	O	SCONJ	O
NPY	O	NOUN	B
has	O	AUX	O
been	O	AUX	O
shown	O	VERB	O
to	O	PART	O
block	O	VERB	B
seizure	B-Disease	NOUN	I
-	O	PUNCT	O
like	O	NOUN	O
events	O	NOUN	B
following	O	VERB	O
high	O	ADJ	B
-	O	PUNCT	O
frequency	O	NOUN	B
stimulation	O	NOUN	B
in	O	ADP	O
hippocampal	O	NOUN	B
slices	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
pilocarpine	B-Chemical	NOUN	B
(	O	PUNCT	O
PILO	B-Chemical	NOUN	B
)	O	PUNCT	O
model	O	NOUN	B
of	O	ADP	O
epilepsy	B-Disease	NOUN	B
is	O	AUX	O
characterized	O	VERB	B
by	O	ADP	O
an	O	DET	O
acute	O	ADJ	B
period	O	NOUN	B
of	O	ADP	O
status	B-Disease	NOUN	B
epilepticus	I-Disease	NOUN	I
followed	O	VERB	O
by	O	ADP	O
spontaneous	O	ADJ	B
recurrent	O	ADJ	O
seizures	B-Disease	NOUN	O
and	O	CCONJ	O
related	O	ADJ	O
brain	B-Disease	NOUN	B
damage	I-Disease	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	B
peroxidase	O	NOUN	B
-	O	PUNCT	O
antiperoxidase	O	NOUN	B
immunostaining	O	NOUN	B
for	O	ADP	O
NPY	O	NOUN	B
in	O	ADP	O
several	O	ADJ	O
brain	O	NOUN	B
regions	O	NOUN	I
in	O	ADP	O
this	O	DET	O
model	O	NOUN	B
.	O	PUNCT	O


PILO	B-Chemical	NOUN	B
-	O	PUNCT	O
injected	O	VERB	B
animals	O	NOUN	B
exhibited	O	VERB	O
NPY	O	NOUN	B
immunoreactivity	O	NOUN	B
in	O	ADP	O
the	O	DET	O
region	O	NOUN	B
of	O	ADP	O
the	O	DET	O
mossy	O	NOUN	B
fibre	O	NOUN	I
terminals	O	NOUN	I
,	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
dentate	O	NOUN	B
gyrus	O	NOUN	I
inner	O	ADJ	B
molecular	O	ADJ	I
layer	O	NOUN	I
and	O	CCONJ	O
,	O	PUNCT	O
in	O	ADP	O
a	O	DET	O
few	O	ADJ	O
cases	O	NOUN	B
,	O	PUNCT	O
within	O	ADP	O
presumed	O	VERB	O
granule	O	NOUN	B
cells	O	NOUN	I
.	O	PUNCT	O


NPY	O	NOUN	B
immunoreactivity	O	NOUN	B
was	O	AUX	O
also	O	ADV	O
dramatically	O	ADV	O
changed	O	VERB	B
in	O	ADP	O
the	O	DET	O
entorhinal	O	ADJ	B
cortex	O	NOUN	I
,	O	PUNCT	O
amygdala	O	NOUN	B
and	O	CCONJ	O
sensorimotor	O	NOUN	B
areas	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
,	O	PUNCT	O
PILO	B-Chemical	NOUN	B
injected	O	VERB	B
animals	O	NOUN	B
exhibited	O	VERB	O
a	O	DET	O
reduction	O	NOUN	B
in	O	ADP	O
the	O	DET	O
number	O	NOUN	O
of	O	ADP	O
NPY	O	NOUN	B
-	O	PUNCT	O
immunoreactive	O	ADJ	B
interneurons	O	NOUN	B
compared	O	VERB	B
with	O	ADP	O
controls	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
results	O	NOUN	B
demonstrate	O	VERB	O
that	O	SCONJ	O
changes	O	NOUN	B
in	O	ADP	O
NPY	O	NOUN	B
expression	O	NOUN	B
,	O	PUNCT	O
including	O	VERB	O
expression	O	NOUN	B
in	O	ADP	O
the	O	DET	O
granule	O	NOUN	B
cells	O	NOUN	I
and	O	CCONJ	O
mossy	O	NOUN	B
fibres	O	NOUN	I
and	O	CCONJ	O
the	O	DET	O
loss	O	NOUN	B
of	O	ADP	O
vulnerable	O	ADJ	B
NPY	O	NOUN	B
neurons	O	NOUN	B
,	O	PUNCT	O
are	O	AUX	O
present	O	ADJ	O
in	O	ADP	O
the	O	DET	O
PILO	B-Chemical	NOUN	B
model	O	NOUN	B
of	O	ADP	O
TLE	B-Disease	PROPN	B


Effect	O	NOUN	B
of	O	ADP	O
myopic	O	ADJ	B
excimer	O	NOUN	B
laser	O	NOUN	B
photorefractive	O	ADJ	I
keratectomy	O	NOUN	I
on	O	ADP	O
the	O	DET	O
electrophysiologic	O	ADJ	B
function	O	NOUN	I
of	O	ADP	O
the	O	DET	O
retina	O	NOUN	B
and	O	CCONJ	O
optic	O	ADJ	B
nerve	O	NOUN	I
.	O	PUNCT	O


PURPOSE	O	NOUN	B
:	O	PUNCT	O
To	O	PART	O
assess	O	VERB	O
by	O	ADP	O
electrophysiologic	O	ADJ	B
testing	O	NOUN	I
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
photorefractive	O	ADJ	B
keratectomy	O	NOUN	I
(	O	PUNCT	O
PRK	O	NOUN	B
)	O	PUNCT	O
on	O	ADP	O
the	O	DET	O
retina	O	NOUN	B
and	O	CCONJ	O
optic	O	ADJ	B
nerve	O	NOUN	I
.	O	PUNCT	O


SETTING	O	NOUN	B
:	O	PUNCT	O
Eye	O	PROPN	B
Clinic	O	PROPN	I
,	O	PUNCT	O
S	O	PROPN	B
.	O	PUNCT	O


Salvatore	O	PROPN	B
Hospital	O	PROPN	I
,	O	PUNCT	O
L	O	PROPN	B
'	O	PART	I
Aquila	O	PROPN	I
University	O	PROPN	I
,	O	PUNCT	O
Italy	O	PROPN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
:	O	PUNCT	O
Standard	O	ADJ	B
pattern	O	NOUN	I
electroretinograms	O	NOUN	I
(	O	PUNCT	O
P	O	NOUN	B
-	O	PUNCT	O
ERGs	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
standard	O	ADJ	B
pattern	O	NOUN	I
visual	O	ADJ	I
evoked	O	ADJ	I
potentials	O	NOUN	I
(	O	PUNCT	O
P	O	NOUN	B
-	O	PUNCT	O
VEPs	O	NOUN	B
)	O	PUNCT	O
were	O	AUX	O
done	O	VERB	O
in	O	ADP	O
25	O	NUM	O
eyes	O	NOUN	B
of	O	ADP	O
25	O	NUM	O
patients	O	NOUN	B
who	O	PRON	O
had	O	AUX	O
myopic	O	ADJ	B
PRK	O	PROPN	B
for	O	ADP	O
an	O	DET	O
attempted	O	VERB	O
correction	O	NOUN	B
between	O	ADP	O
5	O	NUM	O
.	O	PUNCT	O


00	O	NUM	O
and	O	CCONJ	O
15	O	NUM	O
.	O	PUNCT	O


00	O	NUM	O
diopters	O	NOUN	O
(	O	PUNCT	O
D	O	NOUN	B
)(	O	NOUN	O
mean	O	VERB	O
8	O	NUM	O
.	O	PUNCT	O


00	O	NUM	O
D	O	NOUN	O
).	O	PROPN	O
Testing	O	NOUN	O
was	O	AUX	O
done	O	VERB	O
preoperatively	O	ADV	B
and	O	CCONJ	O
3	O	NUM	O
,	O	PUNCT	O
6	O	NUM	O
,	O	PUNCT	O
12	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
18	O	NUM	O
months	O	NOUN	B
postoperatively	O	ADV	B
.	O	PUNCT	O


The	O	DET	O
contralateral	O	ADJ	B
eyes	O	NOUN	B
served	O	VERB	O
as	O	ADP	O
controls	O	NOUN	B
.	O	PUNCT	O


During	O	ADP	O
the	O	DET	O
follow	O	NOUN	B
-	O	PUNCT	O
up	O	ADP	O
,	O	PUNCT	O
3	O	NUM	O
patients	O	NOUN	B
(	O	PUNCT	O
12	O	NUM	O
%)	O	NOUN	O
developed	O	VERB	O
steroid	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
elevated	B-Disease	ADJ	B
intraocular	I-Disease	ADJ	I
pressure	I-Disease	NOUN	I
(	O	PUNCT	O
IOP	O	NOUN	B
)	O	PUNCT	O
that	O	PRON	O
resolved	O	VERB	B
after	O	ADP	O
corticosteroid	B-Chemical	NOUN	B
therapy	O	NOUN	I
was	O	AUX	O
discontinued	O	VERB	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
No	O	DET	O
statistically	O	ADV	B
significant	O	ADJ	I
differences	O	NOUN	O
were	O	AUX	O
seen	O	VERB	O
between	O	ADP	O
treated	O	VERB	B
and	O	CCONJ	O
control	O	ADJ	B
eyes	O	NOUN	I
nor	O	CCONJ	O
between	O	ADP	O
treated	O	VERB	B
eyes	O	NOUN	B
preoperatively	O	ADV	B
and	O	CCONJ	O
postoperatively	O	ADV	B
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
:	O	PUNCT	O
Myopic	O	ADJ	B
excimer	O	NOUN	I
laser	O	NOUN	I
PRK	O	PROPN	B
did	O	AUX	O
not	O	PART	O
seem	O	VERB	O
to	O	PART	O
affect	O	VERB	O
the	O	DET	O
posterior	O	ADJ	B
segment	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
transient	O	ADJ	B
steroid	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
IOP	B-Disease	NOUN	B
rise	I-Disease	VERB	O


Liposomal	O	ADJ	B
daunorubicin	B-Chemical	NOUN	I
in	O	ADP	O
advanced	O	ADJ	O
Kaposi's	B-Disease	NOUN	B
sarcoma	I-Disease	NOUN	I
:	O	PUNCT	O
a	O	DET	O
phase	O	NOUN	B
II	O	NUM	I
study	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
a	O	DET	O
non	O	ADV	B
-	O	PUNCT	O
randomized	O	VERB	B
Phase	O	NOUN	B
II	O	NUM	I
clinical	O	ADJ	B
trial	O	NOUN	I
to	O	PART	O
assess	O	VERB	B
the	O	DET	O
efficacy	O	NOUN	B
and	O	CCONJ	O
safety	O	NOUN	B
of	O	ADP	O
liposomal	O	ADJ	B
daunorubicin	B-Chemical	NOUN	I
(	O	PUNCT	O
DaunoXome	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
AIDS	B-Disease	NOUN	B
related	O	ADJ	O
Kaposi's	B-Disease	NOUN	B
sarcoma	I-Disease	NOUN	I
.	O	PUNCT	O


Eleven	O	NUM	O
homosexual	O	ADJ	B
men	O	NOUN	B
with	O	ADP	O
advanced	O	ADJ	O
Kaposi's	B-Disease	NOUN	B
sarcoma	I-Disease	NOUN	I
were	O	AUX	O
entered	O	VERB	O
in	O	ADP	O
the	O	DET	O
trial	O	NOUN	B
.	O	PUNCT	O


Changes	O	NOUN	B
in	O	ADP	O
size	O	NOUN	B
,	O	PUNCT	O
colour	O	NOUN	B
and	O	CCONJ	O
associated	O	VERB	O
oedema	B-Disease	NOUN	B
of	O	ADP	O
selected	O	VERB	O
'	O	PART	O
target	O	NOUN	B
'	O	PART	O
lesions	O	NOUN	B
were	O	AUX	O
measured	O	VERB	B
.	O	PUNCT	O


Clinical	O	ADJ	B
,	O	PUNCT	O
biochemical	O	ADJ	B
and	O	CCONJ	O
haematological	O	ADJ	B
toxicities	B-Disease	NOUN	B
were	O	AUX	O
assessed	O	VERB	B
.	O	PUNCT	O


Ten	O	NUM	O
subjects	O	NOUN	B
were	O	AUX	O
evaluated	O	VERB	B
.	O	PUNCT	O


A	O	DET	O
partial	O	ADJ	B
response	O	NOUN	I
was	O	AUX	O
achieved	O	VERB	O
in	O	ADP	O
four	O	NUM	O
,	O	PUNCT	O
of	O	ADP	O
whom	O	PRON	O
two	O	NUM	O
subsequently	O	ADV	O
relapsed	O	VERB	B
.	O	PUNCT	O


Stabilization	O	NOUN	B
of	O	ADP	O
Kaposi's	B-Disease	NOUN	B
sarcoma	I-Disease	NOUN	I
occurred	O	VERB	O
in	O	ADP	O
the	O	DET	O
remaining	O	VERB	O
six	O	NUM	O
,	O	PUNCT	O
maintained	O	VERB	B
until	O	ADP	O
the	O	DET	O
end	O	NOUN	O
of	O	ADP	O
the	O	DET	O
trial	O	NOUN	B
period	O	NOUN	B
in	O	ADP	O
four	O	NUM	O
.	O	PUNCT	O


The	O	DET	O
drug	O	NOUN	B
was	O	AUX	O
generally	O	ADV	O
well	O	ADV	O
tolerated	O	ADJ	B
,	O	PUNCT	O
with	O	ADP	O
few	O	ADJ	O
mild	O	ADJ	B
symptoms	O	NOUN	B
of	O	ADP	O
toxicity	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
main	O	ADJ	O
problem	O	NOUN	B
encountered	O	VERB	O
was	O	AUX	O
haematological	O	ADJ	B
toxicity	B-Disease	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
three	O	NUM	O
subjects	O	NOUN	B
experiencing	O	VERB	O
severe	O	ADJ	B
neutropenia	B-Disease	NOUN	B
(	O	PUNCT	O
neutrophil	O	NOUN	B
count	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
x	O	CCONJ	O
10	O	NUM	O
(	O	PUNCT	O
9	O	NUM	O
)/	O	NUM	O
l	O	NOUN	O
).	O	PUNCT	B
There	O	PRON	O
was	O	AUX	O
no	O	DET	O
evidence	O	NOUN	O
of	O	ADP	O
cardiotoxicity	B-Disease	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
this	O	DET	O
small	O	ADJ	O
patient	O	NOUN	B
sample	O	NOUN	I
,	O	PUNCT	O
liposomal	O	ADJ	B
daunorubicin	B-Chemical	NOUN	I
was	O	AUX	O
an	O	DET	O
effective	O	ADJ	B
and	O	CCONJ	O
well	O	ADV	O
tolerated	O	VERB	B
agent	O	NOUN	I
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
Kaposi's	B-Disease	NOUN	B
sarcoma	I-Disease	NOUN	I


Failure	O	NOUN	B
of	O	ADP	O
ancrod	O	NOUN	B
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
heparin	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
arterial	O	ADJ	B
thrombosis	B-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
morbidity	O	NOUN	B
and	O	CCONJ	O
mortality	O	NOUN	B
associated	O	VERB	B
with	O	ADP	I
heparin	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
thrombosis	B-Disease	NOUN	B
remain	O	VERB	O
high	O	ADJ	O
despite	O	SCONJ	O
numerous	O	ADJ	O
empirical	O	ADJ	B
therapies	O	NOUN	I
.	O	PUNCT	O


Ancrod	O	NOUN	B
has	O	AUX	O
been	O	AUX	O
used	O	VERB	O
successfully	O	ADV	O
for	O	ADP	O
prophylaxis	O	NOUN	B
against	O	ADP	O
development	O	NOUN	B
of	O	ADP	O
thrombosis	B-Disease	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
heparin	B-Chemical	NOUN	B
induced	O	VERB	B
platelet	B-Disease	NOUN	B
aggregation	I-Disease	NOUN	I
who	O	PRON	O
require	O	VERB	O
brief	O	ADJ	B
reexposure	O	NOUN	I
to	O	ADP	O
heparin	B-Chemical	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
its	O	PRON	O
success	O	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
who	O	PRON	O
have	O	AUX	O
developed	O	VERB	O
the	O	DET	O
thrombosis	B-Disease	NOUN	B
syndrome	O	NOUN	I
is	O	AUX	O
not	O	PART	O
well	O	ADV	O
defined	O	VERB	O
.	O	PUNCT	O


The	O	DET	O
authors	O	NOUN	B
present	O	VERB	O
a	O	DET	O
case	O	NOUN	B
of	O	ADP	O
failure	O	NOUN	B
of	O	ADP	O
ancrod	O	ADJ	B
treatment	O	NOUN	B
in	O	ADP	O
a	O	DET	O
patient	O	NOUN	B
with	O	ADP	O
heparin	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
thrombosis	B-Disease	NOUN	B


Seizure	B-Disease	NOUN	B
after	O	ADP	O
flumazenil	B-Chemical	NOUN	B
administration	O	NOUN	B
in	O	ADP	O
a	O	DET	O
pediatric	O	ADJ	B
patient	O	NOUN	B
.	O	PUNCT	O


Flumazenil	B-Chemical	NOUN	B
is	O	AUX	O
a	O	DET	O
benzodiazepine	B-Chemical	NOUN	B
receptor	O	NOUN	I
antagonist	O	NOUN	B
used	O	VERB	O
to	O	PART	O
reverse	O	VERB	B
sedation	O	NOUN	I
and	O	CCONJ	O
respiratory	B-Disease	ADJ	B
depression	I-Disease	NOUN	I
induced	O	VERB	B
by	O	ADP	O
benzodiazepines	B-Chemical	NOUN	B
.	O	PUNCT	O


Seizures	B-Disease	NOUN	B
and	O	CCONJ	O
cardiac	B-Disease	ADJ	B
arrhythmias	I-Disease	NOUN	I
have	O	AUX	O
complicated	O	VERB	B
its	O	PRON	O
use	O	NOUN	O
in	O	ADP	O
adult	O	ADJ	B
patients	O	NOUN	B
.	O	PUNCT	O


Overdose	B-Disease	NOUN	B
patients	O	NOUN	B
who	O	PRON	O
have	O	AUX	O
coingested	O	VERB	B
tricyclic	O	ADJ	O
antidepressants	O	NOUN	O
have	O	AUX	O
a	O	DET	O
higher	O	ADJ	O
risk	O	NOUN	B
of	O	ADP	O
these	O	DET	O
complications	O	NOUN	B
.	O	PUNCT	O


Little	O	ADJ	O
information	O	NOUN	B
exists	O	VERB	O
concerning	O	VERB	O
adverse	O	ADJ	B
effects	O	NOUN	I
of	O	ADP	O
flumazenil	B-Chemical	NOUN	B
in	O	ADP	O
children	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
the	O	DET	O
occurrence	O	NOUN	B
of	O	ADP	O
a	O	DET	O
generalized	O	VERB	O
tonic-clonic	B-Disease	ADJ	B
seizure	I-Disease	NOUN	I
in	O	ADP	O
a	O	DET	O
pediatric	O	ADJ	B
patient	O	NOUN	B
following	O	VERB	O
the	O	DET	O
administration	O	NOUN	B
of	O	ADP	O
flumazenil	B-Chemical	NOUN	B


Remodelling	O	VERB	B
of	O	ADP	O
nerve	O	NOUN	B
structure	O	NOUN	I
in	O	ADP	O
experimental	O	ADJ	B
isoniazid	B-Chemical	NOUN	B
neuropathy	B-Disease	NOUN	I
in	O	ADP	O
the	O	DET	O
rat	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
neuropathy	B-Disease	NOUN	B
caused	O	VERB	O
by	O	ADP	O
a	O	DET	O
single	O	ADJ	B
dose	O	NOUN	I
of	O	ADP	O
isoniazid	B-Chemical	NOUN	B


Selective	O	ADJ	O
injection	O	NOUN	B
of	O	ADP	O
iopentol	B-Chemical	NOUN	B
,	O	PUNCT	O
iohexol	B-Chemical	NOUN	B
and	O	CCONJ	O
metrizoate	B-Chemical	NOUN	B
into	O	ADP	O
the	O	DET	O
left	O	ADJ	B
coronary	O	ADJ	I
artery	O	NOUN	I
of	O	ADP	O
the	O	DET	O
dog	O	NOUN	B
.	O	PUNCT	O


Induction	O	NOUN	B
of	O	ADP	O
ventricular	B-Disease	ADJ	B
fibrillation	I-Disease	NOUN	I
and	O	CCONJ	O
decrease	O	NOUN	B
of	O	ADP	O
aortic	O	ADJ	B
pressure	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
twenty	O	NUM	O
beagle	O	ADJ	B
dogs	O	NOUN	I
selective	O	ADJ	O
injections	O	NOUN	O
were	O	AUX	O
made	O	VERB	O
into	O	ADP	O
the	O	DET	O
left	O	ADJ	B
coronary	O	ADJ	I
artery	O	NOUN	I
with	O	ADP	O
iopentol	B-Chemical	NOUN	B
,	O	PUNCT	O
iohexol	B-Chemical	NOUN	B
and	O	CCONJ	O
metrizoate	B-Chemical	NOUN	B
in	O	ADP	O
doses	O	NOUN	B
of	O	ADP	O
4	O	NUM	O
ml	O	NOUN	O
,	O	PUNCT	O
8	O	NUM	O
ml	O	NOUN	O
and	O	CCONJ	O
16	O	NUM	O
ml	O	NOUN	O
.	O	PUNCT	O


Thirty	O	NUM	B
-	O	PUNCT	O
six	O	NUM	B
iopentol	B-Chemical	NOUN	B
injections	O	NOUN	B
,	O	PUNCT	O
35	O	NUM	O
iohexol	B-Chemical	ADJ	B
injections	O	NOUN	B
and	O	CCONJ	O
37	O	NUM	O
metrizoate	B-Chemical	ADJ	B
injections	O	NOUN	I
were	O	AUX	O
made	O	VERB	O
.	O	PUNCT	O


Frequencies	O	NOUN	B
of	O	ADP	O
ventricular	B-Disease	ADJ	B
fibrillation	I-Disease	NOUN	I
were	O	AUX	O
significantly	O	ADV	O
lower	O	ADJ	O
(	O	PUNCT	O
p	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


05	O	NUM	O
)	O	PUNCT	O
after	O	ADP	O
iopentol	B-Chemical	NOUN	B
(	O	PUNCT	O
0	O	NUM	O
%)	O	NOUN	O
and	O	CCONJ	O
iohexol	B-Chemical	NOUN	B
(	O	PUNCT	O
3	O	NUM	O
%)	O	NOUN	O
than	O	ADP	O
after	O	ADP	O
metrizoate	B-Chemical	NOUN	B
(	O	PUNCT	O
22	O	NUM	O
%).	O	ADJ	O
Iopentol	B-Chemical	NOUN	B
and	O	CCONJ	O
iohexol	B-Chemical	NOUN	B
also	O	ADV	O
produced	O	VERB	O
significantly	O	ADV	O
less	O	ADJ	O
decrease	O	NOUN	B
in	O	ADP	O
aortic	O	ADJ	B
blood	O	NOUN	I
pressure	O	NOUN	I
than	O	ADP	O
metrizoate	B-Chemical	NOUN	B


Magnetic	O	ADJ	B
resonance	O	NOUN	I
imaging	O	NOUN	I
of	O	ADP	O
cerebral	O	ADJ	B
venous	B-Disease	ADJ	I
thrombosis	I-Disease	NOUN	I
secondary	O	ADJ	B
to	O	PART	I
"	O	PUNCT	O
low	O	ADJ	B
-	O	PUNCT	O
dose	O	NOUN	B
"	O	PUNCT	O
birth	O	NOUN	B
control	O	NOUN	I
pills	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
clinical	O	ADJ	B
and	O	CCONJ	O
radiographic	O	ADJ	B
features	O	NOUN	B
of	O	ADP	O
cerebral	O	ADJ	B
deep	B-Disease	ADJ	I
venous	I-Disease	ADJ	I
thrombosis	I-Disease	NOUN	I
in	O	ADP	O
a	O	DET	O
21	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
white	O	ADJ	B
woman	O	NOUN	I
are	O	AUX	O
presented	O	VERB	O
.	O	PUNCT	O


This	O	DET	O
nulliparous	O	ADJ	B
patient	O	NOUN	B
presented	O	VERB	O
with	O	ADP	O
relatively	O	ADV	O
mild	O	ADJ	O
clinical	O	ADJ	B
symptoms	O	NOUN	I
and	O	CCONJ	O
progressing	O	VERB	B
mental	O	ADJ	B
status	O	NOUN	I
changes	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
only	O	ADV	O
known	O	ADJ	O
risk	O	NOUN	B
factor	O	NOUN	I
was	O	AUX	O
"	O	PUNCT	O
low	O	ADJ	B
-	O	PUNCT	O
dose	O	NOUN	B
"	O	PUNCT	O
oral	B-Chemical	ADJ	B
contraceptive	I-Chemical	NOUN	I


Relation	O	NOUN	B
of	O	ADP	O
perfusion	O	NOUN	B
defects	O	NOUN	B
observed	O	VERB	O
with	O	ADP	O
myocardial	O	ADJ	B
contrast	O	NOUN	I
echocardiography	O	NOUN	I
to	O	PART	O
the	O	DET	O
severity	O	NOUN	B
of	O	ADP	O
coronary	B-Disease	ADJ	B
stenosis	I-Disease	NOUN	I
:	O	PUNCT	O
correlation	O	NOUN	B
with	O	ADP	O
thallium	B-Chemical	NOUN	B
-	O	PUNCT	O
201	O	NUM	O
single	O	ADJ	B
-	O	PUNCT	O
photon	O	NOUN	B
emission	O	NOUN	O
tomography	O	NOUN	O
.	O	PUNCT	O


It	O	PRON	O
has	O	AUX	O
been	O	AUX	O
previously	O	ADV	O
shown	O	VERB	O
that	O	SCONJ	O
myocardial	O	ADJ	B
contrast	O	NOUN	I
echocardiography	O	NOUN	I
is	O	AUX	O
a	O	DET	O
valuable	O	ADJ	O
technique	O	NOUN	B
for	O	ADP	O
delineating	O	NOUN	O
regions	O	NOUN	B
of	O	ADP	O
myocardial	O	ADJ	B
underperfusion	O	NOUN	I
secondary	O	ADJ	B
to	O	PART	I
coronary	B-Disease	ADJ	B
occlusion	I-Disease	NOUN	I
and	O	CCONJ	O
to	O	PART	O
critical	O	ADJ	O
coronary	B-Disease	ADJ	B
stenoses	I-Disease	NOUN	I
in	O	ADP	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
hyperemic	B-Disease	ADJ	B
stimulation	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
aim	O	NOUN	O
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
determine	O	VERB	O
whether	O	SCONJ	O
myocardial	O	ADJ	B
contrast	O	NOUN	I
echocardiography	O	NOUN	I
performed	O	VERB	O
with	O	ADP	O
a	O	DET	O
stable	O	ADJ	B
solution	O	NOUN	B
of	O	ADP	O
sonicated	O	VERB	B
albumin	O	NOUN	I
could	O	AUX	O
detect	O	VERB	B
regions	O	NOUN	B
of	O	ADP	O
myocardial	O	ADJ	B
underperfusion	O	NOUN	B
resulting	O	VERB	O
from	O	ADP	O
various	O	ADJ	O
degrees	O	NOUN	B
of	O	ADP	O
coronary	B-Disease	ADJ	B
stenosis	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
perfusion	O	NOUN	B
defect	O	NOUN	B
produced	O	VERB	O
in	O	ADP	O
16	O	NUM	O
open	O	ADJ	B
chest	O	ADJ	I
dogs	O	NOUN	I
was	O	AUX	O
compared	O	VERB	B
with	O	ADP	O
the	O	DET	O
anatomic	O	ADJ	B
area	O	NOUN	I
at	O	ADP	O
risk	O	NOUN	B
measured	O	VERB	O
by	O	ADP	O
the	O	DET	O
postmortem	O	NOUN	B
dual	O	ADJ	B
-	O	PUNCT	O
perfusion	O	NOUN	B
technique	O	NOUN	B
and	O	CCONJ	O
with	O	ADP	O
thallium	B-Chemical	NOUN	B
-	O	PUNCT	O
201	O	NUM	O
single	O	ADJ	B
-	O	PUNCT	O
photon	O	NOUN	B
emission	O	NOUN	I
tomography	O	NOUN	I
(	O	PUNCT	O
SPECT	O	PROPN	B
).	O	PUNCT	O
During	O	ADP	O
a	O	DET	O
transient	O	ADJ	B
(	O	PUNCT	O
20	O	NUM	O
-	O	PUNCT	O
s	O	NOUN	O
)	O	PUNCT	O
coronary	B-Disease	ADJ	B
occlusion	I-Disease	NOUN	I
,	O	PUNCT	O
a	O	DET	O
perfusion	O	NOUN	B
defect	O	NOUN	B
was	O	AUX	O
observed	O	VERB	O
with	O	ADP	O
contrast	O	NOUN	B
echocardiography	O	NOUN	I
in	O	ADP	O
14	O	NUM	O
of	O	ADP	O
the	O	DET	O
15	O	NUM	O
dogs	O	NOUN	B
in	O	ADP	O
which	O	DET	O
the	O	DET	O
occlusion	O	NOUN	B
was	O	AUX	O
produced	O	VERB	O
.	O	PUNCT	O


The	O	DET	O
perfusion	O	NOUN	B
defect	O	NOUN	B
correlated	O	VERB	B
significantly	O	ADV	O
with	O	ADP	O
the	O	DET	O
anatomic	O	ADJ	B
area	O	NOUN	I
at	O	ADP	O
risk	O	NOUN	B
(	O	PUNCT	O
r	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


74	O	NUM	O
;	O	PUNCT	O
p	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


002	O	NUM	O
).	O	PUNCT	B
During	O	ADP	O
dipyridamole	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
hyperemia	B-Disease	NOUN	B
,	O	PUNCT	O
12	O	NUM	O
of	O	ADP	O
the	O	DET	O
16	O	NUM	O
dogs	O	NOUN	B
with	O	ADP	O
a	O	DET	O
partial	O	ADJ	B
coronary	B-Disease	ADJ	B
stenosis	I-Disease	NOUN	I
had	O	AUX	O
a	O	DET	O
visible	O	ADJ	B
area	O	NOUN	I
of	O	ADP	O
hypoperfusion	O	NOUN	B
by	O	ADP	O
contrast	O	NOUN	B
echocardiography	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
four	O	NUM	O
dogs	O	NOUN	B
without	O	ADP	O
a	O	DET	O
perfusion	O	NOUN	B
defect	O	NOUN	B
had	O	AUX	O
a	O	DET	O
stenosis	O	NOUN	B
that	O	PRON	O
resulted	O	VERB	O
in	O	ADP	O
a	O	DET	O
mild	O	ADJ	B
(	O	PUNCT	O
0	O	NUM	O
%	O	NOUN	O
to	O	ADP	O
50	O	NUM	O
%)	O	NOUN	O
reduction	O	NOUN	B
in	O	ADP	O
dipyridamole	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
hyperemia	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
size	O	NOUN	B
of	O	ADP	O
the	O	DET	O
perfusion	O	NOUN	B
defect	O	NOUN	B
during	O	ADP	O
stenosis	O	NOUN	B
correlated	O	VERB	B
significantly	O	ADV	O
with	O	ADP	O
the	O	DET	O
anatomic	O	ADJ	B
area	O	NOUN	I
at	O	ADP	O
risk	O	NOUN	B
(	O	PUNCT	O
r	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


61	O	NUM	O
;	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


02	O	NUM	O
).	O	PUNCT	O
Thallium	B-Chemical	PROPN	B
-	O	PUNCT	O
201	O	NUM	O
SPECT	O	PROPN	B
demonstrated	O	VERB	O
a	O	DET	O
perfusion	O	NOUN	B
defect	O	NOUN	B
in	O	ADP	O
all	O	DET	O
14	O	NUM	O
dogs	O	NOUN	B
analyzed	O	VERB	B
during	O	ADP	O
dipyridamole	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
hyperemia	B-Disease	NOUN	B
;	O	PUNCT	O
the	O	DET	O
size	O	NOUN	B
of	O	ADP	O
the	O	DET	O
perfusion	O	NOUN	B
defect	O	NOUN	B
correlated	O	VERB	B
with	O	ADP	O
the	O	DET	O
anatomic	O	ADJ	B
area	O	NOUN	I
at	O	ADP	O
risk	O	NOUN	B
(	O	PUNCT	O
r	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


58	O	NUM	O
;	O	PUNCT	O
p	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


03	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
with	O	ADP	O
the	O	DET	O
perfusion	O	NOUN	B
defect	O	NOUN	B
by	O	ADP	O
contrast	O	NOUN	B
echocardiography	O	NOUN	I
(	O	PUNCT	O
r	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


58	O	NUM	O
;	O	PUNCT	O
p	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


03	O	NUM	O
).	O	PUNCT	O
Thus	O	ADV	O
,	O	PUNCT	O
myocardial	O	ADJ	B
contrast	O	NOUN	I
echocardiography	O	NOUN	I
can	O	AUX	O
be	O	AUX	O
used	O	VERB	O
to	O	PART	O
visualize	O	VERB	B
and	O	CCONJ	O
quantitate	O	VERB	B
the	O	DET	O
amount	O	NOUN	B
of	O	ADP	O
jeopardized	O	ADJ	B
myocardium	O	NOUN	B
during	O	ADP	O
moderate	O	ADJ	B
to	O	ADP	O
severe	O	ADJ	B
degrees	O	NOUN	B
of	O	ADP	O
coronary	B-Disease	ADJ	B
stenosis	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
results	O	NOUN	B
obtained	O	VERB	O
show	O	VERB	O
a	O	DET	O
correlation	O	NOUN	B
with	O	ADP	O
the	O	DET	O
anatomic	O	ADJ	B
area	O	NOUN	I
at	O	ADP	O
risk	O	NOUN	B
similar	O	ADJ	O
to	O	PART	O
that	O	DET	O
obtained	O	VERB	O
with	O	ADP	O
thallium	B-Chemical	NOUN	B


Potential	O	ADJ	B
deleterious	O	ADJ	B
effect	O	NOUN	I
of	O	ADP	O
furosemide	B-Chemical	NOUN	B
in	O	ADP	O
radiocontrast	O	NOUN	B
nephropathy	B-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
purpose	O	NOUN	O
of	O	ADP	O
the	O	DET	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
determine	O	VERB	O
the	O	DET	O
efficacy	O	NOUN	B
of	O	ADP	O
furosemide	B-Chemical	NOUN	B
in	O	ADP	O
addition	O	NOUN	O
to	O	PART	O
intravenous	O	ADJ	B
fluids	O	NOUN	I
in	O	ADP	O
the	O	DET	O
prevention	O	NOUN	B
of	O	ADP	O
radiocontrast	O	NOUN	B
nephropathy	B-Disease	NOUN	I
.	O	PUNCT	O


18	O	NUM	O
patients	O	NOUN	B
,	O	PUNCT	O
referred	O	VERB	O
to	O	PART	O
a	O	DET	O
radiocontrast	O	NOUN	B
study	O	NOUN	I
,	O	PUNCT	O
considered	O	VERB	O
at	O	ADP	O
risk	O	NOUN	B
because	O	SCONJ	O
of	O	ADP	O
preexisting	O	VERB	O
renal	B-Disease	ADJ	B
insufficiency	I-Disease	NOUN	I
,	O	PUNCT	O
were	O	AUX	O
enrolled	O	VERB	O
in	O	ADP	O
a	O	DET	O
prospective	O	ADJ	B
,	O	PUNCT	O
randomized	O	ADJ	B
,	O	PUNCT	O
controlled	O	VERB	B
trial	O	NOUN	I
,	O	PUNCT	O
performed	O	VERB	O
at	O	ADP	O
the	O	DET	O
secondary	O	ADJ	B
care	O	NOUN	I
center	O	NOUN	I
of	O	ADP	O
a	O	DET	O
1	O	NUM	O
,	O	PUNCT	O
100	O	NUM	O
-	O	PUNCT	O
bed	O	NOUN	B
private	O	ADJ	I
university	O	NOUN	I
hospital	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
to	O	ADP	O
fluids	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
treatment	O	NOUN	B
group	O	NOUN	I
received	O	VERB	O
furosemide	B-Chemical	NOUN	B
(	O	PUNCT	O
mean	O	ADJ	B
dose	O	NOUN	I
110	O	NUM	O
mg	O	NOUN	O
)	O	PUNCT	O
intravenously	O	ADV	B
30	O	NUM	O
min	O	NOUN	O
prior	O	ADJ	O
to	O	PART	O
the	O	DET	O
injection	O	NOUN	B
of	O	ADP	O
contrast	O	NOUN	B
material	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
control	O	ADJ	B
group	O	NOUN	I
received	O	VERB	O
fluids	O	NOUN	B
(	O	PUNCT	O
mean	O	NOUN	O
3	O	NUM	O
liters	O	NOUN	B
).	O	PUNCT	O
Radiological	O	ADJ	B
studies	O	NOUN	I
were	O	AUX	O
mostly	O	ADV	O
angiographies	O	NOUN	B
performed	O	VERB	O
with	O	ADP	O
both	O	CCONJ	O
ionic	O	ADJ	B
and	O	CCONJ	O
non	O	ADJ	B
-	O	PUNCT	O
ionic	O	ADJ	B
contrast	O	NOUN	I
material	O	NOUN	I
,	O	PUNCT	O
at	O	ADP	O
an	O	DET	O
average	O	ADJ	B
dose	O	NOUN	B
of	O	ADP	O
245	O	NUM	O
ml	O	NOUN	O
.	O	PUNCT	O


Renal	B-Disease	ADJ	B
function	I-Disease	NOUN	I
significantly	I-Disease	ADV	O
deteriorated	I-Disease	VERB	B
in	O	ADP	O
the	O	DET	O
group	O	NOUN	B
pretreated	O	VERB	B
with	O	ADP	O
furosemide	B-Chemical	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


005	O	NUM	O
by	O	ADP	O
ANOVA	O	NOUN	B
),	O	PUNCT	O
with	O	ADP	O
a	O	DET	O
rise	O	NOUN	O
in	O	ADP	O
serum	O	NOUN	B
creatinine	B-Chemical	NOUN	I
from	O	ADP	O
145	O	NUM	O
+/-	O	CCONJ	O
13	O	NUM	O
to	O	PART	O
182	O	NUM	O
+/-	O	CCONJ	O
16	O	NUM	O
mumol	O	NOUN	B
/	O	SYM	O
l	O	NOUN	O
at	O	ADP	O
24	O	NUM	O
h	O	NOUN	O
,	O	PUNCT	O
while	O	SCONJ	O
no	O	DET	O
change	O	NOUN	O
occurred	O	VERB	O
in	O	ADP	O
the	O	DET	O
control	O	NOUN	B
group	O	NOUN	I
(	O	PUNCT	O
from	O	ADP	O
141	O	NUM	O
+/-	O	CCONJ	O
6	O	NUM	O
to	O	PART	O
142	O	NUM	O
+/-	O	CCONJ	O
7	O	NUM	O
mumol	O	NOUN	B
/	O	SYM	O
l	O	X	B
).	O	PUNCT	B
Renal	B-Disease	ADJ	I
failure	I-Disease	NOUN	I
was	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
weight	B-Disease	NOUN	B
loss	I-Disease	NOUN	I
in	O	ADP	O
the	O	DET	O
furosemide	B-Chemical	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
group	O	NOUN	B
.	O	PUNCT	O


Furosemide	B-Chemical	NOUN	B
may	O	AUX	O
be	O	AUX	O
deleterious	O	ADJ	B
in	O	ADP	O
the	O	DET	O
prevention	O	NOUN	B
of	O	ADP	O
radiocontrast	O	NOUN	B
nephropathy	B-Disease	NOUN	I


The	O	DET	O
renal	O	ADJ	B
pathology	O	NOUN	I
in	O	ADP	O
a	O	DET	O
case	O	NOUN	B
of	O	ADP	O
lithium	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
diabetes	B-Disease	NOUN	B
insipidus	I-Disease	NOUN	I
.	O	PUNCT	O


A	O	DET	O
case	O	NOUN	B
of	O	ADP	O
lithium	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
diabetes	B-Disease	NOUN	B
insipidus	I-Disease	NOUN	I
is	O	AUX	O
reported	O	VERB	O
.	O	PUNCT	O


At	O	ADP	O
necropsy	O	ADJ	B
microscopy	O	NOUN	I
shoed	O	ADJ	B
unique	O	ADJ	B
and	O	CCONJ	O
extensive	O	ADJ	B
damage	O	NOUN	B
to	O	PART	O
cells	O	NOUN	B
lining	O	VERB	I
the	O	DET	O
distal	O	ADJ	B
nephron	O	NOUN	I
.	O	PUNCT	O


It	O	PRON	O
is	O	AUX	O
suggested	O	VERB	O
that	O	SCONJ	O
these	O	DET	O
changes	O	NOUN	B
represent	O	VERB	O
a	O	DET	O
specific	O	ADJ	O
toxic	O	ADJ	B
effect	O	NOUN	O
of	O	ADP	O
lithium	B-Chemical	NOUN	B


Etiologic	O	ADJ	B
factors	O	NOUN	I
in	O	ADP	O
the	O	DET	O
pathogenesis	O	NOUN	B
of	O	ADP	O
liver	B-Disease	NOUN	B
tumors	I-Disease	NOUN	I
associated	O	VERB	B
with	O	ADP	I
oral	B-Chemical	ADJ	B
contraceptives	I-Chemical	NOUN	I
.	O	PUNCT	O


Within	O	ADP	O
the	O	DET	O
last	O	ADJ	O
several	O	ADJ	O
years	O	NOUN	B
,	O	PUNCT	O
previously	O	ADV	O
rare	O	ADJ	O
liver	B-Disease	NOUN	B
tumors	I-Disease	NOUN	I
have	O	AUX	O
been	O	AUX	O
seen	O	VERB	O
in	O	ADP	O
young	O	ADJ	B
women	O	NOUN	B
using	O	VERB	O
oral	B-Chemical	ADJ	B
contraceptive	I-Chemical	ADJ	I
steroids	B-Chemical	NOUN	I
.	O	PUNCT	O


The	O	DET	O
Registry	O	PROPN	B
for	O	ADP	O
Liver	B-Disease	PROPN	B
Tumors	I-Disease	PROPN	I
Associated	O	VERB	B
with	O	ADP	I
Oral	B-Chemical	ADJ	B
Contraceptives	I-Chemical	NOUN	I
at	O	ADP	O
the	O	DET	O
University	O	PROPN	B
of	O	ADP	I
California	O	PROPN	I
,	O	PUNCT	O
Irvine	O	PROPN	B
,	O	PUNCT	O
has	O	AUX	O
clearly	O	ADV	O
identified	O	VERB	B
27	O	NUM	O
cases	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
recent	O	ADJ	O
literature	O	NOUN	B
contains	O	VERB	O
44	O	NUM	O
case	O	NOUN	B
reports	O	NOUN	I
.	O	PUNCT	O


Common	O	ADJ	O
to	O	ADP	O
these	O	DET	O
71	O	NUM	O
cases	O	NOUN	B
has	O	AUX	O
been	O	AUX	O
a	O	DET	O
histopathologic	O	ADJ	B
diagnosis	O	NOUN	I
of	O	ADP	O
focal	B-Disease	ADJ	B
nodular	I-Disease	ADJ	I
hyperplasia	I-Disease	NOUN	I
,	O	PUNCT	O
adenoma	B-Disease	NOUN	B
,	O	PUNCT	O
hamartoma	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
hepatoma	B-Disease	NOUN	B
.	O	PUNCT	O


Significant	O	ADJ	B
statistical	O	ADJ	B
etiologic	O	ADJ	B
factors	O	NOUN	I
include	O	VERB	O
prolonged	O	ADJ	B
uninterrupted	O	ADJ	B
usage	O	NOUN	I
of	O	ADP	O
oral	B-Chemical	ADJ	B
contraceptive	I-Chemical	ADJ	I
steroids	B-Chemical	NOUN	I
.	O	PUNCT	O


Eight	O	NUM	O
deaths	O	NOUN	B
and	O	CCONJ	O
liver	O	NOUN	B
rupture	B-Disease	NOUN	I


Graft-versus-host	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
prophylaxis	O	NOUN	B
with	O	ADP	O
everolimus	B-Chemical	NOUN	B
and	O	CCONJ	O
tacrolimus	B-Chemical	NOUN	B
is	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
a	O	DET	O
high	O	ADJ	O
incidence	O	NOUN	B
of	O	ADP	O
sinusoidal	B-Disease	ADJ	B
obstruction	I-Disease	NOUN	I
syndrome	I-Disease	NOUN	I
and	O	CCONJ	O
microangiopathy	B-Disease	NOUN	B
:	O	PUNCT	O
results	O	NOUN	B
of	O	ADP	O
the	O	DET	O
EVTAC	O	NOUN	B
trial	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
calcineurin	O	NOUN	B
inhibitor	O	NOUN	B
combined	O	VERB	O
with	O	ADP	O
methotrexate	B-Chemical	NOUN	B
is	O	AUX	O
the	O	DET	O
standard	O	ADJ	B
prophylaxis	O	NOUN	B
for	O	ADP	O
graft-versus-host	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
(	O	PUNCT	O
GVHD	B-Disease	NOUN	B
)	O	PUNCT	O
after	O	ADP	O
allogeneic	O	ADJ	B
hematopoietic	O	ADJ	O
stem	O	NOUN	O
cell	O	NOUN	O
transplantation	O	NOUN	O
(	O	PUNCT	O
HSCT	O	NOUN	B
).	O	PUNCT	O
Everolimus	B-Chemical	NOUN	B
,	O	PUNCT	O
a	O	DET	O
derivative	O	NOUN	B
of	O	ADP	O
sirolimus	B-Chemical	NOUN	B
,	O	PUNCT	O
seems	O	VERB	O
to	O	PART	O
mediate	O	VERB	O
antileukemia	O	NOUN	B
effects	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
on	O	ADP	O
a	O	DET	O
combination	O	NOUN	B
of	O	ADP	O
everolimus	B-Chemical	NOUN	B
and	O	CCONJ	O
tacrolimus	B-Chemical	NOUN	B
in	O	ADP	O
24	O	NUM	O
patients	O	NOUN	B
(	O	PUNCT	O
median	O	ADJ	B
age	O	NOUN	I
,	O	PUNCT	O
62	O	NUM	O
years	O	NOUN	B
)	O	PUNCT	O
with	O	ADP	O
either	O	CCONJ	O
myelodysplastic	B-Disease	ADJ	B
syndrome	I-Disease	NOUN	I
(	O	PUNCT	O
MDS	B-Disease	NOUN	B
;	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
17	O	NUM	O
)	O	PUNCT	O
or	O	CCONJ	O
acute	B-Disease	ADJ	B
myeloid	I-Disease	ADJ	I
leukemia	I-Disease	NOUN	I
(	O	PUNCT	O
AML	B-Disease	NOUN	B
;	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
7	O	NUM	O
)	O	PUNCT	O
undergoing	O	VERB	O
intensive	O	ADJ	B
conditioning	O	NOUN	I
followed	O	VERB	O
by	O	ADP	O
HSCT	O	NOUN	B
from	O	ADP	O
related	O	ADJ	O
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
4	O	NUM	O
)	O	PUNCT	O
or	O	CCONJ	O
unrelated	O	ADJ	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
20	O	NUM	O
)	O	PUNCT	O
donors	O	NOUN	B
.	O	PUNCT	O


All	O	DET	O
patients	O	NOUN	B
engrafted	O	VERB	B
,	O	PUNCT	O
and	O	CCONJ	O
only	O	ADV	O
1	O	NUM	O
patient	O	NOUN	B
experienced	O	ADJ	O
grade	O	NOUN	B
IV	O	NUM	I
mucositis	B-Disease	NOUN	I
.	O	PUNCT	O


Nine	O	NUM	O
patients	O	NOUN	B
(	O	PUNCT	O
37	O	NUM	O
%)	O	NOUN	O
developed	O	VERB	O
acute	O	ADJ	B
grade	O	NOUN	I
II	O	NUM	I
-	O	PUNCT	O
IV	O	NUM	B
GVHD	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
11	O	NUM	O
of	O	ADP	O
17	O	NUM	O
evaluable	O	ADJ	O
patients	O	NOUN	B
(	O	PUNCT	O
64	O	NUM	O
%)	O	NOUN	O
developed	O	VERB	O
chronic	O	ADJ	B
extensive	O	ADJ	O
GVHD	B-Disease	NOUN	B
.	O	PUNCT	O


Transplantation-associated	B-Disease	ADJ	B
microangiopathy	I-Disease	NOUN	I
(	O	PUNCT	O
TMA	B-Disease	NOUN	B
)	O	PUNCT	O
occurred	O	VERB	O
in	O	ADP	O
7	O	NUM	O
patients	O	NOUN	B
(	O	PUNCT	O
29	O	NUM	O
%),	O	ADJ	O
with	O	ADP	O
2	O	NUM	O
cases	O	NOUN	B
of	O	ADP	O
acute	B-Disease	ADJ	B
renal	I-Disease	ADJ	I
failure	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
study	O	NOUN	B
was	O	AUX	O
terminated	O	VERB	O
prematurely	O	ADV	B
because	O	SCONJ	O
an	O	DET	O
additional	O	ADJ	O
6	O	NUM	O
patients	O	NOUN	B
(	O	PUNCT	O
25	O	NUM	O
%)	O	NOUN	O
developed	O	VERB	O
sinusoidal	B-Disease	ADJ	B
obstruction	I-Disease	NOUN	I
syndrome	I-Disease	NOUN	I
(	O	PUNCT	O
SOS	B-Disease	NOUN	B
),	O	PUNCT	O
which	O	DET	O
was	O	AUX	O
fatal	O	ADJ	B
in	O	ADP	O
2	O	NUM	O
cases	O	NOUN	B
.	O	PUNCT	O


With	O	ADP	O
a	O	DET	O
median	O	ADJ	B
follow	O	NOUN	B
-	O	PUNCT	O
up	O	NOUN	O
of	O	ADP	O
26	O	NUM	O
months	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
2	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
overall	O	ADJ	B
survival	O	NOUN	B
rate	O	NOUN	I
was	O	AUX	O
47	O	NUM	O
%.	O	NOUN	O
Although	O	SCONJ	O
this	O	DET	O
new	O	ADJ	O
combination	O	NOUN	B
appears	O	VERB	O
to	O	PART	O
be	O	AUX	O
effective	O	ADJ	B
as	O	ADP	O
a	O	DET	O
prophylactic	O	ADJ	B
regimen	O	NOUN	I
for	O	ADP	O
acute	O	ADJ	B
GVHD	B-Disease	NOUN	I
,	O	PUNCT	O
the	O	DET	O
incidence	O	NOUN	B
of	O	ADP	O
TMA	B-Disease	NOUN	B
and	O	CCONJ	O
SOS	B-Disease	NOUN	B


Effect	O	NOUN	B
of	O	ADP	O
some	O	DET	O
convulsants	O	NOUN	B
on	O	ADP	O
the	O	DET	O
protective	O	ADJ	B
activity	O	NOUN	I
of	O	ADP	O
loreclezole	B-Chemical	NOUN	B
and	O	CCONJ	O
its	O	PRON	O
combinations	O	NOUN	B
with	O	ADP	O
valproate	B-Chemical	NOUN	B
or	O	CCONJ	O
clonazepam	B-Chemical	NOUN	B
in	O	ADP	O
amygdala	O	NOUN	B
-	O	PUNCT	O
kindled	O	VERB	B
rats	O	NOUN	B
.	O	PUNCT	O


Loreclezole	B-Chemical	NOUN	B
(	O	PUNCT	O
5	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
)	O	PUNCT	O
exerted	O	VERB	O
a	O	DET	O
significant	O	ADJ	B
protective	O	ADJ	B
action	O	NOUN	I
in	O	ADP	O
amygdala	O	NOUN	B
-	O	PUNCT	O
kindled	O	VERB	B
rats	O	NOUN	B
,	O	PUNCT	O
reducing	O	VERB	B
both	O	DET	O
seizure	B-Disease	NOUN	B
and	O	CCONJ	O
afterdischarge	O	ADJ	B
durations	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
combinations	O	NOUN	B
of	O	ADP	O
loreclezole	B-Chemical	NOUN	B
(	O	PUNCT	O
2	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
)	O	PUNCT	O
with	O	ADP	O
valproate	B-Chemical	NOUN	B
,	O	PUNCT	O
clonazepam	B-Chemical	NOUN	B
,	O	PUNCT	O
or	O	CCONJ	O
carbamazepine	B-Chemical	NOUN	B
(	O	PUNCT	O
applied	O	VERB	O
at	O	ADP	O
their	O	PRON	O
subprotective	O	ADJ	B
doses	O	NOUN	B
)	O	PUNCT	O
also	O	ADV	O
exhibited	O	VERB	O
antiseizure	O	NOUN	B
effect	O	NOUN	I
in	O	ADP	O
this	O	DET	O
test	O	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
only	O	ADV	O
two	O	NUM	O
first	O	ADJ	O
combinations	O	NOUN	B
occurred	O	VERB	O
to	O	PART	O
be	O	AUX	O
of	O	ADP	O
pharmacodynamic	O	ADJ	B
nature	O	NOUN	O
.	O	PUNCT	O


Among	O	ADP	O
several	O	ADJ	O
chemoconvulsants	O	NOUN	B
,	O	PUNCT	O
bicuculline	B-Chemical	NOUN	B
,	O	PUNCT	O
N-methyl-D-aspartic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
and	O	CCONJ	O
BAY	B-Chemical	NOUN	B
k-8644	I-Chemical	PROPN	O
(	O	PUNCT	O
the	O	DET	O
opener	O	NOUN	B
of	O	ADP	O
L	O	NOUN	B
-	O	PUNCT	O
type	O	NOUN	B
calcium	B-Chemical	NOUN	I
channels	O	NOUN	I
)	O	PUNCT	O
reversed	O	VERB	O
the	O	DET	O
protective	O	ADJ	O
activity	O	NOUN	O
of	O	ADP	O
loreclezole	B-Chemical	NOUN	B
alone	O	ADV	O
and	O	CCONJ	O
its	O	PRON	O
combination	O	NOUN	B
with	O	ADP	O
valproate	B-Chemical	NOUN	B
.	O	PUNCT	O


On	O	ADP	O
the	O	DET	O
other	O	ADJ	O
hand	O	NOUN	B
,	O	PUNCT	O
bicuculline	B-Chemical	NOUN	B
,	O	PUNCT	O
aminophylline	B-Chemical	NOUN	B
and	O	CCONJ	O
BAY	B-Chemical	NOUN	B
k-8644	I-Chemical	NOUN	O
inhibited	O	VERB	B
the	O	DET	O
anticonvulsive	O	ADJ	B
action	O	NOUN	I
of	O	ADP	O
loreclezole	B-Chemical	NOUN	B
combined	O	VERB	O
with	O	ADP	O
clonazepam	B-Chemical	NOUN	B
.	O	PUNCT	O


The	O	DET	O
results	O	NOUN	B
support	O	VERB	O
the	O	DET	O
hypothesis	O	NOUN	B
that	O	SCONJ	O
the	O	DET	O
protective	O	ADJ	B
activity	O	NOUN	I
of	O	ADP	O
loreclezole	B-Chemical	NOUN	B
and	O	CCONJ	O
its	O	PRON	O
combinations	O	NOUN	B
with	O	ADP	O
other	O	ADJ	O
antiepileptics	O	NOUN	B
may	O	AUX	O
involve	O	VERB	O
potentiation	O	NOUN	B
of	O	ADP	O
GABAergic	O	ADJ	B
neurotransmission	O	NOUN	I
and	O	CCONJ	O
blockade	O	NOUN	B
of	O	ADP	O
L	O	NOUN	B
-	O	PUNCT	O
type	O	NOUN	B
of	O	ADP	O
calcium	B-Chemical	NOUN	B


Acute	B-Disease	ADJ	B
liver	I-Disease	NOUN	I
failure	I-Disease	NOUN	I
with	O	ADP	O
concurrent	O	ADJ	B
bupropion	B-Chemical	NOUN	B
and	O	CCONJ	O
carbimazole	B-Chemical	NOUN	B
therapy	O	NOUN	I
.	O	PUNCT	O


OBJECTIVE	O	NOUN	O
:	O	PUNCT	O
To	O	PART	O
report	O	VERB	O
a	O	DET	O
case	O	NOUN	B
of	O	ADP	O
fatal	O	ADJ	B
liver	B-Disease	NOUN	B
failure	I-Disease	NOUN	I
possibly	O	ADV	O
associated	O	VERB	B
with	O	ADP	I
concurrent	O	ADJ	B
use	O	NOUN	O
of	O	ADP	O
bupropion	B-Chemical	NOUN	B
and	O	CCONJ	O
carbimazole	B-Chemical	NOUN	B
.	O	PUNCT	O


CASE	O	ADJ	B
SUMMARY	O	NOUN	I
:	O	PUNCT	O
A	O	DET	O
41	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
Chinese	O	ADJ	B
man	O	NOUN	B
with	O	ADP	O
a	O	DET	O
history	O	NOUN	B
of	O	ADP	O
hyperthyroidism	B-Disease	NOUN	B
had	O	AUX	O
been	O	AUX	O
treated	O	VERB	B
with	O	ADP	I
carbimazole	B-Chemical	NOUN	B
and	O	CCONJ	O
propranolol	B-Chemical	NOUN	B
for	O	ADP	O
the	O	DET	O
past	O	ADJ	O
5	O	NUM	O
years	O	NOUN	B
.	O	PUNCT	O


He	O	PRON	O
received	O	VERB	O
a	O	DET	O
10	O	NUM	O
-	O	PUNCT	O
day	O	NOUN	B
course	O	NOUN	B
of	O	ADP	O
bupropion	B-Chemical	NOUN	B
as	O	ADP	O
an	O	DET	O
aid	O	NOUN	O
for	O	ADP	O
smoking	O	NOUN	B
cessation	O	NOUN	B
10	O	NUM	O
weeks	O	NOUN	B
prior	O	ADJ	O
to	O	PART	O
presentation	O	NOUN	B
.	O	PUNCT	O


He	O	PRON	O
developed	O	VERB	O
acute	B-Disease	ADJ	B
liver	I-Disease	NOUN	O
failure	I-Disease	NOUN	O
with	O	ADP	O
rapid	O	ADJ	O
deterioration	O	NOUN	B
of	O	ADP	O
renal	O	ADJ	B
function	O	NOUN	I
.	O	PUNCT	O


Liver	O	NOUN	B
biopsy	O	NOUN	I
showed	O	VERB	O
evidence	O	NOUN	B
of	O	ADP	O
nonspecific	O	ADJ	B
drug-induced	B-Disease	ADJ	B
acute	I-Disease	ADJ	O
liver	I-Disease	NOUN	O
injury	I-Disease	NOUN	O
.	O	PUNCT	O


His	O	PRON	O
condition	O	NOUN	O
was	O	AUX	O
further	O	ADV	O
complicated	O	VERB	O
by	O	ADP	O
sepsis	B-Disease	NOUN	B
and	O	CCONJ	O
coagulopathy	B-Disease	NOUN	B
.	O	PUNCT	O


Death	O	NOUN	B
resulted	O	VERB	O
19	O	NUM	O
days	O	NOUN	B
after	O	ADP	O
the	O	DET	O
onset	O	NOUN	B
of	O	ADP	I
symptoms	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
likelihood	O	NOUN	B
that	O	SCONJ	O
bupropion	B-Chemical	NOUN	B
induced	O	VERB	B
hepatotoxicity	B-Disease	NOUN	B
in	O	ADP	O
our	O	PRON	O
patient	O	NOUN	B
was	O	AUX	O
possible	O	ADJ	O
,	O	PUNCT	O
based	O	VERB	O
on	O	ADP	O
the	O	DET	O
Naranjo	O	NOUN	B
probability	O	NOUN	I
scale	O	NOUN	I
.	O	PUNCT	O


DISCUSSION	O	NOUN	O
:	O	PUNCT	O
Although	O	SCONJ	O
there	O	PRON	O
is	O	AUX	O
increasing	O	VERB	O
evidence	O	NOUN	B
of	O	ADP	O
hepatotoxicity	B-Disease	NOUN	B
induced	O	VERB	B
by	O	ADP	O
bupropion	B-Chemical	NOUN	B
,	O	PUNCT	O
this	O	DET	O
is	O	AUX	O
the	O	DET	O
first	O	ADJ	O
case	O	NOUN	B
of	O	ADP	O
fatality	O	NOUN	B
that	O	PRON	O
could	O	AUX	O
have	O	AUX	O
resulted	O	VERB	O
from	O	ADP	O
acute	B-Disease	ADJ	B
liver	I-Disease	NOUN	O
failure	I-Disease	NOUN	O
in	O	ADP	O
a	O	DET	O
patient	O	NOUN	B
receiving	O	VERB	O
bupropion	B-Chemical	NOUN	B
while	O	SCONJ	O
on	O	ADP	O
concomitant	O	ADJ	B
treatment	O	NOUN	B
with	O	ADP	O
carbimazole	B-Chemical	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
:	O	PUNCT	O
Clinicians	O	NOUN	B
should	O	AUX	O
be	O	AUX	O
aware	O	ADJ	O
of	O	ADP	O
the	O	DET	O
possibility	O	NOUN	O
of	O	ADP	O
acute	B-Disease	ADJ	B
liver	I-Disease	NOUN	I
insult	I-Disease	NOUN	I
induced	O	VERB	B
by	O	ADP	O
bupropion	B-Chemical	NOUN	B
given	O	VERB	O
concurrently	O	ADV	O
with	O	ADP	O
other	O	ADJ	O
hepatotoxic	B-Disease	NOUN	B


Long	O	ADJ	B
term	O	NOUN	I
hormone	O	NOUN	I
therapy	O	NOUN	I
for	O	ADP	O
perimenopausal	O	ADJ	B
and	O	CCONJ	O
postmenopausal	O	ADJ	B
women	O	NOUN	B
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
:	O	PUNCT	O
Hormone	O	NOUN	B
therapy	O	NOUN	I
(	O	PUNCT	O
HT	O	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
widely	O	ADV	O
used	O	VERB	O
for	O	ADP	O
controlling	O	VERB	B
menopausal	O	ADJ	B
symptoms	O	NOUN	O
and	O	CCONJ	O
has	O	AUX	O
also	O	ADV	O
been	O	AUX	O
used	O	VERB	O
for	O	ADP	O
the	O	DET	O
management	O	NOUN	B
and	O	CCONJ	O
prevention	O	NOUN	B
of	O	ADP	O
cardiovascular	B-Disease	ADJ	B
disease	I-Disease	NOUN	I
,	O	PUNCT	O
osteoporosis	B-Disease	NOUN	B
and	O	CCONJ	O
dementia	B-Disease	NOUN	B
in	O	ADP	O
older	O	ADJ	B
women	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
is	O	AUX	O
an	O	DET	O
updated	O	ADJ	O
version	O	NOUN	B
of	O	ADP	O
the	O	DET	O
original	O	ADJ	B
Cochrane	O	PROPN	B
review	O	NOUN	I
first	O	ADV	O
published	O	VERB	B
in	O	ADP	O
2005	O	NUM	O
.	O	PUNCT	O


OBJECTIVES	O	NOUN	O
:	O	PUNCT	O
To	O	PART	O
assess	O	VERB	O
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
long	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
HT	O	NOUN	B
on	O	ADP	O
mortality	O	NOUN	B
,	O	PUNCT	O
cardiovascular	O	ADJ	B
outcomes	O	NOUN	B
,	O	PUNCT	O
cancer	B-Disease	NOUN	B
,	O	PUNCT	O
gallbladder	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
,	O	PUNCT	O
cognition	O	NOUN	B
,	O	PUNCT	O
fractures	B-Disease	NOUN	B
and	O	CCONJ	O
quality	O	NOUN	B
of	O	ADP	I
life	O	NOUN	I
.	O	PUNCT	O


SEARCH	O	NOUN	B
STRATEGY	O	NOUN	O
:	O	PUNCT	O
We	O	PRON	O
searched	O	VERB	O
the	O	DET	O
following	O	VERB	O
databases	O	NOUN	B
to	O	ADP	O
November	O	PROPN	O
2007	O	NUM	O
:	O	PUNCT	O
Trials	O	PROPN	B
Register	O	PROPN	I
of	O	ADP	I
the	O	DET	I
Cochrane	O	PROPN	B
Menstrual	B-Disease	PROPN	I
Disorders	I-Disease	PROPN	I
and	O	CCONJ	O
Subfertility	O	PROPN	B
Group	O	PROPN	I
,	O	PUNCT	O
Cochrane	O	PROPN	B
Central	O	PROPN	I
Register	O	PROPN	I
of	O	ADP	I
Controlled	O	PROPN	I
Trials	O	PROPN	I
,	O	PUNCT	O
MEDLINE	O	PROPN	B
,	O	PUNCT	O
EMBASE	O	PROPN	B
,	O	PUNCT	O
Biological	O	PROPN	B
Abstracts	O	PROPN	I
.	O	PUNCT	O


Also	O	ADV	O
relevant	O	ADJ	B
non	O	ADV	B
-	O	PUNCT	O
indexed	O	VERB	B
journals	O	NOUN	B
and	O	CCONJ	O
conference	O	NOUN	B
abstracts	O	NOUN	I
.	O	PUNCT	O


SELECTION	O	NOUN	B
CRITERIA	O	NOUN	I
:	O	PUNCT	O
Randomised	O	ADJ	B
double	O	ADJ	B
-	O	PUNCT	O
blind	O	NOUN	B
trials	O	NOUN	B
of	O	ADP	O
HT	O	NOUN	B
versus	O	CCONJ	O
placebo	O	NOUN	B
,	O	PUNCT	O
taken	O	VERB	O
for	O	ADP	O
at	O	ADP	O
least	O	ADV	O
one	O	NUM	O
year	O	NOUN	B
by	O	ADP	O
perimenopausal	O	ADJ	B
or	O	CCONJ	O
postmenopausal	O	ADJ	B
women	O	NOUN	B
.	O	PUNCT	O


HT	O	NOUN	B
included	O	VERB	O
oestrogens	B-Chemical	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
or	O	CCONJ	O
without	O	ADP	O
progestogens	B-Chemical	NOUN	B
,	O	PUNCT	O
via	O	ADP	O
oral	O	ADJ	B
,	O	PUNCT	O
transdermal	O	ADJ	B
,	O	PUNCT	O
subcutaneous	O	ADJ	B
or	O	CCONJ	O
transnasal	O	NOUN	B
routes	O	NOUN	I
.	O	PUNCT	O


DATA	O	ADJ	B
COLLECTION	O	PROPN	I
AND	O	CCONJ	O
ANALYSIS	O	NOUN	B
:	O	PUNCT	O
Two	O	NUM	O
authors	O	NOUN	B
independently	O	ADV	O
assessed	O	VERB	B
trial	O	NOUN	B
quality	O	NOUN	B
and	O	CCONJ	O
extracted	O	VERB	O
data	O	NOUN	B
.	O	PUNCT	O


MAIN	O	ADJ	O
RESULTS	O	NOUN	O
:	O	PUNCT	O
Nineteen	O	NUM	O
trials	O	NOUN	B
involving	O	VERB	O
41	O	NUM	O
,	O	PUNCT	O
904	O	NUM	O
women	O	NOUN	B
were	O	AUX	O
included	O	VERB	O
.	O	PUNCT	O


In	O	ADP	O
relatively	O	ADV	O
healthy	O	ADJ	B
women	O	NOUN	B
,	O	PUNCT	O
combined	O	VERB	O
continuous	O	ADJ	B
HT	O	NOUN	B
significantly	O	ADV	O
increased	O	VERB	B
the	O	DET	O
risk	O	NOUN	B
of	O	ADP	O
venous	B-Disease	ADJ	B
thrombo-embolism	I-Disease	NOUN	I
or	O	CCONJ	O
coronary	O	ADJ	B
event	O	NOUN	I
(	O	PUNCT	O
after	O	ADP	O
one	O	NUM	O
year	O	NOUN	B
'	O	PART	O
s	O	NOUN	O
use	O	NOUN	O
),	O	PUNCT	O
stroke	B-Disease	NOUN	B
(	O	PUNCT	O
after	O	ADP	O
three	O	NUM	O
years	O	NOUN	B
),	O	PUNCT	O
breast	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
and	O	CCONJ	O
gallbladder	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
.	O	PUNCT	O


Long	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
oestrogen	B-Chemical	NOUN	B
-	O	PUNCT	O
only	O	ADV	O
HT	O	PROPN	B
significantly	O	ADV	O
increased	O	VERB	B
the	O	DET	O
risk	O	NOUN	B
of	O	ADP	O
venous	B-Disease	ADJ	B
thrombo-embolism	I-Disease	NOUN	I
,	O	PUNCT	O
stroke	B-Disease	NOUN	B
and	O	CCONJ	O
gallbladder	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
(	O	PUNCT	O
after	O	ADP	O
one	O	NUM	O
to	O	ADP	O
two	O	NUM	O
years	O	NOUN	B
,	O	PUNCT	O
three	O	NUM	O
years	O	NOUN	B
and	O	CCONJ	O
seven	O	NUM	O
years	O	NOUN	B
'	O	PART	O
use	O	NOUN	O
respectively	O	ADV	O
),	O	PUNCT	O
but	O	CCONJ	O
did	O	AUX	O
not	O	PART	O
significantly	O	ADV	O
increase	O	VERB	B
the	O	DET	O
risk	O	NOUN	B
of	O	ADP	O
breast	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
only	O	ADV	O
statistically	O	ADV	B
significant	O	ADJ	I
benefits	O	NOUN	B
of	O	ADP	O
HT	O	NOUN	B
were	O	AUX	O
a	O	DET	O
decreased	O	VERB	B
incidence	O	NOUN	B
of	O	ADP	O
fractures	B-Disease	NOUN	B
and	O	CCONJ	O
(	O	PUNCT	O
for	O	ADP	O
combined	O	ADJ	O
HT	O	NOUN	B
)	O	PUNCT	O
colon	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
,	O	PUNCT	O
with	O	ADP	O
long	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
use	O	NOUN	O
.	O	PUNCT	O


Among	O	ADP	O
women	O	NOUN	B
aged	O	ADJ	B
over	O	ADP	O
65	O	NUM	O
who	O	PRON	O
were	O	AUX	O
relatively	O	ADV	O
healthy	O	ADJ	B
(	O	PUNCT	O
i	O	X	O
.	O	PUNCT	O


e	O	X	O
.	O	PUNCT	O


generally	O	ADV	O
fit	O	VERB	B
,	O	PUNCT	O
without	O	ADP	O
overt	O	ADJ	B
disease	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
taking	O	VERB	O
continuous	O	ADJ	B
combined	O	ADJ	O
HT	O	NOUN	B
,	O	PUNCT	O
there	O	PRON	O
was	O	AUX	O
a	O	DET	O
statistically	O	ADV	B
significant	O	ADJ	I
increase	O	NOUN	B
in	O	ADP	O
the	O	DET	O
incidence	O	NOUN	B
of	O	ADP	O
dementia	B-Disease	NOUN	B
.	O	PUNCT	O


Among	O	ADP	O
women	O	NOUN	B
with	O	ADP	O
cardiovascular	B-Disease	ADJ	B
disease	I-Disease	NOUN	I
,	O	PUNCT	O
long	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
use	O	NOUN	O
of	O	ADP	O
combined	O	ADJ	O
continuous	O	ADJ	B
HT	O	NOUN	B
significantly	O	ADV	O
increased	O	VERB	B
the	O	DET	O
risk	O	NOUN	B
of	O	ADP	O
venous	B-Disease	ADJ	B
thrombo-embolism	I-Disease	NOUN	I
.	O	PUNCT	O


One	O	NUM	O
trial	O	NOUN	B
analysed	O	VERB	O
subgroups	O	NOUN	B
of	O	ADP	O
2839	O	NUM	O
relatively	O	ADV	O
healthy	O	ADJ	B
50	O	NUM	O
to	O	PART	O
59	O	NUM	O
year	O	NOUN	B
old	O	ADJ	O
women	O	NOUN	B
taking	O	VERB	O
combined	O	ADJ	O
continuous	O	ADJ	B
HT	O	NOUN	B
and	O	CCONJ	O
1637	O	NUM	O
taking	O	VERB	O
oestrogen	B-Chemical	NOUN	B
-	O	PUNCT	O
only	O	ADJ	O
HT	O	NOUN	B
,	O	PUNCT	O
versus	O	CCONJ	O
similar	O	ADJ	B
-	O	PUNCT	O
sized	O	ADJ	B
placebo	O	ADJ	B
groups	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
only	O	ADV	O
significantly	O	ADV	O
increased	O	VERB	B
risk	O	NOUN	B
reported	O	VERB	O
was	O	AUX	O
for	O	ADP	O
venous	B-Disease	ADJ	B
thrombo-embolism	I-Disease	NOUN	I


Passage	O	NOUN	B
of	O	ADP	O
mannitol	B-Chemical	NOUN	B
into	O	ADP	O
the	O	DET	O
brain	O	NOUN	B
around	O	ADP	O
gliomas	B-Disease	NOUN	B
:	O	PUNCT	O
a	O	DET	O
potential	O	ADJ	B
cause	O	NOUN	B
of	O	ADP	O
rebound	O	ADJ	B
phenomenon	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
study	O	NOUN	B
on	O	ADP	O
21	O	NUM	O
patients	O	NOUN	B
.	O	PUNCT	O


AIM	O	NOUN	B
:	O	PUNCT	O
Widespread	O	ADJ	O
use	O	NOUN	O
of	O	ADP	O
mannitol	B-Chemical	NOUN	B
to	O	PART	O
reduce	O	VERB	O
brain	B-Disease	NOUN	B
edema	I-Disease	NOUN	I
and	O	CCONJ	O
lower	O	ADJ	O
elevated	B-Disease	ADJ	B
ICP	I-Disease	NOUN	B
in	O	ADP	O
brain	B-Disease	NOUN	B
tumor	I-Disease	NOUN	I
patients	O	NOUN	B
continues	O	VERB	O
to	O	PART	O
be	O	AUX	O
afflicted	O	VERB	O
by	O	ADP	O
the	O	DET	O
so	O	ADV	O
-	O	PUNCT	O
called	O	VERB	O
rebound	O	NOUN	B
phenomenon	O	NOUN	B
.	O	PUNCT	O


Leakage	O	NOUN	B
of	O	ADP	O
mannitol	B-Chemical	NOUN	B
into	O	ADP	O
the	O	DET	O
brain	O	NOUN	B
parenchyma	O	NOUN	I
through	O	ADP	O
an	O	DET	O
altered	O	ADJ	O
BBB	O	NOUN	B
and	O	CCONJ	O
secondary	O	ADJ	B
reversal	O	NOUN	B
of	O	ADP	O
osmotic	O	ADJ	B
gradient	O	NOUN	B
is	O	AUX	O
considered	O	VERB	O
the	O	DET	O
major	O	ADJ	O
cause	O	NOUN	O
of	O	ADP	O
rebound	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
has	O	AUX	O
only	O	ADV	O
been	O	AUX	O
demonstrated	O	VERB	O
experimentally	O	ADV	B
in	O	ADP	O
animals	O	NOUN	B
.	O	PUNCT	O


As	O	ADP	O
a	O	DET	O
contribution	O	NOUN	B
to	O	ADP	O
this	O	DET	O
issue	O	NOUN	B
we	O	PRON	O
decided	O	VERB	O
to	O	PART	O
research	O	VERB	B
the	O	DET	O
possible	O	ADJ	O
passage	O	NOUN	B
of	O	ADP	O
mannitol	B-Chemical	NOUN	B
into	O	ADP	O
the	O	DET	O
brain	O	NOUN	B
after	O	ADP	O
administration	O	NOUN	B
to	O	PART	O
21	O	NUM	O
brain	B-Disease	NOUN	B
tumor	I-Disease	NOUN	I
patients	O	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
:	O	PUNCT	O
Mannitol	B-Chemical	NOUN	B
(	O	PUNCT	O
18	O	NUM	O
%	O	NOUN	O
solution	O	NOUN	B
;	O	PUNCT	O
1	O	NUM	O
g	O	NOUN	B
/	O	SYM	O
kg	O	NOUN	B
)	O	PUNCT	O
was	O	AUX	O
administered	O	VERB	B
as	O	ADP	O
a	O	DET	O
bolus	O	NOUN	B
to	O	PART	O
patients	O	NOUN	B
(	O	PUNCT	O
ten	O	NUM	O
had	O	AUX	O
malignant	B-Disease	ADJ	B
glioma	I-Disease	NOUN	I
,	O	PUNCT	O
seven	O	NUM	O
brain	O	NOUN	B
metastases	B-Disease	NOUN	I
and	O	CCONJ	O
four	O	NUM	O
meningioma	B-Disease	NOUN	B
)	O	PUNCT	O
about	O	ADV	O
30	O	NUM	O
minutes	O	NOUN	O
before	O	ADP	O
craniotomy	O	NOUN	B
.	O	PUNCT	O


During	O	ADP	O
resection	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
sample	O	NOUN	B
of	O	ADP	O
the	O	DET	O
surrounding	O	VERB	B
edematous	B-Disease	ADJ	B
white	O	ADJ	I
matter	O	NOUN	I
was	O	AUX	O
taken	O	VERB	O
at	O	ADP	O
the	O	DET	O
same	O	ADJ	O
time	O	NOUN	O
as	O	ADP	O
a	O	DET	O
10	O	NUM	O
ml	O	NOUN	O
venous	O	ADJ	B
blood	O	NOUN	I
sample	O	NOUN	I
.	O	PUNCT	O


Mannitol	B-Chemical	NOUN	B
concentrations	O	NOUN	B
were	O	AUX	O
measured	O	VERB	B
in	O	ADP	O
plasma	O	NOUN	B
and	O	CCONJ	O
white	O	ADJ	B
matter	O	NOUN	I
by	O	ADP	O
a	O	DET	O
modified	O	VERB	B
version	O	NOUN	O
of	O	ADP	O
the	O	DET	O
enzyme	O	NOUN	B
assay	O	NOUN	I
of	O	ADP	O
Blonquist	O	NOUN	O
et	O	X	O
al	O	X	O
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
In	O	ADP	O
most	O	ADJ	O
glioma	B-Disease	NOUN	B
patients	O	NOUN	B
,	O	PUNCT	O
mannitol	B-Chemical	NOUN	B
concentrations	O	NOUN	B
in	O	ADP	O
white	O	ADJ	B
matter	O	NOUN	I
were	O	AUX	O
2	O	NUM	O
to	O	PART	O
6	O	NUM	O
times	O	NOUN	O
higher	O	ADJ	B
than	O	ADP	O
in	O	ADP	O
plasma	O	NOUN	B
(	O	PUNCT	O
mean	O	NOUN	O
3	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
times	O	NOUN	O
).	O	PUNCT	B
In	O	ADP	O
meningioma	B-Disease	NOUN	B
and	O	CCONJ	O
metastases	B-Disease	NOUN	B
patients	O	NOUN	B
plasma	O	NOUN	B
concentrations	O	NOUN	B
of	O	ADP	O
mannitol	B-Chemical	NOUN	B
were	O	AUX	O
higher	O	ADJ	O
than	O	ADP	O
white	O	ADJ	B
matter	O	NOUN	I
concentrations	O	NOUN	B
except	O	SCONJ	O
in	O	ADP	O
three	O	NUM	O
cases	O	NOUN	B
with	O	ADP	O
infiltration	O	NOUN	B
by	O	ADP	O
neoplastic	O	ADJ	B
cells	O	NOUN	I
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
:	O	PUNCT	O
The	O	DET	O
results	O	NOUN	B
of	O	ADP	O
our	O	PRON	O
study	O	NOUN	B
show	O	VERB	O
that	O	SCONJ	O
even	O	ADV	O
after	O	ADP	O
a	O	DET	O
single	O	ADJ	O
bolus	O	NOUN	B
,	O	PUNCT	O
mannitol	B-Chemical	NOUN	B
may	O	AUX	O
leak	O	VERB	B
through	O	ADP	O
the	O	DET	O
altered	O	ADJ	O
BBB	O	NOUN	B
near	O	ADP	B
gliomas	B-Disease	NOUN	B
,	O	PUNCT	O
reversing	O	VERB	B
the	O	DET	O
initial	O	ADJ	O
plasma	O	NOUN	B
-	O	PUNCT	O
to	O	ADP	O
-	O	PUNCT	O
blood	O	NOUN	B
osmotic	O	ADJ	I
gradient	O	NOUN	B
,	O	PUNCT	O
aggravating	O	VERB	B
peritumoral	O	ADJ	I
edema	B-Disease	NOUN	I


Can	O	AUX	O
lidocaine	B-Chemical	NOUN	B
reduce	O	VERB	O
succinylcholine	B-Chemical	NOUN	B
induced	O	VERB	B
postoperative	B-Disease	ADJ	B
myalgia	I-Disease	NOUN	I
?	O	PUNCT	O
This	O	DET	O
study	O	NOUN	B
was	O	AUX	O
undertaken	O	VERB	O
to	O	PART	O
determine	O	VERB	O
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
lidocaine	B-Chemical	NOUN	B
pretreatment	O	NOUN	B
on	O	ADP	O
reduction	O	NOUN	B
of	O	ADP	O
succinylcholine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
myalgia	B-Disease	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
undergoing	O	VERB	O
general	O	ADJ	B
anesthesia	O	NOUN	I
for	O	ADP	O
gynecological	O	ADJ	B
surgery	O	NOUN	I
.	O	PUNCT	O


One	O	NUM	O
hundred	O	NUM	O
and	O	CCONJ	O
thirty	O	NUM	B
-	O	PUNCT	O
five	O	NUM	B
patients	O	NOUN	B
were	O	AUX	O
assigned	O	VERB	O
to	O	PART	O
one	O	NUM	O
of	O	ADP	O
three	O	NUM	O
groups	O	NOUN	B
in	O	ADP	O
a	O	DET	O
prospective	O	ADJ	B
,	O	PUNCT	O
double	O	ADJ	O
blind	O	ADJ	B
,	O	PUNCT	O
randomized	O	ADJ	B
manner	O	NOUN	O
.	O	PUNCT	O


Group	O	PROPN	B
PS	O	PROPN	B
,	O	PUNCT	O
the	O	DET	O
control	O	NOUN	B
group	O	NOUN	I
,	O	PUNCT	O
received	O	VERB	O
normal	O	ADJ	O
saline	O	NOUN	B
and	O	CCONJ	O
succinylcholine	B-Chemical	NOUN	B
1	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
mg	O	NOUN	O
x	O	NOUN	O
kg	O	NOUN	O
(-	O	PUNCT	O
1	O	NUM	O
);	O	ADJ	O
Group	O	PROPN	B
LS	O	NOUN	B
,	O	PUNCT	O
lidocaine	B-Chemical	NOUN	B
1	O	NUM	I
.	O	PUNCT	O


5	O	NUM	O
mg	O	NOUN	O
x	O	NOUN	O
kg	O	NOUN	O
(-	O	PUNCT	O
1	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
succinylcholine	B-Chemical	NOUN	B
1	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
mg	O	NOUN	O
x	O	NOUN	O
kg	O	NOUN	O
(-	O	PUNCT	O
1	O	NUM	O
);	O	ADJ	B
Group	O	PROPN	I
PR	O	NOUN	I
,	O	PUNCT	O
normal	O	ADJ	B
saline	O	NOUN	I
and	O	CCONJ	O
rocuronium	B-Chemical	NOUN	B
0	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
mg	O	NOUN	O
x	O	NOUN	O
kg	O	NOUN	O
(-	O	PUNCT	O
1	O	NUM	O
).	O	PUNCT	O
Morphine	B-Chemical	NOUN	B
0	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
mg	O	NOUN	O
x	O	NOUN	O
kg	O	NOUN	O
(-	O	PUNCT	O
1	O	NUM	O
)	O	PUNCT	O
iv	O	NOUN	O
was	O	AUX	O
given	O	VERB	O
for	O	ADP	O
premedication	O	NOUN	B
and	O	CCONJ	O
all	O	DET	O
patients	O	NOUN	B
were	O	AUX	O
monitored	O	VERB	B
with	O	ADP	O
a	O	DET	O
noninvasive	O	ADJ	B
blood	O	NOUN	I
pressure	O	NOUN	I
monitor	O	NOUN	I
,	O	PUNCT	O
ECG	O	PROPN	B
and	O	CCONJ	O
pulse	O	NOUN	B
oximetry	O	NOUN	I
.	O	PUNCT	O


Anesthesia	O	NOUN	B
was	O	AUX	O
induced	O	VERB	B
with	O	ADP	O
5	O	NUM	O
mg	O	NOUN	O
.	O	PUNCT	O


kg	O	NOUN	O
(-	O	PUNCT	O
1	O	NUM	O
)	O	PUNCT	O
thiopental	B-Chemical	NOUN	B
iv	O	NOUN	O
.	O	PUNCT	O


followed	O	VERB	O
by	O	ADP	O
succinylcholine	B-Chemical	NOUN	B
(	O	PUNCT	O
Group	O	PROPN	B
PS	O	PROPN	B
,	O	PUNCT	O
LS	O	NOUN	B
)	O	PUNCT	O
or	O	CCONJ	O
rocuronium	B-Chemical	NOUN	B
(	O	PUNCT	O
Group	O	PROPN	B
PR	O	NOUN	B
)	O	PUNCT	O
for	O	ADP	O
tracheal	O	ADJ	B
intubation	O	NOUN	I
.	O	PUNCT	O


Following	O	VERB	O
administration	O	NOUN	B
of	O	ADP	O
these	O	DET	O
agents	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
presence	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
degree	O	NOUN	B
of	O	ADP	O
fasciculation	B-Disease	NOUN	B
were	O	AUX	O
assessed	O	VERB	B
visually	O	ADV	B
on	O	ADP	O
a	O	DET	O
four	O	NUM	O
point	O	NOUN	O
scale	O	NOUN	O
by	O	ADP	O
one	O	NUM	O
investigator	O	NOUN	B
who	O	PRON	O
was	O	AUX	O
blinded	O	VERB	B
to	O	ADP	O
the	O	DET	O
drug	O	NOUN	B
administered	O	VERB	I
.	O	PUNCT	O


The	O	DET	O
blood	O	NOUN	B
pressure	O	NOUN	I
and	O	CCONJ	O
heart	O	NOUN	B
rate	O	NOUN	I
of	O	ADP	O
each	O	DET	O
patient	O	NOUN	B
were	O	AUX	O
monitored	O	VERB	B
on	O	ADP	O
nine	O	NUM	O
occasions	O	NOUN	B
.	O	PUNCT	O


Twenty	O	NUM	B
-	O	PUNCT	O
four	O	NUM	O
hours	O	NOUN	B
later	O	ADV	O
,	O	PUNCT	O
any	O	DET	O
myalgia	B-Disease	NOUN	B
experienced	O	VERB	B
was	O	AUX	O
assessed	O	VERB	B
according	O	VERB	O
to	O	ADP	O
a	O	DET	O
structured	O	ADJ	B
questionaire	O	NOUN	I
and	O	CCONJ	O
graded	O	VERB	B
by	O	ADP	O
a	O	DET	O
four	O	NUM	O
point	O	NOUN	O
scale	O	NOUN	O
by	O	ADP	O
one	O	NUM	O
investigator	O	NOUN	B
blinded	O	VERB	B
to	O	ADP	O
the	O	DET	O
intraoperative	O	ADJ	B
management	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
results	O	NOUN	B
indicate	O	VERB	O
that	O	SCONJ	O
muscle	B-Disease	NOUN	B
fasciculation	I-Disease	NOUN	I
was	O	AUX	O
not	O	PART	O
found	O	VERB	O
in	O	ADP	O
Group	O	PROPN	B
PR	O	NOUN	B
while	O	SCONJ	O
the	O	DET	O
patients	O	NOUN	B
in	O	ADP	O
Group	O	NOUN	B
LS	O	NOUN	B
had	O	AUX	O
a	O	DET	O
lower	O	ADJ	O
incidence	O	NOUN	B
of	O	ADP	O
muscle	B-Disease	NOUN	B
fasciculation	I-Disease	NOUN	I
than	O	ADP	O
those	O	DET	O
in	O	ADP	O
Group	O	PROPN	B
PS	O	PROPN	B
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


001	O	NUM	O
).	O	PUNCT	O
At	O	ADP	O
24	O	NUM	O
h	O	NOUN	O
,	O	PUNCT	O
the	O	DET	O
incidence	O	NOUN	B
of	O	ADP	O
myalgia	B-Disease	NOUN	B
was	O	AUX	O
higher	O	ADJ	O
in	O	ADP	O
Group	O	PROPN	B
PS	O	PROPN	B
than	O	ADP	O
in	O	ADP	O
Group	O	PROPN	B
LS	O	NOUN	B
and	O	CCONJ	O
PR	O	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


05	O	NUM	O
).	O	PUNCT	O
A	O	NOUN	O
correlation	O	NOUN	B
was	O	AUX	O
not	O	PART	O
found	O	VERB	O
between	O	ADP	O
the	O	DET	O
incidence	O	NOUN	B
of	O	ADP	O
myalgia	B-Disease	NOUN	B
and	O	CCONJ	O
the	O	DET	O
occurrence	O	NOUN	B
of	O	ADP	O
muscle	B-Disease	NOUN	B
fasciculation	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
changes	O	NOUN	B
in	O	ADP	O
systolic	O	NOUN	B
and	O	CCONJ	O
diastolic	O	ADJ	B
blood	O	NOUN	I
pressure	O	NOUN	I
and	O	CCONJ	O
heart	O	NOUN	B
rate	O	NOUN	I
were	O	AUX	O
not	O	PART	O
significant	O	ADJ	O
among	O	ADP	O
the	O	DET	O
three	O	NUM	O
groups	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
conclusion	O	NOUN	O
,	O	PUNCT	O
where	O	SCONJ	O
succinylcholine	B-Chemical	NOUN	B
is	O	AUX	O
used	O	VERB	O
,	O	PUNCT	O
lidocaine	B-Chemical	NOUN	B
is	O	AUX	O
proven	O	VERB	O
to	O	PART	O
be	O	AUX	O
the	O	DET	O
useful	O	ADJ	O
pretreatment	O	NOUN	B
agent	O	NOUN	I
for	O	ADP	O
the	O	DET	O
reduction	O	NOUN	B
of	O	ADP	O
postoperative	B-Disease	ADJ	B
myalgia	I-Disease	NOUN	I


Open	O	ADJ	B
-	O	PUNCT	O
label	O	NOUN	B
assessment	O	NOUN	B
of	O	ADP	O
levofloxacin	B-Chemical	NOUN	B
for	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
acute	O	ADJ	B
bacterial	O	ADJ	O
sinusitis	B-Disease	NOUN	O
in	O	ADP	O
adults	O	NOUN	B
.	O	PUNCT	O


PURPOSE	O	NOUN	B
:	O	PUNCT	O
To	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
efficacy	O	NOUN	B
and	O	CCONJ	O
safety	O	NOUN	B
of	O	ADP	O
levofloxacin	B-Chemical	NOUN	B
(	O	PUNCT	O
500	O	NUM	O
mg	O	NOUN	O
orally	O	ADV	B
once	O	SCONJ	B
daily	O	ADV	I
for	O	ADP	O
10	O	NUM	O
to	O	PART	O
14	O	NUM	O
days	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
treating	O	VERB	B
adult	O	ADJ	B
outpatients	O	NOUN	B
with	O	ADP	O
acute	O	ADJ	B
bacterial	O	ADJ	O
sinusitis	B-Disease	NOUN	O
.	O	PUNCT	O


PATIENTS	O	NOUN	B
AND	O	CCONJ	O
METHODS	O	NOUN	O
:	O	PUNCT	O
A	O	DET	O
total	O	NOUN	O
of	O	ADP	O
329	O	NUM	O
patients	O	NOUN	B
enrolled	O	VERB	O
in	O	ADP	O
the	O	DET	O
study	O	NOUN	B
at	O	ADP	O
24	O	NUM	O
centers	O	NOUN	B
.	O	PUNCT	O


All	O	DET	O
patients	O	NOUN	B
had	O	AUX	O
a	O	DET	O
pre	O	ADJ	B
-	O	PUNCT	O
therapy	O	NOUN	B
Gram	O	PROPN	B
'	O	PART	O
s	O	NOUN	O
stain	O	NOUN	B
and	O	CCONJ	O
culture	O	NOUN	B
of	O	ADP	O
sinus	O	NOUN	B
exudate	O	NOUN	O
obtained	O	VERB	O
by	O	ADP	O
antral	O	ADJ	B
puncture	O	NOUN	I
or	O	CCONJ	O
nasal	O	ADJ	B
endoscopy	O	NOUN	I
.	O	PUNCT	O


Clinical	O	ADJ	B
response	O	NOUN	I
was	O	AUX	O
assessed	O	VERB	B
on	O	ADP	O
the	O	DET	O
basis	O	NOUN	O
of	O	ADP	O
signs	O	NOUN	B
and	O	CCONJ	O
symptoms	O	NOUN	B
and	O	CCONJ	O
sinus	O	NOUN	B
radiograph	O	NOUN	I
or	O	CCONJ	O
computed	O	VERB	B
tomography	O	NOUN	I
results	O	NOUN	B
.	O	PUNCT	O


Microbiologic	O	ADJ	B
cure	O	NOUN	I
rates	O	NOUN	B
were	O	AUX	O
determined	O	VERB	O
on	O	ADP	O
the	O	DET	O
basis	O	NOUN	O
of	O	ADP	O
presumed	O	VERB	O
plus	O	CCONJ	O
documented	O	VERB	B
eradication	O	NOUN	B
of	O	ADP	O
the	O	DET	O
pre	O	ADJ	B
-	O	PUNCT	O
therapy	O	NOUN	B
pathogen	O	NOUN	B
(	O	PUNCT	O
s	O	NOUN	O
).	O	PUNCT	O
RESULTS	O	NOUN	B
:	O	PUNCT	O
The	O	DET	O
most	O	ADV	O
common	O	ADJ	O
pathogens	O	NOUN	B
were	O	AUX	O
Haemophilus	O	NOUN	B
influenzae	O	NOUN	I
,	O	PUNCT	O
Streptococcus	O	X	B
pneumoniae	O	X	I
,	O	PUNCT	O
Staphylococcus	O	X	B
aureus	O	X	I
,	O	PUNCT	O
and	O	CCONJ	O
Moraxella	O	NOUN	B
catarrhalis	O	NOUN	I
.	O	PUNCT	O


Of	O	ADP	O
300	O	NUM	O
clinically	O	ADV	O
evaluable	O	ADJ	O
patients	O	NOUN	B
,	O	PUNCT	O
175	O	NUM	O
(	O	PUNCT	O
58	O	NUM	O
%)	O	NOUN	O
were	O	AUX	O
cured	O	VERB	B
and	O	CCONJ	O
90	O	NUM	O
(	O	PUNCT	O
30	O	NUM	O
%)	O	NOUN	O
were	O	AUX	O
improved	O	VERB	B
at	O	ADP	O
the	O	DET	O
post	O	NOUN	B
-	O	PUNCT	O
therapy	O	NOUN	B
evaluation	O	NOUN	B
,	O	PUNCT	O
resulting	O	VERB	O
in	O	ADP	O
a	O	DET	O
clinical	O	ADJ	B
success	O	NOUN	I
rate	O	NOUN	B
of	O	ADP	O
88	O	NUM	O
%.	O	NOUN	O
Thirty	O	NUM	B
-	O	PUNCT	O
five	O	NUM	B
patients	O	NOUN	B
(	O	PUNCT	O
12	O	NUM	O
%)	O	NOUN	O
clinically	O	ADV	B
failed	O	VERB	I
treatment	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
microbiologic	O	ADJ	B
eradication	O	NOUN	I
rate	O	NOUN	I
(	O	PUNCT	O
presumed	O	VERB	O
plus	O	CCONJ	O
documented	O	VERB	B
)	O	PUNCT	O
among	O	ADP	O
138	O	NUM	O
microbiologically	O	ADV	B
evaluable	O	ADJ	O
patients	O	NOUN	B
was	O	AUX	O
92	O	NUM	O
%.	O	NOUN	B
Microbiologic	O	ADJ	B
eradication	O	NOUN	O
rates	O	NOUN	O
(	O	PUNCT	O
presumed	O	VERB	O
plus	O	CCONJ	O
documented	O	VERB	B
)	O	PUNCT	O
of	O	ADP	O
the	O	DET	O
most	O	ADV	O
common	O	ADJ	O
pathogens	O	NOUN	B
ranged	O	VERB	O
from	O	ADP	O
93	O	NUM	O
%(	O	NOUN	O
M	O	NOUN	B
.	O	PUNCT	O


catarrhalis	O	NOUN	B
)	O	PUNCT	O
to	O	PART	O
100	O	NUM	O
%(	O	NOUN	O
S	O	NOUN	B
.	O	PUNCT	O


pneumoniae	O	X	B
)	O	PUNCT	O
at	O	ADP	O
the	O	DET	O
post	O	NOUN	B
-	O	PUNCT	O
therapy	O	NOUN	B
visit	O	NOUN	B
.	O	PUNCT	O


All	O	DET	O
but	O	CCONJ	O
one	O	NUM	O
of	O	ADP	O
the	O	DET	O
265	O	NUM	O
patients	O	NOUN	B
who	O	PRON	O
were	O	AUX	O
cured	O	VERB	B
or	O	CCONJ	O
improved	O	VERB	B
at	O	ADP	O
post	O	NOUN	B
-	O	PUNCT	O
therapy	O	NOUN	B
returned	O	VERB	O
for	O	ADP	O
a	O	DET	O
long	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
follow	O	VERB	B
-	O	PUNCT	O
up	O	ADP	B
visit	O	NOUN	I
;	O	PUNCT	O
243	O	NUM	O
(	O	PUNCT	O
92	O	NUM	O
%)	O	NOUN	O
remained	O	VERB	O
well	O	ADV	O
4	O	NUM	O
to	O	PART	O
6	O	NUM	O
weeks	O	NOUN	B
after	O	ADP	O
therapy	O	NOUN	B
;	O	PUNCT	O
and	O	CCONJ	O
21	O	NUM	O
(	O	PUNCT	O
8	O	NUM	O
%)	O	NOUN	O
had	O	AUX	O
a	O	DET	O
relapse	O	NOUN	B
of	O	ADP	O
symptoms	O	NOUN	B
.	O	PUNCT	O


Adverse	O	ADJ	B
events	O	NOUN	I
considered	O	VERB	O
to	O	PART	O
be	O	AUX	O
related	O	ADJ	O
to	O	PART	O
levofloxacin	B-Chemical	NOUN	B
administration	O	NOUN	B
were	O	AUX	O
reported	O	VERB	O
by	O	ADP	O
29	O	NUM	O
patients	O	NOUN	B
(	O	PUNCT	O
9	O	NUM	O
%).	O	NOUN	O
The	O	DET	O
most	O	ADV	O
common	O	ADJ	O
drug	O	NOUN	B
-	O	PUNCT	O
related	O	VERB	B
adverse	O	ADJ	B
events	O	NOUN	I
were	O	AUX	O
diarrhea	B-Disease	NOUN	B
,	O	PUNCT	O
flatulence	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
nausea	B-Disease	NOUN	B
;	O	PUNCT	O
most	O	ADJ	O
adverse	O	ADJ	B
events	O	NOUN	I
were	O	AUX	O
mild	O	ADJ	B
to	O	PART	O
moderate	O	ADJ	B
in	O	ADP	O
severity	O	NOUN	B
.	O	PUNCT	O


CONCLUSION	O	NOUN	B
:	O	PUNCT	O
The	O	DET	O
results	O	NOUN	B
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
indicate	O	VERB	O
that	O	SCONJ	O
levofloxacin	B-Chemical	NOUN	B
500	O	NUM	O
mg	O	NOUN	O
once	O	ADV	B
daily	O	ADV	I
is	O	AUX	O
an	O	DET	O
effective	O	ADJ	B
and	O	CCONJ	O
safe	O	ADJ	O
treatment	O	NOUN	B
for	O	ADP	O
acute	O	ADJ	B
bacterial	O	ADJ	O
sinusitis	B-Disease	NOUN	O


Clinical	O	ADJ	B
evaluation	O	NOUN	O
on	O	ADP	O
combined	O	ADJ	O
administration	O	NOUN	B
of	O	ADP	O
oral	O	ADJ	B
prostacyclin	B-Chemical	NOUN	B
analogue	O	NOUN	I
beraprost	B-Chemical	NOUN	B
and	O	CCONJ	O
phosphodiesterase	O	NOUN	B
inhibitor	O	NOUN	I
cilostazol	B-Chemical	NOUN	B
.	O	PUNCT	O


Among	O	ADP	O
various	O	ADJ	O
oral	O	ADJ	B
antiplatelets	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
combination	O	NOUN	B
of	O	ADP	O
a	O	DET	O
novel	O	ADJ	O
prostacyclin	B-Chemical	NOUN	B
analogue	O	NOUN	I
beraprost	B-Chemical	NOUN	B
(	O	PUNCT	O
BPT	B-Chemical	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
potent	O	ADJ	O
phosphodiesterase	O	NOUN	B
inhibitor	O	NOUN	I
cilostazol	B-Chemical	NOUN	B
(	O	PUNCT	O
CLZ	B-Chemical	NOUN	B
)	O	PUNCT	O
may	O	AUX	O
result	O	VERB	O
in	O	ADP	O
untoward	O	ADJ	O
clinical	O	ADJ	B
effects	O	NOUN	I
due	O	ADJ	O
to	O	PART	O
possible	O	ADJ	O
synergistic	O	ADJ	B
elevation	O	NOUN	B
of	O	ADP	O
intracellular	O	ADJ	B
cAMP	B-Chemical	NOUN	B
(	O	PUNCT	O
cyclic	B-Chemical	ADJ	B
adenosine	I-Chemical	NOUN	I
3',5'-monophosphate	I-Chemical	NOUN	I
).	O	PUNCT	O
Thereby	O	ADV	O
,	O	PUNCT	O
a	O	DET	O
clinical	O	ADJ	B
study	O	NOUN	I
of	O	ADP	O
the	O	DET	O
combined	O	ADJ	B
administration	O	NOUN	B
of	O	ADP	O
the	O	DET	O
two	O	NUM	O
agents	O	NOUN	B
was	O	AUX	O
attempted	O	VERB	O
.	O	PUNCT	O


Twelve	O	NUM	O
healthy	O	ADJ	B
volunteers	O	NOUN	I
were	O	AUX	O
assigned	O	VERB	O
to	O	PART	O
take	O	VERB	O
BPT	B-Chemical	PROPN	B
/	O	SYM	O
CLZ	B-Chemical	NOUN	B
in	O	ADP	O
the	O	DET	O
following	O	VERB	O
schedule	O	NOUN	B
;	O	PUNCT	O
BPT	B-Chemical	NOUN	B
:	O	PUNCT	O
40	O	NUM	O
micrograms	O	NOUN	B
at	O	ADP	O
day	O	NOUN	B
1	O	NUM	O
and	O	CCONJ	O
120	O	NUM	O
micrograms	O	NOUN	O
t	O	NOUN	O
.	O	PUNCT	O


i	O	X	O
.	O	PUNCT	O


d	O	X	O
.	O	PUNCT	O


from	O	ADP	O
day	O	NOUN	B
7	O	NUM	O
to	O	PART	O
14	O	NUM	O
,	O	PUNCT	O
CLZ	B-Chemical	NOUN	B
:	O	PUNCT	O
200	O	NUM	O
mg	O	NOUN	O
t	O	NOUN	O
.	O	PUNCT	O


i	O	X	O
.	O	PUNCT	O


d	O	X	O
.	O	PUNCT	O


from	O	ADP	O
day	O	NOUN	B
3	O	NUM	O
to	O	PART	O
14	O	NUM	O
.	O	PUNCT	O


At	O	ADP	O
various	O	ADJ	O
time	O	NOUN	B
intervals	O	NOUN	I
,	O	PUNCT	O
physical	O	ADJ	B
examination	O	NOUN	I
and	O	CCONJ	O
blood	O	NOUN	B
collection	O	NOUN	I
for	O	ADP	O
ex	O	X	B
vivo	O	X	I
platelet	B-Disease	NOUN	B
aggregation	I-Disease	NOUN	I
and	O	CCONJ	O
determination	O	NOUN	B
of	O	ADP	O
intraplatelet	O	NOUN	B
cAMP	B-Chemical	NOUN	B
were	O	AUX	O
performed	O	VERB	O
.	O	PUNCT	O


Throughout	O	ADP	O
the	O	DET	O
observation	O	NOUN	B
period	O	NOUN	B
,	O	PUNCT	O
no	O	DET	O
significant	O	ADJ	O
alteration	O	NOUN	B
in	O	ADP	O
vital	O	ADJ	B
signs	O	NOUN	I
was	O	AUX	O
observed	O	VERB	B
.	O	PUNCT	O


Seven	O	NUM	O
out	O	ADP	O
of	O	ADP	O
12	O	NUM	O
subjects	O	NOUN	B
experienced	O	VERB	O
headache	B-Disease	NOUN	B
of	O	ADP	O
a	O	DET	O
short	O	ADJ	B
duration	O	NOUN	I
accompanying	O	VERB	O
facial	B-Disease	ADJ	B
flush	I-Disease	NOUN	I
in	O	ADP	O
one	O	NUM	O
and	O	CCONJ	O
nausea	B-Disease	NOUN	B
in	O	ADP	O
one	O	NUM	O
,	O	PUNCT	O
especially	O	ADV	O
after	O	ADP	O
ingestion	O	NOUN	B
of	O	ADP	O
CLZ	B-Chemical	NOUN	B
.	O	PUNCT	O


All	O	DET	O
of	O	ADP	O
these	O	DET	O
symptoms	O	NOUN	B
,	O	PUNCT	O
probably	O	ADV	O
caused	O	VERB	O
by	O	ADP	O
the	O	DET	O
vasodilating	O	ADJ	B
effect	O	NOUN	B
of	O	ADP	O
the	O	DET	O
two	O	NUM	O
agents	O	NOUN	B
,	O	PUNCT	O
were	O	AUX	O
of	O	ADP	O
mild	O	ADJ	B
degree	O	NOUN	B
and	O	CCONJ	O
no	O	DET	O
special	O	ADJ	O
treatment	O	NOUN	B
was	O	AUX	O
required	O	VERB	O
.	O	PUNCT	O


Intraplatelet	O	NOUN	B
cAMP	B-Chemical	NOUN	B
content	O	NOUN	B
was	O	AUX	O
gradually	O	ADV	O
but	O	CCONJ	O
significantly	O	ADV	O
increased	O	VERB	B
to	O	ADP	O
9	O	NUM	O
.	O	PUNCT	O


84	O	NUM	O
+/-	O	CCONJ	O
4	O	NUM	O
.	O	PUNCT	O


59	O	NUM	O
pmol	O	NOUN	O
per	O	ADP	O
10	O	NUM	O
(	O	PUNCT	O
9	O	NUM	O
)	O	PUNCT	O
platelets	O	NOUN	B
at	O	ADP	O
day	O	NOUN	B
14	O	NUM	O
in	O	ADP	O
comparison	O	NOUN	B
with	O	ADP	O
the	O	DET	O
initial	O	ADJ	O
value	O	NOUN	O
(	O	PUNCT	O
6	O	NUM	O
.	O	PUNCT	O


87	O	NUM	O
+/-	O	CCONJ	O
2	O	NUM	O
.	O	PUNCT	O


25	O	NUM	O
pmol	O	NOUN	O
).	O	PUNCT	O
The	O	DET	O
platelet	O	NOUN	B
aggregability	O	NOUN	I
was	O	AUX	O
significantly	O	ADV	O
suppressed	O	VERB	B
at	O	ADP	O
various	O	ADJ	O
time	O	NOUN	B
intervals	O	NOUN	I
but	O	CCONJ	O
no	O	DET	O
additive	O	ADJ	O
or	O	CCONJ	O
synergistic	O	ADJ	B
inhibitory	O	ADJ	B
effect	O	NOUN	O
by	O	ADP	O
the	O	DET	O
combined	O	ADJ	B
administration	O	NOUN	I
was	O	AUX	O
noted	O	VERB	O
.	O	PUNCT	O


In	O	ADP	O
conclusion	O	NOUN	O
,	O	PUNCT	O
the	O	DET	O
combined	O	ADJ	O
administration	O	NOUN	B
of	O	ADP	O
BPT	B-Chemical	NOUN	B
/	O	SYM	O
CLZ	B-Chemical	NOUN	B


Gastrointestinal	O	ADJ	B
tolerability	O	NOUN	B
of	O	ADP	O
etoricoxib	B-Chemical	NOUN	B
in	O	ADP	O
rheumatoid	B-Disease	ADJ	B
arthritis	I-Disease	NOUN	I
patients	O	NOUN	B
:	O	PUNCT	O
results	O	NOUN	B
of	O	ADP	O
the	O	DET	O
etoricoxib	B-Chemical	NOUN	B
vs	O	CCONJ	O
diclofenac	B-Chemical	ADJ	B
sodium	I-Chemical	NOUN	I
gastrointestinal	O	ADJ	O
tolerability	O	NOUN	B
and	O	CCONJ	O
effectiveness	O	NOUN	B
trial	O	NOUN	I
(	O	PUNCT	O
EDGE	O	PROPN	B
-	O	PUNCT	O
II	O	NUM	B
).	O	PUNCT	O
OBJECTIVE	O	NOUN	O
:	O	PUNCT	O
A	O	DET	O
randomised	O	ADJ	B
,	O	PUNCT	O
double	O	ADJ	B
-	O	PUNCT	O
blind	O	ADJ	B
study	O	NOUN	B
to	O	PART	O
compare	O	VERB	B
the	O	DET	O
gastrointestinal	O	ADJ	B
(	O	PUNCT	I
GI	O	NOUN	B
)	O	PUNCT	O
tolerability	O	NOUN	B
,	O	PUNCT	O
safety	O	NOUN	B
and	O	CCONJ	O
efficacy	O	NOUN	B
of	O	ADP	O
etoricoxib	B-Chemical	NOUN	B
and	O	CCONJ	O
diclofenac	B-Chemical	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
rheumatoid	B-Disease	ADJ	B
arthritis	I-Disease	NOUN	I
(	O	PUNCT	O
RA	B-Disease	NOUN	B
).	O	PUNCT	O
PATIENTS	O	NOUN	B
AND	O	CCONJ	O
METHODS	O	NOUN	O
:	O	PUNCT	O
A	O	DET	O
total	O	NOUN	O
of	O	ADP	O
4086	O	NUM	O
patients	O	NOUN	B
(	O	PUNCT	O
mean	O	ADJ	O
age	O	NOUN	B
60	O	NUM	O
.	O	PUNCT	O


8	O	NUM	O
years	O	NOUN	B
)	O	PUNCT	O
diagnosed	O	VERB	B
with	O	ADP	O
RA	B-Disease	NOUN	B
were	O	AUX	O
enrolled	O	VERB	O
and	O	CCONJ	O
received	O	VERB	O
etoricoxib	B-Chemical	NOUN	B
90	O	NUM	O
mg	O	NOUN	O
daily	O	ADV	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
2032	O	NUM	O
)	O	PUNCT	O
or	O	CCONJ	O
diclofenac	B-Chemical	ADJ	B
75	O	NUM	O
mg	O	NOUN	O
twice	O	ADV	O
daily	O	ADV	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
2054	O	NUM	O
).	O	PUNCT	O
Use	O	PROPN	O
of	O	ADP	O
gastroprotective	O	ADJ	B
agents	O	NOUN	I
and	O	CCONJ	O
low	O	ADJ	B
-	O	PUNCT	O
dose	O	NOUN	B
aspirin	B-Chemical	NOUN	B
was	O	AUX	O
allowed	O	VERB	O
.	O	PUNCT	O


The	O	DET	O
prespecified	O	ADJ	O
primary	O	ADJ	O
end	O	NOUN	O
point	O	NOUN	O
consisted	O	VERB	O
of	O	ADP	O
the	O	DET	O
cumulative	O	ADJ	B
rate	O	NOUN	B
of	O	ADP	O
patient	O	NOUN	B
discontinuations	O	NOUN	B
due	O	ADJ	O
to	O	PART	O
clinical	O	ADJ	B
and	O	CCONJ	O
laboratory	O	ADJ	B
GI	O	NOUN	B
adverse	O	ADJ	I
experiences	O	NOUN	I
(	O	PUNCT	O
AEs	O	NOUN	B
).	O	PUNCT	O
General	O	ADJ	B
safety	O	NOUN	I
was	O	AUX	O
also	O	ADV	O
assessed	O	VERB	B
,	O	PUNCT	O
including	O	VERB	O
adjudicated	O	VERB	B
thrombotic	B-Disease	ADJ	B
cardiovascular	I-Disease	ADJ	O
event	O	NOUN	O
data	O	NOUN	B
.	O	PUNCT	O


Efficacy	O	NOUN	B
was	O	AUX	O
evaluated	O	VERB	B
using	O	VERB	O
the	O	DET	O
Patient	O	PROPN	B
Global	O	PROPN	I
Assessment	O	PROPN	I
of	O	ADP	I
Disease	O	PROPN	I
Status	O	PROPN	I
(	O	PUNCT	O
PGADS	O	NOUN	B
;	O	PUNCT	O
0	O	NUM	O
-	O	SYM	O
4	O	NUM	O
point	O	NOUN	O
scale	O	NOUN	O
).	O	PUNCT	O
RESULTS	O	NOUN	O
:	O	PUNCT	O
Mean	O	VERB	B
(	O	PUNCT	O
SD	O	NOUN	B
;	O	PUNCT	O
maximum	O	ADJ	B
)	O	PUNCT	O
duration	O	NOUN	B
of	O	ADP	O
treatment	O	NOUN	B
was	O	AUX	O
19	O	NUM	O
.	O	PUNCT	O


3	O	NUM	O
(	O	PUNCT	O
10	O	NUM	O
.	O	PUNCT	O


3	O	NUM	O
;	O	PUNCT	O
32	O	NUM	O
.	O	PUNCT	O


9	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
19	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
(	O	PUNCT	O
10	O	NUM	O
.	O	PUNCT	O


4	O	NUM	O
;	O	PUNCT	O
33	O	NUM	O
.	O	PUNCT	O


1	O	X	O
)	O	PUNCT	O
months	O	NOUN	B
in	O	ADP	O
the	O	DET	O
etoricoxib	B-Chemical	NOUN	B
and	O	CCONJ	O
diclofenac	B-Chemical	ADJ	B
groups	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


The	O	DET	O
cumulative	O	ADJ	B
discontinuation	O	NOUN	B
rate	O	NOUN	B
due	O	ADJ	O
to	O	PART	O
GI	B-Disease	NOUN	B
AEs	I-Disease	NOUN	B
was	O	AUX	O
significantly	O	ADV	O
lower	O	ADJ	O
with	O	ADP	O
etoricoxib	B-Chemical	NOUN	B
than	O	ADP	O
diclofenac	B-Chemical	NOUN	B
(	O	PUNCT	O
5	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
vs	O	CCONJ	O
8	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
events	O	NOUN	B
per	O	ADP	O
100	O	NUM	O
patient	O	NOUN	B
-	O	PUNCT	O
years	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
;	O	PUNCT	O
hazard	O	ADJ	B
ratio	O	NOUN	I
0	O	NUM	I
.	O	PUNCT	O


62	O	NUM	O
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
:	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


47	O	NUM	O
,	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


81	O	NUM	O
;	O	PUNCT	O
p	O	NUM	O
<	O	X	O
or	O	CCONJ	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


001	O	NUM	O
)).	O	ADJ	O
The	O	DET	O
incidence	O	NOUN	B
of	O	ADP	O
discontinuations	O	NOUN	B
for	O	ADP	O
hypertension	B-Disease	NOUN	B
-	O	PUNCT	O
related	O	ADJ	B
and	O	CCONJ	O
oedema	B-Disease	NOUN	B
-	O	PUNCT	O
related	O	VERB	B
AEs	O	NOUN	B
were	O	AUX	O
significantly	O	ADV	O
higher	O	ADJ	O
with	O	ADP	O
etoricoxib	B-Chemical	NOUN	B
(	O	PUNCT	O
2	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
1	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
%	O	NOUN	O
respectively	O	ADV	O
)	O	PUNCT	O
compared	O	VERB	B
with	O	ADP	O
diclofenac	B-Chemical	NOUN	B
(	O	PUNCT	O
1	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


4	O	NUM	O
%	O	NOUN	O
respectively	O	ADV	O
;	O	PUNCT	O
p	O	X	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


001	O	NUM	O
for	O	ADP	O
hypertension	B-Disease	NOUN	B
and	O	CCONJ	O
p	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


01	O	NUM	O
for	O	ADP	O
oedema	B-Disease	NOUN	B
).	O	PUNCT	O
Etoricoxib	B-Chemical	NOUN	B
and	O	CCONJ	O
diclofenac	B-Chemical	ADJ	B
treatment	O	NOUN	B
resulted	O	VERB	O
in	O	ADP	O
similar	O	ADJ	O
efficacy	O	NOUN	B
(	O	PUNCT	O
PGADS	O	NOUN	B
mean	O	VERB	O
changes	O	NOUN	B
from	O	ADP	O
baseline	O	NOUN	B
-	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


62	O	NUM	O
vs	O	NOUN	O
-	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


58	O	NUM	O
,	O	PUNCT	O
respectively	O	ADV	O
).	O	PUNCT	O
CONCLUSIONS	O	NOUN	O
:	O	PUNCT	O
Etoricoxib	B-Chemical	NOUN	B
90	O	NUM	O
mg	O	NOUN	O
demonstrated	O	VERB	O
a	O	DET	O
significantly	O	ADV	O
lower	O	ADJ	O
risk	O	NOUN	B
for	O	ADP	O
discontinuing	O	VERB	B
treatment	O	NOUN	B
due	O	ADJ	O
to	O	PART	O
GI	B-Disease	NOUN	B
AEs	I-Disease	NOUN	B
compared	O	VERB	O
with	O	ADP	O
diclofenac	B-Chemical	NOUN	B
150	O	NUM	O
mg	O	NOUN	O
.	O	PUNCT	O


Discontinuations	O	NOUN	B
from	O	ADP	O
renovascular	O	ADJ	B
AEs	O	NOUN	B
,	O	PUNCT	O
although	O	SCONJ	O
less	O	ADV	O
common	O	ADJ	O
than	O	ADP	O
discontinuations	O	NOUN	B
from	O	ADP	O
GI	B-Disease	NOUN	B
AEs	I-Disease	NOUN	B
,	O	PUNCT	O
were	O	AUX	O
significantly	O	ADV	O
higher	O	ADJ	O
with	O	ADP	O
etoricoxib	B-Chemical	NOUN	B


Placebo	O	NOUN	B
-	O	PUNCT	O
level	O	NOUN	B
incidence	O	NOUN	B
of	O	ADP	O
extrapyramidal	B-Disease	ADJ	B
symptoms	I-Disease	NOUN	I
(	O	PUNCT	O
EPS	B-Disease	PROPN	B
)	O	PUNCT	O
with	O	ADP	O
quetiapine	B-Chemical	NOUN	B
in	O	ADP	O
controlled	O	VERB	B
studies	O	NOUN	I
of	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
bipolar	B-Disease	ADJ	B
mania	I-Disease	NOUN	I
.	O	PUNCT	O


OBJECTIVES	O	NOUN	O
:	O	PUNCT	O
To	O	PART	O
evaluate	O	VERB	O
extrapyramidal	B-Disease	ADJ	B
symptoms	I-Disease	NOUN	I
(	O	PUNCT	O
EPS	B-Disease	PROPN	B
),	O	PUNCT	O
including	O	VERB	O
akathisia	B-Disease	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
quetiapine	B-Chemical	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
bipolar	B-Disease	ADJ	B
mania	I-Disease	NOUN	I
.	O	PUNCT	O


METHODS	O	NOUN	O
:	O	PUNCT	O
Data	O	NOUN	B
were	O	AUX	O
analyzed	O	VERB	B
from	O	ADP	O
four	O	NUM	O
similarly	O	ADV	O
designed	O	VERB	O
,	O	PUNCT	O
randomized	O	ADJ	B
,	O	PUNCT	O
double	O	ADJ	B
-	O	PUNCT	O
blind	O	NOUN	B
,	O	PUNCT	O
3	O	NUM	O
-	O	PUNCT	O
to	O	PART	O
12	O	NUM	O
-	O	PUNCT	O
week	O	NOUN	B
studies	O	NOUN	B
.	O	PUNCT	O


Two	O	NUM	O
studies	O	NOUN	B
evaluated	O	VERB	O
quetiapine	B-Chemical	NOUN	B
monotherapy	O	NOUN	B
(	O	PUNCT	O
up	O	ADV	O
to	O	PART	O
800	O	NUM	O
mg	O	NOUN	O
/	O	PUNCT	O
day	O	NOUN	B
)(	O	NOUN	O
n	O	NOUN	O
=	O	ADJ	O
209	O	NUM	O
)	O	PUNCT	O
versus	O	CCONJ	O
placebo	O	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
198	O	NUM	O
),	O	PUNCT	O
with	O	ADP	O
lithium	B-Chemical	NOUN	B
or	O	CCONJ	O
haloperidol	B-Chemical	NOUN	B
monotherapy	O	NOUN	B
as	O	ADP	O
respective	O	ADJ	O
active	O	ADJ	B
controls	O	NOUN	I
.	O	PUNCT	O


Two	O	NUM	O
studies	O	NOUN	B
evaluated	O	VERB	O
quetiapine	B-Chemical	NOUN	B
(	O	PUNCT	O
up	O	ADV	O
to	O	PART	O
800	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
day	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
combination	O	NOUN	B
with	O	ADP	O
a	O	DET	O
mood	O	NOUN	B
stabilizer	O	NOUN	I
(	O	PUNCT	O
lithium	B-Chemical	NOUN	B
or	O	CCONJ	O
divalproex	B-Chemical	NOUN	B
,	O	PUNCT	O
QTP	B-Chemical	PROPN	B
+	O	CCONJ	O
Li	B-Chemical	PROPN	B
/	O	PUNCT	O
DVP	B-Chemical	PROPN	B
)(	O	NOUN	O
n	O	NOUN	O
=	O	ADJ	O
196	O	NUM	O
)	O	PUNCT	O
compared	O	VERB	O
to	O	PART	O
placebo	O	NOUN	B
and	O	CCONJ	O
mood	O	NOUN	B
stabilizer	O	NOUN	I
(	O	PUNCT	O
PBO	O	PROPN	B
+	O	CCONJ	O
Li	B-Chemical	PROPN	B
/	O	PUNCT	O
DVP	B-Chemical	PROPN	B
)(	O	NOUN	O
n	O	NOUN	O
=	O	ADJ	O
203	O	NUM	O
).	O	PUNCT	O
Extrapyramidal	B-Disease	ADJ	B
symptoms	I-Disease	NOUN	I
were	O	AUX	O
evaluated	O	VERB	B
using	O	VERB	O
the	O	DET	O
Simpson	O	PROPN	B
-	O	PUNCT	O
Angus	O	PROPN	B
Scale	O	PROPN	I
(	O	PUNCT	O
SAS	O	PROPN	B
),	O	PUNCT	O
the	O	DET	O
Barnes	O	PROPN	B
Akathisia	O	PROPN	I
Rating	O	PROPN	I
Scale	O	NOUN	I
(	O	PUNCT	O
BARS	O	NOUN	B
),	O	PUNCT	O
adverse	O	ADJ	B
event	O	NOUN	I
reports	O	NOUN	B
and	O	CCONJ	O
anticholinergic	O	ADJ	B
drug	O	NOUN	I
usage	O	NOUN	I
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
The	O	DET	O
incidence	O	NOUN	B
of	O	ADP	O
EPS	B-Disease	PROPN	B
-	O	PUNCT	O
related	O	VERB	B
adverse	O	ADJ	B
events	O	NOUN	I
,	O	PUNCT	O
including	O	VERB	O
akathisia	B-Disease	NOUN	B
,	O	PUNCT	O
was	O	AUX	O
no	O	DET	O
different	O	ADJ	O
with	O	ADP	O
quetiapine	B-Chemical	NOUN	B
monotherapy	O	NOUN	B
(	O	PUNCT	O
12	O	NUM	O
.	O	PUNCT	O


9	O	NUM	O
%)	O	NOUN	O
than	O	ADP	O
with	O	ADP	O
placebo	O	NOUN	B
(	O	PUNCT	O
13	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
%).	O	NOUN	O
Similarly	O	ADV	O
,	O	PUNCT	O
EPS	B-Disease	PROPN	B
-	O	PUNCT	O
related	O	VERB	B
adverse	O	ADJ	B
events	O	NOUN	I
with	O	ADP	O
QTP	B-Chemical	PROPN	B
+	O	CCONJ	O
Li	B-Chemical	PROPN	B
/	O	PUNCT	O
DVP	B-Chemical	PROPN	B
(	O	PUNCT	O
21	O	NUM	O
.	O	PUNCT	O


4	O	NUM	O
%)	O	NOUN	O
were	O	AUX	O
no	O	DET	O
different	O	ADJ	O
than	O	ADP	O
with	O	ADP	O
PBO	O	NOUN	B
+	O	CCONJ	O
Li	B-Chemical	PROPN	B
/	O	PUNCT	O
DVP	B-Chemical	PROPN	B
(	O	PUNCT	O
19	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
%).	O	X	O
Adverse	O	ADJ	B
events	O	NOUN	I
related	O	VERB	O
to	O	PART	O
EPS	B-Disease	NOUN	B
occurred	O	VERB	O
in	O	ADP	O
59	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
haloperidol	B-Chemical	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
99	O	NUM	O
)	O	PUNCT	O
monotherapy	O	NOUN	B
,	O	PUNCT	O
whereas	O	SCONJ	O
26	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
lithium	B-Chemical	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
98	O	NUM	O
)	O	PUNCT	O
monotherapy	O	NOUN	B
experienced	O	VERB	O
adverse	O	ADJ	B
events	O	NOUN	I
related	O	VERB	O
to	O	PART	O
EPS	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
incidence	O	NOUN	B
of	O	ADP	O
akathisia	B-Disease	NOUN	B
was	O	AUX	O
low	O	ADJ	B
and	O	CCONJ	O
similar	O	ADJ	O
with	O	ADP	O
quetiapine	B-Chemical	NOUN	B
monotherapy	O	NOUN	B
(	O	PUNCT	O
3	O	NUM	O
.	O	PUNCT	O


3	O	NUM	O
%)	O	NOUN	B
and	O	CCONJ	O
placebo	O	NOUN	B
(	O	PUNCT	O
6	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
%),	O	NOUN	O
and	O	CCONJ	O
with	O	ADP	O
QTP	B-Chemical	PROPN	B
+	O	CCONJ	O
Li	B-Chemical	PROPN	B
/	O	PUNCT	O
DVP	B-Chemical	PROPN	B
(	O	PUNCT	O
3	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
%)	O	NOUN	B
and	O	CCONJ	O
PBO	O	PROPN	B
+	O	CCONJ	O
Li	B-Chemical	PROPN	B
/	O	PUNCT	O
DVP	B-Chemical	PROPN	B
(	O	PUNCT	O
4	O	NUM	O
.	O	PUNCT	O


9	O	NUM	O
%).	O	ADV	O
Lithium	B-Chemical	NOUN	B
was	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
a	O	DET	O
significantly	O	ADV	O
higher	O	ADJ	O
incidence	O	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


05	O	NUM	O
)	O	PUNCT	O
of	O	ADP	O
tremor	B-Disease	NOUN	B
(	O	PUNCT	O
18	O	NUM	O
.	O	PUNCT	O


4	O	NUM	O
%)	O	NOUN	O
than	O	ADP	O
quetiapine	B-Chemical	NOUN	B
(	O	PUNCT	O
5	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
%);	O	NUM	B
cerebellar	O	ADJ	I
tremor	B-Disease	NOUN	I
,	O	PUNCT	O
which	O	DET	O
is	O	AUX	O
a	O	DET	O
known	O	ADJ	O
adverse	O	ADJ	B
effect	O	NOUN	I
of	O	ADP	O
lithium	B-Chemical	NOUN	B
,	O	PUNCT	O
may	O	AUX	O
have	O	AUX	O
contributed	O	VERB	O
to	O	ADP	O
the	O	DET	O
elevated	O	ADJ	B
rate	O	NOUN	B
of	O	ADP	O
tremor	B-Disease	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
receiving	O	VERB	O
lithium	B-Chemical	NOUN	B
therapy	O	NOUN	I
.	O	PUNCT	O


Haloperidol	B-Chemical	NOUN	B
induced	O	VERB	B
a	O	DET	O
significantly	O	ADV	O
higher	O	ADJ	O
incidence	O	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


001	O	NUM	O
)	O	PUNCT	O
of	O	ADP	O
akathisia	B-Disease	NOUN	B
(	O	PUNCT	O
33	O	NUM	O
.	O	PUNCT	O


3	O	NUM	O
%	O	NOUN	O
versus	O	CCONJ	O
5	O	NUM	O
.	O	PUNCT	O


9	O	NUM	O
%),	O	ADJ	O
tremor	B-Disease	NOUN	B
(	O	PUNCT	O
30	O	NUM	O
.	O	PUNCT	O


3	O	NUM	O
%	O	NOUN	O
versus	O	CCONJ	O
7	O	NUM	O
.	O	PUNCT	O


8	O	NUM	O
%),	O	NOUN	B
and	O	CCONJ	O
extrapyramidal	B-Disease	ADJ	B
syndrome	I-Disease	NOUN	I
(	O	PUNCT	O
35	O	NUM	O
.	O	PUNCT	O


4	O	NUM	O
%	O	NOUN	O
versus	O	CCONJ	O
5	O	NUM	O
.	O	PUNCT	O


9	O	NUM	O
%)	O	NOUN	O
than	O	ADP	O
quetiapine	B-Chemical	NOUN	B
.	O	PUNCT	O


No	O	DET	B
significant	O	ADJ	I
differences	O	NOUN	O
were	O	AUX	O
observed	O	VERB	O
between	O	ADP	O
quetiapine	B-Chemical	NOUN	B
and	O	CCONJ	O
placebo	O	NOUN	B
on	O	ADP	O
SAS	O	PROPN	B
and	O	CCONJ	O
BARS	O	PROPN	B
scores	O	NOUN	I
.	O	PUNCT	O


Anticholinergic	O	ADJ	B
use	O	NOUN	O
was	O	AUX	O
low	O	ADJ	B
and	O	CCONJ	O
similar	O	ADJ	O
with	O	ADP	O
quetiapine	B-Chemical	NOUN	B
or	O	CCONJ	O
placebo	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
:	O	PUNCT	O
In	O	ADP	O
bipolar	B-Disease	ADJ	B
mania	I-Disease	NOUN	I
,	O	PUNCT	O
the	O	DET	O
incidence	O	NOUN	B
of	O	ADP	O
EPS	B-Disease	PROPN	B
,	O	PUNCT	O
including	O	VERB	O
akathisia	B-Disease	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
quetiapine	B-Chemical	NOUN	B


Contribution	O	NOUN	B
of	O	ADP	O
the	O	DET	O
sympathetic	O	ADJ	B
nervous	O	ADJ	I
system	O	NOUN	I
to	O	ADP	O
salt	O	NOUN	B
-	O	PUNCT	O
sensitivity	O	NOUN	B
in	O	ADP	O
lifetime	O	NOUN	B
captopril	B-Chemical	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
spontaneously	O	ADV	B
hypertensive	B-Disease	ADJ	I
rats	O	NOUN	B
.	O	PUNCT	O


OBJECTIVE	O	NOUN	B
:	O	PUNCT	O
To	O	PART	O
test	O	VERB	O
the	O	DET	O
hypothesis	O	NOUN	B
that	O	SCONJ	O
,	O	PUNCT	O
in	O	ADP	O
lifetime	O	NOUN	B
captopril	B-Chemical	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
spontaneously	O	ADV	B
hypertensive	B-Disease	ADJ	I
rats	O	NOUN	B
(	O	PUNCT	O
SHR	O	NOUN	B
),	O	PUNCT	O
the	O	DET	O
sympathetic	O	ADJ	B
nervous	O	ADJ	I
system	O	NOUN	I
contributes	O	VERB	O
importantly	O	ADV	O
to	O	PART	O
the	O	DET	O
hypertensive	B-Disease	ADJ	B
effect	O	NOUN	B
of	O	ADP	O
dietary	B-Chemical	ADJ	B
sodium	I-Chemical	NOUN	I
chloride	I-Chemical	NOUN	I
supplementation	O	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
:	O	PUNCT	O
Male	O	ADJ	B
SHR	O	NOUN	I
(	O	PUNCT	O
aged	O	ADJ	B
6	O	NUM	O
weeks	O	NOUN	B
)	O	PUNCT	O
that	O	PRON	O
had	O	AUX	O
been	O	AUX	O
treated	O	VERB	B
from	O	ADP	O
conception	O	NOUN	B
onward	O	ADV	O
with	O	ADP	O
either	O	CCONJ	O
captopril	B-Chemical	NOUN	B
or	O	CCONJ	O
vehicle	O	NOUN	B
remained	O	VERB	O
on	O	ADP	O
a	O	DET	O
basal	O	ADJ	B
sodium	B-Chemical	NOUN	I
chloride	I-Chemical	NOUN	I
diet	O	NOUN	O
or	O	CCONJ	O
were	O	AUX	O
fed	O	VERB	B
a	O	DET	O
high	O	ADJ	O
sodium	B-Chemical	NOUN	B
chloride	I-Chemical	NOUN	I
diet	O	NOUN	O
.	O	PUNCT	O


After	O	ADP	O
2	O	NUM	O
weeks	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
rats	O	NOUN	B
were	O	AUX	O
subjected	O	VERB	O
to	O	PART	O
ganglionic	O	ADJ	B
blockade	O	NOUN	I
and	O	CCONJ	O
2	O	NUM	O
days	O	NOUN	B
later	O	ADV	O
,	O	PUNCT	O
an	O	DET	O
infusion	O	NOUN	B
of	O	ADP	O
clonidine	B-Chemical	NOUN	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
Lifetime	O	NOUN	B
captopril	B-Chemical	NOUN	B
treatment	O	NOUN	B
significantly	O	ADV	O
lowered	O	VERB	B
mean	O	ADJ	O
arterial	O	ADJ	B
pressure	O	NOUN	I
in	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
.	O	PUNCT	O


Intravenous	O	ADJ	B
infusion	O	NOUN	B
of	O	ADP	O
the	O	DET	O
ganglionic	O	ADJ	B
blocker	O	NOUN	I
hexamethonium	B-Chemical	NOUN	B
resulted	O	VERB	O
in	O	ADP	O
a	O	DET	O
rapid	O	ADJ	O
decline	O	NOUN	B
in	O	ADP	O
MAP	O	NOUN	B
that	O	PRON	O
eliminated	O	VERB	O
the	O	DET	O
dietary	B-Chemical	ADJ	B
sodium	I-Chemical	NOUN	I
chloride	I-Chemical	NOUN	I
-	O	PUNCT	O
induced	O	VERB	B
increase	B-Disease	NOUN	B
in	I-Disease	ADP	O
MAP	I-Disease	NOUN	B
in	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
.	O	PUNCT	O


Infusion	O	NOUN	B
of	O	ADP	O
the	O	DET	O
central	O	ADJ	B
nervous	O	ADJ	I
system	O	NOUN	I
alpha2-adrenergic	B-Chemical	ADJ	B
receptor	I-Chemical	NOUN	I
agonist	I-Chemical	NOUN	B
clonidine	B-Chemical	NOUN	B
also	O	ADV	O
resulted	O	VERB	O
in	O	ADP	O
a	O	DET	O
greater	O	ADJ	O
reduction	O	NOUN	B
in	O	ADP	O
MAP	O	NOUN	B
in	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
of	O	ADP	O
SHR	O	NOUN	B
that	O	PRON	O
were	O	AUX	O
fed	O	VERB	B
the	O	DET	O
high	O	ADJ	B
(	O	PUNCT	O
compared	O	VERB	B
with	O	ADP	O
the	O	DET	O
basal	O	ADJ	B
)	O	PUNCT	O
sodium	B-Chemical	NOUN	B
chloride	I-Chemical	NOUN	I
diet	O	NOUN	O
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
:	O	PUNCT	O
In	O	ADP	O
both	O	CCONJ	O
lifetime	O	NOUN	B
captopril	B-Chemical	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
and	O	CCONJ	O
control	O	NOUN	B
SHR	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
sympathetic	O	ADJ	B
nervous	O	ADJ	I
system	O	NOUN	I
contributes	O	VERB	O
to	O	PART	O
the	O	DET	O
pressor	O	ADJ	B
effects	O	NOUN	B
of	O	ADP	O
a	O	DET	O
high	O	ADJ	O
sodium	B-Chemical	NOUN	B
chloride	I-Chemical	NOUN	I


Dose	O	NOUN	B
-	O	PUNCT	O
related	O	VERB	B
beneficial	O	ADJ	B
and	O	CCONJ	O
adverse	O	ADJ	B
effects	O	NOUN	I
of	O	ADP	O
dietary	O	ADJ	B
corticosterone	B-Chemical	NOUN	I
on	O	ADP	O
organophosphorus	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
delayed	O	VERB	B
neuropathy	B-Disease	NOUN	I
in	O	ADP	O
chickens	O	NOUN	B
.	O	PUNCT	O


Tri-ortho-tolyl	B-Chemical	ADJ	B
phosphate	I-Chemical	NOUN	I
(	O	PUNCT	O
TOTP	B-Chemical	NOUN	B
),	O	PUNCT	O
360	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
,	O	PUNCT	O
po	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
0,0'-diisopropyl	B-Chemical	ADJ	O
phosphorofluoridate	I-Chemical	NOUN	B
(	O	PUNCT	O
DFP	B-Chemical	NOUN	B
),	O	PUNCT	O
1	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
sc	O	NOUN	B
,	O	PUNCT	O
were	O	AUX	O
administered	O	VERB	B
to	O	PART	O
adult	O	ADJ	B
White	O	PROPN	B
Leghorn	O	PROPN	I
chickens	O	NOUN	B
24	O	NUM	O
hr	O	NOUN	O
after	O	ADP	O
they	O	PRON	O
were	O	AUX	O
placed	O	VERB	O
on	O	ADP	O
diets	O	NOUN	B
containing	O	VERB	O
0	O	NUM	O
to	O	PART	O
300	O	NUM	O
ppm	O	NOUN	O
corticosterone	B-Chemical	NOUN	B
.	O	PUNCT	O


Supplemented	O	VERB	B
diets	O	NOUN	I
were	O	AUX	O
continued	O	VERB	O
until	O	ADP	O
clinical	O	ADJ	B
signs	O	NOUN	O
and	O	CCONJ	O
lesions	O	NOUN	B
of	O	ADP	O
delayed	O	VERB	B
neuropathy	B-Disease	NOUN	I
appeared	O	VERB	O
.	O	PUNCT	O


Although	O	SCONJ	O
low	O	ADJ	B
concentrations	O	NOUN	B
(	O	PUNCT	O
less	O	ADJ	O
than	O	ADP	O
or	O	CCONJ	O
equal	O	ADJ	O
to	O	PART	O
50	O	NUM	O
ppm	O	NOUN	O
)	O	PUNCT	O
of	O	ADP	O
corticosterone	B-Chemical	NOUN	B
had	O	AUX	O
beneficial	O	ADJ	O
effects	O	NOUN	B
on	O	ADP	O
TOTP	B-Chemical	PROPN	B
-	O	PUNCT	O
induced	O	VERB	B
neuropathy	B-Disease	NOUN	B
,	O	PUNCT	O
greater	O	ADJ	O
than	O	ADP	O
or	O	CCONJ	O
equal	O	ADJ	O
to	O	PART	O
200	O	NUM	O
ppm	O	NOUN	O
exacerbated	O	ADJ	B
clinical	O	ADJ	B
signs	O	NOUN	O
in	O	ADP	O
chickens	O	NOUN	B
given	O	VERB	O
either	O	CCONJ	O
TOTP	B-Chemical	NOUN	B
or	O	CCONJ	O
DFP	B-Chemical	NOUN	B
.	O	PUNCT	O


Neurotoxic	B-Disease	ADJ	B
esterase	O	NOUN	I
activities	O	NOUN	B
24	O	NUM	O
hr	O	NOUN	O
after	O	ADP	O
TOTP	B-Chemical	NOUN	B
or	O	CCONJ	O
DFP	B-Chemical	NOUN	B
were	O	AUX	O
less	O	ADJ	O
than	O	ADP	O
20	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
values	O	NOUN	B
measured	O	VERB	B
in	O	ADP	O
chickens	O	NOUN	B
not	O	PART	O
given	O	VERB	O
organophosphorous	B-Chemical	ADJ	B
compounds	O	NOUN	I
.	O	PUNCT	O


Chickens	O	NOUN	B
given	O	VERB	O
200	O	NUM	O
ppm	O	NOUN	O
corticosterone	B-Chemical	NOUN	B
without	O	ADP	O
TOTP	B-Chemical	NOUN	B
or	O	CCONJ	O
DFP	B-Chemical	NOUN	B
had	O	AUX	O
significantly	O	ADV	O
elevated	O	ADJ	O
activity	O	NOUN	B
of	O	ADP	O
plasma	O	NOUN	B
cholinesterase	O	NOUN	I
and	O	CCONJ	O
significantly	O	ADV	O
inhibited	O	VERB	B
activity	O	NOUN	B
of	O	ADP	O
liver	O	NOUN	B
carboxylesterase	O	NOUN	I
.	O	PUNCT	O


Degenerating	B-Disease	ADJ	B
myelinated	I-Disease	ADJ	B
fibers	I-Disease	NOUN	I
were	O	AUX	O
also	O	ADV	O
evident	O	ADJ	O
in	O	ADP	O
distal	O	ADJ	B
levels	O	NOUN	B
of	O	ADP	O
the	O	DET	O
peripheral	O	ADJ	B
nerves	O	NOUN	I
of	O	ADP	O
chickens	O	NOUN	B
given	O	VERB	O
TOTP	B-Chemical	NOUN	B
or	O	CCONJ	O
DFP	B-Chemical	NOUN	B


In	O	X	B
vivo	O	X	I
characterization	O	NOUN	B
of	O	ADP	O
a	O	DET	O
dual	O	ADJ	O
adenosine	B-Chemical	NOUN	B
A2A/A1	I-Chemical	NOUN	B
receptor	I-Chemical	NOUN	I
antagonist	I-Chemical	NOUN	B
in	O	ADP	O
animal	O	NOUN	B
models	O	NOUN	I
of	O	ADP	O
Parkinson's	B-Disease	ADJ	B
disease	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
in	O	X	B
vivo	O	X	I
characterization	O	NOUN	B
of	O	ADP	O
a	O	DET	O
dual	O	ADJ	O
adenosine	B-Chemical	NOUN	O
A(2A)/A(1)	I-Chemical	ADJ	B
receptor	I-Chemical	NOUN	I
antagonist	I-Chemical	NOUN	B
in	O	ADP	O
several	O	ADJ	O
animal	O	NOUN	B
models	O	NOUN	I
of	O	ADP	O
Parkinson's	B-Disease	ADJ	B
disease	I-Disease	NOUN	I
is	O	AUX	O
described	O	VERB	O
.	O	PUNCT	O


Discovery	O	NOUN	B
and	O	CCONJ	O
scale	O	NOUN	B
-	O	PUNCT	O
up	O	ADP	B
syntheses	O	NOUN	B
of	O	ADP	O
compound	O	NOUN	B
1	O	NUM	I
are	O	AUX	O
described	O	VERB	O
in	O	ADP	O
detail	O	NOUN	O
,	O	PUNCT	O
highlighting	O	VERB	O
optimization	O	NOUN	B
steps	O	NOUN	O
that	O	PRON	O
increased	O	VERB	B
the	O	DET	O
overall	O	ADJ	O
yield	O	NOUN	B
of	O	ADP	O
1	O	NUM	O
from	O	ADP	O
10	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
%	O	NOUN	O
to	O	PART	O
30	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
%.	O	NOUN	B
Compound	O	NOUN	B
1	O	NUM	I
is	O	AUX	O
a	O	DET	O
potent	O	ADJ	O
A	O	NOUN	O
(	O	PUNCT	O
2A	O	NOUN	B
)/	O	NOUN	O
A	O	NOUN	O
(	O	PUNCT	O
1	O	NUM	O
)	O	PUNCT	O
receptor	O	NOUN	O
antagonist	O	NOUN	B
in	O	X	B
vitro	O	X	I
(	O	PUNCT	O
A	O	NOUN	O
(	O	PUNCT	O
2A	O	NOUN	O
)	O	PUNCT	O
K	O	NOUN	O
(	O	PUNCT	O
i	O	PRON	O
)=	O	SYM	O
4	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
nM	O	NOUN	O
;	O	PUNCT	O
A	O	DET	O
(	O	PUNCT	O
1	O	NUM	O
)	O	PUNCT	O
K	O	NOUN	O
(	O	PUNCT	O
i	O	PRON	O
)=	O	SYM	O
17	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
nM	O	NOUN	O
)	O	PUNCT	O
that	O	PRON	O
has	O	AUX	O
excellent	O	ADJ	B
activity	O	NOUN	B
,	O	PUNCT	O
after	O	ADP	O
oral	O	ADJ	B
administration	O	NOUN	I
,	O	PUNCT	O
across	O	ADP	O
a	O	DET	O
number	O	NOUN	O
of	O	ADP	O
animal	O	NOUN	B
models	O	NOUN	I
of	O	ADP	O
Parkinson's	B-Disease	ADJ	B
disease	I-Disease	NOUN	I
including	O	VERB	O
mouse	O	NOUN	B
and	O	CCONJ	O
rat	O	NOUN	B
models	O	NOUN	B
of	O	ADP	O
haloperidol	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
catalepsy	B-Disease	NOUN	B
,	O	PUNCT	O
mouse	O	NOUN	B
model	O	NOUN	I
of	O	ADP	O
reserpine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
akinesia	B-Disease	NOUN	B
,	O	PUNCT	O
rat	O	NOUN	B
6-hydroxydopamine	B-Chemical	NOUN	B
(	O	PUNCT	O
6-OHDA	B-Chemical	NOUN	B
)	O	PUNCT	O
lesion	O	NOUN	B
model	O	NOUN	O
of	O	ADP	O
drug	O	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
rotation	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
MPTP	B-Chemical	NOUN	B


An	O	DET	O
extremely	O	ADV	O
rare	O	ADJ	B
case	O	NOUN	B
of	O	ADP	O
delusional	B-Disease	ADJ	B
parasitosis	I-Disease	NOUN	I
in	O	ADP	O
a	O	DET	O
chronic	B-Disease	ADJ	B
hepatitis	I-Disease	NOUN	I
C	I-Disease	NOUN	I
patient	O	NOUN	B
during	O	ADP	O
pegylated	B-Chemical	ADJ	B
interferon	I-Chemical	NOUN	I
alpha-2b	I-Chemical	NOUN	I
and	O	CCONJ	O
ribavirin	B-Chemical	NOUN	B
treatment	O	NOUN	B
.	O	PUNCT	O


During	O	ADP	O
treatment	O	NOUN	B
of	O	ADP	O
chronic	B-Disease	ADJ	B
hepatitis	I-Disease	NOUN	I
C	I-Disease	NOUN	I
patients	O	NOUN	B
with	O	ADP	O
interferon	O	NOUN	B
and	O	CCONJ	O
ribavirin	B-Chemical	NOUN	B
,	O	PUNCT	O
a	O	DET	O
lot	O	NOUN	O
of	O	ADP	O
side	O	NOUN	B
effects	O	NOUN	I
are	O	AUX	O
described	O	VERB	O
.	O	PUNCT	O


Twenty	O	NUM	B
-	O	PUNCT	O
three	O	NUM	O
percent	O	NOUN	O
to	O	ADP	O
44	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
develop	O	VERB	O
depression	B-Disease	NOUN	B
.	O	PUNCT	O


A	O	DET	O
minority	O	NOUN	B
of	O	ADP	O
patients	O	NOUN	B
evolve	O	VERB	O
to	O	PART	O
psychosis	B-Disease	NOUN	B
.	O	PUNCT	O


To	O	ADP	O
the	O	DET	O
best	O	ADJ	O
of	O	ADP	O
our	O	PRON	O
knowledge	O	NOUN	B
,	O	PUNCT	O
no	O	DET	O
cases	O	NOUN	B
of	O	ADP	O
psychogenic	B-Disease	ADJ	B
parasitosis	I-Disease	NOUN	I
occurring	O	VERB	O
during	O	ADP	O
interferon	O	NOUN	B
therapy	O	NOUN	I
have	O	AUX	O
been	O	AUX	O
described	O	VERB	O
in	O	ADP	O
the	O	DET	O
literature	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
present	O	VERB	O
a	O	DET	O
49	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
woman	O	NOUN	B
who	O	PRON	O
developed	O	VERB	O
a	O	DET	O
delusional	B-Disease	ADJ	B
parasitosis	I-Disease	NOUN	I
during	O	ADP	O
treatment	O	NOUN	B
with	O	ADP	O
pegylated	B-Chemical	ADJ	B
interferon	I-Chemical	NOUN	I
alpha-2b	I-Chemical	NOUN	I
weekly	O	ADJ	B
and	O	CCONJ	O
ribavirin	B-Chemical	NOUN	B
.	O	PUNCT	O


She	O	PRON	O
complained	O	VERB	B
of	O	ADP	O
seeing	O	VERB	O
parasites	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
larvae	O	NOUN	B
of	O	ADP	O
fleas	O	NOUN	B
in	O	ADP	O
her	O	PRON	O
stools	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
could	O	AUX	O
not	O	PART	O
be	O	AUX	O
confirmed	O	VERB	O
by	O	ADP	O
any	O	DET	O
technical	O	ADJ	B
examination	O	NOUN	I
.	O	PUNCT	O


All	O	DET	O
the	O	DET	O
complaints	O	NOUN	B
disappeared	O	VERB	O
after	O	ADP	O
stopping	O	VERB	B
pegylated	B-Chemical	ADJ	B
interferon	I-Chemical	NOUN	I
alpha-2b	I-Chemical	NOUN	I


Possible	O	ADJ	O
neuroleptic	B-Disease	ADJ	B
malignant	I-Disease	ADJ	I
syndrome	I-Disease	NOUN	I
related	O	ADJ	O
to	O	PART	O
concomitant	O	ADJ	B
treatment	O	NOUN	B
with	O	ADP	O
paroxetine	B-Chemical	NOUN	B
and	O	CCONJ	O
alprazolam	B-Chemical	NOUN	B
.	O	PUNCT	O


A	O	DET	O
74	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
man	O	NOUN	B
with	O	ADP	O
depressive	B-Disease	ADJ	B
symptoms	I-Disease	NOUN	I
was	O	AUX	O
admitted	O	VERB	B
to	O	ADP	O
a	O	DET	O
psychiatric	B-Disease	ADJ	B
hospital	O	NOUN	I
due	O	ADP	O
to	O	ADP	O
insomnia	B-Disease	NOUN	B
,	O	PUNCT	O
loss	B-Disease	NOUN	B
of	I-Disease	ADP	I
appetite	I-Disease	NOUN	I
,	O	PUNCT	O
exhaustion	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
agitation	B-Disease	NOUN	B
.	O	PUNCT	O


Medical	O	ADJ	B
treatment	O	NOUN	I
was	O	AUX	O
initiated	O	VERB	O
at	O	ADP	O
a	O	DET	O
daily	O	ADJ	B
dose	O	NOUN	I
of	O	ADP	O
20	O	NUM	O
mg	O	NOUN	O
paroxetine	B-Chemical	NOUN	B
and	O	CCONJ	O
1	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
mg	O	NOUN	O
alprazolam	B-Chemical	NOUN	B
.	O	PUNCT	O


On	O	ADP	O
the	O	DET	O
10th	O	ADJ	O
day	O	NOUN	B
of	O	ADP	O
paroxetine	B-Chemical	NOUN	B
and	O	CCONJ	O
alprazolam	B-Chemical	NOUN	B
treatment	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
patient	O	NOUN	B
exhibited	O	VERB	O
marked	O	ADJ	O
psychomotor	B-Disease	NOUN	B
retardation	I-Disease	NOUN	I
,	O	PUNCT	O
disorientation	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
severe	O	ADJ	B
muscle	B-Disease	NOUN	B
rigidity	I-Disease	NOUN	I
with	O	ADP	O
tremors	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
patient	O	NOUN	B
had	O	AUX	O
a	O	DET	O
fever	B-Disease	NOUN	B
(	O	PUNCT	O
38	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
degrees	O	NOUN	O
C	O	NOUN	O
),	O	PUNCT	O
fluctuating	O	VERB	B
blood	O	NOUN	I
pressure	O	NOUN	I
(	O	PUNCT	O
between	O	ADP	O
165	O	NUM	O
/	O	SYM	O
90	O	NUM	B
and	O	CCONJ	O
130	O	NUM	O
/	O	SYM	O
70	O	NUM	O
mg	O	NOUN	O
mm	O	NOUN	B
Hg	O	NOUN	I
),	O	PUNCT	O
and	O	CCONJ	O
severe	O	ADJ	B
extrapyramidal	B-Disease	ADJ	B
symptoms	I-Disease	NOUN	I
.	O	PUNCT	O


Laboratory	O	NOUN	B
tests	O	NOUN	I
showed	O	VERB	O
an	O	DET	O
elevation	O	NOUN	B
of	O	ADP	O
creatine	B-Chemical	NOUN	B
phosphokinase	O	NOUN	I
(	O	PUNCT	O
2218	O	NUM	O
IU	O	PROPN	B
/	O	SYM	O
L	O	NOUN	B
),	O	PUNCT	O
aspartate	B-Chemical	NOUN	B
aminotransferase	O	NOUN	I
(	O	PUNCT	O
134	O	NUM	O
IU	O	PROPN	B
/	O	SYM	O
L	O	NOUN	B
),	O	PUNCT	O
alanine	B-Chemical	NOUN	B
aminotransferase	O	NOUN	I
(	O	PUNCT	O
78	O	NUM	O
IU	O	PROPN	B
/	O	SYM	O
L	O	NOUN	B
),	O	PUNCT	O
and	O	CCONJ	O
BUN	O	NOUN	B
(	O	PUNCT	O
27	O	NUM	O
.	O	PUNCT	O


9	O	NUM	O
mg	O	NOUN	O
/	O	PUNCT	O
ml	O	NOUN	O
)	O	PUNCT	O
levels	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
patient	O	NOUN	B
received	O	VERB	O
bromocriptine	B-Chemical	NOUN	B
and	O	CCONJ	O
diazepam	B-Chemical	NOUN	B
to	O	PART	O
treat	O	VERB	B
his	O	PRON	O
symptoms	O	NOUN	B
.	O	PUNCT	O


7	O	NUM	O
days	O	NOUN	B
later	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
fever	B-Disease	NOUN	B
disappeared	O	VERB	B
and	O	CCONJ	O
the	O	DET	O
patient	O	NOUN	B
'	O	PART	O
s	O	NOUN	O
serum	O	NOUN	B
CPK	O	NOUN	B
levels	O	NOUN	B
were	O	AUX	O
normalized	O	VERB	O
(	O	PUNCT	O
175	O	NUM	O
IU	O	PROPN	B
/	O	SYM	O
L	O	PROPN	B
).	O	PUNCT	O
This	O	DET	O
patient	O	NOUN	B
presented	O	VERB	O
with	O	ADP	O
symptoms	O	NOUN	B
of	O	ADP	O
neuroleptic	B-Disease	ADJ	B
malignant	I-Disease	ADJ	I
syndrome	I-Disease	NOUN	I
(	O	PUNCT	O
NMS	B-Disease	NOUN	B
),	O	PUNCT	O
thus	O	ADV	O
demonstrating	O	VERB	O
that	O	SCONJ	O
NMS	B-Disease	PROPN	B
-	O	PUNCT	O
like	O	ADJ	B
symptoms	O	NOUN	B
can	O	AUX	O
occur	O	VERB	O
after	O	ADP	O
combined	O	ADJ	O
paroxetine	B-Chemical	NOUN	B
and	O	CCONJ	O
alprazolam	B-Chemical	NOUN	B
treatment	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
adverse	O	ADJ	B
drug	O	NOUN	I
reaction	O	NOUN	I
score	O	NOUN	I
obtained	O	VERB	O
by	O	ADP	O
the	O	DET	O
Naranjo	O	PROPN	B
algorithm	O	NOUN	I
was	O	AUX	O
6	O	NUM	O
in	O	ADP	O
our	O	PRON	O
case	O	NOUN	B
,	O	PUNCT	O
indicating	O	VERB	O
a	O	DET	O
probable	O	ADJ	O
relationship	O	NOUN	B
between	O	ADP	O
the	O	DET	O
patient	O	NOUN	B
'	O	PART	O
s	O	NOUN	O
NMS	B-Disease	PROPN	B
-	O	PUNCT	O
like	O	ADJ	B
adverse	O	ADJ	B
symptoms	O	NOUN	I
and	O	CCONJ	O
the	O	DET	O
combined	O	ADJ	B
treatment	O	NOUN	I
used	O	VERB	O
in	O	ADP	O
this	O	DET	O
case	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
involvement	O	NOUN	B
of	O	ADP	O
physiologic	O	ADJ	B
and	O	CCONJ	O
environmental	O	ADJ	B
aspects	O	NOUN	I
specific	O	ADJ	O
to	O	PART	O
this	O	DET	O
patient	O	NOUN	B
was	O	AUX	O
suspected	O	VERB	B
.	O	PUNCT	O


Several	O	ADJ	O
risk	O	NOUN	B
factors	O	NOUN	I
for	O	ADP	O
NMS	B-Disease	PROPN	B
should	O	AUX	O
be	O	AUX	O
noted	O	VERB	O
in	O	ADP	O
elderly	O	ADJ	B
depressive	B-Disease	ADJ	O
patients	O	NOUN	B
whose	O	DET	O
symptoms	O	NOUN	B
often	O	ADV	O
include	O	VERB	O
dehydration	B-Disease	NOUN	B
,	O	PUNCT	O
agitation	B-Disease	NOUN	B
,	O	PUNCT	O
malnutrition	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
exhaustion	O	NOUN	B
.	O	PUNCT	O


Careful	O	ADJ	O
therapeutic	O	ADJ	B
intervention	O	NOUN	I
is	O	AUX	O
necessary	O	ADJ	O
in	O	ADP	O
cases	O	NOUN	B
involving	O	VERB	O
elderly	O	ADJ	B
patients	O	NOUN	B
who	O	PRON	O
suffer	O	VERB	O
from	O	ADP	O
depression	B-Disease	NOUN	B


Pilocarpine	B-Chemical	NOUN	B
seizures	B-Disease	NOUN	B
cause	O	VERB	O
age	O	NOUN	B
-	O	PUNCT	O
dependent	O	ADJ	B
impairment	B-Disease	NOUN	B
in	I-Disease	ADP	O
auditory	I-Disease	ADJ	B
location	I-Disease	NOUN	I
discrimination	I-Disease	NOUN	I
.	O	PUNCT	O


Children	O	NOUN	B
who	O	PRON	O
have	O	AUX	O
status	B-Disease	NOUN	B
epilepticus	I-Disease	NOUN	I
have	O	AUX	O
continuous	O	ADJ	B
or	O	CCONJ	O
rapidly	O	ADV	O
repeating	O	VERB	O
seizures	B-Disease	NOUN	B
that	O	PRON	O
may	O	AUX	O
be	O	AUX	O
life	O	NOUN	B
-	O	PUNCT	O
threatening	O	ADJ	B
and	O	CCONJ	O
may	O	AUX	O
cause	O	VERB	B
life	O	NOUN	B
-	O	PUNCT	O
long	O	ADJ	B
changes	O	NOUN	B
in	O	ADP	O
brain	O	NOUN	B
and	O	CCONJ	O
behavior	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
extent	O	NOUN	O
to	O	PART	O
which	O	DET	O
status	B-Disease	NOUN	B
epilepticus	I-Disease	NOUN	I
causes	O	VERB	O
deficits	B-Disease	NOUN	B
in	I-Disease	ADP	O
auditory	I-Disease	ADJ	B
discrimination	I-Disease	NOUN	I
is	O	AUX	O
unknown	O	ADJ	O
.	O	PUNCT	O


A	O	DET	O
naturalistic	O	ADJ	B
auditory	O	ADJ	O
location	O	NOUN	O
discrimination	O	NOUN	O
method	O	NOUN	O
was	O	AUX	O
used	O	VERB	O
to	O	PART	O
evaluate	O	VERB	B
this	O	DET	O
question	O	NOUN	O
using	O	VERB	O
an	O	DET	O
animal	O	NOUN	B
model	O	NOUN	I
of	O	ADP	O
status	B-Disease	NOUN	B
epilepticus	I-Disease	NOUN	I
.	O	PUNCT	O


Male	O	NOUN	B
Sprague	O	PROPN	B
-	O	PUNCT	O
Dawley	O	NOUN	B
rats	O	NOUN	B
were	O	AUX	O
injected	O	VERB	B
with	O	ADP	O
saline	O	NOUN	B
on	O	ADP	O
postnatal	O	ADJ	B
day	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
)	O	PUNCT	O
20	O	NUM	O
,	O	PUNCT	O
or	O	CCONJ	O
a	O	DET	O
convulsant	O	ADJ	B
dose	O	NOUN	B
of	O	ADP	O
pilocarpine	B-Chemical	NOUN	B
on	O	ADP	O
P20	O	NOUN	B
or	O	CCONJ	O
P45	O	NOUN	B
.	O	PUNCT	O


Pilocarpine	B-Chemical	NOUN	B
on	O	ADP	O
either	O	DET	O
day	O	NOUN	B
induced	O	VERB	B
status	B-Disease	NOUN	B
epilepticus	I-Disease	NOUN	I
;	O	PUNCT	O
status	B-Disease	NOUN	B
epilepticus	I-Disease	NOUN	I
at	O	ADP	O
P45	O	NOUN	B
resulted	O	VERB	O
in	O	ADP	O
CA3	O	NOUN	B
cell	O	NOUN	I
loss	O	NOUN	O
and	O	CCONJ	O
spontaneous	O	ADJ	B
seizures	B-Disease	NOUN	B
,	O	PUNCT	O
whereas	O	SCONJ	O
P20	O	NOUN	B
rats	O	NOUN	B
had	O	AUX	O
no	O	DET	O
cell	O	NOUN	B
loss	O	NOUN	I
or	O	CCONJ	O
spontaneous	O	ADJ	B
seizures	B-Disease	NOUN	B
.	O	PUNCT	O


Mature	O	ADJ	B
rats	O	NOUN	B
were	O	AUX	O
trained	O	VERB	B
with	O	ADP	O
sound	O	NOUN	B
-	O	PUNCT	O
source	O	NOUN	B
location	O	NOUN	B
and	O	CCONJ	O
sound	O	NOUN	B
-	O	PUNCT	O
silence	O	NOUN	B
discriminations	O	NOUN	B
.	O	PUNCT	O


Control	O	NOUN	B
(	O	PUNCT	O
saline	O	NOUN	O
P20	O	NOUN	O
)	O	PUNCT	O
rats	O	NOUN	B
acquired	O	VERB	O
both	O	DET	O
discriminations	O	NOUN	B
immediately	O	ADV	O
.	O	PUNCT	O


In	O	ADP	O
status	B-Disease	NOUN	B
epilepticus	I-Disease	NOUN	I
(	O	PUNCT	O
P20	O	NOUN	O
)	O	PUNCT	O
rats	O	NOUN	B
,	O	PUNCT	O
acquisition	O	NOUN	B
of	O	ADP	O
the	O	DET	O
sound	O	NOUN	B
-	O	PUNCT	O
source	O	NOUN	B
location	O	NOUN	B
discrimination	O	NOUN	B
was	O	AUX	O
moderately	O	ADV	O
impaired	O	ADJ	B
.	O	PUNCT	O


Status	B-Disease	NOUN	B
epilepticus	I-Disease	NOUN	I
(	O	PUNCT	O
P45	O	NOUN	O
)	O	PUNCT	O
rats	O	NOUN	B
failed	O	VERB	B
to	O	PART	O
acquire	O	VERB	O
either	O	CCONJ	O
sound	O	NOUN	B
-	O	PUNCT	O
source	O	NOUN	B
location	O	NOUN	B
or	O	CCONJ	O
sound	O	NOUN	B
-	O	PUNCT	O
silence	O	NOUN	B
discriminations	O	NOUN	B
.	O	PUNCT	O


Status	B-Disease	NOUN	B
epilepticus	I-Disease	NOUN	I
in	O	ADP	O
rat	O	NOUN	B
causes	O	VERB	O
an	O	DET	O
age	O	NOUN	B
-	O	PUNCT	O
dependent	O	ADJ	B
,	O	PUNCT	O
long	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
impairment	B-Disease	NOUN	B
in	I-Disease	ADP	O
auditory	I-Disease	ADJ	B
discrimination	I-Disease	NOUN	I
.	O	PUNCT	O


This	O	DET	O
impairment	O	NOUN	B
may	O	AUX	O
explain	O	VERB	O
one	O	NUM	O
cause	O	NOUN	O
of	O	ADP	O
impaired	B-Disease	ADJ	B
auditory	I-Disease	ADJ	B
location	I-Disease	NOUN	I
discrimination	I-Disease	NOUN	O


Cardiovascular	O	ADJ	B
risk	O	NOUN	I
with	O	ADP	O
cyclooxygenase	B-Chemical	NOUN	B
inhibitors	I-Chemical	NOUN	I
:	O	PUNCT	O
general	O	ADJ	O
problem	O	NOUN	B
with	O	ADP	O
substance	O	NOUN	B
specific	O	ADJ	O
differences	O	NOUN	O
?	O	PUNCT	O
Randomised	O	ADJ	B
clinical	O	ADJ	I
trials	O	NOUN	I
and	O	CCONJ	O
observational	O	ADJ	B
studies	O	NOUN	I
have	O	AUX	O
shown	O	VERB	O
an	O	DET	O
increased	O	VERB	B
risk	O	NOUN	B
of	O	ADP	O
myocardial	B-Disease	ADJ	B
infarction	I-Disease	NOUN	I
,	O	PUNCT	O
stroke	B-Disease	NOUN	B
,	O	PUNCT	O
hypertension	B-Disease	NOUN	B
and	O	CCONJ	O
heart	B-Disease	NOUN	B
failure	I-Disease	NOUN	I
during	O	ADP	O
treatment	O	NOUN	B
with	O	ADP	O
cyclooxygenase	B-Chemical	NOUN	B
inhibitors	I-Chemical	NOUN	I
.	O	PUNCT	O


Adverse	O	ADJ	B
cardiovascular	O	ADJ	B
effects	O	NOUN	O
occurred	O	VERB	O
mainly	O	ADV	O
,	O	PUNCT	O
but	O	CCONJ	O
not	O	PART	O
exclusively	O	ADV	O
,	O	PUNCT	O
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
concomitant	O	ADJ	B
risk	O	NOUN	B
factors	O	NOUN	I
.	O	PUNCT	O


Cyclooxygenase	B-Chemical	NOUN	B
inhibitors	I-Chemical	NOUN	I
cause	O	VERB	O
complex	O	ADJ	B
changes	O	NOUN	B
in	O	ADP	O
renal	O	ADJ	B
,	O	PUNCT	O
vascular	O	ADJ	B
and	O	CCONJ	O
cardiac	O	ADJ	B
prostanoid	O	NOUN	O
profiles	O	NOUN	O
thereby	O	ADV	O
increasing	O	VERB	O
vascular	O	ADJ	B
resistance	O	NOUN	I
and	O	CCONJ	O
fluid	O	ADJ	B
retention	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
incidence	O	NOUN	B
of	O	ADP	O
cardiovascular	O	ADJ	B
adverse	O	ADJ	O
events	O	NOUN	O
tends	O	VERB	O
to	O	PART	O
increase	O	VERB	B
with	O	ADP	O
the	O	DET	O
daily	O	ADJ	B
dose	O	NOUN	I
and	O	CCONJ	O
total	O	ADJ	B
exposure	O	NOUN	I
time	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
comparison	O	NOUN	B
of	O	ADP	O
individual	O	ADJ	B
selective	O	ADJ	O
and	O	CCONJ	O
unselective	O	ADJ	O
cyclooxygenase	B-Chemical	NOUN	B
inhibitors	I-Chemical	NOUN	I
suggests	O	VERB	O
substance	O	NOUN	B
-	O	PUNCT	O
specific	O	ADJ	B
differences	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
may	O	AUX	O
depend	O	VERB	O
on	O	ADP	O
differences	O	NOUN	B
in	O	ADP	O
pharmacokinetic	O	ADJ	B
parameters	O	NOUN	B
or	O	CCONJ	O
inhibitory	O	ADJ	B
potency	O	NOUN	B
and	O	CCONJ	O
may	O	AUX	O
be	O	AUX	O
contributed	O	VERB	O
by	O	ADP	O
prostaglandin	B-Chemical	NOUN	B
-	O	PUNCT	O
independent	O	ADJ	B
effects	O	NOUN	B
.	O	PUNCT	O


Diagnostic	O	ADJ	B
markers	O	NOUN	I
such	O	ADJ	O
as	O	ADP	O
N-terminal	B-Chemical	ADJ	B
pro	I-Chemical	ADJ	I
brain	I-Chemical	NOUN	I
natriuretic	I-Chemical	ADJ	I
peptide	I-Chemical	NOUN	I
(	O	PUNCT	O
NT-proBNP	B-Chemical	NOUN	B
)	O	PUNCT	O
or	O	CCONJ	O
high	O	ADJ	B
-	O	PUNCT	O
sensitive	O	ADJ	B
C	O	NOUN	B
-	O	PUNCT	O
reactive	O	ADJ	B
protein	O	NOUN	I
might	O	AUX	O
help	O	VERB	O
in	O	ADP	O
the	O	DET	O
early	O	ADJ	B
identification	O	NOUN	B
of	O	ADP	O
patients	O	NOUN	B
at	O	ADP	O
risk	O	NOUN	B
,	O	PUNCT	O
thus	O	ADV	O
avoiding	O	VERB	O
the	O	DET	O
occurrence	O	NOUN	B
of	O	ADP	O
serious	O	ADJ	O
cardiovascular	B-Disease	ADJ	B
toxicity	I-Disease	NOUN	B


Predictors	O	NOUN	B
of	O	ADP	O
decreased	B-Disease	VERB	B
renal	I-Disease	ADJ	O
function	I-Disease	NOUN	O
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
heart	B-Disease	NOUN	B
failure	I-Disease	NOUN	I
during	O	ADP	O
angiotensin	B-Chemical	NOUN	B
-	O	PUNCT	O
converting	O	VERB	B
enzyme	O	NOUN	B
inhibitor	O	NOUN	I
therapy	O	NOUN	I
:	O	PUNCT	O
results	O	NOUN	B
from	O	ADP	O
the	O	DET	O
studies	O	NOUN	B
of	O	ADP	O
left	B-Disease	ADJ	B
ventricular	I-Disease	ADJ	I
dysfunction	I-Disease	NOUN	I
(	O	PUNCT	O
SOLVD	O	NOUN	B
)	O	PUNCT	O
BACKGROUND	O	NOUN	O
:	O	PUNCT	O
Although	O	SCONJ	O
angiotensin	B-Chemical	NOUN	B
-	O	PUNCT	O
converting	O	VERB	B
enzyme	O	NOUN	B
inhibitor	O	NOUN	I
therapy	O	NOUN	I
reduces	O	VERB	O
mortality	O	NOUN	B
rates	O	NOUN	I
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
congestive	B-Disease	ADJ	B
heart	I-Disease	NOUN	I
failure	I-Disease	NOUN	I
(	O	PUNCT	O
CHF	B-Disease	NOUN	B
),	O	PUNCT	O
it	O	PRON	O
may	O	AUX	O
also	O	ADV	O
cause	O	VERB	O
decreased	B-Disease	VERB	B
renal	I-Disease	ADJ	B
function	I-Disease	NOUN	I
.	O	PUNCT	O


Little	O	ADJ	O
information	O	NOUN	B
is	O	AUX	O
available	O	ADJ	O
to	O	PART	O
predict	O	VERB	O
which	O	DET	O
patients	O	NOUN	B
are	O	AUX	O
at	O	ADP	O
highest	O	ADJ	B
risk	O	NOUN	B
for	O	ADP	O
this	O	DET	O
complication	O	NOUN	B
.	O	PUNCT	O


OBJECTIVE	O	NOUN	B
:	O	PUNCT	O
To	O	PART	O
quantify	O	VERB	B
specific	O	ADJ	O
clinical	O	ADJ	B
predictors	O	NOUN	B
of	O	ADP	O
reduction	B-Disease	NOUN	B
in	I-Disease	ADP	O
renal	I-Disease	ADJ	B
function	I-Disease	NOUN	I
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
CHF	B-Disease	NOUN	B
who	O	PRON	O
are	O	AUX	O
prescribed	O	VERB	B
angiotensin	B-Chemical	NOUN	B
-	O	PUNCT	O
converting	O	VERB	B
enzyme	O	NOUN	B
inhibitor	O	NOUN	I
therapy	O	NOUN	I
.	O	PUNCT	O


METHOD	O	NOUN	B
:	O	PUNCT	O
We	O	PRON	O
analyzed	O	VERB	B
data	O	NOUN	B
from	O	ADP	O
the	O	DET	O
Studies	O	PROPN	B
of	O	ADP	O
Left	B-Disease	PROPN	B
Ventricular	I-Disease	PROPN	I
Dysfunction	I-Disease	PROPN	I
(	O	PUNCT	O
SOLVD	O	PROPN	B
),	O	PUNCT	O
a	O	DET	O
randomized	O	ADJ	B
,	O	PUNCT	O
double	O	ADJ	B
-	O	PUNCT	O
blind	O	ADJ	B
,	O	PUNCT	O
placebo	O	NOUN	B
-	O	PUNCT	O
controlled	O	VERB	B
trial	O	NOUN	I
of	O	ADP	O
enalapril	B-Chemical	NOUN	B
for	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
CHF	B-Disease	NOUN	B
.	O	PUNCT	O


There	O	PRON	O
were	O	AUX	O
3379	O	NUM	O
patients	O	NOUN	B
randomly	O	ADV	O
assigned	O	VERB	O
to	O	PART	O
enalapril	B-Chemical	NOUN	B
with	O	ADP	O
a	O	DET	O
median	O	ADJ	B
follow	O	NOUN	B
-	O	PUNCT	O
up	O	NOUN	O
of	O	ADP	O
974	O	NUM	O
days	O	NOUN	B
and	O	CCONJ	O
3379	O	NUM	O
patients	O	NOUN	B
randomly	O	ADV	B
assigned	O	VERB	I
to	O	PART	O
placebo	O	NOUN	B
with	O	ADP	O
a	O	DET	O
mean	O	ADJ	O
follow	O	NOUN	B
-	O	PUNCT	O
up	O	NOUN	O
of	O	ADP	O
967	O	NUM	O
days	O	NOUN	B
.	O	PUNCT	O


Decreased	B-Disease	VERB	B
renal	I-Disease	ADJ	O
function	I-Disease	NOUN	O
was	O	AUX	O
defined	O	VERB	O
as	O	ADP	O
a	O	DET	O
rise	O	NOUN	O
in	O	ADP	O
serum	O	NOUN	B
creatinine	B-Chemical	NOUN	I
>/=	O	NOUN	O
0	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
dL	O	NOUN	B
(	O	PUNCT	O
44	O	NUM	O
micromol	O	NOUN	B
/	O	SYM	O
L	O	NOUN	B
)	O	PUNCT	O
from	O	ADP	O
baseline	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
used	O	VERB	O
time	O	NOUN	B
-	O	PUNCT	O
to	O	ADP	O
-	O	PUNCT	O
event	O	NOUN	B
analysis	O	NOUN	B
to	O	PART	O
identify	O	VERB	O
potential	O	ADJ	B
predictors	O	NOUN	B
of	O	ADP	O
decrease	O	NOUN	B
in	O	ADP	O
renal	O	ADJ	B
function	O	NOUN	I
including	O	VERB	O
age	O	NOUN	B
,	O	PUNCT	O
baseline	O	NOUN	B
ejection	O	NOUN	B
fraction	O	NOUN	I
,	O	PUNCT	O
baseline	O	NOUN	B
creatinine	B-Chemical	NOUN	B
,	O	PUNCT	O
low	O	ADJ	B
systolic	O	ADJ	O
blood	O	NOUN	O
pressure	O	NOUN	O
(<	O	NOUN	O
100	O	NUM	O
mm	O	NOUN	O
Hg	O	NOUN	O
),	O	PUNCT	O
history	O	NOUN	B
of	O	ADP	O
hypertension	B-Disease	NOUN	B
,	O	PUNCT	O
diabetes	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
use	O	NOUN	O
of	O	ADP	O
antiplatelet	O	NOUN	B
,	O	PUNCT	O
diuretic	B-Chemical	ADJ	B
,	O	PUNCT	O
and	O	CCONJ	O
beta	O	NOUN	B
-	O	PUNCT	O
blocker	O	NOUN	B
therapy	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
Patients	O	NOUN	B
randomly	O	ADV	O
assigned	O	VERB	O
to	O	PART	O
enalapril	B-Chemical	NOUN	B
had	O	AUX	O
a	O	DET	O
33	O	NUM	O
%	O	NOUN	O
greater	O	ADJ	O
likelihood	O	NOUN	B
of	O	ADP	O
decreased	B-Disease	VERB	B
renal	I-Disease	ADJ	O
function	I-Disease	NOUN	O
than	O	ADP	O
controls	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=.	O	NOUN	O
003	O	NUM	O
).	O	PUNCT	O
By	O	ADP	O
multivariate	O	ADJ	B
analysis	O	NOUN	I
,	O	PUNCT	O
in	O	ADP	O
both	O	CCONJ	O
the	O	DET	O
placebo	O	NOUN	B
and	O	CCONJ	O
enalapril	B-Chemical	ADJ	B
groups	O	NOUN	I
older	O	ADJ	B
age	O	NOUN	I
,	O	PUNCT	O
diuretic	B-Chemical	ADJ	B
therapy	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
diabetes	B-Disease	NOUN	B
were	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
decreased	B-Disease	VERB	B
renal	I-Disease	ADJ	B
function	I-Disease	NOUN	I
,	O	PUNCT	O
whereas	O	SCONJ	O
beta	O	NOUN	B
-	O	PUNCT	O
blocker	O	NOUN	B
therapy	O	NOUN	B
and	O	CCONJ	O
higher	O	ADJ	B
ejection	O	NOUN	B
fraction	O	NOUN	I
were	O	AUX	O
renoprotective	O	ADJ	B
.	O	PUNCT	O


Older	O	ADJ	B
age	O	NOUN	I
was	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
a	O	DET	O
greater	O	ADJ	O
risk	O	NOUN	B
of	O	ADP	O
developing	O	VERB	O
decreased	B-Disease	VERB	B
renal	I-Disease	ADJ	B
function	I-Disease	NOUN	I
in	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
significantly	O	ADV	O
more	O	ADV	O
so	O	ADV	O
in	O	ADP	O
the	O	DET	O
enalapril	B-Chemical	ADJ	B
group	O	NOUN	I
(	O	PUNCT	O
enalapril	B-Chemical	NOUN	B
:	O	PUNCT	O
risk	O	NOUN	B
ratio	O	NOUN	I
[	O	PUNCT	O
RR	O	NOUN	B
]	O	PUNCT	O
1	O	NUM	O
.	O	PUNCT	O


42	O	NUM	O
per	O	ADP	O
10	O	NUM	O
years	O	NOUN	B
,	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
[	O	PUNCT	O
CI	O	NOUN	B
]	O	PUNCT	O
1	O	NUM	O
.	O	PUNCT	O


32	O	NUM	O
-	O	SYM	O
1	O	NUM	O
.	O	PUNCT	O


52	O	NUM	O
with	O	ADP	O
enalapril	B-Chemical	NOUN	B
;	O	PUNCT	O
placebo	O	NOUN	B
:	O	PUNCT	O
RR	O	NOUN	B
1	O	NUM	O
.	O	PUNCT	O


18	O	NUM	O
,	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
1	O	NUM	O
.	O	PUNCT	O


12	O	NUM	O
-	O	SYM	O
1	O	NUM	O
.	O	PUNCT	O


25	O	NUM	O
).	O	PUNCT	O
Diuretic	B-Chemical	ADJ	B
therapy	O	NOUN	I
was	O	AUX	O
likewise	O	ADV	O
associated	O	VERB	B
with	O	ADP	I
a	O	DET	O
greater	O	ADJ	O
risk	O	NOUN	B
of	O	ADP	O
decreased	B-Disease	VERB	B
renal	I-Disease	ADJ	B
function	I-Disease	NOUN	I
in	O	ADP	O
the	O	DET	O
enalapril	B-Chemical	ADJ	B
group	O	NOUN	I
(	O	PUNCT	O
RR	O	NOUN	B
1	O	NUM	O
.	O	PUNCT	O


89	O	NUM	O
,	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
1	O	NUM	O
.	O	PUNCT	O


70	O	NUM	O
-	O	SYM	O
2	O	NUM	O
.	O	PUNCT	O


08	O	NUM	O
)	O	PUNCT	O
than	O	ADP	O
in	O	ADP	O
the	O	DET	O
placebo	O	ADJ	B
group	O	NOUN	O
(	O	PUNCT	O
RR	O	NOUN	B
1	O	NUM	O
.	O	PUNCT	O


35	O	NUM	O
,	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
1	O	NUM	O
.	O	PUNCT	O


09	O	NUM	O
-	O	SYM	O
1	O	NUM	O
.	O	PUNCT	O


66	O	NUM	O
).	O	PUNCT	O
Conversely	O	ADV	O
,	O	PUNCT	O
enalapril	B-Chemical	NOUN	B
had	O	AUX	O
a	O	DET	O
relative	O	ADJ	O
renoprotective	O	ADJ	B
effect	O	NOUN	I
(	O	PUNCT	O
RR	O	NOUN	B
1	O	NUM	O
.	O	PUNCT	O


33	O	NUM	O
,	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
1	O	NUM	O
.	O	PUNCT	O


13	O	NUM	O
-	O	SYM	O
1	O	NUM	O
.	O	PUNCT	O


53	O	NUM	O
)	O	PUNCT	O
compared	O	VERB	B
with	O	ADP	O
placebo	O	NOUN	B
(	O	PUNCT	O
RR	O	NOUN	B
1	O	NUM	O
.	O	PUNCT	O


96	O	NUM	O
,	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
1	O	NUM	O
.	O	PUNCT	O


57	O	NUM	O
-	O	SYM	O
2	O	NUM	O
.	O	PUNCT	O


44	O	NUM	O
)	O	PUNCT	O
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
diabetes	B-Disease	NOUN	B
.	O	PUNCT	O


A	O	DET	O
lower	O	ADJ	B
risk	O	NOUN	I
of	O	ADP	O
renal	B-Disease	ADJ	B
impairment	I-Disease	NOUN	I
was	O	AUX	O
seen	O	VERB	O
in	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
with	O	ADP	O
beta	O	NOUN	B
-	O	PUNCT	O
blocker	O	NOUN	B
therapy	O	NOUN	I
(	O	PUNCT	O
RR	O	NOUN	B
0	O	NUM	O
.	O	PUNCT	O


70	O	NUM	O
,	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
0	O	NUM	O
.	O	PUNCT	O


57	O	NUM	O
-	O	SYM	O
0	O	NUM	O
.	O	PUNCT	O


85	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
higher	O	ADJ	O
baseline	O	NOUN	B
ejection	O	NOUN	B
fraction	O	NOUN	I
(	O	PUNCT	O
RR	O	NOUN	B
0	O	NUM	O
.	O	PUNCT	O


93	O	NUM	O
per	O	ADP	O
5	O	NUM	O
%	O	NOUN	O
increment	O	NOUN	B
,	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
0	O	NUM	O
.	O	PUNCT	O


91	O	NUM	O
-	O	SYM	O
0	O	NUM	O
.	O	PUNCT	O


96	O	NUM	O
).	O	PUNCT	O
CONCLUSIONS	O	NOUN	O
:	O	PUNCT	O
Enalapril	B-Chemical	NOUN	B
use	O	NOUN	O
caused	O	VERB	O
a	O	DET	O
33	O	NUM	O
%	O	NOUN	O
increase	O	NOUN	B
in	O	ADP	O
the	O	DET	O
risk	O	NOUN	B
of	O	ADP	O
decreased	B-Disease	VERB	B
renal	I-Disease	ADJ	O
function	I-Disease	NOUN	O
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
CHF	B-Disease	NOUN	B
.	O	PUNCT	O


Diuretic	B-Chemical	ADJ	B
use	O	NOUN	I
and	O	CCONJ	O
advanced	O	ADJ	B
age	O	NOUN	I
increased	O	VERB	B
this	O	DET	O
risk	O	NOUN	B
.	O	PUNCT	O


Diabetes	B-Disease	NOUN	B
was	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
an	O	DET	O
increased	O	VERB	B
risk	O	NOUN	B
of	O	ADP	O
renal	B-Disease	ADJ	B
impairment	I-Disease	NOUN	I
in	O	ADP	O
all	O	DET	O
patients	O	NOUN	B
with	O	ADP	O
CHF	B-Disease	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
this	O	DET	O
risk	O	NOUN	B
was	O	AUX	O
reduced	O	VERB	B
in	O	ADP	O
the	O	DET	O
enalapril	B-Chemical	NOUN	B


Pemoline	B-Chemical	NOUN	B
induced	O	VERB	B
acute	O	ADJ	B
choreoathetosis	B-Disease	NOUN	I
:	O	PUNCT	O
case	O	NOUN	B
report	O	NOUN	I
and	O	CCONJ	O
review	O	NOUN	B
of	O	ADP	O
the	O	DET	O
literature	O	NOUN	B
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
:	O	PUNCT	O
Pemoline	B-Chemical	NOUN	B
is	O	AUX	O
an	O	DET	O
oxazolidine	B-Chemical	NOUN	B
derivative	O	NOUN	I
that	O	PRON	O
is	O	AUX	O
structurally	O	ADV	B
different	O	ADJ	O
from	O	ADP	O
amphetamines	B-Chemical	NOUN	B
and	O	CCONJ	O
used	O	VERB	O
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
attention	B-Disease	NOUN	B
deficit	I-Disease	NOUN	I
disorder	I-Disease	NOUN	I
.	O	PUNCT	O


Pemoline	B-Chemical	NOUN	B
has	O	AUX	O
not	O	PART	O
been	O	AUX	O
commonly	O	ADV	O
associated	O	VERB	B
in	O	ADP	I
the	O	DET	O
literature	O	NOUN	B
as	O	ADP	O
a	O	DET	O
cause	O	NOUN	O
of	O	ADP	O
acute	O	ADJ	B
movement	B-Disease	NOUN	O
disorders	I-Disease	NOUN	O
.	O	PUNCT	O


The	O	DET	O
following	O	VERB	O
case	O	NOUN	B
describes	O	VERB	O
two	O	NUM	O
children	O	NOUN	B
acutely	O	ADV	B
poisoned	O	VERB	B
with	O	ADP	O
pemoline	B-Chemical	NOUN	B
who	O	PRON	O
experienced	O	VERB	O
profound	O	ADJ	O
choreoathetosis	B-Disease	NOUN	B
.	O	PUNCT	O


CASE	O	ADJ	B
REPORT	O	PROPN	I
:	O	PUNCT	O
Two	O	NUM	O
,	O	PUNCT	O
3	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
male	O	NOUN	B
,	O	PUNCT	O
identical	O	ADJ	O
twin	O	NOUN	B
siblings	O	NOUN	I
presented	O	VERB	O
to	O	ADP	O
the	O	DET	O
emergency	O	NOUN	B
department	O	NOUN	I
after	O	ADP	O
found	O	VERB	O
playing	O	VERB	O
with	O	ADP	O
a	O	DET	O
an	O	DET	O
empty	O	ADJ	B
bottle	O	NOUN	O
of	O	ADP	O
pemoline	B-Chemical	NOUN	B
originally	O	ADV	O
containing	O	VERB	O
59	O	NUM	O
tablets	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
children	O	NOUN	B
had	O	AUX	O
a	O	DET	O
medical	O	ADJ	B
history	O	NOUN	I
significant	O	ADJ	O
for	O	ADP	O
attention	B-Disease	NOUN	B
deficit	I-Disease	NOUN	I
disorder	I-Disease	NOUN	I
previously	O	ADV	O
treated	O	VERB	B
with	O	ADP	I
methylphenidate	B-Chemical	NOUN	B
without	O	ADP	O
success	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
was	O	AUX	O
their	O	PRON	O
first	O	ADJ	O
day	O	NOUN	B
of	O	ADP	O
pemoline	B-Chemical	NOUN	B
therapy	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
choreoathetoid	B-Disease	ADJ	B
movements	O	NOUN	B
began	O	VERB	O
45	O	NUM	O
min	O	NOUN	O
to	O	PART	O
1	O	NUM	O
h	O	NOUN	O
after	O	ADP	O
ingestion	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
children	O	NOUN	B
gave	O	VERB	O
no	O	DET	B
history	O	NOUN	I
of	O	ADP	O
prior	O	ADJ	O
movement	B-Disease	NOUN	B
disorders	I-Disease	NOUN	I
and	O	CCONJ	O
there	O	PRON	O
was	O	AUX	O
no	O	DET	O
family	O	NOUN	B
history	O	NOUN	I
of	O	ADP	I
movement	B-Disease	NOUN	B
disorders	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
children	O	NOUN	B
received	O	VERB	O
gastrointestinal	O	ADJ	B
decontamination	O	NOUN	I
and	O	CCONJ	O
high	O	ADJ	B
doses	O	NOUN	I
of	O	ADP	O
intravenous	O	ADJ	B
benzodiazepines	B-Chemical	NOUN	O
in	O	ADP	O
an	O	DET	O
attempt	O	NOUN	B
to	O	PART	O
control	O	VERB	B
the	O	DET	O
choreoathetoid	B-Disease	ADJ	B
movements	O	NOUN	B
.	O	PUNCT	O


Despite	O	SCONJ	O
treatment	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
children	O	NOUN	B
continued	O	VERB	O
to	O	PART	O
have	O	AUX	O
choreoathetosis	B-Disease	NOUN	B
for	O	ADP	O
approximately	O	ADV	O
24	O	NUM	O
hours	O	NOUN	B
.	O	PUNCT	O


Forty	O	NUM	B
-	O	PUNCT	O
eight	O	NUM	O
hours	O	NOUN	B
after	O	ADP	O
admission	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
children	O	NOUN	B
appeared	O	VERB	O
to	O	PART	O
be	O	AUX	O
at	O	ADP	O
their	O	PRON	O
baseline	O	NOUN	B
and	O	CCONJ	O
were	O	AUX	O
discharged	O	VERB	B
home	O	ADV	I
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
:	O	PUNCT	O
Pemoline	B-Chemical	ADJ	B
associated	O	ADJ	O
movement	B-Disease	NOUN	B
disorder	I-Disease	NOUN	I
has	O	AUX	O
been	O	AUX	O
rarely	O	ADV	O
reported	O	VERB	O
in	O	ADP	O
the	O	DET	O
acute	O	ADJ	B
toxicology	O	NOUN	O
literature	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
possibility	O	NOUN	O
of	O	ADP	O
choreoathetoid	B-Disease	ADJ	B
movements	O	NOUN	B
should	O	AUX	O
be	O	AUX	O
considered	O	VERB	O
in	O	ADP	O
patients	O	NOUN	B
presenting	O	VERB	O
after	O	ADP	O
pemoline	B-Chemical	NOUN	B
overdose	B-Disease	NOUN	B


Continuous	O	ADJ	B
subcutaneous	O	ADJ	B
administration	O	NOUN	I
of	O	ADP	O
mesna	B-Chemical	NOUN	B
to	O	PART	O
prevent	O	VERB	O
ifosfamide	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
hemorrhagic	B-Disease	ADJ	B
cystitis	I-Disease	NOUN	I
.	O	PUNCT	O


Hemorrhagic	B-Disease	ADJ	B
cystitis	I-Disease	NOUN	I
is	O	AUX	O
a	O	DET	O
major	O	ADJ	O
potential	O	ADJ	B
toxicity	B-Disease	NOUN	B
of	O	ADP	O
ifosfamide	B-Chemical	NOUN	B
that	O	PRON	O
can	O	AUX	O
be	O	AUX	O
prevented	O	VERB	B
by	O	ADP	O
administering	O	VERB	B
mesna	B-Chemical	NOUN	B
along	O	ADP	O
with	O	ADP	O
the	O	DET	O
cytotoxic	O	ADJ	B
agent	O	NOUN	I
.	O	PUNCT	O


Mesna	B-Chemical	NOUN	B
is	O	AUX	O
generally	O	ADV	O
administered	O	VERB	B
by	O	ADP	O
the	O	DET	O
intravenous	O	ADJ	B
route	O	NOUN	I
,	O	PUNCT	O
although	O	SCONJ	O
experience	O	NOUN	O
with	O	ADP	O
oral	O	ADJ	B
delivery	O	NOUN	I
of	O	ADP	O
the	O	DET	O
drug	O	NOUN	B
has	O	AUX	O
increased	O	VERB	B
.	O	PUNCT	O


The	O	DET	O
continuous	O	ADJ	B
subcutaneous	O	ADJ	B
administration	O	NOUN	I
of	O	ADP	O
mesna	B-Chemical	NOUN	B
has	O	AUX	O
the	O	DET	O
advantage	O	NOUN	O
of	O	ADP	O
not	O	PART	O
requiring	O	VERB	O
intravenous	O	ADJ	B
access	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
,	O	PUNCT	O
subcutaneous	O	ADJ	B
delivery	O	NOUN	I
of	O	ADP	O
the	O	DET	O
neutralizing	O	VERB	B
agent	O	NOUN	I
will	O	AUX	O
not	O	PART	O
be	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
the	O	DET	O
risk	O	NOUN	B
of	O	ADP	O
inadequate	O	ADJ	B
urinary	O	ADJ	B
mesna	B-Chemical	NOUN	B
concentrations	O	NOUN	B
,	O	PUNCT	O
such	O	ADJ	O
as	O	ADP	O
in	O	ADP	O
a	O	DET	O
patient	O	NOUN	B
taking	O	VERB	O
oral	O	ADJ	B
mesna	B-Chemical	NOUN	B
who	O	PRON	O
experiences	O	VERB	B
severe	O	ADJ	B
ifosfamide	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
emesis	B-Disease	NOUN	B
and	O	CCONJ	O
is	O	AUX	O
unable	O	ADJ	O
to	O	PART	O
absorb	O	VERB	O
the	O	DET	O
drug	O	NOUN	B
.	O	PUNCT	O


Limited	O	ADJ	B
clinical	O	ADJ	B
experience	O	NOUN	O
with	O	ADP	O
continuous	O	ADJ	B
subcutaneous	O	ADJ	B
mesna	B-Chemical	NOUN	O
administration	O	NOUN	B
suggests	O	VERB	O
it	O	PRON	O
is	O	AUX	O
a	O	DET	O
safe	O	ADJ	O
,	O	PUNCT	O
practical	O	ADJ	B
,	O	PUNCT	O
and	O	CCONJ	O
economic	O	ADJ	B
method	O	NOUN	I
of	O	ADP	O
drug	O	NOUN	B
delivery	O	NOUN	I
that	O	PRON	O
permits	O	VERB	O
ifosfamide	B-Chemical	NOUN	B


Modification	O	NOUN	B
of	O	ADP	O
drug	O	NOUN	B
action	O	NOUN	I
by	O	ADP	O
hyperammonemia	B-Disease	NOUN	B
.	O	PUNCT	O


Pretreatment	O	NOUN	B
with	O	ADP	O
ammonium	B-Chemical	NOUN	B
acetate	I-Chemical	NOUN	I
(	O	PUNCT	O
NH4Ac	B-Chemical	NOUN	B
)(	O	NOUN	O
6	O	NUM	O
mmol	O	NOUN	B
/	O	SYM	O
kg	O	NOUN	O
s	O	NOUN	O
.	O	PUNCT	O


c	O	X	O
.)	O	PUNCT	O
approximately	O	ADV	O
doubled	O	VERB	O
the	O	DET	O
time	O	NOUN	B
morphine	B-Chemical	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
mice	O	NOUN	B
remained	O	VERB	O
on	O	ADP	O
a	O	DET	O
hot	O	ADJ	B
surface	O	NOUN	I
and	O	CCONJ	O
similarly	O	ADV	O
increased	O	VERB	B
muscular	O	ADJ	B
incoordination	B-Disease	NOUN	I
by	O	ADP	O
diazepam	B-Chemical	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
NH4Ac	B-Chemical	NOUN	B
treatment	O	NOUN	B
alone	O	ADV	O
had	O	AUX	O
no	O	DET	B
effect	O	NOUN	I
.	O	PUNCT	O


Thus	O	ADV	O
,	O	PUNCT	O
hyperammonemia	B-Disease	NOUN	B
is	O	AUX	O
capable	O	ADJ	O
of	O	ADP	O
altering	O	VERB	B
drug	O	NOUN	B
action	O	NOUN	I
and	O	CCONJ	O
must	O	AUX	O
be	O	AUX	O
considered	O	VERB	O
along	O	ADP	O
with	O	ADP	O
impaired	O	ADJ	B
drug	O	NOUN	B
metabolism	O	NOUN	I
in	O	ADP	O
enhanced	O	VERB	B
drug	O	NOUN	B
responses	O	NOUN	I
associated	O	VERB	B
with	O	ADP	I
liver	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
.	O	PUNCT	O


Experiments	O	NOUN	B
in	O	X	B
vitro	O	X	I
showed	O	VERB	O
that	O	SCONJ	O
acetylcholine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
catecholamine	B-Chemical	NOUN	B
release	O	NOUN	I
from	O	ADP	O
bovine	O	ADJ	B
adrenal	O	ADJ	B
medulla	O	NOUN	I
is	O	AUX	O
depressed	O	ADJ	B
as	O	ADV	O
much	O	ADJ	O
as	O	ADP	O
50	O	NUM	O
%	O	NOUN	O
by	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


3	O	NUM	O
mM	O	NOUN	O
NH4Ac	B-Chemical	NOUN	B
and	O	CCONJ	O
KCl	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
contractions	O	NOUN	B
of	O	ADP	O
guinea	O	NOUN	B
-	O	PUNCT	O
pig	O	NOUN	B
ileum	O	NOUN	B
were	O	AUX	O
inhibited	O	VERB	B
20	O	NUM	O
%	O	NOUN	O
by	O	ADP	O
5	O	NUM	O
mM	O	NOUN	O
NH4Ac	B-Chemical	NOUN	B
.	O	PUNCT	O


Addition	O	NOUN	B
of	O	ADP	O
excess	O	ADJ	B
calcium	B-Chemical	NOUN	B
reversed	O	VERB	B
the	O	DET	O
depression	B-Disease	NOUN	B
in	O	ADP	O
both	O	DET	O
tissues	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
calcium	B-Chemical	NOUN	B
-	O	PUNCT	O
independent	O	ADJ	B
catecholamine	B-Chemical	NOUN	B
release	O	NOUN	O
by	O	ADP	O
acetaldehyde	B-Chemical	NOUN	B
was	O	AUX	O
not	O	PART	O
blocked	O	VERB	B
by	O	ADP	O
NH4Ac	B-Chemical	NOUN	B
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	B
suggested	O	VERB	O
that	O	SCONJ	O
ammonia	B-Chemical	NOUN	B
blocks	O	VERB	I
calcium	B-Chemical	NOUN	B
channels	O	NOUN	I
.	O	PUNCT	O


Parallels	O	NOUN	B
in	O	ADP	O
the	O	DET	O
actions	O	NOUN	B
of	O	ADP	O
NH4Ac	B-Chemical	NOUN	B
and	O	CCONJ	O
the	O	DET	O
calcium	B-Chemical	NOUN	B
channel	O	NOUN	I
blocker	O	NOUN	I
verapamil	B-Chemical	NOUN	B
support	O	VERB	O
this	O	DET	O
concept	O	NOUN	B
.	O	PUNCT	O


Both	O	CCONJ	O
verapamil	B-Chemical	NOUN	B
(	O	PUNCT	O
10	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	O
i	O	X	O
.	O	PUNCT	O


p	O	NOUN	O
.)	O	NOUN	O
and	O	CCONJ	O
NH4Ac	B-Chemical	NOUN	B
pretreatment	O	NOUN	B
enhanced	O	VERB	B
morphine	B-Chemical	NOUN	B
analgesia	B-Disease	NOUN	B
-	O	PUNCT	O
and	O	CCONJ	O
diazepam	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
muscular	O	ADJ	B
incoordination	B-Disease	NOUN	I
and	O	CCONJ	O
antagonized	O	VERB	B
amphetamine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
motor	O	NOUN	B
activity	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
neither	O	CCONJ	O
verapamil	B-Chemical	NOUN	B
nor	O	CCONJ	O
NH4Ac	B-Chemical	NOUN	B
affected	O	VERB	B
the	O	DET	O
convulsant	O	ADJ	B
action	O	NOUN	B
of	O	ADP	O
metrazol	B-Chemical	NOUN	B
.	O	PUNCT	O


The	O	DET	O
data	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
hyperammonemia	B-Disease	NOUN	B
exerts	O	VERB	O
a	O	DET	O
calcium	B-Chemical	NOUN	B


Risk	O	NOUN	B
of	O	ADP	O
nephropathy	B-Disease	NOUN	O
after	O	ADP	O
consumption	O	NOUN	B
of	O	ADP	O
nonionic	O	ADJ	B
contrast	B-Chemical	NOUN	I
media	I-Chemical	NOUN	I
by	O	ADP	O
children	O	NOUN	B
undergoing	O	VERB	O
cardiac	O	ADJ	B
angiography	O	NOUN	I
:	O	PUNCT	O
a	O	DET	O
prospective	O	ADJ	B
study	O	NOUN	I
.	O	PUNCT	O


Despite	O	SCONJ	O
increasing	O	VERB	O
reports	O	NOUN	B
on	O	ADP	O
nonionic	O	ADJ	B
contrast	B-Chemical	NOUN	I
media	I-Chemical	NOUN	I
-	O	PUNCT	O
induced	O	VERB	B
nephropathy	B-Disease	NOUN	B
(	O	PUNCT	O
CIN	B-Disease	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
hospitalized	O	VERB	B
adult	O	ADJ	I
patients	O	NOUN	B
during	O	ADP	O
cardiac	O	ADJ	B
procedures	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
studies	O	NOUN	B
in	O	ADP	O
pediatrics	O	NOUN	B
are	O	AUX	O
limited	O	VERB	B
,	O	PUNCT	O
with	O	ADP	O
even	O	ADV	O
less	O	ADV	O
focus	O	NOUN	O
on	O	ADP	O
possible	O	ADJ	O
predisposing	O	VERB	B
factors	O	NOUN	I
and	O	CCONJ	O
preventive	O	ADJ	B
measures	O	NOUN	I
for	O	ADP	O
patients	O	NOUN	B
undergoing	O	VERB	O
cardiac	O	ADJ	B
angiography	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
prospective	O	ADJ	B
study	O	NOUN	I
determined	O	VERB	O
the	O	DET	O
incidence	O	NOUN	B
of	O	ADP	O
CIN	B-Disease	NOUN	B
for	O	ADP	O
two	O	NUM	O
nonionic	O	ADJ	B
contrast	B-Chemical	NOUN	I
media	I-Chemical	NOUN	I
(	O	PUNCT	O
CM	B-Chemical	NOUN	B
),	O	PUNCT	O
iopromide	B-Chemical	NOUN	B
and	O	CCONJ	O
iohexol	B-Chemical	NOUN	B
,	O	PUNCT	O
among	O	ADP	O
80	O	NUM	O
patients	O	NOUN	B
younger	O	ADJ	B
than	O	ADP	O
18	O	NUM	O
years	O	NOUN	B
and	O	CCONJ	O
compared	O	VERB	B
the	O	DET	O
rates	O	NOUN	B
for	O	ADP	O
this	O	DET	O
complication	O	NOUN	B
in	O	ADP	O
relation	O	NOUN	O
to	O	PART	O
the	O	DET	O
type	O	NOUN	B
and	O	CCONJ	O
dosage	O	NOUN	B
of	O	ADP	O
CM	B-Chemical	NOUN	B
and	O	CCONJ	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
cyanosis	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
80	O	NUM	O
patients	O	NOUN	B
in	O	ADP	O
the	O	DET	O
study	O	NOUN	B
consecutively	O	ADV	O
received	O	VERB	O
either	O	CCONJ	O
iopromide	B-Chemical	NOUN	B
(	O	PUNCT	O
group	O	NOUN	B
A	O	NOUN	I
,	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
40	O	NUM	O
)	O	PUNCT	O
or	O	CCONJ	O
iohexol	B-Chemical	NOUN	B
(	O	PUNCT	O
group	O	NOUN	B
B	O	NOUN	I
,	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
40	O	NUM	O
).	O	PUNCT	O
Serum	O	NOUN	B
sodium	B-Chemical	NOUN	I
(	O	PUNCT	O
Na	B-Chemical	NOUN	B
),	O	PUNCT	O
potassium	B-Chemical	NOUN	B
(	O	PUNCT	O
K	B-Chemical	NOUN	B
),	O	PUNCT	O
and	O	CCONJ	O
creatinine	B-Chemical	NOUN	B
(	O	PUNCT	O
Cr	B-Chemical	NOUN	B
)	O	PUNCT	O
were	O	AUX	O
measured	O	VERB	B
24	O	NUM	O
h	O	NOUN	O
before	O	ADP	O
angiography	O	NOUN	B
as	O	ADP	O
baseline	O	NOUN	B
values	O	NOUN	B
,	O	PUNCT	O
then	O	ADV	O
measured	O	VERB	B
again	O	ADV	O
at	O	ADP	O
12	O	NUM	O
-,	O	NOUN	O
24	O	NUM	O
-,	O	NOUN	O
and	O	CCONJ	O
48	O	NUM	O
-	O	PUNCT	O
h	O	NOUN	B
intervals	O	NOUN	B
after	O	ADP	O
CM	B-Chemical	NOUN	B
use	O	NOUN	B
.	O	PUNCT	O


Urine	O	NOUN	B
samples	O	NOUN	I
for	O	ADP	O
Na	B-Chemical	NOUN	B
and	O	CCONJ	O
Cr	B-Chemical	NOUN	B
also	O	ADV	O
were	O	AUX	O
checked	O	VERB	O
at	O	ADP	O
the	O	DET	O
same	O	ADJ	O
intervals	O	NOUN	B
.	O	PUNCT	O


Risk	O	NOUN	B
of	O	ADP	O
renal	B-Disease	ADJ	B
failure	I-Disease	NOUN	I
,	O	PUNCT	O
Injury	B-Disease	NOUN	B
to	I-Disease	ADP	O
the	I-Disease	DET	O
kidney	I-Disease	NOUN	B
,	O	PUNCT	O
Failure	B-Disease	NOUN	B
of	I-Disease	ADP	O
kidney	I-Disease	NOUN	O
function	I-Disease	NOUN	O
,	O	PUNCT	O
Loss	B-Disease	NOUN	B
of	I-Disease	ADP	I
kidney	I-Disease	NOUN	I
function	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
End	O	NOUN	B
-	O	PUNCT	O
stage	O	NOUN	B
renal	B-Disease	ADJ	I
damage	I-Disease	NOUN	I
(	O	PUNCT	O
RIFLE	O	NOUN	B
criteria	O	NOUN	I
)	O	PUNCT	O
were	O	AUX	O
used	O	VERB	O
to	O	PART	O
define	O	VERB	O
CIN	B-Disease	NOUN	B
and	O	CCONJ	O
its	O	PRON	O
incidence	O	NOUN	B
in	O	ADP	O
the	O	DET	O
study	O	NOUN	B
population	O	NOUN	I
.	O	PUNCT	O


Accordingly	O	ADV	O
,	O	PUNCT	O
among	O	ADP	O
the	O	DET	O
15	O	NUM	O
CIN	B-Disease	NOUN	B
patients	O	NOUN	B
(	O	PUNCT	O
18	O	NUM	O
.	O	PUNCT	O


75	O	NUM	O
%),	O	ADJ	O
7	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
in	O	ADP	O
group	O	NOUN	B
A	O	NOUN	I
had	O	AUX	O
increased	O	VERB	B
risk	O	NOUN	B
and	O	CCONJ	O
3	O	NUM	O
.	O	PUNCT	O


75	O	NUM	O
%	O	NOUN	O
had	O	AUX	O
renal	B-Disease	ADJ	B
injury	I-Disease	NOUN	I
,	O	PUNCT	O
whereas	O	SCONJ	O
5	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
group	O	NOUN	B
B	O	NOUN	I
had	O	AUX	O
increased	O	VERB	B
risk	O	NOUN	B
and	O	CCONJ	O
2	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
%	O	NOUN	O
had	O	AUX	O
renal	B-Disease	ADJ	B
injury	I-Disease	NOUN	I
.	O	PUNCT	O


Whereas	O	SCONJ	O
33	O	NUM	O
.	O	PUNCT	O


3	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
with	O	ADP	O
CIN	B-Disease	NOUN	B
were	O	AUX	O
among	O	ADP	O
those	O	DET	O
who	O	PRON	O
received	O	VERB	O
the	O	DET	O
proper	O	ADJ	O
dosage	O	NOUN	B
of	O	ADP	O
CM	B-Chemical	NOUN	B
,	O	PUNCT	O
the	O	DET	O
percentage	O	NOUN	B
increased	O	VERB	B
to	O	ADP	O
66	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
%	O	NOUN	O
among	O	ADP	O
those	O	DET	O
who	O	PRON	O
received	O	VERB	O
larger	O	ADJ	B
doses	O	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
a	O	DET	O
significant	O	ADJ	O
difference	O	NOUN	O
in	O	ADP	O
the	O	DET	O
incidence	O	NOUN	B
of	O	ADP	O
CIN	B-Disease	NOUN	B
related	O	ADJ	O
to	O	PART	O
the	O	DET	O
different	O	ADJ	O
dosages	O	NOUN	B
of	O	ADP	O
CM	B-Chemical	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


014	O	NUM	O
).	O	PUNCT	O
Among	O	ADP	O
the	O	DET	O
15	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
CIN	B-Disease	NOUN	B
,	O	PUNCT	O
6	O	NUM	O
had	O	AUX	O
cyanotic	O	ADJ	B
congenital	B-Disease	ADJ	B
heart	I-Disease	NOUN	I
diseases	I-Disease	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
the	O	DET	O
incidence	O	NOUN	B
did	O	AUX	O
not	O	PART	O
differ	O	VERB	O
significantly	O	ADV	O
from	O	ADP	O
that	O	DET	O
for	O	ADP	O
the	O	DET	O
noncyanotic	O	ADJ	B
patients	O	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


243	O	NUM	O
).	O	PUNCT	O
Although	O	SCONJ	O
clinically	O	ADV	B
silent	O	ADJ	I
,	O	PUNCT	O
CIN	B-Disease	NOUN	B
is	O	AUX	O
not	O	PART	O
rare	O	ADJ	O
in	O	ADP	O
pediatrics	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
incidence	O	NOUN	B
depends	O	VERB	O
on	O	ADP	O
dosage	O	NOUN	B
but	O	CCONJ	O
not	O	PART	O
on	O	ADP	O
the	O	DET	O
type	O	NOUN	O
of	O	ADP	O
consumed	O	VERB	B
nonionic	O	ADJ	B
CM	B-Chemical	NOUN	B
,	O	PUNCT	O
nor	O	CCONJ	O
on	O	ADP	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
cyanosis	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
although	O	SCONJ	O
CIN	B-Disease	NOUN	B


A	O	DET	O
case	O	NOUN	B
of	O	ADP	O
ventricular	B-Disease	ADJ	B
tachycardia	I-Disease	NOUN	I
related	O	ADJ	O
to	O	PART	O
caffeine	B-Chemical	NOUN	B
pretreatment	O	NOUN	B
.	O	PUNCT	O


Suboptimal	O	ADJ	B
seizure	B-Disease	NOUN	I
duration	O	NOUN	B
is	O	AUX	O
commonly	O	ADV	O
encountered	O	VERB	O
in	O	ADP	O
electroconvulsive	O	ADJ	B
therapy	O	NOUN	I
practice	O	NOUN	I
,	O	PUNCT	O
especially	O	ADV	O
in	O	ADP	O
older	O	ADJ	B
patients	O	NOUN	B
with	O	ADP	O
higher	O	ADJ	O
seizure	B-Disease	NOUN	B
thresholds	O	NOUN	B
.	O	PUNCT	O


Intravenous	O	ADJ	B
caffeine	B-Chemical	NOUN	I
is	O	AUX	O
commonly	O	ADV	O
used	O	VERB	O
to	O	PART	O
improve	O	VERB	B
seizure	B-Disease	NOUN	B
duration	O	NOUN	B
and	O	CCONJ	O
quality	O	NOUN	B
in	O	ADP	O
such	O	ADJ	O
patients	O	NOUN	B
and	O	CCONJ	O
is	O	AUX	O
generally	O	ADV	O
well	O	ADV	O
tolerated	O	VERB	B
aside	O	ADV	O
from	O	ADP	O
occasional	O	ADJ	O
reports	O	NOUN	B
of	O	ADP	O
relatively	O	ADV	O
benign	O	ADJ	B
ventricular	B-Disease	ADJ	O
ectopy	I-Disease	NOUN	O
.	O	PUNCT	O


We	O	PRON	O
describe	O	VERB	O
a	O	DET	O
patient	O	NOUN	B
with	O	ADP	O
no	O	DET	O
previous	O	ADJ	O
history	O	NOUN	B
of	O	ADP	O
cardiac	B-Disease	ADJ	B
disease	I-Disease	NOUN	I
or	O	CCONJ	O
arrhythmia	B-Disease	NOUN	B
who	O	PRON	O
developed	O	VERB	O
sustained	O	ADJ	B
bigeminy	O	ADV	B
and	O	CCONJ	O
2	O	NUM	O
brief	O	ADJ	O
runs	O	NOUN	O
of	O	ADP	O
ventricular	B-Disease	ADJ	B
tachycardia	I-Disease	NOUN	I
after	O	ADP	O
caffeine	B-Chemical	NOUN	B
administration	O	NOUN	B
.	O	PUNCT	O


Although	O	SCONJ	O
intravenous	O	ADJ	B
caffeine	B-Chemical	NOUN	O
is	O	AUX	O
generally	O	ADV	O
well	O	ADV	O
tolerated	O	ADJ	B
,	O	PUNCT	O
the	O	DET	O
clinician	O	NOUN	B
should	O	AUX	O
be	O	AUX	O
aware	O	ADJ	O
of	O	ADP	O
the	O	DET	O
potential	O	NOUN	B
for	O	ADP	O
unpredictable	O	ADJ	B
and	O	CCONJ	O
serious	O	ADJ	O
ventricular	B-Disease	ADJ	B
arrhythmias	I-Disease	NOUN	I


Optical	O	ADJ	B
coherence	O	NOUN	I
tomography	O	NOUN	I
can	O	AUX	O
measure	O	VERB	B
axonal	O	ADJ	B
loss	O	NOUN	O
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
ethambutol	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
optic	B-Disease	ADJ	B
neuropathy	I-Disease	NOUN	I
.	O	PUNCT	O


PURPOSE	O	NOUN	B
:	O	PUNCT	O
To	O	PART	O
map	O	VERB	B
and	O	CCONJ	O
identify	O	VERB	O
the	O	DET	O
pattern	O	NOUN	B
,	O	PUNCT	O
in	O	X	B
vivo	O	X	I
,	O	PUNCT	O
of	O	ADP	O
axonal	B-Disease	ADJ	B
degeneration	I-Disease	NOUN	I
in	O	ADP	O
ethambutol	B-Chemical	X	B
-	O	PUNCT	O
induced	O	VERB	B
optic	B-Disease	ADJ	B
neuropathy	I-Disease	NOUN	I
using	O	VERB	O
optical	O	ADJ	B
coherence	O	NOUN	I
tomography	O	NOUN	I
(	O	PUNCT	O
OCT	O	NOUN	B
).	O	PUNCT	O
Ethambutol	B-Chemical	PROPN	B
is	O	AUX	O
an	O	DET	O
antimycobacterial	O	ADJ	B
agent	O	NOUN	I
often	O	ADV	O
used	O	VERB	O
to	O	PART	O
treat	O	VERB	B
tuberculosis	B-Disease	NOUN	B
.	O	PUNCT	O


A	O	DET	O
serious	O	ADJ	O
complication	O	NOUN	B
of	O	ADP	O
ethambutol	B-Chemical	NOUN	B
is	O	AUX	O
an	O	DET	O
optic	B-Disease	ADJ	B
neuropathy	I-Disease	NOUN	I
that	O	PRON	O
impairs	O	VERB	B
visual	O	ADJ	B
acuity	O	NOUN	I
,	O	PUNCT	O
contrast	O	NOUN	B
sensitivity	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
color	O	NOUN	B
vision	O	NOUN	I
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
early	O	ADV	B
on	O	ADV	O
,	O	PUNCT	O
when	O	SCONJ	O
the	O	DET	O
toxic	O	ADJ	B
optic	B-Disease	ADJ	B
neuropathy	I-Disease	NOUN	I
is	O	AUX	O
mild	O	ADJ	B
and	O	CCONJ	O
partly	O	ADV	O
reversible	O	ADJ	B
,	O	PUNCT	O
the	O	DET	O
funduscopic	O	ADJ	B
findings	O	NOUN	B
are	O	AUX	O
often	O	ADV	O
subtle	O	ADJ	O
and	O	CCONJ	O
easy	O	ADJ	O
to	O	PART	O
miss	O	VERB	O
.	O	PUNCT	O


METHODS	O	NOUN	O
:	O	PUNCT	O
Three	O	NUM	O
subjects	O	NOUN	B
with	O	ADP	O
a	O	DET	O
history	O	NOUN	B
of	O	ADP	O
ethambutol	B-Chemical	NOUN	B
(	O	PUNCT	O
EMB	B-Chemical	NOUN	B
)-	O	ADJ	O
induced	O	VERB	B
optic	B-Disease	ADJ	B
neuropathy	I-Disease	NOUN	I
of	O	ADP	O
short	O	ADJ	B
-,	O	ADJ	O
intermediate	O	NOUN	B
-,	O	NOUN	O
and	O	CCONJ	O
long	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
visual	B-Disease	ADJ	B
deficits	I-Disease	NOUN	I
were	O	AUX	O
administered	O	VERB	B
a	O	DET	O
full	O	ADJ	O
neuro	O	NOUN	B
-	O	PUNCT	O
ophthalmologic	O	ADJ	B
examination	O	NOUN	B
including	O	VERB	O
visual	O	ADJ	B
acuity	O	NOUN	I
,	O	PUNCT	O
color	O	NOUN	B
vision	O	NOUN	I
,	O	PUNCT	O
contrast	O	NOUN	B
sensitivity	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
fundus	O	NOUN	B
examination	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
,	O	PUNCT	O
OCT	O	NOUN	B
(	O	PUNCT	O
OCT	O	NOUN	B
3000	O	NUM	O
,	O	PUNCT	O
Humphrey	O	PROPN	B
-	O	PUNCT	O
Zeiss	O	PROPN	B
,	O	PUNCT	O
Dublin	O	PROPN	B
,	O	PUNCT	O
CA	O	PROPN	B
)	O	PUNCT	O
was	O	AUX	O
performed	O	VERB	O
on	O	ADP	O
both	O	DET	O
eyes	O	NOUN	B
of	O	ADP	O
each	O	DET	O
subject	O	NOUN	B
using	O	VERB	O
the	O	DET	O
retinal	O	ADJ	B
nerve	O	NOUN	I
fiber	O	NOUN	I
layer	O	NOUN	I
(	O	PUNCT	O
RNFL	O	NOUN	B
)	O	PUNCT	O
analysis	O	NOUN	B
protocol	O	NOUN	I
.	O	PUNCT	O


OCT	O	NOUN	B
interpolates	O	VERB	O
data	O	NOUN	B
from	O	ADP	O
100	O	NUM	O
points	O	NOUN	O
around	O	ADP	O
the	O	DET	O
optic	O	ADJ	B
nerve	O	NOUN	I
to	O	PART	O
effectively	O	ADV	O
map	O	VERB	B
out	O	ADP	O
the	O	DET	O
RNFL	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
The	O	DET	O
results	O	NOUN	B
were	O	AUX	O
compared	O	VERB	B
to	O	PART	O
the	O	DET	O
calculated	O	VERB	B
average	O	ADJ	B
RNFL	O	NOUN	B
of	O	ADP	O
normal	O	ADJ	B
eyes	O	NOUN	I
accumulated	O	VERB	O
from	O	ADP	O
four	O	NUM	O
prior	O	ADJ	O
studies	O	NOUN	B
using	O	VERB	O
OCT	O	NOUN	B
,	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
661	O	NUM	O
.	O	PUNCT	O


In	O	ADP	O
all	O	DET	O
subjects	O	NOUN	B
with	O	ADP	O
history	O	NOUN	B
of	O	ADP	O
EMB	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
optic	B-Disease	ADJ	B
neuropathy	I-Disease	NOUN	I
,	O	PUNCT	O
there	O	PRON	O
was	O	AUX	O
a	O	DET	O
mean	O	ADJ	O
loss	O	NOUN	B
of	O	ADP	O
72	O	NUM	O
%	O	NOUN	O
nerve	O	NOUN	B
fiber	O	NOUN	I
layer	O	NOUN	I
thickness	O	NOUN	B
in	O	ADP	O
the	O	DET	O
temporal	O	ADJ	B
quadrant	O	NOUN	I
(	O	PUNCT	O
patient	O	NOUN	B
A	O	NOUN	O
,	O	PUNCT	O
with	O	ADP	O
eventual	O	ADJ	B
recovery	O	NOUN	B
of	O	ADP	O
visual	O	ADJ	B
acuity	O	NOUN	I
and	O	CCONJ	O
fields	O	NOUN	B
,	O	PUNCT	O
58	O	NUM	O
%	O	NOUN	O
loss	O	NOUN	B
;	O	PUNCT	O
patient	O	NOUN	B
B	O	NOUN	I
,	O	PUNCT	O
with	O	ADP	O
intermediate	O	ADJ	B
visual	B-Disease	ADJ	O
deficits	I-Disease	NOUN	O
,	O	PUNCT	O
68	O	NUM	O
%	O	NOUN	O
loss	O	NOUN	B
;	O	PUNCT	O
patient	O	NOUN	B
C	O	NOUN	I
,	O	PUNCT	O
with	O	ADP	O
chronic	O	ADJ	B
visual	B-Disease	ADJ	I
deficits	I-Disease	NOUN	I
,	O	PUNCT	O
90	O	NUM	O
%	O	NOUN	O
loss	O	NOUN	B
),	O	PUNCT	O
with	O	ADP	O
an	O	DET	O
average	O	ADJ	B
mean	O	ADJ	O
optic	O	ADJ	B
nerve	O	NOUN	I
thickness	O	NOUN	B
of	O	ADP	O
26	O	NUM	O
+/-	O	CCONJ	O
16	O	NUM	O
microm	O	NOUN	B
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
a	O	DET	O
combined	O	ADJ	O
mean	O	ADJ	O
loss	O	NOUN	O
of	O	ADP	O
46	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
fibers	O	NOUN	B
from	O	ADP	O
the	O	DET	O
superior	O	ADJ	B
,	O	PUNCT	O
inferior	O	ADJ	B
,	O	PUNCT	O
and	O	CCONJ	O
nasal	O	ADJ	B
quadrants	O	NOUN	I
in	O	ADP	O
the	O	DET	O
(	O	PUNCT	O
six	O	NUM	O
)	O	PUNCT	O
eyes	O	NOUN	B
of	O	ADP	O
all	O	DET	O
three	O	NUM	O
subjects	O	NOUN	B
(	O	PUNCT	O
mean	O	ADJ	O
average	O	ADJ	O
thickness	O	NOUN	B
of	O	ADP	O
55	O	NUM	O
+/-	O	CCONJ	O
29	O	NUM	O
microm	O	NOUN	B
).	O	PUNCT	O
In	O	ADP	O
both	O	DET	O
sets	O	NOUN	B
(	O	PUNCT	O
four	O	NUM	O
)	O	PUNCT	O
of	O	ADP	O
eyes	O	NOUN	B
of	O	ADP	O
the	O	DET	O
subjects	O	NOUN	B
with	O	ADP	O
persistent	O	ADJ	B
visual	B-Disease	ADJ	B
deficits	I-Disease	NOUN	I
(	O	PUNCT	O
patients	O	NOUN	B
B	O	NOUN	O
and	O	CCONJ	O
C	O	NOUN	B
),	O	PUNCT	O
there	O	PRON	O
was	O	AUX	O
an	O	DET	O
average	O	ADJ	B
loss	O	NOUN	B
of	O	ADP	O
79	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
nerve	O	NOUN	B
fiber	O	NOUN	I
thickness	O	NOUN	B
in	O	ADP	O
the	O	DET	O
temporal	O	ADJ	B
quadrant	O	NOUN	I
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
:	O	PUNCT	O
The	O	DET	O
OCT	O	NOUN	B
results	O	VERB	B
in	O	ADP	O
these	O	DET	O
patients	O	NOUN	B
with	O	ADP	O
EMB	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
optic	B-Disease	ADJ	B
neuropathy	I-Disease	NOUN	I
show	O	VERB	O
considerable	O	ADJ	O
loss	O	NOUN	B
especially	O	ADV	O
of	O	ADP	O
the	O	DET	O
temporal	O	ADJ	B
fibers	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
is	O	AUX	O
consistent	O	ADJ	B
with	O	ADP	I
prior	O	ADJ	O
histopathological	O	ADJ	B
studies	O	NOUN	O
that	O	PRON	O
show	O	VERB	O
predominant	O	ADJ	B
loss	O	NOUN	B
of	O	ADP	O
parvo	O	ADJ	B
-	O	PUNCT	O
cellular	O	ADJ	B
axons	O	NOUN	B
(	O	PUNCT	O
or	O	CCONJ	O
small	O	ADJ	B
-	O	PUNCT	O
caliber	O	NOUN	B
axons	O	NOUN	B
)	O	PUNCT	O
within	O	ADP	O
the	O	DET	O
papillo	O	ADJ	B
-	O	PUNCT	O
macular	O	NOUN	B
bundle	O	NOUN	B
in	O	ADP	O
toxic	O	ADJ	B
or	O	CCONJ	O
hereditary	O	ADJ	B
optic	B-Disease	ADJ	I
neuropathies	I-Disease	NOUN	I
.	O	PUNCT	O


OCT	O	NOUN	B
can	O	AUX	O
be	O	AUX	O
a	O	DET	O
valuable	O	ADJ	O
tool	O	NOUN	O
in	O	ADP	O
the	O	DET	O
quantitative	O	ADJ	B
analysis	O	NOUN	I
of	O	ADP	O
optic	B-Disease	ADJ	B
neuropathies	I-Disease	NOUN	I
.	O	PUNCT	O


Additionally	O	ADV	O
,	O	PUNCT	O
in	O	ADP	O
terms	O	NOUN	O
of	O	ADP	O
management	O	NOUN	B
of	O	ADP	O
EMB	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
optic	B-Disease	ADJ	B
neuropathy	I-Disease	NOUN	I
,	O	PUNCT	O
it	O	PRON	O
is	O	AUX	O
important	O	ADJ	O
to	O	PART	O
properly	O	ADV	O
manage	O	VERB	O
ethambutol	B-Chemical	NOUN	B
dosing	O	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
renal	B-Disease	ADJ	B
impairment	I-Disease	NOUN	I


Effects	O	NOUN	B
of	O	ADP	I
the	O	DET	O
cyclooxygenase	O	NOUN	B
-	O	PUNCT	O
2	O	NUM	O
specific	O	ADJ	O
inhibitor	O	NOUN	B
valdecoxib	B-Chemical	NOUN	B
versus	O	CCONJ	O
nonsteroidal	O	ADJ	B
antiinflammatory	O	ADJ	I
agents	O	NOUN	I
and	O	CCONJ	O
placebo	O	NOUN	B
on	O	ADP	O
cardiovascular	O	ADJ	B
thrombotic	B-Disease	ADJ	I
events	O	NOUN	I
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
arthritis	B-Disease	NOUN	B
.	O	PUNCT	O


There	O	PRON	O
have	O	AUX	O
been	O	AUX	O
concerns	O	NOUN	B
that	O	SCONJ	O
the	O	DET	O
risk	O	NOUN	B
of	O	ADP	O
cardiovascular	O	ADJ	B
thrombotic	B-Disease	ADJ	I
events	O	NOUN	I
may	O	AUX	O
be	O	AUX	O
higher	O	ADJ	B
with	O	ADP	O
cyclooxygenase	O	NOUN	B
(	O	PUNCT	O
COX	O	NOUN	B
)-	O	ADJ	O
2	O	NUM	O
-	O	PUNCT	O
specific	O	ADJ	B
inhibitors	O	NOUN	B
than	O	ADP	O
nonselective	O	ADJ	B
nonsteroidal	O	ADJ	I
antiinflammatory	O	ADJ	I
drugs	O	NOUN	I
(	O	PUNCT	O
NSAIDs	O	NOUN	B
).	O	PUNCT	O
We	O	PRON	O
evaluated	O	VERB	B
cardiovascular	O	ADJ	B
event	O	NOUN	O
data	O	NOUN	B
for	O	ADP	O
valdecoxib	B-Chemical	NOUN	B
,	O	PUNCT	O
a	O	DET	O
new	O	ADJ	O
COX	O	NOUN	B
-	O	PUNCT	O
2	O	NUM	B
-	O	PUNCT	O
specific	O	ADJ	B
inhibitor	O	NOUN	B
in	O	ADP	O
approximately	O	ADV	O
8000	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
osteoarthritis	B-Disease	NOUN	B
and	O	CCONJ	O
rheumatoid	B-Disease	ADJ	B
arthritis	I-Disease	NOUN	I
treated	O	VERB	B
with	O	ADP	I
this	O	DET	O
agent	O	NOUN	B
in	O	ADP	O
randomized	O	ADJ	B
clinical	O	ADJ	I
trials	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
incidence	O	NOUN	B
of	O	ADP	O
cardiovascular	O	ADJ	B
thrombotic	B-Disease	ADJ	I
events	O	NOUN	I
(	O	PUNCT	O
cardiac	O	ADJ	B
,	O	PUNCT	O
cerebrovascular	O	NOUN	B
and	O	CCONJ	O
peripheral	O	ADJ	B
vascular	O	ADJ	I
,	O	PUNCT	O
or	O	CCONJ	O
arterial	O	ADJ	B
thrombotic	B-Disease	ADJ	I
)	O	PUNCT	O
was	O	AUX	O
determined	O	VERB	O
by	O	ADP	O
analyzing	O	VERB	O
pooled	O	ADJ	B
valdecoxib	B-Chemical	NOUN	B
(	O	PUNCT	O
10	O	NUM	O
-	O	SYM	O
80	O	NUM	O
mg	O	NOUN	O
daily	O	ADV	B
),	O	PUNCT	O
nonselective	O	ADJ	B
NSAID	O	NOUN	B
(	O	PUNCT	O
diclofenac	B-Chemical	NOUN	B
75	O	NUM	O
mg	O	NOUN	O
bid	O	NOUN	B
,	O	PUNCT	O
ibuprofen	B-Chemical	NOUN	B
800	O	NUM	O
mg	O	NOUN	O
tid	O	NOUN	B
,	O	PUNCT	O
or	O	CCONJ	O
naproxen	B-Chemical	NOUN	B
500	O	NUM	O
mg	O	NOUN	O
bid	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
placebo	O	ADJ	B
data	O	NOUN	B
from	O	ADP	O
10	O	NUM	O
randomized	O	ADJ	B
osteoarthritis	B-Disease	NOUN	I
and	O	CCONJ	O
rheumatoid	B-Disease	ADJ	B
arthritis	I-Disease	NOUN	I
trials	O	NOUN	B
that	O	PRON	O
were	O	AUX	O
6	O	NUM	O
-	O	SYM	O
52	O	NUM	O
weeks	O	NOUN	B
in	O	ADP	O
duration	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
incidence	O	NOUN	B
rates	O	NOUN	I
of	O	ADP	O
events	O	NOUN	B
were	O	AUX	O
determined	O	VERB	O
in	O	ADP	O
all	O	DET	O
patients	O	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
7934	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
in	O	ADP	O
users	O	NOUN	B
of	O	ADP	O
low	O	ADJ	B
-	O	PUNCT	O
dose	O	NOUN	B
(<	O	NOUN	O
or	O	CCONJ	O
=	O	ADJ	O
325	O	NUM	O
mg	O	NOUN	O
daily	O	ADV	B
)	O	PUNCT	O
aspirin	B-Chemical	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
1051	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
nonusers	O	NOUN	B
of	O	ADP	O
aspirin	B-Chemical	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
6883	O	NUM	O
).	O	PUNCT	O
Crude	O	NOUN	B
and	O	CCONJ	O
exposure	O	NOUN	B
-	O	PUNCT	O
adjusted	O	VERB	B
incidences	O	NOUN	B
of	O	ADP	O
thrombotic	B-Disease	ADJ	B
events	O	NOUN	I
were	O	AUX	O
similar	O	ADJ	O
for	O	ADP	O
valdecoxib	B-Chemical	NOUN	B
,	O	PUNCT	O
NSAIDs	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
placebo	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
risk	O	NOUN	B
of	O	ADP	O
serious	O	ADJ	O
thrombotic	B-Disease	ADJ	B
events	O	NOUN	I
was	O	AUX	O
also	O	ADV	O
similar	O	ADJ	O
for	O	ADP	O
each	O	DET	O
valdecoxib	B-Chemical	NOUN	B
dose	O	NOUN	B
.	O	PUNCT	O


Thrombotic	B-Disease	ADJ	B
risk	O	NOUN	I
was	O	AUX	O
consistently	O	ADV	O
higher	O	ADJ	O
for	O	ADP	O
users	O	NOUN	B
of	O	ADP	O
aspirin	B-Chemical	NOUN	B
users	O	NOUN	B
than	O	ADP	O
nonusers	O	NOUN	B
of	O	ADP	O
aspirin	B-Chemical	NOUN	B
(	O	PUNCT	O
placebo	O	NOUN	B
,	O	PUNCT	O
1	O	NUM	O
.	O	PUNCT	O


4	O	NUM	O
%	O	NOUN	O
vs	O	CCONJ	O
.	O	PUNCT	O


0	O	NUM	O
%;	O	NOUN	O
valdecoxib	B-Chemical	NOUN	B
,	O	PUNCT	O
1	O	NUM	O
.	O	PUNCT	O


7	O	NUM	O
%	O	NOUN	O
vs	O	CCONJ	O
.	O	PUNCT	O


0	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
%;	O	NOUN	O
NSAIDs	O	NOUN	B
,	O	PUNCT	O
1	O	NUM	O
.	O	PUNCT	O


9	O	NUM	O
%	O	NOUN	O
vs	O	CCONJ	O
.	O	PUNCT	O


0	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
%).	O	VERB	O
The	O	DET	O
rates	O	NOUN	B
of	O	ADP	O
events	O	NOUN	B
in	O	ADP	O
users	O	NOUN	B
of	O	ADP	O
aspirin	B-Chemical	NOUN	B
were	O	AUX	O
similar	O	ADJ	O
for	O	ADP	O
all	O	DET	O
3	O	NUM	O
treatment	O	NOUN	B
groups	O	NOUN	I
and	O	CCONJ	O
across	O	ADP	O
valdecoxib	B-Chemical	NOUN	B
doses	O	NOUN	B
.	O	PUNCT	O


Short	O	ADJ	B
-	O	PUNCT	O
and	O	CCONJ	O
intermediate	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
treatment	O	NOUN	B
with	O	ADP	O
therapeutic	O	ADJ	B
(	O	PUNCT	O
10	O	NUM	O
or	O	CCONJ	O
20	O	NUM	O
mg	O	NOUN	O
daily	O	ADV	B
)	O	PUNCT	O
and	O	CCONJ	O
supratherapeutic	O	ADJ	B
(	O	PUNCT	O
40	O	NUM	O
or	O	CCONJ	O
80	O	NUM	O
mg	O	NOUN	O
daily	O	ADV	B
)	O	PUNCT	O
valdecoxib	B-Chemical	NOUN	B
doses	O	NOUN	B
was	O	AUX	O
not	O	PART	O
associated	O	VERB	B
with	O	ADP	I
an	O	DET	O
increased	O	VERB	B
incidence	O	NOUN	B
of	O	ADP	O
thrombotic	B-Disease	ADJ	B
events	O	NOUN	I
relative	O	ADJ	O
to	O	PART	O
nonselective	O	ADJ	B
NSAIDs	O	NOUN	I
or	O	CCONJ	O
placebo	O	NOUN	B
in	O	ADP	O
osteoarthritis	B-Disease	NOUN	B
and	O	CCONJ	O
rheumatoid	B-Disease	ADJ	B
arthritis	I-Disease	NOUN	I


A	O	DET	O
randomized	O	ADJ	B
,	O	PUNCT	O
placebo	O	NOUN	B
-	O	PUNCT	O
controlled	O	VERB	B
,	O	PUNCT	O
crossover	O	NOUN	B
study	O	NOUN	I
of	O	ADP	O
ephedrine	B-Chemical	NOUN	B
for	O	ADP	O
SSRI	O	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
female	O	ADJ	B
sexual	B-Disease	ADJ	B
dysfunction	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
objective	O	NOUN	B
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
determine	O	VERB	O
whether	O	SCONJ	O
ephedrine	B-Chemical	NOUN	B
,	O	PUNCT	O
an	O	DET	O
alpha	O	NOUN	B
-	O	PUNCT	O
and	O	CCONJ	O
beta	O	NOUN	B
-	O	PUNCT	O
adrenergic	O	ADJ	B
agonist	O	NOUN	B
previously	O	ADV	O
shown	O	VERB	O
to	O	PART	O
enhance	O	VERB	O
genital	O	ADJ	B
blood	O	NOUN	I
flow	O	NOUN	I
in	O	ADP	O
women	O	NOUN	B
,	O	PUNCT	O
has	O	AUX	O
beneficial	O	ADJ	O
effects	O	NOUN	B
in	O	ADP	O
reversing	O	VERB	O
antidepressant	O	ADJ	B
-	O	PUNCT	O
induced	O	VERB	B
sexual	B-Disease	ADJ	B
dysfunction	I-Disease	NOUN	I
.	O	PUNCT	O


Nineteen	O	NUM	O
sexually	B-Disease	ADV	B
dysfunctional	I-Disease	ADJ	I
women	O	NOUN	B
receiving	O	VERB	O
either	O	CCONJ	O
fluoxetine	B-Chemical	NOUN	B
,	O	PUNCT	O
sertraline	B-Chemical	NOUN	B
,	O	PUNCT	O
or	O	CCONJ	O
paroxetine	B-Chemical	NOUN	B
participated	O	VERB	O
in	O	ADP	O
an	O	DET	O
eight	O	NUM	O
-	O	PUNCT	O
week	O	NOUN	B
,	O	PUNCT	O
double	O	ADJ	B
-	O	PUNCT	O
blind	O	ADJ	B
,	O	PUNCT	O
placebo	O	NOUN	B
-	O	PUNCT	O
controlled	O	VERB	B
,	O	PUNCT	O
cross	O	VERB	B
-	O	PUNCT	O
over	O	ADP	B
study	O	NOUN	B
of	O	ADP	O
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
ephedrine	B-Chemical	NOUN	B
(	O	PUNCT	O
50	O	NUM	O
mg	O	NOUN	O
)	O	PUNCT	O
on	O	ADP	O
self	O	NOUN	B
-	O	PUNCT	O
report	O	NOUN	B
measures	O	NOUN	B
of	O	ADP	O
sexual	O	ADJ	B
desire	O	NOUN	I
,	O	PUNCT	O
arousal	O	NOUN	B
,	O	PUNCT	O
orgasm	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
sexual	O	ADJ	B
satisfaction	O	NOUN	I
.	O	PUNCT	O


Although	O	SCONJ	O
there	O	PRON	O
were	O	AUX	O
significant	O	ADJ	O
improvements	O	NOUN	B
relative	O	ADJ	O
to	O	PART	O
baseline	O	NOUN	B
in	O	ADP	O
sexual	O	ADJ	B
desire	O	NOUN	I
and	O	CCONJ	O
orgasm	O	NOUN	B
intensity	O	NOUN	B
/	O	SYM	O
pleasure	O	NOUN	B
on	O	ADP	O
50	O	NUM	O
mg	O	NOUN	O
ephedrine	B-Chemical	NOUN	B


Erectile	B-Disease	NOUN	B
dysfunction	I-Disease	NOUN	I
occurs	O	VERB	O
following	O	VERB	O
substantia	O	NOUN	B
nigra	O	NOUN	I
lesions	O	NOUN	B
in	O	ADP	O
the	O	DET	O
rat	O	NOUN	B
.	O	PUNCT	O


Erectile	O	NOUN	B
function	O	NOUN	I
was	O	AUX	O
assessed	O	VERB	B
6	O	NUM	O
weeks	O	NOUN	B
following	O	VERB	O
uni	O	NOUN	B
-	O	PUNCT	O
and	O	CCONJ	O
bilateral	O	ADJ	B
injections	O	NOUN	B
of	O	ADP	O
6-hydroxydopamine	B-Chemical	NOUN	B
in	O	ADP	O
the	O	DET	O
substantia	O	NOUN	B
nigra	O	NOUN	I
nucleus	O	NOUN	I
of	O	ADP	O
the	O	DET	O
brain	O	NOUN	B
.	O	PUNCT	O


Behavioral	O	ADJ	B
apomorphine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
penile	O	ADJ	B
erections	O	NOUN	B
were	O	AUX	O
reduced	O	VERB	B
(	O	PUNCT	O
5	O	NUM	O
/	O	SYM	O
8	O	NUM	B
)	O	PUNCT	O
and	O	CCONJ	O
increased	O	VERB	B
(	O	PUNCT	O
3	O	NUM	O
/	O	SYM	O
8	O	NUM	B
)	O	PUNCT	O
in	O	ADP	O
uni	O	NOUN	B
-	O	PUNCT	O
and	O	CCONJ	O
bilateral	O	ADJ	B
lesioned	O	ADJ	B
animals	O	NOUN	B
.	O	PUNCT	O


Intracavernous	O	ADJ	B
pressures	O	NOUN	I
,	O	PUNCT	O
following	O	VERB	O
electrical	O	ADJ	B
stimulation	O	NOUN	I
of	O	ADP	O
the	O	DET	O
cavernous	O	ADJ	B
nerve	O	NOUN	I
,	O	PUNCT	O
decreased	O	VERB	B
in	O	ADP	O
lesioned	O	ADJ	B
animals	O	NOUN	B
.	O	PUNCT	O


Lesions	O	NOUN	B
of	O	ADP	O
the	O	DET	O
substantia	O	NOUN	B
nigra	O	NOUN	I
were	O	AUX	O
confirmed	O	VERB	O
by	O	ADP	O
histology	O	NOUN	B
.	O	PUNCT	O


Concentration	O	NOUN	B
of	O	ADP	O
dopamine	B-Chemical	NOUN	B
and	O	CCONJ	O
its	O	PRON	O
metabolites	O	NOUN	B
were	O	AUX	O
decreased	O	VERB	B
in	O	ADP	O
the	O	DET	O
striatum	O	NOUN	B
of	O	ADP	O
substantia	O	NOUN	B
nigra	O	NOUN	I
lesioned	O	ADJ	B
rats	O	NOUN	B
.	O	PUNCT	O


Lesions	O	NOUN	B
of	O	ADP	O
the	O	DET	O
substantia	O	NOUN	B
nigra	O	NOUN	I
are	O	AUX	O
therefore	O	ADV	O
associated	O	VERB	B
with	O	ADP	I
erectile	B-Disease	ADJ	B
dysfunction	I-Disease	NOUN	I
in	O	ADP	O
rats	O	NOUN	B
and	O	CCONJ	O
may	O	AUX	O
serve	O	VERB	O
as	O	ADP	O
a	O	DET	O
model	O	NOUN	B
to	O	PART	O
study	O	VERB	B
erectile	B-Disease	NOUN	B
dysfunction	I-Disease	NOUN	I
in	O	ADP	O
Parkinson's	B-Disease	ADJ	O
disease	I-Disease	NOUN	B


Potential	O	ADJ	B
therapeutic	O	ADJ	B
use	O	NOUN	O
of	O	ADP	O
the	O	DET	O
selective	O	ADJ	O
dopamine	B-Chemical	NOUN	B
D1	O	NOUN	I
receptor	O	NOUN	I
agonist	O	NOUN	B
,	O	PUNCT	O
A-86929	B-Chemical	NOUN	B
:	O	PUNCT	O
an	O	DET	O
acute	O	ADJ	B
study	O	NOUN	I
in	O	ADP	O
parkinsonian	B-Disease	ADJ	B
levodopa	B-Chemical	NOUN	B
-	O	PUNCT	O
primed	O	VERB	B
monkeys	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
clinical	O	ADJ	B
utility	O	NOUN	O
of	O	ADP	O
dopamine	B-Chemical	NOUN	B
(	O	PUNCT	O
DA	B-Chemical	NOUN	O
)	O	PUNCT	O
D1	O	NOUN	O
receptor	O	NOUN	O
agonists	O	NOUN	B
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
Parkinson's	B-Disease	ADJ	B
disease	I-Disease	NOUN	I
(	O	PUNCT	O
PD	B-Disease	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
still	O	ADV	O
unclear	O	ADJ	O
.	O	PUNCT	O


The	O	DET	O
therapeutic	O	ADJ	B
use	O	NOUN	O
of	O	ADP	O
selective	O	ADJ	O
DA	B-Chemical	NOUN	B
D1	O	NOUN	I
receptor	O	NOUN	I
agonists	O	NOUN	B
such	O	ADJ	O
as	O	ADP	O
SKF-82958	B-Chemical	NOUN	B
(	O	PUNCT	O
6-chloro-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzaze	B-Chemical	NOUN	O
pine	I-Chemical	NOUN	B
hydrobromide	I-Chemical	NOUN	I
)	O	PUNCT	O
and	O	CCONJ	O
A-77636	B-Chemical	NOUN	B
(	O	PUNCT	O
[1R,	B-Chemical	X	O
3S]	I-Chemical	NOUN	O
3-[1'-admantyl]-1-aminomethyl-3,4-dihydro-5,6-dihydroxy-1H-2-benzo	I-Chemical	NUM	O
pyran	I-Chemical	NOUN	B
hydrochloride	I-Chemical	NOUN	I
)	O	PUNCT	O
seems	O	VERB	O
limited	O	ADJ	B
because	O	SCONJ	O
of	O	ADP	O
their	O	PRON	O
duration	O	NOUN	B
of	O	ADP	O
action	O	NOUN	O
,	O	PUNCT	O
which	O	DET	O
is	O	AUX	O
too	O	ADV	O
short	O	ADJ	O
for	O	ADP	O
SKF-82958	B-Chemical	NOUN	B
(<	O	NOUN	O
1	O	NUM	O
hr	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
too	O	ADV	O
long	O	ADJ	O
for	O	ADP	O
A-77636	B-Chemical	NOUN	B
(>	O	NOUN	O
20	O	NUM	O
hr	O	NOUN	O
,	O	PUNCT	O
leading	O	VERB	O
to	O	PART	O
behavioral	O	ADJ	B
tolerance	O	NOUN	O
).	O	PUNCT	B
We	O	PRON	O
therefore	O	ADV	O
conducted	O	VERB	O
the	O	DET	O
present	O	ADJ	O
acute	O	ADJ	B
dose	O	NOUN	B
-	O	PUNCT	O
response	O	NOUN	B
study	O	NOUN	O
in	O	ADP	O
four	O	NUM	O
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	B-Chemical	NOUN	B
(	O	PUNCT	O
MPTP	B-Chemical	NOUN	B
)-	O	ADJ	O
exposed	O	VERB	B
cynomolgus	O	ADJ	B
monkeys	O	NOUN	B
primed	O	VERB	B
to	O	PART	O
exhibit	O	VERB	O
levodopa	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
dyskinesias	B-Disease	NOUN	B
to	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
locomotor	O	NOUN	B
and	O	CCONJ	O
dyskinetic	B-Disease	ADJ	B
effects	O	NOUN	O
on	O	ADP	O
challenge	O	NOUN	O
with	O	ADP	O
four	O	NUM	O
doses	O	NOUN	B
(	O	PUNCT	O
from	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


03	O	NUM	O
to	O	PART	O
1	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
)	O	PUNCT	O
of	O	ADP	O
A-86929	B-Chemical	NOUN	B
(	O	PUNCT	O
[-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+	B-Chemical	X	O
++azacyclopent-1-	I-Chemical	NOUN	O
ena[c]phenathrene-9-10-diol	I-Chemical	NOUN	B
),	O	PUNCT	O
a	O	DET	O
selective	O	ADJ	O
and	O	CCONJ	O
full	O	ADJ	O
DA	B-Chemical	NOUN	B
D1	O	NOUN	I
-	O	PUNCT	O
like	O	ADJ	B
receptor	O	NOUN	I
agonist	O	NOUN	B
with	O	ADP	O
an	O	DET	O
intermediate	O	ADJ	B
duration	O	NOUN	I
of	O	ADP	O
action	O	NOUN	B
.	O	PUNCT	O


Levodopa	B-Chemical	NOUN	B
and	O	CCONJ	O
the	O	DET	O
DA	B-Chemical	NOUN	B
D2	O	NOUN	I
-	O	PUNCT	O
like	O	ADJ	B
receptor	O	NOUN	I
agonist	O	NOUN	I
,	O	PUNCT	O
LY-171555	B-Chemical	NOUN	B
(	O	PUNCT	O
[4aR-trans]-4,4a,5,6,7,8,8a,9-o-dihydro-5n-propyl-2H-pyrazo	B-Chemical	X	B
lo-3-4-quinoline	I-Chemical	NOUN	I
hydrochloride	I-Chemical	NOUN	I
)	O	PUNCT	O
were	O	AUX	O
also	O	ADV	O
used	O	VERB	O
for	O	ADP	O
comparison	O	NOUN	B
.	O	PUNCT	O


Acute	O	ADJ	B
administration	O	NOUN	I
of	O	ADP	O
A-86929	B-Chemical	NOUN	B
was	O	AUX	O
as	O	ADP	O
efficacious	O	ADJ	B
in	O	ADP	O
alleviating	O	VERB	O
MPTP	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
parkinsonism	B-Disease	NOUN	B
as	O	ADP	O
levodopa	B-Chemical	NOUN	B
and	O	CCONJ	O
LY-171555	B-Chemical	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
was	O	AUX	O
less	O	ADV	O
likely	O	ADJ	O
to	O	PART	O
reproduce	O	VERB	O
the	O	DET	O
levodopa	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
dyskinesias	B-Disease	NOUN	B
in	O	ADP	O
these	O	DET	O
animals	O	NOUN	B
than	O	ADP	O
with	O	ADP	O
either	O	CCONJ	O
LY-171555	B-Chemical	NOUN	B
or	O	CCONJ	O
subsequent	O	ADJ	O
challenge	O	NOUN	O
of	O	ADP	O
levodopa	B-Chemical	NOUN	B
.	O	PUNCT	O


Selective	O	ADJ	O
stimulation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
DA	B-Chemical	NOUN	B
D1	O	NOUN	I
receptor	O	NOUN	I
may	O	AUX	O
provide	O	VERB	O
better	O	ADJ	O
integration	O	NOUN	B
of	O	ADP	O
neural	O	ADJ	B
inputs	O	NOUN	B
transmitted	O	VERB	B
to	O	ADP	O
the	O	DET	O
internal	O	ADJ	B
segment	O	NOUN	I
of	O	ADP	O
the	O	DET	O
globus	O	NOUN	B
pallidus	O	NOUN	I
(	O	PUNCT	O
referred	O	VERB	O
to	O	PART	O
as	O	ADP	O
the	O	DET	O
basal	O	ADJ	B
ganglia	O	NOUN	I
output	O	NOUN	B
)	O	PUNCT	O
compared	O	VERB	O
with	O	ADP	O
levodopa	B-Chemical	NOUN	B
and	O	CCONJ	O
selective	O	ADJ	O
DA	B-Chemical	NOUN	B
D2	O	NOUN	I
receptor	O	NOUN	I
agonist	O	NOUN	B
.	O	PUNCT	O


Potent	O	ADJ	B
DA	B-Chemical	NOUN	B
D1	O	NOUN	I
receptor	O	NOUN	I
agents	O	NOUN	I
with	O	ADP	O
an	O	DET	O
intermediate	O	ADJ	B
duration	O	NOUN	I
of	O	ADP	O
efficacy	O	NOUN	B
such	O	ADJ	O
as	O	ADP	O
A-86929	B-Chemical	NOUN	B
(	O	PUNCT	O
approximately	O	ADV	O
4	O	NUM	O
hr	O	NOUN	O
at	O	ADP	O
higher	O	ADJ	B
doses	O	NOUN	B
tested	O	VERB	B
)	O	PUNCT	O
are	O	AUX	O
potential	O	ADJ	O
therapeutic	O	ADJ	B
tools	O	NOUN	I
in	O	ADP	O
PD	B-Disease	NOUN	B


Deaths	O	NOUN	B
from	O	ADP	O
local	O	ADJ	B
anesthetic	O	ADJ	B
-	O	PUNCT	O
induced	O	VERB	B
convulsions	B-Disease	NOUN	B
in	O	ADP	O
mice	O	NOUN	B
.	O	PUNCT	O


Median	O	ADJ	B
convulsant	O	NOUN	B
(	O	PUNCT	O
CD50	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
median	O	ADJ	B
lethal	O	ADJ	I
(	O	PUNCT	O
LD50	O	NOUN	B
)	O	PUNCT	O
doses	O	NOUN	B
of	O	ADP	O
three	O	NUM	O
representative	O	ADJ	O
local	O	ADJ	B
anesthetics	O	NOUN	O
were	O	AUX	O
determined	O	VERB	O
in	O	ADP	O
adult	O	ADJ	B
mice	O	NOUN	B
to	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
threat	O	NOUN	B
to	O	ADP	O
life	O	NOUN	O
of	O	ADP	O
local	O	ADJ	B
anesthetic	O	ADJ	B
-	O	PUNCT	O
induced	O	VERB	B
convulsions	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
CD50	O	NOUN	B
and	O	CCONJ	O
LD50	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
,	O	PUNCT	O
were	O	AUX	O
57	O	NUM	O
.	O	PUNCT	O


7	O	NUM	O
and	O	CCONJ	O
58	O	NUM	O
.	O	PUNCT	O


7	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
for	O	ADP	O
bupivacaine	B-Chemical	NOUN	B
,	O	PUNCT	O
111	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
and	O	CCONJ	O
133	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	O
for	O	ADP	O
lidocaine	B-Chemical	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
243	O	NUM	O
.	O	PUNCT	O


4	O	NUM	O
and	O	CCONJ	O
266	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	O
for	O	ADP	O
chloroprocaine	B-Chemical	NOUN	B
.	O	PUNCT	O


When	O	SCONJ	O
given	O	VERB	O
intraperitoneally	O	ADV	B
,	O	PUNCT	O
bupivacaine	B-Chemical	NOUN	B
thus	O	ADV	O
was	O	AUX	O
only	O	ADV	O
about	O	ADV	O
twice	O	ADV	O
as	O	ADP	O
toxic	O	ADJ	B
as	O	ADP	O
lidocaine	B-Chemical	NOUN	B
and	O	CCONJ	O
four	O	NUM	O
times	O	NOUN	O
as	O	ADP	O
toxic	O	ADJ	B
as	O	ADP	O
chloroprocaine	B-Chemical	NOUN	B
.	O	PUNCT	O


Convulsions	B-Disease	NOUN	B
always	O	ADV	O
preceded	O	VERB	O
death	O	NOUN	B
,	O	PUNCT	O
except	O	SCONJ	O
after	O	ADP	O
precipitous	O	ADJ	B
cardiopulmonary	B-Disease	ADJ	B
arrest	I-Disease	NOUN	I
from	O	ADP	O
extreme	O	ADJ	O
doses	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
CD50	O	NOUN	B
dose	O	NOUN	B
of	O	ADP	O
local	O	ADJ	B
anesthetic	O	NOUN	I
(	O	PUNCT	O
causing	O	VERB	O
convulsions	B-Disease	NOUN	B
in	O	ADP	O
50	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
mice	O	NOUN	B
)	O	PUNCT	O
was	O	AUX	O
fatal	O	ADJ	B
in	O	ADP	O
90	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
bupivacaine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
seizures	B-Disease	NOUN	B
,	O	PUNCT	O
in	O	ADP	O
57	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
chloroprocaine	B-Chemical	NOUN	B
group	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
in	O	ADP	O
6	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
lidocaine	B-Chemical	NOUN	B
group	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
narrow	O	ADJ	B
gap	O	NOUN	B
between	O	ADP	O
convulsant	O	ADJ	B
and	O	CCONJ	O
lethal	O	ADJ	B
doses	O	NOUN	I
of	O	ADP	O
local	O	ADJ	B
anesthetics	O	NOUN	I
indicates	O	VERB	O
that	O	SCONJ	O
untreated	O	ADJ	B
convulsions	B-Disease	NOUN	B


Myoclonic,	B-Disease	ADJ	B
atonic,	I-Disease	NOUN	B
and	I-Disease	CCONJ	O
absence	I-Disease	NOUN	B
seizures	I-Disease	NOUN	B
following	O	VERB	O
institution	O	NOUN	B
of	O	ADP	O
carbamazepine	B-Chemical	NOUN	B
therapy	O	NOUN	I
in	O	ADP	O
children	O	NOUN	B
.	O	PUNCT	O


Five	O	NUM	O
children	O	NOUN	B
,	O	PUNCT	O
aged	O	ADJ	B
3	O	NUM	O
to	O	PART	O
11	O	NUM	O
years	O	NOUN	B
,	O	PUNCT	O
treated	O	VERB	B
with	O	ADP	I
carbamazepine	B-Chemical	NOUN	B
for	O	ADP	O
epilepsy	B-Disease	NOUN	B
,	O	PUNCT	O
had	O	AUX	O
an	O	DET	O
acute	O	ADJ	B
aberrant	O	ADJ	O
reaction	O	NOUN	B
characterized	O	VERB	B
by	O	ADP	O
the	O	DET	O
onset	O	NOUN	O
of	O	ADP	O
myoclonic,	B-Disease	ADJ	B
atypical	I-Disease	ADJ	B
absence	I-Disease	NOUN	B
and/or	I-Disease	CCONJ	O
atonic	I-Disease	ADJ	B
(minor	I-Disease	PUNCT	O
motor)	I-Disease	ADJ	B
seizures	I-Disease	NOUN	I
within	O	ADP	O
a	O	DET	O
few	O	ADJ	O
days	O	NOUN	B
.	O	PUNCT	O


When	O	SCONJ	O
the	O	DET	O
carbamazepine	B-Chemical	NOUN	B
was	O	AUX	O
discontinued	O	VERB	B
,	O	PUNCT	O
two	O	NUM	O
of	O	ADP	O
the	O	DET	O
children	O	NOUN	B
returned	O	VERB	O
to	O	ADP	O
their	O	PRON	O
former	O	ADJ	B
state	O	NOUN	I
very	O	ADV	O
quickly	O	ADV	O
,	O	PUNCT	O
two	O	NUM	O
had	O	AUX	O
the	O	DET	O
minor	O	ADJ	O
motor	O	NOUN	B
seizures	B-Disease	NOUN	I
resolve	O	VERB	O
in	O	ADP	O
3	O	NUM	O
and	O	CCONJ	O
6	O	NUM	O
months	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
one	O	PRON	O
had	O	AUX	O
the	O	DET	O
seizures	B-Disease	NOUN	B
persist	O	VERB	O
.	O	PUNCT	O


The	O	DET	O
child	O	NOUN	B
in	O	ADP	O
whom	O	PRON	O
the	O	DET	O
seizures	B-Disease	NOUN	B
persisted	O	VERB	B
was	O	AUX	O
later	O	ADV	O
found	O	VERB	O
to	O	PART	O
have	O	AUX	O
ceroid	B-Disease	NOUN	B
lipofuscinosis	I-Disease	NOUN	B


Naloxone	B-Chemical	NOUN	B
reversal	O	NOUN	B
of	O	ADP	O
hypotension	B-Disease	NOUN	B
due	O	ADP	O
to	O	PART	O
captopril	B-Chemical	NOUN	B
overdose	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
hemodynamic	O	ADJ	B
effects	O	NOUN	B
of	O	ADP	O
captopril	B-Chemical	NOUN	B
and	O	CCONJ	O
other	O	ADJ	O
angiotensin-converting	B-Chemical	ADJ	B
enzyme	I-Chemical	NOUN	I
inhibitors	I-Chemical	NOUN	I
may	O	AUX	O
be	O	AUX	O
mediated	O	VERB	O
by	O	ADP	O
the	O	DET	O
endogenous	O	ADJ	B
opioid	O	NOUN	B
system	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
opioid	O	NOUN	B
antagonist	O	NOUN	B
naloxone	B-Chemical	NOUN	B
has	O	AUX	O
been	O	AUX	O
shown	O	VERB	O
to	O	PART	O
block	O	VERB	B
or	O	CCONJ	O
reverse	O	VERB	B
the	O	DET	O
hypotensive	B-Disease	ADJ	B
actions	O	NOUN	O
of	O	ADP	O
captopril	B-Chemical	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
a	O	DET	O
case	O	NOUN	B
of	O	ADP	O
an	O	DET	O
intentional	O	ADJ	B
captopril	B-Chemical	NOUN	B
overdose	B-Disease	NOUN	B
,	O	PUNCT	O
manifested	O	VERB	O
by	O	ADP	O
marked	O	ADJ	O
hypotension	B-Disease	NOUN	B
,	O	PUNCT	O
that	O	PRON	O
resolved	O	VERB	B
promptly	O	ADV	O
with	O	ADP	O
the	O	DET	O
administration	O	NOUN	B
of	O	ADP	O
naloxone	B-Chemical	NOUN	B
.	O	PUNCT	O


To	O	ADP	O
our	O	PRON	O
knowledge	O	NOUN	B
,	O	PUNCT	O
this	O	DET	O
is	O	AUX	O
the	O	DET	O
first	O	ADJ	O
reported	O	VERB	O
case	O	NOUN	B
of	O	ADP	O
captopril	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
hypotension	B-Disease	NOUN	B
treated	O	VERB	B
with	O	ADP	I
naloxone	B-Chemical	NOUN	B
.	O	PUNCT	O


Our	O	PRON	O
experience	O	NOUN	O
demonstrates	O	VERB	O
a	O	DET	O
possible	O	ADJ	O
role	O	NOUN	O
of	O	ADP	O
naloxone	B-Chemical	NOUN	B
in	O	ADP	O
the	O	DET	O
reversal	O	NOUN	B
of	O	ADP	O
hypotension	B-Disease	NOUN	B
resulting	O	VERB	O
from	O	ADP	O
captopril	B-Chemical	NOUN	B


Carbamazepine	B-Chemical	PROPN	B
-	O	PUNCT	O
induced	O	VERB	B
cardiac	B-Disease	ADJ	B
dysfunction	I-Disease	NOUN	I
.	O	PUNCT	O


Characterization	O	NOUN	B
of	O	ADP	O
two	O	NUM	O
distinct	O	ADJ	O
clinical	O	ADJ	B
syndromes	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
patient	O	NOUN	B
with	O	ADP	O
sinus	O	NOUN	B
bradycardia	B-Disease	NOUN	I
and	O	CCONJ	O
atrioventricular	B-Disease	ADJ	B
block	I-Disease	NOUN	I
,	O	PUNCT	O
induced	O	VERB	B
by	O	ADP	O
carbamazepine	B-Chemical	NOUN	B
,	O	PUNCT	O
prompted	O	VERB	O
an	O	DET	O
extensive	O	ADJ	B
literature	O	NOUN	B
review	O	NOUN	I
of	O	ADP	O
all	O	DET	O
previously	O	ADV	O
reported	O	VERB	O
cases	O	NOUN	B
.	O	PUNCT	O


From	O	ADP	O
the	O	DET	O
analysis	O	NOUN	B
of	O	ADP	O
these	O	DET	O
cases	O	NOUN	B
,	O	PUNCT	O
two	O	NUM	O
distinct	O	ADJ	O
forms	O	NOUN	O
of	O	ADP	O
carbamazepine	B-Chemical	NOUN	B
-	O	PUNCT	O
associated	O	VERB	B
cardiac	B-Disease	ADJ	B
dysfunction	I-Disease	NOUN	I
emerged	O	VERB	O
.	O	PUNCT	O


One	O	NUM	O
patient	O	NOUN	B
group	O	NOUN	I
developed	O	VERB	O
sinus	B-Disease	NOUN	B
tachycardias	I-Disease	NOUN	I
in	O	ADP	O
the	O	DET	O
setting	O	NOUN	O
of	O	ADP	O
a	O	DET	O
massive	O	ADJ	B
carbamazepine	B-Chemical	NOUN	B
overdose	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
second	O	ADJ	O
group	O	NOUN	B
consisted	O	VERB	O
almost	O	ADV	O
exclusively	O	ADV	O
of	O	ADP	O
elderly	O	ADJ	B
women	O	NOUN	I
who	O	PRON	O
developed	O	VERB	O
potentially	O	ADV	O
life	O	NOUN	B
-	O	PUNCT	O
threatening	O	VERB	B
bradyarrhythmias	B-Disease	NOUN	B
or	O	CCONJ	O
atrioventricular	B-Disease	ADJ	B
conduction	I-Disease	NOUN	I
delay	I-Disease	NOUN	I
,	O	PUNCT	O
associated	O	VERB	B
with	O	ADP	I
either	O	CCONJ	O
therapeutic	O	ADJ	B
or	O	CCONJ	O
modestly	O	ADV	O
elevated	O	ADJ	B
carbamazepine	B-Chemical	NOUN	B
serum	O	NOUN	O
levels	O	NOUN	O
.	O	PUNCT	O


Because	O	SCONJ	O
carbamazepine	B-Chemical	NOUN	B
is	O	AUX	O
widely	O	ADV	O
used	O	VERB	O
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
many	O	ADJ	O
neurologic	O	ADJ	B
and	O	CCONJ	O
psychiatric	B-Disease	ADJ	B


Glutamatergic	O	ADJ	B
neurotransmission	O	NOUN	I
mediated	O	VERB	O
by	O	ADP	O
NMDA	B-Chemical	NOUN	B
receptors	O	NOUN	I
in	O	ADP	O
the	O	DET	O
inferior	O	ADJ	B
colliculus	O	NOUN	I
can	O	AUX	O
modulate	O	VERB	O
haloperidol	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
catalepsy	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
inferior	O	ADJ	B
colliculus	O	NOUN	I
(	O	PUNCT	O
IC	O	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
primarily	O	ADV	O
involved	O	VERB	O
in	O	ADP	O
the	O	DET	O
processing	O	NOUN	B
of	O	ADP	O
auditory	O	ADJ	B
information	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
it	O	PRON	O
is	O	AUX	O
distinguished	O	VERB	O
from	O	ADP	O
other	O	ADJ	O
auditory	O	ADJ	B
nuclei	O	NOUN	I
in	O	ADP	O
the	O	DET	O
brainstem	O	NOUN	B
by	O	ADP	O
its	O	PRON	O
connections	O	NOUN	B
with	O	ADP	O
structures	O	NOUN	B
of	O	ADP	O
the	O	DET	O
motor	O	NOUN	B
system	O	NOUN	I
.	O	PUNCT	O


Functional	O	ADJ	B
evidence	O	NOUN	B
relating	O	VERB	O
the	O	DET	O
IC	O	NOUN	B
to	O	PART	O
motor	O	NOUN	B
behavior	O	NOUN	I
derives	O	VERB	O
from	O	ADP	O
experiments	O	NOUN	B
showing	O	VERB	O
that	O	SCONJ	O
activation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
IC	O	NOUN	B
by	O	ADP	O
electrical	O	ADJ	B
stimulation	O	NOUN	I
or	O	CCONJ	O
excitatory	O	ADJ	B
amino	B-Chemical	NOUN	B
acid	I-Chemical	NOUN	I
microinjection	O	NOUN	I
causes	O	VERB	O
freezing	O	NOUN	B
,	O	PUNCT	O
escape	O	NOUN	B
-	O	PUNCT	O
like	O	ADJ	B
behavior	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
immobility	O	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
nature	O	NOUN	O
of	O	ADP	O
this	O	DET	O
immobility	O	NOUN	B
is	O	AUX	O
still	O	ADV	O
unclear	O	ADJ	O
.	O	PUNCT	O


The	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
examined	O	VERB	O
the	O	DET	O
influence	O	NOUN	B
of	O	ADP	O
excitatory	O	ADJ	B
amino	B-Chemical	NOUN	B
acid	I-Chemical	NOUN	I
-	O	PUNCT	O
mediated	O	VERB	B
mechanisms	O	NOUN	B
in	O	ADP	O
the	O	DET	O
IC	O	NOUN	B
on	O	ADP	O
the	O	DET	O
catalepsy	B-Disease	NOUN	B
induced	O	VERB	B
by	O	ADP	O
the	O	DET	O
dopamine	B-Chemical	NOUN	B
receptor	O	NOUN	I
blocker	O	NOUN	I
haloperidol	B-Chemical	NOUN	B
administered	O	VERB	B
systemically	O	ADV	B
(	O	PUNCT	O
1	O	NUM	O
or	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
rats	O	NOUN	B
.	O	PUNCT	O


Haloperidol	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
catalepsy	B-Disease	NOUN	B
was	O	AUX	O
challenged	O	VERB	O
with	O	ADP	O
prior	O	ADJ	O
intracollicular	O	ADJ	B
microinjections	O	NOUN	B
of	O	ADP	O
glutamate	B-Chemical	NOUN	B
NMDA	B-Chemical	NOUN	I
receptor	O	NOUN	I
antagonists	O	NOUN	B
,	O	PUNCT	O
MK-801	B-Chemical	NOUN	B
(	O	PUNCT	O
15	O	NUM	O
or	O	CCONJ	O
30	O	NUM	O
mmol	O	NOUN	O
/	O	SYM	O
0	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
microl	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
AP7	B-Chemical	NOUN	B
(	O	PUNCT	O
10	O	NUM	O
or	O	CCONJ	O
20	O	NUM	O
nmol	O	NOUN	O
/	O	SYM	O
0	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
microl	O	NOUN	B
),	O	PUNCT	O
or	O	CCONJ	O
of	O	ADP	O
the	O	DET	O
NMDA	B-Chemical	NOUN	B
receptor	O	NOUN	I
agonist	O	NOUN	B
N-methyl-d-aspartate	B-Chemical	NOUN	B
(	O	PUNCT	O
NMDA	B-Chemical	NOUN	B
,	O	PUNCT	O
20	O	NUM	O
or	O	CCONJ	O
30	O	NUM	O
nmol	O	NOUN	O
/	O	SYM	O
0	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
microl	O	NOUN	B
).	O	PUNCT	O
The	O	DET	O
results	O	NOUN	B
showed	O	VERB	O
that	O	SCONJ	O
intracollicular	O	ADJ	B
microinjection	O	NOUN	B
of	O	ADP	O
MK-801	B-Chemical	NOUN	B
and	O	CCONJ	O
AP7	B-Chemical	NOUN	B
previous	O	ADJ	O
to	O	PART	O
systemic	O	ADJ	B
injections	O	NOUN	I
of	O	ADP	O
haloperidol	B-Chemical	NOUN	B
significantly	O	ADV	O
attenuated	O	VERB	B
the	O	DET	O
catalepsy	B-Disease	NOUN	B
,	O	PUNCT	O
as	O	ADP	O
indicated	O	VERB	O
by	O	ADP	O
a	O	DET	O
reduced	O	VERB	B
latency	O	NOUN	B
to	O	PART	O
step	O	VERB	O
down	O	ADP	O
from	O	ADP	O
a	O	DET	O
horizontal	O	ADJ	B
bar	O	NOUN	I
.	O	PUNCT	O


Accordingly	O	ADV	O
,	O	PUNCT	O
intracollicular	O	ADJ	B
microinjection	O	NOUN	B
of	O	ADP	O
NMDA	B-Chemical	NOUN	B
increased	O	VERB	B
the	O	DET	O
latency	O	NOUN	B
to	O	PART	O
step	O	VERB	O
down	O	ADP	O
the	O	DET	O
bar	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
findings	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
glutamate	B-Chemical	NOUN	B
-	O	PUNCT	O
mediated	O	VERB	B
mechanisms	O	NOUN	B
in	O	ADP	O
the	O	DET	O
neural	O	ADJ	B
circuits	O	NOUN	I
at	O	ADP	O
the	O	DET	O
IC	O	NOUN	B
level	O	NOUN	B
influence	O	VERB	B
haloperidol	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
catalepsy	B-Disease	NOUN	B


Metabotropic	O	ADJ	B
glutamate	B-Chemical	NOUN	I
7	O	NUM	I
receptor	O	NOUN	I
subtype	O	NOUN	B
modulates	O	VERB	B
motor	O	NOUN	B
symptoms	O	NOUN	I
in	O	ADP	O
rodent	O	ADJ	B
models	O	NOUN	B
of	O	ADP	O
Parkinson's	B-Disease	ADJ	B
disease	I-Disease	NOUN	I
.	O	PUNCT	O


Metabotropic	O	ADJ	B
glutamate	B-Chemical	NOUN	I
(	O	PUNCT	I
mGlu	O	NOUN	B
)	O	PUNCT	O
receptors	O	NOUN	O
modulate	O	VERB	B
synaptic	O	ADJ	B
transmission	O	NOUN	I
in	O	ADP	O
the	O	DET	O
central	O	ADJ	B
nervous	O	ADJ	I
system	O	NOUN	I
and	O	CCONJ	O
represent	O	VERB	O
promising	O	ADJ	O
therapeutic	O	ADJ	B
targets	O	NOUN	O
for	O	ADP	O
symptomatic	O	ADJ	B
treatment	O	NOUN	B
of	O	ADP	O
Parkinson's	B-Disease	ADJ	B
disease	I-Disease	NOUN	I
(	O	PUNCT	O
PD	B-Disease	NOUN	B
).	O	PUNCT	O
Among	O	ADP	O
the	O	DET	O
eight	O	NUM	O
mGlu	O	NOUN	B
receptor	O	NOUN	I
subtypes	O	NOUN	B
,	O	PUNCT	O
mGlu7	O	NOUN	B
receptor	O	NOUN	I
is	O	AUX	O
prominently	O	ADV	O
expressed	O	VERB	B
in	O	ADP	O
the	O	DET	O
basal	O	ADJ	B
ganglia	O	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
its	O	PRON	O
role	O	NOUN	O
in	O	ADP	O
restoring	O	VERB	B
motor	O	NOUN	B
function	O	NOUN	I
in	O	ADP	O
animal	O	NOUN	B
models	O	NOUN	I
of	O	ADP	O
PD	B-Disease	NOUN	B
is	O	AUX	O
not	O	PART	O
known	O	VERB	O
.	O	PUNCT	O


The	O	DET	O
effects	O	NOUN	B
of	O	ADP	O
N,N'-dibenzhydrylethane-1,2-diamine	B-Chemical	NOUN	B
dihydrochloride	I-Chemical	NOUN	I
(	O	PUNCT	O
AMN082	B-Chemical	NOUN	B
),	O	PUNCT	O
the	O	DET	O
first	O	ADJ	O
selective	O	ADJ	O
allosteric	O	ADJ	B
activator	O	NOUN	I
of	O	ADP	O
mGlu7	O	NOUN	B
receptors	O	NOUN	I
,	O	PUNCT	O
were	O	AUX	O
thus	O	ADV	O
tested	O	VERB	B
in	O	ADP	O
different	O	ADJ	O
rodent	O	ADJ	B
models	O	NOUN	B
of	O	ADP	O
PD	B-Disease	NOUN	B
.	O	PUNCT	O


Here	O	ADV	O
,	O	PUNCT	O
we	O	PRON	O
show	O	VERB	O
that	O	SCONJ	O
oral	O	ADJ	B
(	O	PUNCT	O
5	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
)	O	PUNCT	O
or	O	CCONJ	O
intrastriatal	O	ADJ	B
administration	O	NOUN	I
(	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
and	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
nmol	O	NOUN	O
)	O	PUNCT	O
of	O	ADP	O
AMN082	B-Chemical	NOUN	B
reverses	O	VERB	O
haloperidol	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
catalepsy	B-Disease	NOUN	B
in	O	ADP	O
rats	O	NOUN	B
.	O	PUNCT	O


AMN082	B-Chemical	NOUN	B
(	O	PUNCT	O
2	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
and	O	CCONJ	O
5	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
)	O	PUNCT	O
reduces	O	VERB	B
apomorphine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
rotations	O	NOUN	B
in	O	ADP	O
unilateral	O	ADJ	B
6-hydroxydopamine	B-Chemical	NOUN	B
(	O	PUNCT	O
6-OHDA	B-Chemical	NOUN	B
)-	O	ADJ	O
lesioned	O	ADJ	B
rats	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
a	O	DET	O
more	O	ADV	O
complex	O	ADJ	B
task	O	NOUN	B
commonly	O	ADV	O
used	O	VERB	O
to	O	PART	O
evaluate	O	VERB	B
major	O	ADJ	O
akinetic	B-Disease	ADJ	B
symptoms	O	NOUN	O
of	O	ADP	O
PD	B-Disease	NOUN	B
patients	O	NOUN	B
,	O	PUNCT	O
5	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
AMN082	B-Chemical	NOUN	B
reverses	O	VERB	B
the	O	DET	O
increased	O	VERB	B
reaction	O	NOUN	B
time	O	NOUN	O
to	O	PART	O
respond	O	VERB	O
to	O	PART	O
a	O	DET	O
cue	O	NOUN	B
of	O	ADP	O
bilateral	O	ADJ	B
6-OHDA	B-Chemical	NOUN	B
-	O	PUNCT	O
lesioned	O	VERB	B
rats	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
,	O	PUNCT	O
AMN082	B-Chemical	NOUN	B
reduces	O	VERB	B
the	O	DET	O
duration	O	NOUN	B
of	O	ADP	O
haloperidol	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
catalepsy	B-Disease	NOUN	B
in	O	ADP	O
a	O	DET	O
mGlu7	O	NOUN	B
receptor	O	NOUN	I
-	O	PUNCT	O
dependent	O	ADJ	B
manner	O	NOUN	O
in	O	ADP	O
wild	O	ADJ	B
-	O	PUNCT	O
type	O	NOUN	B
but	O	CCONJ	O
not	O	PART	O
mGlu7	O	NOUN	B
receptor	O	NOUN	I
knockout	O	NOUN	B
mice	O	NOUN	I
.	O	PUNCT	O


Higher	O	ADJ	B
doses	O	NOUN	B
of	O	ADP	O
AMN082	B-Chemical	NOUN	B
(	O	PUNCT	O
10	O	NUM	O
and	O	CCONJ	O
20	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	O
p	O	NOUN	O
.	O	PUNCT	O


o	O	INTJ	O
.)	O	NOUN	O
have	O	AUX	O
no	O	DET	O
effect	O	NOUN	O
on	O	ADP	O
the	O	DET	O
same	O	ADJ	O
models	O	NOUN	B
of	O	ADP	O
PD	B-Disease	NOUN	B
.	O	PUNCT	O


Overall	O	ADV	O
these	O	DET	O
findings	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
mGlu7	O	NOUN	B
receptor	O	NOUN	I
activation	O	NOUN	B
can	O	AUX	O
reverse	O	VERB	B
motor	O	NOUN	I
dysfunction	O	NOUN	I
associated	O	VERB	B
with	O	ADP	I
reduced	O	VERB	B
dopamine	B-Chemical	NOUN	B


Nimodipine	B-Chemical	NOUN	B
prevents	O	VERB	B
memory	B-Disease	NOUN	B
impairment	I-Disease	NOUN	I
caused	O	VERB	O
by	O	ADP	O
nitroglycerin	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
hypotension	B-Disease	NOUN	B
in	O	ADP	O
adult	O	ADJ	B
mice	O	NOUN	B
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
:	O	PUNCT	O
Hypotension	B-Disease	NOUN	B
and	O	CCONJ	O
a	O	DET	O
resultant	O	ADJ	O
decrease	O	NOUN	B
in	O	ADP	O
cerebral	O	ADJ	B
blood	O	NOUN	I
flow	O	NOUN	I
have	O	AUX	O
been	O	AUX	O
implicated	O	VERB	O
in	O	ADP	O
the	O	DET	O
development	O	NOUN	B
of	O	ADP	O
cognitive	B-Disease	ADJ	B
dysfunction	I-Disease	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
tested	O	VERB	B
the	O	DET	O
hypothesis	O	NOUN	B
that	O	SCONJ	O
nimodipine	B-Chemical	NOUN	B
(	O	PUNCT	O
NIMO	B-Chemical	NOUN	B
)	O	PUNCT	O
administered	O	VERB	B
at	O	ADP	O
the	O	DET	O
onset	O	NOUN	B
of	O	ADP	I
nitroglycerin	B-Chemical	NOUN	B
(	O	PUNCT	O
NTG	B-Chemical	NOUN	B
)-	O	ADJ	O
induced	O	VERB	B
hypotension	B-Disease	NOUN	B
would	O	AUX	O
preserve	O	VERB	O
long	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
associative	O	NOUN	B
memory	O	NOUN	I
.	O	PUNCT	O


METHODS	O	NOUN	O
:	O	PUNCT	O
The	O	DET	O
passive	O	ADJ	B
avoidance	O	NOUN	I
(	O	PUNCT	O
PA	O	NOUN	B
)	O	PUNCT	O
paradigm	O	NOUN	B
was	O	AUX	O
used	O	VERB	O
to	O	PART	O
assess	O	VERB	B
memory	O	NOUN	B
retention	O	NOUN	I
.	O	PUNCT	O


For	O	ADP	O
PA	O	PROPN	B
training	O	NOUN	I
,	O	PUNCT	O
latencies	O	NOUN	B
(	O	PUNCT	O
seconds	O	NOUN	B
)	O	PUNCT	O
were	O	AUX	O
recorded	O	VERB	O
for	O	ADP	O
entry	O	NOUN	B
from	O	ADP	O
a	O	DET	O
suspended	O	VERB	O
platform	O	NOUN	O
into	O	ADP	O
a	O	DET	O
Plexiglas	O	PROPN	B
tube	O	NOUN	I
where	O	SCONJ	O
a	O	DET	O
shock	O	NOUN	B
was	O	AUX	O
automatically	O	ADV	B
delivered	O	VERB	O
.	O	PUNCT	O


Latencies	O	NOUN	B
were	O	AUX	O
recorded	O	VERB	O
48	O	NUM	O
h	O	NOUN	O
later	O	ADV	O
for	O	ADP	O
a	O	DET	O
testing	O	NOUN	B
trial	O	NOUN	I
.	O	PUNCT	O


Ninety	O	NUM	B
-	O	PUNCT	O
six	O	NUM	B
Swiss	O	ADJ	B
-	O	PUNCT	O
Webster	O	PROPN	B
mice	O	NOUN	I
(	O	PUNCT	O
30	O	NUM	O
-	O	SYM	O
35	O	NUM	O
g	O	NOUN	O
,	O	PUNCT	O
6	O	NUM	O
-	O	SYM	O
8	O	NUM	O
wk	O	NOUN	O
),	O	PUNCT	O
were	O	AUX	O
randomized	O	VERB	B
into	O	ADP	O
6	O	NUM	O
groups	O	NOUN	B
1	O	NUM	O
)	O	PUNCT	O
saline	O	NOUN	B
(	O	PUNCT	O
control	O	NOUN	B
),	O	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
NTG	B-Chemical	NOUN	B
immediately	O	ADV	O
after	O	ADP	O
learning	O	NOUN	B
,	O	PUNCT	O
3	O	X	O
)	O	PUNCT	O
NTG	B-Chemical	NOUN	B
3	O	NUM	O
h	O	NOUN	O
after	O	ADP	O
learning	O	NOUN	B
,	O	PUNCT	O
4	O	X	O
)	O	PUNCT	O
NTG	B-Chemical	NOUN	B
and	O	CCONJ	O
NIMO	B-Chemical	NOUN	B
,	O	PUNCT	O
5	O	NUM	O
)	O	PUNCT	O
vehicle	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
6	O	NUM	O
)	O	PUNCT	O
NIMO	B-Chemical	NOUN	B
alone	O	ADV	O
.	O	PUNCT	O


The	O	DET	O
extent	O	NOUN	O
of	O	ADP	O
hypotension	B-Disease	NOUN	B
and	O	CCONJ	O
changes	O	NOUN	B
in	O	ADP	O
brain	O	NOUN	B
tissue	O	NOUN	I
oxygenation	O	NOUN	I
(	O	PUNCT	O
PbtO	O	NOUN	B
(	O	PUNCT	O
2	O	NUM	O
))	O	PUNCT	O
and	O	CCONJ	O
in	O	ADP	O
cerebral	O	ADJ	B
blood	O	NOUN	I
flow	O	NOUN	I
were	O	AUX	O
studied	O	VERB	O
in	O	ADP	O
a	O	DET	O
separate	O	ADJ	O
group	O	NOUN	B
of	O	ADP	O
animals	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
All	O	DET	O
groups	O	NOUN	B
exhibited	O	VERB	O
similar	O	ADJ	O
training	O	NOUN	B
latencies	O	NOUN	B
(	O	PUNCT	O
17	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
+/-	O	CCONJ	O
4	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
s	O	NOUN	O
).	O	PUNCT	B
Mice	O	NOUN	B
subjected	O	VERB	O
to	O	ADP	O
hypotensive	B-Disease	ADJ	B
episodes	O	NOUN	I
showed	O	VERB	O
a	O	DET	O
significant	O	ADJ	O
decrease	O	NOUN	B
in	O	ADP	O
latency	O	NOUN	B
time	O	NOUN	I
(	O	PUNCT	O
178	O	NUM	O
+/-	O	CCONJ	O
156	O	NUM	O
s	O	NOUN	O
)	O	PUNCT	O
compared	O	VERB	B
with	O	ADP	O
those	O	DET	O
injected	O	VERB	B
with	O	ADP	O
saline	O	NOUN	B
,	O	PUNCT	O
NTG	B-Chemical	NOUN	B
+	O	CCONJ	O
NIMO	B-Chemical	NOUN	B
,	O	PUNCT	O
or	O	CCONJ	O
delayed	O	VERB	B
NTG	B-Chemical	NOUN	B
(	O	PUNCT	O
580	O	NUM	O
+/-	O	CCONJ	O
81	O	NUM	O
s	O	NOUN	O
,	O	PUNCT	O
557	O	NUM	O
+/-	O	CCONJ	O
67	O	NUM	O
s	O	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
493	O	NUM	O
+/-	O	CCONJ	O
146	O	NUM	O
s	O	NOUN	O
,	O	PUNCT	O
respectively	O	ADV	O
).	O	PUNCT	O
A	O	DET	O
Kruskal	O	PROPN	B
-	O	PUNCT	O
Wallis	O	PROPN	B
1	O	NUM	I
-	O	PUNCT	O
way	O	NOUN	B
analysis	O	NOUN	I
of	O	ADP	I
variance	O	NOUN	I
indicated	O	VERB	O
a	O	DET	O
significant	O	ADJ	O
difference	O	NOUN	O
among	O	ADP	O
the	O	DET	O
4	O	NUM	O
treatment	O	NOUN	B
groups	O	NOUN	I
(	O	PUNCT	O
H	O	NOUN	O
=	O	ADJ	O
15	O	NUM	O
.	O	PUNCT	O


34	O	NUM	O
;	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


001	O	NUM	O
).	O	PUNCT	O
In	O	ADP	O
a	O	DET	O
separate	O	ADJ	O
group	O	NOUN	B
of	O	ADP	O
mice	O	NOUN	B
not	O	PART	O
subjected	O	VERB	O
to	O	ADP	O
behavioral	O	ADJ	B
studies	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
same	O	ADJ	O
dose	O	NOUN	B
of	O	ADP	O
NTG	B-Chemical	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
3	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
NTG	B-Chemical	NOUN	B
+	O	CCONJ	O
NIMO	B-Chemical	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
3	O	NUM	O
)	O	PUNCT	O
caused	O	VERB	O
mean	O	ADJ	O
arterial	O	ADJ	B
blood	O	NOUN	I
pressure	O	NOUN	I
to	O	PART	O
decrease	O	VERB	B
from	O	ADP	O
85	O	NUM	O
.	O	PUNCT	O


9	O	NUM	O
+/-	O	CCONJ	O
3	O	NUM	O
.	O	PUNCT	O


8	O	NUM	O
mm	O	X	B
Hg	O	X	I
sem	O	VERB	I
to	O	ADP	O
31	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
+/-	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


8	O	NUM	O
mm	O	X	B
Hg	O	X	I
sem	O	NOUN	I
and	O	CCONJ	O
from	O	ADP	O
86	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
+/-	O	CCONJ	O
3	O	NUM	O
.	O	PUNCT	O


7	O	NUM	O
mm	O	X	B
Hg	O	X	I
sem	O	VERB	I
to	O	ADP	O
32	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
+/-	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
mm	O	X	B
Hg	O	X	I
sem	O	NOUN	I
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


Mean	O	VERB	O
arterial	O	ADJ	B
blood	O	NOUN	I
pressure	O	NOUN	I
in	O	ADP	O
mice	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
NIMO	B-Chemical	NOUN	B
alone	O	ADV	O
decreased	O	VERB	B
from	O	ADP	O
88	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
+/-	O	CCONJ	O
3	O	NUM	O
.	O	PUNCT	O


8	O	NUM	O
mm	O	X	B
Hg	O	NOUN	I
to	O	PART	O
80	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
+/-	O	CCONJ	O
2	O	NUM	O
.	O	PUNCT	O


9	O	NUM	O
mm	O	NOUN	B
Hg	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
intergroup	O	NOUN	B
difference	O	NOUN	O
was	O	AUX	O
statistically	O	ADV	B
significant	O	ADJ	I
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


05	O	NUM	O
).	O	NOUN	B
PbtO	O	NOUN	B
(	O	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
decreased	O	VERB	B
from	O	ADP	O
51	O	NUM	O
.	O	PUNCT	O


7	O	NUM	O
+/-	O	CCONJ	O
4	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
mm	O	X	B
Hg	O	X	I
sem	O	VERB	I
to	O	ADP	O
33	O	NUM	O
.	O	PUNCT	O


8	O	NUM	O
+/-	O	CCONJ	O
5	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
mm	O	X	B
Hg	O	X	I
sem	O	NOUN	I
in	O	ADP	O
the	O	DET	O
NTG	B-Chemical	NOUN	B
group	O	NOUN	B
and	O	CCONJ	O
from	O	ADP	O
38	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
+/-	O	CCONJ	O
6	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
mm	O	X	B
Hg	O	X	I
sem	O	NOUN	I
to	O	ADP	O
25	O	NUM	O
.	O	PUNCT	O


4	O	NUM	O
+/-	O	CCONJ	O
2	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
mm	O	X	B
Hg	O	X	I
sem	O	NOUN	I
in	O	ADP	O
the	O	DET	O
NTG	B-Chemical	NOUN	B
+	O	CCONJ	O
NIMO	B-Chemical	NOUN	B
groups	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


There	O	PRON	O
were	O	AUX	O
no	O	DET	O
significant	O	ADJ	O
differences	O	NOUN	O
among	O	ADP	O
groups	O	NOUN	B
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
:	O	PUNCT	O
In	O	ADP	O
a	O	DET	O
PA	O	NOUN	B
retention	O	NOUN	I
paradigm	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
injection	O	NOUN	B
of	O	ADP	O
NTG	B-Chemical	NOUN	B
immediately	O	ADV	O
after	O	ADP	O
learning	O	NOUN	B
produced	O	VERB	O
a	O	DET	O
significant	O	ADJ	O
impairment	O	NOUN	B
of	O	ADP	O
long	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
associative	O	NOUN	B
memory	O	NOUN	I
in	O	ADP	O
mice	O	NOUN	B
,	O	PUNCT	O
whereas	O	SCONJ	O
delayed	O	VERB	B
induced	O	VERB	B
hypotension	B-Disease	NOUN	B
had	O	AUX	O
no	O	DET	B
effect	O	NOUN	I
.	O	PUNCT	O


NIMO	B-Chemical	NOUN	B
attenuated	O	VERB	B
the	O	DET	O
disruption	O	NOUN	B
in	O	ADP	O
consolidation	O	NOUN	B
of	O	ADP	O
long	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
memory	O	NOUN	B
caused	O	VERB	O
by	O	ADP	O
NTG	B-Chemical	NOUN	B
but	O	CCONJ	O
did	O	AUX	O
not	O	PART	O
improve	O	VERB	O
latency	O	NOUN	B
in	O	ADP	O
the	O	DET	O
absence	O	NOUN	B
of	O	ADP	O
hypotension	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
observed	O	VERB	O
effect	O	NOUN	B
of	O	ADP	O
NIMO	B-Chemical	NOUN	B
may	O	AUX	O
have	O	AUX	O
been	O	AUX	O
attributable	O	ADJ	O
to	O	ADP	O
the	O	DET	O
preservation	O	NOUN	B
of	O	ADP	O
calcium	B-Chemical	NOUN	B
homeostasis	O	NOUN	O
during	O	ADP	O
hypotension	B-Disease	NOUN	B


Fatal	O	ADJ	B
haemopericardium	B-Disease	NOUN	O
and	O	CCONJ	O
gastrointestinal	B-Disease	ADJ	B
haemorrhage	I-Disease	NOUN	I
due	O	ADJ	O
to	O	PART	O
possible	O	ADJ	O
interaction	O	NOUN	B
of	O	ADP	O
cranberry	O	ADJ	B
juice	O	NOUN	I
with	O	ADP	O
warfarin	B-Chemical	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
a	O	DET	O
case	O	NOUN	B
of	O	ADP	O
fatal	O	ADJ	B
internal	O	ADJ	B
haemorrhage	B-Disease	NOUN	I
in	O	ADP	O
an	O	DET	O
elderly	O	ADJ	B
man	O	NOUN	I
who	O	PRON	O
consumed	O	VERB	O
only	O	ADV	O
cranberry	O	ADJ	B
juice	O	NOUN	I
for	O	ADP	O
two	O	NUM	O
weeks	O	NOUN	B
while	O	SCONJ	O
maintaining	O	VERB	O
his	O	PRON	O
usual	O	ADJ	O
dosage	O	NOUN	B
of	O	ADP	O
warfarin	B-Chemical	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
propose	O	VERB	O
that	O	SCONJ	O
naturally	O	ADV	O
occurring	O	VERB	O
compounds	O	NOUN	B
such	O	ADJ	O
as	O	ADP	O
flavonoids	B-Chemical	NOUN	B
,	O	PUNCT	O
which	O	DET	O
are	O	AUX	O
present	O	ADJ	O
in	O	ADP	O
fruit	O	NOUN	B
juices	O	NOUN	I
,	O	PUNCT	O
may	O	AUX	O
increase	O	VERB	B
the	O	DET	O
potency	O	NOUN	B
of	O	ADP	O
warfarin	B-Chemical	NOUN	B
by	O	ADP	O
competing	O	VERB	O
for	O	ADP	O
the	O	DET	O
enzymes	O	NOUN	B
that	O	PRON	O
normally	O	ADV	O
inactivate	O	VERB	B
warfarin	B-Chemical	NOUN	B


Isoproterenol	B-Chemical	NOUN	B
induces	O	VERB	O
primary	O	ADJ	B
loss	O	NOUN	I
of	O	ADP	O
dystrophin	O	NOUN	B
in	O	ADP	O
rat	O	NOUN	B
hearts	O	NOUN	B
:	O	PUNCT	O
correlation	O	NOUN	B
with	O	ADP	O
myocardial	B-Disease	ADJ	B
injury	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
mechanism	O	NOUN	B
of	O	ADP	O
isoproterenol	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
myocardial	B-Disease	ADJ	B
damage	I-Disease	NOUN	I
is	O	AUX	O
unknown	O	ADJ	O
,	O	PUNCT	O
but	O	CCONJ	O
a	O	DET	O
mismatch	O	NOUN	B
of	O	ADP	O
oxygen	B-Chemical	NOUN	B
supply	O	NOUN	I
vs	O	CCONJ	O
.	O	PUNCT	O


demand	O	NOUN	O
following	O	VERB	O
coronary	O	ADJ	B
hypotension	B-Disease	NOUN	I
and	O	CCONJ	O
myocardial	B-Disease	ADJ	B
hyperactivity	I-Disease	NOUN	I
is	O	AUX	O
the	O	DET	O
best	O	ADJ	O
explanation	O	NOUN	B
for	O	ADP	O
the	O	DET	O
complex	O	ADJ	B
morphological	O	ADJ	B
alterations	O	NOUN	B
observed	O	VERB	B
.	O	PUNCT	O


Severe	O	ADJ	B
alterations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
structural	O	ADJ	B
integrity	O	NOUN	B
of	O	ADP	O
the	O	DET	O
sarcolemma	O	NOUN	B
of	O	ADP	O
cardiomyocytes	O	NOUN	B
have	O	AUX	O
been	O	AUX	O
demonstrated	O	VERB	O
to	O	PART	O
be	O	AUX	O
caused	O	VERB	O
by	O	ADP	O
isoproterenol	B-Chemical	NOUN	B
.	O	PUNCT	O


Taking	O	VERB	O
into	O	ADP	O
account	O	NOUN	O
that	O	SCONJ	O
the	O	DET	O
sarcolemmal	O	ADJ	B
integrity	O	NOUN	B
is	O	AUX	O
stabilized	O	VERB	B
by	O	ADP	O
the	O	DET	O
dystrophin	O	NOUN	B
-	O	PUNCT	O
glycoprotein	O	NOUN	B
complex	O	NOUN	I
(	O	PUNCT	O
DGC	O	NOUN	B
)	O	PUNCT	O
that	O	PRON	O
connects	O	VERB	O
actin	O	NOUN	B
and	O	CCONJ	O
laminin	O	NOUN	B
in	O	ADP	O
contractile	O	NOUN	B
machinery	O	NOUN	I
and	O	CCONJ	O
extracellular	O	ADJ	B
matrix	O	NOUN	I
and	O	CCONJ	O
by	O	ADP	O
integrins	O	NOUN	B
,	O	PUNCT	O
this	O	DET	O
study	O	NOUN	B
tests	O	VERB	I
the	O	DET	O
hypothesis	O	NOUN	B
that	O	SCONJ	O
isoproterenol	B-Chemical	NOUN	B
affects	O	VERB	O
sarcolemmal	O	ADJ	B
stability	O	NOUN	I
through	O	ADP	O
changes	O	NOUN	B
in	O	ADP	O
the	O	DET	O
DGC	O	NOUN	B
and	O	CCONJ	O
integrins	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
found	O	VERB	O
different	O	ADJ	O
sensitivity	O	NOUN	B
of	O	ADP	O
the	O	DET	O
DGC	O	NOUN	B
and	O	CCONJ	O
integrin	O	NOUN	B
to	O	PART	O
isoproterenol	B-Chemical	NOUN	B
subcutaneous	O	ADJ	B
administration	O	NOUN	I
.	O	PUNCT	O


Immunofluorescent	O	ADJ	B
staining	O	NOUN	I
revealed	O	VERB	O
that	O	SCONJ	O
dystrophin	O	NOUN	B
is	O	AUX	O
the	O	DET	O
most	O	ADV	O
sensitive	O	ADJ	B
among	O	ADP	O
the	O	DET	O
structures	O	NOUN	B
connecting	O	VERB	O
the	O	DET	O
actin	O	NOUN	B
in	O	ADP	O
the	O	DET	O
cardiomyocyte	O	NOUN	B
cytoskeleton	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
extracellular	O	ADJ	B
matrix	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
sarcomeric	O	ADJ	B
actin	O	NOUN	I
dissolution	O	NOUN	B
occurred	O	VERB	O
after	O	ADP	O
the	O	DET	O
reduction	O	NOUN	B
or	O	CCONJ	O
loss	O	NOUN	B
of	O	ADP	O
dystrophin	O	NOUN	B
.	O	PUNCT	O


Subsequently	O	ADV	O
,	O	PUNCT	O
after	O	ADP	O
lysis	O	NOUN	B
of	O	ADP	O
myofilaments	O	NOUN	B
,	O	PUNCT	O
gamma	O	NOUN	B
-	O	PUNCT	O
sarcoglycan	O	NOUN	B
,	O	PUNCT	O
beta	O	NOUN	B
-	O	PUNCT	O
dystroglycan	O	NOUN	B
,	O	PUNCT	O
beta1	O	NOUN	B
-	O	PUNCT	O
integrin	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
laminin	O	NOUN	B
alpha	O	NOUN	I
-	O	PUNCT	O
2	O	NUM	B
expressions	O	NOUN	B
were	O	AUX	O
reduced	O	VERB	B
followed	O	VERB	O
by	O	ADP	O
their	O	PRON	O
breakdown	O	NOUN	B
,	O	PUNCT	O
as	O	ADP	O
epiphenomena	O	ADJ	B
of	O	ADP	O
the	O	DET	O
myocytolytic	O	ADJ	B
process	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
conclusion	O	NOUN	O
,	O	PUNCT	O
administration	O	NOUN	B
of	O	ADP	O
isoproterenol	B-Chemical	NOUN	B
to	O	PART	O
rats	O	NOUN	B
results	O	VERB	B
in	O	ADP	O
primary	O	ADJ	B
loss	O	NOUN	I
of	O	ADP	O
dystrophin	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
most	O	ADV	O
sensitive	O	ADJ	B
among	O	ADP	O
the	O	DET	O
structural	O	ADJ	B
proteins	O	NOUN	I
that	O	PRON	O
form	O	VERB	O
the	O	DET	O
DGC	O	NOUN	B
that	O	PRON	O
connects	O	VERB	O
the	O	DET	O
extracellular	O	ADJ	B
matrix	O	NOUN	I
and	O	CCONJ	O
the	O	DET	O
cytoskeleton	O	NOUN	B
in	O	ADP	O
cardiomyocyte	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
changes	O	NOUN	B
,	O	PUNCT	O
related	O	ADJ	O
to	O	PART	O
ischaemic	B-Disease	ADJ	B
injury	I-Disease	NOUN	I
,	O	PUNCT	O
explain	O	VERB	O
the	O	DET	O
severe	O	ADJ	B
alterations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
structural	O	ADJ	B
integrity	O	NOUN	B
of	O	ADP	O
the	O	DET	O
sarcolemma	O	NOUN	B
of	O	ADP	O
cardiomyocytes	O	NOUN	B
and	O	CCONJ	O
hence	O	ADV	O
severe	O	ADJ	B
and	O	CCONJ	O
irreversible	O	ADJ	B
injury	O	NOUN	B
induced	O	VERB	B
by	O	ADP	O
isoproterenol	B-Chemical	NOUN	B


High	O	ADJ	B
fat	B-Chemical	ADJ	B
diet	O	NOUN	I
-	O	PUNCT	O
fed	O	VERB	B
obese	B-Disease	ADJ	B
rats	O	NOUN	B
are	O	AUX	O
highly	O	ADV	O
sensitive	O	ADJ	B
to	O	PART	O
doxorubicin	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
cardiotoxicity	B-Disease	NOUN	B
.	O	PUNCT	O


Often	O	ADV	O
,	O	PUNCT	O
chemotherapy	O	NOUN	B
by	O	ADP	O
doxorubicin	B-Chemical	NOUN	B
(	O	PUNCT	O
Adriamycin	B-Chemical	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
limited	O	VERB	O
due	O	ADP	O
to	O	ADP	O
life	O	NOUN	B
threatening	O	VERB	O
cardiotoxicity	B-Disease	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
during	O	ADP	O
and	O	CCONJ	O
posttherapy	O	NOUN	B
.	O	PUNCT	O


Recently	O	ADV	O
,	O	PUNCT	O
we	O	PRON	O
have	O	AUX	O
shown	O	VERB	O
that	O	SCONJ	O
moderate	O	ADJ	B
diet	O	NOUN	B
restriction	O	NOUN	I
remarkably	O	ADV	O
protects	O	VERB	O
against	O	ADP	O
doxorubicin	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
cardiotoxicity	B-Disease	NOUN	B
.	O	PUNCT	O


This	O	DET	O
cardioprotection	O	NOUN	B
is	O	AUX	O
accompanied	O	VERB	O
by	O	ADP	O
decreased	O	VERB	B
cardiac	O	ADJ	B
oxidative	O	ADJ	O
stress	O	NOUN	O
and	O	CCONJ	O
triglycerides	B-Chemical	NOUN	B
and	O	CCONJ	O
increased	O	VERB	B
cardiac	O	ADJ	B
fatty	O	ADJ	I
-	O	PUNCT	O
acid	O	NOUN	B
oxidation	O	NOUN	I
,	O	PUNCT	O
ATP	B-Chemical	NOUN	B
synthesis	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
upregulated	O	VERB	B
JAK	O	NOUN	B
/	O	PUNCT	O
STAT3	O	NOUN	B
pathway	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
current	O	ADJ	O
study	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
investigated	O	VERB	B
whether	O	SCONJ	O
a	O	DET	O
physiological	O	ADJ	B
intervention	O	NOUN	B
by	O	ADP	O
feeding	O	VERB	B
40	O	NUM	O
%	O	NOUN	O
high	O	ADJ	B
fat	B-Chemical	ADJ	I
diet	O	NOUN	I
(	O	PUNCT	O
HFD	O	NOUN	B
),	O	PUNCT	O
which	O	DET	O
induces	O	VERB	O
obesity	B-Disease	NOUN	B
in	O	ADP	O
male	O	NOUN	B
Sprague	O	PROPN	B
-	O	PUNCT	O
Dawley	O	NOUN	B
rats	O	NOUN	B
(	O	PUNCT	O
250	O	NUM	O
-	O	SYM	O
275	O	NUM	O
g	O	NOUN	O
),	O	PUNCT	O
sensitizes	O	VERB	B
to	O	PART	O
doxorubicin	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
cardiotoxicity	B-Disease	NOUN	B
.	O	PUNCT	O


A	O	DET	O
LD	O	NOUN	B
(	O	PUNCT	O
10	O	NUM	O
)	O	PUNCT	O
dose	O	NOUN	B
(	O	PUNCT	O
8	O	NUM	O
mg	O	NOUN	O
doxorubicin	B-Chemical	NOUN	B
/	O	SYM	O
kg	O	NOUN	B
,	O	PUNCT	O
ip	O	NOUN	B
)	O	PUNCT	O
administered	O	VERB	B
on	O	ADP	O
day	O	NOUN	B
43	O	NUM	O
of	O	ADP	O
the	O	DET	O
HFD	O	PROPN	B
feeding	O	NOUN	B
regimen	O	NOUN	B
led	O	VERB	O
to	O	PART	O
higher	O	ADJ	O
cardiotoxicity	B-Disease	NOUN	B
,	O	PUNCT	O
cardiac	B-Disease	ADJ	B
dysfunction	I-Disease	NOUN	I
,	O	PUNCT	O
lipid	O	NOUN	B
peroxidation	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
80	O	NUM	O
%	O	NOUN	O
mortality	O	NOUN	B
in	O	ADP	O
the	O	DET	O
obese	B-Disease	ADJ	B
(	O	PUNCT	O
OB	B-Disease	NOUN	B
)	O	PUNCT	O
rats	O	NOUN	B
in	O	ADP	O
the	O	DET	O
absence	O	NOUN	B
of	O	ADP	O
any	O	DET	O
significant	O	ADJ	B
renal	B-Disease	ADJ	B
or	I-Disease	CCONJ	O
hepatic	I-Disease	ADJ	B
toxicity	I-Disease	NOUN	B
.	O	PUNCT	O


Doxorubicin	B-Chemical	NOUN	B
toxicokinetics	O	NOUN	B
studies	O	NOUN	I
revealed	O	VERB	O
no	O	DET	O
change	O	NOUN	O
in	O	ADP	O
accumulation	O	NOUN	B
of	O	ADP	O
doxorubicin	B-Chemical	NOUN	B
and	O	CCONJ	O
doxorubicinol	B-Chemical	NOUN	B
(	O	PUNCT	O
toxic	O	ADJ	B
metabolite	O	NOUN	I
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
normal	O	ADJ	B
diet	O	NOUN	I
-	O	PUNCT	O
fed	O	VERB	B
(	O	PUNCT	O
ND	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
OB	B-Disease	NOUN	B
hearts	O	NOUN	B
.	O	PUNCT	O


Mechanistic	O	ADJ	B
studies	O	NOUN	I
revealed	O	VERB	O
that	O	SCONJ	O
OB	B-Disease	NOUN	B
rats	O	NOUN	B
are	O	AUX	O
sensitized	O	VERB	B
due	O	ADJ	O
to	O	ADP	O
:(	O	PUNCT	O
1	O	NUM	O
)	O	PUNCT	O
higher	O	ADJ	O
oxyradical	O	ADJ	B
stress	O	NOUN	I
leading	O	VERB	O
to	O	PART	O
upregulation	O	NOUN	B
of	O	ADP	O
uncoupling	O	NOUN	B
proteins	O	NOUN	I
2	O	NUM	I
and	O	CCONJ	O
3	O	NUM	O
,(	O	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
downregulation	O	NOUN	B
of	O	ADP	O
cardiac	O	ADJ	B
peroxisome	O	NOUN	I
proliferators	O	NOUN	I
activated	O	VERB	B
receptor	O	NOUN	I
-	O	PUNCT	O
alpha	O	NOUN	B
,(	O	PUNCT	O
3	O	NUM	O
)	O	PUNCT	O
decreased	O	VERB	B
plasma	O	NOUN	B
adiponectin	O	NOUN	O
levels	O	NOUN	B
,(	O	PUNCT	O
4	O	X	O
)	O	PUNCT	O
decreased	O	VERB	B
cardiac	O	ADJ	B
fatty	O	ADJ	I
-	O	PUNCT	O
acid	O	NOUN	B
oxidation	O	NOUN	I
(	O	PUNCT	O
666	O	NUM	O
.	O	PUNCT	O


9	O	NUM	O
+/-	O	CCONJ	O
14	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
nmol	O	NOUN	B
/	O	PUNCT	O
min	O	NOUN	B
/	O	SYM	O
g	O	NOUN	B
heart	O	NOUN	B
in	O	ADP	O
ND	O	NOUN	B
versus	O	CCONJ	O
400	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
+/-	O	CCONJ	O
11	O	NUM	O
.	O	PUNCT	O


8	O	NUM	O
nmol	O	NOUN	B
/	O	PUNCT	O
min	O	NOUN	B
/	O	SYM	O
g	O	NOUN	B
heart	O	NOUN	B
in	O	ADP	O
OB	B-Disease	PROPN	B
),(	O	PUNCT	O
5	O	NUM	O
)	O	PUNCT	O
decreased	O	VERB	B
mitochondrial	O	ADJ	B
AMP	B-Chemical	NOUN	B
-	O	PUNCT	O
alpha2	O	NOUN	B
protein	O	NOUN	I
kinase	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
(	O	PUNCT	O
6	O	NUM	O
)	O	PUNCT	O
86	O	NUM	O
%	O	NOUN	O
drop	O	NOUN	B
in	O	ADP	O
cardiac	O	ADJ	B
ATP	B-Chemical	NOUN	B
levels	O	NOUN	B
accompanied	O	VERB	O
by	O	ADP	O
decreased	O	VERB	B
ATP	B-Chemical	NOUN	B
/	O	SYM	O
ADP	B-Chemical	NOUN	B
ratio	O	NOUN	B
after	O	ADP	O
doxorubicin	B-Chemical	NOUN	B
administration	O	NOUN	O
.	O	PUNCT	O


Decreased	O	VERB	B
cardiac	O	ADJ	O
erythropoietin	O	NOUN	O
and	O	CCONJ	O
increased	O	VERB	B
SOCS3	O	NOUN	B
further	O	ADV	O
downregulated	O	VERB	B
the	O	DET	O
cardioprotective	O	ADJ	B
JAK	O	NOUN	B
/	O	PUNCT	O
STAT3	O	NOUN	B
pathway	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
conclusion	O	NOUN	O
,	O	PUNCT	O
HFD	O	PROPN	B
-	O	PUNCT	O
induced	O	VERB	B
obese	B-Disease	ADJ	B
rats	O	NOUN	B
are	O	AUX	O
highly	O	ADV	O
sensitized	O	VERB	B
to	O	PART	O
doxorubicin	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
cardiotoxicity	B-Disease	NOUN	B
by	O	ADP	O
substantially	O	ADV	O
downregulating	O	VERB	B
cardiac	O	ADJ	B
mitochondrial	O	ADJ	B
ATP	B-Chemical	NOUN	B


Complete	O	ADJ	B
atrioventricular	B-Disease	ADJ	B
block	I-Disease	NOUN	I
secondary	O	ADJ	O
to	O	PART	O
lithium	B-Chemical	NOUN	B
therapy	O	NOUN	I
.	O	PUNCT	O


Sinus	B-Disease	NOUN	B
node	I-Disease	NOUN	I
dysfunction	I-Disease	NOUN	I
has	O	AUX	O
been	O	AUX	O
reported	O	VERB	O
most	O	ADV	O
frequently	O	ADV	O
among	O	ADP	O
the	O	DET	O
adverse	O	ADJ	B
cardiovascular	O	ADJ	B
effects	O	NOUN	B
of	O	ADP	O
lithium	B-Chemical	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
present	O	ADJ	O
case	O	NOUN	B
,	O	PUNCT	O
complete	O	VERB	O
atrioventricular	B-Disease	ADJ	B
(AV)	I-Disease	NOUN	O
block	I-Disease	NOUN	B
with	O	ADP	I
syncopal	B-Disease	NOUN	B
attacks	I-Disease	NOUN	B
developed	O	VERB	O
secondary	O	ADJ	B
to	O	PART	I
lithium	B-Chemical	NOUN	B
therapy	O	NOUN	I
,	O	PUNCT	O
necessitating	O	VERB	O
permanent	O	ADJ	B
pacemaker	O	NOUN	O
implantation	O	NOUN	B
.	O	PUNCT	O


Serum	O	NOUN	B
lithium	B-Chemical	NOUN	I
levels	O	NOUN	I
remained	O	VERB	O
under	O	ADP	O
or	O	CCONJ	O
within	O	ADP	O
the	O	DET	O
therapeutic	O	ADJ	B
range	O	NOUN	O
during	O	ADP	O
the	O	DET	O
syncopal	B-Disease	NOUN	B
attacks	I-Disease	NOUN	B
.	O	PUNCT	O


Lithium	B-Chemical	NOUN	B


Neuroleptic	B-Disease	ADJ	B
malignant	I-Disease	ADJ	I
syndrome	I-Disease	NOUN	I
induced	O	VERB	B
by	O	ADP	O
ziprasidone	B-Chemical	NOUN	B
on	O	ADP	O
the	O	DET	O
second	O	ADJ	O
day	O	NOUN	B
of	O	ADP	O
treatment	O	NOUN	B
.	O	PUNCT	O


Neuroleptic	B-Disease	ADJ	B
malignant	I-Disease	ADJ	I
syndrome	I-Disease	NOUN	I
(	O	PUNCT	O
NMS	B-Disease	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
the	O	DET	O
rarest	O	ADJ	B
and	O	CCONJ	O
most	O	ADV	O
serious	O	ADJ	O
of	O	ADP	O
the	O	DET	O
neuroleptic	O	ADJ	B
-	O	PUNCT	O
induced	O	VERB	B
movement	B-Disease	NOUN	B
disorders	I-Disease	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
describe	O	VERB	O
a	O	DET	O
case	O	NOUN	B
of	O	ADP	O
neuroleptic	B-Disease	ADJ	B
malignant	I-Disease	ADJ	I
syndrome	I-Disease	NOUN	I
(	O	PUNCT	O
NMS	B-Disease	NOUN	B
)	O	PUNCT	O
associated	O	VERB	B
with	O	ADP	I
the	O	DET	O
use	O	NOUN	O
of	O	ADP	O
ziprasidone	B-Chemical	NOUN	B
.	O	PUNCT	O


Although	O	SCONJ	O
conventional	O	ADJ	B
neuroleptics	O	NOUN	B
are	O	AUX	O
more	O	ADV	O
frequently	O	ADV	O
associated	O	VERB	B
with	O	ADP	I
NMS	B-Disease	NOUN	B
,	O	PUNCT	O
atypical	O	ADJ	B
antipsychotic	O	ADJ	B
drugs	O	NOUN	I
like	O	ADP	O
ziprasidone	B-Chemical	NOUN	B
may	O	AUX	O
also	O	ADV	O
be	O	AUX	O
a	O	DET	O
cause	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
patient	O	NOUN	B
is	O	AUX	O
a	O	DET	O
24	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
male	O	NOUN	B
with	O	ADP	O
a	O	DET	O
history	O	NOUN	B
of	O	ADP	O
schizophrenia	B-Disease	NOUN	B
who	O	PRON	O
developed	O	VERB	O
signs	O	NOUN	B
and	O	CCONJ	O
symptoms	O	NOUN	B
of	O	ADP	O
NMS	B-Disease	NOUN	B
after	O	ADP	O
2	O	NUM	O
days	O	NOUN	B
of	O	ADP	O
treatment	O	NOUN	B
with	O	ADP	O
an	O	DET	O
80	O	NUM	O
-	O	PUNCT	O
mg	O	NOUN	B
/	O	PUNCT	O
day	O	NOUN	B
dose	O	NOUN	B
of	O	ADP	O
orally	O	ADV	B
administrated	O	VERB	B
ziprasidone	B-Chemical	NOUN	B
.	O	PUNCT	O


This	O	DET	O
case	O	NOUN	B
is	O	AUX	O
the	O	DET	O
earliest	O	ADJ	O
(	O	PUNCT	O
second	O	ADJ	O
day	O	NOUN	B
of	O	ADP	O
treatment	O	NOUN	B
)	O	PUNCT	O
NMS	B-Disease	NOUN	B
due	O	ADJ	O
to	O	PART	O
ziprasidone	B-Chemical	NOUN	B


Role	O	NOUN	O
of	O	ADP	O
mangiferin	B-Chemical	NOUN	B
on	O	ADP	O
biochemical	O	ADJ	B
alterations	O	NOUN	B
and	O	CCONJ	O
antioxidant	O	ADJ	B
status	O	NOUN	I
in	O	ADP	O
isoproterenol	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
myocardial	B-Disease	ADJ	B
infarction	I-Disease	NOUN	I
in	O	ADP	O
rats	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
current	O	ADJ	O
study	O	NOUN	B
dealt	O	VERB	O
with	O	ADP	O
the	O	DET	O
protective	O	ADJ	O
role	O	NOUN	O
of	O	ADP	O
mangiferin	B-Chemical	NOUN	B
,	O	PUNCT	O
a	O	DET	O
polyphenol	B-Chemical	NOUN	B
from	O	ADP	O
Mangifera	O	PROPN	B
indica	O	PROPN	I
Linn	O	PROPN	I
.(	O	SYM	I
Anacardiaceae	O	PROPN	I
),	O	PUNCT	O
on	O	ADP	O
isoproterenol	B-Chemical	NOUN	B
(	O	PUNCT	O
ISPH	B-Chemical	NOUN	B
)-	O	ADJ	O
induced	O	VERB	B
myocardial	B-Disease	ADJ	B
infarction	I-Disease	NOUN	I
(	O	PUNCT	O
MI	B-Disease	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
rats	O	NOUN	B
through	O	ADP	O
its	O	PRON	O
antioxidative	O	ADJ	B
mechanism	O	NOUN	B
.	O	PUNCT	O


Subcutaneous	O	ADJ	B
injection	O	NOUN	I
of	O	ADP	O
ISPH	B-Chemical	NOUN	B
(	O	PUNCT	O
200	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
body	O	NOUN	B
weight	O	NOUN	I
in	O	ADP	O
1	O	NUM	O
ml	O	NOUN	O
saline	O	NOUN	B
)	O	PUNCT	O
to	O	PART	O
rats	O	NOUN	B
for	O	ADP	O
2	O	NUM	O
consecutive	O	ADJ	B
days	O	NOUN	B
caused	O	VERB	O
myocardial	B-Disease	ADJ	B
damage	I-Disease	NOUN	I
in	O	ADP	O
rat	O	NOUN	B
heart	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
was	O	AUX	O
determined	O	VERB	O
by	O	ADP	O
the	O	DET	O
increased	O	VERB	B
activity	O	NOUN	B
of	O	ADP	O
serum	O	NOUN	B
lactate	B-Chemical	NOUN	I
dehydrogenase	O	NOUN	I
(	O	PUNCT	O
LDH	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
creatine	B-Chemical	NOUN	B
phosphokinase	O	NOUN	I
isoenzymes	O	NOUN	I
(	O	PUNCT	O
CK	O	NOUN	B
-	O	PUNCT	O
MB	O	PROPN	B
),	O	PUNCT	O
increased	O	VERB	B
uric	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
level	O	NOUN	I
and	O	CCONJ	O
reduced	O	VERB	B
plasma	O	NOUN	B
iron	B-Chemical	NOUN	B
binding	O	NOUN	I
capacity	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
protective	O	ADJ	O
role	O	NOUN	O
of	O	ADP	O
mangiferin	B-Chemical	NOUN	B
was	O	AUX	O
analyzed	O	VERB	B
by	O	ADP	O
triphenyl	B-Chemical	NOUN	B
tetrazolium	I-Chemical	NOUN	I
chloride	I-Chemical	NOUN	I
(	O	PUNCT	O
TTC	B-Chemical	NOUN	O
)	O	PUNCT	O
test	O	NOUN	O
used	O	VERB	O
for	O	ADP	O
macroscopic	O	ADJ	B
enzyme	O	NOUN	B
mapping	O	NOUN	I
assay	O	NOUN	I
of	O	ADP	O
the	O	DET	O
ischemic	B-Disease	ADJ	B
myocardium	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
heart	O	NOUN	B
tissue	O	NOUN	I
antioxidant	O	ADJ	B
enzymes	O	NOUN	I
such	O	ADJ	O
as	O	ADP	O
superoxide	B-Chemical	NOUN	B
dismutase	O	NOUN	I
,	O	PUNCT	O
catalase	O	NOUN	B
,	O	PUNCT	O
glutathione	B-Chemical	NOUN	B
peroxidase	O	NOUN	I
,	O	PUNCT	O
glutathione	B-Chemical	NOUN	B
transferase	O	NOUN	I
and	O	CCONJ	O
glutathione	B-Chemical	NOUN	B
reductase	O	NOUN	I
activities	O	NOUN	B
,	O	PUNCT	O
non	O	ADJ	B
-	O	PUNCT	O
enzymic	O	ADJ	B
antioxidants	O	NOUN	B
such	O	ADJ	O
as	O	ADP	O
cerruloplasmin	O	NOUN	B
,	O	PUNCT	O
Vitamin	B-Chemical	NOUN	B
C	I-Chemical	PROPN	I
,	O	PUNCT	O
Vitamin	B-Chemical	PROPN	B
E	I-Chemical	PROPN	I
and	O	CCONJ	O
glutathione	B-Chemical	NOUN	B
levels	O	NOUN	O
were	O	AUX	O
altered	O	VERB	O
in	O	ADP	O
MI	B-Disease	NOUN	B
rats	O	NOUN	B
.	O	PUNCT	O


Upon	O	SCONJ	O
pretreatment	O	NOUN	B
with	O	ADP	O
mangiferin	B-Chemical	NOUN	B
(	O	PUNCT	O
100	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
body	O	NOUN	B
weight	O	NOUN	I
suspended	O	VERB	O
in	O	ADP	O
2	O	NUM	O
ml	O	NOUN	O
of	O	ADP	O
dimethyl	B-Chemical	ADJ	B
sulphoxide	I-Chemical	NOUN	I
)	O	PUNCT	O
given	O	VERB	O
intraperitoneally	O	ADV	B
for	O	ADP	O
28	O	NUM	O
days	O	NOUN	B
to	O	ADP	O
MI	B-Disease	NOUN	B
rats	O	NOUN	B
protected	O	VERB	O
the	O	DET	O
above	O	ADV	B
-	O	PUNCT	O
mentioned	O	VERB	B
parameters	O	NOUN	B
to	O	PART	O
fall	O	VERB	B
from	O	ADP	O
the	O	DET	O
normal	O	ADJ	B
levels	O	NOUN	I
.	O	PUNCT	O


Activities	O	NOUN	B
of	O	ADP	O
heart	O	NOUN	B
tissue	O	NOUN	I
enzymic	O	ADJ	B
antioxidants	O	NOUN	I
and	O	CCONJ	O
serum	O	NOUN	B
non	O	NOUN	B
-	O	PUNCT	O
enzymic	O	ADJ	B
antioxidants	O	NOUN	B
levels	O	NOUN	B
rose	O	VERB	O
significantly	O	ADV	O
upon	O	SCONJ	O
mangiferin	B-Chemical	NOUN	B
administration	O	NOUN	B
as	O	ADP	O
compared	O	VERB	O
to	O	ADP	O
ISPH	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
MI	B-Disease	NOUN	B
rats	O	NOUN	B
.	O	PUNCT	O


From	O	ADP	O
the	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
it	O	PRON	O
is	O	AUX	O
concluded	O	VERB	O
that	O	SCONJ	O
mangiferin	B-Chemical	NOUN	B
exerts	O	VERB	O
a	O	DET	O
beneficial	O	ADJ	O
effect	O	NOUN	O
against	O	ADP	O
ISPH	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
MI	B-Disease	PROPN	B
due	O	ADP	O
to	O	ADP	O
its	O	PRON	O
antioxidant	O	ADJ	B
potential	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
regulated	O	VERB	O
the	O	DET	O
tissues	O	NOUN	B
defense	O	NOUN	B
system	O	NOUN	I
against	O	ADP	O
cardiac	B-Disease	ADJ	B
damage	I-Disease	NOUN	I


Remifentanil	B-Chemical	NOUN	B
pretreatment	O	NOUN	B
reduces	O	VERB	B
myoclonus	B-Disease	NOUN	B
after	O	ADP	O
etomidate	B-Chemical	NOUN	B
.	O	PUNCT	O


STUDY	O	NOUN	O
OBJECTIVE	O	NOUN	O
:	O	PUNCT	O
The	O	DET	O
aim	O	NOUN	O
of	O	ADP	O
the	O	DET	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
compare	O	VERB	B
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
pretreatment	O	NOUN	B
with	O	ADP	O
remifentanil	B-Chemical	NOUN	B
1	O	NUM	O
microg	O	NOUN	B
/	O	PUNCT	O
kg	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
gender	O	NOUN	B
on	O	ADP	O
the	O	DET	O
incidence	O	NOUN	B
of	O	ADP	O
myoclonus	B-Disease	NOUN	B
after	O	ADP	O
anesthesia	O	NOUN	B
induction	O	NOUN	B
with	O	ADP	O
etomidate	B-Chemical	NOUN	B
.	O	PUNCT	O


DESIGN	O	NOUN	O
:	O	PUNCT	O
This	O	DET	O
was	O	AUX	O
a	O	DET	O
randomized	O	ADJ	B
,	O	PUNCT	O
double	O	ADJ	B
-	O	PUNCT	O
blind	O	NOUN	B
study	O	NOUN	B
.	O	PUNCT	O


SETTING	O	NOUN	O
:	O	PUNCT	O
The	O	DET	O
study	O	NOUN	B
was	O	AUX	O
conducted	O	VERB	O
at	O	ADP	O
a	O	DET	O
university	O	NOUN	B
hospital	O	NOUN	I
.	O	PUNCT	O


PATIENTS	O	NOUN	B
:	O	PUNCT	O
Sixty	O	NUM	O
patients	O	NOUN	B
were	O	AUX	O
pretreated	O	VERB	B
in	O	ADP	O
a	O	DET	O
randomized	O	ADJ	B
double	O	ADV	B
-	O	PUNCT	O
blinded	O	VERB	B
fashion	O	NOUN	O
with	O	ADP	O
remifentanil	B-Chemical	NOUN	B
1	O	NUM	O
microg	O	NOUN	B
/	O	PUNCT	O
kg	O	NOUN	B
or	O	CCONJ	O
placebo	O	NOUN	B
.	O	PUNCT	O


Two	O	NUM	O
minutes	O	NOUN	O
after	O	ADP	O
remifentanil	B-Chemical	NOUN	B
or	O	CCONJ	O
placebo	O	ADJ	B
injection	O	NOUN	B
,	O	PUNCT	O
etomidate	B-Chemical	NOUN	B
0	O	NUM	O
.	O	PUNCT	O


3	O	NUM	O
mg	O	NOUN	O
/	O	PUNCT	O
kg	O	NOUN	B
was	O	AUX	O
given	O	VERB	O
.	O	PUNCT	O


MEASUREMENTS	O	NOUN	B
:	O	PUNCT	O
Myoclonus	B-Disease	NOUN	B
was	O	AUX	O
recorded	O	VERB	O
with	O	ADP	O
a	O	DET	O
scale	O	NOUN	O
of	O	ADP	O
0	O	NUM	O
to	O	PART	O
3	O	NUM	O
.	O	PUNCT	O


The	O	DET	O
grade	O	NOUN	B
of	O	ADP	I
sedation	O	NOUN	B
(	O	PUNCT	O
none	O	NOUN	O
,	O	PUNCT	O
mild	O	ADJ	B
,	O	PUNCT	O
moderate	O	ADJ	B
,	O	PUNCT	O
severe	O	ADJ	B
),	O	PUNCT	O
nausea	B-Disease	NOUN	B
,	O	PUNCT	O
pruritus	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
apnea	B-Disease	NOUN	B
were	O	AUX	O
recorded	O	VERB	O
after	O	ADP	O
injection	O	NOUN	B
of	O	ADP	O
both	O	DET	O
drugs	O	NOUN	B
.	O	PUNCT	O


MAIN	O	ADJ	O
RESULTS	O	NOUN	O
:	O	PUNCT	O
The	O	DET	O
incidence	O	NOUN	B
of	O	ADP	O
myoclonus	B-Disease	NOUN	B
was	O	AUX	O
significantly	O	ADV	O
lower	O	ADJ	O
in	O	ADP	O
the	O	DET	O
remifentanil	B-Chemical	NOUN	B
group	O	NOUN	B
(	O	PUNCT	O
6	O	NUM	O
.	O	PUNCT	O


7	O	NUM	O
%)	O	NOUN	O
than	O	ADP	O
in	O	ADP	O
the	O	DET	O
placebo	O	ADJ	B
group	O	NOUN	B
(	O	PUNCT	O
70	O	NUM	O
%)(	O	NOUN	O
P	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


001	O	NUM	O
).	O	PUNCT	O
of	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
experienced	O	VERB	O
sedation	O	NOUN	B
,	O	PUNCT	O
apnea	B-Disease	NOUN	B
,	O	PUNCT	O
nausea	B-Disease	NOUN	B
,	O	PUNCT	O
or	O	CCONJ	O
pruritus	B-Disease	NOUN	B
after	O	ADP	O
injection	O	NOUN	B
of	O	ADP	O
both	O	DET	O
drugs	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
placebo	O	ADJ	B
group	O	NOUN	B
,	O	PUNCT	O
male	O	ADJ	B
patients	O	NOUN	B
were	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
significantly	O	ADV	O
increased	O	VERB	B
incidence	O	NOUN	B
of	O	ADP	O
myoclonus	B-Disease	NOUN	B
after	O	ADP	O
etomidate	B-Chemical	NOUN	B
administration	O	NOUN	B
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
:	O	PUNCT	O
Pretreatment	O	NOUN	B
with	O	ADP	O
remifentanil	B-Chemical	NOUN	B
1	O	NUM	O
microg	O	NOUN	B
/	O	PUNCT	O
kg	O	NOUN	O
reduced	O	VERB	B
myoclonus	B-Disease	NOUN	B
after	O	ADP	O
etomidate	B-Chemical	NOUN	B
induction	O	NOUN	B
without	O	ADP	O
side	O	NOUN	B
effects	O	NOUN	I
such	O	ADJ	O
as	O	ADP	O
sedation	O	NOUN	B
,	O	PUNCT	O
apnea	B-Disease	NOUN	B
,	O	PUNCT	O
nausea	B-Disease	NOUN	B
,	O	PUNCT	O
or	O	CCONJ	O
pruritus	B-Disease	NOUN	B
.	O	PUNCT	O


Men	O	NOUN	B
experience	O	NOUN	B
increased	O	VERB	B
incidence	O	NOUN	B
of	O	ADP	O
myoclonus	B-Disease	NOUN	B
than	O	ADP	O
women	O	NOUN	B
after	O	ADP	O
etomidate	B-Chemical	NOUN	B


Daidzein	B-Chemical	NOUN	B
activates	O	VERB	B
choline	B-Chemical	NOUN	B
acetyltransferase	O	NOUN	I
from	O	ADP	O
MC	O	PROPN	B
-	O	PUNCT	O
IXC	O	PROPN	B
cells	O	NOUN	B
and	O	CCONJ	O
improves	O	VERB	B
drug	O	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
amnesia	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
choline	B-Chemical	NOUN	B
acetyltransferase	O	NOUN	I
(	O	PUNCT	O
ChAT	O	NOUN	B
)	O	PUNCT	O
activator	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
enhances	O	VERB	O
cholinergic	O	ADJ	B
transmission	O	NOUN	B
via	O	ADP	O
an	O	DET	O
augmentation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
enzymatic	O	ADJ	B
production	O	NOUN	B
of	O	ADP	O
acetylcholine	B-Chemical	NOUN	B
(	O	PUNCT	O
ACh	B-Chemical	NOUN	B
),	O	PUNCT	O
is	O	AUX	O
an	O	DET	O
important	O	ADJ	O
factor	O	NOUN	B
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
Alzheimer's	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
(	O	PUNCT	O
AD	B-Disease	NOUN	B
).	O	PUNCT	O
Methanolic	O	ADJ	B
extracts	O	NOUN	I
from	O	ADP	O
Pueraria	O	PROPN	B
thunbergiana	O	NOUN	I
exhibited	O	VERB	O
an	O	DET	O
activation	O	NOUN	B
effect	O	NOUN	O
(	O	PUNCT	O
46	O	NUM	O
%)	O	NOUN	O
on	O	ADP	O
ChAT	O	NOUN	B
in	O	X	B
vitro	O	X	I
.	O	PUNCT	O


Via	O	ADP	O
the	O	DET	O
sequential	O	ADJ	B
isolation	O	NOUN	B
of	O	ADP	O
Pueraria	O	PROPN	B
thunbergiana	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
active	O	ADJ	B
component	O	NOUN	I
was	O	AUX	O
ultimately	O	ADV	O
identified	O	VERB	O
as	O	ADP	O
daidzein	B-Chemical	NOUN	B
(	O	PUNCT	O
4',7-dihydroxy-isoflavone	B-Chemical	NOUN	B
).	O	PUNCT	O
In	O	ADP	O
order	O	NOUN	O
to	O	PART	O
investigate	O	VERB	B
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
daidzein	B-Chemical	NOUN	B
from	O	ADP	O
Pueraria	O	PROPN	B
thunbergiana	O	NOUN	I
on	O	ADP	O
scopolamine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
impairments	B-Disease	NOUN	B
of	I-Disease	ADP	O
learning	I-Disease	NOUN	B
and	I-Disease	CCONJ	O
memory	I-Disease	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
conducted	O	VERB	O
a	O	DET	O
series	O	NOUN	O
of	O	ADP	O
in	O	X	B
vivo	O	X	I
tests	O	NOUN	I
.	O	PUNCT	O


Administration	O	NOUN	B
of	O	ADP	O
daidzein	B-Chemical	NOUN	B
(	O	PUNCT	O
4	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
body	O	NOUN	I
weight	O	NOUN	I
)	O	PUNCT	O
to	O	PART	O
mice	O	NOUN	B
was	O	AUX	O
shown	O	VERB	O
significantly	O	ADV	O
to	O	PART	O
reverse	O	VERB	B
scopolamine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
amnesia	B-Disease	NOUN	B
,	O	PUNCT	O
according	O	VERB	O
to	O	ADP	O
the	O	DET	O
results	O	NOUN	B
of	O	ADP	O
a	O	DET	O
Y	O	NOUN	B
-	O	PUNCT	O
maze	O	NOUN	B
test	O	NOUN	O
.	O	PUNCT	O


Injections	O	NOUN	B
of	O	ADP	O
scopolamine	B-Chemical	NOUN	B
into	O	ADP	O
mice	O	NOUN	B
resulted	O	VERB	O
in	O	ADP	O
impaired	O	ADJ	B
performance	O	NOUN	B
on	O	ADP	O
Y	O	NOUN	B
-	O	PUNCT	O
maze	O	NOUN	B
tests	O	NOUN	B
(	O	PUNCT	O
a	O	DET	O
37	O	NUM	O
%	O	NOUN	O
decreases	O	VERB	B
in	O	ADP	O
alternation	O	NOUN	B
behavior	O	NOUN	I
).	O	PUNCT	O
By	O	ADP	O
way	O	NOUN	O
of	O	ADP	O
contrast	O	NOUN	B
,	O	PUNCT	O
mice	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
daidzein	B-Chemical	NOUN	B
prior	O	ADV	O
to	O	PART	O
the	O	DET	O
scopolamine	B-Chemical	NOUN	B
injections	O	NOUN	B
were	O	AUX	O
noticeably	O	ADV	O
protected	O	VERB	O
from	O	ADP	O
this	O	DET	O
performance	O	NOUN	B
impairment	O	NOUN	I
(	O	PUNCT	O
an	O	DET	O
approximately	O	ADV	O
12	O	NUM	O
%-	O	NOUN	B
21	O	NUM	O
%	O	NOUN	O
decrease	O	NOUN	B
in	O	ADP	O
alternation	O	NOUN	B
behavior	O	NOUN	I
).	O	PUNCT	O
These	O	DET	O
results	O	NOUN	B
indicate	O	VERB	O
that	O	SCONJ	O
daidzein	B-Chemical	NOUN	B
might	O	AUX	O
play	O	VERB	O
a	O	DET	O
role	O	NOUN	O
in	O	ADP	O
acetylcholine	B-Chemical	NOUN	B
biosynthesis	O	NOUN	I
as	O	ADP	O
a	O	DET	O
ChAT	O	NOUN	B
activator	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
that	O	SCONJ	O
it	O	PRON	O
also	O	ADV	O
ameliorates	O	VERB	B
scopolamine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
amnesia	B-Disease	NOUN	B


Possible	O	ADJ	O
azithromycin	B-Chemical	NOUN	B
-	O	PUNCT	O
associated	O	VERB	B
hiccups	B-Disease	NOUN	B
.	O	PUNCT	O


OBJECTIVE	O	NOUN	O
:	O	PUNCT	O
To	O	PART	O
report	O	VERB	O
a	O	DET	O
case	O	NOUN	B
of	O	ADP	O
persistent	O	ADJ	B
hiccups	B-Disease	NOUN	B
associated	O	VERB	B
by	O	ADP	I
azithromycin	B-Chemical	NOUN	B
therapy	O	NOUN	B
.	O	PUNCT	O


CASE	O	ADJ	B
SUMMARY	O	NOUN	I
:	O	PUNCT	O
A	O	DET	O
76	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
man	O	NOUN	B
presented	O	VERB	O
with	O	ADP	O
persistent	O	ADJ	B
hiccups	B-Disease	NOUN	B
after	O	ADP	O
beginning	O	VERB	O
azithromycin	B-Chemical	NOUN	B
for	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
pharyngitis	B-Disease	NOUN	B
.	O	PUNCT	O


Hiccups	B-Disease	NOUN	B
were	O	AUX	O
persistent	O	ADJ	B
and	O	CCONJ	O
exhausting	O	NOUN	B
.	O	PUNCT	O


Discontinuation	O	NOUN	B
of	O	ADP	O
azithromycin	B-Chemical	NOUN	B
and	O	CCONJ	O
therapy	O	NOUN	B
with	O	ADP	O
baclofen	B-Chemical	NOUN	B
finally	O	ADV	O
resolved	O	VERB	B
hiccups	B-Disease	NOUN	B
.	O	PUNCT	O


No	O	DET	O
organic	O	ADJ	B
cause	O	NOUN	O
of	O	ADP	O
hiccups	B-Disease	NOUN	B
was	O	AUX	O
identified	O	VERB	B
despite	O	SCONJ	O
extensive	O	ADJ	O
investigation	O	NOUN	B
.	O	PUNCT	O


DISCUSSION	O	NOUN	O
:	O	PUNCT	O
Pharmacotherapeutic	O	ADJ	B
agents	O	NOUN	I
have	O	AUX	O
been	O	AUX	O
uncommonly	O	ADV	O
associated	O	VERB	B
with	O	ADP	I
hiccups	B-Disease	NOUN	B
.	O	PUNCT	O


Corticosteroids	O	NOUN	B
(	O	PUNCT	O
dexamethasone	B-Chemical	NOUN	B
and	O	CCONJ	O
methylprednisolone	B-Chemical	NOUN	B
),	O	PUNCT	O
benzodiazepines	B-Chemical	NOUN	B
(	O	PUNCT	O
midazolam	B-Chemical	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
general	O	ADJ	B
anaesthesia	O	NOUN	I
have	O	AUX	O
been	O	AUX	O
the	O	DET	O
specific	O	ADJ	O
agents	O	NOUN	B
mentioned	O	VERB	O
most	O	ADV	O
frequently	O	ADV	O
in	O	ADP	O
the	O	DET	O
literature	O	NOUN	B
as	O	ADP	O
being	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
the	O	DET	O
development	O	NOUN	B
of	O	ADP	O
hiccups	B-Disease	NOUN	B
.	O	PUNCT	O


Few	O	ADJ	O
cases	O	NOUN	B
of	O	ADP	O
drug	O	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
hiccups	B-Disease	NOUN	B
have	O	AUX	O
been	O	AUX	O
reported	O	VERB	O
related	O	ADJ	O
to	O	PART	O
macrolide	B-Chemical	NOUN	B
antimicrobials	O	NOUN	B
.	O	PUNCT	O


Using	O	VERB	O
the	O	DET	O
Naranjo	O	NOUN	B
adverse	O	ADJ	I
effect	O	NOUN	I
reaction	O	NOUN	I
probability	O	NOUN	I
scale	O	NOUN	I
this	O	DET	O
event	O	NOUN	B
could	O	AUX	O
be	O	AUX	O
classified	O	VERB	O
as	O	ADP	O
possible	O	ADJ	O
(	O	PUNCT	O
score	O	NOUN	B
5	O	NUM	O
points	O	NOUN	O
),	O	PUNCT	O
mostly	O	ADV	O
because	O	SCONJ	O
of	O	ADP	O
the	O	DET	O
close	O	ADJ	O
temporal	O	ADJ	B
sequence	O	NOUN	I
,	O	PUNCT	O
previous	O	ADJ	O
reports	O	NOUN	B
on	O	ADP	O
this	O	DET	O
reaction	O	NOUN	B
with	O	ADP	O
other	O	ADJ	O
macrolides	B-Chemical	NOUN	B
and	O	CCONJ	O
the	O	DET	O
absence	O	NOUN	B
of	O	ADP	O
any	O	DET	O
alternative	O	ADJ	B
explanation	O	NOUN	B
for	O	ADP	O
hiccups	B-Disease	NOUN	B
.	O	PUNCT	O


Our	O	PRON	O
hypothesis	O	NOUN	B
is	O	AUX	O
that	O	SCONJ	O
a	O	DET	O
vagal	O	ADJ	B
mechanism	O	NOUN	B
mediated	O	VERB	O
by	O	ADP	O
azithromycin	B-Chemical	NOUN	B
could	O	AUX	O
be	O	AUX	O
the	O	DET	O
pathogenesis	O	NOUN	B
of	O	ADP	O
hiccups	B-Disease	NOUN	B
in	O	ADP	O
our	O	PRON	O
patient	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	B
:	O	PUNCT	O
Diagnosis	O	NOUN	B
of	O	ADP	O
drug	O	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
hiccups	B-Disease	NOUN	B
is	O	AUX	O
difficult	O	ADJ	O
and	O	CCONJ	O
often	O	ADV	O
achieved	O	VERB	O
only	O	ADV	O
by	O	ADP	O
a	O	DET	O
process	O	NOUN	B
of	O	ADP	O
elimination	O	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
macrolide	B-Chemical	NOUN	B
antimicrobials	O	NOUN	B
have	O	AUX	O
been	O	AUX	O
reported	O	VERB	O
to	O	PART	O
be	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
hiccups	B-Disease	NOUN	B


Time	O	NOUN	B
trends	O	NOUN	B
in	O	ADP	O
warfarin	B-Chemical	NOUN	B
-	O	PUNCT	O
associated	O	VERB	B
hemorrhage	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
annual	O	ADJ	B
incidence	O	NOUN	B
of	O	ADP	O
warfarin	B-Chemical	NOUN	B
-	O	PUNCT	O
related	O	ADJ	B
bleeding	B-Disease	NOUN	B
at	O	ADP	O
Brigham	O	PROPN	B
and	O	CCONJ	O
Women	O	PROPN	B
'	O	PART	O
s	O	PROPN	O
Hospital	O	PROPN	B
increased	O	VERB	B
from	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


97	O	NUM	O
/	O	SYM	O
1	O	NUM	O
,	O	PUNCT	O
000	O	NUM	O
patient	O	NOUN	B
admissions	O	NOUN	I
in	O	ADP	O
the	O	DET	O
first	O	ADJ	O
time	O	NOUN	O
period	O	NOUN	O
(	O	PUNCT	O
January	O	PROPN	O
1995	O	NUM	O
to	O	ADP	O
October	O	PROPN	O
1998	O	NUM	O
)	O	PUNCT	O
to	O	PART	O
1	O	NUM	O
.	O	PUNCT	O


19	O	NUM	O
/	O	SYM	O
1	O	NUM	O
,	O	PUNCT	O
000	O	NUM	O
patient	O	NOUN	B
admissions	O	NOUN	I
in	O	ADP	O
the	O	DET	O
second	O	ADJ	O
time	O	NOUN	O
period	O	NOUN	O
(	O	PUNCT	O
November	O	PROPN	O
1998	O	NUM	O
to	O	ADP	O
August	O	PROPN	O
2002	O	NUM	O
)	O	PUNCT	O
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
proportion	O	NOUN	B
of	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
major	O	ADJ	B
and	O	CCONJ	O
intracranial	B-Disease	ADJ	B
bleeding	I-Disease	NOUN	I


Fatal	O	ADJ	B
haemorrhagic	B-Disease	ADJ	O
myocarditis	I-Disease	NOUN	O
secondary	O	ADJ	B
to	O	PART	I
cyclophosphamide	B-Chemical	NOUN	B
therapy	O	NOUN	I
.	O	PUNCT	O


Haemorrhagic	B-Disease	ADJ	B
myocarditis	I-Disease	NOUN	I
is	O	AUX	O
a	O	DET	O
rare	O	ADJ	B
but	O	CCONJ	O
important	O	ADJ	O
complication	O	NOUN	B
of	O	ADP	O
cyclophosphamide	B-Chemical	NOUN	B


Glyceryl	B-Chemical	NOUN	B
trinitrate	I-Chemical	NOUN	I
induces	O	VERB	O
attacks	O	NOUN	B
of	O	ADP	O
migraine	B-Disease	NOUN	B
without	I-Disease	ADP	O
aura	I-Disease	NOUN	B
in	O	ADP	O
sufferers	O	NOUN	B
of	O	ADP	O
migraine	B-Disease	NOUN	B
with	I-Disease	ADP	O
aura	I-Disease	NOUN	B
.	O	PUNCT	O


Migraine	B-Disease	NOUN	B
with	I-Disease	ADP	O
aura	I-Disease	NOUN	B
and	O	CCONJ	O
migraine	B-Disease	NOUN	B
without	I-Disease	ADP	O
aura	I-Disease	NOUN	B
have	O	AUX	O
the	O	DET	O
same	O	ADJ	O
pain	B-Disease	NOUN	B
phase	O	NOUN	I
,	O	PUNCT	O
thus	O	ADV	O
indicating	O	VERB	O
that	O	SCONJ	O
migraine	B-Disease	NOUN	B
with	I-Disease	ADP	O
aura	I-Disease	NOUN	B
and	O	CCONJ	O
migraine	B-Disease	NOUN	B
without	I-Disease	ADP	O
aura	I-Disease	NOUN	B
share	O	VERB	O
a	O	DET	O
common	O	ADJ	O
pathway	O	NOUN	B
of	O	ADP	O
nociception	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
recent	O	ADJ	O
years	O	NOUN	B
,	O	PUNCT	O
increasing	O	VERB	B
evidence	O	NOUN	B
has	O	AUX	O
suggested	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
messenger	O	NOUN	B
molecule	O	NOUN	I
nitric	B-Chemical	ADJ	I
oxide	I-Chemical	NOUN	I
(	O	PUNCT	O
NO	B-Chemical	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
involved	O	VERB	O
in	O	ADP	O
pain	B-Disease	NOUN	B
mechanisms	O	NOUN	I
of	O	ADP	O
migraine	B-Disease	NOUN	B
without	I-Disease	ADP	O
aura	I-Disease	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
order	O	NOUN	O
to	O	PART	O
clarify	O	VERB	O
whether	O	SCONJ	O
the	O	DET	O
same	O	ADJ	O
is	O	AUX	O
true	O	ADJ	O
for	O	ADP	O
migraine	B-Disease	NOUN	B
with	I-Disease	ADP	O
aura	I-Disease	NOUN	B
,	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
we	O	PRON	O
examined	O	VERB	O
the	O	DET	O
headache	B-Disease	NOUN	B
response	O	NOUN	B
to	O	PART	O
intravenous	O	ADJ	B
infusion	O	NOUN	B
of	O	ADP	O
glyceryl	B-Chemical	NOUN	B
trinitrate	I-Chemical	NOUN	I
(	O	PUNCT	O
GTN	B-Chemical	NOUN	B
)(	O	NOUN	O
0	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
microg	O	NOUN	B
/	O	SYM	O
kg	O	NOUN	B
/	O	PUNCT	O
min	O	NOUN	B
for	O	ADP	O
20	O	NUM	O
min	O	NOUN	O
)	O	PUNCT	O
in	O	ADP	O
12	O	NUM	O
sufferers	O	NOUN	B
of	O	ADP	O
migraine	B-Disease	NOUN	B
with	I-Disease	ADP	O
aura	I-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
specific	O	ADJ	O
aim	O	NOUN	B
was	O	AUX	O
to	O	PART	O
elucidate	O	VERB	O
whether	O	SCONJ	O
an	O	DET	O
aura	O	NOUN	B
and	O	CCONJ	O
/	O	SYM	O
or	O	CCONJ	O
an	O	DET	O
attack	O	NOUN	B
of	O	ADP	O
migraine	B-Disease	NOUN	B
without	I-Disease	ADP	O
aura	I-Disease	NOUN	B
could	O	AUX	O
be	O	AUX	O
induced	O	VERB	B
.	O	PUNCT	O


Fourteen	O	NUM	O
healthy	O	ADJ	B
subjects	O	NOUN	I
served	O	VERB	O
as	O	ADP	O
controls	O	NOUN	B
.	O	PUNCT	O


Aura	O	ADJ	B
symptoms	O	NOUN	B
were	O	AUX	O
not	O	PART	O
elicited	O	VERB	O
in	O	ADP	O
any	O	DET	O
subject	O	NOUN	B
.	O	PUNCT	O


Headache	B-Disease	NOUN	B
was	O	AUX	O
more	O	ADV	O
severe	O	ADJ	B
in	O	ADP	O
migraineurs	B-Disease	NOUN	B
than	O	ADP	O
in	O	ADP	O
the	O	DET	O
controls	O	NOUN	B
during	O	ADP	O
and	O	CCONJ	O
immediately	O	ADV	O
after	O	ADP	O
GTN	B-Chemical	NOUN	B
infusion	O	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


037	O	NUM	O
)	O	PUNCT	O
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
during	O	ADP	O
the	O	DET	O
following	O	VERB	O
11	O	NUM	O
h	O	NOUN	O
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


008	O	NUM	O
).	O	PUNCT	B
In	O	ADP	O
the	O	DET	O
controls	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
GTN	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
headache	B-Disease	NOUN	B
gradually	O	ADV	B
disappeared	O	VERB	O
,	O	PUNCT	O
whereas	O	SCONJ	O
in	O	ADP	O
migraineurs	B-Disease	NOUN	B
peak	O	ADJ	B
headache	B-Disease	NOUN	I
intensity	O	NOUN	B
occurred	O	VERB	O
at	O	ADP	O
a	O	DET	O
mean	O	ADJ	O
time	O	NOUN	O
of	O	ADP	O
240	O	NUM	O
min	O	NOUN	O
post	O	NOUN	B
-	O	PUNCT	O
infusion	O	NOUN	B
.	O	PUNCT	O


At	O	ADP	O
this	O	DET	O
time	O	NOUN	O
the	O	DET	O
induced	O	VERB	B
headache	B-Disease	NOUN	B
in	O	ADP	O
6	O	NUM	O
of	O	ADP	O
12	O	NUM	O
migraineurs	B-Disease	NOUN	B
fulfilled	O	VERB	O
the	O	DET	O
diagnostic	O	ADJ	B
criteria	O	NOUN	I
for	O	ADP	O
migraine	B-Disease	NOUN	B
without	I-Disease	ADP	O
aura	I-Disease	NOUN	B
of	O	ADP	O
the	O	DET	O
International	O	PROPN	B
Headache	B-Disease	PROPN	I
Society	O	PROPN	I
.	O	PUNCT	O


The	O	DET	O
results	O	NOUN	B
therefore	O	ADV	O
suggest	O	VERB	O
that	O	SCONJ	O
NO	B-Chemical	NOUN	B
is	O	AUX	O
involved	O	VERB	O
in	O	ADP	O
the	O	DET	O
pain	B-Disease	NOUN	B
mechanisms	O	NOUN	I
of	O	ADP	O
migraine	B-Disease	NOUN	B
with	I-Disease	ADP	O
aura	I-Disease	NOUN	B
.	O	PUNCT	O


Since	O	SCONJ	O
cortical	O	ADJ	B
spreading	O	NOUN	I
depression	B-Disease	NOUN	B
has	O	AUX	O
been	O	AUX	O
shown	O	VERB	O
to	O	PART	O
liberate	O	VERB	O
NO	B-Chemical	NOUN	B
in	O	ADP	O
animals	O	NOUN	B
,	O	PUNCT	O
this	O	DET	O
finding	O	NOUN	B
may	O	AUX	O
help	O	VERB	O
our	O	PRON	O
understanding	O	NOUN	O
of	O	ADP	O
the	O	DET	O
coupling	O	NOUN	B
between	O	ADP	O
cortical	O	ADJ	B
spreading	O	NOUN	I
depression	B-Disease	NOUN	B
and	O	CCONJ	O
headache	B-Disease	NOUN	B
in	O	ADP	O
migraine	B-Disease	NOUN	B
with	I-Disease	ADP	O
aura	I-Disease	NOUN	B


Stroke	B-Disease	NOUN	B
and	O	CCONJ	O
cocaine	B-Chemical	NOUN	B
or	O	CCONJ	O
amphetamine	B-Chemical	NOUN	B
use	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
association	O	NOUN	B
of	O	ADP	O
cocaine	B-Chemical	NOUN	B
and	O	CCONJ	O
amphetamine	B-Chemical	NOUN	B
use	O	NOUN	O
with	O	ADP	O
hemorrhagic	O	ADJ	B
and	O	CCONJ	O
ischemic	B-Disease	ADJ	B
stroke	B-Disease	NOUN	I
is	O	AUX	O
based	O	VERB	O
almost	O	ADV	O
solely	O	ADV	O
on	O	ADP	O
data	O	NOUN	B
from	O	ADP	O
case	O	NOUN	B
series	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
limited	O	ADJ	O
number	O	NOUN	O
of	O	ADP	O
epidemiologic	O	ADJ	B
studies	O	NOUN	I
of	O	ADP	O
stroke	B-Disease	NOUN	B
and	O	CCONJ	O
use	O	NOUN	O
of	O	ADP	O
cocaine	B-Chemical	NOUN	B
and	O	CCONJ	O
/	O	PUNCT	O
or	O	CCONJ	O
amphetamine	B-Chemical	NOUN	B
have	O	AUX	O
been	O	AUX	O
done	O	VERB	O
in	O	ADP	O
settings	O	NOUN	O
that	O	PRON	O
serve	O	VERB	O
mostly	O	ADV	O
the	O	DET	O
poor	O	ADJ	B
and	O	CCONJ	O
/	O	SYM	O
or	O	CCONJ	O
minorities	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
case	O	NOUN	B
-	O	PUNCT	O
control	O	NOUN	B
study	O	NOUN	I
was	O	AUX	O
conducted	O	VERB	O
in	O	ADP	O
the	O	DET	O
defined	O	VERB	O
population	O	NOUN	B
comprising	O	VERB	O
members	O	NOUN	B
of	O	ADP	O
Kaiser	O	PROPN	B
Permanente	O	PROPN	I
of	O	ADP	O
Northern	O	PROPN	B
and	O	CCONJ	O
Southern	O	PROPN	B
California	O	PROPN	I
.	O	PUNCT	O


We	O	PRON	O
attempted	O	VERB	O
to	O	PART	O
identify	O	VERB	O
all	O	DET	O
incident	O	NOUN	B
strokes	B-Disease	NOUN	B
in	O	ADP	O
women	O	NOUN	B
ages	O	VERB	B
15	O	NUM	O
-	O	SYM	O
44	O	NUM	O
years	O	NOUN	B
during	O	ADP	O
a	O	DET	O
3	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
period	O	NOUN	B
using	O	VERB	O
hospital	O	NOUN	B
admission	O	NOUN	I
and	O	CCONJ	O
discharge	O	NOUN	B
records	O	NOUN	I
,	O	PUNCT	O
emergency	O	NOUN	B
department	O	NOUN	I
logs	O	VERB	I
,	O	PUNCT	O
and	O	CCONJ	O
payment	O	NOUN	B
requests	O	NOUN	B
for	O	ADP	O
out	O	ADV	O
-	O	PUNCT	O
of	O	ADP	O
-	O	PUNCT	O
plan	O	NOUN	B
hospitalizations	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
selected	O	VERB	O
controls	O	NOUN	B
,	O	PUNCT	O
matched	O	VERB	B
on	O	ADP	O
age	O	NOUN	B
and	O	CCONJ	O
facility	O	NOUN	B
of	O	ADP	O
usual	O	ADJ	B
care	O	NOUN	I
,	O	PUNCT	O
at	O	ADP	O
random	O	ADJ	B
from	O	ADP	O
healthy	O	ADJ	B
members	O	NOUN	I
of	O	ADP	O
the	O	DET	O
health	O	NOUN	B
plan	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
obtained	O	VERB	O
information	O	NOUN	B
in	O	ADP	O
face	O	NOUN	B
-	O	PUNCT	O
to	O	ADP	O
-	O	PUNCT	O
face	O	NOUN	B
interviews	O	NOUN	B
.	O	PUNCT	O


There	O	PRON	O
were	O	AUX	O
347	O	NUM	O
confirmed	O	VERB	O
stroke	B-Disease	NOUN	B
cases	O	NOUN	B
and	O	CCONJ	O
1	O	NUM	O
,	O	PUNCT	O
021	O	NUM	O
controls	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
univariate	O	NOUN	B
matched	O	ADJ	O
odds	O	NOUN	O
ratio	O	NOUN	O
for	O	ADP	O
stroke	B-Disease	NOUN	B
in	O	ADP	O
women	O	NOUN	B
who	O	PRON	O
admitted	O	VERB	B
to	O	ADP	O
using	O	VERB	O
cocaine	B-Chemical	NOUN	B
and	O	CCONJ	O
/	O	PUNCT	O
or	O	CCONJ	O
amphetamine	B-Chemical	NOUN	B
was	O	AUX	O
8	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
=	O	ADJ	O
3	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
-	O	SYM	O
20	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
).	O	PUNCT	O
After	O	ADP	O
further	O	ADJ	O
adjustment	O	NOUN	B
for	O	ADP	O
potential	O	ADJ	B
confounders	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
odds	O	NOUN	B
ratio	O	NOUN	I
in	O	ADP	O
women	O	NOUN	B
who	O	PRON	O
reported	O	VERB	O
using	O	VERB	O
cocaine	B-Chemical	NOUN	B
and	O	CCONJ	O
/	O	PUNCT	O
or	O	CCONJ	O
amphetamine	B-Chemical	NOUN	B
was	O	AUX	O
7	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
=	O	ADJ	O
2	O	NUM	O
.	O	PUNCT	O


8	O	NUM	O
-	O	SYM	O
17	O	NUM	O
.	O	PUNCT	O


9	O	NUM	O
).	O	PUNCT	O
The	O	DET	O
use	O	NOUN	O
of	O	ADP	O
cocaine	B-Chemical	NOUN	B
and	O	CCONJ	O
/	O	PUNCT	O
or	O	CCONJ	O
amphetamine	B-Chemical	NOUN	B
is	O	AUX	O
a	O	DET	O
strong	O	ADJ	O
risk	O	NOUN	B
factor	O	NOUN	I
for	O	ADP	O
stroke	B-Disease	NOUN	B


Prevention	O	NOUN	B
of	O	ADP	O
breast	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
with	O	ADP	O
tamoxifen	B-Chemical	NOUN	B
:	O	PUNCT	O
preliminary	O	ADJ	O
findings	O	NOUN	B
from	O	ADP	O
the	O	DET	O
Italian	O	ADJ	B
randomised	O	ADJ	B
trial	O	NOUN	I
among	O	ADP	O
hysterectomised	O	ADJ	B
women	O	NOUN	B
.	O	PUNCT	O


Italian	O	ADJ	B
Tamoxifen	B-Chemical	PROPN	B
Prevention	O	PROPN	I
Study	O	PROPN	O
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
:	O	PUNCT	O
Tamoxifen	B-Chemical	NOUN	B
is	O	AUX	O
a	O	DET	O
candidate	O	NOUN	O
chemopreventive	O	ADJ	B
agent	O	NOUN	I
in	O	ADP	O
breast	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
,	O	PUNCT	O
although	O	SCONJ	O
the	O	DET	O
drug	O	NOUN	B
may	O	AUX	O
be	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
the	O	DET	O
development	O	NOUN	B
of	O	ADP	O
endometrial	B-Disease	ADJ	B
cancer	I-Disease	NOUN	I
.	O	PUNCT	O


Therefore	O	ADV	O
we	O	PRON	O
did	O	AUX	O
a	O	DET	O
trial	O	NOUN	B
in	O	ADP	O
hysterectomised	O	ADJ	B
women	O	NOUN	B
of	O	ADP	O
tamoxifen	B-Chemical	NOUN	B
as	O	ADP	O
a	O	DET	O
chemopreventive	O	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
:	O	PUNCT	O
In	O	ADP	O
October	O	PROPN	O
,	O	PUNCT	O
1992	O	NUM	O
,	O	PUNCT	O
we	O	PRON	O
started	O	VERB	O
a	O	DET	O
double	O	ADJ	B
-	O	PUNCT	O
blind	O	ADJ	B
placebo	O	NOUN	B
-	O	PUNCT	O
controlled	O	VERB	B
,	O	PUNCT	O
randomised	O	ADJ	B
trial	O	NOUN	I
of	O	ADP	O
tamoxifen	B-Chemical	NOUN	B
in	O	ADP	O
women	O	NOUN	B
(	O	PUNCT	O
mainly	O	ADV	O
in	O	ADP	O
Italy	O	PROPN	B
)	O	PUNCT	O
who	O	PRON	O
did	O	AUX	O
not	O	PART	O
have	O	AUX	O
breast	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
and	O	CCONJ	O
who	O	PRON	O
had	O	AUX	O
had	O	AUX	O
a	O	DET	O
hysterectomy	O	NOUN	B
.	O	PUNCT	O


Women	O	NOUN	B
were	O	AUX	O
randomised	O	VERB	B
to	O	PART	O
receive	O	VERB	O
tamoxifen	B-Chemical	NOUN	B
20	O	NUM	O
mg	O	NOUN	O
per	O	ADP	O
day	O	NOUN	B
or	O	CCONJ	O
placebo	O	NOUN	B
,	O	PUNCT	O
both	O	CCONJ	O
orally	O	ADV	B
for	O	ADP	O
5	O	NUM	O
years	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
original	O	ADJ	O
plan	O	NOUN	B
was	O	AUX	O
to	O	PART	O
follow	O	VERB	O
the	O	DET	O
intervention	O	NOUN	B
phase	O	NOUN	O
by	O	ADP	O
5	O	NUM	O
years	O	NOUN	B
'	O	PART	O
follow	O	NOUN	B
-	O	PUNCT	O
up	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
June	O	PROPN	O
,	O	PUNCT	O
1997	O	NUM	O
,	O	PUNCT	O
the	O	DET	O
trialists	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
data	O	NOUN	B
-	O	PUNCT	O
monitoring	O	VERB	B
committee	O	NOUN	B
decided	O	VERB	O
to	O	PART	O
end	O	VERB	O
recruitment	O	NOUN	B
primarily	O	ADV	O
because	O	SCONJ	O
of	O	ADP	O
the	O	DET	O
number	O	NOUN	O
of	O	ADP	O
women	O	NOUN	B
dropping	O	VERB	O
out	O	ADP	O
of	O	ADP	O
the	O	DET	O
study	O	NOUN	B
.	O	PUNCT	O


Recruitment	O	NOUN	B
ended	O	VERB	O
on	O	ADP	O
July	O	PROPN	O
11	O	NUM	O
,	O	PUNCT	O
1997	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
study	O	NOUN	B
will	O	AUX	O
continue	O	VERB	O
as	O	ADP	O
planned	O	VERB	B
.	O	PUNCT	O


The	O	DET	O
primary	O	ADJ	O
endpoints	O	NOUN	B
are	O	AUX	O
the	O	DET	O
occurrence	O	NOUN	B
of	O	ADP	O
and	O	CCONJ	O
deaths	O	NOUN	B
from	O	ADP	O
breast	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
.	O	PUNCT	O


This	O	DET	O
preliminary	O	ADJ	O
interim	O	ADJ	B
analysis	O	NOUN	I
is	O	AUX	O
based	O	VERB	O
on	O	ADP	O
intention	O	NOUN	B
-	O	PUNCT	O
to	O	PART	O
-	O	PUNCT	O
treat	O	NOUN	B
.	O	PUNCT	O


FINDINGS	O	NOUN	B
:	O	PUNCT	O
5408	O	NUM	O
women	O	NOUN	B
were	O	AUX	O
randomised	O	VERB	B
;	O	PUNCT	O
participating	O	VERB	O
women	O	NOUN	B
have	O	AUX	O
a	O	DET	O
median	O	ADJ	B
follow	O	NOUN	B
-	O	PUNCT	O
up	O	NOUN	O
of	O	ADP	O
46	O	NUM	O
months	O	NOUN	B
for	O	ADP	O
major	O	ADJ	O
endpoints	O	NOUN	B
.	O	PUNCT	O


41	O	NUM	O
cases	O	NOUN	B
of	O	ADP	O
breast	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
occurred	O	VERB	O
so	O	ADV	O
far	O	ADV	O
;	O	PUNCT	O
there	O	PRON	O
have	O	AUX	O
been	O	AUX	O
no	O	DET	B
deaths	O	NOUN	I
from	O	ADP	O
breast	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
.	O	PUNCT	O


There	O	PRON	O
is	O	AUX	O
no	O	DET	O
difference	O	NOUN	O
in	O	ADP	O
breast-cancer	B-Disease	NOUN	B
frequency	O	NOUN	I
between	O	ADP	O
the	O	DET	O
placebo	O	NOUN	B
(	O	PUNCT	O
22	O	NUM	O
cases	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
tamoxifen	B-Chemical	NOUN	B
(	O	PUNCT	O
19	O	NUM	O
)	O	PUNCT	O
arms	O	NOUN	O
.	O	PUNCT	O


There	O	PRON	O
is	O	AUX	O
a	O	DET	O
statistically	O	ADV	B
significant	O	ADJ	I
reduction	O	NOUN	B
of	O	ADP	O
breast	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
among	O	ADP	O
women	O	NOUN	B
receiving	O	VERB	O
tamoxifen	B-Chemical	NOUN	B
who	O	PRON	O
also	O	ADV	O
used	O	VERB	O
hormone	O	NOUN	B
-	O	PUNCT	O
replacement	O	NOUN	B
therapy	O	NOUN	I
during	O	ADP	O
the	O	DET	O
trial	O	NOUN	B
:	O	PUNCT	O
among	O	ADP	O
390	O	NUM	O
women	O	NOUN	B
on	O	ADP	O
such	O	ADJ	O
therapy	O	NOUN	B
and	O	CCONJ	O
allocated	O	VERB	O
to	O	ADP	O
placebo	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
found	O	VERB	O
eight	O	NUM	O
cases	O	NOUN	B
of	O	ADP	O
breast	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
compared	O	VERB	B
with	O	ADP	O
one	O	NUM	O
case	O	NOUN	B
among	O	ADP	O
362	O	NUM	O
women	O	NOUN	B
allocated	O	VERB	O
to	O	PART	O
tamoxifen	B-Chemical	NOUN	B
.	O	PUNCT	O


Compared	O	VERB	B
with	O	ADP	O
the	O	DET	O
placebo	O	NOUN	B
group	O	NOUN	B
,	O	PUNCT	O
there	O	PRON	O
was	O	AUX	O
a	O	DET	O
significantly	O	ADV	O
increased	O	VERB	B
risk	O	NOUN	B
of	O	ADP	O
vascular	B-Disease	ADJ	B
events	I-Disease	NOUN	I
and	O	CCONJ	O
hypertriglyceridaemia	B-Disease	NOUN	B
among	O	ADP	O
women	O	NOUN	B
on	O	ADP	O
tamoxifen	B-Chemical	NOUN	B
.	O	PUNCT	O


INTERPRETATION	O	NOUN	B
:	O	PUNCT	O
Although	O	SCONJ	O
this	O	DET	O
preliminary	O	ADJ	B
analysis	O	NOUN	I
has	O	AUX	O
low	O	ADJ	O
power	O	NOUN	B
,	O	PUNCT	O
in	O	ADP	O
this	O	DET	O
cohort	O	NOUN	B
of	O	ADP	O
women	O	NOUN	B
at	O	ADP	O
low	O	ADJ	B
-	O	PUNCT	O
to	O	ADP	O
-	O	PUNCT	O
normal	O	ADJ	B
risk	O	NOUN	B
of	O	ADP	O
breast	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
,	O	PUNCT	O
the	O	DET	O
postulated	O	ADJ	O
protective	O	ADJ	B
effects	O	NOUN	I
of	O	ADP	O
tamoxifen	B-Chemical	NOUN	B
are	O	AUX	O
not	O	PART	O
yet	O	ADV	O
apparent	O	ADJ	B
.	O	PUNCT	O


Women	O	NOUN	B
using	O	VERB	O
hormone	O	NOUN	B
-	O	PUNCT	O
replacement	O	NOUN	B
therapy	O	NOUN	I
appear	O	VERB	O
to	O	PART	O
have	O	AUX	O
benefited	O	VERB	O
from	O	ADP	O
use	O	NOUN	O
of	O	ADP	O
tamoxifen	B-Chemical	NOUN	B
.	O	PUNCT	O


There	O	PRON	O
were	O	AUX	O
no	O	DET	O
deaths	O	NOUN	O
from	O	ADP	O
breast	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
recorded	O	VERB	O
in	O	ADP	O
women	O	NOUN	B
in	O	ADP	O
the	O	DET	O
study	O	NOUN	B
.	O	PUNCT	O


It	O	PRON	O
is	O	AUX	O
essential	O	ADJ	O
to	O	PART	O
continue	O	VERB	O
follow	O	VERB	B
-	O	PUNCT	O
up	O	NOUN	O
to	O	PART	O
quantify	O	VERB	B
the	O	DET	O
long	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
risks	O	NOUN	B
and	O	CCONJ	O
benefits	O	NOUN	B
of	O	ADP	O
tamoxifen	B-Chemical	NOUN	B


A	O	DET	O
measure	O	NOUN	B
of	O	ADP	O
pupillary	B-Disease	ADJ	B
oscillation	I-Disease	NOUN	B
as	O	ADP	O
a	O	DET	O
marker	O	NOUN	B
of	O	ADP	O
cocaine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
paranoia	B-Disease	NOUN	B
.	O	PUNCT	O


Cocaine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
paranoia	B-Disease	NOUN	B
(	O	PUNCT	O
CIP	B-Disease	NOUN	B
)	O	PUNCT	O
remains	O	VERB	O
an	O	DET	O
important	O	ADJ	O
drug	O	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
model	O	NOUN	B
of	O	ADP	O
idiopathic	O	ADJ	B
paranoia	B-Disease	NOUN	I
for	O	ADP	O
which	O	DET	O
no	O	DET	O
psychophysiologic	O	ADJ	B
marker	O	NOUN	I
has	O	AUX	O
yet	O	ADV	O
emerged	O	VERB	O
.	O	PUNCT	O


Measures	O	NOUN	B
of	O	ADP	O
pupillary	B-Disease	ADJ	B
oscillation	I-Disease	NOUN	B
were	O	AUX	O
able	O	ADJ	O
to	O	PART	O
significantly	O	ADV	O
distinguish	O	VERB	O
a	O	DET	O
group	O	NOUN	B
of	O	ADP	O
abstinent	O	ADJ	B
crack	B-Chemical	NOUN	B
cocaine	I-Chemical	NOUN	B
abusers	O	NOUN	I
endorsing	O	VERB	O
past	O	ADJ	O
CIP	B-Disease	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
32	O	NUM	O
)	O	PUNCT	O
from	O	ADP	O
another	O	DET	O
group	O	NOUN	B
of	O	ADP	O
crack	B-Chemical	NOUN	B
addicts	O	NOUN	I
who	O	PRON	O
denied	O	VERB	O
past	O	ADP	O
CIP	B-Disease	NOUN	B


Seizures	B-Disease	NOUN	B
induced	O	VERB	B
by	O	ADP	O
combined	O	ADJ	O
levomepromazine	B-Chemical	NOUN	B
-	O	PUNCT	O
fluvoxamine	B-Chemical	NOUN	B
treatment	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
a	O	DET	O
case	O	NOUN	B
of	O	ADP	O
combined	O	ADJ	B
levomepromazine	B-Chemical	NOUN	B
-	O	PUNCT	O
fluvoxamine	B-Chemical	NOUN	B
treatment	O	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
seizures	B-Disease	NOUN	B
.	O	PUNCT	O


It	O	PRON	O
seems	O	VERB	O
that	O	SCONJ	O
combined	O	ADJ	B
treatment	O	NOUN	B
of	O	ADP	O
fluvoxamine	B-Chemical	NOUN	B
with	O	ADP	O
phenothiazines	B-Chemical	NOUN	B


Why	O	SCONJ	O
may	O	AUX	O
epsilon-aminocaproic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
(	O	PUNCT	O
EACA	B-Chemical	NOUN	B
)	O	PUNCT	O
induce	O	VERB	B
myopathy	B-Disease	NOUN	B
in	O	ADP	O
man	O	NOUN	B
?	O	PUNCT	O
Report	O	NOUN	B
of	O	ADP	O
a	O	DET	O
case	O	NOUN	B
and	O	CCONJ	O
literature	O	NOUN	B
review	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
case	O	NOUN	B
of	O	ADP	O
necrotizing	B-Disease	VERB	B
myopathy	I-Disease	NOUN	I
due	O	ADJ	O
to	O	PART	O
a	O	DET	O
short	O	ADJ	B
epsilon-aminocaproic	B-Chemical	ADJ	I
acid	I-Chemical	NOUN	I
(	O	PUNCT	O
EACA	B-Chemical	NOUN	B
)	O	PUNCT	O
treatment	O	NOUN	B
in	O	ADP	O
a	O	DET	O
72	O	NUM	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
patient	O	NOUN	B
with	O	ADP	O
subarachnoid	B-Disease	ADJ	B
haemorrhage	I-Disease	NOUN	I
(	O	PUNCT	O
SAH	B-Disease	NOUN	B


Comparison	O	NOUN	B
of	O	ADP	O
the	O	DET	O
effectiveness	O	NOUN	B
of	O	ADP	O
ranitidine	B-Chemical	NOUN	B
and	O	CCONJ	O
cimetidine	B-Chemical	NOUN	B
in	O	ADP	O
inhibiting	O	VERB	B
acid	O	NOUN	B
secretion	O	NOUN	I
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
gastric	O	ADJ	B
hypersecretory	O	ADJ	I
states	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
H2	O	NOUN	B
-	O	PUNCT	O
histamine	B-Chemical	NOUN	B
receptor	O	NOUN	I
antagonists	O	NOUN	B
ranitidine	B-Chemical	NOUN	B
and	O	CCONJ	O
cimetidine	B-Chemical	NOUN	B
were	O	AUX	O
compared	O	VERB	B
for	O	ADP	O
their	O	PRON	O
abilities	O	NOUN	B
to	O	PART	O
control	O	VERB	B
gastric	O	ADJ	I
acid	O	NOUN	I
hypersecretion	O	NOUN	I
on	O	ADP	O
a	O	DET	O
short	O	ADJ	B
-	O	PUNCT	O
and	O	CCONJ	O
long	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
basis	O	NOUN	O
in	O	ADP	O
22	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
gastric	O	ADJ	B
acid	O	NOUN	I
hypersecretory	O	ADJ	I
states	O	NOUN	I
.	O	PUNCT	O


Nineteen	O	NUM	O
patients	O	NOUN	B
had	O	AUX	O
Zollinger-Ellison	B-Disease	NOUN	B
syndrome	I-Disease	NOUN	I
,	O	PUNCT	O
one	O	NUM	O
patient	O	NOUN	B
had	O	AUX	O
systemic	B-Disease	ADJ	B
mastocytosis	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
two	O	NUM	O
patients	O	NOUN	B
had	O	AUX	O
idiopathic	O	ADJ	B
hypersecretion	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
rates	O	NOUN	B
of	O	ADP	O
onset	O	NOUN	O
of	O	ADP	O
the	O	DET	O
action	O	NOUN	B
of	O	ADP	O
cimetidine	B-Chemical	NOUN	B
and	O	CCONJ	O
ranitidine	B-Chemical	NOUN	B
were	O	AUX	O
the	O	DET	O
same	O	ADJ	O
.	O	PUNCT	O


The	O	DET	O
actions	O	NOUN	B
of	O	ADP	O
both	O	DET	O
drugs	O	NOUN	B
were	O	AUX	O
increased	O	VERB	B
by	O	ADP	O
anticholinergic	O	ADJ	B
agents	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
there	O	PRON	O
was	O	AUX	O
a	O	DET	O
close	O	ADJ	O
correlation	O	NOUN	B
between	O	ADP	O
the	O	DET	O
daily	O	ADJ	B
maintenance	O	NOUN	O
dose	O	NOUN	O
of	O	ADP	O
each	O	DET	O
drug	O	NOUN	B
needed	O	VERB	O
to	O	PART	O
control	O	VERB	B
acid	O	NOUN	I
secretion	O	NOUN	I
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
ranitidine	B-Chemical	NOUN	B
was	O	AUX	O
threefold	O	ADV	O
more	O	ADV	O
potent	O	ADJ	O
than	O	ADP	O
cimetidine	B-Chemical	NOUN	B
both	O	CCONJ	O
in	O	ADP	O
acute	O	ADJ	B
inhibition	O	NOUN	I
studies	O	NOUN	I
and	O	CCONJ	O
in	O	ADP	O
the	O	DET	O
median	O	ADJ	B
maintenance	O	NOUN	O
dose	O	NOUN	O
needed	O	VERB	O
(	O	PUNCT	O
1	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
g	O	NOUN	O
per	O	ADP	O
day	O	NOUN	B
for	O	ADP	O
ranitidine	B-Chemical	NOUN	B
and	O	CCONJ	O
3	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
g	O	NOUN	O
per	O	ADP	O
day	O	NOUN	B
for	O	ADP	O
cimetidine	B-Chemical	NOUN	B
).	O	PUNCT	O
Sixty	O	NUM	O
percent	O	NOUN	O
of	O	ADP	O
the	O	DET	O
males	O	NOUN	B
developed	O	VERB	O
breast	O	NOUN	B
changes	O	NOUN	I
or	O	CCONJ	O
impotence	B-Disease	NOUN	B
while	O	SCONJ	O
taking	O	VERB	O
cimetidine	B-Chemical	NOUN	B
and	O	CCONJ	O
in	O	ADP	O
all	O	DET	O
cases	O	NOUN	B
these	O	DET	O
changes	O	NOUN	B
disappeared	O	VERB	O
when	O	SCONJ	O
cimetidine	B-Chemical	NOUN	B
was	O	AUX	O
replaced	O	VERB	O
by	O	ADP	O
ranitidine	B-Chemical	NOUN	B
.	O	PUNCT	O


Treatment	O	NOUN	B
with	O	ADP	O
high	O	ADJ	B
doses	O	NOUN	I
of	O	ADP	O
cimetidine	B-Chemical	NOUN	B
(	O	PUNCT	O
one	O	NUM	O
to	O	PART	O
60	O	NUM	O
months	O	NOUN	B
;	O	PUNCT	O
median	O	ADJ	B
,	O	PUNCT	O
11	O	NUM	O
months	O	NOUN	B
)	O	PUNCT	O
or	O	CCONJ	O
ranitidine	B-Chemical	NOUN	B
(	O	PUNCT	O
two	O	NUM	O
to	O	PART	O
31	O	NUM	O
months	O	NOUN	B
;	O	PUNCT	O
median	O	ADJ	B
,	O	PUNCT	O
14	O	NUM	O
months	O	NOUN	B
)	O	PUNCT	O
was	O	AUX	O
not	O	PART	O
associated	O	VERB	B
with	O	ADP	I
hepatic	B-Disease	ADJ	B
or	I-Disease	CCONJ	O
hematologic	I-Disease	ADJ	B
toxicity	I-Disease	NOUN	B
or	O	CCONJ	O
alterations	O	NOUN	B
of	O	ADP	O
serum	O	NOUN	B
gastrin	O	NOUN	B
concentrations	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
ranitidine	B-Chemical	NOUN	B
therapy	O	NOUN	B
was	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
a	O	DET	O
significantly	O	ADV	O
lower	O	ADJ	O
serum	O	NOUN	B
creatinine	B-Chemical	NOUN	I
level	O	NOUN	I
than	O	ADP	O
seen	O	VERB	O
with	O	ADP	O
cimetidine	B-Chemical	NOUN	B
therapy	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
results	O	NOUN	B
show	O	VERB	O
that	O	SCONJ	O
both	O	DET	O
drugs	O	NOUN	B
can	O	AUX	O
adequately	O	ADV	O
inhibit	O	VERB	B
acid	O	NOUN	B
secretion	O	NOUN	I
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
gastric	O	ADJ	B
hypersecretory	O	ADJ	I
states	O	NOUN	I
.	O	PUNCT	O


Both	O	DET	O
are	O	AUX	O
safe	O	ADJ	O
at	O	ADP	O
high	O	ADJ	B
doses	O	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
ranitidine	B-Chemical	NOUN	B
is	O	AUX	O
threefold	O	ADV	O
more	O	ADV	O
potent	O	ADJ	O
and	O	CCONJ	O
does	O	AUX	O
not	O	PART	O
cause	O	VERB	O
the	O	DET	O
antiandrogen	O	ADJ	B
side	O	NOUN	B
effects	O	NOUN	I
frequently	O	ADV	O
seen	O	VERB	O
with	O	ADP	O
high	O	ADJ	B
doses	O	NOUN	I
of	O	ADP	O
cimetidine	B-Chemical	NOUN	B


A	O	DET	O
catch	O	NOUN	B
in	O	ADP	O
the	O	DET	O
Reye	B-Disease	PROPN	B
.	O	PUNCT	O


Twenty	O	NUM	B
-	O	PUNCT	O
six	O	NUM	O
cases	O	NOUN	B
of	O	ADP	O
Reye	B-Disease	NOUN	B
syndrome	I-Disease	NOUN	I
from	O	ADP	O
The	O	DET	O
Children	O	PROPN	B
'	O	PART	O
s	O	PROPN	O
Hospital	O	PROPN	B
,	O	PUNCT	O
Camperdown	O	PROPN	B
,	O	PUNCT	O
Australia	O	PROPN	B
,	O	PUNCT	O
occurring	O	VERB	O
between	O	ADP	O
1973	O	NUM	O
and	O	CCONJ	O
1982	O	NUM	O
were	O	AUX	O
reviewed	O	VERB	B
.	O	PUNCT	O


Of	O	ADP	O
these	O	DET	O
,	O	PUNCT	O
20	O	NUM	O
cases	O	NOUN	B
met	O	VERB	O
the	O	DET	O
US	O	PROPN	B
Public	O	PROPN	B
Health	O	PROPN	I
Service	O	PROPN	I
Centers	O	PROPN	I
for	O	ADP	I
Disease	O	PROPN	I
Control	O	PROPN	O
criteria	O	NOUN	O
for	O	ADP	O
the	O	DET	O
diagnosis	O	NOUN	B
of	O	ADP	O
Reye	B-Disease	NOUN	B
syndrome	I-Disease	NOUN	I
.	O	PUNCT	O


Aspirin	B-Chemical	NOUN	B
or	O	CCONJ	O
salicylate	B-Chemical	NOUN	B
ingestion	O	NOUN	B
had	O	AUX	O
occurred	O	VERB	O
in	O	ADP	O
only	O	ADV	O
one	O	NUM	O
of	O	ADP	O
the	O	DET	O
20	O	NUM	O
cases	O	NOUN	B
(	O	PUNCT	O
5	O	NUM	O
%),	O	ADJ	O
and	O	CCONJ	O
paracetamol	B-Chemical	NOUN	B
(	O	PUNCT	O
acetaminophen	B-Chemical	NOUN	B
)	O	PUNCT	O
had	O	AUX	O
been	O	AUX	O
administered	O	VERB	B
in	O	ADP	O
only	O	ADV	O
six	O	NUM	O
of	O	ADP	O
the	O	DET	O
cases	O	NOUN	B
(	O	PUNCT	O
30	O	NUM	O
%).	O	ADJ	O
Pathologic	O	ADJ	B
confirmation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
diagnosis	O	NOUN	B
of	O	ADP	O
Reye	B-Disease	NOUN	B
syndrome	I-Disease	NOUN	I
was	O	AUX	O
accomplished	O	VERB	O
in	O	ADP	O
90	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
cases	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
incidence	O	NOUN	B
of	O	ADP	O
Reye	B-Disease	NOUN	B
syndrome	I-Disease	NOUN	I
in	O	ADP	O
New	O	ADJ	B
South	O	PROPN	I
Wales	O	PROPN	I
,	O	PUNCT	O
Australia	O	PROPN	B
,	O	PUNCT	O
is	O	AUX	O
estimated	O	VERB	O
from	O	ADP	O
this	O	DET	O
study	O	NOUN	B
to	O	PART	O
be	O	AUX	O
approximately	O	ADV	O
nine	O	NUM	O
cases	O	NOUN	B
per	O	ADP	O
1	O	NUM	O
million	O	NUM	O
children	O	NOUN	B
compared	O	VERB	B
with	O	ADP	O
recent	O	ADJ	O
US	O	PROPN	B
data	O	NOUN	B
of	O	ADP	O
ten	O	NUM	O
to	O	PART	O
20	O	NUM	O
cases	O	NOUN	B
per	O	ADP	O
1	O	NUM	O
million	O	NUM	O
children	O	NOUN	B
and	O	CCONJ	O
three	O	NUM	O
to	O	PART	O
seven	O	NUM	O
cases	O	NOUN	B
per	O	ADP	O
1	O	NUM	O
million	O	NUM	O
children	O	NOUN	B
in	O	ADP	O
Great	O	PROPN	B
Britain	O	PROPN	I
.	O	PUNCT	O


The	O	DET	O
mortality	O	NOUN	B
for	O	ADP	O
these	O	DET	O
Reye	B-Disease	NOUN	B
syndrome	I-Disease	NOUN	I
cases	O	NOUN	B
in	O	ADP	O
Australia	O	PROPN	B
was	O	AUX	O
45	O	NUM	O
%	O	NOUN	O
as	O	ADP	O
compared	O	VERB	B
with	O	ADP	O
a	O	DET	O
32	O	NUM	O
%	O	NOUN	O
case	O	NOUN	B
-	O	PUNCT	O
fatality	O	NOUN	B
rate	O	NOUN	B
in	O	ADP	O
the	O	DET	O
United	O	PROPN	B
States	O	PROPN	I
.	O	PUNCT	O


In	O	ADP	O
Australia	O	PROPN	B
,	O	PUNCT	O
the	O	DET	O
pediatric	O	ADJ	B
usage	O	NOUN	B
of	O	ADP	O
aspirin	B-Chemical	NOUN	B
has	O	AUX	O
been	O	AUX	O
extremely	O	ADV	O
low	O	ADJ	B
for	O	ADP	O
the	O	DET	O
past	O	ADJ	O
25	O	NUM	O
years	O	NOUN	B
(	O	PUNCT	O
less	O	ADJ	O
than	O	ADP	O
1	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
total	O	ADJ	O
dosage	O	NOUN	B
units	O	NOUN	O
sold	O	VERB	B
),	O	PUNCT	O
with	O	ADP	O
paracetamol	B-Chemical	NOUN	B
(	O	PUNCT	O
acetaminophen	B-Chemical	NOUN	B
)	O	PUNCT	O
dominating	O	VERB	O
the	O	DET	O
pediatric	O	ADJ	B
analgesic	O	NOUN	B
and	O	CCONJ	O
antipyretic	O	ADJ	B
market	O	NOUN	B
.	O	PUNCT	O


Reye	B-Disease	NOUN	B
syndrome	I-Disease	NOUN	I
may	O	AUX	O
be	O	AUX	O
disappearing	O	VERB	O
from	O	ADP	O
Australia	O	PROPN	B
despite	O	SCONJ	O
a	O	DET	O
total	O	ADJ	O
lack	O	NOUN	O
of	O	ADP	O
association	O	NOUN	B
with	O	ADP	O
salicylates	B-Chemical	NOUN	B
or	O	CCONJ	O
aspirin	B-Chemical	NOUN	B


St.	B-Disease	PROPN	B
Anthony's	I-Disease	PROPN	O
fire	I-Disease	NOUN	B
,	O	PUNCT	O
then	O	ADV	O
and	O	CCONJ	O
now	O	ADV	O
:	O	PUNCT	O
a	O	DET	O
case	O	NOUN	B
report	O	NOUN	I
and	O	CCONJ	O
historical	O	ADJ	B
review	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
rare	O	ADJ	B
case	O	NOUN	B
of	O	ADP	O
morbid	O	NOUN	B
vasospasm	B-Disease	NOUN	I
,	O	PUNCT	O
together	O	ADV	O
with	O	ADP	O
striking	O	ADJ	O
angiographic	O	ADJ	B
findings	O	NOUN	B
,	O	PUNCT	O
is	O	AUX	O
described	O	VERB	O
secondary	O	ADJ	B
to	O	PART	O
the	O	DET	O
ingestion	O	NOUN	B
of	O	ADP	O
methysergide	B-Chemical	NOUN	B
by	O	ADP	O
a	O	DET	O
48	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
woman	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
brief	O	ADJ	O
review	O	NOUN	O
of	O	ADP	O
the	O	DET	O
literature	O	NOUN	B
on	O	ADP	O
similar	O	ADJ	O
cases	O	NOUN	B
is	O	AUX	O
presented	O	VERB	O
.	O	PUNCT	O


A	O	DET	O
discussion	O	NOUN	B
of	O	ADP	O
the	O	DET	O
history	O	NOUN	B
of	O	ADP	O
ergot	B-Chemical	NOUN	B
includes	O	VERB	O
its	O	PRON	O
original	O	ADJ	B
discovery	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
epidemics	O	NOUN	B
of	O	ADP	O
gangrene	B-Disease	NOUN	B
that	O	SCONJ	O
it	O	PRON	O
has	O	AUX	O
caused	O	VERB	O
through	O	ADP	O
the	O	DET	O
ages	O	NOUN	B
and	O	CCONJ	O
its	O	PRON	O
past	O	NOUN	O
and	O	CCONJ	O
present	O	ADJ	O
role	O	NOUN	O
in	O	ADP	O
the	O	DET	O
management	O	NOUN	B
of	O	ADP	O
migraine	B-Disease	NOUN	B
headache	I-Disease	NOUN	I
.	O	PUNCT	O


Despite	O	SCONJ	O
the	O	DET	O
advent	O	NOUN	B
of	O	ADP	O
calcium	B-Chemical	NOUN	B
channel	O	NOUN	I
blockers	O	NOUN	I
and	O	CCONJ	O
beta	O	NOUN	B
-	O	PUNCT	O
adrenergic	O	ADJ	B
antagonists	O	NOUN	B
,	O	PUNCT	O
ergot	B-Chemical	NOUN	B
preparations	O	NOUN	I
continue	O	VERB	O
to	O	PART	O
play	O	VERB	O
a	O	DET	O
major	O	ADJ	O
role	O	NOUN	O
in	O	ADP	O
migraine	B-Disease	NOUN	B
therapy	O	NOUN	I
,	O	PUNCT	O
so	O	SCONJ	O
that	O	SCONJ	O
the	O	DET	O
danger	O	NOUN	B
of	O	ADP	O
St.	B-Disease	PROPN	B
Anthony's	I-Disease	PROPN	O
fire	I-Disease	NOUN	B


Beta	O	NOUN	B
-	O	PUNCT	O
2	O	NUM	B
-	O	PUNCT	O
adrenoceptor	O	NOUN	B
-	O	PUNCT	O
mediated	O	VERB	B
hypokalemia	B-Disease	NOUN	B
and	O	CCONJ	O
its	O	PRON	O
abolishment	O	NOUN	B
by	O	ADP	O
oxprenolol	B-Chemical	NOUN	B
.	O	PUNCT	O


The	O	DET	O
time	O	NOUN	B
course	O	NOUN	I
and	O	CCONJ	O
concentration	O	NOUN	B
-	O	PUNCT	O
effect	O	NOUN	B
relationship	O	NOUN	B
of	O	ADP	O
terbutaline	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
hypokalemia	B-Disease	NOUN	B
was	O	AUX	O
studied	O	VERB	O
,	O	PUNCT	O
using	O	VERB	O
computer	O	NOUN	B
-	O	PUNCT	O
aided	O	VERB	B
pharmacokinetic	O	ADJ	B
-	O	PUNCT	O
dynamic	O	ADJ	B
modeling	O	NOUN	O
.	O	PUNCT	O


Subsequently	O	ADV	O
we	O	PRON	O
investigated	O	VERB	B
the	O	DET	O
efficacy	O	NOUN	B
of	O	ADP	O
oxprenolol	B-Chemical	NOUN	B
in	O	ADP	O
antagonizing	O	VERB	B
such	O	ADJ	O
hypokalemia	B-Disease	NOUN	B
,	O	PUNCT	O
together	O	ADV	O
with	O	ADP	O
the	O	DET	O
pharmacokinetic	O	ADJ	B
interaction	O	NOUN	B
between	O	ADP	O
both	O	DET	O
drugs	O	NOUN	B
.	O	PUNCT	O


Six	O	NUM	O
healthy	O	ADJ	B
subjects	O	NOUN	I
were	O	AUX	O
given	O	VERB	O
a	O	DET	O
0	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
mg	O	NOUN	O
subcutaneous	O	ADJ	B
dose	O	NOUN	I
of	O	ADP	O
terbutaline	B-Chemical	NOUN	B
on	O	ADP	O
two	O	NUM	O
occasions	O	NOUN	B
:	O	PUNCT	O
1	O	NUM	O
hour	O	NOUN	B
after	O	ADP	O
oral	O	ADJ	B
administration	O	NOUN	I
of	O	ADP	O
a	O	DET	O
placebo	O	NOUN	B
and	O	CCONJ	O
1	O	NUM	O
hour	O	NOUN	B
after	O	ADP	O
80	O	NUM	O
mg	O	NOUN	O
oxprenolol	B-Chemical	NOUN	B
orally	O	ADV	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
7	O	NUM	O
-	O	PUNCT	O
hour	O	NOUN	B
period	O	NOUN	B
after	O	ADP	O
terbutaline	B-Chemical	NOUN	B
administration	O	NOUN	B
,	O	PUNCT	O
plasma	O	NOUN	B
samples	O	NOUN	I
were	O	AUX	O
taken	O	VERB	O
for	O	ADP	O
determination	O	NOUN	B
of	O	ADP	O
plasma	O	NOUN	B
potassium	B-Chemical	NOUN	O
levels	O	NOUN	O
and	O	CCONJ	O
drug	O	NOUN	B
concentrations	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
sigmoid	O	NOUN	B
Emax	O	PROPN	B
model	O	NOUN	I
offered	O	VERB	O
a	O	DET	O
good	O	ADJ	O
description	O	NOUN	B
of	O	ADP	O
the	O	DET	O
relation	O	NOUN	O
between	O	ADP	O
terbutaline	B-Chemical	NOUN	B
concentrations	O	NOUN	B
and	O	CCONJ	O
potassium	B-Chemical	NOUN	B
effects	O	NOUN	I
.	O	PUNCT	O


Oxprenolol	B-Chemical	PROPN	B
caused	O	VERB	O
decreases	O	NOUN	B
of	O	ADP	O
65	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
56	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
terbutaline	B-Chemical	NOUN	B
volume	O	NOUN	B
of	O	ADP	O
distribution	O	NOUN	B
and	O	CCONJ	O
clearance	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
,	O	PUNCT	O
and	O	CCONJ	O
an	O	DET	O
increase	O	NOUN	B
of	O	ADP	O
130	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
its	O	PRON	O
AUC	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
spite	O	NOUN	O
of	O	ADP	O
higher	O	ADJ	B
terbutaline	B-Chemical	NOUN	B
concentrations	O	NOUN	B
after	O	ADP	O
oxprenolol	B-Chemical	NOUN	B
pretreatment	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
hypokalemia	B-Disease	NOUN	B


Midline	O	ADJ	B
B3	O	NOUN	I
serotonin	B-Chemical	NOUN	B
nerves	O	NOUN	I
in	O	ADP	O
rat	O	NOUN	B
medulla	O	NOUN	B
are	O	AUX	O
involved	O	VERB	O
in	O	ADP	O
hypotensive	B-Disease	ADJ	B
effect	O	NOUN	I
of	O	ADP	O
methyldopa	B-Chemical	NOUN	B
.	O	PUNCT	O


Previous	O	ADJ	O
experiments	O	NOUN	B
in	O	ADP	O
this	O	DET	O
laboratory	O	NOUN	B
have	O	AUX	O
shown	O	VERB	O
that	O	SCONJ	O
microinjection	O	NOUN	B
of	O	ADP	O
methyldopa	B-Chemical	NOUN	B
onto	O	ADP	O
the	O	DET	O
ventrolateral	O	ADJ	B
cells	O	NOUN	I
of	O	ADP	O
the	O	DET	O
B3	O	NOUN	B
serotonin	B-Chemical	NOUN	B
neurons	O	NOUN	B
in	O	ADP	O
the	O	DET	O
medulla	O	NOUN	B
elicits	O	VERB	O
a	O	DET	O
hypotensive	B-Disease	ADJ	B
response	O	NOUN	I
mediated	O	VERB	O
by	O	ADP	O
a	O	DET	O
projection	O	NOUN	B
descending	O	VERB	I
into	O	ADP	O
the	O	DET	O
spinal	O	ADJ	B
cord	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
present	O	ADJ	O
experiments	O	NOUN	B
were	O	AUX	O
designed	O	VERB	O
to	O	PART	O
investigate	O	VERB	B
the	O	DET	O
role	O	NOUN	O
of	O	ADP	O
the	O	DET	O
midline	O	NOUN	B
cells	O	NOUN	I
of	O	ADP	O
the	O	DET	O
B3	O	NOUN	B
serotonin	B-Chemical	NOUN	B
neurons	O	NOUN	B
in	O	ADP	O
the	O	DET	O
medulla	O	NOUN	B
,	O	PUNCT	O
coinciding	O	VERB	O
with	O	ADP	O
the	O	DET	O
raphe	O	NOUN	B
magnus	O	X	I
.	O	PUNCT	O


In	O	ADP	O
spontaneously	O	ADV	B
hypertensive	B-Disease	ADJ	I
,	O	PUNCT	O
stroke	B-Disease	NOUN	B
-	O	PUNCT	O
prone	O	ADJ	B
rats	O	NOUN	B
,	O	PUNCT	O
microinjection	O	NOUN	B
of	O	ADP	O
methyldopa	B-Chemical	NOUN	B
into	O	ADP	O
the	O	DET	O
area	O	NOUN	B
of	O	ADP	O
the	O	DET	O
midline	O	NOUN	B
B3	O	NOUN	I
serotonin	B-Chemical	NOUN	B
cell	O	NOUN	I
group	O	NOUN	O
in	O	ADP	O
the	O	DET	O
ventral	O	ADJ	B
medulla	O	NOUN	I
caused	O	VERB	O
a	O	DET	O
potent	O	ADJ	O
hypotension	B-Disease	NOUN	B
of	O	ADP	O
30	O	NUM	O
-	O	SYM	O
40	O	NUM	O
mm	O	NOUN	B
Hg	O	NOUN	I
,	O	PUNCT	O
which	O	DET	O
was	O	AUX	O
maximal	O	ADJ	B
2	O	NUM	O
-	O	SYM	O
3	O	NUM	O
h	O	NOUN	O
after	O	ADP	O
administration	O	NOUN	B
and	O	CCONJ	O
was	O	AUX	O
abolished	O	VERB	O
by	O	ADP	O
the	O	DET	O
serotonin	B-Chemical	NOUN	B
neurotoxin	O	NOUN	I
5,7-dihydroxytryptamine	B-Chemical	NOUN	I
(	O	PUNCT	O
5,7-DHT	B-Chemical	NOUN	B
)	O	PUNCT	O
injected	O	VERB	O
intracerebroventricularly	O	ADV	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
intraspinal	O	ADJ	B
injection	O	NOUN	I
of	O	ADP	O
5,7-DHT	B-Chemical	NOUN	B
to	O	PART	O
produce	O	VERB	O
a	O	DET	O
more	O	ADV	O
selective	O	ADJ	O
lesion	O	NOUN	B
of	O	ADP	O
only	O	ADV	O
descending	O	ADJ	B
serotonin	B-Chemical	NOUN	B
projections	O	NOUN	B
in	O	ADP	O
the	O	DET	O
spinal	O	ADJ	B
cord	O	NOUN	I
did	O	AUX	O
not	O	PART	O
affect	O	VERB	O
this	O	DET	O
hypotension	B-Disease	NOUN	B
.	O	PUNCT	O


Further	O	ADV	O
,	O	PUNCT	O
5,7-DHT	B-Chemical	NOUN	B
lesion	O	NOUN	I
of	O	ADP	O
serotonin	B-Chemical	NOUN	B
nerves	O	NOUN	I
travelling	O	VERB	O
in	O	ADP	O
the	O	DET	O
median	O	ADJ	O
forebrain	O	NOUN	B
bundle	O	NOUN	B
,	O	PUNCT	O
one	O	NUM	O
of	O	ADP	O
the	O	DET	O
main	O	ADJ	O
ascending	O	NOUN	B
pathways	O	NOUN	O
from	O	ADP	O
the	O	DET	O
B3	O	NOUN	B
serotonin	B-Chemical	NOUN	I
cells	O	NOUN	I
,	O	PUNCT	O
did	O	AUX	O
not	O	PART	O
affect	O	VERB	O
the	O	DET	O
fall	O	NOUN	B
in	O	ADP	O
blood	O	NOUN	B
pressure	O	NOUN	I
associated	O	VERB	B
with	O	ADP	I
a	O	DET	O
midline	O	NOUN	B
B3	O	NOUN	I
serotonin	B-Chemical	NOUN	O
methyldopa	B-Chemical	NOUN	B
injection	O	NOUN	B
.	O	PUNCT	O


It	O	PRON	O
is	O	AUX	O
concluded	O	VERB	O
therefore	O	ADV	O
that	O	DET	O
,	O	PUNCT	O
unlike	O	ADP	O
the	O	DET	O
ventrolateral	O	ADJ	B
B3	O	NOUN	I
cells	O	NOUN	I
which	O	DET	O
mediate	O	VERB	O
a	O	DET	O
methyldopa	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
hypotension	B-Disease	NOUN	B
via	O	ADP	O
descending	O	ADJ	B
projections	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
midline	O	NOUN	B
serotonin	B-Chemical	NOUN	O
B3	O	NOUN	O
cells	O	NOUN	O
in	O	ADP	O
the	O	DET	O
medulla	O	NOUN	B
contribute	O	VERB	O
to	O	PART	O
the	O	DET	O
hypotensive	B-Disease	ADJ	B
action	O	NOUN	I
of	O	ADP	O
methyldopa	B-Chemical	NOUN	B


Yohimbine	B-Chemical	NOUN	B
treatment	O	NOUN	B
of	O	ADP	O
sexual	B-Disease	ADJ	B
side	I-Disease	NOUN	I
effects	I-Disease	NOUN	I
induced	O	VERB	B
by	O	ADP	O
serotonin	B-Chemical	NOUN	B
reuptake	O	NOUN	I
blockers	O	NOUN	I
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
:	O	PUNCT	O
Preclinical	O	ADJ	B
and	O	CCONJ	O
clinical	O	ADJ	B
studies	O	NOUN	I
suggest	O	VERB	O
that	O	SCONJ	O
yohimbine	B-Chemical	NOUN	B
facilitates	O	VERB	O
sexual	O	ADJ	B
behavior	O	NOUN	I
and	O	CCONJ	O
may	O	AUX	O
be	O	AUX	O
helpful	O	ADJ	O
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
male	B-Disease	NOUN	B
impotence	I-Disease	NOUN	B
.	O	PUNCT	O


A	O	DET	O
single	O	ADJ	O
case	O	NOUN	O
report	O	NOUN	O
suggests	O	VERB	O
that	O	SCONJ	O
yohimbine	B-Chemical	NOUN	B
may	O	AUX	O
be	O	AUX	O
used	O	VERB	O
to	O	PART	O
treat	O	VERB	B
the	O	DET	O
sexual	B-Disease	ADJ	B
side	I-Disease	NOUN	I
effects	I-Disease	NOUN	I
of	O	ADP	O
clomipramine	B-Chemical	NOUN	B
.	O	PUNCT	O


This	O	DET	O
study	O	NOUN	B
evaluated	O	VERB	B
yohimbine	B-Chemical	NOUN	B
as	O	ADP	O
a	O	DET	O
treatment	O	NOUN	B
for	O	ADP	O
the	O	DET	O
sexual	B-Disease	ADJ	B
side	I-Disease	NOUN	I
effects	I-Disease	NOUN	I
caused	O	VERB	O
by	O	ADP	O
serotonin	B-Chemical	NOUN	B
reuptake	O	NOUN	I
blockers	O	NOUN	I
.	O	PUNCT	O


METHOD	O	NOUN	B
:	O	PUNCT	O
Six	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
either	O	DET	O
obsessive	B-Disease	ADJ	B
compulsive	I-Disease	ADJ	I
disorder	I-Disease	NOUN	I
,	O	PUNCT	O
trichotillomania	B-Disease	NOUN	B
,	O	PUNCT	O
anxiety	B-Disease	NOUN	B
,	O	PUNCT	O
or	O	CCONJ	O
affective	B-Disease	ADJ	B
disorders	I-Disease	NOUN	I
who	O	PRON	O
suffered	O	VERB	O
sexual	B-Disease	ADJ	B
side	I-Disease	NOUN	I
effects	I-Disease	NOUN	I
after	O	ADP	O
treatment	O	NOUN	B
with	O	ADP	O
serotonin	B-Chemical	NOUN	B
reuptake	O	NOUN	I
blockers	O	NOUN	I
were	O	AUX	O
given	O	VERB	O
yohimbine	B-Chemical	NOUN	B
on	O	ADP	O
a	O	DET	O
p	O	NOUN	O
.	O	PUNCT	O


r	O	NOUN	O
.	O	PUNCT	O


n	O	NOUN	O
.	O	PUNCT	O


basis	O	NOUN	O
in	O	ADP	O
an	O	DET	O
open	O	ADJ	O
clinical	O	ADJ	O
trial	O	NOUN	O
.	O	PUNCT	O


Various	O	ADJ	O
doses	O	NOUN	B
of	O	ADP	O
yohimbine	B-Chemical	NOUN	B
were	O	AUX	O
used	O	VERB	O
to	O	PART	O
determine	O	VERB	O
the	O	DET	O
ideal	O	ADJ	B
dose	O	NOUN	I
for	O	ADP	O
each	O	DET	O
patient	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
Five	O	NUM	O
of	O	ADP	O
the	O	DET	O
six	O	NUM	O
patients	O	NOUN	B
experienced	O	VERB	O
improved	O	ADJ	B
sexual	O	ADJ	B
functioning	O	NOUN	I
after	O	ADP	O
taking	O	VERB	O
yohimbine	B-Chemical	NOUN	B
.	O	PUNCT	O


One	O	NUM	O
patient	O	NOUN	B
who	O	PRON	O
failed	O	VERB	B
to	O	PART	O
comply	O	VERB	O
with	O	ADP	O
yohimbine	B-Chemical	NOUN	B
treatment	O	NOUN	B
had	O	AUX	O
no	O	DET	O
therapeutic	O	ADJ	B
effects	O	NOUN	I
.	O	PUNCT	O


Side	O	ADJ	B
effects	O	NOUN	I
of	O	ADP	O
yohimbine	B-Chemical	NOUN	B
included	O	VERB	O
excessive	O	ADJ	B
sweating	O	NOUN	B
,	O	PUNCT	O
increased	O	VERB	B
anxiety	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
wound	O	NOUN	B
-	O	PUNCT	O
up	O	ADP	B
feeling	O	NOUN	O
in	O	ADP	O
some	O	DET	O
patients	O	NOUN	B
.	O	PUNCT	O


CONCLUSION	O	NOUN	B
:	O	PUNCT	O
The	O	DET	O
results	O	NOUN	B
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
indicate	O	VERB	O
that	O	SCONJ	O
yohimbine	B-Chemical	NOUN	B
may	O	AUX	O
be	O	AUX	O
an	O	DET	O
effective	O	ADJ	B
treatment	O	NOUN	B
for	O	ADP	O
the	O	DET	O
sexual	B-Disease	ADJ	B
side	I-Disease	NOUN	I
effects	I-Disease	NOUN	I
caused	O	VERB	O
by	O	ADP	O
serotonin	B-Chemical	NOUN	B
reuptake	O	NOUN	I
blockers	O	NOUN	I
.	O	PUNCT	O


Future	O	ADJ	B
controlled	O	VERB	B
studies	O	NOUN	I
are	O	AUX	O
needed	O	VERB	O
to	O	PART	O
further	O	ADV	O
investigate	O	VERB	B
the	O	DET	O
effectiveness	O	NOUN	B
and	O	CCONJ	O
safety	O	NOUN	B
of	O	ADP	O
yohimbine	B-Chemical	NOUN	B


Hypersensitivity	B-Disease	NOUN	B
immune	O	ADJ	I
reaction	O	NOUN	I
as	O	ADP	O
a	O	DET	O
mechanism	O	NOUN	B
for	O	ADP	O
dilevalol	B-Chemical	ADJ	B
-	O	PUNCT	O
associated	O	VERB	B
hepatitis	B-Disease	NOUN	B
.	O	PUNCT	O


OBJECTIVE	O	NOUN	B
:	O	PUNCT	O
To	O	PART	O
assess	O	VERB	O
lymphocyte	O	NOUN	B
reactivity	O	NOUN	I
to	O	PART	O
dilevalol	B-Chemical	NOUN	B
and	O	CCONJ	O
to	O	PART	O
serum	O	NOUN	B
containing	O	VERB	O
putative	O	ADJ	O
ex	O	X	B
vivo	O	X	I
dilevalol	B-Chemical	ADJ	B
antigens	O	NOUN	O
or	O	CCONJ	O
metabolites	O	NOUN	B
in	O	ADP	O
a	O	DET	O
case	O	NOUN	B
of	O	ADP	O
dilevalol	B-Chemical	ADV	B
-	O	PUNCT	O
induced	O	VERB	B
liver	B-Disease	NOUN	B
injury	I-Disease	NOUN	I
.	O	PUNCT	O


PATIENT	O	NOUN	B
:	O	PUNCT	O
A	O	DET	O
58	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
woman	O	NOUN	B
with	O	ADP	O
a	O	DET	O
clinical	O	ADJ	B
diagnosis	O	NOUN	I
of	O	ADP	O
dilevalol	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
liver	B-Disease	NOUN	B
injury	I-Disease	NOUN	I
.	O	PUNCT	O


METHODS	O	NOUN	O
:	O	PUNCT	O
Peripheral	O	ADJ	B
blood	O	NOUN	I
mononuclear	O	ADJ	I
cells	O	NOUN	I
collected	O	VERB	O
from	O	ADP	O
the	O	DET	O
patient	O	NOUN	B
were	O	AUX	O
cultured	O	VERB	B
in	O	ADP	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
a	O	DET	O
solution	O	NOUN	B
of	O	ADP	O
dilevalol	B-Chemical	NOUN	B
and	O	CCONJ	O
also	O	ADV	O
with	O	ADP	O
sera	O	NOUN	B
collected	O	VERB	O
from	O	ADP	O
a	O	DET	O
volunteer	O	NOUN	B
before	O	ADP	O
and	O	CCONJ	O
after	O	ADP	O
dilevalol	B-Chemical	ADJ	B
intake	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
similar	O	ADJ	O
protocol	O	NOUN	B
was	O	AUX	O
performed	O	VERB	O
with	O	ADP	O
lymphocytes	O	NOUN	B
from	O	ADP	O
a	O	DET	O
healthy	O	ADJ	B
subject	O	NOUN	I
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
No	O	DET	O
lymphocyte	O	NOUN	B
proliferation	O	NOUN	I
was	O	AUX	O
observed	O	VERB	O
either	O	CCONJ	O
in	O	ADP	O
the	O	DET	O
patient	O	NOUN	B
or	O	CCONJ	O
in	O	ADP	O
the	O	DET	O
healthy	O	ADJ	B
volunteer	O	NOUN	B
in	O	ADP	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
dilevalol	B-Chemical	ADJ	B
solutions	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
significant	O	ADJ	B
proliferative	O	ADJ	B
response	O	NOUN	I
to	O	PART	O
serum	O	NOUN	B
collected	O	VERB	O
after	O	ADP	O
dilevalol	B-Chemical	ADJ	B
intake	O	NOUN	B
was	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
the	O	DET	O
case	O	NOUN	B
of	O	ADP	O
the	O	DET	O
patient	O	NOUN	B
compared	O	VERB	B
with	O	ADP	O
the	O	DET	O
proliferative	O	ADJ	B
response	O	NOUN	I
to	O	PART	O
the	O	DET	O
serum	O	NOUN	B
collected	O	VERB	B
before	O	ADP	O
the	O	DET	O
drug	O	NOUN	B
intake	O	NOUN	I
.	O	PUNCT	O


No	O	DET	B
reactivity	O	NOUN	I
was	O	AUX	O
found	O	VERB	O
when	O	SCONJ	O
lymphocytes	O	NOUN	B
from	O	ADP	O
the	O	DET	O
healthy	O	ADJ	B
subject	O	NOUN	I
were	O	AUX	O
tested	O	VERB	B
under	O	ADP	O
similar	O	ADJ	O
conditions	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
:	O	PUNCT	O
The	O	DET	O
methodology	O	NOUN	B
used	O	VERB	O
allowed	O	VERB	O
the	O	DET	O
detection	O	NOUN	B
of	O	ADP	O
lymphocyte	O	NOUN	B
sensitization	O	NOUN	I
to	O	PART	O
sera	O	NOUN	B
containing	O	VERB	O
ex	O	X	B
vivo	O	X	I
-	O	PUNCT	O
prepared	O	VERB	B
dilevalol	B-Chemical	ADJ	B
antigens	O	NOUN	B
,	O	PUNCT	O
suggesting	O	VERB	O
the	O	DET	O
involvement	O	NOUN	B
of	O	ADP	O
an	O	DET	O
immunologic	O	ADJ	B
mechanism	O	NOUN	B
in	O	ADP	O
dilevalol	B-Chemical	ADJ	B
-	O	PUNCT	O
induced	O	VERB	B
liver	B-Disease	NOUN	B
injury	I-Disease	NOUN	I


Reversible	O	ADJ	B
myocardial	B-Disease	ADJ	B
hypertrophy	I-Disease	NOUN	I
induced	O	VERB	B
by	O	ADP	O
tacrolimus	B-Chemical	NOUN	B
in	O	ADP	O
a	O	DET	O
pediatric	O	ADJ	B
heart	O	NOUN	B
transplant	O	NOUN	I
recipient	O	NOUN	B
:	O	PUNCT	O
case	O	NOUN	B
report	O	NOUN	I
.	O	PUNCT	O


Tacrolimus	B-Chemical	NOUN	B
is	O	AUX	O
a	O	DET	O
potent	O	ADJ	O
immunosuppressant	O	NOUN	B
that	O	PRON	O
is	O	AUX	O
frequently	O	ADV	O
used	O	VERB	O
in	O	ADP	O
organ	O	NOUN	B
transplantation	O	NOUN	I
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
adverse	O	ADJ	B
effects	O	NOUN	I
include	O	VERB	O
cardiac	B-Disease	ADJ	B
toxicity	I-Disease	NOUN	B
.	O	PUNCT	O


Herein	O	ADV	O
we	O	PRON	O
describe	O	VERB	O
transient	O	ADJ	B
myocardial	B-Disease	ADJ	I
hypertrophy	I-Disease	NOUN	I
induced	O	VERB	B
by	O	ADP	O
tacrolimus	B-Chemical	NOUN	B
after	O	ADP	O
heart	O	NOUN	B
transplantation	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
hypertrophy	B-Disease	NOUN	B
caused	O	VERB	O
no	O	DET	O
clinical	O	ADJ	B
symptoms	O	NOUN	I
but	O	CCONJ	O
was	O	AUX	O
noted	O	VERB	O
because	O	SCONJ	O
of	O	ADP	O
elevation	O	NOUN	B
of	O	ADP	O
plasma	O	NOUN	B
brain	O	NOUN	O
natriuretic	O	ADJ	O
peptide	O	NOUN	O
concentration	O	NOUN	B
and	O	CCONJ	O
confirmed	O	VERB	O
at	O	ADP	O
echocardiography	O	NOUN	B
.	O	PUNCT	O


Initially	O	ADV	O
,	O	PUNCT	O
allograft	O	NOUN	B
rejection	O	NOUN	B
was	O	AUX	O
feared	O	VERB	O
;	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
myocardial	O	ADJ	B
biopsy	O	NOUN	I
samples	O	NOUN	I
revealed	O	VERB	O
only	O	ADV	O
interstitial	O	ADJ	B
edema	B-Disease	NOUN	I
and	O	CCONJ	O
mild	O	ADJ	B
myocardial	B-Disease	ADJ	B
hypertrophy	I-Disease	NOUN	I
;	O	PUNCT	O
neither	O	CCONJ	O
cellular	O	ADJ	B
nor	O	CCONJ	O
humoral	O	ADJ	B
rejection	O	NOUN	I
was	O	AUX	O
detected	O	VERB	B
.	O	PUNCT	O


The	O	DET	O
blood	O	NOUN	B
tacrolimus	B-Chemical	NOUN	B
concentration	O	NOUN	B
was	O	AUX	O
higher	O	ADJ	O
than	O	ADP	O
usual	O	ADJ	O
at	O	ADP	O
that	O	DET	O
time	O	NOUN	B
;	O	PUNCT	O
thus	O	ADV	O
,	O	PUNCT	O
tacrolimus	B-Chemical	NOUN	B
dosage	O	NOUN	B
was	O	AUX	O
reduced	O	VERB	B
.	O	PUNCT	O


Myocardial	B-Disease	ADJ	B
hypertrophy	I-Disease	NOUN	I
completely	O	ADV	O
resolved	O	VERB	B
upon	O	SCONJ	O
reducing	O	VERB	B
the	O	DET	O
target	O	NOUN	B
concentration	O	NOUN	B
of	O	ADP	O
tacrolimus	B-Chemical	NOUN	B
and	O	CCONJ	O
did	O	AUX	O
not	O	PART	O
recur	O	VERB	O
,	O	PUNCT	O
as	O	ADP	O
confirmed	O	VERB	O
at	O	ADP	O
echocardiography	O	NOUN	B
and	O	CCONJ	O
myocardial	O	ADJ	B
biopsy	O	NOUN	I
.	O	PUNCT	O


Thus	O	ADV	O
,	O	PUNCT	O
we	O	PRON	O
conclude	O	VERB	O
that	O	SCONJ	O
tacrolimus	B-Chemical	NOUN	B
induces	O	VERB	O
reversible	O	ADJ	B
myocardial	B-Disease	ADJ	B
hypertrophy	I-Disease	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
patients	O	NOUN	B
receiving	O	VERB	O
tacrolimus	B-Chemical	NOUN	B


Comparison	O	NOUN	B
of	O	ADP	O
unilateral	O	ADJ	B
pallidotomy	O	NOUN	B
and	O	CCONJ	O
subthalamotomy	O	NOUN	B
findings	O	NOUN	B
in	O	ADP	O
advanced	O	ADJ	B
idiopathic	B-Disease	ADJ	I
Parkinson's	I-Disease	ADJ	I
disease	I-Disease	NOUN	I
.	O	PUNCT	O


A	O	DET	O
prospective	O	ADJ	B
,	O	PUNCT	O
randomized	O	ADJ	B
,	O	PUNCT	O
double	O	ADJ	B
-	O	PUNCT	O
blind	O	NOUN	B
pilot	O	NOUN	B
study	O	NOUN	I
to	O	PART	O
compare	O	VERB	B
the	O	DET	O
results	O	NOUN	B
of	O	ADP	O
stereotactic	O	ADJ	B
unilateral	O	ADJ	I
pallidotomy	O	NOUN	I
and	O	CCONJ	O
subthalamotomy	O	NOUN	B
in	O	ADP	O
advanced	O	ADJ	B
idiopathic	B-Disease	ADJ	I
Parkinson's	I-Disease	ADJ	I
disease	I-Disease	NOUN	I
(	O	PUNCT	O
PD	B-Disease	NOUN	B
)	O	PUNCT	O
refractory	O	ADJ	B
to	O	PART	O
medical	O	ADJ	B
treatment	O	NOUN	I
was	O	AUX	O
designed	O	VERB	O
.	O	PUNCT	O


Ten	O	NUM	O
consecutive	O	ADJ	B
patients	O	NOUN	B
(	O	PUNCT	O
mean	O	ADJ	O
age	O	NOUN	B
,	O	PUNCT	O
58	O	NUM	O
.	O	PUNCT	O


4	O	NUM	O
+/-	O	CCONJ	O
6	O	NUM	O
.	O	PUNCT	O


8	O	NUM	O
years	O	NOUN	B
;	O	PUNCT	O
7	O	NUM	O
men	O	NOUN	B
,	O	PUNCT	O
3	O	NUM	O
women	O	NOUN	B
)	O	PUNCT	O
with	O	ADP	O
similar	O	ADJ	O
characteristics	O	NOUN	B
at	O	ADP	O
the	O	DET	O
duration	O	NOUN	B
of	O	ADP	I
disease	O	NOUN	I
(	O	PUNCT	O
mean	O	ADJ	B
disease	O	NOUN	I
time	O	NOUN	I
,	O	PUNCT	O
8	O	NUM	O
.	O	PUNCT	O


4	O	NUM	O
+/-	O	CCONJ	O
3	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
years	O	NOUN	B
),	O	PUNCT	O
disabling	O	VERB	O
motor	O	NOUN	B
fluctuations	O	NOUN	I
(	O	PUNCT	O
Hoehn	O	NOUN	O
_	O	NOUN	O
Yahr	O	NOUN	B
stage	O	NOUN	I
3	O	NUM	I
-	O	SYM	O
5	O	NUM	O
in	O	ADP	O
off	O	ADJ	B
-	O	PUNCT	O
drug	O	NOUN	B
phases	O	NOUN	I
)	O	PUNCT	O
and	O	CCONJ	O
levodopa	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
dyskinesias	B-Disease	NOUN	B
were	O	AUX	O
selected	O	VERB	O
.	O	PUNCT	O


All	O	DET	O
patients	O	NOUN	B
had	O	AUX	O
bilateral	O	ADJ	B
symptoms	O	NOUN	B
and	O	CCONJ	O
their	O	PRON	O
levodopa	B-Chemical	NOUN	B
equivalent	O	ADJ	O
dosing	O	NOUN	B
were	O	AUX	O
analysed	O	VERB	B
.	O	PUNCT	O


Six	O	NUM	O
patients	O	NOUN	B
were	O	AUX	O
operated	O	VERB	O
on	O	ADP	O
in	O	ADP	O
the	O	DET	O
globus	O	NOUN	B
pallidus	O	NOUN	I
interna	O	NOUN	I
(	O	PUNCT	O
GPi	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
four	O	NUM	O
in	O	ADP	O
the	O	DET	O
subthalamic	O	ADJ	B
nucleus	O	NOUN	I
(	O	PUNCT	O
STN	O	NOUN	B
).	O	PUNCT	O
Clinical	O	ADJ	B
evaluation	O	NOUN	I
included	O	VERB	O
the	O	DET	O
use	O	NOUN	O
of	O	ADP	O
the	O	DET	O
Unified	O	PROPN	B
Parkinson's	B-Disease	PROPN	I
Disease	I-Disease	PROPN	I
Rating	O	PROPN	I
Scale	O	NOUN	I
(	O	PUNCT	O
UPDRS	O	NOUN	B
),	O	PUNCT	O
Hoehn_Yahr	O	ADJ	B
score	O	NOUN	B
and	O	CCONJ	O
Schwab	O	PROPN	B
England	O	PROPN	I
activities	O	NOUN	I
of	O	ADP	O
daily	O	ADJ	B
living	O	NOUN	I
(	O	PUNCT	O
ADL	O	NOUN	B
)	O	PUNCT	O
score	O	NOUN	O
in	O	ADP	O
'	O	PUNCT	O
on	O	ADP	O
'-	O	PROPN	B
and	O	CCONJ	O
'	O	PUNCT	O
off	O	ADP	B
'-	O	ADJ	I
drug	O	NOUN	B
conditions	O	NOUN	I
before	O	ADP	O
surgery	O	NOUN	B
and	O	CCONJ	O
6	O	NUM	O
months	O	NOUN	B
after	O	ADP	O
surgery	O	NOUN	B
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
statistically	O	ADV	B
significant	O	ADJ	I
improvement	O	NOUN	B
in	O	ADP	O
all	O	DET	O
contralateral	O	ADJ	B
major	O	ADJ	O
parkinsonian	B-Disease	ADJ	B
motor	O	NOUN	B
signs	O	NOUN	O
in	O	ADP	O
all	O	DET	O
patients	O	NOUN	B
followed	O	VERB	O
for	O	ADP	O
6	O	NUM	O
months	O	NOUN	B
.	O	PUNCT	O


Levodopa	B-Chemical	NOUN	B
equivalent	O	ADJ	O
daily	O	ADJ	B
intake	O	NOUN	B
was	O	AUX	O
significantly	O	ADV	O
reduced	O	VERB	B
in	O	ADP	O
the	O	DET	O
STN	O	NOUN	B
group	O	NOUN	B
.	O	PUNCT	O


Changes	O	NOUN	B
in	O	ADP	O
UPDRS	O	NOUN	B
,	O	PUNCT	O
Hoehn	O	PROPN	B
_	O	NOUN	I
Yahr	O	PROPN	I
and	O	CCONJ	I
Schwab	O	PROPN	I
England	O	PROPN	I
ADL	O	PROPN	I
scores	O	NOUN	B
were	O	AUX	O
similar	O	ADJ	O
in	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
.	O	PUNCT	O


Cognitive	O	ADJ	B
functions	O	NOUN	I
were	O	AUX	O
unchanged	O	ADJ	B
in	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
.	O	PUNCT	O


Complications	O	NOUN	B
were	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
two	O	NUM	O
patients	O	NOUN	B
:	O	PUNCT	O
one	O	NUM	O
had	O	AUX	O
a	O	DET	O
left	O	ADJ	B
homonymous	B-Disease	ADJ	I
hemianopsia	I-Disease	NOUN	I
after	O	ADP	O
pallidotomy	O	NOUN	B
and	O	CCONJ	O
another	O	DET	O
one	O	NOUN	O
developed	O	VERB	O
left	O	VERB	B
hemiballistic	O	ADJ	I
movements	O	NOUN	O
3	O	NUM	O
days	O	NOUN	B
after	O	ADP	O
subthalamotomy	O	NOUN	B
which	O	DET	O
partly	O	ADV	O
improved	O	VERB	B
within	O	ADP	O
1	O	NUM	O
month	O	NOUN	B
with	O	ADP	O
Valproate	B-Chemical	NOUN	B
1000	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
day	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
findings	O	NOUN	B
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
lesions	O	NOUN	B
of	O	ADP	O
the	O	DET	O
unilateral	O	ADJ	B
STN	O	NOUN	B
and	O	CCONJ	O
GPi	O	NOUN	B
are	O	AUX	O
equally	O	ADV	O
effective	O	ADJ	B
treatment	O	NOUN	B
for	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
advanced	O	ADJ	B
PD	B-Disease	NOUN	I


Protective	O	ADJ	B
effects	O	NOUN	I
of	O	ADP	O
antithrombin	O	NOUN	B
on	O	ADP	O
puromycin	B-Chemical	NOUN	B
aminonucleoside	I-Chemical	NOUN	B
nephrosis	B-Disease	NOUN	I
in	O	ADP	O
rats	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
investigated	O	VERB	B
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
antithrombin	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
plasma	O	NOUN	B
inhibitor	O	NOUN	I
of	O	ADP	O
coagulation	O	NOUN	B
factors	O	NOUN	I
,	O	PUNCT	O
in	O	ADP	O
rats	O	NOUN	B
with	O	ADP	O
puromycin	B-Chemical	NOUN	B
aminonucleoside	I-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
nephrosis	B-Disease	NOUN	B
,	O	PUNCT	O
which	O	DET	O
is	O	AUX	O
an	O	DET	O
experimental	O	ADJ	B
model	O	NOUN	I
of	O	ADP	O
human	O	ADJ	B
nephrotic	B-Disease	ADJ	I
syndrome	I-Disease	NOUN	I
.	O	PUNCT	O


Antithrombin	O	NOUN	B
(	O	PUNCT	O
50	O	NUM	O
or	O	CCONJ	O
500	O	NUM	O
IU	O	PROPN	B
/	O	SYM	O
kg	O	NOUN	B
/	O	SYM	O
i	O	PROPN	B
.	O	PUNCT	O


v	O	ADP	O
.)	O	NOUN	O
was	O	AUX	O
administered	O	VERB	B
to	O	ADP	O
rats	O	NOUN	B
once	O	ADV	O
a	O	DET	O
day	O	NOUN	B
for	O	ADP	O
10	O	NUM	O
days	O	NOUN	B
immediately	O	ADV	O
after	O	ADP	O
the	O	DET	O
injection	O	NOUN	B
of	O	ADP	O
puromycin	B-Chemical	NOUN	B
aminonucleoside	I-Chemical	NOUN	B
(	O	PUNCT	O
50	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
/	O	SYM	O
i	O	PROPN	B
.	O	PUNCT	O


v	O	ADP	O
.).	O	NOUN	O
Treatment	O	NOUN	B
with	O	ADP	O
antithrombin	O	NOUN	B
attenuated	O	VERB	B
the	O	DET	O
puromycin	B-Chemical	NOUN	B
aminonucleoside	I-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
hematological	B-Disease	ADJ	B
abnormalities	I-Disease	NOUN	I
.	O	PUNCT	O


Puromycin	B-Chemical	NOUN	B
aminonucleoside	I-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
renal	B-Disease	ADJ	B
dysfunction	I-Disease	NOUN	I
and	O	CCONJ	O
hyperlipidemia	B-Disease	NOUN	B
were	O	AUX	O
also	O	ADV	O
suppressed	O	VERB	B
.	O	PUNCT	O


Histopathological	O	ADJ	B
examination	O	NOUN	B
revealed	O	VERB	O
severe	O	ADJ	B
renal	B-Disease	ADJ	B
damage	I-Disease	NOUN	I
such	O	ADJ	O
as	O	ADP	O
proteinaceous	O	ADJ	B
casts	O	NOUN	I
in	O	ADP	O
tubuli	O	NOUN	B
and	O	CCONJ	O
tubular	O	ADJ	B
expansion	O	NOUN	B
in	O	ADP	O
the	O	DET	O
kidney	O	NOUN	B
of	O	ADP	O
control	O	NOUN	B
rats	O	NOUN	B
,	O	PUNCT	O
while	O	SCONJ	O
an	O	DET	O
improvement	O	NOUN	B
of	O	ADP	O
the	O	DET	O
damage	O	NOUN	B
was	O	AUX	O
seen	O	VERB	O
in	O	ADP	O
antithrombin	O	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
rats	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
,	O	PUNCT	O
antithrombin	O	NOUN	B
treatment	O	NOUN	B
markedly	O	ADV	O
suppressed	O	VERB	B
puromycin	B-Chemical	NOUN	B
aminonucleoside	I-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
apoptosis	O	NOUN	B
of	O	ADP	O
renal	O	ADJ	B
tubular	O	ADJ	I
epithelial	O	ADJ	I
cells	O	NOUN	I
.	O	PUNCT	O


Furthermore	O	ADV	O
,	O	PUNCT	O
puromycin	B-Chemical	ADJ	B
aminonucleoside	I-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
increases	O	NOUN	B
in	O	ADP	O
renal	O	ADJ	B
cytokine	O	NOUN	B
content	O	NOUN	O
were	O	AUX	O
also	O	ADV	O
decreased	O	VERB	B
.	O	PUNCT	O


These	O	DET	O
findings	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
thrombin	O	NOUN	B
plays	O	VERB	O
an	O	DET	O
important	O	ADJ	O
role	O	NOUN	O
in	O	ADP	O
the	O	DET	O
pathogenesis	O	NOUN	B
of	O	ADP	O
puromycin	B-Chemical	NOUN	B
aminonucleoside	I-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
nephrotic	B-Disease	ADJ	B
syndrome	I-Disease	NOUN	I
.	O	PUNCT	O


Treatment	O	NOUN	B
with	O	ADP	O
antithrombin	O	NOUN	B
may	O	AUX	O
be	O	AUX	O
clinically	O	ADV	B
effective	O	ADJ	B
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
nephrotic	B-Disease	ADJ	B
syndrome	I-Disease	NOUN	I


Reverse	O	VERB	B
or	O	CCONJ	O
inverted	O	ADJ	B
left	B-Disease	VERB	I
ventricular	I-Disease	ADJ	I
apical	I-Disease	ADJ	I
ballooning	I-Disease	NOUN	I
syndrome	I-Disease	NOUN	I
(	O	PUNCT	O
reverse	O	ADJ	B
Takotsubo	B-Disease	NOUN	I
cardiomyopathy	I-Disease	NOUN	I
)	O	PUNCT	O
in	O	ADP	O
a	O	DET	O
young	O	ADJ	B
woman	O	NOUN	B
in	O	ADP	O
the	O	DET	O
setting	O	NOUN	O
of	O	ADP	O
amphetamine	B-Chemical	NOUN	B
use	O	NOUN	B
.	O	PUNCT	O


Transient	O	ADJ	B
left	B-Disease	VERB	B
ventricular	I-Disease	ADJ	I
apical	I-Disease	ADJ	I
ballooning	I-Disease	NOUN	I
syndrome	I-Disease	NOUN	I
was	O	AUX	O
first	O	ADV	O
described	O	VERB	O
in	O	ADP	O
Japan	O	PROPN	B
as	O	ADP	O
"	O	PUNCT	O
Takotsubo	B-Disease	NOUN	B
cardiomyopathy	I-Disease	NOUN	I
."	O	PUNCT	O
This	O	DET	O
syndrome	O	NOUN	B
has	O	AUX	O
been	O	AUX	O
identified	O	VERB	B
in	O	ADP	O
many	O	ADJ	O
other	O	ADJ	O
countries	O	NOUN	B
.	O	PUNCT	O


Many	O	ADJ	O
variations	O	NOUN	B
of	O	ADP	O
this	O	DET	O
syndrome	O	NOUN	B
have	O	AUX	O
been	O	AUX	O
recently	O	ADV	O
described	O	VERB	O
in	O	ADP	O
the	O	DET	O
literature	O	NOUN	B
.	O	PUNCT	O


One	O	NUM	O
of	O	ADP	O
the	O	DET	O
rarest	O	ADJ	B
is	O	AUX	O
the	O	DET	O
reverse	O	ADJ	B
type	O	NOUN	I
of	O	ADP	O
this	O	DET	O
syndrome	O	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
hyperdynamic	O	ADJ	B
apex	O	NOUN	I
and	O	CCONJ	O
complete	O	VERB	B
akinesia	B-Disease	NOUN	B
of	O	ADP	O
the	O	DET	O
base	O	NOUN	B
(	O	PUNCT	O
as	O	ADP	O
opposed	O	VERB	O
to	O	ADP	O
the	O	DET	O
classic	O	ADJ	O
apical	B-Disease	ADJ	B
ballooning	I-Disease	NOUN	O
).	O	PUNCT	B
In	O	ADP	O
this	O	DET	O
article	O	NOUN	O
,	O	PUNCT	O
we	O	PRON	O
report	O	VERB	O
an	O	DET	O
interesting	O	ADJ	O
case	O	NOUN	B
of	O	ADP	O
a	O	DET	O
young	O	ADJ	B
woman	O	NOUN	B
who	O	PRON	O
presented	O	VERB	O
with	O	ADP	O
this	O	DET	O
rare	O	ADJ	B
type	O	NOUN	O
of	O	ADP	O
reverse	O	ADJ	B
apical	B-Disease	ADJ	I
ballooning	I-Disease	NOUN	I
syndrome	I-Disease	NOUN	I
occurring	O	VERB	O
after	O	ADP	O
amphetamine	B-Chemical	NOUN	B


Attenuated	O	VERB	B
disruption	O	NOUN	B
of	O	ADP	O
prepulse	O	NOUN	B
inhibition	O	NOUN	I
by	O	ADP	O
dopaminergic	O	ADJ	B
stimulation	O	NOUN	I
after	O	ADP	O
maternal	O	ADJ	B
deprivation	O	NOUN	I
and	O	CCONJ	O
adolescent	O	ADJ	B
corticosterone	B-Chemical	NOUN	B
treatment	O	NOUN	B
in	O	ADP	O
rats	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
development	O	NOUN	B
of	O	ADP	O
schizophrenia	B-Disease	NOUN	B
may	O	AUX	O
include	O	VERB	O
an	O	DET	O
early	O	ADJ	B
neurodevelopmental	O	ADJ	B
stress	O	NOUN	I
component	O	NOUN	I
which	O	DET	O
increases	O	VERB	B
vulnerability	O	NOUN	B
to	O	ADP	O
later	O	ADV	O
stressful	O	ADJ	B
life	O	NOUN	I
events	O	NOUN	I
,	O	PUNCT	O
in	O	ADP	O
combination	O	NOUN	B
leading	O	VERB	O
to	O	PART	O
overt	O	ADJ	B
disease	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
investigated	O	VERB	B
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
an	O	DET	O
early	O	ADJ	B
stress	O	NOUN	I
,	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
form	O	NOUN	O
of	O	ADP	O
maternal	O	ADJ	B
deprivation	O	NOUN	I
,	O	PUNCT	O
combined	O	VERB	O
with	O	ADP	O
a	O	DET	O
later	O	ADJ	O
stress	O	NOUN	B
,	O	PUNCT	O
simulated	O	VERB	B
by	O	ADP	O
chronic	O	ADJ	B
periadolescent	O	ADJ	B
corticosterone	B-Chemical	NOUN	B
treatment	O	NOUN	B
,	O	PUNCT	O
on	O	ADP	O
behaviour	O	NOUN	B
in	O	ADP	O
rats	O	NOUN	B
.	O	PUNCT	O


Acute	O	ADJ	B
treatment	O	NOUN	O
with	O	ADP	O
apomorphine	B-Chemical	NOUN	B
caused	O	VERB	O
disruption	O	NOUN	B
of	O	ADP	O
prepulse	O	NOUN	B
inhibition	O	NOUN	I
(	O	PUNCT	O
PPI	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
controls	O	NOUN	B
and	O	CCONJ	O
in	O	ADP	O
rats	O	NOUN	B
that	O	PRON	O
had	O	AUX	O
undergone	O	VERB	O
either	O	CCONJ	O
maternal	O	ADJ	B
deprivation	O	NOUN	I
or	O	CCONJ	O
corticosterone	B-Chemical	NOUN	B
treatment	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
was	O	AUX	O
surprisingly	O	ADV	O
absent	O	ADJ	B
in	O	ADP	O
rats	O	NOUN	B
that	O	PRON	O
had	O	AUX	O
undergone	O	VERB	O
the	O	DET	O
combined	O	ADJ	O
early	O	ADJ	B
and	O	CCONJ	O
late	O	ADJ	B
stress	O	NOUN	I
.	O	PUNCT	O


Amphetamine	B-Chemical	NOUN	B
treatment	O	NOUN	B
significantly	O	ADV	O
disrupted	O	VERB	B
PPI	O	NOUN	B
in	O	ADP	O
both	O	CCONJ	O
non	O	ADV	B
-	O	PUNCT	O
deprived	O	VERB	B
groups	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
was	O	AUX	O
absent	O	ADJ	B
in	O	ADP	O
both	O	CCONJ	O
maternally	O	ADV	B
deprived	O	VERB	O
groups	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
serotonin	B-Chemical	NOUN	B
-	O	PUNCT	O
1A	O	NOUN	B
receptor	O	NOUN	I
agonist	O	NOUN	B
,	O	PUNCT	O
8-OH-DPAT	B-Chemical	NOUN	B
,	O	PUNCT	O
induced	O	VERB	B
a	O	DET	O
significant	O	ADJ	O
disruption	O	NOUN	B
of	O	ADP	O
PPI	O	NOUN	B
in	O	ADP	O
all	O	DET	O
groups	O	NOUN	B
.	O	PUNCT	O


Amphetamine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
locomotor	B-Disease	NOUN	B
hyperactivity	I-Disease	NOUN	I
was	O	AUX	O
similar	O	ADJ	O
in	O	ADP	O
all	O	DET	O
groups	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	B
show	O	VERB	O
an	O	DET	O
inhibitory	O	ADJ	B
interaction	O	NOUN	B
of	O	ADP	O
early	O	ADJ	B
stress	O	NOUN	I
,	O	PUNCT	O
caused	O	VERB	O
by	O	ADP	O
maternal	O	ADJ	B
deprivation	O	NOUN	I
,	O	PUNCT	O
combined	O	VERB	O
with	O	ADP	O
'	O	PUNCT	O
adolescent	O	ADJ	B
'	O	PART	O
stress	O	NOUN	B
,	O	PUNCT	O
simulated	O	VERB	B
by	O	ADP	O
corticosterone	B-Chemical	NOUN	B
treatment	O	NOUN	B
,	O	PUNCT	O
on	O	ADP	O
dopaminergic	O	ADJ	B
regulation	O	NOUN	I
of	O	ADP	O
PPI	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
altered	O	ADJ	O
effects	O	NOUN	B
of	O	ADP	O
apomorphine	B-Chemical	NOUN	B
and	O	CCONJ	O
amphetamine	B-Chemical	NOUN	B
could	O	AUX	O
indicate	O	VERB	O
differential	O	ADJ	O
changes	O	NOUN	O
in	O	ADP	O
dopamine	B-Chemical	NOUN	B


Peripheral	O	ADJ	B
iron	B-Chemical	NOUN	I
dextran	I-Chemical	NOUN	I
induced	O	VERB	B
degeneration	B-Disease	NOUN	B
of	I-Disease	ADP	O
dopaminergic	I-Disease	ADJ	B
neurons	I-Disease	NOUN	B
in	O	ADP	O
rat	O	NOUN	B
substantia	O	NOUN	B
nigra	O	NOUN	I
.	O	PUNCT	O


Iron	B-Chemical	NOUN	B
accumulation	O	NOUN	B
is	O	AUX	O
considered	O	VERB	O
to	O	PART	O
be	O	AUX	O
involved	O	VERB	O
in	O	ADP	O
the	O	DET	O
pathogenesis	O	NOUN	B
of	O	ADP	O
Parkinson's	B-Disease	ADJ	B
disease	I-Disease	NOUN	I
.	O	PUNCT	O


To	O	PART	O
demonstrate	O	VERB	O
the	O	DET	O
relationship	O	NOUN	B
between	O	ADP	O
peripheral	O	ADJ	B
iron	B-Chemical	NOUN	B
overload	O	NOUN	I
and	O	CCONJ	O
dopaminergic	O	ADJ	B
neuron	O	NOUN	I
loss	O	NOUN	B
in	O	ADP	O
rat	O	NOUN	B
substantia	O	NOUN	O
nigra	O	NOUN	O
(	O	PUNCT	O
SN	O	NOUN	B
),	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
we	O	PRON	O
used	O	VERB	O
fast	O	ADV	B
cyclic	O	ADJ	I
voltammetry	O	NOUN	I
,	O	PUNCT	O
tyrosine	B-Chemical	NOUN	B
hydroxylase	O	NOUN	I
(	O	PUNCT	O
TH	O	NOUN	B
)	O	PUNCT	O
immunohistochemistry	O	NOUN	B
,	O	PUNCT	O
Perls	O	PROPN	B
'	O	PART	O
iron	B-Chemical	NOUN	B
staining	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
high	O	ADJ	B
performance	O	NOUN	I
liquid	O	ADJ	I
chromatography	O	NOUN	I
-	O	PUNCT	O
electrochemical	O	ADJ	B
detection	O	NOUN	B
to	O	PART	O
study	O	VERB	B
the	O	DET	O
degeneration	B-Disease	NOUN	B
of	I-Disease	ADP	O
dopaminergic	I-Disease	ADJ	B
neurons	I-Disease	NOUN	B
and	O	CCONJ	O
increased	O	VERB	B
iron	B-Chemical	NOUN	B
content	O	NOUN	I
in	O	ADP	O
the	O	DET	O
SN	O	NOUN	B
of	O	ADP	O
iron	B-Chemical	NOUN	B
dextran	I-Chemical	NOUN	I
overloaded	O	ADJ	O
animals	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
findings	O	NOUN	B
showed	O	VERB	O
that	O	SCONJ	O
peripheral	O	ADJ	B
iron	B-Chemical	NOUN	B
dextran	I-Chemical	NOUN	I
overload	O	NOUN	I
increased	O	VERB	B
the	O	DET	O
iron	B-Chemical	NOUN	B
staining	O	NOUN	I
positive	O	ADJ	I
cells	O	NOUN	I
and	O	CCONJ	O
reduced	O	VERB	B
the	O	DET	O
number	O	NOUN	O
of	O	ADP	O
TH	O	NOUN	B
-	O	PUNCT	O
immunoreactive	O	ADJ	B
neurons	O	NOUN	B
in	O	ADP	O
the	O	DET	O
SN	O	NOUN	B
.	O	PUNCT	O


As	O	ADP	O
a	O	DET	O
result	O	NOUN	B
,	O	PUNCT	O
dopamine	B-Chemical	NOUN	B
release	O	NOUN	B
and	O	CCONJ	O
content	O	NOUN	B
,	O	PUNCT	O
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
its	O	PRON	O
metabolites	O	NOUN	B
contents	O	NOUN	B
were	O	AUX	O
decreased	O	VERB	B
in	O	ADP	O
caudate	O	NOUN	B
putamen	O	NOUN	I
.	O	PUNCT	O


Even	O	ADV	O
more	O	ADV	O
dramatic	O	ADJ	O
changes	O	NOUN	B
were	O	AUX	O
found	O	VERB	O
in	O	ADP	O
chronic	O	ADJ	B
overload	O	NOUN	I
group	O	NOUN	I
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
peripheral	O	ADJ	B
iron	B-Chemical	NOUN	B
dextran	I-Chemical	NOUN	I
can	O	AUX	O
increase	O	VERB	B
the	O	DET	O
iron	B-Chemical	NOUN	B
level	O	NOUN	I
in	O	ADP	O
the	O	DET	O
SN	O	NOUN	B
,	O	PUNCT	O
where	O	SCONJ	O
excessive	O	ADJ	B
iron	B-Chemical	NOUN	B
causes	O	VERB	O
the	O	DET	O
degeneration	B-Disease	NOUN	B
of	I-Disease	ADP	O
dopaminergic	I-Disease	ADJ	B
neurons	I-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
chronic	O	ADJ	B
iron	B-Chemical	NOUN	O
overload	O	NOUN	O
may	O	AUX	O
be	O	AUX	O
more	O	ADV	O
destructive	O	ADJ	B
to	O	PART	O
dopaminergic	O	ADJ	B
neurons	O	NOUN	B
than	O	ADP	O
the	O	DET	O
acute	O	ADJ	B
iron	B-Chemical	NOUN	O


Warfarin	B-Chemical	PROPN	B
-	O	PUNCT	O
induced	O	VERB	B
leukocytoclastic	B-Disease	ADJ	B
vasculitis	I-Disease	NOUN	I
.	O	PUNCT	O


Skin	O	NOUN	B
reactions	O	NOUN	I
associated	O	VERB	B
with	O	ADP	I
oral	O	ADJ	B
coumarin	B-Chemical	NOUN	B
-	O	PUNCT	O
derived	O	VERB	B
anticoagulants	O	NOUN	B
are	O	AUX	O
an	O	DET	O
uncommon	O	ADJ	O
occurrence	O	NOUN	B
.	O	PUNCT	O


Leukocytoclastic	B-Disease	ADJ	B
vasculitis	I-Disease	NOUN	I
(	O	PUNCT	O
LV	B-Disease	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
primarily	O	ADV	O
a	O	DET	O
cutaneous	B-Disease	ADJ	B
small	I-Disease	ADJ	I
vessel	I-Disease	NOUN	I
vasculitis	I-Disease	NOUN	I
,	O	PUNCT	O
though	O	SCONJ	O
systemic	O	ADJ	B
involvement	O	NOUN	B
may	O	AUX	O
be	O	AUX	O
encountered	O	VERB	O
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
4	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
late	O	ADJ	B
-	O	PUNCT	O
onset	O	NOUN	B
LV	B-Disease	PROPN	B
probably	O	ADV	O
due	O	ADP	O
to	O	ADP	O
warfarin	B-Chemical	NOUN	B
.	O	PUNCT	O


All	O	DET	O
4	O	NUM	O
patients	O	NOUN	B
presented	O	VERB	O
with	O	ADP	O
skin	B-Disease	NOUN	B
eruptions	I-Disease	NOUN	I
that	O	PRON	O
developed	O	VERB	O
after	O	ADP	O
receiving	O	VERB	O
warfarin	B-Chemical	NOUN	B
for	O	ADP	O
several	O	ADJ	O
years	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
results	O	NOUN	B
of	O	ADP	O
skin	B-Disease	NOUN	B
lesion	I-Disease	NOUN	O
biopsies	O	NOUN	B
were	O	AUX	O
available	O	ADJ	O
in	O	ADP	O
3	O	NUM	O
patients	O	NOUN	B
,	O	PUNCT	O
confirming	O	VERB	O
LV	B-Disease	PROPN	B
Cutaneous	I-Disease	ADJ	B
lesions	I-Disease	NOUN	I
resolved	O	VERB	B
in	O	ADP	O
all	O	DET	O
patients	O	NOUN	B
after	O	ADP	O
warfarin	B-Chemical	NOUN	B
was	O	AUX	O
discontinued	O	VERB	B
.	O	PUNCT	O


In	O	ADP	O
2	O	NUM	O
of	O	ADP	O
the	O	DET	O
4	O	NUM	O
patients	O	NOUN	B
,	O	PUNCT	O
rechallenge	O	NOUN	B
with	O	ADP	O
warfarin	B-Chemical	NOUN	B
led	O	VERB	O
to	O	PART	O
recurrence	O	NOUN	B
of	O	ADP	O
the	O	DET	O
lesions	O	NOUN	B
.	O	PUNCT	O


LV	B-Disease	PROPN	B
may	O	AUX	O
be	O	AUX	O
a	O	DET	O
late	O	ADJ	B
-	O	PUNCT	O
onset	O	NOUN	B
adverse	O	ADJ	B
reaction	O	NOUN	I
associated	O	VERB	B
with	O	ADP	I
warfarin	B-Chemical	NOUN	B


The	O	DET	O
activation	O	NOUN	B
of	O	ADP	O
spinal	O	ADJ	B
N-methyl-D-aspartate	B-Chemical	NOUN	I
receptors	O	NOUN	I
may	O	AUX	O
contribute	O	VERB	O
to	O	PART	O
degeneration	O	NOUN	B
of	O	ADP	O
spinal	O	ADJ	B
motor	O	NOUN	I
neurons	O	NOUN	I
induced	O	VERB	B
by	O	ADP	O
neuraxial	O	ADJ	B
morphine	B-Chemical	NOUN	B
after	O	ADP	O
a	O	DET	O
noninjurious	O	ADJ	B
interval	O	NOUN	I
of	O	ADP	O
spinal	B-Disease	ADJ	B
cord	I-Disease	NOUN	I
ischemia	I-Disease	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
investigated	O	VERB	B
the	O	DET	O
relationship	O	NOUN	B
between	O	ADP	O
the	O	DET	O
degeneration	O	NOUN	B
of	O	ADP	O
spinal	O	ADJ	B
motor	O	NOUN	I
neurons	O	NOUN	I
and	O	CCONJ	O
activation	O	NOUN	B
of	O	ADP	O
N-methyl-d-aspartate	B-Chemical	NOUN	B
(	O	PUNCT	O
NMDA	B-Chemical	NOUN	B
)	O	PUNCT	O
receptors	O	NOUN	O
after	O	ADP	O
neuraxial	O	ADJ	B
morphine	B-Chemical	NOUN	B
following	O	VERB	O
a	O	DET	O
noninjurious	O	ADJ	B
interval	O	NOUN	I
of	O	ADP	O
aortic	B-Disease	ADJ	B
occlusion	I-Disease	NOUN	I
in	O	ADP	O
rats	O	NOUN	B
.	O	PUNCT	O


Spinal	B-Disease	ADJ	B
cord	I-Disease	NOUN	I
ischemia	I-Disease	NOUN	I
was	O	AUX	O
induced	O	VERB	B
by	O	ADP	O
aortic	B-Disease	ADJ	B
occlusion	I-Disease	NOUN	I
for	O	ADP	O
6	O	NUM	O
min	O	NOUN	O
with	O	ADP	O
a	O	DET	O
balloon	O	NOUN	B
catheter	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
a	O	DET	O
microdialysis	O	NOUN	B
study	O	NOUN	I
,	O	PUNCT	O
10	O	NUM	O
muL	O	NOUN	O
of	O	ADP	O
saline	O	NOUN	B
(	O	PUNCT	O
group	O	NOUN	B
C	O	NOUN	I
;	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
8	O	NUM	O
)	O	PUNCT	O
or	O	CCONJ	O
30	O	NUM	O
mug	O	NOUN	B
of	O	ADP	O
morphine	B-Chemical	NOUN	B
(	O	PUNCT	O
group	O	NOUN	B
M	O	NOUN	I
;	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
8	O	NUM	O
)	O	PUNCT	O
was	O	AUX	O
injected	O	VERB	B
intrathecally	O	ADV	B
(	O	PUNCT	O
IT	O	NOUN	B
)	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
h	O	NOUN	O
after	O	ADP	O
reflow	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
30	O	NUM	O
mug	O	NOUN	B
of	O	ADP	O
morphine	B-Chemical	NOUN	B
(	O	PUNCT	O
group	O	NOUN	B
SM	O	NOUN	B
;	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
8	O	NUM	O
)	O	PUNCT	O
or	O	CCONJ	O
10	O	NUM	O
muL	O	NOUN	O
of	O	ADP	O
saline	O	NOUN	B
(	O	PUNCT	O
group	O	NOUN	B
SC	O	NOUN	B
;	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
8	O	NUM	O
)	O	PUNCT	O
was	O	AUX	O
injected	O	VERB	O
IT	O	PROPN	B
0	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
h	O	NOUN	O
after	O	ADP	O
sham	O	NOUN	B
operation	O	NOUN	B
.	O	PUNCT	O


Microdialysis	O	NOUN	B
samples	O	NOUN	B
were	O	AUX	O
collected	O	VERB	O
preischemia	O	NOUN	B
,	O	PUNCT	O
before	O	ADP	O
IT	O	NOUN	B
injection	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
at	O	ADP	O
2	O	NUM	O
,	O	PUNCT	O
4	O	NUM	O
,	O	PUNCT	O
8	O	NUM	O
,	O	PUNCT	O
24	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
48	O	NUM	O
h	O	NOUN	O
of	O	ADP	O
reperfusion	O	NOUN	B
(	O	PUNCT	O
after	O	ADP	O
IT	O	NOUN	B
injection	O	NOUN	B
).	O	PUNCT	O
Second	O	ADV	O
,	O	PUNCT	O
we	O	PRON	O
investigated	O	VERB	B
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
IT	O	NOUN	B
MK-801	B-Chemical	NOUN	B
(	O	PUNCT	O
30	O	NUM	O
mug	O	NOUN	B
)	O	PUNCT	O
on	O	ADP	O
the	O	DET	O
histopathologic	O	ADJ	B
changes	O	NOUN	B
in	O	ADP	O
the	O	DET	O
spinal	O	ADJ	B
cord	O	NOUN	I
after	O	ADP	O
morphine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
spastic	B-Disease	ADJ	B
paraparesis	I-Disease	NOUN	I
.	O	PUNCT	O


After	O	ADP	O
IT	O	NOUN	B
morphine	B-Chemical	NOUN	B
,	O	PUNCT	O
the	O	DET	O
cerebrospinal	O	ADJ	B
fluid	O	NOUN	I
(	O	PUNCT	O
CSF	O	NOUN	B
)	O	PUNCT	O
glutamate	B-Chemical	NOUN	B
concentration	O	NOUN	B
was	O	AUX	O
increased	O	VERB	B
in	O	ADP	O
group	O	NOUN	B
M	O	NOUN	I
relative	O	ADJ	O
to	O	PART	O
both	O	CCONJ	O
baseline	O	NOUN	B
and	O	CCONJ	O
group	O	NOUN	B
C	O	NOUN	I
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


05	O	NUM	O
).	O	PUNCT	O
This	O	DET	O
increase	O	NOUN	B
persisted	O	VERB	O
for	O	ADP	O
8	O	NUM	O
hrs	O	NOUN	O
.	O	PUNCT	O


IT	O	NOUN	B
MK-801	B-Chemical	NOUN	B
significantly	O	ADV	O
reduced	O	VERB	B
the	O	DET	O
number	O	NOUN	O
of	O	ADP	O
dark	O	ADV	B
-	O	PUNCT	O
stained	O	VERB	B
alpha	O	NOUN	I
-	O	PUNCT	O
motoneurons	O	NOUN	B
after	O	ADP	O
morphine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
spastic	B-Disease	ADJ	B
paraparesis	I-Disease	NOUN	I
compared	O	VERB	O
with	O	ADP	O
the	O	DET	O
saline	O	NOUN	B
group	O	NOUN	I
.	O	PUNCT	O


These	O	DET	O
data	O	NOUN	B
indicate	O	VERB	O
that	O	SCONJ	O
IT	O	NOUN	B
morphine	B-Chemical	NOUN	B
induces	O	VERB	O
spastic	B-Disease	ADJ	B
paraparesis	I-Disease	NOUN	I
with	O	ADP	O
a	O	DET	O
concomitant	O	ADJ	B
increase	O	NOUN	B
in	O	ADP	O
CSF	O	NOUN	B
glutamate	B-Chemical	NOUN	B
,	O	PUNCT	O
which	O	DET	O
is	O	AUX	O
involved	O	VERB	O
in	O	ADP	O
NMDA	B-Chemical	NOUN	B
receptor	O	NOUN	I
activation	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
suggest	O	VERB	O
that	O	SCONJ	O
opioids	O	NOUN	B
may	O	AUX	O
be	O	AUX	O
neurotoxic	B-Disease	ADJ	B
in	O	ADP	O
the	O	DET	O
setting	O	NOUN	O
of	O	ADP	O
spinal	B-Disease	ADJ	B
cord	I-Disease	NOUN	I
ischemia	I-Disease	NOUN	I
via	O	ADP	O
NMDA	B-Chemical	NOUN	B


Reduced	O	VERB	B
sodium	B-Chemical	NOUN	B
channel	O	NOUN	I
density	O	NOUN	B
,	O	PUNCT	O
altered	O	ADJ	O
voltage	O	NOUN	B
dependence	O	NOUN	O
of	O	ADP	O
inactivation	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
increased	O	VERB	B
susceptibility	O	NOUN	B
to	O	PART	O
seizures	B-Disease	NOUN	B
in	O	ADP	O
mice	O	NOUN	B
lacking	O	VERB	B
sodium	B-Chemical	NOUN	B
channel	O	NOUN	I
beta	O	NOUN	I
2	O	NUM	I
-	O	PUNCT	O
subunits	O	NOUN	B
.	O	PUNCT	O


Sodium	B-Chemical	NOUN	B
channel	O	NOUN	I
beta	O	NOUN	I
-	O	PUNCT	O
subunits	O	NOUN	B
modulate	O	VERB	B
channel	O	NOUN	B
gating	O	NOUN	I
,	O	PUNCT	O
assembly	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
cell	O	NOUN	B
surface	O	NOUN	I
expression	O	NOUN	B
in	O	ADP	O
heterologous	O	ADJ	B
cell	O	NOUN	B
systems	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
generated	O	VERB	O
beta2	O	NOUN	B
(-/-)	O	NOUN	O
mice	O	NOUN	B
to	O	PART	O
investigate	O	VERB	B
the	O	DET	O
role	O	NOUN	O
of	O	ADP	O
beta2	O	NOUN	B
in	O	ADP	O
control	O	NOUN	B
of	O	ADP	O
sodium	B-Chemical	NOUN	B
channel	O	NOUN	I
density	O	NOUN	I
,	O	PUNCT	O
localization	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
function	O	NOUN	B
in	O	ADP	O
neurons	O	NOUN	B
in	O	X	B
vivo	O	X	I
.	O	PUNCT	O


Measurements	O	NOUN	B
of	O	ADP	O
[(	O	X	O
3	O	X	O
)	O	PUNCT	O
H	O	NOUN	O
]	O	PUNCT	O
saxitoxin	B-Chemical	NOUN	O
(	O	PUNCT	O
STX	B-Chemical	NOUN	B
)	O	PUNCT	O
binding	O	NOUN	B
showed	O	VERB	O
a	O	DET	O
significant	O	ADJ	O
reduction	O	NOUN	B
in	O	ADP	O
the	O	DET	O
level	O	NOUN	B
of	O	ADP	O
plasma	O	NOUN	B
membrane	O	NOUN	I
sodium	B-Chemical	NOUN	I
channels	O	NOUN	I
in	O	ADP	O
beta2	O	NOUN	B
(-/-)	O	NOUN	O
neurons	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
loss	O	NOUN	B
of	O	ADP	O
beta2	O	NOUN	B
resulted	O	VERB	O
in	O	ADP	O
negative	O	ADJ	B
shifts	O	NOUN	B
in	O	ADP	O
the	O	DET	O
voltage	O	NOUN	B
dependence	O	NOUN	O
of	O	ADP	O
inactivation	O	NOUN	B
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
significant	O	ADJ	O
decreases	O	NOUN	B
in	O	ADP	O
sodium	B-Chemical	NOUN	B
current	O	ADJ	O
density	O	NOUN	B
in	O	ADP	O
acutely	O	ADV	O
dissociated	O	VERB	O
hippocampal	O	ADJ	B
neurons	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
integral	O	NOUN	B
of	O	ADP	O
the	O	DET	O
compound	O	NOUN	B
action	O	NOUN	I
potential	O	NOUN	O
in	O	ADP	O
optic	O	ADJ	B
nerve	O	NOUN	I
was	O	AUX	O
significantly	O	ADV	O
reduced	O	VERB	B
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
threshold	O	NOUN	B
for	O	ADP	O
action	O	NOUN	B
potential	O	ADJ	I
generation	O	NOUN	O
was	O	AUX	O
increased	O	VERB	B
,	O	PUNCT	O
indicating	O	VERB	O
a	O	DET	O
reduction	O	NOUN	B
in	O	ADP	O
the	O	DET	O
level	O	NOUN	B
of	O	ADP	O
functional	O	ADJ	B
plasma	O	NOUN	O
membrane	O	NOUN	O
sodium	B-Chemical	NOUN	B
channels	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
contrast	O	NOUN	O
,	O	PUNCT	O
the	O	DET	O
conduction	O	NOUN	B
velocity	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
number	O	NOUN	B
and	O	CCONJ	O
size	O	NOUN	B
of	O	ADP	O
axons	O	NOUN	B
in	O	ADP	O
the	O	DET	O
optic	O	ADJ	B
nerve	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
specific	O	ADJ	O
localization	O	NOUN	B
of	O	ADP	O
Na	B-Chemical	NOUN	B
(	O	PUNCT	O
v	O	NOUN	O
)	O	PUNCT	O
1	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
channels	O	NOUN	B
in	O	ADP	O
the	O	DET	O
nodes	O	NOUN	B
of	O	ADP	O
Ranvier	O	PROPN	B
were	O	AUX	O
unchanged	O	ADJ	B
.	O	PUNCT	O


beta2	O	NOUN	B
(-/-)	O	NOUN	O
mice	O	NOUN	B
displayed	O	VERB	O
increased	O	VERB	B
susceptibility	O	NOUN	B
to	O	ADP	O
seizures	B-Disease	NOUN	B
,	O	PUNCT	O
as	O	ADP	O
indicated	O	VERB	O
by	O	ADP	O
reduced	O	VERB	B
latency	O	NOUN	B
and	O	CCONJ	O
threshold	O	NOUN	B
for	O	ADP	O
pilocarpine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
seizures	B-Disease	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
seemed	O	VERB	O
normal	O	ADJ	B
in	O	ADP	O
other	O	ADJ	O
neurological	O	ADJ	B
tests	O	NOUN	I
.	O	PUNCT	O


Our	O	PRON	O
observations	O	NOUN	B
show	O	VERB	O
that	O	SCONJ	O
beta2	O	NOUN	B
-	O	PUNCT	O
subunits	O	NOUN	B
play	O	VERB	O
an	O	DET	O
important	O	ADJ	O
role	O	NOUN	O
in	O	ADP	O
the	O	DET	O
regulation	O	NOUN	B
of	O	ADP	O
sodium	B-Chemical	NOUN	B


Screening	O	VERB	B
for	O	ADP	O
stimulant	O	ADJ	B
use	O	NOUN	O
in	O	ADP	O
adult	O	ADJ	B
emergency	O	NOUN	B
department	O	NOUN	I
seizure	B-Disease	NOUN	O
patients	O	NOUN	B
.	O	PUNCT	O


OBJECTIVE	O	NOUN	B
:	O	PUNCT	O
The	O	DET	O
objective	O	NOUN	B
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
determine	O	VERB	O
the	O	DET	O
prevalence	O	NOUN	B
of	O	ADP	O
positive	O	ADJ	B
plasma	O	NOUN	O
drug	O	NOUN	O
screening	O	NOUN	O
for	O	ADP	O
cocaine	B-Chemical	NOUN	B
or	O	CCONJ	O
amphetamine	B-Chemical	NOUN	B
in	O	ADP	O
adult	O	ADJ	B
emergency	O	NOUN	B
department	O	NOUN	I
seizure	B-Disease	NOUN	O
patients	O	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
:	O	PUNCT	O
This	O	DET	O
prospective	O	ADJ	B
study	O	NOUN	I
evaluated	O	VERB	O
consecutive	O	ADJ	O
eligible	O	ADJ	O
seizure	B-Disease	NOUN	B
patients	O	NOUN	B
who	O	PRON	O
had	O	AUX	O
a	O	DET	O
plasma	O	NOUN	B
sample	O	NOUN	O
collected	O	VERB	O
as	O	ADP	O
part	O	NOUN	O
of	O	ADP	O
their	O	PRON	O
clinical	O	ADJ	B
evaluation	O	NOUN	I
.	O	PUNCT	O


Plasma	O	NOUN	B
was	O	AUX	O
tested	O	VERB	B
for	O	ADP	O
amphetamine	B-Chemical	NOUN	B
and	O	CCONJ	O
the	O	DET	O
cocaine	B-Chemical	NOUN	B
metabolite	O	NOUN	B
benzoylecgonine	B-Chemical	NOUN	B
using	O	VERB	O
enzyme	O	NOUN	B
-	O	PUNCT	O
mediated	O	VERB	B
immunoassay	O	NOUN	O
methodology	O	NOUN	O
.	O	PUNCT	O


Plasma	O	NOUN	B
samples	O	NOUN	B
with	O	ADP	O
benzoylecgonine	B-Chemical	NOUN	B
greater	O	ADJ	O
than	O	ADP	O
150	O	NUM	O
ng	O	NOUN	O
/	O	PUNCT	O
mL	O	NOUN	B
or	O	CCONJ	O
an	O	DET	O
amphetamine	B-Chemical	NOUN	B
greater	O	ADJ	B
than	O	ADP	O
500	O	NUM	O
ng	O	NOUN	O
/	O	PUNCT	O
mL	O	NOUN	B
were	O	AUX	O
defined	O	VERB	O
as	O	ADP	O
positive	O	ADJ	B
.	O	PUNCT	O


Patient	O	ADJ	B
demographics	O	NOUN	B
,	O	PUNCT	O
history	O	NOUN	B
of	O	ADP	O
underlying	O	VERB	O
drug	O	NOUN	B
or	O	CCONJ	O
alcohol	B-Chemical	NOUN	B
-	O	PUNCT	O
related	O	VERB	B
seizure	B-Disease	NOUN	B
disorder	O	NOUN	I
,	O	PUNCT	O
estimated	O	VERB	B
time	O	NOUN	O
from	O	ADP	O
seizure	B-Disease	NOUN	B
to	O	PART	O
sample	O	VERB	B
collection	O	NOUN	I
,	O	PUNCT	O
history	O	NOUN	B
or	O	CCONJ	O
suspicion	O	NOUN	B
of	O	ADP	O
cocaine	B-Disease	NOUN	B
or	I-Disease	CCONJ	O
amphetamine	I-Disease	NOUN	B
abuse	I-Disease	NOUN	I
,	O	PUNCT	O
results	O	NOUN	B
of	O	ADP	O
clinical	O	ADJ	B
urine	O	NOUN	O
testing	O	NOUN	O
for	O	ADP	O
drugs	O	NOUN	B
of	O	ADP	O
abuse	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
assay	O	NOUN	B
results	O	NOUN	B
were	O	AUX	O
recorded	O	VERB	O
without	O	ADP	O
patient	O	NOUN	B
identifiers	O	NOUN	O
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
Fourteen	O	NUM	O
of	O	ADP	O
248	O	NUM	O
(	O	PUNCT	O
5	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
%,	O	NOUN	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
2	O	NUM	O
.	O	PUNCT	O


7	O	NUM	O
%-	O	NOUN	B
8	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
%)	O	NOUN	O
plasma	O	NOUN	B
samples	O	NOUN	O
were	O	AUX	O
positive	O	ADJ	B
by	O	ADP	O
immunoassay	O	NOUN	B
testing	O	NOUN	I
for	O	ADP	O
benzoylecgonine	B-Chemical	NOUN	B
and	O	CCONJ	O
no	O	DET	O
samples	O	NOUN	O
(	O	PUNCT	O
0	O	NUM	O
%,	O	NOUN	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
0	O	NUM	O
-	O	SYM	O
1	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
%)	O	NOUN	O
were	O	AUX	O
positive	O	ADJ	B
for	O	ADP	O
amphetamine	B-Chemical	NOUN	B
.	O	PUNCT	O


Positive	O	ADJ	B
test	O	NOUN	I
results	O	NOUN	O
were	O	AUX	O
more	O	ADV	O
common	O	ADJ	O
in	O	ADP	O
patient	O	NOUN	B
visits	O	NOUN	I
where	O	SCONJ	O
there	O	PRON	O
was	O	AUX	O
a	O	DET	O
history	O	NOUN	B
or	O	CCONJ	O
suspicion	O	NOUN	B
of	O	ADP	O
cocaine	B-Disease	NOUN	B
or	I-Disease	CCONJ	O
amphetamine	I-Disease	NOUN	B
abuse	I-Disease	NOUN	I
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


0005	O	NUM	O
).	O	PUNCT	O
CONCLUSIONS	O	NOUN	O
:	O	PUNCT	O
During	O	ADP	O
this	O	DET	O
study	O	NOUN	B
period	O	NOUN	B
,	O	PUNCT	O
routine	O	ADJ	B
plasma	O	NOUN	B
screening	O	NOUN	B
for	O	ADP	O
cocaine	B-Chemical	NOUN	B
and	O	CCONJ	O
amphetamines	B-Chemical	NOUN	B
in	O	ADP	O
adult	O	ADJ	B
seizure	B-Disease	NOUN	B
patients	O	NOUN	B
had	O	AUX	O
a	O	DET	O
low	O	ADJ	B
yield	O	NOUN	B
.	O	PUNCT	O


As	O	ADP	O
a	O	DET	O
result	O	NOUN	B
,	O	PUNCT	O
routine	O	ADJ	B
plasma	O	NOUN	B
screening	O	NOUN	B
would	O	AUX	O
yield	O	VERB	O
few	O	ADJ	O
cases	O	NOUN	B
of	O	ADP	O
stimulant	O	ADJ	B
drug	O	NOUN	O
in	O	ADP	O
which	O	DET	O
there	O	PRON	O
was	O	AUX	O
neither	O	CCONJ	O
a	O	DET	O
history	O	NOUN	B
nor	O	CCONJ	O
suspicion	O	NOUN	B
of	O	ADP	O
drug	B-Disease	NOUN	B
abuse	I-Disease	NOUN	I


Evidence	O	NOUN	B
of	O	ADP	O
functional	O	ADJ	B
somatotopy	O	NOUN	O
in	O	ADP	O
GPi	O	NOUN	B
from	O	ADP	O
results	O	NOUN	B
of	O	ADP	O
pallidotomy	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
objective	O	NOUN	B
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
explore	O	VERB	O
the	O	DET	O
functional	O	ADJ	B
anatomy	O	NOUN	B
of	O	ADP	O
the	O	DET	O
globus	O	NOUN	B
pallidus	O	NOUN	I
internus	O	NOUN	I
(	O	PUNCT	O
GPi	O	NOUN	B
)	O	PUNCT	O
by	O	ADP	O
studying	O	VERB	O
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	O
unilateral	O	ADJ	B
pallidotomy	O	NOUN	B
on	O	ADP	O
parkinsonian	B-Disease	ADJ	B
'	O	PUNCT	O
off	O	ADP	O
'	O	PART	O
signs	O	NOUN	B
and	O	CCONJ	O
levodopa	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
dyskinesias	B-Disease	NOUN	B
(	O	PUNCT	O
LID	B-Disease	PROPN	B
).	O	PUNCT	O
We	O	PRON	O
found	O	VERB	O
significant	O	ADJ	O
positive	O	ADJ	B
correlations	O	NOUN	B
between	O	ADP	O
the	O	DET	O
preoperative	O	ADJ	B
levodopa	B-Chemical	NOUN	B
responsiveness	O	NOUN	B
of	O	ADP	O
motor	O	NOUN	B
signs	O	NOUN	I
and	O	CCONJ	O
the	O	DET	O
levodopa	B-Chemical	NOUN	B
responsiveness	O	NOUN	B
of	O	ADP	O
scores	O	NOUN	B
in	O	ADP	O
timed	O	ADJ	B
tests	O	NOUN	I
(	O	PUNCT	O
Core	O	NOUN	B
Assessment	O	PROPN	I
Program	O	PROPN	I
for	O	ADP	O
Intracerebral	O	PROPN	B
Transplantations	O	PROPN	I
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
contralateral	O	ADJ	B
limbs	O	NOUN	O
and	O	CCONJ	O
the	O	DET	O
improvement	O	NOUN	B
in	O	ADP	O
these	O	DET	O
scores	O	NOUN	B
after	O	ADP	O
surgery	O	NOUN	B
,	O	PUNCT	O
whereas	O	SCONJ	O
there	O	PRON	O
was	O	AUX	O
no	O	DET	O
correlation	O	NOUN	B
with	O	ADP	O
the	O	DET	O
improvement	O	NOUN	B
in	O	ADP	O
LID	B-Disease	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
also	O	ADV	O
found	O	VERB	O
a	O	DET	O
highly	O	ADV	O
significant	O	ADJ	O
correlation	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
:<	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


0001	O	NUM	O
,	O	PUNCT	O
r	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


8	O	NUM	O
)	O	PUNCT	O
between	O	ADP	O
the	O	DET	O
volume	O	NOUN	B
of	O	ADP	O
the	O	DET	O
ventral	O	ADJ	B
lesion	O	NOUN	I
in	O	ADP	O
the	O	DET	O
GPi	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
improvement	O	NOUN	B
in	O	ADP	O
LID	B-Disease	NOUN	B
in	O	ADP	O
the	O	DET	O
contralateral	O	ADJ	B
limbs	O	NOUN	I
,	O	PUNCT	O
whereas	O	SCONJ	O
there	O	PRON	O
was	O	AUX	O
no	O	DET	O
correlation	O	NOUN	B
between	O	ADP	O
the	O	DET	O
ventral	O	ADJ	B
volume	O	NOUN	I
and	O	CCONJ	O
the	O	DET	O
improvement	O	NOUN	B
in	O	ADP	O
parkinsonian	B-Disease	ADJ	B
'	O	PUNCT	O
off	O	ADP	O
'	O	PART	O
signs	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
volumes	O	NOUN	B
of	O	ADP	O
the	O	DET	O
total	O	ADJ	O
lesion	O	NOUN	O
cylinder	O	NOUN	O
and	O	CCONJ	O
the	O	DET	O
dorsal	O	ADJ	B
lesion	O	NOUN	B
did	O	AUX	O
not	O	PART	O
correlate	O	VERB	O
with	O	ADP	O
the	O	DET	O
outcome	O	NOUN	B
of	O	ADP	O
either	O	CCONJ	O
dyskinesias	B-Disease	NOUN	B
or	O	CCONJ	O
parkinsonian	B-Disease	ADJ	B
'	O	PUNCT	O
off	O	ADP	O
'	O	PART	O
signs	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
differential	O	ADJ	O
predictive	O	ADJ	O
value	O	NOUN	O
of	O	ADP	O
levodopa	B-Chemical	NOUN	B
responsiveness	O	NOUN	B
for	O	ADP	O
the	O	DET	O
outcome	O	NOUN	B
of	O	ADP	O
parkinsonian	B-Disease	ADJ	B
'	O	PUNCT	O
off	O	ADP	O
'	O	PART	O
signs	O	NOUN	B
and	O	CCONJ	O
LID	B-Disease	NOUN	B
and	O	CCONJ	O
the	O	DET	O
different	O	ADJ	O
correlations	O	NOUN	B
of	O	ADP	O
ventral	O	ADJ	B
lesion	O	NOUN	I
volume	O	NOUN	I
with	O	ADP	O
dyskinesias	B-Disease	NOUN	B
and	O	CCONJ	O
parkinsonian	B-Disease	ADJ	B
'	O	PUNCT	O
off	O	ADP	O
'	O	PART	O
signs	O	NOUN	B
indicate	O	VERB	O
that	O	SCONJ	O
different	O	ADJ	O
anatomical	O	ADJ	B
or	O	CCONJ	O
pathophysiological	O	ADJ	B
substrates	O	NOUN	B
may	O	AUX	O
be	O	AUX	O
responsible	O	ADJ	O
for	O	ADP	O
the	O	DET	O
generation	O	NOUN	B
of	O	ADP	O
parkinsonian	B-Disease	ADJ	B
'	O	PUNCT	O
off	O	ADP	O
'	O	PART	O
signs	O	NOUN	B
and	O	CCONJ	O
dyskinesias	B-Disease	NOUN	B
.	O	PUNCT	O


Whereas	O	SCONJ	O
cells	O	NOUN	B
in	O	ADP	O
a	O	DET	O
wider	O	ADJ	O
area	O	NOUN	O
of	O	ADP	O
the	O	DET	O
GPi	O	NOUN	B
may	O	AUX	O
be	O	AUX	O
implicated	O	VERB	O
in	O	ADP	O
parkinsonism	B-Disease	NOUN	B
,	O	PUNCT	O
the	O	DET	O
ventral	O	ADJ	B
GPi	O	NOUN	I
seems	O	VERB	O
to	O	PART	O
be	O	AUX	O
crucial	O	ADJ	O
for	O	ADP	O
the	O	DET	O
manifestation	O	NOUN	B
of	O	ADP	O
LID	B-Disease	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
suggest	O	VERB	O
that	O	SCONJ	O
our	O	PRON	O
observations	O	NOUN	B
are	O	AUX	O
additional	O	ADJ	O
proof	O	NOUN	O
of	O	ADP	O
the	O	DET	O
functional	O	ADJ	B
somatotopy	O	NOUN	O
of	O	ADP	O
the	O	DET	O
systems	O	NOUN	B
within	O	ADP	O
the	O	DET	O
GPi	O	NOUN	B
that	O	PRON	O
mediate	O	VERB	O
parkinsonism	B-Disease	NOUN	B
and	O	CCONJ	O
dyskinesias	B-Disease	NOUN	B


Pain	B-Disease	NOUN	B
responses	O	NOUN	I
in	O	ADP	O
methadone	B-Chemical	NOUN	B
-	O	PUNCT	O
maintained	O	VERB	B
opioid	O	NOUN	B
abusers	O	NOUN	I
.	O	PUNCT	O


Providing	O	VERB	O
pain	B-Disease	NOUN	B
management	O	NOUN	I
for	O	ADP	O
known	O	VERB	O
opioid	O	NOUN	B
abusers	O	NOUN	I
is	O	AUX	O
a	O	DET	O
challenging	O	ADJ	O
clinical	O	ADJ	B
task	O	NOUN	I
,	O	PUNCT	O
in	O	ADP	O
part	O	NOUN	O
because	O	SCONJ	O
little	O	ADJ	O
is	O	AUX	O
known	O	VERB	O
about	O	ADP	O
their	O	PRON	O
pain	B-Disease	NOUN	B
experience	O	NOUN	B
and	O	CCONJ	O
analgesic	O	NOUN	B
requirements	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
study	O	NOUN	B
was	O	AUX	O
designed	O	VERB	O
to	O	PART	O
describe	O	VERB	O
pain	B-Disease	NOUN	B
tolerance	O	NOUN	I
and	O	CCONJ	O
analgesic	O	NOUN	B
response	O	NOUN	I
in	O	ADP	O
a	O	DET	O
sample	O	NOUN	B
of	O	ADP	O
opioid	B-Disease	NOUN	B
addicts	I-Disease	NOUN	I
stabilized	O	VERB	B
in	O	ADP	O
methadone	B-Chemical	NOUN	B
-	O	PUNCT	O
maintenance	O	NOUN	B
(	O	PUNCT	O
MM	O	NOUN	B
)	O	PUNCT	O
treatment	O	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
60	O	NUM	O
)	O	PUNCT	O
in	O	ADP	O
comparison	O	NOUN	B
to	O	PART	O
matched	O	VERB	B
nondependent	O	ADJ	B
control	O	ADJ	I
subjects	O	NOUN	I
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
60	O	NUM	O
).	O	NOUN	O
By	O	ADP	O
using	O	VERB	O
a	O	DET	O
placebo	O	NOUN	B
-	O	PUNCT	O
controlled	O	VERB	B
,	O	PUNCT	O
two	O	NUM	O
-	O	PUNCT	O
way	O	NOUN	B
factorial	O	ADJ	B
design	O	NOUN	I
,	O	PUNCT	O
tolerance	O	NOUN	B
to	O	ADP	O
cold	O	ADJ	B
-	O	PUNCT	O
pressor	O	NOUN	B
(	O	PUNCT	O
CP	O	NOUN	B
)	O	PUNCT	O
pain	B-Disease	NOUN	O
was	O	AUX	O
examined	O	VERB	B
,	O	PUNCT	O
both	O	CCONJ	O
before	O	ADP	O
and	O	CCONJ	O
after	O	ADP	O
oral	O	ADJ	B
administration	O	NOUN	I
of	O	ADP	O
therapeutic	O	ADJ	B
doses	O	NOUN	I
of	O	ADP	O
common	O	ADJ	O
opioid	O	NOUN	B
(	O	PUNCT	O
hydromorphone	B-Chemical	NOUN	B
2	O	NUM	O
mg	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
nonsteroidal	O	ADJ	B
anti	O	ADJ	I
-	O	PUNCT	O
inflammatory	O	ADJ	B
(	O	PUNCT	O
ketorolac	B-Chemical	NOUN	B
10	O	NUM	O
mg	O	NOUN	O
)	O	PUNCT	O
analgesic	O	NOUN	B
agents	O	NOUN	I
.	O	PUNCT	O


Results	O	NOUN	B
showed	O	VERB	O
that	O	SCONJ	O
MM	O	NOUN	B
individuals	O	NOUN	B
were	O	AUX	O
significantly	O	ADV	O
less	O	ADV	O
tolerant	O	ADJ	B
of	O	ADP	O
CP	O	NOUN	B
pain	B-Disease	NOUN	B
than	O	ADP	O
control	O	ADJ	B
subjects	O	NOUN	I
,	O	PUNCT	O
replicating	O	VERB	B
previous	O	ADJ	O
work	O	NOUN	O
.	O	PUNCT	O


Analgesic	O	ADJ	B
effects	O	NOUN	I
were	O	AUX	O
significant	O	ADJ	O
neither	O	CCONJ	O
for	O	ADP	O
medication	O	NOUN	B
nor	O	CCONJ	O
group	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
data	O	NOUN	B
indicate	O	VERB	O
that	O	SCONJ	O
MM	O	NOUN	B
opioid	O	NOUN	B
abusers	O	NOUN	B
represent	O	VERB	O
a	O	DET	O
pain-intolerant	B-Disease	ADJ	B
subset	O	NOUN	I
of	O	ADP	O
clinical	O	ADJ	B
patients	O	NOUN	B
.	O	PUNCT	O


Their	O	PRON	O
complaints	O	NOUN	B
of	O	ADP	O
pain	B-Disease	NOUN	B


Urine	O	NOUN	B
N	O	NOUN	I
-	O	PUNCT	O
acetyl	O	ADJ	B
-	O	PUNCT	O
beta	O	NOUN	B
-	O	PUNCT	O
D	O	PROPN	B
-	O	PUNCT	O
glucosaminidase	O	NOUN	B
--	O	PUNCT	O
a	O	DET	O
marker	O	NOUN	B
of	O	ADP	O
tubular	O	ADJ	B
damage	O	NOUN	I
?	O	PUNCT	O
BACKGROUND	O	NOUN	O
:	O	PUNCT	O
Although	O	SCONJ	O
an	O	DET	O
indicator	O	NOUN	B
of	O	ADP	O
renal	B-Disease	ADJ	B
tubular	I-Disease	ADJ	I
dysfunction	I-Disease	NOUN	I
,	O	PUNCT	O
an	O	DET	O
increased	O	VERB	B
urinary	O	ADJ	B
N	O	NOUN	B
-	O	PUNCT	O
acetyl	O	ADJ	B
-	O	PUNCT	O
beta	O	NOUN	B
-	O	PUNCT	O
D	O	NOUN	B
-	O	PUNCT	O
glucosaminidase	O	NOUN	B
(	O	PUNCT	O
NAG	O	NOUN	B
)	O	PUNCT	O
activity	O	NOUN	B
might	O	AUX	O
reflect	O	VERB	O
increased	O	VERB	B
lysosomal	O	ADJ	B
activity	O	NOUN	I
in	O	ADP	O
renal	O	ADJ	B
tubular	O	ADJ	I
cells	O	NOUN	I
.	O	PUNCT	O


METHODS	O	NOUN	O
:	O	PUNCT	O
Puromycin	B-Chemical	NOUN	B
aminonucleoside	I-Chemical	NOUN	I
(	O	PUNCT	O
PAN	B-Chemical	NOUN	B
)	O	PUNCT	O
was	O	AUX	O
administered	O	VERB	B
to	O	ADP	O
Sprague	O	PROPN	B
Dawley	O	NOUN	I
rats	O	NOUN	I
to	O	PART	O
induce	O	VERB	B
proteinuria	B-Disease	NOUN	B
.	O	PUNCT	O


Total	O	ADJ	B
protein	O	NOUN	I
,	O	PUNCT	O
albumin	O	NOUN	B
,	O	PUNCT	O
NAG	O	NOUN	B
activity	O	NOUN	B
and	O	CCONJ	O
protein	O	NOUN	B
electrophoretic	O	ADJ	I
pattern	O	NOUN	I
were	O	AUX	O
assessed	O	VERB	B
in	O	ADP	O
daily	O	ADJ	B
urine	O	NOUN	B
samples	O	NOUN	I
for	O	ADP	O
33	O	NUM	O
days	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
morphological	O	ADJ	B
appearance	O	NOUN	B
of	O	ADP	O
the	O	DET	O
kidneys	O	NOUN	B
was	O	AUX	O
examined	O	VERB	O
on	O	ADP	O
days	O	NOUN	B
three	O	NUM	O
,	O	PUNCT	O
four	O	NUM	O
,	O	PUNCT	O
six	O	NUM	O
,	O	PUNCT	O
eight	O	NUM	O
and	O	CCONJ	O
thirty	O	NUM	O
three	O	NUM	O
and	O	CCONJ	O
the	O	DET	O
NAG	O	NOUN	B
isoenzyme	O	NOUN	B
patterns	O	NOUN	B
on	O	ADP	O
days	O	NOUN	B
zero	O	NUM	O
,	O	PUNCT	O
four	O	NUM	O
,	O	PUNCT	O
eight	O	NUM	O
and	O	CCONJ	O
thirty	O	NUM	O
three	O	NUM	O
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
Following	O	VERB	O
intravenous	O	ADJ	B
PAN	B-Chemical	NOUN	B
urine	O	NOUN	B
volume	O	NOUN	I
and	O	CCONJ	O
urine	O	NOUN	B
NAG	O	NOUN	B
activity	O	NOUN	B
increased	O	VERB	B
significantly	O	ADV	O
by	O	ADP	O
day	O	NOUN	B
two	O	NUM	O
,	O	PUNCT	O
but	O	CCONJ	O
returned	O	VERB	O
to	O	ADP	O
normal	O	ADJ	O
by	O	ADP	O
day	O	NOUN	B
four	O	NUM	O
.	O	PUNCT	O


After	O	ADP	O
day	O	NOUN	B
four	O	NUM	O
all	O	DET	O
treated	O	VERB	B
animals	O	NOUN	B
exhibited	O	VERB	O
a	O	DET	O
marked	O	ADJ	O
rise	O	NOUN	O
in	O	ADP	O
urine	O	NOUN	B
albumin	O	NOUN	I
,	O	PUNCT	O
total	O	ADJ	O
protein	O	NOUN	O
excretion	O	NOUN	B
and	O	CCONJ	O
NAG	O	NOUN	B
activity	O	NOUN	B
.	O	PUNCT	O


Electrophoresis	O	NOUN	B
showed	O	VERB	O
a	O	DET	O
generalised	O	ADJ	O
increase	O	NOUN	B
in	O	ADP	O
middle	O	ADJ	B
and	O	CCONJ	O
high	O	ADJ	O
molecular	O	ADJ	B
weight	O	NOUN	I
urine	O	NOUN	B
proteins	O	NOUN	I
from	O	ADP	O
day	O	NOUN	B
four	O	NUM	O
onwards	O	NOUN	O
.	O	PUNCT	O


Protein	O	NOUN	B
droplets	O	VERB	I
first	O	ADV	O
appeared	O	VERB	O
prominent	O	ADJ	O
in	O	ADP	O
tubular	O	ADJ	B
cells	O	NOUN	I
on	O	ADP	O
day	O	NOUN	B
four	O	NUM	O
.	O	PUNCT	O


Peak	O	ADJ	B
urine	O	NOUN	I
NAG	O	NOUN	B
activity	O	NOUN	B
and	O	CCONJ	O
a	O	DET	O
change	O	NOUN	O
in	O	ADP	O
NAG	O	NOUN	B
isoenzyme	O	NOUN	B
pattern	O	NOUN	O
coincided	O	VERB	O
with	O	ADP	O
both	O	CCONJ	O
the	O	DET	O
peak	O	NOUN	B
proteinuria	B-Disease	NOUN	I


Over	O	ADP	O
expression	O	NOUN	B
of	O	ADP	O
vascular	O	ADJ	B
endothelial	O	ADJ	I
growth	O	NOUN	I
factor	O	NOUN	I
and	O	CCONJ	O
its	O	PRON	O
receptor	O	NOUN	B
during	O	ADP	O
the	O	DET	O
development	O	NOUN	B
of	O	ADP	O
estrogen	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
rat	O	NOUN	B
pituitary	B-Disease	ADJ	B
tumors	I-Disease	NOUN	I
may	O	AUX	O
mediate	O	VERB	O
estrogen	B-Chemical	NOUN	B
-	O	PUNCT	O
initiated	O	VERB	B
tumor	B-Disease	NOUN	B
angiogenesis	O	NOUN	I
.	O	PUNCT	O


Estrogens	B-Chemical	NOUN	B
,	O	PUNCT	O
which	O	DET	O
have	O	AUX	O
been	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
several	O	ADJ	O
types	O	NOUN	O
of	O	ADP	O
human	O	ADJ	B
and	O	CCONJ	O
animal	O	NOUN	B
cancers	B-Disease	NOUN	I
,	O	PUNCT	O
can	O	AUX	O
induce	O	VERB	B
tumor	B-Disease	NOUN	B
angiogenesis	O	NOUN	I
in	O	ADP	O
the	O	DET	O
pituitary	O	NOUN	B
of	O	ADP	O
Fischer	O	NOUN	O
344	O	NUM	O
rats	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
mechanistic	O	ADJ	O
details	O	NOUN	O
of	O	ADP	O
tumor	B-Disease	NOUN	B
angiogenesis	O	NOUN	I
induction	O	NOUN	B
,	O	PUNCT	O
during	O	ADP	O
estrogen	B-Chemical	NOUN	B
carcinogenesis	B-Disease	NOUN	I
,	O	PUNCT	O
are	O	AUX	O
still	O	ADV	O
unknown	O	ADJ	O
.	O	PUNCT	O


To	O	PART	O
elucidate	O	VERB	O
the	O	DET	O
role	O	NOUN	O
of	O	ADP	O
estrogen	B-Chemical	NOUN	B
in	O	ADP	O
the	O	DET	O
regulation	O	NOUN	B
of	O	ADP	O
tumor	B-Disease	NOUN	B
angiogenesis	O	NOUN	I
in	O	ADP	O
the	O	DET	O
pituitary	O	NOUN	B
of	O	ADP	O
female	O	ADJ	B
rats	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
density	O	NOUN	B
of	O	ADP	O
blood	O	NOUN	B
vessels	O	NOUN	I
was	O	AUX	O
analysed	O	VERB	B
using	O	VERB	O
factor	O	NOUN	B
VIII	O	NOUN	I
related	O	ADJ	I
antigen	O	NOUN	I
(	O	PUNCT	O
FVIIIRAg	O	NOUN	B
)	O	PUNCT	O
immunohistochemistry	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
expression	O	NOUN	B
of	O	ADP	O
vascular	O	ADJ	B
endothelial	O	ADJ	I
growth	O	NOUN	I
factor	O	NOUN	I
/	O	PUNCT	O
vascular	O	ADJ	B
permeability	O	NOUN	I
factor	O	NOUN	I
(	O	PUNCT	O
VEGF	O	NOUN	B
/	O	SYM	O
VPF	O	NOUN	B
)	O	PUNCT	O
was	O	AUX	O
examined	O	VERB	O
by	O	ADP	O
Western	O	NOUN	B
blot	O	NOUN	I
and	O	CCONJ	O
immunohistochemical	O	ADJ	B
analysis	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
expression	O	NOUN	B
of	O	ADP	O
VEGF	O	NOUN	B
receptor	O	NOUN	I
(	O	PUNCT	O
VEGFR	O	NOUN	B
-	O	PUNCT	O
2	O	NUM	B
/	O	SYM	O
Flk	O	PROPN	B
-	O	PUNCT	O
1	O	NUM	B
/	O	SYM	O
KDR	O	NOUN	B
)	O	PUNCT	O
was	O	AUX	O
also	O	ADV	O
examined	O	VERB	O
by	O	ADP	O
immunohistochemistry	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
results	O	NOUN	B
demonstrated	O	VERB	O
that	O	SCONJ	O
17beta-estradiol	B-Chemical	NOUN	B
(	O	PUNCT	O
E2	B-Chemical	NOUN	B
)	O	PUNCT	O
induces	O	VERB	B
neovascularization	O	NOUN	B
,	O	PUNCT	O
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
the	O	DET	O
growth	O	NOUN	B
and	O	CCONJ	O
enlargement	O	NOUN	B
of	O	ADP	O
blood	O	NOUN	B
vessels	O	NOUN	I
after	O	ADP	O
7	O	NUM	O
days	O	NOUN	B
of	O	ADP	O
exposure	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
high	O	ADJ	B
tumor	B-Disease	NOUN	B
angiogenic	O	ADJ	B
potential	O	NOUN	B
was	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
an	O	DET	O
elevated	O	ADJ	B
VEGF	O	NOUN	B
/	O	SYM	O
VPF	O	NOUN	B
protein	O	NOUN	O
expression	O	NOUN	B
in	O	ADP	O
the	O	DET	O
E2	B-Chemical	NOUN	B
exposed	O	VERB	O
pituitary	O	NOUN	B
of	O	ADP	O
ovariectomized	O	ADJ	B
(	O	PUNCT	O
OVEX	O	NOUN	B
)	O	PUNCT	O
rats	O	NOUN	B
.	O	PUNCT	O


VEGF	O	NOUN	B
/	O	SYM	O
VPF	O	NOUN	B
and	O	CCONJ	O
FVIIIRAg	O	NOUN	B
immunohistochemistry	O	NOUN	O
and	O	CCONJ	O
endothelial	O	ADJ	B
specific	O	ADJ	O
lectin	O	NOUN	O
(	O	PUNCT	O
UEA1	O	NOUN	B
)	O	PUNCT	O
binding	O	NOUN	B
studies	O	NOUN	I
,	O	PUNCT	O
indicate	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
elevation	O	NOUN	B
of	O	ADP	O
VEGF	O	NOUN	B
protein	O	NOUN	I
expression	O	NOUN	B
initially	O	ADV	O
occurred	O	VERB	O
in	O	ADP	O
both	O	DET	O
blood	O	NOUN	B
vessels	O	NOUN	I
and	O	CCONJ	O
non	O	ADJ	B
-	O	PUNCT	O
endothelial	O	ADJ	B
cells	O	NOUN	I
.	O	PUNCT	O


After	O	ADP	O
15	O	NUM	O
days	O	NOUN	B
of	O	ADP	O
E2	B-Chemical	NOUN	B
exposure	O	NOUN	B
,	O	PUNCT	O
VEGF	O	NOUN	B
/	O	SYM	O
VPF	O	NOUN	B
protein	O	NOUN	O
expression	O	NOUN	B
,	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
non	O	ADJ	B
-	O	PUNCT	O
endothelial	O	ADJ	B
cell	O	NOUN	I
population	O	NOUN	O
,	O	PUNCT	O
sharply	O	ADV	O
declined	O	VERB	B
and	O	CCONJ	O
was	O	AUX	O
restricted	O	ADJ	O
to	O	PART	O
the	O	DET	O
blood	O	NOUN	B
vessels	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
function	O	NOUN	B
of	O	ADP	O
non	O	ADJ	B
-	O	PUNCT	O
endothelial	O	ADJ	B
-	O	PUNCT	O
derived	O	VERB	B
VEGF	O	NOUN	B
is	O	AUX	O
not	O	PART	O
clear	O	ADJ	O
.	O	PUNCT	O


Furthermore	O	ADV	O
,	O	PUNCT	O
immunohistochemical	O	ADJ	B
studies	O	NOUN	I
demonstrated	O	VERB	O
that	O	SCONJ	O
VEGFR	O	NOUN	B
-	O	PUNCT	O
2	O	NUM	B
(	O	PUNCT	O
flk	O	NOUN	B
-	O	PUNCT	O
1	O	NUM	B
/	O	SYM	O
KDR	O	NOUN	B
),	O	PUNCT	O
expression	O	NOUN	B
was	O	AUX	O
elevated	O	VERB	B
significantly	O	ADV	O
in	O	ADP	O
the	O	DET	O
endothelial	O	ADJ	B
cells	O	NOUN	I
of	O	ADP	O
microblood	O	NOUN	B
vessels	O	NOUN	I
after	O	ADP	O
7	O	NUM	O
days	O	NOUN	B
of	O	ADP	O
E2	B-Chemical	NOUN	B
exposure	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
findings	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
over	O	ADP	O
expression	O	NOUN	B
of	O	ADP	O
VEGF	O	NOUN	B
and	O	CCONJ	O
its	O	PRON	O
receptor	O	NOUN	B
(	O	PUNCT	O
VEGFR	O	NOUN	B
-	O	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
may	O	AUX	O
play	O	VERB	O
an	O	DET	O
important	O	ADJ	O
role	O	NOUN	O
in	O	ADP	O
the	O	DET	O
initial	O	ADJ	O
step	O	NOUN	O
of	O	ADP	O
the	O	DET	O
regulation	O	NOUN	B
of	O	ADP	O
estrogen	B-Chemical	NOUN	B
induced	O	ADJ	B
tumor	B-Disease	NOUN	B


Pravastatin	B-Chemical	NOUN	B
-	O	PUNCT	O
associated	O	VERB	B
myopathy	B-Disease	NOUN	B
.	O	PUNCT	O


Report	O	NOUN	B
of	O	ADP	O
a	O	DET	O
case	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
case	O	NOUN	B
of	O	ADP	O
acute	O	ADJ	B
inflammatory	B-Disease	ADJ	I
myopathy	I-Disease	NOUN	I
associated	O	VERB	B
with	O	ADP	I
the	O	DET	O
use	O	NOUN	O
of	O	ADP	O
pravastatin	B-Chemical	NOUN	B
,	O	PUNCT	O
a	O	DET	O
new	O	ADJ	O
hydrophilic	O	ADJ	B
3	O	NUM	O
-	O	PUNCT	O
hydroxy	O	NOUN	B
-	O	PUNCT	O
3	O	NUM	O
methylglutaril	O	NOUN	O
coenzyme	O	NOUN	O
A	O	NOUN	O
reductase	O	NOUN	O
inhibitor	O	NOUN	O
,	O	PUNCT	O
is	O	AUX	O
reported	O	VERB	O
.	O	PUNCT	O


The	O	DET	O
patient	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
69	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
man	O	NOUN	B
was	O	AUX	O
affected	O	VERB	B
by	O	ADP	O
non-insulin-dependent	B-Disease	ADJ	B
diabetes	I-Disease	NOUN	I
mellitus	I-Disease	NOUN	I
and	O	CCONJ	O
hypertension	B-Disease	NOUN	B
.	O	PUNCT	O


He	O	PRON	O
assumed	O	VERB	O
pravastatin	B-Chemical	NOUN	B
(	O	PUNCT	O
20	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
day	O	NOUN	B
)	O	PUNCT	O
because	O	SCONJ	O
of	O	ADP	O
hypercholesterolemia	B-Disease	NOUN	B
.	O	PUNCT	O


He	O	PRON	O
was	O	AUX	O
admitted	O	VERB	B
with	O	ADP	I
acute	O	ADJ	B
myopathy	B-Disease	NOUN	I
of	O	ADP	O
the	O	DET	O
lower	O	ADJ	B
limbs	O	NOUN	I
which	O	DET	O
resolved	O	VERB	B
in	O	ADP	O
a	O	DET	O
few	O	ADJ	O
days	O	NOUN	B
after	O	ADP	O
pravastatin	B-Chemical	NOUN	B
discontinuation	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
previously	O	ADV	O
unknown	O	ADJ	O
hypothyroidism	B-Disease	NOUN	B
,	O	PUNCT	O
probably	O	ADV	O
due	O	ADJ	O
to	O	PART	O
chronic	O	ADJ	B
autoimmune	B-Disease	ADJ	I
thyroiditis	I-Disease	NOUN	I
,	O	PUNCT	O
was	O	AUX	O
evidenced	O	VERB	O
.	O	PUNCT	O


Muscle	O	PROPN	B
biopsy	O	NOUN	I
(	O	PUNCT	O
left	O	VERB	B
gastrocnemius	O	NOUN	I
)	O	PUNCT	O
revealed	O	VERB	O
a	O	DET	O
perimysial	O	ADJ	B
and	O	CCONJ	O
endomysial	O	ADJ	B
inflammatory	O	ADJ	I
infiltrate	O	NOUN	I
with	O	ADP	O
a	O	DET	O
prevalence	O	NOUN	B
of	O	ADP	O
CD4	O	NOUN	B
+	O	CCONJ	O
lymphocytes	O	NOUN	B
.	O	PUNCT	O


While	O	SCONJ	O
lovastatin	B-Chemical	NOUN	B
and	O	CCONJ	O
simvastatin	B-Chemical	NOUN	B
have	O	AUX	O
been	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
toxic	O	ADJ	B
myopathy	B-Disease	NOUN	I
,	O	PUNCT	O
pravastatin	B-Chemical	NOUN	B
-	O	PUNCT	O
associated	O	VERB	B
myopathy	B-Disease	NOUN	B


Dose	O	NOUN	B
-	O	PUNCT	O
effect	O	NOUN	B
and	O	CCONJ	O
structure	O	NOUN	B
-	O	PUNCT	O
function	O	NOUN	B
relationships	O	NOUN	B
in	O	ADP	O
doxorubicin	B-Chemical	NOUN	B
cardiomyopathy	B-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
cardiomyopathy	B-Disease	NOUN	B
(	O	PUNCT	O
CM	B-Disease	NOUN	B
)	O	PUNCT	O
produced	O	VERB	O
by	O	ADP	O
the	O	DET	O
anticancer	O	NOUN	B
drug	O	NOUN	I
doxorubicin	B-Chemical	NOUN	I
(	O	PUNCT	O
DXR	B-Chemical	NOUN	B
)(	O	NOUN	O
Adriamycin	B-Chemical	NOUN	B
)	O	PUNCT	O
provides	O	VERB	O
a	O	DET	O
unique	O	ADJ	B
opportunity	O	NOUN	O
to	O	PART	O
analyze	O	VERB	B
dose	O	NOUN	B
-	O	PUNCT	O
effect	O	NOUN	B
and	O	CCONJ	O
structure	O	NOUN	B
-	O	PUNCT	O
function	O	NOUN	B
relationships	O	NOUN	B
during	O	ADP	O
development	O	NOUN	B
of	O	ADP	O
myocardial	B-Disease	ADJ	B
disease	I-Disease	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
measured	O	VERB	B
the	O	DET	O
degree	O	NOUN	B
of	O	ADP	O
morphologic	O	ADJ	B
damage	O	NOUN	I
by	O	ADP	O
ultrastructural	O	ADJ	B
examination	O	NOUN	B
of	O	ADP	O
endomyocardial	O	ADJ	B
biopsy	O	NOUN	I
and	O	CCONJ	O
the	O	DET	O
degree	O	NOUN	B
of	O	ADP	O
performance	O	NOUN	B
abnormally	O	ADV	B
by	O	ADP	O
right	O	ADJ	B
heart	O	NOUN	I
catheterization	O	NOUN	I
in	O	ADP	O
patients	O	NOUN	B
receiving	O	VERB	O
DXR	B-Chemical	NOUN	B
.	O	PUNCT	O


Morphologic	O	ADJ	B
damage	O	NOUN	I
was	O	AUX	O
variable	O	ADJ	B
but	O	CCONJ	O
was	O	AUX	O
proportional	O	ADJ	O
to	O	ADP	O
the	O	DET	O
total	O	ADJ	O
cumulative	O	ADJ	B
DXR	B-Chemical	NOUN	B
dose	O	NOUN	B
between	O	ADP	O
100	O	NUM	O
and	O	CCONJ	O
600	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
m2	O	NOUN	B
.	O	PUNCT	O


Performance	O	NOUN	B
abnormalities	O	NOUN	I
correlated	O	VERB	B
weakly	O	ADV	O
with	O	ADP	O
dose	O	NOUN	B
,	O	PUNCT	O
exhibited	O	VERB	O
a	O	DET	O
curvilinear	O	ADJ	B
relationship	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
had	O	AUX	O
a	O	DET	O
"	O	PUNCT	O
threshold	O	NOUN	B
"	O	PUNCT	O
for	O	ADP	O
expression	O	NOUN	B
.	O	PUNCT	O


Catheterization	O	NOUN	B
abnormalities	O	NOUN	I
correlated	O	VERB	B
well	O	ADV	O
with	O	ADP	O
morphologic	O	ADJ	B
damage	O	NOUN	I
(	O	PUNCT	O
r	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


57	O	NUM	O
to	O	PART	O
0	O	NUM	O
.	O	PUNCT	O


78	O	NUM	O
)	O	PUNCT	O
in	O	ADP	O
a	O	DET	O
subgroup	O	NOUN	B
of	O	ADP	O
patients	O	NOUN	B
in	O	ADP	O
whom	O	PRON	O
exercise	O	VERB	B
hemodynamics	O	NOUN	B
were	O	AUX	O
measured	O	VERB	B
,	O	PUNCT	O
and	O	CCONJ	O
this	O	DET	O
relationship	O	NOUN	B
also	O	ADV	O
exhibited	O	VERB	O
a	O	DET	O
curvilinear	O	ADJ	B
,	O	PUNCT	O
threshold	O	NOUN	B
configuration	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
DXR	B-Chemical	PROPN	B
-	O	PUNCT	O
CM	B-Disease	NOUN	B
myocardial	B-Disease	ADJ	B
damage	I-Disease	NOUN	I
is	O	AUX	O
proportional	O	ADJ	O
to	O	PART	O
the	O	DET	O
degree	O	NOUN	B
of	O	ADP	O
cytotoxic	O	ADJ	B
insult	O	NOUN	I
(	O	PUNCT	O
DXR	B-Chemical	NOUN	B


Fatal	O	ADJ	B
aplastic	B-Disease	ADJ	B
anemia	I-Disease	NOUN	I
following	O	VERB	O
topical	O	ADJ	B
administration	O	NOUN	I
of	O	ADP	O
ophthalmic	O	ADJ	B
chloramphenicol	B-Chemical	NOUN	I
.	O	PUNCT	O


A	O	DET	O
73	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
woman	O	NOUN	B
died	O	VERB	B
of	O	ADP	O
aplastic	B-Disease	ADJ	B
anemia	I-Disease	NOUN	I
less	O	ADJ	O
than	O	ADP	O
two	O	NUM	O
months	O	NOUN	B
after	O	ADP	O
undergoing	O	VERB	O
cataract	B-Disease	NOUN	B
extraction	O	NOUN	I
and	O	CCONJ	O
beginning	O	VERB	O
topical	O	ADJ	B
therapy	O	NOUN	I
with	O	ADP	O
chloramphenicol	B-Chemical	NOUN	B
.	O	PUNCT	O


The	O	DET	O
first	O	ADJ	O
signs	O	NOUN	O
of	O	ADP	O
pancytopenia	B-Disease	NOUN	B
began	O	VERB	O
within	O	ADP	O
one	O	NUM	O
month	O	NOUN	B
of	O	ADP	O
the	O	DET	O
surgery	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
pattern	O	NOUN	B
of	O	ADP	O
the	O	DET	O
aplastic	B-Disease	ADJ	B
anemia	I-Disease	NOUN	I
was	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
an	O	DET	O
idiosyncratic	O	ADJ	B
response	O	NOUN	I
to	O	PART	O
chloramphenicol	B-Chemical	NOUN	B
.	O	PUNCT	O


This	O	DET	O
was	O	AUX	O
the	O	DET	O
second	O	ADJ	O
report	O	NOUN	O
of	O	ADP	O
fatal	O	ADJ	B
aplastic	B-Disease	ADJ	B
anemia	I-Disease	NOUN	I
after	O	ADP	O
topical	O	ADJ	B
treatment	O	NOUN	I
with	O	ADP	O
chloramphenicol	B-Chemical	NOUN	B
for	O	ADP	O
ocular	O	ADJ	B
conditions	O	NOUN	I
,	O	PUNCT	O
although	O	SCONJ	O
two	O	NUM	O
cases	O	NOUN	B
of	O	ADP	O
reversible	O	ADJ	B
bone	B-Disease	NOUN	B
marrow	I-Disease	NOUN	I
hypoplasia	I-Disease	NOUN	I
have	O	AUX	O
also	O	ADV	O
been	O	AUX	O
reported	O	VERB	O
.	O	PUNCT	O


Any	O	DET	O
other	O	ADJ	O
suspected	O	ADJ	B
cases	O	NOUN	B
of	O	ADP	O
ocular	B-Disease	ADJ	B
toxicity	I-Disease	NOUN	B
associated	O	VERB	B
with	O	ADP	I
topically	O	ADV	B
applied	O	VERB	O
chloramphenicol	B-Chemical	NOUN	B


Bradycardia	B-Disease	NOUN	B
due	O	ADP	O
to	O	PART	O
trihexyphenidyl	B-Chemical	NOUN	B
hydrochloride	I-Chemical	NOUN	I
.	O	PUNCT	O


A	O	DET	O
chronic	O	ADJ	B
schizophrenic	B-Disease	ADJ	O
patient	O	NOUN	O
was	O	AUX	O
treated	O	VERB	B
with	O	ADP	I
an	O	DET	O
anticholinergic	O	ADJ	B
drug	O	NOUN	I
,	O	PUNCT	O
trihexyphenidyl	B-Chemical	NOUN	B
hydrochloride	I-Chemical	NOUN	I
.	O	PUNCT	O


The	O	DET	O
patient	O	NOUN	B
developed	O	VERB	O
,	O	PUNCT	O
paradoxically	O	ADV	O
,	O	PUNCT	O
sinus	O	ADJ	B
bradycardia	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
reaction	O	NOUN	B
was	O	AUX	O
specific	O	ADJ	O
to	O	PART	O
trihexyphenidyl	B-Chemical	NOUN	B
and	O	CCONJ	O
not	O	PART	O
to	O	PART	O
other	O	ADJ	O
anticholinergic	O	ADJ	B
drugs	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
antidyskinetic	O	ADJ	B
drug	O	NOUN	I
is	O	AUX	O
widely	O	ADV	O
used	O	VERB	O
in	O	ADP	O
clinical	O	ADJ	B
psychiatric	B-Disease	ADJ	O


Experimental	O	ADJ	B
cyclosporine	B-Chemical	NOUN	B
nephrotoxicity	B-Disease	NOUN	B
:	O	PUNCT	O
risk	O	NOUN	B
of	O	ADP	O
concomitant	O	ADJ	B
chemotherapy	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
role	O	NOUN	O
of	O	ADP	O
cyclosporine	B-Chemical	NOUN	B
(	O	PUNCT	O
CSA	B-Chemical	NOUN	B
)	O	PUNCT	O
alone	O	ADV	O
or	O	CCONJ	O
in	O	ADP	O
combination	O	NOUN	B
with	O	ADP	O
various	O	ADJ	O
chemotherapeutics	O	NOUN	B
in	O	ADP	O
the	O	DET	O
development	O	NOUN	B
of	O	ADP	O
renal	B-Disease	ADJ	B
toxicity	I-Disease	NOUN	B
was	O	AUX	O
evaluated	O	VERB	B
in	O	ADP	O
rats	O	NOUN	B
.	O	PUNCT	O


Administration	O	NOUN	B
of	O	ADP	O
20	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
/	O	SYM	O
day	O	NOUN	B
CSA	B-Chemical	PROPN	B
for	O	ADP	O
4	O	NUM	O
weeks	O	NOUN	B
caused	O	VERB	O
renal	O	ADJ	B
functional	O	ADJ	I
and	O	CCONJ	O
structural	O	ADJ	B
changes	O	NOUN	O
similar	O	ADJ	O
to	O	PART	O
those	O	DET	O
reported	O	VERB	O
in	O	ADP	O
man	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
combined	O	ADJ	O
administration	O	NOUN	B
of	O	ADP	O
CSA	B-Chemical	PROPN	B
and	O	CCONJ	O
various	O	ADJ	O
chemotherapeutic	O	ADJ	B
drugs	O	NOUN	I
with	O	ADP	O
a	O	DET	O
nephrotoxic	B-Disease	ADJ	B
potential	O	NOUN	B
,	O	PUNCT	O
such	O	ADJ	O
as	O	ADP	O
gentamicin	B-Chemical	NOUN	B
(	O	PUNCT	O
at	O	ADP	O
therapeutic	O	ADJ	B
doses	O	NOUN	I
),	O	PUNCT	O
amphothericin	B-Chemical	NOUN	B
B	I-Chemical	NOUN	I
and	O	CCONJ	O
ketoconazole	B-Chemical	NOUN	B
,	O	PUNCT	O
which	O	DET	O
are	O	AUX	O
frequently	O	ADV	O
used	O	VERB	O
in	O	ADP	O
immunosuppressed	O	ADJ	B
patients	O	NOUN	B
,	O	PUNCT	O
did	O	AUX	O
not	O	PART	O
aggravate	O	VERB	B
the	O	DET	O
CSA	B-Chemical	NOUN	B
induced	O	ADJ	B
toxicity	B-Disease	NOUN	B
in	O	ADP	O
the	O	DET	O
rat	O	NOUN	B
model	O	NOUN	B
.	O	PUNCT	O


Gentamicin	B-Chemical	NOUN	B
at	O	ADP	O
toxic	O	ADJ	B
doses	O	NOUN	I
,	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
increased	O	VERB	B
CSA	B-Chemical	NOUN	B
nephrotoxicity	B-Disease	NOUN	B
.	O	PUNCT	O


Thus	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
nephrotoxicity	B-Disease	NOUN	B
induced	O	VERB	B
by	O	ADP	O
CSA	B-Chemical	NOUN	B


Receptor	O	NOUN	B
mechanisms	O	NOUN	B
of	O	ADP	O
nicotine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
locomotor	B-Disease	NOUN	B
hyperactivity	I-Disease	NOUN	I
in	O	ADP	O
chronic	O	ADJ	B
nicotine	B-Chemical	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
rats	O	NOUN	B
.	O	PUNCT	O


Rats	O	NOUN	B
were	O	AUX	O
pretreated	O	VERB	B
with	O	ADP	O
saline	O	NOUN	B
or	O	CCONJ	O
nicotine	B-Chemical	NOUN	B
(	O	PUNCT	O
1	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
per	O	ADP	O
day	O	NOUN	B
)	O	PUNCT	O
by	O	ADP	O
subcutaneously	O	ADV	B
implanting	O	VERB	I
each	O	DET	O
animal	O	NOUN	B
with	O	ADP	O
an	O	DET	O
Alzet	O	NOUN	B
osmotic	O	ADJ	I
mini	O	NOUN	I
-	O	PUNCT	O
pump	O	NOUN	B
which	O	DET	O
continuously	O	ADV	O
released	O	VERB	B
saline	O	NOUN	B
or	O	CCONJ	O
nicotine	B-Chemical	NOUN	B
for	O	ADP	O
1	O	NUM	O
,	O	PUNCT	O
5	O	NUM	O
and	O	CCONJ	O
14	O	NUM	O
days	O	NOUN	B
.	O	PUNCT	O


At	O	ADP	O
the	O	DET	O
end	O	NOUN	O
of	O	ADP	O
each	O	DET	O
pretreatment	O	NOUN	B
period	O	NOUN	B
,	O	PUNCT	O
animals	O	NOUN	B
were	O	AUX	O
used	O	VERB	O
for	O	ADP	O
(	O	PUNCT	O
i	O	X	O
)	O	PUNCT	O
determining	O	VERB	O
their	O	PRON	O
locomotor	O	NOUN	B
response	O	NOUN	I
to	O	PART	O
acutely	O	ADV	O
injected	O	VERB	B
nicotine	B-Chemical	NOUN	B
(	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
,	O	PUNCT	O
s	O	NOUN	O
.	O	PUNCT	O


c	O	X	O
.)	O	NOUN	O
and	O	CCONJ	O
(	O	PUNCT	O
ii	O	X	O
)	O	PUNCT	O
measuring	O	VERB	B
the	O	DET	O
density	O	NOUN	B
of	O	ADP	O
L	O	NOUN	B
-[	O	NUM	O
3H	O	NOUN	B
]	O	PUNCT	O
nicotine	B-Chemical	NOUN	B
and	O	CCONJ	O
[	O	PUNCT	O
3H	O	NOUN	B
]	O	PUNCT	O
spiperone	B-Chemical	NOUN	B
binding	O	NOUN	B
sites	O	NOUN	I
in	O	ADP	O
the	O	DET	O
striatum	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
observed	O	VERB	O
no	O	DET	O
changes	O	NOUN	O
in	O	ADP	O
nicotine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
locomotor	O	NOUN	B
response	O	NOUN	I
,	O	PUNCT	O
striatal	O	ADJ	B
L	O	NOUN	O
-[	O	NOUN	O
3H	O	NOUN	B
]	O	PUNCT	O
nicotine	B-Chemical	NOUN	B
and	O	CCONJ	O
[	O	PUNCT	O
3H	O	NOUN	B
]	O	PUNCT	O
spiperone	B-Chemical	NOUN	B
binding	O	NOUN	B
in	O	ADP	O
the	O	DET	O
animals	O	NOUN	B
pretreated	O	VERB	B
with	O	ADP	O
nicotine	B-Chemical	NOUN	B
for	O	ADP	O
1	O	NUM	O
day	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
rats	O	NOUN	B
which	O	DET	O
were	O	AUX	O
pretreated	O	VERB	B
with	O	ADP	O
nicotine	B-Chemical	NOUN	B
for	O	ADP	O
5	O	NUM	O
days	O	NOUN	B
,	O	PUNCT	O
there	O	PRON	O
was	O	AUX	O
a	O	DET	O
significant	O	ADJ	O
increase	O	NOUN	B
in	O	ADP	O
the	O	DET	O
nicotine	B-Chemical	NOUN	B
-	O	PUNCT	O
stimulated	O	VERB	B
locomotor	O	NOUN	B
response	O	NOUN	I
which	O	DET	O
was	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
an	O	DET	O
increase	O	NOUN	B
in	O	ADP	O
the	O	DET	O
number	O	NOUN	O
of	O	ADP	O
L	O	NOUN	B
-[	O	NUM	O
3H	O	NOUN	B
]	O	PUNCT	O
nicotine	B-Chemical	NOUN	B
binding	O	NOUN	B
sites	O	NOUN	I
and	O	CCONJ	O
also	O	ADV	O
with	O	ADP	O
an	O	DET	O
elevated	O	ADJ	B
dopamine	B-Chemical	NOUN	B
(	O	PUNCT	O
DA	B-Chemical	NOUN	B
)	O	PUNCT	O
level	O	NOUN	B
in	O	ADP	O
the	O	DET	O
striatum	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
number	O	NOUN	O
of	O	ADP	O
striatal	O	NOUN	B
[	O	PUNCT	O
3H	O	NOUN	B
]	O	PUNCT	O
spiperone	B-Chemical	NOUN	B
binding	O	NOUN	B
sites	O	NOUN	I
was	O	AUX	O
not	O	PART	O
affected	O	VERB	B
.	O	PUNCT	O


In	O	ADP	O
animals	O	NOUN	B
pretreated	O	VERB	B
with	O	ADP	O
nicotine	B-Chemical	NOUN	B
for	O	ADP	O
14	O	NUM	O
days	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
nicotine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
locomotor	O	NOUN	B
response	O	NOUN	I
remained	O	VERB	O
to	O	PART	O
be	O	AUX	O
potentiated	O	VERB	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
this	O	DET	O
response	O	NOUN	B
was	O	AUX	O
correlated	O	VERB	B
with	O	ADP	O
an	O	DET	O
elevated	O	ADJ	B
number	O	NOUN	O
of	O	ADP	O
striatal	O	NOUN	B
[	O	PUNCT	O
3H	O	NOUN	B
]	O	PUNCT	O
spiperone	B-Chemical	NOUN	B
binding	O	NOUN	I
sites	O	NOUN	I
,	O	PUNCT	O
whereas	O	SCONJ	O
the	O	DET	O
number	O	NOUN	O
of	O	ADP	O
striatal	O	ADJ	B
L	O	NOUN	B
-[	O	NOUN	O
3H	O	NOUN	B
]	O	PUNCT	O
nicotine	B-Chemical	NOUN	B
binding	O	NOUN	B
sites	O	NOUN	I
and	O	CCONJ	O
the	O	DET	O
striatal	O	ADJ	B
DA	B-Chemical	NOUN	B
level	O	NOUN	I
were	O	AUX	O
normal	O	ADJ	O
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
chronic	O	ADJ	B
nicotine	B-Chemical	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
rats	O	NOUN	B
develop	O	VERB	O
locomotor	B-Disease	NOUN	B
hyperactivity	I-Disease	NOUN	I
in	O	ADP	O
response	O	NOUN	B
to	O	PART	O
nicotine	B-Chemical	NOUN	B
initially	O	ADV	B
due	O	ADJ	O
to	O	PART	O
increases	O	NOUN	B
of	O	ADP	O
both	O	CCONJ	O
the	O	DET	O
density	O	NOUN	B
of	O	ADP	O
nicotinic	O	ADJ	B
receptors	O	NOUN	I
and	O	CCONJ	O
DA	B-Chemical	NOUN	B
concentration	O	NOUN	B
,	O	PUNCT	O
followed	O	VERB	O
by	O	ADP	O
inducing	O	VERB	B
DA	B-Chemical	NOUN	B


Hydrocortisone	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
hypertension	B-Disease	NOUN	B
in	O	ADP	O
humans	O	NOUN	B
:	O	PUNCT	O
pressor	O	ADJ	B
responsiveness	O	NOUN	B
and	O	CCONJ	O
sympathetic	O	ADJ	B
function	O	NOUN	I
.	O	PUNCT	O


Oral	O	ADJ	B
hydrocortisone	B-Chemical	NOUN	O
increases	O	VERB	B
blood	O	NOUN	B
pressure	O	NOUN	I
and	O	CCONJ	O
enhances	O	VERB	B
pressor	O	ADJ	B
responsiveness	O	NOUN	B
in	O	ADP	O
normal	O	ADJ	O
human	O	ADJ	B
subjects	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
studied	O	VERB	O
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
1	O	NUM	O
week	O	NOUN	B
of	O	ADP	O
oral	O	ADJ	B
hydrocortisone	B-Chemical	NOUN	I
(	O	PUNCT	O
200	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
day	O	NOUN	B
)	O	PUNCT	O
on	O	ADP	O
blood	O	NOUN	B
pressure	O	NOUN	I
,	O	PUNCT	O
cardiac	O	ADJ	B
output	O	NOUN	I
,	O	PUNCT	O
total	O	ADJ	B
peripheral	O	ADJ	I
resistance	O	NOUN	I
,	O	PUNCT	O
forearm	O	ADJ	B
vascular	O	ADJ	I
resistance	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
norepinephrine	B-Chemical	NOUN	B
spillover	O	NOUN	B
to	O	PART	O
plasma	O	NOUN	B
in	O	ADP	O
eight	O	NUM	O
healthy	O	ADJ	B
male	O	NOUN	B
volunteers	O	NOUN	I
.	O	PUNCT	O


Although	O	SCONJ	O
diastolic	O	ADJ	B
blood	O	NOUN	I
pressure	O	NOUN	I
remained	O	VERB	O
unchanged	O	ADJ	B
,	O	PUNCT	O
systolic	O	ADJ	B
blood	O	NOUN	I
pressure	O	NOUN	I
increased	O	VERB	B
from	O	ADP	O
119	O	NUM	O
to	O	PART	O
135	O	NUM	O
mm	O	X	B
Hg	O	NOUN	I
(	O	PUNCT	O
SED	O	NOUN	B
+/-	O	CCONJ	O
3	O	NUM	O
.	O	PUNCT	O


4	O	NUM	O
,	O	PUNCT	O
p	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


01	O	NUM	O
),	O	PUNCT	O
associated	O	VERB	B
with	O	ADP	I
an	O	DET	O
increased	B-Disease	VERB	B
cardiac	I-Disease	ADJ	B
output	I-Disease	NOUN	I
(	O	PUNCT	O
5	O	NUM	O
.	O	PUNCT	O


85	O	NUM	O
-	O	SYM	O
7	O	NUM	O
.	O	PUNCT	O


73	O	NUM	O
l	O	NOUN	O
/	O	SYM	O
min	O	NOUN	B
,	O	PUNCT	O
SED	O	NOUN	B
+/-	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


46	O	NUM	O
,	O	PUNCT	O
p	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


01	O	NUM	O
).	O	PUNCT	O
Total	O	ADJ	O
peripheral	O	ADJ	O
vascular	O	ADJ	B
resistance	O	NOUN	I
fell	O	VERB	O
from	O	ADP	O
15	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
to	O	PART	O
12	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
mm	O	X	O
Hg	O	X	B
/	O	SYM	O
l	O	NOUN	B
/	O	SYM	O
min	O	NOUN	B
(	O	PUNCT	O
SED	O	NOUN	B
+/-	O	CCONJ	O
1	O	NUM	O
.	O	PUNCT	O


03	O	NUM	O
,	O	PUNCT	O
p	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


05	O	NUM	O
).	O	PUNCT	B
Resting	O	VERB	I
forearm	O	NOUN	I
vascular	O	ADJ	I
resistance	O	NOUN	I
remained	O	VERB	O
unchanged	O	ADJ	B
,	O	PUNCT	O
but	O	CCONJ	O
the	O	DET	O
reflex	O	ADJ	B
response	O	NOUN	I
to	O	ADP	O
the	O	DET	O
cold	O	ADJ	B
pressor	O	NOUN	I
test	O	NOUN	I
was	O	AUX	O
accentuated	O	VERB	B
,	O	PUNCT	O
the	O	DET	O
rise	O	NOUN	O
in	O	ADP	O
resistance	O	NOUN	B
increasing	O	VERB	B
from	O	ADP	O
10	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
mm	O	X	B
Hg	O	X	I
/	O	PUNCT	O
ml	O	NOUN	B
/	O	SYM	O
100	O	NUM	O
ml	O	NOUN	O
/	O	PUNCT	O
min	O	NOUN	B
(	O	PUNCT	O
R	O	NOUN	B
units	O	NOUN	I
)	O	PUNCT	O
before	O	ADP	O
treatment	O	NOUN	B
to	O	PART	O
32	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
R	O	NOUN	B
units	O	NOUN	I
after	O	ADP	O
treatment	O	NOUN	B
(	O	PUNCT	O
SED	O	NOUN	B
+/-	O	CCONJ	O
6	O	NUM	O
.	O	PUNCT	O


4	O	NUM	O
,	O	PUNCT	O
p	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


025	O	NUM	O
).	O	PUNCT	O
The	O	DET	O
rise	O	NOUN	O
in	O	ADP	O
forearm	O	ADJ	B
vascular	O	ADJ	B
resistance	O	NOUN	I
accompanying	O	VERB	O
intra	O	ADJ	B
-	O	PUNCT	O
arterial	O	ADJ	B
norepinephrine	B-Chemical	NOUN	B
(	O	PUNCT	O
25	O	NUM	O
,	O	PUNCT	O
50	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
100	O	NUM	O
ng	O	NOUN	O
/	O	PUNCT	O
min	O	NOUN	B
)	O	PUNCT	O
was	O	AUX	O
also	O	ADV	O
significantly	O	ADV	O
greater	O	ADJ	O
after	O	ADP	O
hydrocortisone	B-Chemical	NOUN	B
,	O	PUNCT	O
increasing	O	VERB	B
from	O	ADP	O
an	O	DET	O
average	O	NOUN	B
of	O	ADP	O
14	O	NUM	O
.	O	PUNCT	O


9	O	NUM	O
+/-	O	CCONJ	O
2	O	NUM	O
.	O	PUNCT	O


4	O	NUM	O
R	O	NOUN	O
units	O	NOUN	O
before	O	ADP	O
treatment	O	NOUN	B
to	O	PART	O
35	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
+/-	O	CCONJ	O
5	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
R	O	NOUN	O
units	O	NOUN	O
after	O	ADP	O
hydrocortisone	B-Chemical	NOUN	B
(	O	PUNCT	O
SED	O	NOUN	B
+/-	O	CCONJ	O
6	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
,	O	PUNCT	O
p	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


05	O	NUM	O
).	O	PUNCT	O
A	O	DET	O
shift	O	NOUN	B
to	O	PART	O
the	O	DET	O
left	O	NOUN	B
in	O	ADP	O
the	O	DET	O
dose	O	NOUN	B
-	O	PUNCT	O
response	O	NOUN	B
relation	O	NOUN	B
and	O	CCONJ	O
fall	O	VERB	B
in	O	ADP	O
threshold	O	NOUN	B
suggested	O	VERB	O
increased	O	VERB	B
sensitivity	O	NOUN	B
to	O	PART	O
norepinephrine	B-Chemical	NOUN	B
after	O	ADP	O
treatment	O	NOUN	B
.	O	PUNCT	O


Measurement	O	NOUN	B
of	O	ADP	O
resting	O	VERB	O
norepinephrine	B-Chemical	NOUN	B
spillover	O	NOUN	O
rate	O	NOUN	O
to	O	ADP	O
plasma	O	NOUN	B
and	O	CCONJ	O
norepinephrine	B-Chemical	NOUN	B
uptake	O	NOUN	B
indicated	O	VERB	O
that	O	SCONJ	O
overall	O	ADJ	O
resting	O	VERB	B
sympathetic	O	ADJ	I
nervous	O	ADJ	I
system	O	NOUN	I
activity	O	NOUN	I
was	O	AUX	O
not	O	PART	O
increased	O	VERB	B
.	O	PUNCT	O


The	O	DET	O
rise	B-Disease	NOUN	O
in	I-Disease	ADP	O
resting	I-Disease	VERB	B
blood	I-Disease	NOUN	I
pressure	I-Disease	NOUN	I
with	O	ADP	O
hydrocortisone	B-Chemical	NOUN	B
is	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
an	O	DET	O
increased	B-Disease	VERB	B
cardiac	I-Disease	ADJ	B
output	I-Disease	NOUN	I


Effects	O	NOUN	B
of	O	ADP	I
suprofen	B-Chemical	NOUN	B
on	O	ADP	O
the	O	DET	O
isolated	O	VERB	B
perfused	O	ADJ	B
rat	O	NOUN	B
kidney	O	NOUN	B
.	O	PUNCT	O


Although	O	SCONJ	O
suprofen	B-Chemical	NOUN	B
has	O	AUX	O
been	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
the	O	DET	O
development	O	NOUN	B
of	O	ADP	O
acute	B-Disease	ADJ	B
renal	I-Disease	ADJ	I
failure	I-Disease	NOUN	I
in	O	ADP	O
greater	O	ADJ	O
than	O	ADP	O
100	O	NUM	O
subjects	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
mechanism	O	NOUN	B
of	O	ADP	O
damage	O	NOUN	B
remains	O	VERB	O
unclear	O	ADJ	B
.	O	PUNCT	O


The	O	DET	O
direct	O	ADJ	O
nephrotoxic	B-Disease	ADJ	B
effects	O	NOUN	B
of	O	ADP	O
a	O	DET	O
single	O	ADJ	B
dose	O	NOUN	I
of	O	ADP	O
15	O	NUM	O
mg	O	NOUN	O
of	O	ADP	O
suprofen	B-Chemical	NOUN	B
were	O	AUX	O
compared	O	VERB	B
in	O	ADP	O
the	O	DET	O
recirculating	O	NOUN	B
isolated	O	VERB	O
rat	O	NOUN	B
kidney	O	NOUN	B
perfused	O	VERB	B
with	O	ADP	O
cell	O	NOUN	B
-	O	PUNCT	O
free	O	ADJ	B
buffer	O	NOUN	B
with	O	ADP	O
or	O	CCONJ	O
without	O	ADP	O
the	O	DET	O
addition	O	NOUN	O
of	O	ADP	O
5	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
dL	O	NOUN	B
of	O	ADP	O
uric	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
.	O	PUNCT	O


There	O	PRON	O
were	O	AUX	O
no	O	DET	O
significant	O	ADJ	O
differences	O	NOUN	O
in	O	ADP	O
renal	O	ADJ	B
sodium	B-Chemical	NOUN	I
excretion	O	NOUN	B
,	O	PUNCT	O
oxygen	B-Chemical	NOUN	B
consumption	O	NOUN	I
,	O	PUNCT	O
or	O	CCONJ	O
urinary	O	ADJ	B
flow	O	NOUN	I
rates	O	NOUN	O
in	O	ADP	O
kidneys	O	NOUN	B
perfused	O	VERB	B
with	O	ADP	O
suprofen	B-Chemical	NOUN	B
compared	O	VERB	B
with	O	ADP	O
the	O	DET	O
drug	O	NOUN	B
-	O	PUNCT	O
free	O	ADJ	B
control	O	NOUN	O
groups	O	NOUN	O
.	O	PUNCT	O


In	O	ADP	O
contrast	O	NOUN	O
,	O	PUNCT	O
a	O	DET	O
significant	O	ADJ	O
decline	O	NOUN	B
in	O	ADP	O
glomerular	O	ADJ	B
filtration	O	NOUN	I
rate	O	NOUN	I
was	O	AUX	O
found	O	VERB	O
after	O	ADP	O
the	O	DET	O
introduction	O	NOUN	B
of	O	ADP	O
suprofen	B-Chemical	NOUN	B
to	O	PART	O
the	O	DET	O
kidney	O	NOUN	B
perfused	O	VERB	B
with	O	ADP	O
uric	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
;	O	PUNCT	O
no	O	DET	O
changes	O	NOUN	O
were	O	AUX	O
found	O	VERB	O
with	O	ADP	O
suprofen	B-Chemical	NOUN	B
in	O	ADP	O
the	O	DET	O
absence	O	NOUN	B
of	O	ADP	O
uric	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
.	O	PUNCT	O


A	O	DET	O
significant	O	ADJ	O
decrease	O	NOUN	B
in	O	ADP	O
the	O	DET	O
baseline	O	NOUN	B
excretion	O	NOUN	B
rate	O	NOUN	B
of	O	ADP	O
uric	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
was	O	AUX	O
found	O	VERB	O
in	O	ADP	O
rats	O	NOUN	B
given	O	VERB	O
suprofen	B-Chemical	NOUN	B
,	O	PUNCT	O
compared	O	VERB	B
with	O	ADP	O
drug	O	NOUN	B
-	O	PUNCT	O
free	O	ADJ	B
controls	O	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
fractional	O	ADJ	B
excretion	O	NOUN	I
of	O	ADP	O
uric	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
was	O	AUX	O
unchanged	O	ADJ	B
between	O	ADP	O
the	O	DET	O
groups	O	NOUN	B
over	O	ADP	O
the	O	DET	O
experimental	O	ADJ	B
period	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
summary	O	NOUN	O
,	O	PUNCT	O
suprofen	B-Chemical	NOUN	B
causes	O	VERB	O
acute	B-Disease	ADJ	B
declines	I-Disease	NOUN	B
in	I-Disease	ADP	O
renal	I-Disease	ADJ	B
function	I-Disease	NOUN	I
,	O	PUNCT	O
most	O	ADV	O
likely	O	ADV	O
by	O	ADP	O
directly	O	ADV	O
altering	O	VERB	B
the	O	DET	O
intrarenal	O	ADJ	B
distribution	O	NOUN	B
of	O	ADP	O
uric	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I


Cocaine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
brainstem	O	NOUN	B
seizures	B-Disease	NOUN	I
and	O	CCONJ	O
behavior	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
variety	O	NOUN	O
of	O	ADP	O
abnormal	O	ADJ	B
sensory	O	ADJ	B
/	O	SYM	O
motor	O	NOUN	B
behaviors	O	NOUN	I
associated	O	VERB	B
with	O	ADP	I
electrical	O	ADJ	B
discharges	O	NOUN	I
recorded	O	VERB	O
from	O	ADP	O
the	O	DET	O
bilateral	O	ADJ	B
brainstem	O	NOUN	B
were	O	AUX	O
induced	O	VERB	B
in	O	ADP	O
adult	O	ADJ	B
WKY	O	NOUN	B
rats	O	NOUN	B
by	O	ADP	O
mechanical	O	ADJ	B
(	O	PUNCT	O
electrode	O	NOUN	B
implants	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
DC	O	NOUN	B
electrical	O	ADJ	B
current	O	ADJ	I
stimulations	O	NOUN	B
and	O	CCONJ	O
by	O	ADP	O
acute	O	ADJ	B
and	O	CCONJ	O
chronic	O	ADJ	B
administration	O	NOUN	I
of	O	ADP	O
cocaine	B-Chemical	NOUN	B
.	O	PUNCT	O


The	O	DET	O
electrode	O	NOUN	B
implant	O	NOUN	B
implicated	O	VERB	O
one	O	NUM	O
side	O	NOUN	O
or	O	CCONJ	O
the	O	DET	O
other	O	ADJ	O
of	O	ADP	O
the	O	DET	O
reticular	O	ADJ	B
system	O	NOUN	I
of	O	ADP	O
the	O	DET	O
brainstem	O	NOUN	B
but	O	CCONJ	O
subjects	O	NOUN	B
were	O	AUX	O
not	O	PART	O
incapacitated	O	VERB	B
by	O	ADP	O
the	O	DET	O
stimulations	O	NOUN	B
.	O	PUNCT	O


Cocaine	B-Chemical	NOUN	B
(	O	PUNCT	O
40	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
)	O	PUNCT	O
was	O	AUX	O
injected	O	VERB	B
subcutaneously	O	ADV	B
for	O	ADP	O
an	O	DET	O
acute	O	ADJ	B
experiment	O	NOUN	B
and	O	CCONJ	O
subsequent	O	ADJ	O
20	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
doses	O	NOUN	B
twice	O	ADV	O
daily	O	ADV	B
for	O	ADP	O
3	O	NUM	O
days	O	NOUN	B
in	O	ADP	O
a	O	DET	O
chronic	O	ADJ	B
study	O	NOUN	I
.	O	PUNCT	O


Cocaine	B-Chemical	NOUN	B
generated	O	VERB	O
more	O	ADV	O
abnormal	O	ADJ	B
behaviors	O	NOUN	O
in	O	ADP	O
the	O	DET	O
brainstem	O	NOUN	B
perturbation	O	NOUN	I
group	O	NOUN	O
,	O	PUNCT	O
especially	O	ADV	O
the	O	DET	O
electrically	O	ADV	B
perturbated	O	ADJ	O
subjects	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
abnormal	O	ADJ	B
behaviors	O	NOUN	O
were	O	AUX	O
yawning	O	VERB	B
,	O	PUNCT	O
retrocollis	O	ADV	B
,	O	PUNCT	O
hyperactivity	B-Disease	NOUN	B
,	O	PUNCT	O
hypersensitivity	B-Disease	NOUN	B
,"	O	PUNCT	O
beating	O	VERB	B
drum	O	NOUN	I
"	O	PUNCT	O
behavior	O	NOUN	B
,	O	PUNCT	O
squealing	O	VERB	B
,	O	PUNCT	O
head	O	NOUN	B
bobbing	O	NOUN	I
,	O	PUNCT	O
circling	O	NOUN	B
,	O	PUNCT	O
sniffing	O	NOUN	B
,	O	PUNCT	O
abnormal	O	ADJ	B
posturing	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
facial	O	ADJ	B
twitching	O	NOUN	I
.	O	PUNCT	O


Shifts	O	NOUN	B
in	O	ADP	O
the	O	DET	O
power	O	NOUN	B
frequency	O	NOUN	I
spectra	O	NOUN	I
of	O	ADP	O
the	O	DET	O
discharge	O	NOUN	B
patterns	O	NOUN	I
were	O	AUX	O
noted	O	VERB	O
between	O	ADP	O
quiet	O	ADJ	B
and	O	CCONJ	O
pacing	O	VERB	B
behavioral	O	ADJ	B
states	O	NOUN	O
.	O	PUNCT	O


Hypersensitivity	B-Disease	NOUN	B
to	O	PART	O
various	O	ADJ	O
auditory	O	ADJ	B
,	O	PUNCT	O
tactile	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
visual	O	ADJ	B
stimulation	O	NOUN	I
was	O	AUX	O
present	O	ADJ	O
and	O	CCONJ	O
shifts	O	NOUN	B
in	O	ADP	O
the	O	DET	O
brainstem	O	NOUN	B
ambient	O	ADJ	O
power	O	NOUN	O
spectral	O	ADJ	O
frequency	O	NOUN	O
occurred	O	VERB	O
in	O	ADP	O
response	O	NOUN	B
to	O	PART	O
tactile	O	NOUN	B
stimulation	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
findings	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
brainstem	O	NOUN	B
generates	O	VERB	O
and	O	CCONJ	O
propagates	O	VERB	B
pathological	O	ADJ	B
discharges	O	NOUN	O
that	O	PRON	O
can	O	AUX	O
be	O	AUX	O
elicited	O	VERB	O
by	O	ADP	O
mechanical	O	ADJ	B
and	O	CCONJ	O
DC	O	NOUN	B
electrical	O	ADJ	B
perturbation	O	NOUN	I
.	O	PUNCT	O


Cocaine	B-Chemical	NOUN	B


Increased	O	VERB	B
sulfation	O	NOUN	B
and	O	CCONJ	O
decreased	O	VERB	B
7alpha	O	NOUN	B
-	O	PUNCT	O
hydroxylation	O	NOUN	B
of	O	ADP	O
deoxycholic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
in	O	ADP	O
ethinyl	B-Chemical	NOUN	B
estradiol	I-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
cholestasis	B-Disease	NOUN	B
in	O	ADP	O
rats	O	NOUN	B
.	O	PUNCT	O


Deoxycholic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
conjugation	O	NOUN	I
,	O	PUNCT	O
transport	O	NOUN	B
capacity	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
metabolism	O	NOUN	B
were	O	AUX	O
compared	O	VERB	B
in	O	ADP	O
control	O	NOUN	B
and	O	CCONJ	O
ethinyl	B-Chemical	NOUN	B
estradiol	I-Chemical	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
rats	O	NOUN	B
.	O	PUNCT	O


Control	O	ADJ	B
rats	O	NOUN	B
were	O	AUX	O
found	O	VERB	O
to	O	PART	O
have	O	AUX	O
a	O	DET	O
lower	O	ADJ	O
capacity	O	NOUN	B
to	O	PART	O
transport	O	VERB	B
deoxycholic	B-Chemical	ADJ	I
acid	I-Chemical	NOUN	I
than	O	ADP	O
taurodeoxycholic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
both	O	DET	O
were	O	AUX	O
decreased	O	VERB	B
by	O	ADP	O
ethinyl	B-Chemical	NOUN	B
estradiol	I-Chemical	NOUN	B
treatment	O	NOUN	B
.	O	PUNCT	O


During	O	ADP	O
[	O	PUNCT	O
24	O	NUM	O
-	O	PUNCT	O
14C	O	NOUN	B
]	O	PUNCT	O
sodium	B-Chemical	NOUN	B
deoxycholate	I-Chemical	NOUN	I
infusion	O	NOUN	B
,[	O	PUNCT	O
14C	O	NOUN	B
]	O	PUNCT	O
biliary	O	ADJ	B
bile	B-Chemical	NOUN	I
acid	I-Chemical	NOUN	I
secretion	O	NOUN	B
increased	O	VERB	B
,	O	PUNCT	O
but	O	CCONJ	O
bile	O	NOUN	B
flow	O	NOUN	I
did	O	AUX	O
not	O	PART	O
change	O	VERB	O
significantly	O	ADV	O
in	O	ADP	O
either	O	CCONJ	O
control	O	NOUN	B
or	O	CCONJ	O
ethinyl	B-Chemical	NOUN	B
estradiol	I-Chemical	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
rats	O	NOUN	B
.	O	PUNCT	O


Ethinyl	B-Chemical	NOUN	B
estradiol	I-Chemical	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
animals	O	NOUN	B
excreted	O	VERB	B
significantly	O	ADV	O
less	O	ADJ	O
14C	O	NOUN	B
as	O	ADP	O
taurocholic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
than	O	ADP	O
did	O	AUX	O
control	O	NOUN	B
animals	O	NOUN	I
,	O	PUNCT	O
consistent	O	ADJ	B
with	O	ADP	I
an	O	DET	O
impairment	O	NOUN	B
of	O	ADP	O
7alpha	O	NOUN	B
-	O	PUNCT	O
hydroxylation	O	NOUN	B
of	O	ADP	O
taurodeoxycholic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
.	O	PUNCT	O


Ethinyl	B-Chemical	NOUN	B
estradiol	I-Chemical	NOUN	B
treatment	O	NOUN	B
did	O	AUX	O
not	O	PART	O
impair	O	VERB	B
conjugation	O	NOUN	B
of	O	ADP	O
deoxycholic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
did	O	AUX	O
result	O	VERB	O
in	O	ADP	O
an	O	DET	O
increase	O	NOUN	B
in	O	ADP	O
sulfation	O	NOUN	B
of	O	ADP	O
taurodeoxycholic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
from	O	ADP	O
1	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
controls	O	NOUN	B
to	O	ADP	O
nearly	O	ADV	O
4	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
%(	O	NOUN	O
P	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


01	O	NUM	O
).	O	PUNCT	O
These	O	DET	O
results	O	NOUN	B
are	O	AUX	O
consistent	O	ADJ	B
with	O	ADP	I
the	O	DET	O
hypothesis	O	NOUN	B
that	O	SCONJ	O
the	O	DET	O
rat	O	NOUN	B
has	O	AUX	O
a	O	DET	O
poorer	O	ADJ	B
tolerance	O	NOUN	I
for	O	ADP	O
deoxycholic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
than	O	ADP	O
do	O	AUX	O
certain	O	ADJ	O
other	O	ADJ	O
species	O	NOUN	B
.	O	PUNCT	O


Furthermore	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
rat	O	NOUN	B
converts	O	VERB	O
deoxycholic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
,	O	PUNCT	O
a	O	DET	O
poor	O	ADJ	O
choleretic	O	NOUN	B
,	O	PUNCT	O
to	O	PART	O
taurocholic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
,	O	PUNCT	O
a	O	DET	O
good	O	ADJ	O
choleretic	O	NOUN	B
.	O	PUNCT	O


When	O	SCONJ	O
this	O	DET	O
conversion	O	NOUN	B
is	O	AUX	O
impaired	O	ADJ	B
with	O	ADP	O
ethinyl	B-Chemical	NOUN	B
estradiol	I-Chemical	NOUN	I
treatment	O	NOUN	B
,	O	PUNCT	O
sulfation	O	NOUN	B
may	O	AUX	O
be	O	AUX	O
an	O	DET	O
important	O	ADJ	O
alternate	O	ADJ	B
pathway	O	NOUN	I
for	O	ADP	O
excretion	O	NOUN	B
of	O	ADP	O
this	O	DET	O
potentially	O	ADV	O
harmful	O	ADJ	O
bile	B-Chemical	NOUN	B
acid	I-Chemical	NOUN	I


Effects	O	NOUN	B
of	O	ADP	I
ouabain	B-Chemical	NOUN	B
on	O	ADP	O
myocardial	O	ADJ	B
oxygen	B-Chemical	NOUN	I
supply	O	NOUN	I
and	O	CCONJ	O
demand	O	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
chronic	O	ADJ	B
coronary	B-Disease	ADJ	I
artery	I-Disease	NOUN	I
disease	I-Disease	NOUN	I
.	O	PUNCT	O


A	O	DET	O
hemodynamic	O	ADJ	B
,	O	PUNCT	O
volumetric	O	ADJ	B
,	O	PUNCT	O
and	O	CCONJ	O
metabolic	O	ADJ	B
study	O	NOUN	I
in	O	ADP	O
patients	O	NOUN	B
without	O	ADP	O
heart	B-Disease	NOUN	B
failure	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
effects	O	NOUN	B
of	O	ADP	O
digitalis	B-Chemical	NOUN	B
glycosides	I-Chemical	NOUN	I
on	O	ADP	O
myocardial	O	ADJ	B
oxygen	B-Chemical	NOUN	I
supply	O	NOUN	I
and	O	CCONJ	O
demand	O	NOUN	B
are	O	AUX	O
of	O	ADP	O
particular	O	ADJ	O
interest	O	NOUN	O
in	O	ADP	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
obstructive	O	ADJ	B
coronary	B-Disease	ADJ	I
artery	I-Disease	NOUN	I
disease	I-Disease	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
have	O	AUX	O
not	O	PART	O
been	O	AUX	O
measured	O	VERB	B
previously	O	ADV	O
in	O	ADP	O
man	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
assessed	O	VERB	B
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
ouabain	B-Chemical	NOUN	B
(	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


015	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
body	O	NOUN	B
weight	O	NOUN	I
)	O	PUNCT	O
on	O	ADP	O
hemodynamic	O	ADJ	B
,	O	PUNCT	O
volumetric	O	ADJ	B
,	O	PUNCT	O
and	O	CCONJ	O
metabolic	O	ADJ	B
parameters	O	NOUN	B
in	O	ADP	O
11	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
severe	O	ADJ	B
chronic	O	ADJ	B
coronary	B-Disease	ADJ	I
artery	I-Disease	NOUN	I
disease	I-Disease	NOUN	I
without	O	ADP	O
clinical	O	ADJ	B
congestive	B-Disease	ADJ	B
heart	I-Disease	NOUN	I
failure	I-Disease	NOUN	I
.	O	PUNCT	O


Because	O	SCONJ	O
the	O	DET	O
protocol	O	NOUN	B
was	O	AUX	O
long	O	ADJ	O
and	O	CCONJ	O
involved	O	VERB	O
interventions	O	NOUN	B
which	O	DET	O
might	O	AUX	O
affect	O	VERB	O
the	O	DET	O
determinations	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
also	O	ADV	O
studied	O	VERB	O
in	O	ADP	O
nine	O	NUM	O
patients	O	NOUN	B
using	O	VERB	O
an	O	DET	O
identical	O	ADJ	B
protocol	O	NOUN	B
except	O	SCONJ	O
that	O	SCONJ	O
ouabain	B-Chemical	NOUN	B
administration	O	NOUN	B
was	O	AUX	O
omitted	O	VERB	O
.	O	PUNCT	O


Left	O	ADJ	B
ventricular	O	ADJ	I
end	O	NOUN	I
-	O	PUNCT	O
diastolic	O	ADJ	B
pressure	O	NOUN	I
and	O	CCONJ	O
left	O	VERB	B
ventricular	O	ADJ	I
end	O	NOUN	I
-	O	PUNCT	O
diastolic	O	NOUN	B
volume	O	NOUN	B
fell	O	VERB	O
in	O	ADP	O
each	O	DET	O
patient	O	NOUN	B
given	O	VERB	O
ouabain	B-Chemical	NOUN	B
,	O	PUNCT	O
even	O	ADV	O
though	O	SCONJ	O
they	O	PRON	O
were	O	AUX	O
initially	O	ADV	O
elevated	O	ADJ	B
in	O	ADP	O
only	O	ADV	O
two	O	NUM	O
patients	O	NOUN	B
.	O	PUNCT	O


Left	O	ADJ	B
ventricular	O	ADJ	I
end	O	NOUN	I
-	O	PUNCT	O
diastolic	O	ADJ	B
pressure	O	NOUN	I
fell	O	VERB	O
from	O	ADP	O
11	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
+/-	O	CCONJ	O
1	O	NUM	O
.	O	PUNCT	O


4	O	NUM	O
(	O	PUNCT	O
mean	O	NOUN	O
+/-	O	CCONJ	O
SE	O	NOUN	B
)	O	PUNCT	O
to	O	PART	O
5	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
+/-	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


9	O	NUM	O
mm	O	NOUN	B
Hg	O	NOUN	I
(	O	PUNCT	O
P	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


001	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
left	O	VERB	B
ventricular	O	ADJ	I
end	O	NOUN	I
-	O	PUNCT	O
diastolic	O	NOUN	B
volume	O	NOUN	B
fell	O	VERB	O
from	O	ADP	O
100	O	NUM	O
+/-	O	CCONJ	O
17	O	NUM	O
to	O	PART	O
82	O	NUM	O
+/-	O	CCONJ	O
12	O	NUM	O
ml	O	NOUN	O
/	O	SYM	O
m2	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


01	O	NUM	O
)	O	PUNCT	O
1	O	NUM	O
h	O	NOUN	O
after	O	ADP	O
ouabain	B-Chemical	NOUN	B
infusion	O	NOUN	B
was	O	AUX	O
completed	O	VERB	O
.	O	PUNCT	O


The	O	DET	O
maximum	O	ADJ	B
velocity	O	NOUN	B
of	O	ADP	O
contractile	O	NOUN	B
element	O	NOUN	I
shortening	O	NOUN	B
increased	O	VERB	B
from	O	ADP	O
1	O	NUM	O
.	O	PUNCT	O


68	O	NUM	O
+/-	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


11	O	NUM	O
ml	O	NOUN	O
/	O	PUNCT	O
s	O	NOUN	O
to	O	PART	O
2	O	NUM	O
.	O	PUNCT	O


18	O	NUM	O
+/-	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


21	O	NUM	O
muscle	O	NOUN	B
-	O	PUNCT	O
lengths	O	NOUN	B
/	O	SYM	O
s	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


05	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
is	O	AUX	O
consistent	O	ADJ	B
with	O	ADP	I
an	O	DET	O
increase	O	NOUN	B
in	O	ADP	O
contractility	O	NOUN	B
.	O	PUNCT	O


No	O	DET	B
significant	O	ADJ	I
change	O	NOUN	O
in	O	ADP	O
these	O	DET	O
parameters	O	NOUN	B
occurred	O	VERB	O
in	O	ADP	O
the	O	DET	O
control	O	NOUN	B
patients	O	NOUN	B
.	O	PUNCT	O


No	O	DET	B
significant	O	ADJ	I
change	O	NOUN	O
in	O	ADP	O
myocardial	O	ADJ	B
oxygen	B-Chemical	NOUN	I
consumption	O	NOUN	I
occurred	O	VERB	O
after	O	ADP	O
ouabain	B-Chemical	NOUN	B
administration	O	NOUN	B
but	O	CCONJ	O
this	O	DET	O
may	O	AUX	O
be	O	AUX	O
related	O	ADJ	O
to	O	PART	O
a	O	DET	O
greater	O	ADJ	O
decrease	O	NOUN	B
in	O	ADP	O
mean	O	ADJ	O
arterial	O	ADJ	B
pressure	O	NOUN	I
in	O	ADP	O
the	O	DET	O
ouabain	B-Chemical	NOUN	B
patients	O	NOUN	B
than	O	ADP	O
in	O	ADP	O
the	O	DET	O
control	O	NOUN	B
patients	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
conclude	O	VERB	O
that	O	SCONJ	O
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
chronic	O	ADJ	B
coronary	B-Disease	ADJ	I
artery	I-Disease	NOUN	I
disease	I-Disease	NOUN	I
who	O	PRON	O
are	O	AUX	O
not	O	PART	O
in	O	ADP	O
clinical	O	ADJ	B
congestive	B-Disease	ADJ	B
heart	I-Disease	NOUN	I
failure	I-Disease	NOUN	I
left	B-Disease	VERB	B
ventricular	I-Disease	ADJ	I
end-diastolic	I-Disease	ADJ	I
volume	I-Disease	NOUN	I
falls	I-Disease	VERB	I
after	O	ADP	O
ouabain	B-Chemical	NOUN	B
administration	O	NOUN	B
even	O	ADV	O
when	O	SCONJ	O
it	O	PRON	O
is	O	AUX	O
initially	O	ADV	O
normal	O	ADJ	B
.	O	PUNCT	O


Though	O	SCONJ	O
this	O	DET	O
fall	O	NOUN	B
would	O	AUX	O
be	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
a	O	DET	O
decrease	O	NOUN	B
in	O	ADP	O
wall	O	NOUN	B
tension	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
,	O	PUNCT	O
therefore	O	ADV	O
,	O	PUNCT	O
of	O	ADP	O
myocardial	O	ADJ	B
oxygen	B-Chemical	NOUN	I
consumption	O	NOUN	I
,	O	PUNCT	O
it	O	PRON	O
may	O	AUX	O
not	O	PART	O
be	O	AUX	O
of	O	ADP	O
sufficient	O	ADJ	B
magnitude	O	NOUN	B
to	O	PART	O
prevent	O	VERB	B
a	O	DET	O
net	O	ADJ	O
increase	O	NOUN	B
in	O	ADP	O
myocardial	O	ADJ	B
oxygen	B-Chemical	NOUN	I


Prolongation	B-Disease	NOUN	B
of	I-Disease	ADP	O
the	I-Disease	DET	O
QT	I-Disease	NOUN	B
interval	I-Disease	NOUN	I
related	O	ADJ	O
to	O	PART	O
cisapride	B-Chemical	NOUN	B
-	O	PUNCT	O
diltiazem	B-Chemical	NOUN	B
interaction	O	NOUN	B
.	O	PUNCT	O


Cisapride	B-Chemical	NOUN	B
,	O	PUNCT	O
a	O	DET	O
cytochrome	O	NOUN	B
P450	O	NOUN	I
3A4	O	NOUN	I
(	O	PUNCT	O
CYP3A4	O	NOUN	B
)	O	PUNCT	O
substrate	O	NOUN	B
,	O	PUNCT	O
is	O	AUX	O
widely	O	ADV	O
prescribed	O	VERB	B
for	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
gastrointestinal	B-Disease	ADJ	B
motility	I-Disease	NOUN	I
disorders	I-Disease	NOUN	I
.	O	PUNCT	O


Prolongation	B-Disease	NOUN	B
of	I-Disease	ADP	O
QT	I-Disease	NOUN	B
interval	I-Disease	NOUN	I
,	O	PUNCT	O
torsades	B-Disease	X	B
de	I-Disease	X	I
pointes	I-Disease	X	I
,	O	PUNCT	O
and	O	CCONJ	O
sudden	B-Disease	ADJ	B
cardiac	I-Disease	ADJ	I
death	I-Disease	NOUN	I
have	O	AUX	O
been	O	AUX	O
reported	O	VERB	O
after	O	ADP	O
concomitant	O	ADJ	B
administration	O	NOUN	B
with	O	ADP	O
erythromycin	B-Chemical	NOUN	B
or	O	CCONJ	O
azole	B-Chemical	NOUN	B
antifungal	O	ADJ	I
agents	O	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
not	O	PART	O
with	O	ADP	O
other	O	ADJ	O
CYP3A4	O	NOUN	B
inhibitors	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
possible	O	ADJ	O
drug	O	NOUN	B
interaction	O	NOUN	I
occurred	O	VERB	O
in	O	ADP	O
a	O	DET	O
45	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
woman	O	NOUN	B
who	O	PRON	O
was	O	AUX	O
taking	O	VERB	O
cisapride	B-Chemical	NOUN	B
for	O	ADP	O
gastroesophageal	B-Disease	ADJ	B
reflux	I-Disease	NOUN	I
disorder	I-Disease	NOUN	I
and	O	CCONJ	O
diltiazem	B-Chemical	NOUN	B
,	O	PUNCT	O
an	O	DET	O
agent	O	NOUN	B
that	O	PRON	O
has	O	AUX	O
inhibitory	O	ADJ	B
effect	O	NOUN	O
on	O	ADP	O
CYP3A4	O	NOUN	B
,	O	PUNCT	O
for	O	ADP	O
hypertension	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
patient	O	NOUN	B
was	O	AUX	O
in	O	ADP	O
near	O	ADP	B
syncope	B-Disease	NOUN	I
and	O	CCONJ	O
had	O	AUX	O
QT-interval	B-Disease	ADJ	B
prolongation	I-Disease	NOUN	B
.	O	PUNCT	O


After	O	ADP	O
discontinuing	O	VERB	B
cisapride	B-Chemical	NOUN	B
,	O	PUNCT	O
the	O	DET	O
QT	O	NOUN	B
interval	O	NOUN	I
returned	O	VERB	O
to	O	ADP	O
normal	O	ADJ	B
and	O	CCONJ	O
symptoms	O	NOUN	B
did	O	AUX	O
not	O	PART	O
recur	O	VERB	O
.	O	PUNCT	O


We	O	PRON	O
suggest	O	VERB	O
that	O	SCONJ	O
caution	O	NOUN	O
be	O	AUX	O
taken	O	VERB	O
when	O	SCONJ	O
cisapride	B-Chemical	NOUN	B
is	O	AUX	O
prescribed	O	VERB	B
with	O	ADP	O
any	O	DET	O
potent	O	ADJ	O
inhibitor	O	NOUN	B
of	O	ADP	O
CYP3A4	O	NOUN	B
,	O	PUNCT	O
including	O	VERB	O
diltiazem	B-Chemical	NOUN	B


Paclitaxel	B-Chemical	NOUN	B
combined	O	VERB	O
with	O	ADP	O
carboplatin	B-Chemical	NOUN	B
in	O	ADP	O
the	O	DET	O
first	O	ADJ	B
-	O	PUNCT	O
line	O	NOUN	B
treatment	O	NOUN	B
of	O	ADP	O
advanced	O	ADJ	B
ovarian	B-Disease	ADJ	I
cancer	I-Disease	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
a	O	DET	O
phase	O	NOUN	B
I	O	NOUN	I
study	O	VERB	I
to	O	PART	O
determine	O	VERB	O
the	O	DET	O
maximum	O	NOUN	B
tolerated	O	ADJ	O
dose	O	NOUN	O
of	O	ADP	O
paclitaxel	B-Chemical	NOUN	B
(	O	PUNCT	O
Taxol	B-Chemical	PROPN	B
;	O	PUNCT	O
Bristol	O	PROPN	B
-	O	PUNCT	O
Myers	O	PROPN	B
Squibb	O	PROPN	I
Company	O	PROPN	I
,	O	PUNCT	O
Princeton	O	PROPN	B
,	O	PUNCT	O
NJ	O	PROPN	B
)	O	PUNCT	O
given	O	VERB	O
as	O	ADP	O
a	O	DET	O
3	O	NUM	O
-	O	PUNCT	O
hour	O	NOUN	B
infusion	O	NOUN	B
in	O	ADP	O
combination	O	NOUN	B
with	O	ADP	O
carboplatin	B-Chemical	NOUN	B
administered	O	VERB	B
every	O	DET	O
21	O	NUM	O
days	O	NOUN	B
to	O	ADP	O
women	O	NOUN	B
with	O	ADP	O
advanced	O	ADJ	B
ovarian	B-Disease	ADJ	I
cancer	I-Disease	NOUN	I
,	O	PUNCT	O
paclitaxel	B-Chemical	NOUN	B
doses	O	NOUN	B
were	O	AUX	O
escalated	O	VERB	B
as	O	ADP	O
follows	O	VERB	O
:	O	PUNCT	O
level	O	NOUN	B
1	O	NUM	O
,	O	PUNCT	O
135	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
m2	O	NOUN	B
;	O	PUNCT	O
level	O	NOUN	B
2	O	NUM	O
,	O	PUNCT	O
160	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
m2	O	NOUN	B
;	O	PUNCT	O
level	O	NOUN	B
3	O	NUM	O
,	O	PUNCT	O
185	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
m2	O	NOUN	B
;	O	PUNCT	O
and	O	CCONJ	O
level	O	NOUN	B
4	O	NUM	O
,	O	PUNCT	O
210	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
m2	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
fixed	O	ADJ	B
dose	O	NOUN	I
of	O	ADP	O
carboplatin	B-Chemical	NOUN	B
at	O	ADP	O
levels	O	NOUN	B
1	O	NUM	O
through	O	ADP	O
4	O	NUM	O
was	O	AUX	O
given	O	VERB	O
to	O	PART	O
achieve	O	VERB	O
an	O	DET	O
area	O	NOUN	B
under	O	ADP	O
the	O	DET	O
concentration	O	NOUN	B
-	O	PUNCT	O
time	O	NOUN	B
curve	O	NOUN	I
(	O	PUNCT	O
AUC	O	NOUN	B
)	O	PUNCT	O
of	O	ADP	O
5	O	NUM	O
using	O	VERB	O
the	O	DET	O
Calvert	O	PROPN	B
formula	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
levels	O	NOUN	B
5	O	NUM	O
and	O	CCONJ	O
6	O	NUM	O
the	O	DET	O
carboplatin	B-Chemical	NOUN	B
dose	O	NOUN	B
was	O	AUX	O
targeted	O	VERB	B
at	O	ADP	O
AUCs	O	NOUN	B
of	O	ADP	O
6	O	NUM	O
and	O	CCONJ	O
7	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
,	O	PUNCT	O
respectively	O	ADV	O
,	O	PUNCT	O
combined	O	VERB	O
with	O	ADP	O
a	O	DET	O
fixed	O	ADJ	O
paclitaxel	B-Chemical	NOUN	B
dose	O	NOUN	B
of	O	ADP	O
185	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
m2	O	NOUN	B
.	O	PUNCT	O


To	O	ADP	O
date	O	NOUN	O
,	O	PUNCT	O
30	O	NUM	O
previously	O	ADV	O
untreated	O	ADJ	B
patients	O	NOUN	B
,	O	PUNCT	O
all	O	DET	O
with	O	ADP	O
a	O	DET	O
good	O	ADJ	O
performance	O	NOUN	O
status	O	NOUN	O
(	O	PUNCT	O
Eastern	O	PROPN	B
Cooperative	O	PROPN	I
Oncology	O	PROPN	I
Group	O	PROPN	I
0	O	NUM	I
to	O	PART	O
2	O	NUM	O
)	O	PUNCT	O
have	O	AUX	O
been	O	AUX	O
entered	O	VERB	O
into	O	ADP	O
this	O	DET	O
ongoing	O	ADJ	O
study	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
dose	O	NOUN	B
-	O	PUNCT	O
limiting	O	VERB	B
toxicity	B-Disease	NOUN	B
of	O	ADP	O
the	O	DET	O
combination	O	NOUN	B
was	O	AUX	O
myelosuppression	B-Disease	NOUN	B
(	O	PUNCT	O
leukopenia	B-Disease	NOUN	B
,	O	PUNCT	O
granulocytopenia	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
thrombocytopenia	B-Disease	NOUN	B
).	O	PUNCT	O
Neurotoxicity	B-Disease	NOUN	B
was	O	AUX	O
largely	O	ADV	O
moderate	O	ADJ	B
.	O	PUNCT	O


So	O	ADV	O
far	O	ADV	O
,	O	PUNCT	O
14	O	NUM	O
patients	O	NOUN	B
are	O	AUX	O
evaluable	O	ADJ	O
for	O	ADP	O
response	O	NOUN	B
;	O	PUNCT	O
of	O	ADP	O
these	O	DET	O
,	O	PUNCT	O
eight	O	NUM	O
(	O	PUNCT	O
57	O	NUM	O
%)	O	NOUN	O
showed	O	VERB	O
objective	O	ADJ	B
(	O	PUNCT	O
complete	O	ADJ	B
or	O	CCONJ	O
partial	O	ADJ	B
)	O	PUNCT	O
response	O	NOUN	B
and	O	CCONJ	O
disease	O	NOUN	B
stabilized	O	VERB	B
in	O	ADP	O
six	O	NUM	O
patients	O	NOUN	B
.	O	PUNCT	O


No	O	DET	O
patient	O	NOUN	B
had	O	AUX	O
disease	O	NOUN	B
progression	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
conclude	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
combination	O	NOUN	B
of	O	ADP	O
paclitaxel	B-Chemical	NOUN	B
185	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
m2	O	NOUN	B
administered	O	VERB	B
as	O	ADP	O
a	O	DET	O
3	O	NUM	O
-	O	PUNCT	O
hour	O	NOUN	B
infusion	O	NOUN	B
followed	O	VERB	O
immediately	O	ADV	O
by	O	ADP	O
a	O	DET	O
1	O	NUM	O
-	O	PUNCT	O
hour	O	NOUN	B
infusion	O	NOUN	B
of	O	ADP	O
carboplatin	B-Chemical	NOUN	B
at	O	ADP	O
an	O	DET	O
AUC	O	NOUN	B
of	O	ADP	O
6	O	NUM	O
can	O	AUX	O
be	O	AUX	O
administered	O	VERB	B
safely	O	ADV	O
in	O	ADP	O
a	O	DET	O
21	O	NUM	O
-	O	PUNCT	O
day	O	NOUN	B
schedule	O	NOUN	B
in	O	ADP	O
the	O	DET	O
outpatient	O	ADJ	B
setting	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
recommended	O	VERB	B
dose	O	NOUN	B
for	O	ADP	O
phase	O	NOUN	B
III	O	NUM	I
studies	O	NOUN	I
is	O	AUX	O
paclitaxel	B-Chemical	NOUN	B
185	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
m2	O	NOUN	B
and	O	CCONJ	O
carboplatin	B-Chemical	NOUN	B


Treatment	O	NOUN	B
of	O	ADP	O
tacrolimus	B-Chemical	NOUN	B
-	O	PUNCT	O
related	O	VERB	B
adverse	O	ADJ	B
effects	O	NOUN	I
by	O	ADP	O
conversion	O	NOUN	B
to	O	PART	O
cyclosporine	B-Chemical	NOUN	B
in	O	ADP	O
liver	O	NOUN	B
transplant	O	NOUN	I
recipients	O	NOUN	B
.	O	PUNCT	O


When	O	SCONJ	O
tacrolimus	B-Chemical	NOUN	B
side	O	NOUN	B
effects	O	NOUN	I
persist	O	VERB	O
despite	O	SCONJ	O
dose	O	NOUN	B
reduction	O	NOUN	B
,	O	PUNCT	O
conversion	O	NOUN	B
to	O	PART	O
cyclosporine	B-Chemical	NOUN	B
-	O	PUNCT	O
based	O	VERB	B
immunosuppression	O	NOUN	B
(	O	PUNCT	O
CyA	O	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
necessary	O	ADJ	O
.	O	PUNCT	O


We	O	PRON	O
characterized	O	VERB	B
tacrolimus	B-Chemical	NOUN	B
side	O	NOUN	B
effects	O	NOUN	I
that	O	PRON	O
warranted	O	VERB	O
discontinuation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
drug	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
outcomes	O	NOUN	B
after	O	ADP	O
conversion	O	NOUN	B
.	O	PUNCT	O


Of	O	ADP	O
388	O	NUM	O
liver	O	NOUN	B
recipients	O	NOUN	I
who	O	PRON	O
received	O	VERB	O
tacrolimus	B-Chemical	NOUN	B
as	O	ADP	O
primary	O	ADJ	B
immunosuppression	O	NOUN	I
,	O	PUNCT	O
70	O	NUM	O
required	O	VERB	O
conversion	O	NOUN	B
to	O	PART	O
CyA	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
recorded	O	VERB	O
indication	O	NOUN	B
for	O	ADP	O
conversion	O	NOUN	B
,	O	PUNCT	O
whether	O	SCONJ	O
conversion	O	NOUN	B
was	O	AUX	O
early	O	ADJ	B
or	O	CCONJ	O
late	O	ADJ	O
after	O	ADP	O
transplantation	O	NOUN	B
,	O	PUNCT	O
tacrolimus	B-Chemical	NOUN	B
dose	O	NOUN	B
and	O	CCONJ	O
trough	O	NOUN	B
blood	O	NOUN	I
level	O	NOUN	I
at	O	ADP	O
conversion	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
incidence	O	NOUN	B
of	O	ADP	O
rejection	O	NOUN	B
after	O	ADP	O
conversion	O	NOUN	B
.	O	PUNCT	O


Conversion	O	NOUN	B
was	O	AUX	O
early	O	ADJ	O
in	O	ADP	O
29	O	NUM	O
patients	O	NOUN	B
(	O	PUNCT	O
41	O	NUM	O
.	O	PUNCT	O


4	O	NUM	O
%)	O	NOUN	O
and	O	CCONJ	O
late	O	ADJ	O
in	O	ADP	O
41	O	NUM	O
(	O	PUNCT	O
58	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
%).	O	ADJ	O
Indications	O	PROPN	B
for	O	ADP	O
early	O	ADJ	B
conversion	O	NOUN	B
were	O	AUX	O
neurotoxicity	B-Disease	NOUN	B
(	O	PUNCT	O
20	O	NUM	O
),	O	PUNCT	O
(insulin-dependent)	B-Disease	NOUN	B
diabetes	I-Disease	NOUN	I
mellitus	I-Disease	NOUN	I
(	O	PUNCT	O
IDDM	B-Disease	NOUN	B
)(	O	NOUN	O
5	O	NUM	O
),	O	PUNCT	O
nephrotoxicity	B-Disease	NOUN	B
(	O	PUNCT	O
3	O	NUM	O
),	O	PUNCT	O
gastrointestinal	B-Disease	ADJ	B
(GI)	I-Disease	ADJ	O
toxicity	I-Disease	NOUN	B
(	O	PUNCT	O
6	O	NUM	O
),	O	PUNCT	O
and	O	CCONJ	O
cardiomyopathy	B-Disease	NOUN	B
(	O	PUNCT	O
1	O	NUM	O
),	O	PUNCT	O
and	O	CCONJ	O
for	O	ADP	O
late	O	ADJ	O
conversion	O	NOUN	B
were	O	AUX	O
neurotoxicity	B-Disease	NOUN	B
(	O	PUNCT	O
15	O	NUM	O
),	O	PART	O
IDDM	B-Disease	NOUN	B
(	O	PUNCT	O
12	O	NUM	O
),	O	PUNCT	O
nephrotoxicity	B-Disease	NOUN	B
(	O	PUNCT	O
3	O	NUM	O
),	O	PUNCT	O
GI	B-Disease	NOUN	B
toxicity	I-Disease	NOUN	B
(	O	PUNCT	O
5	O	NUM	O
),	O	PUNCT	O
hepatotoxicity	B-Disease	NOUN	B
(	O	PUNCT	O
6	O	NUM	O
),	O	PUNCT	O
post-transplant	B-Disease	ADJ	B
lmphoproliferate	I-Disease	ADJ	I
disease	I-Disease	NOUN	I
(	O	PUNCT	O
PTLD	B-Disease	NOUN	B
)(	O	NOUN	O
2	O	NUM	O
),	O	PUNCT	O
cardiomyopathy	B-Disease	NOUN	B
(	O	PUNCT	O
1	O	NUM	O
),	O	PUNCT	O
hemolytic	B-Disease	ADJ	B
anemia	I-Disease	NOUN	I
(	O	PUNCT	O
1	O	NUM	O
),	O	PUNCT	O
and	O	CCONJ	O
pruritus	B-Disease	NOUN	B
(	O	PUNCT	O
1	O	NUM	O
).	O	PUNCT	O
All	O	DET	O
early	O	ADV	B
-	O	PUNCT	O
conversion	O	NOUN	B
patients	O	NOUN	B
showed	O	VERB	O
improvement	O	NOUN	B
/	O	SYM	O
resolution	O	NOUN	B
of	O	ADP	O
symptoms	O	NOUN	B
.	O	PUNCT	O


Among	O	ADP	O
late	O	ADJ	B
-	O	PUNCT	O
conversion	O	NOUN	B
patients	O	NOUN	B
,	O	PUNCT	O
37	O	NUM	O
(	O	PUNCT	O
90	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
%)	O	NOUN	O
had	O	AUX	O
improvement	O	NOUN	B
/	O	SYM	O
resolution	O	NOUN	B
;	O	PUNCT	O
in	O	ADP	O
4	O	NUM	O
(	O	PUNCT	O
9	O	NUM	O
.	O	PUNCT	O


8	O	NUM	O
%),	O	ADJ	O
adverse	O	ADJ	B
effects	O	NOUN	I
persisted	O	VERB	O
.	O	PUNCT	O


The	O	DET	O
overall	O	ADJ	O
rejection	O	NOUN	B
rate	O	NOUN	O
was	O	AUX	O
30	O	NUM	O
%.	O	NOUN	O
Sixty	O	NUM	B
-	O	PUNCT	O
two	O	NUM	O
patients	O	NOUN	B
(	O	PUNCT	O
88	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
%)	O	NOUN	B
are	O	AUX	O
alive	O	ADJ	B
with	O	ADP	O
functioning	O	VERB	O
grafts	O	NOUN	B
686	O	NUM	O
+/-	O	CCONJ	O
362	O	NUM	O
days	O	NOUN	B
(	O	PUNCT	O
range	O	NOUN	B
,	O	PUNCT	O
154	O	NUM	O
-	O	PUNCT	O
1433	O	NUM	O
days	O	NOUN	B
)	O	PUNCT	O
after	O	ADP	O
conversion	O	NOUN	B
.	O	PUNCT	O


When	O	SCONJ	O
tacrolimus	B-Chemical	NOUN	B


Relative	O	ADJ	O
efficacy	O	NOUN	B
and	O	CCONJ	O
toxicity	B-Disease	NOUN	B
of	O	ADP	O
netilmicin	B-Chemical	NOUN	B
and	O	CCONJ	O
tobramycin	B-Chemical	NOUN	B
in	O	ADP	O
oncology	O	NOUN	B
patients	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
prospectively	O	ADV	O
compared	O	VERB	B
the	O	DET	O
efficacy	O	NOUN	B
and	O	CCONJ	O
safety	O	NOUN	B
of	O	ADP	O
netilmicin	B-Chemical	NOUN	B
sulfate	I-Chemical	NOUN	I
or	O	CCONJ	O
tobramycin	B-Chemical	NOUN	B
sulfate	I-Chemical	NOUN	I
in	O	ADP	O
conjunction	O	NOUN	B
with	O	ADP	O
piperacillin	B-Chemical	NOUN	B
sodium	I-Chemical	NOUN	I
in	O	ADP	O
118	O	NUM	O
immunocompromised	O	ADJ	B
patients	O	NOUN	B
with	O	ADP	O
presumed	O	VERB	O
severe	O	ADJ	B
infections	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
two	O	NUM	O
treatment	O	NOUN	B
regimens	O	NOUN	I
were	O	AUX	O
equally	O	ADV	O
efficacious	O	ADJ	B
.	O	PUNCT	O


Nephrotoxicity	B-Disease	NOUN	B
occurred	O	VERB	O
in	O	ADP	O
a	O	DET	O
similar	O	ADJ	O
proportion	O	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
netilmicin	B-Chemical	NOUN	B
and	O	CCONJ	O
tobramycin	B-Chemical	NOUN	B
(	O	PUNCT	O
17	O	NUM	O
%	O	NOUN	O
vs	O	CCONJ	O
11	O	NUM	O
%).	O	ADJ	B
Ototoxicity	B-Disease	NOUN	B
occurred	O	VERB	O
in	O	ADP	O
four	O	NUM	O
(	O	PUNCT	O
9	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
%)	O	NOUN	O
of	O	ADP	O
42	O	NUM	O
netilmicin	B-Chemical	NOUN	B
and	O	CCONJ	O
piperacillin	B-Chemical	NOUN	B
and	O	CCONJ	O
in	O	ADP	O
12	O	NUM	O
(	O	PUNCT	O
22	O	NUM	O
%)	O	NOUN	O
of	O	ADP	O
54	O	NUM	O
tobramycin	B-Chemical	NOUN	B
and	O	CCONJ	O
piperacillin	B-Chemical	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
patients	O	NOUN	B
.	O	PUNCT	O


Of	O	ADP	O
those	O	DET	O
evaluated	O	VERB	B
with	O	ADP	O
posttherapy	O	NOUN	B
audiograms	O	NOUN	B
,	O	PUNCT	O
three	O	NUM	O
of	O	ADP	O
four	O	NUM	O
netilmicin	B-Chemical	NOUN	B
and	O	CCONJ	O
piperacillin	B-Chemical	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
patients	O	NOUN	B
had	O	AUX	O
auditory	O	ADJ	B
thresholds	O	NOUN	I
return	O	VERB	B
to	O	ADP	I
baseline	O	NOUN	B
compared	O	VERB	B
with	O	ADP	O
one	O	NUM	O
of	O	ADP	O
nine	O	NUM	O
tobramycin	B-Chemical	NOUN	B
and	O	CCONJ	O
piperacillin	B-Chemical	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
patients	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
number	O	NOUN	O
of	O	ADP	O
greater	O	ADJ	O
than	O	ADP	O
or	O	CCONJ	O
equal	O	ADJ	O
to	O	PART	O
15	O	NUM	O
-	O	PUNCT	O
dB	O	NOUN	B
increases	O	NOUN	B
in	O	ADP	O
auditory	O	ADJ	B
threshold	O	NOUN	B
as	O	ADP	O
a	O	DET	O
proportion	O	NOUN	B
of	O	ADP	O
total	O	NOUN	O
greater	O	ADJ	O
than	O	ADP	O
or	O	CCONJ	O
equal	O	ADJ	O
to	O	PART	O
15	O	NUM	O
-	O	PUNCT	O
dB	O	NOUN	B
changes	O	NOUN	B
(	O	PUNCT	O
increases	O	NOUN	B
and	O	CCONJ	O
decreases	O	VERB	B
)	O	PUNCT	O
was	O	AUX	O
significantly	O	ADV	O
lower	O	ADJ	O
in	O	ADP	O
netilmicin	B-Chemical	NOUN	B
and	O	CCONJ	O
piperacillin	B-Chemical	NOUN	B
-	O	PUNCT	O
vs	O	CCONJ	O
tobramycin	B-Chemical	NOUN	B
and	O	CCONJ	O
piperacillin	B-Chemical	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
patients	O	NOUN	B
(	O	PUNCT	O
18	O	NUM	O
of	O	ADP	O
78	O	NUM	O
vs	O	CCONJ	O
67	O	NUM	O
of	O	ADP	O
115	O	NUM	O
).	O	PROPN	O
We	O	PRON	O
conclude	O	VERB	O
that	O	SCONJ	O
aminoglycoside	B-Chemical	NOUN	B
-	O	PUNCT	O
associated	O	VERB	B
ototoxicity	B-Disease	NOUN	B
was	O	AUX	O
less	O	ADV	O
severe	O	ADJ	B
and	O	CCONJ	O
more	O	ADV	O
often	O	ADV	O
reversible	O	ADJ	B
with	O	ADP	O
netilmicin	B-Chemical	NOUN	B
than	O	ADP	O
with	O	ADP	O
tobramycin	B-Chemical	NOUN	B


Effect	O	NOUN	B
of	O	ADP	O
prostaglandin	B-Chemical	NOUN	B
synthetase	O	NOUN	I
inhibitors	O	NOUN	I
on	O	ADP	O
experimentally	O	ADV	B
induced	O	VERB	B
convulsions	B-Disease	NOUN	B
in	O	ADP	O
rats	O	NOUN	B
.	O	PUNCT	O


To	O	PART	O
investigate	O	VERB	B
the	O	DET	O
relationship	O	NOUN	B
of	O	ADP	O
prostaglandins	B-Chemical	NOUN	B
(	O	PUNCT	O
PGs	B-Chemical	NOUN	B
)	O	PUNCT	O
to	O	PART	O
seizure	B-Disease	VERB	B
induction	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
six	O	NUM	O
PG	O	NOUN	B
synthetase	O	NOUN	I
inhibitors	O	NOUN	O
on	O	ADP	O
convulsions	B-Disease	NOUN	B
induced	O	VERB	B
by	O	ADP	O
flurothyl	B-Chemical	NOUN	B
,	O	PUNCT	O
picrotoxin	B-Chemical	NOUN	B
,	O	PUNCT	O
pentetrazol	B-Chemical	NOUN	B
(	O	PUNCT	O
PTZ	B-Chemical	NOUN	B
),	O	PUNCT	O
electroshock	O	NOUN	B
or	O	CCONJ	O
bicuculline	B-Chemical	NOUN	B
were	O	AUX	O
evaluated	O	VERB	B
.	O	PUNCT	O


Ibuprofen	B-Chemical	NOUN	B
,	O	PUNCT	O
sulindac	B-Chemical	NOUN	B
,	O	PUNCT	O
mefenamic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
low	O	ADJ	B
dose	O	NOUN	B
meclofenamic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
increased	O	VERB	B
the	O	DET	O
latency	O	NOUN	B
-	O	PUNCT	O
to	O	PART	O
-	O	PUNCT	O
onset	O	NOUN	B
in	O	ADP	O
the	O	DET	O
flurothyl	B-Chemical	NOUN	B
and	O	CCONJ	O
/	O	SYM	O
or	O	CCONJ	O
PTZ	B-Chemical	NOUN	B
models	O	NOUN	B
;	O	PUNCT	O
the	O	DET	O
electroshock	O	NOUN	B
,	O	PUNCT	O
picrotoxin	B-Chemical	NOUN	B
and	O	CCONJ	O
bicuculline	B-Chemical	NOUN	B
models	O	NOUN	B
were	O	AUX	O
not	O	PART	O
significantly	O	ADV	O
affected	O	VERB	B
by	O	ADP	O
any	O	DET	O
of	O	ADP	O
the	O	DET	O
pretreatment	O	NOUN	B
agents	O	NOUN	I
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
PGs	B-Chemical	NOUN	B
are	O	AUX	O
involved	O	VERB	O
in	O	ADP	O
the	O	DET	O
mechanism	O	NOUN	B
(	O	PUNCT	O
s	O	NOUN	O
)	O	PUNCT	O
underlying	O	VERB	O
fluorthyl	B-Chemical	NOUN	B
-	O	PUNCT	O
and	O	CCONJ	O
PTZ	B-Chemical	PROPN	B
-	O	PUNCT	O
induced	O	VERB	B
convulsions	B-Disease	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
not	O	PART	O
picrotoxin	B-Chemical	NOUN	B
-,	O	ADJ	O
electroshock	O	NOUN	B
-,	O	NOUN	O
or	O	CCONJ	O
bicuculline	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
convulsions	B-Disease	NOUN	B


Angiotensin	O	NOUN	B
-	O	PUNCT	O
converting	O	VERB	B
enzyme	O	NOUN	B
(	O	PUNCT	O
ACE	O	NOUN	B
)	O	PUNCT	O
inhibitor	O	NOUN	B
-	O	PUNCT	O
associated	O	VERB	B
angioedema	B-Disease	NOUN	B
of	O	ADP	O
the	O	DET	O
stomach	O	NOUN	B
and	O	CCONJ	O
small	O	ADJ	B
intestine	O	NOUN	I
:	O	PUNCT	O
a	O	DET	O
case	O	NOUN	B
report	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
is	O	AUX	O
a	O	DET	O
case	O	NOUN	B
report	O	NOUN	I
on	O	ADP	O
a	O	DET	O
45	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
old	O	ADJ	O
African	O	PROPN	B
-	O	PUNCT	O
American	O	ADJ	B
female	O	NOUN	B
with	O	ADP	O
newly	O	ADV	O
diagnosed	O	VERB	B
hypertension	B-Disease	NOUN	B
,	O	PUNCT	O
who	O	PRON	O
was	O	AUX	O
started	O	VERB	O
on	O	ADP	O
a	O	DET	O
combination	O	NOUN	B
pill	O	NOUN	B
of	O	ADP	O
amlodipine	B-Chemical	NOUN	B
/	O	SYM	O
benazapril	B-Chemical	NOUN	B
10	O	NUM	O
/	O	SYM	O
5	O	NUM	O
mg	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
very	O	ADV	O
next	O	ADJ	O
day	O	NOUN	B
,	O	PUNCT	O
she	O	PRON	O
presented	O	VERB	O
at	O	ADP	O
the	O	DET	O
emergency	O	NOUN	B
room	O	NOUN	I
(	O	PUNCT	O
ER	O	NOUN	B
)	O	PUNCT	O
with	O	ADP	O
abdominal	B-Disease	ADJ	B
pain	I-Disease	NOUN	I
,	O	PUNCT	O
nausea	B-Disease	NOUN	B
and	O	CCONJ	O
vomiting	B-Disease	NOUN	B
.	O	PUNCT	O


Physical	O	ADJ	B
exam	O	NOUN	I
,	O	PUNCT	O
complete	O	ADJ	O
metabolic	O	ADJ	B
panel	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
hemogram	O	NOUN	B
were	O	AUX	O
in	O	ADP	O
the	O	DET	O
normal	O	ADJ	B
range	O	NOUN	I
.	O	PUNCT	O


She	O	PRON	O
was	O	AUX	O
discharged	O	VERB	B
from	O	ADP	O
the	O	DET	O
ER	O	NOUN	B
after	O	ADP	O
a	O	DET	O
few	O	ADJ	O
hours	O	NOUN	O
of	O	ADP	O
treatment	O	NOUN	B
with	O	ADP	O
fluid	O	NOUN	B
and	O	CCONJ	O
analgesics	O	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
she	O	PRON	O
returned	O	VERB	O
to	O	ADP	O
the	O	DET	O
ER	O	NOUN	B
the	O	DET	O
next	O	ADJ	O
day	O	NOUN	B
with	O	ADP	O
the	O	DET	O
same	O	ADJ	O
complaints	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
time	O	NOUN	O
the	O	DET	O
physical	O	ADJ	B
exam	O	NOUN	I
was	O	AUX	O
significant	O	ADJ	O
for	O	ADP	O
a	O	DET	O
distended	O	ADJ	B
abdomen	O	NOUN	B
with	O	ADP	O
dullness	O	NOUN	B
to	O	ADP	O
percussion	O	NOUN	B
.	O	PUNCT	O


CT	O	NOUN	B
scan	O	NOUN	I
of	O	ADP	O
the	O	DET	O
abdomen	O	NOUN	B
revealed	O	VERB	O
markedly	O	ADV	O
thickened	O	ADJ	B
antrum	O	NOUN	B
of	O	ADP	O
the	O	DET	O
stomach	O	NOUN	B
,	O	PUNCT	O
duodenum	O	NOUN	B
and	O	CCONJ	O
jejunum	O	NOUN	B
,	O	PUNCT	O
along	O	ADP	O
with	O	ADP	O
fluid	O	NOUN	B
in	O	ADP	O
the	O	DET	O
abdominal	O	ADJ	B
and	O	CCONJ	O
pelvic	O	ADJ	B
cavity	O	NOUN	I
.	O	PUNCT	O


Angiotensin	O	NOUN	B
-	O	PUNCT	O
converting	O	VERB	B
enzyme	O	NOUN	B
inhibitor	O	NOUN	I
(	O	PUNCT	O
ACEI	O	NOUN	B
)-	O	ADJ	O
induced	O	VERB	B
angioedema	B-Disease	NOUN	B
was	O	AUX	O
suspected	O	VERB	B
,	O	PUNCT	O
and	O	CCONJ	O
anti	O	ADJ	B
-	O	PUNCT	O
hypertensive	B-Disease	ADJ	B
medications	O	NOUN	B
were	O	AUX	O
discontinued	O	VERB	B
.	O	PUNCT	O


Her	O	PRON	O
symptoms	O	NOUN	B
improved	O	VERB	B
within	O	ADP	O
the	O	DET	O
next	O	ADJ	O
24	O	NUM	O
hours	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
repeat	O	NOUN	O
CT	O	NOUN	B
after	O	ADP	O
72	O	NUM	O
hours	O	NOUN	B
revealed	O	VERB	O
marked	O	ADJ	O
improvement	O	NOUN	B
in	O	ADP	O
stomach	O	NOUN	B
and	O	CCONJ	O
small	O	ADJ	B
bowel	O	NOUN	I
thickening	O	NOUN	I
and	O	CCONJ	O
resolution	O	NOUN	B
of	O	ADP	O
ascites	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
recognition	O	NOUN	B
of	O	ADP	O
angiotensin	B-Chemical	NOUN	B
-	O	PUNCT	O
converting	O	VERB	B
enzyme	O	NOUN	B
(	O	PUNCT	O
ACE	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
angiotensin	B-Chemical	NOUN	B
receptor	O	NOUN	I
blocker	O	NOUN	I
(	O	PUNCT	O
ARB	O	NOUN	B
)	O	PUNCT	O
intestinal	B-Disease	ADJ	B
angioedema	I-Disease	NOUN	O


Valproic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
I	O	NUM	I
:	O	PUNCT	O
time	O	NOUN	B
course	O	NOUN	I
of	O	ADP	O
lipid	O	NOUN	B
peroxidation	O	NOUN	I
biomarkers	O	NOUN	B
,	O	PUNCT	O
liver	B-Disease	NOUN	B
toxicity	I-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
valproic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
metabolite	O	NOUN	B
levels	O	NOUN	B
in	O	ADP	O
rats	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
single	O	ADJ	B
dose	O	NOUN	I
of	O	ADP	O
valproic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
(	O	PUNCT	O
VPA	B-Chemical	NOUN	B
),	O	PUNCT	O
which	O	DET	O
is	O	AUX	O
a	O	DET	O
widely	O	ADV	O
used	O	VERB	O
antiepileptic	O	ADJ	B
drug	O	NOUN	I
,	O	PUNCT	O
is	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
oxidative	O	ADJ	B
stress	O	NOUN	I
in	O	ADP	O
rats	O	NOUN	B
,	O	PUNCT	O
as	O	ADP	O
recently	O	ADV	O
demonstrated	O	VERB	O
by	O	ADP	O
elevated	O	ADJ	B
levels	O	NOUN	B
of	O	ADP	O
15-F(2t)-isoprostane	B-Chemical	NOUN	B
(	O	PUNCT	O
15-F(2t)-IsoP	B-Chemical	NOUN	B
).	O	PUNCT	O
To	O	PART	O
determine	O	VERB	O
whether	O	SCONJ	O
there	O	PRON	O
was	O	AUX	O
a	O	DET	O
temporal	O	ADJ	B
relationship	O	NOUN	B
between	O	ADP	O
VPA	B-Chemical	PROPN	B
-	O	PUNCT	O
associated	O	VERB	B
oxidative	O	ADJ	B
stress	O	NOUN	I
and	O	CCONJ	O
hepatotoxicity	B-Disease	NOUN	B
,	O	PUNCT	O
adult	O	ADJ	B
male	O	NOUN	B
Sprague	O	PROPN	B
-	O	PUNCT	O
Dawley	O	NOUN	B
rats	O	NOUN	B
were	O	AUX	O
treated	O	VERB	B
ip	O	NOUN	B
with	O	ADP	O
VPA	B-Chemical	NOUN	B
(	O	PUNCT	O
500	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
)	O	PUNCT	O
or	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


9	O	NUM	O
%	O	NOUN	O
saline	O	NOUN	B
(	O	PUNCT	O
vehicle	O	NOUN	B
)	O	PUNCT	O
once	O	ADV	B
daily	O	ADV	I
for	O	ADP	O
2	O	NUM	O
,	O	PUNCT	O
4	O	NUM	O
,	O	PUNCT	O
7	O	NUM	O
,	O	PUNCT	O
10	O	NUM	O
,	O	PUNCT	O
or	O	CCONJ	O
14	O	NUM	O
days	O	NOUN	B
.	O	PUNCT	O


Oxidative	O	ADJ	B
stress	O	NOUN	I
was	O	AUX	O
assessed	O	VERB	B
by	O	ADP	O
determining	O	VERB	O
plasma	O	NOUN	B
and	O	CCONJ	O
liver	O	NOUN	B
levels	O	NOUN	I
of	O	ADP	O
15-F(2t)-IsoP	B-Chemical	NOUN	B
,	O	PUNCT	O
lipid	B-Chemical	NOUN	B
hydroperoxides	I-Chemical	NOUN	I
(	O	PUNCT	O
LPO	B-Chemical	NOUN	B
),	O	PUNCT	O
and	O	CCONJ	O
thiobarbituric	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
reactive	I-Chemical	ADJ	O
substances	I-Chemical	NOUN	O
(	O	PUNCT	O
TBARs	B-Chemical	NOUN	B
).	O	PUNCT	O
Plasma	O	NOUN	B
and	O	CCONJ	O
liver	O	NOUN	B
15-F(2t)-IsoP	B-Chemical	NOUN	I
were	O	AUX	O
elevated	O	VERB	B
and	O	CCONJ	O
reached	O	VERB	O
a	O	DET	O
plateau	O	NOUN	B
after	O	ADP	O
day	O	NOUN	B
2	O	NUM	O
of	O	ADP	O
VPA	B-Chemical	NOUN	B
treatment	O	NOUN	B
compared	O	VERB	O
to	O	PART	O
control	O	NOUN	B
.	O	PUNCT	O


Liver	O	NOUN	B
LPO	B-Chemical	NOUN	B
levels	O	NOUN	B
were	O	AUX	O
not	O	PART	O
elevated	O	ADJ	B
until	O	ADP	O
day	O	NOUN	B
7	O	NUM	O
of	O	ADP	O
treatment	O	NOUN	B
(	O	PUNCT	O
1	O	NUM	O
.	O	PUNCT	O


8	O	NUM	O
-	O	PUNCT	O
fold	O	ADJ	B
versus	O	ADP	O
control	O	NOUN	B
,	O	PUNCT	O
p	O	X	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


05	O	NUM	O
).	O	PUNCT	B
Liver	O	NOUN	B
and	O	CCONJ	O
plasma	O	NOUN	B
TBARs	B-Chemical	NOUN	B
were	O	AUX	O
not	O	PART	O
increased	O	VERB	B
until	O	ADP	O
14	O	NUM	O
days	O	NOUN	B
(	O	PUNCT	O
2	O	NUM	O
-	O	PUNCT	O
fold	O	ADJ	B
vs	O	ADV	O
.	O	PUNCT	O


control	O	NOUN	B
,	O	PUNCT	O
p	O	X	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


05	O	NUM	O
).	O	PUNCT	B
Liver	B-Disease	NOUN	B
toxicity	I-Disease	NOUN	B
was	O	AUX	O
evaluated	O	VERB	B
based	O	VERB	O
on	O	ADP	O
serum	O	NOUN	B
levels	O	NOUN	O
of	O	ADP	O
alpha	O	NOUN	B
-	O	PUNCT	O
glutathione	B-Chemical	NOUN	B
S	O	NOUN	I
-	O	PUNCT	O
transferase	O	NOUN	B
(	O	PUNCT	O
alpha	O	NOUN	B
-	O	PUNCT	O
GST	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
by	O	ADP	O
histology	O	NOUN	B
.	O	PUNCT	O


Serum	O	NOUN	B
alpha	O	NOUN	I
-	O	PUNCT	O
GST	O	NOUN	B
levels	O	NOUN	B
were	O	AUX	O
significantly	O	ADV	O
elevated	O	VERB	B
by	O	ADP	O
day	O	NOUN	B
4	O	NUM	O
,	O	PUNCT	O
which	O	DET	O
corresponded	O	VERB	O
to	O	PART	O
hepatotoxicity	B-Disease	NOUN	B
as	O	ADP	O
shown	O	VERB	O
by	O	ADP	O
the	O	DET	O
increasing	O	VERB	B
incidence	O	NOUN	B
of	O	ADP	O
inflammation	B-Disease	NOUN	B
of	O	ADP	O
the	O	DET	O
liver	O	NOUN	B
capsule	O	NOUN	I
,	O	PUNCT	O
necrosis	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
steatosis	B-Disease	NOUN	B
throughout	O	ADP	O
the	O	DET	O
study	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
liver	O	NOUN	B
levels	O	NOUN	I
of	O	ADP	O
beta	O	NOUN	B
-	O	PUNCT	O
oxidation	O	NOUN	B
metabolites	O	NOUN	B
of	O	ADP	O
VPA	B-Chemical	NOUN	B
were	O	AUX	O
decreased	O	VERB	B
by	O	ADP	O
day	O	NOUN	B
14	O	NUM	O
,	O	PUNCT	O
while	O	SCONJ	O
the	O	DET	O
levels	O	NOUN	B
of	O	ADP	O
4-ene-VPA	B-Chemical	NOUN	B
and	O	CCONJ	O
(	O	PUNCT	O
E	O	NOUN	O
)-	O	ADJ	O
2,4-diene-VPA	B-Chemical	NOUN	O
were	O	AUX	O
not	O	PART	O
elevated	O	ADJ	B
throughout	O	ADP	O
the	O	DET	O
study	O	NOUN	B
.	O	PUNCT	O


Overall	O	ADV	O
,	O	PUNCT	O
these	O	DET	O
findings	O	NOUN	B
indicate	O	VERB	O
that	O	SCONJ	O
VPA	B-Chemical	NOUN	B
treatment	O	NOUN	B
results	O	VERB	O
in	O	ADP	O
oxidative	O	ADJ	B
stress	O	NOUN	I
,	O	PUNCT	O
as	O	ADP	O
measured	O	VERB	B
by	O	ADP	O
levels	O	NOUN	B
of	O	ADP	O
15-F(2t)-IsoP	B-Chemical	NOUN	B
,	O	PUNCT	O
which	O	DET	O
precedes	O	VERB	O
the	O	DET	O
onset	O	NOUN	O
of	O	ADP	O
necrosis	B-Disease	NOUN	B
,	O	PUNCT	O
steatosis	B-Disease	NOUN	B


Pheochromocytoma	B-Disease	NOUN	B
unmasked	O	ADJ	O
by	O	ADP	O
amisulpride	B-Chemical	NOUN	B
and	O	CCONJ	O
tiapride	B-Chemical	NOUN	B
.	O	PUNCT	O


OBJECTIVE	O	NOUN	B
:	O	PUNCT	O
To	O	PART	O
describe	O	VERB	O
the	O	DET	O
unmasking	O	NOUN	B
of	O	ADP	O
pheochromocytoma	B-Disease	NOUN	B
in	O	ADP	O
a	O	DET	O
patient	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
amisulpride	B-Chemical	NOUN	B
and	O	CCONJ	O
tiapride	B-Chemical	NOUN	B
.	O	PUNCT	O


CASE	O	ADJ	B
SUMMARY	O	NOUN	I
:	O	PUNCT	O
A	O	DET	O
42	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
white	O	ADJ	O
man	O	NOUN	B
developed	O	VERB	O
acute	O	ADJ	B
hypertension	B-Disease	NOUN	I
with	O	ADP	O
severe	O	ADJ	B
headache	B-Disease	NOUN	B
and	O	CCONJ	O
vomiting	B-Disease	NOUN	B
2	O	NUM	I
hours	O	NOUN	B
after	O	ADP	O
the	O	DET	O
first	O	ADJ	O
doses	O	NOUN	B
of	O	ADP	O
amisulpride	B-Chemical	NOUN	B
100	O	NUM	O
mg	O	NOUN	O
and	O	CCONJ	O
tiapride	B-Chemical	NOUN	B
100	O	NUM	O
mg	O	NOUN	O
.	O	PUNCT	O


Both	O	DET	O
drugs	O	NOUN	B
were	O	AUX	O
immediately	O	ADV	O
discontinued	O	VERB	B
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
patient	O	NOUN	B
recovered	O	VERB	B
after	O	ADP	O
subsequent	O	ADJ	O
nicardipine	B-Chemical	NOUN	B
and	O	CCONJ	O
verapamil	B-Chemical	NOUN	B
treatment	O	NOUN	B
.	O	PUNCT	O


Abdominal	O	ADJ	B
ultrasound	O	NOUN	I
showed	O	VERB	O
an	O	DET	O
adrenal	O	ADJ	B
mass	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
postoperative	O	ADJ	B
histologic	O	ADJ	B
examination	O	NOUN	I
confirmed	O	VERB	O
the	O	DET	O
diagnosis	O	NOUN	B
of	O	ADP	O
pheochromocytoma	B-Disease	NOUN	B
.	O	PUNCT	O


DISCUSSION	O	NOUN	O
:	O	PUNCT	O
Drug	O	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
symptoms	O	NOUN	B
of	O	ADP	O
pheochromocytoma	B-Disease	NOUN	B
are	O	AUX	O
often	O	ADV	O
associated	O	VERB	B
with	O	ADP	I
the	O	DET	O
use	O	NOUN	O
of	O	ADP	O
substituted	O	VERB	B
benzamide	B-Chemical	NOUN	I
drugs	O	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
the	O	DET	O
underlying	O	ADJ	O
mechanism	O	NOUN	B
is	O	AUX	O
unknown	O	ADJ	O
.	O	PUNCT	O


In	O	ADP	O
our	O	PRON	O
case	O	NOUN	B
,	O	PUNCT	O
use	O	NOUN	O
of	O	ADP	O
the	O	DET	O
Naranjo	O	NOUN	B
probability	O	NOUN	I
scale	O	NOUN	I
indicated	O	VERB	O
a	O	DET	O
possible	O	ADJ	O
relationship	O	NOUN	B
between	O	ADP	O
the	O	DET	O
hypertensive	B-Disease	ADJ	B
crisis	O	NOUN	I
and	O	CCONJ	O
amisulpride	B-Chemical	NOUN	B
and	O	CCONJ	O
tiapride	B-Chemical	NOUN	B
therapy	O	NOUN	I
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
:	O	PUNCT	O
As	O	ADP	O
of	O	ADP	O
March	O	PROPN	O
24	O	NUM	O
,	O	PUNCT	O
2005	O	NUM	O
,	O	PUNCT	O
this	O	DET	O
is	O	AUX	O
the	O	DET	O
first	O	ADJ	O
reported	O	VERB	O
case	O	NOUN	B
of	O	ADP	O
amisulpride	B-Chemical	NOUN	B
-	O	PUNCT	O
and	O	CCONJ	O
tiapride	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
hypertensive	B-Disease	ADJ	B
crisis	O	NOUN	I
in	O	ADP	O
a	O	DET	O
patient	O	NOUN	B
with	O	ADP	O
pheochromocytoma	B-Disease	NOUN	B
.	O	PUNCT	O


Physicians	O	NOUN	B
and	O	CCONJ	O
other	O	ADJ	O
healthcare	O	NOUN	B
professionals	O	NOUN	I
should	O	AUX	O
be	O	AUX	O
aware	O	ADJ	O
of	O	ADP	O
this	O	DET	O
potential	O	ADJ	B
adverse	O	ADJ	B
effect	O	NOUN	I
of	O	ADP	O
tiapride	B-Chemical	NOUN	B
and	O	CCONJ	O
amisulpride	B-Chemical	NOUN	B


Quantitative	O	ADJ	B
drug	O	NOUN	I
levels	O	NOUN	I
in	O	ADP	O
stimulant	O	ADJ	B
psychosis	B-Disease	NOUN	B
:	O	PUNCT	O
relationship	O	NOUN	B
to	O	PART	O
symptom	O	NOUN	B
severity	O	NOUN	B
,	O	PUNCT	O
catecholamines	B-Chemical	NOUN	B
and	O	CCONJ	O
hyperkinesia	B-Disease	NOUN	B
.	O	PUNCT	O


To	O	PART	O
examine	O	VERB	O
the	O	DET	O
relationship	O	NOUN	B
between	O	ADP	O
quantitative	O	ADJ	B
stimulant	O	ADJ	B
drug	O	NOUN	O
levels	O	NOUN	O
,	O	PUNCT	O
catecholamines	B-Chemical	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
psychotic	B-Disease	ADJ	B
symptoms	I-Disease	NOUN	O
,	O	PUNCT	O
nineteen	O	NUM	O
patients	O	NOUN	B
in	O	ADP	O
a	O	DET	O
psychiatric	B-Disease	ADJ	B
emergency	O	NOUN	I
service	O	NOUN	I
with	O	ADP	O
a	O	DET	O
diagnosis	O	NOUN	B
of	O	ADP	O
amphetamine	B-Chemical	NOUN	B
-	O	PUNCT	O
or	O	CCONJ	O
cocaine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
psychosis	B-Disease	NOUN	B
were	O	AUX	O
interviewed	O	VERB	B
,	O	PUNCT	O
and	O	CCONJ	O
plasma	O	NOUN	B
and	O	CCONJ	O
urine	O	NOUN	B
were	O	AUX	O
collected	O	VERB	O
for	O	ADP	O
quantitative	O	ADJ	B
assays	O	NOUN	I
of	O	ADP	O
stimulant	O	ADJ	B
drug	O	NOUN	O
and	O	CCONJ	O
catecholamine	B-Chemical	NOUN	B
metabolite	O	NOUN	B
levels	O	NOUN	B
.	O	PUNCT	O


Methamphetamine	B-Chemical	NOUN	B
or	O	CCONJ	O
amphetamine	B-Chemical	NOUN	B
levels	O	NOUN	O
were	O	AUX	O
related	O	ADJ	O
to	O	PART	O
several	O	ADJ	O
psychopathology	O	NOUN	B
scores	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
global	O	ADJ	B
hyperkinesia	B-Disease	NOUN	I
rating	O	NOUN	I
.	O	PUNCT	O


HVA	O	NOUN	B
levels	O	NOUN	B
were	O	AUX	O
related	O	ADJ	O
to	O	PART	O
global	O	ADJ	B
hyperkinesia	B-Disease	NOUN	I
but	O	CCONJ	O
not	O	PART	O
to	O	PART	O
psychopathology	O	NOUN	B
ratings	O	NOUN	B
.	O	PUNCT	O


Although	O	SCONJ	O
many	O	ADJ	O
other	O	ADJ	O
factors	O	NOUN	B
such	O	ADJ	O
as	O	ADP	O
sensitization	O	NOUN	B
may	O	AUX	O
play	O	VERB	O
a	O	DET	O
role	O	NOUN	O
,	O	PUNCT	O
intensity	O	NOUN	B
of	O	ADP	O
stimulant	O	ADJ	B
-	O	PUNCT	O
induced	O	VERB	B
psychotic	B-Disease	ADJ	B
symptoms	I-Disease	NOUN	O
and	O	CCONJ	O
stereotypies	B-Disease	NOUN	B


Delayed	O	VERB	B
asystolic	B-Disease	ADJ	B
cardiac	B-Disease	ADJ	B
arrest	I-Disease	NOUN	I
after	O	ADP	O
diltiazem	B-Chemical	NOUN	B
overdose	B-Disease	NOUN	B
;	O	PUNCT	O
resuscitation	O	NOUN	B
with	O	ADP	O
high	O	ADJ	B
dose	O	NOUN	I
intravenous	O	ADJ	B
calcium	B-Chemical	NOUN	O
.	O	PUNCT	O


A	O	DET	O
51	O	NUM	O
year	O	NOUN	B
old	O	ADJ	O
man	O	NOUN	B
took	O	VERB	O
a	O	DET	O
mixed	O	ADJ	O
overdose	B-Disease	NOUN	B
including	O	VERB	O
1	O	NUM	O
.	O	PUNCT	O


8	O	NUM	O
-	O	SYM	O
3	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
g	O	NOUN	O
of	O	ADP	O
diltiazem	B-Chemical	NOUN	B
,	O	PUNCT	O
paracetamol	B-Chemical	NOUN	B
,	O	PUNCT	O
aspirin	B-Chemical	NOUN	B
,	O	PUNCT	O
isosorbide	B-Chemical	NOUN	B
nitrate	B-Chemical	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
alcohol	B-Chemical	NOUN	B
.	O	PUNCT	O


He	O	PRON	O
initially	O	ADV	B
presented	O	VERB	O
to	O	ADP	O
hospital	O	NOUN	B
after	O	ADP	O
six	O	NUM	O
hours	O	NOUN	O
with	O	ADP	O
mild	O	ADJ	B
hypotension	B-Disease	NOUN	B
and	O	CCONJ	O
was	O	AUX	O
treated	O	VERB	B
with	O	ADP	I
activated	O	VERB	B
charcoal	O	NOUN	I
and	O	CCONJ	O
intravenous	O	ADJ	B
fluids	O	NOUN	I
.	O	PUNCT	O


Eighteen	O	NUM	B
hours	O	NOUN	I
after	O	ADP	O
the	O	DET	O
overdose	B-Disease	NOUN	B
he	O	PRON	O
had	O	AUX	O
two	O	NUM	O
generalised	O	ADJ	O
tonic-clonic	B-Disease	ADJ	B
seizures	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
patient	O	NOUN	B
remained	O	VERB	O
unresponsive	O	ADJ	O
with	O	ADP	O
junctional	O	ADJ	B
bradycardia	B-Disease	NOUN	I
,	O	PUNCT	O
unrecordable	O	ADJ	B
blood	O	NOUN	I
pressure	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
then	O	ADV	O
became	O	VERB	O
asystolic	B-Disease	ADJ	B
.	O	PUNCT	O


He	O	PRON	O
was	O	AUX	O
resuscitated	O	VERB	B
with	O	ADP	O
high	O	ADJ	B
dose	O	NOUN	I
(	O	PUNCT	O
13	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
g	O	NOUN	O
)	O	PUNCT	O
intravenous	O	ADJ	B
calcium	B-Chemical	NOUN	B
and	O	CCONJ	O
adrenaline	B-Chemical	NOUN	B
(	O	PUNCT	O
epinephrine	B-Chemical	NOUN	B
).	O	PUNCT	O
He	O	PRON	O
required	O	VERB	O
inotropic	O	ADJ	B
support	O	NOUN	O
and	O	CCONJ	O
temporary	O	ADJ	B
pacing	O	NOUN	B
over	O	ADP	O
the	O	DET	O
next	O	ADJ	O
48	O	NUM	O
hours	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
case	O	NOUN	B
suggests	O	VERB	O
there	O	PRON	O
is	O	AUX	O
a	O	DET	O
role	O	NOUN	O
for	O	ADP	O
aggressive	O	ADJ	B
high	O	ADJ	O
dose	O	NOUN	O
intravenous	O	ADJ	B
calcium	B-Chemical	NOUN	O
therapy	O	NOUN	O
in	O	ADP	O
severe	O	ADJ	B
diltiazem	B-Chemical	NOUN	B
overdose	B-Disease	NOUN	B
,	O	PUNCT	O
particularly	O	ADV	O
with	O	ADP	O
the	O	DET	O
onset	O	NOUN	B
of	O	ADP	I
asystole	B-Disease	NOUN	B
.	O	PUNCT	O


It	O	PRON	O
should	O	AUX	O
be	O	AUX	O
considered	O	VERB	O
early	O	ADV	B
in	O	ADP	O
cases	O	NOUN	B
of	O	ADP	O
cardiac	B-Disease	ADJ	B
arrest	I-Disease	NOUN	I
after	O	ADP	O
diltiazem	B-Chemical	NOUN	B
overdose	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
case	O	NOUN	B
also	O	ADV	O
highlights	O	VERB	O
the	O	DET	O
problems	O	NOUN	B
with	O	ADP	O
delayed	O	VERB	B
toxicity	B-Disease	NOUN	B


Renal	B-Disease	ADJ	B
papillary	I-Disease	ADJ	I
necrosis	I-Disease	NOUN	I
due	O	ADP	O
to	O	PART	O
naproxen	B-Chemical	NOUN	B
.	O	PUNCT	O


A	O	DET	O
31	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
man	O	NOUN	B
with	O	ADP	O
rheumatoid	B-Disease	ADJ	B
arthritis	I-Disease	NOUN	I
,	O	PUNCT	O
who	O	PRON	O
had	O	AUX	O
previously	O	ADV	O
been	O	AUX	O
treated	O	VERB	B
with	O	ADP	I
sulindac	B-Chemical	NOUN	B
,	O	PUNCT	O
fenoprofen	B-Chemical	ADJ	B
calcium	I-Chemical	NOUN	B
,	O	PUNCT	O
high	O	ADJ	B
dose	O	NOUN	I
salicylates	B-Chemical	NOUN	B
and	O	CCONJ	O
gold	B-Chemical	NOUN	B
salts	O	NOUN	I
,	O	PUNCT	O
developed	O	VERB	O
renal	B-Disease	ADJ	B
papillary	I-Disease	ADJ	I
necrosis	I-Disease	NOUN	I
(	O	PUNCT	O
RPN	B-Disease	NOUN	B
)	O	PUNCT	O
4	O	NUM	O
months	O	NOUN	B
after	O	ADP	O
institution	O	NOUN	B
of	O	ADP	O
naproxen	B-Chemical	NOUN	B
therapy	O	NOUN	I
.	O	PUNCT	O


No	O	DET	O
other	O	ADJ	O
factor	O	NOUN	B
predisposing	O	VERB	B
to	O	PART	O
RPN	B-Disease	NOUN	B
could	O	AUX	O
be	O	AUX	O
discovered	O	VERB	O
.	O	PUNCT	O


Sulindac	B-Chemical	NOUN	B
was	O	AUX	O
substituted	O	VERB	B
for	O	ADP	O
naproxen	B-Chemical	NOUN	B
and	O	CCONJ	O
no	O	DET	O
further	O	ADV	O
adverse	O	ADJ	B
renal	O	ADJ	I
effects	O	NOUN	I
occurred	O	VERB	O
over	O	ADP	O
the	O	DET	O
next	O	ADJ	O
12	O	NUM	O
months	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
review	O	VERB	B
previous	O	ADJ	O
reports	O	NOUN	B
linking	O	VERB	O
RPN	B-Disease	NOUN	B
to	O	PART	O
antiinflammatory	O	ADJ	B
drug	O	NOUN	I
use	O	NOUN	I
and	O	CCONJ	O
discuss	O	VERB	O
possible	O	ADJ	O
advantages	O	NOUN	O
of	O	ADP	O
sulindac	B-Chemical	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
who	O	PRON	O
have	O	AUX	O
experienced	O	VERB	O
renal	B-Disease	ADJ	B
toxicity	I-Disease	NOUN	B


Adverse	O	ADJ	B
interaction	O	NOUN	I
between	O	ADP	O
beta-adrenergic	B-Chemical	ADJ	B
blocking	I-Chemical	VERB	O
drugs	I-Chemical	NOUN	B
and	O	CCONJ	O
verapamil	B-Chemical	NOUN	B
--	O	PUNCT	O
report	O	NOUN	B
of	O	ADP	O
three	O	NUM	O
cases	O	NOUN	B
.	O	PUNCT	O


Three	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
ischaemic	B-Disease	ADJ	B
heart	I-Disease	NOUN	I
disease	I-Disease	NOUN	I
developed	O	VERB	O
profound	O	ADJ	O
cardiac	B-Disease	ADJ	B
failure	I-Disease	NOUN	I
,	O	PUNCT	O
hypotension	B-Disease	NOUN	B
and	O	CCONJ	O
bradycardia	B-Disease	NOUN	B
during	O	ADP	O
combined	O	ADJ	B
therapy	O	NOUN	I
with	O	ADP	O
verapamil	B-Chemical	NOUN	B
and	O	CCONJ	O
beta-adrenergic	B-Chemical	ADJ	B
blocking	I-Chemical	VERB	O
drugs	I-Chemical	NOUN	B
.	O	PUNCT	O


This	O	DET	O
clinical	O	ADJ	B
picture	O	NOUN	I
resolved	O	VERB	B
completely	O	ADV	B
with	O	ADP	I
cessation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
combined	O	ADJ	B
therapy	O	NOUN	I
.	O	PUNCT	O


Baseline	O	NOUN	B
left	O	VERB	B
ventricular	O	ADJ	I
function	O	NOUN	I
,	O	PUNCT	O
assessed	O	VERB	B
by	O	ADP	O
cardiac	O	ADJ	B
catheterisation	O	NOUN	I
or	O	CCONJ	O
nuclear	O	ADJ	B
angiography	O	NOUN	I
,	O	PUNCT	O
was	O	AUX	O
normal	O	ADJ	O
in	O	ADP	O
two	O	NUM	O
patients	O	NOUN	B
and	O	CCONJ	O
only	O	ADV	O
mildly	O	ADV	B
reduced	O	VERB	B
in	O	ADP	O
the	O	DET	O
other	O	ADJ	O
.	O	PUNCT	O


Simultaneously	O	ADV	B
administration	O	NOUN	B
of	O	ADP	O
beta-adrenergic	B-Chemical	ADJ	B
blocking	I-Chemical	VERB	O
drugs	I-Chemical	NOUN	B
and	O	CCONJ	O
verapamil	B-Chemical	NOUN	B


Adverse	O	ADJ	B
reactions	O	NOUN	I
to	O	PART	O
bendrofluazide	B-Chemical	NOUN	B
and	O	CCONJ	O
propranolol	B-Chemical	NOUN	B
for	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
mild	O	ADJ	B
hypertension	B-Disease	NOUN	I
.	O	PUNCT	O


Report	O	PROPN	B
of	O	ADP	O
Medical	O	PROPN	O
Research	O	PROPN	O
Council	O	PROPN	O
Working	O	PROPN	O
Party	O	PROPN	O
on	O	ADP	O
Mild	O	ADJ	B
to	O	ADP	O
Moderate	O	PROPN	B
Hypertension	B-Disease	NOUN	I
.	O	PUNCT	O


Participants	O	NOUN	B
in	O	ADP	O
the	O	DET	O
Medical	O	PROPN	B
Research	O	PROPN	I
Council	O	PROPN	I
treatment	O	NOUN	I
trial	O	NOUN	I
for	O	ADP	O
mild	O	ADJ	B
hypertension	B-Disease	NOUN	I
are	O	AUX	O
randomly	O	ADV	O
allocated	O	VERB	O
to	O	ADP	O
one	O	NUM	O
of	O	ADP	O
four	O	NUM	O
treatment	O	NOUN	B
groups	O	NOUN	I
:	O	PUNCT	O
bendrofluazide	B-Chemical	ADJ	B
,	O	PUNCT	O
propranolol	B-Chemical	NOUN	B
,	O	PUNCT	O
or	O	CCONJ	O
a	O	DET	O
placebo	O	NOUN	B
for	O	ADP	O
either	O	DET	O
of	O	ADP	O
these	O	DET	O
drugs	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
trial	O	NOUN	B
is	O	AUX	O
single	O	ADJ	B
-	O	PUNCT	O
blind	O	NOUN	B
.	O	PUNCT	O


23	O	NUM	O
582	O	NUM	O
patient	O	NOUN	B
-	O	PUNCT	O
years	O	NOUN	B
of	O	ADP	O
observation	O	NOUN	B
have	O	AUX	O
been	O	AUX	O
completed	O	VERB	O
so	O	ADV	O
far	O	ADV	O
,	O	PUNCT	O
10	O	NUM	O
684	O	NUM	O
on	O	ADP	O
active	O	ADJ	B
drugs	O	NOUN	B
and	O	CCONJ	O
12	O	NUM	O
898	O	NUM	O
on	O	ADP	O
placebos	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
results	O	NOUN	B
show	O	VERB	O
an	O	DET	O
association	O	NOUN	B
between	O	ADP	O
bendrofluazide	B-Chemical	ADJ	B
treatment	O	NOUN	B
and	O	CCONJ	O
impotence	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
impotence	B-Disease	NOUN	B
also	O	ADV	O
occurred	O	VERB	O
more	O	ADV	O
frequently	O	ADV	O
in	O	ADP	O
patients	O	NOUN	B
taking	O	VERB	O
propranolol	B-Chemical	NOUN	B
than	O	ADP	O
in	O	ADP	O
those	O	DET	O
taking	O	VERB	O
placebos	O	NOUN	B
.	O	PUNCT	O


Other	O	ADJ	O
adverse	O	ADJ	B
reactions	O	NOUN	I
significantly	O	ADV	O
linked	O	VERB	O
with	O	ADP	O
active	O	ADJ	B
drugs	O	NOUN	B
include	O	VERB	O
impaired	B-Disease	ADJ	B
glucose	I-Disease	NOUN	O
tolerance	I-Disease	NOUN	O
in	O	ADP	O
men	O	NOUN	B
and	O	CCONJ	O
women	O	NOUN	B
and	O	CCONJ	O
gout	B-Disease	NOUN	B
in	O	ADP	O
men	O	NOUN	B
,	O	PUNCT	O
associated	O	VERB	B
with	O	ADP	I
bendrofluazide	B-Chemical	ADJ	B
treatment	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
Raynaud's	B-Disease	NOUN	B
phenomenon	I-Disease	NOUN	B
and	O	CCONJ	O
dyspnoea	B-Disease	NOUN	B
in	O	ADP	O
men	O	NOUN	B
and	O	CCONJ	O
women	O	NOUN	B
taking	O	VERB	O
propranolol	B-Chemical	NOUN	B
.	O	PUNCT	O


No	O	DET	O
corneal	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
is	O	AUX	O
known	O	VERB	O
to	O	PART	O
have	O	AUX	O
occurred	O	VERB	O
in	O	ADP	O
the	O	DET	O
propranolol	B-Chemical	NOUN	B
group	O	NOUN	B
.	O	PUNCT	O


Mean	O	VERB	O
serum	O	NOUN	O
potassium	B-Chemical	NOUN	O
level	O	NOUN	O
fell	O	VERB	O
,	O	PUNCT	O
and	O	CCONJ	O
urea	B-Chemical	NOUN	B
and	O	CCONJ	O
uric	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
levels	O	NOUN	I
rose	O	VERB	O
,	O	PUNCT	O
in	O	ADP	O
men	O	NOUN	B
and	O	CCONJ	O
women	O	NOUN	B
taking	O	VERB	O
bendrofluazide	B-Chemical	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
propranolol	B-Chemical	NOUN	B
group	O	NOUN	B
,	O	PUNCT	O
serum	O	NOUN	B
potassium	B-Chemical	NOUN	I
and	O	CCONJ	O
uric	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
levels	O	NOUN	I
rose	O	VERB	O
in	O	ADP	O
both	O	DET	O
sexes	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
the	O	DET	O
urea	B-Chemical	NOUN	B


Dexmedetomidine	B-Chemical	NOUN	B
and	O	CCONJ	O
cardiac	O	ADJ	B
protection	O	NOUN	I
for	O	ADP	O
non	O	ADJ	B
-	O	PUNCT	O
cardiac	O	ADJ	B
surgery	O	NOUN	I
:	O	PUNCT	O
a	O	DET	O
meta	O	ADJ	B
-	O	PUNCT	O
analysis	O	NOUN	B
of	O	ADP	O
randomised	O	ADJ	B
controlled	O	ADJ	I
trials	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
conducted	O	VERB	O
a	O	DET	O
systematic	O	ADJ	B
review	O	NOUN	I
of	O	ADP	O
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	O
dexmedetomidine	B-Chemical	NOUN	B
on	O	ADP	O
cardiac	O	ADJ	B
outcomes	O	NOUN	I
following	O	VERB	O
non	O	ADJ	B
-	O	PUNCT	O
cardiac	O	ADJ	B
surgery	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
included	O	VERB	O
prospective	O	ADJ	B
,	O	PUNCT	O
randomised	O	VERB	B
peri	O	NOUN	B
-	O	PUNCT	O
operative	O	ADJ	B
studies	O	NOUN	I
of	O	ADP	O
dexmedetomidine	B-Chemical	NOUN	B
that	O	PRON	O
reported	O	VERB	O
mortality	O	NOUN	B
,	O	PUNCT	O
cardiac	O	ADJ	B
morbidity	O	NOUN	I
or	O	CCONJ	O
adverse	O	ADJ	B
drug	O	NOUN	I
events	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
PubMed	O	NOUN	B
Central	O	ADJ	I
and	O	CCONJ	O
EMBASE	O	PROPN	B
search	O	NOUN	B
was	O	AUX	O
conducted	O	VERB	O
up	O	ADP	O
to	O	ADP	O
July	O	PROPN	O
2007	O	NUM	O
.	O	PUNCT	O


The	O	DET	O
reference	O	NOUN	O
lists	O	NOUN	B
of	O	ADP	O
identified	O	VERB	O
papers	O	NOUN	B
were	O	AUX	O
examined	O	VERB	O
for	O	ADP	O
further	O	ADJ	O
trials	O	NOUN	B
.	O	PUNCT	O


Of	O	ADP	O
425	O	NUM	O
studies	O	NOUN	B
identified	O	VERB	B
,	O	PUNCT	O
20	O	NUM	O
were	O	AUX	O
included	O	VERB	O
in	O	ADP	O
the	O	DET	O
meta	O	ADJ	B
-	O	PUNCT	O
analysis	O	NOUN	B
(	O	PUNCT	O
840	O	NUM	O
patients	O	NOUN	B
).	O	PUNCT	O
Dexmedetomidine	B-Chemical	NOUN	B
was	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
a	O	DET	O
trend	O	NOUN	O
towards	O	ADP	O
improved	O	VERB	B
cardiac	O	ADJ	B
outcomes	O	NOUN	I
;	O	PUNCT	O
all	O	DET	O
-	O	PUNCT	O
cause	O	NOUN	B
mortality	O	NOUN	B
(	O	PUNCT	O
OR	O	CCONJ	B
0	O	NUM	O
.	O	PUNCT	O


27	O	NUM	O
,	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
0	O	NUM	O
.	O	PUNCT	O


01	O	NUM	O
-	O	SYM	O
7	O	NUM	O
.	O	PUNCT	O


13	O	NUM	O
,	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


44	O	NUM	O
),	O	PUNCT	O
non	O	NOUN	B
-	O	PUNCT	O
fatal	O	ADJ	B
myocardial	B-Disease	ADJ	B
infarction	I-Disease	NOUN	I
(	O	PUNCT	O
OR	O	NOUN	B
0	O	NUM	O
.	O	PUNCT	O


26	O	NUM	O
,	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
0	O	NUM	O
.	O	PUNCT	O


04	O	NUM	O
-	O	SYM	O
1	O	NUM	O
.	O	PUNCT	O


60	O	NUM	O
,	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


14	O	NUM	O
),	O	PUNCT	O
and	O	CCONJ	O
myocardial	B-Disease	ADJ	B
ischaemia	I-Disease	NOUN	I
(	O	PUNCT	O
OR	O	ADV	B
0	O	NUM	O
.	O	PUNCT	O


65	O	NUM	O
,	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
0	O	NUM	O
.	O	PUNCT	O


26	O	NUM	O
-	O	SYM	O
1	O	NUM	O
.	O	PUNCT	O


63	O	NUM	O
,	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


36	O	NUM	O
).	O	PROPN	O
Peri	O	PROPN	B
-	O	PUNCT	O
operative	O	ADJ	B
hypotension	B-Disease	NOUN	O
(	O	PUNCT	O
26	O	NUM	O
%,	O	INTJ	B
OR	O	CCONJ	B
3	O	NUM	O
.	O	PUNCT	O


80	O	NUM	O
,	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
1	O	NUM	O
.	O	PUNCT	O


91	O	NUM	O
-	O	SYM	O
7	O	NUM	O
.	O	PUNCT	O


54	O	NUM	O
,	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


0001	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
bradycardia	B-Disease	NOUN	B
(	O	PUNCT	O
17	O	NUM	O
%,	O	ADV	O
OR	O	CCONJ	B
5	O	NUM	O
.	O	PUNCT	O


45	O	NUM	O
,	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
2	O	NUM	O
.	O	PUNCT	O


98	O	NUM	O
-	O	SYM	O
9	O	NUM	B
.	O	PUNCT	O


95	O	NUM	O
,	O	PUNCT	O
p	O	X	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


00001	O	NUM	O
)	O	PUNCT	O
were	O	AUX	O
significantly	O	ADV	O
increased	O	VERB	B
.	O	PUNCT	O


An	O	DET	O
anticholinergic	O	NOUN	B
did	O	AUX	O
not	O	PART	O
reduce	O	VERB	O
the	O	DET	O
incidence	O	NOUN	B
of	O	ADP	O
bradycardia	B-Disease	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


43	O	NUM	O
).	O	PUNCT	O
A	O	DET	O
randomised	O	ADJ	B
placebo	O	NOUN	B
-	O	PUNCT	O
controlled	O	VERB	B
trial	O	NOUN	I
of	O	ADP	O
dexmedetomidine	B-Chemical	NOUN	B


Differential	O	ADJ	B
diagnosis	O	NOUN	I
of	O	ADP	O
high	O	ADJ	B
serum	O	NOUN	B
creatine	B-Chemical	NOUN	O
kinase	O	NOUN	O
levels	O	NOUN	B
in	O	ADP	O
systemic	B-Disease	ADJ	B
lupus	I-Disease	NOUN	I
erythematosus	I-Disease	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
the	O	DET	O
clinical	O	ADJ	B
and	O	CCONJ	O
bioptic	O	ADJ	B
findings	O	NOUN	B
for	O	ADP	O
a	O	DET	O
57	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
woman	O	NOUN	B
with	O	ADP	O
severe	O	ADJ	B
chloroquine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
myopathy	B-Disease	NOUN	B
.	O	PUNCT	O


Since	O	SCONJ	O
1989	O	NUM	O
,	O	PUNCT	O
she	O	PRON	O
had	O	AUX	O
been	O	AUX	O
suffering	O	VERB	B
from	O	ADP	O
systemic	B-Disease	ADJ	B
lupus	I-Disease	NOUN	I
erythematosus	I-Disease	NOUN	I
(	O	PUNCT	O
SLE	B-Disease	NOUN	B
)	O	PUNCT	O
with	O	ADP	O
renal	B-Disease	ADJ	B
involvement	I-Disease	NOUN	B
and	O	CCONJ	O
undergone	O	VERB	O
periods	O	NOUN	B
of	O	ADP	O
treatment	O	NOUN	B
with	O	ADP	O
azathioprine	B-Chemical	NOUN	B
and	O	CCONJ	O
cyclophosphamide	B-Chemical	NOUN	B
.	O	PUNCT	O


Additional	O	ADJ	O
therapy	O	NOUN	B
with	O	ADP	O
chloroquine	B-Chemical	NOUN	B
(	O	PUNCT	O
CQ	B-Chemical	NOUN	B
)	O	PUNCT	O
was	O	AUX	O
started	O	VERB	O
because	O	SCONJ	O
of	O	ADP	O
arthralgia	B-Disease	NOUN	B
.	O	PUNCT	O


At	O	ADP	O
the	O	DET	O
same	O	ADJ	O
time	O	NOUN	B
,	O	PUNCT	O
slightly	O	ADV	O
increased	O	VERB	B
creatine	B-Chemical	NOUN	B
kinase	O	NOUN	I
(	O	PUNCT	O
CK	O	NOUN	B
)	O	PUNCT	O
levels	O	NOUN	B
were	O	AUX	O
noted	O	VERB	O
.	O	PUNCT	O


Myositis	B-Disease	NOUN	B
was	O	AUX	O
suspected	O	VERB	B
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
patient	O	NOUN	B
was	O	AUX	O
treated	O	VERB	B
with	O	ADP	I
steroids	B-Chemical	NOUN	B
.	O	PUNCT	O


The	O	DET	O
CK	O	NOUN	B
increase	O	NOUN	B
persisted	O	VERB	B
,	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
and	O	CCONJ	O
she	O	PRON	O
developed	O	VERB	O
progressive	O	ADJ	B
muscular	B-Disease	ADJ	B
weakness	I-Disease	NOUN	I
and	O	CCONJ	O
muscular	B-Disease	ADJ	B
atrophy	I-Disease	NOUN	I
.	O	PUNCT	O


Routine	O	ADJ	B
controls	O	NOUN	I
revealed	O	VERB	O
markedly	O	ADV	O
elevated	O	ADJ	B
CK	O	NOUN	B
levels	O	NOUN	B
of	O	ADP	O
1	O	NUM	O
,	O	PUNCT	O
700	O	NUM	O
U	O	NOUN	B
/	O	SYM	O
l	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
neurological	O	ADJ	B
and	O	CCONJ	O
electrophysiological	O	ADJ	B
findings	O	NOUN	I
were	O	AUX	O
not	O	PART	O
typical	O	ADJ	O
of	O	ADP	O
myositis	B-Disease	NOUN	B
.	O	PUNCT	O


Thus	O	ADV	O
,	O	PUNCT	O
muscle	O	NOUN	B
biopsy	O	NOUN	I
of	O	ADP	O
the	O	DET	O
deltoid	O	NOUN	B
muscle	O	NOUN	I
was	O	AUX	O
performed	O	VERB	O
in	O	ADP	O
order	O	NOUN	O
to	O	PART	O
exclude	O	VERB	O
polymyositis	B-Disease	NOUN	B
or	O	CCONJ	O
toxic	O	ADJ	B
myopathy	B-Disease	NOUN	I
.	O	PUNCT	O


As	O	ADP	O
it	O	PRON	O
revealed	O	VERB	O
chloroquine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
myopathy	B-Disease	NOUN	B
,	O	PUNCT	O
medication	O	NOUN	B
was	O	AUX	O
stopped	O	VERB	O
.	O	PUNCT	O


Discriminating	O	NOUN	B
between	O	ADP	O
primary	O	ADJ	B
SLE	B-Disease	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
affection	B-Disease	NOUN	B
of	I-Disease	ADP	O
the	I-Disease	DET	O
musculoskeletal	I-Disease	ADJ	B
system	I-Disease	NOUN	I
and	O	CCONJ	O
drug	O	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
side	O	NOUN	B
effects	O	NOUN	I
is	O	AUX	O
important	O	ADJ	O
for	O	ADP	O
appropriate	O	ADJ	O
treatment	O	NOUN	B
of	O	ADP	O
SLE	B-Disease	NOUN	B


Intravenous	O	ADJ	B
ribavirin	B-Chemical	NOUN	O
treatment	O	NOUN	B
for	O	ADP	O
severe	O	ADJ	B
adenovirus	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
in	O	ADP	O
immunocompromised	O	ADJ	B
children	O	NOUN	I
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
:	O	PUNCT	O
Adenovirus	O	NOUN	B
is	O	AUX	O
an	O	DET	O
important	O	ADJ	O
cause	O	NOUN	B
of	O	ADP	O
morbidity	O	NOUN	B
and	O	CCONJ	O
mortality	O	NOUN	B
in	O	ADP	O
the	O	DET	O
immunocompromised	O	ADJ	B
host	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
incidence	O	NOUN	B
of	O	ADP	O
severe	O	ADJ	B
adenovirus	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
in	O	ADP	O
pediatrics	O	NOUN	B
is	O	AUX	O
increasing	O	VERB	B
in	O	ADP	O
association	O	NOUN	B
with	O	ADP	I
growing	O	VERB	O
numbers	O	NOUN	O
of	O	ADP	O
immunocompromised	O	ADJ	B
children	O	NOUN	I
,	O	PUNCT	O
where	O	SCONJ	O
case	O	NOUN	B
fatality	O	NOUN	I
rates	O	NOUN	I
as	O	ADV	O
high	O	ADJ	O
as	O	ADP	O
50	O	NUM	O
%	O	NOUN	O
to	O	PART	O
80	O	NUM	O
%	O	NOUN	O
have	O	AUX	O
been	O	AUX	O
reported	O	VERB	O
.	O	PUNCT	O


There	O	PRON	O
are	O	AUX	O
no	O	DET	O
approved	O	VERB	O
antiviral	O	ADJ	B
agents	O	NOUN	I
with	O	ADP	O
proven	O	VERB	O
efficacy	O	NOUN	B
for	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
severe	O	ADJ	B
adenovirus	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
,	O	PUNCT	O
nor	O	CCONJ	O
are	O	AUX	O
there	O	PRON	O
any	O	DET	O
prospective	O	ADJ	O
randomized	O	ADJ	B
,	O	PUNCT	O
controlled	O	VERB	B
trials	O	NOUN	I
of	O	ADP	O
potentially	O	ADV	O
useful	O	ADJ	O
anti	O	ADJ	B
-	O	PUNCT	O
adenovirus	O	NOUN	B
therapies	O	NOUN	B
.	O	PUNCT	O


Apparent	O	ADJ	B
clinical	O	ADJ	B
success	O	NOUN	I
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
severe	O	ADJ	B
adenovirus	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
is	O	AUX	O
limited	O	ADJ	O
to	O	ADP	O
a	O	DET	O
few	O	ADJ	O
case	O	NOUN	B
reports	O	NOUN	I
and	O	CCONJ	O
small	O	ADJ	O
series	O	NOUN	B
.	O	PUNCT	O


Experience	O	NOUN	B
is	O	AUX	O
greatest	O	ADJ	O
with	O	ADP	O
intravenous	O	ADJ	B
ribavirin	B-Chemical	NOUN	O
and	O	CCONJ	O
cidofovir	B-Chemical	NOUN	B
.	O	PUNCT	O


Ribavirin	B-Chemical	NOUN	B
,	O	PUNCT	O
a	O	DET	O
guanosine	B-Chemical	NOUN	B
analogue	O	NOUN	I
,	O	PUNCT	O
has	O	AUX	O
broad	O	ADJ	O
antiviral	O	ADJ	B
activity	O	NOUN	I
against	O	ADP	O
both	O	CCONJ	O
RNA	O	NOUN	B
and	O	CCONJ	O
DNA	O	NOUN	B
viruses	O	NOUN	I
,	O	PUNCT	O
including	O	VERB	O
documented	O	VERB	B
activity	O	NOUN	B
against	O	ADP	O
adenovirus	O	NOUN	B
in	O	X	B
vitro	O	X	I
.	O	PUNCT	O


Ribavirin	B-Chemical	NOUN	B
is	O	AUX	O
licensed	O	VERB	B
in	O	ADP	O
aerosol	O	NOUN	B
form	O	NOUN	O
for	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
respiratory	B-Disease	ADJ	B
syncytial	I-Disease	ADJ	I
virus	I-Disease	NOUN	I
infection	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
orally	O	ADV	B
in	O	ADP	O
combination	O	NOUN	B
with	O	ADP	O
interferon	O	NOUN	B
to	O	PART	O
treat	O	VERB	B
hepatitis	B-Disease	NOUN	B
C	I-Disease	NOUN	I
.	O	PUNCT	O


Intravenous	O	ADJ	B
ribavirin	B-Chemical	NOUN	I
is	O	AUX	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
choice	O	NOUN	O
for	O	ADP	O
infection	B-Disease	NOUN	B
with	I-Disease	ADP	O
hemorrhagic	I-Disease	ADJ	B
fever	I-Disease	NOUN	I
viruses	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
most	O	ADV	O
common	O	ADJ	O
adverse	O	ADJ	B
effect	O	NOUN	I
of	O	ADP	O
intravenous	O	ADJ	B
ribavirin	B-Chemical	NOUN	I
is	O	AUX	O
reversible	O	ADJ	O
mild	O	ADJ	O
anemia	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
use	O	NOUN	O
of	O	ADP	O
cidofovir	B-Chemical	NOUN	B
in	O	ADP	O
severe	O	ADJ	B
adenovirus	B-Disease	NOUN	B
infection	I-Disease	NOUN	I
has	O	AUX	O
been	O	AUX	O
limited	O	VERB	O
by	O	ADP	O
adverse	O	ADJ	B
effects	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
most	O	ADV	O
significant	O	ADJ	B
of	O	ADP	O
which	O	DET	O
is	O	AUX	O
nephrotoxicity	B-Disease	NOUN	B
.	O	PUNCT	O


OBJECTIVE	O	NOUN	B
:	O	PUNCT	O
We	O	PRON	O
report	O	VERB	O
our	O	PRON	O
experience	O	NOUN	O
with	O	ADP	O
intravenous	O	ADJ	B
ribavirin	B-Chemical	NOUN	I
therapy	O	NOUN	I
for	O	ADP	O
severe	O	ADJ	B
adenovirus	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
in	O	ADP	O
a	O	DET	O
series	O	NOUN	O
of	O	ADP	O
immunocompromised	O	ADJ	B
children	O	NOUN	I
and	O	CCONJ	O
review	O	VERB	B
the	O	DET	O
literature	O	NOUN	B
.	O	PUNCT	O


DESIGN	O	NOUN	B
/	O	PUNCT	O
METHODS	O	NOUN	B
:	O	PUNCT	O
We	O	PRON	O
retrospectively	O	ADV	B
reviewed	O	VERB	B
the	O	DET	O
medical	O	ADJ	B
records	O	NOUN	I
of	O	ADP	O
5	O	NUM	O
children	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
intravenous	O	ADJ	B
ribavirin	B-Chemical	NOUN	I
for	O	ADP	O
documented	O	VERB	B
severe	O	ADJ	B
adenovirus	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
.	O	PUNCT	O


Two	O	NUM	O
patients	O	NOUN	B
developed	O	VERB	O
adenovirus	O	NOUN	B
hemorrhagic	B-Disease	ADJ	I
cystitis	I-Disease	NOUN	I
after	O	ADP	O
cardiac	O	ADJ	B
and	O	CCONJ	O
bone	O	NOUN	B
marrow	O	NOUN	I
transplants	O	NOUN	I
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


The	O	DET	O
bone	O	NOUN	B
marrow	O	NOUN	I
transplant	O	NOUN	I
patient	O	NOUN	B
also	O	ADV	O
received	O	VERB	O
intravenous	O	ADJ	B
cidofovir	B-Chemical	NOUN	B
for	O	ADP	O
progressive	O	ADJ	B
disseminated	O	ADJ	O
disease	O	NOUN	O
.	O	PUNCT	O


An	O	DET	O
additional	O	ADJ	O
3	O	NUM	O
children	O	NOUN	B
developed	O	VERB	O
adenovirus	B-Disease	NOUN	B
pneumonia	I-Disease	NOUN	I
;	O	PUNCT	O
2	O	NUM	O
were	O	AUX	O
neonates	O	NOUN	B
,	O	PUNCT	O
1	O	NUM	O
of	O	ADP	O
whom	O	PRON	O
had	O	AUX	O
partial	O	ADJ	B
DiGeorge	B-Disease	ADJ	B
syndrome	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
remaining	O	VERB	O
infant	O	NOUN	B
had	O	AUX	O
recently	O	ADV	O
undergone	O	VERB	O
a	O	DET	O
cardiac	O	ADJ	B
transplant	O	NOUN	I
.	O	PUNCT	O


Intravenous	O	ADJ	B
ribavirin	B-Chemical	NOUN	I
was	O	AUX	O
administered	O	VERB	B
on	O	ADP	O
a	O	DET	O
compassionate	O	ADJ	B
-	O	PUNCT	O
use	O	NOUN	B
protocol	O	NOUN	I
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
Complete	O	ADJ	B
clinical	O	ADJ	B
recovery	O	NOUN	I
followed	O	VERB	O
later	O	ADV	O
by	O	ADP	O
viral	O	ADJ	B
clearance	O	NOUN	I
was	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
2	O	NUM	O
children	O	NOUN	B
:	O	PUNCT	O
the	O	DET	O
cardiac	O	ADJ	B
transplant	O	NOUN	I
recipient	O	NOUN	B
with	O	ADP	O
adenovirus	O	NOUN	B
hemorrhagic	B-Disease	ADJ	I
cystitis	I-Disease	NOUN	I
and	O	CCONJ	O
the	O	DET	O
immunocompetent	O	ADJ	B
neonate	O	NOUN	B
with	O	ADP	O
adenovirus	B-Disease	NOUN	B
pneumonia	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
remaining	O	VERB	O
3	O	NUM	O
children	O	NOUN	B
died	O	VERB	B
of	O	ADP	O
adenovirus	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
.	O	PUNCT	O


Intravenous	O	ADJ	B
ribavirin	B-Chemical	NOUN	I
therapy	O	NOUN	I
was	O	AUX	O
well	O	ADV	O
tolerated	O	VERB	B
.	O	PUNCT	O


Use	O	NOUN	O
of	O	ADP	O
cidofovir	B-Chemical	NOUN	B
in	O	ADP	O
1	O	NUM	O
child	O	NOUN	B
was	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
progressive	B-Disease	ADJ	B
renal	I-Disease	ADJ	B
failure	I-Disease	NOUN	I
and	O	CCONJ	O
neutropenia	B-Disease	NOUN	B
.	O	PUNCT	O


DISCUSSION	O	NOUN	O
:	O	PUNCT	O
Our	O	PRON	O
series	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
is	O	AUX	O
representative	O	ADJ	O
of	O	ADP	O
the	O	DET	O
spectrum	O	NOUN	B
of	O	ADP	O
immunocompromised	O	ADJ	B
children	O	NOUN	I
at	O	ADP	O
greatest	O	ADJ	O
risk	O	NOUN	B
for	O	ADP	O
severe	O	ADJ	B
adenovirus	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
,	O	PUNCT	O
namely	O	ADV	O
solid	O	ADJ	B
-	O	PUNCT	O
organ	O	NOUN	B
and	O	CCONJ	O
bone	O	NOUN	B
marrow	O	NOUN	I
transplant	O	NOUN	I
recipients	O	NOUN	B
,	O	PUNCT	O
neonates	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
children	O	NOUN	B
with	O	ADP	O
immunodeficiency	B-Disease	NOUN	B
.	O	PUNCT	O


Although	O	SCONJ	O
intravenous	O	ADJ	B
ribavirin	B-Chemical	NOUN	B
was	O	AUX	O
not	O	PART	O
effective	O	ADJ	B
for	O	ADP	O
all	O	DET	O
children	O	NOUN	B
with	O	ADP	O
severe	O	ADJ	B
adenovirus	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
in	O	ADP	O
this	O	DET	O
series	O	NOUN	B
or	O	CCONJ	O
in	O	ADP	O
the	O	DET	O
literature	O	NOUN	B
,	O	PUNCT	O
therapy	O	NOUN	B
is	O	AUX	O
unlikely	O	ADJ	O
to	O	PART	O
be	O	AUX	O
of	O	ADP	O
benefit	O	NOUN	B
if	O	SCONJ	O
begun	O	VERB	O
late	O	ADV	O
in	O	ADP	O
the	O	DET	O
course	O	NOUN	B
of	O	ADP	O
the	O	DET	O
infection	B-Disease	NOUN	B
.	O	PUNCT	O


Early	O	ADJ	B
identification	O	NOUN	B
,	O	PUNCT	O
eg	O	ADP	O
by	O	ADP	O
polymerase	O	NOUN	B
chain	O	NOUN	I
reaction	O	NOUN	I
of	O	ADP	O
those	O	DET	O
patients	O	NOUN	B
at	O	ADP	O
risk	O	NOUN	B
of	O	ADP	O
disseminated	O	ADJ	B
adenovirus	B-Disease	NOUN	I
disease	I-Disease	NOUN	I
may	O	AUX	O
permit	O	VERB	O
earlier	O	ADV	O
antiviral	O	ADJ	B
treatment	O	NOUN	I
and	O	CCONJ	O
better	O	ADJ	O
evaluation	O	NOUN	B
of	O	ADP	O
therapeutic	O	ADJ	B
response	O	NOUN	I
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
:	O	PUNCT	O
Two	O	NUM	O
of	O	ADP	O
5	O	NUM	O
children	O	NOUN	B
with	O	ADP	O
severe	O	ADJ	B
adenovirus	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
treated	O	VERB	B
with	O	ADP	I
intravenous	O	ADJ	B
ribavirin	B-Chemical	NOUN	I
recovered	O	VERB	B
.	O	PUNCT	O


The	O	DET	O
availability	O	NOUN	O
of	O	ADP	O
newer	O	ADJ	O
rapid	O	ADJ	O
diagnostic	O	ADJ	B
techniques	O	NOUN	I
,	O	PUNCT	O
such	O	ADJ	O
as	O	ADP	O
polymerase	O	NOUN	B
chain	O	NOUN	I
reaction	O	NOUN	I
,	O	PUNCT	O
may	O	AUX	O
make	O	VERB	O
earlier	O	ADV	O
,	O	PUNCT	O
more	O	ADV	O
effective	O	ADJ	B
treatment	O	NOUN	B
of	O	ADP	O
adenovirus	B-Disease	NOUN	B
infection	I-Disease	NOUN	I
possible	O	ADJ	O
.	O	PUNCT	O


Given	O	VERB	O
the	O	DET	O
seriousness	O	NOUN	B
and	O	CCONJ	O
increasing	O	VERB	B
prevalence	O	NOUN	B
of	O	ADP	O
adenovirus	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
in	O	ADP	O
certain	O	ADJ	O
hosts	O	NOUN	B
,	O	PUNCT	O
especially	O	ADV	O
children	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
large	O	ADJ	O
,	O	PUNCT	O
multicenter	O	ADJ	B
clinical	O	ADJ	I
trial	O	NOUN	I
of	O	ADP	O
potentially	O	ADV	O
useful	O	ADJ	O
anti	O	ADJ	B
-	O	PUNCT	O
adenoviral	O	ADJ	B
therapies	O	NOUN	I
,	O	PUNCT	O
such	O	ADJ	O
as	O	ADP	O
intravenous	O	ADJ	B
ribavirin	B-Chemical	NOUN	O


Hepatotoxicity	B-Disease	NOUN	B
of	O	ADP	O
amiodarone	B-Chemical	NOUN	B
.	O	PUNCT	O


Amiodarone	B-Chemical	NOUN	B
has	O	AUX	O
proved	O	VERB	O
very	O	ADV	O
effective	O	ADJ	B
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
otherwise	O	ADV	O
resistant	O	ADJ	B
cardiac	O	ADJ	B
tachyarrhythmias	B-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
use	O	NOUN	O
of	O	ADP	O
amiodarone	B-Chemical	NOUN	B
has	O	AUX	O
,	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
been	O	AUX	O
limited	O	VERB	O
due	O	ADP	O
to	O	ADP	O
its	O	PRON	O
serious	O	ADJ	O
side	O	NOUN	B
-	O	PUNCT	O
effects	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
patient	O	NOUN	B
with	O	ADP	O
cholestatic	B-Disease	ADJ	B
hepatitis	I-Disease	NOUN	I
due	O	ADP	O
to	O	PART	O
amiodarone	B-Chemical	NOUN	B
treatment	O	NOUN	B
is	O	AUX	O
presented	O	VERB	O
below	O	ADV	O
and	O	CCONJ	O
a	O	DET	O
review	O	NOUN	B
of	O	ADP	O
the	O	DET	O
hepatotoxicity	B-Disease	NOUN	B
of	O	ADP	O
amiodarone	B-Chemical	NOUN	B
is	O	AUX	O
given	O	VERB	O
.	O	PUNCT	O


It	O	PRON	O
is	O	AUX	O
concluded	O	VERB	O
that	O	SCONJ	O
solid	O	ADJ	B
evidence	O	NOUN	B
exists	O	VERB	O
of	O	ADP	O
hepatic	B-Disease	ADJ	B
injury	I-Disease	NOUN	I
due	O	ADJ	O
to	O	PART	O
amiodarone	B-Chemical	NOUN	B
treatment	O	NOUN	B
,	O	PUNCT	O
including	O	VERB	O
steatosis	B-Disease	NOUN	B
,	O	PUNCT	O
alterations	O	NOUN	B
resembling	O	VERB	O
alcoholic	B-Disease	ADJ	B
hepatitis	I-Disease	NOUN	I
,	O	PUNCT	O
cholestatic	B-Disease	ADJ	B
hepatitis	I-Disease	NOUN	I
and	O	CCONJ	O
micronodular	O	ADJ	B
cirrhosis	B-Disease	NOUN	I
of	I-Disease	ADP	O
the	I-Disease	DET	O
liver	I-Disease	NOUN	B
.	O	PUNCT	O


Patients	O	NOUN	B
receiving	O	VERB	O
amiodarone	B-Chemical	NOUN	B
should	O	AUX	O
be	O	AUX	O
regularly	O	ADV	O
screened	O	VERB	B
with	O	ADP	O
respect	O	NOUN	O
to	O	PART	O
hepatic	O	ADJ	B
enzyme	O	NOUN	O
levels	O	NOUN	O
.	O	PUNCT	O


Therapy	O	NOUN	B
should	O	AUX	O
be	O	AUX	O
discontinued	O	VERB	B
on	O	ADP	O
the	O	DET	O
suspicion	O	NOUN	B
of	O	ADP	O
cholestatic	B-Disease	ADJ	B
injury	I-Disease	NOUN	I
or	O	CCONJ	O
hepatomegaly	B-Disease	NOUN	B


Catalepsy	B-Disease	NOUN	B
induced	O	VERB	B
by	O	ADP	O
combinations	O	NOUN	B
of	O	ADP	O
ketamine	B-Chemical	NOUN	B
and	O	CCONJ	O
morphine	B-Chemical	NOUN	B
:	O	PUNCT	O
potentiation	O	NOUN	B
,	O	PUNCT	O
antagonism	O	NOUN	B
,	O	PUNCT	O
tolerance	O	NOUN	B
and	O	CCONJ	O
cross	O	NOUN	B
-	O	PUNCT	O
tolerance	O	NOUN	B
in	O	ADP	O
the	O	DET	O
rat	O	NOUN	B
.	O	PUNCT	O


Previous	O	ADJ	O
studies	O	NOUN	B
demonstrated	O	VERB	O
that	O	SCONJ	O
both	O	CCONJ	O
ketamine	B-Chemical	NOUN	B
and	O	CCONJ	O
morphine	B-Chemical	NOUN	B
induced	O	VERB	B
analgesia	B-Disease	NOUN	B
and	O	CCONJ	O
catalepsy	B-Disease	NOUN	B
in	O	ADP	O
the	O	DET	O
rat	O	NOUN	B
.	O	PUNCT	O


Pre	O	NOUN	B
-	O	PUNCT	O
treatment	O	NOUN	B
with	O	ADP	O
ketamine	B-Chemical	NOUN	B
produced	O	VERB	O
cross	O	NOUN	B
-	O	PUNCT	O
tolerance	O	NOUN	B
to	O	PART	O
morphine	B-Chemical	NOUN	B
,	O	PUNCT	O
whereas	O	SCONJ	O
pretreatment	O	NOUN	B
with	O	ADP	O
morphine	B-Chemical	NOUN	B
did	O	AUX	O
not	O	PART	O
induce	O	VERB	B
cross	O	NOUN	B
-	O	PUNCT	O
tolerance	O	NOUN	B
to	O	ADP	O
ketamine	B-Chemical	NOUN	B
but	O	CCONJ	O
rather	O	ADV	O
augmented	O	VERB	B
the	O	DET	O
cataleptic	B-Disease	ADJ	B
response	O	NOUN	I
;	O	PUNCT	O
this	O	DET	O
augmentation	O	NOUN	B
was	O	AUX	O
attributed	O	VERB	O
to	O	PART	O
residual	O	ADJ	B
morphine	B-Chemical	NOUN	B
in	O	ADP	O
the	O	DET	O
brain	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
present	O	ADJ	O
studies	O	NOUN	B
explored	O	VERB	O
the	O	DET	O
duration	O	NOUN	B
of	O	ADP	O
the	O	DET	O
loss	O	NOUN	B
of	O	ADP	O
righting	O	VERB	B
reflex	O	NOUN	I
induced	O	VERB	B
by	O	ADP	O
sub	O	ADV	B
-	O	PUNCT	O
effective	O	ADJ	B
doses	O	NOUN	B
of	O	ADP	O
ketamine	B-Chemical	NOUN	B
and	O	CCONJ	O
morphine	B-Chemical	NOUN	B
,	O	PUNCT	O
administered	O	VERB	B
simultaneously	O	ADV	B
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
mutual	O	ADJ	B
potentiation	O	NOUN	I
between	O	ADP	O
sub	O	ADV	B
-	O	PUNCT	O
effective	O	ADJ	B
doses	O	NOUN	B
of	O	ADP	O
ketamine	B-Chemical	NOUN	B
and	O	CCONJ	O
morphine	B-Chemical	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
sub	O	X	B
-	O	PUNCT	O
effective	O	ADJ	B
doses	O	NOUN	B
of	O	ADP	O
ketamine	B-Chemical	NOUN	B
partly	O	ADV	O
antagonized	O	VERB	B
fully	O	ADV	B
-	O	PUNCT	O
effective	O	ADJ	B
doses	O	NOUN	B
of	O	ADP	O
morphine	B-Chemical	NOUN	B
.	O	PUNCT	O


Latency	O	NOUN	B
to	O	ADP	O
the	O	DET	O
loss	O	NOUN	B
of	O	ADP	O
righting	O	VERB	B
reflex	O	NOUN	I
,	O	PUNCT	O
rigidity	B-Disease	NOUN	B
and	O	CCONJ	O
behavior	O	NOUN	B
on	O	ADP	O
recovery	O	NOUN	B
,	O	PUNCT	O
reflected	O	VERB	O
the	O	DET	O
relative	O	ADJ	O
predominance	O	NOUN	O
of	O	ADP	O
ketamine	B-Chemical	NOUN	B
or	O	CCONJ	O
morphine	B-Chemical	NOUN	B
in	O	ADP	O
each	O	DET	O
combination	O	NOUN	B
.	O	PUNCT	O


Naloxone	B-Chemical	NOUN	B
inhibited	O	VERB	B
the	O	DET	O
induced	O	VERB	B
cataleptic	B-Disease	ADJ	B
effects	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
degree	O	NOUN	B
and	O	CCONJ	O
time	O	NOUN	B
course	O	NOUN	I
of	O	ADP	O
development	O	NOUN	B
of	O	ADP	O
tolerance	O	NOUN	B
to	O	PART	O
daily	O	ADJ	O
administration	O	NOUN	B
of	O	ADP	O
sub	O	ADV	B
-	O	PUNCT	O
effective	O	ADJ	B
dose	O	NOUN	B
combinations	O	NOUN	B
of	O	ADP	O
ketamine	B-Chemical	NOUN	B
and	O	CCONJ	O
morphine	B-Chemical	NOUN	B
were	O	AUX	O
similar	O	ADJ	O
.	O	PUNCT	O


Rats	O	NOUN	B
,	O	PUNCT	O
tolerant	O	ADJ	B
to	O	ADP	O
ketamine	B-Chemical	NOUN	B
-	O	PUNCT	O
dominant	O	ADJ	B
combinations	O	NOUN	B
,	O	PUNCT	O
were	O	AUX	O
cross	O	NOUN	B
-	O	PUNCT	O
tolerant	O	ADJ	B
to	O	ADP	O
both	O	DET	O
drugs	O	NOUN	B
,	O	PUNCT	O
while	O	SCONJ	O
those	O	DET	O
tolerant	O	ADJ	B
to	O	PART	O
morphine	B-Chemical	NOUN	B
-	O	PUNCT	O
dominant	O	ADJ	B
combinations	O	NOUN	B
were	O	AUX	O
cross	O	NOUN	B
-	O	PUNCT	O
tolerant	O	ADJ	B
to	O	PART	O
morphine	B-Chemical	NOUN	B
but	O	CCONJ	O
showed	O	VERB	O
either	O	CCONJ	O
no	O	DET	O
cross	O	NOUN	B
-	O	PUNCT	O
tolerance	O	NOUN	B
or	O	CCONJ	O
an	O	DET	O
augmented	O	ADJ	B
response	O	NOUN	B
to	O	PART	O
ketamine	B-Chemical	NOUN	B
.	O	PUNCT	O


While	O	SCONJ	O
the	O	DET	O
mutual	O	ADJ	B
potentiation	O	NOUN	I
,	O	PUNCT	O
antagonism	O	NOUN	B
and	O	CCONJ	O
tolerance	O	NOUN	B
suggest	O	VERB	O
common	O	ADJ	O
mechanisms	O	NOUN	B
for	O	ADP	O
the	O	DET	O
induced	O	VERB	B
catalepsy	B-Disease	NOUN	B
,	O	PUNCT	O
differences	O	NOUN	O
in	O	ADP	O
latency	O	NOUN	B
,	O	PUNCT	O
rigidity	B-Disease	NOUN	B
and	O	CCONJ	O
behavior	O	NOUN	B
,	O	PUNCT	O
asymmetry	O	NOUN	B
of	O	ADP	O
cross	O	NOUN	B
-	O	PUNCT	O
tolerance	O	NOUN	B
and	O	CCONJ	O
a	O	DET	O
widely	O	ADV	B
-	O	PUNCT	O
different	O	ADJ	B
ID50	O	NOUN	B
for	O	ADP	O
naloxone	B-Chemical	NOUN	B


Acute	B-Disease	ADJ	B
renal	I-Disease	ADJ	I
failure	I-Disease	NOUN	I
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
AIDS	B-Disease	NOUN	B
on	O	ADP	O
tenofovir	B-Chemical	NOUN	B
while	O	SCONJ	O
receiving	O	VERB	O
prolonged	O	ADJ	B
vancomycin	B-Chemical	NOUN	B
course	O	NOUN	O
for	O	ADP	O
osteomyelitis	B-Disease	NOUN	B
.	O	PUNCT	O


Renal	B-Disease	ADJ	B
failure	I-Disease	NOUN	I
developed	O	VERB	O
after	O	ADP	O
a	O	DET	O
prolonged	O	ADJ	B
course	O	NOUN	B
of	O	ADP	O
vancomycin	B-Chemical	NOUN	B
therapy	O	NOUN	I
in	O	ADP	O
2	O	NUM	O
patients	O	NOUN	B
who	O	PRON	O
were	O	AUX	O
receiving	O	VERB	O
tenofovir	B-Chemical	NOUN	B
disoproxil	I-Chemical	NOUN	I
fumarate	I-Chemical	NOUN	I
as	O	ADP	O
part	O	NOUN	O
of	O	ADP	O
an	O	DET	O
antiretroviral	O	ADJ	B
regimen	O	NOUN	I
.	O	PUNCT	O


Tenofovir	B-Chemical	PROPN	B
has	O	AUX	O
been	O	AUX	O
implicated	O	VERB	O
in	O	ADP	O
the	O	DET	O
development	O	NOUN	B
of	O	ADP	O
Fanconi	B-Disease	NOUN	B
syndrome	I-Disease	NOUN	I
and	O	CCONJ	O
renal	B-Disease	ADJ	B
insufficiency	I-Disease	NOUN	I
because	O	SCONJ	O
of	O	ADP	O
its	O	PRON	O
effects	O	NOUN	B
on	O	ADP	O
the	O	DET	O
proximal	O	ADJ	B
renal	O	ADJ	I
tubule	O	NOUN	I
.	O	PUNCT	O


Vancomycin	B-Chemical	NOUN	B
nephrotoxicity	B-Disease	NOUN	B
is	O	AUX	O
infrequent	O	ADJ	B
but	O	CCONJ	O
may	O	AUX	O
result	O	VERB	O
from	O	ADP	O
coadministration	O	NOUN	B
with	O	ADP	O
a	O	DET	O
nephrotoxic	B-Disease	ADJ	B
agent	O	NOUN	I
.	O	PUNCT	O


Clinicians	O	NOUN	B
should	O	AUX	O
be	O	AUX	O
aware	O	ADJ	O
that	O	SCONJ	O
tenofovir	B-Chemical	NOUN	B
may	O	AUX	O
raise	O	VERB	O
the	O	DET	O
risk	O	NOUN	B
of	O	ADP	O
renal	B-Disease	ADJ	B
failure	I-Disease	NOUN	I
during	O	ADP	O
prolonged	O	ADJ	B
administration	O	NOUN	B
of	O	ADP	O
vancomycin	B-Chemical	NOUN	B


Delayed	O	VERB	B
leukoencephalopathy	B-Disease	NOUN	I
with	O	ADP	O
stroke	B-Disease	NOUN	B
-	O	PUNCT	O
like	O	ADJ	B
presentation	O	NOUN	B
in	O	ADP	O
chemotherapy	O	NOUN	B
recipients	O	NOUN	B
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
:	O	PUNCT	O
A	O	DET	O
transient	O	ADJ	B
leukoencephalopathy	B-Disease	NOUN	I
mimicking	O	VERB	O
cerebrovascular	B-Disease	ADJ	B
accident	I-Disease	NOUN	O
has	O	AUX	O
been	O	AUX	O
described	O	VERB	O
as	O	ADP	O
a	O	DET	O
complication	O	NOUN	B
of	O	ADP	O
chemotherapy	O	NOUN	B
,	O	PUNCT	O
most	O	ADV	O
commonly	O	ADV	O
in	O	ADP	O
recipients	O	NOUN	B
of	O	ADP	O
intrathecal	O	ADJ	B
methotrexate	B-Chemical	NOUN	I
for	O	ADP	O
childhood	O	NOUN	B
leukaemia	B-Disease	NOUN	I
.	O	PUNCT	O


Recently	O	ADV	O
published	O	VERB	O
neuroimaging	O	NOUN	B
data	O	NOUN	O
suggest	O	VERB	O
a	O	DET	O
common	O	ADJ	O
pathophysiology	O	NOUN	B
associated	O	VERB	B
with	O	ADP	I
a	O	DET	O
variety	O	NOUN	O
of	O	ADP	O
chemotherapy	O	NOUN	B
agents	O	NOUN	I
and	O	CCONJ	O
modes	O	NOUN	B
of	O	ADP	O
administration	O	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
:	O	PUNCT	O
We	O	PRON	O
reviewed	O	VERB	B
the	O	DET	O
medical	O	ADJ	B
literature	O	NOUN	I
for	O	ADP	O
single	O	ADJ	O
reports	O	NOUN	B
and	O	CCONJ	O
case	O	NOUN	B
series	O	NOUN	I
of	O	ADP	O
patients	O	NOUN	B
presenting	O	VERB	O
with	O	ADP	O
stroke	B-Disease	NOUN	B
-	O	PUNCT	O
like	O	ADJ	B
episodes	O	NOUN	B
while	O	SCONJ	O
receiving	O	VERB	O
systemic	O	ADJ	B
or	O	CCONJ	O
intrathecal	O	ADJ	B
chemotherapy	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
only	O	ADV	O
included	O	VERB	O
studies	O	NOUN	B
providing	O	VERB	O
detailed	O	ADJ	O
neuroimaging	O	ADJ	B
data	O	NOUN	O
.	O	PUNCT	O


Patients	O	NOUN	B
with	O	ADP	O
cerebrovascular	B-Disease	NOUN	B
accidents	I-Disease	NOUN	I
were	O	AUX	O
excluded	O	VERB	O
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
We	O	PRON	O
identified	O	VERB	B
27	O	NUM	O
reports	O	NOUN	B
of	O	ADP	O
toxic	O	ADJ	B
leukoencephalopathy	B-Disease	NOUN	O
in	O	ADP	O
patients	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
methotrexate	B-Chemical	NOUN	B
(	O	PUNCT	O
intrathecal	O	ADJ	B
,	O	PUNCT	O
systemic	O	ADJ	B
),	O	PUNCT	O
5-fluorouracil	B-Chemical	NOUN	B
and	O	CCONJ	O
its	O	PRON	O
derivative	O	ADJ	B
carmofur	B-Chemical	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
capecitabine	B-Chemical	NOUN	B
.	O	PUNCT	O


Diffusion	O	NOUN	B
weighted	O	VERB	I
imaging	O	NOUN	I
(	O	PUNCT	O
DWI	O	NOUN	B
)	O	PUNCT	O
of	O	ADP	O
all	O	DET	O
patients	O	NOUN	B
revealed	O	VERB	O
well	O	ADV	O
demarcated	O	ADJ	O
hyperintense	O	ADJ	B
lesions	B-Disease	NOUN	B
within	I-Disease	ADP	O
the	I-Disease	DET	O
subcortical	I-Disease	ADJ	B
white	I-Disease	ADJ	B
matter	I-Disease	NOUN	I
of	O	ADP	O
the	O	DET	O
cerebral	O	ADJ	B
hemispheres	O	NOUN	I
and	O	CCONJ	O
the	O	DET	O
corpus	O	NOUN	B
callosum	O	NOUN	I
,	O	PUNCT	O
corresponding	O	VERB	O
to	O	ADP	O
areas	O	NOUN	B
of	O	ADP	O
decreased	O	VERB	B
proton	O	NOUN	B
diffusion	O	NOUN	I
on	O	ADP	O
apparent	O	ADJ	B
diffusion	O	NOUN	I
coefficient	O	NOUN	I
(	O	PUNCT	O
ADC	O	NOUN	B
)	O	PUNCT	O
maps	O	NOUN	B
(	O	PUNCT	O
available	O	ADJ	O
in	O	ADP	O
21	O	NUM	O
/	O	SYM	O
27	O	NUM	O
patients	O	NOUN	B
).	O	PUNCT	B
Lesions	O	NOUN	B
exceeded	O	VERB	O
the	O	DET	O
confines	O	NOUN	O
of	O	ADP	O
adjacent	O	ADJ	B
vascular	O	ADJ	B
territories	O	NOUN	I
.	O	PUNCT	O


Complete	O	ADJ	B
resolution	O	NOUN	B
of	O	ADP	O
symptoms	O	NOUN	B
within	O	ADP	O
1	O	NUM	O
-	O	SYM	O
4	O	NUM	O
days	O	NOUN	B
was	O	AUX	O
accompanied	O	VERB	O
by	O	ADP	O
normalisation	O	NOUN	B
of	O	ADP	O
ADC	O	NOUN	B
abnormalities	O	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
fluid	O	ADJ	B
attenuated	O	VERB	O
inversion	O	NOUN	O
recovery	O	NOUN	O
(	O	PUNCT	O
FLAIR	O	NOUN	B
)	O	PUNCT	O
sequences	O	NOUN	O
frequently	O	ADV	O
revealed	O	VERB	O
persistent	O	ADJ	B
white	B-Disease	ADJ	B
matter	I-Disease	NOUN	I
abnormalities	I-Disease	NOUN	O
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
:	O	PUNCT	O
Several	O	ADJ	O
pathophysiological	O	ADJ	B
models	O	NOUN	B
of	O	ADP	O
delayed	O	VERB	B
leukoencephalopathy	B-Disease	NOUN	I
after	O	ADP	O
exposure	O	NOUN	B
to	O	PART	I
intrathecal	O	ADJ	B
or	O	CCONJ	O
systemic	O	ADJ	B
chemotherapy	O	NOUN	I
have	O	AUX	O
been	O	AUX	O
proposed	O	VERB	O
.	O	PUNCT	O


DWI	O	NOUN	B
findings	O	VERB	B
in	O	ADP	O
this	O	DET	O
cohort	O	NOUN	B
are	O	AUX	O
indicative	O	ADJ	B
of	O	ADP	O
cytotoxic	B-Disease	ADJ	B
oedema	I-Disease	NOUN	B
within	I-Disease	ADP	O
cerebral	I-Disease	ADJ	B
white	I-Disease	ADJ	I
matter	I-Disease	NOUN	I


Down	O	NOUN	B
-	O	PUNCT	O
regulation	O	NOUN	B
of	O	ADP	O
norepinephrine	B-Chemical	NOUN	B
transporter	O	NOUN	I
function	O	NOUN	O
induced	O	VERB	B
by	O	ADP	O
chronic	O	ADJ	B
administration	O	NOUN	I
of	O	ADP	O
desipramine	B-Chemical	NOUN	B
linking	O	VERB	O
to	O	PART	O
the	O	DET	O
alteration	O	NOUN	B
of	O	ADP	O
sensitivity	O	NOUN	B
of	O	ADP	O
local	O	ADJ	B
-	O	PUNCT	O
anesthetics	O	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
convulsions	B-Disease	NOUN	B
and	O	CCONJ	O
the	O	DET	O
counteraction	O	NOUN	B
by	O	ADP	O
co	O	X	B
-	O	PUNCT	O
administration	O	NOUN	B
with	O	ADP	O
local	O	ADJ	B
anesthetics	O	NOUN	I
.	O	PUNCT	O


Alterations	O	NOUN	B
of	O	ADP	O
norepinephrine	B-Chemical	NOUN	B
transporter	O	NOUN	I
(	O	PUNCT	O
NET	O	NOUN	B
)	O	PUNCT	O
function	O	NOUN	B
by	O	ADP	O
chronic	O	ADJ	B
inhibition	O	NOUN	I
of	O	ADP	O
NET	O	NOUN	B
in	O	ADP	O
relation	O	NOUN	O
to	O	PART	O
sensitization	O	NOUN	B
to	O	PART	O
seizures	B-Disease	NOUN	B
induce	O	VERB	B
by	O	ADP	O
cocaine	B-Chemical	NOUN	B
and	O	CCONJ	O
local	O	ADJ	B
anesthetics	O	NOUN	I
were	O	AUX	O
studied	O	VERB	O
in	O	ADP	O
mice	O	NOUN	B
.	O	PUNCT	O


Daily	O	ADJ	B
administration	O	NOUN	B
of	O	ADP	O
desipramine	B-Chemical	NOUN	B
,	O	PUNCT	O
an	O	DET	O
inhibitor	O	NOUN	B
of	O	ADP	O
the	O	DET	O
NET	O	NOUN	B
,	O	PUNCT	O
for	O	ADP	O
5	O	NUM	O
days	O	NOUN	B
decreased	O	VERB	B
[(	O	X	O
3	O	X	O
)	O	PUNCT	O
H	O	NOUN	O
]	O	PUNCT	O
norepinephrine	B-Chemical	NOUN	B
uptake	O	NOUN	B
in	O	ADP	O
the	O	DET	O
P2	O	NOUN	O
fractions	O	NOUN	B
of	O	ADP	O
hippocampus	O	NOUN	B
but	O	CCONJ	O
not	O	PART	O
cortex	O	NOUN	B
,	O	PUNCT	O
striatum	O	NOUN	B
or	O	CCONJ	O
amygdalae	O	NOUN	B
.	O	PUNCT	O


Co	O	PROPN	B
-	O	PUNCT	O
administration	O	NOUN	B
of	O	ADP	O
lidocaine	B-Chemical	NOUN	B
,	O	PUNCT	O
bupivacaine	B-Chemical	NOUN	B
or	O	CCONJ	O
tricaine	B-Chemical	NOUN	B
with	O	ADP	O
desipramine	B-Chemical	NOUN	B
reversed	O	VERB	O
this	O	DET	O
effect	O	NOUN	B
.	O	PUNCT	O


Daily	O	ADJ	B
treatment	O	NOUN	B
of	O	ADP	O
cocaine	B-Chemical	NOUN	B
increased	O	VERB	B
[(	O	X	O
3	O	X	O
)	O	PUNCT	O
H	O	NOUN	O
]	O	PUNCT	O
norepinephrine	B-Chemical	NOUN	B
uptake	O	NOUN	B
into	O	ADP	O
the	O	DET	O
hippocampus	O	NOUN	B
.	O	PUNCT	O


Daily	O	ADJ	B
administration	O	NOUN	B
of	O	ADP	O
desipramine	B-Chemical	NOUN	B
increased	O	VERB	B
the	O	DET	O
incidence	O	NOUN	B
of	O	ADP	O
appearance	O	NOUN	B
of	O	ADP	O
lidocaine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
convulsions	B-Disease	NOUN	B
and	O	CCONJ	O
decreased	O	VERB	B
that	O	DET	O
of	O	ADP	O
cocaine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
convulsions	B-Disease	NOUN	B
.	O	PUNCT	O


Co	O	PROPN	B
-	O	PUNCT	O
administration	O	NOUN	B
of	O	ADP	O
lidocaine	B-Chemical	NOUN	B
with	O	ADP	O
desipramine	B-Chemical	NOUN	B
reversed	O	VERB	O
the	O	DET	O
changes	O	NOUN	B
of	O	ADP	O
convulsive	B-Disease	ADJ	B
activity	O	NOUN	I
of	O	ADP	O
lidocaine	B-Chemical	NOUN	B
and	O	CCONJ	O
cocaine	B-Chemical	NOUN	B
induced	O	VERB	B
by	O	ADP	O
repeated	O	VERB	O
administration	O	NOUN	B
of	O	ADP	O
desipramine	B-Chemical	NOUN	B
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
down	O	NOUN	B
-	O	PUNCT	O
regulation	O	NOUN	B
of	O	ADP	O
hippocampal	O	ADJ	B
NET	O	NOUN	B
induced	O	VERB	B
by	O	ADP	O
chronic	O	ADJ	B
administration	O	NOUN	I
of	O	ADP	O
desipramine	B-Chemical	NOUN	B
may	O	AUX	O
be	O	AUX	O
relevant	O	ADJ	O
to	O	PART	O
desipramine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
sensitization	O	NOUN	B
of	O	ADP	O
lidocaine	B-Chemical	NOUN	B
convulsions	B-Disease	NOUN	I
.	O	PUNCT	O


Inhibition	O	NOUN	B
of	O	ADP	O
Na	B-Chemical	NOUN	B
(+)	O	ADJ	B
channels	O	NOUN	I
by	O	ADP	O
local	O	ADJ	B
anesthetics	O	NOUN	I
may	O	AUX	O
regulate	O	VERB	O
desipramine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
down	O	NOUN	B
-	O	PUNCT	O
regulation	O	NOUN	B
of	O	ADP	O
NET	O	NOUN	B
function	O	NOUN	B
.	O	PUNCT	O


Repeated	O	VERB	B
administration	O	NOUN	B
of	O	ADP	O
cocaine	B-Chemical	NOUN	B
induces	O	VERB	B
up	O	ADP	B
-	O	PUNCT	O
regulation	O	NOUN	B
of	O	ADP	O
hippocampal	O	ADJ	B
NET	O	NOUN	B
function	O	NOUN	B
.	O	PUNCT	O


Desipramine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
sensitization	O	NOUN	B
of	O	ADP	O
lidocaine	B-Chemical	NOUN	B
seizures	B-Disease	NOUN	I
may	O	AUX	O
have	O	AUX	O
a	O	DET	O
mechanism	O	NOUN	B
distinct	O	ADJ	O
from	O	ADP	O
kindling	O	NOUN	B
resulting	O	VERB	O
from	O	ADP	O
repeated	O	VERB	O
administration	O	NOUN	B
of	O	ADP	O
cocaine	B-Chemical	NOUN	B


Definition	O	NOUN	B
and	O	CCONJ	O
management	O	NOUN	B
of	O	ADP	O
anemia	B-Disease	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
infected	B-Disease	VERB	B
with	I-Disease	ADP	O
hepatitis	I-Disease	NOUN	B
C	I-Disease	NOUN	I
virus	I-Disease	NOUN	I
.	O	PUNCT	O


Chronic	B-Disease	ADJ	B
infection	I-Disease	NOUN	I
with	I-Disease	ADP	O
hepatitis	I-Disease	NOUN	B
C	I-Disease	NOUN	I
virus	I-Disease	NOUN	I
(	O	PUNCT	O
HCV	O	NOUN	B
)	O	PUNCT	O
can	O	AUX	O
progress	O	VERB	B
to	O	PART	O
cirrhosis	B-Disease	NOUN	B
,	O	PUNCT	O
hepatocellular	B-Disease	NOUN	B
carcinoma	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
end-stage	B-Disease	ADJ	B
liver	I-Disease	NOUN	B
disease	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
current	O	ADJ	O
best	O	ADJ	O
treatment	O	NOUN	B
for	O	ADP	O
HCV	B-Disease	NOUN	B
infection	I-Disease	NOUN	B
is	O	AUX	O
combination	O	NOUN	B
therapy	O	NOUN	I
with	O	ADP	O
pegylated	O	ADJ	B
interferon	B-Chemical	NOUN	I
and	O	CCONJ	O
ribavirin	B-Chemical	NOUN	B
.	O	PUNCT	O


Although	O	SCONJ	O
this	O	DET	O
regimen	O	NOUN	B
produces	O	VERB	O
sustained	O	ADJ	O
virologic	O	ADJ	B
responses	O	NOUN	I
(	O	PUNCT	O
SVRs	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
approximately	O	ADV	O
50	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
,	O	PUNCT	O
it	O	PRON	O
can	O	AUX	O
be	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
a	O	DET	O
potentially	O	ADV	O
dose	O	NOUN	B
-	O	PUNCT	O
limiting	O	VERB	B
hemolytic	B-Disease	ADJ	B
anemia	I-Disease	NOUN	B
.	O	PUNCT	O


Hemoglobin	O	NOUN	B
concentrations	O	NOUN	I
decrease	O	VERB	B
mainly	O	ADV	O
as	O	ADP	O
a	O	DET	O
result	O	NOUN	O
of	O	ADP	O
ribavirin	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
hemolysis	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
this	O	DET	O
anemia	B-Disease	NOUN	B
can	O	AUX	O
be	O	AUX	O
problematic	O	ADJ	O
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
HCV	B-Disease	NOUN	B
infection	I-Disease	NOUN	B
,	O	PUNCT	O
especially	O	ADV	O
those	O	DET	O
who	O	PRON	O
have	O	AUX	O
comorbid	O	ADJ	B
renal	B-Disease	ADJ	I
or	I-Disease	CCONJ	O
cardiovascular	I-Disease	ADJ	B
disorders	I-Disease	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
general	O	ADJ	O
,	O	PUNCT	O
anemia	B-Disease	NOUN	B
can	O	AUX	O
increase	O	VERB	B
the	O	DET	O
risk	O	NOUN	B
of	O	ADP	O
morbidity	O	NOUN	B
and	O	CCONJ	O
mortality	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
may	O	AUX	O
have	O	AUX	O
negative	O	ADJ	B
effects	O	NOUN	B
on	O	ADP	O
cerebral	O	ADJ	B
function	O	NOUN	I
and	O	CCONJ	O
quality	O	NOUN	B
of	O	ADP	I
life	O	NOUN	I
.	O	PUNCT	O


Although	O	SCONJ	O
ribavirin	B-Chemical	NOUN	B
-	O	PUNCT	O
associated	O	VERB	B
anemia	B-Disease	NOUN	B
can	O	AUX	O
be	O	AUX	O
reversed	O	VERB	O
by	O	ADP	O
dose	O	NOUN	B
reduction	O	NOUN	B
or	O	CCONJ	O
discontinuation	O	NOUN	B
,	O	PUNCT	O
this	O	DET	O
approach	O	NOUN	O
compromises	O	VERB	O
outcomes	O	NOUN	B
by	O	ADP	O
significantly	O	ADV	O
decreasing	O	VERB	B
SVR	O	NOUN	B
rates	O	NOUN	B
.	O	PUNCT	O


Recombinant	O	ADJ	B
human	O	ADJ	B
erythropoietin	O	NOUN	B
has	O	AUX	O
been	O	AUX	O
used	O	VERB	O
to	O	PART	O
manage	O	VERB	O
ribavirin	B-Chemical	NOUN	B
-	O	PUNCT	O
associated	O	VERB	B
anemia	B-Disease	NOUN	B
but	O	CCONJ	O
has	O	AUX	O
other	O	ADJ	O
potential	O	ADJ	B
disadvantages	O	NOUN	B
.	O	PUNCT	O


Viramidine	B-Chemical	NOUN	B
,	O	PUNCT	O
a	O	DET	O
liver	O	NOUN	B
-	O	PUNCT	O
targeting	O	VERB	B
prodrug	O	NOUN	B
of	O	ADP	O
ribavirin	B-Chemical	NOUN	B
,	O	PUNCT	O
has	O	AUX	O
the	O	DET	O
potential	O	NOUN	B
to	O	PART	O
maintain	O	VERB	O
the	O	DET	O
virologic	O	ADJ	B
efficacy	O	NOUN	B
of	O	ADP	O
ribavirin	B-Chemical	NOUN	B
while	O	SCONJ	O
decreasing	O	VERB	B
the	O	DET	O
risk	O	NOUN	B
of	O	ADP	O
hemolytic	B-Disease	ADJ	B
anemia	I-Disease	NOUN	I
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
chronic	B-Disease	ADJ	B
hepatitis	I-Disease	NOUN	I
C	I-Disease	NOUN	I


Calcium	B-Chemical	NOUN	B
carbonate	I-Chemical	NOUN	I
toxicity	B-Disease	NOUN	B
:	O	PUNCT	O
the	O	DET	O
updated	O	ADJ	O
milk-alkali	B-Disease	ADJ	B
syndrome	I-Disease	NOUN	I
;	O	PUNCT	O
report	O	NOUN	O
of	O	ADP	O
3	O	NUM	O
cases	O	NOUN	B
and	O	CCONJ	O
review	O	NOUN	B
of	O	ADP	O
the	O	DET	O
literature	O	NOUN	B
.	O	PUNCT	O


OBJECTIVE	O	NOUN	B
:	O	PUNCT	O
To	O	PART	O
describe	O	VERB	O
3	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
calcium	B-Chemical	NOUN	B
carbonate	I-Chemical	NOUN	I
-	O	PUNCT	O
induced	O	VERB	B
hypercalcemia	B-Disease	NOUN	B
and	O	CCONJ	O
gain	O	VERB	O
insights	O	NOUN	O
into	O	ADP	O
the	O	DET	O
cause	O	NOUN	B
and	O	CCONJ	O
management	O	NOUN	B
of	O	ADP	O
the	O	DET	O
milk-alkali	B-Disease	ADJ	B
syndrome	I-Disease	NOUN	I
.	O	PUNCT	O


METHODS	O	NOUN	O
:	O	PUNCT	O
We	O	PRON	O
report	O	VERB	O
the	O	DET	O
clinical	O	ADJ	B
and	O	CCONJ	O
laboratory	O	ADJ	B
data	O	NOUN	I
in	O	ADP	O
3	O	NUM	O
patients	O	NOUN	B
who	O	PRON	O
presented	O	VERB	O
with	O	ADP	O
severe	O	ADJ	B
hypercalcemia	B-Disease	NOUN	B
(	O	PUNCT	O
corrected	O	VERB	O
serum	O	NOUN	O
calcium	B-Chemical	NOUN	O
>	O	X	O
or	O	CCONJ	O
=	O	ADJ	O
14	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
dL	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
review	O	VERB	B
the	O	DET	O
pertinent	O	ADJ	O
literature	O	NOUN	B
on	O	ADP	O
milk-alkali	B-Disease	ADJ	B
syndrome	I-Disease	NOUN	I
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
The	O	DET	O
3	O	NUM	O
patients	O	NOUN	B
had	O	AUX	O
acute	B-Disease	ADJ	B
renal	I-Disease	ADJ	I
insufficiency	I-Disease	NOUN	I
,	O	PUNCT	O
relative	O	ADJ	O
metabolic	B-Disease	ADJ	B
alkalosis	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
low	O	ADJ	B
parathyroid	O	ADJ	I
hormone	O	NOUN	I
(	O	PUNCT	O
PTH	O	NOUN	B
),	O	PUNCT	O
PTH	O	NOUN	B
-	O	PUNCT	O
related	O	VERB	B
peptide	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
1,25-dihydroxyvitamin	B-Chemical	NOUN	B
D	I-Chemical	NOUN	I
concentrations	O	NOUN	B
.	O	PUNCT	O


No	O	DET	O
malignant	O	ADJ	B
lesion	O	NOUN	O
was	O	AUX	O
found	O	VERB	O
.	O	PUNCT	O


Treatment	O	NOUN	B
included	O	VERB	O
aggressive	O	ADJ	B
hydration	O	NOUN	B
and	O	CCONJ	O
varied	O	ADJ	O
amounts	O	NOUN	O
of	O	ADP	O
furosemide	B-Chemical	NOUN	B
.	O	PUNCT	O


The	O	DET	O
2	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
the	O	DET	O
higher	O	ADJ	B
serum	O	NOUN	B
calcium	B-Chemical	NOUN	B
concentrations	O	NOUN	I
received	O	VERB	O
pamidronate	B-Chemical	NOUN	B
intravenously	O	ADV	B
(	O	PUNCT	O
60	O	NUM	O
and	O	CCONJ	O
30	O	NUM	O
mg	O	NOUN	O
,	O	PUNCT	O
respectively	O	ADV	O
),	O	PUNCT	O
which	O	DET	O
caused	O	VERB	O
severe	O	ADJ	B
hypocalcemia	B-Disease	NOUN	B
.	O	PUNCT	O


Of	O	ADP	O
the	O	DET	O
3	O	NUM	O
patients	O	NOUN	B
,	O	PUNCT	O
2	O	NUM	O
were	O	AUX	O
ingesting	O	VERB	B
acceptable	O	ADJ	O
doses	O	NOUN	B
of	O	ADP	O
elemental	O	ADJ	B
calcium	B-Chemical	NOUN	I
(	O	PUNCT	O
1	O	NUM	O
g	O	NOUN	O
and	O	CCONJ	O
2	O	NUM	O
g	O	NOUN	O
daily	O	ADV	B
,	O	PUNCT	O
respectively	O	ADV	O
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
form	O	NOUN	O
of	O	ADP	O
calcium	B-Chemical	NOUN	B
carbonate	I-Chemical	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
to	O	PART	O
our	O	PRON	O
highlighted	O	VERB	O
cases	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
review	O	VERB	B
the	O	DET	O
history	O	NOUN	B
,	O	PUNCT	O
classification	O	NOUN	B
,	O	PUNCT	O
pathophysiologic	O	ADJ	B
features	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
treatment	O	NOUN	B
of	O	ADP	O
milk-alkali	B-Disease	ADJ	B
syndrome	I-Disease	NOUN	I
and	O	CCONJ	O
summarize	O	VERB	O
the	O	DET	O
cases	O	NOUN	B
reported	O	VERB	O
from	O	ADP	O
early	O	ADJ	B
1995	O	NUM	O
to	O	ADP	O
November	O	PROPN	O
2003	O	NUM	O
.	O	PUNCT	O


CONCLUSION	O	NOUN	B
:	O	PUNCT	O
Milk-alkali	B-Disease	ADJ	B
syndrome	I-Disease	NOUN	I
may	O	AUX	O
be	O	AUX	O
a	O	DET	O
common	O	ADJ	O
cause	O	NOUN	O
of	O	ADP	O
unexplained	O	ADJ	O
hypercalcemia	B-Disease	NOUN	B
and	O	CCONJ	O
can	O	AUX	O
be	O	AUX	O
precipitated	O	VERB	O
by	O	ADP	O
small	O	ADJ	O
amounts	O	NOUN	O
of	O	ADP	O
orally	O	ADV	B
ingested	O	VERB	B
calcium	B-Chemical	NOUN	B
carbonate	I-Chemical	NOUN	I
in	O	ADP	O
susceptible	O	ADJ	B
persons	O	NOUN	B
.	O	PUNCT	O


Treatment	O	NOUN	B
with	O	ADP	O
hydration	O	NOUN	B
,	O	PUNCT	O
furosemide	B-Chemical	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
discontinuation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
calcium	B-Chemical	NOUN	B
and	O	CCONJ	O
vitamin	B-Chemical	NOUN	B
D	I-Chemical	NOUN	I
source	O	NOUN	B
is	O	AUX	O
adequate	O	ADJ	B
.	O	PUNCT	O


Pamidronate	B-Chemical	NOUN	B
treatment	O	NOUN	B
is	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
considerable	O	ADJ	O
risk	O	NOUN	B
for	O	ADP	O
hypocalcemia	B-Disease	NOUN	B
,	O	PUNCT	O
even	O	ADV	O
in	O	ADP	O
cases	O	NOUN	B
of	O	ADP	O
initially	O	ADV	O
severe	O	ADJ	O
hypercalcemia	B-Disease	NOUN	B


Management	O	NOUN	B
strategies	O	NOUN	O
for	O	ADP	O
ribavirin	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
hemolytic	B-Disease	ADJ	B
anemia	I-Disease	NOUN	B
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
hepatitis	B-Disease	NOUN	B
C	I-Disease	NOUN	I
:	O	PUNCT	O
clinical	O	ADJ	B
and	O	CCONJ	O
economic	O	ADJ	B
implications	O	NOUN	O
.	O	PUNCT	O


OBJECTIVES	O	NOUN	O
:	O	PUNCT	O
Recently	O	ADV	O
published	O	VERB	B
studies	O	NOUN	I
have	O	AUX	O
demonstrated	O	VERB	O
increased	O	VERB	B
efficacy	O	NOUN	B
and	O	CCONJ	O
cost	O	NOUN	B
-	O	PUNCT	O
effectiveness	O	NOUN	B
of	O	ADP	O
combination	O	NOUN	B
therapy	O	NOUN	I
with	O	ADP	O
interferon	O	NOUN	B
and	O	CCONJ	O
alpha	O	NOUN	B
-	O	PUNCT	O
2b	O	NOUN	B
/	O	SYM	O
ribavirin	B-Chemical	NOUN	B
compared	O	VERB	O
with	O	ADP	O
interferon-alpha	B-Chemical	NOUN	B
monotherapy	O	NOUN	I
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
chronic	B-Disease	ADJ	B
hepatitis	I-Disease	NOUN	I
C	I-Disease	NOUN	I
(	O	PUNCT	O
CHC	B-Disease	NOUN	B
).	O	PUNCT	O
Combination	O	NOUN	B
therapy	O	NOUN	I
is	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
a	O	DET	O
clinically	O	ADV	B
important	O	ADJ	O
adverse	O	ADJ	B
effect	O	NOUN	I
:	O	PUNCT	O
ribavirin	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
hemolytic	B-Disease	ADJ	B
anemia	I-Disease	NOUN	I
(	O	PUNCT	O
RIHA	B-Disease	NOUN	B
).	O	PUNCT	O
The	O	DET	O
objective	O	NOUN	B
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
direct	O	ADJ	O
health	O	NOUN	B
-	O	PUNCT	O
care	O	NOUN	B
costs	O	NOUN	B
and	O	CCONJ	O
management	O	NOUN	B
of	O	ADP	O
RIHA	B-Disease	NOUN	B
during	O	ADP	O
treatment	O	NOUN	B
of	O	ADP	O
CHC	B-Disease	NOUN	B
in	O	ADP	O
a	O	DET	O
clinical	O	ADJ	B
trial	O	NOUN	I
setting	O	NOUN	I
.	O	PUNCT	O


METHODS	O	NOUN	O
:	O	PUNCT	O
A	O	DET	O
systematic	O	ADJ	B
literature	O	NOUN	I
review	O	NOUN	I
was	O	AUX	O
conducted	O	VERB	O
to	O	PART	O
synthesize	O	VERB	B
information	O	NOUN	B
on	O	ADP	O
the	O	DET	O
incidence	O	NOUN	B
and	O	CCONJ	O
management	O	NOUN	B
of	O	ADP	O
RIHA	B-Disease	NOUN	B
.	O	PUNCT	O


Decision	O	NOUN	B
-	O	PUNCT	O
analytic	O	ADJ	B
techniques	O	NOUN	B
were	O	AUX	O
used	O	VERB	O
to	O	PART	O
estimate	O	VERB	B
the	O	DET	O
cost	O	NOUN	B
of	O	ADP	O
treating	O	VERB	B
RIHA	B-Disease	NOUN	B
.	O	PUNCT	O


Uncertainty	O	PROPN	B
was	O	AUX	O
evaluated	O	VERB	B
using	O	VERB	O
sensitivity	O	NOUN	B
analyses	O	NOUN	I
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
RIHA	B-Disease	NOUN	B
,	O	PUNCT	O
defined	O	VERB	O
as	O	ADP	O
a	O	DET	O
reduction	O	NOUN	B
in	O	ADP	O
hemoglobin	O	NOUN	B
to	O	PART	O
less	O	ADJ	O
than	O	ADP	O
100	O	NUM	O
g	O	NOUN	B
/	O	SYM	O
L	O	NOUN	B
,	O	PUNCT	O
occurs	O	VERB	O
in	O	ADP	O
approximately	O	ADV	O
7	O	NUM	O
%	O	NOUN	O
to	O	PART	O
9	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
combination	O	NOUN	B
therapy	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
standard	O	NOUN	B
of	O	ADP	I
care	O	NOUN	I
for	O	ADP	O
management	O	NOUN	B
of	O	ADP	O
RIHA	B-Disease	NOUN	B
is	O	AUX	O
reduction	O	NOUN	B
or	O	CCONJ	O
discontinuation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
ribavirin	B-Chemical	NOUN	B
dosage	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
estimated	O	VERB	B
the	O	DET	O
direct	O	ADJ	O
cost	O	NOUN	B
of	O	ADP	O
treating	O	VERB	B
clinically	O	ADV	B
significant	O	ADJ	I
RIHA	B-Disease	NOUN	B
to	O	PART	O
be	O	AUX	O
170	O	NUM	O
per	O	ADP	O
patient	O	NOUN	B
receiving	O	VERB	O
combination	O	NOUN	B
therapy	O	NOUN	I
per	O	ADP	O
48	O	NUM	O
-	O	PUNCT	O
week	O	NOUN	B
treatment	O	NOUN	B
course	O	NOUN	I
(	O	PUNCT	O
range	O	NOUN	O
68	O	NUM	O
-	O	SYM	O
692	O	NUM	O
).	O	PUNCT	O
The	O	DET	O
results	O	NOUN	B
of	O	ADP	O
the	O	DET	O
one	O	NUM	O
-	O	PUNCT	O
way	O	NOUN	B
sensitivity	O	NOUN	I
analyses	O	NOUN	B
ranged	O	VERB	O
from	O	ADP	O
57	O	NUM	O
to	O	PART	O
317	O	NUM	O
.	O	PUNCT	O


In	O	ADP	O
comparison	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
cost	O	NOUN	B
of	O	ADP	O
48	O	NUM	O
weeks	O	NOUN	B
of	O	ADP	O
combination	O	NOUN	B
therapy	O	NOUN	I
is	O	AUX	O
16	O	NUM	O
,	O	PUNCT	O
459	O	NUM	O
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
:	O	PUNCT	O
The	O	DET	O
direct	O	ADJ	O
cost	O	NOUN	B
of	O	ADP	O
treating	O	VERB	B
clinically	O	ADV	B
significant	O	ADJ	I
RIHA	B-Disease	NOUN	B
is	O	AUX	O
1	O	NUM	O
%(	O	NOUN	O
170	O	NUM	O
/	O	SYM	O
16	O	NUM	O
,	O	PUNCT	O
459	O	NUM	O
)	O	PUNCT	O
of	O	ADP	O
drug	O	NOUN	B
treatment	O	NOUN	I
costs	O	NOUN	I
.	O	PUNCT	O


Questions	O	NOUN	B
remain	O	VERB	O
about	O	ADP	O
the	O	DET	O
optimal	O	ADJ	B
dose	O	NOUN	B
of	O	ADP	O
ribavirin	B-Chemical	NOUN	B
and	O	CCONJ	O
the	O	DET	O
incidence	O	NOUN	B
of	O	ADP	O
RIHA	B-Disease	NOUN	B
in	O	ADP	O
a	O	DET	O
real	O	ADJ	B
-	O	PUNCT	O
world	O	NOUN	B
population	O	NOUN	B
.	O	PUNCT	O


Despite	O	SCONJ	O
these	O	DET	O
uncertainties	O	NOUN	B
,	O	PUNCT	O
this	O	DET	O
initial	O	ADJ	O
evaluation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
direct	O	ADJ	O
cost	O	NOUN	B
of	O	ADP	O
treating	O	VERB	B
RIHA	B-Disease	NOUN	B


Effects	O	NOUN	B
of	O	ADP	I
amine	B-Chemical	NOUN	B
pretreatment	O	NOUN	B
on	O	ADP	O
ketamine	B-Chemical	NOUN	B
catatonia	B-Disease	NOUN	B
in	O	ADP	O
pinealectomized	O	VERB	B
or	O	CCONJ	O
hypophysectomized	O	ADJ	B
animals	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
present	O	ADJ	O
studies	O	NOUN	B
were	O	AUX	O
designed	O	VERB	O
to	O	PART	O
clarify	O	VERB	O
the	O	DET	O
role	O	NOUN	O
of	O	ADP	O
catecholamines	B-Chemical	NOUN	B
and	O	CCONJ	O
pineal	O	ADJ	B
idolamines	O	NOUN	I
on	O	ADP	O
ketamine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
catatonia	B-Disease	NOUN	B
in	O	ADP	O
the	O	DET	O
intact	O	ADJ	B
,	O	PUNCT	O
pinealectomized	O	ADJ	B
or	O	CCONJ	O
hypophysectomized	O	ADJ	B
chick	O	NOUN	B
and	O	CCONJ	O
rat	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
pinealectomized	O	ADJ	B
chick	O	NOUN	O
,	O	PUNCT	O
pretreatment	O	NOUN	B
with	O	ADP	O
dopamine	B-Chemical	NOUN	B
increased	O	VERB	B
the	O	DET	O
duration	O	NOUN	B
of	O	ADP	O
catatonia	B-Disease	NOUN	B
(	O	PUNCT	O
DOC	O	NOUN	B
)	O	PUNCT	O
after	O	ADP	O
ketamine	B-Chemical	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
pretreatment	O	NOUN	B
with	O	ADP	O
norepinephrine	B-Chemical	NOUN	B
did	O	AUX	O
not	O	PART	O
.	O	PUNCT	O


The	O	DET	O
pineal	O	ADJ	B
indolamines	O	NOUN	I
exhibited	O	VERB	O
mixed	O	ADJ	O
actions	O	NOUN	B
.	O	PUNCT	O


Serotonin	B-Chemical	NOUN	B
and	O	CCONJ	O
N-acetyl	B-Chemical	ADJ	B
serotonin	I-Chemical	NOUN	I
which	O	DET	O
augmented	O	VERB	B
ketamine	B-Chemical	NOUN	B
DOC	O	NOUN	B
,	O	PUNCT	O
did	O	AUX	O
not	O	PART	O
do	O	AUX	O
so	O	ADV	O
in	O	ADP	O
the	O	DET	O
absence	O	NOUN	B
of	O	ADP	O
the	O	DET	O
pineal	O	ADJ	B
gland	O	NOUN	I
,	O	PUNCT	O
whereas	O	SCONJ	O
melatonin	B-Chemical	NOUN	B
potentiated	O	VERB	B
the	O	DET	O
ketamine	B-Chemical	NOUN	B
DOC	O	NOUN	B
in	O	ADP	O
both	O	CCONJ	O
the	O	DET	O
intact	O	ADJ	B
and	O	CCONJ	O
pinealectomized	O	ADJ	B
chick	O	NOUN	O
.	O	PUNCT	O


Ketamine	B-Chemical	NOUN	B
was	O	AUX	O
more	O	ADV	O
potent	O	ADJ	O
in	O	ADP	O
the	O	DET	O
hypophysectomized	O	ADJ	B
chick	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
circadian	O	ADJ	B
rhythm	O	NOUN	I
noted	O	VERB	O
in	O	ADP	O
the	O	DET	O
intact	O	ADJ	B
chick	O	NOUN	B
was	O	AUX	O
absent	O	ADJ	B
;	O	PUNCT	O
furthermore	O	ADV	O
,	O	PUNCT	O
melatonin	B-Chemical	NOUN	B
did	O	AUX	O
not	O	PART	O
augment	O	VERB	O
the	O	DET	O
ketamine	B-Chemical	NOUN	B
DOC	O	NOUN	B
whereas	O	SCONJ	O
dopamine	B-Chemical	NOUN	B
continued	O	VERB	O
to	O	PART	O
do	O	AUX	O
so	O	ADV	O
.	O	PUNCT	O


This	O	DET	O
study	O	NOUN	B
did	O	AUX	O
not	O	PART	O
demonstrate	O	VERB	O
a	O	DET	O
species	O	NOUN	B
difference	O	NOUN	O
regarding	O	VERB	O
the	O	DET	O
role	O	NOUN	O
of	O	ADP	O
the	O	DET	O
amines	B-Chemical	NOUN	B
on	O	ADP	O
the	O	DET	O
pineal	O	NOUN	B
in	O	ADP	O
spite	O	NOUN	O
of	O	ADP	O
the	O	DET	O
immature	O	ADJ	B
blood	O	NOUN	B
-	O	PUNCT	O
brain	O	NOUN	B
barrier	O	NOUN	O
in	O	ADP	O
the	O	DET	O
young	O	ADJ	B
chick	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
intact	O	ADJ	B
barrier	O	NOUN	B
in	O	ADP	O
the	O	DET	O
rat	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
,	O	PUNCT	O
these	O	DET	O
data	O	NOUN	B
indicate	O	VERB	O
a	O	DET	O
direct	O	ADJ	O
role	O	NOUN	O
of	O	ADP	O
the	O	DET	O
pituitary	O	NOUN	B
in	O	ADP	O
the	O	DET	O
augmentation	O	NOUN	B
of	O	ADP	O
ketamine	B-Chemical	NOUN	B
DOC	O	NOUN	B
induced	O	VERB	B
by	O	ADP	O
melatonin	B-Chemical	NOUN	B
.	O	PUNCT	O


Furthermore	O	ADV	O
,	O	PUNCT	O
dopamine	B-Chemical	NOUN	B
appeared	O	VERB	O
to	O	PART	O
act	O	VERB	O
on	O	ADP	O
systems	O	NOUN	B
more	O	ADV	O
closely	O	ADV	O
involved	O	VERB	O
with	O	ADP	O
the	O	DET	O
induction	O	NOUN	B
of	O	ADP	O
ketamine	B-Chemical	NOUN	B
catatonia	B-Disease	NOUN	B


Multicenter	O	NOUN	B
,	O	PUNCT	O
double	O	ADJ	B
-	O	PUNCT	O
blind	O	NOUN	B
,	O	PUNCT	O
multiple	O	ADJ	B
-	O	PUNCT	O
dose	O	NOUN	B
,	O	PUNCT	O
parallel	O	ADJ	B
-	O	PUNCT	O
groups	O	NOUN	B
efficacy	O	NOUN	B
and	O	CCONJ	O
safety	O	NOUN	B
trial	O	NOUN	I
of	O	ADP	O
azelastine	B-Chemical	NOUN	B
,	O	PUNCT	O
chlorpheniramine	B-Chemical	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
placebo	O	NOUN	B
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
spring	B-Disease	NOUN	B
allergic	I-Disease	ADJ	B
rhinitis	I-Disease	NOUN	I
.	O	PUNCT	O


Azelastine	B-Chemical	NOUN	B
,	O	PUNCT	O
a	O	DET	O
novel	O	ADJ	O
antiallergic	O	ADJ	B
medication	O	NOUN	I
,	O	PUNCT	O
was	O	AUX	O
compared	O	VERB	O
with	O	ADP	O
chlorpheniramine	B-Chemical	NOUN	B
maleate	I-Chemical	NOUN	B
and	O	CCONJ	O
placebo	O	NOUN	B
for	O	ADP	O
efficacy	O	NOUN	B
and	O	CCONJ	O
safety	O	NOUN	B
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
spring	B-Disease	NOUN	B
allergic	I-Disease	ADJ	B
rhinitis	I-Disease	NOUN	I
in	O	ADP	O
a	O	DET	O
multicenter	O	NOUN	B
,	O	PUNCT	O
double	O	ADJ	B
-	O	PUNCT	O
blind	O	NOUN	B
,	O	PUNCT	O
multiple	O	ADJ	B
-	O	PUNCT	O
dose	O	NOUN	B
,	O	PUNCT	O
parallel	O	ADJ	B
-	O	PUNCT	O
groups	O	NOUN	B
study	O	NOUN	B
.	O	PUNCT	O


One	O	NUM	O
hundred	O	NUM	O
fifty	O	NUM	O
-	O	PUNCT	O
five	O	NUM	B
subjects	O	NOUN	B
participated	O	VERB	O
.	O	PUNCT	O


Subjects	O	NOUN	B
ranged	O	VERB	O
in	O	ADP	O
age	O	NOUN	B
from	O	ADP	O
18	O	NUM	O
to	O	PART	O
60	O	NUM	O
years	O	NOUN	B
of	O	ADP	O
age	O	NOUN	B
and	O	CCONJ	O
had	O	AUX	O
at	O	ADP	O
least	O	ADJ	O
a	O	DET	O
2	O	NUM	B
-	O	PUNCT	O
year	O	NOUN	B
history	O	NOUN	B
of	O	ADP	O
spring	B-Disease	NOUN	B
allergic	I-Disease	ADJ	B
rhinitis	I-Disease	NOUN	I
,	O	PUNCT	O
confirmed	O	VERB	O
by	O	ADP	O
positive	O	ADJ	B
skin	O	NOUN	B
test	O	NOUN	I
to	O	ADP	O
spring	O	NOUN	B
aeroallergens	O	NOUN	B
.	O	PUNCT	O


Medications	O	NOUN	B
were	O	AUX	O
given	O	VERB	O
four	O	NUM	O
times	O	NOUN	O
daily	O	ADV	B
;	O	PUNCT	O
the	O	DET	O
azelastine	B-Chemical	NOUN	B
groups	O	NOUN	O
received	O	VERB	O
0	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
,	O	PUNCT	O
1	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
,	O	PUNCT	O
or	O	CCONJ	O
2	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
mg	O	NOUN	O
in	O	ADP	O
the	O	DET	O
morning	O	NOUN	B
and	O	CCONJ	O
evening	O	NOUN	B
with	O	ADP	O
placebo	O	NOUN	B
in	O	ADP	O
the	O	DET	O
early	O	ADJ	B
and	O	CCONJ	O
late	O	ADJ	B
afternoon	O	NOUN	I
;	O	PUNCT	O
the	O	DET	O
chlorpheniramine	B-Chemical	NOUN	B
group	O	NOUN	B
received	O	VERB	O
4	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
mg	O	NOUN	O
four	O	NUM	O
times	O	NOUN	O
daily	O	ADV	B
.	O	PUNCT	O


Daily	O	ADJ	O
subject	O	ADJ	O
symptom	O	NOUN	B
cards	O	NOUN	I
were	O	AUX	O
completed	O	VERB	O
during	O	ADP	O
a	O	DET	O
screening	O	NOUN	B
period	O	NOUN	O
to	O	PART	O
assess	O	VERB	O
pretreatment	O	NOUN	B
symptoms	O	NOUN	B
and	O	CCONJ	O
during	O	ADP	O
a	O	DET	O
4	O	NUM	B
-	O	PUNCT	O
week	O	NOUN	B
treatment	O	NOUN	B
period	O	NOUN	B
while	O	SCONJ	O
subjects	O	NOUN	B
received	O	VERB	O
study	O	NOUN	B
medications	O	NOUN	B
.	O	PUNCT	O


Individual	O	ADJ	B
symptoms	O	NOUN	B
,	O	PUNCT	O
total	O	ADJ	O
symptoms	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
major	O	ADJ	O
symptoms	O	NOUN	B
were	O	AUX	O
compared	O	VERB	B
to	O	PART	O
determine	O	VERB	O
efficacy	O	NOUN	B
of	O	ADP	O
medication	O	NOUN	B
.	O	PUNCT	O


Elicited	O	VERB	B
,	O	PUNCT	O
volunteered	O	VERB	B
,	O	PUNCT	O
and	O	CCONJ	O
observed	O	VERB	B
adverse	O	ADJ	B
experiences	O	NOUN	I
were	O	AUX	O
recorded	O	VERB	O
for	O	ADP	O
each	O	DET	O
subject	O	NOUN	B
and	O	CCONJ	O
compared	O	VERB	B
among	O	ADP	O
groups	O	NOUN	B
.	O	PUNCT	O


Vital	O	NOUN	B
signs	O	NOUN	I
,	O	PUNCT	O
body	O	NOUN	B
weights	O	NOUN	I
,	O	PUNCT	O
serum	O	NOUN	B
chemistry	O	NOUN	I
values	O	NOUN	I
,	O	PUNCT	O
complete	O	ADJ	B
blood	O	NOUN	B
cell	O	NOUN	I
counts	O	NOUN	I
,	O	PUNCT	O
urine	O	NOUN	B
studies	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
electrocardiograms	O	NOUN	B
were	O	AUX	O
obtained	O	VERB	O
for	O	ADP	O
each	O	DET	O
subject	O	NOUN	B
and	O	CCONJ	O
compared	O	VERB	B
among	O	ADP	O
groups	O	NOUN	B
.	O	PUNCT	O


Symptoms	O	NOUN	B
relief	O	NOUN	B
in	O	ADP	O
the	O	DET	O
group	O	NOUN	B
receiving	O	VERB	O
the	O	DET	O
highest	O	ADJ	B
concentration	O	NOUN	B
of	O	ADP	O
azelastine	B-Chemical	NOUN	B
(	O	PUNCT	O
2	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
mg	O	NOUN	O
twice	O	ADV	O
daily	O	ADV	B
)	O	PUNCT	O
was	O	AUX	O
statistically	O	ADV	B
greater	O	ADJ	I
than	O	ADP	O
in	O	ADP	O
the	O	DET	O
placebo	O	ADJ	B
group	O	NOUN	B
during	O	ADP	O
all	O	DET	O
weeks	O	NOUN	B
of	O	ADP	O
the	O	DET	O
study	O	NOUN	B
.	O	PUNCT	O


Lower	O	ADJ	B
doses	O	NOUN	I
of	O	ADP	O
azelastine	B-Chemical	NOUN	B
were	O	AUX	O
statistically	O	ADV	B
more	O	ADV	O
effective	O	ADJ	B
than	O	ADP	O
placebo	O	NOUN	B
only	O	ADV	O
during	O	ADP	O
portions	O	NOUN	B
of	O	ADP	O
the	O	DET	O
first	O	ADJ	O
3	O	NUM	O
weeks	O	NOUN	B
of	O	ADP	O
the	O	DET	O
study	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
contrast	O	NOUN	O
,	O	PUNCT	O
although	O	SCONJ	O
the	O	DET	O
chlorpheniramine	B-Chemical	NOUN	B
group	O	NOUN	B
did	O	AUX	O
have	O	AUX	O
fewer	O	ADJ	O
symptoms	O	NOUN	B
than	O	ADP	O
the	O	DET	O
placebo	O	ADJ	B
group	O	NOUN	B
during	O	ADP	O
the	O	DET	O
study	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
difference	O	NOUN	O
never	O	ADV	O
reached	O	VERB	O
statistical	O	ADJ	B
significance	O	NOUN	I
during	O	ADP	O
any	O	DET	O
week	O	NOUN	B
of	O	ADP	O
the	O	DET	O
study	O	NOUN	B
.	O	PUNCT	O


There	O	PRON	O
were	O	AUX	O
no	O	DET	O
serious	O	ADJ	O
side	O	NOUN	B
effects	O	NOUN	I
in	O	ADP	O
any	O	DET	O
of	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
groups	O	NOUN	I
.	O	PUNCT	O


Drowsiness	B-Disease	PROPN	B
and	O	CCONJ	O
altered	B-Disease	ADJ	O
taste	I-Disease	NOUN	B
perception	I-Disease	NOUN	B
were	O	AUX	O
increased	O	VERB	B
significantly	O	ADV	O
over	O	ADP	O
placebo	O	NOUN	B
only	O	ADV	O
in	O	ADP	O
the	O	DET	O
high	O	ADJ	B
-	O	PUNCT	O
dose	O	NOUN	B
azelastine	B-Chemical	NOUN	B
group	O	NOUN	I
.	O	PUNCT	O


Azelastine	B-Chemical	NOUN	B
appears	O	VERB	O
to	O	PART	O
be	O	AUX	O
a	O	DET	O
safe	O	ADJ	O
,	O	PUNCT	O
efficacious	O	ADJ	B
medication	O	NOUN	B
for	O	ADP	O
seasonal	B-Disease	ADJ	B
allergic	I-Disease	ADJ	I
rhinitis	I-Disease	NOUN	I


Obsolete	O	ADJ	B
but	O	CCONJ	O
dangerous	O	ADJ	O
antacid	O	NOUN	B
preparations	O	NOUN	I
.	O	PUNCT	O


One	O	NUM	O
case	O	NOUN	B
of	O	ADP	O
acute	O	ADJ	B
hypercalcaemia	B-Disease	NOUN	I
and	O	CCONJ	O
two	O	NUM	O
of	O	ADP	O
recurrent	O	ADJ	B
nephrolithiasis	B-Disease	NOUN	B
are	O	AUX	O
reported	O	VERB	O
in	O	ADP	O
patients	O	NOUN	B
who	O	PRON	O
had	O	AUX	O
regularly	O	ADV	O
consumed	O	VERB	O
large	O	ADJ	O
amounts	O	NOUN	O
of	O	ADP	O
calcium	B-Chemical	NOUN	B
carbon-ate	I-Chemical	NOUN	I
-	O	PUNCT	O
sodium	B-Chemical	NOUN	B
bicarbonate	I-Chemical	NOUN	I


Prolonged	O	ADJ	B
paralysis	B-Disease	NOUN	B
due	O	ADP	O
to	O	PART	O
nondepolarizing	B-Chemical	VERB	B
neuromuscular	I-Chemical	ADJ	I
blocking	I-Chemical	NOUN	O
agents	I-Chemical	NOUN	O
and	O	CCONJ	O
corticosteroids	B-Chemical	NOUN	B
.	O	PUNCT	O


The	O	DET	O
long	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
use	O	NOUN	B
of	O	ADP	I
nondepolarizing	B-Chemical	ADJ	B
neuromuscular	I-Chemical	ADJ	I
blocking	I-Chemical	NOUN	I
agents	I-Chemical	NOUN	I
(	O	PUNCT	O
ND-NMBA	B-Chemical	X	B
)	O	PUNCT	O
has	O	AUX	O
recently	O	ADV	O
been	O	AUX	O
implicated	O	VERB	O
as	O	ADP	O
a	O	DET	O
cause	O	NOUN	O
of	O	ADP	O
prolonged	O	ADJ	B
muscle	B-Disease	NOUN	B
weakness	I-Disease	NOUN	I
,	O	PUNCT	O
although	O	SCONJ	O
the	O	DET	O
site	O	NOUN	B
of	O	ADP	O
the	O	DET	O
lesion	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
predisposing	O	VERB	B
factors	O	NOUN	I
have	O	AUX	O
been	O	AUX	O
unclear	O	ADJ	B
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
3	O	NUM	O
patients	O	NOUN	B
(	O	PUNCT	O
age	O	NOUN	B
37	O	NUM	O
-	O	SYM	O
52	O	NUM	O
years	O	NOUN	B
)	O	PUNCT	O
with	O	ADP	O
acute	O	ADJ	B
respiratory	B-Disease	ADJ	I
insufficiency	I-Disease	NOUN	I
who	O	PRON	O
developed	O	VERB	O
prolonged	O	ADJ	B
weakness	B-Disease	NOUN	I
following	O	VERB	O
the	O	DET	O
discontinuation	O	NOUN	B
of	O	ADP	O
ND-NMBAs	B-Chemical	NOUN	B
.	O	PUNCT	O


Two	O	NUM	O
patients	O	NOUN	B
also	O	ADV	O
received	O	VERB	O
intravenous	O	ADJ	B
corticosteroids	B-Chemical	NOUN	I
.	O	PUNCT	O


Renal	O	ADJ	B
function	O	NOUN	I
was	O	AUX	O
normal	O	ADJ	B
but	O	CCONJ	O
hepatic	O	ADJ	B
function	O	NOUN	I
was	O	AUX	O
impaired	O	ADJ	B
in	O	ADP	O
all	O	DET	O
patients	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
all	O	DET	O
had	O	AUX	O
acidosis	B-Disease	NOUN	B
.	O	PUNCT	O


Electrophysiologic	O	ADJ	B
studies	O	NOUN	I
revealed	O	VERB	O
low	O	ADJ	B
amplitude	O	NOUN	O
compound	O	NOUN	O
motor	O	NOUN	O
action	O	NOUN	O
potentials	O	NOUN	O
,	O	PUNCT	O
normal	O	ADJ	B
sensory	O	ADJ	I
studies	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
fibrillations	O	NOUN	B
.	O	PUNCT	O


Repetitive	O	ADJ	B
stimulation	O	NOUN	I
at	O	ADP	O
2	O	NUM	O
Hz	O	NOUN	O
showed	O	VERB	O
a	O	DET	O
decremental	O	ADJ	B
response	O	NOUN	I
in	O	ADP	O
2	O	NUM	O
patients	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
serum	O	NOUN	B
vecuronium	B-Chemical	NOUN	I
level	O	NOUN	I
measured	O	VERB	B
in	O	ADP	O
1	O	NUM	O
patient	O	NOUN	B
14	O	NUM	O
days	O	NOUN	B
after	O	ADP	O
the	O	DET	O
drug	O	NOUN	B
had	O	AUX	O
been	O	AUX	O
discontinued	O	VERB	B
was	O	AUX	O
172	O	NUM	O
ng	O	NOUN	O
/	O	SYM	O
mL	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
muscle	O	NOUN	B
biopsy	O	NOUN	I
in	O	ADP	O
this	O	DET	O
patient	O	NOUN	B
showed	O	VERB	O
loss	B-Disease	NOUN	B
of	I-Disease	ADP	O
thick,	I-Disease	ADJ	B
myosin	I-Disease	NOUN	I
filaments	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
weakness	B-Disease	NOUN	B
in	O	ADP	O
these	O	DET	O
patients	O	NOUN	B
is	O	AUX	O
due	O	ADJ	O
to	O	PART	O
pathology	B-Disease	NOUN	B
at	I-Disease	ADP	O
both	I-Disease	CCONJ	O
the	I-Disease	DET	O
neuromuscular	I-Disease	ADJ	B
junction	I-Disease	NOUN	I
(	O	PUNCT	O
most	O	ADV	O
likely	O	ADV	O
due	O	ADJ	O
to	O	PART	O
ND-NMBA	B-Chemical	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
muscle	O	NOUN	B
(	O	PUNCT	O
most	O	ADV	O
likely	O	ADV	O
due	O	ADJ	O
to	O	PART	O
corticosteroids	B-Chemical	NOUN	B
).	O	PUNCT	O
Hepatic	B-Disease	ADJ	B
dysfunction	I-Disease	NOUN	I
and	O	CCONJ	O
acidosis	B-Disease	NOUN	B


Prostaglandin	B-Chemical	NOUN	B
E2	I-Chemical	NOUN	I
-	O	PUNCT	O
induced	O	VERB	B
bladder	B-Disease	NOUN	B
hyperactivity	I-Disease	NOUN	I
in	O	ADP	O
normal	O	ADJ	B
,	O	PUNCT	O
conscious	O	ADJ	B
rats	O	NOUN	B
:	O	PUNCT	O
involvement	O	NOUN	B
of	O	ADP	O
tachykinins	B-Chemical	NOUN	B
?	O	PUNCT	O
In	O	ADP	O
normal	O	ADJ	O
conscious	O	ADJ	B
rats	O	NOUN	B
investigated	O	VERB	B
by	O	ADP	O
continuous	O	ADJ	B
cystometry	O	NOUN	B
,	O	PUNCT	O
intravesically	O	ADV	B
instilled	O	VERB	B
prostaglandin	B-Chemical	NOUN	B
(PG)	I-Chemical	NOUN	O
E2	I-Chemical	NOUN	B
facilitated	O	VERB	O
micturition	O	NOUN	B
and	O	CCONJ	O
increased	O	VERB	B
basal	O	ADJ	B
intravesical	O	ADJ	I
pressure	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
effect	O	NOUN	B
was	O	AUX	O
attenuated	O	VERB	B
by	O	ADP	O
both	O	CCONJ	O
the	O	DET	O
NK1	O	NOUN	B
receptor	O	NOUN	I
selective	O	ADJ	O
antagonist	O	NOUN	B
RP	B-Chemical	NOUN	B
67,580	I-Chemical	NUM	O
and	O	CCONJ	O
the	O	DET	O
NK2	O	NOUN	B
receptor	O	NOUN	I
selective	O	ADJ	O
antagonist	O	NOUN	B
SR	B-Chemical	ADJ	B
48,968	I-Chemical	NUM	O
,	O	PUNCT	O
given	O	VERB	O
intra	O	ADJ	B
-	O	PUNCT	O
arterially	O	ADJ	B
,	O	PUNCT	O
suggesting	O	VERB	O
that	O	SCONJ	O
it	O	PRON	O
was	O	AUX	O
mediated	O	VERB	O
by	O	ADP	O
stimulation	O	NOUN	B
of	O	ADP	O
both	O	CCONJ	O
NK1	O	NOUN	B
and	O	CCONJ	O
NK2	O	NOUN	B
receptors	O	NOUN	I
.	O	PUNCT	O


Intra	O	NOUN	B
-	O	PUNCT	O
arterially	O	ADV	B
given	O	VERB	O
PGE2	B-Chemical	NOUN	B
produced	O	VERB	O
a	O	DET	O
distinct	O	ADJ	O
increase	O	NOUN	B
in	O	ADP	O
bladder	O	ADJ	B
pressure	O	NOUN	I
before	O	ADP	O
initiating	O	VERB	O
a	O	DET	O
micturition	O	NOUN	B
reflex	O	NOUN	I
,	O	PUNCT	O
indicating	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
PG	B-Chemical	NOUN	B
had	O	AUX	O
a	O	DET	O
direct	O	ADJ	O
contractant	O	ADJ	B
effect	O	NOUN	B
on	O	ADP	O
the	O	DET	O
detrusor	O	NOUN	B
smooth	O	ADJ	I
muscle	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
intra	O	ADJ	B
-	O	PUNCT	O
arterial	O	ADJ	B
PGE2	B-Chemical	NOUN	B
could	O	AUX	O
not	O	PART	O
be	O	AUX	O
blocked	O	VERB	B
by	O	ADP	O
intra	O	ADJ	B
-	O	PUNCT	O
arterial	O	ADJ	B
RP	B-Chemical	NOUN	B
67,580	I-Chemical	NUM	O
or	O	CCONJ	O
SR	B-Chemical	ADJ	B
48,968	I-Chemical	NUM	O
,	O	PUNCT	O
which	O	DET	O
opens	O	VERB	O
the	O	DET	O
possibility	O	NOUN	O
that	O	SCONJ	O
the	O	DET	O
micturition	O	NOUN	B
reflex	O	NOUN	I
elicited	O	VERB	O
by	O	ADP	O
intra	O	ADJ	B
-	O	PUNCT	O
arterial	O	ADJ	B
PGE2	B-Chemical	NOUN	B
was	O	AUX	O
mediated	O	VERB	O
by	O	ADP	O
pathways	O	NOUN	B
other	O	ADJ	O
than	O	ADP	O
the	O	DET	O
reflex	O	NOUN	B
initiated	O	VERB	B
when	O	SCONJ	O
the	O	DET	O
PG	B-Chemical	NOUN	B
was	O	AUX	O
given	O	VERB	O
intravesically	O	ADV	B
.	O	PUNCT	O


The	O	DET	O
present	O	ADJ	O
results	O	NOUN	B
thus	O	ADV	O
suggest	O	VERB	O
that	O	SCONJ	O
intra	O	ADJ	B
-	O	PUNCT	O
arterial	O	ADJ	B
PGE2	B-Chemical	NOUN	B
,	O	PUNCT	O
given	O	VERB	O
near	O	ADP	B
the	O	DET	O
bladder	O	NOUN	B
,	O	PUNCT	O
may	O	AUX	O
initiate	O	VERB	O
micturition	O	NOUN	B
in	O	ADP	O
the	O	DET	O
normal	O	ADJ	O
rat	O	NOUN	B
chiefly	O	NOUN	O
by	O	ADP	O
directly	O	ADV	O
contracting	O	VERB	B
the	O	DET	O
smooth	O	ADJ	B
muscle	O	NOUN	I
of	O	ADP	O
the	O	DET	O
detrusor	O	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
when	O	SCONJ	O
given	O	VERB	O
intravesically	O	ADV	B
,	O	PUNCT	O
PGE2	B-Chemical	NOUN	B
may	O	AUX	O
stimulate	O	VERB	B
micturition	O	NOUN	B
by	O	ADP	O
releasing	O	VERB	B
tachykinins	B-Chemical	NOUN	B
from	O	ADP	O
nerves	O	NOUN	B
in	O	ADP	O
and	O	CCONJ	O
/	O	SYM	O
or	O	CCONJ	O
immediately	O	ADV	O
below	O	ADP	O
the	O	DET	O
urothelium	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
tachykinins	B-Chemical	NOUN	B
,	O	PUNCT	O
in	O	ADP	O
turn	O	NOUN	O
,	O	PUNCT	O
initiate	O	VERB	O
a	O	DET	O
micturition	O	NOUN	B
reflex	O	NOUN	I
by	O	ADP	O
stimulating	O	VERB	O
NK1	O	NOUN	B
and	O	CCONJ	O
NK2	O	NOUN	B
receptors	O	NOUN	I
.	O	PUNCT	O


Prostanoids	B-Chemical	NOUN	B
may	O	AUX	O
,	O	PUNCT	O
via	O	ADP	O
release	O	NOUN	B
of	O	ADP	O
tachykinins	B-Chemical	NOUN	B
,	O	PUNCT	O
contribute	O	VERB	O
to	O	PART	O
both	O	CCONJ	O
urge	O	NOUN	B
and	O	CCONJ	O
bladder	B-Disease	NOUN	B
hyperactivity	I-Disease	NOUN	I


Thiazide	B-Chemical	NOUN	B
diuretics	O	NOUN	B
,	O	PUNCT	O
hypokalemia	B-Disease	NOUN	B
and	O	CCONJ	O
cardiac	B-Disease	ADJ	B
arrhythmias	I-Disease	NOUN	I
.	O	PUNCT	O


Thiazide	B-Chemical	NOUN	B
diuretics	O	NOUN	B
are	O	AUX	O
widely	O	ADV	O
accepted	O	VERB	O
as	O	ADP	O
the	O	DET	O
cornerstone	O	NOUN	B
of	O	ADP	O
antihypertensive	O	ADJ	B
treatment	O	NOUN	I
programs	O	NOUN	I
.	O	PUNCT	O


Hypokalemia	B-Disease	NOUN	B
is	O	AUX	O
a	O	DET	O
commonly	O	ADV	O
encountered	O	VERB	O
metabolic	O	ADJ	B
consequence	O	NOUN	B
of	O	ADP	I
chronic	O	ADJ	B
thiazide	B-Chemical	NOUN	I
therapy	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
treated	O	VERB	B
38	O	NUM	O
patients	O	NOUN	B
(	O	PUNCT	O
22	O	NUM	O
low	O	ADJ	B
renin	O	NOUN	B
,	O	PUNCT	O
16	O	NUM	O
normal	O	ADJ	O
renin	O	NOUN	B
)	O	PUNCT	O
with	O	ADP	O
moderate	O	ADJ	B
diastolic	B-Disease	ADJ	I
hypertension	I-Disease	NOUN	I
with	O	ADP	O
hydrochlorothiazide	B-Chemical	NOUN	B
(	O	PUNCT	O
HCTC	B-Chemical	NOUN	B
)	O	PUNCT	O
administered	O	VERB	B
on	O	ADP	O
a	O	DET	O
twice	O	ADV	O
daily	O	ADJ	O
schedule	O	NOUN	O
.	O	PUNCT	O


Initial	O	ADJ	B
dose	O	NOUN	B
was	O	AUX	O
50	O	NUM	O
mg	O	NOUN	O
and	O	CCONJ	O
the	O	DET	O
dose	O	NOUN	B
was	O	AUX	O
increased	O	VERB	B
at	O	ADP	O
monthly	O	ADJ	B
intervals	O	NOUN	B
to	O	ADP	O
100	O	NUM	O
mg	O	NOUN	O
,	O	PUNCT	O
150	O	NUM	O
mg	O	NOUN	O
and	O	CCONJ	O
200	O	NUM	O
mg	O	NOUN	O
daily	O	ADV	B
until	O	ADP	O
blood	O	NOUN	B
pressure	O	NOUN	I
normalized	O	VERB	B
.	O	PUNCT	O


The	O	DET	O
serum	O	NOUN	B
K	B-Chemical	NOUN	I
during	O	ADP	O
the	O	DET	O
control	O	NOUN	B
period	O	NOUN	O
was	O	AUX	O
4	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
+/-	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
mEq	O	NOUN	B
/	O	SYM	O
l	O	X	O
an	O	DET	O
on	O	ADP	O
50	O	NUM	O
,	O	PUNCT	O
100	O	NUM	O
,	O	PUNCT	O
150	O	NUM	O
and	O	CCONJ	O
200	O	NUM	O
mg	O	NOUN	O
HCTZ	B-Chemical	NOUN	B
daily	O	ADV	O
3	O	NUM	O
.	O	PUNCT	O


9	O	NUM	O
+/-	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


3	O	NUM	O
,	O	PUNCT	O
3	O	NUM	O
.	O	PUNCT	O


4	O	NUM	O
+/-	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
,	O	PUNCT	O
2	O	NUM	O
.	O	PUNCT	O


9	O	NUM	O
+/-	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
2	O	NUM	O
.	O	PUNCT	O


4	O	NUM	O
+/-	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


3	O	NUM	O
mEq	O	NOUN	B
/	O	SYM	O
l	O	NOUN	O
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


Corresponding	O	ADJ	O
figures	O	NOUN	B
for	O	ADP	O
whole	O	ADJ	B
body	O	NOUN	I
K	B-Chemical	NOUN	I
were	O	AUX	O
4107	O	NUM	O
+/-	O	CCONJ	O
208	O	NUM	O
,	O	PUNCT	O
3722	O	NUM	O
+/-	O	CCONJ	O
319	O	NUM	O
,	O	PUNCT	O
3628	O	NUM	O
+/-	O	CCONJ	O
257	O	NUM	O
,	O	PUNCT	O
3551	O	NUM	O
+/-	O	CCONJ	O
336	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
3269	O	NUM	O
+/-	O	CCONJ	O
380	O	NUM	O
mEq	O	NOUN	O
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


In	O	ADP	O
13	O	NUM	O
patients	O	NOUN	B
we	O	PRON	O
observed	O	VERB	O
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	O
HCTZ	B-Chemical	NOUN	B
therapy	O	NOUN	B
(	O	PUNCT	O
100	O	NUM	O
mg	O	NOUN	O
daily	O	ADV	B
)	O	PUNCT	O
on	O	ADP	O
the	O	DET	O
occurrence	O	NOUN	B
of	O	ADP	O
PVC	O	NOUN	B
'	O	PART	O
s	O	NOUN	O
during	O	ADP	O
rest	O	NOUN	O
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
during	O	ADP	O
static	O	ADJ	B
and	O	CCONJ	O
dynamic	O	ADJ	B
exercise	O	NOUN	I
.	O	PUNCT	O


During	O	ADP	O
rest	O	NOUN	B
we	O	PRON	O
observed	O	VERB	B
0	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
+/-	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


08	O	NUM	O
PVC	O	PROPN	B
beats	O	NOUN	B
/	O	SYM	O
min	O	NOUN	B
+/-	O	CCONJ	O
SEM	O	NOUN	B
and	O	CCONJ	O
during	O	ADP	O
static	O	ADJ	B
and	O	CCONJ	O
dynamic	O	ADJ	B
exercise	O	NOUN	I
0	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
+/-	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


06	O	NUM	O
and	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


8	O	NUM	O
+/-	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


15	O	NUM	O
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


Corresponding	O	ADJ	O
figures	O	NOUN	O
during	O	ADP	O
HCTZ	B-Chemical	NOUN	B
therapy	O	NOUN	B
100	O	NUM	O
mg	O	NOUN	O
daily	O	ADV	B
were	O	AUX	O
1	O	NUM	O
.	O	PUNCT	O


4	O	NUM	O
+/-	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
,	O	PUNCT	O
3	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
+/-	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


7	O	NUM	O
and	O	CCONJ	O
5	O	NUM	O
.	O	PUNCT	O


7	O	NUM	O
4	O	NUM	O
/-	O	SYM	O
0	O	NUM	O
.	O	PUNCT	O


8	O	NUM	O
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


The	O	DET	O
occurrence	O	NOUN	B
of	O	ADP	O
PVC	O	PROPN	B
'	O	PART	O
s	O	NOUN	O
correlated	O	VERB	B
significantly	O	ADV	O
with	O	ADP	O
the	O	DET	O
fall	O	NOUN	B
in	O	ADP	O
serum	O	NOUN	B
K	B-Chemical	NOUN	I
+	O	CCONJ	O
observed	O	VERB	B
r	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


72	O	NUM	O
,	O	PUNCT	O
p	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


001	O	NUM	O
.	O	PUNCT	O


In	O	ADP	O
conclusion	O	NOUN	O
we	O	PRON	O
found	O	VERB	O
that	O	SCONJ	O
thiazide	B-Chemical	ADJ	B
diuretics	O	NOUN	B
cause	O	VERB	O
hypokalemia	B-Disease	NOUN	B
and	O	CCONJ	O
depletion	O	NOUN	B
of	O	ADP	O
body	O	NOUN	B
potassium	B-Chemical	NOUN	I
.	O	PUNCT	O


The	O	DET	O
more	O	ADV	O
profound	O	ADJ	O
hypokalemia	B-Disease	NOUN	B


Diuretics	O	NOUN	B
,	O	PUNCT	O
potassium	B-Chemical	NOUN	B
and	O	CCONJ	O
arrhythmias	B-Disease	NOUN	B
in	O	ADP	O
hypertensive	B-Disease	ADJ	B
coronary	B-Disease	ADJ	I
disease	I-Disease	NOUN	I
.	O	PUNCT	O


It	O	PRON	O
has	O	AUX	O
been	O	AUX	O
proposed	O	VERB	O
that	O	SCONJ	O
modest	O	ADJ	O
changes	O	NOUN	B
in	O	ADP	O
plasma	O	NOUN	B
potassium	B-Chemical	NOUN	O
can	O	AUX	O
alter	O	VERB	O
the	O	DET	O
tendency	O	NOUN	O
towards	O	ADP	O
cardiac	B-Disease	ADJ	B
arrhythmias	I-Disease	NOUN	I
.	O	PUNCT	O


If	O	SCONJ	O
this	O	DET	O
were	O	AUX	O
so	O	ADV	O
,	O	PUNCT	O
patients	O	NOUN	B
with	O	ADP	O
coronary	B-Disease	ADJ	B
artery	I-Disease	NOUN	I
disease	I-Disease	NOUN	I
might	O	AUX	O
be	O	AUX	O
especially	O	ADV	O
susceptible	O	ADJ	B
.	O	PUNCT	O


Thus	O	ADV	O
,	O	PUNCT	O
myocardial	O	ADJ	B
electrical	O	ADJ	B
excitability	O	NOUN	I
was	O	AUX	O
measured	O	VERB	B
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
mild	O	ADJ	B
essential	O	ADJ	I
hypertension	B-Disease	NOUN	I
and	O	CCONJ	O
known	O	ADJ	O
coronary	B-Disease	ADJ	B
artery	I-Disease	NOUN	I
disease	I-Disease	NOUN	I
after	O	ADP	O
8	O	NUM	O
weeks	O	NOUN	B
of	O	ADP	O
treatment	O	NOUN	B
with	O	ADP	O
a	O	DET	O
potassium	B-Chemical	NOUN	B
-	O	PUNCT	O
conserving	O	VERB	B
diuretic	O	ADJ	B
(	O	PUNCT	O
amiloride	B-Chemical	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
similar	O	ADJ	O
period	O	NOUN	B
on	O	ADP	O
a	O	DET	O
potassium	B-Chemical	NOUN	B
-	O	PUNCT	O
losing	O	VERB	B
diuretic	O	ADJ	B
(	O	PUNCT	O
chlorthalidone	B-Chemical	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
a	O	DET	O
randomised	O	ADJ	B
study	O	NOUN	I
.	O	PUNCT	O


Plasma	O	NOUN	B
potassium	B-Chemical	NOUN	B
concentrations	O	NOUN	B
were	O	AUX	O
on	O	ADP	O
average	O	ADJ	B
1	O	NUM	O
mmol	O	NOUN	O
/	O	SYM	O
L	O	NOUN	B
lower	O	ADJ	B
during	O	ADP	O
the	O	DET	O
chlorthalidone	B-Chemical	NOUN	B
phase	O	NOUN	B
compared	O	VERB	O
to	O	PART	O
amiloride	B-Chemical	NOUN	B
therapy	O	NOUN	I
.	O	PUNCT	O


Blood	O	NOUN	B
pressure	O	NOUN	I
and	O	CCONJ	O
volume	O	NOUN	B
states	O	NOUN	I
as	O	ADP	O
assessed	O	VERB	B
by	O	ADP	O
bodyweight	O	NOUN	B
,	O	PUNCT	O
plasma	O	NOUN	B
renin	O	NOUN	B
and	O	CCONJ	O
noradrenaline	B-Chemical	NOUN	B
(	O	PUNCT	O
norepinephrine	B-Chemical	NOUN	B
)	O	PUNCT	O
concentrations	O	NOUN	B
were	O	AUX	O
similar	O	ADJ	O
on	O	ADP	O
the	O	DET	O
2	O	NUM	O
regimens	O	NOUN	B
.	O	PUNCT	O


Compared	O	VERB	O
to	O	PART	O
amiloride	B-Chemical	NOUN	B
treatment	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
chlorthalidone	B-Chemical	NOUN	B
phase	O	NOUN	B
was	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
an	O	DET	O
increased	O	VERB	B
frequency	O	NOUN	B
of	O	ADP	O
ventricular	B-Disease	ADJ	B
ectopic	I-Disease	ADJ	I
beats	I-Disease	NOUN	I
(	O	PUNCT	O
24	O	NUM	O
-	O	PUNCT	O
hour	O	NOUN	B
Holter	O	PROPN	B
monitoring	O	NOUN	I
)	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
higher	O	ADJ	O
Lown	O	PROPN	B
grading	O	NOUN	I
,	O	PUNCT	O
increased	O	VERB	B
upslope	O	NOUN	B
and	O	CCONJ	O
duration	O	NOUN	B
of	O	ADP	O
the	O	DET	O
monophasic	O	ADJ	B
action	O	NOUN	O
potential	O	NOUN	O
,	O	PUNCT	O
prolonged	O	ADJ	B
ventricular	O	ADJ	B
effective	O	ADJ	O
refractory	O	ADJ	B
period	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
increased	O	VERB	B
electrical	O	ADJ	B
instability	O	NOUN	I
during	O	ADP	O
programmed	O	VERB	B
ventricular	O	ADJ	I
stimulation	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
above	O	ADJ	O
results	O	NOUN	B
indicate	O	VERB	O
that	O	SCONJ	O
because	O	SCONJ	O
potassium	B-Chemical	NOUN	B
-	O	PUNCT	O
losing	O	VERB	B
diuretic	O	ADJ	B
therapy	O	NOUN	I
can	O	AUX	O
increase	O	VERB	B
myocardial	O	ADJ	B
electrical	O	ADJ	O
excitability	O	NOUN	O
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
ischaemic	B-Disease	ADJ	B
heart	I-Disease	NOUN	I
disease	I-Disease	NOUN	I
,	O	PUNCT	O
even	O	ADV	O
minor	O	ADJ	O
falls	O	VERB	B
in	O	ADP	O
plasma	O	NOUN	B
potassium	B-Chemical	NOUN	O


GABA	B-Chemical	NOUN	B
involvement	O	NOUN	B
in	O	ADP	O
naloxone	B-Chemical	NOUN	B
induced	O	VERB	B
reversal	O	NOUN	B
of	O	ADP	O
respiratory	B-Disease	ADJ	B
paralysis	I-Disease	NOUN	I
produced	O	VERB	O
by	O	ADP	O
thiopental	B-Chemical	NOUN	B
.	O	PUNCT	O


No	O	DET	B
agent	O	NOUN	I
is	O	AUX	O
yet	O	ADV	O
available	O	ADJ	O
to	O	PART	O
reverse	O	VERB	B
respiratory	B-Disease	ADJ	I
paralysis	I-Disease	NOUN	I
produced	O	VERB	O
by	O	ADP	O
CNS	O	NOUN	B
depressants	O	NOUN	B
,	O	PUNCT	O
such	O	ADJ	O
as	O	ADP	O
general	O	ADJ	B
anesthetics	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
this	O	DET	O
study	O	NOUN	B
naloxone	B-Chemical	NOUN	B
reversed	O	VERB	O
respiratory	B-Disease	ADJ	B
paralysis	I-Disease	NOUN	I
induced	O	VERB	B
by	O	ADP	O
thiopental	B-Chemical	NOUN	B
in	O	ADP	O
rats	O	NOUN	B
.	O	PUNCT	O


25	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
,	O	PUNCT	O
i	O	X	O
.	O	PUNCT	O


v	O	NOUN	O
.	O	PUNCT	O


thiopental	B-Chemical	NOUN	B
produced	O	VERB	O
anesthesia	O	NOUN	B
without	O	ADP	O
altering	O	VERB	B
respiratory	O	ADJ	B
rate	O	NOUN	I
,	O	PUNCT	O
increased	O	VERB	B
GABA	B-Chemical	NOUN	B
,	O	PUNCT	O
decreased	O	VERB	B
glutamate	B-Chemical	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
had	O	AUX	O
no	O	DET	B
effect	O	NOUN	I
on	O	ADP	O
aspartate	B-Chemical	NOUN	B
or	O	CCONJ	O
glycine	B-Chemical	NOUN	B
levels	O	NOUN	B
compared	O	VERB	B
to	O	PART	O
controls	O	NOUN	B
in	O	ADP	O
rat	O	NOUN	B
cortex	O	NOUN	B
and	O	CCONJ	O
brain	O	NOUN	B
stem	O	NOUN	I
.	O	PUNCT	O


Pretreatment	O	NOUN	B
of	O	ADP	O
rats	O	NOUN	B
with	O	ADP	O
thiosemicarbazide	B-Chemical	NOUN	B
for	O	ADP	O
30	O	NUM	O
minutes	O	NOUN	O
abolished	O	VERB	O
the	O	DET	O
anesthetic	O	ADJ	B
action	O	NOUN	I
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
the	O	DET	O
respiratory	O	ADJ	B
depressant	O	ADJ	O
action	O	NOUN	O
of	O	ADP	O
thiopental	B-Chemical	NOUN	B
.	O	PUNCT	O


50	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
,	O	PUNCT	O
i	O	X	O
.	O	PUNCT	O


v	O	NOUN	O
.	O	PUNCT	O


thiopental	B-Chemical	NOUN	B
produced	O	VERB	O
respiratory	B-Disease	ADJ	B
arrest	I-Disease	NOUN	I
with	O	ADP	O
further	O	ADJ	O
increase	O	NOUN	B
in	O	ADP	O
GABA	B-Chemical	NOUN	B
and	O	CCONJ	O
decrease	O	NOUN	B
in	O	ADP	O
glutamate	B-Chemical	NOUN	B
again	O	ADV	O
in	O	ADP	O
cortex	O	NOUN	B
and	O	CCONJ	O
brain	O	NOUN	B
stem	O	NOUN	I
without	O	ADP	O
affecting	O	VERB	B
any	O	DET	O
of	O	ADP	O
the	O	DET	O
amino	B-Chemical	NOUN	B
acids	I-Chemical	NOUN	I
studied	O	VERB	O
in	O	ADP	O
four	O	NUM	O
regions	O	NOUN	B
of	O	ADP	O
rat	O	NOUN	B
brain	O	NOUN	B
.	O	PUNCT	O


Naloxone	B-Chemical	NOUN	B
(	O	PUNCT	O
2	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
,	O	PUNCT	O
i	O	X	O
.	O	PUNCT	O


v	O	ADP	O
.)	O	NOUN	O
reversed	O	VERB	B
respiratory	B-Disease	ADJ	B
paralysis	I-Disease	NOUN	I
,	O	PUNCT	O
glutamate	B-Chemical	NOUN	B
and	O	CCONJ	O
GABA	B-Chemical	NOUN	B
levels	O	NOUN	B
to	O	PART	O
control	O	NOUN	B
values	O	NOUN	I
in	O	ADP	O
brain	O	NOUN	B
stem	O	NOUN	I
and	O	CCONJ	O
cortex	O	NOUN	B
with	O	ADP	O
no	O	DET	O
changes	O	NOUN	O
in	O	ADP	O
caudate	O	NOUN	B
or	O	CCONJ	O
cerebellum	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
data	O	NOUN	B
suggest	O	VERB	O
naloxone	B-Chemical	NOUN	B
reverses	O	VERB	B
respiratory	B-Disease	ADJ	B
paralysis	I-Disease	NOUN	I
produced	O	VERB	O
by	O	ADP	O
thiopental	B-Chemical	NOUN	B
and	O	CCONJ	O
involves	O	VERB	O
GABA	B-Chemical	NOUN	B


National	O	ADJ	B
project	O	NOUN	I
on	O	ADP	O
the	O	DET	O
prevention	O	NOUN	B
of	O	ADP	O
mother	O	NOUN	B
-	O	PUNCT	O
to	O	ADP	O
-	O	PUNCT	O
infant	O	NOUN	B
infection	B-Disease	NOUN	B
by	I-Disease	ADP	O
hepatitis	I-Disease	NOUN	B
B	I-Disease	NOUN	I
virus	I-Disease	NOUN	I
in	O	ADP	O
Japan	O	PROPN	B
.	O	PUNCT	O


In	O	ADP	O
Japan	O	PROPN	B
,	O	PUNCT	O
a	O	DET	O
nationwide	O	ADJ	B
prevention	O	NOUN	B
program	O	NOUN	I
against	O	ADP	O
mother	O	NOUN	B
-	O	PUNCT	O
to	O	ADP	O
-	O	PUNCT	O
infant	O	NOUN	B
infection	B-Disease	NOUN	B
by	I-Disease	ADP	O
hepatitis	I-Disease	NOUN	B
B	I-Disease	NOUN	I
virus	I-Disease	NOUN	I
(	O	PUNCT	O
HBV	O	NOUN	B
)	O	PUNCT	O
started	O	VERB	O
in	O	ADP	O
1985	O	NUM	O
.	O	PUNCT	O


This	O	DET	O
program	O	NOUN	B
consists	O	VERB	O
of	O	ADP	O
double	O	ADJ	O
screenings	O	NOUN	B
of	O	ADP	O
pregnant	O	ADJ	B
women	O	NOUN	I
and	O	CCONJ	O
prophylactic	O	ADJ	B
treatment	O	NOUN	I
to	O	PART	O
the	O	DET	O
infants	O	NOUN	B
born	O	VERB	B
to	O	PART	O
both	O	CCONJ	O
hepatitis	B-Chemical	NOUN	B
B	I-Chemical	NOUN	I
surface	I-Chemical	NOUN	I
antigen	I-Chemical	NOUN	I
(	O	PUNCT	O
HBsAg	B-Chemical	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
hepatitis	B-Chemical	NOUN	B
B	I-Chemical	NOUN	I
e	I-Chemical	NOUN	I
antigen	I-Chemical	NOUN	I
(	O	PUNCT	O
HBeAg	B-Chemical	NOUN	B
)	O	PUNCT	O
positive	O	ADJ	B
mothers	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
infants	O	NOUN	B
are	O	AUX	O
treated	O	VERB	B
with	O	ADP	I
two	O	NUM	O
injections	O	NOUN	B
of	O	ADP	O
hepatitis	B-Disease	NOUN	B
B	I-Disease	NOUN	I
immune	O	ADJ	I
globulin	O	NOUN	I
(	O	PUNCT	O
HBIG	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
at	O	ADP	O
least	O	ADJ	O
three	O	NUM	O
injections	O	NOUN	B
of	O	ADP	O
plasma	O	NOUN	B
derived	O	ADJ	O
hepatitis	B-Chemical	NOUN	B
B	I-Chemical	NOUN	I
vaccine	I-Chemical	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
sent	O	VERB	O
questionnaires	O	NOUN	B
about	O	ADP	O
the	O	DET	O
numbers	O	NOUN	O
of	O	ADP	O
each	O	DET	O
procedure	O	NOUN	B
or	O	CCONJ	O
examination	O	NOUN	B
during	O	ADP	O
nine	O	NUM	O
months	O	NOUN	B
of	O	ADP	O
investigation	O	NOUN	B
period	O	NOUN	B
to	O	ADP	O
each	O	DET	O
local	O	ADJ	B
government	O	NOUN	B
in	O	ADP	O
1986	O	NUM	O
and	O	CCONJ	O
1987	O	NUM	O
.	O	PUNCT	O


93	O	NUM	O
.	O	PUNCT	O


4	O	NUM	O
%	O	NOUN	O
pregnant	O	ADJ	B
women	O	NOUN	I
had	O	AUX	O
the	O	DET	O
chance	O	NOUN	B
to	O	PART	O
be	O	AUX	O
examined	O	VERB	B
for	O	ADP	O
HBsAg	B-Chemical	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
positive	O	ADJ	B
rate	O	NOUN	B
was	O	AUX	O
1	O	NUM	O
.	O	PUNCT	O


4	O	NUM	O
to	O	PART	O
1	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
%.	O	NOUN	O
The	O	DET	O
HBeAg	B-Chemical	NOUN	B
positive	O	ADJ	I
rate	O	NOUN	I
in	O	ADP	O
HBsAg	B-Chemical	NOUN	B
positive	O	ADJ	B
was	O	AUX	O
23	O	NUM	O
to	O	PART	O
26	O	NUM	O
%.	O	NOUN	B
The	O	DET	O
HBsAg	B-Chemical	NOUN	B


Nociceptive	O	ADJ	B
effects	O	NOUN	I
induced	O	VERB	B
by	O	ADP	O
intrathecal	O	ADJ	B
administration	O	NOUN	I
of	O	ADP	O
prostaglandin	B-Chemical	NOUN	B
D2,	I-Chemical	NOUN	I
E2,	I-Chemical	NOUN	O
or	I-Chemical	CCONJ	O
F2	I-Chemical	NOUN	O
alpha	I-Chemical	NOUN	O
to	O	PART	O
conscious	O	ADJ	B
mice	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
intrathecal	O	ADJ	B
administration	O	NOUN	I
of	O	ADP	O
prostaglandins	B-Chemical	NOUN	B
on	O	ADP	O
pain	B-Disease	NOUN	B
responses	O	NOUN	I
in	O	ADP	O
conscious	O	ADJ	B
mice	O	NOUN	I
were	O	AUX	O
evaluated	O	VERB	B
by	O	ADP	O
using	O	VERB	O
hot	O	ADJ	B
plate	O	NOUN	I
and	O	CCONJ	O
acetic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
writhing	O	NOUN	I
tests	O	NOUN	I
.	O	PUNCT	O


Prostaglandin	B-Chemical	NOUN	B
D2	I-Chemical	NOUN	I
(	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
-	O	PUNCT	O
3	O	NUM	O
ng	O	NOUN	O
/	O	SYM	O
mouse	O	NOUN	B
)	O	PUNCT	O
had	O	AUX	O
a	O	DET	O
hyperalgesic	B-Disease	ADJ	B
action	O	NOUN	I
on	O	ADP	O
the	O	DET	O
response	O	NOUN	B
to	O	ADP	O
a	O	DET	O
hot	O	ADJ	B
plate	O	NOUN	I
during	O	ADP	O
a	O	DET	O
3	O	NUM	O
-	O	PUNCT	O
60	O	NUM	O
min	O	NOUN	O
period	O	NOUN	B
after	O	ADP	O
injection	O	NOUN	B
.	O	PUNCT	O


Prostaglandin	B-Chemical	NOUN	B
E2	I-Chemical	NOUN	I
showed	O	VERB	O
a	O	DET	O
hyperalgesic	B-Disease	ADJ	B
effect	O	NOUN	I
at	O	ADP	O
doses	O	NOUN	B
of	O	ADP	O
1	O	NUM	O
pg	B-Chemical	NOUN	O
to	O	PART	O
10	O	NUM	O
ng	O	NOUN	O
/	O	SYM	O
mouse	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
the	O	DET	O
effect	O	NOUN	B
lasted	O	VERB	O
shorter	O	ADJ	B
(	O	PUNCT	O
3	O	NUM	O
-	O	PUNCT	O
30	O	NUM	O
min	O	NOUN	O
)	O	PUNCT	O
than	O	ADP	O
that	O	DET	O
of	O	ADP	O
prostaglandin	B-Chemical	NOUN	B
D2	I-Chemical	NOUN	I
.	O	PUNCT	O


Similar	O	ADJ	O
results	O	NOUN	B
were	O	AUX	O
obtained	O	VERB	O
by	O	ADP	O
acetic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
writhing	O	NOUN	I
tests	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
hyperalgesic	B-Disease	ADJ	B
effect	O	NOUN	B
of	O	ADP	O
prostaglandin	B-Chemical	NOUN	B
D2	I-Chemical	NOUN	I
was	O	AUX	O
blocked	O	VERB	B
by	O	ADP	O
simultaneous	O	ADJ	B
injection	O	NOUN	B
of	O	ADP	O
a	O	DET	O
substance	O	NOUN	B
P	O	NOUN	I
antagonist	O	NOUN	I
(	O	PUNCT	O
greater	O	ADJ	O
than	O	ADP	O
or	O	CCONJ	O
equal	O	ADJ	O
to	O	PART	O
100	O	NUM	O
ng	O	NOUN	O
)	O	PUNCT	O
but	O	CCONJ	O
not	O	PART	O
by	O	ADP	O
AH6809	B-Chemical	NOUN	B
,	O	PUNCT	O
a	O	DET	O
prostanoid	O	ADJ	B
EP1	O	NOUN	B
-	O	PUNCT	O
receptor	O	NOUN	B
antagonist	O	NOUN	B
.	O	PUNCT	O


Conversely	O	ADV	O
,	O	PUNCT	O
prostaglandin	B-Chemical	NOUN	B
E2	I-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
hyperalgesia	B-Disease	NOUN	B
was	O	AUX	O
blocked	O	VERB	B
by	O	ADP	O
AH6809	B-Chemical	NOUN	B
(	O	PUNCT	O
greater	O	ADJ	O
than	O	ADP	O
or	O	CCONJ	O
equal	O	ADJ	O
to	O	PART	O
500	O	NUM	O
ng	O	NOUN	O
)	O	PUNCT	O
but	O	CCONJ	O
not	O	PART	O
by	O	ADP	O
the	O	DET	O
substance	O	NOUN	B
P	O	NOUN	I
antagonist	O	NOUN	I
.	O	PUNCT	O


Prostaglandin	B-Chemical	NOUN	B
F2	I-Chemical	PROPN	I
alpha	I-Chemical	NOUN	I
had	O	AUX	O
little	O	ADJ	O
effect	O	NOUN	B
on	O	ADP	O
pain	B-Disease	NOUN	B
responses	O	NOUN	I
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	B
demonstrate	O	VERB	O
that	O	SCONJ	O
both	O	CCONJ	O
prostaglandin	B-Chemical	NOUN	B
D2	I-Chemical	NOUN	I
and	O	CCONJ	O
prostaglandin	B-Chemical	NOUN	B
E2	I-Chemical	NOUN	I
exert	O	VERB	O
hyperalgesia	B-Disease	NOUN	B


Swallowing	O	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
atrial	B-Disease	ADJ	B
tachyarrhythmia	I-Disease	NOUN	I
triggered	O	VERB	B
by	O	ADP	I
salbutamol	B-Chemical	NOUN	B
:	O	PUNCT	O
case	O	NOUN	B
report	O	NOUN	I
and	O	CCONJ	O
review	O	NOUN	B
of	O	ADP	O
the	O	DET	O
literature	O	NOUN	B
.	O	PUNCT	O


CASE	O	NOUN	B
:	O	PUNCT	O
A	O	DET	O
49	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
patient	O	NOUN	B
experienced	O	VERB	O
chest	O	ADJ	B
discomfort	O	NOUN	I
while	O	SCONJ	O
swallowing	O	VERB	B
.	O	PUNCT	O


On	O	ADP	O
electrocardiogram	O	NOUN	B
,	O	PUNCT	O
episodes	O	NOUN	B
of	O	ADP	O
atrial	B-Disease	ADJ	B
tachyarrhythmia	I-Disease	NOUN	I
were	O	AUX	O
recorded	O	VERB	O
immediately	O	ADV	O
after	O	ADP	O
swallowing	O	VERB	B
;	O	PUNCT	O
24	O	NUM	O
-	O	PUNCT	O
hour	O	NOUN	B
Holter	O	PROPN	B
monitoring	O	NOUN	I
recorded	O	VERB	O
several	O	ADJ	O
events	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
arrhythmia	B-Disease	NOUN	B
resolved	O	VERB	B
after	O	ADP	O
therapy	O	NOUN	B
with	O	ADP	O
atenolol	B-Chemical	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
recurred	O	VERB	O
a	O	DET	O
year	O	NOUN	B
later	O	ADV	O
.	O	PUNCT	O


The	O	DET	O
patient	O	NOUN	B
noticed	O	VERB	O
that	O	SCONJ	O
before	O	ADP	O
these	O	DET	O
episodes	O	NOUN	B
he	O	PRON	O
had	O	AUX	O
been	O	AUX	O
using	O	VERB	O
an	O	DET	O
inhalator	O	NOUN	B
of	O	ADP	O
salbutamol	B-Chemical	NOUN	B
.	O	PUNCT	O


After	O	ADP	O
stopping	O	VERB	B
the	O	DET	O
beta	O	NOUN	B
-	O	PUNCT	O
agonist	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
after	O	ADP	O
a	O	DET	O
week	O	NOUN	B
with	O	ADP	O
the	O	DET	O
atenolol	B-Chemical	NOUN	B
,	O	PUNCT	O
the	O	DET	O
arrhythmia	B-Disease	NOUN	B
disappeared	O	VERB	O
.	O	PUNCT	O


DISCUSSION	O	NOUN	O
:	O	PUNCT	O
Swallowing	O	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
atrial	B-Disease	ADJ	B
tachyarrhythmia	I-Disease	NOUN	I
(	O	PUNCT	O
SIAT	B-Disease	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
a	O	DET	O
rare	O	ADJ	B
phenomenon	O	NOUN	B
.	O	PUNCT	O


Fewer	O	ADJ	O
than	O	ADP	O
50	O	NUM	O
cases	O	NOUN	B
of	O	ADP	O
SIAT	B-Disease	PROPN	B
have	O	AUX	O
been	O	AUX	O
described	O	VERB	O
in	O	ADP	O
the	O	DET	O
literature	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
article	O	NOUN	B
summarizes	O	VERB	O
all	O	DET	O
the	O	DET	O
cases	O	NOUN	B
published	O	VERB	B
,	O	PUNCT	O
creating	O	VERB	O
a	O	DET	O
comprehensive	O	ADJ	B
review	O	NOUN	B
of	O	ADP	O
the	O	DET	O
current	O	ADJ	O
knowledge	O	NOUN	B
and	O	CCONJ	O
approach	O	NOUN	O
to	O	ADP	O
SIAT	B-Disease	NOUN	B
.	O	PUNCT	O


It	O	PRON	O
discusses	O	VERB	O
demographics	O	NOUN	B
,	O	PUNCT	O
clinical	O	ADJ	B
characteristics	O	NOUN	I
and	O	CCONJ	O
types	O	NOUN	O
of	O	ADP	O
arrhythmia	B-Disease	NOUN	B
,	O	PUNCT	O
postulated	O	ADJ	O
mechanisms	O	NOUN	B
of	O	ADP	O
SIAT	B-Disease	PROPN	B
,	O	PUNCT	O
and	O	CCONJ	O
different	O	ADJ	O
treatment	O	NOUN	B
possibilities	O	NOUN	O
such	O	ADJ	O
as	O	ADP	O
medications	O	NOUN	B
,	O	PUNCT	O
surgery	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
radiofrequency	O	NOUN	B
catheter	O	NOUN	I
ablation	O	NOUN	I
(	O	PUNCT	O
RFCA	O	NOUN	B
).	O	PUNCT	O
CONCLUSION	O	NOUN	O
:	O	PUNCT	O
Salbutamol	B-Chemical	NOUN	B
is	O	AUX	O
presented	O	VERB	O
here	O	ADV	O
as	O	ADP	O
a	O	DET	O
possible	O	ADJ	O
trigger	O	NOUN	O
for	O	ADP	O
SIAT	B-Disease	PROPN	B
.	O	PUNCT	O


Although	O	SCONJ	O
it	O	PRON	O
is	O	AUX	O
difficult	O	ADJ	O
to	O	PART	O
define	O	VERB	O
causality	O	NOUN	B
in	O	ADP	O
a	O	DET	O
case	O	NOUN	B
report	O	NOUN	I
,	O	PUNCT	O
it	O	PRON	O
is	O	AUX	O
logical	O	ADJ	O
to	O	PART	O
think	O	VERB	O
that	O	SCONJ	O
a	O	DET	O
beta	O	NOUN	B
-	O	PUNCT	O
agonist	O	NOUN	B
like	O	ADP	O
salbutamol	B-Chemical	NOUN	B
(	O	PUNCT	O
known	O	VERB	O
to	O	PART	O
induce	O	VERB	B
tachycardia	B-Disease	NOUN	B
)	O	PUNCT	O
may	O	AUX	O
be	O	AUX	O
the	O	DET	O
trigger	O	NOUN	B
of	O	ADP	O
adrenergic	O	ADJ	B
reflexes	O	NOUN	I
originating	O	VERB	O
in	O	ADP	O
the	O	DET	O
esophagus	O	NOUN	B
while	O	SCONJ	O
swallowing	O	VERB	B
and	O	CCONJ	O
that	O	SCONJ	O
a	O	DET	O
beta	O	NOUN	B
-	O	PUNCT	O
blocker	O	NOUN	B
such	O	ADJ	O
as	O	ADP	O
atenolol	B-Chemical	ADJ	B


Coenzyme	B-Chemical	NOUN	B
Q10	I-Chemical	NOUN	I
treatment	O	NOUN	B
ameliorates	O	VERB	B
acute	O	ADJ	B
cisplatin	B-Chemical	NOUN	B
nephrotoxicity	B-Disease	NOUN	B
in	O	ADP	O
mice	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
nephroprotective	O	ADJ	B
effect	O	NOUN	I
of	O	ADP	O
coenzyme	B-Chemical	ADJ	B
Q10	I-Chemical	NOUN	I
was	O	AUX	O
investigated	O	VERB	B
in	O	ADP	O
mice	O	NOUN	B
with	O	ADP	O
acute	B-Disease	ADJ	B
renal	I-Disease	ADJ	I
injury	I-Disease	NOUN	I
induced	O	VERB	B
by	O	ADP	O
a	O	DET	O
single	O	ADJ	O
i	O	NOUN	O
.	O	PUNCT	O


p	O	NOUN	O
.	O	PUNCT	O


injection	O	NOUN	B
of	O	ADP	O
cisplatin	B-Chemical	NOUN	B
(	O	PUNCT	O
5	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
).	O	PUNCT	O
Coenzyme	B-Chemical	NOUN	B
Q10	I-Chemical	NOUN	I
treatment	O	NOUN	B
(	O	PUNCT	O
10	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
/	O	PUNCT	O
day	O	NOUN	B
,	O	PUNCT	O
i	O	X	O
.	O	PUNCT	O


p	O	NOUN	O
.)	O	PUNCT	O
was	O	AUX	O
applied	O	VERB	O
for	O	ADP	O
6	O	NUM	O
consecutive	O	ADJ	B
days	O	NOUN	B
,	O	PUNCT	O
starting	O	VERB	O
1	O	NUM	O
day	O	NOUN	B
before	O	ADP	O
cisplatin	B-Chemical	NOUN	B
administration	O	NOUN	B
.	O	PUNCT	O


Coenzyme	B-Chemical	NOUN	B
Q10	I-Chemical	NOUN	I
significantly	O	ADV	O
reduced	O	VERB	O
blood	B-Chemical	NOUN	B
urea	I-Chemical	NOUN	I
nitrogen	I-Chemical	NOUN	B
and	O	CCONJ	O
serum	O	NOUN	B
creatinine	B-Chemical	NOUN	I
levels	O	NOUN	I
which	O	DET	O
were	O	AUX	O
increased	O	VERB	B
by	O	ADP	O
cisplatin	B-Chemical	NOUN	B
.	O	PUNCT	O


Coenzyme	B-Chemical	NOUN	B
Q10	I-Chemical	NOUN	I
significantly	O	ADV	O
compensated	O	VERB	O
deficits	O	NOUN	B
in	O	ADP	O
the	O	DET	O
antioxidant	O	ADJ	B
defense	O	NOUN	O
mechanisms	O	NOUN	O
(	O	PUNCT	O
reduced	B-Chemical	VERB	B
glutathione	I-Chemical	NOUN	B
level	O	NOUN	O
and	O	CCONJ	O
superoxide	B-Chemical	NOUN	B
dismutase	O	NOUN	I
activity	O	NOUN	I
),	O	PUNCT	O
suppressed	O	VERB	B
lipid	O	NOUN	B
peroxidation	O	NOUN	I
,	O	PUNCT	O
decreased	O	VERB	B
the	O	DET	O
elevations	O	NOUN	B
of	O	ADP	O
tumor	B-Disease	NOUN	B
necrosis	B-Disease	NOUN	I
factor	O	NOUN	I
-	O	PUNCT	O
alpha	O	NOUN	B
,	O	PUNCT	O
nitric	B-Chemical	ADJ	B
oxide	I-Chemical	NOUN	I
and	O	CCONJ	O
platinum	B-Chemical	NOUN	B
ion	O	NOUN	I
concentration	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
attenuated	O	VERB	B
the	O	DET	O
reductions	O	NOUN	B
of	O	ADP	O
selenium	B-Chemical	NOUN	B
and	O	CCONJ	O
zinc	B-Chemical	NOUN	B
ions	O	NOUN	O
in	O	ADP	O
renal	O	ADJ	B
tissue	O	NOUN	I
resulted	O	VERB	O
from	O	ADP	O
cisplatin	B-Chemical	NOUN	B
administration	O	NOUN	B
.	O	PUNCT	O


Also	O	ADV	O
,	O	PUNCT	O
histopathological	O	ADJ	B
renal	B-Disease	ADJ	B
tissue	I-Disease	NOUN	I
damage	I-Disease	NOUN	O
mediated	O	VERB	O
by	O	ADP	O
cisplatin	B-Chemical	NOUN	B
was	O	AUX	O
ameliorated	O	VERB	B
by	O	ADP	O
coenzyme	B-Chemical	ADJ	B
Q10	I-Chemical	NOUN	I
treatment	O	NOUN	B
.	O	PUNCT	O


Immunohistochemical	O	ADJ	B
analysis	O	NOUN	I
revealed	O	VERB	O
that	O	SCONJ	O
coenzyme	B-Chemical	ADJ	B
Q10	I-Chemical	NOUN	I
significantly	O	ADV	O
decreased	O	VERB	B
the	O	DET	O
cisplatin	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
overexpression	O	NOUN	B
of	O	ADP	O
inducible	O	ADJ	B
nitric	B-Chemical	ADJ	O
oxide	I-Chemical	NOUN	O
synthase	O	NOUN	O
,	O	PUNCT	O
nuclear	O	ADJ	B
factor	O	NOUN	I
-	O	PUNCT	O
kappaB	O	NOUN	B
,	O	PUNCT	O
caspase	O	NOUN	B
-	O	PUNCT	O
3	O	NUM	B
and	O	CCONJ	O
p53	O	NOUN	B
in	O	ADP	O
renal	O	ADJ	B
tissue	O	NOUN	I
.	O	PUNCT	O


It	O	PRON	O
was	O	AUX	O
concluded	O	VERB	O
that	O	SCONJ	O
coenzyme	B-Chemical	ADJ	B
Q10	I-Chemical	NOUN	I
represents	O	VERB	O
a	O	DET	O
potential	O	ADJ	B
therapeutic	O	ADJ	B
option	O	NOUN	O
to	O	PART	O
protect	O	VERB	O
against	O	ADP	O
acute	O	ADJ	B
cisplatin	B-Chemical	NOUN	B
nephrotoxicity	B-Disease	NOUN	B


Metformin	B-Chemical	NOUN	B
prevents	O	VERB	O
experimental	O	ADJ	B
gentamicin	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
nephropathy	B-Disease	NOUN	B
by	O	ADP	O
a	O	DET	O
mitochondria	O	NOUN	B
-	O	PUNCT	O
dependent	O	ADJ	B
pathway	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
antidiabetic	O	ADJ	B
drug	O	NOUN	I
metformin	B-Chemical	NOUN	B
can	O	AUX	O
diminish	O	VERB	O
apoptosis	O	NOUN	B
induced	O	VERB	B
by	O	ADP	O
oxidative	O	ADJ	B
stress	O	NOUN	I
in	O	ADP	O
endothelial	O	ADJ	B
cells	O	NOUN	I
and	O	CCONJ	O
prevent	O	VERB	B
vascular	B-Disease	ADJ	B
dysfunction	I-Disease	NOUN	I
even	O	ADV	O
in	O	ADP	O
nondiabetic	O	ADJ	B
patients	O	NOUN	B
.	O	PUNCT	O


Here	O	ADV	O
we	O	PRON	O
tested	O	VERB	B
whether	O	SCONJ	O
it	O	PRON	O
has	O	AUX	O
a	O	DET	O
beneficial	O	ADJ	O
effect	O	NOUN	B
in	O	ADP	O
a	O	DET	O
rat	O	NOUN	B
model	O	NOUN	B
of	O	ADP	O
gentamicin	B-Chemical	NOUN	B
toxicity	B-Disease	NOUN	B
.	O	PUNCT	O


Mitochondrial	O	ADJ	B
analysis	O	NOUN	I
,	O	PUNCT	O
respiration	O	NOUN	B
intensity	O	NOUN	I
,	O	PUNCT	O
levels	O	NOUN	B
of	O	ADP	O
reactive	O	ADJ	B
oxygen	B-Chemical	NOUN	I
species	O	NOUN	I
,	O	PUNCT	O
permeability	O	NOUN	B
transition	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
cytochrome	O	NOUN	B
c	O	NOUN	I
release	O	NOUN	B
were	O	AUX	O
assessed	O	VERB	B
3	O	NUM	O
and	O	CCONJ	O
6	O	NUM	O
days	O	NOUN	B
after	O	ADP	O
gentamicin	B-Chemical	NOUN	B
administration	O	NOUN	B
.	O	PUNCT	O


Metformin	B-Chemical	NOUN	B
treatment	O	NOUN	B
fully	O	ADV	O
blocked	O	VERB	B
gentamicin	B-Chemical	NOUN	B
-	O	PUNCT	O
mediated	O	VERB	B
acute	B-Disease	ADJ	B
renal	I-Disease	ADJ	I
failure	I-Disease	NOUN	I
.	O	PUNCT	O


This	O	DET	O
was	O	AUX	O
accompanied	O	VERB	O
by	O	ADP	O
a	O	DET	O
lower	O	ADJ	O
activity	O	NOUN	B
of	O	ADP	O
N	O	NOUN	B
-	O	PUNCT	O
acetyl	O	ADJ	B
-	O	PUNCT	O
beta	O	NOUN	B
-	O	PUNCT	O
D	O	NOUN	B
-	O	PUNCT	O
glucosaminidase	O	NOUN	B
,	O	PUNCT	O
together	O	ADV	O
with	O	ADP	O
a	O	DET	O
decrease	O	NOUN	B
of	O	ADP	O
lipid	O	NOUN	B
peroxidation	O	NOUN	I
and	O	CCONJ	O
increase	O	NOUN	B
of	O	ADP	O
antioxidant	O	ADJ	B
systems	O	NOUN	I
.	O	PUNCT	O


Metformin	B-Chemical	NOUN	B
also	O	ADV	O
protected	O	VERB	O
the	O	DET	O
kidney	O	NOUN	B
from	O	ADP	O
histological	O	ADJ	B
damage	O	NOUN	B
6	O	NUM	O
days	O	NOUN	B
after	O	ADP	O
gentamicin	B-Chemical	NOUN	B
administration	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
in	O	X	B
vivo	O	X	I
markers	O	NOUN	B
of	O	ADP	O
kidney	B-Disease	NOUN	B
dysfunction	I-Disease	NOUN	I
and	O	CCONJ	O
their	O	PRON	O
correction	O	NOUN	B
by	O	ADP	O
metformin	B-Chemical	NOUN	B
were	O	AUX	O
complemented	O	VERB	B
by	O	ADP	O
in	O	X	B
vitro	O	X	I
studies	O	NOUN	I
of	O	ADP	O
mitochondrial	O	ADJ	B
function	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
found	O	VERB	O
that	O	SCONJ	O
gentamicin	B-Chemical	NOUN	B
treatment	O	NOUN	B
depleted	O	VERB	B
respiratory	O	ADJ	O
components	O	NOUN	O
(	O	PUNCT	O
cytochrome	O	NOUN	B
c	O	NOUN	I
,	O	PUNCT	O
NADH	O	NOUN	B
),	O	PUNCT	O
probably	O	ADV	O
due	O	ADJ	O
to	O	ADP	O
the	O	DET	O
opening	O	NOUN	B
of	O	ADP	O
mitochondrial	O	ADJ	B
transition	O	NOUN	O
pores	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
injuries	O	NOUN	B
,	O	PUNCT	O
partly	O	ADV	O
mediated	O	VERB	O
by	O	ADP	O
a	O	DET	O
rise	O	NOUN	O
in	O	ADP	O
reactive	O	ADJ	B
oxygen	B-Chemical	NOUN	I
species	O	NOUN	I
from	O	ADP	O
the	O	DET	O
electron	O	NOUN	B
transfer	O	NOUN	I
chain	O	NOUN	I
,	O	PUNCT	O
were	O	AUX	O
significantly	O	ADV	O
decreased	O	VERB	B
by	O	ADP	O
metformin	B-Chemical	NOUN	B
.	O	PUNCT	O


Thus	O	ADV	O
,	O	PUNCT	O
our	O	PRON	O
study	O	NOUN	B
suggests	O	VERB	O
that	O	SCONJ	O
pleiotropic	O	ADJ	B
effects	O	NOUN	I
of	O	ADP	O
metformin	B-Chemical	NOUN	B
can	O	AUX	O
lessen	O	VERB	O
gentamicin	B-Chemical	NOUN	B
nephrotoxicity	B-Disease	NOUN	B


Sedation	O	NOUN	B
depth	O	NOUN	O
during	O	ADP	O
spinal	O	ADJ	B
anesthesia	O	NOUN	I
and	O	CCONJ	O
the	O	DET	O
development	O	NOUN	B
of	O	ADP	O
postoperative	B-Disease	ADJ	B
delirium	I-Disease	NOUN	O
in	O	ADP	O
elderly	O	ADJ	B
patients	O	NOUN	I
undergoing	O	VERB	O
hip	B-Disease	NOUN	B
fracture	I-Disease	NOUN	I
repair	O	NOUN	I
.	O	PUNCT	O


OBJECTIVE	O	NOUN	B
:	O	PUNCT	O
To	O	PART	O
determine	O	VERB	O
whether	O	SCONJ	O
limiting	O	VERB	O
intraoperative	O	ADJ	B
sedation	O	NOUN	B
depth	O	NOUN	O
during	O	ADP	O
spinal	O	ADJ	B
anesthesia	O	NOUN	I
for	O	ADP	O
hip	B-Disease	NOUN	B
fracture	I-Disease	NOUN	I
repair	O	NOUN	I
in	O	ADP	O
elderly	O	ADJ	B
patients	O	NOUN	B
can	O	AUX	O
decrease	O	VERB	B
the	O	DET	O
prevalence	O	NOUN	B
of	O	ADP	O
postoperative	B-Disease	ADJ	B
delirium	I-Disease	NOUN	I
.	O	PUNCT	O


PATIENTS	O	NOUN	B
AND	O	CCONJ	O
METHODS	O	NOUN	O
:	O	PUNCT	O
We	O	PRON	O
performed	O	VERB	O
a	O	DET	O
double	O	ADJ	B
-	O	PUNCT	O
blind	O	NOUN	B
,	O	PUNCT	O
randomized	O	ADJ	B
controlled	O	VERB	I
trial	O	NOUN	I
at	O	ADP	O
an	O	DET	O
academic	O	ADJ	B
medical	O	ADJ	I
center	O	NOUN	I
of	O	ADP	O
elderly	O	ADJ	B
patients	O	NOUN	B
(>	O	NOUN	B
or	O	CCONJ	O
=	O	ADJ	O
65	O	NUM	O
years	O	NOUN	B
)	O	PUNCT	O
without	O	ADP	O
preoperative	O	ADJ	B
delirium	B-Disease	NOUN	B
or	O	CCONJ	O
severe	O	ADJ	B
dementia	B-Disease	NOUN	B
who	O	PRON	O
underwent	O	VERB	O
hip	B-Disease	NOUN	B
fracture	I-Disease	NOUN	I
repair	O	NOUN	I
under	O	ADP	O
spinal	O	ADJ	B
anesthesia	O	NOUN	I
with	O	ADP	O
propofol	B-Chemical	NOUN	B
sedation	O	NOUN	B
.	O	PUNCT	O


Sedation	O	ADJ	B
depth	O	NOUN	O
was	O	AUX	O
titrated	O	VERB	B
using	O	VERB	O
processed	O	VERB	O
electroencephalography	O	NOUN	B
with	O	ADP	O
the	O	DET	O
bispectral	O	ADJ	B
index	O	NOUN	I
(	O	PUNCT	O
BIS	O	NOUN	B
),	O	PUNCT	O
and	O	CCONJ	O
patients	O	NOUN	B
were	O	AUX	O
randomized	O	VERB	B
to	O	PART	O
receive	O	VERB	O
either	O	CCONJ	O
deep	O	ADJ	B
(	O	PUNCT	O
BIS	O	NOUN	B
,	O	PUNCT	O
approximately	O	ADV	O
50	O	NUM	O
)	O	PUNCT	O
or	O	CCONJ	O
light	O	ADJ	B
(	O	PUNCT	O
BIS	O	NOUN	B
,>	O	NOUN	O
or	O	CCONJ	O
=	O	ADJ	O
80	O	NUM	O
)	O	PUNCT	O
sedation	O	NOUN	B
.	O	PUNCT	O


Postoperative	B-Disease	ADJ	B
delirium	I-Disease	NOUN	I
was	O	AUX	O
assessed	O	VERB	B
as	O	ADP	O
defined	O	VERB	O
by	O	ADP	O
Diagnostic	O	PROPN	B
and	O	CCONJ	O
Statistical	O	PROPN	O
Manual	O	PROPN	O
of	O	ADP	O
Mental	B-Disease	PROPN	O
Disorders	I-Disease	PROPN	O
(	O	PUNCT	O
Third	O	PROPN	B
Edition	O	PROPN	I
Revised	O	PROPN	I
)	O	PUNCT	O
criteria	O	NOUN	B
using	O	VERB	O
the	O	DET	O
Confusion	O	PROPN	B
Assessment	O	NOUN	I
Method	O	PROPN	I
beginning	O	VERB	O
at	O	ADP	O
any	O	DET	O
time	O	NOUN	O
from	O	ADP	O
the	O	DET	O
second	O	ADJ	O
day	O	NOUN	B
after	O	ADP	O
surgery	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
From	O	ADP	O
April	O	PROPN	O
2	O	NUM	O
,	O	PUNCT	O
2005	O	NUM	O
,	O	PUNCT	O
through	O	ADP	O
October	O	PROPN	O
30	O	NUM	O
,	O	PUNCT	O
2008	O	NUM	O
,	O	PUNCT	O
a	O	DET	O
total	O	NOUN	O
of	O	ADP	O
114	O	NUM	O
patients	O	NOUN	B
were	O	AUX	O
randomized	O	VERB	B
.	O	PUNCT	O


The	O	DET	O
prevalence	O	NOUN	B
of	O	ADP	O
postoperative	B-Disease	ADJ	B
delirium	I-Disease	NOUN	I
was	O	AUX	O
significantly	O	ADV	O
lower	O	ADJ	O
in	O	ADP	O
the	O	DET	O
light	O	ADJ	B
sedation	O	NOUN	I
group	O	NOUN	O
(	O	PUNCT	O
11	O	NUM	O
/	O	SYM	O
57	O	NUM	O
[	O	PUNCT	O
19	O	NUM	O
%]	O	NOUN	O
vs	O	CCONJ	O
23	O	NUM	O
/	O	SYM	O
57	O	NUM	O
[	O	PUNCT	O
40	O	NUM	O
%]	O	NOUN	O
in	O	ADP	O
the	O	DET	O
deep	O	ADJ	B
sedation	O	NOUN	I
group	O	NOUN	O
;	O	PUNCT	O
P	O	NOUN	O
=.	O	NOUN	O
02	O	NUM	O
),	O	PUNCT	O
indicating	O	VERB	O
that	O	SCONJ	O
1	O	NUM	O
incident	O	NOUN	B
of	O	ADP	O
delirium	B-Disease	NOUN	B
will	O	AUX	O
be	O	AUX	O
prevented	O	VERB	B
for	O	ADP	O
every	O	DET	O
4	O	NUM	O
.	O	PUNCT	O


7	O	NUM	O
patients	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
light	O	ADJ	O
sedation	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
mean	O	NOUN	O
+/-	O	CCONJ	O
SD	O	NOUN	B
number	O	NOUN	O
of	O	ADP	O
days	O	NOUN	B
of	O	ADP	O
delirium	B-Disease	NOUN	B
during	O	ADP	O
hospitalization	O	NOUN	B
was	O	AUX	O
lower	O	ADJ	O
in	O	ADP	O
the	O	DET	O
light	O	ADJ	B
sedation	O	NOUN	I
group	O	NOUN	B
than	O	ADP	O
in	O	ADP	O
the	O	DET	O
deep	O	ADJ	B
sedation	O	NOUN	I
group	O	NOUN	I
(	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
+/-	O	CCONJ	O
1	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
days	O	NOUN	B
vs	O	CCONJ	O
1	O	NUM	O
.	O	PUNCT	O


4	O	NUM	O
+/-	O	CCONJ	O
4	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
days	O	NOUN	B
;	O	PUNCT	O
P	O	NOUN	O
=.	O	NOUN	O
01	O	NUM	O
).	O	PUNCT	O
CONCLUSION	O	NOUN	O
:	O	PUNCT	O
The	O	DET	O
use	O	NOUN	O
of	O	ADP	O
light	O	ADJ	O
propofol	B-Chemical	NOUN	B
sedation	O	NOUN	B
decreased	O	VERB	B
the	O	DET	O
prevalence	O	NOUN	B
of	O	ADP	O
postoperative	B-Disease	ADJ	B
delirium	I-Disease	NOUN	I
by	O	ADP	O
50	O	NUM	O
%	O	NOUN	O
compared	O	VERB	B
with	O	ADP	O
deep	O	ADJ	B
sedation	O	NOUN	I
.	O	PUNCT	O


Limiting	O	VERB	O
depth	O	NOUN	B
of	O	ADP	O
sedation	O	NOUN	B
during	O	ADP	O
spinal	O	ADJ	B
anesthesia	O	NOUN	I
is	O	AUX	O
a	O	DET	O
simple	O	ADJ	O
,	O	PUNCT	O
safe	O	ADJ	O
,	O	PUNCT	O
and	O	CCONJ	O
cost	O	NOUN	B
-	O	PUNCT	O
effective	O	ADJ	B
intervention	O	NOUN	B
for	O	ADP	O
preventing	O	VERB	B
postoperative	B-Disease	ADJ	B
delirium	I-Disease	NOUN	O


Sorafenib	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
acute	O	ADJ	B
myocardial	B-Disease	ADJ	I
infarction	I-Disease	NOUN	I
due	O	ADP	O
to	O	PART	O
coronary	B-Disease	ADJ	B
artery	I-Disease	NOUN	I
spasm	I-Disease	NOUN	I
.	O	PUNCT	O


A	O	DET	O
65	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
man	O	NOUN	B
with	O	ADP	O
advanced	O	ADJ	B
renal	B-Disease	ADJ	I
cell	I-Disease	NOUN	I
carcinoma	I-Disease	NOUN	I
was	O	AUX	O
admitted	O	VERB	B
due	O	ADP	O
to	O	ADP	O
continuing	O	VERB	B
chest	B-Disease	ADJ	I
pain	I-Disease	NOUN	I
at	O	ADP	O
rest	O	NOUN	B
.	O	PUNCT	O


Two	O	NUM	O
weeks	O	NOUN	B
before	O	ADP	O
his	O	PRON	O
admission	O	NOUN	B
,	O	PUNCT	O
sorafenib	B-Chemical	NOUN	B
had	O	AUX	O
been	O	AUX	O
started	O	VERB	B
.	O	PUNCT	O


He	O	PRON	O
was	O	AUX	O
diagnosed	O	VERB	B
with	O	ADP	O
non	O	ADJ	B
-	O	PUNCT	O
ST	O	PROPN	B
-	O	PUNCT	O
elevation	O	NOUN	B
myocardial	B-Disease	ADJ	B
infarction	I-Disease	NOUN	I
by	O	ADP	O
laboratory	O	ADJ	B
data	O	NOUN	I
and	O	CCONJ	O
electrocardiogram	O	NOUN	B
.	O	PUNCT	O


Enhanced	O	VERB	B
heart	O	NOUN	O
magnetic	O	ADJ	B
resonance	O	NOUN	I
imaging	O	NOUN	I
also	O	ADV	O
showed	O	VERB	O
subendocardial	B-Disease	ADJ	B
infarction	I-Disease	NOUN	I
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
there	O	PRON	O
was	O	AUX	O
no	O	DET	O
stenosis	O	NOUN	B
in	O	ADP	O
coronary	O	ADJ	B
arteries	O	NOUN	I
on	O	ADP	O
angiography	O	NOUN	B
.	O	PUNCT	O


Coronary	B-Disease	ADJ	B
artery	I-Disease	NOUN	I
spasm	I-Disease	NOUN	I
was	O	AUX	O
induced	O	VERB	B
by	O	ADP	O
a	O	DET	O
provocative	O	ADJ	B
test	O	NOUN	I
.	O	PUNCT	O


Cessation	O	NOUN	B
of	O	ADP	O
sorafenib	B-Chemical	NOUN	B
and	O	CCONJ	O
administration	O	NOUN	B
of	O	ADP	O
Ca	B-Chemical	NOUN	B
-	O	PUNCT	O
channel	O	NOUN	B
blocker	O	NOUN	I
and	O	CCONJ	O
nitrates	B-Chemical	NOUN	B
ameliorated	O	VERB	B
his	O	PRON	O
symptoms	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
relapse	O	NOUN	B
occurred	O	VERB	O
after	O	ADP	O
resumption	O	NOUN	B
of	O	ADP	O
sorafenib	B-Chemical	NOUN	B
.	O	PUNCT	O


Addition	O	NOUN	B
of	O	ADP	O
oral	O	ADJ	B
nicorandil	B-Chemical	NOUN	B
reduced	O	VERB	B
his	O	PRON	O
symptoms	O	NOUN	B
and	O	CCONJ	O
maintained	O	VERB	B
stable	B-Disease	ADJ	B
angina	I-Disease	ADJ	O
status	O	NOUN	O
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
the	O	DET	O
first	O	ADJ	O
case	O	NOUN	B
of	O	ADP	O
sorafenib	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
coronary	B-Disease	ADJ	B
artery	I-Disease	NOUN	I
spasm	I-Disease	NOUN	I
.	O	PUNCT	O


Sorafenib	B-Chemical	NOUN	B
is	O	AUX	O
a	O	DET	O
multikinase	O	ADJ	B
inhibitor	O	NOUN	I
that	O	PRON	O
targets	O	VERB	B
signaling	O	NOUN	B
pathways	O	NOUN	I
necessary	O	ADJ	O
for	O	ADP	O
cellular	O	ADJ	B
proliferation	O	NOUN	I
and	O	CCONJ	O
survival	O	NOUN	B
.	O	PUNCT	O


On	O	ADP	O
the	O	DET	O
other	O	ADJ	O
hand	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
Rho	O	NOUN	B
/	O	PUNCT	O
ROCK	O	NOUN	B
pathway	O	NOUN	B
has	O	AUX	O
an	O	DET	O
important	O	ADJ	O
role	O	NOUN	O
in	O	ADP	O
the	O	DET	O
pathogenesis	O	NOUN	B
of	O	ADP	O
coronary	B-Disease	ADJ	B
artery	I-Disease	NOUN	I
spasm	I-Disease	NOUN	I
.	O	PUNCT	O


Our	O	PRON	O
report	O	NOUN	B
may	O	AUX	O
show	O	VERB	O
an	O	DET	O
adverse	O	ADJ	B
effect	O	NOUN	I
on	O	ADP	O
the	O	DET	O
Rho	O	NOUN	B
/	O	PUNCT	O
ROCK	O	NOUN	B
pathway	O	NOUN	B
by	O	ADP	O
sorafenib	B-Chemical	NOUN	B


Anxiogenic	O	ADJ	B
potential	O	NOUN	I
of	O	ADP	O
ciprofloxacin	B-Chemical	NOUN	B
and	O	CCONJ	O
norfloxacin	B-Chemical	NOUN	B
in	O	ADP	O
rats	O	NOUN	B
.	O	PUNCT	O


INTRODUCTION	O	NOUN	O
:	O	PUNCT	O
The	O	DET	O
possible	O	ADJ	O
anxiogenic	O	ADJ	B
effects	O	NOUN	I
of	O	ADP	O
fluoroquinolones	B-Chemical	NOUN	B
,	O	PUNCT	O
namely	O	ADV	O
ciprofloxacin	B-Chemical	NOUN	B
and	O	CCONJ	O
norfloxacin	B-Chemical	NOUN	B
,	O	PUNCT	O
were	O	AUX	O
investigated	O	VERB	B
in	O	ADP	O
adult	O	ADJ	B
Charles	O	PROPN	O
Foster	O	PROPN	O
albino	O	NOUN	B
rats	O	NOUN	B
of	O	ADP	O
either	O	CCONJ	O
sex	O	NOUN	B
,	O	PUNCT	O
weighing	O	VERB	B
150	O	NUM	O
-	O	SYM	O
200	O	NUM	O
g	O	NOUN	O
.	O	PUNCT	O


METHODS	O	NOUN	O
:	O	PUNCT	O
The	O	DET	O
drugs	O	NOUN	B
were	O	AUX	O
given	O	VERB	O
orally	O	ADV	B
,	O	PUNCT	O
in	O	ADP	O
doses	O	NOUN	B
of	O	ADP	O
50	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	O
for	O	ADP	O
five	O	NUM	O
consecutive	O	ADJ	B
days	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
experiments	O	NOUN	B
were	O	AUX	O
performed	O	VERB	O
on	O	ADP	O
the	O	DET	O
fifth	O	ADJ	O
day	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
tests	O	NOUN	B
included	O	VERB	O
open	O	ADJ	B
-	O	PUNCT	O
field	O	NOUN	B
exploratory	O	ADJ	O
behaviour	O	NOUN	O
,	O	PUNCT	O
elevated	O	ADJ	B
plus	O	CCONJ	I
maze	O	NOUN	I
and	O	CCONJ	O
elevated	O	ADJ	B
zero	O	NUM	O
maze	O	NOUN	O
,	O	PUNCT	O
social	O	ADJ	B
interaction	O	NOUN	I
and	O	CCONJ	O
novelty	O	NOUN	B
-	O	PUNCT	O
suppressed	O	VERB	B
feeding	O	NOUN	B
latency	O	NOUN	O
behaviour	O	NOUN	O
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
The	O	DET	O
results	O	NOUN	B
indicate	O	VERB	O
that	O	SCONJ	O
ciprofloxacin	B-Chemical	NOUN	B
-	O	PUNCT	O
and	O	CCONJ	O
norfloxacin	B-Chemical	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
rats	O	NOUN	B
showed	O	VERB	O
anxious	B-Disease	ADJ	B
behaviour	I-Disease	NOUN	I
in	O	ADP	O
comparison	O	NOUN	B
to	O	PART	O
control	O	ADJ	B
rats	O	NOUN	B
in	O	ADP	O
all	O	DET	O
the	O	DET	O
parameters	O	NOUN	B
studied	O	VERB	O
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
ciprofloxacin	B-Chemical	NOUN	B
-	O	PUNCT	O
and	O	CCONJ	O
norfloxacin	B-Chemical	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
rats	O	NOUN	B
did	O	AUX	O
not	O	PART	O
differ	O	VERB	O
significantly	O	ADV	O
from	O	ADP	O
each	O	DET	O
other	O	ADJ	O
in	O	ADP	O
various	O	ADJ	O
behavioural	O	ADJ	B
parameters	O	NOUN	I
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
:	O	PUNCT	O
The	O	DET	O
present	O	ADJ	O
experimental	O	ADJ	B
findings	O	NOUN	I
substantiate	O	VERB	O
the	O	DET	O
clinically	O	ADV	B
observed	O	VERB	O
anxiogenic	O	ADJ	B
potential	O	NOUN	I
of	O	ADP	O
ciprofloxacin	B-Chemical	NOUN	B
and	O	CCONJ	O
norfloxacin	B-Chemical	NOUN	B


Myocardial	O	ADJ	B
Fas	O	NOUN	I
ligand	O	NOUN	B
expression	O	NOUN	B
increases	O	VERB	B
susceptibility	O	NOUN	B
to	O	PART	O
AZT	B-Chemical	PROPN	B
-	O	PUNCT	O
induced	O	VERB	B
cardiomyopathy	B-Disease	NOUN	B
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
:	O	PUNCT	O
Dilated	B-Disease	ADJ	B
cardiomyopathy	I-Disease	NOUN	I
(	O	PUNCT	O
DCM	B-Disease	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
myocarditis	B-Disease	NOUN	B
occur	O	VERB	O
in	O	ADP	O
many	O	ADJ	O
HIV-infected	B-Disease	ADJ	B
individuals	O	NOUN	B
,	O	PUNCT	O
resulting	O	VERB	O
in	O	ADP	O
symptomatic	O	ADJ	B
heart	B-Disease	NOUN	B
failure	I-Disease	NOUN	I
in	O	ADP	O
up	O	ADV	O
to	O	PART	O
5	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
.	O	PUNCT	O


Highly	O	ADV	O
active	O	ADJ	O
antiretroviral	O	ADJ	B
therapy	O	NOUN	I
(	O	PUNCT	O
HAART	O	NOUN	B
)	O	PUNCT	O
has	O	AUX	O
significantly	O	ADV	O
reduced	O	VERB	B
morbidity	O	NOUN	B
and	O	CCONJ	O
mortality	O	NOUN	B
of	O	ADP	O
acquired	B-Disease	VERB	B
immunodeficiency	I-Disease	NOUN	I
syndrome	I-Disease	NOUN	I
(	O	PUNCT	O
AIDS	B-Disease	NOUN	B
),	O	PUNCT	O
but	O	CCONJ	O
has	O	AUX	O
resulted	O	VERB	O
in	O	ADP	O
an	O	DET	O
increase	O	NOUN	B
in	O	ADP	O
cardiac	B-Disease	ADJ	B
and	I-Disease	CCONJ	O
skeletal	I-Disease	ADJ	B
myopathies	I-Disease	NOUN	I
.	O	PUNCT	O


METHODS	O	NOUN	O
AND	O	CCONJ	O
RESULTS	O	NOUN	B
:	O	PUNCT	O
In	O	ADP	O
order	O	NOUN	O
to	O	PART	O
investigate	O	VERB	B
whether	O	SCONJ	O
the	O	DET	O
HAART	O	NOUN	B
component	O	NOUN	O
zidovudine	B-Chemical	NOUN	B
(	O	PUNCT	O
3'-azido-2',3'-deoxythymidine	B-Chemical	NOUN	B
;	O	PUNCT	O
AZT	B-Chemical	NOUN	B
)	O	PUNCT	O
triggers	O	VERB	B
the	O	DET	O
Fas	O	NOUN	B
-	O	PUNCT	O
dependent	O	ADJ	B
cell	O	NOUN	B
-	O	PUNCT	O
death	O	NOUN	B
pathway	O	NOUN	B
and	O	CCONJ	O
cause	O	VERB	O
cytoskeletal	O	ADJ	B
disruption	O	NOUN	B
in	O	ADP	O
a	O	DET	O
murine	O	ADJ	B
model	O	NOUN	B
of	O	ADP	O
DCM	B-Disease	NOUN	B
,	O	PUNCT	O
8	O	NUM	O
-	O	PUNCT	O
week	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
transgenic	O	ADJ	I
(	O	PUNCT	O
expressing	O	VERB	B
Fas	O	NOUN	B
ligand	O	NOUN	B
in	O	ADP	O
the	O	DET	O
myocardium	O	NOUN	B
:	O	PUNCT	O
FasL	O	NOUN	B
Tg	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
non	O	ADJ	B
-	O	PUNCT	O
transgenic	O	ADJ	B
(	O	PUNCT	O
NTg	O	NOUN	B
)	O	PUNCT	O
mice	O	NOUN	B
received	O	VERB	O
water	O	NOUN	B
ad	O	NOUN	B
libitum	O	NOUN	I
containing	O	VERB	O
different	O	ADJ	O
concentrations	O	NOUN	B
of	O	ADP	O
AZT	B-Chemical	NOUN	B
(	O	PUNCT	O
0	O	NUM	O
,	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


07	O	NUM	O
,	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


7	O	NUM	O
mg	O	NOUN	O
/	O	PUNCT	O
ml	O	NOUN	O
).	O	PUNCT	O
After	O	ADP	O
6	O	NUM	O
weeks	O	NOUN	B
,	O	PUNCT	O
cardiac	O	ADJ	B
function	O	NOUN	I
was	O	AUX	O
assessed	O	VERB	B
by	O	ADP	O
echocardiography	O	NOUN	B
and	O	CCONJ	O
morphology	O	NOUN	B
was	O	AUX	O
assessed	O	VERB	B
by	O	ADP	O
histopathologic	O	ADJ	B
and	O	CCONJ	O
immunohistochemical	O	ADJ	B
methods	O	NOUN	I
.	O	PUNCT	O


NTg	O	NOUN	B
and	O	CCONJ	O
untreated	O	ADJ	B
FasL	O	NOUN	B
Tg	O	NOUN	B
mice	O	NOUN	I
showed	O	VERB	O
little	O	ADJ	O
or	O	CCONJ	O
no	O	DET	O
change	O	NOUN	O
in	O	ADP	O
cardiac	O	ADJ	B
structure	O	NOUN	I
or	O	CCONJ	O
function	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
contrast	O	NOUN	O
,	O	PUNCT	O
AZT	B-Chemical	PROPN	B
-	O	PUNCT	O
treated	O	VERB	B
FasL	O	NOUN	B
Tg	O	NOUN	B
mice	O	NOUN	I
developed	O	VERB	O
cardiac	B-Disease	ADJ	B
dilation	I-Disease	NOUN	I
and	O	CCONJ	O
depressed	O	ADJ	B
cardiac	O	ADJ	I
function	O	NOUN	I
in	O	ADP	O
a	O	DET	O
dose	O	NOUN	B
-	O	PUNCT	O
dependent	O	ADJ	B
manner	O	NOUN	O
,	O	PUNCT	O
with	O	ADP	O
concomitant	O	ADJ	B
inflammatory	O	ADJ	B
infiltration	O	NOUN	I
of	O	ADP	O
both	O	DET	O
ventricles	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
changes	O	NOUN	B
were	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
an	O	DET	O
increased	O	VERB	B
sarcolemmal	O	ADJ	B
expression	O	NOUN	B
of	O	ADP	O
Fas	O	NOUN	B
and	O	CCONJ	O
FasL	O	NOUN	B
,	O	PUNCT	O
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
increased	O	VERB	B
activation	O	NOUN	B
of	O	ADP	O
caspase	O	NOUN	B
3	O	NUM	I
,	O	PUNCT	O
translocation	O	NOUN	B
of	O	ADP	O
calpain	O	NOUN	B
1	O	NUM	I
to	O	PART	O
the	O	DET	O
sarcolemma	O	NOUN	B
and	O	CCONJ	O
sarcomere	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
increased	O	VERB	B
numbers	O	NOUN	O
of	O	ADP	O
cells	O	NOUN	B
undergoing	O	VERB	O
apoptosis	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
were	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
changes	O	NOUN	B
in	O	ADP	O
dystrophin	O	NOUN	B
and	O	CCONJ	O
cardiac	O	ADJ	B
troponin	O	NOUN	O
I	O	NUM	O
localization	O	NOUN	B
,	O	PUNCT	O
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
loss	O	NOUN	B
of	O	ADP	O
sarcolemmal	O	ADJ	B
integrity	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
:	O	PUNCT	O
The	O	DET	O
expression	O	NOUN	B
of	O	ADP	O
Fas	O	NOUN	B
ligand	O	NOUN	B
in	O	ADP	O
the	O	DET	O
myocardium	O	NOUN	B
,	O	PUNCT	O
as	O	ADP	O
identified	O	VERB	B
in	O	ADP	O
HIV	O	NOUN	B
-	O	PUNCT	O
positive	O	ADJ	B
patients	O	NOUN	B
,	O	PUNCT	O
might	O	AUX	O
increase	O	VERB	B
the	O	DET	O
susceptibility	O	NOUN	B
to	O	PART	O
HAART	O	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
cardiomyopathy	B-Disease	NOUN	B
due	O	ADJ	O
to	O	PART	O
activation	O	NOUN	B
of	O	ADP	O
apoptotic	O	ADJ	B
pathways	O	NOUN	I
,	O	PUNCT	O
resulting	O	VERB	O
in	O	ADP	O
cardiac	B-Disease	ADJ	B
dilation	I-Disease	NOUN	I
and	I-Disease	CCONJ	O
dysfunction	I-Disease	NOUN	B


Valproate	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
chorea	B-Disease	NOUN	B
and	O	CCONJ	O
encephalopathy	B-Disease	NOUN	B
in	O	ADP	O
atypical	O	ADJ	B
nonketotic	B-Disease	ADJ	B
hyperglycinemia	I-Disease	NOUN	I
.	O	PUNCT	O


Nonketotic	B-Disease	ADJ	B
hyperglycinemia	I-Disease	NOUN	I
is	O	AUX	O
a	O	DET	O
disorder	B-Disease	NOUN	B
of	I-Disease	ADP	O
amino	I-Disease	NOUN	B
acid	I-Disease	NOUN	I
metabolism	I-Disease	NOUN	I
in	O	ADP	O
which	O	DET	O
a	O	DET	O
defect	O	NOUN	B
in	O	ADP	O
the	O	DET	O
glycine	B-Chemical	NOUN	B
cleavage	O	NOUN	I
system	O	NOUN	I
leads	O	VERB	O
to	O	PART	O
an	O	DET	O
accumulation	O	NOUN	B
of	O	ADP	O
glycine	B-Chemical	NOUN	B
in	O	ADP	O
the	O	DET	O
brain	O	NOUN	B
and	O	CCONJ	O
other	O	ADJ	O
body	O	NOUN	B
compartments	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
classical	O	ADJ	O
form	O	NOUN	O
it	O	PRON	O
presents	O	VERB	O
as	O	ADP	O
neonatal	O	ADJ	B
apnea	B-Disease	NOUN	B
,	O	PUNCT	O
intractable	O	ADJ	B
seizures	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
hypotonia	B-Disease	NOUN	B
,	O	PUNCT	O
followed	O	VERB	O
by	O	ADP	O
significant	O	ADJ	B
psychomotor	B-Disease	NOUN	B
retardation	I-Disease	NOUN	I
.	O	PUNCT	O


An	O	DET	O
important	O	ADJ	O
subset	O	NOUN	O
of	O	ADP	O
children	O	NOUN	B
with	O	ADP	O
nonketotic	B-Disease	ADJ	B
hyperglycinemia	I-Disease	NOUN	I
are	O	AUX	O
atypical	O	ADJ	B
variants	O	NOUN	B
who	O	PRON	O
present	O	VERB	O
in	O	ADP	O
a	O	DET	O
heterogeneous	O	ADJ	B
manner	O	NOUN	O
.	O	PUNCT	O


This	O	DET	O
report	O	NOUN	B
describes	O	VERB	O
a	O	DET	O
patient	O	NOUN	B
with	O	ADP	O
mild	O	ADJ	B
language	B-Disease	NOUN	O
delay	I-Disease	NOUN	O
and	O	CCONJ	O
mental	B-Disease	ADJ	B
retardation	I-Disease	NOUN	I
,	O	PUNCT	O
who	O	PRON	O
was	O	AUX	O
found	O	VERB	O
to	O	PART	O
have	O	AUX	O
nonketotic	B-Disease	ADJ	B
hyperglycinemia	I-Disease	NOUN	I
following	O	VERB	O
her	O	PRON	O
presentation	O	NOUN	B
with	O	ADP	O
acute	O	ADJ	B
encephalopathy	B-Disease	NOUN	I
and	O	CCONJ	O
chorea	B-Disease	NOUN	B
shortly	O	ADV	O
after	O	ADP	O
initiation	O	NOUN	B
of	O	ADP	O
valproate	B-Chemical	NOUN	B


Microinjection	O	NOUN	B
of	O	ADP	O
ritanserin	B-Chemical	NOUN	B
into	O	ADP	O
the	O	DET	O
CA1	O	NOUN	B
region	O	NOUN	I
of	O	ADP	O
hippocampus	O	NOUN	B
improves	O	VERB	O
scopolamine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
amnesia	B-Disease	NOUN	B
in	O	ADP	O
adult	O	ADJ	B
male	O	NOUN	B
rats	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
ritanserin	B-Chemical	NOUN	B
(	O	PUNCT	O
5	O	NUM	O
-	O	PUNCT	O
HT2	O	NOUN	B
antagonist	O	NOUN	B
)	O	PUNCT	O
on	O	ADP	O
scopolamine	B-Chemical	NOUN	B
(	O	PUNCT	O
muscarinic	O	ADJ	B
cholinergic	O	ADJ	I
antagonist	O	NOUN	I
)-	O	ADJ	O
induced	O	VERB	B
amnesia	B-Disease	NOUN	B
in	O	ADP	O
Morris	O	PROPN	B
water	O	NOUN	I
maze	O	NOUN	I
(	O	PUNCT	O
MWM	O	NOUN	B
)	O	PUNCT	O
was	O	AUX	O
investigated	O	VERB	B
.	O	PUNCT	O


Rats	O	NOUN	B
were	O	AUX	O
divided	O	VERB	O
into	O	ADP	O
eight	O	NUM	O
groups	O	NOUN	B
and	O	CCONJ	O
bilaterally	O	ADV	B
cannulated	O	VERB	B
into	O	ADP	O
CA1	O	NOUN	B
region	O	NOUN	I
of	O	ADP	O
the	O	DET	O
hippocampus	O	NOUN	B
.	O	PUNCT	O


One	O	NUM	O
week	O	NOUN	B
later	O	ADV	O
,	O	PUNCT	O
they	O	PRON	O
received	O	VERB	O
repeatedly	O	ADV	B
vehicles	O	NOUN	B
(	O	PUNCT	O
saline	O	NOUN	B
,	O	PUNCT	O
DMSO	B-Chemical	NOUN	B
,	O	PUNCT	O
saline	O	NOUN	B
+	O	CCONJ	O
DMSO	B-Chemical	NOUN	B
),	O	PUNCT	O
scopolamine	B-Chemical	NOUN	B
(	O	PUNCT	O
2	O	NUM	O
microg	O	NOUN	B
/	O	SYM	O
0	O	NUM	B
.	O	PUNCT	O


5	O	NUM	O
microl	O	NOUN	B
saline	O	NOUN	B
/	O	SYM	O
side	O	NOUN	B
;	O	PUNCT	O
30	O	NUM	O
min	O	NOUN	O
before	O	ADP	O
training	O	NOUN	B
),	O	PUNCT	O
ritanserin	B-Chemical	NOUN	B
(	O	PUNCT	O
2	O	NUM	O
,	O	PUNCT	O
4	O	NUM	O
and	O	CCONJ	O
8	O	NUM	O
microg	O	NOUN	B
/	O	SYM	O
0	O	NUM	B
.	O	PUNCT	O


5	O	NUM	O
microl	O	NOUN	B
DMSO	B-Chemical	NOUN	B
/	O	SYM	O
side	O	NOUN	B
;	O	PUNCT	O
20	O	NUM	O
min	O	NOUN	O
before	O	ADP	O
training	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
scopolamine	B-Chemical	NOUN	B
(	O	PUNCT	O
2	O	NUM	O
microg	O	NOUN	B
/	O	SYM	O
0	O	NUM	B
.	O	PUNCT	O


5	O	NUM	O
microl	O	NOUN	B
;	O	PUNCT	O
30	O	NUM	O
min	O	NOUN	O
before	O	ADP	O
ritanserin	B-Chemical	NOUN	B
injection	O	NOUN	B
)+	O	PUNCT	O
ritanserin	B-Chemical	NOUN	B
(	O	PUNCT	O
4	O	NUM	O
microg	O	NOUN	B
/	O	SYM	O
0	O	NUM	B
.	O	PUNCT	O


5	O	NUM	O
microl	O	NOUN	B
DMSO	B-Chemical	NOUN	B
)	O	PUNCT	O
through	O	ADP	O
cannulae	O	ADJ	B
each	O	DET	O
day	O	NOUN	B
.	O	PUNCT	O


Animals	O	NOUN	B
were	O	AUX	O
tested	O	VERB	B
for	O	ADP	O
four	O	NUM	O
consecutive	O	ADJ	B
days	O	NOUN	B
(	O	PUNCT	O
4	O	NUM	O
trial	O	NOUN	B
/	O	SYM	O
day	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
MWM	O	PROPN	B
during	O	ADP	O
which	O	DET	O
the	O	DET	O
position	O	NOUN	O
of	O	ADP	O
hidden	O	ADJ	B
platform	O	NOUN	I
was	O	AUX	O
unchanged	O	ADJ	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
fifth	O	ADJ	O
day	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
platform	O	NOUN	B
was	O	AUX	O
elevated	O	VERB	B
above	O	ADP	O
the	O	DET	O
water	O	NOUN	B
surface	O	NOUN	B
in	O	ADP	O
another	O	DET	O
position	O	NOUN	O
to	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
function	O	NOUN	B
of	O	ADP	O
motor	O	NOUN	B
,	O	PUNCT	O
motivational	O	ADJ	B
and	O	CCONJ	O
visual	O	ADJ	B
systems	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
results	O	NOUN	B
showed	O	VERB	O
a	O	DET	O
significant	O	ADJ	O
increase	O	NOUN	B
in	O	ADP	O
escape	O	NOUN	O
latencies	O	NOUN	B
and	O	CCONJ	O
traveled	O	VERB	B
distances	O	NOUN	B
to	O	PART	O
find	O	VERB	O
platform	O	NOUN	B
in	O	ADP	O
scopolamine	B-Chemical	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
group	O	NOUN	B
as	O	ADP	O
compared	O	VERB	O
to	O	PART	O
saline	O	NOUN	B
group	O	NOUN	I
.	O	PUNCT	O


Ritanserin	B-Chemical	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
rats	O	NOUN	B
(	O	PUNCT	O
4	O	NUM	O
microg	O	NOUN	B
/	O	SYM	O
0	O	NUM	B
.	O	PUNCT	O


5	O	NUM	O
microl	O	NOUN	B
/	O	SYM	O
side	O	NOUN	B
)	O	PUNCT	O
showed	O	VERB	O
a	O	DET	O
significant	O	ADJ	O
decrease	O	NOUN	B
in	O	ADP	O
the	O	DET	O
mentioned	O	VERB	O
parameters	O	NOUN	B
as	O	ADP	O
compared	O	VERB	O
to	O	ADP	O
DMSO	B-Chemical	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
group	O	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
scopolamine	B-Chemical	NOUN	B
and	O	CCONJ	O
ritanserin	B-Chemical	NOUN	B
co	O	X	B
-	O	PUNCT	O
administration	O	NOUN	B
resulted	O	VERB	O
in	O	ADP	O
a	O	DET	O
significant	O	ADJ	O
decrease	O	NOUN	B
in	O	ADP	O
escape	O	NOUN	O
latencies	O	NOUN	B
and	O	CCONJ	O
traveled	O	VERB	B
distances	O	NOUN	B
as	O	ADP	O
compared	O	VERB	B
to	O	PART	O
the	O	DET	O
scopolamine	B-Chemical	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
rats	O	NOUN	B
.	O	PUNCT	O


Our	O	PRON	O
findings	O	NOUN	B
show	O	VERB	O
that	O	SCONJ	O
microinjection	O	NOUN	B
of	O	ADP	O
ritanserin	B-Chemical	NOUN	B
into	O	ADP	O
the	O	DET	O
CA1	O	NOUN	B
region	O	NOUN	I
of	O	ADP	O
the	O	DET	O
hippocampus	O	NOUN	B
improves	O	VERB	B
the	O	DET	O
scopolamine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
amnesia	B-Disease	NOUN	B


Hypoxia	B-Disease	NOUN	B
in	O	ADP	O
renal	B-Disease	ADJ	B
disease	I-Disease	NOUN	I
with	O	ADP	O
proteinuria	B-Disease	NOUN	B
and	O	CCONJ	O
/	O	PUNCT	O
or	O	CCONJ	O
glomerular	O	ADJ	B
hypertension	B-Disease	NOUN	I
.	O	PUNCT	O


Despite	O	SCONJ	O
the	O	DET	O
increasing	O	VERB	B
need	O	NOUN	O
to	O	PART	O
identify	O	VERB	O
and	O	CCONJ	O
quantify	O	VERB	B
tissue	O	NOUN	B
oxygenation	O	NOUN	I
at	O	ADP	O
the	O	DET	O
cellular	O	ADJ	B
level	O	NOUN	I
,	O	PUNCT	O
relatively	O	ADV	O
few	O	ADJ	O
methods	O	NOUN	B
have	O	AUX	O
been	O	AUX	O
available	O	ADJ	O
.	O	PUNCT	O


In	O	ADP	O
this	O	DET	O
study	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
developed	O	VERB	O
a	O	DET	O
new	O	ADJ	O
hypoxia	B-Disease	NOUN	B
-	O	PUNCT	O
responsive	O	ADJ	B
reporter	O	NOUN	B
vector	O	NOUN	I
using	O	VERB	O
a	O	DET	O
hypoxia	B-Disease	NOUN	B
-	O	PUNCT	O
responsive	O	ADJ	B
element	O	NOUN	B
of	O	ADP	O
the	O	DET	O
5	O	NUM	O
'	O	PART	O
vascular	O	ADJ	B
endothelial	O	ADJ	I
growth	O	NOUN	I
factor	O	NOUN	I
untranslated	O	ADJ	I
region	O	NOUN	I
and	O	CCONJ	O
generated	O	VERB	O
a	O	DET	O
novel	O	ADJ	O
hypoxia	B-Disease	NOUN	B
-	O	PUNCT	O
sensing	O	VERB	B
transgenic	O	ADJ	B
rat	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
then	O	ADV	O
applied	O	VERB	O
this	O	DET	O
animal	O	NOUN	B
model	O	NOUN	I
to	O	PART	O
the	O	DET	O
detection	O	NOUN	B
of	O	ADP	O
tubulointerstitial	O	ADJ	B
hypoxia	B-Disease	NOUN	I
in	O	ADP	O
the	O	DET	O
diseased	B-Disease	ADJ	B
kidney	I-Disease	NOUN	I
.	O	PUNCT	O


With	O	ADP	O
this	O	DET	O
model	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
were	O	AUX	O
able	O	ADJ	O
to	O	PART	O
identify	O	VERB	O
diffuse	O	ADJ	B
cortical	O	ADJ	O
hypoxia	B-Disease	NOUN	O
in	O	ADP	O
the	O	DET	O
puromycin	B-Chemical	NOUN	B
aminonucleoside	I-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
nephrotic	B-Disease	ADJ	B
syndrome	I-Disease	NOUN	I
and	O	CCONJ	O
focal	O	ADJ	B
and	O	CCONJ	O
segmental	O	ADJ	B
hypoxia	B-Disease	NOUN	O
in	O	ADP	O
the	O	DET	O
remnant	O	ADJ	B
kidney	O	NOUN	B
model	O	NOUN	I
.	O	PUNCT	O


Expression	O	NOUN	B
of	O	ADP	O
the	O	DET	O
hypoxia	B-Disease	NOUN	B
-	O	PUNCT	O
responsive	O	ADJ	B
transgene	O	NOUN	B
increased	O	VERB	B
throughout	O	ADP	O
the	O	DET	O
observation	O	NOUN	B
period	O	NOUN	B
,	O	PUNCT	O
reaching	O	VERB	O
2	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
-	O	PUNCT	O
fold	O	NOUN	B
at	O	ADP	O
2	O	NUM	O
weeks	O	NOUN	B
in	O	ADP	O
the	O	DET	O
puromycin	B-Chemical	NOUN	B
aminonucleoside	I-Chemical	NOUN	B
model	O	NOUN	B
and	O	CCONJ	O
2	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
-	O	PUNCT	O
fold	O	NOUN	B
at	O	ADP	O
4	O	NUM	O
weeks	O	NOUN	B
in	O	ADP	O
the	O	DET	O
remnant	O	ADJ	B
kidney	O	NOUN	B
model	O	NOUN	I
,	O	PUNCT	O
whereas	O	SCONJ	O
that	O	DET	O
of	O	ADP	O
vascular	O	ADJ	B
endothelial	O	ADJ	I
growth	O	NOUN	I
factor	O	NOUN	I
showed	O	VERB	O
a	O	DET	O
mild	O	ADJ	B
decrease	O	NOUN	B
,	O	PUNCT	O
reflecting	O	VERB	O
distinct	O	ADJ	O
behaviors	O	NOUN	B
of	O	ADP	O
the	O	DET	O
two	O	NUM	O
genes	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
degree	O	NOUN	B
of	O	ADP	O
hypoxia	B-Disease	NOUN	B
showed	O	VERB	O
a	O	DET	O
positive	O	ADJ	B
correlation	O	NOUN	B
with	O	ADP	O
microscopic	O	ADJ	B
tubulointerstitial	B-Disease	ADJ	B
injury	I-Disease	NOUN	I
in	O	ADP	O
both	O	DET	O
models	O	NOUN	B
.	O	PUNCT	O


Finally	O	ADV	O
,	O	PUNCT	O
we	O	PRON	O
identified	O	VERB	B
the	O	DET	O
localization	O	NOUN	B
of	O	ADP	O
proliferating	O	VERB	B
cell	O	NOUN	I
nuclear	O	ADJ	I
antigen	O	NOUN	I
-	O	PUNCT	O
positive	O	ADJ	B
,	O	PUNCT	O
ED	O	PROPN	B
-	O	PUNCT	O
1	O	NUM	B
-	O	PUNCT	O
positive	O	ADJ	B
,	O	PUNCT	O
and	O	CCONJ	O
terminal	O	ADJ	B
dUTP	O	NOUN	O
nick	O	NOUN	O
-	O	PUNCT	O
end	O	NOUN	B
labeled	O	VERB	B
-	O	PUNCT	O
positive	O	ADJ	B
cells	O	NOUN	B
in	O	ADP	O
the	O	DET	O
hypoxic	B-Disease	ADJ	B
cortical	O	ADJ	O
area	O	NOUN	O
in	O	ADP	O
the	O	DET	O
remnant	O	ADJ	B
kidney	O	NOUN	B
model	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
propose	O	VERB	O
here	O	ADV	O
a	O	DET	O
possible	O	ADJ	O
pathological	O	ADJ	B
tie	O	NOUN	O
between	O	ADP	O
chronic	O	ADJ	B
tubulointerstitial	O	ADJ	O
hypoxia	B-Disease	NOUN	O
and	O	CCONJ	O
progressive	O	ADJ	B
glomerular	B-Disease	ADJ	O
diseases	I-Disease	NOUN	O


Consensus	O	NOUN	B
statement	O	NOUN	B
concerning	O	VERB	O
cardiotoxicity	B-Disease	NOUN	B
occurring	O	VERB	O
during	O	ADP	O
haematopoietic	O	ADJ	B
stem	O	NOUN	I
cell	O	NOUN	I
transplantation	O	NOUN	I
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
autoimmune	B-Disease	ADJ	B
diseases	I-Disease	NOUN	I
,	O	PUNCT	O
with	O	ADP	O
special	O	ADJ	O
reference	O	NOUN	O
to	O	PART	O
systemic	B-Disease	ADJ	B
sclerosis	I-Disease	NOUN	I
and	O	CCONJ	O
multiple	B-Disease	ADJ	B
sclerosis	I-Disease	NOUN	I
.	O	PUNCT	O


Autologous	O	ADJ	B
haematopoietic	O	ADJ	O
stem	O	NOUN	O
cell	O	NOUN	O
transplantation	O	NOUN	O
is	O	AUX	O
now	O	ADV	O
a	O	DET	O
feasible	O	ADJ	O
and	O	CCONJ	O
effective	O	ADJ	B
treatment	O	NOUN	B
for	O	ADP	O
selected	O	VERB	O
patients	O	NOUN	B
with	O	ADP	O
severe	O	ADJ	B
autoimmune	B-Disease	ADJ	B
diseases	I-Disease	NOUN	I
.	O	PUNCT	O


Worldwide	O	PROPN	B
,	O	PUNCT	O
over	O	ADP	O
650	O	NUM	O
patients	O	NOUN	B
have	O	AUX	O
been	O	AUX	O
transplanted	O	VERB	B
in	O	ADP	O
the	O	DET	O
context	O	NOUN	B
of	O	ADP	O
phase	O	NOUN	B
I	O	NUM	I
and	O	CCONJ	O
II	O	NUM	O
clinical	O	ADJ	B
trials	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
results	O	NOUN	B
are	O	AUX	O
encouraging	O	VERB	O
enough	O	ADV	O
to	O	PART	O
begin	O	VERB	O
randomised	O	ADJ	B
phase	O	NOUN	I
III	O	NUM	I
trials	O	NOUN	I
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
as	O	ADP	O
predicted	O	VERB	B
,	O	PUNCT	O
significant	O	ADJ	O
transplant	O	NOUN	B
-	O	PUNCT	O
related	O	VERB	B
morbidity	O	NOUN	B
and	O	CCONJ	O
mortality	O	NOUN	B
have	O	AUX	O
been	O	AUX	O
observed	O	VERB	B
.	O	PUNCT	O


This	O	DET	O
is	O	AUX	O
primarily	O	ADV	O
due	O	ADJ	O
to	O	ADP	O
complications	O	NOUN	B
related	O	ADJ	O
to	O	PART	O
either	O	CCONJ	O
the	O	DET	O
stage	O	NOUN	B
of	O	ADP	O
the	O	DET	O
disease	O	NOUN	B
at	O	ADP	O
transplant	O	NOUN	B
or	O	CCONJ	O
due	O	ADP	O
to	O	ADP	O
infections	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
number	O	NOUN	O
of	O	ADP	O
deaths	O	NOUN	B
related	O	ADJ	O
to	O	PART	O
cardiac	B-Disease	ADJ	B
toxicity	I-Disease	NOUN	B
is	O	AUX	O
low	O	ADJ	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
caution	O	NOUN	B
is	O	AUX	O
required	O	VERB	O
when	O	SCONJ	O
cyclophosphamide	B-Chemical	NOUN	B
or	O	CCONJ	O
anthracyclines	B-Chemical	NOUN	B
such	O	ADJ	O
as	O	ADP	O
mitoxantrone	B-Chemical	NOUN	B
are	O	AUX	O
used	O	VERB	O
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
a	O	DET	O
possible	O	ADJ	O
underlying	O	VERB	O
heart	B-Disease	NOUN	B
damage	I-Disease	NOUN	I
,	O	PUNCT	O
for	O	ADP	O
example	O	NOUN	O
,	O	PUNCT	O
systemic	B-Disease	ADJ	B
sclerosis	I-Disease	NOUN	I
patients	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
November	O	PROPN	O
2002	O	NUM	O
,	O	PUNCT	O
a	O	DET	O
meeting	O	NOUN	B
was	O	AUX	O
held	O	VERB	O
in	O	ADP	O
Florence	O	PROPN	B
,	O	PUNCT	O
bringing	O	VERB	O
together	O	ADV	O
a	O	DET	O
number	O	NOUN	O
of	O	ADP	O
experts	O	NOUN	B
in	O	ADP	O
various	O	ADJ	O
fields	O	NOUN	B
,	O	PUNCT	O
including	O	VERB	O
rheumatology	O	NOUN	B
,	O	PUNCT	O
cardiology	O	NOUN	B
,	O	PUNCT	O
neurology	O	NOUN	B
,	O	PUNCT	O
pharmacology	O	NOUN	B
and	O	CCONJ	O
transplantation	O	NOUN	B
medicine	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
object	O	NOUN	B
of	O	ADP	O
the	O	DET	O
meeting	O	NOUN	B
was	O	AUX	O
to	O	PART	O
analyse	O	VERB	O
existing	O	VERB	O
data	O	NOUN	B
,	O	PUNCT	O
both	O	CCONJ	O
published	O	VERB	B
or	O	CCONJ	O
available	O	ADJ	O
,	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
European	O	PROPN	B
Group	O	PROPN	I
for	O	ADP	O
Blood	O	PROPN	B
and	O	CCONJ	O
Marrow	O	PROPN	O
Transplantation	O	PROPN	O
autoimmune	B-Disease	ADJ	O
disease	I-Disease	NOUN	O


Immunohistochemical	O	ADJ	B
study	O	NOUN	I
on	O	ADP	O
inducible	O	ADJ	B
type	O	NOUN	O
of	O	ADP	O
nitric	B-Chemical	ADJ	B
oxide	I-Chemical	NOUN	I
(	O	PUNCT	O
iNOS	O	NOUN	B
),	O	PUNCT	O
basic	O	ADJ	O
fibroblast	O	NOUN	B
growth	O	NOUN	I
factor	O	NOUN	I
(	O	PUNCT	O
bFGF	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
tumor	B-Disease	NOUN	B
growth	O	NOUN	I
factor	O	NOUN	I
-	O	PUNCT	O
beta1	O	NOUN	B
(	O	PUNCT	O
TGF	O	NOUN	B
-	O	PUNCT	O
beta1	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
arteritis	B-Disease	NOUN	B
induced	O	VERB	B
in	O	ADP	O
rats	O	NOUN	B
by	O	ADP	O
fenoldopam	B-Chemical	NOUN	B
and	O	CCONJ	O
theophylline	B-Chemical	NOUN	B
,	O	PUNCT	O
vasodilators	O	NOUN	B
.	O	PUNCT	O


Arteritis	B-Disease	NOUN	B
induced	O	VERB	B
in	O	ADP	O
rats	O	NOUN	B
by	O	ADP	O
vasodilators	O	NOUN	B
,	O	PUNCT	O
fenoldopam	B-Chemical	NOUN	B
and	O	CCONJ	O
theophylline	B-Chemical	NOUN	B
,	O	PUNCT	O
was	O	AUX	O
examined	O	VERB	O
immunohistochemically	O	ADV	B
for	O	ADP	O
expressions	O	NOUN	B
of	O	ADP	O
inducible	O	ADJ	B
type	O	NOUN	O
of	O	ADP	O
nitric	B-Chemical	ADJ	B
oxide	I-Chemical	NOUN	I
synthase	O	NOUN	I
(	O	PUNCT	O
iNOS	O	NOUN	B
),	O	PUNCT	O
basic	O	ADJ	O
fibroblast	O	NOUN	B
growth	O	NOUN	I
factor	O	NOUN	I
(	O	PUNCT	O
bFGF	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
tumor	B-Disease	NOUN	B
growth	O	NOUN	I
factor	O	NOUN	I
-	O	PUNCT	O
beta1	O	NOUN	B
(	O	PUNCT	O
TGF	O	NOUN	B
-	O	PUNCT	O
beta1	O	NOUN	B
).	O	PUNCT	O
Rats	O	NOUN	B
were	O	AUX	O
administered	O	VERB	B
fenoldopam	B-Chemical	NOUN	B
for	O	ADP	O
24	O	NUM	O
hours	O	NOUN	O
by	O	ADP	O
intravenous	O	ADJ	B
infusion	O	NOUN	B
with	O	ADP	O
or	O	CCONJ	O
without	O	ADP	O
following	O	VERB	O
repeated	O	VERB	O
daily	O	ADV	B
oral	O	ADJ	B
administrations	O	NOUN	I
of	O	ADP	O
theophylline	B-Chemical	NOUN	B
.	O	PUNCT	O


Irrespective	O	ADJ	O
of	O	ADP	O
theophylline	B-Chemical	NOUN	B
administration	O	NOUN	B
,	O	PUNCT	O
iNOS	O	NOUN	B
antigens	O	NOUN	B
were	O	AUX	O
remarkably	O	ADV	O
abundant	O	ADJ	B
in	O	ADP	O
ED	O	PROPN	B
-	O	PUNCT	O
1	O	NUM	B
-	O	PUNCT	O
positive	O	ADJ	B
cells	O	NOUN	B
on	O	ADP	O
day	O	NOUN	B
5	O	NUM	O
and	O	CCONJ	O
8	O	NUM	O
post	O	NOUN	B
-	O	PUNCT	O
fenoldopam	B-Chemical	NOUN	B
-	O	PUNCT	O
infusion	O	NOUN	B
(	O	PUNCT	O
DPI	O	NOUN	B
);	O	ADJ	O
bFGF	O	NOUN	B
antigens	O	NOUN	B
were	O	AUX	O
remarkably	O	ADV	O
abundant	O	ADJ	B
in	O	ADP	O
ED	O	PROPN	B
-	O	PUNCT	O
1	O	NUM	B
-	O	PUNCT	O
positive	O	ADJ	B
cells	O	NOUN	B
on	O	ADP	O
1	O	NUM	O
and	O	CCONJ	O
3	O	NUM	O
DPI	O	NOUN	B
;	O	PUNCT	O
TGF	O	NOUN	B
-	O	PUNCT	O
beta1	O	NOUN	B
antigens	O	NOUN	O
were	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
ED	O	PROPN	B
-	O	PUNCT	O
1	O	NUM	B
-	O	PUNCT	O
positive	O	ADJ	B
cells	O	NOUN	B
on	O	ADP	O
and	O	CCONJ	O
after	O	ADP	O
5	O	NUM	O
DPI	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
peak	O	NOUN	B
expression	O	NOUN	I
of	O	ADP	O
iNOS	O	NOUN	B
antigen	O	NOUN	O
was	O	AUX	O
followed	O	VERB	O
by	O	ADP	O
that	O	DET	O
of	O	ADP	O
bFGF	O	NOUN	B
antigen	O	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
bFGF	O	NOUN	B
may	O	AUX	O
have	O	AUX	O
a	O	DET	O
suppressive	O	ADJ	B
effect	O	NOUN	I
on	O	ADP	O
iNOS	O	NOUN	B
expression	O	NOUN	B
in	O	ADP	O
these	O	DET	O
rat	O	NOUN	B
arteritis	B-Disease	NOUN	B


Low-molecular-weight	B-Chemical	NOUN	B
heparin	I-Chemical	NOUN	I
for	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
mechanical	O	ADJ	B
heart	O	NOUN	I
valves	O	NOUN	I
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
:	O	PUNCT	O
The	O	DET	O
interruption	O	NOUN	B
of	O	ADP	O
oral	O	ADJ	B
anticoagulant	O	NOUN	I
(	O	PUNCT	O
OAC	O	NOUN	B
)	O	PUNCT	O
administration	O	NOUN	B
is	O	AUX	O
sometimes	O	ADV	O
indicated	O	VERB	O
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
mechanical	O	ADJ	B
heart	O	NOUN	I
valves	O	NOUN	I
,	O	PUNCT	O
mainly	O	ADV	O
before	O	ADP	O
noncardiac	O	ADJ	B
surgery	O	NOUN	I
,	O	PUNCT	O
non	O	ADJ	B
-	O	PUNCT	O
surgical	O	ADJ	B
interventions	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
pregnancy	O	NOUN	B
.	O	PUNCT	O


Unfractionated	B-Chemical	VERB	B
heparin	I-Chemical	NOUN	I
(	O	PUNCT	O
UH	B-Chemical	PROPN	B
)	O	PUNCT	O
is	O	AUX	O
currently	O	ADV	O
the	O	DET	O
substitute	O	NOUN	O
for	O	ADP	O
selected	O	VERB	O
patients	O	NOUN	B
.	O	PUNCT	O


Low-molecular-weight	B-Chemical	NOUN	B
heparin	I-Chemical	NOUN	I
(	O	PUNCT	O
LMWH	B-Chemical	NOUN	B
)	O	PUNCT	O
offers	O	VERB	O
theoretical	O	ADJ	B
advantages	O	NOUN	I
over	O	ADP	O
UH	B-Chemical	PROPN	B
,	O	PUNCT	O
but	O	CCONJ	O
is	O	AUX	O
not	O	PART	O
currently	O	ADV	O
considered	O	VERB	O
in	O	ADP	O
clinical	O	ADJ	B
guidelines	O	NOUN	I
as	O	ADP	O
an	O	DET	O
alternative	O	NOUN	B
to	O	ADP	O
UH	B-Chemical	PROPN	B
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
prosthetic	O	ADJ	B
valves	O	NOUN	I
.	O	PUNCT	O


HYPOTHESIS	O	NOUN	B
:	O	PUNCT	O
The	O	DET	O
aim	O	NOUN	O
of	O	ADP	O
the	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
review	O	VERB	B
the	O	DET	O
data	O	NOUN	B
accumulated	O	VERB	O
so	O	ADV	O
far	O	ADV	O
on	O	ADP	O
the	O	DET	O
use	O	NOUN	O
of	O	ADP	O
LMWH	B-Chemical	NOUN	B
in	O	ADP	O
this	O	DET	O
patient	O	NOUN	B
population	O	NOUN	I
and	O	CCONJ	O
to	O	PART	O
discuss	O	VERB	O
its	O	PRON	O
applicability	O	NOUN	B
in	O	ADP	O
common	O	ADJ	O
practice	O	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
:	O	PUNCT	O
For	O	ADP	O
this	O	DET	O
paper	O	NOUN	O
,	O	PUNCT	O
the	O	DET	O
current	O	ADJ	O
medical	O	ADJ	B
literature	O	NOUN	I
on	O	ADP	O
LMWH	B-Chemical	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
mechanical	O	ADJ	B
heart	O	NOUN	I
valves	O	NOUN	I
was	O	AUX	O
extensively	O	ADV	O
reviewed	O	VERB	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
There	O	PRON	O
were	O	AUX	O
eight	O	NUM	O
series	O	NOUN	B
and	O	CCONJ	O
six	O	NUM	O
case	O	NOUN	B
reports	O	NOUN	I
.	O	PUNCT	O


of	O	ADP	O
the	O	DET	O
studies	O	NOUN	B
was	O	AUX	O
randomized	O	VERB	B
,	O	PUNCT	O
and	O	CCONJ	O
only	O	ADV	O
one	O	NUM	O
was	O	AUX	O
prospective	O	ADJ	B
.	O	PUNCT	O


Data	O	NOUN	B
to	O	PART	O
establish	O	VERB	O
the	O	DET	O
thromboembolic	B-Disease	ADJ	B
risk	O	NOUN	B
were	O	AUX	O
incomplete	O	ADJ	B
.	O	PUNCT	O


After	O	ADP	O
excluding	O	VERB	O
case	O	NOUN	B
reports	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
following	O	VERB	O
groups	O	NOUN	B
were	O	AUX	O
constructed	O	VERB	O
:(	O	PUNCT	O
a	O	DET	O
)	O	PUNCT	O
short	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
administration	O	NOUN	B
,	O	PUNCT	O
after	O	ADP	O
valve	O	NOUN	B
insertion	O	NOUN	I
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
212	O	NUM	O
);(	O	PUNCT	O
b	O	X	O
)	O	PUNCT	O
short	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
,	O	PUNCT	O
perioperative	O	ADJ	B
(	O	PUNCT	O
noncardiac	O	ADJ	B
)/	O	NOUN	O
periprocedural	O	NOUN	O
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
114	O	NUM	O
);(	O	PUNCT	O
c	O	NOUN	O
)	O	PUNCT	O
long	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
,	O	PUNCT	O
due	O	ADP	O
to	O	PART	O
intolerance	O	NOUN	B
to	O	ADP	O
OAC	O	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
16	O	NUM	O
);(	O	PUNCT	O
d	O	NOUN	O
)	O	PUNCT	O
long	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
,	O	PUNCT	O
in	O	ADP	O
pregnancy	O	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
10	O	NUM	O
).	O	PUNCT	O
The	O	DET	O
incidence	O	NOUN	B
rate	O	NOUN	B
of	O	ADP	O
thromboembolism	B-Disease	NOUN	B
was	O	AUX	O
0	O	NUM	O
.	O	PUNCT	O


9	O	NUM	O
%	O	NOUN	O
for	O	ADP	O
all	O	DET	O
the	O	DET	O
studies	O	NOUN	B
and	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
,	O	PUNCT	O
0	O	NUM	O
,	O	PUNCT	O
20	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
0	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
groups	O	NOUN	B
a	O	DET	O
,	O	PUNCT	O
b	O	X	O
,	O	PUNCT	O
c	O	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
d	O	NOUN	O
,	O	PUNCT	O
respectively	O	ADV	O
;	O	PUNCT	O
for	O	ADP	O
hemorrhage	B-Disease	NOUN	B
,	O	PUNCT	O
the	O	DET	O
overall	O	ADJ	O
rate	O	NOUN	B
was	O	AUX	O
3	O	NUM	O
.	O	PUNCT	O


4	O	NUM	O
%(	O	NOUN	O
3	O	NUM	O
.	O	PUNCT	O


8	O	NUM	O
,	O	PUNCT	O
2	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
,	O	PUNCT	O
10	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
0	O	NUM	O
%	O	NOUN	O
for	O	ADP	O
the	O	DET	O
respective	O	ADJ	O
groups	O	NOUN	B
).	O	PUNCT	O
CONCLUSIONS	O	NOUN	O
:	O	PUNCT	O
In	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
mechanical	O	ADJ	B
heart	O	NOUN	I
valves	O	NOUN	I
,	O	PUNCT	O
short	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
LMWH	B-Chemical	NOUN	B
therapy	O	NOUN	B
compares	O	VERB	O
favorably	O	ADV	O
with	O	ADP	O
UH	B-Chemical	PROPN	B
.	O	PUNCT	O


Data	O	NOUN	B
on	O	ADP	O
mid	O	ADJ	B
-	O	PUNCT	O
and	O	CCONJ	O
long	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
LMWH	B-Chemical	NOUN	B
administration	O	NOUN	B
in	O	ADP	O
these	O	DET	O
patients	O	NOUN	B
are	O	AUX	O
sparse	O	ADJ	O
.	O	PUNCT	O


Further	O	ADV	O
randomized	O	ADJ	B
studies	O	NOUN	I
are	O	AUX	O
needed	O	VERB	O
to	O	PART	O
confirm	O	VERB	B
the	O	DET	O
safety	O	NOUN	B
and	O	CCONJ	O
precise	O	ADJ	O
indications	O	NOUN	B
for	O	ADP	O
the	O	DET	O
use	O	NOUN	O
of	O	ADP	O
LMWH	B-Chemical	NOUN	B


Topiramate	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
nephrolithiasis	B-Disease	NOUN	B
.	O	PUNCT	O


Topiramate	B-Chemical	NOUN	B
is	O	AUX	O
a	O	DET	O
recently	O	ADV	O
developed	O	VERB	O
antiepileptic	O	ADJ	B
medication	O	NOUN	I
that	O	PRON	O
is	O	AUX	O
becoming	O	VERB	O
more	O	ADV	O
widely	O	ADV	O
prescribed	O	VERB	B
because	O	SCONJ	O
of	O	ADP	O
its	O	PRON	O
efficacy	O	NOUN	B
in	O	ADP	O
treating	O	VERB	B
refractory	B-Disease	ADJ	B
seizures	I-Disease	NOUN	I
.	O	PUNCT	O


Urologists	O	NOUN	B
should	O	AUX	O
be	O	AUX	O
aware	O	ADJ	O
that	O	SCONJ	O
this	O	DET	O
medication	O	NOUN	B
can	O	AUX	O
cause	O	VERB	O
metabolic	B-Disease	ADJ	B
acidosis	I-Disease	NOUN	O
in	O	ADP	O
patients	O	NOUN	B
secondary	O	ADJ	B
to	O	PART	I
inhibition	O	NOUN	B
of	O	ADP	O
carbonic	O	ADJ	B
anhydrase	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
,	O	PUNCT	O
a	O	DET	O
distal	O	ADJ	B
tubular	O	ADJ	B
acidification	O	NOUN	I
defect	O	NOUN	I
may	O	AUX	O
result	O	VERB	O
,	O	PUNCT	O
thus	O	ADV	O
impairing	O	VERB	B
the	O	DET	O
normal	O	ADJ	O
compensatory	O	ADJ	O
drop	O	NOUN	B
in	O	ADP	O
urine	O	NOUN	B
pH	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
factors	O	NOUN	B
can	O	AUX	O
lead	O	VERB	O
to	O	PART	O
the	O	DET	O
development	O	NOUN	B
of	O	ADP	O
calcium	B-Chemical	NOUN	B
phosphate	I-Chemical	NOUN	I
nephrolithiasis	B-Disease	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
the	O	DET	O
first	O	ADJ	O
two	O	NUM	O
cases	O	NOUN	B
of	O	ADP	O
topiramate	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
nephrolithiasis	B-Disease	NOUN	B


Spironolactone	B-Chemical	NOUN	B
:	O	PUNCT	O
is	O	AUX	O
it	O	PRON	O
a	O	DET	O
novel	O	ADJ	O
drug	O	NOUN	B
for	O	ADP	O
the	O	DET	O
prevention	O	NOUN	B
of	O	ADP	O
amphotericin	B-Chemical	NOUN	B
B	I-Chemical	NOUN	B
-	O	PUNCT	O
related	O	VERB	B
hypokalemia	B-Disease	NOUN	B
in	O	ADP	O
cancer	B-Disease	NOUN	B
patients	O	NOUN	B
?	O	PUNCT	O
OBJECTIVE	O	NOUN	O
:	O	PUNCT	O
Nephrotoxicity	B-Disease	NOUN	B
is	O	AUX	O
the	O	DET	O
major	O	ADJ	O
adverse	O	ADJ	B
effect	O	NOUN	I
of	O	ADP	O
amphotericin	B-Chemical	NOUN	B
B	I-Chemical	NOUN	I
(	O	PUNCT	O
AmB	B-Chemical	NOUN	B
),	O	PUNCT	O
often	O	ADV	O
limiting	O	VERB	O
administration	O	NOUN	B
of	O	ADP	O
full	O	ADJ	B
dosage	O	NOUN	I
.	O	PUNCT	O


Selective	O	ADJ	B
distal	O	ADJ	I
tubular	O	ADJ	O
epithelial	O	ADJ	O
toxicity	B-Disease	NOUN	B
seems	O	VERB	O
to	O	PART	O
be	O	AUX	O
responsible	O	ADJ	O
for	O	ADP	O
the	O	DET	O
profound	O	ADJ	O
potassium	B-Chemical	NOUN	B
wasting	O	NOUN	I
that	O	PRON	O
is	O	AUX	O
a	O	DET	O
major	O	ADJ	O
clinical	O	ADJ	B
side	O	NOUN	B
effect	O	NOUN	I
of	O	ADP	O
treatment	O	NOUN	B
with	O	ADP	O
AmB	B-Chemical	NOUN	B
.	O	PUNCT	O


Potassium	B-Chemical	NOUN	B
depletion	O	NOUN	B
also	O	ADV	O
potentiates	O	VERB	B
the	O	DET	O
tubular	O	ADJ	B
toxicity	B-Disease	NOUN	B
of	O	ADP	O
AmB	B-Chemical	NOUN	B
.	O	PUNCT	O


This	O	DET	O
study	O	NOUN	B
was	O	AUX	O
designed	O	VERB	O
to	O	PART	O
assess	O	VERB	B
the	O	DET	O
ability	O	NOUN	O
of	O	ADP	O
spironolactone	B-Chemical	NOUN	B
to	O	PART	O
reduce	O	VERB	B
potassium	B-Chemical	NOUN	B
requirements	O	NOUN	B
and	O	CCONJ	O
to	O	PART	O
prevent	O	VERB	O
hypokalemia	B-Disease	NOUN	B
in	O	ADP	O
neutropenic	B-Disease	ADJ	B
patients	O	NOUN	B
on	O	ADP	O
AmB	B-Chemical	NOUN	B
treatment	O	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
:	O	PUNCT	O
In	O	ADP	O
this	O	DET	O
study	O	NOUN	B
26	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
various	O	ADJ	O
hematological	B-Disease	ADJ	B
disorders	I-Disease	NOUN	I
were	O	AUX	O
randomized	O	VERB	B
to	O	PART	O
receive	O	VERB	O
either	O	CCONJ	O
intravenous	O	ADJ	B
AmB	B-Chemical	NOUN	B
alone	O	ADV	O
or	O	CCONJ	O
AmB	B-Chemical	NOUN	B
and	O	CCONJ	O
oral	O	ADJ	B
spironolactone	B-Chemical	NOUN	B
100	O	NUM	O
mg	O	NOUN	O
twice	O	ADV	O
daily	O	ADV	B
when	O	SCONJ	O
developing	O	VERB	O
a	O	DET	O
proven	O	VERB	B
or	O	CCONJ	O
suspected	O	VERB	O
fungal	B-Disease	ADJ	B
infection	I-Disease	NOUN	I
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
Patients	O	NOUN	B
receiving	O	VERB	O
concomitant	O	ADJ	B
AmB	B-Chemical	NOUN	B
and	O	CCONJ	O
spironolactone	B-Chemical	NOUN	B
had	O	AUX	O
significantly	O	ADV	O
higher	O	ADJ	O
plasma	O	NOUN	B
potassium	B-Chemical	NOUN	B
levels	O	NOUN	O
than	O	ADP	O
those	O	DET	O
receiving	O	VERB	O
AmB	B-Chemical	NOUN	B
alone	O	ADV	O
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


0027	O	NUM	O
).	O	PUNCT	B
Those	O	DET	O
patients	O	NOUN	B
receiving	O	VERB	O
AmB	B-Chemical	NOUN	B
and	O	CCONJ	O
spironolactone	B-Chemical	NOUN	B
required	O	VERB	O
significantly	O	ADV	O
less	O	ADJ	O
potassium	B-Chemical	NOUN	B
supplementation	O	NOUN	B
to	O	PART	O
maintain	O	VERB	O
their	O	PRON	O
plasma	O	NOUN	B
potassium	B-Chemical	NOUN	B
within	O	ADP	O
the	O	DET	O
normal	O	ADJ	B
range	O	NOUN	I
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


022	O	NUM	O
).	O	PUNCT	O
Moreover	O	ADV	O
,	O	PUNCT	O
urinary	O	ADJ	B
potassium	B-Chemical	NOUN	I
losses	O	NOUN	I
were	O	AUX	O
significantly	O	ADV	O
less	O	ADJ	O
in	O	ADP	O
patients	O	NOUN	B
receiving	O	VERB	O
AmB	B-Chemical	NOUN	B
and	O	CCONJ	O
spironolactone	B-Chemical	NOUN	B
than	O	ADP	O
those	O	DET	O
receiving	O	VERB	O
AmB	B-Chemical	NOUN	B
alone	O	ADV	O
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


040	O	NUM	O
).	O	PUNCT	O
CONCLUSION	O	NOUN	O
:	O	PUNCT	O
This	O	DET	O
study	O	NOUN	B
showed	O	VERB	O
that	O	SCONJ	O
spironolactone	B-Chemical	NOUN	B
can	O	AUX	O
reduce	O	VERB	B
potassium	B-Chemical	NOUN	B
requirements	O	NOUN	B
and	O	CCONJ	O
prevent	O	VERB	O
hypokalemia	B-Disease	NOUN	B
by	O	ADP	O
reducing	O	VERB	B
urinary	O	ADJ	B
potassium	B-Chemical	NOUN	O
loss	O	NOUN	O
in	O	ADP	O
neutropenic	B-Disease	ADJ	B
patients	O	NOUN	B
on	O	ADP	O
AmB	B-Chemical	NOUN	B


Dopamine	B-Chemical	NOUN	B
D2	O	NOUN	I
receptor	O	NOUN	I
signaling	O	NOUN	O
controls	O	VERB	O
neuronal	O	ADJ	B
cell	O	NOUN	I
death	O	NOUN	O
induced	O	VERB	B
by	O	ADP	O
muscarinic	O	NOUN	B
and	O	CCONJ	O
glutamatergic	O	ADJ	B
drugs	O	NOUN	I
.	O	PUNCT	O


Dopamine	B-Chemical	NOUN	B
(	O	PUNCT	O
DA	B-Chemical	NOUN	B
),	O	PUNCT	O
through	O	ADP	O
D1	O	NOUN	B
/	O	SYM	O
D2	O	NOUN	B
receptor	O	NOUN	I
-	O	PUNCT	O
mediated	O	VERB	B
signaling	O	NOUN	B
,	O	PUNCT	O
plays	O	VERB	O
a	O	DET	O
major	O	ADJ	O
role	O	NOUN	O
in	O	ADP	O
the	O	DET	O
control	O	NOUN	B
of	O	ADP	O
epileptic	B-Disease	ADJ	B
seizures	I-Disease	NOUN	I
arising	O	VERB	O
in	O	ADP	O
the	O	DET	O
limbic	O	ADJ	B
system	O	NOUN	B
.	O	PUNCT	O


Excitotoxicity	B-Disease	NOUN	B
leading	O	VERB	O
to	O	PART	O
neuronal	O	ADJ	B
cell	O	NOUN	I
death	O	NOUN	O
in	O	ADP	O
the	O	DET	O
affected	O	VERB	B
areas	O	NOUN	I
is	O	AUX	O
a	O	DET	O
major	O	ADJ	O
consequence	O	NOUN	B
of	O	ADP	I
seizures	B-Disease	NOUN	B
at	O	ADP	O
the	O	DET	O
cellular	O	ADJ	B
level	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
this	O	DET	O
respect	O	NOUN	O
,	O	PUNCT	O
little	O	ADJ	O
is	O	AUX	O
known	O	VERB	O
about	O	ADP	O
the	O	DET	O
role	O	NOUN	O
of	O	ADP	O
DA	B-Chemical	NOUN	B
receptors	O	NOUN	I
in	O	ADP	O
the	O	DET	O
occurrence	O	NOUN	B
of	O	ADP	O
epilepsy	B-Disease	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
neuronal	O	ADJ	B
cell	O	NOUN	I
death	O	NOUN	O
.	O	PUNCT	O


Here	O	ADV	O
we	O	PRON	O
analyze	O	VERB	B
the	O	DET	O
occurrence	O	NOUN	B
of	O	ADP	O
seizures	B-Disease	NOUN	B
and	O	CCONJ	O
neurotoxicity	B-Disease	NOUN	B
in	O	ADP	O
D2R	O	NOUN	B
-/-	O	ADJ	O
mice	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
the	O	DET	O
cholinergic	O	ADJ	B
agonist	O	NOUN	B
pilocarpine	B-Chemical	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
compared	O	VERB	O
these	O	DET	O
results	O	NOUN	B
with	O	ADP	O
those	O	DET	O
previously	O	ADV	O
obtained	O	VERB	O
with	O	ADP	O
kainic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
(	O	PUNCT	O
KA	B-Chemical	NOUN	B
),	O	PUNCT	O
a	O	DET	O
potent	O	ADJ	O
glutamate	B-Chemical	NOUN	B
agonist	O	NOUN	B
.	O	PUNCT	O


Importantly	O	ADV	O
,	O	PUNCT	O
D2R	O	NOUN	B
-/-	O	ADJ	O
mice	O	NOUN	B
develop	O	VERB	O
seizures	B-Disease	NOUN	B
at	O	ADP	O
doses	O	NOUN	B
of	O	ADP	O
both	O	DET	O
drugs	O	NOUN	B
that	O	PRON	O
are	O	AUX	O
not	O	PART	O
epileptogenic	O	ADJ	B
for	O	ADP	O
WT	O	NOUN	B
littermates	O	NOUN	I
and	O	CCONJ	O
show	O	VERB	O
greater	O	ADJ	O
neurotoxicity	B-Disease	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
pilocarpine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
seizures	B-Disease	NOUN	B
result	O	VERB	B
in	O	ADP	O
a	O	DET	O
more	O	ADV	O
widespread	O	ADJ	B
neuronal	O	ADJ	B
death	O	NOUN	I
in	O	ADP	O
both	O	CCONJ	O
WT	O	NOUN	B
and	O	CCONJ	O
D2R	O	NOUN	B
-/-	O	ADJ	O
brains	O	NOUN	B
in	O	ADP	O
comparison	O	NOUN	B
to	O	PART	O
KA	B-Chemical	NOUN	B
.	O	PUNCT	O


Thus	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
absence	O	NOUN	B
of	O	ADP	O
D2R	O	NOUN	B
lowers	O	VERB	O
the	O	DET	O
threshold	O	NOUN	B
for	O	ADP	O
seizures	B-Disease	NOUN	B
induced	O	VERB	B
by	O	ADP	O
both	O	CCONJ	O
glutamate	B-Chemical	NOUN	B
and	O	CCONJ	O
acetylcholine	B-Chemical	NOUN	B
.	O	PUNCT	O


Moreover	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
dopaminergic	O	ADJ	B
control	O	NOUN	O
of	O	ADP	O
epilepsy	B-Disease	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
neurodegeneration	B-Disease	NOUN	B


Treatment	O	NOUN	B
of	O	ADP	O
risperidone	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
hyperprolactinemia	B-Disease	NOUN	B
with	O	ADP	O
a	O	DET	O
dopamine	B-Chemical	NOUN	B
agonist	O	NOUN	B
in	O	ADP	O
children	O	NOUN	B
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
:	O	PUNCT	O
Risperidone	B-Chemical	NOUN	B
,	O	PUNCT	O
a	O	DET	O
potent	O	ADJ	O
antagonist	O	NOUN	B
of	O	ADP	O
both	O	CCONJ	O
serotonergic	O	NOUN	B
(	O	PUNCT	O
5HT2A	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
dopaminergic	O	ADJ	B
D2	O	NOUN	I
receptors	O	NOUN	I
is	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
hyperprolactinemia	B-Disease	NOUN	B
in	O	ADP	O
adults	O	NOUN	B
and	O	CCONJ	O
children	O	NOUN	B
.	O	PUNCT	O


Chronically	O	ADV	B
elevated	O	ADJ	O
prolactin	O	NOUN	B
levels	O	NOUN	I
in	O	ADP	O
children	O	NOUN	B
with	O	ADP	O
prolactinomas	B-Disease	NOUN	B
may	O	AUX	O
be	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
arrested	O	VERB	B
growth	O	NOUN	B
and	O	CCONJ	O
development	O	NOUN	B
resulting	O	VERB	O
in	O	ADP	O
either	O	DET	O
delayed	B-Disease	VERB	B
puberty	I-Disease	NOUN	I
or	O	CCONJ	O
short	O	ADJ	B
stature	O	NOUN	I
.	O	PUNCT	O


These	O	DET	O
possibilities	O	NOUN	O
stress	O	VERB	B
the	O	DET	O
importance	O	NOUN	O
of	O	ADP	O
developing	O	VERB	O
a	O	DET	O
safe	O	ADJ	O
and	O	CCONJ	O
effective	O	ADJ	B
approach	O	NOUN	O
to	O	ADP	O
drug	O	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
hyperprolactinemia	B-Disease	NOUN	B
in	O	ADP	O
youth	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
the	O	DET	O
successful	O	ADJ	O
treatment	O	NOUN	B
of	O	ADP	O
risperidone	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
hyperprolactinemia	B-Disease	NOUN	B
with	O	ADP	O
cabergoline	B-Chemical	NOUN	B
in	O	ADP	O
youth	O	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
:	O	PUNCT	O
We	O	PRON	O
undertook	O	VERB	O
a	O	DET	O
retrospective	O	ADJ	B
case	O	NOUN	O
review	O	NOUN	O
of	O	ADP	O
four	O	NUM	O
children	O	NOUN	B
with	O	ADP	O
risperidone	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
hyperprolactinemia	B-Disease	NOUN	B
treated	O	VERB	B
with	O	ADP	I
cabergoline	B-Chemical	NOUN	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
Four	O	NUM	O
males	O	NOUN	B
(	O	PUNCT	O
age	O	NOUN	B
6	O	NUM	O
-	O	SYM	O
11	O	NUM	O
years	O	NOUN	B
)	O	PUNCT	O
with	O	ADP	O
Diagnostic	O	PROPN	B
and	O	CCONJ	O
Statistical	O	PROPN	O
Manual	O	PROPN	O
of	O	ADP	O
Mental	B-Disease	PROPN	O
Disorders	I-Disease	PROPN	O
(	O	PUNCT	O
fourth	O	ADJ	O
edition	O	NOUN	O
)	O	PUNCT	O
bipolar	B-Disease	ADJ	B
disorder	I-Disease	NOUN	I
or	O	CCONJ	O
psychoses	B-Disease	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
risperidone	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
elevations	O	NOUN	B
in	O	ADP	O
serum	O	NOUN	B
prolactin	O	NOUN	I
levels	O	NOUN	I
(	O	PUNCT	O
57	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
-	O	PUNCT	O
129	O	NUM	O
ng	O	NOUN	O
/	O	PUNCT	O
mL	O	NOUN	B
,	O	PUNCT	O
normal	O	ADJ	O
5	O	NUM	O
-	O	SYM	O
15	O	NUM	O
ng	O	NOUN	O
/	O	PUNCT	O
mL	O	NOUN	B
),	O	PUNCT	O
were	O	AUX	O
treated	O	VERB	B
with	O	ADP	I
cabergoline	B-Chemical	NOUN	B
(	O	PUNCT	O
mean	O	ADJ	B
dose	O	NOUN	I
2	O	NUM	I
.	O	PUNCT	O


13	O	NUM	O
+/-	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


09	O	NUM	O
mg	O	NOUN	O
/	O	PUNCT	O
week	O	NOUN	B
).	O	PUNCT	O
When	O	SCONJ	O
serum	O	NOUN	B
prolactin	O	NOUN	B
levels	O	NOUN	I
normalized	O	VERB	B
in	O	ADP	O
all	O	DET	O
four	O	NUM	O
subjects	O	NOUN	B
(	O	PUNCT	O
mean	O	NOUN	O
11	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
+/-	O	CCONJ	O
10	O	NUM	O
.	O	PUNCT	O


9	O	NUM	O
ng	O	NOUN	O
/	O	PUNCT	O
mL	O	NOUN	B
),	O	PUNCT	O
the	O	DET	O
cabergoline	B-Chemical	NOUN	B
dose	O	NOUN	B
was	O	AUX	O
reduced	O	VERB	B
to	O	PART	O
1	O	NUM	O
mg	O	NOUN	O
/	O	PUNCT	O
week	O	NOUN	B
in	O	ADP	O
three	O	NUM	O
of	O	ADP	O
four	O	NUM	O
subjects	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
mean	O	ADJ	O
duration	O	NOUN	B
of	O	ADP	O
therapy	O	NOUN	B
with	O	ADP	O
cabergoline	B-Chemical	NOUN	B
was	O	AUX	O
523	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
+/-	O	CCONJ	O
129	O	NUM	O
.	O	PUNCT	O


7	O	NUM	O
days	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
mean	O	ADJ	O
duration	O	NOUN	B
of	O	ADP	O
therapy	O	NOUN	B
with	O	ADP	O
risperidone	B-Chemical	NOUN	B
was	O	AUX	O
788	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
+/-	O	CCONJ	O
162	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
days	O	NOUN	B
.	O	PUNCT	O


Cabergoline	B-Chemical	NOUN	B
was	O	AUX	O
well	O	ADV	O
tolerated	O	VERB	B
without	O	ADP	O
adverse	O	ADJ	B
effects	O	NOUN	I
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
:	O	PUNCT	O
Cabergoline	B-Chemical	NOUN	B
may	O	AUX	O
be	O	AUX	O
useful	O	ADJ	O
for	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
risperidone	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
hyperprolactinemia	B-Disease	NOUN	B


Cholestatic	B-Disease	ADJ	B
jaundice	I-Disease	NOUN	I
associated	O	VERB	B
with	O	ADP	I
the	O	DET	O
use	O	NOUN	O
of	O	ADP	O
metformin	B-Chemical	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
a	O	DET	O
patient	O	NOUN	B
who	O	PRON	O
developed	O	VERB	O
cholestatic	B-Disease	ADJ	B
jaundice	I-Disease	NOUN	I
shortly	O	ADV	O
after	O	ADP	O
initiation	O	NOUN	B
of	O	ADP	O
treatment	O	NOUN	B
with	O	ADP	O
metformin	B-Chemical	NOUN	B
hydrochloride	I-Chemical	NOUN	B
.	O	PUNCT	O


Ultrasound	O	NOUN	B
of	O	ADP	O
the	O	DET	O
liver	O	NOUN	B
and	O	CCONJ	O
abdominal	O	ADJ	B
CT	O	NOUN	I
were	O	AUX	O
normal	O	ADJ	O
.	O	PUNCT	O


An	O	DET	O
ERCP	O	NOUN	B
showed	O	VERB	O
normal	O	ADJ	O
biliary	O	ADJ	B
anatomy	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
percutaneous	O	ADJ	B
liver	O	NOUN	I
biopsy	O	NOUN	I
was	O	AUX	O
obtained	O	VERB	O
showing	O	VERB	O
marked	O	ADJ	O
cholestasis	B-Disease	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
portal	O	ADJ	B
edema	B-Disease	NOUN	I
,	O	PUNCT	O
ductular	O	ADJ	B
proliferation	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
acute	O	ADJ	B
inflammation	B-Disease	NOUN	B
.	O	PUNCT	O


Metformin	B-Chemical	NOUN	B
hydrochloride	I-Chemical	NOUN	B
was	O	AUX	O
discontinued	O	VERB	B
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
patient	O	NOUN	B
'	O	PART	O
s	O	NOUN	O
jaundice	B-Disease	NOUN	B
resolved	O	VERB	B
slowly	O	ADV	O
over	O	ADP	O
a	O	DET	O
period	O	NOUN	B
of	O	ADP	O
several	O	ADJ	O
months	O	NOUN	B
.	O	PUNCT	O


Given	O	VERB	O
the	O	DET	O
onset	O	NOUN	O
of	O	ADP	O
his	O	PRON	O
jaundice	B-Disease	NOUN	B
2	O	NUM	I
wk	O	NOUN	O
after	O	ADP	O
the	O	DET	O
initiation	O	NOUN	B
of	O	ADP	O
metformin	B-Chemical	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
believe	O	VERB	O
that	O	SCONJ	O
this	O	DET	O
case	O	NOUN	B
represents	O	VERB	O
an	O	DET	O
example	O	NOUN	O
of	O	ADP	O
metformin	B-Chemical	NOUN	B
-	O	PUNCT	O
associated	O	VERB	B
hepatotoxicity	B-Disease	NOUN	B


Electro	O	PROPN	B
-	O	PUNCT	O
oculography	O	NOUN	B
,	O	PUNCT	O
electroretinography	O	NOUN	B
,	O	PUNCT	O
visual	O	ADJ	B
evoked	O	ADJ	O
potentials	O	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
multifocal	O	ADJ	B
electroretinography	O	NOUN	I
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
vigabatrin	B-Chemical	NOUN	B
-	O	PUNCT	O
attributed	O	VERB	B
visual	B-Disease	ADJ	B
field	I-Disease	NOUN	I
constriction	I-Disease	NOUN	I
.	O	PUNCT	O


PURPOSE	O	NOUN	B
:	O	PUNCT	O
Symptomatic	O	ADJ	B
visual	B-Disease	ADJ	B
field	I-Disease	NOUN	I
constriction	I-Disease	NOUN	I
thought	O	VERB	O
to	O	PART	O
be	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
vigabatrin	B-Chemical	NOUN	B
has	O	AUX	O
been	O	AUX	O
reported	O	VERB	O
.	O	PUNCT	O


The	O	DET	O
current	O	ADJ	O
study	O	NOUN	B
investigated	O	VERB	B
the	O	DET	O
visual	O	ADJ	B
fields	O	NOUN	I
and	O	CCONJ	O
visual	O	ADJ	B
electrophysiology	O	NOUN	I
of	O	ADP	O
eight	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
known	O	ADJ	O
vigabatrin	B-Chemical	NOUN	B
-	O	PUNCT	O
attributed	O	VERB	B
visual	B-Disease	ADJ	B
field	I-Disease	NOUN	I
loss	I-Disease	NOUN	I
,	O	PUNCT	O
three	O	NUM	O
of	O	ADP	O
whom	O	PRON	O
were	O	AUX	O
reported	O	VERB	O
previously	O	ADV	O
.	O	PUNCT	O


Six	O	NUM	O
of	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
were	O	AUX	O
no	O	DET	O
longer	O	ADV	O
receiving	O	VERB	O
vigabatrin	B-Chemical	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
:	O	PUNCT	O
The	O	DET	O
central	O	ADJ	B
and	O	CCONJ	O
peripheral	O	ADJ	B
fields	O	NOUN	I
were	O	AUX	O
examined	O	VERB	O
with	O	ADP	O
the	O	DET	O
Humphrey	O	PROPN	B
Visual	O	PROPN	I
Field	O	PROPN	I
Analyzer	O	PROPN	I
.	O	PUNCT	O


Full	O	ADJ	B
visual	O	ADJ	I
electrophysiology	O	NOUN	I
,	O	PUNCT	O
including	O	VERB	O
flash	O	NOUN	B
electroretinography	O	NOUN	I
(	O	PUNCT	O
ERG	O	NOUN	B
),	O	PUNCT	O
pattern	O	NOUN	B
electroretinography	O	NOUN	I
,	O	PUNCT	O
multifocal	O	ADJ	B
ERG	O	NOUN	B
using	O	VERB	O
the	O	DET	O
VERIS	O	PROPN	B
system	O	NOUN	I
,	O	PUNCT	O
electro	O	NOUN	B
-	O	PUNCT	O
oculography	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
flash	O	NOUN	B
and	O	CCONJ	O
pattern	O	NOUN	B
visual	O	ADJ	O
evoked	O	ADJ	O
potentials	O	NOUN	O
,	O	PUNCT	O
was	O	AUX	O
undertaken	O	VERB	O
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
Seven	O	NUM	O
patients	O	NOUN	B
showed	O	VERB	O
marked	O	ADJ	O
visual	B-Disease	ADJ	B
field	I-Disease	NOUN	I
constriction	I-Disease	NOUN	I
with	O	ADP	O
some	O	DET	O
sparing	O	NOUN	B
of	O	ADP	O
the	O	DET	O
temporal	O	ADJ	B
visual	O	ADJ	O
field	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
eighth	O	ADJ	O
exhibited	O	VERB	O
concentric	O	ADJ	B
constriction	O	NOUN	I
.	O	PUNCT	O


Most	O	ADV	O
electrophysiological	O	ADJ	B
responses	O	NOUN	I
were	O	AUX	O
usually	O	ADV	O
just	O	ADV	O
within	O	ADP	O
normal	O	ADJ	O
limits	O	NOUN	O
;	O	PUNCT	O
two	O	NUM	O
patients	O	NOUN	B
had	O	AUX	O
subnormal	O	ADJ	B
Arden	O	PROPN	B
electro	O	NOUN	I
-	O	PUNCT	O
oculography	O	NOUN	B
indices	O	NOUN	B
;	O	PUNCT	O
and	O	CCONJ	O
one	O	NUM	O
patient	O	NOUN	B
showed	O	VERB	O
an	O	DET	O
abnormally	O	ADV	O
delayed	O	VERB	O
photopic	O	ADJ	O
b	O	NOUN	O
wave	O	NOUN	O
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
five	O	NUM	O
patients	O	NOUN	B
showed	O	VERB	O
delayed	O	VERB	B
30	O	NUM	O
-	O	PUNCT	O
Hz	O	NOUN	O
flicker	O	NOUN	O
b	O	NOUN	O
waves	O	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
seven	O	NUM	O
patients	O	NOUN	B
showed	O	VERB	O
delayed	O	VERB	B
oscillatory	O	ADJ	B
potentials	O	NOUN	I
.	O	PUNCT	O


Multifocal	O	ADJ	B
ERG	O	NOUN	B
showed	O	VERB	O
abnormalities	O	NOUN	B
that	O	PRON	O
sometimes	O	ADV	O
correlated	O	VERB	B
with	O	ADP	O
the	O	DET	O
visual	O	ADJ	B
field	O	NOUN	I
appearance	O	NOUN	B
and	O	CCONJ	O
confirmed	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
deficit	O	NOUN	B
occurs	O	VERB	B
at	O	ADP	O
the	O	DET	O
retinal	O	ADJ	B
level	O	NOUN	B
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
:	O	PUNCT	O
Marked	O	ADJ	O
visual	B-Disease	ADJ	B
field	I-Disease	NOUN	I
constriction	I-Disease	NOUN	I
appears	O	VERB	O
to	O	PART	O
be	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
vigabatrin	B-Chemical	NOUN	B
therapy	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
field	O	NOUN	B
defects	O	NOUN	I
and	O	CCONJ	O
some	O	DET	O
electrophysiological	O	ADJ	B
abnormalities	O	NOUN	I
persist	O	VERB	O
when	O	SCONJ	O
vigabatrin	B-Chemical	NOUN	B


Conversion	O	NOUN	B
to	O	PART	O
rapamycin	B-Chemical	NOUN	B
immunosuppression	O	NOUN	B
in	O	ADP	O
renal	O	ADJ	B
transplant	O	NOUN	I
recipients	O	NOUN	B
:	O	PUNCT	O
report	O	NOUN	B
of	O	ADP	O
an	O	DET	O
initial	O	ADJ	B
experience	O	NOUN	B
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
:	O	PUNCT	O
The	O	DET	O
aim	O	NOUN	O
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
is	O	AUX	O
to	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	O
RAPA	B-Chemical	NOUN	B
conversion	O	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
undergoing	O	VERB	O
cyclosporine	B-Chemical	NOUN	B
(	O	PUNCT	O
CsA	B-Chemical	NOUN	B
)	O	PUNCT	O
or	O	CCONJ	O
tacrolimus	B-Chemical	NOUN	B
(	O	PUNCT	O
Tac	B-Chemical	NOUN	B
)	O	PUNCT	O
toxicity	B-Disease	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
:	O	PUNCT	O
Twenty	O	NUM	O
renal	O	ADJ	B
transplant	O	NOUN	I
recipients	O	NOUN	B
were	O	AUX	O
switched	O	VERB	O
to	O	PART	O
fixed	O	VERB	B
dose	O	NOUN	I
rapamycin	B-Chemical	NOUN	I
(	O	PUNCT	O
RAPA	B-Chemical	NOUN	B
)(	O	NOUN	O
5	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
day	O	NOUN	B
)	O	PUNCT	O
0	O	NUM	O
to	O	PART	O
204	O	NUM	O
months	O	NOUN	B
posttransplant	O	ADJ	B
.	O	PUNCT	O


Drug	O	NOUN	B
monitoring	O	NOUN	I
was	O	AUX	O
not	O	PART	O
initially	O	ADV	O
used	O	VERB	O
to	O	PART	O
adjust	O	VERB	O
doses	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
indications	O	NOUN	B
for	O	ADP	O
switch	O	NOUN	B
were	O	AUX	O
chronic	O	ADJ	B
CsA	B-Chemical	NOUN	I
or	O	CCONJ	O
Tac	B-Chemical	NOUN	B
nephrotoxicity	B-Disease	NOUN	B
(	O	PUNCT	O
12	O	NUM	O
),	O	PUNCT	O
acute	O	ADJ	B
CsA	B-Chemical	NOUN	B
or	O	CCONJ	O
Tac	B-Chemical	NOUN	B
toxicity	B-Disease	NOUN	B
(	O	PUNCT	O
3	O	NUM	O
),	O	PUNCT	O
severe	O	ADJ	B
facial	B-Disease	ADJ	B
dysmorphism	I-Disease	NOUN	I
(	O	PUNCT	O
2	O	NUM	O
),	O	PUNCT	O
posttransplant	B-Disease	ADJ	B
lymphoproliferative	I-Disease	ADJ	I
disorder	I-Disease	NOUN	I
(	O	PUNCT	O
PTLD	B-Disease	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
remission	O	NOUN	B
(	O	PUNCT	O
2	O	NUM	O
),	O	PUNCT	O
and	O	CCONJ	O
hepatotoxicity	B-Disease	NOUN	B
in	O	ADP	O
1	O	NUM	O
.	O	PUNCT	O


Follow	O	PROPN	B
-	O	PUNCT	O
up	O	NOUN	O
is	O	AUX	O
7	O	NUM	O
to	O	PART	O
24	O	NUM	O
months	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
In	O	ADP	O
the	O	DET	O
12	O	NUM	O
patients	O	NOUN	B
switched	O	VERB	O
because	O	SCONJ	O
of	O	ADP	O
chronic	O	ADJ	B
nephrotoxicity	B-Disease	NOUN	B
there	O	PRON	O
was	O	AUX	O
a	O	DET	O
significant	O	ADJ	O
decrease	O	NOUN	B
in	O	ADP	O
serum	O	NOUN	B
creatinine	B-Chemical	NOUN	I
[	O	PUNCT	O
233	O	NUM	O
+/-	O	CCONJ	O
34	O	NUM	O
to	O	PART	O
210	O	NUM	O
+/-	O	CCONJ	O
56	O	NUM	O
micromol	O	NOUN	B
/	O	SYM	O
liter	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


05	O	NUM	O
)	O	PUNCT	O
at	O	ADP	O
6	O	NUM	O
months	O	NOUN	B
].	O	PROPN	O
Facial	B-Disease	ADJ	B
dysmorphism	I-Disease	NOUN	I
improved	O	VERB	B
in	O	ADP	O
two	O	NUM	O
patients	O	NOUN	B
.	O	PUNCT	O


No	O	DET	O
relapse	O	NOUN	B
of	O	ADP	O
PTLD	B-Disease	NOUN	B
was	O	AUX	O
observed	O	VERB	B
.	O	PUNCT	O


Five	O	NUM	O
patients	O	NOUN	B
developed	O	VERB	O
pneumonia	B-Disease	NOUN	B
(	O	PUNCT	O
two	O	NUM	O
Pneumocystis	B-Disease	NOUN	B
carinii	I-Disease	NOUN	I
pneumonia	I-Disease	NOUN	B
,	O	PUNCT	O
one	O	NUM	O
infectious	B-Disease	ADJ	B
mononucleosis	I-Disease	NOUN	I
with	O	ADP	O
polyclonal	O	ADJ	B
PTLD	B-Disease	NOUN	I
lung	O	NOUN	I
infiltrate	O	NOUN	I
)	O	PUNCT	O
and	O	CCONJ	O
two	O	NUM	O
had	O	AUX	O
bronchiolitis	B-Disease	NOUN	B
obliterans	I-Disease	NOUN	I
.	O	PUNCT	O


There	O	PRON	O
were	O	AUX	O
no	O	DET	O
deaths	O	NOUN	O
.	O	PUNCT	O


RAPA	B-Chemical	NOUN	B
was	O	AUX	O
discontinued	O	VERB	B
in	O	ADP	O
four	O	NUM	O
patients	O	NOUN	B
,	O	PUNCT	O
because	O	SCONJ	O
of	O	ADP	O
pneumonia	B-Disease	NOUN	B
in	O	ADP	O
two	O	NUM	O
,	O	PUNCT	O
PTLD	B-Disease	NOUN	B
in	O	ADP	O
one	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
oral	O	ADJ	B
aphtous	B-Disease	ADJ	B
ulcers	I-Disease	NOUN	I
in	O	ADP	O
one	O	NUM	O
.	O	PUNCT	O


RAPA	B-Chemical	NOUN	B
levels	O	NOUN	B
were	O	AUX	O
high	O	ADJ	O
(>	O	NOUN	O
15	O	NUM	O
ng	O	NOUN	O
/	O	PUNCT	O
ml	O	NOUN	O
)	O	PUNCT	O
in	O	ADP	O
7	O	NUM	O
of	O	ADP	O
13	O	NUM	O
(	O	PUNCT	O
54	O	NUM	O
%)	O	NOUN	O
patients	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
:	O	PUNCT	O
RAPA	B-Chemical	NOUN	B
conversion	O	NOUN	B
provides	O	VERB	O
adequate	O	ADJ	B
immunosuppression	O	NOUN	B
to	O	PART	O
enable	O	VERB	O
CsA	B-Chemical	NOUN	B
withdrawal	O	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
when	O	SCONJ	O
converting	O	VERB	O
patients	O	NOUN	B
to	O	PART	O
RAPA	B-Chemical	NOUN	B
drug	O	NOUN	B
levels	O	NOUN	I
should	O	AUX	O
be	O	AUX	O
monitored	O	VERB	B
to	O	PART	O
avoid	O	VERB	O
over	O	ADP	B
-	O	PUNCT	O
immunosuppression	O	NOUN	B
and	O	CCONJ	O
adequate	O	ADJ	B
antiviral	O	ADJ	B
and	O	CCONJ	O
Pneumocystis	B-Disease	NOUN	B
carinii	I-Disease	NOUN	I
pneumonia	I-Disease	NOUN	I


Worsening	O	NOUN	B
of	O	ADP	O
levodopa	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
dyskinesias	B-Disease	NOUN	B
by	O	ADP	O
motor	O	NOUN	B
and	O	CCONJ	O
mental	O	ADJ	B
tasks	O	NOUN	I
.	O	PUNCT	O


Ten	O	NUM	O
patients	O	NOUN	B
who	O	PRON	O
had	O	AUX	O
Parkinson's	B-Disease	ADJ	O
disease	I-Disease	NOUN	B
with	O	ADP	O
disabling	O	VERB	O
dyskinesia	B-Disease	NOUN	B
were	O	AUX	O
included	O	VERB	O
in	O	ADP	O
this	O	DET	O
study	O	NOUN	B
to	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
role	O	NOUN	O
of	O	ADP	O
mental	O	ADJ	B
(	O	PUNCT	O
mental	O	ADJ	B
calculation	O	NOUN	I
)	O	PUNCT	O
and	O	CCONJ	O
motor	O	NOUN	B
(	O	PUNCT	O
flexion	O	NOUN	B
/	O	SYM	O
extension	O	NOUN	B
of	O	ADP	O
right	O	ADJ	B
fingers	O	NOUN	I
,	O	PUNCT	O
flexion	O	NOUN	B
/	O	SYM	O
extension	O	NOUN	B
of	O	ADP	O
left	O	VERB	B
fingers	O	NOUN	I
,	O	PUNCT	O
flexion	O	NOUN	B
/	O	SYM	O
extension	O	NOUN	B
of	O	ADP	O
the	O	DET	O
neck	O	NOUN	B
,	O	PUNCT	O
speaking	O	VERB	B
aloud	O	ADJ	I
)	O	PUNCT	O
tasks	O	NOUN	O
on	O	ADP	O
the	O	DET	O
worsening	O	NOUN	B
of	O	ADP	O
peak	O	NOUN	B
-	O	PUNCT	O
dose	O	NOUN	B
dyskinesia	B-Disease	NOUN	B
following	O	VERB	O
administration	O	NOUN	B
of	O	ADP	O
an	O	DET	O
effective	O	ADJ	B
single	O	ADJ	B
dose	O	NOUN	I
of	O	ADP	O
apomorphine	B-Chemical	NOUN	B
.	O	PUNCT	O


Compared	O	VERB	B
with	O	ADP	O
the	O	DET	O
score	O	NOUN	B
at	O	ADP	O
rest	O	NOUN	B
(	O	PUNCT	O
1	O	NUM	O
.	O	PUNCT	O


3	O	NUM	O
+/-	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


3	O	X	O
),	O	PUNCT	O
a	O	DET	O
significant	O	ADJ	O
aggravation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
dyskinesia	B-Disease	NOUN	B
score	O	NOUN	B
was	O	AUX	O
observed	O	VERB	O
during	O	ADP	O
speaking	O	VERB	B
aloud	O	ADJ	B
(	O	PUNCT	O
5	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
+/-	O	CCONJ	O
1	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
,	O	PUNCT	O
p	O	X	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


05	O	NUM	O
),	O	PUNCT	O
movements	O	NOUN	B
of	O	ADP	O
right	O	ADJ	B
(	O	PUNCT	O
4	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
+/-	O	CCONJ	O
1	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
,	O	PUNCT	O
p	O	X	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


05	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
left	O	VERB	B
(	O	PUNCT	O
3	O	NUM	O
.	O	PUNCT	O


7	O	NUM	O
+/-	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


8	O	NUM	O
,	O	PUNCT	O
p	O	X	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


05	O	NUM	O
)	O	PUNCT	O
fingers	O	NOUN	B
,	O	PUNCT	O
movements	O	NOUN	B
of	O	ADP	O
the	O	DET	O
neck	O	NOUN	B
(	O	PUNCT	O
5	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
+/-	O	CCONJ	O
1	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
,	O	PUNCT	O
p	O	X	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


05	O	NUM	O
),	O	PUNCT	O
and	O	CCONJ	O
mental	O	ADJ	B
calculation	O	NOUN	I
(	O	PUNCT	O
3	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
+/-	O	CCONJ	O
1	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
,	O	PUNCT	O
p	O	X	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


05	O	NUM	O
).	O	PUNCT	O
These	O	DET	O
results	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
activation	O	NOUN	B
tasks	O	NOUN	O
such	O	ADJ	O
as	O	ADP	O
"	O	PUNCT	O
speaking	O	VERB	B
aloud	O	ADJ	B
"	O	PUNCT	O
could	O	AUX	O
be	O	AUX	O
used	O	VERB	O
for	O	ADP	O
objective	O	ADJ	O
assessment	O	NOUN	B
of	O	ADP	O
dyskinesia	B-Disease	NOUN	B


Structural	B-Disease	ADJ	B
and	I-Disease	CCONJ	O
functional	I-Disease	ADJ	B
impairment	I-Disease	NOUN	I
of	I-Disease	ADP	O
mitochondria	I-Disease	NOUN	B
in	O	ADP	O
adriamycin	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
cardiomyopathy	B-Disease	NOUN	B
in	O	ADP	O
mice	O	NOUN	B
:	O	PUNCT	O
suppression	O	NOUN	B
of	O	ADP	O
cytochrome	O	NOUN	B
c	O	NOUN	I
oxidase	O	NOUN	I
II	O	NUM	I
gene	O	NOUN	B
expression	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
use	O	NOUN	O
of	O	ADP	O
adriamycin	B-Chemical	NOUN	B
(	O	PUNCT	O
ADR	B-Chemical	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
cancer	B-Disease	NOUN	B
chemotherapy	O	NOUN	I
has	O	AUX	O
been	O	AUX	O
limited	O	VERB	O
due	O	ADJ	O
to	O	ADP	O
its	O	PRON	O
cumulative	O	ADJ	B
cardiovascular	B-Disease	ADJ	B
toxicity	I-Disease	NOUN	B
.	O	PUNCT	O


Earlier	O	ADJ	O
observations	O	NOUN	B
that	O	SCONJ	O
ADR	B-Chemical	NOUN	B
interacts	O	VERB	O
with	O	ADP	O
mitochondrial	O	ADJ	B
cytochrome	O	NOUN	I
c	O	NOUN	I
oxidase	O	NOUN	I
(	O	PUNCT	O
COX	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
suppresses	O	VERB	B
its	O	PRON	O
enzyme	O	NOUN	B
activity	O	NOUN	I
led	O	VERB	O
us	O	PRON	O
to	O	PART	O
investigate	O	VERB	B
ADR	B-Chemical	NOUN	B
'	O	PART	O
s	O	NOUN	O
action	O	NOUN	B
on	O	ADP	O
the	O	DET	O
cardiovascular	O	ADJ	B
functions	O	NOUN	I
and	O	CCONJ	O
heart	O	NOUN	B
mitochondrial	O	ADJ	B
morphology	O	NOUN	B
in	O	ADP	O
Balb	O	NOUN	B
-	O	PUNCT	O
c	O	NOUN	O
mice	O	NOUN	B
i	O	NUM	O
.	O	PUNCT	O


p	O	NOUN	O
.	O	PUNCT	O


treated	O	VERB	B
with	O	ADP	I
ADR	B-Chemical	NOUN	B
for	O	ADP	O
several	O	ADJ	O
weeks	O	NOUN	B
.	O	PUNCT	O


At	O	ADP	O
various	O	ADJ	O
times	O	NOUN	O
during	O	ADP	O
treatment	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
animals	O	NOUN	B
were	O	AUX	O
assessed	O	VERB	B
for	O	ADP	O
cardiovascular	O	ADJ	B
functions	O	NOUN	I
by	O	ADP	O
electrocardiography	O	NOUN	B
and	O	CCONJ	O
for	O	ADP	O
heart	O	NOUN	B
tissue	O	NOUN	I
damage	O	NOUN	O
by	O	ADP	O
electron	O	NOUN	B
microscopy	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
parallel	O	NOUN	O
,	O	PUNCT	O
total	O	ADJ	O
RNA	O	NOUN	B
was	O	AUX	O
extracted	O	VERB	O
from	O	ADP	O
samples	O	NOUN	B
of	O	ADP	O
dissected	O	ADJ	B
heart	O	NOUN	B
and	O	CCONJ	O
analyzed	O	VERB	B
by	O	ADP	O
Northern	O	NOUN	B
blot	O	NOUN	I
hybridization	O	NOUN	I
to	O	PART	O
determine	O	VERB	O
the	O	DET	O
steady	O	ADJ	B
-	O	PUNCT	O
state	O	NOUN	B
level	O	NOUN	B
of	O	ADP	O
three	O	NUM	O
RNA	O	NOUN	B
transcripts	O	NOUN	B
encoded	O	VERB	B
by	O	ADP	O
the	O	DET	O
COXII	O	NOUN	B
,	O	PUNCT	O
COXIII	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
COXIV	O	NOUN	B
genes	O	NOUN	I
.	O	PUNCT	O


Similarly	O	ADV	O
,	O	PUNCT	O
samples	O	NOUN	B
obtained	O	VERB	O
from	O	ADP	O
the	O	DET	O
liver	O	NOUN	B
of	O	ADP	O
the	O	DET	O
same	O	ADJ	O
animals	O	NOUN	B
were	O	AUX	O
analyzed	O	VERB	B
for	O	ADP	O
comparative	O	ADJ	B
studies	O	NOUN	I
.	O	PUNCT	O


Our	O	PRON	O
results	O	NOUN	B
indicated	O	VERB	O
that	O	SCONJ	O
1	O	X	O
)	O	PUNCT	O
treatment	O	NOUN	B
of	O	ADP	O
mice	O	NOUN	B
with	O	ADP	O
ADR	B-Chemical	NOUN	B
caused	O	VERB	O
cardiovascular	B-Disease	ADJ	B
arrhythmias	I-Disease	NOUN	I
characterized	O	VERB	B
by	O	ADP	O
bradycardia	B-Disease	NOUN	B
,	O	PUNCT	O
extension	O	NOUN	B
of	O	ADP	O
ventricular	O	ADJ	B
depolarization	O	NOUN	I
time	O	NOUN	I
(	O	PUNCT	O
tQRS	O	NOUN	B
),	O	PUNCT	O
and	O	CCONJ	O
failure	O	NOUN	B
of	O	ADP	O
QRS	O	NOUN	B
at	O	ADP	O
high	O	ADJ	O
concentrations	O	NOUN	B
(	O	PUNCT	O
10	O	NUM	O
-	O	SYM	O
14	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
body	O	NOUN	B
weight	O	NOUN	I
cumulative	O	ADJ	B
dose	O	NOUN	O
);	O	NOUN	O
2	O	NUM	O
)	O	PUNCT	O
the	O	DET	O
heart	O	NOUN	B
mitochondria	O	NOUN	B
underwent	O	VERB	O
swelling	B-Disease	NOUN	B
,	O	PUNCT	O
fusion	O	NOUN	B
,	O	PUNCT	O
dissolution	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
/	O	PUNCT	O
or	O	CCONJ	O
disruption	O	NOUN	B
of	O	ADP	O
mitochondrial	O	ADJ	B
cristae	O	NOUN	O
after	O	ADP	O
several	O	ADJ	O
weeks	O	NOUN	B
of	O	ADP	O
treatment	O	NOUN	B
.	O	PUNCT	O


Such	O	ADJ	O
abnormalities	O	NOUN	B
were	O	AUX	O
not	O	PART	O
observed	O	VERB	O
in	O	ADP	O
the	O	DET	O
mitochondria	O	NOUN	B
of	O	ADP	O
liver	O	NOUN	B
tissue	O	NOUN	I
;	O	PUNCT	O
and	O	CCONJ	O
3	O	X	O
)	O	PUNCT	O
among	O	ADP	O
the	O	DET	O
three	O	NUM	O
genes	O	NOUN	B
of	O	ADP	O
COX	O	NOUN	B
enzyme	O	NOUN	B
examined	O	VERB	B
,	O	PUNCT	O
only	O	ADV	O
COXII	O	NOUN	B
gene	O	NOUN	B
expression	O	NOUN	I
was	O	AUX	O
suppressed	O	VERB	B
by	O	ADP	O
ADR	B-Chemical	NOUN	B
treatment	O	NOUN	B
,	O	PUNCT	O
mainly	O	ADV	O
after	O	ADP	O
8	O	NUM	O
weeks	O	NOUN	B
in	O	ADP	O
both	O	CCONJ	O
heart	O	NOUN	B
and	O	CCONJ	O
liver	O	NOUN	B
.	O	PUNCT	O


Knowing	O	VERB	O
that	O	SCONJ	O
heart	O	NOUN	B
mitochondria	O	NOUN	B
represent	O	VERB	O
almost	O	ADV	O
40	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
heart	O	NOUN	B
muscle	O	NOUN	I
by	O	ADP	O
weight	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
conclude	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
deteriorating	O	VERB	B
effects	O	NOUN	B
of	O	ADP	O
ADR	B-Chemical	NOUN	B
on	O	ADP	O
cardiovascular	O	ADJ	B
function	O	NOUN	I
involve	O	VERB	O
mitochondrial	B-Disease	ADJ	B
structural	I-Disease	ADJ	B
and	I-Disease	CCONJ	O
functional	I-Disease	ADJ	B
impairment	I-Disease	NOUN	I


Enhanced	O	VERB	B
bradycardia	B-Disease	NOUN	B
induced	O	VERB	B
by	O	ADP	O
beta	O	NOUN	B
-	O	PUNCT	O
adrenoceptor	O	NOUN	B
antagonists	O	NOUN	B
in	O	ADP	O
rats	O	NOUN	B
pretreated	O	VERB	B
with	O	ADP	O
isoniazid	B-Chemical	NOUN	B
.	O	PUNCT	O


High	O	ADJ	B
doses	O	NOUN	I
of	O	ADP	O
isoniazid	B-Chemical	NOUN	B
increase	O	VERB	B
hypotension	B-Disease	NOUN	B
induced	O	VERB	B
by	O	ADP	O
vasodilators	O	NOUN	B
and	O	CCONJ	O
change	O	VERB	O
the	O	DET	O
accompanying	O	VERB	O
reflex	O	ADJ	B
tachycardia	B-Disease	NOUN	I
to	O	ADP	O
bradycardia	B-Disease	NOUN	B
,	O	PUNCT	O
an	O	DET	O
interaction	O	NOUN	B
attributed	O	VERB	O
to	O	PART	O
decreased	O	VERB	B
synthesis	O	NOUN	B
of	O	ADP	O
brain	O	NOUN	B
gamma-aminobutyric	B-Chemical	ADJ	I
acid	I-Chemical	NOUN	I
(	O	PUNCT	O
GABA	B-Chemical	NOUN	B
).	O	PUNCT	O
In	O	ADP	O
the	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
possible	O	ADJ	O
enhancement	O	NOUN	B
by	O	ADP	O
isoniazid	B-Chemical	NOUN	B
of	O	ADP	O
bradycardia	B-Disease	NOUN	B
induced	O	VERB	B
by	O	ADP	O
beta	O	NOUN	B
-	O	PUNCT	O
adrenoceptor	O	NOUN	B
antagonists	O	NOUN	B
was	O	AUX	O
determined	O	VERB	O
in	O	ADP	O
rats	O	NOUN	B
anaesthetised	O	VERB	B
with	O	ADP	O
chloralose	B-Chemical	NOUN	B
-	O	PUNCT	O
urethane	B-Chemical	NOUN	B
.	O	PUNCT	O


Isoniazid	B-Chemical	NOUN	B
significantly	O	ADV	O
increased	O	VERB	B
bradycardia	B-Disease	NOUN	B
after	O	ADP	O
propranolol	B-Chemical	NOUN	B
,	O	PUNCT	O
pindolol	B-Chemical	NOUN	B
,	O	PUNCT	O
labetalol	B-Chemical	NOUN	B
and	O	CCONJ	O
atenolol	B-Chemical	ADV	B
,	O	PUNCT	O
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
after	O	ADP	O
clonidine	B-Chemical	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
not	O	PART	O
after	O	ADP	O
hexamethonium	B-Chemical	NOUN	B
or	O	CCONJ	O
carbachol	B-Chemical	NOUN	B
.	O	PUNCT	O


Enhancement	O	NOUN	B
was	O	AUX	O
not	O	PART	O
observed	O	VERB	O
in	O	ADP	O
rats	O	NOUN	B
pretreated	O	VERB	B
with	O	ADP	O
methylatropine	B-Chemical	NOUN	B
or	O	CCONJ	O
previously	O	ADV	O
vagotomised	O	VERB	B
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	B
are	O	AUX	O
compatible	O	ADJ	O
with	O	ADP	O
interference	O	NOUN	B
by	O	ADP	O
isoniazid	B-Chemical	NOUN	B


Epileptogenic	O	ADJ	B
activity	O	NOUN	O
of	O	ADP	O
folic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
after	O	ADP	O
drug	O	NOUN	B
induces	O	VERB	O
SLE	B-Disease	NOUN	B
(	O	PUNCT	O
folic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
and	O	CCONJ	O
epilepsy	B-Disease	NOUN	B
)	O	PUNCT	O
OBJECTIVE	O	NOUN	O
:	O	PUNCT	O
To	O	PART	O
study	O	VERB	B
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
folic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
-	O	PUNCT	O
containing	O	VERB	B
multivitamin	O	NOUN	B
supplementation	O	NOUN	B
in	O	ADP	O
epileptic	B-Disease	ADJ	B
women	O	NOUN	I
before	O	ADP	O
and	O	CCONJ	O
during	O	ADP	O
pregnancy	O	NOUN	B
in	O	ADP	O
order	O	NOUN	O
to	O	PART	O
determine	O	VERB	O
the	O	DET	O
rate	O	NOUN	B
of	O	ADP	O
structural	O	ADJ	B
birth	B-Disease	NOUN	I
defects	I-Disease	NOUN	O
and	O	CCONJ	O
epilepsy	B-Disease	NOUN	B
-	O	PUNCT	O
related	O	VERB	B
side	O	NOUN	B
effects	O	NOUN	I
.	O	PUNCT	O


STUDY	O	NOUN	O
DESIGN	O	NOUN	O
:	O	PUNCT	O
First	O	ADV	O
a	O	DET	O
randomised	O	ADJ	B
trial	O	NOUN	I
,	O	PUNCT	O
later	O	ADJ	O
periconception	O	NOUN	B
care	O	NOUN	I
including	O	VERB	O
in	O	ADP	O
total	O	ADJ	O
12225	O	NUM	O
females	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
Of	O	ADP	O
60	O	NUM	O
epileptic	B-Disease	ADJ	B
women	O	NOUN	I
with	O	ADP	O
periconceptional	O	ADJ	B
folic	B-Chemical	ADJ	I
acid	I-Chemical	NOUN	I
(	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


8	O	NUM	O
mg	O	NOUN	O
)-	O	ADJ	O
containing	O	VERB	O
multivitamin	O	NOUN	B
supplementation	O	NOUN	B
,	O	PUNCT	O
no	O	DET	O
one	O	NOUN	O
developed	O	VERB	O
epilepsy	B-Disease	PROPN	B
-	O	PUNCT	O
related	O	VERB	B
side	O	NOUN	B
effects	O	NOUN	I
during	O	ADP	O
the	O	DET	O
periconception	O	NOUN	B
period	O	NOUN	B
.	O	PUNCT	O


One	O	NUM	O
epileptic	B-Disease	ADJ	B
woman	O	NOUN	I
delivered	O	VERB	O
a	O	DET	O
newborn	O	NOUN	B
with	O	ADP	O
cleft	B-Disease	NOUN	B
lip	I-Disease	NOUN	I
and	I-Disease	CCONJ	I
palate	I-Disease	NOUN	B
.	O	PUNCT	O


Another	O	DET	O
patient	O	NOUN	B
exhibited	O	VERB	O
with	O	ADP	O
a	O	DET	O
cluster	O	NOUN	B
of	O	ADP	O
seizures	B-Disease	NOUN	B
after	O	ADP	O
the	O	DET	O
periconception	O	NOUN	B
period	O	NOUN	B
using	O	VERB	O
another	O	DET	O
multivitamin	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
22	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
epileptic	B-Disease	ADJ	B
woman	O	NOUN	I
was	O	AUX	O
treated	O	VERB	B
continuously	O	ADV	O
by	O	ADP	O
carbamazepine	B-Chemical	NOUN	B
and	O	CCONJ	O
a	O	DET	O
folic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
(	O	PUNCT	O
1	O	NUM	O
mg	O	NOUN	O
)-	O	ADJ	O
containing	O	VERB	O
multivitamin	O	NOUN	B
from	O	ADP	O
the	O	DET	O
20th	O	ADJ	O
week	O	NOUN	B
of	O	ADP	O
gestation	O	NOUN	B
.	O	PUNCT	O


She	O	PRON	O
developed	O	VERB	O
status	B-Disease	NOUN	B
epilepticus	I-Disease	NOUN	I
and	O	CCONJ	O
later	O	ADJ	O
symptoms	O	NOUN	B
of	O	ADP	O
systemic	B-Disease	ADJ	B
lupus	I-Disease	NOUN	I
erythematodes	I-Disease	NOUN	I
.	O	PUNCT	O


Her	O	PRON	O
pregnancy	O	NOUN	B
ended	O	VERB	O
with	O	ADP	O
stillbirth	B-Disease	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
:	O	PUNCT	O
The	O	DET	O
epileptic	B-Disease	ADJ	B
pregnant	O	ADJ	I
patient	O	NOUN	B
'	O	PART	O
s	O	NOUN	O
autoimmune	B-Disease	ADJ	B
disease	I-Disease	NOUN	I
(	O	PUNCT	O
probably	O	ADV	O
drug	O	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
lupus	B-Disease	NOUN	B
)	O	PUNCT	O
could	O	AUX	O
damage	O	VERB	B
the	O	DET	O
blood	O	NOUN	B
-	O	PUNCT	O
brain	O	NOUN	B
barrier	O	NOUN	O
,	O	PUNCT	O
therefore	O	ADV	O
the	O	DET	O
therapeutic	O	ADJ	B
dose	O	NOUN	I
(>	O	NOUN	B
or	O	CCONJ	O
=	O	ADJ	O
1	O	NUM	O
mg	O	NOUN	O
)	O	PUNCT	O
of	O	ADP	O
folic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
triggered	O	VERB	B
a	O	DET	O
cluster	O	NOUN	B
of	O	ADP	O
seizures	B-Disease	NOUN	B
.	O	PUNCT	O


Physiological	O	ADJ	B
dose	O	NOUN	I
(<	O	NOUN	O
1	O	NUM	O
mg	O	NOUN	O
)	O	PUNCT	O
of	O	ADP	O
folic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
both	O	CCONJ	O
in	O	ADP	O
healthy	O	ADJ	B
and	O	CCONJ	O
60	O	NUM	O
epileptic	B-Disease	ADJ	B
women	O	NOUN	I
,	O	PUNCT	O
all	O	DET	O
without	O	ADP	O
any	O	DET	O
autoimmune	B-Disease	ADJ	B
disease	I-Disease	NOUN	I
,	O	PUNCT	O
did	O	AUX	O
not	O	PART	O
increase	O	VERB	B
the	O	DET	O
risk	O	NOUN	B
for	O	ADP	O
epileptic	B-Disease	ADJ	B
seizures	I-Disease	NOUN	I


Effects	O	NOUN	B
of	O	ADP	I
cisapride	B-Chemical	NOUN	B
on	O	ADP	O
symptoms	O	NOUN	B
and	O	CCONJ	O
postcibal	O	ADJ	B
small	O	ADJ	B
-	O	PUNCT	O
bowel	O	NOUN	B
motor	O	NOUN	B
function	O	NOUN	I
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
irritable	B-Disease	ADJ	B
bowel	I-Disease	NOUN	I
syndrome	I-Disease	NOUN	I
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
:	O	PUNCT	O
Irritable	B-Disease	ADJ	B
bowel	I-Disease	NOUN	I
syndrome	I-Disease	NOUN	I
is	O	AUX	O
a	O	DET	O
common	O	ADJ	O
cause	O	NOUN	B
of	O	ADP	O
abdominal	B-Disease	ADJ	B
pain	I-Disease	NOUN	I
and	O	CCONJ	O
discomfort	O	NOUN	B
and	O	CCONJ	O
may	O	AUX	O
be	O	AUX	O
related	O	ADJ	O
to	O	PART	O
disordered	B-Disease	ADJ	B
gastrointestinal	I-Disease	ADJ	I
motility	I-Disease	NOUN	I
.	O	PUNCT	O


Our	O	PRON	O
aim	O	NOUN	O
was	O	AUX	O
to	O	PART	O
assess	O	VERB	B
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
long	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
treatment	O	NOUN	B
with	O	ADP	O
a	O	DET	O
prokinetic	O	ADJ	B
agent	O	NOUN	I
,	O	PUNCT	O
cisapride	B-Chemical	NOUN	B
,	O	PUNCT	O
on	O	ADP	O
postprandial	O	ADJ	B
jejunal	O	ADJ	B
motility	O	NOUN	I
and	O	CCONJ	O
symptoms	O	NOUN	B
in	O	ADP	O
the	O	DET	O
irritable	B-Disease	ADJ	B
bowel	I-Disease	NOUN	I
syndrome	I-Disease	NOUN	I
(	O	PUNCT	O
IBS	B-Disease	PROPN	B
).	O	PUNCT	O
METHODS	O	NOUN	O
:	O	PUNCT	O
Thirty	O	NUM	B
-	O	PUNCT	O
eight	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
IBS	B-Disease	NOUN	B
(	O	PUNCT	O
constipation	B-Disease	NOUN	B
-	O	PUNCT	O
predominant	O	ADJ	B
,	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
17	O	NUM	O
;	O	PUNCT	O
diarrhoea	B-Disease	ADJ	B
-	O	PUNCT	O
predominant	O	ADJ	B
,	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
21	O	NUM	O
)	O	PUNCT	O
underwent	O	VERB	O
24	O	NUM	O
-	O	PUNCT	O
h	O	NOUN	B
ambulatory	O	ADJ	B
jejunal	O	ADJ	I
manometry	O	NOUN	I
before	O	ADP	O
and	O	CCONJ	O
after	O	ADP	O
12	O	NUM	O
week	O	NOUN	B
'	O	PART	O
s	O	NOUN	O
treatment	O	NOUN	B
[	O	PUNCT	O
cisapride	B-Chemical	NOUN	B
,	O	PUNCT	O
5	O	NUM	O
mg	O	NOUN	O
three	O	NUM	O
times	O	NOUN	O
daily	O	ADV	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
19	O	NUM	O
)	O	PUNCT	O
or	O	CCONJ	O
placebo	O	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
19	O	NUM	O
)].	O	ADJ	O
RESULTS	O	NOUN	B
:	O	PUNCT	O
In	O	ADP	O
diarrhoea	B-Disease	NOUN	B
-	O	PUNCT	O
predominant	O	ADJ	B
patients	O	NOUN	B
significant	O	ADJ	O
differences	O	NOUN	O
in	O	ADP	O
contraction	O	NOUN	B
characteristics	O	NOUN	B
were	O	AUX	O
observed	O	VERB	O
between	O	ADP	O
the	O	DET	O
cisapride	B-Chemical	NOUN	B
and	O	CCONJ	O
placebo	O	NOUN	B
groups	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
cisapride	B-Chemical	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
diarrhoea	B-Disease	NOUN	B
-	O	PUNCT	O
predominant	O	ADJ	B
patients	O	NOUN	B
the	O	DET	O
mean	O	ADJ	O
contraction	O	NOUN	B
amplitude	O	NOUN	B
was	O	AUX	O
higher	O	ADJ	B
(	O	PUNCT	O
29	O	NUM	O
.	O	PUNCT	O


3	O	NUM	O
+/-	O	CCONJ	O
3	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
versus	O	CCONJ	O
24	O	NUM	O
.	O	PUNCT	O


9	O	NUM	O
+/-	O	CCONJ	O
2	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
mm	O	NOUN	B
Hg	O	NOUN	I
,	O	PUNCT	O
cisapride	B-Chemical	NOUN	B
versus	O	CCONJ	O
placebo	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


001	O	NUM	O
);	O	ADJ	O
pretreatment	O	NOUN	B
,	O	PUNCT	O
25	O	NUM	O
.	O	PUNCT	O


7	O	NUM	O
+/-	O	CCONJ	O
6	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
mm	O	X	O
Hg	O	NOUN	O
),	O	PUNCT	O
the	O	DET	O
mean	O	ADJ	B
contraction	O	NOUN	I
duration	O	NOUN	O
longer	O	ADV	O
(	O	PUNCT	O
3	O	NUM	O
.	O	PUNCT	O


4	O	NUM	O
+/-	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
versus	O	CCONJ	O
3	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
+/-	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
sec	O	NOUN	O
,	O	PUNCT	O
cisapride	B-Chemical	NOUN	B
versus	O	CCONJ	O
placebo	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


001	O	NUM	O
);	O	ADJ	O
pretreatment	O	NOUN	B
,	O	PUNCT	O
3	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
+/-	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
sec	O	NOUN	O
),	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
mean	O	ADJ	B
contraction	O	NOUN	I
frequency	O	NOUN	O
lower	O	ADJ	O
(	O	PUNCT	O
2	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
+/-	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
versus	O	CCONJ	O
2	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
+/-	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


4	O	NUM	O
cont	O	NOUN	O
./	O	NOUN	O
min	O	NOUN	O
,	O	PUNCT	O
cisapride	B-Chemical	NOUN	B
versus	O	CCONJ	O
placebo	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


001	O	NUM	O
);	O	ADJ	O
pretreatment	O	NOUN	B
,	O	PUNCT	O
2	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
+/-	O	CCONJ	O
1	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
cont	O	NOUN	O
./	O	NOUN	O
min	O	NOUN	O
]	O	PUNCT	O
than	O	ADP	O
patients	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
placebo	O	NOUN	B
.	O	PUNCT	O


No	O	DET	B
significant	O	ADJ	I
differences	O	NOUN	O
in	O	ADP	O
jejunal	O	ADJ	B
motility	O	NOUN	I
were	O	AUX	O
found	O	VERB	O
in	O	ADP	O
the	O	DET	O
constipation	B-Disease	NOUN	B
-	O	PUNCT	O
predominant	O	ADJ	B
IBS	B-Disease	NOUN	B
group	O	NOUN	B
.	O	PUNCT	O


Symptoms	O	NOUN	B
were	O	AUX	O
assessed	O	VERB	B
by	O	ADP	O
using	O	VERB	O
a	O	DET	O
visual	O	ADJ	B
analogue	O	NOUN	I
scale	O	NOUN	I
before	O	ADP	O
and	O	CCONJ	O
after	O	ADP	O
treatment	O	NOUN	B
.	O	PUNCT	O


Symptom	O	NOUN	B
scores	O	NOUN	I
relating	O	VERB	O
to	O	ADP	O
the	O	DET	O
severity	O	NOUN	B
of	O	ADP	O
constipation	B-Disease	NOUN	B
were	O	AUX	O
lower	O	ADJ	O
in	O	ADP	O
cisapride	B-Chemical	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
constipation	B-Disease	NOUN	B
-	O	PUNCT	O
predominant	O	ADJ	B
IBS	B-Disease	NOUN	B
patients	O	NOUN	B
[	O	PUNCT	O
score	O	NOUN	B
,	O	PUNCT	O
54	O	NUM	O
+/-	O	CCONJ	O
5	O	NUM	O
versus	O	CCONJ	O
67	O	NUM	O
+/-	O	CCONJ	O
14	O	NUM	O
mm	O	NOUN	O
,	O	PUNCT	O
cisapride	B-Chemical	NOUN	B
versus	O	CCONJ	O
placebo	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


05	O	NUM	O
);	O	ADJ	O
pretreatment	O	NOUN	B
,	O	PUNCT	O
62	O	NUM	O
+/-	O	CCONJ	O
19	O	NUM	O
mm	O	PROPN	O
].	O	PROPN	O
Diarrhoea	B-Disease	PROPN	B
-	O	PUNCT	O
predominant	O	ADJ	B
IBS	B-Disease	NOUN	B
patients	O	NOUN	B
had	O	AUX	O
a	O	DET	O
higher	O	ADJ	O
pain	B-Disease	NOUN	B
score	O	NOUN	I
after	O	ADP	O
cisapride	B-Chemical	NOUN	B
therapy	O	NOUN	I
[	O	PUNCT	O
score	O	NOUN	B
,	O	PUNCT	O
55	O	NUM	O
+/-	O	CCONJ	O
15	O	NUM	O
versus	O	CCONJ	O
34	O	NUM	O
+/-	O	CCONJ	O
12	O	NUM	O
mm	O	NOUN	O
,	O	PUNCT	O
cisapride	B-Chemical	NOUN	B
versus	O	CCONJ	O
placebo	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


05	O	NUM	O
);	O	ADJ	O
pretreatment	O	NOUN	B
,	O	PUNCT	O
67	O	NUM	O
+/-	O	CCONJ	O
19	O	NUM	O
mm	O	PROPN	O
].	O	PROPN	O
CONCLUSION	O	NOUN	O
:	O	PUNCT	O
Cisapride	B-Chemical	NOUN	B
affects	O	VERB	O
jejunal	O	ADJ	B
contraction	O	NOUN	I
characteristics	O	NOUN	B
and	O	CCONJ	O
some	O	DET	O
symptoms	O	NOUN	B
in	O	ADP	O
IBS	B-Disease	NOUN	B


Clarithromycin	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
ventricular	B-Disease	ADJ	B
tachycardia	I-Disease	NOUN	I
.	O	PUNCT	O


Clarithromycin	B-Chemical	NOUN	B
is	O	AUX	O
a	O	DET	O
relatively	O	ADV	O
new	O	ADJ	O
macrolide	B-Chemical	NOUN	B
antibiotic	O	NOUN	B
that	O	PRON	O
offers	O	VERB	O
twice	O	ADV	B
-	O	PUNCT	O
daily	O	ADJ	B
dosing	O	NOUN	B
.	O	PUNCT	O


It	O	PRON	O
differs	O	VERB	O
from	O	ADP	O
erythromycin	B-Chemical	NOUN	B
only	O	ADV	O
in	O	ADP	O
the	O	DET	O
methylation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
hydroxyl	O	NOUN	B
group	O	NOUN	I
at	O	ADP	O
position	O	NOUN	O
6	O	NUM	O
.	O	PUNCT	O


Although	O	SCONJ	O
the	O	DET	O
side	O	NOUN	B
-	O	PUNCT	O
effect	O	NOUN	B
profile	O	NOUN	B
of	O	ADP	O
erythromycin	B-Chemical	NOUN	B
is	O	AUX	O
established	O	VERB	O
,	O	PUNCT	O
including	O	VERB	O
gastroenteritis	B-Disease	NOUN	B
and	O	CCONJ	O
interactions	O	NOUN	B
with	O	ADP	O
other	O	ADJ	O
drugs	O	NOUN	B
subject	O	ADJ	I
to	O	ADP	O
hepatic	O	ADJ	B
mixed	O	ADJ	B
-	O	PUNCT	O
function	O	NOUN	B
oxidase	O	NOUN	O
metabolism	O	NOUN	O
,	O	PUNCT	O
experience	O	NOUN	O
with	O	ADP	O
the	O	DET	O
newer	O	ADJ	O
macrolides	B-Chemical	NOUN	B
is	O	AUX	O
still	O	ADV	O
being	O	AUX	O
recorded	O	VERB	O
.	O	PUNCT	O


Cardiotoxicity	B-Disease	NOUN	B
has	O	AUX	O
been	O	AUX	O
demonstrated	O	VERB	O
after	O	ADP	O
both	O	CCONJ	O
intravenous	O	ADJ	B
and	O	CCONJ	O
oral	O	ADJ	B
administration	O	NOUN	I
of	O	ADP	O
erythromycin	B-Chemical	NOUN	B
but	O	CCONJ	O
has	O	AUX	O
never	O	ADV	O
been	O	AUX	O
reported	O	VERB	O
with	O	ADP	O
the	O	DET	O
newer	O	ADJ	O
macrolides	B-Chemical	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
a	O	DET	O
case	O	NOUN	B
of	O	ADP	O
ventricular	B-Disease	ADJ	B
dysrhythmias	I-Disease	NOUN	I
that	O	PRON	O
occurred	O	VERB	O
after	O	ADP	O
six	O	NUM	O
therapeutic	O	ADJ	B
doses	O	NOUN	I
of	O	ADP	O
clarithromycin	B-Chemical	NOUN	B
.	O	PUNCT	O


The	O	DET	O
dysrhythmias	B-Disease	NOUN	B


Persistent	O	ADJ	B
nephrogenic	B-Disease	ADJ	O
diabetes	I-Disease	NOUN	O
insipidus	I-Disease	NOUN	B
following	O	VERB	O
lithium	B-Chemical	NOUN	B
therapy	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
the	O	DET	O
case	O	NOUN	B
of	O	ADP	O
a	O	DET	O
patient	O	NOUN	B
who	O	PRON	O
developed	O	VERB	O
severe	O	ADJ	B
hypernatraemic	O	ADJ	B
dehydration	B-Disease	NOUN	O
following	O	VERB	O
a	O	DET	O
head	B-Disease	NOUN	B
injury	I-Disease	NOUN	I
.	O	PUNCT	O


Ten	O	NUM	O
years	O	NOUN	B
previously	O	ADV	O
he	O	PRON	O
had	O	AUX	O
been	O	AUX	O
diagnosed	O	VERB	B
to	O	PART	O
have	O	AUX	O
lithium	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
nephrogenic	B-Disease	ADJ	B
diabetes	I-Disease	NOUN	I
insipidus	I-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
lithium	B-Chemical	NOUN	B
therapy	O	NOUN	I
had	O	AUX	O
been	O	AUX	O
discontinued	O	VERB	B
.	O	PUNCT	O


He	O	PRON	O
remained	O	VERB	O
thirsty	O	ADJ	B
and	O	CCONJ	O
polyuric	B-Disease	ADJ	B
despite	O	SCONJ	O
cessation	O	NOUN	B
of	O	ADP	O
lithium	B-Chemical	NOUN	B
and	O	CCONJ	O
investigations	O	NOUN	B
on	O	ADP	O
admission	O	NOUN	B
showed	O	VERB	O
him	O	PRON	O
to	O	PART	O
have	O	AUX	O
normal	O	ADJ	O
osmoregulated	O	ADJ	B
thirst	O	NOUN	I
and	O	CCONJ	O
vasopressin	B-Chemical	NOUN	B
secretion	O	NOUN	I
,	O	PUNCT	O
with	O	ADP	O
clear	O	ADJ	O
evidence	O	NOUN	B
of	O	ADP	O
nephrogenic	B-Disease	ADJ	B
diabetes	I-Disease	NOUN	I
insipidus	I-Disease	NOUN	I
.	O	PUNCT	O


Lithium	B-Chemical	NOUN	B
induced	O	VERB	B
nephrogenic	B-Disease	ADJ	B
diabetes	I-Disease	NOUN	I
insipidus	I-Disease	NOUN	B
is	O	AUX	O
considered	O	VERB	O
to	O	PART	O
be	O	AUX	O
reversible	O	ADJ	O
on	O	ADP	O
cessation	O	NOUN	B
of	O	ADP	O
therapy	O	NOUN	B
but	O	CCONJ	O
polyuria	B-Disease	NOUN	B
persisted	O	VERB	O
in	O	ADP	O
this	O	DET	O
patient	O	NOUN	B
for	O	ADP	O
ten	O	NUM	O
years	O	NOUN	B
after	O	ADP	O
lithium	B-Chemical	NOUN	B
was	O	AUX	O
stopped	O	VERB	B
.	O	PUNCT	O


We	O	PRON	O
discuss	O	VERB	O
the	O	DET	O
possible	O	ADJ	O
renal	O	ADJ	B
mechanisms	O	NOUN	I
and	O	CCONJ	O
the	O	DET	O
implications	O	NOUN	O
for	O	ADP	O
management	O	NOUN	B
of	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
lithium	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
nephrogenic	B-Disease	ADJ	B
diabetes	I-Disease	NOUN	I
insipidus	I-Disease	NOUN	I


Late	O	ADJ	B
cardiotoxicity	B-Disease	NOUN	I
after	O	ADP	O
treatment	O	NOUN	B
for	O	ADP	O
a	O	DET	O
malignant	O	ADJ	B
bone	B-Disease	NOUN	I
tumor	I-Disease	NOUN	I
.	O	PUNCT	O


Cardiac	O	ADJ	B
function	O	NOUN	I
was	O	AUX	O
assessed	O	VERB	B
in	O	ADP	O
long	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
survivors	O	NOUN	B
of	O	ADP	O
malignant	O	ADJ	B
bone	B-Disease	NOUN	I
tumors	I-Disease	NOUN	I
who	O	PRON	O
were	O	AUX	O
treated	O	VERB	B
according	O	VERB	O
to	O	ADP	O
Rosen's	B-Chemical	NOUN	B
T5	I-Chemical	NOUN	I
or	I-Chemical	CCONJ	O
T10	I-Chemical	NOUN	O
protocol	I-Chemical	NOUN	B
,	O	PUNCT	O
both	O	CCONJ	O
including	O	VERB	O
doxorubicin	B-Chemical	NOUN	B
.	O	PUNCT	O


Thirty	O	NUM	B
-	O	PUNCT	O
one	O	NUM	O
patients	O	NOUN	B
,	O	PUNCT	O
age	O	NOUN	B
10	O	NUM	O
-	O	SYM	O
45	O	NUM	O
years	O	NOUN	B
(	O	PUNCT	O
median	O	ADJ	O
age	O	NOUN	B
17	O	NUM	O
.	O	PUNCT	O


8	O	NUM	O
years	O	NOUN	B
)	O	PUNCT	O
were	O	AUX	O
evaluated	O	VERB	B
2	O	NUM	O
.	O	PUNCT	O


3	O	NUM	O
-	O	SYM	O
14	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
years	O	NOUN	B
(	O	PUNCT	O
median	O	NOUN	B
8	O	NUM	O
.	O	PUNCT	O


9	O	NUM	O
years	O	NOUN	B
)	O	PUNCT	O
following	O	VERB	O
completion	O	NOUN	B
of	O	ADP	O
treatment	O	NOUN	B
.	O	PUNCT	O


Cumulative	O	ADJ	B
doses	O	NOUN	B
of	O	ADP	O
doxorubicin	B-Chemical	NOUN	B
were	O	AUX	O
225	O	NUM	O
-	O	PUNCT	O
550	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
m2	O	NOUN	B
(	O	PUNCT	O
median	O	ADJ	B
dose	O	NOUN	I
360	O	NUM	O
).	O	PUNCT	O
The	O	DET	O
evaluation	O	NOUN	B
consisted	O	VERB	O
of	O	ADP	O
a	O	DET	O
history	O	NOUN	B
,	O	PUNCT	O
physical	O	ADJ	B
examination	O	NOUN	I
,	O	PUNCT	O
electrocardiogram	O	NOUN	B
(	O	PUNCT	O
ECG	O	PROPN	B
),	O	PUNCT	O
signal	O	NOUN	B
averaged	O	VERB	I
ECG	O	PROPN	B
,	O	PUNCT	O
24	O	NUM	O
-	O	PUNCT	O
hour	O	NOUN	B
ambulatory	O	ADJ	B
ECG	O	PROPN	O
,	O	PUNCT	O
echocardiography	O	NOUN	B
and	O	CCONJ	O
radionuclide	O	NOUN	B
angiography	O	NOUN	I
.	O	PUNCT	O


Eighteen	O	NUM	O
of	O	ADP	O
31	O	NUM	O
(	O	PUNCT	O
58	O	NUM	O
%)	O	NOUN	O
patients	O	NOUN	B
showed	O	VERB	O
cardiac	B-Disease	ADJ	B
toxicity	I-Disease	NOUN	B
,	O	PUNCT	O
defined	O	VERB	O
as	O	ADP	O
having	O	VERB	O
one	O	NUM	O
or	O	CCONJ	O
more	O	ADJ	O
of	O	ADP	O
the	O	DET	O
following	O	VERB	O
abnormalities	O	NOUN	B
:	O	PUNCT	O
late	O	ADJ	B
potentials	O	NOUN	I
,	O	PUNCT	O
complex	O	ADJ	B
ventricular	B-Disease	ADJ	I
arrhythmias	I-Disease	NOUN	I
,	O	PUNCT	O
left	O	VERB	B
ventricular	B-Disease	ADJ	I
dilation	I-Disease	NOUN	I
,	O	PUNCT	O
decreased	O	VERB	B
shortening	O	NOUN	B
fraction	O	NOUN	B
,	O	PUNCT	O
or	O	CCONJ	O
decreased	O	VERB	B
ejection	O	NOUN	B
fraction	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
incidence	O	NOUN	B
of	O	ADP	O
cardiac	B-Disease	ADJ	B
abnormalities	I-Disease	NOUN	I
increased	O	VERB	B
with	O	ADP	O
length	O	NOUN	B
of	O	ADP	O
follow	O	NOUN	B
-	O	PUNCT	O
up	O	NOUN	O
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
or	O	CCONJ	O
=.	O	NOUN	O
05	O	NUM	O
).	O	PUNCT	O
No	O	DET	O
correlation	O	NOUN	B
could	O	AUX	O
be	O	AUX	O
demonstrated	O	VERB	O
between	O	ADP	O
cumulative	O	ADJ	B
dose	O	NOUN	B
of	O	ADP	O
doxorubicin	B-Chemical	NOUN	B
and	O	CCONJ	O
cardiac	O	ADJ	B
status	O	NOUN	I
,	O	PUNCT	O
except	O	SCONJ	O
for	O	ADP	O
heart	O	NOUN	B
rate	O	NOUN	I
variability	O	NOUN	B
.	O	PUNCT	O


When	O	SCONJ	O
adjusted	O	VERB	O
to	O	ADP	O
body	O	NOUN	B
surface	O	NOUN	I
area	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
left	O	ADJ	B
ventricular	O	ADJ	I
posterior	O	ADJ	I
wall	O	NOUN	I
thickness	O	NOUN	I
(	O	PUNCT	O
LVPW	O	NOUN	B
index	O	NOUN	I
)	O	PUNCT	O
was	O	AUX	O
decreased	O	VERB	B
in	O	ADP	O
all	O	DET	O
patients	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
incidence	O	NOUN	B
of	O	ADP	O
doxorubicin	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
cardiotoxicity	B-Disease	NOUN	B
is	O	AUX	O
high	O	ADJ	B
and	O	CCONJ	O
increases	O	VERB	B
with	O	ADP	O
follow	O	NOUN	B
-	O	PUNCT	O
up	O	NOUN	O
,	O	PUNCT	O
irrespective	O	ADV	O
of	O	ADP	O
cumulative	O	ADJ	B
dose	O	NOUN	B
.	O	PUNCT	O


Life	O	NOUN	B
-	O	PUNCT	O
long	O	ADJ	B
cardiac	O	ADJ	B
follow	O	NOUN	B
-	O	PUNCT	O
up	O	NOUN	O
in	O	ADP	O
these	O	DET	O
patients	O	NOUN	B
is	O	AUX	O
warranted	O	VERB	O
.	O	PUNCT	O


The	O	DET	O
results	O	NOUN	B
of	O	ADP	O
our	O	PRON	O
study	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
heart	O	NOUN	B
rate	O	NOUN	I
variability	O	NOUN	B
and	O	CCONJ	O
LVPW	O	NOUN	B
index	O	NOUN	I
could	O	AUX	O
be	O	AUX	O
sensitive	O	ADJ	B
indicators	O	NOUN	B
for	O	ADP	O
cardiotoxicity	B-Disease	NOUN	B


Venous	B-Disease	ADJ	B
complications	I-Disease	NOUN	B
of	O	ADP	O
midazolam	B-Chemical	NOUN	B
versus	O	CCONJ	O
diazepam	B-Chemical	NOUN	B
.	O	PUNCT	O


Although	O	SCONJ	O
some	O	DET	O
studies	O	NOUN	B
have	O	AUX	O
suggested	O	VERB	O
fewer	O	ADJ	O
venous	B-Disease	ADJ	B
complications	I-Disease	NOUN	I
are	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
midazolam	B-Chemical	NOUN	B
than	O	ADP	O
with	O	ADP	O
diazepam	B-Chemical	NOUN	B
for	O	ADP	O
endoscopic	O	ADJ	B
procedures	O	NOUN	I
,	O	PUNCT	O
this	O	DET	O
variable	O	NOUN	B
has	O	AUX	O
not	O	PART	O
been	O	AUX	O
well	O	ADV	O
documented	O	VERB	B
.	O	PUNCT	O


We	O	PRON	O
prospectively	O	ADV	O
evaluated	O	VERB	B
the	O	DET	O
incidence	O	NOUN	B
of	O	ADP	O
venous	B-Disease	ADJ	B
complications	I-Disease	NOUN	I
after	O	ADP	O
intravenous	O	ADJ	B
injection	O	NOUN	I
of	O	ADP	O
diazepam	B-Chemical	NOUN	B
or	O	CCONJ	O
midazolam	B-Chemical	NOUN	B
in	O	ADP	O
122	O	NUM	O
consecutive	O	ADJ	B
patients	O	NOUN	B
undergoing	O	VERB	O
colonoscopy	O	NOUN	B
and	O	CCONJ	O
esophagogastroduodenoscopy	O	NOUN	B
.	O	PUNCT	O


Overall	O	ADV	O
,	O	PUNCT	O
venous	B-Disease	ADJ	B
complications	I-Disease	NOUN	I
were	O	AUX	O
more	O	ADV	O
frequent	O	ADJ	B
with	O	ADP	O
diazepam	B-Chemical	NOUN	B
(	O	PUNCT	O
22	O	NUM	O
of	O	ADP	O
62	O	NUM	O
patients	O	NOUN	B
)	O	PUNCT	O
than	O	ADP	O
with	O	ADP	O
midazolam	B-Chemical	NOUN	B
(	O	PUNCT	O
4	O	NUM	O
of	O	ADP	O
60	O	NUM	O
patients	O	NOUN	B
)(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


001	O	NUM	O
).	O	PUNCT	O
A	O	DET	O
palpable	O	ADJ	B
venous	O	ADJ	B
cord	O	NOUN	I
was	O	AUX	O
present	O	ADJ	O
in	O	ADP	O
23	O	NUM	O
%(	O	NOUN	O
14	O	NUM	O
of	O	ADP	O
62	O	NUM	O
)	O	PUNCT	O
of	O	ADP	O
patients	O	NOUN	B
in	O	ADP	O
the	O	DET	O
diazepam	B-Chemical	NOUN	B
group	O	NOUN	B
,	O	PUNCT	O
compared	O	VERB	B
with	O	ADP	O
2	O	NUM	O
%(	O	NOUN	O
1	O	NUM	O
of	O	ADP	O
60	O	NUM	O
patients	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
midazolam	B-Chemical	NOUN	B
group	O	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


002	O	X	O
).	O	PUNCT	B
Pain	B-Disease	NOUN	I
at	O	ADP	O
the	O	DET	O
injection	O	NOUN	B
site	O	NOUN	I
occurred	O	VERB	O
in	O	ADP	O
35	O	NUM	O
%(	O	NOUN	O
22	O	NUM	O
of	O	ADP	O
62	O	NUM	O
)	O	PUNCT	O
of	O	ADP	O
patients	O	NOUN	B
in	O	ADP	O
the	O	DET	O
diazepam	B-Chemical	NOUN	B
group	O	NOUN	B
compared	O	VERB	B
with	O	ADP	O
7	O	NUM	O
%(	O	NOUN	O
4	O	NUM	O
of	O	ADP	O
60	O	NUM	O
patients	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
midazolam	B-Chemical	NOUN	B
group	O	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


001	O	NUM	O
).	O	PUNCT	B
Swelling	B-Disease	NOUN	B
and	O	CCONJ	O
warmth	O	NOUN	B
at	O	ADP	O
the	O	DET	O
injection	O	NOUN	B
site	O	NOUN	I
were	O	AUX	O
not	O	PART	O
significantly	O	ADV	O
different	O	ADJ	O
between	O	ADP	O
the	O	DET	O
two	O	NUM	O
groups	O	NOUN	B
.	O	PUNCT	O


Smoking	O	NOUN	B
,	O	PUNCT	O
nonsteroidal	O	ADJ	B
anti	O	ADJ	I
-	O	PUNCT	O
inflammatory	O	ADJ	B
drug	O	NOUN	B
use	O	NOUN	I
,	O	PUNCT	O
intravenous	O	ADJ	B
catheter	O	NOUN	I
site	O	NOUN	I
,	O	PUNCT	O
dwell	O	ADJ	B
time	O	NOUN	I
of	O	ADP	O
the	O	DET	O
needle	O	NOUN	B
,	O	PUNCT	O
alcohol	B-Chemical	NOUN	B
use	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
pain	B-Disease	NOUN	B
during	O	ADP	O
the	O	DET	O
injection	O	NOUN	B
had	O	AUX	O
no	O	DET	B
effect	O	NOUN	I
on	O	ADP	O
the	O	DET	O
incidence	O	NOUN	B
of	O	ADP	O
venous	B-Disease	ADJ	B
complications	I-Disease	NOUN	I


Tetany	B-Disease	NOUN	B
and	O	CCONJ	O
rhabdomyolysis	B-Disease	NOUN	B
due	O	ADJ	O
to	O	PART	O
surreptitious	O	ADJ	B
furosemide	B-Chemical	NOUN	B
--	O	PUNCT	O
importance	O	NOUN	O
of	O	ADP	O
magnesium	B-Chemical	NOUN	B
supplementation	O	NOUN	I
.	O	PUNCT	O


Diuretics	O	NOUN	B
may	O	AUX	O
induce	O	VERB	B
hypokalemia	B-Disease	NOUN	B
,	O	PUNCT	O
hypocalcemia	B-Disease	NOUN	B
and	O	CCONJ	O
hypomagnesemia	B-Disease	NOUN	B
.	O	PUNCT	O


While	O	SCONJ	O
severe	O	ADJ	B
hypokalemia	B-Disease	NOUN	B
may	O	AUX	O
cause	O	VERB	O
muscle	B-Disease	NOUN	B
weakness	I-Disease	NOUN	I
,	O	PUNCT	O
severe	O	ADJ	B
hypomagnesemia	B-Disease	NOUN	B
is	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
muscle	B-Disease	NOUN	B
spasms	I-Disease	NOUN	I
and	O	CCONJ	O
tetany	B-Disease	NOUN	B
which	O	DET	O
cannot	O	VERB	O
be	O	AUX	O
corrected	O	VERB	O
by	O	ADP	O
potassium	B-Chemical	NOUN	B
and	O	CCONJ	O
calcium	B-Chemical	NOUN	B
supplementation	O	NOUN	I
alone	O	ADV	O
(	O	PUNCT	O
1	O	NUM	O
,	O	PUNCT	O
2	O	NUM	O
).	O	PUNCT	O
Surreptitious	O	ADJ	B
diuretic	O	ADJ	O
ingestion	O	NOUN	B
has	O	AUX	O
been	O	AUX	O
described	O	VERB	O
,	O	PUNCT	O
mainly	O	ADV	O
in	O	ADP	O
women	O	NOUN	B
who	O	PRON	O
are	O	AUX	O
concerned	O	ADJ	O
that	O	SCONJ	O
they	O	PRON	O
are	O	AUX	O
obese	B-Disease	ADJ	B
or	O	CCONJ	O
edematous	B-Disease	ADJ	B
.	O	PUNCT	O


Symptomatic	O	ADJ	B
hypokalemia	B-Disease	NOUN	B
has	O	AUX	O
been	O	AUX	O
reported	O	VERB	O
in	O	ADP	O
such	O	ADJ	O
patients	O	NOUN	B
(	O	PUNCT	O
3	O	NUM	O
-	O	SYM	O
7	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
in	O	ADP	O
one	O	NUM	O
case	O	NOUN	B
hypocalcemia	B-Disease	NOUN	B
was	O	AUX	O
observed	O	VERB	O
(	O	PUNCT	O
8	O	NUM	O
),	O	PUNCT	O
but	O	CCONJ	O
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	O
magnesium	B-Chemical	NOUN	B


Loss	O	NOUN	B
of	O	ADP	O
glutamate	B-Chemical	NOUN	B
decarboxylase	O	NOUN	I
mRNA	O	NOUN	B
-	O	PUNCT	O
containing	O	VERB	B
neurons	O	NOUN	B
in	O	ADP	O
the	O	DET	O
rat	O	NOUN	B
dentate	O	NOUN	B
gyrus	O	NOUN	I
following	O	VERB	O
pilocarpine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
seizures	B-Disease	NOUN	B
.	O	PUNCT	O


In	O	X	B
situ	O	X	I
hybridization	O	NOUN	I
methods	O	NOUN	I
were	O	AUX	O
used	O	VERB	O
to	O	PART	O
determine	O	VERB	O
if	O	SCONJ	O
glutamic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
decarboxylase	O	NOUN	I
(	O	PUNCT	O
GAD	O	NOUN	B
)	O	PUNCT	O
mRNA	O	NOUN	B
-	O	PUNCT	O
containing	O	VERB	B
neurons	O	NOUN	B
within	O	ADP	O
the	O	DET	O
hilus	O	NOUN	B
of	O	ADP	O
the	O	DET	O
dentate	O	NOUN	B
gyrus	O	NOUN	I
are	O	AUX	O
vulnerable	O	ADJ	B
to	O	ADP	O
seizure	B-Disease	VERB	B
-	O	PUNCT	O
induced	O	VERB	B
damage	O	NOUN	B
in	O	ADP	O
a	O	DET	O
model	O	NOUN	B
of	O	ADP	O
chronic	O	ADJ	B
seizures	B-Disease	NOUN	I
.	O	PUNCT	O


Sprague	O	PROPN	B
-	O	PUNCT	O
Dawley	O	NOUN	B
rats	O	NOUN	B
were	O	AUX	O
injected	O	VERB	B
intraperitoneally	O	ADV	B
with	O	ADP	O
pilocarpine	B-Chemical	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
hippocampal	O	NOUN	B
formation	O	NOUN	B
was	O	AUX	O
studied	O	VERB	O
histologically	O	ADV	B
at	O	ADP	O
1	O	NUM	O
,	O	PUNCT	O
2	O	NUM	O
,	O	PUNCT	O
4	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
8	O	NUM	O
week	O	NOUN	B
intervals	O	NOUN	B
after	O	ADP	O
pilocarpine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
seizures	B-Disease	NOUN	B
.	O	PUNCT	O


In	O	X	B
situ	O	X	I
hybridization	O	NOUN	I
histochemistry	O	NOUN	I
,	O	PUNCT	O
using	O	VERB	O
a	O	DET	O
digoxigenin	B-Chemical	NOUN	B
-	O	PUNCT	O
labeled	O	VERB	B
GAD	O	NOUN	B
cRNA	O	NOUN	B
probe	O	NOUN	I
,	O	PUNCT	O
demonstrated	O	VERB	O
a	O	DET	O
substantial	O	ADJ	O
decrease	O	NOUN	B
in	O	ADP	O
the	O	DET	O
number	O	NOUN	O
of	O	ADP	O
GAD	O	NOUN	B
mRNA	O	NOUN	B
-	O	PUNCT	O
containing	O	VERB	B
neurons	O	NOUN	B
in	O	ADP	O
the	O	DET	O
hilus	O	NOUN	B
of	O	ADP	O
the	O	DET	O
dentate	O	NOUN	B
gyrus	O	NOUN	I
in	O	ADP	O
the	O	DET	O
pilocarpine	B-Chemical	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
rats	O	NOUN	B
as	O	ADP	O
compared	O	VERB	O
to	O	PART	O
controls	O	NOUN	B
at	O	ADP	O
all	O	DET	O
time	O	NOUN	B
intervals	O	NOUN	I
.	O	PUNCT	O


Additional	O	ADJ	O
neuronanatomical	O	ADJ	B
studies	O	NOUN	I
,	O	PUNCT	O
including	O	VERB	O
cresyl	B-Chemical	ADJ	B
violet	I-Chemical	NOUN	I
staining	O	NOUN	I
,	O	PUNCT	O
neuronal	B-Disease	ADJ	B
degeneration	I-Disease	NOUN	I
methods	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
histochemical	O	ADJ	B
localization	O	NOUN	B
of	O	ADP	O
glial	O	ADJ	B
fibrillary	O	ADJ	I
acidic	O	ADJ	I
protein	O	NOUN	I
,	O	PUNCT	O
suggested	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
decrease	O	NOUN	B
in	O	ADP	O
the	O	DET	O
number	O	NOUN	O
of	O	ADP	O
GAD	O	NOUN	B
mRNA	O	NOUN	B
-	O	PUNCT	O
containing	O	VERB	B
neurons	O	NOUN	B
was	O	AUX	O
related	O	ADJ	O
to	O	PART	O
neuronal	B-Disease	ADJ	B
loss	I-Disease	NOUN	O
rather	O	ADV	O
than	O	ADP	O
to	O	PART	O
a	O	DET	O
decrease	O	NOUN	B
in	O	ADP	O
GAD	O	NOUN	B
mRNA	O	NOUN	B
levels	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
loss	O	NOUN	B
of	O	ADP	O
GAD	O	NOUN	B
mRNA	O	NOUN	B
-	O	PUNCT	O
containing	O	VERB	B
neurons	O	NOUN	B
in	O	ADP	O
the	O	DET	O
hilus	O	NOUN	B
contrasted	O	VERB	O
with	O	ADP	O
the	O	DET	O
relative	O	ADJ	O
preservation	O	NOUN	B
of	O	ADP	O
labeled	O	VERB	B
putative	O	ADJ	B
basket	O	NOUN	I
cells	O	NOUN	I
along	O	ADP	O
the	O	DET	O
inner	O	ADJ	B
margin	O	NOUN	I
of	O	ADP	O
the	O	DET	O
granule	O	NOUN	B
cell	O	NOUN	I
layer	O	NOUN	I
.	O	PUNCT	O


Quantitative	O	ADJ	B
analyses	O	NOUN	I
of	O	ADP	O
labeled	O	VERB	B
neurons	O	NOUN	B
in	O	ADP	O
three	O	NUM	O
regions	O	NOUN	B
of	O	ADP	O
the	O	DET	O
dentate	O	NOUN	B
gyrus	O	NOUN	I
in	O	ADP	O
the	O	DET	O
1	O	NUM	O
and	O	CCONJ	O
2	O	NUM	O
week	O	NOUN	B
groups	O	NOUN	B
showed	O	VERB	O
statistically	O	ADV	B
significant	O	ADJ	I
decreases	O	NOUN	B
in	O	ADP	O
the	O	DET	O
mean	O	ADJ	O
number	O	NOUN	O
of	O	ADP	O
GAD	O	NOUN	B
mRNA	O	NOUN	B
-	O	PUNCT	O
containing	O	VERB	B
neurons	O	NOUN	B
in	O	ADP	O
the	O	DET	O
hilus	O	NOUN	B
of	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
of	O	ADP	O
experimental	O	ADJ	B
animals	O	NOUN	I
.	O	PUNCT	O


No	O	DET	B
significant	O	ADJ	I
differences	O	NOUN	O
were	O	AUX	O
found	O	VERB	O
in	O	ADP	O
the	O	DET	O
molecular	O	ADJ	B
layer	O	NOUN	I
or	O	CCONJ	O
the	O	DET	O
granule	O	NOUN	B
cell	O	NOUN	I
layer	O	NOUN	I
,	O	PUNCT	O
which	O	DET	O
included	O	VERB	O
labeled	O	VERB	B
neurons	O	NOUN	B
along	O	ADP	O
the	O	DET	O
lower	O	ADJ	B
margin	O	NOUN	B
of	O	ADP	O
the	O	DET	O
granule	O	NOUN	B
cell	O	NOUN	I
layer	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
results	O	NOUN	B
indicate	O	VERB	O
that	O	SCONJ	O
,	O	PUNCT	O
in	O	ADP	O
this	O	DET	O
model	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
subpopulation	O	NOUN	B
of	O	ADP	O
GAD	O	NOUN	B
mRNA	O	NOUN	B
-	O	PUNCT	O
containing	O	VERB	B
neurons	O	NOUN	B
within	O	ADP	O
the	O	DET	O
dentate	O	NOUN	B
gyrus	O	NOUN	I
is	O	AUX	O
selectively	O	ADV	O
vulnerable	O	ADJ	B
to	O	ADP	O
seizure	B-Disease	VERB	B
-	O	PUNCT	O
induced	O	VERB	B
damage	O	NOUN	B
.	O	PUNCT	O


Such	O	ADJ	O
differential	O	ADJ	B
vulnerability	O	NOUN	B
appears	O	VERB	O
to	O	PART	O
be	O	AUX	O
another	O	DET	O
indication	O	NOUN	B
of	O	ADP	O
the	O	DET	O
heterogeneity	O	NOUN	B
of	O	ADP	O
GABA	B-Chemical	NOUN	B


Protective	O	ADJ	B
effect	O	NOUN	I
of	O	ADP	O
misoprostol	B-Chemical	NOUN	B
on	O	ADP	O
indomethacin	B-Chemical	NOUN	B
induced	O	VERB	B
renal	B-Disease	ADJ	B
dysfunction	I-Disease	NOUN	I
in	O	ADP	O
elderly	O	ADJ	B
patients	O	NOUN	I
.	O	PUNCT	O


OBJECTIVE	O	NOUN	B
:	O	PUNCT	O
To	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
possible	O	ADJ	O
protective	O	ADJ	B
effects	O	NOUN	I
of	O	ADP	O
misoprostol	B-Chemical	NOUN	B
on	O	ADP	O
renal	O	ADJ	B
function	O	NOUN	I
in	O	ADP	O
hospitalized	O	VERB	B
elderly	O	ADJ	O
patients	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
indomethacin	B-Chemical	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
:	O	PUNCT	O
Forty	O	NUM	B
-	O	PUNCT	O
five	O	NUM	B
hospitalized	O	VERB	B
elderly	O	ADJ	O
patients	O	NOUN	B
(>	O	NOUN	O
65	O	NUM	O
years	O	NOUN	O
old	O	ADJ	O
)	O	PUNCT	O
who	O	PRON	O
required	O	VERB	O
therapy	O	NOUN	B
with	O	ADP	O
nonsteroidal	O	ADJ	B
antiinflammatory	O	ADJ	I
drugs	O	NOUN	I
(	O	PUNCT	O
NSAID	O	NOUN	B
)	O	PUNCT	O
were	O	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
to	O	PART	O
receive	O	VERB	O
either	O	CCONJ	O
indomethacin	B-Chemical	NOUN	B
,	O	PUNCT	O
150	O	NUM	O
mg	O	NOUN	O
/	O	PUNCT	O
day	O	NOUN	B
(	O	PUNCT	O
Group	O	PROPN	B
A	O	PROPN	O
),	O	PUNCT	O
or	O	CCONJ	O
indomethacin	B-Chemical	NOUN	B
150	O	NUM	O
mg	O	NOUN	O
/	O	PUNCT	O
day	O	NOUN	B
plus	O	CCONJ	O
misoprostol	B-Chemical	NOUN	B
at	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
mg	O	NOUN	O
/	O	PUNCT	O
day	O	NOUN	B
(	O	PUNCT	O
Group	O	PROPN	B
B	O	NOUN	I
).	O	PUNCT	I
Laboratory	O	NOUN	O
variables	O	NOUN	O
of	O	ADP	O
renal	O	ADJ	B
function	O	NOUN	I
[	O	PUNCT	O
serum	O	NOUN	B
creatinine	B-Chemical	NOUN	I
,	O	PUNCT	O
blood	B-Chemical	NOUN	B
urea	I-Chemical	NOUN	I
nitrogen	I-Chemical	NOUN	I
(	O	PUNCT	O
BUN	B-Chemical	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
electrolytes	O	NOUN	B
]	O	PUNCT	O
were	O	AUX	O
evaluated	O	VERB	B
before	O	ADP	O
initiation	O	NOUN	B
of	O	ADP	O
therapy	O	NOUN	B
and	O	CCONJ	O
every	O	DET	O
2	O	NUM	O
days	O	NOUN	B
,	O	PUNCT	O
until	O	ADP	O
termination	O	NOUN	B
of	O	ADP	O
the	O	DET	O
study	O	NOUN	B
(	O	PUNCT	O
a	O	DET	O
period	O	NOUN	B
of	O	ADP	O
at	O	ADP	O
least	O	ADJ	O
6	O	NUM	O
days	O	NOUN	B
).	O	PUNCT	O
Response	O	NOUN	B
to	O	PART	O
treatment	O	NOUN	B
was	O	AUX	O
estimated	O	VERB	O
by	O	ADP	O
the	O	DET	O
visual	O	ADJ	B
analog	O	NOUN	I
scale	O	NOUN	I
for	O	ADP	O
severity	O	NOUN	B
of	O	ADP	O
pain	B-Disease	NOUN	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
Forty	O	NUM	B
-	O	PUNCT	O
two	O	NUM	O
patients	O	NOUN	B
completed	O	VERB	O
the	O	DET	O
study	O	NOUN	B
,	O	PUNCT	O
22	O	NUM	O
in	O	ADP	O
Group	O	PROPN	B
A	O	PROPN	O
and	O	CCONJ	O
20	O	NUM	O
in	O	ADP	O
Group	O	PROPN	B
B	O	NOUN	I
.	O	PUNCT	O


BUN	B-Chemical	NOUN	B
and	O	CCONJ	O
creatinine	B-Chemical	NOUN	B
increased	O	VERB	B
by	O	ADP	O
>	O	X	O
50	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
baseline	O	NOUN	B
levels	O	NOUN	B
in	O	ADP	O
54	O	NUM	O
and	O	CCONJ	O
45	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
Group	O	PROPN	B
A	O	DET	O
patients	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
,	O	PUNCT	O
compared	O	VERB	O
to	O	PART	O
only	O	ADV	O
20	O	NUM	O
and	O	CCONJ	O
10	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
Group	O	NOUN	B
B	O	NOUN	O
patients	O	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


05	O	NUM	O
).	O	NOUN	B
Potassium	B-Chemical	NOUN	I
(	O	PUNCT	O
K	B-Chemical	NOUN	B
)	O	PUNCT	O
increment	O	NOUN	B
of	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
mEq	O	NOUN	B
/	O	SYM	O
l	O	NOUN	B
or	O	CCONJ	O
more	O	ADJ	O
was	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
50	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
Group	O	PROPN	B
A	O	PROPN	O
,	O	PUNCT	O
but	O	CCONJ	O
in	O	ADP	O
only	O	ADV	O
15	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
Group	O	NOUN	B
B	O	NOUN	O
patients	O	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


05	O	NUM	O
).	O	PUNCT	O
The	O	DET	O
mean	O	ADJ	O
increments	O	NOUN	B
in	O	ADP	O
BUN	B-Chemical	NOUN	B
,	O	PUNCT	O
creatinine	B-Chemical	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
K	B-Chemical	NOUN	B
were	O	AUX	O
reduced	O	VERB	B
by	O	ADP	O
63	O	NUM	O
,	O	PUNCT	O
80	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
42	O	NUM	O
%,	O	ADJ	B
respectively	O	ADV	O
,	O	PUNCT	O
in	O	ADP	O
Group	O	NOUN	B
B	O	NOUN	O
patients	O	NOUN	B
compared	O	VERB	O
to	O	ADP	O
Group	O	PROPN	B
A	O	PROPN	O
.	O	PUNCT	O


Response	O	NOUN	B
to	O	PART	O
treatment	O	NOUN	B
did	O	AUX	O
not	O	PART	O
differ	O	VERB	O
significantly	O	ADV	O
between	O	ADP	O
the	O	DET	O
2	O	NUM	O
groups	O	NOUN	B
.	O	PUNCT	O


CONCLUSION	O	NOUN	B
:	O	PUNCT	O
Hospitalized	O	VERB	B
elderly	O	ADJ	I
patients	O	NOUN	B
are	O	AUX	O
at	O	ADP	O
risk	O	NOUN	B
for	O	ADP	O
developing	O	VERB	O
indomethacin	B-Chemical	NOUN	B
related	O	ADJ	O
renal	B-Disease	ADJ	B
dysfunction	I-Disease	NOUN	I
.	O	PUNCT	O


Addition	O	NOUN	B
of	O	ADP	O
misoprostol	B-Chemical	NOUN	B
can	O	AUX	O
minimize	O	VERB	O
this	O	DET	O
renal	B-Disease	ADJ	B
impairment	I-Disease	NOUN	I
without	O	ADP	O
affecting	O	VERB	B
pain	B-Disease	NOUN	B


Nephrotoxic	B-Disease	NOUN	B
effects	O	NOUN	B
of	O	ADP	O
aminoglycoside	B-Chemical	ADJ	B
treatment	O	NOUN	B
on	O	ADP	O
renal	O	ADJ	B
protein	O	NOUN	I
reabsorption	O	NOUN	I
and	O	CCONJ	O
accumulation	O	NOUN	B
.	O	PUNCT	O


To	O	PART	O
quantify	O	VERB	B
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	O
gentamicin	B-Chemical	NOUN	B
,	O	PUNCT	O
kanamycin	B-Chemical	NOUN	B
and	O	CCONJ	O
netilmicin	B-Chemical	NOUN	B
on	O	ADP	O
renal	O	ADJ	B
protein	O	NOUN	I
reabsorption	O	NOUN	I
and	O	CCONJ	O
accumulation	O	NOUN	B
,	O	PUNCT	O
these	O	DET	O
drugs	O	NOUN	B
were	O	AUX	O
administered	O	VERB	B
to	O	PART	O
rats	O	NOUN	B
intraperitoneally	O	ADV	B
(	O	PUNCT	O
30	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
/	O	PUNCT	O
day	O	NOUN	B
)	O	PUNCT	O
for	O	ADP	O
7	O	NUM	O
,	O	PUNCT	O
14	O	NUM	O
or	O	CCONJ	O
21	O	NUM	O
days	O	NOUN	B
.	O	PUNCT	O


Scanning	O	ADJ	B
electron	O	NOUN	I
microscopy	O	NOUN	I
of	O	ADP	O
the	O	DET	O
glomerular	O	ADJ	B
endothelia	O	NOUN	I
,	O	PUNCT	O
urinary	O	ADJ	B
measurements	O	NOUN	I
of	O	ADP	O
sodium	B-Chemical	NOUN	B
,	O	PUNCT	O
potassium	B-Chemical	NOUN	B
,	O	PUNCT	O
endogenous	O	ADJ	B
lysozyme	O	NOUN	B
,	O	PUNCT	O
N	O	NOUN	B
-	O	PUNCT	O
acetyl	O	ADJ	B
-	O	PUNCT	O
beta	O	NOUN	B
-	O	PUNCT	O
D	O	NOUN	B
-	O	PUNCT	O
glucosaminidase	O	NOUN	B
(	O	PUNCT	O
NAG	O	NOUN	B
)	O	PUNCT	O
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
clearance	O	NOUN	B
and	O	CCONJ	O
accumulation	O	NOUN	B
experiments	O	NOUN	O
after	O	ADP	O
i	O	PRON	O
.	O	PUNCT	O


v	O	NOUN	O
.	O	PUNCT	O


administration	O	NOUN	B
of	O	ADP	O
egg	O	NOUN	B
-	O	PUNCT	O
white	O	ADJ	B
lysozyme	O	NOUN	B
and	O	CCONJ	O
measurements	O	NOUN	B
of	O	ADP	O
inulin	O	NOUN	B
clearance	O	NOUN	B
(	O	PUNCT	O
GFR	O	NOUN	B
)	O	PUNCT	O
were	O	AUX	O
done	O	VERB	O
in	O	ADP	O
each	O	DET	O
treatment	O	NOUN	B
group	O	NOUN	I
.	O	PUNCT	O


Gentamicin	B-Chemical	NOUN	B
administration	O	NOUN	B
decreased	O	VERB	B
diameter	O	NOUN	B
,	O	PUNCT	O
density	O	NOUN	B
and	O	CCONJ	O
shape	O	NOUN	B
of	O	ADP	O
endothelial	O	ADJ	B
fenestrae	O	NOUN	I
.	O	PUNCT	O


Kanamycin	B-Chemical	NOUN	B
and	O	CCONJ	O
netilmicin	B-Chemical	NOUN	B
appeared	O	VERB	O
to	O	PART	O
have	O	AUX	O
no	O	DET	O
effect	O	NOUN	O
at	O	ADP	O
the	O	DET	O
dose	O	NOUN	B
used	O	VERB	O
.	O	PUNCT	O


All	O	DET	O
three	O	NUM	O
aminoglycosides	B-Chemical	NOUN	B
decreased	O	VERB	B
GFR	O	NOUN	B
and	O	CCONJ	O
increased	O	VERB	B
urinary	O	ADJ	B
excretion	O	NOUN	B
of	O	ADP	O
sodium	B-Chemical	NOUN	B
and	O	CCONJ	O
potassium	B-Chemical	NOUN	B
.	O	PUNCT	O


While	O	SCONJ	O
gentamicin	B-Chemical	NOUN	B
and	O	CCONJ	O
kanamycin	B-Chemical	NOUN	B
decreased	O	VERB	B
the	O	DET	O
percentage	O	NOUN	B
reabsorption	O	NOUN	B
and	O	CCONJ	O
accumulation	O	NOUN	B
of	O	ADP	O
lysozyme	O	NOUN	B
after	O	ADP	O
i	O	PRON	O
.	O	PUNCT	O


v	O	NOUN	O
.	O	PUNCT	O


administration	O	NOUN	B
of	O	ADP	O
egg	O	NOUN	B
-	O	PUNCT	O
white	O	ADJ	B
lysozyme	O	NOUN	B
netilmicin	B-Chemical	NOUN	B
had	O	AUX	O
no	O	DET	B
effect	O	NOUN	I
.	O	PUNCT	O


Daily	O	ADJ	B
excretion	O	NOUN	B
of	O	ADP	O
total	O	ADJ	B
protein	O	NOUN	I
,	O	PUNCT	O
endogenous	O	ADJ	B
lysozyme	O	NOUN	B
and	O	CCONJ	O
NAG	O	NOUN	B
increased	O	VERB	B
only	O	ADV	O
after	O	ADP	O
treatment	O	NOUN	B
with	O	ADP	O
kanamycin	B-Chemical	NOUN	B
and	O	CCONJ	O
gentamicin	B-Chemical	NOUN	B
.	O	PUNCT	O


Thus	O	ADV	O
,	O	PUNCT	O
aminoglycosides	B-Chemical	NOUN	B
may	O	AUX	O
act	O	VERB	O
as	O	ADP	O
nephrotoxicants	O	NOUN	B
at	O	ADP	O
glomerular	O	ADJ	B
and	O	CCONJ	O
/	O	SYM	O
or	O	CCONJ	O
tubular	O	ADJ	B
level	O	NOUN	O
inducing	O	VERB	O
impairment	B-Disease	NOUN	B
of	I-Disease	ADP	O
renal	I-Disease	ADJ	B
reabsorption	I-Disease	NOUN	I


Pharmacology	O	NOUN	B
of	O	ADP	O
GYKI-41	B-Chemical	PROPN	B
099	I-Chemical	NUM	O
(	O	PUNCT	O
chlorpropanol	B-Chemical	NOUN	B
,	O	PUNCT	O
Tobanum	B-Chemical	PROPN	B
)	O	PUNCT	O
a	O	DET	O
new	O	ADJ	O
potent	O	ADJ	O
beta	O	NOUN	B
-	O	PUNCT	O
adrenergic	O	ADJ	B
antagonist	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
compound	O	NOUN	B
GYKI-41	B-Chemical	NOUN	B
099	I-Chemical	NUM	O
,	O	PUNCT	O
as	O	ADP	O
a	O	DET	O
beta	O	NOUN	B
-	O	PUNCT	O
adrenergic	O	ADJ	B
antagonist	O	NOUN	B
,	O	PUNCT	O
is	O	AUX	O
3	O	NUM	O
-	O	SYM	O
8	O	NUM	O
times	O	NOUN	O
more	O	ADV	O
potent	O	ADJ	O
than	O	ADP	O
propranolol	B-Chemical	NOUN	B
in	O	X	B
vitro	O	X	I
and	O	CCONJ	O
in	O	X	B
vivo	O	X	I
.	O	PUNCT	O


Its	O	PRON	O
antiarrhythmic	O	ADJ	B
effectiveness	O	NOUN	I
surpasses	O	VERB	O
that	O	DET	O
of	O	ADP	O
propranolol	B-Chemical	NOUN	B
and	O	CCONJ	O
pindolol	B-Chemical	NOUN	B
inhibiting	O	VERB	B
the	O	DET	O
ouabain	B-Chemical	NOUN	B
arrhythmia	B-Disease	NOUN	I
in	O	ADP	O
dogs	O	NOUN	B
and	O	CCONJ	O
cats	O	NOUN	B
.	O	PUNCT	O


GYKI-41	B-Chemical	NOUN	B
900	I-Chemical	NUM	O
has	O	AUX	O
a	O	DET	O
negligible	O	ADJ	O
cardiodepressant	O	ADJ	B
activity	O	NOUN	I
;	O	PUNCT	O
it	O	PRON	O
is	O	AUX	O
not	O	PART	O
cardioselective	O	ADJ	B
.	O	PUNCT	O


The	O	DET	O
compound	O	NOUN	B
shows	O	VERB	O
a	O	DET	O
rapid	O	ADJ	B
and	O	CCONJ	O
long	O	ADJ	B
lasting	O	ADJ	I
effect	O	NOUN	I
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
a	O	DET	O
prolonged	O	ADJ	B
elimination	O	NOUN	B
of	O	ADP	O
the	O	DET	O
radioactivity	O	NOUN	B
after	O	ADP	O
the	O	DET	O
injection	O	NOUN	B
of	O	ADP	O
14C-41	B-Chemical	DET	O
099	I-Chemical	NUM	O


Chorea	B-Disease	NOUN	B
associated	O	VERB	B
with	O	ADP	I
oral	B-Chemical	ADJ	B
contraception	I-Chemical	NOUN	I
.	O	PUNCT	O


Three	O	NUM	O
patients	O	NOUN	B
developed	O	VERB	O
chorea	B-Disease	NOUN	B
while	O	SCONJ	O
receiving	O	VERB	O
oral	B-Chemical	ADJ	B
contraceptives	I-Chemical	NOUN	I
.	O	PUNCT	O


Two	O	NUM	O
were	O	AUX	O
young	O	ADJ	B
patients	O	NOUN	B
whose	O	DET	O
chorea	B-Disease	NOUN	B
developed	O	VERB	O
long	O	ADV	O
after	O	ADP	O
treatment	O	NOUN	B
had	O	AUX	O
been	O	AUX	O
started	O	VERB	B
and	O	CCONJ	O
disappeared	O	VERB	O
soon	O	ADV	O
after	O	ADP	O
it	O	PRON	O
had	O	AUX	O
been	O	AUX	O
discontinued	O	VERB	B
.	O	PUNCT	O


The	O	DET	O
third	O	ADJ	O
patient	O	NOUN	B
had	O	AUX	O
acute	O	ADJ	B
amphetamine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
chorea	B-Disease	NOUN	B
after	O	ADP	O
prolonged	O	ADJ	B
oral	B-Chemical	ADJ	B
contraception	I-Chemical	NOUN	I
.	O	PUNCT	O


Prolonged	O	ADJ	B
administration	O	NOUN	B
of	O	ADP	O
female	O	ADJ	B
sex	O	NOUN	B
hormones	O	NOUN	I
is	O	AUX	O
a	O	DET	O
possible	O	ADJ	O
cause	O	NOUN	O
of	O	ADP	O
chorea	B-Disease	NOUN	B
in	O	ADP	O
women	O	NOUN	B
who	O	PRON	O
have	O	AUX	O
not	O	PART	O
previously	O	ADV	O
had	O	AUX	O
chorea	B-Disease	NOUN	B
or	O	CCONJ	O
rheumatic	B-Disease	ADJ	B
fever	I-Disease	NOUN	I


Reversal	O	ADJ	B
of	O	ADP	O
ammonia	B-Chemical	NOUN	B
coma	B-Disease	NOUN	I
in	O	ADP	O
rats	O	NOUN	B
by	O	ADP	O
L-dopa	B-Chemical	NOUN	B
:	O	PUNCT	O
a	O	DET	O
peripheral	O	ADJ	B
effect	O	NOUN	I
.	O	PUNCT	O


Ammonia	B-Chemical	NOUN	B
coma	B-Disease	NOUN	I
was	O	AUX	O
produced	O	VERB	O
in	O	ADP	O
rats	O	NOUN	B
within	O	ADP	O
10	O	NUM	O
to	O	PART	O
15	O	NUM	O
minutes	O	NOUN	B
of	O	ADP	O
an	O	DET	O
intraperitonealinjection	O	NOUN	B
of	O	ADP	O
1	O	NUM	O
.	O	PUNCT	O


7	O	NUM	O
mmol	O	NOUN	O
NH4CL	B-Chemical	NOUN	O
.	O	PUNCT	O


This	O	DET	O
coma	B-Disease	NOUN	B
was	O	AUX	O
prevented	O	VERB	B
with	O	ADP	O
1	O	NUM	O
.	O	PUNCT	O


68	O	NUM	O
mmol	O	NOUN	O
L-dopa	B-Chemical	NOUN	B
given	O	VERB	O
by	O	ADP	O
gastric	O	ADJ	B
intubation	O	NOUN	I
15	O	NUM	O
minutes	O	NOUN	B
before	O	ADP	O
the	O	DET	O
ammonium	B-Chemical	NOUN	B
salt	I-Chemical	NOUN	I
injection	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
L-dopa	B-Chemical	NOUN	B
was	O	AUX	O
correlated	O	VERB	B
with	O	ADP	O
a	O	DET	O
decrease	O	NOUN	B
in	O	ADP	O
blood	O	NOUN	B
and	O	CCONJ	O
brain	O	NOUN	B
ammonia	B-Chemical	NOUN	I
,	O	PUNCT	O
an	O	DET	O
increase	O	NOUN	B
in	O	ADP	O
brain	O	NOUN	B
dopamine	B-Chemical	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
an	O	DET	O
increase	O	NOUN	B
in	O	ADP	O
renal	O	ADJ	B
excretion	O	NOUN	B
of	O	ADP	O
ammonia	B-Chemical	NOUN	B
and	O	CCONJ	O
urea	B-Chemical	NOUN	B
.	O	PUNCT	O


Intraventricular	O	ADJ	B
infusion	O	NOUN	B
of	O	ADP	O
dopamine	B-Chemical	NOUN	B
sufficient	O	ADJ	B
to	O	PART	O
raise	O	VERB	O
the	O	DET	O
brain	O	NOUN	B
dopamine	B-Chemical	NOUN	B
to	O	ADP	O
the	O	DET	O
same	O	ADJ	O
extent	O	NOUN	O
did	O	AUX	O
not	O	PART	O
prevent	O	VERB	O
the	O	DET	O
ammonia	B-Chemical	NOUN	B
coma	B-Disease	NOUN	I
nor	O	CCONJ	O
affect	O	VERB	O
the	O	DET	O
blood	O	NOUN	B
and	O	CCONJ	O
brain	O	NOUN	B
ammonia	B-Chemical	NOUN	I
concentrations	O	NOUN	B
.	O	PUNCT	O


Bilateral	O	ADJ	B
nephrectomy	O	NOUN	I
eliminated	O	VERB	O
the	O	DET	O
beneficial	O	ADJ	O
effect	O	NOUN	B
of	O	ADP	O
L-dopa	B-Chemical	NOUN	B
on	O	ADP	O
blood	O	NOUN	B
and	O	CCONJ	O
brain	O	NOUN	B
ammonia	B-Chemical	NOUN	I
and	O	CCONJ	O
the	O	DET	O
ammonia	B-Chemical	NOUN	B
coma	B-Disease	NOUN	I
was	O	AUX	O
not	O	PART	O
prevented	O	VERB	B
.	O	PUNCT	O


Thus	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
reduction	O	NOUN	B
in	O	ADP	O
blood	O	NOUN	B
and	O	CCONJ	O
brain	O	NOUN	B
ammonia	B-Chemical	NOUN	I
and	O	CCONJ	O
the	O	DET	O
prevention	O	NOUN	B
of	O	ADP	O
ammonia	B-Chemical	NOUN	B
coma	B-Disease	NOUN	I
after	O	ADP	O
L-dopa	B-Chemical	NOUN	B
,	O	PUNCT	O
can	O	AUX	O
be	O	AUX	O
accounted	O	VERB	O
for	O	ADP	O
by	O	ADP	O
the	O	DET	O
peripheral	O	ADJ	B
effect	O	NOUN	I
of	O	ADP	O
dopamine	B-Chemical	NOUN	B
on	O	ADP	O
renal	O	ADJ	B
function	O	NOUN	I
rather	O	ADV	O
than	O	ADP	O
its	O	PRON	O
central	O	ADJ	B
action	O	NOUN	I
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	B
provide	O	VERB	O
a	O	DET	O
reasonable	O	ADJ	O
explanation	O	NOUN	B
for	O	ADP	O
the	O	DET	O
beneficial	O	ADJ	B
effects	O	NOUN	B
observed	O	VERB	O
in	O	ADP	O
some	O	DET	O
encephalopathic	B-Disease	ADJ	B
patients	O	NOUN	I
receiving	O	VERB	O
L-dopa	B-Chemical	NOUN	B


Heparin	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
thrombocytopenia	B-Disease	NOUN	B
after	O	ADP	O
liver	O	NOUN	B
transplantation	O	NOUN	I
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
:	O	PUNCT	O
Unfractionated	B-Chemical	VERB	B
heparin	I-Chemical	NOUN	I
sodium	I-Chemical	NOUN	I
(	O	PUNCT	O
UFH	B-Chemical	NOUN	B
)	O	PUNCT	O
or	O	CCONJ	O
low-molecular	B-Chemical	ADJ	B
weight	I-Chemical	NOUN	I
heparin	I-Chemical	NOUN	I
(	O	PUNCT	O
LMWH	O	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
used	O	VERB	O
in	O	ADP	O
anticoagulant	O	ADJ	B
protocols	O	NOUN	B
at	O	ADP	O
several	O	ADJ	O
institutions	O	NOUN	B
to	O	PART	O
prevent	O	VERB	B
thrombosis	B-Disease	NOUN	B
after	O	ADP	O
liver	O	NOUN	B
transplantation	O	NOUN	I
.	O	PUNCT	O


Heparin	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
thrombocytopenia	B-Disease	NOUN	B
(	O	PUNCT	O
HIT	B-Disease	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
an	O	DET	O
adverse	O	ADJ	B
immune	O	ADJ	I
-	O	PUNCT	O
mediated	O	VERB	B
reaction	O	NOUN	B
to	O	ADP	O
heparin	B-Chemical	NOUN	B
,	O	PUNCT	O
resulting	O	VERB	O
in	O	ADP	O
platelet	O	NOUN	B
count	O	NOUN	I
decreases	O	VERB	B
of	O	ADP	O
more	O	ADJ	O
than	O	ADP	O
50	O	NUM	O
%.	O	NOUN	O
The	O	DET	O
frequencies	O	NOUN	B
of	O	ADP	O
HIT	B-Disease	NOUN	B
after	O	ADP	O
liver	O	NOUN	B
transplantation	O	NOUN	I
and	O	CCONJ	O
platelet	O	NOUN	B
factor	O	NOUN	I
4	O	NUM	I
/	O	SYM	O
heparin	B-Chemical	NOUN	B
-	O	PUNCT	O
reactive	O	ADJ	B
antibody	O	NOUN	I
(	O	PUNCT	O
HIT	B-Disease	NOUN	B
antibody	O	NOUN	I
)	O	PUNCT	O
positivity	O	NOUN	B
in	O	ADP	O
liver	O	NOUN	B
transplantation	O	NOUN	I
patients	O	NOUN	B
,	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
are	O	AUX	O
unknown	O	ADJ	O
.	O	PUNCT	O


PATIENTS	O	NOUN	B
AND	O	CCONJ	O
METHODS	O	NOUN	O
:	O	PUNCT	O
The	O	DET	O
32	O	NUM	O
men	O	NOUN	B
and	O	CCONJ	O
20	O	NUM	O
women	O	NOUN	B
underwent	O	VERB	O
living	O	NOUN	B
donor	O	NOUN	I
liver	O	NOUN	B
transplantation	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
started	O	VERB	O
LMWH	O	NOUN	B
(	O	PUNCT	O
25	O	NUM	O
IU	O	PROPN	B
/	O	SYM	O
kg	O	NOUN	B
/	O	PUNCT	O
h	O	NOUN	B
)	O	PUNCT	O
on	O	ADP	O
postoperative	O	ADJ	B
day	O	NOUN	B
(	O	PUNCT	O
POD	O	NOUN	B
)	O	PUNCT	O
1	O	NUM	O
,	O	PUNCT	O
switching	O	NOUN	B
to	O	PART	O
UFH	B-Chemical	NOUN	B
(	O	PUNCT	O
5000	O	NUM	O
U	O	NOUN	B
/	O	PUNCT	O
d	O	X	B
)	O	PUNCT	O
on	O	ADP	O
POD	O	NOUN	B
2	O	NUM	O
or	O	CCONJ	O
3	O	NUM	O
.	O	PUNCT	O


The	O	DET	O
dose	O	NOUN	B
of	O	ADP	O
UFH	B-Chemical	NOUN	B
was	O	AUX	O
changed	O	VERB	O
according	O	VERB	O
to	O	PART	O
the	O	DET	O
activated	O	VERB	B
clotting	O	NOUN	I
time	O	NOUN	I
level	O	NOUN	I
.	O	PUNCT	O


HIT	B-Disease	NOUN	B
antibody	O	NOUN	B
levels	O	NOUN	B
were	O	AUX	O
measured	O	VERB	B
the	O	DET	O
day	O	NOUN	B
before	O	ADP	O
surgery	O	NOUN	B
and	O	CCONJ	O
on	O	ADP	O
POD	O	PROPN	B
7	O	NUM	O
and	O	CCONJ	O
14	O	NUM	O
.	O	PUNCT	O


Platelet	O	NOUN	B
count	O	NOUN	I
was	O	AUX	O
measured	O	VERB	O
daily	O	ADV	O
for	O	ADP	O
3	O	NUM	O
weeks	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
The	O	DET	O
average	O	ADJ	B
platelet	O	NOUN	B
counts	O	VERB	I
preoperatively	O	ADV	B
,	O	PUNCT	O
and	O	CCONJ	O
on	O	ADP	O
POD	O	PROPN	B
7	O	NUM	O
,	O	PUNCT	O
14	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
21	O	NUM	O
were	O	AUX	O
65	O	NUM	O
,	O	PUNCT	O
88	O	NUM	O
,	O	PUNCT	O
149	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
169	O	NUM	O
x	O	NOUN	O
10	O	NUM	O
(	O	PUNCT	O
9	O	NUM	O
)/	O	PROPN	B
L	O	PROPN	I
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


Two	O	NUM	O
patients	O	NOUN	B
developed	O	VERB	O
hepatic	O	ADJ	B
artery	O	NOUN	I
thrombosis	B-Disease	NOUN	I
on	O	ADP	O
POD	O	NOUN	B
11	O	NUM	O
and	O	CCONJ	O
19	O	NUM	O
,	O	PUNCT	O
respectively	O	ADV	O
,	O	PUNCT	O
although	O	SCONJ	O
they	O	PRON	O
were	O	AUX	O
HIT	B-Disease	NOUN	B
antibody	O	NOUN	B
-	O	PUNCT	O
negative	O	ADJ	B
and	O	CCONJ	O
their	O	PRON	O
platelet	O	NOUN	B
counts	O	NOUN	I
were	O	AUX	O
stable	O	ADJ	B
.	O	PUNCT	O


In	O	ADP	O
2	O	NUM	O
other	O	ADJ	O
patients	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
platelet	O	NOUN	B
count	O	NOUN	I
decreased	O	VERB	B
suddenly	O	ADV	O
from	O	ADP	O
107	O	NUM	O
x	O	NOUN	O
10	O	NUM	O
(	O	PUNCT	O
9	O	NUM	O
)/	O	PROPN	B
L	O	NOUN	I
on	O	ADP	O
POD	O	PROPN	B
4	O	NUM	O
to	O	PART	O
65	O	NUM	O
x	O	CCONJ	O
10	O	NUM	O
(	O	PUNCT	O
9	O	NUM	O
)/	O	PROPN	B
L	O	NOUN	I
on	O	ADP	O
POD	O	NOUN	B
6	O	NUM	O
and	O	CCONJ	O
from	O	ADP	O
76	O	NUM	O
x	O	NOUN	O
10	O	NUM	O
(	O	PUNCT	O
9	O	NUM	O
)/	O	PROPN	B
L	O	NOUN	I
on	O	ADP	O
POD	O	PROPN	B
7	O	NUM	O
to	O	PART	O
33	O	NUM	O
x	O	NOUN	O
10	O	NUM	O
(	O	PUNCT	O
9	O	NUM	O
)/	O	PROPN	B
L	O	NOUN	I
on	O	ADP	O
POD	O	PROPN	B
9	O	NUM	O
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


The	O	DET	O
heparin	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
platelet	B-Disease	NOUN	B
aggregation	I-Disease	NOUN	I
test	O	NOUN	I
was	O	AUX	O
negative	O	ADJ	B
in	O	ADP	O
these	O	DET	O
patients	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
percentage	O	NOUN	B
of	O	ADP	O
HIT	B-Disease	NOUN	B
antibody	O	NOUN	B
-	O	PUNCT	O
positive	O	ADJ	B
patients	O	NOUN	B
was	O	AUX	O
0	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
%	O	NOUN	O
preoperatively	O	ADV	B
,	O	PUNCT	O
5	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
%	O	NOUN	O
on	O	ADP	O
POD	O	PROPN	B
7	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
5	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
%	O	NOUN	O
on	O	ADP	O
POD	O	PROPN	B
14	O	NUM	O
.	O	PUNCT	O


of	O	ADP	O
the	O	DET	O
subjects	O	NOUN	B
/	O	PUNCT	O
patients	O	NOUN	B
developed	O	VERB	O
UFH	B-Chemical	PROPN	B
-	O	PUNCT	O
related	O	VERB	B
HIT	B-Disease	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
:	O	PUNCT	O
In	O	ADP	O
our	O	PRON	O
series	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
occurrence	O	NOUN	B
of	O	ADP	O
HIT	B-Disease	NOUN	B


PTU	B-Chemical	NOUN	B
-	O	PUNCT	O
associated	O	VERB	B
vasculitis	B-Disease	NOUN	B
in	O	ADP	O
a	O	DET	O
girl	O	NOUN	B
with	O	ADP	O
Turner	B-Disease	PROPN	B
Syndrome	I-Disease	NOUN	I
and	O	CCONJ	O
Graves'	B-Disease	ADJ	O
disease	I-Disease	NOUN	O
.	O	PUNCT	O


Palpable	O	ADJ	B
purpura	B-Disease	NOUN	I
is	O	AUX	O
a	O	DET	O
concerning	O	VERB	O
clinical	O	ADJ	B
finding	O	NOUN	I
in	O	ADP	O
pediatric	O	ADJ	B
patients	O	NOUN	B
and	O	CCONJ	O
can	O	AUX	O
have	O	AUX	O
many	O	ADJ	O
causes	O	NOUN	O
,	O	PUNCT	O
including	O	VERB	O
infectious	O	ADJ	B
and	O	CCONJ	O
autoimmune	O	ADJ	B
processes	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
rare	O	ADJ	B
cause	O	NOUN	B
,	O	PUNCT	O
drug	O	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
vasculitis	B-Disease	NOUN	B
,	O	PUNCT	O
may	O	AUX	O
result	O	VERB	O
from	O	ADP	O
the	O	DET	O
production	O	NOUN	B
of	O	ADP	O
antineutrophil	O	NOUN	B
cytoplasmic	O	ADJ	I
antibodies	O	NOUN	I
(	O	PUNCT	O
ANCAs	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
response	O	NOUN	B
to	O	PART	O
a	O	DET	O
medication	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
a	O	DET	O
girl	O	NOUN	B
with	O	ADP	O
Turner	B-Disease	NOUN	B
syndrome	I-Disease	NOUN	I
and	O	CCONJ	O
Graves'	B-Disease	ADJ	B
disease	I-Disease	NOUN	I
who	O	PRON	O
presented	O	VERB	O
with	O	ADP	O
palpable	O	ADJ	B
purpuric	B-Disease	ADJ	B
lesions	I-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
diagnosis	O	NOUN	B
of	O	ADP	O
propylthiouracil	B-Chemical	NOUN	B
(	O	PUNCT	O
PTU	B-Chemical	NOUN	B
)-	O	ADJ	O
associated	O	VERB	O
vasculitis	B-Disease	NOUN	B
was	O	AUX	O
made	O	VERB	O
by	O	ADP	O
observation	O	NOUN	B
of	O	ADP	O
consistent	O	ADJ	O
clinical	O	ADJ	B
features	O	NOUN	O
,	O	PUNCT	O
the	O	DET	O
detection	O	NOUN	B
of	O	ADP	O
elevated	O	ADJ	B
ANA	O	NOUN	B
and	O	CCONJ	O
ANCA	O	NOUN	B
in	O	ADP	O
the	O	DET	O
blood	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
observed	O	VERB	O
clinical	O	ADJ	B
resolution	O	NOUN	I
of	O	ADP	O
symptoms	O	NOUN	B
following	O	VERB	O
withdrawal	O	NOUN	B
of	O	ADP	I
PTU	B-Chemical	NOUN	B
.	O	PUNCT	O


Subsequent	O	ADJ	O
treatment	O	NOUN	B
of	O	ADP	O
persistent	O	ADJ	B
hyperthyroidism	B-Disease	NOUN	B
with	O	ADP	O
radioablation	O	NOUN	B
did	O	AUX	O
not	O	PART	O
result	O	VERB	O
in	O	ADP	O
an	O	DET	O
exacerbation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
vasculitis	B-Disease	NOUN	B


Succinylcholine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
masseter	B-Disease	NOUN	B
muscle	I-Disease	NOUN	I
rigidity	I-Disease	NOUN	B
during	O	ADP	O
bronchoscopic	O	ADJ	B
removal	O	NOUN	B
of	O	ADP	O
a	O	DET	O
tracheal	O	ADJ	B
foreign	O	ADJ	B
body	O	NOUN	I
.	O	PUNCT	O


Masseter	B-Disease	NOUN	B
muscle	I-Disease	NOUN	I
rigidity	I-Disease	NOUN	B
during	O	ADP	O
general	O	ADJ	B
anesthesia	O	NOUN	I
is	O	AUX	O
considered	O	VERB	O
an	O	DET	O
early	O	ADJ	B
warning	O	NOUN	B
sign	O	NOUN	O
of	O	ADP	O
a	O	DET	O
possible	O	ADJ	O
episode	O	NOUN	B
of	O	ADP	O
malignant	B-Disease	ADJ	B
hyperthermia	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
decision	O	NOUN	B
whether	O	SCONJ	O
to	O	PART	O
continue	O	VERB	O
or	O	CCONJ	O
discontinue	O	VERB	B
the	O	DET	O
procedure	O	NOUN	B
depends	O	VERB	O
on	O	ADP	O
the	O	DET	O
urgency	O	NOUN	B
of	O	ADP	O
the	O	DET	O
surgery	O	NOUN	B
and	O	CCONJ	O
severity	O	NOUN	B
of	O	ADP	O
masseter	B-Disease	NOUN	B
muscle	I-Disease	NOUN	I
rigidity	I-Disease	NOUN	B
.	O	PUNCT	O


Here	O	ADV	O
,	O	PUNCT	O
we	O	PRON	O
describe	O	VERB	O
a	O	DET	O
case	O	NOUN	B
of	O	ADP	O
severe	O	ADJ	B
masseter	B-Disease	NOUN	B
muscle	I-Disease	NOUN	I
rigidity	I-Disease	NOUN	I
(	O	PUNCT	O
jaw	B-Disease	NOUN	O
of	I-Disease	ADP	O
steel	I-Disease	NOUN	B
)	O	PUNCT	O
after	O	ADP	O
succinylcholine	B-Chemical	NOUN	B
(	O	PUNCT	O
Sch	B-Chemical	NOUN	B
)	O	PUNCT	O
administration	O	NOUN	B
during	O	ADP	O
general	O	ADJ	O
anesthetic	O	ADJ	B
management	O	NOUN	I
for	O	ADP	O
rigid	O	ADJ	B
bronchoscopic	O	ADJ	B
removal	O	NOUN	O
of	O	ADP	O
a	O	DET	O
tracheal	O	ADJ	B
foreign	O	ADJ	B
body	O	NOUN	I
.	O	PUNCT	O


Anesthesia	O	PROPN	B
was	O	AUX	O
continued	O	VERB	O
uneventfully	O	ADV	B
with	O	ADP	I
propofol	B-Chemical	NOUN	B
infusion	O	NOUN	B
while	O	SCONJ	O
all	O	DET	O
facilities	O	NOUN	B
were	O	AUX	O
available	O	ADJ	O
to	O	PART	O
detect	O	VERB	B
and	O	CCONJ	O
treat	O	VERB	B
malignant	B-Disease	ADJ	B
hyperthermia	I-Disease	NOUN	I


Minor	O	ADJ	B
neurological	B-Disease	ADJ	B
dysfunction	I-Disease	NOUN	I
,	O	PUNCT	O
cognitive	O	ADJ	B
development	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
somatic	O	ADJ	B
development	O	NOUN	I
at	O	ADP	O
the	O	DET	O
age	O	NOUN	B
of	O	ADP	O
3	O	NUM	O
to	O	PART	O
7	O	NUM	O
years	O	NOUN	B
after	O	ADP	O
dexamethasone	B-Chemical	NOUN	B
treatment	O	NOUN	B
in	O	ADP	O
very	O	ADV	B
-	O	PUNCT	O
low	O	ADJ	B
birth	O	NOUN	B
-	O	PUNCT	O
weight	O	NOUN	B
infants	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
objective	O	NOUN	B
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
assess	O	VERB	O
minor	O	ADJ	B
neurological	B-Disease	ADJ	I
dysfunction	I-Disease	NOUN	I
,	O	PUNCT	O
cognitive	O	ADJ	B
development	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
somatic	O	ADJ	B
development	O	NOUN	I
after	O	ADP	O
dexamethasone	B-Chemical	NOUN	B
therapy	O	NOUN	O
in	O	ADP	O
very	O	ADV	B
-	O	PUNCT	O
low	O	ADJ	B
-	O	PUNCT	O
birthweight	O	NOUN	B
infants	O	NOUN	B
.	O	PUNCT	O


Thirty	O	NUM	B
-	O	PUNCT	O
three	O	NUM	O
children	O	NOUN	B
after	O	ADP	O
dexamethasone	B-Chemical	NOUN	B
treatment	O	NOUN	B
were	O	AUX	O
matched	O	VERB	O
to	O	ADP	O
33	O	NUM	O
children	O	NOUN	B
without	O	ADP	O
dexamethasone	B-Chemical	NOUN	B
treatment	O	NOUN	B
.	O	PUNCT	O


Data	O	NOUN	B
were	O	AUX	O
assessed	O	VERB	B
at	O	ADP	O
the	O	DET	O
age	O	NOUN	B
of	O	ADP	O
3	O	NUM	O
-	O	SYM	O
7	O	NUM	O
years	O	NOUN	B
.	O	PUNCT	O


Dexamethasone	B-Chemical	NOUN	B
was	O	AUX	O
started	O	VERB	O
between	O	ADP	O
the	O	DET	O
7th	O	ADJ	O
and	O	CCONJ	O
the	O	DET	O
28th	O	ADJ	O
day	O	NOUN	B
of	O	ADP	O
life	O	NOUN	B
over	O	ADP	O
7	O	NUM	O
days	O	NOUN	B
with	O	ADP	O
a	O	DET	O
total	O	ADJ	O
dose	O	NOUN	B
of	O	ADP	O
2	O	NUM	O
.	O	PUNCT	O


35	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
/	O	SYM	O
day	O	NOUN	B
.	O	PUNCT	O


Exclusion	O	NOUN	B
criteria	O	NOUN	I
were	O	AUX	O
asphyxia	B-Disease	NOUN	B
,	O	PUNCT	O
malformations	B-Disease	NOUN	B
,	O	PUNCT	O
major	O	ADJ	O
surgical	O	ADJ	B
interventions	O	NOUN	I
,	O	PUNCT	O
small	O	ADJ	B
for	O	ADP	O
gestational	O	ADJ	B
age	O	NOUN	I
,	O	PUNCT	O
intraventricular	O	ADJ	B
haemorrhage	B-Disease	NOUN	I
grades	O	NOUN	I
III	O	NUM	I
and	O	CCONJ	I
IV	O	NUM	I
,	O	PUNCT	O
periventricular	B-Disease	ADJ	B
leukomalacia	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
severe	O	ADJ	B
psychomotor	B-Disease	NOUN	B
retardation	I-Disease	NOUN	I
.	O	PUNCT	O


Each	O	DET	O
child	O	NOUN	B
was	O	AUX	O
examined	O	VERB	O
by	O	ADP	O
a	O	DET	O
neuropediatrician	O	NOUN	B
for	O	ADP	O
minor	O	ADJ	O
neurological	B-Disease	ADJ	B
dysfunctions	I-Disease	NOUN	I
and	O	CCONJ	O
tested	O	VERB	B
by	O	ADP	O
a	O	DET	O
psychologist	O	NOUN	B
for	O	ADP	O
cognitive	O	ADJ	B
development	O	NOUN	I
with	O	ADP	O
a	O	DET	O
Kaufman	O	PROPN	B
Assessment	O	PROPN	I
Battery	O	PROPN	I
for	O	ADP	O
Children	O	PROPN	B
and	O	CCONJ	O
a	O	DET	O
Draw	O	PROPN	B
-	O	PUNCT	O
a	O	DET	O
-	O	PUNCT	O
Man	O	PROPN	B
Test	O	PROPN	I
.	O	PUNCT	O


There	O	PRON	O
were	O	AUX	O
no	O	DET	O
differences	O	NOUN	O
in	O	ADP	O
demographic	O	ADJ	B
data	O	NOUN	I
,	O	PUNCT	O
growth	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
socio	O	NOUN	B
-	O	PUNCT	O
economic	O	ADJ	B
status	O	NOUN	I
between	O	ADP	O
the	O	DET	O
two	O	NUM	O
groups	O	NOUN	B
.	O	PUNCT	O


Fine	O	ADJ	B
motor	O	NOUN	B
skills	O	NOUN	I
and	O	CCONJ	O
gross	O	ADJ	B
motor	O	NOUN	I
function	O	NOUN	I
were	O	AUX	O
significantly	O	ADV	O
better	O	ADJ	O
in	O	ADP	O
the	O	DET	O
control	O	NOUN	B
group	O	NOUN	I
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


01	O	NUM	O
).	O	PUNCT	O
In	O	ADP	O
the	O	DET	O
Draw	O	PROPN	B
-	O	PUNCT	O
a	O	DET	O
-	O	PUNCT	O
Man	O	PROPN	B
Test	O	PROPN	I
,	O	PUNCT	O
the	O	DET	O
control	O	NOUN	B
group	O	NOUN	I
showed	O	VERB	O
better	O	ADJ	O
results	O	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


001	O	NUM	O
).	O	PUNCT	O
There	O	PRON	O
were	O	AUX	O
no	O	DET	O
differences	O	NOUN	O
in	O	ADP	O
development	O	NOUN	B
of	O	ADP	O
speech	O	NOUN	B
,	O	PUNCT	O
social	O	ADJ	B
development	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
Kaufman	O	PROPN	B
Assessment	O	PROPN	I
Battery	O	PROPN	I
for	O	ADP	I
Children	O	PROPN	B
.	O	PUNCT	O


After	O	ADP	O
dexamethasone	B-Chemical	NOUN	B
treatment	O	NOUN	B
,	O	PUNCT	O
children	O	NOUN	B
showed	O	VERB	O
a	O	DET	O
higher	O	ADJ	O
rate	O	NOUN	B
of	O	ADP	O
minor	O	ADJ	B
neurological	B-Disease	ADJ	B
dysfunctions	I-Disease	NOUN	I
.	O	PUNCT	O


Neurological	O	ADJ	B
development	O	NOUN	I
was	O	AUX	O
affected	O	VERB	B
even	O	ADV	O
without	O	ADP	O
neurological	O	ADJ	B
diagnosis	O	NOUN	I
.	O	PUNCT	O


Further	O	ADV	O
long	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
follow	O	VERB	B
-	O	PUNCT	O
up	O	ADP	O
studies	O	NOUN	B
will	O	AUX	O
be	O	AUX	O
necessary	O	ADJ	O
to	O	PART	O
fully	O	ADV	O
evaluate	O	VERB	B
the	O	DET	O
impact	O	NOUN	B
of	O	ADP	O
dexamethasone	B-Chemical	NOUN	B


Force	O	ADJ	B
overflow	O	NOUN	B
and	O	CCONJ	O
levodopa	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
dyskinesias	B-Disease	NOUN	B
in	O	ADP	O
Parkinson's	B-Disease	ADJ	O
disease	I-Disease	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
assessed	O	VERB	B
force	O	NOUN	B
coordination	O	NOUN	B
of	O	ADP	O
the	O	DET	O
hand	O	NOUN	B
in	O	ADP	O
Parkinson's	B-Disease	ADJ	O
disease	I-Disease	NOUN	B
and	O	CCONJ	O
its	O	PRON	O
relationship	O	NOUN	B
to	O	PART	O
motor	O	NOUN	B
complications	O	NOUN	I
of	O	ADP	O
levodopa	B-Chemical	NOUN	B
therapy	O	NOUN	B
,	O	PUNCT	O
particularly	O	ADV	O
to	O	PART	O
levodopa	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
dyskinesias	B-Disease	NOUN	B
(	O	PUNCT	O
LID	B-Disease	NOUN	B
).	O	PUNCT	O
We	O	PRON	O
studied	O	VERB	O
two	O	NUM	O
groups	O	NOUN	B
of	O	ADP	O
Parkinson's	B-Disease	ADJ	O
disease	I-Disease	NOUN	B
patients	O	NOUN	B
with	O	ADP	O
(	O	PUNCT	O
Parkinson's	B-Disease	ADJ	O
disease	I-Disease	NOUN	B
+	O	CCONJ	O
LID	B-Disease	NOUN	B
,	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
23	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
without	O	ADP	O
levodopa	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
dyskinesias	B-Disease	NOUN	B
(	O	PUNCT	O
Parkinson's	B-Disease	ADJ	O
disease	I-Disease	NOUN	B
-	O	PUNCT	O
LID	B-Disease	PROPN	B
,	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
10	O	NUM	O
),	O	PUNCT	O
and	O	CCONJ	O
age	O	NOUN	B
-	O	PUNCT	O
matched	O	VERB	B
healthy	O	ADJ	B
controls	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
motor	O	NOUN	B
score	O	NOUN	I
of	O	ADP	O
the	O	DET	O
Unified	O	PROPN	B
Parkinson's	B-Disease	PROPN	I
Disease	I-Disease	PROPN	I
Rating	O	PROPN	I
Scale	O	NOUN	I
,	O	PUNCT	O
a	O	DET	O
dyskinesia	B-Disease	NOUN	B
score	O	NOUN	B
and	O	CCONJ	O
force	O	NOUN	B
in	O	ADP	O
a	O	DET	O
grip	O	NOUN	B
-	O	PUNCT	O
lift	O	NOUN	B
paradigm	O	NOUN	B
were	O	AUX	O
assessed	O	VERB	B
ON	O	NOUN	B
and	O	CCONJ	O
OFF	O	VERB	B
levodopa	B-Chemical	NOUN	B
.	O	PUNCT	O


A	O	DET	O
pathological	O	ADJ	B
increase	O	NOUN	B
of	O	ADP	O
forces	O	NOUN	B
was	O	AUX	O
seen	O	VERB	O
in	O	ADP	O
ON	O	PROPN	B
-	O	PUNCT	O
state	O	NOUN	B
in	O	ADP	O
Parkinson's	B-Disease	ADJ	O
disease	I-Disease	NOUN	B
+	O	CCONJ	O
LID	B-Disease	NOUN	B
only	O	ADV	O
.	O	PUNCT	O


In	O	ADP	O
Parkinson's	B-Disease	ADJ	O
disease	I-Disease	NOUN	B
+	O	CCONJ	O
LID	B-Disease	NOUN	B
,	O	PUNCT	O
the	O	DET	O
force	O	NOUN	B
involved	O	VERB	O
in	O	ADP	O
pressing	O	VERB	O
down	O	ADP	O
the	O	DET	O
object	O	NOUN	B
before	O	ADP	O
lifting	O	VERB	B
was	O	AUX	O
significantly	O	ADV	O
increased	O	VERB	B
by	O	ADP	O
levodopa	B-Chemical	NOUN	B
(	O	PUNCT	O
by	O	ADP	O
61	O	NUM	O
%,	O	NOUN	O
P	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


05	O	NUM	O
).	O	PUNCT	O
An	O	DET	O
overshooting	O	NOUN	B
of	O	ADP	O
peak	O	ADJ	B
grip	O	NOUN	I
force	O	NOUN	I
by	O	ADP	O
51	O	NUM	O
%(	O	NOUN	O
P	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


05	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
of	O	ADP	O
static	O	ADJ	B
grip	O	NOUN	I
force	O	NOUN	I
by	O	ADP	O
45	O	NUM	O
%(	O	NOUN	O
P	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


01	O	NUM	O
)	O	PUNCT	O
was	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
the	O	DET	O
ON	O	PROPN	B
-	O	PUNCT	O
compared	O	VERB	B
with	O	ADP	O
the	O	DET	O
OFF	O	PROPN	B
-	O	PUNCT	O
drug	O	NOUN	B
condition	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
contrast	O	NOUN	O
,	O	PUNCT	O
no	O	DET	O
excessive	O	ADJ	O
force	O	NOUN	B
was	O	AUX	O
found	O	VERB	O
in	O	ADP	O
Parkinson's	B-Disease	ADJ	O
disease	I-Disease	NOUN	B
-	O	PUNCT	O
LID	B-Disease	PROPN	B
.	O	PUNCT	O


Peak	O	ADJ	B
grip	O	NOUN	I
force	O	NOUN	I
in	O	ADP	O
ON	O	PROPN	B
-	O	PUNCT	O
state	O	NOUN	B
was	O	AUX	O
140	O	NUM	O
%(	O	NOUN	O
P	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


05	O	NUM	O
)	O	PUNCT	O
higher	O	ADJ	B
in	O	ADP	O
Parkinson's	B-Disease	ADJ	O
disease	I-Disease	NOUN	B
+	O	CCONJ	O
LID	B-Disease	NOUN	B
than	O	ADP	O
in	O	ADP	O
Parkinson's	B-Disease	ADJ	O
disease	I-Disease	NOUN	B
-	O	PUNCT	O
LID	B-Disease	PROPN	B
,	O	PUNCT	O
while	O	SCONJ	O
static	O	ADJ	B
grip	O	NOUN	I
force	O	NOUN	I
was	O	AUX	O
increased	O	VERB	B
by	O	ADP	O
138	O	NUM	O
%(	O	NOUN	O
P	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


01	O	NUM	O
)	O	PUNCT	O
between	O	ADP	O
groups	O	NOUN	B
.	O	PUNCT	O


Severity	O	NOUN	B
of	O	ADP	O
peak	O	NOUN	B
-	O	PUNCT	O
dose	O	NOUN	B
dyskinesias	B-Disease	NOUN	B
was	O	AUX	O
strongly	O	ADV	O
correlated	O	VERB	B
with	O	ADP	O
grip	O	NOUN	B
force	O	NOUN	I
in	O	ADP	O
ON	O	PROPN	B
-	O	PUNCT	O
state	O	NOUN	B
(	O	PUNCT	O
r	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


79	O	NUM	O
with	O	ADP	O
peak	O	NOUN	B
force	O	NOUN	I
,	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


01	O	NUM	O
).	O	PUNCT	O
No	O	DET	O
correlation	O	NOUN	B
was	O	AUX	O
observed	O	VERB	O
between	O	ADP	O
forces	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
motor	O	NOUN	B
score	O	NOUN	I
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
with	O	ADP	O
the	O	DET	O
daily	O	ADJ	B
dose	O	NOUN	I
of	O	ADP	O
dopaminergic	O	ADJ	B
medication	O	NOUN	I
.	O	PUNCT	O


Force	O	ADJ	B
excess	O	NOUN	B
was	O	AUX	O
only	O	ADV	O
observed	O	VERB	B
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
LID	B-Disease	NOUN	B
and	O	CCONJ	O
motor	O	NOUN	B
fluctuations	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
close	O	ADJ	O
relationship	O	NOUN	B
was	O	AUX	O
seen	O	VERB	O
between	O	ADP	O
the	O	DET	O
overshooting	O	NOUN	B
of	O	ADP	O
forces	O	NOUN	B
and	O	CCONJ	O
dyskinesias	B-Disease	NOUN	B
in	O	ADP	O
the	O	DET	O
ON	O	PROPN	B
-	O	PUNCT	O
drug	O	NOUN	B
condition	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
postulate	O	VERB	O
that	O	SCONJ	O
both	O	DET	O
LID	B-Disease	PROPN	B


Postinfarction	O	ADJ	B
ventricular	B-Disease	ADJ	I
septal	I-Disease	ADJ	I
defect	I-Disease	NOUN	I
associated	O	VERB	B
with	O	ADP	I
long	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
steroid	B-Chemical	NOUN	B
therapy	O	NOUN	I
.	O	PUNCT	O


Two	O	NUM	O
cases	O	NOUN	B
of	O	ADP	O
postinfarction	O	NOUN	B
ventricular	B-Disease	ADJ	I
septal	I-Disease	ADJ	I
rupture	I-Disease	NOUN	I
in	O	ADP	O
patients	O	NOUN	B
on	O	ADP	O
long	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
steroid	B-Chemical	NOUN	B
therapy	O	NOUN	I
are	O	AUX	O
presented	O	VERB	O
and	O	CCONJ	O
the	O	DET	O
favourable	O	ADJ	O
outcome	O	NOUN	B
in	O	ADP	O
both	O	DET	O
cases	O	NOUN	B
described	O	VERB	O
.	O	PUNCT	O


A	O	DET	O
possible	O	ADJ	O
association	O	NOUN	B
between	O	ADP	O
steroid	B-Chemical	NOUN	B
therapy	O	NOUN	I
and	O	CCONJ	O
subsequent	O	ADJ	O
postinfarction	O	NOUN	B
septal	B-Disease	ADJ	I
rupture	I-Disease	NOUN	I


Angioedema	B-Disease	NOUN	B
associated	O	VERB	B
with	O	ADP	I
droperidol	B-Chemical	NOUN	B
administration	O	NOUN	B
.	O	PUNCT	O


Angioedema	B-Disease	NOUN	B
,	O	PUNCT	O
also	O	ADV	O
known	O	VERB	O
as	O	ADP	O
angioneurotic	B-Disease	ADJ	B
edema	I-Disease	NOUN	I
or	O	CCONJ	O
Quincke's	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
,	O	PUNCT	O
is	O	AUX	O
a	O	DET	O
well	O	ADV	O
-	O	PUNCT	O
demarcated	O	VERB	B
,	O	PUNCT	O
localized	O	ADJ	B
edema	B-Disease	NOUN	B
involving	O	VERB	O
the	O	DET	O
subcutaneous	O	ADJ	B
tissues	O	NOUN	I
that	O	PRON	O
may	O	AUX	O
cause	O	VERB	O
upper-airway	B-Disease	ADJ	B
obstruction	I-Disease	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
the	O	DET	O
case	O	NOUN	B
of	O	ADP	O
a	O	DET	O
previously	O	ADV	O
healthy	O	ADJ	B
19	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
man	O	NOUN	B
with	O	ADP	O
no	O	DET	O
known	O	ADJ	O
drug	B-Disease	NOUN	B
allergies	I-Disease	NOUN	I
in	O	ADP	O
whom	O	PRON	O
angioedema	B-Disease	NOUN	B
with	O	ADP	O
significant	O	ADJ	B
tongue	B-Disease	NOUN	B
swelling	I-Disease	NOUN	I
and	O	CCONJ	O
protrusion	O	NOUN	B
developed	O	VERB	O
within	O	ADP	O
10	O	NUM	O
minutes	O	NOUN	O
of	O	ADP	O
the	O	DET	O
administration	O	NOUN	B
of	O	ADP	O
a	O	DET	O
single	O	ADJ	B
IV	O	NUM	I
dose	O	NOUN	B
of	O	ADP	O
droperidol	B-Chemical	NOUN	B


Clarithromycin	B-Chemical	PROPN	B
-	O	PUNCT	O
associated	O	VERB	B
visual	B-Disease	ADJ	B
hallucinations	I-Disease	NOUN	I
in	O	ADP	O
a	O	DET	O
patient	O	NOUN	B
with	O	ADP	O
chronic	B-Disease	ADJ	B
renal	I-Disease	ADJ	I
failure	I-Disease	NOUN	I
on	O	ADP	O
continuous	O	ADJ	B
ambulatory	O	ADJ	B
peritoneal	O	ADJ	O
dialysis	O	NOUN	B
.	O	PUNCT	O


Visual	B-Disease	ADJ	B
hallucinations	I-Disease	NOUN	I
are	O	AUX	O
a	O	DET	O
rare	O	ADJ	B
event	O	NOUN	B
in	O	ADP	O
chronic	B-Disease	ADJ	B
renal	I-Disease	ADJ	I
failure	I-Disease	NOUN	I
and	O	CCONJ	O
not	O	PART	O
related	O	ADJ	O
to	O	PART	O
uremia	B-Disease	NOUN	B
per	O	X	O
se	O	X	O
.	O	PUNCT	O


Unreported	O	VERB	B
in	O	ADP	O
the	O	DET	O
literature	O	NOUN	B
is	O	AUX	O
visual	B-Disease	ADJ	B
hallucinations	I-Disease	NOUN	I
occurring	O	VERB	O
in	O	ADP	O
association	O	NOUN	B
with	O	ADP	O
the	O	DET	O
new	O	ADJ	O
macrolide	B-Chemical	NOUN	B
antibiotic	O	NOUN	B
,	O	PUNCT	O
clarithromycin	B-Chemical	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
describe	O	VERB	O
such	O	DET	O
a	O	DET	O
case	O	NOUN	B
in	O	ADP	O
a	O	DET	O
patient	O	NOUN	B
with	O	ADP	O
end-stage	B-Disease	ADJ	B
renal	I-Disease	ADJ	I
disease	I-Disease	NOUN	I
(	O	PUNCT	O
ESRD	B-Disease	NOUN	B
)	O	PUNCT	O
maintained	O	VERB	B
on	O	ADP	O
continuous	O	ADJ	B
ambulatory	O	ADJ	B
peritoneal	O	ADJ	I
dialysis	O	NOUN	I
(	O	PUNCT	O
CAPD	O	NOUN	B
).	O	PUNCT	O
The	O	DET	O
combination	O	NOUN	B
of	O	ADP	O
a	O	DET	O
relatively	O	ADV	O
high	O	ADJ	O
dose	O	NOUN	B
of	O	ADP	O
clarithromycin	B-Chemical	NOUN	B
in	O	ADP	O
face	O	NOUN	O
of	O	ADP	O
chronic	B-Disease	ADJ	B
renal	I-Disease	ADJ	I
failure	I-Disease	NOUN	I
in	O	ADP	O
a	O	DET	O
functionally	O	ADV	O
anephric	O	ADJ	B
patient	O	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
underlying	O	VERB	O
aluminum	B-Chemical	NOUN	B
intoxication	O	NOUN	B
,	O	PUNCT	O
may	O	AUX	O
have	O	AUX	O
facilitated	O	VERB	O
the	O	DET	O
appearance	O	NOUN	B
of	O	ADP	O
this	O	DET	O
neurotoxic	B-Disease	ADJ	B
side	O	NOUN	B
effect	O	NOUN	I
.	O	PUNCT	O


It	O	PRON	O
is	O	AUX	O
important	O	ADJ	O
to	O	PART	O
understand	O	VERB	O
the	O	DET	O
pharmacokinetics	O	NOUN	B
of	O	ADP	O
medications	O	NOUN	B
in	O	ADP	O
face	O	NOUN	O
of	O	ADP	O
chronic	B-Disease	ADJ	B
renal	I-Disease	ADJ	I
failure	I-Disease	NOUN	I
,	O	PUNCT	O
the	O	DET	O
possibility	O	NOUN	O
of	O	ADP	O
drug	O	NOUN	B
interactions	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
how	O	SCONJ	O
these	O	DET	O
factors	O	NOUN	B
should	O	AUX	O
help	O	VERB	O
guide	O	VERB	O
medication	O	NOUN	B
therapy	O	NOUN	I
in	O	ADP	O
the	O	DET	O
ESRD	B-Disease	NOUN	B


Acute	O	ADJ	B
renal	B-Disease	ADJ	I
toxicity	I-Disease	NOUN	I
of	O	ADP	O
doxorubicin	B-Chemical	NOUN	B
(	O	PUNCT	O
adriamycin	B-Chemical	NOUN	B
)-	O	ADJ	O
loaded	O	VERB	B
cyanoacrylate	B-Chemical	NOUN	B
nanoparticles	O	NOUN	B
.	O	PUNCT	O


Acute	O	ADJ	B
doxorubicin	B-Chemical	NOUN	B
-	O	PUNCT	O
loaded	O	VERB	B
nanoparticle	O	NOUN	B
(	O	PUNCT	O
DXNP	O	NOUN	B
)	O	PUNCT	O
renal	B-Disease	ADJ	B
toxicity	I-Disease	NOUN	B
was	O	AUX	O
explored	O	VERB	O
in	O	ADP	O
both	O	CCONJ	O
normal	O	ADJ	O
rats	O	NOUN	B
and	O	CCONJ	O
rats	O	NOUN	B
with	O	ADP	O
experimental	O	ADJ	B
glomerulonephritis	B-Disease	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
normal	O	ADJ	O
rats	O	NOUN	B
,	O	PUNCT	O
2	O	NUM	O
/	O	SYM	O
6	O	NUM	O
rats	O	NOUN	B
given	O	VERB	O
free	O	ADJ	B
doxorubicin	B-Chemical	NOUN	I
(	O	PUNCT	O
DX	B-Chemical	NOUN	B
)(	O	NOUN	O
5	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
)	O	PUNCT	O
died	O	VERB	B
within	O	ADP	O
one	O	NUM	O
week	O	NOUN	B
,	O	PUNCT	O
whereas	O	SCONJ	O
all	O	DET	O
control	O	ADJ	B
animals	O	NOUN	I
and	O	CCONJ	O
all	O	DET	O
rats	O	NOUN	B
having	O	VERB	O
received	O	VERB	O
free	O	ADJ	B
NP	O	PROPN	B
or	O	CCONJ	O
DXNP	O	PROPN	B
survived	O	VERB	O
.	O	PUNCT	O


A	O	DET	O
3	O	NUM	O
times	O	NOUN	O
higher	O	ADJ	B
proteinuria	B-Disease	NOUN	B
appeared	O	VERB	O
in	O	ADP	O
animals	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
DXNP	O	NOUN	B
than	O	ADP	O
in	O	ADP	O
those	O	DET	O
treated	O	VERB	B
with	O	ADP	I
DX	B-Chemical	NOUN	B
.	O	PUNCT	O


Free	O	PROPN	B
NP	O	PROPN	B
did	O	AUX	O
not	O	PART	O
provoke	O	VERB	O
any	O	DET	O
proteinuria	B-Disease	NOUN	B
.	O	PUNCT	O


Two	O	NUM	O
hr	O	NOUN	O
post	O	NOUN	B
-	O	PUNCT	O
injection	O	NOUN	B
,	O	PUNCT	O
DXNP	O	PROPN	B
was	O	AUX	O
2	O	NUM	O
.	O	PUNCT	O


7	O	NUM	O
times	O	NOUN	O
more	O	ADV	O
concentrated	O	VERB	O
in	O	ADP	O
kidneys	O	NOUN	B
than	O	ADP	O
free	O	ADJ	B
DX	B-Chemical	NOUN	I
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


025	O	NUM	O
).	O	PUNCT	B
In	O	ADP	O
rats	O	NOUN	B
with	O	ADP	O
immune	O	ADJ	B
experimental	O	ADJ	I
glomerulonephritis	B-Disease	NOUN	I
,	O	PUNCT	O
5	O	NUM	O
/	O	SYM	O
6	O	NUM	O
rats	O	NOUN	B
given	O	VERB	O
DX	B-Chemical	NOUN	B
died	O	VERB	B
within	O	ADP	O
7	O	NUM	O
days	O	NOUN	B
,	O	PUNCT	O
in	O	ADP	O
contrast	O	NOUN	O
to	O	PART	O
animals	O	NOUN	B
treated	O	VERB	B
by	O	ADP	O
DXNP	O	PROPN	B
,	O	PUNCT	O
NP	O	PROPN	B
,	O	PUNCT	O
or	O	CCONJ	O
untreated	O	ADJ	B
,	O	PUNCT	O
which	O	DET	O
all	O	DET	O
survived	O	VERB	O
.	O	PUNCT	O


Proteinuria	B-Disease	NOUN	B
appeared	O	VERB	O
in	O	ADP	O
all	O	DET	O
series	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
was	O	AUX	O
2	O	NUM	O
-	O	SYM	O
5	O	NUM	O
times	O	NOUN	O
more	O	ADV	O
intense	O	ADJ	B
(	O	PUNCT	O
p	O	NOUN	O
>	O	NOUN	O
0	O	NUM	O
.	O	PUNCT	O


001	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
prolonged	O	ADJ	B
after	O	ADP	O
doxorubicin	B-Chemical	NOUN	B
treatment	O	NOUN	O
(	O	PUNCT	O
400	O	NUM	O
-	O	SYM	O
700	O	NUM	O
mg	O	NOUN	O
/	O	PUNCT	O
day	O	NOUN	B
),	O	PUNCT	O
without	O	ADP	O
significant	O	ADJ	O
difference	O	NOUN	O
between	O	ADP	O
DXNP	O	NOUN	B
and	O	CCONJ	O
DX	B-Chemical	NOUN	B
.	O	PUNCT	O


Rats	O	NOUN	B
treated	O	VERB	B
by	O	ADP	O
unloaded	O	ADJ	O
NP	O	PROPN	B
behaved	O	VERB	O
as	O	ADP	O
controls	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	B
demonstrate	O	VERB	O
that	O	SCONJ	O
,	O	PUNCT	O
in	O	ADP	O
these	O	DET	O
experimental	O	ADJ	B
conditions	O	NOUN	I
,	O	PUNCT	O
DXNP	O	PROPN	B
killed	O	VERB	B
less	O	ADJ	O
animals	O	NOUN	B
than	O	ADP	O
free	O	ADJ	B
DX	B-Chemical	NOUN	I
,	O	PUNCT	O
despite	O	SCONJ	O
of	O	ADP	O
an	O	DET	O
enhanced	O	VERB	B
renal	B-Disease	ADJ	B
toxicity	I-Disease	NOUN	B
of	O	ADP	O
the	O	DET	O
former	O	NOUN	O
.	O	PUNCT	O


Both	O	DET	O
effects	O	NOUN	B
(	O	PUNCT	O
better	O	ADJ	O
survival	O	NOUN	B
and	O	CCONJ	O
nephrosis	B-Disease	NOUN	B


Etoposide	B-Chemical	NOUN	B
-	O	PUNCT	O
related	O	VERB	B
myocardial	B-Disease	ADJ	B
infarction	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
occurrence	O	NOUN	B
of	O	ADP	O
a	O	DET	O
myocardial	B-Disease	ADJ	B
infarction	I-Disease	NOUN	I
is	O	AUX	O
reported	O	VERB	O
after	O	ADP	O
chemotherapy	O	NOUN	B
containing	O	VERB	O
etoposide	B-Chemical	NOUN	B
,	O	PUNCT	O
in	O	ADP	O
a	O	DET	O
man	O	NOUN	B
with	O	ADP	O
no	O	DET	O
risk	O	NOUN	B
factors	O	NOUN	I
for	O	ADP	O
coronary	B-Disease	ADJ	B
heart	I-Disease	NOUN	I
disease	I-Disease	NOUN	I


Subjective	O	ADJ	B
assessment	O	NOUN	I
of	O	ADP	O
sexual	B-Disease	ADJ	B
dysfunction	I-Disease	NOUN	I
of	O	ADP	O
patients	O	NOUN	B
on	O	ADP	O
long	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
administration	O	NOUN	B
of	O	ADP	O
digoxin	B-Chemical	NOUN	B
.	O	PUNCT	O


Various	O	ADJ	O
data	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
male	O	NOUN	B
patients	O	NOUN	B
who	O	PRON	O
have	O	AUX	O
received	O	VERB	O
digoxin	B-Chemical	NOUN	B
on	O	ADP	O
a	O	DET	O
longterm	O	ADJ	B
basis	O	NOUN	O
have	O	AUX	O
increased	O	VERB	B
levels	O	NOUN	B
of	O	ADP	O
serum	O	NOUN	B
estrogen	B-Chemical	NOUN	I
and	O	CCONJ	O
decreased	O	VERB	B
levels	O	NOUN	B
of	O	ADP	O
plasma	O	NOUN	B
testosterone	B-Chemical	NOUN	B
and	O	CCONJ	O
luteinizing	O	NOUN	B
hormone	O	NOUN	I
(	O	PUNCT	O
LH	O	NOUN	B
).	O	PUNCT	O
This	O	DET	O
study	O	NOUN	B
was	O	AUX	O
undertaken	O	VERB	O
to	O	PART	O
investigate	O	VERB	B
the	O	DET	O
links	O	NOUN	O
between	O	ADP	O
the	O	DET	O
long	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
administration	O	NOUN	B
of	O	ADP	O
digoxin	B-Chemical	NOUN	B
therapy	O	NOUN	I
and	O	CCONJ	O
sexual	O	ADJ	B
behavior	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
digoxin	B-Chemical	NOUN	B
on	O	ADP	O
plasma	O	NOUN	B
levels	O	NOUN	B
of	O	ADP	O
estradiol	B-Chemical	NOUN	B
,	O	PUNCT	O
testosterone	B-Chemical	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
LH	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
patients	O	NOUN	B
of	O	ADP	O
the	O	DET	O
study	O	NOUN	B
and	O	CCONJ	O
control	O	NOUN	B
group	O	NOUN	I
(	O	PUNCT	O
without	O	ADP	O
digoxin	B-Chemical	NOUN	B
)	O	PUNCT	O
were	O	AUX	O
of	O	ADP	O
similar	O	ADJ	O
cardiac	O	ADJ	B
functional	O	ADJ	I
capacity	O	NOUN	I
and	O	CCONJ	O
age	O	NOUN	B
(	O	PUNCT	O
25	O	NUM	O
-	O	SYM	O
40	O	NUM	O
years	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
were	O	AUX	O
randomly	O	ADV	O
selected	O	VERB	O
from	O	ADP	O
the	O	DET	O
rheumatic	B-Disease	ADJ	B
heart	I-Disease	NOUN	I
disease	I-Disease	NOUN	I
patients	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
subjective	O	ADJ	B
assessment	O	NOUN	I
of	O	ADP	O
sexual	O	ADJ	B
behavior	O	NOUN	I
in	O	ADP	O
the	O	DET	O
study	O	NOUN	B
and	O	CCONJ	O
control	O	NOUN	B
groups	O	NOUN	I
was	O	AUX	O
carried	O	VERB	O
out	O	ADP	O
,	O	PUNCT	O
using	O	VERB	O
parameters	O	NOUN	B
such	O	ADJ	O
as	O	ADP	O
sexual	O	ADJ	B
desire	O	NOUN	I
,	O	PUNCT	O
sexual	O	ADJ	B
excitement	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
frequency	O	NOUN	B
of	O	ADP	O
sexual	O	ADJ	B
relations	O	NOUN	I
.	O	PUNCT	O


Personal	O	ADJ	B
interviews	O	NOUN	I
and	O	CCONJ	O
a	O	DET	O
questionnaire	O	NOUN	B
were	O	AUX	O
also	O	ADV	O
used	O	VERB	O
for	O	ADP	O
the	O	DET	O
evaluation	O	NOUN	B
of	O	ADP	O
sexual	O	ADJ	B
behavior	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
findings	O	NOUN	B
support	O	VERB	O
the	O	DET	O
reports	O	NOUN	B
concerning	O	VERB	O
digoxin	B-Chemical	NOUN	B
effect	O	NOUN	B
on	O	ADP	O
plasma	O	NOUN	B
estradiol	B-Chemical	NOUN	B
,	O	PUNCT	O
testosterone	B-Chemical	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
LH	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
differences	O	NOUN	B
in	O	ADP	O
the	O	DET	O
means	O	NOUN	O
were	O	AUX	O
significant	O	ADJ	B
.	O	PUNCT	O


Tests	O	NOUN	B
used	O	VERB	O
to	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
changes	O	NOUN	B
in	O	ADP	O
sexual	O	ADJ	B
behavior	O	NOUN	I
showed	O	VERB	O
a	O	DET	O
significant	O	ADJ	O
decrease	B-Disease	NOUN	B
in	I-Disease	ADP	O
sexual	I-Disease	ADJ	B
desire	I-Disease	NOUN	I


Fatal	O	ADJ	B
aplastic	B-Disease	ADJ	B
anemia	I-Disease	NOUN	I
due	O	ADJ	O
to	O	PART	O
indomethacin	B-Chemical	NOUN	B
--	O	PUNCT	O
lymphocyte	O	NOUN	B
transformation	O	NOUN	I
tests	O	NOUN	I
in	O	X	B
vitro	O	X	I
.	O	PUNCT	O


Although	O	SCONJ	O
indomethacin	B-Chemical	NOUN	B
has	O	AUX	O
been	O	AUX	O
implicated	O	VERB	O
as	O	ADP	O
a	O	DET	O
possible	O	ADJ	O
cause	O	NOUN	O
of	O	ADP	O
aplastic	B-Disease	ADJ	B
anemia	I-Disease	NOUN	I
on	O	ADP	O
the	O	DET	O
basis	O	NOUN	O
of	O	ADP	O
a	O	DET	O
few	O	ADJ	O
clinical	O	ADJ	B
observations	O	NOUN	I
,	O	PUNCT	O
its	O	PRON	O
role	O	NOUN	O
has	O	AUX	O
not	O	PART	O
been	O	AUX	O
definitely	O	ADV	O
established	O	VERB	O
.	O	PUNCT	O


A	O	DET	O
case	O	NOUN	B
of	O	ADP	O
fatal	O	ADJ	B
aplastic	B-Disease	ADJ	B
anemia	I-Disease	NOUN	I
is	O	AUX	O
described	O	VERB	O
in	O	ADP	O
which	O	DET	O
no	O	DET	O
drugs	O	NOUN	B
other	O	ADJ	O
than	O	ADP	O
allopurinol	B-Chemical	NOUN	B
and	O	CCONJ	O
indomethacin	B-Chemical	NOUN	B
were	O	AUX	O
given	O	VERB	O
.	O	PUNCT	O


Indomethacin	B-Chemical	NOUN	B
was	O	AUX	O
first	O	ADV	O
given	O	VERB	O
four	O	NUM	O
weeks	O	NOUN	B
prior	O	ADV	O
to	O	PART	O
the	O	DET	O
onset	O	NOUN	B
of	O	ADP	I
symptoms	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
positive	O	ADJ	B
lymphocyte	O	NOUN	B
transformation	O	NOUN	I
test	O	NOUN	I
with	O	ADP	O
indomethacin	B-Chemical	NOUN	B
in	O	X	B
vitro	O	X	I
further	O	ADV	O
substantiates	O	VERB	O
the	O	DET	O
potential	O	ADJ	O
role	O	NOUN	O
of	O	ADP	O
this	O	DET	O
drug	O	NOUN	B
in	O	ADP	O
causing	O	VERB	O
aplastic	B-Disease	ADJ	B
anemia	I-Disease	NOUN	I


Plasma	O	NOUN	B
and	O	CCONJ	O
urinary	O	ADJ	B
lipids	O	NOUN	I
and	O	CCONJ	O
lipoproteins	O	NOUN	B
during	O	ADP	O
the	O	DET	O
development	O	NOUN	B
of	O	ADP	O
nephrotic	B-Disease	ADJ	B
syndrome	I-Disease	NOUN	I
induced	O	VERB	B
in	O	ADP	O
the	O	DET	O
rat	O	NOUN	B
by	O	ADP	O
puromycin	B-Chemical	NOUN	B
aminonucleoside	I-Chemical	NOUN	B
.	O	PUNCT	O


This	O	DET	O
study	O	NOUN	B
was	O	AUX	O
undertaken	O	VERB	O
to	O	PART	O
ascertain	O	VERB	O
whether	O	SCONJ	O
the	O	DET	O
alterations	O	NOUN	B
of	O	ADP	O
plasma	O	NOUN	B
lipoproteins	O	NOUN	I
found	O	VERB	O
in	O	ADP	O
nephrotic	B-Disease	ADJ	B
syndrome	I-Disease	NOUN	I
induced	O	VERB	B
by	O	ADP	O
puromycin	B-Chemical	NOUN	B
aminonucleoside	I-Chemical	NOUN	B
were	O	AUX	O
due	O	ADJ	O
to	O	PART	O
nephrotic	B-Disease	ADJ	B
syndrome	I-Disease	NOUN	I
per	O	X	O
se	O	X	O
,	O	PUNCT	O
or	O	CCONJ	O
,	O	PUNCT	O
at	O	ADP	O
least	O	ADJ	O
in	O	ADP	O
part	O	NOUN	O
,	O	PUNCT	O
to	O	PART	O
the	O	DET	O
aminonucleoside	B-Chemical	NOUN	B
.	O	PUNCT	O


The	O	DET	O
purpose	O	NOUN	O
of	O	ADP	O
the	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
investigate	O	VERB	B
the	O	DET	O
changes	O	NOUN	B
in	O	ADP	O
plasma	O	NOUN	B
and	O	CCONJ	O
urinary	O	ADJ	B
lipoproteins	O	NOUN	I
during	O	ADP	O
the	O	DET	O
administration	O	NOUN	B
of	O	ADP	O
puromycin	B-Chemical	NOUN	B
aminonucleoside	I-Chemical	NOUN	B
(	O	PUNCT	O
20	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	O
for	O	ADP	O
7	O	NUM	O
days	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
subsequent	O	ADJ	O
development	O	NOUN	B
of	O	ADP	O
nephrotic	B-Disease	ADJ	B
syndrome	I-Disease	NOUN	I
.	O	PUNCT	O


Since	O	SCONJ	O
massive	O	ADJ	B
albuminuria	B-Disease	NOUN	B
occurred	O	VERB	O
after	O	ADP	O
6	O	NUM	O
days	O	NOUN	B
of	O	ADP	O
treatment	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
time	O	NOUN	B
-	O	PUNCT	O
course	O	NOUN	B
study	O	NOUN	B
was	O	AUX	O
divided	O	VERB	O
into	O	ADP	O
two	O	NUM	O
stages	O	NOUN	B
:	O	PUNCT	O
pre	O	ADJ	B
-	O	PUNCT	O
nephrotic	B-Disease	ADJ	B
stage	O	NOUN	I
(	O	PUNCT	O
day	O	NOUN	B
1	O	NUM	O
-	O	SYM	O
5	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
nephrotic	B-Disease	ADJ	B
stage	O	NOUN	I
(	O	PUNCT	O
day	O	NOUN	B
6	O	NUM	O
-	O	SYM	O
11	O	NUM	O
).	O	PUNCT	B
In	O	ADP	O
pre	O	ADJ	B
-	O	PUNCT	O
nephrotic	B-Disease	ADJ	B
stage	O	NOUN	O
the	O	DET	O
plasma	O	NOUN	B
level	O	NOUN	B
of	O	ADP	O
fatty	B-Chemical	ADJ	B
acids	I-Chemical	NOUN	I
,	O	PUNCT	O
triacylglycerol	B-Chemical	NOUN	B
and	O	CCONJ	O
VLDL	O	NOUN	B
decreased	O	VERB	B
while	O	SCONJ	O
that	O	DET	O
of	O	ADP	O
phospholipid	O	NOUN	B
,	O	PUNCT	O
cholesteryl	B-Chemical	NOUN	B
esters	I-Chemical	NOUN	I
and	O	CCONJ	O
HDL	O	NOUN	B
remained	O	VERB	O
constant	O	ADJ	B
.	O	PUNCT	O


Plasma	O	NOUN	B
apolipoprotein	O	NOUN	B
A	O	NOUN	I
-	O	PUNCT	O
I	O	PRON	B
tended	O	VERB	O
to	O	PART	O
increase	O	VERB	B
(	O	PUNCT	O
40	O	NUM	O
%	O	NOUN	O
increase	O	NOUN	B
at	O	ADP	O
day	O	NOUN	B
5	O	NUM	O
).	O	PUNCT	B
At	O	ADP	O
the	O	DET	O
beginning	O	NOUN	O
of	O	ADP	O
nephrotic	B-Disease	ADJ	B
stage	O	NOUN	I
(	O	PUNCT	O
day	O	NOUN	B
6	O	NUM	O
)	O	PUNCT	O
the	O	DET	O
concentration	O	NOUN	B
of	O	ADP	O
plasma	O	NOUN	B
albumin	O	NOUN	I
dropped	O	VERB	O
to	O	ADP	O
a	O	DET	O
very	O	ADV	O
low	O	ADJ	B
level	O	NOUN	B
,	O	PUNCT	O
while	O	SCONJ	O
that	O	DET	O
of	O	ADP	O
apolipoprotein	O	NOUN	B
A	O	NOUN	I
-	O	PUNCT	O
I	O	PRON	B
increased	O	VERB	B
abruptly	O	ADV	O
(	O	PUNCT	O
4	O	NUM	O
-	O	PUNCT	O
fold	O	ADJ	B
increase	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
continued	O	VERB	O
to	O	PART	O
rise	O	VERB	O
,	O	PUNCT	O
although	O	SCONJ	O
less	O	ADV	O
steeply	O	ADV	O
,	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
following	O	VERB	O
days	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
plasma	O	NOUN	B
concentration	O	NOUN	B
of	O	ADP	O
HDL	O	NOUN	B
followed	O	VERB	O
the	O	DET	O
same	O	ADJ	O
pattern	O	NOUN	B
.	O	PUNCT	O


Plasma	O	NOUN	B
VLDL	O	NOUN	B
and	O	CCONJ	O
LDL	O	NOUN	B
increased	O	VERB	B
at	O	ADP	O
a	O	DET	O
later	O	ADJ	O
stage	O	NOUN	B
(	O	PUNCT	O
day	O	NOUN	B
9	O	NUM	O
).	O	PUNCT	O
Plasma	O	NOUN	B
apolipoprotein	O	NOUN	B
A	O	NOUN	I
-	O	PUNCT	O
I	O	PRON	B
was	O	AUX	O
found	O	VERB	O
not	O	PART	O
only	O	ADV	O
in	O	ADP	O
HDL	O	NOUN	B
(	O	PUNCT	O
1	O	NUM	O
.	O	PUNCT	O


063	O	NUM	O
-	O	SYM	O
1	O	NUM	O
.	O	PUNCT	O


210	O	NUM	O
g	O	NOUN	B
/	O	SYM	O
ml	O	NOUN	O
)	O	PUNCT	O
but	O	CCONJ	O
also	O	ADV	O
in	O	ADP	O
the	O	DET	O
LDL	O	NOUN	B
density	O	NOUN	I
class	O	NOUN	I
(	O	PUNCT	O
1	O	NUM	O
.	O	PUNCT	O


025	O	NUM	O
-	O	SYM	O
1	O	NUM	O
.	O	PUNCT	O


050	O	NUM	O
g	O	NOUN	B
/	O	SYM	O
ml	O	NOUN	O
).	O	PUNCT	O
In	O	ADP	O
the	O	DET	O
pre	O	ADJ	B
-	O	PUNCT	O
nephrotic	B-Disease	ADJ	B
stage	O	NOUN	I
lipoproteinuria	O	NOUN	O
was	O	AUX	O
negligible	O	ADJ	B
,	O	PUNCT	O
while	O	SCONJ	O
in	O	ADP	O
the	O	DET	O
early	O	ADJ	B
nephrotic	B-Disease	ADJ	B
stage	O	NOUN	I
the	O	DET	O
urinary	O	ADJ	B
loss	O	NOUN	I
of	O	ADP	O
plasma	O	NOUN	B
lipoproteins	O	NOUN	I
consisted	O	VERB	O
mainly	O	ADV	O
of	O	ADP	O
HDL	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
observations	O	NOUN	B
indicate	O	VERB	O
that	O	SCONJ	O
puromycin	B-Chemical	NOUN	B
aminonucleoside	I-Chemical	NOUN	B
alters	O	VERB	O
plasma	O	NOUN	B
lipoproteins	O	NOUN	I
by	O	ADP	O
lowering	O	VERB	B
VLDL	O	NOUN	B
and	O	CCONJ	O
increasing	O	VERB	B
HDL	O	NOUN	B
.	O	PUNCT	O


It	O	PRON	O
is	O	AUX	O
likely	O	ADJ	O
that	O	SCONJ	O
the	O	DET	O
early	O	ADJ	B
and	O	CCONJ	O
striking	O	ADJ	O
increase	O	NOUN	B
of	O	ADP	O
plasma	O	NOUN	B
HDL	O	NOUN	O
found	O	VERB	O
in	O	ADP	O
nephrotic	B-Disease	ADJ	B


Circulating	O	VERB	B
lysosomal	O	ADJ	B
enzymes	O	NOUN	I
and	O	CCONJ	O
acute	B-Disease	ADJ	B
hepatic	I-Disease	ADJ	I
necrosis	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
activities	O	NOUN	B
of	O	ADP	O
the	O	DET	O
lysosomal	O	ADJ	B
enzymes	O	NOUN	I
acid	O	NOUN	O
and	O	CCONJ	O
neutral	O	ADJ	B
protease	O	NOUN	I
,	O	PUNCT	O
N	O	NOUN	B
-	O	PUNCT	O
acetylglucosaminidase	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
acid	O	NOUN	B
phosphatase	O	NOUN	I
were	O	AUX	O
measured	O	VERB	B
in	O	ADP	O
the	O	DET	O
serum	O	NOUN	B
of	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
fulminant	B-Disease	ADJ	B
hepatic	I-Disease	ADJ	B
failure	I-Disease	NOUN	I
.	O	PUNCT	O


Acid	O	NOUN	B
protease	O	NOUN	I
(	O	PUNCT	O
cathepsin	O	NOUN	B
D	O	NOUN	I
)	O	PUNCT	O
activity	O	NOUN	B
was	O	AUX	O
increased	O	VERB	B
about	O	ADV	O
tenfold	O	ADV	O
in	O	ADP	O
patients	O	NOUN	B
who	O	PRON	O
died	O	VERB	B
and	O	CCONJ	O
nearly	O	ADV	O
fourfold	O	ADV	O
in	O	ADP	O
those	O	DET	O
who	O	PRON	O
survived	O	VERB	O
fulminant	B-Disease	ADJ	B
hepatic	I-Disease	ADJ	B
failure	I-Disease	NOUN	I
after	O	ADP	O
paracetamol	B-Chemical	NOUN	B
overdose	B-Disease	NOUN	I
,	O	PUNCT	O
whereas	O	SCONJ	O
activities	O	NOUN	B
were	O	AUX	O
increased	O	VERB	B
equally	O	ADV	O
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
fulminant	B-Disease	ADJ	B
hepatic	I-Disease	ADJ	B
failure	I-Disease	NOUN	I
due	O	ADJ	O
to	O	PART	O
viral	B-Disease	ADJ	B
hepatitis	I-Disease	NOUN	I
whether	O	SCONJ	O
or	O	CCONJ	O
not	O	PART	O
they	O	PRON	O
survived	O	VERB	O
.	O	PUNCT	O


A	O	DET	O
correlation	O	NOUN	B
was	O	AUX	O
found	O	VERB	O
between	O	ADP	O
serum	O	NOUN	B
acid	O	NOUN	I
protease	O	NOUN	I
activity	O	NOUN	I
and	O	CCONJ	O
prothrombin	O	NOUN	B
time	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
increase	O	NOUN	B
in	O	ADP	O
cathepsin	O	NOUN	B
D	O	NOUN	I
activity	O	NOUN	B
was	O	AUX	O
sustained	O	ADJ	B
over	O	ADP	O
several	O	ADJ	O
days	O	NOUN	B
compared	O	VERB	O
with	O	ADP	O
aspartate	B-Chemical	NOUN	B


Transketolase	O	NOUN	B
abnormality	O	NOUN	B
in	O	ADP	O
tolazamide	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
Wernicke's	B-Disease	NOUN	O
encephalopathy	I-Disease	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
studied	O	VERB	O
a	O	DET	O
thiamine	B-Chemical	NOUN	B
-	O	PUNCT	O
dependent	O	ADJ	B
enzyme	O	NOUN	B
,	O	PUNCT	O
transketolase	O	NOUN	B
,	O	PUNCT	O
from	O	ADP	O
fibroblasts	O	NOUN	B
of	O	ADP	O
a	O	DET	O
diabetic	B-Disease	ADJ	B
patient	O	NOUN	B
who	O	PRON	O
developed	O	VERB	O
Wernicke's	B-Disease	NOUN	O
encephalopathy	I-Disease	NOUN	B
when	O	SCONJ	O
treated	O	VERB	B
with	O	ADP	I
tolazamide	B-Chemical	NOUN	B
,	O	PUNCT	O
in	O	ADP	O
order	O	NOUN	O
to	O	PART	O
delineate	O	VERB	O
if	O	SCONJ	O
this	O	DET	O
patient	O	NOUN	B
also	O	ADV	O
had	O	AUX	O
transketolase	O	NOUN	B
abnormality	O	NOUN	I
[	O	PUNCT	O
high	O	ADJ	O
Km	O	NOUN	B
for	O	ADP	O
thiamine	B-Chemical	NOUN	B
pyrophosphate	I-Chemical	NOUN	I
(	O	PUNCT	O
TPP	B-Chemical	PROPN	B
)],	O	PUNCT	O
as	O	ADP	O
previously	O	ADV	O
reported	O	VERB	O
in	O	ADP	O
postalcoholic	O	ADJ	B
Wernicke-Korsakoff	B-Disease	ADJ	B
syndrome	I-Disease	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
to	O	PART	O
this	O	DET	O
patient	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
also	O	ADV	O
studied	O	VERB	O
this	O	DET	O
enzyme	O	NOUN	B
from	O	ADP	O
three	O	NUM	O
diabetic	B-Disease	ADJ	B
kindreds	O	NOUN	B
without	O	ADP	O
any	O	DET	O
history	O	NOUN	B
of	O	ADP	O
Wernicke's	B-Disease	NOUN	O
encephalopathy	I-Disease	NOUN	B
and	O	CCONJ	O
from	O	ADP	O
four	O	NUM	O
normal	O	ADJ	B
controls	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
found	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
above	O	ADV	B
-	O	PUNCT	O
mentioned	O	VERB	B
patient	O	NOUN	B
and	O	CCONJ	O
one	O	NUM	O
of	O	ADP	O
the	O	DET	O
diabetic	B-Disease	ADJ	B
kindreds	O	NOUN	B
with	O	ADP	O
no	O	DET	B
history	O	NOUN	I
of	O	ADP	O
Wernicke's	B-Disease	NOUN	O
encephalopathy	I-Disease	NOUN	B
had	O	AUX	O
abnormal	O	ADJ	B
transketolase	O	NOUN	B
as	O	ADP	O
determined	O	VERB	O
by	O	ADP	O
its	O	PRON	O
Km	O	NOUN	B
for	O	ADP	O
TPP	B-Chemical	PROPN	B
.	O	PUNCT	O


These	O	DET	O
data	O	NOUN	B
suggest	O	VERB	O
a	O	DET	O
similarity	O	NOUN	B
between	O	ADP	O
postalcoholic	O	ADJ	B
Wernicke-Korsakoff	B-Disease	ADJ	B
syndrome	I-Disease	NOUN	I
and	O	CCONJ	O
the	O	DET	O
patient	O	NOUN	B
with	O	ADP	O
tolazamide	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
Wernicke's	B-Disease	NOUN	O
encephalopathy	I-Disease	NOUN	B


Mechanisms	O	NOUN	B
of	O	ADP	O
myocardial	B-Disease	ADJ	B
ischemia	I-Disease	NOUN	I
induced	O	VERB	B
by	O	ADP	O
epinephrine	B-Chemical	NOUN	B
:	O	PUNCT	O
comparison	O	NOUN	B
with	O	ADP	O
exercise	O	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
ischemia	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
role	O	NOUN	O
of	O	ADP	O
epinephrine	B-Chemical	NOUN	B
in	O	ADP	O
eliciting	O	VERB	O
myocardial	B-Disease	ADJ	B
ischemia	I-Disease	NOUN	I
was	O	AUX	O
examined	O	VERB	O
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
coronary	B-Disease	ADJ	B
artery	I-Disease	NOUN	I
disease	I-Disease	NOUN	I
.	O	PUNCT	O


Objective	O	ADJ	O
signs	O	NOUN	O
of	O	ADP	O
ischemia	B-Disease	NOUN	B
and	O	CCONJ	O
factors	O	NOUN	B
increasing	O	VERB	O
myocardial	O	ADJ	B
oxygen	B-Chemical	NOUN	I
consumption	O	NOUN	I
were	O	AUX	O
compared	O	VERB	O
during	O	ADP	O
epinephrine	B-Chemical	NOUN	B
infusion	O	NOUN	B
and	O	CCONJ	O
supine	O	ADJ	B
bicycle	O	NOUN	I
exercise	O	NOUN	B
.	O	PUNCT	O


Both	O	CCONJ	O
epinephrine	B-Chemical	NOUN	B
and	O	CCONJ	O
exercise	O	NOUN	B
produced	O	VERB	O
myocardial	B-Disease	ADJ	B
ischemia	I-Disease	NOUN	I
as	O	ADP	O
evidenced	O	VERB	O
by	O	ADP	O
ST	O	ADJ	B
segment	O	NOUN	O
depression	B-Disease	NOUN	O
and	O	CCONJ	O
angina	B-Disease	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
mechanisms	O	NOUN	B
of	O	ADP	O
myocardial	B-Disease	ADJ	B
ischemia	I-Disease	NOUN	I
induced	O	VERB	B
by	O	ADP	O
epinephrine	B-Chemical	NOUN	B
were	O	AUX	O
significantly	O	ADV	O
different	O	ADJ	O
from	O	ADP	O
those	O	DET	O
of	O	ADP	O
exercise	O	NOUN	B
.	O	PUNCT	O


Exercise	O	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
myocardial	B-Disease	ADJ	B
ischemia	I-Disease	NOUN	I
was	O	AUX	O
marked	O	VERB	O
predominantly	O	ADV	O
by	O	ADP	O
increased	O	VERB	B
heart	O	NOUN	B
rate	O	NOUN	I
and	O	CCONJ	O
rate	O	NOUN	B
-	O	PUNCT	O
pressure	O	NOUN	B
product	O	NOUN	B
with	O	ADP	O
a	O	DET	O
minor	O	ADJ	O
contribution	O	NOUN	B
of	O	ADP	O
end	O	NOUN	B
-	O	PUNCT	O
diastolic	O	ADJ	B
volume	O	NOUN	B
,	O	PUNCT	O
while	O	SCONJ	O
epinephrine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
ischemia	B-Disease	NOUN	B
was	O	AUX	O
characterized	O	VERB	B
by	O	ADP	O
a	O	DET	O
marked	O	ADJ	O
increase	O	NOUN	B
in	O	ADP	O
contractility	O	NOUN	B
and	O	CCONJ	O
a	O	DET	O
less	O	ADV	O
pronounced	O	ADJ	O
increase	O	NOUN	B
in	O	ADP	O
heart	O	NOUN	B
rate	O	NOUN	I
and	O	CCONJ	O
rate	O	NOUN	B
-	O	PUNCT	O
pressure	O	NOUN	B
product	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
findings	O	NOUN	B
indicate	O	VERB	O
that	O	SCONJ	O
ischemia	B-Disease	NOUN	B
produced	O	VERB	O
by	O	ADP	O
epinephrine	B-Chemical	NOUN	B


Transient	O	ADJ	B
contralateral	B-Disease	ADJ	O
rotation	I-Disease	NOUN	O
following	O	VERB	O
unilateral	O	ADJ	B
substantia	B-Disease	NOUN	B
nigra	I-Disease	NOUN	I
lesion	I-Disease	NOUN	B
reflects	O	VERB	O
susceptibility	O	NOUN	B
of	O	ADP	O
the	O	DET	O
nigrostriatal	O	ADJ	B
system	O	NOUN	I
to	O	PART	O
exhaustion	O	VERB	B
by	O	ADP	O
amphetamine	B-Chemical	NOUN	B
.	O	PUNCT	O


Following	O	VERB	O
unilateral	O	ADJ	B
6-OHDA	B-Chemical	NOUN	B
induced	O	VERB	B
SN	B-Disease	NOUN	B
lesion	I-Disease	NOUN	B
,	O	PUNCT	O
a	O	DET	O
transient	O	ADJ	B
period	O	NOUN	B
of	O	ADP	O
contralateral	B-Disease	ADJ	B
rotation	I-Disease	NOUN	I
has	O	AUX	O
been	O	AUX	O
reported	O	VERB	O
to	O	PART	O
precede	O	VERB	O
the	O	DET	O
predominant	O	ADJ	B
ipsilateral	B-Disease	ADJ	B
circling	I-Disease	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
order	O	NOUN	O
to	O	PART	O
clarify	O	VERB	O
the	O	DET	O
nature	O	NOUN	B
of	O	ADP	O
this	O	DET	O
initial	O	ADJ	O
contralateral	B-Disease	ADJ	B
rotation	I-Disease	NOUN	O
we	O	PRON	O
examined	O	VERB	O
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
the	O	DET	O
duration	O	NOUN	B
of	O	ADP	O
recovery	O	NOUN	B
period	O	NOUN	B
after	O	ADP	O
the	O	DET	O
lesion	O	NOUN	B
,	O	PUNCT	O
on	O	ADP	O
amphetamine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
rotational	B-Disease	ADJ	B
behavior	I-Disease	NOUN	I
.	O	PUNCT	O


Three	O	NUM	B
days	O	NOUN	I
post	O	NOUN	B
lesion	O	NOUN	B
,	O	PUNCT	O
most	O	ADJ	O
rats	O	NOUN	B
circled	O	VERB	B
predominantly	O	ADV	O
contralaterally	O	ADV	O
to	O	PART	O
the	O	DET	O
lesion	O	NOUN	B
.	O	PUNCT	O


Such	O	ADJ	O
contralateral	B-Disease	ADJ	B
rotation	I-Disease	NOUN	O
may	O	AUX	O
result	O	VERB	O
from	O	ADP	O
either	O	CCONJ	O
degeneration	O	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
breakdown	O	NOUN	B
of	O	ADP	O
the	O	DET	O
DA	O	NOUN	B
pool	O	NOUN	O
,	O	PUNCT	O
or	O	CCONJ	O
lesion	O	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
increase	O	NOUN	B
of	O	ADP	O
DA	O	NOUN	B
turnover	O	NOUN	B
in	O	ADP	O
the	O	DET	O
spared	O	VERB	O
neurons	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
substantial	O	ADJ	O
degree	O	NOUN	B
of	O	ADP	O
contralateral	O	ADJ	B
preference	O	NOUN	B
was	O	AUX	O
still	O	ADV	O
evident	O	ADJ	O
when	O	SCONJ	O
amphetamine	B-Chemical	NOUN	B
was	O	AUX	O
administered	O	VERB	B
for	O	ADP	O
the	O	DET	O
first	O	ADJ	O
time	O	NOUN	O
24	O	NUM	O
days	O	NOUN	B
after	O	ADP	O
lesioning	O	VERB	B
,	O	PUNCT	O
indicating	O	VERB	O
involvement	O	NOUN	B
of	O	ADP	O
spared	O	VERB	B
cells	O	NOUN	I
in	O	ADP	O
the	O	DET	O
contralateral	B-Disease	ADJ	B
rotation	I-Disease	NOUN	I
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
regardless	O	ADV	O
of	O	ADP	O
the	O	DET	O
duration	O	NOUN	B
of	O	ADP	O
recovery	O	NOUN	B
(	O	PUNCT	O
and	O	CCONJ	O
irrespective	O	ADV	O
of	O	ADP	O
either	O	DET	O
lesion	O	NOUN	B
volume	O	NOUN	I
,	O	PUNCT	O
amphetamine	B-Chemical	NOUN	B
dose	O	NOUN	O
,	O	PUNCT	O
or	O	CCONJ	O
post	O	NOUN	B
-	O	PUNCT	O
lesion	O	NOUN	B
motor	O	NOUN	B
exercise	O	NOUN	I
),	O	PUNCT	O
amphetamine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
rotation	B-Disease	NOUN	B
tended	O	VERB	O
to	O	PART	O
become	O	VERB	O
gradually	O	ADV	O
more	O	ADV	O
ipsilateral	O	ADJ	B
as	O	ADP	O
the	O	DET	O
observation	O	NOUN	B
session	O	NOUN	B
progressed	O	VERB	O
,	O	PUNCT	O
and	O	CCONJ	O
all	O	DET	O
rats	O	NOUN	B
circled	O	VERB	B
ipsilaterally	O	ADV	B
to	O	PART	O
the	O	DET	O
lesion	O	NOUN	B
in	O	ADP	O
response	O	NOUN	B
to	O	PART	O
further	O	ADJ	O
amphetamine	B-Chemical	NOUN	B
injections	O	NOUN	I
.	O	PUNCT	O


These	O	DET	O
findings	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
amphetamine	B-Chemical	NOUN	B
has	O	AUX	O
an	O	DET	O
irreversible	O	ADJ	B
effect	O	NOUN	B
on	O	ADP	O
the	O	DET	O
post	O	NOUN	B
-	O	PUNCT	O
lesion	O	NOUN	B
DA	O	NOUN	B
pool	O	NOUN	I
contributing	O	VERB	O
to	O	PART	O
contralateral	B-Disease	ADJ	B
rotation	I-Disease	NOUN	O


Thyroid	O	NOUN	B
function	O	NOUN	I
and	O	CCONJ	O
urine	O	NOUN	B
-	O	PUNCT	O
concentrating	O	VERB	B
ability	O	NOUN	B
during	O	ADP	O
lithium	B-Chemical	NOUN	B
treatment	O	NOUN	B
.	O	PUNCT	O


It	O	PRON	O
has	O	AUX	O
been	O	AUX	O
suggested	O	VERB	O
that	O	SCONJ	O
adenylate	O	ADJ	B
cyclase	O	NOUN	I
inhibition	O	NOUN	B
may	O	AUX	O
be	O	AUX	O
important	O	ADJ	O
in	O	ADP	O
the	O	DET	O
development	O	NOUN	B
of	O	ADP	O
both	O	CCONJ	O
nephrogenic	B-Disease	ADJ	B
diabetes	I-Disease	NOUN	I
insipidus	I-Disease	NOUN	I
and	O	CCONJ	O
hypothyroidism	B-Disease	NOUN	B
during	O	ADP	O
lithium	B-Chemical	NOUN	B
treatment	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
measured	O	VERB	B
serum	O	NOUN	B
thyroxine	B-Chemical	NOUN	O
and	O	CCONJ	O
urine	O	NOUN	B
-	O	PUNCT	O
concentrating	O	VERB	B
ability	O	NOUN	B
(	O	PUNCT	O
Umax	O	PROPN	B
)	O	PUNCT	O
in	O	ADP	O
response	O	NOUN	B
to	O	PART	I
desmopressin	O	NOUN	B
(	O	PUNCT	O
DDAVP	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
85	O	NUM	O
patients	O	NOUN	B
receiving	O	VERB	O
lithium	B-Chemical	NOUN	B
.	O	PUNCT	O


Hypothyroidism	B-Disease	NOUN	B
developed	O	VERB	O
in	O	ADP	O
eight	O	NUM	O
patients	O	NOUN	B
while	O	SCONJ	O
they	O	PRON	O
were	O	AUX	O
taking	O	VERB	O
lithium	B-Chemical	NOUN	B
.	O	PUNCT	O


Impaired	O	ADJ	B
Umax	O	PROPN	O
was	O	AUX	O
found	O	VERB	O
in	O	ADP	O
both	O	CCONJ	O
euthyroid	O	ADJ	B
and	O	CCONJ	O
hypothyroid	B-Disease	ADJ	B
patients	O	NOUN	B
while	O	SCONJ	O
some	O	DET	O
hypothyroid	B-Disease	ADJ	B
patients	O	NOUN	B
concentrated	O	VERB	O
their	O	PRON	O
urine	O	NOUN	B
well	O	ADV	O
.	O	PUNCT	O


It	O	PRON	O
is	O	AUX	O
concluded	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
dominant	O	ADJ	B
mechanisms	O	NOUN	B
by	O	ADP	O
which	O	DET	O
lithium	B-Chemical	NOUN	B


Sensitivity	O	NOUN	B
of	O	ADP	O
erythroid	O	ADJ	B
progenitor	O	NOUN	I
colonies	O	NOUN	B
to	O	PART	O
erythropoietin	O	NOUN	B
in	O	ADP	O
azidothymidine	B-Chemical	NOUN	B
treated	O	ADJ	B
immunodeficient	B-Disease	ADJ	B
mice	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
anaemia	B-Disease	NOUN	B
induced	O	VERB	B
by	O	ADP	O
3'-azido-3'dideoxythymidine	B-Chemical	NOUN	O
(	O	PUNCT	O
AZT	B-Chemical	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
poorly	O	ADV	O
understood	O	VERB	O
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
used	O	VERB	O
a	O	DET	O
murine	O	ADJ	B
model	O	NOUN	B
of	O	ADP	O
AIDS	B-Disease	NOUN	B
,	O	PUNCT	O
infection	B-Disease	NOUN	B
of	O	ADP	O
female	O	ADJ	B
C57BL	O	NOUN	B
/	O	SYM	O
6	O	NUM	O
mice	O	NOUN	B
with	O	ADP	O
LP	O	NOUN	B
-	O	PUNCT	O
BM5	O	NOUN	B
murine	O	NOUN	O
leukaemia	B-Disease	NOUN	O
(	O	PUNCT	O
MuLV	O	NOUN	B
)	O	PUNCT	O
virus	O	NOUN	B
,	O	PUNCT	O
to	O	PART	O
determine	O	VERB	O
if	O	SCONJ	O
AZT	B-Chemical	PROPN	B
-	O	PUNCT	O
induced	O	VERB	B
anaemia	B-Disease	NOUN	B
is	O	AUX	O
due	O	ADJ	O
,	O	PUNCT	O
in	O	ADP	O
part	O	NOUN	O
,	O	PUNCT	O
to	O	PART	O
decreased	O	VERB	B
responsiveness	O	NOUN	B
of	O	ADP	O
erythropoietic	O	ADJ	B
precursors	O	NOUN	I
(	O	PUNCT	O
BFU	O	PROPN	B
-	O	PUNCT	O
e	O	X	O
)	O	PUNCT	O
to	O	PART	O
erythropoietin	O	NOUN	B
(	O	PUNCT	O
EPO	O	NOUN	B
).	O	PUNCT	O
Mice	O	NOUN	B
in	O	ADP	O
the	O	DET	O
early	O	ADJ	B
stage	O	NOUN	I
of	O	ADP	O
LP	O	PROPN	B
-	O	PUNCT	O
BM5	O	NOUN	B
MuLV	O	NOUN	O
disease	O	NOUN	O
were	O	AUX	O
given	O	VERB	O
AZT	B-Chemical	NOUN	B
in	O	ADP	O
their	O	PRON	O
drinking	O	NOUN	B
water	O	NOUN	I
at	O	ADP	O
1	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
and	O	CCONJ	O
2	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
ml	O	NOUN	O
.	O	PUNCT	O


AZT	B-Chemical	NOUN	B
produced	O	VERB	O
anaemia	B-Disease	NOUN	B
in	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
,	O	PUNCT	O
in	O	ADP	O
a	O	DET	O
dose	O	NOUN	B
-	O	PUNCT	O
dependent	O	ADJ	B
fashion	O	NOUN	B
.	O	PUNCT	O


Despite	O	SCONJ	O
the	O	DET	O
anaemia	B-Disease	NOUN	B
,	O	PUNCT	O
the	O	DET	O
number	O	NOUN	O
of	O	ADP	O
splenic	O	ADJ	B
and	O	CCONJ	O
bone	O	NOUN	B
marrow	O	NOUN	I
BFU	O	PROPN	B
-	O	PUNCT	O
e	O	NOUN	B
in	O	ADP	O
AZT	B-Chemical	NOUN	B
treated	O	ADJ	B
mice	O	NOUN	B
increased	O	VERB	B
up	O	ADV	O
to	O	PART	O
five	O	NUM	O
-	O	PUNCT	O
fold	O	NOUN	B
over	O	ADP	O
levels	O	NOUN	B
observed	O	VERB	O
in	O	ADP	O
infected	O	ADJ	B
untreated	O	ADJ	B
animals	O	NOUN	I
after	O	ADP	O
15	O	NUM	O
d	O	NOUN	O
of	O	ADP	O
treatment	O	NOUN	B
.	O	PUNCT	O


Colony	O	NOUN	B
formation	O	NOUN	B
by	O	ADP	O
splenic	O	ADJ	B
and	O	CCONJ	O
bone	O	NOUN	B
marrow	O	NOUN	I
BFUe	O	NOUN	B
was	O	AUX	O
stimulated	O	VERB	B
at	O	ADP	O
lower	O	ADJ	O
concentrations	O	NOUN	B
of	O	ADP	O
EPO	O	NOUN	B
in	O	ADP	O
mice	O	NOUN	B
receiving	O	VERB	O
AZT	B-Chemical	NOUN	B
for	O	ADP	O
15	O	NUM	O
d	O	NOUN	O
than	O	ADP	O
for	O	ADP	O
infected	O	ADJ	B
,	O	PUNCT	O
untreated	O	ADJ	B
mice	O	NOUN	O
.	O	PUNCT	O


By	O	ADP	O
day	O	NOUN	B
30	O	NUM	O
,	O	PUNCT	O
sensitivity	O	NOUN	B
of	O	ADP	O
both	O	CCONJ	O
splenic	O	ADJ	B
and	O	CCONJ	O
bone	O	NOUN	B
marrow	O	NOUN	I
BFU	O	PROPN	B
-	O	PUNCT	O
e	O	PROPN	O
of	O	ADP	O
treated	O	VERB	B
animals	O	NOUN	B
returned	O	VERB	O
to	O	PART	O
that	O	DET	O
observed	O	VERB	B
from	O	ADP	O
cells	O	NOUN	B
of	O	ADP	O
infected	O	ADJ	B
untreated	O	ADJ	B
animals	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
mean	O	ADJ	O
plasma	O	NOUN	B
levels	O	NOUN	O
of	O	ADP	O
EPO	O	NOUN	B
observed	O	VERB	B
in	O	ADP	O
AZT	B-Chemical	NOUN	B
treated	O	ADJ	B
mice	O	NOUN	B
were	O	AUX	O
appropriate	O	ADJ	O
for	O	ADP	O
the	O	DET	O
degree	O	NOUN	B
of	O	ADP	O
anaemia	B-Disease	NOUN	B
observed	O	VERB	B
when	O	SCONJ	O
compared	O	VERB	B
with	O	ADP	O
phenylhydrazine	B-Chemical	NOUN	B
(	O	PUNCT	O
PHZ	B-Chemical	NOUN	B
)	O	PUNCT	O
treated	O	VERB	B
mice	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
numbers	O	NOUN	O
of	O	ADP	O
BFU	O	PROPN	B
-	O	PUNCT	O
e	O	PROPN	B
and	O	CCONJ	O
the	O	DET	O
percentage	O	NOUN	B
of	O	ADP	O
bone	O	NOUN	B
marrow	O	NOUN	I
erythroblasts	O	NOUN	I
observed	O	VERB	O
were	O	AUX	O
comparable	O	ADJ	O
in	O	ADP	O
AZT	B-Chemical	NOUN	B
and	O	CCONJ	O
PHZ	B-Chemical	NOUN	B
treated	O	VERB	B
mice	O	NOUN	B
with	O	ADP	O
similar	O	ADJ	O
degrees	O	NOUN	B
of	O	ADP	O
anaemia	B-Disease	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
reticulocytosis	B-Disease	NOUN	B
was	O	AUX	O
inappropriate	O	ADJ	O
for	O	ADP	O
the	O	DET	O
degree	O	NOUN	B
of	O	ADP	O
anaemia	B-Disease	NOUN	B
observed	O	VERB	B
in	O	ADP	O
AZT	B-Chemical	NOUN	B
treated	O	ADJ	B
infected	O	ADJ	B
mice	O	NOUN	B
.	O	PUNCT	O


AZT	B-Chemical	PROPN	B
-	O	PUNCT	O
induced	O	VERB	B
peripheral	O	ADJ	B
anaemia	B-Disease	NOUN	I


Detection	O	NOUN	B
of	O	ADP	O
abnormal	O	ADJ	B
cardiac	O	ADJ	O
adrenergic	O	ADJ	O
neuron	O	NOUN	O
activity	O	NOUN	B
in	O	ADP	O
adriamycin	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
cardiomyopathy	B-Disease	NOUN	B
with	O	ADP	O
iodine-125-metaiodobenzylguanidine	B-Chemical	NOUN	B
.	O	PUNCT	O


Radiolabeled	B-Chemical	VERB	B
metaiodobenzylguanidine	I-Chemical	NOUN	I
(	O	PUNCT	O
MIBG	B-Chemical	NOUN	B
),	O	PUNCT	O
an	O	DET	O
analog	O	NOUN	B
of	O	ADP	O
norepinephrine	B-Chemical	NOUN	B
(	O	PUNCT	O
NE	B-Chemical	NOUN	B
),	O	PUNCT	O
serves	O	VERB	O
as	O	ADP	O
an	O	DET	O
index	O	NOUN	O
of	O	ADP	O
adrenergic	O	ADJ	B
neuron	O	NOUN	I
integrity	O	NOUN	B
and	O	CCONJ	O
function	O	NOUN	B
.	O	PUNCT	O


Using	O	VERB	O
a	O	DET	O
rat	O	NOUN	B
model	O	NOUN	B
of	O	ADP	O
adriamycin	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
cardiomyopathy	B-Disease	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
tested	O	VERB	B
the	O	DET	O
hypothesis	O	NOUN	B
that	O	SCONJ	O
abnormal	O	ADJ	B
cardiac	O	ADJ	B
adrenergic	O	ADJ	I
neuron	O	NOUN	I
activity	O	NOUN	B
may	O	AUX	O
appear	O	VERB	O
and	O	CCONJ	O
be	O	AUX	O
exacerbated	O	ADJ	B
dose	O	NOUN	B
-	O	PUNCT	O
dependently	O	ADV	B
in	O	ADP	O
adriamycin	B-Chemical	NOUN	B
cardiomyopathy	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
degree	O	NOUN	B
of	O	ADP	O
vacuolar	B-Disease	ADJ	B
degeneration	I-Disease	NOUN	I
of	I-Disease	ADP	O
myocardial	I-Disease	ADJ	B
cells	I-Disease	NOUN	I
was	O	AUX	O
analyzed	O	VERB	B
in	O	ADP	O
relation	O	NOUN	O
to	O	PART	O
the	O	DET	O
duration	O	NOUN	B
of	O	ADP	O
adriamycin	B-Chemical	NOUN	B
treatment	O	NOUN	B
(	O	PUNCT	O
2	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
,	O	PUNCT	O
once	O	SCONJ	O
a	O	DET	O
week	O	NOUN	B
).	O	PUNCT	B
There	O	PRON	O
were	O	AUX	O
no	O	DET	O
abnormalities	O	NOUN	B
or	O	CCONJ	O
only	O	ADV	O
isolated	O	VERB	B
degeneration	O	NOUN	B
in	O	ADP	O
the	O	DET	O
1	O	NUM	O
-	O	PUNCT	O
or	O	CCONJ	O
2	O	NUM	O
-	O	PUNCT	O
wk	O	NOUN	B
treatment	O	NOUN	B
groups	O	NOUN	I
,	O	PUNCT	O
isolated	O	VERB	B
or	O	CCONJ	O
scattered	O	VERB	B
degeneration	O	NOUN	B
in	O	ADP	O
half	O	NOUN	O
of	O	ADP	O
the	O	DET	O
3	O	NUM	O
-	O	PUNCT	O
wk	O	NOUN	O
group	O	NOUN	B
,	O	PUNCT	O
frequent	O	ADJ	B
scattered	O	ADJ	B
degeneration	O	NOUN	B
in	O	ADP	O
the	O	DET	O
4	O	NUM	O
-	O	PUNCT	O
wk	O	NOUN	B
group	O	NOUN	B
,	O	PUNCT	O
scattered	O	VERB	B
or	O	CCONJ	O
focal	O	ADJ	B
degeneration	O	NOUN	I
in	O	ADP	O
the	O	DET	O
5	O	NUM	O
-	O	PUNCT	O
wk	O	NOUN	O
group	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
extensive	O	ADJ	B
degeneration	O	NOUN	B
in	O	ADP	O
the	O	DET	O
8	O	NUM	O
-	O	PUNCT	O
wk	O	NOUN	O
group	O	NOUN	B
.	O	PUNCT	O


Myocardial	O	ADJ	B
accumulation	O	NOUN	B
of	O	ADP	O
[	O	PUNCT	O
125I	O	NUM	O
]	O	PUNCT	O
MIBG	B-Chemical	NOUN	B
4	O	NUM	O
hr	O	NOUN	O
after	O	ADP	O
intravenous	O	ADJ	B
injection	O	NOUN	I
did	O	AUX	O
not	O	PART	O
differ	O	VERB	O
between	O	ADP	O
the	O	DET	O
controls	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
groups	O	NOUN	B
treated	O	VERB	B
3	O	NUM	O
wk	O	NOUN	O
or	O	CCONJ	O
less	O	ADJ	O
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
4	O	NUM	O
-	O	PUNCT	O
wk	O	NOUN	B
group	O	NOUN	B
had	O	AUX	O
a	O	DET	O
slightly	O	ADV	O
lower	O	ADJ	O
accumulation	O	NOUN	B
in	O	ADP	O
the	O	DET	O
right	O	ADJ	B
ventricular	O	ADJ	I
wall	O	NOUN	I
(	O	PUNCT	O
82	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
control	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
significantly	O	ADV	O
lower	O	ADJ	O
accumulation	O	NOUN	B
in	O	ADP	O
the	O	DET	O
left	O	ADJ	B
ventricular	O	ADJ	I
wall	O	NOUN	I
(	O	PUNCT	O
about	O	ADV	O
66	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
control	O	NOUN	B
:	O	PUNCT	O
p	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


05	O	NUM	O
).	O	PUNCT	O
In	O	ADP	O
the	O	DET	O
5	O	NUM	O
-	O	PUNCT	O
wk	O	NOUN	O
group	O	NOUN	B
,	O	PUNCT	O
MIBG	B-Chemical	NOUN	B
accumulation	O	NOUN	B
in	O	ADP	O
the	O	DET	O
right	O	ADJ	B
and	O	CCONJ	O
left	O	VERB	B
ventricular	O	ADJ	I
wall	O	NOUN	I
was	O	AUX	O
35	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
27	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
that	O	DET	O
in	O	ADP	O
controls	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
(	O	PUNCT	O
p	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


001	O	NUM	O
).	O	PUNCT	O
In	O	ADP	O
the	O	DET	O
8	O	NUM	O
-	O	PUNCT	O
wk	O	NOUN	O
group	O	NOUN	B
,	O	PUNCT	O
MIBG	B-Chemical	NOUN	B
accumulation	O	NOUN	B
in	O	ADP	O
the	O	DET	O
right	O	ADJ	B
and	O	CCONJ	O
left	O	VERB	B
ventricular	O	ADJ	I
wall	O	NOUN	I
was	O	AUX	O
18	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
14	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
that	O	DET	O
in	O	ADP	O
controls	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
(	O	PUNCT	O
p	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


001	O	NUM	O
).	O	PUNCT	O
Thus	O	ADV	O
,	O	PUNCT	O
MIBG	B-Chemical	NOUN	B
accumulation	O	NOUN	B
in	O	ADP	O
the	O	DET	O
myocardium	O	NOUN	B
decreased	O	VERB	B
in	O	ADP	O
an	O	DET	O
adriamycin	B-Chemical	NOUN	B
dose	O	NOUN	B
-	O	PUNCT	O
dependent	O	ADJ	B
manner	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
appearance	O	NOUN	B
of	O	ADP	O
impaired	O	ADJ	B
cardiac	O	ADJ	B
adrenergic	O	ADJ	I
neuron	O	NOUN	I
activity	O	NOUN	B
in	O	ADP	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
slight	O	ADJ	O
myocardial	B-Disease	ADJ	B
impairment	I-Disease	NOUN	I
(	O	PUNCT	O
scattered	O	ADJ	B
or	O	CCONJ	O
focal	O	ADJ	B
vacuolar	B-Disease	NOUN	I
degeneration	I-Disease	NOUN	I
)	O	PUNCT	O
indicates	O	VERB	O
that	O	SCONJ	O
MIBG	B-Chemical	NOUN	B
scintigraphy	O	NOUN	B
may	O	AUX	O
be	O	AUX	O
a	O	DET	O
useful	O	ADJ	O
method	O	NOUN	B
for	O	ADP	O
detection	O	NOUN	B
of	O	ADP	O
adriamycin	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
cardiomyopathy	B-Disease	NOUN	B


Amnestic	B-Disease	ADJ	B
syndrome	I-Disease	NOUN	I
associated	O	VERB	B
with	O	ADP	I
propranolol	B-Chemical	NOUN	B
toxicity	B-Disease	NOUN	B
:	O	PUNCT	O
a	O	DET	O
case	O	NOUN	B
report	O	NOUN	I
.	O	PUNCT	O


An	O	DET	O
elderly	O	ADJ	B
woman	O	NOUN	B
developed	O	VERB	O
an	O	DET	O
Alzheimer	B-Disease	PROPN	B
-	O	PUNCT	O
like	O	ADJ	B
subacute	O	ADJ	B
dementia	B-Disease	NOUN	I
as	O	ADP	O
a	O	DET	O
result	O	NOUN	O
of	O	ADP	O
propranolol	B-Chemical	NOUN	B
toxicity	B-Disease	NOUN	B
.	O	PUNCT	O


Analysis	O	NOUN	B
of	O	ADP	O
the	O	DET	O
manifestations	O	NOUN	B
showed	O	VERB	O
that	O	SCONJ	O
severe	O	ADJ	B
impairment	O	NOUN	B
of	O	ADP	O
memory	O	NOUN	B
accounted	O	VERB	O
for	O	ADP	O
virtually	O	ADV	O
all	O	DET	O
of	O	ADP	O
the	O	DET	O
abnormalities	O	NOUN	B
.	O	PUNCT	O


There	O	PRON	O
is	O	AUX	O
evidence	O	NOUN	B
that	O	SCONJ	O
cerebral	O	ADJ	B
reactions	O	NOUN	I
to	O	PART	O
drug	O	NOUN	B
toxicity	B-Disease	NOUN	B


Biphasic	O	ADJ	B
response	O	NOUN	I
of	O	ADP	O
the	O	DET	O
SA	O	PROPN	B
node	O	NOUN	O
of	O	ADP	O
the	O	DET	O
dog	O	NOUN	B
heart	O	NOUN	B
in	O	X	B
vivo	O	X	I
to	O	PART	O
selective	O	ADJ	O
administration	O	NOUN	B
of	O	ADP	O
ketamine	B-Chemical	NOUN	B
.	O	PUNCT	O


Effect	O	NOUN	B
of	O	ADP	O
ketamine	B-Chemical	NOUN	B
on	O	ADP	O
the	O	DET	O
SA	O	PROPN	B
node	O	NOUN	O
of	O	ADP	O
the	O	DET	O
dog	O	NOUN	B
heart	O	NOUN	B
was	O	AUX	O
studied	O	VERB	O
in	O	X	B
vivo	O	X	I
using	O	VERB	O
a	O	DET	O
selective	O	ADJ	O
perfusion	O	NOUN	O
technique	O	NOUN	O
of	O	ADP	O
the	O	DET	O
SA	O	PROPN	B
node	O	NOUN	I
artery	O	NOUN	I
.	O	PUNCT	O


Injections	O	NOUN	B
of	O	ADP	O
ketamine	B-Chemical	NOUN	B
in	O	ADP	O
doses	O	NOUN	B
from	O	ADP	O
100	O	NUM	O
microgram	O	NOUN	B
to	O	PART	O
3	O	NUM	O
mg	O	NOUN	O
into	O	ADP	O
the	O	DET	O
artery	O	NOUN	B
produced	O	VERB	O
a	O	DET	O
depression	B-Disease	NOUN	B
of	O	ADP	O
the	O	DET	O
SA	O	PROPN	B
nodal	O	ADJ	B
activity	O	NOUN	I
by	O	ADP	O
a	O	DET	O
direct	O	ADJ	O
action	O	NOUN	O
.	O	PUNCT	O


This	O	DET	O
depression	B-Disease	NOUN	B
was	O	AUX	O
followed	O	VERB	O
by	O	ADP	O
the	O	DET	O
sudden	O	ADJ	B
appearance	O	NOUN	B
of	O	ADP	O
a	O	DET	O
stimulatory	O	ADJ	B
phase	O	NOUN	I
.	O	PUNCT	O


Bilateral	O	ADJ	B
vagotomy	O	NOUN	B
and	O	CCONJ	O
sympathectomy	O	NOUN	B
or	O	CCONJ	O
prior	O	ADJ	O
administration	O	NOUN	B
of	O	ADP	O
a	O	DET	O
ganglion	O	NOUN	B
blocker	O	NOUN	I
failed	O	VERB	B
to	O	PART	O
inhibit	O	VERB	B
the	O	DET	O
occurrence	O	NOUN	B
of	O	ADP	O
the	O	DET	O
ketamine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
tachycardia	B-Disease	NOUN	B
,	O	PUNCT	O
while	O	SCONJ	O
it	O	PRON	O
was	O	AUX	O
completely	O	ADV	O
abolished	O	VERB	B
in	O	ADP	O
the	O	DET	O
reserpinized	O	ADJ	B
dogs	O	NOUN	I
or	O	CCONJ	O
by	O	ADP	O
a	O	DET	O
prior	O	ADJ	O
injection	O	NOUN	B
of	O	ADP	O
a	O	DET	O
beta	O	NOUN	B
-	O	PUNCT	O
blocking	O	VERB	B
agent	O	NOUN	B
into	O	ADP	O
the	O	DET	O
SA	O	PROPN	B
node	O	NOUN	I
artery	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
may	O	AUX	O
indicate	O	VERB	O
that	O	SCONJ	O
an	O	DET	O
activation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
peripheral	O	ADJ	B
adrenergic	O	ADJ	B
mechanism	O	NOUN	B
plays	O	VERB	O
an	O	DET	O
important	O	ADJ	O
role	O	NOUN	O
in	O	ADP	O
the	O	DET	O
induction	O	NOUN	B
of	O	ADP	O
the	O	DET	O
excitatory	O	ADJ	B
effect	O	NOUN	O
of	O	ADP	O
ketamine	B-Chemical	NOUN	B


The	O	DET	O
use	O	NOUN	O
of	O	ADP	O
serum	O	NOUN	B
cholinesterase	O	NOUN	I
in	O	ADP	O
succinylcholine	B-Chemical	NOUN	B
apnoea	B-Disease	NOUN	I
.	O	PUNCT	O


Fifteen	O	NUM	O
patients	O	NOUN	B
demonstrating	O	VERB	O
unexpected	O	ADJ	O
prolonged	O	ADJ	B
apnoea	B-Disease	NOUN	B
lasting	O	NOUN	O
several	O	ADJ	O
hours	O	NOUN	O
after	O	ADP	O
succinylcholine	B-Chemical	NOUN	B
have	O	AUX	O
been	O	AUX	O
treated	O	VERB	B
by	O	ADP	O
a	O	DET	O
new	O	ADJ	O
preparation	O	NOUN	B
of	O	ADP	O
human	O	ADJ	B
serum	O	NOUN	B
cholinesterase	O	NOUN	I
.	O	PUNCT	O


Adequate	O	ADJ	B
spontaneous	O	ADJ	B
respiration	O	NOUN	B
was	O	AUX	O
re	O	ADP	B
-	O	PUNCT	O
established	O	VERB	B
in	O	ADP	O
an	O	DET	O
average	O	ADJ	O
period	O	NOUN	B
of	O	ADP	O
ten	O	NUM	O
minutes	O	NOUN	B
after	O	ADP	O
the	O	DET	O
injection	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
12	O	NUM	O
patients	O	NOUN	B
biochemical	O	ADJ	B
genetic	O	ADJ	B
examinations	O	NOUN	I
confirmed	O	VERB	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
an	O	DET	O
atypical	O	ADJ	B
serum	O	NOUN	B
cholinesterase	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
three	O	NUM	O
patients	O	NOUN	B
none	O	NOUN	O
of	O	ADP	O
the	O	DET	O
usual	O	ADJ	O
variants	O	NOUN	B
were	O	AUX	O
found	O	VERB	O
.	O	PUNCT	O


It	O	PRON	O
is	O	AUX	O
therefore	O	ADV	O
supposed	O	VERB	O
that	O	SCONJ	O
other	O	ADJ	O
unknown	O	ADJ	O
variants	O	NOUN	B
of	O	ADP	O
serum	O	NOUN	B
cholinesterase	O	NOUN	I
exist	O	VERB	O
which	O	DET	O
cannot	O	VERB	O
hydrolyze	O	VERB	B
succinylcholine	B-Chemical	NOUN	B
.	O	PUNCT	O


The	O	DET	O
use	O	NOUN	O
of	O	ADP	O
serum	O	NOUN	B
cholinesterase	O	NOUN	I
in	O	ADP	O
succinylcholine	B-Chemical	NOUN	B
apnoea	B-Disease	NOUN	I


Orthostatic	B-Disease	ADJ	B
hypotension	I-Disease	NOUN	O
occurs	O	VERB	O
following	O	VERB	O
alpha	O	NOUN	B
2	O	NUM	I
-	O	PUNCT	O
adrenoceptor	O	NOUN	B
blockade	O	NOUN	B
in	O	ADP	O
chronic	O	ADJ	B
prazosin	B-Chemical	NOUN	I
-	O	PUNCT	O
pretreated	O	VERB	B
conscious	O	ADJ	B
spontaneously	O	ADV	I
hypertensive	B-Disease	ADJ	B
rats	O	NOUN	B
.	O	PUNCT	O


1	O	X	O
.	O	PUNCT	O


Studies	O	NOUN	B
were	O	AUX	O
performed	O	VERB	O
to	O	PART	O
evaluate	O	VERB	B
whether	O	SCONJ	O
chronic	O	ADJ	B
prazosin	B-Chemical	NOUN	B
treatment	O	NOUN	B
alters	O	VERB	O
the	O	DET	O
alpha	O	NOUN	B
2	O	NUM	I
-	O	PUNCT	O
adrenoceptor	O	NOUN	B
function	O	NOUN	B
for	O	ADP	O
orthostatic	O	ADJ	B
control	O	NOUN	B
of	O	ADP	O
arterial	O	ADJ	B
blood	O	NOUN	I
pressure	O	NOUN	I
in	O	ADP	O
conscious	O	ADJ	B
spontaneously	O	ADV	I
hypertensive	B-Disease	ADJ	I
rats	O	NOUN	B
(	O	PUNCT	O
SHR	O	NOUN	B
).	O	NOUN	O
2	O	NUM	O
.	O	PUNCT	O


Conscious	O	ADJ	B
SHR	O	NOUN	I
(	O	PUNCT	O
male	O	NOUN	B
300	O	NUM	O
-	O	SYM	O
350	O	NUM	O
g	O	NOUN	O
)	O	PUNCT	O
were	O	AUX	O
subjected	O	VERB	O
to	O	ADP	O
90	O	NUM	O
degrees	O	NOUN	B
head	O	NOUN	B
-	O	PUNCT	O
up	O	ADP	O
tilts	O	NOUN	B
for	O	ADP	O
60	O	NUM	O
s	O	NOUN	O
following	O	VERB	O
acute	O	ADJ	B
administration	O	NOUN	I
of	O	ADP	O
prazosin	B-Chemical	NOUN	B
(	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
mg	O	NOUN	O
kg	O	NOUN	O
-	O	PUNCT	O
1	O	NUM	O
i	O	NUM	O
.	O	PUNCT	O


p	O	NOUN	O
.)	O	NOUN	O
or	O	CCONJ	O
rauwolscine	B-Chemical	NOUN	B
(	O	PUNCT	O
3	O	NUM	O
mg	O	NOUN	O
kg	O	NOUN	O
-	O	PUNCT	O
1	O	NUM	O
i	O	NUM	O
.	O	PUNCT	O


v	O	ADP	O
.).	O	PUNCT	O
Orthostatic	B-Disease	ADJ	B
hypotension	I-Disease	NOUN	O
was	O	AUX	O
determined	O	VERB	O
by	O	ADP	O
the	O	DET	O
average	O	ADJ	B
decrease	O	NOUN	B
(%)	O	PUNCT	B
in	O	ADP	O
mean	O	ADJ	O
arterial	O	ADJ	O
pressure	O	NOUN	O
(	O	PUNCT	O
MAP	O	NOUN	B
femoral	O	NOUN	I
)	O	PUNCT	O
over	O	ADP	O
the	O	DET	O
60	O	NUM	O
-	O	PUNCT	O
s	O	NOUN	O
tilt	O	NOUN	B
period	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
basal	O	ADJ	B
MAP	O	NOUN	I
of	O	ADP	O
conscious	O	ADJ	B
SHR	O	NOUN	I
was	O	AUX	O
reduced	O	VERB	B
to	O	PART	O
a	O	DET	O
similar	O	ADJ	O
extent	O	NOUN	O
by	O	ADP	O
prazosin	B-Chemical	NOUN	B
(-	O	PUNCT	O
23	O	NUM	O
%(-)-	O	NOUN	O
26	O	NUM	O
%	O	NOUN	O
MAP	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
rauwolscine	B-Chemical	NOUN	B
(-	O	PUNCT	O
16	O	NUM	O
%(-)-	O	NOUN	O
33	O	NUM	O
%	O	NOUN	O
MAP	O	NOUN	B
).	O	PUNCT	O
However	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
head	O	NOUN	B
-	O	PUNCT	O
up	O	ADP	O
tilt	O	NOUN	B
induced	O	VERB	B
orthostatic	B-Disease	ADJ	B
hypotension	I-Disease	NOUN	O
in	O	ADP	O
the	O	DET	O
SHR	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
prazosin	B-Chemical	NOUN	B
(-	O	PUNCT	O
16	O	NUM	O
%	O	NOUN	O
MAP	O	NOUN	B
,	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
6	O	NUM	O
),	O	PUNCT	O
but	O	CCONJ	O
not	O	PART	O
in	O	ADP	O
the	O	DET	O
SHR	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
rauwolscine	B-Chemical	NOUN	B
(	O	PUNCT	O
less	O	ADJ	O
than	O	ADP	O
+	O	CCONJ	O
2	O	NUM	O
%	O	NOUN	O
MAP	O	NOUN	B
,	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
6	O	NUM	O
).	O	PUNCT	O
3	O	NUM	O
.	O	PUNCT	O


Conscious	O	ADJ	B
SHR	O	NOUN	I
were	O	AUX	O
treated	O	VERB	B
for	O	ADP	O
4	O	NUM	O
days	O	NOUN	B
with	O	ADP	O
prazosin	B-Chemical	NOUN	B
at	O	ADP	O
2	O	NUM	O
mg	O	NOUN	O
kg	O	NOUN	O
-	O	PUNCT	O
1	O	NUM	O
day	O	NOUN	B
-	O	PUNCT	O
1	O	NUM	O
i	O	NUM	O
.	O	PUNCT	O


p	O	NOUN	O
.	O	PUNCT	O


for	O	ADP	O
chronic	O	ADJ	B
alpha	O	NOUN	I
1	O	NUM	I
-	O	PUNCT	O
adrenoceptor	O	NOUN	B
blockade	O	NOUN	B
.	O	PUNCT	O


MAP	O	NOUN	B
in	O	ADP	O
conscious	O	ADJ	B
SHR	O	NOUN	I
after	O	ADP	O
chronic	O	ADJ	B
prazosin	B-Chemical	NOUN	I
treatment	O	NOUN	B
was	O	AUX	O
14	O	NUM	O
%	O	NOUN	O
lower	O	ADJ	O
than	O	ADP	O
in	O	ADP	O
the	O	DET	O
untreated	O	ADJ	B
SHR	O	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
8	O	NUM	O
).	O	PUNCT	O
Head	O	PROPN	B
-	O	PUNCT	O
up	O	ADP	O
tilts	O	NOUN	B
in	O	ADP	O
these	O	DET	O
rats	O	NOUN	B
did	O	AUX	O
not	O	PART	O
produce	O	VERB	O
orthostatic	B-Disease	ADJ	B
hypotension	I-Disease	NOUN	B
when	O	SCONJ	O
performed	O	VERB	O
either	O	CCONJ	O
prior	O	ADJ	O
to	O	PART	O
or	O	CCONJ	O
after	O	ADP	O
acute	O	ADJ	B
dosing	O	NOUN	B
of	O	ADP	O
prazosin	B-Chemical	NOUN	B
(	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
mg	O	NOUN	O
kg	O	NOUN	O
-	O	PUNCT	O
1	O	NUM	O
i	O	NUM	O
.	O	PUNCT	O


p	O	NOUN	O
.).	O	NOUN	O
Conversely	O	ADV	O
,	O	PUNCT	O
administration	O	NOUN	B
of	O	ADP	O
rauwolscine	B-Chemical	NOUN	B
(	O	PUNCT	O
3	O	NUM	O
mg	O	NOUN	O
kg	O	NOUN	O
-	O	PUNCT	O
1	O	NUM	O
i	O	NUM	O
.	O	PUNCT	O


v	O	ADP	O
.)	O	NOUN	O
in	O	ADP	O
chronic	O	ADJ	B
prazosin	B-Chemical	NOUN	I
treated	O	ADJ	B
SHR	O	NOUN	B
decreased	O	VERB	B
the	O	DET	O
basal	O	ADJ	B
MAP	O	NOUN	I
by	O	ADP	O
12	O	NUM	O
-	O	SYM	O
31	O	NUM	O
%(	O	NOUN	O
n	O	NOUN	O
=	O	ADJ	O
4	O	NUM	O
),	O	PUNCT	O
and	O	CCONJ	O
subsequent	O	ADJ	O
tilts	O	NOUN	B
induced	O	VERB	B
further	O	ADJ	O
drops	O	NOUN	B
of	O	ADP	O
MAP	O	NOUN	B
by	O	ADP	O
19	O	NUM	O
-	O	SYM	O
23	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
these	O	DET	O
rats	O	NOUN	B
.	O	PUNCT	O


4	O	X	O
.	O	PUNCT	O


The	O	DET	O
pressor	O	ADJ	B
responses	O	NOUN	B
and	O	CCONJ	O
bradycardia	B-Disease	NOUN	B
to	O	PART	O
the	O	DET	O
alpha	O	NOUN	B
1	O	NUM	I
-	O	PUNCT	O
agonist	O	NOUN	B
cirazoline	B-Chemical	NOUN	B
(	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
and	O	CCONJ	O
2	O	NUM	O
micrograms	O	NOUN	O
kg	O	NOUN	O
-	O	PUNCT	O
1	O	NUM	O
i	O	NUM	O
.	O	PUNCT	O


v	O	ADP	O
.),	O	PUNCT	O
the	O	DET	O
alpha	O	NOUN	B
2	O	NUM	I
-	O	PUNCT	O
agonist	O	NOUN	B
Abbott-53693	B-Chemical	PROPN	B
(	O	PUNCT	O
1	O	NUM	O
and	O	CCONJ	O
3	O	NUM	O
micrograms	O	NOUN	B
kg	O	NOUN	O
-	O	PUNCT	O
1	O	NUM	O
i	O	NUM	O
.	O	PUNCT	O


v	O	ADP	O
.),	O	NOUN	O
and	O	CCONJ	O
noradrenaline	B-Chemical	NOUN	B
(	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
and	O	CCONJ	O
1	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
micrograms	O	NOUN	B
kg	O	NOUN	O
-	O	PUNCT	O
1	O	NUM	O
i	O	NUM	O
.	O	PUNCT	O


v	O	ADP	O
.)	O	NOUN	O
were	O	AUX	O
determined	O	VERB	O
in	O	ADP	O
conscious	O	ADJ	B
SHR	O	NOUN	I
with	O	ADP	O
and	O	CCONJ	O
without	O	ADP	O
chronic	O	ADJ	B
prazosin	B-Chemical	NOUN	B
pretreatment	O	NOUN	B
.	O	PUNCT	O


Both	O	CCONJ	O
the	O	DET	O
pressor	O	NOUN	B
and	O	CCONJ	O
bradycardia	B-Disease	NOUN	B
effects	O	NOUN	B
of	O	ADP	O
cirazoline	B-Chemical	NOUN	B
were	O	AUX	O
abolished	O	VERB	O
in	O	ADP	O
chronic	O	ADJ	B
prazosin	B-Chemical	NOUN	I
treated	O	ADJ	B
SHR	O	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
4	O	NUM	O
)	O	PUNCT	O
as	O	ADP	O
compared	O	VERB	B
to	O	PART	O
the	O	DET	O
untreated	O	ADJ	B
SHR	O	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
4	O	NUM	O
).	O	PUNCT	O
On	O	ADP	O
the	O	DET	O
other	O	ADJ	O
hand	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
pressor	O	ADJ	B
effects	O	NOUN	B
of	O	ADP	O
Abbott-53693	B-Chemical	PROPN	B
were	O	AUX	O
similar	O	ADJ	O
in	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
of	O	ADP	O
SHR	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
the	O	DET	O
accompanying	O	VERB	O
bradycardia	B-Disease	NOUN	B
was	O	AUX	O
greater	O	ADJ	O
in	O	ADP	O
SHR	O	NOUN	B
with	O	ADP	O
chronic	O	ADJ	B
prazosin	B-Chemical	NOUN	I
treatment	O	NOUN	B
than	O	ADP	O
without	O	ADP	O
such	O	ADJ	O
treatment	O	NOUN	B
.	O	PUNCT	O


Furthermore	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
bradycardia	B-Disease	NOUN	B
that	O	PRON	O
accompanied	O	VERB	O
the	O	DET	O
noradrenaline	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
pressor	O	NOUN	B
effect	O	NOUN	O
in	O	ADP	O
SHR	O	NOUN	B
was	O	AUX	O
similar	O	ADJ	O
with	O	ADP	O
and	O	CCONJ	O
without	O	ADP	O
chronic	O	ADJ	B
prazosin	B-Chemical	NOUN	I


Coexistence	O	NOUN	B
of	O	ADP	O
cerebral	B-Disease	ADJ	B
venous	I-Disease	ADJ	B
sinus	I-Disease	NOUN	I
and	I-Disease	CCONJ	O
internal	I-Disease	ADJ	B
carotid	I-Disease	NOUN	I
artery	I-Disease	NOUN	I
thrombosis	I-Disease	NOUN	I
associated	O	VERB	B
with	O	ADP	I
exogenous	O	ADJ	B
sex	O	NOUN	B
hormones	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
case	O	NOUN	B
report	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
forty	O	NUM	B
-	O	PUNCT	O
six	O	NUM	B
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
premenopausal	O	ADJ	B
woman	O	NOUN	B
developed	O	VERB	O
headache	B-Disease	NOUN	B
,	O	PUNCT	O
nausea	B-Disease	NOUN	B
and	O	CCONJ	O
vomiting	B-Disease	NOUN	B
,	O	PUNCT	O
left	O	VERB	B
hemiparesis	B-Disease	NOUN	I
and	O	CCONJ	O
seizure	B-Disease	VERB	B
two	O	NUM	O
days	O	NOUN	B
after	O	ADP	O
parenteral	O	ADJ	B
use	O	NOUN	O
of	O	ADP	O
progesterone	B-Chemical	NOUN	B
and	O	CCONJ	O
estradiol	B-Chemical	NOUN	B
.	O	PUNCT	O


Diabetes	B-Disease	NOUN	B
mellitus	I-Disease	NOUN	I
(	O	PUNCT	O
DM	B-Disease	NOUN	B
)	O	PUNCT	O
was	O	AUX	O
found	O	VERB	O
during	O	ADP	O
admission	O	NOUN	B
.	O	PUNCT	O


Computed	O	ADJ	B
tomography	O	NOUN	I
showed	O	VERB	O
a	O	DET	O
hemorrhagic	B-Disease	ADJ	B
infarct	I-Disease	NOUN	I
in	O	ADP	O
the	O	DET	O
right	O	ADJ	B
frontal	O	ADJ	I
lobe	O	NOUN	I
and	O	CCONJ	O
increased	O	VERB	B
density	O	NOUN	B
in	O	ADP	O
the	O	DET	O
superior	O	ADJ	B
sagittal	O	ADJ	O
sinus	O	NOUN	O
(	O	PUNCT	O
SSS	O	PROPN	B
).	O	ADJ	O
Left	O	ADJ	B
carotid	O	NOUN	I
angiography	O	NOUN	I
found	O	VERB	O
occlusion	B-Disease	NOUN	B
of	I-Disease	ADP	O
the	I-Disease	DET	O
left	I-Disease	ADJ	B
internal	I-Disease	ADJ	I
carotid	I-Disease	NOUN	I
artery	I-Disease	NOUN	I
(	O	PUNCT	O
ICA	O	PROPN	B
).	O	ADJ	O
Right	O	ADJ	B
carotid	O	NOUN	I
angiograms	O	NOUN	I
failed	O	VERB	B
to	O	PART	O
show	O	VERB	O
the	O	DET	O
SSS	O	PROPN	B
and	O	CCONJ	O
inferior	O	ADJ	B
sagittal	O	ADJ	I
sinus	O	NOUN	I
,	O	PUNCT	O
suggestive	O	ADJ	O
of	O	ADP	O
venous	B-Disease	ADJ	B
sinus	I-Disease	NOUN	I
thrombosis	I-Disease	NOUN	I
.	O	PUNCT	O


Coexistence	O	NOUN	B
of	O	ADP	O
the	O	DET	O
cerebral	B-Disease	ADJ	B
artery	I-Disease	NOUN	I
and	I-Disease	CCONJ	O
the	I-Disease	DET	O
venous	I-Disease	ADJ	B
sinus	I-Disease	NOUN	I
occlusion	I-Disease	NOUN	I
has	O	AUX	O
been	O	AUX	O
described	O	VERB	O
infrequently	O	ADV	O
.	O	PUNCT	O


In	O	ADP	O
this	O	DET	O
case	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
authors	O	NOUN	B
postulate	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
use	O	NOUN	O
of	O	ADP	O
estradiol	B-Chemical	NOUN	B
and	O	CCONJ	O
progesterone	B-Chemical	NOUN	B
and	O	CCONJ	O
the	O	DET	O
underlying	O	ADJ	O
DM	B-Disease	NOUN	B
increased	O	VERB	B
vascular	O	ADJ	B
thrombogenicity	O	NOUN	I
,	O	PUNCT	O
which	O	DET	O
provided	O	VERB	O
a	O	DET	O
common	O	ADJ	O
denominator	O	NOUN	B
for	O	ADP	O
thrombosis	B-Disease	NOUN	B
of	I-Disease	ADP	O
both	I-Disease	CCONJ	O
the	I-Disease	DET	O
ICA	I-Disease	NOUN	B
and	I-Disease	CCONJ	O
the	I-Disease	DET	O
venous	I-Disease	ADJ	B
sinus	I-Disease	NOUN	I


Chloroquine	B-Chemical	NOUN	B
related	O	VERB	O
complete	O	ADJ	O
heart	B-Disease	NOUN	B
block	I-Disease	NOUN	I
with	O	ADP	O
blindness	B-Disease	NOUN	B
:	O	PUNCT	O
case	O	NOUN	B
report	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
27	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
old	O	ADJ	B
African	O	ADJ	B
woman	O	NOUN	I
with	O	ADP	O
history	O	NOUN	B
of	O	ADP	O
regular	O	ADJ	O
chloroquine	B-Chemical	NOUN	B
ingestion	O	NOUN	B
presented	O	VERB	O
with	O	ADP	O
progressive	O	ADJ	B
deterioration	B-Disease	NOUN	B
of	I-Disease	ADP	O
vision	I-Disease	NOUN	B
,	O	PUNCT	O
easy	O	ADJ	O
fatiguability	B-Disease	NOUN	B
,	O	PUNCT	O
dyspnoea	B-Disease	NOUN	B
,	O	PUNCT	O
dizziness	B-Disease	ADJ	B
progressing	O	VERB	O
to	O	ADP	O
syncopal	B-Disease	NOUN	B
attacks	I-Disease	NOUN	B
.	O	PUNCT	O


Ophthalmological	O	ADJ	B
assessment	O	NOUN	I
revealed	O	VERB	O
features	O	NOUN	B
of	O	ADP	O
chloroquine	B-Chemical	NOUN	B
retinopathy	B-Disease	NOUN	I
,	O	PUNCT	O
cardiac	O	ADJ	B
assessment	O	NOUN	I
revealed	O	VERB	O
features	O	NOUN	B
of	O	ADP	O
heart	B-Disease	NOUN	B
failure	I-Disease	NOUN	I
and	O	CCONJ	O
a	O	DET	O
complete	O	ADJ	O
heart	B-Disease	NOUN	B
block	I-Disease	NOUN	I
with	O	ADP	O
right	B-Disease	ADJ	B
bundle	I-Disease	NOUN	I
branch	I-Disease	NOUN	I
block	I-Disease	NOUN	I
pattern	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
heart	B-Disease	NOUN	B
block	I-Disease	NOUN	I
was	O	AUX	O
treated	O	VERB	B
by	O	ADP	O
pacemaker	O	NOUN	B
insertion	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
heart	B-Disease	NOUN	B
failure	I-Disease	NOUN	I
resolved	O	VERB	B
spontaneously	O	ADV	B
following	O	VERB	O
chloroquine	B-Chemical	NOUN	B
discontinuation	O	NOUN	B
.	O	PUNCT	O


She	O	PRON	O
however	O	ADV	O
remains	O	VERB	O
blind	B-Disease	ADJ	B


Systemic	O	ADJ	B
toxicity	B-Disease	NOUN	B
and	O	CCONJ	O
resuscitation	O	NOUN	B
in	O	ADP	O
bupivacaine	B-Chemical	NOUN	B
-,	O	NOUN	O
levobupivacaine	B-Chemical	NOUN	B
-,	O	NOUN	O
or	O	CCONJ	O
ropivacaine	B-Chemical	NOUN	B
-	O	PUNCT	O
infused	O	VERB	B
rats	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
compared	O	VERB	B
the	O	DET	O
systemic	O	ADJ	B
toxicity	B-Disease	NOUN	B
of	O	ADP	O
bupivacaine	B-Chemical	NOUN	B
,	O	PUNCT	O
levobupivacaine	B-Chemical	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
ropivacaine	B-Chemical	NOUN	B
in	O	ADP	O
anesthetized	O	ADJ	B
rats	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
also	O	ADV	O
compared	O	VERB	O
the	O	DET	O
ability	O	NOUN	O
to	O	PART	O
resuscitate	O	VERB	B
rats	O	NOUN	B
after	O	ADP	O
lethal	O	ADJ	B
doses	O	NOUN	I
of	O	ADP	O
these	O	DET	O
local	O	ADJ	B
anesthetics	O	NOUN	I
.	O	PUNCT	O


Bupivacaine	B-Chemical	NOUN	B
,	O	PUNCT	O
levobupivacaine	B-Chemical	NOUN	B
,	O	PUNCT	O
or	O	CCONJ	O
ropivacaine	B-Chemical	NOUN	B
was	O	AUX	O
infused	O	VERB	B
at	O	ADP	O
a	O	DET	O
rate	O	NOUN	B
of	O	ADP	O
2	O	NUM	O
mg	O	NOUN	O
.	O	PUNCT	O


kg	O	NOUN	O
(-	O	PUNCT	O
1	O	NUM	O
).	O	ADJ	O
min	O	NOUN	O
(-	O	PUNCT	O
1	O	NUM	O
)	O	PUNCT	O
while	O	SCONJ	O
electrocardiogram	O	NOUN	B
,	O	PUNCT	O
electroencephalogram	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
arterial	O	ADJ	B
pressure	O	NOUN	I
were	O	AUX	O
continuously	O	ADV	O
monitored	O	VERB	B
.	O	PUNCT	O


When	O	SCONJ	O
asystole	B-Disease	NOUN	B
was	O	AUX	O
recorded	O	VERB	O
,	O	PUNCT	O
drug	O	NOUN	B
infusion	O	NOUN	I
was	O	AUX	O
stopped	O	VERB	B
and	O	CCONJ	O
a	O	DET	O
resuscitation	O	NOUN	B
sequence	O	NOUN	I
was	O	AUX	O
begun	O	VERB	O
.	O	PUNCT	O


Epinephrine	B-Chemical	NOUN	B
0	O	NUM	O
.	O	PUNCT	O


01	O	NUM	O
mg	O	NOUN	O
/	O	PUNCT	O
kg	O	NOUN	B
was	O	AUX	O
administered	O	VERB	B
at	O	ADP	O
1	O	NUM	O
-	O	PUNCT	O
min	O	NOUN	B
intervals	O	NOUN	B
while	O	SCONJ	O
external	O	ADJ	B
cardiac	O	ADJ	B
compressions	O	NOUN	I
were	O	AUX	O
applied	O	VERB	O
.	O	PUNCT	O


Resuscitation	O	NOUN	B
was	O	AUX	O
considered	O	VERB	O
successful	O	ADJ	O
when	O	SCONJ	O
a	O	DET	O
systolic	O	NOUN	B
arterial	O	ADJ	I
pressure	O	NOUN	I
>	O	NOUN	O
or	O	CCONJ	O
=	O	ADJ	O
100	O	NUM	O
mm	O	X	B
Hg	O	NOUN	I
was	O	AUX	O
achieved	O	VERB	O
within	O	ADP	O
5	O	NUM	O
min	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
cumulative	O	ADJ	B
doses	O	NOUN	B
of	O	ADP	O
levobupivacaine	B-Chemical	NOUN	B
and	O	CCONJ	O
ropivacaine	B-Chemical	NOUN	B
that	O	PRON	O
produced	O	VERB	O
seizures	B-Disease	NOUN	B
were	O	AUX	O
similar	O	ADJ	O
and	O	CCONJ	O
were	O	AUX	O
larger	O	ADJ	O
than	O	ADP	O
those	O	DET	O
of	O	ADP	O
bupivacaine	B-Chemical	NOUN	B
.	O	PUNCT	O


The	O	DET	O
cumulative	O	ADJ	B
doses	O	NOUN	B
of	O	ADP	O
levobupivacaine	B-Chemical	NOUN	B
that	O	PRON	O
produced	O	VERB	O
dysrhythmias	B-Disease	NOUN	B
and	O	CCONJ	O
asystole	B-Disease	NOUN	B
were	O	AUX	O
smaller	O	ADJ	O
than	O	ADP	O
the	O	DET	O
corresponding	O	ADJ	O
doses	O	NOUN	B
of	O	ADP	O
ropivacaine	B-Chemical	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
they	O	PRON	O
were	O	AUX	O
larger	O	ADJ	O
than	O	ADP	O
those	O	DET	O
of	O	ADP	O
bupivacaine	B-Chemical	NOUN	B
.	O	PUNCT	O


The	O	DET	O
number	O	NOUN	O
of	O	ADP	O
successful	O	ADJ	O
resuscitations	O	NOUN	B
did	O	AUX	O
not	O	PART	O
differ	O	VERB	O
among	O	ADP	O
groups	O	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
a	O	DET	O
smaller	O	ADJ	O
dose	O	NOUN	B
of	O	ADP	O
epinephrine	B-Chemical	NOUN	B
was	O	AUX	O
required	O	VERB	O
in	O	ADP	O
the	O	DET	O
Ropivacaine	B-Chemical	NOUN	B
group	O	NOUN	B
than	O	ADP	O
in	O	ADP	O
the	O	DET	O
other	O	ADJ	O
groups	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
conclude	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
systemic	O	ADJ	B
toxicity	B-Disease	NOUN	B
of	O	ADP	O
levobupivacaine	B-Chemical	NOUN	B
is	O	AUX	O
intermediate	O	ADJ	B
between	O	ADP	O
that	O	DET	O
of	O	ADP	O
ropivacaine	B-Chemical	NOUN	B
and	O	CCONJ	O
bupivacaine	B-Chemical	NOUN	B
when	O	SCONJ	O
administered	O	VERB	B
at	O	ADP	O
the	O	DET	O
same	O	ADJ	O
rate	O	NOUN	B
and	O	CCONJ	O
that	O	SCONJ	O
ropivacaine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
cardiac	B-Disease	ADJ	B
arrest	I-Disease	NOUN	I
appears	O	VERB	O
to	O	PART	O
be	O	AUX	O
more	O	ADV	O
susceptible	O	ADJ	B
to	O	PART	O
treatment	O	NOUN	B
than	O	ADP	O
that	O	DET	O
induced	O	VERB	B
by	O	ADP	O
bupivacaine	B-Chemical	NOUN	B
or	O	CCONJ	O
levobupivacaine	B-Chemical	NOUN	B


22-oxacalcitriol	B-Chemical	NOUN	B
suppresses	O	VERB	B
secondary	B-Disease	ADJ	B
hyperparathyroidism	I-Disease	NOUN	I
without	O	ADP	O
inducing	O	VERB	B
low	B-Disease	ADJ	B
bone	I-Disease	NOUN	B
turnover	I-Disease	NOUN	B
in	O	ADP	O
dogs	O	NOUN	B
with	O	ADP	O
renal	B-Disease	ADJ	B
failure	I-Disease	NOUN	I
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
:	O	PUNCT	O
Calcitriol	B-Chemical	NOUN	B
therapy	O	NOUN	I
suppresses	O	VERB	B
serum	O	NOUN	B
levels	O	NOUN	I
of	O	ADP	O
parathyroid	O	ADJ	B
hormone	O	NOUN	I
(	O	PUNCT	O
PTH	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
renal	B-Disease	ADJ	B
failure	I-Disease	NOUN	I
but	O	CCONJ	O
has	O	AUX	O
several	O	ADJ	O
drawbacks	O	NOUN	B
,	O	PUNCT	O
including	O	VERB	O
hypercalcemia	B-Disease	NOUN	B
and	O	CCONJ	O
/	O	SYM	O
or	O	CCONJ	O
marked	O	ADJ	O
suppression	B-Disease	NOUN	B
of	I-Disease	ADP	O
bone	I-Disease	NOUN	B
turnover	I-Disease	NOUN	B
,	O	PUNCT	O
which	O	DET	O
may	O	AUX	O
lead	O	VERB	O
to	O	PART	O
adynamic	B-Disease	ADJ	B
bone	I-Disease	NOUN	I
disease	I-Disease	NOUN	I
.	O	PUNCT	O


A	O	DET	O
new	O	ADJ	O
vitamin	B-Chemical	NOUN	B
D	I-Chemical	NOUN	I
analogue	O	NOUN	I
,	O	PUNCT	O
22-oxacalcitriol	B-Chemical	NOUN	B
(	O	PUNCT	O
OCT	B-Chemical	NOUN	B
),	O	PUNCT	O
has	O	AUX	O
been	O	AUX	O
shown	O	VERB	O
to	O	PART	O
have	O	AUX	O
promising	O	ADJ	O
characteristics	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
study	O	NOUN	B
was	O	AUX	O
undertaken	O	VERB	O
to	O	PART	O
determine	O	VERB	O
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	O
OCT	B-Chemical	NOUN	B
on	O	ADP	O
serum	O	NOUN	B
PTH	O	NOUN	B
levels	O	NOUN	B
and	O	CCONJ	O
bone	O	NOUN	B
turnover	O	NOUN	B
in	O	ADP	O
states	O	NOUN	B
of	O	ADP	O
normal	O	ADJ	B
or	O	CCONJ	O
impaired	B-Disease	ADJ	B
renal	I-Disease	ADJ	I
function	I-Disease	NOUN	I
.	O	PUNCT	O


METHODS	O	NOUN	O
:	O	PUNCT	O
Sixty	O	NUM	O
dogs	O	NOUN	B
were	O	AUX	O
either	O	CCONJ	O
nephrectomized	O	ADJ	B
(	O	PUNCT	O
Nx	O	NOUN	B
,	O	PUNCT	O
N	O	NOUN	O
=	O	ADJ	O
38	O	NUM	O
)	O	PUNCT	O
or	O	CCONJ	O
sham	O	NOUN	B
-	O	PUNCT	O
operated	O	VERB	B
(	O	PUNCT	O
Sham	O	PROPN	B
,	O	PUNCT	O
N	O	NOUN	O
=	O	ADJ	O
22	O	NUM	O
).	O	PUNCT	O
The	O	DET	O
animals	O	NOUN	B
received	O	VERB	O
supplemental	O	ADJ	B
phosphate	B-Chemical	NOUN	I
to	O	PART	O
enhance	O	VERB	O
PTH	O	NOUN	B
secretion	O	NOUN	B
.	O	PUNCT	O


Fourteen	O	NUM	O
weeks	O	NOUN	B
after	O	ADP	O
the	O	DET	O
start	O	NOUN	O
of	O	ADP	O
phosphate	B-Chemical	NOUN	B
supplementation	O	NOUN	B
,	O	PUNCT	O
half	O	NOUN	O
of	O	ADP	O
the	O	DET	O
Nx	O	NOUN	B
and	O	CCONJ	O
Sham	O	NOUN	B
dogs	O	NOUN	B
received	O	VERB	O
doses	O	NOUN	B
of	O	ADP	O
OCT	B-Chemical	NOUN	B
(	O	PUNCT	O
three	O	NUM	O
times	O	NOUN	O
per	O	ADP	O
week	O	NOUN	B
);	O	ADJ	O
the	O	DET	O
other	O	ADJ	O
half	O	NOUN	O
were	O	AUX	O
given	O	VERB	O
vehicle	O	NOUN	B
for	O	ADP	O
60	O	NUM	O
weeks	O	NOUN	B
.	O	PUNCT	O


Thereafter	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
treatment	O	NOUN	B
modalities	O	NOUN	B
for	O	ADP	O
a	O	DET	O
subset	O	NOUN	O
of	O	ADP	O
animals	O	NOUN	B
were	O	AUX	O
crossed	O	VERB	O
over	O	ADP	O
for	O	ADP	O
an	O	DET	O
additional	O	ADJ	O
eight	O	NUM	O
months	O	NOUN	B
.	O	PUNCT	O


Biochemical	O	ADJ	B
and	O	CCONJ	O
hormonal	O	ADJ	B
indices	O	NOUN	I
of	O	ADP	O
calcium	B-Chemical	NOUN	B
and	O	CCONJ	O
bone	O	NOUN	B
metabolism	O	NOUN	I
were	O	AUX	O
measured	O	VERB	B
throughout	O	ADP	O
the	O	DET	O
study	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
bone	O	NOUN	B
biopsies	O	NOUN	I
were	O	AUX	O
done	O	VERB	O
at	O	ADP	O
baseline	O	NOUN	B
,	O	PUNCT	O
60	O	NUM	O
weeks	O	NOUN	B
after	O	ADP	O
OCT	B-Chemical	NOUN	B
or	O	CCONJ	O
vehicle	O	NOUN	B
treatment	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
at	O	ADP	O
the	O	DET	O
end	O	NOUN	O
of	O	ADP	O
the	O	DET	O
crossover	O	NOUN	B
period	O	NOUN	O
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
In	O	ADP	O
Nx	O	NOUN	O
dogs	O	NOUN	B
,	O	PUNCT	O
OCT	B-Chemical	NOUN	B
significantly	O	ADV	O
decreased	O	VERB	B
serum	O	NOUN	B
PTH	O	NOUN	B
levels	O	NOUN	B
soon	O	ADV	O
after	O	ADP	O
the	O	DET	O
induction	O	NOUN	B
of	O	ADP	O
renal	B-Disease	ADJ	B
insufficiency	I-Disease	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
long	O	ADV	B
-	O	PUNCT	O
standing	O	VERB	B
secondary	B-Disease	ADJ	B
hyperparathyroidism	I-Disease	NOUN	I
,	O	PUNCT	O
OCT	B-Chemical	NOUN	B
(	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


03	O	NUM	O
microg	O	NOUN	B
/	O	SYM	O
kg	O	NOUN	B
)	O	PUNCT	O
stabilized	O	VERB	B
serum	O	NOUN	B
PTH	O	NOUN	B
levels	O	NOUN	B
during	O	ADP	O
the	O	DET	O
first	O	ADJ	O
months	O	NOUN	B
.	O	PUNCT	O


Serum	O	NOUN	B
PTH	O	NOUN	B
levels	O	NOUN	B
rose	O	VERB	O
thereafter	O	ADV	O
,	O	PUNCT	O
but	O	CCONJ	O
the	O	DET	O
rise	O	NOUN	O
was	O	AUX	O
less	O	ADV	O
pronounced	O	ADJ	O
compared	O	VERB	B
with	O	ADP	O
baseline	O	NOUN	B
than	O	ADP	O
the	O	DET	O
rise	O	NOUN	O
seen	O	VERB	O
in	O	ADP	O
Nx	O	NOUN	O
control	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
effects	O	NOUN	B
were	O	AUX	O
accompanied	O	VERB	O
by	O	ADP	O
episodes	O	NOUN	B
of	O	ADP	O
hypercalcemia	B-Disease	NOUN	B
and	O	CCONJ	O
hyperphosphatemia	B-Disease	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
animals	O	NOUN	B
with	O	ADP	O
normal	O	ADJ	B
renal	O	ADJ	I
function	O	NOUN	I
,	O	PUNCT	O
OCT	B-Chemical	NOUN	B
induced	O	VERB	B
a	O	DET	O
transient	O	ADJ	B
decrease	O	NOUN	B
in	O	ADP	O
serum	O	NOUN	B
PTH	O	NOUN	B
levels	O	NOUN	B
at	O	ADP	O
a	O	DET	O
dose	O	NOUN	B
of	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
microg	O	NOUN	B
/	O	SYM	O
kg	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
was	O	AUX	O
not	O	PART	O
sustained	O	ADJ	O
with	O	ADP	O
lowering	O	NOUN	B
of	O	ADP	O
the	O	DET	O
doses	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
Nx	O	NOUN	O
dogs	O	NOUN	B
,	O	PUNCT	O
OCT	B-Chemical	NOUN	B
reversed	O	VERB	O
abnormal	O	ADJ	B
bone	O	NOUN	B
formation	O	NOUN	I
,	O	PUNCT	O
such	O	ADJ	O
as	O	ADP	O
woven	B-Disease	ADJ	O
osteoid	I-Disease	NOUN	B
and	O	CCONJ	O
fibrosis	B-Disease	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
did	O	AUX	O
not	O	PART	O
significantly	O	ADV	O
alter	O	VERB	O
the	O	DET	O
level	O	NOUN	B
of	O	ADP	O
bone	O	NOUN	B
turnover	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
,	O	PUNCT	O
OCT	B-Chemical	NOUN	B
improved	O	VERB	O
mineralization	O	NOUN	B
lag	O	NOUN	B
time	O	NOUN	I
,(	O	PUNCT	O
that	O	ADV	O
is	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
rate	O	NOUN	B
at	O	ADP	O
which	O	DET	O
osteoid	O	NOUN	B
mineralizes	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
both	O	CCONJ	O
Nx	O	NOUN	B
and	O	CCONJ	O
Sham	O	NOUN	B
dogs	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
:	O	PUNCT	O
These	O	DET	O
results	O	NOUN	B
indicate	O	VERB	O
that	O	SCONJ	O
even	O	ADV	O
though	O	SCONJ	O
OCT	B-Chemical	NOUN	B
does	O	AUX	O
not	O	PART	O
completely	O	ADV	O
prevent	O	VERB	B
the	O	DET	O
occurrence	O	NOUN	B
of	O	ADP	O
hypercalcemia	B-Disease	NOUN	B
in	O	ADP	O
experimental	O	ADJ	B
dogs	O	NOUN	B
with	O	ADP	O
renal	B-Disease	ADJ	B
insufficiency	I-Disease	NOUN	I
,	O	PUNCT	O
it	O	PRON	O
may	O	AUX	O
be	O	AUX	O
of	O	ADP	O
use	O	NOUN	O
in	O	ADP	O
the	O	DET	O
management	O	NOUN	B
of	O	ADP	O
secondary	B-Disease	ADJ	B
hyperparathyroidism	I-Disease	NOUN	I
because	O	SCONJ	O
it	O	PRON	O
does	O	AUX	O
not	O	PART	O
induce	O	VERB	B
low	B-Disease	ADJ	B
bone	I-Disease	NOUN	B
turnover	I-Disease	NOUN	B
and	O	CCONJ	O
,	O	PUNCT	O
therefore	O	ADV	O
,	O	PUNCT	O
does	O	AUX	O
not	O	PART	O
increase	O	VERB	B
the	O	DET	O
risk	O	NOUN	B
of	O	ADP	O
adynamic	B-Disease	ADJ	B
bone	I-Disease	NOUN	I
disease	I-Disease	NOUN	I


Chemotherapy	O	NOUN	B
of	O	ADP	O
advanced	O	ADJ	B
inoperable	O	ADJ	O
non-small	B-Disease	NOUN	O
cell	I-Disease	NOUN	O
lung	I-Disease	NOUN	O
cancer	I-Disease	NOUN	O
with	O	ADP	O
paclitaxel	B-Chemical	NOUN	B
:	O	PUNCT	O
a	O	DET	O
phase	O	NOUN	B
II	O	NUM	I
trial	O	NOUN	I
.	O	PUNCT	O


Paclitaxel	B-Chemical	NOUN	B
(	O	PUNCT	O
Taxol	B-Chemical	PROPN	B
;	O	PUNCT	O
Bristol	O	PROPN	B
-	O	PUNCT	O
Myers	O	PROPN	B
Squibb	O	PROPN	I
Company	O	PROPN	I
,	O	PUNCT	O
Princeton	O	PROPN	B
,	O	PUNCT	O
NJ	O	PROPN	B
)	O	PUNCT	O
has	O	AUX	O
demonstrated	O	VERB	O
significant	O	ADJ	O
antineoplastic	O	ADJ	B
activity	O	NOUN	I
against	O	ADP	O
different	O	ADJ	O
tumor	B-Disease	NOUN	B
types	O	NOUN	I
,	O	PUNCT	O
notably	O	ADV	O
ovarian	B-Disease	ADJ	B
and	I-Disease	CCONJ	O
breast	I-Disease	NOUN	B
carcinoma	I-Disease	NOUN	I
.	O	PUNCT	O


Two	O	NUM	O
phase	O	NOUN	B
II	O	NUM	I
trials	O	NOUN	I
of	O	ADP	O
24	O	NUM	O
-	O	PUNCT	O
hour	O	NOUN	B
paclitaxel	B-Chemical	NOUN	B
infusions	O	NOUN	B
in	O	ADP	O
chemotherapy	O	NOUN	B
-	O	PUNCT	O
naive	O	ADJ	B
patients	O	NOUN	B
with	O	ADP	O
stage	O	NOUN	B
IIIB	O	NOUN	I
or	O	CCONJ	O
IV	O	NUM	B
non-small	B-Disease	NOUN	I
cell	I-Disease	NOUN	I
lung	I-Disease	NOUN	I
cancer	I-Disease	NOUN	I
(	O	PUNCT	O
NSCLC	B-Disease	NOUN	B
)	O	PUNCT	O
reported	O	VERB	O
response	O	NOUN	B
rates	O	NOUN	I
of	O	ADP	O
21	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
24	O	NUM	O
%.	O	NOUN	O
Leukopenia	B-Disease	NOUN	B
was	O	AUX	O
dose	O	NOUN	B
limiting	O	VERB	O
:	O	PUNCT	O
as	O	ADV	O
many	O	ADJ	O
as	O	ADP	O
62	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
experienced	O	VERB	O
grade	O	NOUN	B
4	O	NUM	I
leukopenia	B-Disease	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
investigated	O	VERB	B
the	O	DET	O
efficacy	O	NOUN	B
and	O	CCONJ	O
toxicity	B-Disease	NOUN	B
of	O	ADP	O
a	O	DET	O
3	O	NUM	B
-	O	PUNCT	O
hour	O	NOUN	B
paclitaxel	B-Chemical	NOUN	B
infusion	O	NOUN	B
in	O	ADP	O
a	O	DET	O
phase	O	NOUN	B
II	O	NUM	I
trial	O	NOUN	I
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
inoperable	O	ADJ	B
stage	O	NOUN	I
IIIB	O	NOUN	I
or	O	CCONJ	O
IV	O	NUM	B
NSCLC	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
58	O	NUM	O
patients	O	NOUN	B
treated	O	VERB	B
(	O	PUNCT	O
41	O	NUM	O
men	O	NOUN	B
and	O	CCONJ	O
17	O	NUM	O
women	O	NOUN	B
)	O	PUNCT	O
had	O	AUX	O
a	O	DET	O
median	O	ADJ	O
age	O	NOUN	B
of	O	ADP	O
59	O	NUM	O
years	O	NOUN	B
(	O	PUNCT	O
age	O	NOUN	B
range	O	NOUN	O
,	O	PUNCT	O
25	O	NUM	O
to	O	PART	O
75	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
performance	O	NOUN	B
status	O	NOUN	O
of	O	ADP	O
0	O	NUM	O
through	O	ADP	O
2	O	NUM	O
.	O	PUNCT	O


Most	O	ADJ	O
patients	O	NOUN	B
(	O	PUNCT	O
72	O	NUM	O
.	O	PUNCT	O


4	O	NUM	O
%)	O	NOUN	O
had	O	AUX	O
stage	O	NOUN	B
IV	O	NUM	I
NSCLC	B-Disease	NOUN	B
.	O	PUNCT	O


Paclitaxel	B-Chemical	NOUN	B
225	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
m2	O	NOUN	B
was	O	AUX	O
infused	O	VERB	B
over	O	ADP	O
3	O	NUM	O
hours	O	NOUN	B
every	O	DET	O
3	O	NUM	O
weeks	O	NOUN	B
with	O	ADP	O
standard	O	ADJ	B
prophylactic	O	ADJ	B
premedication	O	NOUN	I
.	O	PUNCT	O


Of	O	ADP	O
50	O	NUM	O
patients	O	NOUN	B
evaluable	O	ADJ	O
for	O	ADP	O
response	O	NOUN	B
,	O	PUNCT	O
12	O	NUM	O
(	O	PUNCT	O
24	O	NUM	O
%)	O	NOUN	O
had	O	AUX	O
partial	O	ADJ	B
remission	O	NOUN	I
,	O	PUNCT	O
26	O	NUM	O
(	O	PUNCT	O
52	O	NUM	O
%)	O	NOUN	O
had	O	AUX	O
no	O	DET	O
change	O	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
12	O	NUM	O
had	O	AUX	O
disease	O	NOUN	B
progression	O	NOUN	I
(	O	PUNCT	O
24	O	NUM	O
%).	O	ADJ	O
Hematologic	O	ADJ	B
toxicities	B-Disease	NOUN	B
were	O	AUX	O
mild	O	ADJ	B
:	O	PUNCT	O
only	O	ADV	O
one	O	NUM	O
patient	O	NOUN	B
(	O	PUNCT	O
2	O	NUM	O
%)	O	NOUN	O
developed	O	VERB	O
grade	O	NOUN	B
3	O	NUM	I
or	O	CCONJ	O
4	O	NUM	O
neutropenia	B-Disease	NOUN	B
,	O	PUNCT	O
while	O	SCONJ	O
29	O	NUM	O
%	O	NOUN	O
had	O	AUX	O
grade	O	NOUN	O
1	O	NUM	O
or	O	CCONJ	O
2	O	NUM	O
.	O	PUNCT	O


Grade	O	NOUN	B
1	O	NUM	I
or	O	CCONJ	O
2	O	NUM	O
polyneuropathy	B-Disease	NOUN	B
affected	O	VERB	B
56	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
while	O	SCONJ	O
only	O	ADV	O
one	O	NUM	O
(	O	PUNCT	O
2	O	NUM	O
%)	O	NOUN	O
experienced	O	VERB	O
severe	O	ADJ	B
polyneuropathy	B-Disease	NOUN	B
.	O	PUNCT	O


Similarly	O	ADV	O
,	O	PUNCT	O
grade	O	NOUN	B
1	O	NUM	I
or	O	CCONJ	O
2	O	NUM	O
myalgia	B-Disease	NOUN	B
/	O	PUNCT	O
arthralgia	B-Disease	NOUN	B
was	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
63	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
only	O	ADV	O
14	O	NUM	O
.	O	PUNCT	O


3	O	NUM	O
%	O	NOUN	O
experienced	O	ADJ	O
grade	O	NOUN	B
3	O	NUM	I
or	O	CCONJ	O
4	O	NUM	O
.	O	PUNCT	O


Nausea	B-Disease	NOUN	B
and	O	CCONJ	O
vomiting	B-Disease	NOUN	B
were	O	AUX	O
infrequent	O	ADJ	B
,	O	PUNCT	O
with	O	ADP	O
14	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
experiencing	O	VERB	O
grade	O	NOUN	B
1	O	NUM	I
or	O	CCONJ	O
2	O	NUM	O
and	O	CCONJ	O
only	O	ADV	O
2	O	NUM	O
%	O	NOUN	O
experiencing	O	VERB	O
grade	O	NOUN	B
3	O	NUM	I
or	O	CCONJ	O
4	O	NUM	O
.	O	PUNCT	O


Paclitaxel	B-Chemical	NOUN	B
is	O	AUX	O
thus	O	ADV	O
an	O	DET	O
active	O	ADJ	B
single	O	ADJ	I
agent	O	NOUN	I
in	O	ADP	O
this	O	DET	O
patient	O	NOUN	B
population	O	NOUN	I
,	O	PUNCT	O
with	O	ADP	O
a	O	DET	O
3	O	NUM	B
-	O	PUNCT	O
hour	O	NOUN	B
infusion	O	NOUN	B
proving	O	VERB	O
comparably	O	ADV	O
effective	O	ADJ	B
to	O	PART	O
a	O	DET	O
24	O	NUM	B
-	O	PUNCT	O
hour	O	NOUN	B
infusion	O	NOUN	B
and	O	CCONJ	O
superior	O	ADJ	B
in	O	ADP	O
terms	O	NOUN	O
of	O	ADP	O
the	O	DET	O
incidence	O	NOUN	B
of	O	ADP	O
hematologic	O	ADJ	B
and	O	CCONJ	O
nonhematologic	O	ADJ	B
toxicity	B-Disease	NOUN	B
.	O	PUNCT	O


Further	O	ADJ	O
phase	O	NOUN	B
II	O	NUM	I
studies	O	NOUN	I
with	O	ADP	O
paclitaxel	B-Chemical	NOUN	B
combined	O	VERB	O
with	O	ADP	O
other	O	ADJ	O
drugs	O	NOUN	B
active	O	ADJ	B
against	O	ADP	O
NSCLC	B-Disease	NOUN	B
are	O	AUX	O
indicated	O	VERB	B
,	O	PUNCT	O
and	O	CCONJ	O
phase	O	NOUN	B
III	O	NUM	I
studies	O	NOUN	I
comparing	O	VERB	O
paclitaxel	B-Chemical	NOUN	B


Cerebral	B-Disease	ADJ	B
hemorrhage	I-Disease	NOUN	I
associated	O	VERB	B
with	O	ADP	I
phenylpropanolamine	B-Chemical	NOUN	B
in	O	ADP	O
combination	O	NOUN	B
with	O	ADP	O
caffeine	B-Chemical	NOUN	B
.	O	PUNCT	O


Phenylpropanolamine	B-Chemical	NOUN	B
(	O	PUNCT	O
PPA	B-Chemical	PROPN	B
)	O	PUNCT	O
is	O	AUX	O
a	O	DET	O
drug	O	NOUN	B
that	O	PRON	O
has	O	AUX	O
been	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
serious	O	ADJ	O
side	O	NOUN	B
effects	O	NOUN	I
including	O	VERB	O
stroke	B-Disease	NOUN	B
.	O	PUNCT	O


It	O	PRON	O
is	O	AUX	O
often	O	ADV	O
combined	O	VERB	O
with	O	ADP	O
caffeine	B-Chemical	NOUN	B
in	O	ADP	O
diet	O	NOUN	B
preparations	O	NOUN	I
and	O	CCONJ	O
"	O	PUNCT	O
look	O	NOUN	B
-	O	PUNCT	O
alike	O	ADJ	B
"	O	PUNCT	O
pills	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
order	O	NOUN	O
to	O	PART	O
determine	O	VERB	O
if	O	SCONJ	O
PPA	B-Chemical	PROPN	B
/	O	PUNCT	O
caffeine	B-Chemical	NOUN	B
can	O	AUX	O
lead	O	VERB	O
to	O	PART	O
stroke	B-Disease	NOUN	B
in	O	ADP	O
normotensive	O	ADJ	B
and	O	CCONJ	O
/	O	SYM	O
or	O	CCONJ	O
hypertensive	B-Disease	ADJ	B
rats	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
administered	O	VERB	B
the	O	DET	O
combination	O	NOUN	B
in	O	ADP	O
six	O	NUM	O
times	O	NOUN	O
the	O	DET	O
allowed	O	VERB	O
human	O	ADJ	B
dose	O	NOUN	B
calculated	O	VERB	B
on	O	ADP	O
a	O	DET	O
per	O	ADP	O
weight	O	NOUN	O
basis	O	NOUN	O
for	O	ADP	O
the	O	DET	O
rats	O	NOUN	B
two	O	NUM	O
times	O	NOUN	O
per	O	ADP	O
day	O	NOUN	B
for	O	ADP	O
five	O	NUM	O
days	O	NOUN	B
.	O	PUNCT	O


Subarachnoid	B-Disease	ADJ	B
and	I-Disease	CCONJ	O
cerebral	I-Disease	ADJ	B
hemorrhage	I-Disease	NOUN	I
was	O	AUX	O
noted	O	VERB	O
in	O	ADP	O
18	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
hypertensive	B-Disease	ADJ	B
rats	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
single	O	ADJ	O
PPA	B-Chemical	PROPN	B
/	O	SYM	O
caffeine	B-Chemical	NOUN	B
administration	O	NOUN	B
(	O	PUNCT	O
same	O	ADJ	O
dose	O	NOUN	B
)	O	PUNCT	O
lead	O	VERB	O
to	O	PART	O
acute	O	ADJ	B
hypertension	B-Disease	NOUN	I
in	O	ADP	O
both	O	CCONJ	O
the	O	DET	O
normotensive	O	ADJ	B
and	O	CCONJ	O
hypertensive	B-Disease	ADJ	B
animals	O	NOUN	I
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
PPA	B-Chemical	PROPN	B
/	O	SYM	O
caffeine	B-Chemical	NOUN	B
can	O	AUX	O
lead	O	VERB	O
to	O	PART	O
cerebral	B-Disease	ADJ	B
hemorrhage	I-Disease	NOUN	I
in	O	ADP	O
previously	O	ADV	O
hypertensive	B-Disease	ADJ	B


Long	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
efficacy	O	NOUN	B
and	O	CCONJ	O
toxicity	B-Disease	NOUN	B
of	O	ADP	O
high	O	ADJ	B
-	O	PUNCT	O
dose	O	NOUN	B
amiodarone	B-Chemical	NOUN	B
therapy	O	NOUN	I
for	O	ADP	O
ventricular	B-Disease	ADJ	B
tachycardia	I-Disease	NOUN	I
or	O	CCONJ	O
ventricular	B-Disease	ADJ	B
fibrillation	I-Disease	NOUN	I
.	O	PUNCT	O


Amiodarone	B-Chemical	NOUN	B
was	O	AUX	O
administered	O	VERB	B
to	O	PART	O
154	O	NUM	O
patients	O	NOUN	B
who	O	PRON	O
had	O	AUX	O
sustained	O	ADJ	B
,	O	PUNCT	O
symptomatic	O	ADJ	B
ventricular	B-Disease	ADJ	B
tachycardia	I-Disease	NOUN	I
(	O	PUNCT	I
VT	B-Disease	NOUN	B
)(	O	NOUN	O
n	O	NOUN	O
=	O	ADJ	O
118	O	NUM	O
)	O	PUNCT	O
or	O	CCONJ	O
a	O	DET	O
cardiac	B-Disease	ADJ	B
arrest	I-Disease	NOUN	I
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
36	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
who	O	PRON	O
were	O	AUX	O
refractory	O	ADJ	B
to	O	PART	O
conventional	O	ADJ	O
antiarrhythmic	O	ADJ	B
drugs	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
loading	O	NOUN	B
dose	O	NOUN	I
was	O	AUX	O
800	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
day	O	NOUN	B
for	O	ADP	O
6	O	NUM	O
weeks	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
maintenance	O	NOUN	B
dose	O	NOUN	I
was	O	AUX	O
600	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
day	O	NOUN	B
.	O	PUNCT	O


Sixty	O	NUM	B
-	O	PUNCT	O
nine	O	NUM	O
percent	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
continued	O	VERB	O
treatment	O	NOUN	B
with	O	ADP	O
amiodarone	B-Chemical	NOUN	B
and	O	CCONJ	O
had	O	AUX	O
no	O	DET	O
recurrence	O	NOUN	B
of	O	ADP	O
symptomatic	O	ADJ	B
VT	B-Disease	NOUN	B
or	O	CCONJ	O
ventricular	B-Disease	ADJ	B
fibrillation	I-Disease	NOUN	I
(	O	PUNCT	O
VF	B-Disease	PROPN	B
)	O	PUNCT	O
over	O	ADP	O
a	O	DET	O
follow	O	NOUN	B
-	O	PUNCT	O
up	O	NOUN	O
of	O	ADP	O
6	O	NUM	O
to	O	PART	O
52	O	NUM	O
months	O	NOUN	B
(	O	PUNCT	O
mean	O	NOUN	O
+/-	O	CCONJ	O
standard	O	ADJ	B
deviation	O	NOUN	I
14	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
+/-	O	CCONJ	O
8	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
).	O	PUNCT	O
Six	O	NUM	O
percent	O	NOUN	O
of	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
had	O	AUX	O
a	O	DET	O
nonfatal	O	ADJ	B
recurrence	O	NOUN	I
of	O	ADP	O
VT	B-Disease	NOUN	B
and	O	CCONJ	O
were	O	AUX	O
successfully	O	ADV	O
managed	O	VERB	O
by	O	ADP	O
continuing	O	VERB	O
amiodarone	B-Chemical	NOUN	B
at	O	ADP	O
a	O	DET	O
higher	O	ADJ	B
dose	O	NOUN	B
or	O	CCONJ	O
by	O	ADP	O
the	O	DET	O
addition	O	NOUN	O
of	O	ADP	O
a	O	DET	O
conventional	O	ADJ	B
antiarrhythmic	O	ADJ	B
drug	O	NOUN	I
.	O	PUNCT	O


One	O	NUM	O
or	O	CCONJ	O
more	O	ADV	O
adverse	O	ADJ	B
drug	O	NOUN	I
reactions	O	NOUN	I
occurred	O	VERB	O
in	O	ADP	O
51	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
.	O	PUNCT	O


Adverse	O	ADJ	B
effects	O	NOUN	I
forced	O	VERB	O
a	O	DET	O
reduction	O	NOUN	B
in	O	ADP	O
the	O	DET	O
dose	O	NOUN	B
of	O	ADP	O
amiodarone	B-Chemical	NOUN	B
in	O	ADP	O
41	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
discontinuation	O	NOUN	B
of	O	ADP	O
amiodarone	B-Chemical	NOUN	B
in	O	ADP	O
10	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
most	O	ADV	O
common	O	ADJ	O
symptomatic	O	ADJ	B
adverse	O	ADJ	B
reactions	O	NOUN	I
were	O	AUX	O
tremor	B-Disease	NOUN	B
or	O	CCONJ	O
ataxia	B-Disease	NOUN	B
(	O	PUNCT	O
35	O	NUM	O
%),	O	ADJ	O
nausea	B-Disease	ADJ	B
and	O	CCONJ	O
anorexia	B-Disease	NOUN	B
(	O	PUNCT	O
8	O	NUM	O
%),	O	ADJ	O
visual	B-Disease	ADJ	B
halos	I-Disease	NOUN	I
or	I-Disease	CCONJ	O
blurring	I-Disease	NOUN	B
(	O	PUNCT	O
6	O	NUM	O
%),	O	ADJ	O
thyroid	B-Disease	NOUN	B
function	I-Disease	NOUN	I
abnormalities	I-Disease	NOUN	I
(	O	PUNCT	O
6	O	NUM	O
%)	O	NOUN	B
and	O	CCONJ	O
pulmonary	B-Disease	ADJ	B
interstitial	I-Disease	ADJ	I
infiltrates	I-Disease	NOUN	I
(	O	PUNCT	O
5	O	NUM	O
%).	O	NOUN	O
Although	O	SCONJ	O
large	O	ADJ	B
-	O	PUNCT	O
dose	O	NOUN	B
amiodarone	B-Chemical	NOUN	B
is	O	AUX	O
highly	O	ADV	O
effective	O	ADJ	B
in	O	ADP	O
the	O	DET	O
long	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
treatment	O	NOUN	B
of	O	ADP	O
VT	B-Disease	NOUN	B
or	O	CCONJ	O
VF	B-Disease	PROPN	B
refractory	O	ADJ	I
to	O	PART	O
conventional	O	ADJ	O
antiarrhythmic	O	ADJ	B
drugs	O	NOUN	I
,	O	PUNCT	O
it	O	PRON	O
causes	O	VERB	O
significant	O	ADJ	O
toxicity	B-Disease	NOUN	B
in	O	ADP	O
approximately	O	ADV	O
50	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
when	O	SCONJ	O
the	O	DET	O
dose	O	NOUN	B
is	O	AUX	O
adjusted	O	VERB	O
based	O	VERB	O
on	O	ADP	O
clinical	O	ADJ	B
response	O	NOUN	I
or	O	CCONJ	O
the	O	DET	O
development	O	NOUN	B
of	O	ADP	O
adverse	O	ADJ	B
effects	O	NOUN	I
,	O	PUNCT	O
75	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
VT	B-Disease	NOUN	B
or	O	CCONJ	O
VF	B-Disease	PROPN	B
can	O	AUX	O
be	O	AUX	O
successfully	O	ADV	O
managed	O	VERB	O
with	O	ADP	O
amiodarone	B-Chemical	NOUN	B


Effect	O	NOUN	B
of	O	ADP	O
calcium	B-Chemical	NOUN	B
chloride	I-Chemical	NOUN	I
and	O	CCONJ	O
4-aminopyridine	B-Chemical	NOUN	B
therapy	O	NOUN	I
on	O	ADP	O
desipramine	B-Chemical	NOUN	B
toxicity	B-Disease	NOUN	B
in	O	ADP	O
rats	O	NOUN	B
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
:	O	PUNCT	O
Hypotension	B-Disease	NOUN	B
is	O	AUX	O
a	O	DET	O
major	O	ADJ	O
contributor	O	NOUN	O
to	O	ADP	O
mortality	O	NOUN	B
in	O	ADP	O
tricyclic	O	ADJ	B
antidepressant	O	ADJ	I
overdose	B-Disease	NOUN	B
.	O	PUNCT	O


Recent	O	ADJ	O
data	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
tricyclic	O	ADJ	B
antidepressants	O	NOUN	I
inhibit	O	VERB	B
calcium	B-Chemical	NOUN	B
influx	O	NOUN	O
in	O	ADP	O
some	O	DET	O
tissues	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
study	O	NOUN	B
addressed	O	VERB	O
the	O	DET	O
potential	O	ADJ	O
role	O	NOUN	O
of	O	ADP	O
calcium	B-Chemical	NOUN	B
channel	O	NOUN	I
blockade	O	NOUN	I
in	O	ADP	O
tricyclic	O	ADJ	B
antidepressant	O	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
hypotension	B-Disease	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
:	O	PUNCT	O
Two	O	NUM	O
interventions	O	NOUN	B
were	O	AUX	O
studied	O	VERB	O
that	O	PRON	O
have	O	AUX	O
been	O	AUX	O
shown	O	VERB	O
previously	O	ADV	O
to	O	PART	O
improve	O	VERB	B
blood	O	NOUN	B
pressure	O	NOUN	I
with	O	ADP	O
calcium	B-Chemical	NOUN	B
channel	O	NOUN	I
blocker	O	NOUN	I
overdose	B-Disease	NOUN	B
.	O	PUNCT	O


CaCl2	B-Chemical	NOUN	B
and	O	CCONJ	O
4-aminopyridine	B-Chemical	NOUN	B
.	O	PUNCT	O


Anesthetized	O	ADJ	B
rats	O	NOUN	B
received	O	VERB	O
the	O	DET	O
tricyclic	O	ADJ	B
antidepressant	O	ADJ	O
desipramine	B-Chemical	NOUN	B
IP	O	NOUN	B
to	O	PART	O
produce	O	VERB	O
hypotension	B-Disease	NOUN	B
,	O	PUNCT	O
QRS	O	NOUN	B
prolongation	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
bradycardia	B-Disease	NOUN	B
.	O	PUNCT	O


Fifteen	O	NUM	O
min	O	NOUN	O
later	O	ADV	O
,	O	PUNCT	O
animals	O	NOUN	B
received	O	VERB	O
CaCl2	B-Chemical	NOUN	B
,	O	PUNCT	O
NaHCO3	B-Chemical	NOUN	B
,	O	PUNCT	O
or	O	CCONJ	O
saline	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
a	O	DET	O
second	O	ADJ	O
experiment	O	NOUN	B
,	O	PUNCT	O
rats	O	NOUN	B
received	O	VERB	O
tricyclic	O	ADJ	B
antidepressant	O	ADJ	B
desipramine	B-Chemical	NOUN	B
IP	O	NOUN	B
followed	O	VERB	O
in	O	ADP	O
15	O	NUM	O
min	O	NOUN	O
by	O	ADP	O
4-aminopyridine	B-Chemical	NOUN	B
or	O	CCONJ	O
saline	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
NaHCO3	B-Chemical	NOUN	B
briefly	O	NOUN	O
(	O	PUNCT	O
5	O	NUM	O
min	O	NOUN	O
)	O	PUNCT	O
reversed	O	VERB	B
hypotension	B-Disease	NOUN	B
and	O	CCONJ	O
QRS	O	NOUN	B
prolongation	O	NOUN	I
.	O	PUNCT	O


CaCl2	B-Chemical	NOUN	B
and	O	CCONJ	O
4-aminopyridine	B-Chemical	NOUN	B
failed	O	VERB	B
to	O	PART	O
improve	O	VERB	B
blood	O	NOUN	B
pressure	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
incidence	O	NOUN	B
of	O	ADP	O
ventricular	B-Disease	ADJ	B
arrhythmias	I-Disease	NOUN	I
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


004	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
seizures	B-Disease	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


03	O	NUM	O
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
CaCl2	B-Chemical	NOUN	B
group	O	NOUN	B
was	O	AUX	O
higher	O	ADJ	O
than	O	ADP	O
the	O	DET	O
other	O	ADJ	O
groups	O	NOUN	B
.	O	PUNCT	O


CONCLUSION	O	NOUN	B
:	O	PUNCT	O
The	O	DET	O
administration	O	NOUN	B
of	O	ADP	O
CaCl2	B-Chemical	NOUN	B
or	O	CCONJ	O
4-aminopyridine	B-Chemical	NOUN	B
did	O	AUX	O
not	O	PART	O
reverse	O	VERB	B
tricyclic	O	ADJ	I
antidepressant	O	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
hypotension	B-Disease	NOUN	B
in	O	ADP	O
rats	O	NOUN	B
.	O	PUNCT	O


CaCl2	B-Chemical	NOUN	B
therapy	O	NOUN	I
may	O	AUX	O
possibly	O	ADV	O
worsen	O	VERB	B
both	O	CCONJ	O
cardiovascular	B-Disease	ADJ	B
and	I-Disease	CCONJ	O
central	I-Disease	ADJ	B
nervous	I-Disease	ADJ	I
system	I-Disease	NOUN	I
toxicity	I-Disease	NOUN	B
.	O	PUNCT	O


These	O	DET	O
findings	O	NOUN	B
do	O	AUX	O
not	O	PART	O
support	O	VERB	O
a	O	DET	O
role	O	NOUN	O
for	O	ADP	O
calcium	B-Chemical	NOUN	B
channel	O	NOUN	I
inhibition	O	NOUN	B
in	O	ADP	O
the	O	DET	O
pathogenesis	O	NOUN	B
of	O	ADP	O
tricyclic	O	ADJ	B
antidepressant	O	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
hypotension	B-Disease	NOUN	B


Phase	O	NOUN	B
I	O	NUM	I
trial	O	NOUN	I
of	O	ADP	O
13-cis-retinoic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
in	O	ADP	O
children	O	NOUN	B
with	O	ADP	O
neuroblastoma	B-Disease	NOUN	B
following	O	VERB	O
bone	O	NOUN	B
marrow	O	NOUN	I
transplantation	O	NOUN	I
.	O	PUNCT	O


PURPOSE	O	NOUN	B
:	O	PUNCT	O
Treatment	O	NOUN	B
of	O	ADP	O
neuroblastoma	B-Disease	NOUN	B
cell	O	NOUN	B
lines	O	NOUN	I
with	O	ADP	O
13-cis-retinoic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
(	O	PUNCT	O
cis-RA	B-Chemical	NOUN	B
)	O	PUNCT	O
can	O	AUX	O
cause	O	VERB	O
sustained	O	ADJ	O
inhibition	O	NOUN	B
of	O	ADP	O
proliferation	O	NOUN	B
.	O	PUNCT	O


Since	O	SCONJ	O
cis-RA	B-Chemical	NOUN	B
has	O	AUX	O
demonstrated	O	VERB	O
clinical	O	ADJ	B
responses	O	NOUN	I
in	O	ADP	O
neuroblastoma	B-Disease	NOUN	B
patients	O	NOUN	B
,	O	PUNCT	O
it	O	PRON	O
may	O	AUX	O
be	O	AUX	O
effective	O	ADJ	B
in	O	ADP	O
preventing	O	VERB	B
relapse	O	NOUN	B
after	O	ADP	O
cytotoxic	O	ADJ	B
therapy	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
phase	O	NOUN	B
I	O	NOUN	I
trial	O	NOUN	I
was	O	AUX	O
designed	O	VERB	O
to	O	PART	O
determine	O	VERB	O
the	O	DET	O
maximal	O	ADJ	B
-	O	PUNCT	O
tolerated	O	VERB	B
dosage	O	NOUN	B
(	O	PUNCT	O
MTD	O	NOUN	B
),	O	PUNCT	O
toxicities	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
pharmacokinetics	O	NOUN	B
of	O	ADP	O
cis-RA	B-Chemical	NOUN	B
administered	O	VERB	B
on	O	ADP	O
an	O	DET	O
intermittent	O	ADJ	B
schedule	O	NOUN	I
in	O	ADP	O
children	O	NOUN	B
with	O	ADP	O
neuroblastoma	B-Disease	NOUN	B
following	O	VERB	O
bone	O	NOUN	B
marrow	O	NOUN	I
transplantation	O	NOUN	I
(	O	PUNCT	O
BMT	O	NOUN	B
).	O	PUNCT	O
PATIENTS	O	NOUN	B
AND	O	CCONJ	O
METHODS	O	NOUN	O
:	O	PUNCT	O
Fifty	O	NUM	B
-	O	PUNCT	O
one	O	NUM	O
assessable	O	ADJ	O
patients	O	NOUN	B
,	O	PUNCT	O
2	O	NUM	O
to	O	PART	O
12	O	NUM	O
years	O	NOUN	B
of	O	ADP	O
age	O	NOUN	B
,	O	PUNCT	O
were	O	AUX	O
treated	O	VERB	B
with	O	ADP	I
oral	O	ADJ	B
cis-RA	B-Chemical	NOUN	B
administered	O	VERB	B
in	O	ADP	O
two	O	NUM	O
equally	O	ADV	O
divided	O	ADJ	O
doses	O	NOUN	B
daily	O	ADV	B
for	O	ADP	O
2	O	NUM	O
weeks	O	NOUN	B
,	O	PUNCT	O
followed	O	VERB	O
by	O	ADP	O
a	O	DET	O
2	O	NUM	B
-	O	PUNCT	O
week	O	NOUN	B
rest	O	NOUN	B
period	O	NOUN	B
,	O	PUNCT	O
for	O	ADP	O
up	O	ADV	O
to	O	PART	O
12	O	NUM	O
courses	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
dose	O	NOUN	B
was	O	AUX	O
escalated	O	VERB	B
from	O	ADP	O
100	O	NUM	O
to	O	PART	O
200	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
m2	O	NOUN	B
/	O	SYM	O
d	O	NOUN	O
until	O	ADP	O
dose	O	NOUN	B
-	O	PUNCT	O
limiting	O	VERB	B
toxicity	B-Disease	NOUN	B
(	O	PUNCT	O
DLT	O	NOUN	B
)	O	PUNCT	O
was	O	AUX	O
observed	O	VERB	B
.	O	PUNCT	O


A	O	DET	O
single	O	ADJ	O
intrapatient	O	ADJ	B
dose	O	NOUN	O
escalation	O	NOUN	B
was	O	AUX	O
permitted	O	VERB	O
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
The	O	DET	O
MTD	O	NOUN	B
of	O	ADP	O
cis-RA	B-Chemical	NOUN	B
was	O	AUX	O
160	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
m2	O	NOUN	B
/	O	SYM	O
d	O	NOUN	B
.	O	PUNCT	O


Dose	O	NOUN	B
-	O	PUNCT	O
limiting	O	VERB	B
toxicities	B-Disease	NOUN	B
in	O	ADP	O
six	O	NUM	O
of	O	ADP	O
nine	O	NUM	O
patients	O	NOUN	B
at	O	ADP	O
200	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
m2	O	NOUN	B
/	O	SYM	O
d	O	NOUN	O
included	O	VERB	O
hypercalcemia	B-Disease	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
3	O	NUM	O
),	O	PUNCT	O
rash	B-Disease	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
2	O	NUM	O
),	O	PUNCT	O
and	O	CCONJ	O
anemia	B-Disease	NOUN	B
/	O	SYM	O
thrombocytopenia	B-Disease	NOUN	B
/	O	PUNCT	O
emesis	B-Disease	NOUN	B
/	O	SYM	O
rash	B-Disease	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
1	O	NUM	O
).	O	PUNCT	O
All	O	DET	O
toxicities	B-Disease	NOUN	B
resolved	O	VERB	B
after	O	ADP	O
cis-RA	B-Chemical	NOUN	B
was	O	AUX	O
discontinued	O	VERB	B
.	O	PUNCT	O


Three	O	NUM	O
complete	O	ADJ	O
responses	O	NOUN	B
were	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
marrow	O	NOUN	B
metastases	B-Disease	NOUN	I
.	O	PUNCT	O


Serum	O	NOUN	B
levels	O	NOUN	O
of	O	ADP	O
7	O	NUM	O
.	O	PUNCT	O


4	O	NUM	O
+/-	O	CCONJ	O
3	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
mumol	O	NOUN	B
/	O	SYM	O
L	O	NOUN	B
(	O	PUNCT	O
peak	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
4	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
+/-	O	CCONJ	O
2	O	NUM	O
.	O	PUNCT	O


8	O	NUM	O
mumol	O	NOUN	B
/	O	SYM	O
L	O	NOUN	B
(	O	PUNCT	O
trough	O	NOUN	B
)	O	PUNCT	O
at	O	ADP	O
the	O	DET	O
MTD	O	NOUN	B
were	O	AUX	O
maintained	O	VERB	B
during	O	ADP	O
14	O	NUM	O
days	O	NOUN	B
of	O	ADP	O
therapy	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
DLT	O	NOUN	B
correlated	O	VERB	B
with	O	ADP	O
serum	O	NOUN	B
levels	O	NOUN	I
>	O	NOUN	O
or	O	CCONJ	O
=	O	ADJ	O
10	O	NUM	O
mumol	O	NOUN	B
/	O	SYM	O
L	O	NOUN	B
.	O	PUNCT	O


CONCLUSION	O	NOUN	B
:	O	PUNCT	O
The	O	DET	O
MTD	O	NOUN	B
of	O	ADP	O
cis-RA	B-Chemical	NOUN	B
given	O	VERB	O
on	O	ADP	O
this	O	DET	O
intermittent	O	ADJ	B
schedule	O	NOUN	I
was	O	AUX	O
160	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
m2	O	NOUN	B
/	O	SYM	O
d	O	NOUN	B
.	O	PUNCT	O


Serum	O	NOUN	B
levels	O	NOUN	B
known	O	VERB	O
to	O	PART	O
be	O	AUX	O
effective	O	ADJ	B
against	O	ADP	O
neuroblastoma	B-Disease	NOUN	B
in	O	X	B
vitro	O	X	I
were	O	AUX	O
achieved	O	VERB	O
at	O	ADP	O
this	O	DET	O
dose	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
DLT	O	NOUN	B
included	O	VERB	O
hypercalcemia	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
may	O	AUX	O
be	O	AUX	O
predicted	O	VERB	O
by	O	ADP	O
serum	O	NOUN	B
cis-RA	B-Chemical	ADJ	B
levels	O	NOUN	O
.	O	PUNCT	O


Monitoring	O	NOUN	B
of	O	ADP	O
serum	O	NOUN	B
calcium	B-Chemical	NOUN	I
and	O	CCONJ	O
cis-RA	B-Chemical	NOUN	B


Effect	O	NOUN	B
of	O	ADP	O
calcium	B-Chemical	NOUN	B
chloride	I-Chemical	NOUN	I
on	O	ADP	O
gross	O	ADJ	B
behavioural	O	ADJ	O
changes	O	NOUN	O
produced	O	VERB	O
by	O	ADP	O
carbachol	B-Chemical	NOUN	B
and	O	CCONJ	O
eserine	B-Chemical	NOUN	B
in	O	ADP	O
cats	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
calcium	B-Chemical	NOUN	B
chloride	I-Chemical	NOUN	I
injected	O	VERB	B
into	O	ADP	O
the	O	DET	O
cerebral	O	ADJ	B
ventricles	O	NOUN	I
of	O	ADP	O
group	O	NOUN	B
-	O	PUNCT	O
housed	O	VERB	B
unanaesthetized	O	ADJ	B
cats	O	NOUN	B
upon	O	SCONJ	O
vocalization	O	NOUN	B
(	O	PUNCT	O
rage	O	NOUN	B
,	O	PUNCT	O
hissing	O	VERB	B
and	O	CCONJ	O
snarling	O	VERB	B
),	O	PUNCT	O
fighting	O	NOUN	B
(	O	PUNCT	O
attack	O	NOUN	B
with	O	ADP	O
paws	O	NOUN	B
and	O	CCONJ	O
claws	O	NOUN	B
,	O	PUNCT	O
defense	O	NOUN	B
with	O	ADP	O
paws	O	NOUN	B
and	O	CCONJ	O
claws	O	NOUN	B
and	O	CCONJ	O
biting	O	VERB	B
),	O	PUNCT	O
mydriasis	B-Disease	NOUN	B
,	O	PUNCT	O
tremor	B-Disease	NOUN	B
and	O	CCONJ	O
clonic-tonic	B-Disease	ADJ	B
convulsions	I-Disease	NOUN	I
produced	O	VERB	O
by	O	ADP	O
carbachol	B-Chemical	NOUN	B
and	O	CCONJ	O
eserine	B-Chemical	NOUN	B
injected	O	VERB	B
similarly	O	ADV	O
was	O	AUX	O
investigated	O	VERB	B
.	O	PUNCT	O


Calcium	B-Chemical	NOUN	B
chloride	I-Chemical	NOUN	I
depressed	O	ADJ	B
or	O	CCONJ	O
almost	O	ADV	O
completely	O	ADV	O
abolished	O	VERB	O
the	O	DET	O
vocalization	O	NOUN	B
and	O	CCONJ	O
fighting	O	NOUN	B
due	O	ADP	O
to	O	PART	O
carbachol	B-Chemical	NOUN	B
and	O	CCONJ	O
eserine	B-Chemical	NOUN	B
.	O	PUNCT	O


On	O	ADP	O
the	O	DET	O
other	O	ADJ	O
hand	O	NOUN	B
,	O	PUNCT	O
mydriasis	B-Disease	NOUN	B
,	O	PUNCT	O
tremor	B-Disease	NOUN	B
and	O	CCONJ	O
clonic-tonic	B-Disease	ADJ	B
convulsions	I-Disease	NOUN	I
evoked	O	VERB	B
by	O	ADP	O
carbachol	B-Chemical	NOUN	B
and	O	CCONJ	O
eserine	B-Chemical	NOUN	B
were	O	AUX	O
not	O	PART	O
significantly	O	ADV	O
changed	O	VERB	O
by	O	ADP	O
calcium	B-Chemical	NOUN	B
chloride	I-Chemical	NOUN	I
.	O	PUNCT	O


It	O	PRON	O
is	O	AUX	O
apparent	O	ADJ	B
that	O	SCONJ	O
calcium	B-Chemical	NOUN	B
chloride	I-Chemical	NOUN	I
can	O	AUX	O
"	O	PUNCT	O
dissociate	O	VERB	B
"	O	PUNCT	O
vocalization	O	NOUN	B
and	O	CCONJ	O
fighting	O	NOUN	B
from	O	ADP	O
autonomic	O	ADJ	B
and	O	CCONJ	O
motor	O	NOUN	B
phenomena	O	NOUN	I
such	O	ADJ	O
as	O	ADP	O
mydriasis	B-Disease	NOUN	B
,	O	PUNCT	O
tremor	B-Disease	NOUN	B
and	O	CCONJ	O
clonic-tonic	B-Disease	ADJ	B
convulsions	I-Disease	NOUN	I
caused	O	VERB	O
by	O	ADP	O
carbachol	B-Chemical	NOUN	B
and	O	CCONJ	O
eserine	B-Chemical	NOUN	B
.	O	PUNCT	O


Calcium	B-Chemical	NOUN	B
chloride	I-Chemical	NOUN	I
inhibited	O	VERB	B
the	O	DET	O
vocalization	O	NOUN	B
and	O	CCONJ	O
fighting	O	NOUN	B
produced	O	VERB	O
by	O	ADP	O
carbachol	B-Chemical	NOUN	B
and	O	CCONJ	O
eserine	B-Chemical	NOUN	B
most	O	ADV	O
probably	O	ADV	O
by	O	ADP	O
a	O	DET	O
nonspecific	O	ADJ	B
stabilizing	O	NOUN	O
action	O	NOUN	O
on	O	ADP	O
central	O	ADJ	O
muscarinic	O	ADJ	B
cholinoceptive	O	ADJ	O
sites	O	NOUN	O
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	O
further	O	ADV	O
support	O	VERB	O
the	O	DET	O
view	O	NOUN	O
that	O	SCONJ	O
calcium	B-Chemical	NOUN	B
ions	O	NOUN	I
in	O	ADP	O
excess	O	NOUN	B
have	O	AUX	O
an	O	DET	O
atropine	B-Chemical	NOUN	B


Multiple	O	ADJ	B
side	O	NOUN	B
effects	O	NOUN	I
of	O	ADP	O
penicillamine	B-Chemical	NOUN	B
therapy	O	NOUN	B
in	O	ADP	O
one	O	NUM	O
patient	O	NOUN	B
with	O	ADP	O
rheumatoid	B-Disease	ADJ	B
arthritis	I-Disease	NOUN	I
.	O	PUNCT	O


Skin	B-Disease	NOUN	B
rashes	I-Disease	NOUN	I
,	O	PUNCT	O
proteinuria	B-Disease	NOUN	B
,	O	PUNCT	O
systemic	B-Disease	ADJ	B
lupus	I-Disease	NOUN	I
erythematosus	I-Disease	NOUN	I
,	O	PUNCT	O
polymyositis	B-Disease	NOUN	B
and	O	CCONJ	O
myasthenia	B-Disease	NOUN	B
gravis	I-Disease	NOUN	I
have	O	AUX	O
all	O	DET	O
been	O	AUX	O
recorded	O	VERB	O
as	O	ADP	O
complications	O	NOUN	B
of	O	ADP	O
penicillamine	B-Chemical	NOUN	B
therapy	O	NOUN	I
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
rheumatoid	B-Disease	ADJ	B
arthritis	I-Disease	NOUN	I
.	O	PUNCT	O


A	O	DET	O
patient	O	NOUN	B
who	O	PRON	O
had	O	AUX	O
developed	O	VERB	O
all	O	DET	O
5	O	NUM	O
is	O	AUX	O
now	O	ADV	O
described	O	VERB	O
.	O	PUNCT	O


The	O	DET	O
skin	B-Disease	NOUN	B
lesion	I-Disease	NOUN	I
resembled	O	VERB	O
elastosis	B-Disease	NOUN	B
perforans	I-Disease	NOUN	I
serpiginosa	I-Disease	NOUN	I
,	O	PUNCT	O
which	O	DET	O
has	O	AUX	O
been	O	AUX	O
reported	O	VERB	O
as	O	ADP	O
a	O	DET	O
rare	O	ADJ	B
side	O	NOUN	B
effect	O	NOUN	I
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
Wilson's	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
but	O	CCONJ	O
not	O	PART	O
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
rheumatoid	B-Disease	ADJ	B
arthritis	I-Disease	NOUN	I
treated	O	VERB	B
with	O	ADP	I
penicillamine	B-Chemical	NOUN	B


Electrocardiographic	O	ADJ	B
changes	O	NOUN	O
and	O	CCONJ	O
cardiac	B-Disease	ADJ	B
arrhythmias	I-Disease	NOUN	I
in	O	ADP	O
patients	O	NOUN	B
receiving	O	VERB	O
psychotropic	O	ADJ	B
drugs	O	NOUN	I
.	O	PUNCT	O


Eight	O	NUM	O
patients	O	NOUN	B
had	O	AUX	O
cardiac	O	ADJ	B
manifestations	O	NOUN	I
that	O	PRON	O
were	O	AUX	O
life	O	NOUN	B
-	O	PUNCT	O
threatening	O	VERB	B
in	O	ADP	O
five	O	NUM	O
while	O	SCONJ	O
taking	O	VERB	O
psychotropic	O	ADJ	B
drugs	O	NOUN	I
,	O	PUNCT	O
either	O	CCONJ	O
phenothiazines	B-Chemical	NOUN	B
or	O	CCONJ	O
tricyclic	O	ADJ	B
antidepressants	O	NOUN	I
.	O	PUNCT	O


Although	O	SCONJ	O
most	O	ADJ	O
patients	O	NOUN	B
were	O	AUX	O
receiving	O	VERB	O
several	O	ADJ	O
drugs	O	NOUN	B
,	O	PUNCT	O
Mellaril	B-Chemical	NOUN	B
(	O	PUNCT	O
thioridazine	B-Chemical	NOUN	B
)	O	PUNCT	O
appeared	O	VERB	O
to	O	PART	O
be	O	AUX	O
responsible	O	ADJ	O
for	O	ADP	O
five	O	NUM	O
cases	O	NOUN	B
of	O	ADP	O
ventricular	B-Disease	ADJ	B
tachycardia	I-Disease	NOUN	I
,	O	PUNCT	O
one	O	NUM	O
of	O	ADP	O
which	O	DET	O
was	O	AUX	O
fatal	O	ADJ	B
in	O	ADP	O
a	O	DET	O
35	O	NUM	O
year	O	NOUN	B
old	O	ADJ	O
woman	O	NOUN	B
.	O	PUNCT	O


Supraventricular	B-Disease	ADJ	B
tachycardia	I-Disease	NOUN	I
developed	O	VERB	O
in	O	ADP	O
one	O	NUM	O
patient	O	NOUN	B
receiving	O	VERB	O
Thorazine	B-Chemical	NOUN	B
(	O	PUNCT	O
chlorpromazine	B-Chemical	NOUN	B
).	O	PUNCT	O
Aventyl	B-Chemical	NOUN	B
(	O	PUNCT	O
nortriptyline	B-Chemical	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
Elavil	B-Chemical	NOUN	B
(	O	PUNCT	O
amitriptyline	B-Chemical	NOUN	B
)	O	PUNCT	O
each	O	DET	O
produced	O	VERB	O
left	B-Disease	ADJ	B
bundle	I-Disease	NOUN	I
branch	I-Disease	NOUN	I
block	I-Disease	NOUN	I
in	O	ADP	O
a	O	DET	O
73	O	NUM	O
year	O	NOUN	B
old	O	ADJ	O
woman	O	NOUN	B
.	O	PUNCT	O


Electrocardiographic	O	ADJ	B
T	O	NOUN	I
and	O	CCONJ	O
U	O	NOUN	B
wave	O	NOUN	I
abnormalities	O	NOUN	I
were	O	AUX	O
present	O	ADJ	O
in	O	ADP	O
most	O	ADJ	O
patients	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
ventricular	B-Disease	ADJ	B
arrhythmias	I-Disease	NOUN	I
responded	O	VERB	O
to	O	PART	O
intravenous	O	ADJ	B
administration	O	NOUN	I
of	O	ADP	O
lidocaine	B-Chemical	NOUN	B
and	O	CCONJ	O
to	O	PART	O
direct	O	VERB	O
current	O	ADJ	O
electric	O	ADJ	B
shock	O	NOUN	I
;	O	PUNCT	O
ventricular	O	ADJ	B
pacing	O	NOUN	I
was	O	AUX	O
required	O	VERB	O
in	O	ADP	O
some	O	DET	O
instances	O	NOUN	O
and	O	CCONJ	O
intravenous	O	ADJ	B
administration	O	NOUN	I
of	O	ADP	O
propranolol	B-Chemical	NOUN	B
combined	O	VERB	O
with	O	ADP	O
ventricular	O	ADJ	B
pacing	O	NOUN	I
in	O	ADP	O
one	O	NUM	O
.	O	PUNCT	O


The	O	DET	O
tachyarrhythmias	B-Disease	NOUN	B
generally	O	ADV	O
subsided	O	VERB	O
within	O	ADP	O
48	O	NUM	O
hours	O	NOUN	B
after	O	ADP	O
administration	O	NOUN	B
of	O	ADP	O
the	O	DET	O
drugs	O	NOUN	B
was	O	AUX	O
stopped	O	VERB	B
.	O	PUNCT	O


Five	O	NUM	O
of	O	ADP	O
the	O	DET	O
eight	O	NUM	O
patients	O	NOUN	B
were	O	AUX	O
50	O	NUM	O
years	O	NOUN	B
of	O	ADP	O
age	O	NOUN	B
or	O	CCONJ	O
younger	O	ADJ	B
;	O	PUNCT	O
only	O	ADV	O
one	O	NUM	O
clearly	O	ADV	O
had	O	AUX	O
antecedent	O	ADJ	B
heart	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
.	O	PUNCT	O


Major	O	ADJ	B
cardiac	B-Disease	ADJ	B
arrhythmias	I-Disease	NOUN	I
are	O	AUX	O
a	O	DET	O
potential	O	ADJ	B
hazard	O	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
without	O	ADP	O
heart	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
who	O	PRON	O
are	O	AUX	O
receiving	O	VERB	O
customary	O	ADJ	O
therapeutic	O	ADJ	B
doses	O	NOUN	I
of	O	ADP	O
psychotropic	O	ADJ	B
drugs	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
prospective	O	ADJ	B
clinical	O	ADJ	I
trial	O	NOUN	I
is	O	AUX	O
suggested	O	VERB	O
to	O	PART	O
quantify	O	VERB	B
the	O	DET	O
risk	O	NOUN	B
of	O	ADP	O
cardiac	B-Disease	ADJ	B
complications	I-Disease	NOUN	I
to	O	ADP	O
patients	O	NOUN	B
receiving	O	VERB	O
phenothiazines	B-Chemical	NOUN	B


Serotonergic	O	ADJ	B
drugs	O	NOUN	I
,	O	PUNCT	O
benzodiazepines	B-Chemical	NOUN	B
and	O	CCONJ	O
baclofen	B-Chemical	NOUN	B
block	O	NOUN	I
muscimol	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
myoclonic	B-Disease	ADJ	B
jerks	I-Disease	NOUN	I
in	O	ADP	O
a	O	DET	O
strain	O	NOUN	B
of	O	ADP	O
mice	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
male	O	ADJ	B
Swiss	O	ADJ	B
mice	O	NOUN	I
,	O	PUNCT	O
muscimol	B-Chemical	NOUN	B
produced	O	VERB	O
myoclonic	B-Disease	ADJ	B
jerks	I-Disease	NOUN	I
.	O	PUNCT	O


A	O	DET	O
3	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
(	O	PUNCT	O
i	O	PRON	O
.	O	PUNCT	O


p	O	X	O
.)	O	NUM	O
dose	O	NOUN	B
induced	O	VERB	B
this	O	DET	O
response	O	NOUN	B
in	O	ADP	O
all	O	DET	O
of	O	ADP	O
the	O	DET	O
mice	O	NOUN	B
tested	O	VERB	B
and	O	CCONJ	O
the	O	DET	O
peak	O	ADJ	B
response	O	NOUN	I
of	O	ADP	O
73	O	NUM	O
jerks	O	NOUN	B
per	O	ADP	O
min	O	NOUN	O
was	O	AUX	O
observed	O	VERB	O
between	O	ADP	O
27	O	NUM	O
and	O	CCONJ	O
45	O	NUM	O
min	O	NOUN	O
.	O	PUNCT	O


Increasing	O	VERB	B
the	O	DET	O
brain	O	NOUN	B
serotonin	B-Chemical	NOUN	B
levels	O	NOUN	B
by	O	ADP	O
the	O	DET	O
administration	O	NOUN	B
of	O	ADP	O
5-hydroxytryptophan	B-Chemical	NOUN	B
(	O	PUNCT	O
80	O	NUM	O
-	O	SYM	O
160	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
combination	O	NOUN	B
with	O	ADP	O
a	O	DET	O
peripheral	O	ADJ	B
decarboxylase	O	NOUN	I
inhibitor	O	NOUN	O
resulted	O	VERB	O
in	O	ADP	O
an	O	DET	O
inhibition	O	NOUN	B
of	O	ADP	O
the	O	DET	O
muscimol	B-Chemical	NOUN	B
effect	O	NOUN	O
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
in	O	ADP	O
a	O	DET	O
similar	O	ADJ	O
experiment	O	NOUN	B
l-dopa	B-Chemical	NOUN	B
(	O	PUNCT	O
80	O	NUM	O
-	O	SYM	O
160	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
)	O	PUNCT	O
was	O	AUX	O
without	O	ADP	O
effect	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
doses	O	NOUN	B
of	O	ADP	O
3	O	NUM	O
-	O	SYM	O
10	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
serotonin	B-Chemical	NOUN	B
receptor	O	NOUN	I
agonist	O	NOUN	I
MK-212	B-Chemical	NOUN	B
caused	O	VERB	O
a	O	DET	O
dose	O	NOUN	B
-	O	PUNCT	O
dependent	O	ADJ	B
blockade	O	NOUN	B
of	O	ADP	O
the	O	DET	O
response	O	NOUN	B
of	O	ADP	O
muscimol	B-Chemical	NOUN	B
.	O	PUNCT	O


Of	O	ADP	O
the	O	DET	O
benzodiazepines	B-Chemical	NOUN	B
,	O	PUNCT	O
clonazepam	B-Chemical	NOUN	B
(	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
-	O	SYM	O
0	O	NUM	O
.	O	PUNCT	O


3	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
)	O	PUNCT	O
was	O	AUX	O
found	O	VERB	O
to	O	PART	O
be	O	AUX	O
several	O	ADJ	O
fold	O	ADV	O
more	O	ADV	O
potent	O	ADJ	O
than	O	ADP	O
diazepam	B-Chemical	NOUN	B
(	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


3	O	NUM	O
-	O	SYM	O
3	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
blocking	O	VERB	B
the	O	DET	O
myoclonic	B-Disease	ADJ	B
jerks	I-Disease	NOUN	I
.	O	PUNCT	O


While	O	SCONJ	O
(-)-	O	NOUN	B
baclofen	B-Chemical	NOUN	I
(	O	PUNCT	O
1	O	NUM	O
-	O	PUNCT	O
3	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
)	O	PUNCT	O
proved	O	VERB	O
to	O	PART	O
be	O	AUX	O
an	O	DET	O
effective	O	ADJ	B
antagonist	O	NOUN	B
of	O	ADP	O
muscimol	B-Chemical	NOUN	B
,	O	PUNCT	O
its	O	PRON	O
(+)-	O	NOUN	B
isomer	O	NOUN	B
(	O	PUNCT	O
5	O	NUM	O
-	O	SYM	O
20	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
)	O	PUNCT	O
lacked	O	VERB	O
this	O	DET	O
property	O	NOUN	B
.	O	PUNCT	O


Considering	O	VERB	O
the	O	DET	O
fact	O	NOUN	O
that	O	SCONJ	O
5-HTP	B-Chemical	NOUN	B
and	O	CCONJ	O
the	O	DET	O
benzodiazepines	B-Chemical	NOUN	B
have	O	AUX	O
been	O	AUX	O
found	O	VERB	O
to	O	PART	O
be	O	AUX	O
beneficial	O	ADJ	O
in	O	ADP	O
the	O	DET	O
management	O	NOUN	B
of	O	ADP	O
clinical	O	ADJ	B
myoclonus	B-Disease	NOUN	I
,	O	PUNCT	O
the	O	DET	O
muscimol	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
myoclonus	B-Disease	NOUN	B
seems	O	VERB	O
to	O	PART	O
be	O	AUX	O
a	O	DET	O
satisfactory	O	ADJ	B
animal	O	NOUN	B
model	O	NOUN	I
that	O	PRON	O
may	O	AUX	O
prove	O	VERB	O
useful	O	ADJ	O
for	O	ADP	O
the	O	DET	O
development	O	NOUN	B
of	O	ADP	O
new	O	ADJ	O
drug	O	NOUN	B
treatments	O	NOUN	I
for	O	ADP	O
this	O	DET	O
condition	O	NOUN	B
.	O	PUNCT	O


Our	O	PRON	O
present	O	ADJ	O
study	O	NOUN	B
indicated	O	VERB	O
the	O	DET	O
possible	O	ADJ	O
value	O	NOUN	O
of	O	ADP	O
MK-212	B-Chemical	NOUN	B
and	O	CCONJ	O
(-)-	O	NOUN	B
baclofen	B-Chemical	NOUN	I
in	O	ADP	O
the	O	DET	O
management	O	NOUN	B
of	O	ADP	O
clinical	O	ADJ	B
myoclonus	B-Disease	NOUN	I


Hyperglycemic	B-Disease	ADJ	B
acidotic	I-Disease	ADJ	O
coma	I-Disease	NOUN	O
and	O	CCONJ	O
death	O	NOUN	B
in	O	ADP	O
Kearns-Sayre	B-Disease	ADJ	B
syndrome	I-Disease	NOUN	I
.	O	PUNCT	O


This	O	DET	O
paper	O	NOUN	O
presents	O	VERB	O
the	O	DET	O
clinical	O	ADJ	B
and	O	CCONJ	O
metabolic	O	ADJ	B
findings	O	NOUN	B
in	O	ADP	O
two	O	NUM	O
young	O	ADJ	B
boys	O	NOUN	B
with	O	ADP	O
long	O	ADV	B
-	O	PUNCT	O
standing	O	VERB	B
Kearns-Sayre	B-Disease	ADJ	B
syndrome	I-Disease	NOUN	I
.	O	PUNCT	O


Following	O	VERB	O
short	O	ADJ	B
exposure	O	NOUN	I
to	O	PART	I
oral	O	ADJ	B
prednisone	B-Chemical	NOUN	I
,	O	PUNCT	O
both	O	DET	O
boys	O	NOUN	B
developed	O	VERB	O
lethargy	B-Disease	NOUN	B
,	O	PUNCT	O
increasing	O	VERB	B
somnolence	B-Disease	NOUN	B
,	O	PUNCT	O
polydipsia	B-Disease	NOUN	B
,	O	PUNCT	O
polyphagia	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
polyuria	B-Disease	NOUN	B
.	O	PUNCT	O


Both	O	DET	O
presented	O	VERB	O
in	O	ADP	O
the	O	DET	O
emergency	O	NOUN	B
room	O	NOUN	I
with	O	ADP	O
profound	O	ADJ	O
coma	B-Disease	NOUN	B
,	O	PUNCT	O
hypotension	B-Disease	NOUN	B
,	O	PUNCT	O
severe	O	ADJ	B
hyperglycemia	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
acidosis	B-Disease	NOUN	B
.	O	PUNCT	O


Nonketotic	O	ADJ	B
lactic	B-Disease	ADJ	O
acidosis	I-Disease	NOUN	O
was	O	AUX	O
present	O	ADJ	O
in	O	ADP	O
one	O	NUM	O
and	O	CCONJ	O
ketosis	B-Disease	NOUN	B
without	O	ADP	O
a	O	DET	O
known	O	ADJ	O
serum	O	NOUN	B
lactate	B-Chemical	NOUN	I
level	O	NOUN	I
was	O	AUX	O
present	O	ADJ	O
in	O	ADP	O
the	O	DET	O
other	O	ADJ	O
.	O	PUNCT	O


Respiratory	B-Disease	ADJ	B
failure	I-Disease	NOUN	I
rapidly	O	ADV	O
ensued	O	VERB	B
and	O	CCONJ	O
both	O	DET	O
patients	O	NOUN	B
expired	O	VERB	B
in	O	ADP	O
spite	O	NOUN	O
of	O	ADP	O
efforts	O	NOUN	O
at	O	ADP	O
resuscitation	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
believe	O	VERB	O
these	O	DET	O
two	O	NUM	O
cases	O	NOUN	B
represent	O	VERB	O
a	O	DET	O
newly	O	ADV	O
described	O	VERB	O
and	O	CCONJ	O
catastrophic	O	ADJ	B
metabolic-endocrine	B-Disease	ADJ	B
failure	I-Disease	NOUN	I
in	O	ADP	O
the	O	DET	O
Kearns-Sayre	B-Disease	NOUN	B
syndrome	I-Disease	NOUN	I


Effects	O	NOUN	B
of	O	ADP	I
active	O	ADJ	B
constituents	O	NOUN	I
of	O	ADP	O
Crocus	O	X	B
sativus	O	X	I
L	O	NOUN	I
.,	O	PUNCT	I
crocin	B-Chemical	NOUN	B
on	O	ADP	O
streptozocin	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
model	O	NOUN	B
of	O	ADP	O
sporadic	O	ADJ	B
Alzheimer's	B-Disease	NOUN	O
disease	I-Disease	NOUN	O
in	O	ADP	O
male	O	NOUN	B
rats	O	NOUN	B
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
:	O	PUNCT	O
The	O	DET	O
involvement	O	NOUN	B
of	O	ADP	O
water	O	NOUN	B
-	O	PUNCT	O
soluble	O	ADJ	B
carotenoids	B-Chemical	NOUN	B
,	O	PUNCT	O
crocins	B-Chemical	NOUN	B
,	O	PUNCT	O
as	O	ADP	O
the	O	DET	O
main	O	ADJ	O
and	O	CCONJ	O
active	O	ADJ	B
components	O	NOUN	I
of	O	ADP	O
Crocus	O	X	B
sativus	O	X	I
L	O	NOUN	I
.	O	PUNCT	O


extract	O	NOUN	B
in	O	ADP	O
learning	O	NOUN	B
and	O	CCONJ	O
memory	O	NOUN	B
processes	O	NOUN	I
has	O	AUX	O
been	O	AUX	O
proposed	O	VERB	O
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
crocins	B-Chemical	NOUN	B
on	O	ADP	O
sporadic	O	ADJ	B
Alzheimer's	B-Disease	NOUN	O
disease	I-Disease	NOUN	O
induced	O	VERB	B
by	O	ADP	O
intracerebroventricular	O	NOUN	B
(	O	PUNCT	O
icv	O	NOUN	B
)	O	PUNCT	O
streptozocin	B-Chemical	NOUN	B
(	O	PUNCT	O
STZ	B-Chemical	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
male	O	NOUN	B
rats	O	NOUN	B
was	O	AUX	O
investigated	O	VERB	B
.	O	PUNCT	O


METHODS	O	NOUN	O
:	O	PUNCT	O
Male	O	ADJ	B
adult	O	NOUN	B
Wistar	O	NOUN	B
rats	O	NOUN	I
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
90	O	NUM	O
and	O	CCONJ	O
260	O	NUM	O
-	O	PUNCT	O
290	O	NUM	O
g	O	NOUN	O
)	O	PUNCT	O
were	O	AUX	O
divided	O	VERB	O
into	O	ADP	O
1	O	NUM	O
,	O	PUNCT	O
control	O	NOUN	B
;	O	PUNCT	O
2	O	NUM	O
and	O	CCONJ	O
3	O	NUM	O
,	O	PUNCT	O
crocins	B-Chemical	NOUN	B
(	O	PUNCT	O
15	O	NUM	O
and	O	CCONJ	O
30	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
);	O	NOUN	O
4	O	NUM	O
,	O	PUNCT	O
STZ	B-Chemical	NOUN	B
;	O	PUNCT	O
5	O	NUM	O
and	O	CCONJ	O
6	O	NUM	O
,	O	PUNCT	O
STZ	B-Chemical	NOUN	B
+	O	CCONJ	O
crocins	B-Chemical	NOUN	B
(	O	PUNCT	O
15	O	NUM	O
and	O	CCONJ	O
30	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
)	O	PUNCT	O
groups	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
Alzheimer's	B-Disease	NOUN	O
disease	I-Disease	NOUN	B
groups	O	NOUN	B
,	O	PUNCT	O
rats	O	NOUN	B
were	O	AUX	O
injected	O	VERB	B
with	O	ADP	O
STZ	B-Chemical	NOUN	B
-	O	PUNCT	O
icv	O	NOUN	B
bilaterally	O	ADV	B
(	O	PUNCT	O
3	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
first	O	ADJ	O
day	O	NOUN	B
and	O	CCONJ	O
3	O	NUM	O
days	O	NOUN	B
later	O	ADV	O
,	O	PUNCT	O
a	O	DET	O
similar	O	ADJ	O
STZ	B-Chemical	NOUN	B
-	O	PUNCT	O
icv	O	NOUN	B
application	O	NOUN	B
was	O	AUX	O
repeated	O	VERB	O
.	O	PUNCT	O


In	O	ADP	O
STZ	B-Chemical	NOUN	B
+	O	CCONJ	O
crocin	B-Chemical	NOUN	B
animal	O	NOUN	B
groups	O	NOUN	B
,	O	PUNCT	O
crocin	B-Chemical	NOUN	B
was	O	AUX	O
applied	O	VERB	O
in	O	ADP	O
doses	O	NOUN	B
of	O	ADP	O
15	O	NUM	O
and	O	CCONJ	O
30	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
,	O	PUNCT	O
i	O	X	O
.	O	PUNCT	O


p	O	X	O
.,	O	NOUN	O
one	O	NUM	O
day	O	NOUN	B
pre	O	ADJ	B
-	O	PUNCT	O
surgery	O	NOUN	B
and	O	CCONJ	O
continued	O	VERB	O
for	O	ADP	O
three	O	NUM	O
weeks	O	NOUN	B
.	O	PUNCT	O


Prescription	O	NOUN	B
of	O	ADP	O
crocin	B-Chemical	NOUN	B
in	O	ADP	O
each	O	DET	O
dose	O	NOUN	B
was	O	AUX	O
repeated	O	VERB	O
once	O	ADV	O
for	O	ADP	O
two	O	NUM	O
days	O	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
learning	O	NOUN	B
and	O	CCONJ	O
memory	O	NOUN	B
performance	O	NOUN	B
was	O	AUX	O
assessed	O	VERB	B
using	O	VERB	O
passive	O	ADJ	B
avoidance	O	NOUN	I
paradigm	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
for	O	ADP	O
spatial	O	ADJ	B
cognition	O	NOUN	I
evaluation	O	NOUN	B
,	O	PUNCT	O
Y	O	NOUN	B
-	O	PUNCT	O
maze	O	NOUN	B
task	O	NOUN	B
was	O	AUX	O
used	O	VERB	O
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
It	O	PRON	O
was	O	AUX	O
found	O	VERB	O
out	O	ADP	O
that	O	SCONJ	O
crocin	B-Chemical	NOUN	B
(	O	PUNCT	O
30	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
)-	O	ADJ	O
treated	O	VERB	B
STZ	B-Chemical	NOUN	B
-	O	PUNCT	O
injected	O	VERB	B
rats	O	NOUN	B
show	O	VERB	O
higher	O	ADJ	O
correct	O	ADJ	B
choices	O	NOUN	B
and	O	CCONJ	O
lower	O	ADJ	B
errors	O	NOUN	B
in	O	ADP	O
Y	O	NOUN	B
-	O	PUNCT	O
maze	O	NOUN	B
than	O	ADP	O
vehicle	O	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
STZ	B-Chemical	NOUN	B
-	O	PUNCT	O
injected	O	VERB	B
rats	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
,	O	PUNCT	O
crocin	B-Chemical	NOUN	B
in	O	ADP	O
the	O	DET	O
mentioned	O	VERB	O
dose	O	NOUN	B
could	O	AUX	O
significantly	O	ADV	O
attenuated	O	VERB	B
learning	B-Disease	NOUN	B
and	I-Disease	CCONJ	O
memory	I-Disease	NOUN	B
impairment	I-Disease	NOUN	I
in	O	ADP	O
treated	O	VERB	B
STZ	B-Chemical	NOUN	B
-	O	PUNCT	O
injected	O	VERB	B
group	O	NOUN	B
in	O	ADP	O
passive	O	ADJ	B
avoidance	O	NOUN	I
test	O	NOUN	I
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
:	O	PUNCT	O
Therefore	O	ADV	O
,	O	PUNCT	O
these	O	DET	O
results	O	NOUN	B
demonstrate	O	VERB	O
the	O	DET	O
effectiveness	O	NOUN	B
of	O	ADP	O
crocin	B-Chemical	NOUN	B
(	O	PUNCT	O
30	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
antagonizing	O	VERB	B
the	O	DET	O
cognitive	B-Disease	ADJ	B
deficits	I-Disease	NOUN	I
caused	O	VERB	O
by	O	ADP	O
STZ	B-Chemical	NOUN	B
-	O	PUNCT	O
icv	O	NOUN	B
in	O	ADP	O
rats	O	NOUN	B
and	O	CCONJ	O
its	O	PRON	O
potential	O	NOUN	B
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
neurodegenerative	B-Disease	ADJ	B
diseases	I-Disease	NOUN	I
such	O	ADJ	O
as	O	ADP	O
Alzheimer's	B-Disease	NOUN	O
disease	I-Disease	NOUN	B


Rosaceiform	O	NOUN	B
dermatitis	B-Disease	NOUN	I
associated	O	VERB	B
with	O	ADP	I
topical	O	ADJ	B
tacrolimus	B-Chemical	NOUN	O
treatment	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
describe	O	VERB	O
herein	O	ADV	O
3	O	NUM	O
patients	O	NOUN	B
who	O	PRON	O
developed	O	VERB	O
rosacea	B-Disease	NOUN	B
-	O	PUNCT	O
like	O	ADJ	B
dermatitis	B-Disease	NOUN	B
eruptions	B-Disease	NOUN	I
while	O	SCONJ	O
using	O	VERB	O
0	O	NUM	O
.	O	PUNCT	O


03	O	NUM	O
%	O	NOUN	O
or	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
%	O	NOUN	O
tacrolimus	B-Chemical	NOUN	B
ointment	O	NOUN	B
for	O	ADP	O
facial	B-Disease	ADJ	B
dermatitis	I-Disease	NOUN	I
.	O	PUNCT	O


Skin	O	NOUN	B
biopsy	O	NOUN	I
specimens	O	NOUN	I
showed	O	VERB	O
telangiectasia	B-Disease	NOUN	B
and	O	CCONJ	O
noncaseating	O	ADJ	B
epithelioid	O	ADJ	B
granulomatous	O	ADJ	B
tissue	O	NOUN	I
formation	O	NOUN	I
in	O	ADP	O
the	O	DET	O
papillary	O	NOUN	B
to	O	PART	O
mid	O	ADJ	O
dermis	O	NOUN	B
.	O	PUNCT	O


Continuous	O	ADJ	B
topical	O	ADJ	B
use	O	NOUN	O
of	O	ADP	O
immunomodulators	O	NOUN	B
such	O	ADJ	O
as	O	ADP	O
tacrolimus	B-Chemical	NOUN	B
or	O	CCONJ	O
pimecrolimus	B-Chemical	NOUN	B
should	O	AUX	O
be	O	AUX	O
regarded	O	VERB	O
as	O	ADP	O
a	O	DET	O
potential	O	ADJ	B
cause	O	NOUN	B
of	O	ADP	O
rosaceiform	O	NOUN	B
dermatitis	B-Disease	NOUN	I


A	O	DET	O
novel	O	ADJ	O
animal	O	NOUN	B
model	O	NOUN	I
to	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
ability	O	NOUN	O
of	O	ADP	O
a	O	DET	O
drug	O	NOUN	B
delivery	O	NOUN	I
system	O	NOUN	I
to	O	PART	O
promote	O	VERB	B
the	O	DET	O
passage	O	NOUN	B
through	O	ADP	O
the	O	DET	O
BBB	O	PROPN	B
.	O	PUNCT	O


The	O	DET	O
purpose	O	NOUN	O
of	O	ADP	O
this	O	DET	O
investigation	O	NOUN	B
was	O	AUX	O
to	O	PART	O
explore	O	VERB	O
the	O	DET	O
potentiality	O	NOUN	B
of	O	ADP	O
a	O	DET	O
novel	O	ADJ	O
animal	O	NOUN	B
model	O	NOUN	I
to	O	PART	O
be	O	AUX	O
used	O	VERB	O
for	O	ADP	O
the	O	DET	O
in	O	X	B
vivo	O	X	I
evaluation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
ability	O	NOUN	B
of	O	ADP	O
a	O	DET	O
drug	O	NOUN	B
delivery	O	NOUN	I
system	O	NOUN	I
to	O	PART	O
promote	O	VERB	B
the	O	DET	O
passage	O	NOUN	B
through	O	ADP	O
the	O	DET	O
blood	O	NOUN	B
-	O	PUNCT	O
brain	O	NOUN	B
barrier	O	NOUN	I
(	O	PUNCT	O
BBB	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
/	O	SYM	O
or	O	CCONJ	O
to	O	PART	O
improve	O	VERB	B
the	O	DET	O
brain	O	NOUN	B
localization	O	NOUN	B
of	O	ADP	O
a	O	DET	O
bioactive	O	ADJ	B
compound	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
Tween	O	NOUN	B
80	O	NUM	O
-	O	PUNCT	O
coated	O	VERB	B
poly-L-lactid	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
nanoparticles	O	NOUN	B
was	O	AUX	O
used	O	VERB	O
as	O	ADP	O
a	O	DET	O
model	O	NOUN	B
of	O	ADP	O
colloidal	O	ADJ	B
drug	O	NOUN	I
delivery	O	NOUN	I
system	O	NOUN	I
,	O	PUNCT	O
able	O	ADJ	O
to	O	PART	O
trespass	O	VERB	B
the	O	DET	O
BBB	O	PROPN	B
.	O	PUNCT	O


Tacrine	B-Chemical	NOUN	B
,	O	PUNCT	O
administered	O	VERB	B
in	O	ADP	O
LiCl	B-Chemical	NOUN	B
pre	O	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
rats	O	NOUN	B
,	O	PUNCT	O
induces	O	VERB	O
electrocorticographic	O	ADJ	B
seizures	B-Disease	NOUN	I
and	O	CCONJ	O
delayed	O	VERB	B
hippocampal	B-Disease	NOUN	B
damage	I-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
toxic	O	ADJ	B
effects	O	NOUN	O
of	O	ADP	O
tacrine	B-Chemical	NOUN	B
-	O	PUNCT	O
loaded	O	VERB	B
poly-L-lactid	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
nanoparticles	O	NOUN	I
(	O	PUNCT	O
5mg	O	NOUN	B
/	O	SYM	O
kg	O	NOUN	B
),	O	PUNCT	O
a	O	DET	O
saline	O	NOUN	B
solution	O	NOUN	I
of	O	ADP	O
tacrine	B-Chemical	NOUN	B
(	O	PUNCT	O
5mg	O	NOUN	B
/	O	SYM	O
kg	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
an	O	DET	O
empty	O	ADJ	B
colloidal	O	ADJ	B
nanoparticle	O	NOUN	B
suspension	O	NOUN	O
were	O	AUX	O
compared	O	VERB	O
following	O	VERB	O
i	O	PRON	O
.	O	PUNCT	O


p	O	NOUN	O
.	O	PUNCT	O


administration	O	NOUN	B
in	O	ADP	O
LiCl	B-Chemical	NOUN	B
-	O	PUNCT	O
pre	O	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
Wistar	O	PROPN	B
rats	O	NOUN	I
.	O	PUNCT	O


All	O	DET	O
the	O	DET	O
animals	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
tacrine	B-Chemical	NOUN	B
-	O	PUNCT	O
loaded	O	VERB	B
nanoparticles	O	NOUN	B
showed	O	VERB	O
an	O	DET	O
earlier	O	ADJ	O
outcome	O	NOUN	B
of	O	ADP	O
CNS	O	NOUN	B
adverse	O	ADJ	B
symptoms	O	NOUN	I
,	O	PUNCT	O
i	O	X	O
.	O	PUNCT	O


e	O	X	O
.	O	PUNCT	O


epileptic	B-Disease	ADJ	B
onset	O	NOUN	I
,	O	PUNCT	O
with	O	ADP	O
respect	O	NOUN	O
to	O	PART	O
those	O	DET	O
animals	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
the	O	DET	O
free	O	ADJ	B
compound	O	NOUN	I
(	O	PUNCT	O
10	O	NUM	O
min	O	NOUN	O
vs	O	CCONJ	O
.	O	PUNCT	O


22	O	NUM	O
min	O	NOUN	O
respectively	O	ADV	O
).	O	PUNCT	B
In	O	ADP	O
addition	O	NOUN	O
,	O	PUNCT	O
tacrine	B-Chemical	NOUN	B
-	O	PUNCT	O
loaded	O	VERB	B
nanoparticles	O	NOUN	B
administration	O	NOUN	B
induced	O	VERB	B
damage	B-Disease	NOUN	B
of	I-Disease	ADP	O
neuronal	I-Disease	ADJ	B
cells	I-Disease	NOUN	I
in	O	ADP	O
CA1	O	NOUN	B
field	O	NOUN	I
of	O	ADP	O
the	O	DET	O
hippocampus	O	NOUN	B
in	O	ADP	O
all	O	DET	O
treated	O	VERB	B
animals	O	NOUN	B
,	O	PUNCT	O
while	O	SCONJ	O
the	O	DET	O
saline	O	NOUN	B
solution	O	NOUN	I
of	O	ADP	O
tacrine	B-Chemical	NOUN	B
only	O	ADV	O
in	O	ADP	O
60	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
animals	O	NOUN	B
.	O	PUNCT	O


Empty	O	ADJ	B
nanoparticles	O	NOUN	B
provided	O	VERB	O
similar	O	ADJ	O
results	O	NOUN	B
to	O	PART	O
control	O	NOUN	B
(	O	PUNCT	O
saline	O	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
)	O	PUNCT	O
group	O	NOUN	B
of	O	ADP	O
animals	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
conclusion	O	NOUN	O
,	O	PUNCT	O
the	O	DET	O
evaluation	O	NOUN	B
of	O	ADP	O
time	O	NOUN	B
-	O	PUNCT	O
to	O	PART	O
-	O	PUNCT	O
onset	O	NOUN	B
of	O	ADP	I
symptoms	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
severity	O	NOUN	B
of	O	ADP	O
neurodegenerative	O	ADJ	B
processes	O	NOUN	I
induced	O	VERB	B
by	O	ADP	O
the	O	DET	O
tacrine	B-Chemical	NOUN	B
-	O	PUNCT	O
lithium	B-Chemical	NOUN	B
model	O	NOUN	B
of	O	ADP	O
epilepsy	B-Disease	NOUN	B


The	O	DET	O
antiarrhythmic	O	ADJ	B
effect	O	NOUN	I
and	O	CCONJ	O
possible	O	ADJ	O
ionic	O	ADJ	B
mechanisms	O	NOUN	I
of	O	ADP	O
pilocarpine	B-Chemical	NOUN	B
on	O	ADP	O
animal	O	NOUN	B
models	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
study	O	NOUN	B
was	O	AUX	O
designed	O	VERB	O
to	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	O
pilocarpine	B-Chemical	NOUN	B
and	O	CCONJ	O
explore	O	VERB	O
the	O	DET	O
underlying	O	ADJ	O
ionic	O	ADJ	B
mechanism	O	NOUN	I
,	O	PUNCT	O
using	O	VERB	O
both	O	CCONJ	O
aconitine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
rat	O	NOUN	B
and	O	CCONJ	O
ouabain	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
guinea	O	NOUN	B
pig	O	NOUN	B
arrhythmia	B-Disease	NOUN	B
models	O	NOUN	I
.	O	PUNCT	O


Confocal	O	ADJ	B
microscopy	O	NOUN	I
was	O	AUX	O
used	O	VERB	O
to	O	PART	O
measure	O	VERB	B
intracellular	O	ADJ	B
free	O	ADJ	B
-	O	PUNCT	O
calcium	B-Chemical	NOUN	B
concentrations	O	NOUN	B
([	O	PUNCT	B
Ca	B-Chemical	NOUN	B
(	O	PUNCT	O
2	O	NUM	O
+)](	O	NUM	O
i	O	NUM	O
))	O	PUNCT	O
in	O	ADP	O
isolated	O	VERB	B
myocytes	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
current	O	ADJ	O
data	O	NOUN	B
showed	O	VERB	O
that	O	SCONJ	O
pilocarpine	B-Chemical	NOUN	B
significantly	O	ADV	O
delayed	O	VERB	B
onset	O	NOUN	B
of	O	ADP	I
arrhythmias	B-Disease	NOUN	B
,	O	PUNCT	O
decreased	O	VERB	B
the	O	DET	O
time	O	NOUN	B
course	O	NOUN	I
of	O	ADP	O
ventricular	B-Disease	ADJ	B
tachycardia	I-Disease	NOUN	I
and	I-Disease	CCONJ	O
fibrillation	I-Disease	NOUN	B
,	O	PUNCT	O
reduced	O	VERB	B
arrhythmia	B-Disease	NOUN	B
score	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
increased	O	VERB	B
the	O	DET	O
survival	O	NOUN	B
time	O	NOUN	I
of	O	ADP	O
arrhythmic	B-Disease	ADJ	O
rats	O	NOUN	B
and	O	CCONJ	O
guinea	O	NOUN	B
pigs	O	NOUN	B
.[	O	PUNCT	O
Ca	B-Chemical	NOUN	B
(	O	PUNCT	O
2	O	NUM	O
+)](	O	NUM	O
i	O	NUM	O
)	O	PUNCT	O
overload	O	NOUN	B
induced	O	VERB	B
by	O	ADP	O
aconitine	B-Chemical	NOUN	B
or	O	CCONJ	O
ouabain	B-Chemical	NOUN	B
was	O	AUX	O
reduced	O	VERB	B
in	O	ADP	O
isolated	O	VERB	B
myocytes	O	NOUN	B
pretreated	O	VERB	B
with	O	ADP	O
pilocarpine	B-Chemical	NOUN	B
.	O	PUNCT	O


Moreover	O	ADV	O
,	O	PUNCT	O
M	O	NOUN	B
(	O	PUNCT	O
3	O	NUM	O
)-	O	ADJ	O
muscarinic	O	ADJ	B
acetylcholine	B-Chemical	NOUN	I
receptor	O	NOUN	I
(	O	PUNCT	O
mAChR	O	NOUN	B
)	O	PUNCT	O
antagonist	O	NOUN	B
4-DAMP	B-Chemical	NOUN	B
(	O	PUNCT	O
4-diphenylacetoxy-N-methylpiperidine-methiodide	B-Chemical	NOUN	O
)	O	PUNCT	O
partially	O	ADV	O
abolished	O	VERB	O
the	O	DET	O
beneficial	O	ADJ	O
effects	O	NOUN	B
of	O	ADP	O
pilocarpine	B-Chemical	NOUN	B
.	O	PUNCT	O


These	O	DET	O
data	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
pilocarpine	B-Chemical	NOUN	B
produced	O	VERB	O
antiarrhythmic	O	ADJ	B
actions	O	NOUN	I
on	O	ADP	O
arrhythmic	B-Disease	ADJ	B
rat	O	NOUN	I
and	O	CCONJ	O
guinea	O	NOUN	B
pig	O	NOUN	B
models	O	NOUN	B
induced	O	VERB	B
by	O	ADP	O
aconitine	B-Chemical	NOUN	B
or	O	CCONJ	O
ouabain	B-Chemical	NOUN	B
via	O	ADP	O
stimulating	O	VERB	O
the	O	DET	O
cardiac	O	ADJ	B
M	O	NOUN	I
(	O	PUNCT	O
3	O	NUM	O
)-	O	ADJ	O
mAChR	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
mechanism	O	NOUN	B
may	O	AUX	O
be	O	AUX	O
related	O	ADJ	O
to	O	PART	O
the	O	DET	O
improvement	O	NOUN	B
of	O	ADP	O
Ca	B-Chemical	NOUN	B


Disulfiram	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
transient	O	ADJ	B
optic	B-Disease	ADJ	B
and	I-Disease	CCONJ	O
peripheral	I-Disease	ADJ	B
neuropathy	I-Disease	NOUN	I
:	O	PUNCT	O
a	O	DET	O
case	O	NOUN	B
report	O	NOUN	I
.	O	PUNCT	O


AIM	O	NOUN	B
:	O	PUNCT	O
To	O	PART	O
report	O	VERB	O
a	O	DET	O
case	O	NOUN	B
of	O	ADP	O
optic	B-Disease	ADJ	B
and	I-Disease	CCONJ	O
peripheral	I-Disease	ADJ	B
neuropathy	I-Disease	NOUN	I
after	O	ADP	O
chronic	O	ADJ	B
use	O	NOUN	O
of	O	ADP	O
disulfiram	B-Chemical	NOUN	B
for	O	ADP	O
alcohol	B-Disease	NOUN	B
dependence	I-Disease	NOUN	I
management	O	NOUN	I
.	O	PUNCT	O


MATERIALS	O	NOUN	O
AND	O	CCONJ	O
METHODS	O	NOUN	O
:	O	PUNCT	O
A	O	DET	O
case	O	NOUN	B
report	O	NOUN	I
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
A	O	DET	O
57	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
male	O	NOUN	B
presented	O	VERB	O
with	O	ADP	O
gradual	O	ADJ	O
loss	B-Disease	NOUN	O
of	I-Disease	ADP	O
vision	I-Disease	NOUN	O
in	O	ADP	O
both	O	DET	O
eyes	O	NOUN	B
with	O	ADP	O
intermittent	O	ADJ	B
headaches	B-Disease	NOUN	I
for	O	ADP	O
2	O	NUM	O
months	O	NOUN	B
.	O	PUNCT	O


He	O	PRON	O
also	O	ADV	O
complained	O	VERB	O
of	O	ADP	O
paraesthesia	B-Disease	NOUN	B
with	O	ADP	O
numbness	B-Disease	NOUN	B
in	O	ADP	O
both	O	DET	O
feet	O	NOUN	B
.	O	PUNCT	O


His	O	PRON	O
vision	O	NOUN	B
was	O	AUX	O
6	O	NUM	O
/	O	SYM	O
15	O	NUM	O
and	O	CCONJ	O
2	O	NUM	O
/	O	SYM	O
60	O	NUM	O
in	O	ADP	O
the	O	DET	O
right	O	ADJ	B
and	O	CCONJ	O
left	O	VERB	B
eyes	O	NOUN	I
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


Fundoscopy	O	NOUN	B
revealed	O	VERB	O
bilaterally	O	ADV	B
swollen	O	VERB	O
optic	O	ADJ	B
nerve	O	NOUN	I
heads	O	NOUN	I
.	O	PUNCT	O


Visual	O	ADJ	B
field	O	NOUN	I
testing	O	NOUN	I
confirmed	O	VERB	O
bilateral	O	ADJ	B
central	O	ADJ	B
-	O	PUNCT	O
caecal	O	ADJ	B
scotomata	B-Disease	NOUN	B
.	O	PUNCT	O


He	O	PRON	O
had	O	AUX	O
been	O	AUX	O
taking	O	VERB	O
disulfiram	B-Chemical	NOUN	B
for	O	ADP	O
alcohol	B-Disease	NOUN	B
dependence	I-Disease	NOUN	I
for	O	ADP	O
the	O	DET	O
preceding	O	VERB	O
3	O	NUM	O
years	O	NOUN	B
.	O	PUNCT	O


Disulfiram	B-Chemical	NOUN	B
discontinuation	O	NOUN	B
lead	O	VERB	O
to	O	PART	O
an	O	DET	O
immediate	O	ADJ	O
symptomatic	O	ADJ	B
improvement	O	NOUN	B
.	O	PUNCT	O


CONCLUSION	O	NOUN	B
:	O	PUNCT	O
Physicians	O	NOUN	B
initiating	O	VERB	O
long	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
disulfiram	B-Chemical	NOUN	B


Sustained	O	ADJ	B
clinical	O	ADJ	B
improvement	O	NOUN	I
of	O	ADP	O
a	O	DET	O
patient	O	NOUN	B
with	O	ADP	O
decompensated	O	ADJ	B
hepatitis	B-Disease	NOUN	I
B	I-Disease	NOUN	I
virus	O	NOUN	I
-	O	PUNCT	O
related	O	ADJ	B
cirrhosis	B-Disease	NOUN	B
after	O	ADP	O
treatment	O	NOUN	B
with	O	ADP	O
lamivudine	B-Chemical	NOUN	B
monotherapy	O	NOUN	B
.	O	PUNCT	O


Hepatitis	B-Disease	NOUN	B
B	I-Disease	NOUN	I
virus	I-Disease	NOUN	I
(HBV)	I-Disease	ADJ	I
infection	I-Disease	NOUN	O
,	O	PUNCT	O
which	O	DET	O
causes	O	VERB	O
liver	B-Disease	NOUN	B
cirrhosis	I-Disease	NOUN	I
and	O	CCONJ	O
hepatocellular	B-Disease	NOUN	B
carcinoma	I-Disease	NOUN	I
,	O	PUNCT	O
remains	O	VERB	O
a	O	DET	O
major	O	ADJ	O
health	O	NOUN	B
problem	O	NOUN	I
in	O	ADP	O
Asian	O	ADJ	B
countries	O	NOUN	B
.	O	PUNCT	O


Recent	O	ADJ	O
development	O	NOUN	B
of	O	ADP	O
vaccine	O	NOUN	B
for	O	ADP	O
prevention	O	NOUN	B
is	O	AUX	O
reported	O	VERB	O
to	O	PART	O
be	O	AUX	O
successful	O	ADJ	O
in	O	ADP	O
reducing	O	VERB	B
the	O	DET	O
size	O	NOUN	B
of	O	ADP	O
chronically	O	ADV	B
infected	O	ADJ	B
carriers	O	NOUN	B
,	O	PUNCT	O
although	O	SCONJ	O
the	O	DET	O
standard	O	ADJ	B
medical	O	ADJ	B
therapies	O	NOUN	I
have	O	AUX	O
not	O	PART	O
been	O	AUX	O
established	O	VERB	O
up	O	ADP	O
to	O	ADP	O
now	O	ADV	O
.	O	PUNCT	O


In	O	ADP	O
this	O	DET	O
report	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
encountered	O	VERB	O
a	O	DET	O
patient	O	NOUN	B
with	O	ADP	O
decompensated	O	ADJ	B
HBV	O	NOUN	B
-	O	PUNCT	O
related	O	VERB	B
cirrhosis	B-Disease	NOUN	B
who	O	PRON	O
exhibited	O	VERB	O
the	O	DET	O
dramatic	O	ADJ	O
improvements	O	NOUN	B
after	O	ADP	O
antiviral	O	ADJ	B
therapy	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
patient	O	NOUN	B
was	O	AUX	O
a	O	DET	O
50	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
woman	O	NOUN	B
.	O	PUNCT	O


Previous	O	ADJ	O
conventional	O	ADJ	O
medical	O	ADJ	B
treatments	O	NOUN	I
were	O	AUX	O
not	O	PART	O
effective	O	ADJ	B
for	O	ADP	O
this	O	DET	O
patient	O	NOUN	B
,	O	PUNCT	O
thus	O	ADV	O
this	O	DET	O
patient	O	NOUN	B
had	O	AUX	O
been	O	AUX	O
referred	O	VERB	O
to	O	ADP	O
our	O	PRON	O
hospital	O	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
administration	O	NOUN	B
of	O	ADP	O
lamivudine	B-Chemical	NOUN	B
,	O	PUNCT	O
a	O	DET	O
reverse	O	ADJ	B
transcriptase	O	NOUN	I
inhibitor	O	NOUN	I
,	O	PUNCT	O
for	O	ADP	O
23	O	NUM	O
months	O	NOUN	B
dramatically	O	ADV	O
improved	O	VERB	B
her	O	PRON	O
liver	O	NOUN	B
severity	O	NOUN	I
.	O	PUNCT	O


During	O	ADP	O
this	O	DET	O
period	O	NOUN	B
,	O	PUNCT	O
no	O	DET	O
drug	O	NOUN	B
resistant	O	ADJ	I
mutant	O	ADJ	O
HBV	O	NOUN	B
emerged	O	VERB	O
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
serum	O	NOUN	B
HBV	O	NOUN	B
-	O	PUNCT	O
DNA	O	NOUN	B
level	O	NOUN	B
was	O	AUX	O
continuously	O	ADV	O
suppressed	O	VERB	B
.	O	PUNCT	O


These	O	DET	O
virological	O	ADJ	B
responses	O	NOUN	I
were	O	AUX	O
also	O	ADV	O
maintained	O	VERB	B
even	O	ADV	O
after	O	ADP	O
the	O	DET	O
antiviral	O	ADJ	B
therapy	O	NOUN	I
was	O	AUX	O
discontinued	O	VERB	B
.	O	PUNCT	O


Moreover	O	ADV	O
,	O	PUNCT	O
both	O	CCONJ	O
hepatitis	B-Chemical	NOUN	B
B	I-Chemical	NOUN	I
surface	I-Chemical	NOUN	I
antigen	I-Chemical	NOUN	I
and	I-Chemical	CCONJ	O
e	I-Chemical	NOUN	B
antigen	I-Chemical	NOUN	I
were	O	AUX	O
observed	O	VERB	O
to	O	PART	O
have	O	AUX	O
disappeared	O	VERB	O
in	O	ADP	O
this	O	DET	O
patient	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
administration	O	NOUN	B
of	O	ADP	O
lamivudine	B-Chemical	NOUN	B
to	O	PART	O
patients	O	NOUN	B
with	O	ADP	O
HBV	O	NOUN	B
-	O	PUNCT	O
related	O	VERB	B
cirrhosis	B-Disease	NOUN	B


Dual	O	ADJ	B
effects	O	NOUN	I
of	O	ADP	O
melatonin	B-Chemical	NOUN	B
on	O	ADP	O
barbiturate	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
narcosis	B-Disease	NOUN	B
in	O	ADP	O
rats	O	NOUN	B
.	O	PUNCT	O


Melatonin	B-Chemical	NOUN	B
affects	O	VERB	O
the	O	DET	O
circadian	O	ADJ	B
sleep	O	NOUN	B
/	O	SYM	O
wake	O	NOUN	B
cycle	O	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
it	O	PRON	O
is	O	AUX	O
not	O	PART	O
clear	O	ADJ	O
whether	O	SCONJ	O
it	O	PRON	O
may	O	AUX	O
influence	O	VERB	B
drug	O	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
narcosis	B-Disease	NOUN	B
.	O	PUNCT	O


Sodium	B-Chemical	NOUN	B
thiopenthal	I-Chemical	NOUN	I
was	O	AUX	O
administered	O	VERB	B
intraperitoneally	O	ADV	B
into	O	ADP	O
male	O	NOUN	B
rats	O	NOUN	B
pre	O	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
with	O	ADP	O
melatonin	B-Chemical	NOUN	B
(	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


05	O	NUM	O
,	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
,	O	PUNCT	O
5	O	NUM	O
and	O	CCONJ	O
50	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
).	O	PUNCT	O
Melatonin	B-Chemical	NOUN	B
pre	O	NOUN	B
-	O	PUNCT	O
treatment	O	NOUN	B
affected	O	VERB	B
in	O	ADP	O
a	O	DET	O
dual	O	ADJ	O
manner	O	NOUN	O
barbiturate	B-Chemical	NOUN	B
narcosis	B-Disease	NOUN	I
,	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
no	O	DET	O
dose	O	NOUN	B
-	O	PUNCT	O
effect	O	NOUN	B
correlation	O	NOUN	B
was	O	AUX	O
found	O	VERB	O
.	O	PUNCT	O


In	O	ADP	O
particular	O	ADJ	O
,	O	PUNCT	O
low	O	ADJ	B
doses	O	NOUN	I
reduced	O	VERB	B
the	O	DET	O
latency	O	NOUN	B
to	O	PART	O
and	O	CCONJ	O
prolonged	O	VERB	B
the	O	DET	O
duration	O	NOUN	B
of	O	ADP	O
barbiturate	B-Chemical	NOUN	B
narcosis	B-Disease	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
contrast	O	NOUN	O
,	O	PUNCT	O
the	O	DET	O
highest	O	ADJ	B
dose	O	NOUN	B
of	O	ADP	O
melatonin	B-Chemical	NOUN	B
(	O	PUNCT	O
50	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
)	O	PUNCT	O
caused	O	VERB	O
a	O	DET	O
paradoxical	O	ADJ	B
increase	O	NOUN	B
in	O	ADP	O
the	O	DET	O
latency	O	NOUN	B
and	O	CCONJ	O
produced	O	VERB	O
a	O	DET	O
sustained	O	ADJ	O
reduction	O	NOUN	B
of	O	ADP	O
the	O	DET	O
duration	O	NOUN	B
of	O	ADP	O
narcosis	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
reduction	O	NOUN	B
in	O	ADP	O
mortality	O	NOUN	B
rate	O	NOUN	I
.	O	PUNCT	O


Melatonin	B-Chemical	NOUN	B
0	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
and	O	CCONJ	O
5	O	NUM	O
mg	O	NOUN	O
/	O	PUNCT	O
kg	O	NOUN	B
influenced	O	VERB	B
the	O	DET	O
duration	O	NOUN	B
but	O	CCONJ	O
not	O	PART	O
the	O	DET	O
latency	O	NOUN	B
of	O	ADP	O
ketamine	B-Chemical	NOUN	B
-	O	PUNCT	O
or	O	CCONJ	O
diazepam	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
narcosis	B-Disease	NOUN	B
.	O	PUNCT	O


Thus	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
dual	O	ADJ	B
action	O	NOUN	I
of	O	ADP	O
melatonin	B-Chemical	NOUN	B
on	O	ADP	O
pharmacological	O	ADJ	B
narcosis	B-Disease	NOUN	I
seems	O	VERB	O
to	O	PART	O
be	O	AUX	O
specific	O	ADJ	O
for	O	ADP	O
the	O	DET	O
barbiturate	B-Chemical	NOUN	B


Effects	O	NOUN	B
of	O	ADP	O
NIK-247	B-Chemical	NOUN	B
on	O	ADP	O
cholinesterase	O	NOUN	B
and	O	CCONJ	O
scopolamine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
amnesia	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
effects	O	NOUN	B
of	O	ADP	O
NIK-247	B-Chemical	NOUN	B
on	O	ADP	O
cholinesterase	O	NOUN	B
,	O	PUNCT	O
scopolamine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
amnesia	B-Disease	NOUN	B
and	O	CCONJ	O
spontaneous	O	ADJ	B
movement	O	NOUN	B
were	O	AUX	O
examined	O	VERB	B
and	O	CCONJ	O
compared	O	VERB	B
with	O	ADP	O
those	O	DET	O
of	O	ADP	O
the	O	DET	O
well	O	ADV	B
-	O	PUNCT	O
known	O	VERB	B
cholinesterase	O	NOUN	B
inhibitors	O	NOUN	I
tacrine	B-Chemical	NOUN	B
and	O	CCONJ	O
E-2020	B-Chemical	NOUN	B
.	O	PUNCT	O


NIK-247	B-Chemical	NOUN	B
,	O	PUNCT	O
tacrine	B-Chemical	NOUN	B
and	O	CCONJ	O
E-2020	B-Chemical	NOUN	B
all	O	DET	O
strongly	O	ADV	O
inhibited	O	VERB	B
acetylcholinesterase	O	NOUN	B
(	O	PUNCT	O
AChE	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
human	O	ADJ	B
red	O	ADJ	B
blood	O	NOUN	I
cells	O	NOUN	I
(	O	PUNCT	O
IC50s	O	NOUN	B
=	O	ADJ	O
1	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
x	O	CCONJ	O
10	O	NUM	O
(-	O	PUNCT	O
6	O	NUM	O
),	O	PUNCT	O
2	O	NUM	O
.	O	PUNCT	O


9	O	NUM	O
x	O	NOUN	O
10	O	NUM	O
(-	O	PUNCT	O
7	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
3	O	NUM	O
.	O	PUNCT	O


7	O	NUM	O
x	O	NOUN	O
10	O	NUM	O
(-	O	PUNCT	O
8	O	NUM	O
)	O	PUNCT	O
M	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
).	O	PUNCT	B
In	O	ADP	O
addition	O	NOUN	O
,	O	PUNCT	O
NIK-247	B-Chemical	NOUN	B
and	O	CCONJ	O
tacrine	B-Chemical	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
not	O	PART	O
E-2020	B-Chemical	NOUN	B
,	O	PUNCT	O
strongly	O	ADV	O
inhibited	O	VERB	B
butyrylcholinestrase	O	NOUN	B
(	O	PUNCT	O
BuChE	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
human	O	ADJ	B
serum	O	NOUN	B
.	O	PUNCT	O


All	O	DET	O
three	O	NUM	O
drugs	O	NOUN	B
produced	O	VERB	O
mixed	O	ADJ	O
inhibition	O	NOUN	B
of	O	ADP	O
AChE	O	NOUN	B
activity	O	NOUN	B
.	O	PUNCT	O


Moreover	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
inhibitory	O	ADJ	B
effect	O	NOUN	O
of	O	ADP	O
NIK-247	B-Chemical	NOUN	B
on	O	ADP	O
AChE	O	NOUN	B
was	O	AUX	O
reversible	O	ADJ	B
.	O	PUNCT	O


All	O	DET	O
compounds	O	NOUN	B
at	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
-	O	SYM	O
1	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	O
p	O	NOUN	O
.	O	PUNCT	O


o	O	X	O
.	O	PUNCT	O


significantly	O	ADV	O
improved	O	VERB	O
the	O	DET	O
amnesia	B-Disease	NOUN	B
induced	O	VERB	B
by	O	ADP	O
scopolamine	B-Chemical	NOUN	B
(	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	O
s	O	NOUN	O
.	O	PUNCT	O


c	O	X	O
.)	O	NOUN	O
in	O	ADP	O
rats	O	NOUN	B
performing	O	VERB	O
a	O	DET	O
passive	O	ADJ	B
avoidance	O	NOUN	O
task	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
three	O	NUM	O
compounds	O	NOUN	B
at	O	ADP	O
1	O	NUM	O
and	O	CCONJ	O
3	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	O
p	O	NOUN	O
.	O	PUNCT	O


o	O	X	O
.	O	PUNCT	O


did	O	AUX	O
not	O	PART	O
significantly	O	ADV	O
decrease	O	VERB	B
spontaneous	O	ADJ	B
movement	O	NOUN	B
by	O	ADP	O
rats	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
findings	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
NIK-247	B-Chemical	NOUN	B
at	O	ADP	O
a	O	DET	O
low	O	ADJ	B
dose	O	NOUN	I
(	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
-	O	SYM	O
1	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	O
p	O	NOUN	O
.	O	PUNCT	O


o	O	INTJ	O
.)	O	NOUN	O
improves	O	VERB	O
scopolamine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
amnesia	B-Disease	NOUN	B
but	O	CCONJ	O
does	O	AUX	O
not	O	PART	O
affect	O	VERB	O
spontaneous	O	ADJ	B
movement	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
findings	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
NIK-247	B-Chemical	PROPN	B
may	O	AUX	O
be	O	AUX	O
a	O	DET	O
useful	O	ADJ	O
drug	O	NOUN	B
for	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
Alzheimer's	B-Disease	NOUN	B
disease	I-Disease	NOUN	I


Nightmares	O	NOUN	B
and	O	CCONJ	O
hallucinations	B-Disease	NOUN	B
after	O	ADP	O
long	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
intake	O	NOUN	B
of	O	ADP	O
tramadol	B-Chemical	NOUN	B
combined	O	VERB	B
with	O	ADP	O
antidepressants	O	NOUN	B
.	O	PUNCT	O


Tramadol	B-Chemical	NOUN	B
is	O	AUX	O
a	O	DET	O
weak	O	ADJ	B
opioid	O	NOUN	B
with	O	ADP	O
effects	O	NOUN	B
on	O	ADP	O
adrenergic	O	ADJ	B
and	O	CCONJ	O
serotonergic	O	ADJ	B
neurotransmission	O	NOUN	B
that	O	PRON	O
is	O	AUX	O
used	O	VERB	O
to	O	PART	O
treat	O	VERB	B
cancer	B-Disease	NOUN	B
pain	B-Disease	NOUN	I
and	O	CCONJ	O
chronic	O	ADJ	B
non	O	ADJ	O
malignant	O	ADJ	O
pain	B-Disease	NOUN	O
.	O	PUNCT	O


This	O	DET	O
drug	O	NOUN	B
was	O	AUX	O
initiated	O	VERB	O
in	O	ADP	O
association	O	NOUN	B
with	O	ADP	O
paroxetine	B-Chemical	NOUN	B
and	O	CCONJ	O
dosulepine	B-Chemical	ADJ	B
hydrochloride	I-Chemical	NOUN	I
in	O	ADP	O
a	O	DET	O
tetraparetic	B-Disease	ADJ	B
patient	O	NOUN	B
with	O	ADP	O
chronic	B-Disease	ADJ	B
pain	I-Disease	NOUN	I
.	O	PUNCT	O


Fifty	O	PROPN	B
-	O	PUNCT	O
six	O	NUM	B
days	O	NOUN	B
after	O	ADP	O
initiation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
the	O	DET	O
patient	O	NOUN	B
presented	O	VERB	O
hallucinations	B-Disease	NOUN	B
that	O	SCONJ	O
only	O	ADV	O
stopped	O	VERB	O
after	O	ADP	O
the	O	DET	O
withdrawal	O	NOUN	B
of	O	ADP	I
psycho	O	NOUN	B
-	O	PUNCT	O
active	O	ADJ	B
drugs	O	NOUN	B
and	O	CCONJ	O
tramadol	B-Chemical	NOUN	B
.	O	PUNCT	O


The	O	DET	O
case	O	NOUN	B
report	O	NOUN	I
questions	O	VERB	O
the	O	DET	O
long	O	ADJ	B
term	O	NOUN	I
use	O	NOUN	O
of	O	ADP	O
pain	B-Disease	NOUN	B
killers	O	NOUN	B
combined	O	VERB	O
with	O	ADP	O
psycho	O	NOUN	B
-	O	PUNCT	O
active	O	ADJ	B
drugs	O	NOUN	B
in	O	ADP	O
chronic	O	ADJ	B
non	O	ADJ	O
malignant	O	ADJ	O
pain	B-Disease	NOUN	O
,	O	PUNCT	O
especially	O	ADV	O
if	O	SCONJ	O
pain	B-Disease	NOUN	B


Apparent	O	ADJ	B
cure	O	NOUN	I
of	O	ADP	O
rheumatoid	B-Disease	ADJ	B
arthritis	I-Disease	NOUN	I
by	O	ADP	O
bone	O	NOUN	B
marrow	O	NOUN	I
transplantation	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
describe	O	VERB	O
the	O	DET	O
induction	O	NOUN	B
of	O	ADP	O
sustained	O	ADJ	B
remissions	O	NOUN	B
and	O	CCONJ	O
possible	O	ADJ	O
cure	O	NOUN	B
of	O	ADP	O
severe	O	ADJ	B
erosive	O	ADJ	B
rheumatoid	B-Disease	ADJ	I
arthritis	I-Disease	NOUN	I
(	O	PUNCT	O
RA	B-Disease	NOUN	B
)	O	PUNCT	O
by	O	ADP	O
bone	O	NOUN	B
marrow	O	NOUN	I
transplantation	O	NOUN	I
(	O	PUNCT	O
BMT	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
2	O	NUM	O
patients	O	NOUN	B
.	O	PUNCT	O


BMT	O	NOUN	B
was	O	AUX	O
used	O	VERB	O
to	O	PART	O
treat	O	VERB	B
severe	O	ADJ	B
aplastic	B-Disease	ADJ	B
anemia	I-Disease	NOUN	I
which	O	DET	O
was	O	AUX	O
caused	O	VERB	O
by	O	ADP	O
gold	B-Chemical	NOUN	B
in	O	ADP	O
one	O	NUM	O
case	O	NOUN	B
and	O	CCONJ	O
D-penicillamine	B-Chemical	NOUN	B
in	O	ADP	O
the	O	DET	O
other	O	ADJ	O
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
8	O	NUM	O
and	O	CCONJ	O
6	O	NUM	O
years	O	NOUN	B
since	O	SCONJ	O
the	O	DET	O
transplants	O	NOUN	B
(	O	PUNCT	O
representing	O	VERB	O
8	O	NUM	O
and	O	CCONJ	O
4	O	NUM	O
years	O	NOUN	B
since	O	SCONJ	O
cessation	O	NOUN	B
of	O	ADP	O
all	O	DET	O
immunosuppressive	O	ADJ	B
therapy	O	NOUN	I
,	O	PUNCT	O
respectively	O	ADV	O
),	O	PUNCT	O
the	O	DET	O
RA	B-Disease	NOUN	B
in	O	ADP	O
each	O	DET	O
case	O	NOUN	B
has	O	AUX	O
been	O	AUX	O
completely	O	ADV	O
quiescent	O	ADJ	B
.	O	PUNCT	O


Although	O	SCONJ	O
short	O	ADJ	B
term	O	NOUN	I
remission	O	NOUN	I
of	O	ADP	O
severe	O	ADJ	B
RA	B-Disease	NOUN	B
following	O	VERB	O
BMT	O	NOUN	B
has	O	AUX	O
been	O	AUX	O
reported	O	VERB	O
,	O	PUNCT	O
these	O	DET	O
are	O	AUX	O
the	O	DET	O
first	O	ADJ	O
cases	O	NOUN	B
for	O	ADP	O
which	O	DET	O
prolonged	O	ADJ	B
followup	O	NOUN	B
has	O	AUX	O
been	O	AUX	O
available	O	ADJ	O
.	O	PUNCT	O


This	O	DET	O
experience	O	NOUN	B
raises	O	VERB	O
the	O	DET	O
question	O	NOUN	O
of	O	ADP	O
the	O	DET	O
role	O	NOUN	O
of	O	ADP	O
BMT	O	NOUN	B
itself	O	PRON	O
as	O	ADP	O
a	O	DET	O
therapeutic	O	ADJ	B
option	O	NOUN	O
for	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
uncontrolled	O	ADJ	B
destructive	O	ADJ	B
synovitis	B-Disease	NOUN	B


Urinary	O	ADJ	B
enzymes	O	NOUN	I
and	O	CCONJ	O
protein	O	NOUN	B
patterns	O	NOUN	I
as	O	ADP	O
indicators	O	NOUN	B
of	O	ADP	O
injury	B-Disease	NOUN	B
to	I-Disease	PART	O
different	I-Disease	ADJ	O
regions	I-Disease	NOUN	B
of	I-Disease	ADP	O
the	I-Disease	DET	O
kidney	I-Disease	NOUN	B
.	O	PUNCT	O


Acute	B-Disease	ADJ	B
experimental	I-Disease	ADJ	O
models	I-Disease	NOUN	O
of	I-Disease	ADP	O
renal	I-Disease	ADJ	B
damage	I-Disease	NOUN	I
to	O	PART	O
the	O	DET	O
proximal	O	ADJ	B
tubular	O	ADJ	B
,	O	PUNCT	O
glomerular	O	ADJ	B
,	O	PUNCT	O
and	O	CCONJ	O
papillary	O	ADJ	B
regions	O	NOUN	I
of	O	ADP	O
the	O	DET	O
rat	O	NOUN	B
were	O	AUX	O
produced	O	VERB	O
by	O	ADP	O
administration	O	NOUN	B
of	O	ADP	O
hexachloro-1:3-butadiene	B-Chemical	NOUN	B
(	O	PUNCT	O
HCBD	B-Chemical	NOUN	B
),	O	PUNCT	O
puromycin	B-Chemical	NOUN	B
aminonucleoside	I-Chemical	NOUN	B
(	O	PUNCT	O
PAN	B-Chemical	NOUN	B
),	O	PUNCT	O
and	O	CCONJ	O
2-bromoethylamine	B-Chemical	NOUN	B
(	O	PUNCT	O
BEA	B-Chemical	NOUN	B
),	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


Several	O	ADJ	O
routine	O	ADJ	O
indicators	O	NOUN	B
of	O	ADP	O
nephrotoxicity	B-Disease	NOUN	B
,	O	PUNCT	O
the	O	DET	O
enzymes	O	NOUN	B
alkaline	O	NOUN	B
phosphatase	O	NOUN	I
and	O	CCONJ	O
N	O	NOUN	B
-	O	PUNCT	O
acetyl	O	ADJ	B
-	O	PUNCT	O
beta	O	NOUN	B
-	O	PUNCT	O
glucosaminidase	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
molecular	O	ADJ	B
weight	O	NOUN	I
of	O	ADP	O
protein	B-Disease	NOUN	B
excretion	I-Disease	NOUN	B
were	O	AUX	O
determined	O	VERB	O
on	O	ADP	O
urine	O	NOUN	B
samples	O	NOUN	I
.	O	PUNCT	O


Tubular	O	ADJ	B
damage	O	NOUN	I
produced	O	VERB	O
by	O	ADP	O
HCBD	B-Chemical	NOUN	B
or	O	CCONJ	O
BEA	B-Chemical	NOUN	B
was	O	AUX	O
discriminated	O	VERB	O
both	O	CCONJ	O
quantitatively	O	ADV	B
and	O	CCONJ	O
qualitatively	O	ADV	B
from	O	ADP	O
glomerular	B-Disease	ADJ	B
damage	I-Disease	NOUN	I
produced	O	VERB	O
by	O	ADP	O
PAN	B-Chemical	PROPN	B
.	O	PUNCT	O


The	O	DET	O
latter	O	ADJ	O
was	O	AUX	O
characterized	O	VERB	B
by	O	ADP	O
a	O	DET	O
pronounced	O	ADJ	O
increase	O	NOUN	B
in	O	ADP	O
protein	B-Disease	NOUN	B
excretion	I-Disease	NOUN	B
,	O	PUNCT	O
especially	O	ADV	O
proteins	O	NOUN	B
with	O	ADP	O
molecular	O	ADJ	B
weight	O	NOUN	I
greater	O	ADJ	O
than	O	ADP	O
40	O	NUM	O
,	O	PUNCT	O
000	O	NUM	O
Da	O	NOUN	O
.	O	PUNCT	O


In	O	ADP	O
contrast	O	NOUN	O
,	O	PUNCT	O
protein	B-Disease	NOUN	B
excretion	I-Disease	NOUN	B
in	O	ADP	O
tubular	O	ADJ	B
damage	O	NOUN	I
was	O	AUX	O
raised	O	VERB	O
only	O	ADV	O
slightly	O	ADV	O
and	O	CCONJ	O
characterized	O	VERB	B
by	O	ADP	O
excretion	B-Disease	NOUN	B
of	I-Disease	ADP	O
proteins	I-Disease	NOUN	B
of	O	ADP	O
a	O	DET	O
wide	O	ADJ	O
range	O	NOUN	O
of	O	ADP	O
molecular	O	ADJ	B
weights	O	NOUN	I
.	O	PUNCT	O


Proximal	O	ADJ	B
tubular	O	ADJ	B
damage	O	NOUN	I
caused	O	VERB	O
by	O	ADP	O
HCBD	B-Chemical	NOUN	B
and	O	CCONJ	O
papillary	O	ADJ	B
damage	O	NOUN	I
caused	O	VERB	O
by	O	ADP	O
BEA	B-Chemical	NOUN	B
were	O	AUX	O
distinguished	O	VERB	O
both	O	CCONJ	O
by	O	ADP	O
conventional	O	ADJ	O
urinalysis	O	NOUN	B
(	O	PUNCT	O
volume	O	NOUN	B
and	O	CCONJ	O
specific	O	ADJ	O
gravity	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
by	O	ADP	O
measurement	O	NOUN	B
of	O	ADP	O
the	O	DET	O
two	O	NUM	O
urinary	O	ADJ	B
enzymes	O	NOUN	I
.	O	PUNCT	O


Alkaline	O	NOUN	B
phosphatase	O	NOUN	I
and	O	CCONJ	O
glucose	B-Chemical	NOUN	B
were	O	AUX	O
markedly	O	ADV	B
and	O	CCONJ	O
transiently	O	ADV	B
elevated	O	ADJ	B
in	O	ADP	O
proximal	O	ADJ	B
tubular	O	ADJ	O
damage	O	NOUN	O
and	O	CCONJ	O
N	O	NOUN	B
-	O	PUNCT	O
acetyl	O	ADJ	B
-	O	PUNCT	O
beta	O	NOUN	B
-	O	PUNCT	O
glucosaminidase	O	NOUN	B
showed	O	VERB	O
a	O	DET	O
sustained	O	ADJ	O
elevation	O	NOUN	B
in	O	ADP	O
papillary	O	ADJ	B
damage	O	NOUN	I
.	O	PUNCT	O


It	O	PRON	O
is	O	AUX	O
concluded	O	VERB	O
that	O	SCONJ	O
both	O	CCONJ	O
selective	O	ADJ	O
urinary	O	ADJ	B
enzymes	O	NOUN	I
and	O	CCONJ	O
the	O	DET	O
molecular	O	ADJ	B
weight	O	NOUN	I
pattern	O	NOUN	I
of	O	ADP	O
urinary	O	ADJ	B
proteins	O	NOUN	I
can	O	AUX	O
be	O	AUX	O
used	O	VERB	O
to	O	PART	O
provide	O	VERB	O
diagnostic	O	ADJ	B
information	O	NOUN	B
about	O	ADP	O
the	O	DET	O
possible	O	ADJ	O
site	O	NOUN	B
of	O	ADP	O
renal	B-Disease	ADJ	B
damage	I-Disease	NOUN	I


Neuromuscular	B-Disease	ADJ	B
blockade	I-Disease	NOUN	I
with	O	ADP	O
magnesium	B-Chemical	NOUN	B
sulfate	I-Chemical	NOUN	I
and	O	CCONJ	O
nifedipine	B-Chemical	NOUN	B
.	O	PUNCT	O


A	O	DET	O
patient	O	NOUN	B
who	O	PRON	O
received	O	VERB	O
tocolysis	O	NOUN	B
with	O	ADP	O
nifedipine	B-Chemical	NOUN	B
developed	O	VERB	O
neuromuscular	B-Disease	ADJ	B
blockade	I-Disease	NOUN	I
after	O	ADP	O
500	O	NUM	O
mg	O	NOUN	O
of	O	ADP	O
magnesium	B-Chemical	NOUN	B
sulfate	I-Chemical	NOUN	I
was	O	AUX	O
administered	O	VERB	B
.	O	PUNCT	O


This	O	DET	O
reaction	O	NOUN	B
demonstrates	O	VERB	O
that	O	SCONJ	O
nifedipine	B-Chemical	NOUN	B
can	O	AUX	O
seriously	O	ADV	O
potentiate	O	VERB	B
the	O	DET	O
toxicity	B-Disease	NOUN	B
of	O	ADP	O
magnesium	B-Chemical	NOUN	B


Ifosfamide	B-Chemical	NOUN	B
continuous	O	ADJ	O
infusion	O	NOUN	B
without	O	ADP	O
mesna	B-Chemical	NOUN	B
.	O	PUNCT	O


A	O	DET	O
phase	O	NOUN	B
I	O	NOUN	I
trial	O	NOUN	I
of	O	ADP	O
a	O	DET	O
14	O	NUM	B
-	O	PUNCT	O
day	O	NOUN	B
cycle	O	NOUN	B
.	O	PUNCT	O


Twenty	O	NUM	O
patients	O	NOUN	B
received	O	VERB	O
27	O	NUM	O
courses	O	NOUN	B
of	O	ADP	O
ifosfamide	B-Chemical	NOUN	B
administered	O	VERB	B
as	O	ADP	O
a	O	DET	O
24	O	NUM	O
-	O	PUNCT	O
hour	O	NOUN	B
continuous	O	ADJ	B
infusion	O	NOUN	B
for	O	ADP	O
14	O	NUM	O
days	O	NOUN	B
without	O	ADP	O
Mesna	B-Chemical	PROPN	B
.	O	PUNCT	O


The	O	DET	O
goal	O	NOUN	B
of	O	ADP	O
the	O	DET	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
deliver	O	VERB	B
a	O	DET	O
dose	O	NOUN	B
rate	O	NOUN	I
and	O	CCONJ	O
total	O	ADJ	O
cumulative	O	ADJ	B
dose	O	NOUN	B
of	O	ADP	O
ifosfamide	B-Chemical	NOUN	B
that	O	PRON	O
would	O	AUX	O
be	O	AUX	O
comparable	O	ADJ	O
to	O	PART	O
standard	O	ADJ	O
bolus	O	NOUN	B
or	O	CCONJ	O
short	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
infusions	O	NOUN	B
administered	O	VERB	B
with	O	ADP	O
Mesna	B-Chemical	NOUN	B
.	O	PUNCT	O


Dose	O	NOUN	B
escalations	O	NOUN	B
proceeded	O	VERB	O
from	O	ADP	O
200	O	NUM	O
to	O	PART	O
300	O	NUM	O
,	O	PUNCT	O
400	O	NUM	O
,	O	PUNCT	O
450	O	NUM	O
,	O	PUNCT	O
500	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
550	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
m2	O	NOUN	B
/	O	SYM	O
d	O	NOUN	B
.	O	PUNCT	O


Four	O	NUM	O
patients	O	NOUN	B
developed	O	VERB	O
transient	O	ADJ	B
microscopic	O	ADJ	I
hematuria	B-Disease	NOUN	I
at	O	ADP	O
400	O	NUM	O
,	O	PUNCT	O
450	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
500	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
m2	O	NOUN	B
/	O	SYM	O
d	O	NOUN	B
.	O	PUNCT	O


There	O	PRON	O
were	O	AUX	O
no	O	DET	O
instances	O	NOUN	O
of	O	ADP	O
macroscopic	O	ADJ	B
hematuria	B-Disease	NOUN	I
.	O	PUNCT	O


At	O	ADP	O
550	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
m2	O	NOUN	B
/	O	SYM	O
d	O	NOUN	O
,	O	PUNCT	O
three	O	NUM	O
patients	O	NOUN	B
experienced	O	VERB	O
nonurologic	O	ADJ	B
toxicity	B-Disease	NOUN	B
;	O	PUNCT	O
confusion	B-Disease	NOUN	B
(	O	PUNCT	O
1	O	NUM	O
),	O	PUNCT	O
nausea	B-Disease	NOUN	B
(	O	PUNCT	O
1	O	NUM	O
),	O	PUNCT	O
and	O	CCONJ	O
Grade	O	NOUN	B
2	O	NUM	I
leukopenia	B-Disease	NOUN	I
(	O	PUNCT	O
1	O	NUM	O
).	O	PUNCT	O
The	O	DET	O
recommended	O	ADJ	B
dose	O	NOUN	B
of	O	ADP	O
500	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
m2	O	NOUN	B
/	O	SYM	O
d	O	NOUN	B
delivers	O	VERB	O
a	O	DET	O
total	O	ADJ	O
dose	O	NOUN	B
of	O	ADP	O
7	O	NUM	O
g	O	NOUN	B
/	O	SYM	O
m2	O	NOUN	B
per	O	ADP	I
cycle	O	NOUN	I
,	O	PUNCT	O
which	O	DET	O
is	O	AUX	O
comparable	O	ADJ	O
to	O	PART	O
that	O	DET	O
delivered	O	VERB	O
in	O	ADP	O
clinical	O	ADJ	B
practice	O	NOUN	I
for	O	ADP	O
bolus	O	NOUN	B
or	O	CCONJ	O
short	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
infusion	O	NOUN	B
.	O	PUNCT	O


Because	O	SCONJ	O
few	O	ADJ	O
patients	O	NOUN	B
received	O	VERB	O
multiple	O	ADJ	B
courses	O	NOUN	B
over	O	ADP	O
time	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
cumulative	O	ADJ	B
effects	O	NOUN	B
are	O	AUX	O
indeterminate	O	ADJ	B
in	O	ADP	O
the	O	DET	O
present	O	ADJ	O
trial	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
frequency	O	NOUN	B
and	O	CCONJ	O
predictability	O	NOUN	B
of	O	ADP	O
hematuria	B-Disease	NOUN	B
are	O	AUX	O
not	O	PART	O
precise	O	ADJ	O
,	O	PUNCT	O
and	O	CCONJ	O
at	O	ADP	O
least	O	ADV	O
daily	O	ADJ	B
monitoring	O	NOUN	B
by	O	ADP	O
urine	O	NOUN	B
Hematest	O	PROPN	I
is	O	AUX	O
essential	O	ADJ	B
,	O	PUNCT	O
adding	O	VERB	O
Mesna	B-Chemical	PROPN	B
to	O	PART	O
the	O	DET	O
infusate	O	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
persistent	O	ADJ	B
hematuria	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
protracted	O	ADJ	B
infusion	O	NOUN	B
schedule	O	NOUN	B
for	O	ADP	O
ifosfamide	B-Chemical	NOUN	B
permits	O	VERB	O
convenient	O	ADJ	O
outpatient	O	ADJ	B
administration	O	NOUN	O
without	O	ADP	O
Mesna	B-Chemical	NOUN	B


Myocardial	B-Disease	ADJ	B
infarction	I-Disease	NOUN	I
in	O	ADP	O
pregnancy	O	NOUN	B
associated	O	VERB	B
with	O	ADP	I
clomiphene	B-Chemical	NOUN	B
citrate	I-Chemical	NOUN	I
for	O	ADP	O
ovulation	O	NOUN	B
induction	O	NOUN	B
:	O	PUNCT	O
a	O	DET	O
case	O	NOUN	B
report	O	NOUN	I
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
:	O	PUNCT	O
Clomiphene	B-Chemical	NOUN	B
citrate	I-Chemical	NOUN	I
(	O	PUNCT	O
CC	B-Chemical	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
commonly	O	ADV	O
prescribed	O	VERB	B
for	O	ADP	O
ovulation	O	NOUN	B
induction	O	NOUN	B
.	O	PUNCT	O


It	O	PRON	O
is	O	AUX	O
considered	O	VERB	O
safe	O	ADJ	O
,	O	PUNCT	O
with	O	ADP	O
minimal	O	ADJ	B
side	O	NOUN	B
effects	O	NOUN	I
.	O	PUNCT	O


Thromboembolism	B-Disease	NOUN	B
is	O	AUX	O
a	O	DET	O
rare	O	ADJ	B
but	O	CCONJ	O
life	O	NOUN	B
-	O	PUNCT	O
threatening	O	VERB	B
complication	O	NOUN	B
that	O	PRON	O
has	O	AUX	O
been	O	AUX	O
reported	O	VERB	O
after	O	ADP	O
ovulation	O	NOUN	B
induction	O	NOUN	B
with	O	ADP	O
CC	B-Chemical	NOUN	B
.	O	PUNCT	O


Spontaneous	O	ADJ	B
coronary	B-Disease	ADJ	B
thrombosis	I-Disease	NOUN	I
or	O	CCONJ	O
thromboembolism	B-Disease	NOUN	B
with	O	ADP	O
subsequent	O	ADJ	O
clot	O	NOUN	B
lysis	O	NOUN	I
has	O	AUX	O
been	O	AUX	O
suggested	O	VERB	O
as	O	ADP	O
one	O	NUM	O
of	O	ADP	O
the	O	DET	O
most	O	ADV	O
common	O	ADJ	O
causes	O	NOUN	O
of	O	ADP	O
myocardial	B-Disease	ADJ	B
infarction	I-Disease	NOUN	I
(	O	PUNCT	O
MI	B-Disease	NOUN	B
)	O	PUNCT	O
during	O	ADP	O
pregnancy	O	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
a	O	DET	O
subsequently	O	ADV	O
normal	O	ADJ	O
coronary	O	ADJ	O
angiogram	O	NOUN	O
.	O	PUNCT	O


CASE	O	NOUN	B
:	O	PUNCT	O
A	O	DET	O
33	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
woman	O	NOUN	B
with	O	ADP	O
a	O	DET	O
5	O	NUM	O
-	O	PUNCT	O
week	O	NOUN	B
gestation	O	NOUN	B
had	O	AUX	O
recently	O	ADV	O
received	O	VERB	O
CC	B-Chemical	NOUN	B
for	O	ADP	O
ovulation	O	NOUN	B
induction	O	NOUN	B
and	O	CCONJ	O
presented	O	VERB	O
with	O	ADP	O
chest	B-Disease	ADJ	B
pain	I-Disease	NOUN	I
.	O	PUNCT	O


An	O	DET	O
electrocardiogram	O	NOUN	B
showed	O	VERB	O
a	O	DET	O
lateral	O	ADJ	B
and	O	CCONJ	O
anterior	O	ADJ	B
wall	O	NOUN	I
myocardial	B-Disease	ADJ	I
infarction	I-Disease	NOUN	I
.	O	PUNCT	O


Cardiac	O	ADJ	B
enzymes	O	NOUN	I
showed	O	VERB	O
a	O	DET	O
peak	O	ADJ	O
rise	O	NOUN	O
in	O	ADP	O
troponin	O	NOUN	B
I	O	NUM	I
to	O	PART	O
9	O	NUM	O
.	O	PUNCT	O


10	O	NUM	O
ng	O	NOUN	O
/	O	SYM	O
mL	O	NOUN	B
.	O	PUNCT	O


An	O	DET	O
initial	O	ADJ	O
exercise	O	NOUN	B
stress	O	NOUN	I
test	O	NOUN	I
was	O	AUX	O
normal	O	ADJ	O
.	O	PUNCT	O


At	O	ADP	O
the	O	DET	O
time	O	NOUN	O
of	O	ADP	O
admission	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
patient	O	NOUN	B
was	O	AUX	O
at	O	ADP	O
high	O	ADJ	O
risk	O	NOUN	B
of	O	ADP	O
radiation	B-Disease	NOUN	B
injury	I-Disease	NOUN	I
to	O	ADP	O
the	O	DET	O
fetus	O	NOUN	B
,	O	PUNCT	O
so	O	CCONJ	O
a	O	DET	O
coronary	O	ADJ	B
angiogram	O	NOUN	I
was	O	AUX	O
postponed	O	VERB	O
until	O	ADP	O
the	O	DET	O
second	O	ADJ	O
trimester	O	NOUN	B
.	O	PUNCT	O


It	O	PRON	O
showed	O	VERB	O
normal	O	ADJ	O
coronary	O	ADJ	B
vessels	O	NOUN	I
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
:	O	PUNCT	O
This	O	DET	O
appears	O	VERB	O
to	O	PART	O
be	O	AUX	O
the	O	DET	O
first	O	ADJ	O
reported	O	VERB	O
case	O	NOUN	B
documenting	O	VERB	O
a	O	DET	O
possible	O	ADJ	O
association	O	NOUN	B
between	O	ADP	O
CC	B-Chemical	NOUN	B
and	O	CCONJ	O
myocardial	B-Disease	ADJ	B
infarction	I-Disease	NOUN	I
.	O	PUNCT	O


Thrombosis	B-Disease	NOUN	B
might	O	AUX	O
be	O	AUX	O
a	O	DET	O
rare	O	ADJ	B
but	O	CCONJ	O
hazardous	O	ADJ	B
complication	O	NOUN	B
of	O	ADP	O
CC	B-Chemical	NOUN	B


Hepatonecrosis	B-Disease	NOUN	B
and	O	CCONJ	O
cholangitis	B-Disease	NOUN	B
related	O	ADJ	O
to	O	PART	O
long	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
phenobarbital	B-Chemical	NOUN	B
therapy	O	NOUN	I
:	O	PUNCT	O
an	O	DET	O
autopsy	O	NOUN	B
report	O	NOUN	B
of	O	ADP	O
two	O	NUM	O
patients	O	NOUN	B
.	O	PUNCT	O


Phenobarbital	B-Chemical	NOUN	B
(	O	PUNCT	O
PB	B-Chemical	NOUN	B
)	O	PUNCT	O
has	O	AUX	O
a	O	DET	O
reputation	O	NOUN	B
for	O	ADP	O
safety	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
it	O	PRON	O
is	O	AUX	O
commonly	O	ADV	O
believed	O	VERB	O
that	O	SCONJ	O
PB	B-Chemical	NOUN	B
-	O	PUNCT	O
related	O	VERB	B
increases	O	NOUN	B
in	O	ADP	O
serum	O	NOUN	B
aminotransferase	O	NOUN	I
levels	O	NOUN	I
do	O	AUX	O
not	O	PART	O
indicate	O	VERB	O
or	O	CCONJ	O
predict	O	VERB	O
the	O	DET	O
development	O	NOUN	B
of	O	ADP	O
significant	O	ADJ	B
chronic	O	ADJ	B
liver	B-Disease	NOUN	I
disease	I-Disease	NOUN	I
.	O	PUNCT	O


Here	O	ADV	O
we	O	PRON	O
report	O	VERB	O
of	O	ADP	O
two	O	NUM	O
adult	O	ADJ	B
patients	O	NOUN	B
with	O	ADP	O
a	O	DET	O
long	O	ADJ	B
history	O	NOUN	I
of	O	ADP	O
epilepsy	B-Disease	NOUN	B
treated	O	VERB	B
with	O	ADP	I
PB	B-Chemical	NOUN	B
who	O	PRON	O
died	O	VERB	B
suddenly	O	ADV	O
:	O	PUNCT	O
one	O	NUM	O
as	O	ADP	O
consequence	O	NOUN	B
of	O	ADP	I
cardiac	B-Disease	ADJ	B
arrest	I-Disease	NOUN	I
,	O	PUNCT	O
the	O	DET	O
other	O	ADJ	O
of	O	ADP	O
acute	O	ADJ	B
bronchopneumonia	B-Disease	NOUN	I
.	O	PUNCT	O


At	O	ADP	O
autopsy	O	NOUN	B
,	O	PUNCT	O
analysis	O	NOUN	B
of	O	ADP	O
liver	O	NOUN	B
parenchyma	O	NOUN	I
revealed	O	VERB	O
rich	O	ADJ	B
portal	O	ADJ	I
inflammatory	O	ADJ	I
infiltrate	O	NOUN	I
,	O	PUNCT	O
which	O	DET	O
consisted	O	VERB	O
of	O	ADP	O
mixed	O	ADJ	O
eosinophil	O	NOUN	B
and	O	CCONJ	O
monocyte	O	NOUN	B
cells	O	NOUN	I
,	O	PUNCT	O
associated	O	VERB	B
with	O	ADP	I
several	O	ADJ	O
foci	O	NOUN	B
of	O	ADP	O
necrosis	B-Disease	NOUN	B
surrounded	O	VERB	B
by	O	ADP	O
a	O	DET	O
hard	O	ADJ	B
ring	O	NOUN	I
of	O	ADP	O
non	O	ADJ	B
-	O	PUNCT	O
specific	O	ADJ	B
granulomatous	O	ADJ	B
tissue	O	NOUN	I
.	O	PUNCT	O


Inflammatory	O	ADJ	B
reactions	O	NOUN	I
of	O	ADP	O
internal	O	ADJ	B
and	O	CCONJ	O
external	O	ADJ	O
hepatic	O	ADJ	B
biliary	O	ADJ	I
ducts	O	NOUN	I
were	O	AUX	O
also	O	ADV	O
seen	O	VERB	O
.	O	PUNCT	O


Our	O	PRON	O
findings	O	NOUN	B
illustrate	O	VERB	O
that	O	SCONJ	O
PB	B-Chemical	NOUN	B
may	O	AUX	O
be	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
chronic	O	ADJ	B
liver	B-Disease	NOUN	I
damage	I-Disease	NOUN	I
,	O	PUNCT	O
which	O	DET	O
may	O	AUX	O
lead	O	VERB	O
to	O	ADP	O
more	O	ADV	O
serious	O	ADJ	B
and	O	CCONJ	O
deleterious	O	ADJ	B
consequences	O	NOUN	B
.	O	PUNCT	O


For	O	ADP	O
this	O	DET	O
reason	O	NOUN	O
,	O	PUNCT	O
each	O	DET	O
clinician	O	NOUN	B
should	O	AUX	O
recognize	O	VERB	O
this	O	DET	O
entity	O	NOUN	B
in	O	ADP	O
the	O	DET	O
differential	O	ADJ	B
diagnosis	O	NOUN	I
of	O	ADP	O
PB	B-Chemical	NOUN	B
-	O	PUNCT	O
related	O	ADJ	B
asymptomatic	O	ADJ	B
chronic	B-Disease	ADJ	B
hepatic	I-Disease	ADJ	I
enzyme	I-Disease	NOUN	I
dysfunction	I-Disease	NOUN	I


Ethambutol	B-Chemical	PROPN	B
-	O	PUNCT	O
associated	O	VERB	B
optic	B-Disease	ADJ	B
neuropathy	I-Disease	NOUN	I
.	O	PUNCT	O


INTRODUCTION	O	NOUN	O
:	O	PUNCT	O
Ethambutol	B-Chemical	NOUN	B
is	O	AUX	O
used	O	VERB	O
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
tuberculosis	B-Disease	NOUN	B
,	O	PUNCT	O
which	O	DET	O
is	O	AUX	O
still	O	ADV	O
prevalent	O	ADJ	O
in	O	ADP	O
Southeast	O	PROPN	B
Asia	O	PROPN	I
,	O	PUNCT	O
and	O	CCONJ	O
can	O	AUX	O
be	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
permanent	O	ADJ	B
visual	B-Disease	ADJ	B
loss	I-Disease	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
3	O	NUM	O
cases	O	NOUN	B
which	O	DET	O
presented	O	VERB	O
with	O	ADP	O
bitemporal	B-Disease	ADJ	B
hemianopia	I-Disease	NOUN	I
.	O	PUNCT	O


CLINICAL	O	NOUN	O
PICTURE	O	NOUN	O
:	O	PUNCT	O
Three	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
ethambutol	B-Chemical	NOUN	B
-	O	PUNCT	O
associated	O	VERB	B
toxic	O	ADJ	B
optic	B-Disease	ADJ	B
neuropathy	I-Disease	NOUN	I
are	O	AUX	O
described	O	VERB	O
.	O	PUNCT	O


All	O	DET	O
3	O	NUM	O
patients	O	NOUN	B
had	O	AUX	O
loss	B-Disease	NOUN	B
of	I-Disease	ADP	O
central	I-Disease	ADJ	B
visual	I-Disease	ADJ	I
acuity,	I-Disease	ADJ	O
colour	I-Disease	NOUN	B
vision	I-Disease	NOUN	I
(Ishihara)	I-Disease	NOUN	O
and	I-Disease	CCONJ	O
visual	I-Disease	ADJ	B
field	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
visual	B-Disease	ADJ	B
field	I-Disease	NOUN	I
loss	I-Disease	NOUN	I
had	O	AUX	O
a	O	DET	O
bitemporal	O	ADJ	B
flavour	O	NOUN	I
,	O	PUNCT	O
suggesting	O	VERB	O
involvement	O	NOUN	B
of	O	ADP	O
the	O	DET	O
optic	O	ADJ	B
chiasm	O	NOUN	I
.	O	PUNCT	O


TREATMENT	O	NOUN	B
:	O	PUNCT	O
Despite	O	SCONJ	O
stopping	O	VERB	B
ethambutol	B-Chemical	NOUN	B
on	O	ADP	O
diagnosis	O	NOUN	B
,	O	PUNCT	O
visual	O	ADJ	B
function	O	NOUN	I
continued	O	VERB	O
to	O	PART	O
deteriorate	O	VERB	B
for	O	ADP	O
a	O	DET	O
few	O	ADJ	O
months	O	NOUN	B
.	O	PUNCT	O


Subsequent	O	ADJ	O
improvement	O	NOUN	B
was	O	AUX	O
mild	O	ADJ	B
in	O	ADP	O
2	O	NUM	O
cases	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
third	O	ADJ	O
case	O	NOUN	B
,	O	PUNCT	O
visual	O	ADJ	B
acuity	O	NOUN	I
and	O	CCONJ	O
colour	O	NOUN	B
vision	O	NOUN	I
normalised	O	VERB	B
but	O	CCONJ	O
the	O	DET	O
optic	O	ADJ	B
discs	O	NOUN	I
were	O	AUX	O
pale	O	ADJ	B
.	O	PUNCT	O


OUTCOME	O	NOUN	B
:	O	PUNCT	O
All	O	DET	O
3	O	NUM	O
patients	O	NOUN	B
had	O	AUX	O
some	O	DET	O
permanent	O	ADJ	B
loss	B-Disease	NOUN	I
of	I-Disease	ADP	O
visual	I-Disease	ADJ	B
function	I-Disease	NOUN	I
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
:	O	PUNCT	O
Ethambutol	B-Chemical	NOUN	B
usage	O	NOUN	B
is	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
permanent	O	ADJ	B
visual	B-Disease	ADJ	B
loss	I-Disease	NOUN	I
and	O	CCONJ	O
should	O	AUX	O
be	O	AUX	O
avoided	O	VERB	O
if	O	SCONJ	O
possible	O	ADJ	O
or	O	CCONJ	O
used	O	VERB	O
with	O	ADP	O
caution	O	NOUN	O
and	O	CCONJ	O
proper	O	ADJ	O
ophthalmological	O	ADJ	B
follow	O	NOUN	B
-	O	PUNCT	O
up	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
author	O	NOUN	B
postulates	O	VERB	O
that	O	SCONJ	O
in	O	ADP	O
cases	O	NOUN	B
of	O	ADP	O
ethambutol	B-Chemical	NOUN	B
associated	O	VERB	O
chiasmopathy	O	NOUN	B
,	O	PUNCT	O
ethambutol	B-Chemical	X	B


Tolerability	O	NOUN	B
of	O	ADP	O
nimesulide	B-Chemical	NOUN	B
and	O	CCONJ	O
paracetamol	B-Chemical	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
NSAID	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
urticaria	B-Disease	NOUN	B
/	O	SYM	O
angioedema	B-Disease	NOUN	B
.	O	PUNCT	O


Previous	O	ADJ	O
studies	O	NOUN	B
evaluated	O	VERB	B
the	O	DET	O
tolerance	O	NOUN	B
of	O	ADP	O
nimesulide	B-Chemical	NOUN	B
and	O	CCONJ	O
paracetamol	B-Chemical	NOUN	B
in	O	ADP	O
subjects	O	NOUN	B
with	O	ADP	O
cutaneous	O	ADJ	B
,	O	PUNCT	O
respiratory	O	ADJ	B
and	O	CCONJ	O
anaphylactoid	O	ADJ	B
reactions	O	NOUN	I
induced	O	VERB	B
by	O	ADP	O
nonsteroidal	B-Chemical	ADJ	B
anti-inflammatory	I-Chemical	ADJ	I
drugs	I-Chemical	NOUN	I
(	O	PUNCT	O
NSAIDs	B-Chemical	NOUN	B
).	O	PUNCT	O
In	O	ADP	O
this	O	DET	O
study	O	NOUN	B
we	O	PRON	O
investigated	O	VERB	B
tolerability	O	NOUN	B
and	O	CCONJ	O
reliability	O	NOUN	B
of	O	ADP	O
nimesulide	B-Chemical	NOUN	B
and	O	CCONJ	O
paracetamol	B-Chemical	NOUN	B
in	O	ADP	O
a	O	DET	O
very	O	ADV	O
large	O	ADJ	O
number	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
an	O	DET	O
exclusive	O	ADJ	O
well	O	ADV	O
-	O	PUNCT	O
documented	O	VERB	B
history	O	NOUN	B
of	O	ADP	O
NSAID	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
urticaria	B-Disease	NOUN	B
/	O	SYM	O
angioedema	B-Disease	NOUN	B
.	O	PUNCT	O


Furthermore	O	ADV	O
,	O	PUNCT	O
we	O	PRON	O
evaluated	O	VERB	B
whether	O	SCONJ	O
some	O	DET	O
factors	O	NOUN	B
have	O	AUX	O
the	O	DET	O
potential	O	NOUN	B
to	O	PART	O
increase	O	VERB	B
the	O	DET	O
risk	O	NOUN	B
of	O	ADP	O
reaction	O	NOUN	B
to	O	PART	O
paracetamol	B-Chemical	NOUN	B
and	O	CCONJ	O
nimesulide	B-Chemical	NOUN	B
.	O	PUNCT	O


A	O	DET	O
single	O	ADJ	B
-	O	PUNCT	O
placebo	O	NOUN	B
-	O	PUNCT	O
controlled	O	VERB	B
oral	O	ADJ	B
challenge	O	NOUN	O
procedure	O	NOUN	O
with	O	ADP	O
nimesulide	B-Chemical	NOUN	B
or	O	CCONJ	O
paracetamol	B-Chemical	NOUN	B
was	O	AUX	O
applied	O	VERB	O
to	O	PART	O
829	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
a	O	DET	O
history	O	NOUN	B
of	O	ADP	O
NSAID	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
urticaria	B-Disease	NOUN	B
/	O	SYM	O
angioedema	B-Disease	NOUN	B
.	O	PUNCT	O


A	O	DET	O
total	O	NOUN	O
of	O	ADP	O
75	O	NUM	O
/	O	SYM	O
829	O	NUM	O
(	O	PUNCT	O
9	O	NUM	O
.	O	PUNCT	O


4	O	NUM	O
%)	O	NOUN	O
patients	O	NOUN	B
experienced	O	VERB	O
reactions	O	NOUN	B
to	O	PART	O
nimesulide	B-Chemical	NOUN	B
or	O	CCONJ	O
paracetamol	B-Chemical	NOUN	B
.	O	PUNCT	O


Of	O	ADP	O
the	O	DET	O
715	O	NUM	O
patients	O	NOUN	B
tested	O	VERB	B
with	O	ADP	O
nimesulide	B-Chemical	NOUN	B
62	O	NUM	O
(	O	PUNCT	O
8	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
%)	O	NOUN	B
showed	O	VERB	O
a	O	DET	O
positive	O	ADJ	B
test	O	NOUN	I
,	O	PUNCT	O
while	O	SCONJ	O
of	O	ADP	O
114	O	NUM	O
subjects	O	NOUN	B
submitted	O	VERB	O
to	O	ADP	O
the	O	DET	O
challenge	O	NOUN	O
with	O	ADP	O
paracetamol	B-Chemical	NOUN	B
,	O	PUNCT	O
13	O	NUM	O
(	O	PUNCT	O
9	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
%)	O	NOUN	O
did	O	AUX	O
not	O	PART	O
tolerate	O	VERB	O
this	O	DET	O
drug	O	NOUN	B
.	O	PUNCT	O


Furthermore	O	ADV	O
,	O	PUNCT	O
18	O	NUM	O
.	O	PUNCT	O


28	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
a	O	DET	O
history	O	NOUN	B
of	O	ADP	O
chronic	O	ADJ	B
urticaria	B-Disease	NOUN	I
and	O	CCONJ	O
11	O	NUM	O
.	O	PUNCT	O


8	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
subjects	O	NOUN	B
with	O	ADP	O
an	O	DET	O
history	O	NOUN	B
of	O	ADP	O
NSAID	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
urticaria	B-Disease	NOUN	B
/	O	PUNCT	O
angioedema	B-Disease	NOUN	B
or	O	CCONJ	O
angioedema	B-Disease	NOUN	B
alone	O	ADV	O
(	O	PUNCT	O
with	O	ADP	O
or	O	CCONJ	O
without	O	ADP	O
chronic	O	ADJ	B
urticaria	B-Disease	NOUN	I
)	O	PUNCT	O
resulted	O	VERB	O
to	O	PART	O
be	O	AUX	O
intolerant	O	ADJ	B
to	O	PART	O
alternative	O	ADJ	O
drugs	O	NOUN	B
.	O	PUNCT	O


Taken	O	VERB	O
together	O	ADV	O
,	O	PUNCT	O
our	O	PRON	O
results	O	NOUN	O
confirm	O	VERB	O
the	O	DET	O
good	O	ADJ	O
tolerability	O	NOUN	B
of	O	ADP	O
nimesulide	B-Chemical	NOUN	B
and	O	CCONJ	O
paracetamol	B-Chemical	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
who	O	PRON	O
experienced	O	VERB	O
urticaria	B-Disease	NOUN	B
/	O	PUNCT	O
angioedema	B-Disease	NOUN	B
caused	O	VERB	O
by	O	ADP	O
NSAIDs	B-Chemical	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
risk	O	NOUN	B
of	O	ADP	O
reaction	O	NOUN	B
to	O	PART	O
these	O	DET	O
alternative	O	ADJ	B
study	O	NOUN	I
drugs	O	NOUN	B
is	O	AUX	O
statistically	O	ADV	O
increased	O	VERB	B
by	O	ADP	O
a	O	DET	O
history	O	NOUN	B
of	O	ADP	O
chronic	O	ADJ	B
urticaria	B-Disease	NOUN	I
and	O	CCONJ	O
,	O	PUNCT	O
above	O	ADP	O
all	O	ADV	O
,	O	PUNCT	O
by	O	ADP	O
a	O	DET	O
history	O	NOUN	B
of	O	ADP	O
NSAID	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
angioedema	B-Disease	NOUN	B


Effects	O	NOUN	B
of	O	ADP	I
verapamil	B-Chemical	NOUN	B
on	O	ADP	O
atrial	B-Disease	ADJ	B
fibrillation	I-Disease	NOUN	I
and	O	CCONJ	O
its	O	PRON	O
electrophysiological	O	ADJ	B
determinants	O	NOUN	I
in	O	ADP	O
dogs	O	NOUN	B
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
:	O	PUNCT	O
Atrial	B-Disease	ADJ	B
tachycardia	I-Disease	NOUN	I
-	O	PUNCT	O
induced	O	VERB	B
remodeling	O	NOUN	B
promotes	O	VERB	B
the	O	DET	O
occurrence	O	NOUN	B
and	O	CCONJ	O
maintenance	O	NOUN	B
of	O	ADP	O
atrial	B-Disease	ADJ	B
fibrillation	I-Disease	NOUN	I
(	O	PUNCT	O
AF	B-Disease	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
decreases	O	VERB	B
L	O	NOUN	B
-	O	PUNCT	O
type	O	NOUN	B
Ca	B-Chemical	NOUN	B
(	O	PUNCT	O
2	O	NUM	O
+)	O	NOUN	O
current	O	NOUN	O
.	O	PUNCT	O


There	O	PRON	O
is	O	AUX	O
also	O	ADV	O
a	O	DET	O
clinical	O	ADJ	B
suggestion	O	NOUN	O
that	O	SCONJ	O
acute	O	ADJ	B
L	O	NOUN	B
-	O	PUNCT	O
type	O	NOUN	B
Ca	B-Chemical	NOUN	B
(	O	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
channel	O	NOUN	O
blockade	O	NOUN	O
can	O	AUX	O
promote	O	VERB	B
AF	B-Disease	PROPN	B
,	O	PUNCT	O
consistent	O	ADJ	B
with	O	ADP	I
an	O	DET	O
AF	B-Disease	NOUN	B
promoting	O	NOUN	B
effect	O	NOUN	B
of	O	ADP	O
Ca	B-Chemical	NOUN	B
(	O	PUNCT	O
2	O	NUM	O
+)	O	NOUN	O
channel	O	NOUN	B
inhibition	O	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
:	O	PUNCT	O
To	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
potential	O	ADJ	B
mechanisms	O	NOUN	B
of	O	ADP	O
AF	B-Disease	NOUN	B
promotion	O	NOUN	B
by	O	ADP	O
Ca	B-Chemical	NOUN	B
(	O	PUNCT	O
2	O	NUM	O
+)	O	NOUN	O
channel	O	NOUN	B
blockers	O	NOUN	I
,	O	PUNCT	O
we	O	PRON	O
administered	O	VERB	B
verapamil	B-Chemical	NOUN	B
to	O	PART	O
morphine	B-Chemical	NOUN	B
-	O	PUNCT	O
chloralose	B-Chemical	NOUN	B
anesthetized	O	ADJ	B
dogs	O	NOUN	B
.	O	PUNCT	O


Diltiazem	B-Chemical	NOUN	B
was	O	AUX	O
used	O	VERB	O
as	O	ADP	O
a	O	DET	O
comparison	O	NOUN	B
drug	O	NOUN	B
and	O	CCONJ	O
autonomic	O	ADJ	B
blockade	O	NOUN	I
with	O	ADP	O
atropine	B-Chemical	NOUN	B
and	O	CCONJ	O
nadolol	B-Chemical	NOUN	B
was	O	AUX	O
applied	O	VERB	O
in	O	ADP	O
some	O	DET	O
experiments	O	NOUN	B
.	O	PUNCT	O


Epicardial	O	ADJ	B
mapping	O	NOUN	I
with	O	ADP	O
240	O	NUM	O
epicardial	O	ADJ	B
electrodes	O	NOUN	I
was	O	AUX	O
used	O	VERB	O
to	O	PART	O
evaluate	O	VERB	B
activation	O	NOUN	B
during	O	ADP	O
AF	B-Disease	NOUN	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
Verapamil	B-Chemical	NOUN	B
caused	O	VERB	O
AF	B-Disease	NOUN	B
promotion	O	NOUN	B
in	O	ADP	O
six	O	NUM	O
dogs	O	NOUN	B
,	O	PUNCT	O
increasing	O	VERB	B
mean	O	ADJ	O
duration	O	NOUN	B
of	O	ADP	O
AF	B-Disease	NOUN	B
induced	O	VERB	B
by	O	ADP	O
burst	O	NOUN	B
pacing	O	NOUN	I
,	O	PUNCT	O
from	O	ADP	O
8	O	NUM	O
+/-	O	CCONJ	O
4	O	NUM	O
s	O	NOUN	O
(	O	PUNCT	O
mean	O	NOUN	O
+/-	O	CCONJ	O
S	O	NOUN	B
.	O	PUNCT	O


E	O	NOUN	B
.)	O	X	O
to	O	PART	O
95	O	NUM	O
+/-	O	CCONJ	O
39	O	NUM	O
s	O	NOUN	O
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


01	O	NUM	O
vs	O	CCONJ	O
.	O	PUNCT	O


control	O	NOUN	B
)	O	PUNCT	O
at	O	ADP	O
a	O	DET	O
loading	O	NOUN	B
dose	O	NOUN	I
of	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
and	O	CCONJ	O
228	O	NUM	O
+/-	O	CCONJ	O
101	O	NUM	O
s	O	NOUN	O
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


0005	O	NUM	O
vs	O	CCONJ	O
.	O	PUNCT	O


control	O	NOUN	B
)	O	PUNCT	O
at	O	ADP	O
a	O	DET	O
dose	O	NOUN	B
of	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
.	O	PUNCT	O


Underlying	O	VERB	O
electrophysiological	O	ADJ	B
mechanisms	O	NOUN	I
were	O	AUX	O
studied	O	VERB	O
in	O	ADP	O
detail	O	NOUN	O
in	O	ADP	O
five	O	NUM	O
additional	O	ADJ	O
dogs	O	NOUN	B
under	O	ADP	O
control	O	NOUN	B
conditions	O	NOUN	I
and	O	CCONJ	O
in	O	ADP	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
the	O	DET	O
higher	O	ADJ	B
dose	O	NOUN	B
of	O	ADP	O
verapamil	B-Chemical	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
these	O	DET	O
experiments	O	NOUN	B
,	O	PUNCT	O
verapamil	B-Chemical	NOUN	B
shortened	O	VERB	O
mean	O	ADJ	O
effective	O	ADJ	O
refractory	O	ADJ	B
period	O	NOUN	O
(	O	PUNCT	O
ERP	O	NOUN	B
)	O	PUNCT	O
from	O	ADP	O
122	O	NUM	O
+/-	O	CCONJ	O
5	O	NUM	O
to	O	PART	O
114	O	NUM	O
+/-	O	CCONJ	O
4	O	NUM	O
ms	O	NOUN	O
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


02	O	NUM	O
)	O	PUNCT	O
at	O	ADP	O
a	O	DET	O
cycle	O	NOUN	B
length	O	NOUN	I
of	O	ADP	O
300	O	NUM	O
ms	O	NOUN	O
,	O	PUNCT	O
decreased	O	VERB	B
ERP	O	NOUN	B
heterogeneity	O	NOUN	B
(	O	PUNCT	O
from	O	ADP	O
15	O	NUM	O
+/-	O	CCONJ	O
1	O	NUM	O
to	O	PART	O
10	O	NUM	O
+/-	O	CCONJ	O
1	O	NUM	O
%,	O	NOUN	O
P	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


05	O	NUM	O
),	O	PUNCT	O
heterogeneously	O	ADV	B
accelerated	O	VERB	O
atrial	O	ADJ	B
conduction	O	NOUN	I
and	O	CCONJ	O
decreased	O	VERB	B
the	O	DET	O
cycle	O	NOUN	B
length	O	NOUN	I
of	O	ADP	I
AF	B-Disease	NOUN	I
(	O	PUNCT	O
94	O	NUM	O
+/-	O	CCONJ	O
4	O	NUM	O
to	O	PART	O
84	O	NUM	O
+/-	O	CCONJ	O
3	O	NUM	O
ms	O	NOUN	O
,	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


005	O	NUM	O
).	O	PUNCT	O
Diltiazem	B-Chemical	NOUN	B
did	O	AUX	O
not	O	PART	O
affect	O	VERB	O
ERP	O	NOUN	B
,	O	PUNCT	O
AF	B-Disease	NOUN	B
cycle	O	NOUN	I
length	O	NOUN	B
or	O	CCONJ	O
AF	B-Disease	NOUN	B
duration	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
produced	O	VERB	O
conduction	O	NOUN	B
acceleration	O	NOUN	I
similar	O	ADJ	O
to	O	PART	O
that	O	DET	O
caused	O	VERB	O
by	O	ADP	O
verapamil	B-Chemical	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
5	O	NUM	O
).	O	PUNCT	O
In	O	ADP	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
autonomic	O	ADJ	B
blockade	O	NOUN	I
,	O	PUNCT	O
verapamil	B-Chemical	NOUN	B
failed	O	VERB	B
to	O	PART	O
promote	O	VERB	B
AF	B-Disease	PROPN	B
and	O	CCONJ	O
increased	O	VERB	B
,	O	PUNCT	O
rather	O	ADV	O
than	O	ADP	O
decreasing	O	VERB	B
,	O	PUNCT	O
refractoriness	O	NOUN	B
.	O	PUNCT	O


Neither	O	CCONJ	O
verapamil	B-Chemical	NOUN	B
nor	O	CCONJ	O
diltiazem	B-Chemical	NOUN	B
affected	O	VERB	O
atrial	O	ADJ	B
conduction	O	NOUN	I
in	O	ADP	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
autonomic	O	ADJ	B
blockade	O	NOUN	I
.	O	PUNCT	O


Epicardial	O	ADJ	B
mapping	O	NOUN	I
suggested	O	VERB	O
that	O	SCONJ	O
verapamil	B-Chemical	NOUN	B
promoted	O	VERB	O
AF	B-Disease	PROPN	B
by	O	ADP	O
increasing	O	VERB	B
the	O	DET	O
number	O	NOUN	O
of	O	ADP	O
simultaneous	O	ADJ	B
wavefronts	O	NOUN	B
reflected	O	VERB	O
by	O	ADP	O
separate	O	ADJ	O
zones	O	NOUN	B
of	O	ADP	O
reactivation	O	NOUN	B
in	O	ADP	O
each	O	DET	O
cycle	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
:	O	PUNCT	O
Verapamil	B-Chemical	NOUN	B
promotes	O	VERB	O
AF	B-Disease	NOUN	B
in	O	ADP	O
normal	O	ADJ	O
dogs	O	NOUN	B
by	O	ADP	O
promoting	O	VERB	O
multiple	O	ADJ	B
circuit	O	NOUN	I
reentry	O	NOUN	O
,	O	PUNCT	O
an	O	DET	O
effect	O	NOUN	B
dependent	O	ADJ	O
on	O	ADP	O
intact	O	ADJ	B
autonomic	O	ADJ	B
tone	O	NOUN	I
and	O	CCONJ	O
not	O	PART	O
shared	O	VERB	O
by	O	ADP	O
diltiazem	B-Chemical	NOUN	B


Hypotension	B-Disease	NOUN	B
,	O	PUNCT	O
bradycardia	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
asystole	B-Disease	NOUN	B
after	O	ADP	O
high	O	ADJ	B
-	O	PUNCT	O
dose	O	NOUN	B
intravenous	O	ADJ	B
methylprednisolone	B-Chemical	NOUN	B
in	O	ADP	O
a	O	DET	O
monitored	O	VERB	B
patient	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
a	O	DET	O
case	O	NOUN	B
of	O	ADP	O
hypotension	B-Disease	NOUN	B
,	O	PUNCT	O
bradycardia	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
asystole	B-Disease	ADJ	B
after	O	ADP	O
intravenous	O	ADJ	B
administration	O	NOUN	I
of	O	ADP	O
high	O	ADJ	B
-	O	PUNCT	O
dose	O	NOUN	B
methylprednisolone	B-Chemical	NOUN	B
in	O	ADP	O
a	O	DET	O
73	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
patient	O	NOUN	B
who	O	PRON	O
underwent	O	VERB	O
electrocardiographic	O	ADJ	B
(	O	PUNCT	I
ECG	O	PROPN	B
)	O	PUNCT	O
monitoring	O	NOUN	B
throughout	O	ADP	O
the	O	DET	O
episode	O	NOUN	B
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
a	O	DET	O
history	O	NOUN	B
of	O	ADP	O
ischemic	B-Disease	ADJ	B
cardiac	B-Disease	ADJ	I
disease	I-Disease	NOUN	I
9	O	NUM	O
years	O	NOUN	B
earlier	O	ADV	O
.	O	PUNCT	O


The	O	DET	O
patient	O	NOUN	B
was	O	AUX	O
admitted	O	VERB	B
with	O	ADP	I
a	O	DET	O
pulmonary-renal	B-Disease	ADJ	B
syndrome	I-Disease	NOUN	I
with	O	ADP	O
hemoptysis	B-Disease	NOUN	B
,	O	PUNCT	O
rapidly	O	ADV	O
progressive	O	ADJ	B
renal	B-Disease	ADJ	B
failure	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
hypoxemia	B-Disease	NOUN	B
that	O	PRON	O
required	O	VERB	O
mechanical	O	ADJ	B
ventilation	O	NOUN	I
in	O	ADP	O
the	O	DET	O
intensive	O	ADJ	B
care	O	NOUN	I
unit	O	NOUN	I
.	O	PUNCT	O


After	O	ADP	O
receiving	O	VERB	O
advanced	O	ADJ	B
cardiopulmonary	O	NOUN	I
resuscitation	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
patient	O	NOUN	B
recovered	O	VERB	O
cardiac	O	ADJ	B
rhythm	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
ECG	O	PROPN	B
showed	O	VERB	O
a	O	DET	O
junctional	O	ADJ	B
rhythm	O	NOUN	I
without	O	ADP	O
ventricular	B-Disease	ADJ	B
arrhythmia	I-Disease	NOUN	I
.	O	PUNCT	O


This	O	DET	O
study	O	NOUN	B
reviews	O	VERB	B
the	O	DET	O
current	O	ADJ	O
proposed	O	VERB	O
mechanisms	O	NOUN	B
of	O	ADP	O
sudden	B-Disease	ADJ	B
death	I-Disease	NOUN	I
after	O	ADP	O
a	O	DET	O
high	O	ADJ	B
dose	O	NOUN	I
of	O	ADP	O
intravenous	O	ADJ	B
methylprednisolone	B-Chemical	NOUN	I
(	O	PUNCT	O
IVMP	B-Chemical	NOUN	B
).	O	PUNCT	O
These	O	DET	O
mechanisms	O	NOUN	B
are	O	AUX	O
not	O	PART	O
well	O	ADV	O
understood	O	VERB	O
because	O	SCONJ	O
,	O	PUNCT	O
in	O	ADP	O
most	O	ADJ	O
cases	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
patients	O	NOUN	B
were	O	AUX	O
not	O	PART	O
monitored	O	VERB	O
at	O	ADP	O
the	O	DET	O
moment	O	NOUN	B
of	O	ADP	O
the	O	DET	O
event	O	NOUN	B
.	O	PUNCT	O


Rapid	O	ADJ	B
infusion	O	NOUN	B
and	O	CCONJ	O
underlying	O	VERB	O
cardiac	B-Disease	ADJ	B
disease	I-Disease	NOUN	I
were	O	AUX	O
important	O	ADJ	O
risk	O	NOUN	B
factors	O	NOUN	I
in	O	ADP	O
the	O	DET	O
case	O	NOUN	B
reported	O	VERB	O
here	O	ADV	O
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
authors	O	NOUN	B
discount	O	VERB	B
ventricular	B-Disease	ADJ	I
arrhythmia	I-Disease	NOUN	I


Lifetime	O	NOUN	B
treatment	O	NOUN	B
of	O	ADP	O
mice	O	NOUN	B
with	O	ADP	O
azidothymidine	B-Chemical	NOUN	B
(	O	PUNCT	O
AZT	B-Chemical	NOUN	B
)	O	PUNCT	O
produces	O	VERB	O
myelodysplasia	B-Disease	NOUN	B
.	O	PUNCT	O


AZT	B-Chemical	PROPN	B
has	O	AUX	O
induced	O	VERB	B
a	O	DET	O
macrocytic	B-Disease	ADJ	B
anemia	I-Disease	NOUN	I
in	O	ADP	O
AIDS	B-Disease	NOUN	B
patients	O	NOUN	B
on	O	ADP	O
long	O	ADJ	B
term	O	NOUN	I
AZT	B-Chemical	NOUN	B
therapy	O	NOUN	I
.	O	PUNCT	O


It	O	PRON	O
is	O	AUX	O
generally	O	ADV	O
assumed	O	VERB	O
that	O	SCONJ	O
DNA	O	NOUN	B
elongation	O	NOUN	I
is	O	AUX	O
stopped	O	VERB	O
by	O	ADP	O
the	O	DET	O
insertion	O	NOUN	B
of	O	ADP	O
AZT	B-Chemical	NOUN	B
into	O	ADP	O
the	O	DET	O
chain	O	NOUN	B
in	O	ADP	O
place	O	NOUN	O
of	O	ADP	O
thymidine	B-Chemical	NOUN	B
thus	O	ADV	O
preventing	O	VERB	B
the	O	DET	O
phosphate	B-Chemical	NOUN	B
hydroxyl	O	NOUN	I
linkages	O	NOUN	I
and	O	CCONJ	O
therefore	O	ADV	O
suppresses	O	VERB	B
hemopoietic	O	ADJ	B
progenitor	O	NOUN	I
cell	O	NOUN	I
proliferation	O	NOUN	O
in	O	ADP	O
an	O	DET	O
early	O	ADJ	B
stage	O	NOUN	I
of	O	ADP	O
differentiation	O	NOUN	B
.	O	PUNCT	O


CBA	O	NOUN	B
/	O	PUNCT	O
Ca	O	NOUN	B
male	O	NOUN	B
mice	O	NOUN	O
started	O	VERB	O
on	O	ADP	O
AZT	B-Chemical	NOUN	B
0	O	NUM	O
.	O	PUNCT	O


75	O	NUM	O
mg	O	NOUN	O
/	O	PUNCT	O
ml	O	NOUN	O
H2O	O	NOUN	B
at	O	ADP	O
84	O	NUM	O
days	O	NOUN	B
of	O	ADP	O
age	O	NOUN	B
and	O	CCONJ	O
kept	O	VERB	O
on	O	ADP	O
it	O	PRON	O
for	O	ADP	O
687	O	NUM	O
days	O	NOUN	B
when	O	SCONJ	O
dosage	O	NOUN	B
reduced	O	VERB	B
to	O	PART	O
0	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
mg	O	NOUN	O
/	O	PUNCT	O
ml	O	NOUN	O
H2O	O	NOUN	B
for	O	ADP	O
a	O	DET	O
group	O	NOUN	B
,	O	PUNCT	O
another	O	DET	O
group	O	NOUN	B
removed	O	VERB	O
from	O	ADP	O
AZT	B-Chemical	PROPN	B
to	O	PART	O
see	O	VERB	O
recovery	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
third	O	ADJ	O
group	O	NOUN	B
remained	O	VERB	O
on	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


75	O	NUM	O
mg	O	NOUN	O
.	O	PUNCT	O


At	O	ADP	O
687	O	NUM	O
days	O	NOUN	B
mice	O	NOUN	B
that	O	PRON	O
had	O	AUX	O
been	O	AUX	O
on	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


75	O	NUM	O
mg	O	NOUN	O
had	O	AUX	O
average	O	ADJ	B
platelet	O	NOUN	B
counts	O	NOUN	I
of	O	ADP	O
2	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
x	O	CCONJ	O
10	O	NUM	O
(	O	PUNCT	O
6	O	NUM	O
).	O	PUNCT	O
Histological	O	ADJ	B
examination	O	NOUN	O
on	O	ADP	O
9	O	NUM	O
of	O	ADP	O
10	O	NUM	O
mice	O	NOUN	B
with	O	ADP	O
such	O	ADJ	O
thrombocytopenia	B-Disease	NOUN	B
showed	O	VERB	O
changes	O	NOUN	O
compatible	O	ADJ	O
with	O	ADP	O
myelodysplastic	B-Disease	ADJ	B
syndrome	I-Disease	NOUN	I
(	O	PUNCT	O
MDS	B-Disease	NOUN	B
).	O	PUNCT	O
A	O	DET	O
variety	O	NOUN	O
of	O	ADP	O
histological	O	ADJ	B
patterns	O	NOUN	O
was	O	AUX	O
observed	O	VERB	B
.	O	PUNCT	O


There	O	PRON	O
were	O	AUX	O
two	O	NUM	O
cases	O	NOUN	B
of	O	ADP	O
hypocellular	O	ADJ	B
myelodysplasia	B-Disease	NOUN	I
,	O	PUNCT	O
two	O	NUM	O
cases	O	NOUN	B
of	O	ADP	O
hypersegmented	O	VERB	B
myelodysplastic	B-Disease	ADJ	I
granulocytosis	O	NOUN	I
,	O	PUNCT	O
two	O	NUM	O
cases	O	NOUN	B
of	O	ADP	O
hypercellular	O	ADJ	B
marrow	O	NOUN	I
with	O	ADP	O
abnormal	O	ADJ	B
megakaryocytes	O	NOUN	B
with	O	ADP	O
bizarre	O	ADJ	B
nuclei	O	NOUN	I
,	O	PUNCT	O
one	O	NUM	O
case	O	NOUN	B
of	O	ADP	O
megakaryocytic	O	ADJ	B
myelosis	O	NOUN	I
associated	O	VERB	B
with	O	ADP	I
a	O	DET	O
hyperplastic	B-Disease	ADJ	B
marrow	I-Disease	NOUN	I
,	O	PUNCT	O
dysmyelopoiesis	B-Disease	NOUN	B
and	O	CCONJ	O
a	O	DET	O
hypocellular	B-Disease	ADJ	B
marrow	I-Disease	NOUN	I
and	O	CCONJ	O
two	O	NUM	O
cases	O	NOUN	B
of	O	ADP	O
myelodysplasia	B-Disease	NOUN	B
with	O	ADP	O
dyserythropoiesis	B-Disease	NOUN	B
,	O	PUNCT	O
hemosiderosis	B-Disease	NOUN	B
and	O	CCONJ	O
a	O	DET	O
hypocellular	B-Disease	ADJ	B
marrow	I-Disease	NOUN	I
.	O	PUNCT	O


Above	O	ADP	O
mentioned	O	VERB	O
AZT	B-Chemical	NOUN	B
incorporation	O	NOUN	B
may	O	AUX	O
have	O	AUX	O
induced	O	VERB	B
an	O	DET	O
ineffective	O	ADJ	B
hemopoiesis	O	NOUN	B
in	O	ADP	O
the	O	DET	O
primitive	O	ADJ	B
hemopoietic	O	ADJ	B
progenitor	O	NOUN	I
cells	O	NOUN	I
,	O	PUNCT	O
which	O	DET	O
is	O	AUX	O
known	O	VERB	O
to	O	PART	O
be	O	AUX	O
seen	O	VERB	O
commonly	O	ADV	O
in	O	ADP	O
the	O	DET	O
myelodysplastic	B-Disease	ADJ	B
syndrome	I-Disease	NOUN	I


Influence	O	NOUN	B
of	O	ADP	O
diet	O	NOUN	B
free	O	ADJ	I
of	O	ADP	O
NAD	B-Chemical	NOUN	B
-	O	PUNCT	O
precursors	O	NOUN	B
on	O	ADP	O
acetaminophen	B-Chemical	NOUN	B
hepatotoxicity	B-Disease	NOUN	B
in	O	ADP	O
mice	O	NOUN	B
.	O	PUNCT	O


Recently	O	ADV	O
,	O	PUNCT	O
we	O	PRON	O
demonstrated	O	VERB	O
the	O	DET	O
hepatoprotective	O	ADJ	B
effects	O	NOUN	B
of	O	ADP	O
nicotinic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
amide	I-Chemical	NOUN	I
,	O	PUNCT	O
a	O	DET	O
selective	O	ADJ	O
inhibitor	O	NOUN	B
of	O	ADP	O
poly(ADP-ribose)	B-Chemical	ADJ	B
polymerase	O	NOUN	I
(	O	PUNCT	O
PARP	O	NOUN	B
;	O	PUNCT	O
EC	O	NOUN	B
2	O	NUM	I
.	O	PUNCT	O


4	O	X	O
.	O	PUNCT	O


2	O	X	O
.	O	PUNCT	O


30	O	NUM	O
)	O	PUNCT	O
on	O	ADP	O
mice	O	NOUN	B
suffering	O	VERB	B
from	O	ADP	O
acetaminophen	B-Chemical	NOUN	B
(	O	PUNCT	O
AAP	B-Chemical	NOUN	B
)-	O	ADJ	O
hepatitis	B-Disease	NOUN	B
,	O	PUNCT	O
suggesting	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
AAP	B-Chemical	PROPN	B
-	O	PUNCT	O
induced	O	VERB	B
liver	B-Disease	NOUN	B
injury	I-Disease	NOUN	I
involves	O	VERB	O
a	O	DET	O
step	O	NOUN	O
which	O	DET	O
depends	O	VERB	O
on	O	ADP	O
adenoribosylation	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
investigates	O	VERB	B
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
a	O	DET	O
diet	O	NOUN	B
free	O	ADJ	I
of	O	ADP	O
precursors	O	NOUN	B
of	O	ADP	O
NAD	B-Chemical	NOUN	B
,	O	PUNCT	O
the	O	DET	O
substrate	O	NOUN	B
on	O	ADP	O
which	O	DET	O
PARP	O	NOUN	B
acts	O	VERB	O
,	O	PUNCT	O
in	O	ADP	O
female	O	ADJ	B
NMRI	O	NOUN	B
mice	O	NOUN	O
with	O	ADP	O
AAP	B-Chemical	NOUN	B
hepatitis	B-Disease	NOUN	I
and	O	CCONJ	O
evaluates	O	VERB	B
the	O	DET	O
influence	O	NOUN	B
of	O	ADP	O
simultaneous	O	ADJ	B
ethanol	B-Chemical	NOUN	B
consumption	O	NOUN	B
in	O	ADP	O
these	O	DET	O
animals	O	NOUN	B
.	O	PUNCT	O


Liver	B-Disease	NOUN	B
injuries	I-Disease	NOUN	I
were	O	AUX	O
quantified	O	VERB	B
as	O	ADP	O
serum	O	NOUN	B
activities	O	NOUN	I
of	O	ADP	O
glutamate	B-Chemical	NOUN	B
-	O	PUNCT	O
oxaloacetate	B-Chemical	NOUN	B
transaminase	O	NOUN	I
(	O	PUNCT	O
GOT	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
glutamate	B-Chemical	NOUN	B
-	O	PUNCT	O
pyruvate	B-Chemical	NOUN	B
transaminase	O	NOUN	I
(	O	PUNCT	O
GPT	O	NOUN	B
).	O	PUNCT	O
While	O	SCONJ	O
AAP	B-Chemical	PROPN	B
caused	O	VERB	O
a	O	DET	O
117	O	NUM	O
-	O	PUNCT	O
fold	O	ADJ	B
elevation	O	NOUN	B
of	O	ADP	O
serum	O	NOUN	B
transaminase	O	NOUN	O
activities	O	NOUN	O
in	O	ADP	O
mice	O	NOUN	B
kept	O	VERB	O
on	O	ADP	O
a	O	DET	O
standard	O	ADJ	O
laboratory	O	ADJ	B
diet	O	NOUN	I
,	O	PUNCT	O
which	O	DET	O
was	O	AUX	O
significantly	O	ADV	O
exacerbated	O	VERB	B
by	O	ADP	O
ethanol	B-Chemical	NOUN	B
and	O	CCONJ	O
inhibited	O	VERB	B
by	O	ADP	O
nicotinic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
amide	I-Chemical	NOUN	I
(	O	PUNCT	O
NAA	B-Chemical	NOUN	B
),	O	PUNCT	O
adverse	O	ADJ	B
effects	O	NOUN	I
were	O	AUX	O
noted	O	VERB	O
in	O	ADP	O
animals	O	NOUN	B
fed	O	VERB	B
a	O	DET	O
diet	O	NOUN	B
free	O	ADJ	I
of	O	ADP	O
precursors	O	NOUN	B
of	O	ADP	O
NAD	B-Chemical	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
these	O	DET	O
animals	O	NOUN	B
,	O	PUNCT	O
only	O	ADV	O
minor	O	ADJ	O
increases	O	NOUN	B
of	O	ADP	O
serum	O	NOUN	B
transaminase	O	NOUN	O
activities	O	NOUN	O
were	O	AUX	O
measured	O	VERB	B
in	O	ADP	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
AAP	B-Chemical	PROPN	B
,	O	PUNCT	O
and	O	CCONJ	O
unlike	O	ADP	O
the	O	DET	O
exacerbation	O	NOUN	B
caused	O	VERB	O
by	O	ADP	O
ethanol	B-Chemical	NOUN	B
in	O	ADP	O
mice	O	NOUN	B
on	O	ADP	O
a	O	DET	O
standard	O	ADJ	B
diet	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
liver	B-Disease	NOUN	B
damage	I-Disease	NOUN	I
was	O	AUX	O
inhibited	O	VERB	B
by	O	ADP	O
50	O	NUM	O
%	O	NOUN	O
by	O	ADP	O
ethanol	B-Chemical	NOUN	B
.	O	PUNCT	O


A	O	DET	O
further	O	ADV	O
64	O	NUM	O
%	O	NOUN	O
reduction	O	NOUN	B
of	O	ADP	O
hepatitis	B-Disease	NOUN	B
was	O	AUX	O
observed	O	VERB	B
,	O	PUNCT	O
when	O	SCONJ	O
NAA	B-Chemical	NOUN	B
was	O	AUX	O
given	O	VERB	O
to	O	ADP	O
ethanol	B-Chemical	NOUN	B
/	O	SYM	O
AAP	B-Chemical	PROPN	B
-	O	PUNCT	O
mice	O	NOUN	B
.	O	PUNCT	O


Our	O	PRON	O
results	O	NOUN	B
provide	O	VERB	O
evidence	O	NOUN	B
that	O	SCONJ	O
the	O	DET	O
AAP	B-Chemical	PROPN	B
-	O	PUNCT	O
induced	O	VERB	B
hepatitis	B-Disease	NOUN	B
and	O	CCONJ	O
its	O	PRON	O
exacerbation	O	NOUN	B
by	O	ADP	O
ethanol	B-Chemical	NOUN	B
can	O	AUX	O
either	O	CCONJ	O
be	O	AUX	O
reduced	O	VERB	B
by	O	ADP	O
end	O	NOUN	B
-	O	PUNCT	O
product	O	NOUN	B
inhibition	O	NOUN	B
of	O	ADP	O
PARP	O	NOUN	B
by	O	ADP	O
NAA	B-Chemical	NOUN	B
or	O	CCONJ	O
by	O	ADP	O
dietary	O	ADJ	B
depletion	O	NOUN	I
of	O	ADP	O
the	O	DET	O
enzyme	O	NOUN	B
'	O	PART	O
s	O	NOUN	O
substrate	O	ADJ	B
NAD	B-Chemical	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
see	O	VERB	O
the	O	DET	O
main	O	ADJ	O
application	O	NOUN	O
of	O	ADP	O
NAA	B-Chemical	NOUN	B
as	O	ADP	O
for	O	ADP	O
the	O	DET	O
combinational	O	ADJ	B
use	O	NOUN	O
in	O	ADP	O
pharmaceutical	O	ADJ	B
preparations	O	NOUN	I
of	O	ADP	O
acetaminophen	B-Chemical	NOUN	B
in	O	ADP	O
order	O	NOUN	O
to	O	PART	O
avoid	O	VERB	O
hepatic	B-Disease	ADJ	B
damage	I-Disease	NOUN	I


Antiarrhythmic	O	ADJ	B
plasma	O	NOUN	B
concentrations	O	NOUN	B
of	O	ADP	O
cibenzoline	B-Chemical	NOUN	B
on	O	ADP	O
canine	O	ADJ	B
ventricular	B-Disease	ADJ	B
arrhythmias	I-Disease	NOUN	I
.	O	PUNCT	O


Using	O	VERB	O
two	O	NUM	O
-	O	PUNCT	O
stage	O	NOUN	B
coronary	O	ADJ	B
ligation	O	NOUN	I
-,	O	NOUN	O
digitalis	B-Chemical	NOUN	B
-,	O	NOUN	O
and	O	CCONJ	O
adrenaline	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
canine	O	NOUN	B
ventricular	B-Disease	ADJ	B
arrhythmias	I-Disease	NOUN	I
,	O	PUNCT	O
antiarrhythmic	O	ADJ	B
effects	O	NOUN	I
of	O	ADP	O
cibenzoline	B-Chemical	NOUN	B
were	O	AUX	O
examined	O	VERB	B
and	O	CCONJ	O
the	O	DET	O
minimum	O	ADJ	B
effective	O	ADJ	B
plasma	O	NOUN	B
concentration	O	NOUN	B
for	O	ADP	O
each	O	DET	O
arrhythmia	B-Disease	NOUN	B
model	O	NOUN	B
was	O	AUX	O
determined	O	VERB	O
.	O	PUNCT	O


Cibenzoline	B-Chemical	NOUN	B
suppressed	O	VERB	B
all	O	DET	O
the	O	DET	O
arrhythmias	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
minimum	O	ADJ	B
effective	O	ADJ	B
plasma	O	NOUN	B
concentrations	O	NOUN	B
for	O	ADP	O
arrhythmias	B-Disease	NOUN	B
induced	O	VERB	B
by	O	ADP	O
24	O	NUM	O
-	O	PUNCT	O
h	O	NOUN	B
coronary	O	ADJ	B
ligation	O	NOUN	I
,	O	PUNCT	O
48	O	NUM	O
-	O	PUNCT	O
h	O	NOUN	B
coronary	O	ADJ	B
ligation	O	NOUN	I
,	O	PUNCT	O
digitalis	B-Chemical	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
adrenaline	B-Chemical	NOUN	B
were	O	AUX	O
1	O	NUM	O
.	O	PUNCT	O


9	O	NUM	O
+/-	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


9	O	NUM	O
(	O	PUNCT	O
by	O	ADP	O
8	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	O
i	O	X	O
.	O	PUNCT	O


v	O	ADP	O
.),	O	SYM	O
1	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
+/-	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
(	O	PUNCT	O
by	O	ADP	O
8	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	O
i	O	X	O
.	O	PUNCT	O


v	O	ADP	O
.),	O	ADV	O
0	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
+/-	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
(	O	PUNCT	O
by	O	ADP	O
2	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	O
i	O	X	O
.	O	PUNCT	O


v	O	ADP	O
.),	O	NOUN	O
and	O	CCONJ	O
3	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
+/-	O	CCONJ	O
1	O	NUM	O
.	O	PUNCT	O


3	O	NUM	O
(	O	PUNCT	O
by	O	ADP	O
5	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	O
i	O	X	O
.	O	PUNCT	O


v	O	PART	O
.)	O	ADJ	O
micrograms	O	NOUN	B
/	O	SYM	O
ml	O	NOUN	O
,	O	PUNCT	O
respectively	O	ADV	O
(	O	PUNCT	O
mean	O	NOUN	O
+/-	O	CCONJ	O
SDM	O	NOUN	B
,	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
6	O	NUM	O
-	O	SYM	O
7	O	NUM	O
).	O	PUNCT	O
The	O	DET	O
concentration	O	NOUN	B
for	O	ADP	O
adrenaline	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
arrhythmia	B-Disease	NOUN	B
was	O	AUX	O
significantly	O	ADV	O
higher	O	ADJ	O
than	O	ADP	O
those	O	DET	O
for	O	ADP	O
the	O	DET	O
other	O	ADJ	O
types	O	NOUN	O
of	O	ADP	O
arrhythmias	B-Disease	NOUN	B
.	O	PUNCT	O


This	O	DET	O
pharmacological	O	ADJ	B
profile	O	NOUN	I
is	O	AUX	O
similar	O	ADJ	O
to	O	PART	O
those	O	DET	O
of	O	ADP	O
mexiletine	B-Chemical	NOUN	B
and	O	CCONJ	O
tocainide	B-Chemical	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
all	O	DET	O
three	O	NUM	O
drugs	O	NOUN	B
have	O	AUX	O
central	O	ADJ	B
nervous	O	ADJ	I
system	O	NOUN	I
(	O	PUNCT	O
CNS	O	NOUN	B
)	O	PUNCT	O
stimulant	O	ADJ	B
action	O	NOUN	I
.	O	PUNCT	O


Because	O	SCONJ	O
cibenzoline	B-Chemical	NOUN	B
had	O	AUX	O
only	O	ADV	O
weak	O	ADJ	B
hypotensive	B-Disease	ADJ	B
and	O	CCONJ	O
sinus	O	NOUN	B
node	O	NOUN	I
depressive	B-Disease	ADJ	I
effects	O	NOUN	I
and	O	CCONJ	O
was	O	AUX	O
found	O	VERB	O
to	O	PART	O
be	O	AUX	O
orally	O	ADV	B
active	O	ADJ	O
when	O	SCONJ	O
given	O	VERB	O
to	O	PART	O
coronary	O	ADJ	B
ligation	O	NOUN	I
arrhythmia	B-Disease	NOUN	I


Immunopathology	O	NOUN	B
of	O	ADP	O
penicillamine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
glomerular	B-Disease	ADJ	B
disease	I-Disease	NOUN	I
.	O	PUNCT	O


Four	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
rheumatoid	B-Disease	ADJ	B
arthritis	I-Disease	NOUN	I
developed	O	VERB	O
heavy	O	ADJ	B
proteinuria	B-Disease	NOUN	I
after	O	ADP	O
five	O	NUM	O
to	O	PART	O
12	O	NUM	O
months	O	NOUN	B
of	O	ADP	O
treatment	O	NOUN	B
with	O	ADP	O
D-penicillamine	B-Chemical	NOUN	B
.	O	PUNCT	O


Light	O	ADJ	B
microscopy	O	NOUN	I
of	O	ADP	O
renal	O	ADJ	B
biopsy	O	NOUN	I
samples	O	NOUN	I
showed	O	VERB	O
minimal	O	ADJ	O
glomerular	O	ADJ	O
capillary	O	ADJ	O
wall	O	NOUN	O
thickening	O	NOUN	O
and	O	CCONJ	O
mesangial	O	ADJ	B
matrix	O	NOUN	I
increase	O	NOUN	B
,	O	PUNCT	O
or	O	CCONJ	O
no	O	DET	O
departure	O	NOUN	O
from	O	ADP	O
normal	O	ADJ	B
.	O	PUNCT	O


Electron	O	NOUN	B
microscopy	O	NOUN	I
,	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
revealed	O	VERB	O
subepithelial	O	ADJ	B
electron	O	NOUN	O
-	O	PUNCT	O
dense	O	ADJ	B
deposits	O	NOUN	B
,	O	PUNCT	O
fusion	O	NOUN	B
of	O	ADP	O
epithelial	O	ADJ	B
cell	O	NOUN	I
foot	O	NOUN	O
processes	O	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
evidence	O	NOUN	B
of	O	ADP	O
mesangial	O	ADJ	B
cell	O	NOUN	I
hyperactivity	O	NOUN	I
.	O	PUNCT	O


Immunofluorescence	O	NOUN	B
microscopy	O	NOUN	I
demonstrated	O	VERB	O
granular	O	ADJ	B
capillary	O	ADJ	B
wall	O	NOUN	I
deposits	O	NOUN	I
of	O	ADP	O
IgG	O	NOUN	B
and	O	CCONJ	O
C3	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
findings	O	NOUN	B
were	O	AUX	O
similar	O	ADJ	O
to	O	PART	O
those	O	DET	O
in	O	ADP	O
early	O	ADJ	O
membranous	B-Disease	ADJ	B
glomerulonephritis	I-Disease	NOUN	I


Ventricular	B-Disease	ADJ	B
fibrillation	I-Disease	NOUN	I
from	O	ADP	O
diatrizoate	B-Chemical	NOUN	B
with	O	ADP	O
and	O	CCONJ	O
without	O	ADP	O
chelating	O	NOUN	B
agents	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
toxicity	B-Disease	NOUN	B
of	O	ADP	O
Renografin	B-Chemical	NOUN	B
76%	I-Chemical	PROPN	O
was	O	AUX	O
compared	O	VERB	B
with	O	ADP	O
that	O	DET	O
of	O	ADP	O
Hypaque	B-Chemical	NOUN	B
76%	I-Chemical	PROPN	I
by	O	ADP	O
selective	O	ADJ	O
injection	O	NOUN	B
of	O	ADP	O
each	O	DET	O
into	O	ADP	O
the	O	DET	O
right	O	ADJ	B
coronary	O	ADJ	I
artery	O	NOUN	I
of	O	ADP	O
dogs	O	NOUN	B
.	O	PUNCT	O


Renografin	B-Chemical	NOUN	B
contains	O	VERB	O
the	O	DET	O
chelating	O	NOUN	B
agents	O	NOUN	I
sodium	B-Chemical	NOUN	B
citrate	I-Chemical	NOUN	I
and	O	CCONJ	O
disodium	B-Chemical	NOUN	B
edetate	I-Chemical	NOUN	I
,	O	PUNCT	O
while	O	SCONJ	O
Hypaque	B-Chemical	NOUN	B
contains	O	VERB	O
calcium	B-Chemical	NOUN	B
disodium	I-Chemical	NOUN	I
edetate	I-Chemical	NOUN	I
and	O	CCONJ	O
no	O	DET	O
sodium	B-Chemical	NOUN	B
citrate	I-Chemical	NOUN	I
.	O	PUNCT	O


Ventricular	B-Disease	ADJ	B
fibrillation	I-Disease	NOUN	I
occurred	O	VERB	O
significantly	O	ADV	O
more	O	ADV	O
often	O	ADV	O
with	O	ADP	O
Renografin	B-Chemical	NOUN	B
,	O	PUNCT	O
suggesting	O	VERB	O
that	O	SCONJ	O
chelating	O	NOUN	B
agents	O	NOUN	I
contribute	O	VERB	O
to	O	PART	O
toxicity	B-Disease	NOUN	B


Rapid	O	ADJ	O
reversal	O	NOUN	B
of	O	ADP	O
anticoagulation	O	NOUN	B
reduces	O	VERB	O
hemorrhage	B-Disease	NOUN	B
volume	O	NOUN	B
in	O	ADP	O
a	O	DET	O
mouse	O	NOUN	B
model	O	NOUN	I
of	O	ADP	O
warfarin	B-Chemical	NOUN	B
-	O	PUNCT	O
associated	O	VERB	B
intracerebral	B-Disease	ADJ	B
hemorrhage	I-Disease	NOUN	I
.	O	PUNCT	O


Warfarin	B-Chemical	PROPN	B
-	O	PUNCT	O
associated	O	VERB	B
intracerebral	B-Disease	ADJ	B
hemorrhage	I-Disease	NOUN	I
(	O	PUNCT	O
W	O	PROPN	B
-	O	PUNCT	O
ICH	B-Disease	PROPN	B
)	O	PUNCT	O
is	O	AUX	O
a	O	DET	O
severe	O	ADJ	B
type	O	NOUN	O
of	O	ADP	O
stroke	B-Disease	NOUN	B
.	O	PUNCT	O


There	O	PRON	O
is	O	AUX	O
no	O	DET	O
consensus	O	NOUN	B
on	O	ADP	O
the	O	DET	O
optimal	O	ADJ	B
treatment	O	NOUN	B
for	O	ADP	O
W	O	NOUN	B
-	O	PUNCT	O
ICH	B-Disease	PROPN	B
.	O	PUNCT	O


Using	O	VERB	O
a	O	DET	O
mouse	O	NOUN	B
model	O	NOUN	I
,	O	PUNCT	O
we	O	PRON	O
tested	O	VERB	B
whether	O	SCONJ	O
the	O	DET	O
rapid	O	ADJ	O
reversal	O	NOUN	B
of	O	ADP	O
anticoagulation	O	NOUN	B
using	O	VERB	O
human	O	ADJ	B
prothrombin	B-Chemical	NOUN	I
complex	I-Chemical	NOUN	I
concentrate	I-Chemical	NOUN	I
(	O	PUNCT	O
PCC	B-Chemical	NOUN	B
)	O	PUNCT	O
can	O	AUX	O
reduce	O	VERB	B
hemorrhagic	O	ADJ	B
blood	O	NOUN	B
volume	O	NOUN	I
.	O	PUNCT	O


Male	O	ADJ	B
CD	O	PROPN	B
-	O	PUNCT	O
1	O	NUM	O
mice	O	NOUN	B
were	O	AUX	O
treated	O	VERB	B
with	O	ADP	I
warfarin	B-Chemical	NOUN	B
(	O	PUNCT	O
2	O	NUM	O
mg	O	NOUN	O
/	O	PUNCT	O
kg	O	NOUN	O
over	O	ADP	O
24	O	NUM	O
h	O	NOUN	O
),	O	PUNCT	O
resulting	O	VERB	O
in	O	ADP	O
a	O	DET	O
mean	O	NOUN	O
(+/-	O	PUNCT	O
s	O	NOUN	O
.	O	PUNCT	O


d	O	X	O
.)	O	PUNCT	O
International	O	PROPN	B
Normalized	O	PROPN	I
Ratio	O	PROPN	I
of	O	ADP	O
3	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
+/-	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


9	O	NUM	O
.	O	PUNCT	O


First	O	ADV	O
,	O	PUNCT	O
we	O	PRON	O
showed	O	VERB	O
that	O	SCONJ	O
an	O	DET	O
intravenous	O	ADJ	B
administration	O	NOUN	I
of	O	ADP	O
human	O	ADJ	B
PCC	B-Chemical	NOUN	B
rapidly	O	ADV	O
reversed	O	VERB	O
anticoagulation	O	NOUN	B
in	O	ADP	O
mice	O	NOUN	B
.	O	PUNCT	O


Second	O	ADV	O
,	O	PUNCT	O
a	O	DET	O
stereotactic	O	ADJ	B
injection	O	NOUN	I
of	O	ADP	O
collagenase	O	NOUN	B
was	O	AUX	O
administered	O	VERB	B
to	O	PART	O
induce	O	VERB	B
hemorrhage	B-Disease	NOUN	B
in	O	ADP	O
the	O	DET	O
right	O	ADJ	B
striatum	O	NOUN	I
.	O	PUNCT	O


Forty	O	NUM	B
-	O	PUNCT	O
five	O	NUM	O
minutes	O	NOUN	B
later	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
animals	O	NOUN	B
were	O	AUX	O
randomly	O	ADV	O
treated	O	VERB	B
with	O	ADP	I
PCC	B-Chemical	NOUN	B
(	O	PUNCT	O
100	O	NUM	O
U	O	NOUN	B
/	O	SYM	O
kg	O	NOUN	B
)	O	PUNCT	O
or	O	CCONJ	O
saline	O	NOUN	B
i	O	NUM	I
.	O	PUNCT	O


v	O	PART	O
.(	O	NUM	O
n	O	NOUN	O
=	O	ADJ	O
12	O	NUM	O
per	O	ADP	O
group	O	NOUN	B
).	O	PUNCT	B
Twenty	O	NUM	B
-	O	PUNCT	O
four	O	NUM	O
hours	O	NOUN	B
after	O	ADP	O
hemorrhage	B-Disease	NOUN	B
induction	O	NOUN	B
,	O	PUNCT	O
hemorrhagic	O	ADJ	B
blood	O	NOUN	I
volume	O	NOUN	I
was	O	AUX	O
quantified	O	VERB	B
using	O	VERB	O
a	O	DET	O
photometric	O	ADJ	B
hemoglobin	O	NOUN	I
assay	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
mean	O	ADJ	O
hemorrhagic	O	ADJ	B
blood	O	NOUN	I
volume	O	NOUN	I
was	O	AUX	O
reduced	O	VERB	B
in	O	ADP	O
PCC	B-Chemical	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
animals	O	NOUN	B
(	O	PUNCT	O
6	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
+/-	O	CCONJ	O
3	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
microL	O	NOUN	B
)	O	PUNCT	O
compared	O	VERB	B
with	O	ADP	O
saline	O	NOUN	B
controls	O	NOUN	I
(	O	PUNCT	O
15	O	NUM	O
.	O	PUNCT	O


3	O	NUM	O
+/-	O	CCONJ	O
11	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
microL	O	NOUN	B
,	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


015	O	NUM	O
).	O	PUNCT	O
In	O	ADP	O
the	O	DET	O
saline	O	NOUN	B
group	O	NOUN	I
,	O	PUNCT	O
45	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
mice	O	NOUN	B
developed	O	VERB	O
large	O	ADJ	O
hematomas	B-Disease	NOUN	B
(	O	PUNCT	O
i	O	X	O
.	O	PUNCT	O


e	O	X	O
.,>	O	VERB	O
15	O	NUM	O
microL	O	NOUN	O
).	O	PUNCT	O
In	O	ADP	O
contrast	O	NOUN	O
,	O	PUNCT	O
such	O	ADJ	O
extensive	O	ADJ	B
lesions	O	NOUN	B
were	O	AUX	O
never	O	ADV	O
found	O	VERB	O
in	O	ADP	O
the	O	DET	O
PCC	B-Chemical	NOUN	B
group	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
provide	O	VERB	O
experimental	O	ADJ	B
data	O	NOUN	O
suggesting	O	VERB	O
PCC	B-Chemical	NOUN	B
to	O	PART	O
be	O	AUX	O
an	O	DET	O
effective	O	ADJ	B
acute	O	ADJ	B
treatment	O	NOUN	O
for	O	ADP	O
W	O	NOUN	B
-	O	PUNCT	O
ICH	B-Disease	PROPN	B
in	O	ADP	O
terms	O	NOUN	O
of	O	ADP	O
reducing	O	VERB	B
hemorrhagic	O	ADJ	B
blood	O	NOUN	I
volume	O	NOUN	I
.	O	PUNCT	O


Future	O	ADJ	O
studies	O	NOUN	B
are	O	AUX	O
needed	O	VERB	O
to	O	PART	O
assess	O	VERB	B
the	O	DET	O
therapeutic	O	ADJ	B
potential	O	ADJ	B
emerging	O	VERB	O
from	O	ADP	O
our	O	PRON	O
finding	O	NOUN	B
for	O	ADP	O
human	O	ADJ	B
W	O	PROPN	O
-	O	PUNCT	O
ICH	B-Disease	PROPN	B


Impact	O	NOUN	B
of	O	ADP	O
alcohol	B-Chemical	NOUN	B
exposure	O	NOUN	I
after	O	ADP	O
pregnancy	O	NOUN	B
recognition	O	NOUN	I
on	O	ADP	O
ultrasonographic	O	ADJ	B
fetal	O	ADJ	B
growth	O	NOUN	I
measures	O	NOUN	B
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
:	O	PUNCT	O
More	O	ADJ	O
than	O	ADP	O
3	O	NUM	O
decades	O	NOUN	B
after	O	ADP	O
Jones	O	PROPN	B
and	O	CCONJ	O
Smith	O	PROPN	B
(	O	PUNCT	O
1973	O	NUM	O
)	O	PUNCT	O
reported	O	VERB	O
on	O	ADP	O
the	O	DET	O
devastation	O	NOUN	B
caused	O	VERB	O
by	O	ADP	O
alcohol	B-Chemical	NOUN	B
exposure	O	NOUN	I
on	O	ADP	O
fetal	O	ADJ	B
development	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
rates	O	NOUN	B
of	O	ADP	O
heavy	O	ADJ	B
drinking	O	NOUN	I
during	O	ADP	O
pregnancy	O	NOUN	B
remain	O	VERB	O
relatively	O	ADV	O
unchanged	O	ADJ	B
.	O	PUNCT	O


Early	O	ADJ	B
identification	O	NOUN	B
of	O	ADP	O
fetal	O	ADJ	B
alcohol	B-Chemical	NOUN	O
exposure	O	NOUN	O
and	O	CCONJ	O
maternal	O	ADJ	B
abstinence	O	NOUN	B
led	O	VERB	O
to	O	PART	O
better	O	ADJ	O
infant	O	NOUN	B
outcomes	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
study	O	NOUN	B
examined	O	VERB	O
the	O	DET	O
utility	O	NOUN	O
of	O	ADP	O
biometry	O	NOUN	B
for	O	ADP	O
detecting	O	VERB	B
alcohol	B-Chemical	NOUN	B
-	O	PUNCT	O
related	O	VERB	B
fetal	O	ADJ	B
growth	B-Disease	NOUN	I
impairment	I-Disease	NOUN	O
.	O	PUNCT	O


METHODS	O	NOUN	O
:	O	PUNCT	O
We	O	PRON	O
obtained	O	VERB	O
fetal	O	ADJ	B
ultrasound	O	NOUN	O
measures	O	NOUN	B
from	O	ADP	O
routine	O	ADJ	O
ultrasound	O	NOUN	B
examinations	O	NOUN	I
for	O	ADP	O
167	O	NUM	O
pregnant	O	ADJ	B
hazardous	O	ADJ	O
drinkers	O	NOUN	O
who	O	PRON	O
were	O	AUX	O
enrolled	O	VERB	O
in	O	ADP	O
a	O	DET	O
brief	O	ADJ	O
alcohol	B-Chemical	NOUN	B
intervention	O	NOUN	I
study	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
fetal	O	ADJ	B
measures	O	NOUN	I
for	O	ADP	O
women	O	NOUN	B
who	O	PRON	O
quit	O	VERB	O
after	O	ADP	O
learning	O	NOUN	B
of	O	ADP	O
their	O	PRON	O
pregnancies	O	NOUN	B
were	O	AUX	O
compared	O	VERB	B
with	O	ADP	O
measures	O	NOUN	B
for	O	ADP	O
women	O	NOUN	B
who	O	PRON	O
continued	O	VERB	O
some	O	DET	O
drinking	O	NOUN	B
throughout	O	ADP	O
the	O	DET	O
course	O	NOUN	B
of	O	ADP	O
their	O	PRON	O
pregnancies	O	NOUN	B
.	O	PUNCT	O


Because	O	SCONJ	O
intensity	O	NOUN	B
of	O	ADP	O
alcohol	B-Chemical	NOUN	B
consumption	O	NOUN	I
is	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
poorer	O	ADJ	B
fetal	O	ADJ	B
outcomes	O	NOUN	B
,	O	PUNCT	O
separate	O	ADJ	O
analyses	O	NOUN	B
were	O	AUX	O
conducted	O	VERB	O
for	O	ADP	O
the	O	DET	O
heavy	O	ADJ	B
(	O	PUNCT	O
average	O	NOUN	B
of	O	ADP	O
>	O	NOUN	O
or	O	CCONJ	O
=	O	ADJ	O
5	O	NUM	O
drinks	O	NOUN	B
per	O	ADP	O
drinking	O	NOUN	B
day	O	NOUN	I
)	O	PUNCT	O
alcohol	B-Chemical	NOUN	B
consumers	O	NOUN	I
.	O	PUNCT	O


Fetal	O	ADJ	B
measures	O	NOUN	O
from	O	ADP	O
the	O	DET	O
heavy	O	ADV	B
-	O	PUNCT	O
exposed	O	VERB	B
fetuses	O	NOUN	B
were	O	AUX	O
also	O	ADV	O
compared	O	VERB	O
with	O	ADP	O
measures	O	NOUN	B
from	O	ADP	O
a	O	DET	O
nondrinking	O	ADJ	B
group	O	NOUN	I
that	O	PRON	O
was	O	AUX	O
representative	O	ADJ	O
of	O	ADP	O
normal	O	ADJ	B
,	O	PUNCT	O
uncomplicated	O	ADJ	B
pregnancies	O	NOUN	I
from	O	ADP	O
our	O	PRON	O
clinics	O	NOUN	B
.	O	PUNCT	O


Analyses	O	NOUN	B
of	O	ADP	O
covariance	O	NOUN	B
were	O	AUX	O
used	O	VERB	O
to	O	PART	O
determine	O	VERB	O
whether	O	SCONJ	O
there	O	PRON	O
were	O	AUX	O
differences	O	NOUN	O
between	O	ADP	O
groups	O	NOUN	B
after	O	ADP	O
controlling	O	VERB	B
for	O	ADP	O
influences	O	NOUN	B
of	O	ADP	O
gestational	O	ADJ	B
age	O	NOUN	I
and	O	CCONJ	O
drug	B-Disease	NOUN	B
abuse	I-Disease	NOUN	I
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
Nearly	O	ADV	O
half	O	NOUN	O
of	O	ADP	O
the	O	DET	O
pregnant	O	ADJ	B
drinkers	O	NOUN	I
abstained	O	VERB	B
after	O	ADP	O
learning	O	NOUN	B
of	O	ADP	O
their	O	PRON	O
pregnancies	O	NOUN	B
.	O	PUNCT	O


When	O	SCONJ	O
women	O	NOUN	B
reportedly	O	ADV	O
quit	O	VERB	O
drinking	O	NOUN	B
early	O	ADV	O
in	O	ADP	O
their	O	PRON	O
pregnancies	O	NOUN	B
,	O	PUNCT	O
fetal	O	ADJ	B
growth	O	NOUN	I
measures	O	NOUN	O
were	O	AUX	O
not	O	PART	O
significantly	O	ADV	O
different	O	ADJ	O
from	O	ADP	O
a	O	DET	O
non	O	ADJ	B
-	O	PUNCT	O
alcohol	B-Chemical	NOUN	B
-	O	PUNCT	O
exposed	O	VERB	B
group	O	NOUN	B
,	O	PUNCT	O
regardless	O	ADV	O
of	O	ADP	O
prior	O	ADJ	B
drinking	O	NOUN	B
patterns	O	NOUN	I
.	O	PUNCT	O


Any	O	DET	O
alcohol	B-Chemical	NOUN	B
consumption	O	NOUN	I
postpregnancy	O	NOUN	B
recognition	O	NOUN	I
among	O	ADP	O
the	O	DET	O
heavy	O	ADJ	B
drinkers	O	NOUN	I
resulted	O	VERB	O
in	O	ADP	O
reduced	B-Disease	VERB	B
cerebellar	I-Disease	ADJ	B
growth	I-Disease	NOUN	I
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
decreased	B-Disease	VERB	B
cranial	I-Disease	ADJ	B
to	I-Disease	PART	O
body	I-Disease	NOUN	B
growth	I-Disease	NOUN	I
in	O	ADP	O
comparison	O	NOUN	B
with	O	ADP	O
women	O	NOUN	B
who	O	PRON	O
either	O	CCONJ	O
quit	O	VERB	B
drinking	O	NOUN	I
or	O	CCONJ	O
who	O	PRON	O
were	O	AUX	O
nondrinkers	O	NOUN	B
.	O	PUNCT	O


Amphetamine	B-Chemical	NOUN	B
abuse	O	NOUN	I
was	O	AUX	O
predictive	O	ADJ	B
of	O	ADP	O
larger	O	ADJ	O
cranial	O	ADJ	B
to	O	PART	O
body	O	NOUN	B
growth	O	NOUN	I
ratios	O	NOUN	I
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
:	O	PUNCT	O
Alterations	O	NOUN	B
in	O	ADP	O
fetal	O	ADJ	B
biometric	O	ADJ	O
measurements	O	NOUN	O
were	O	AUX	O
observed	O	VERB	O
among	O	ADP	O
the	O	DET	O
heavy	O	ADJ	B
drinkers	O	NOUN	I
only	O	ADV	O
when	O	SCONJ	O
they	O	PRON	O
continued	O	VERB	O
drinking	O	NOUN	B
after	O	ADP	O
becoming	O	VERB	O
aware	O	ADJ	O
of	O	ADP	O
their	O	PRON	O
pregnancies	O	NOUN	B
.	O	PUNCT	O


Although	O	SCONJ	O
the	O	DET	O
reliance	O	NOUN	O
on	O	ADP	O
self	O	NOUN	B
-	O	PUNCT	O
reported	O	VERB	B
drinking	O	NOUN	B
is	O	AUX	O
a	O	DET	O
limitation	O	NOUN	B
in	O	ADP	O
this	O	DET	O
study	O	NOUN	B
,	O	PUNCT	O
these	O	DET	O
findings	O	NOUN	B
support	O	VERB	O
the	O	DET	O
benefits	O	NOUN	B
of	O	ADP	O
early	O	ADJ	B
abstinence	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
potential	O	NOUN	B
for	O	ADP	O
ultrasound	O	NOUN	B
examinations	O	NOUN	I
in	O	ADP	O
the	O	DET	O
detection	O	NOUN	B
of	O	ADP	O
fetal	O	ADJ	B
alcohol	B-Chemical	NOUN	I


Urinary	O	ADJ	B
symptoms	O	NOUN	O
and	O	CCONJ	O
quality	O	NOUN	B
of	O	ADP	I
life	O	NOUN	I
changes	O	NOUN	I
in	O	ADP	O
Thai	O	ADJ	B
women	O	NOUN	B
with	O	ADP	O
overactive	B-Disease	ADJ	B
bladder	I-Disease	NOUN	I
after	O	ADP	O
tolterodine	B-Chemical	NOUN	B
treatment	O	NOUN	B
.	O	PUNCT	O


OBJECTIVES	O	NOUN	O
:	O	PUNCT	O
To	O	PART	O
study	O	VERB	B
the	O	DET	O
urinary	O	ADJ	B
symptoms	O	NOUN	I
and	O	CCONJ	O
quality	O	NOUN	B
of	O	ADP	I
life	O	NOUN	I
changes	O	NOUN	I
in	O	ADP	O
Thai	O	ADJ	B
women	O	NOUN	B
with	O	ADP	O
overactive	B-Disease	ADJ	B
bladder	I-Disease	NOUN	I
(	O	PUNCT	O
OAB	B-Disease	NOUN	B
)	O	PUNCT	O
after	O	ADP	O
tolterodine	B-Chemical	NOUN	B
treatment	O	NOUN	B
.	O	PUNCT	O


MATERIAL	O	NOUN	B
AND	O	CCONJ	O
METHOD	O	NOUN	O
:	O	PUNCT	O
Thirty	O	NUM	O
women	O	NOUN	B
(	O	PUNCT	O
aged	O	ADJ	B
30	O	NUM	O
-	O	SYM	O
77	O	NUM	O
years	O	NOUN	B
)	O	PUNCT	O
diagnosed	O	VERB	B
as	O	ADP	O
having	O	VERB	O
OAB	B-Disease	NOUN	B
at	O	ADP	O
the	O	DET	O
Gynecology	O	PROPN	B
Clinic	O	PROPN	I
,	O	PUNCT	O
King	O	PROPN	B
Chulalongkorn	O	PROPN	I
Memorial	O	PROPN	I
Hospital	O	PROPN	I
from	O	ADP	O
January	O	PROPN	O
to	O	ADP	O
April	O	PROPN	O
2004	O	NUM	O
were	O	AUX	O
included	O	VERB	O
in	O	ADP	O
the	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
.	O	PUNCT	O


Tolterodine	B-Chemical	NOUN	B
2	O	NUM	O
mg	O	NOUN	O
,	O	PUNCT	O
twice	O	ADV	O
daily	O	ADV	B
was	O	AUX	O
given	O	VERB	O
.	O	PUNCT	O


After	O	ADP	O
8	O	NUM	O
weeks	O	NOUN	B
treatment	O	NOUN	B
,	O	PUNCT	O
changes	O	NOUN	B
in	O	ADP	O
micturition	O	NOUN	B
diary	O	NOUN	I
variables	O	NOUN	B
and	O	CCONJ	O
tolerability	O	NOUN	B
were	O	AUX	O
determined	O	VERB	O
.	O	PUNCT	O


Short	O	ADJ	B
form	O	NOUN	I
36	O	NUM	I
(	O	PUNCT	O
SF36	O	NOUN	O
)	O	PUNCT	O
questionaires	O	NOUN	O
(	O	PUNCT	O
Thai	O	ADJ	B
version	O	NOUN	B
)	O	PUNCT	O
were	O	AUX	O
given	O	VERB	O
before	O	ADP	O
and	O	CCONJ	O
after	O	ADP	O
8	O	NUM	O
weeks	O	NOUN	B
of	O	ADP	O
treatment	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
At	O	ADP	O
8	O	NUM	O
weeks	O	NOUN	B
,	O	PUNCT	O
all	O	DET	O
micturition	O	NOUN	B
per	O	ADP	O
day	O	NOUN	B
decreased	O	VERB	B
from	O	ADP	O
16	O	NUM	O
.	O	PUNCT	O


7	O	NUM	O
+/-	O	CCONJ	O
5	O	NUM	O
.	O	PUNCT	O


3	O	NUM	O
to	O	PART	O
6	O	NUM	O
.	O	PUNCT	O


7	O	NUM	O
+/-	O	CCONJ	O
2	O	NUM	O
.	O	PUNCT	O


4	O	NUM	O
times	O	NOUN	O
per	O	ADP	O
day	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
number	O	NOUN	O
of	O	ADP	O
nocturia	B-Disease	NOUN	B
episodes	O	NOUN	B
decreased	O	VERB	B
from	O	ADP	O
5	O	NUM	O
.	O	PUNCT	O


4	O	NUM	O
+/-	O	CCONJ	O
4	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
to	O	PART	O
1	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
+/-	O	CCONJ	O
1	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
times	O	NOUN	O
per	O	ADP	O
night	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
most	O	ADV	O
common	O	ADJ	O
side	O	NOUN	B
effect	O	NOUN	I
was	O	AUX	O
dry	B-Disease	ADJ	B
month	I-Disease	NOUN	I
in	O	ADP	O
5	O	NUM	O
cases	O	NOUN	B
(	O	PUNCT	O
16	O	NUM	O
.	O	PUNCT	O


7	O	NUM	O
%)	O	NOUN	O
with	O	ADP	O
2	O	NUM	O
cases	O	NOUN	B
reporting	O	VERB	O
a	O	DET	O
moderate	O	ADJ	B
degree	O	NOUN	B
and	O	CCONJ	O
1	O	NUM	O
case	O	NOUN	B
with	O	ADP	O
severe	O	ADJ	B
degree	O	NOUN	B
.	O	PUNCT	O


Only	O	ADV	O
one	O	NUM	O
case	O	NOUN	B
(	O	PUNCT	O
3	O	NUM	O
.	O	PUNCT	O


3	O	NUM	O
%)	O	NOUN	O
withdrew	O	VERB	O
from	O	ADP	O
the	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
due	O	ADJ	O
to	O	PART	O
a	O	DET	O
severe	O	ADJ	B
dry	B-Disease	ADJ	B
mouth	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
SF	O	PROPN	B
-	O	PUNCT	O
36	O	NUM	O
scores	O	NOUN	B
changed	O	VERB	O
significantly	O	ADV	O
in	O	ADP	O
the	O	DET	O
domains	O	NOUN	B
of	O	ADP	O
physical	O	ADJ	B
functioning	O	NOUN	I
,	O	PUNCT	O
role	O	NOUN	O
function	O	NOUN	B
emotional	O	ADJ	B
,	O	PUNCT	O
social	O	ADJ	B
function	O	NOUN	I
and	O	CCONJ	O
mental	O	ADJ	B
heath	O	NOUN	I
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
:	O	PUNCT	O
Tolterodine	B-Chemical	NOUN	B
was	O	AUX	O
well	O	ADV	O
tolerated	O	VERB	B
and	O	CCONJ	O
its	O	PRON	O
effects	O	NOUN	B
improved	O	VERB	B
the	O	DET	O
quality	O	NOUN	B
of	O	ADP	I
life	O	NOUN	I
in	O	ADP	O
Thai	O	ADJ	B
women	O	NOUN	B
with	O	ADP	O
OAB	B-Disease	NOUN	B


Absence	O	NOUN	B
of	O	ADP	O
acute	O	ADJ	B
cerebral	O	ADJ	I
vasoconstriction	O	NOUN	I
after	O	ADP	O
cocaine	B-Chemical	NOUN	B
-	O	PUNCT	O
associated	O	VERB	B
subarachnoid	B-Disease	ADJ	B
hemorrhage	I-Disease	NOUN	B
.	O	PUNCT	O


INTRODUCTION	O	NOUN	O
:	O	PUNCT	O
Cocaine	B-Chemical	NOUN	B
use	O	NOUN	I
has	O	AUX	O
been	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
neurovascular	B-Disease	ADJ	B
complications	I-Disease	NOUN	I
,	O	PUNCT	O
including	O	VERB	O
arterial	O	ADJ	B
vasoconstriction	O	NOUN	I
and	O	CCONJ	O
vasculitis	B-Disease	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
there	O	PRON	O
are	O	AUX	O
few	O	ADJ	O
studies	O	NOUN	B
of	O	ADP	O
angiographic	O	ADJ	B
effects	O	NOUN	B
of	O	ADP	O
cocaine	B-Chemical	NOUN	B
on	O	ADP	O
human	O	ADJ	B
cerebral	O	ADJ	B
arteries	O	NOUN	I
.	O	PUNCT	O


Information	O	NOUN	B
on	O	ADP	O
these	O	DET	O
effects	O	NOUN	B
could	O	AUX	O
be	O	AUX	O
obtained	O	VERB	O
from	O	ADP	O
angiograms	O	NOUN	B
of	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
cocaine	B-Chemical	NOUN	B
-	O	PUNCT	O
associated	O	VERB	B
subarachnoid	B-Disease	ADJ	B
hemorrhage	I-Disease	NOUN	O
(	O	PUNCT	O
SAH	B-Disease	NOUN	B
)	O	PUNCT	O
who	O	PRON	O
underwent	O	VERB	O
angiography	O	NOUN	B
shortly	O	ADV	O
after	O	ADP	O
cocaine	B-Chemical	NOUN	B
use	O	NOUN	O
.	O	PUNCT	O


METHODS	O	NOUN	O
:	O	PUNCT	O
We	O	PRON	O
screened	O	VERB	B
patients	O	NOUN	B
with	O	ADP	O
SAH	B-Disease	NOUN	B
retrospectively	O	ADV	B
and	O	CCONJ	O
identified	O	VERB	B
those	O	DET	O
with	O	ADP	O
positive	O	ADJ	B
urine	O	NOUN	B
toxicology	O	NOUN	I
for	O	ADP	O
cocaine	B-Chemical	NOUN	B
or	O	CCONJ	O
its	O	PRON	O
metabolites	O	NOUN	B
.	O	PUNCT	O


Quantitative	O	ADJ	B
arterial	O	ADJ	I
diameter	O	NOUN	I
measurements	O	NOUN	I
from	O	ADP	O
angiograms	O	NOUN	B
of	O	ADP	O
these	O	DET	O
patients	O	NOUN	B
were	O	AUX	O
compared	O	VERB	O
to	O	PART	O
measurements	O	NOUN	B
from	O	ADP	O
control	O	NOUN	B
patients	O	NOUN	B
with	O	ADP	O
SAH	B-Disease	NOUN	B
who	O	PRON	O
were	O	AUX	O
matched	O	VERB	B
for	O	ADP	O
factors	O	NOUN	B
known	O	VERB	O
to	O	PART	O
influence	O	VERB	B
arterial	O	ADJ	B
diameter	O	NOUN	B
.	O	PUNCT	O


Qualitative	O	ADJ	B
comparisons	O	NOUN	B
of	O	ADP	O
small	O	ADJ	B
artery	O	NOUN	I
changes	O	NOUN	B
also	O	ADV	O
were	O	AUX	O
made	O	VERB	O
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
Thirteen	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
positive	O	ADJ	B
cocaine	B-Chemical	NOUN	B
toxicology	O	NOUN	B
were	O	AUX	O
compared	O	VERB	O
to	O	PART	O
26	O	NUM	O
controls	O	NOUN	B
.	O	PUNCT	O


There	O	PRON	O
were	O	AUX	O
no	O	DET	O
significant	O	ADJ	O
differences	O	NOUN	O
between	O	ADP	O
groups	O	NOUN	B
in	O	ADP	O
the	O	DET	O
mean	O	ADJ	O
diameters	O	NOUN	B
of	O	ADP	O
the	O	DET	O
intradural	O	ADJ	B
internal	O	ADJ	I
carotid	O	NOUN	I
,	O	PUNCT	O
sphenoidal	O	ADJ	B
segment	O	NOUN	O
of	O	ADP	O
the	O	DET	O
middle	O	ADJ	B
cerebral	O	ADJ	I
,	O	PUNCT	O
precommunicating	O	NOUN	B
segment	O	NOUN	B
of	O	ADP	O
the	O	DET	O
anterior	O	ADJ	B
cerebral	O	ADJ	I
,	O	PUNCT	O
or	O	CCONJ	O
basilar	O	ADJ	B
arteries	O	NOUN	I
(	O	PUNCT	O
p	O	NOUN	O
greater	O	ADJ	O
than	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


05	O	NUM	O
for	O	ADP	O
all	O	DET	O
comparisons	O	NOUN	B
,	O	PUNCT	O
unpaired	O	VERB	O
t	O	NOUN	O
-	O	PUNCT	O
tests	O	NOUN	B
).	O	PUNCT	B
There	O	PRON	O
also	O	ADV	O
were	O	AUX	O
no	O	DET	O
significant	O	ADJ	O
differences	O	NOUN	O
between	O	ADP	O
groups	O	NOUN	B
when	O	SCONJ	O
expressing	O	VERB	B
diameters	O	NOUN	B
as	O	ADP	O
the	O	DET	O
sum	O	NOUN	O
of	O	ADP	O
the	O	DET	O
precommunicating	O	NOUN	B
segment	O	NOUN	B
of	O	ADP	O
the	O	DET	O
anterior	O	ADJ	B
cerebral	O	ADJ	B
+	O	CCONJ	O
sphenoidal	O	ADJ	B
segment	O	NOUN	B
of	O	ADP	O
the	O	DET	O
middle	O	ADJ	B
cerebral	O	ADJ	I
+	O	CCONJ	O
supraclinoid	O	ADJ	B
internal	O	ADJ	I
carotid	O	NOUN	I
artery	O	NOUN	I
+	O	CCONJ	O
basilar	O	ADJ	B
artery	O	NOUN	I
divided	O	VERB	O
by	O	ADP	O
the	O	DET	O
diameter	O	NOUN	B
of	O	ADP	O
the	O	DET	O
petrous	O	ADJ	B
internal	O	ADJ	I
carotid	O	NOUN	I
artery	O	NOUN	I
(	O	PUNCT	O
p	O	NOUN	O
greater	O	ADJ	O
than	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


05	O	NUM	O
,	O	PUNCT	O
unpaired	O	VERB	O
t	O	NOUN	O
-	O	PUNCT	O
tests	O	NOUN	B
).	O	PUNCT	O
Qualitative	O	ADJ	B
assessments	O	NOUN	I
showed	O	VERB	O
two	O	NUM	O
arterial	O	ADJ	B
irregularities	O	NOUN	B
in	O	ADP	O
the	O	DET	O
distal	O	ADJ	B
vasculature	O	NOUN	B
in	O	ADP	O
each	O	DET	O
group	O	NOUN	B
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
:	O	PUNCT	O
No	O	DET	O
quantitative	O	ADJ	B
evidence	O	NOUN	B
for	O	ADP	O
narrowing	O	NOUN	B
of	O	ADP	O
large	O	ADJ	O
cerebral	O	ADJ	B
arteries	O	NOUN	I
or	O	CCONJ	O
qualitative	O	ADJ	B
angiographic	O	ADJ	B
evidence	O	NOUN	B
for	O	ADP	O
distal	O	ADJ	B
narrowing	O	NOUN	B
or	O	CCONJ	O
vasculitis	B-Disease	NOUN	B
could	O	AUX	O
be	O	AUX	O
found	O	VERB	O
in	O	ADP	O
patients	O	NOUN	B
who	O	PRON	O
underwent	O	VERB	O
angiography	O	NOUN	B
after	O	ADP	O
aneurysmal	B-Disease	ADJ	B
SAH	B-Disease	NOUN	B
associated	O	VERB	B
with	O	ADP	I
cocaine	B-Chemical	NOUN	B


Atrial	B-Disease	ADJ	B
fibrillation	I-Disease	NOUN	I
following	O	VERB	O
chemotherapy	O	NOUN	B
for	O	ADP	O
stage	O	NOUN	B
IIIE	O	PROPN	I
diffuse	O	ADJ	O
large	O	ADJ	O
B	O	NOUN	B
-	O	PUNCT	O
cell	O	NOUN	B
gastric	B-Disease	ADJ	I
lymphoma	I-Disease	NOUN	I
in	O	ADP	O
a	O	DET	O
patient	O	NOUN	B
with	O	ADP	O
myotonic	B-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
(	O	PUNCT	O
Steinert's	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
).	O	PUNCT	O
The	O	DET	O
authors	O	NOUN	B
describe	O	VERB	O
the	O	DET	O
unusual	O	ADJ	O
association	O	NOUN	B
between	O	ADP	O
diffuse	O	ADJ	B
B	O	NOUN	B
-	O	PUNCT	O
cell	O	NOUN	B
gastric	B-Disease	ADJ	I
lymphoma	I-Disease	NOUN	I
and	O	CCONJ	O
myotonic	B-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
,	O	PUNCT	O
the	O	DET	O
most	O	ADV	O
common	O	ADJ	O
form	O	NOUN	O
of	O	ADP	O
adult	O	ADJ	B
muscular	B-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
sudden	O	ADJ	B
atrial	B-Disease	ADJ	I
fibrillation	I-Disease	NOUN	I
following	O	VERB	O
one	O	NUM	O
cycle	O	NOUN	B
of	O	ADP	O
doxorubicin	B-Chemical	NOUN	B
-	O	PUNCT	O
based	O	VERB	B
chemotherapy	O	NOUN	B
in	O	ADP	O
the	O	DET	O
same	O	ADJ	O
patient	O	NOUN	B
.	O	PUNCT	O


Atrial	B-Disease	ADJ	B
fibrillation	I-Disease	NOUN	I
or	O	CCONJ	O
other	O	ADJ	O
cardiac	B-Disease	ADJ	B
arrhythmias	I-Disease	NOUN	I
are	O	AUX	O
unusual	O	ADJ	O
complications	O	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
chemotherapy	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
cardiac	B-Disease	ADJ	B
toxicity	I-Disease	NOUN	B
intrinsically	O	ADV	O
associated	O	VERB	B
with	O	ADP	I
the	O	DET	O
aggressive	O	ADJ	B
chemotherapy	O	NOUN	I
employed	O	VERB	O
could	O	AUX	O
function	O	VERB	B
as	O	ADP	O
a	O	DET	O
triggering	O	VERB	O
factor	O	NOUN	O
for	O	ADP	O
the	O	DET	O
arrhythmia	B-Disease	NOUN	B


A	O	DET	O
phase	O	NOUN	B
II	O	NUM	I
study	O	NOUN	I
of	O	ADP	O
thalidomide	B-Chemical	NOUN	B
in	O	ADP	O
advanced	O	ADJ	B
metastatic	O	ADJ	I
renal	B-Disease	ADJ	I
cell	I-Disease	NOUN	I
carcinoma	I-Disease	NOUN	I
.	O	PUNCT	O


OBJECTIVES	O	NOUN	O
:	O	PUNCT	O
To	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
toxicity	B-Disease	NOUN	B
and	O	CCONJ	O
activity	O	NOUN	B
of	O	ADP	O
thalidomide	B-Chemical	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
advanced	O	ADJ	B
metastatic	O	ADJ	I
renal	B-Disease	ADJ	I
cell	I-Disease	NOUN	I
cancer	I-Disease	NOUN	I
and	O	CCONJ	O
to	O	PART	O
measure	O	VERB	B
changes	O	NOUN	B
of	O	ADP	O
one	O	NUM	O
angiogenic	O	ADJ	B
factor	O	NOUN	I
,	O	PUNCT	O
vascular	O	ADJ	B
endothelial	O	ADJ	I
growth	O	NOUN	I
factor	O	NOUN	I
(	O	PUNCT	O
VEGF	O	NOUN	B
)	O	PUNCT	O
165	O	NUM	O
,	O	PUNCT	O
with	O	ADP	O
therapy	O	NOUN	B
.	O	PUNCT	O


PATIENTS	O	NOUN	B
AND	O	CCONJ	O
METHODS	O	NOUN	O
:	O	PUNCT	O
29	O	NUM	O
patients	O	NOUN	B
were	O	AUX	O
enrolled	O	VERB	O
on	O	ADP	O
a	O	DET	O
study	O	NOUN	B
of	O	ADP	O
thalidomide	B-Chemical	NOUN	B
using	O	VERB	O
an	O	DET	O
intra	O	ADJ	B
-	O	PUNCT	O
patient	O	NOUN	B
dose	O	NOUN	B
escalation	O	NOUN	B
schedule	O	NOUN	O
.	O	PUNCT	O


Patients	O	NOUN	B
began	O	VERB	O
thalidomide	B-Chemical	NOUN	B
at	O	ADP	O
400	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
d	O	NOUN	B
and	O	CCONJ	O
escalated	O	VERB	B
as	O	ADP	O
tolerated	O	VERB	B
to	O	PART	O
1200	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
d	O	NOUN	O
by	O	ADP	O
day	O	NOUN	B
54	O	NUM	O
.	O	PUNCT	O


Fifty	O	NUM	B
-	O	PUNCT	O
nine	O	NUM	B
per	O	ADP	O
cent	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
had	O	AUX	O
had	O	AUX	O
previous	O	ADJ	O
therapy	O	NOUN	B
with	O	ADP	O
IL	O	NOUN	B
-	O	PUNCT	O
2	O	NUM	B
and	O	CCONJ	O
52	O	NUM	O
%	O	NOUN	O
were	O	AUX	O
performance	O	NOUN	B
status	O	NOUN	O
2	O	NUM	O
or	O	CCONJ	O
3	O	NUM	O
.	O	PUNCT	O


Systemic	O	ADJ	B
plasma	O	NOUN	B
VEGF165	O	NOUN	B
levels	O	NOUN	B
were	O	AUX	O
measured	O	VERB	B
by	O	ADP	O
dual	O	ADJ	O
monoclonal	O	ADJ	O
ELISA	O	NOUN	O
in	O	ADP	O
8	O	NUM	O
patients	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
24	O	NUM	O
patients	O	NOUN	B
were	O	AUX	O
evaluable	O	ADJ	O
for	O	ADP	O
response	O	NOUN	B
with	O	ADP	O
one	O	NUM	O
partial	O	ADJ	B
response	O	NOUN	B
of	O	ADP	O
11	O	NUM	O
months	O	NOUN	B
duration	O	NOUN	B
of	O	ADP	O
a	O	DET	O
patient	O	NOUN	B
with	O	ADP	O
hepatic	O	ADJ	B
and	O	CCONJ	O
pulmonary	O	ADJ	B
metastases	B-Disease	NOUN	I
(	O	PUNCT	O
4	O	NUM	O
%),	O	ADJ	O
one	O	NUM	O
minor	O	ADJ	B
response	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
2	O	NUM	O
patients	O	NOUN	B
stable	O	ADJ	B
for	O	ADP	O
over	O	ADP	O
6	O	NUM	O
months	O	NOUN	B
.	O	PUNCT	O


Somnolence	B-Disease	NOUN	B
and	O	CCONJ	O
constipation	B-Disease	NOUN	B
were	O	AUX	O
prominent	O	ADJ	O
toxicities	B-Disease	NOUN	B
and	O	CCONJ	O
most	O	ADJ	O
patients	O	NOUN	B
could	O	AUX	O
not	O	PART	O
tolerate	O	VERB	O
the	O	DET	O
1200	O	NUM	O
mg	O	NOUN	O
/	O	PUNCT	O
day	O	NOUN	B
dose	O	NOUN	B
level	O	NOUN	B
.	O	PUNCT	O


Systemic	O	ADJ	B
plasma	O	NOUN	B
VEGF165	O	NOUN	B
levels	O	NOUN	B
did	O	AUX	O
not	O	PART	O
change	O	VERB	O
with	O	ADP	O
therapy	O	NOUN	B
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
:	O	PUNCT	O
These	O	DET	O
results	O	NOUN	B
are	O	AUX	O
consistent	O	ADJ	B
with	O	ADP	I
a	O	DET	O
low	O	ADJ	B
level	O	NOUN	B
of	O	ADP	O
activity	O	NOUN	B
of	O	ADP	O
thalidomide	B-Chemical	NOUN	B
in	O	ADP	O
renal	B-Disease	ADJ	B
cell	I-Disease	NOUN	I
carcinoma	I-Disease	NOUN	I
.	O	PUNCT	O


Administration	O	NOUN	B
of	O	ADP	O
doses	O	NOUN	B
over	O	ADP	O
800	O	NUM	O
mg	O	NOUN	O
/	O	PUNCT	O
day	O	NOUN	B
was	O	AUX	O
difficult	O	ADJ	O
to	O	PART	O
achieve	O	VERB	O
in	O	ADP	O
this	O	DET	O
patient	O	NOUN	B
population	O	NOUN	I
,	O	PUNCT	O
however	O	ADV	O
lower	O	ADJ	B
doses	O	NOUN	I
were	O	AUX	O
practical	O	ADJ	O
.	O	PUNCT	O


The	O	DET	O
dose	O	NOUN	B
-	O	PUNCT	O
response	O	NOUN	B
relationship	O	NOUN	B
,	O	PUNCT	O
if	O	SCONJ	O
any	O	DET	O
,	O	PUNCT	O
of	O	ADP	O
thalidomide	B-Chemical	NOUN	B
for	O	ADP	O
renal	B-Disease	ADJ	B
cell	I-Disease	NOUN	I
carcinoma	I-Disease	NOUN	I


The	O	DET	O
striatum	O	NOUN	B
as	O	ADP	O
a	O	DET	O
target	O	NOUN	B
for	O	ADP	O
anti	O	ADJ	B
-	O	PUNCT	O
rigor	O	NOUN	B
effects	O	NOUN	B
of	O	ADP	O
an	O	DET	O
antagonist	O	NOUN	B
of	O	ADP	O
mGluR1	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
not	O	PART	O
an	O	DET	O
agonist	O	NOUN	B
of	O	ADP	O
group	O	NOUN	B
II	O	NUM	I
metabotropic	O	NOUN	I
glutamate	B-Chemical	NOUN	I
receptors	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
aim	O	NOUN	O
of	O	ADP	O
the	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
find	O	VERB	O
out	O	ADP	O
whether	O	SCONJ	O
the	O	DET	O
metabotropic	O	NOUN	B
receptor	O	NOUN	I
1	O	NUM	I
(	O	PUNCT	O
mGluR1	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
group	O	NOUN	B
II	O	NUM	I
mGluRs	O	NOUN	I
,	O	PUNCT	O
localized	O	ADJ	B
in	O	ADP	O
the	O	DET	O
striatum	O	NOUN	B
,	O	PUNCT	O
are	O	AUX	O
involved	O	VERB	O
in	O	ADP	O
antiparkinsonian	O	ADJ	B
-	O	PUNCT	O
like	O	ADJ	B
effects	O	NOUN	B
in	O	ADP	O
rats	O	NOUN	B
.	O	PUNCT	O


Haloperidol	B-Chemical	NOUN	B
(	O	PUNCT	O
1	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
ip	O	NOUN	B
)	O	PUNCT	O
induced	O	VERB	B
parkinsonian	B-Disease	ADJ	B
-	O	PUNCT	O
like	O	ADJ	B
muscle	B-Disease	NOUN	B
rigidity	I-Disease	NOUN	I
,	O	PUNCT	O
measured	O	VERB	B
as	O	ADP	O
an	O	DET	O
increased	O	VERB	B
resistance	O	NOUN	B
of	O	ADP	O
a	O	DET	O
rat	O	NOUN	B
'	O	PART	O
s	O	NOUN	O
hind	O	ADJ	B
foot	O	NOUN	O
to	O	PART	O
passive	O	ADJ	B
flexion	O	NOUN	B
and	O	CCONJ	O
extension	O	NOUN	B
at	O	ADP	O
the	O	DET	O
ankle	O	NOUN	B
joint	O	NOUN	I
.	O	PUNCT	O


(RS)-1-aminoindan-1,5-dicarboxylic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
(	O	PUNCT	O
AIDA	B-Chemical	NOUN	B
;	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
-	O	PUNCT	O
15	O	NUM	O
microg	O	NOUN	B
/	O	SYM	O
0	O	NUM	B
.	O	PUNCT	O


5	O	NUM	O
microl	O	NOUN	B
),	O	PUNCT	O
a	O	DET	O
potent	O	ADJ	O
and	O	CCONJ	O
selective	O	ADJ	O
mGluR1	O	NOUN	B
antagonist	O	NOUN	B
,	O	PUNCT	O
or	O	CCONJ	O
(2R,4R)-4-aminopyrrolidine-2,4-dicarboxylate	B-Chemical	NOUN	B
(	O	PUNCT	O
2R,4R-APDC	B-Chemical	ADJ	B
;	O	PUNCT	O
7	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
-	O	PUNCT	O
15	O	NUM	O
microg	O	NOUN	B
/	O	SYM	O
0	O	NUM	B
.	O	PUNCT	O


5	O	NUM	O
microl	O	NOUN	B
),	O	PUNCT	O
a	O	DET	O
selective	O	ADJ	B
group	O	NOUN	I
II	O	NUM	I
agonist	O	NOUN	I
,	O	PUNCT	O
was	O	AUX	O
injected	O	VERB	O
bilaterally	O	ADV	B
into	O	ADP	O
the	O	DET	O
striatum	O	NOUN	B
of	O	ADP	O
haloperidol	B-Chemical	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
animals	O	NOUN	B
.	O	PUNCT	O


AIDA	B-Chemical	NOUN	B
in	O	ADP	O
doses	O	NOUN	B
of	O	ADP	O
7	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
-	O	PUNCT	O
15	O	NUM	O
microg	O	NOUN	B
/	O	SYM	O
0	O	NUM	B
.	O	PUNCT	O


5	O	NUM	O
microl	O	NOUN	B
diminished	O	VERB	B
the	O	DET	O
haloperidol	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
muscle	B-Disease	NOUN	B
rigidity	I-Disease	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
contrast	O	NOUN	O
,	O	PUNCT	O
2R,4R-APDC	B-Chemical	ADJ	O
injections	O	NOUN	B
were	O	AUX	O
ineffective	O	ADJ	B
.	O	PUNCT	O


The	O	DET	O
present	O	ADJ	O
results	O	NOUN	B
may	O	AUX	O
suggest	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
blockade	O	NOUN	B
of	O	ADP	O
striatal	O	ADJ	B
mGluR1	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
not	O	PART	O
the	O	DET	O
stimulation	O	NOUN	B
of	O	ADP	O
group	O	NOUN	B
II	O	NUM	I
mGluRs	O	NOUN	I
,	O	PUNCT	O
may	O	AUX	O
ameliorate	O	VERB	O
parkinsonian	B-Disease	ADJ	B
muscle	B-Disease	NOUN	O
rigidity	I-Disease	NOUN	B


Acute	O	ADJ	B
cholestatic	B-Disease	ADJ	I
hepatitis	I-Disease	NOUN	I
after	O	ADP	O
exposure	O	NOUN	B
to	O	PART	I
isoflurane	B-Chemical	NOUN	B
.	O	PUNCT	O


OBJECTIVE	O	NOUN	O
:	O	PUNCT	O
To	O	PART	O
report	O	VERB	O
a	O	DET	O
case	O	NOUN	B
of	O	ADP	O
acute	O	ADJ	B
cholestatic	B-Disease	ADJ	I
hepatitis	I-Disease	NOUN	I
following	O	VERB	O
exposure	O	NOUN	B
to	O	PART	I
the	O	DET	O
inhalational	O	ADJ	B
anesthetic	O	ADJ	B
isoflurane	B-Chemical	NOUN	I
.	O	PUNCT	O


CASE	O	ADJ	B
SUMMARY	O	NOUN	I
:	O	PUNCT	O
A	O	DET	O
70	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
healthy	O	ADJ	B
woman	O	NOUN	B
from	O	ADP	O
Iraq	O	PROPN	B
developed	O	VERB	O
acute	O	ADJ	B
cholestatic	B-Disease	ADJ	I
hepatitis	I-Disease	NOUN	I
3	O	NUM	I
weeks	O	NOUN	B
following	O	VERB	O
repair	O	NOUN	B
of	O	ADP	O
the	O	DET	O
right	O	ADJ	B
rotator	O	NOUN	I
cuff	O	NOUN	I
under	O	ADP	O
general	O	ADJ	B
anesthesia	O	NOUN	I
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
no	O	DET	O
evidence	O	NOUN	O
for	O	ADP	O
viral	O	ADJ	B
,	O	PUNCT	O
autoimmune	O	ADJ	B
,	O	PUNCT	O
or	O	CCONJ	O
metabolic	O	ADJ	B
causes	O	NOUN	O
of	O	ADP	O
hepatitis	B-Disease	NOUN	B
.	O	PUNCT	O


No	O	DET	O
other	O	ADJ	O
medications	O	NOUN	B
were	O	AUX	O
involved	O	VERB	O
except	O	SCONJ	O
for	O	ADP	O
dipyrone	B-Chemical	NOUN	B
for	O	ADP	O
analgesia	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
alanine	B-Chemical	NOUN	B
aminotransferase	O	NOUN	I
was	O	AUX	O
elevated	O	ADJ	B
to	O	PART	O
a	O	DET	O
peak	O	ADJ	O
concentration	O	NOUN	B
of	O	ADP	O
1533	O	NUM	O
U	O	PROPN	B
/	O	SYM	O
L	O	PROPN	B
and	O	CCONJ	O
the	O	DET	O
serum	O	NOUN	B
bilirubin	B-Chemical	NOUN	B
reached	O	VERB	O
a	O	DET	O
peak	O	NOUN	O
of	O	ADP	O
17	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
dL	O	NOUN	B
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
slow	O	ADJ	B
improvement	O	NOUN	I
over	O	ADP	O
4	O	NUM	O
months	O	NOUN	B
.	O	PUNCT	O


Accidental	O	ADJ	B
reexposure	O	NOUN	I
by	O	ADP	O
the	O	DET	O
patient	O	NOUN	B
to	O	PART	O
dipyrone	B-Chemical	NOUN	B
was	O	AUX	O
uneventful	O	ADJ	B
.	O	PUNCT	O


DISCUSSION	O	NOUN	O
:	O	PUNCT	O
The	O	DET	O
clinical	O	ADJ	B
and	O	CCONJ	O
histologic	O	ADJ	B
picture	O	NOUN	I
of	O	ADP	O
this	O	DET	O
case	O	NOUN	B
resembles	O	VERB	O
halothane	B-Disease	NOUN	B
hepatitis	I-Disease	NOUN	B
,	O	PUNCT	O
which	O	DET	O
has	O	AUX	O
a	O	DET	O
significant	O	ADJ	B
mortality	O	NOUN	B
rate	O	NOUN	I
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
:	O	PUNCT	O
Isoflurane	B-Chemical	NOUN	B
,	O	PUNCT	O
a	O	DET	O
common	O	ADJ	O
anesthetic	O	ADJ	B
agent	O	NOUN	I
,	O	PUNCT	O
can	O	AUX	O
cause	O	VERB	O
severe	O	ADJ	O
cholestatic	B-Disease	ADJ	B
hepatitis	I-Disease	NOUN	I


Calcitonin	O	NOUN	B
gene	O	NOUN	I
-	O	PUNCT	O
related	O	ADJ	B
peptide	O	NOUN	B
levels	O	NOUN	O
during	O	ADP	O
nitric	B-Chemical	ADJ	B
oxide	I-Chemical	NOUN	I
-	O	PUNCT	O
induced	O	VERB	B
headache	B-Disease	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
chronic	O	ADJ	B
tension-type	B-Disease	ADJ	I
headache	I-Disease	NOUN	I
.	O	PUNCT	O


It	O	PRON	O
has	O	AUX	O
been	O	AUX	O
proposed	O	VERB	O
that	O	SCONJ	O
nitric	B-Chemical	ADJ	B
oxide	I-Chemical	NOUN	I
(	O	PUNCT	O
NO	B-Chemical	NOUN	B
)	O	PUNCT	O
induced	O	VERB	B
headache	B-Disease	NOUN	B
in	O	ADP	O
primary	B-Disease	ADJ	B
headaches	I-Disease	NOUN	I
may	O	AUX	O
be	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
release	O	NOUN	B
of	O	ADP	O
calcitonin	O	NOUN	B
gene	O	NOUN	I
-	O	PUNCT	O
related	O	VERB	B
peptide	O	NOUN	B
(	O	PUNCT	O
CGRP	O	NOUN	B
).	O	PUNCT	O
In	O	ADP	O
the	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
we	O	PRON	O
aimed	O	VERB	O
to	O	PART	O
investigate	O	VERB	B
plasma	O	NOUN	B
levels	O	NOUN	O
of	O	ADP	O
CGRP	O	NOUN	B
during	O	ADP	O
headache	B-Disease	NOUN	B
induced	O	VERB	B
by	O	ADP	O
the	O	DET	O
NO	B-Chemical	NOUN	B
donor	O	NOUN	B
glyceryl	B-Chemical	NOUN	I
trinitrate	I-Chemical	NOUN	I
(	O	PUNCT	O
GTN	B-Chemical	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
16	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
chronic	O	ADJ	B
tension-type	B-Disease	ADJ	I
headache	I-Disease	NOUN	I
and	O	CCONJ	O
16	O	NUM	O
healthy	O	ADJ	B
controls	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
subjects	O	NOUN	B
were	O	AUX	O
randomly	O	ADV	O
allocated	O	VERB	O
to	O	PART	O
receive	O	VERB	O
0	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
microg	O	NOUN	B
/	O	SYM	O
kg	O	NOUN	B
/	O	PUNCT	O
min	O	NOUN	B
GTN	B-Chemical	NOUN	B
or	O	CCONJ	O
placebo	O	NOUN	B
over	O	ADP	O
20	O	NUM	O
min	O	NOUN	O
on	O	ADP	O
two	O	NUM	O
headache	B-Disease	NOUN	B
-	O	PUNCT	O
free	O	ADJ	B
days	O	NOUN	B
.	O	PUNCT	O


Blood	O	NOUN	B
samples	O	NOUN	I
were	O	AUX	O
collected	O	VERB	O
at	O	ADP	O
baseline	O	NOUN	B
,	O	PUNCT	O
10	O	NUM	O
,	O	PUNCT	O
20	O	NUM	O
and	O	CCONJ	O
60	O	NUM	O
min	O	NOUN	O
after	O	ADP	O
start	O	NOUN	O
of	O	ADP	O
infusion	O	NOUN	B
.	O	PUNCT	O


Both	O	DET	O
patients	O	NOUN	B
and	O	CCONJ	O
controls	O	NOUN	B
developed	O	VERB	O
significantly	O	ADV	O
stronger	O	ADJ	O
immediate	O	ADJ	O
headache	B-Disease	NOUN	B
on	O	ADP	O
the	O	DET	O
GTN	B-Chemical	NOUN	B
day	O	NOUN	B
than	O	ADP	O
on	O	ADP	O
the	O	DET	O
placebo	O	NOUN	B
day	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
headache	B-Disease	NOUN	B
was	O	AUX	O
significantly	O	ADV	O
more	O	ADV	O
pronounced	O	ADJ	O
in	O	ADP	O
patients	O	NOUN	B
than	O	ADP	O
in	O	ADP	O
controls	O	NOUN	B
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
no	O	DET	O
difference	O	NOUN	O
between	O	ADP	O
the	O	DET	O
area	O	NOUN	B
under	O	ADP	O
the	O	DET	O
CGRP	O	NOUN	B
curve	O	NOUN	I
(	O	PUNCT	O
AUCCGRP	O	NOUN	B
)	O	PUNCT	O
on	O	ADP	O
GTN	B-Chemical	NOUN	B
vs	O	ADV	O
.	O	PUNCT	O


placebo	O	ADJ	B
day	O	NOUN	B
in	O	ADP	O
either	O	DET	O
patients	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


65	O	NUM	O
)	O	PUNCT	O
or	O	CCONJ	O
controls	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


48	O	NUM	O
).	O	PUNCT	O
The	O	DET	O
AUCCGRP	O	NOUN	B
recorded	O	VERB	O
on	O	ADP	O
the	O	DET	O
GTN	B-Chemical	NOUN	B
day	O	NOUN	B
did	O	AUX	O
not	O	PART	O
differ	O	VERB	O
between	O	ADP	O
patients	O	NOUN	B
and	O	CCONJ	O
controls	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


36	O	NUM	O
).	O	NOUN	O
Both	O	CCONJ	O
in	O	ADP	O
patients	O	NOUN	B
and	O	CCONJ	O
controls	O	NOUN	B
,	O	PUNCT	O
CGRP	O	NOUN	B
levels	O	NOUN	B
changed	O	VERB	O
significantly	O	ADV	O
over	O	ADP	O
time	O	NOUN	B
,	O	PUNCT	O
on	O	ADP	O
both	O	CCONJ	O
the	O	DET	O
GTN	B-Chemical	NOUN	B
and	O	CCONJ	O
placebo	O	ADJ	B
days	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


05	O	NUM	O
).	O	PUNCT	O
The	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
indicates	O	VERB	O
that	O	SCONJ	O
NO	B-Chemical	PROPN	B
-	O	PUNCT	O
induced	O	VERB	B
immediate	O	ADJ	O
headache	B-Disease	NOUN	B


Myocardial	B-Disease	ADJ	B
ischemia	I-Disease	NOUN	I
due	O	ADP	O
to	O	ADP	O
coronary	B-Disease	ADJ	B
artery	I-Disease	NOUN	I
spasm	I-Disease	NOUN	I
during	O	ADP	O
dobutamine	B-Chemical	NOUN	B
stress	O	NOUN	I
echocardiography	O	NOUN	I
.	O	PUNCT	O


Dobutamine	B-Chemical	NOUN	B
stress	O	NOUN	I
echocardiography	O	NOUN	I
(	O	PUNCT	O
DSE	O	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
a	O	DET	O
useful	O	ADJ	O
and	O	CCONJ	O
safe	O	ADJ	O
provocation	O	NOUN	B
test	O	NOUN	I
for	O	ADP	O
myocardial	B-Disease	ADJ	B
ischemia	I-Disease	NOUN	I
.	O	PUNCT	O


Until	O	ADP	O
now	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
test	O	NOUN	B
has	O	AUX	O
been	O	AUX	O
focused	O	VERB	O
only	O	ADV	O
on	O	ADP	O
the	O	DET	O
organic	O	ADJ	B
lesion	O	NOUN	O
in	O	ADP	O
the	O	DET	O
coronary	O	ADJ	B
artery	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
positive	O	ADJ	B
DSE	O	NOUN	B
has	O	AUX	O
indicated	O	VERB	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
significant	O	ADJ	B
fixed	O	ADJ	B
coronary	B-Disease	ADJ	I
artery	I-Disease	NOUN	I
stenosis	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
aim	O	NOUN	O
of	O	ADP	O
the	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
is	O	AUX	O
to	O	PART	O
examine	O	VERB	O
whether	O	SCONJ	O
myocardial	B-Disease	ADJ	B
ischemia	I-Disease	NOUN	I
due	O	ADP	O
to	O	ADP	O
coronary	B-Disease	ADJ	B
spasm	I-Disease	NOUN	I
is	O	AUX	O
induced	O	VERB	B
by	O	ADP	O
dobutamine	B-Chemical	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
performed	O	VERB	O
DSE	O	NOUN	B
on	O	ADP	O
51	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
coronary	B-Disease	ADJ	B
spastic	I-Disease	ADJ	I
angina	I-Disease	ADJ	I
but	O	CCONJ	O
without	O	ADP	O
significant	O	ADJ	B
fixed	O	ADJ	B
coronary	B-Disease	ADJ	I
artery	I-Disease	NOUN	I
stenosis	I-Disease	NOUN	I
.	O	PUNCT	O


All	O	DET	O
patients	O	NOUN	B
had	O	AUX	O
anginal	B-Disease	ADJ	B
attacks	O	NOUN	I
at	O	ADP	O
rest	O	NOUN	B
with	O	ADP	O
ST	O	ADJ	B
elevation	O	NOUN	B
on	O	ADP	O
the	O	DET	O
electrocardiogram	O	NOUN	B
(	O	PUNCT	O
variant	B-Disease	ADJ	B
angina	I-Disease	ADJ	I
).	O	PUNCT	O
Coronary	O	ADJ	B
spasm	O	NOUN	I
was	O	AUX	O
induced	O	VERB	B
by	O	ADP	O
intracoronary	O	ADJ	B
injection	O	NOUN	I
of	O	ADP	O
acetylcholine	B-Chemical	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
no	O	DET	O
fixed	O	ADJ	O
coronary	B-Disease	ADJ	O
artery	I-Disease	NOUN	O
stenosis	I-Disease	NOUN	O
was	O	AUX	O
documented	O	VERB	B
on	O	ADP	O
angiograms	O	NOUN	B
in	O	ADP	O
all	O	DET	O
patients	O	NOUN	B
.	O	PUNCT	O


DSE	O	NOUN	B
was	O	AUX	O
performed	O	VERB	O
with	O	ADP	O
intravenous	O	ADJ	B
dobutamine	B-Chemical	NOUN	O
infusion	O	NOUN	B
with	O	ADP	O
an	O	DET	O
incremental	O	ADJ	B
doses	O	NOUN	I
of	O	ADP	O
5	O	NUM	O
,	O	PUNCT	O
10	O	NUM	O
,	O	PUNCT	O
20	O	NUM	O
,	O	PUNCT	O
30	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
40	O	NUM	O
microg	O	NOUN	B
/	O	SYM	O
kg	O	NOUN	B
/	O	SYM	O
min	O	NOUN	B
every	O	DET	O
5	O	NUM	O
minutes	O	NOUN	B
.	O	PUNCT	O


Of	O	ADP	O
the	O	DET	O
51	O	NUM	O
patients	O	NOUN	B
,	O	PUNCT	O
7	O	NUM	O
patients	O	NOUN	B
showed	O	VERB	O
asynergy	O	NOUN	B
with	O	ADP	O
ST	O	ADJ	B
elevation	O	NOUN	B
.	O	PUNCT	O


All	O	DET	O
7	O	NUM	O
patients	O	NOUN	B
(	O	PUNCT	O
13	O	NUM	O
.	O	PUNCT	O


7	O	NUM	O
%)	O	NOUN	O
had	O	AUX	O
chest	B-Disease	ADJ	B
pain	I-Disease	NOUN	I
during	O	ADP	O
asynergy	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
both	O	DET	O
chest	B-Disease	ADJ	B
pain	I-Disease	NOUN	I
and	O	CCONJ	O
electrocardiographic	O	ADJ	B
changes	O	NOUN	I
were	O	AUX	O
preceded	O	VERB	O
by	O	ADP	O
asynergy	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
findings	O	NOUN	B
indicate	O	VERB	O
that	O	SCONJ	O
dobutamine	B-Chemical	NOUN	B
can	O	AUX	O
provoke	O	VERB	O
coronary	B-Disease	ADJ	B
spasm	I-Disease	NOUN	I
in	O	ADP	O
some	O	DET	O
patients	O	NOUN	B
with	O	ADP	O
coronary	B-Disease	ADJ	B
spastic	I-Disease	ADJ	I
angina	I-Disease	NOUN	I
.	O	PUNCT	O


When	O	SCONJ	O
DSE	O	NOUN	B
is	O	AUX	O
performed	O	VERB	O
to	O	PART	O
evaluate	O	VERB	B
coronary	B-Disease	ADJ	B
artery	I-Disease	NOUN	I
disease	I-Disease	NOUN	I
,	O	PUNCT	O
not	O	PART	O
only	O	ADV	O
fixed	O	VERB	B
coronary	B-Disease	ADJ	I
stenosis	I-Disease	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
also	O	ADV	O
coronary	B-Disease	ADJ	B
spasm	I-Disease	NOUN	I


Nitric	B-Chemical	ADJ	B
oxide	I-Chemical	NOUN	I
synthase	O	NOUN	I
expression	O	NOUN	B
in	O	ADP	O
the	O	DET	O
course	O	NOUN	B
of	O	ADP	O
lead	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
hypertension	B-Disease	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
recently	O	ADV	O
showed	O	VERB	O
elevated	O	ADJ	B
reactive	O	ADJ	B
oxygen	B-Chemical	NOUN	I
species	O	NOUN	I
(	O	PUNCT	O
ROS	O	NOUN	B
),	O	PUNCT	O
reduced	O	VERB	B
urinary	O	ADJ	B
excretion	O	NOUN	B
of	O	ADP	O
NO	B-Chemical	NOUN	B
metabolites	O	NOUN	B
(	O	PUNCT	O
NOx	O	NOUN	B
),	O	PUNCT	O
and	O	CCONJ	O
increased	O	VERB	B
NO	B-Chemical	NOUN	B
sequestration	O	NOUN	B
as	O	ADP	O
nitrotyrosine	B-Chemical	NOUN	B
in	O	ADP	O
various	O	ADJ	O
tissues	O	NOUN	B
in	O	ADP	O
rats	O	NOUN	B
with	O	ADP	O
lead	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
hypertension	B-Disease	NOUN	B
.	O	PUNCT	O


This	O	DET	O
study	O	NOUN	B
was	O	AUX	O
designed	O	VERB	O
to	O	PART	O
discern	O	VERB	O
whether	O	SCONJ	O
the	O	DET	O
reduction	O	NOUN	B
in	O	ADP	O
urinary	O	ADJ	B
NOx	O	NOUN	B
in	O	ADP	O
lead	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
hypertension	B-Disease	NOUN	B
is	O	AUX	O
,	O	PUNCT	O
in	O	ADP	O
part	O	NOUN	O
,	O	PUNCT	O
due	O	ADP	O
to	O	PART	O
depressed	O	ADJ	B
NO	B-Chemical	NOUN	O
synthase	O	NOUN	O
(	O	PUNCT	O
NOS	O	NOUN	B
)	O	PUNCT	O
expression	O	NOUN	B
.	O	PUNCT	O


Male	O	NOUN	B
Sprague	O	PROPN	B
-	O	PUNCT	O
Dawley	O	NOUN	B
rats	O	NOUN	B
were	O	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
to	O	PART	O
a	O	DET	O
lead	B-Chemical	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
group	O	NOUN	B
(	O	PUNCT	O
given	O	VERB	O
lead	B-Chemical	NOUN	B
acetate	I-Chemical	NOUN	I
,	O	PUNCT	O
100	O	NUM	O
ppm	O	NOUN	O
,	O	PUNCT	O
in	O	ADP	O
drinking	O	NOUN	B
water	O	NOUN	I
and	O	CCONJ	O
regular	O	ADJ	O
rat	O	NOUN	B
chow	O	NOUN	B
),	O	PUNCT	O
a	O	DET	O
group	O	NOUN	B
given	O	VERB	O
lead	B-Chemical	NOUN	O
and	O	CCONJ	O
vitamin	B-Chemical	NOUN	B
E	I-Chemical	PROPN	I
-	O	PUNCT	O
fortified	O	VERB	B
chow	O	NOUN	B
,	O	PUNCT	O
or	O	CCONJ	O
a	O	DET	O
normal	O	ADJ	O
control	O	NOUN	O
group	O	NOUN	O
given	O	VERB	O
either	O	CCONJ	O
regular	O	ADJ	B
food	O	NOUN	B
and	O	CCONJ	O
water	O	NOUN	B
or	O	CCONJ	O
vitamin	B-Chemical	NOUN	B
E	I-Chemical	PROPN	I
-	O	PUNCT	O
fortified	O	VERB	B
food	O	NOUN	B
for	O	ADP	O
12	O	NUM	O
weeks	O	NOUN	B
.	O	PUNCT	O


Tail	O	NOUN	B
blood	O	NOUN	I
pressure	O	NOUN	I
,	O	PUNCT	O
urinary	O	ADJ	B
NOx	O	NOUN	B
excretion	O	NOUN	B
,	O	PUNCT	O
plasma	O	NOUN	B
malondialdehyde	B-Chemical	NOUN	I
(	O	PUNCT	O
MDA	B-Chemical	NOUN	B
),	O	PUNCT	O
and	O	CCONJ	O
endothelial	O	ADJ	B
and	O	CCONJ	O
inducible	O	ADJ	B
NOS	O	NOUN	B
(	O	PUNCT	O
eNOS	O	NOUN	B
and	O	CCONJ	O
iNOS	O	NOUN	B
)	O	PUNCT	O
isotypes	O	NOUN	B
in	O	ADP	O
the	O	DET	O
aorta	O	NOUN	B
and	O	CCONJ	O
kidney	O	NOUN	B
were	O	AUX	O
measured	O	VERB	B
.	O	PUNCT	O


The	O	DET	O
lead	B-Chemical	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
group	O	NOUN	B
exhibited	O	VERB	O
a	O	DET	O
rise	O	NOUN	O
in	O	ADP	O
blood	O	NOUN	B
pressure	O	NOUN	I
and	O	CCONJ	O
plasma	O	NOUN	B
MDA	B-Chemical	NOUN	B
concentration	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
fall	O	NOUN	B
in	O	ADP	O
urinary	O	ADJ	B
NOx	O	NOUN	B
excretion	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
paradoxical	O	ADJ	B
rise	O	NOUN	O
in	O	ADP	O
vascular	O	ADJ	B
and	O	CCONJ	O
renal	O	ADJ	B
tissue	O	NOUN	I
eNOS	O	NOUN	B
and	O	CCONJ	O
iNOS	O	NOUN	B
expression	O	NOUN	B
.	O	PUNCT	O


Vitamin	B-Chemical	NOUN	B
E	I-Chemical	NOUN	I
supplementation	O	NOUN	I
ameliorated	O	VERB	O
hypertension	B-Disease	NOUN	B
,	O	PUNCT	O
lowered	O	VERB	B
plasma	O	NOUN	B
MDA	B-Chemical	NOUN	B
concentration	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
raised	O	VERB	B
urinary	O	ADJ	B
NOx	O	NOUN	B
excretion	O	NOUN	B
while	O	SCONJ	O
significantly	O	ADV	O
lowering	O	VERB	O
vascular	O	ADJ	B
,	O	PUNCT	O
but	O	CCONJ	O
not	O	PART	O
renal	O	ADJ	B
,	O	PUNCT	O
tissue	O	NOUN	B
eNOS	O	NOUN	B
and	O	CCONJ	O
iNOS	O	NOUN	B
expression	O	NOUN	B
.	O	PUNCT	O


Vitamin	B-Chemical	NOUN	B
E	I-Chemical	NOUN	I
supplementation	O	NOUN	B
had	O	AUX	O
no	O	DET	B
effect	O	NOUN	I
on	O	ADP	O
either	O	DET	O
blood	O	NOUN	B
pressure	O	NOUN	I
,	O	PUNCT	O
plasma	O	NOUN	B
MDA	B-Chemical	NOUN	B
,	O	PUNCT	O
or	O	CCONJ	O
NOS	O	NOUN	B
expression	O	NOUN	B
in	O	ADP	O
the	O	DET	O
control	O	NOUN	B
group	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
study	O	NOUN	B
also	O	ADV	O
revealed	O	VERB	O
significant	O	ADJ	O
inhibition	O	NOUN	B
of	O	ADP	O
NOS	O	NOUN	B
enzymatic	O	ADJ	B
activity	O	NOUN	I
by	O	ADP	O
lead	B-Chemical	NOUN	O
in	O	ADP	O
cell	O	NOUN	B
-	O	PUNCT	O
free	O	ADJ	B
preparations	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
conclusion	O	NOUN	O
,	O	PUNCT	O
lead	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
hypertension	B-Disease	NOUN	B
in	O	ADP	O
this	O	DET	O
model	O	NOUN	B
was	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
a	O	DET	O
compensatory	O	ADJ	B
upregulation	O	NOUN	B
of	O	ADP	O
renal	O	ADJ	B
and	O	CCONJ	O
vascular	O	ADJ	B
eNOS	O	NOUN	I
and	O	CCONJ	O
iNOS	O	NOUN	B
expression	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
is	O	AUX	O
,	O	PUNCT	O
in	O	ADP	O
part	O	NOUN	O
,	O	PUNCT	O
due	O	ADP	O
to	O	PART	O
ROS	O	NOUN	B
-	O	PUNCT	O
mediated	O	VERB	B
NO	B-Chemical	NOUN	B
inactivation	O	NOUN	B
,	O	PUNCT	O
lead	B-Chemical	NOUN	B
-	O	PUNCT	O
associated	O	VERB	B
inhibition	O	NOUN	B
of	O	ADP	O
NOS	O	NOUN	B
activity	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
perhaps	O	ADV	O
stimulatory	O	ADJ	B
actions	O	NOUN	O
of	O	ADP	O
increased	O	VERB	B
shear	O	NOUN	B
stress	O	NOUN	I
associated	O	VERB	B
with	O	ADP	I
hypertension	B-Disease	NOUN	B


Risk	O	NOUN	B
for	O	ADP	O
valvular	B-Disease	ADJ	B
heart	I-Disease	NOUN	I
disease	I-Disease	NOUN	I
among	O	ADP	O
users	O	NOUN	B
of	O	ADP	O
fenfluramine	B-Chemical	NOUN	B
and	O	CCONJ	O
dexfenfluramine	B-Chemical	NOUN	B
who	O	PRON	O
underwent	O	VERB	O
echocardiography	O	NOUN	B
before	O	ADP	O
use	O	NOUN	B
of	O	ADP	I
medication	O	NOUN	B
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
:	O	PUNCT	O
Because	O	SCONJ	O
uncontrolled	O	ADJ	B
echocardiographic	O	ADJ	B
surveys	O	NOUN	B
suggested	O	VERB	O
that	O	SCONJ	O
up	O	ADV	O
to	O	PART	O
30	O	NUM	O
%	O	NOUN	O
to	O	ADP	O
38	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
users	O	NOUN	B
of	O	ADP	O
fenfluramine	B-Chemical	NOUN	B
and	O	CCONJ	O
dexfenfluramine	B-Chemical	NOUN	B
had	O	AUX	O
valvular	B-Disease	ADJ	B
disease	I-Disease	NOUN	I
,	O	PUNCT	O
these	O	DET	O
drugs	O	NOUN	B
were	O	AUX	O
withdrawn	O	VERB	O
from	O	ADP	O
the	O	DET	O
market	O	NOUN	B
.	O	PUNCT	O


OBJECTIVE	O	NOUN	B
:	O	PUNCT	O
To	O	PART	O
determine	O	VERB	O
the	O	DET	O
risk	O	NOUN	B
for	O	ADP	O
new	O	ADJ	O
or	O	CCONJ	O
worsening	O	VERB	B
valvular	B-Disease	ADJ	B
abnormalities	I-Disease	NOUN	I
among	O	ADP	O
users	O	NOUN	B
of	O	ADP	O
fenfluramine	B-Chemical	NOUN	B
or	O	CCONJ	O
dexfenfluramine	B-Chemical	NOUN	B
who	O	PRON	O
underwent	O	VERB	O
echocardiography	O	NOUN	B
before	O	ADP	O
they	O	PRON	O
began	O	VERB	O
to	O	PART	O
take	O	VERB	O
these	O	DET	O
medications	O	NOUN	B
.	O	PUNCT	O


DESIGN	O	NOUN	O
:	O	PUNCT	O
Cohort	O	NOUN	B
study	O	NOUN	I
.	O	PUNCT	O


SETTING	O	NOUN	B
:	O	PUNCT	O
Academic	O	ADJ	B
primary	O	ADJ	I
care	O	NOUN	I
practices	O	NOUN	I
.	O	PUNCT	O


PATIENTS	O	NOUN	B
:	O	PUNCT	O
46	O	NUM	O
patients	O	NOUN	B
who	O	PRON	O
used	O	VERB	O
fenfluramine	B-Chemical	NOUN	B
or	O	CCONJ	O
dexfenfluramine	B-Chemical	NOUN	B
for	O	ADP	O
14	O	NUM	O
days	O	NOUN	B
or	O	CCONJ	O
more	O	ADV	O
and	O	CCONJ	O
had	O	AUX	O
echocardiograms	O	NOUN	B
obtained	O	VERB	O
before	O	ADP	O
therapy	O	NOUN	B
.	O	PUNCT	O


MEASUREMENTS	O	NOUN	B
:	O	PUNCT	O
Follow	O	VERB	B
-	O	PUNCT	O
up	O	ADP	O
echocardiography	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
primary	O	ADJ	B
outcome	O	NOUN	I
was	O	AUX	O
new	O	ADJ	O
or	O	CCONJ	O
worsening	O	VERB	B
valvulopathy	B-Disease	NOUN	B
,	O	PUNCT	O
defined	O	VERB	O
as	O	ADP	O
progression	O	NOUN	B
of	O	ADP	O
either	O	CCONJ	O
aortic	B-Disease	ADJ	B
or	I-Disease	CCONJ	O
mitral	I-Disease	ADJ	B
regurgitation	I-Disease	NOUN	I
by	O	ADP	O
at	O	ADP	O
least	O	ADJ	O
one	O	NUM	O
degree	O	NOUN	B
of	O	ADP	O
severity	O	NOUN	B
and	O	CCONJ	O
disease	O	NOUN	B
that	O	PRON	O
met	O	VERB	O
U	O	NOUN	B
.	O	PUNCT	O


S	O	NOUN	B
.	O	PUNCT	O


Food	O	NOUN	B
and	O	CCONJ	I
Drug	O	PROPN	I
Administration	O	PROPN	I
criteria	O	NOUN	I
(	O	PUNCT	O
at	O	ADP	O
least	O	ADJ	O
mild	O	ADJ	O
aortic	B-Disease	ADJ	B
regurgitation	I-Disease	NOUN	I
or	O	CCONJ	O
moderate	O	ADJ	B
mitral	B-Disease	ADJ	O
regurgitation	I-Disease	NOUN	O
).	O	PUNCT	O
RESULTS	O	NOUN	O
:	O	PUNCT	O
Two	O	NUM	O
patients	O	NOUN	B
(	O	PUNCT	O
4	O	NUM	O
.	O	PUNCT	O


3	O	NUM	O
%[	O	NOUN	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
,	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
%	O	NOUN	O
to	O	PART	O
14	O	NUM	O
.	O	PUNCT	O


8	O	NUM	O
%])	O	INTJ	O
receiving	O	VERB	O
fenfluramine	B-Chemical	NOUN	B
-	O	PUNCT	O
phentermine	B-Chemical	NOUN	B
developed	O	VERB	O
valvular	B-Disease	ADJ	B
heart	I-Disease	NOUN	I
disease	I-Disease	NOUN	I
.	O	PUNCT	O


One	O	NUM	O
had	O	AUX	O
baseline	O	NOUN	B
bicuspid	B-Disease	ADJ	B
aortic	I-Disease	ADJ	I
valve	I-Disease	NOUN	I
and	O	CCONJ	O
mild	O	ADJ	B
aortic	B-Disease	ADJ	O
regurgitation	I-Disease	NOUN	O
that	O	PRON	O
progressed	O	VERB	O
to	O	PART	O
moderate	O	ADJ	B
regurgitation	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
second	O	ADJ	O
patient	O	NOUN	B
developed	O	VERB	O
new	O	ADJ	O
moderate	O	ADJ	B
aortic	B-Disease	ADJ	B
insufficiency	I-Disease	NOUN	I
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
:	O	PUNCT	O
Users	O	NOUN	B
of	O	ADP	O
diet	O	ADJ	B
medications	O	NOUN	I
are	O	AUX	O
at	O	ADP	O
risk	O	NOUN	B
for	O	ADP	O
valvular	B-Disease	ADJ	B
heart	I-Disease	NOUN	I
disease	I-Disease	NOUN	I


Carboplatin	B-Chemical	NOUN	B
toxic	O	ADJ	B
effects	O	NOUN	I
on	O	ADP	O
the	O	DET	O
peripheral	O	ADJ	B
nervous	O	ADJ	I
system	O	NOUN	I
of	O	ADP	O
the	O	DET	O
rat	O	NOUN	B
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
:	O	PUNCT	O
The	O	DET	O
most	O	ADV	O
striking	O	ADJ	O
of	O	ADP	O
carboplatin	B-Chemical	NOUN	B
'	O	PART	O
s	O	NOUN	O
advantages	O	NOUN	O
(	O	PUNCT	O
CBDCA	B-Chemical	NOUN	B
)	O	PUNCT	O
over	O	ADP	O
cisplatin	B-Chemical	NOUN	B
(	O	PUNCT	O
CDDP	B-Chemical	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
its	O	PRON	O
markedly	O	ADV	O
reduced	O	VERB	B
rate	O	NOUN	B
of	O	ADP	O
neurotoxic	B-Disease	ADJ	B
effects	O	NOUN	I
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
use	O	NOUN	O
of	O	ADP	O
CBDCA	B-Chemical	NOUN	B
higher	O	ADJ	B
-	O	PUNCT	O
intensity	O	NOUN	B
schedules	O	NOUN	O
and	O	CCONJ	O
the	O	DET	O
association	O	NOUN	B
with	O	ADP	O
other	O	ADJ	O
neurotoxic	B-Disease	ADJ	B
drugs	O	NOUN	B
in	O	ADP	O
polychemotherapy	O	NOUN	B
may	O	AUX	O
cause	O	VERB	O
some	O	DET	O
concern	O	NOUN	O
about	O	ADP	O
its	O	PRON	O
safety	O	NOUN	B
with	O	ADP	O
respect	O	NOUN	O
to	O	PART	O
peripheral	B-Disease	ADJ	B
nervous	I-Disease	ADJ	I
system	I-Disease	NOUN	I
damage	I-Disease	NOUN	B
.	O	PUNCT	O


MATERIALS	O	NOUN	O
AND	O	CCONJ	O
METHODS	O	NOUN	O
:	O	PUNCT	O
Two	O	NUM	O
different	O	ADJ	O
schedules	O	NOUN	B
of	O	ADP	O
CBDCA	B-Chemical	NOUN	B
administration	O	NOUN	B
(	O	PUNCT	O
10	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
and	O	CCONJ	O
15	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	O
i	O	X	O
.	O	PUNCT	O


p	O	NOUN	O
.	O	PUNCT	O


twice	O	DET	O
a	O	DET	O
week	O	NOUN	B
for	O	ADP	O
nine	O	NUM	O
times	O	NOUN	O
)	O	PUNCT	O
were	O	AUX	O
evaluated	O	VERB	B
in	O	ADP	O
Wistar	O	ADJ	B
rats	O	NOUN	I
.	O	PUNCT	O


Neurotoxicity	B-Disease	NOUN	B
was	O	AUX	O
assessed	O	VERB	B
for	O	ADP	O
behavioral	O	ADJ	B
(	O	PUNCT	O
tail	O	NOUN	B
-	O	PUNCT	O
flick	O	NOUN	B
test	O	NOUN	I
),	O	PUNCT	O
neurophysiological	O	ADJ	B
(	O	PUNCT	O
nerve	O	NOUN	B
conduction	O	NOUN	I
velocity	O	NOUN	I
in	O	ADP	O
the	O	DET	O
tail	O	NOUN	B
nerve	O	NOUN	I
),	O	ADJ	O
morphological	O	ADJ	B
,	O	PUNCT	O
morphometrical	O	ADJ	B
and	O	CCONJ	O
analytical	O	ADJ	B
effects	O	NOUN	I
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
CBDCA	B-Chemical	NOUN	B
administration	O	NOUN	B
induced	O	VERB	B
dose	O	NOUN	B
-	O	PUNCT	O
dependent	O	ADJ	B
peripheral	B-Disease	ADJ	B
neurotoxicity	I-Disease	NOUN	B
.	O	PUNCT	O


Pain	B-Disease	NOUN	B
perception	O	NOUN	I
and	O	CCONJ	O
nerve	O	NOUN	B
conduction	O	NOUN	I
velocity	O	NOUN	I
in	O	ADP	O
the	O	DET	O
tail	O	NOUN	B
were	O	AUX	O
significantly	O	ADV	O
impaired	O	ADJ	B
,	O	PUNCT	O
particularly	O	ADV	O
after	O	ADP	O
the	O	DET	O
high	O	ADJ	B
-	O	PUNCT	O
dose	O	NOUN	B
treatment	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
dorsal	O	ADJ	B
root	O	NOUN	I
ganglia	O	NOUN	I
sensory	O	ADJ	B
neurons	O	NOUN	I
and	O	CCONJ	O
,	O	PUNCT	O
to	O	PART	O
a	O	DET	O
lesser	O	ADJ	B
extent	O	NOUN	B
,	O	PUNCT	O
satellite	O	NOUN	B
cells	O	NOUN	I
showed	O	VERB	O
the	O	DET	O
same	O	ADJ	O
changes	O	NOUN	B
as	O	ADP	O
those	O	DET	O
induced	O	VERB	B
by	O	ADP	O
CDDP	B-Chemical	NOUN	B
,	O	PUNCT	O
mainly	O	ADV	O
affecting	O	VERB	B
the	O	DET	O
nucleus	O	NOUN	B
and	O	CCONJ	O
nucleolus	O	NOUN	B
of	O	ADP	O
ganglionic	O	ADJ	B
sensory	O	ADJ	O
neurons	O	NOUN	O
.	O	PUNCT	O


Moreover	O	ADV	O
,	O	PUNCT	O
significant	O	ADJ	B
amounts	O	NOUN	O
of	O	ADP	O
platinum	B-Chemical	NOUN	B
were	O	AUX	O
detected	O	VERB	B
in	O	ADP	O
the	O	DET	O
dorsal	O	ADJ	B
root	O	NOUN	I
ganglia	O	NOUN	I
and	O	CCONJ	O
kidney	O	NOUN	B
after	O	ADP	O
CBDCA	B-Chemical	NOUN	B
treatment	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
:	O	PUNCT	O
CBDCA	B-Chemical	NOUN	B
is	O	AUX	O
neurotoxic	B-Disease	ADJ	B
in	O	ADP	O
our	O	PRON	O
model	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
type	O	NOUN	O
of	O	ADP	O
pathological	O	ADJ	B
changes	O	NOUN	B
it	O	PRON	O
induces	O	VERB	B
are	O	AUX	O
so	O	ADV	O
closely	O	ADV	O
similar	O	ADJ	O
to	O	PART	O
those	O	DET	O
caused	O	VERB	O
by	O	ADP	O
CDDP	B-Chemical	NOUN	B
that	O	SCONJ	O
it	O	PRON	O
is	O	AUX	O
probable	O	ADJ	O
that	O	SCONJ	O
neurotoxicity	B-Disease	NOUN	B
is	O	AUX	O
induced	O	VERB	B
in	O	ADP	O
the	O	DET	O
two	O	NUM	O
drugs	O	NOUN	B
by	O	ADP	O
the	O	DET	O
same	O	ADJ	O
mechanism	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
model	O	NOUN	B
can	O	AUX	O
be	O	AUX	O
used	O	VERB	O
alone	O	ADV	O
or	O	CCONJ	O
in	O	ADP	O
combination	O	NOUN	B
with	O	ADP	O
other	O	ADJ	O
drugs	O	NOUN	B
to	O	PART	O
explore	O	VERB	O
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
CBDCA	B-Chemical	NOUN	B


Iatrogenic	O	ADJ	B
risks	O	NOUN	B
of	O	ADP	O
endometrial	B-Disease	ADJ	B
carcinoma	I-Disease	NOUN	I
after	O	ADP	O
treatment	O	NOUN	B
for	O	ADP	O
breast	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
in	O	ADP	O
a	O	DET	O
large	O	ADJ	O
French	O	ADJ	B
case	O	NOUN	O
-	O	PUNCT	O
control	O	NOUN	B
study	O	NOUN	I
.	O	PUNCT	O


F	O	NOUN	B
d	O	NOUN	O
ration	O	NOUN	B
Nationale	O	PROPN	O
des	O	X	O
Centres	O	PROPN	O
de	O	PROPN	O
Lutte	O	PROPN	O
Contre	O	PROPN	O
le	O	PROPN	O
Cancer	O	PROPN	O
(	O	PUNCT	O
FNCLCC	O	PROPN	B
).	O	PUNCT	O
Since	O	SCONJ	O
tamoxifen	B-Chemical	NOUN	B
is	O	AUX	O
widely	O	ADV	O
used	O	VERB	O
in	O	ADP	O
breast	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
treatment	O	NOUN	B
and	O	CCONJ	O
has	O	AUX	O
been	O	AUX	O
proposed	O	VERB	O
for	O	ADP	O
the	O	DET	O
prevention	O	NOUN	B
of	O	ADP	O
breast	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
,	O	PUNCT	O
its	O	PRON	O
endometrial	O	ADJ	B
iatrogenic	O	ADJ	B
effects	O	NOUN	B
must	O	AUX	O
be	O	AUX	O
carefully	O	ADV	O
examined	O	VERB	B
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
investigated	O	VERB	B
the	O	DET	O
association	O	NOUN	B
between	O	ADP	O
endometrial	B-Disease	ADJ	B
cancer	I-Disease	NOUN	I
and	O	CCONJ	O
tamoxifen	B-Chemical	NOUN	B
use	O	NOUN	B
or	O	CCONJ	O
other	O	ADJ	O
treatments	O	NOUN	B
in	O	ADP	O
women	O	NOUN	B
treated	O	VERB	B
for	O	ADP	O
breast	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
in	O	ADP	O
a	O	DET	O
case	O	NOUN	B
-	O	PUNCT	O
control	O	NOUN	B
study	O	NOUN	I
.	O	PUNCT	O


Cases	O	NOUN	B
of	O	ADP	O
endometrial	B-Disease	ADJ	B
cancer	I-Disease	NOUN	I
diagnosed	O	VERB	B
after	O	ADP	O
breast	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
135	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
467	O	NUM	O
controls	O	NOUN	B
matched	O	VERB	B
for	O	ADP	O
age	O	NOUN	B
,	O	PUNCT	O
year	O	NOUN	B
of	O	ADP	O
diagnosis	O	NOUN	B
of	O	ADP	O
breast	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
and	O	CCONJ	O
hospital	O	NOUN	B
and	O	CCONJ	O
survival	O	NOUN	B
time	O	NOUN	I
with	O	ADP	O
an	O	DET	O
intact	O	ADJ	B
uterus	O	NOUN	B
were	O	AUX	O
included	O	VERB	O
.	O	PUNCT	O


Women	O	NOUN	B
who	O	PRON	O
had	O	AUX	O
received	O	VERB	O
tamoxifen	B-Chemical	NOUN	B
were	O	AUX	O
significantly	O	ADV	O
more	O	ADV	O
likely	O	ADJ	O
to	O	PART	O
have	O	AUX	O
endometrial	B-Disease	ADJ	B
cancer	I-Disease	NOUN	I
diagnosed	O	VERB	B
than	O	ADP	O
those	O	DET	O
who	O	PRON	O
had	O	AUX	O
not	O	PART	O
(	O	PUNCT	O
crude	O	ADJ	B
relative	O	ADJ	I
risk	O	NOUN	I
=	O	ADJ	O
4	O	NUM	O
.	O	PUNCT	O


9	O	NUM	O
,	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


0001	O	NUM	O
).	O	PUNCT	O
Univariate	O	NOUN	B
and	O	CCONJ	O
adjusted	O	VERB	O
analyses	O	NOUN	B
showed	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
risk	O	NOUN	B
increased	O	VERB	B
with	O	ADP	O
the	O	DET	O
length	O	NOUN	B
of	O	ADP	I
treatment	O	NOUN	I
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


0001	O	NUM	O
)	O	PUNCT	O
or	O	CCONJ	O
the	O	DET	O
cumulative	O	ADJ	B
dose	O	NOUN	B
of	O	ADP	O
tamoxifen	B-Chemical	NOUN	B
received	O	VERB	O
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


0001	O	NUM	O
),	O	PUNCT	O
irrespective	O	ADV	O
of	O	ADP	O
the	O	DET	O
daily	O	ADJ	B
dose	O	NOUN	I
.	O	PUNCT	O


Women	O	NOUN	B
who	O	PRON	O
had	O	AUX	O
undergone	O	VERB	O
pelvic	O	ADJ	B
radiotherapy	O	NOUN	I
also	O	ADV	O
had	O	AUX	O
a	O	DET	O
higher	O	ADJ	B
risk	O	NOUN	I
(	O	PUNCT	O
crude	O	ADJ	B
relative	O	ADJ	I
risk	O	NOUN	I
=	O	ADJ	O
7	O	NUM	O
.	O	PUNCT	O


8	O	NUM	O
,	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


0001	O	NUM	O
).	O	PUNCT	O
After	O	ADP	O
adjusting	O	VERB	O
for	O	ADP	O
confounding	O	NOUN	B
factors	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
risk	O	NOUN	B
was	O	AUX	O
higher	O	ADJ	O
for	O	ADP	O
tamoxifen	B-Chemical	NOUN	B
users	O	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


0012	O	NUM	O
),	O	PUNCT	O
treatment	O	NOUN	B
for	O	ADP	O
more	O	ADJ	O
than	O	ADP	O
3	O	NUM	O
years	O	NOUN	B
(	O	PUNCT	O
all	O	DET	O
p	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


03	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
pelvic	O	ADJ	B
radiotherapy	O	NOUN	I
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


012	O	NUM	O
).	O	PUNCT	O
Women	O	NOUN	B
who	O	PRON	O
had	O	AUX	O
endometrial	B-Disease	ADJ	B
cancer	I-Disease	NOUN	I
and	O	CCONJ	O
had	O	AUX	O
received	O	VERB	O
tamoxifen	B-Chemical	NOUN	B
had	O	AUX	O
more	O	ADV	O
advanced	B-Disease	ADJ	B
disease	I-Disease	NOUN	I
and	O	CCONJ	O
poorer	O	ADJ	B
prognosis	O	NOUN	I
than	O	ADP	O
those	O	DET	O
with	O	ADP	O
endometrial	B-Disease	ADJ	B
cancer	I-Disease	NOUN	I
who	O	PRON	O
had	O	AUX	O
not	O	PART	O
received	O	VERB	O
this	O	DET	O
treatment	O	NOUN	B
.	O	PUNCT	O


Our	O	PRON	O
results	O	NOUN	O
suggest	O	VERB	O
a	O	DET	O
causal	O	ADJ	O
role	O	NOUN	O
of	O	ADP	O
tamoxifen	B-Chemical	NOUN	B
in	O	ADP	O
endometrial	B-Disease	ADJ	B
cancer	I-Disease	NOUN	I
,	O	PUNCT	O
particularly	O	ADV	O
when	O	SCONJ	O
used	O	VERB	O
as	O	ADP	O
currently	O	ADV	O
proposed	O	VERB	O
for	O	ADP	O
breast	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
prevention	O	NOUN	B
.	O	PUNCT	O


Pelvic	O	ADJ	B
radiotherapy	O	NOUN	I
may	O	AUX	O
be	O	AUX	O
an	O	DET	O
additional	O	ADJ	O
iatrogenic	O	ADJ	B
factor	O	NOUN	I
for	O	ADP	O
women	O	NOUN	B
with	O	ADP	O
breast	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
.	O	PUNCT	O


Endometrial	B-Disease	ADJ	B
cancers	I-Disease	NOUN	I
diagnosed	O	VERB	B
in	O	ADP	O
women	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
tamoxifen	B-Chemical	NOUN	B
have	O	AUX	O
poorer	O	ADJ	B
prognosis	O	NOUN	I
.	O	PUNCT	O


Women	O	NOUN	B
who	O	PRON	O
receive	O	VERB	O
tamoxifen	B-Chemical	NOUN	B
for	O	ADP	O
breast	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
should	O	AUX	O
be	O	AUX	O
offered	O	VERB	O
gynaecological	O	ADJ	B
surveillance	O	NOUN	I
during	O	ADP	O
and	O	CCONJ	O
after	O	ADP	O
treatment	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
long	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
evaluation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
risk	O	NOUN	B
-	O	PUNCT	O
benefit	O	NOUN	B
ratio	O	NOUN	B
of	O	ADP	O
tamoxifen	B-Chemical	NOUN	B
as	O	ADP	O
a	O	DET	O
preventive	O	ADJ	B
treatment	O	NOUN	I
for	O	ADP	O
breast	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I


Granulosa	B-Disease	NOUN	B
cell	I-Disease	NOUN	I
tumor	I-Disease	NOUN	O
of	I-Disease	ADP	O
the	I-Disease	DET	O
ovary	I-Disease	NOUN	B
associated	O	VERB	B
with	O	ADP	I
antecedent	O	ADJ	O
tamoxifen	B-Chemical	NOUN	B
use	O	NOUN	B
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
:	O	PUNCT	O
Increased	O	VERB	B
attention	O	NOUN	B
has	O	AUX	O
been	O	AUX	O
focused	O	VERB	O
recently	O	ADV	O
on	O	ADP	O
the	O	DET	O
estrogenic	O	ADJ	B
effects	O	NOUN	O
of	O	ADP	O
tamoxifen	B-Chemical	NOUN	B
.	O	PUNCT	O


Review	O	NOUN	B
of	O	ADP	O
the	O	DET	O
literature	O	NOUN	B
reveals	O	VERB	O
an	O	DET	O
association	O	NOUN	B
between	O	ADP	O
tamoxifen	B-Chemical	NOUN	B
use	O	NOUN	B
and	O	CCONJ	O
gynecologic	O	ADJ	B
tumors	B-Disease	NOUN	I
.	O	PUNCT	O


CASE	O	NOUN	B
:	O	PUNCT	O
A	O	DET	O
52	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
postmenopausal	O	ADJ	B
woman	O	NOUN	B
was	O	AUX	O
treated	O	VERB	B
with	O	ADP	I
tamoxifen	B-Chemical	NOUN	B
for	O	ADP	O
stage	O	NOUN	B
II	O	NUM	I
estrogen	B-Chemical	NOUN	I
receptor	O	NOUN	I
-	O	PUNCT	O
positive	O	ADJ	B
breast	B-Disease	NOUN	B
carcinoma	I-Disease	NOUN	I
.	O	PUNCT	O


Her	O	PRON	O
aspartate	B-Chemical	NOUN	B
transaminase	O	NOUN	I
and	O	CCONJ	O
alanine	B-Chemical	NOUN	B
transaminase	O	NOUN	I
levels	O	NOUN	O
increase	O	VERB	B
markedly	O	ADV	O
after	O	ADP	O
6	O	NUM	O
months	O	NOUN	B
of	O	ADP	O
tamoxifen	B-Chemical	NOUN	B
use	O	NOUN	B
.	O	PUNCT	O


After	O	ADP	O
an	O	DET	O
additional	O	ADJ	O
17	O	NUM	O
months	O	NOUN	B
of	O	ADP	O
elevated	O	ADJ	B
serum	O	NOUN	B
transaminases	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
patient	O	NOUN	B
was	O	AUX	O
found	O	VERB	O
to	O	PART	O
have	O	AUX	O
a	O	DET	O
stage	O	NOUN	B
Ic	O	NOUN	O
granulosa	B-Disease	NOUN	O
cell	I-Disease	NOUN	O
tumor	I-Disease	NOUN	O
of	I-Disease	ADP	O
the	I-Disease	DET	O
ovary	I-Disease	NOUN	B
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
:	O	PUNCT	O
Patients	O	NOUN	B
with	O	ADP	O
tamoxifen	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
liver	B-Disease	NOUN	B
dysfunction	I-Disease	NOUN	I
may	O	AUX	O
be	O	AUX	O
at	O	ADP	O
increased	O	VERB	B
risk	O	NOUN	B
for	O	ADP	O
granulosa	B-Disease	NOUN	B
cell	I-Disease	NOUN	I
tumors	I-Disease	NOUN	O
because	O	SCONJ	O
of	O	ADP	O
alterations	O	NOUN	B
in	O	ADP	O
tamoxifen	B-Chemical	NOUN	B


A	O	DET	O
murine	O	ADJ	B
model	O	NOUN	B
of	O	ADP	O
adenomyosis	B-Disease	NOUN	B
:	O	PUNCT	O
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
hyperprolactinemia	B-Disease	NOUN	B
induced	O	VERB	B
by	O	ADP	O
fluoxetine	B-Chemical	NOUN	B
hydrochloride	I-Chemical	NOUN	B
,	O	PUNCT	O
a	O	DET	O
selective	O	ADJ	O
serotonin	B-Chemical	NOUN	B
reuptake	O	NOUN	I
inhibitor	O	NOUN	I
,	O	PUNCT	O
on	O	ADP	O
adenomyosis	B-Disease	NOUN	B
induction	O	NOUN	B
in	O	ADP	O
Wistar	O	ADJ	B
albino	O	NOUN	I
rats	O	NOUN	I
.	O	PUNCT	O


OBJECTIVE	O	NOUN	B
:	O	PUNCT	O
The	O	DET	O
aim	O	NOUN	O
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
investigate	O	VERB	B
whether	O	SCONJ	O
fluoxetine	B-Chemical	NOUN	B
given	O	VERB	O
to	O	PART	O
castrated	O	VERB	B
and	O	CCONJ	O
noncastrated	O	ADJ	B
rats	O	NOUN	I
caused	O	VERB	O
hyperprolactinemia	B-Disease	NOUN	B
and	O	CCONJ	O
its	O	PRON	O
effects	O	NOUN	B
with	O	ADP	I
respect	O	NOUN	O
to	O	PART	O
adenomyosis	B-Disease	NOUN	B
.	O	PUNCT	O


DESIGN	O	NOUN	O
:	O	PUNCT	O
Fluoxetine	B-Chemical	NOUN	B
,	O	PUNCT	O
a	O	DET	O
serotonin	B-Chemical	NOUN	B
reuptake	O	NOUN	I
inhibitor	O	NOUN	I
,	O	PUNCT	O
was	O	AUX	O
given	O	VERB	O
to	O	ADP	O
Wistar	O	PROPN	B
Albino	O	PROPN	I
rats	O	NOUN	I
for	O	ADP	O
98	O	NUM	O
days	O	NOUN	B
to	O	PART	O
produce	O	VERB	O
hyperprolactinemia	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
drug	O	NOUN	B
was	O	AUX	O
given	O	VERB	O
to	O	ADP	O
two	O	NUM	O
groups	O	NOUN	B
consisting	O	VERB	O
of	O	ADP	O
castrated	O	VERB	B
and	O	CCONJ	O
noncastrated	O	ADJ	B
rats	O	NOUN	B
and	O	CCONJ	O
compared	O	VERB	B
to	O	ADP	O
two	O	NUM	O
groups	O	NOUN	B
of	O	ADP	O
castrated	O	VERB	B
and	O	CCONJ	O
noncastrated	O	ADJ	B
controls	O	NOUN	I
.	O	PUNCT	O


Prolactin	O	NOUN	B
levels	O	NOUN	O
were	O	AUX	O
measured	O	VERB	B
and	O	CCONJ	O
the	O	DET	O
uteri	O	NOUN	B
of	O	ADP	O
the	O	DET	O
rats	O	NOUN	B
were	O	AUX	O
removed	O	VERB	O
for	O	ADP	O
histopathological	O	ADJ	B
analysis	O	NOUN	I
at	O	ADP	O
the	O	DET	O
end	O	NOUN	O
of	O	ADP	O
98	O	NUM	O
days	O	NOUN	B
.	O	PUNCT	O


SETTING	O	NOUN	B
:	O	PUNCT	O
Marmara	O	PROPN	B
University	O	PROPN	I
School	O	PROPN	I
of	O	ADP	I
Medicine	O	PROPN	I
,	O	PUNCT	O
Department	O	PROPN	B
of	O	ADP	O
Histology	O	PROPN	B
and	O	CCONJ	O
Embryology	O	PROPN	B
,	O	PUNCT	O
Zeynep	O	PROPN	B
Kamil	O	PROPN	I
Women	O	PROPN	B
and	O	CCONJ	O
Children	O	PROPN	B
'	O	PART	O
s	O	PROPN	O
Hospital	O	PROPN	B
.	O	PUNCT	O


MAIN	O	PROPN	O
OUTCOME	O	NOUN	O
MEASURES	O	NOUN	O
:	O	PUNCT	O
Serum	O	NOUN	B
prolactin	O	NOUN	I
levels	O	NOUN	I
,	O	PUNCT	O
uterine	O	ADJ	B
histopathology	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
The	O	DET	O
prolactin	O	NOUN	B
levels	O	NOUN	O
of	O	ADP	O
castrated	O	VERB	B
and	O	CCONJ	O
noncastrated	O	ADJ	B
groups	O	NOUN	I
treated	O	VERB	B
with	O	ADP	I
fluoxetine	B-Chemical	NOUN	B
were	O	AUX	O
statistically	O	ADV	O
significantly	O	ADV	O
higher	O	ADJ	O
when	O	SCONJ	O
compared	O	VERB	B
to	O	PART	O
their	O	PRON	O
respective	O	ADJ	O
control	O	NOUN	B
groups	O	NOUN	I
.	O	PUNCT	O


Histological	O	ADJ	B
studies	O	NOUN	I
revealed	O	VERB	O
11	O	NUM	O
cases	O	NOUN	B
of	O	ADP	O
adenomyosis	B-Disease	NOUN	B
,	O	PUNCT	O
all	O	DET	O
within	O	ADP	O
the	O	DET	O
noncastrated	O	ADJ	B
group	O	NOUN	I
receiving	O	VERB	O
fluoxetine	B-Chemical	NOUN	B
.	O	PUNCT	O


CONCLUSION	O	NOUN	B
:	O	PUNCT	O
It	O	PRON	O
was	O	AUX	O
suggested	O	VERB	O
that	O	SCONJ	O
high	O	ADJ	O
serum	O	NOUN	B
prolactin	O	NOUN	O
levels	O	NOUN	O
cause	O	VERB	O
degeneration	O	NOUN	B
of	O	ADP	O
myometrial	O	ADJ	B
cells	O	NOUN	I
in	O	ADP	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
ovarian	O	ADJ	B
steroids	B-Chemical	NOUN	I
that	O	PRON	O
results	O	VERB	B
in	O	ADP	O
a	O	DET	O
myometrial	O	ADJ	B
invasion	O	NOUN	B
by	O	ADP	O
endometrial	O	ADJ	B
stroma	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
invasion	O	NOUN	B
eventually	O	ADV	O
progresses	O	VERB	O
to	O	PART	O
adenomyosis	B-Disease	NOUN	B


Effects	O	NOUN	B
of	O	ADP	I
deliberate	O	ADJ	B
hypotension	B-Disease	NOUN	B
induced	O	VERB	B
by	O	ADP	O
labetalol	B-Chemical	NOUN	B
with	O	ADP	O
isoflurane	B-Chemical	NOUN	B
on	O	ADP	O
neuropsychological	O	ADJ	B
function	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
deliberate	O	ADJ	B
hypotension	B-Disease	NOUN	B
on	O	ADP	O
brain	O	NOUN	B
function	O	NOUN	I
measured	O	VERB	B
by	O	ADP	O
neuropsychological	O	ADJ	B
tests	O	NOUN	I
was	O	AUX	O
studied	O	VERB	O
in	O	ADP	O
41	O	NUM	O
adult	O	ADJ	B
patients	O	NOUN	B
.	O	PUNCT	O


Twenty	O	NUM	B
-	O	PUNCT	O
four	O	NUM	B
patients	O	NOUN	B
were	O	AUX	O
anaesthetized	O	VERB	B
for	O	ADP	O
middle	O	ADJ	B
-	O	PUNCT	O
ear	O	NOUN	B
surgery	O	NOUN	B
with	O	ADP	O
deliberate	O	ADJ	B
hypotension	B-Disease	NOUN	B
induced	O	VERB	B
by	O	ADP	O
labetalol	B-Chemical	NOUN	B
with	O	ADP	O
isoflurane	B-Chemical	NOUN	B
(	O	PUNCT	O
hypotensive	B-Disease	ADJ	B
group	O	NOUN	I
).	O	PUNCT	O
Seventeen	O	NUM	O
patients	O	NOUN	B
without	O	ADP	O
hypotension	B-Disease	NOUN	B
served	O	VERB	O
as	O	ADP	O
a	O	DET	O
control	O	ADJ	B
group	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
mean	O	ADJ	O
arterial	O	ADJ	B
pressure	O	NOUN	I
was	O	AUX	O
77	O	NUM	O
+/-	O	CCONJ	O
2	O	NUM	O
mmHg	O	NOUN	B
(	O	PUNCT	O
10	O	NUM	O
.	O	PUNCT	O


3	O	NUM	O
+/-	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


3	O	NUM	O
kPa	O	NOUN	B
)	O	PUNCT	O
before	O	ADP	O
hypotension	B-Disease	NOUN	B
and	O	CCONJ	O
50	O	NUM	O
+/-	O	CCONJ	O
0	O	NUM	O
mmHg	O	NOUN	B
(	O	PUNCT	O
6	O	NUM	O
.	O	PUNCT	O


7	O	NUM	O
+/-	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
kPa	O	NOUN	B
)	O	PUNCT	O
during	O	ADP	O
hypotension	B-Disease	NOUN	B
in	O	ADP	O
the	O	DET	O
hypotensive	B-Disease	ADJ	B
group	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
86	O	NUM	O
+/-	O	CCONJ	O
2	O	NUM	O
mmHg	O	NOUN	B
(	O	PUNCT	O
11	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
+/-	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


3	O	NUM	O
kPa	O	NOUN	B
)	O	PUNCT	O
during	O	ADP	O
anaesthesia	O	NOUN	B
in	O	ADP	O
the	O	DET	O
control	O	NOUN	B
group	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
following	O	VERB	O
psychological	O	ADJ	B
tests	O	NOUN	I
were	O	AUX	O
performed	O	VERB	O
:	O	PUNCT	O
four	O	NUM	O
subtests	O	NOUN	B
of	O	ADP	O
the	O	DET	O
Wechsler	O	PROPN	B
Adult	O	PROPN	I
Intelligence	O	PROPN	I
Scale	O	PROPN	I
(	O	PUNCT	O
similarities	O	NOUN	B
,	O	PUNCT	O
digit	O	ADJ	B
span	O	NOUN	I
,	O	PUNCT	O
vocabulary	O	NOUN	B
and	O	CCONJ	O
digit	O	ADJ	B
symbol	O	NOUN	I
),	O	PUNCT	O
Trail	O	PROPN	B
-	O	PUNCT	O
Making	O	PROPN	B
tests	O	NOUN	B
A	O	NOUN	O
and	O	CCONJ	O
B	O	NOUN	B
,	O	PUNCT	O
Zung	O	ADJ	B
tests	O	NOUN	I
(	O	PUNCT	O
self	O	NOUN	B
-	O	PUNCT	O
rating	O	NOUN	B
anxiety	B-Disease	NOUN	B
scale	O	NOUN	I
and	O	CCONJ	O
self	O	NOUN	B
-	O	PUNCT	O
rating	O	NOUN	B
depression	B-Disease	NOUN	B
scale	O	NOUN	I
)	O	PUNCT	O
and	O	CCONJ	O
two	O	NUM	B
-	O	PUNCT	O
part	O	NOUN	B
memory	O	NOUN	B
test	O	NOUN	I
battery	O	NOUN	O
with	O	ADP	O
immediate	O	ADJ	B
and	O	CCONJ	O
delayed	O	VERB	B
recall	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
tests	O	NOUN	B
were	O	AUX	O
performed	O	VERB	O
preoperatively	O	ADV	B
and	O	CCONJ	O
2	O	NUM	O
days	O	NOUN	B
postoperatively	O	ADV	B
.	O	PUNCT	O


There	O	PRON	O
were	O	AUX	O
no	O	DET	O
statistically	O	ADV	B
significant	O	ADJ	I
differences	O	NOUN	O
between	O	ADP	O
the	O	DET	O
groups	O	NOUN	B
in	O	ADP	O
any	O	DET	O
of	O	ADP	O
the	O	DET	O
tests	O	NOUN	B
in	O	ADP	O
the	O	DET	O
changes	O	NOUN	B
from	O	ADP	O
preoperative	O	ADJ	B
value	O	NOUN	O
to	O	ADP	O
postoperative	O	ADJ	B
value	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
results	O	NOUN	B
indicate	O	VERB	O
that	O	SCONJ	O
hypotension	B-Disease	NOUN	B
induced	O	VERB	B
by	O	ADP	O
labetalol	B-Chemical	NOUN	B
with	O	ADP	O
isoflurane	B-Chemical	NOUN	B


Auditory	O	ADJ	B
disturbance	O	NOUN	I
associated	O	VERB	B
with	O	ADP	I
interscalene	O	NOUN	B
brachial	O	ADJ	I
plexus	O	NOUN	I
block	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
performed	O	VERB	O
an	O	DET	O
audiometric	O	ADJ	B
study	O	NOUN	I
in	O	ADP	O
20	O	NUM	O
patients	O	NOUN	B
who	O	PRON	O
underwent	O	VERB	O
surgery	O	NOUN	B
of	O	ADP	O
the	O	DET	O
shoulder	O	NOUN	B
region	O	NOUN	I
under	O	ADP	O
an	O	DET	O
interscalene	O	NOUN	B
brachial	O	ADJ	I
plexus	O	NOUN	I
block	O	NOUN	I
(	O	PUNCT	O
IBPB	O	NOUN	B
).	O	PUNCT	O
Bupivacaine	B-Chemical	NOUN	B
0	O	NUM	O
.	O	PUNCT	O


75	O	NUM	O
%	O	NOUN	O
with	O	ADP	O
adrenaline	B-Chemical	NOUN	B
was	O	AUX	O
given	O	VERB	O
followed	O	VERB	O
by	O	ADP	O
a	O	DET	O
24	O	NUM	O
-	O	PUNCT	O
hr	O	NOUN	B
continuous	O	ADJ	B
infusion	O	NOUN	B
of	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


25	O	NUM	O
%	O	NOUN	O
bupivacaine	B-Chemical	NOUN	B
.	O	PUNCT	O


Three	O	NUM	O
audiometric	O	ADJ	B
threshold	O	NOUN	O
measurements	O	NOUN	B
(	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


25	O	NUM	O
-	O	SYM	O
18	O	NUM	O
kHz	O	NOUN	O
)	O	PUNCT	O
were	O	AUX	O
made	O	VERB	O
:	O	PUNCT	O
the	O	DET	O
first	O	ADJ	O
before	O	ADP	O
IBPB	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
second	O	ADJ	O
2	O	NUM	O
-	O	SYM	O
6	O	NUM	O
h	O	NOUN	O
after	O	ADP	O
surgery	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
third	O	NOUN	O
on	O	ADP	O
the	O	DET	O
first	O	ADJ	O
day	O	NOUN	B
after	O	ADP	O
operation	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
four	O	NUM	O
patients	O	NOUN	B
hearing	B-Disease	VERB	B
impairment	I-Disease	NOUN	I
on	O	ADP	O
the	O	DET	O
side	O	NOUN	O
of	O	ADP	O
the	O	DET	O
block	O	NOUN	B
was	O	AUX	O
demonstrated	O	VERB	O
after	O	ADP	O
operation	O	NOUN	B
,	O	PUNCT	O
in	O	ADP	O
three	O	NUM	O
measurements	O	NOUN	B
on	O	ADP	O
the	O	DET	O
day	O	NOUN	B
of	O	ADP	O
surgery	O	NOUN	B
and	O	CCONJ	O
in	O	ADP	O
one	O	NUM	O
on	O	ADP	O
the	O	DET	O
following	O	VERB	O
day	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
frequencies	O	NOUN	B
at	O	ADP	O
which	O	DET	O
the	O	DET	O
impairment	O	NOUN	B
occurred	O	VERB	O
varied	O	ADJ	O
between	O	ADP	O
patients	O	NOUN	B
;	O	PUNCT	O
in	O	ADP	O
one	O	NUM	O
only	O	ADV	O
low	O	ADJ	B
frequencies	O	NOUN	B
(	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


25	O	NUM	O
-	O	SYM	O
0	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
kHz	O	NOUN	O
)	O	PUNCT	O
were	O	AUX	O
involved	O	VERB	O
.	O	PUNCT	O


The	O	DET	O
maximum	O	ADJ	O
change	O	NOUN	O
in	O	ADP	O
threshold	O	NOUN	B
was	O	AUX	O
35	O	NUM	O
dB	O	NOUN	O
at	O	ADP	O
6	O	NUM	O
kHz	O	NOUN	O
measured	O	VERB	B
at	O	ADP	O
the	O	DET	O
end	O	NOUN	O
of	O	ADP	O
the	O	DET	O
continuous	O	ADJ	B
infusion	O	NOUN	B
of	O	ADP	O
bupivacaine	B-Chemical	NOUN	B
.	O	PUNCT	O


This	O	DET	O
patient	O	NOUN	B
had	O	AUX	O
hearing	O	VERB	B
threshold	O	NOUN	I
changes	O	NOUN	B
(	O	PUNCT	O
15	O	NUM	O
-	O	SYM	O
20	O	NUM	O
dB	O	NOUN	O
)	O	PUNCT	O
at	O	ADP	O
6	O	NUM	O
-	O	SYM	O
10	O	NUM	O
kHz	O	NOUN	O
on	O	ADP	O
the	O	DET	O
opposite	O	ADJ	O
side	O	NOUN	O
also	O	ADV	O
.	O	PUNCT	O


IBPB	O	NOUN	B
may	O	AUX	O
cause	O	VERB	O
transient	O	ADJ	B
auditory	B-Disease	ADJ	I
dysfunction	I-Disease	NOUN	I


Midazolam	B-Chemical	NOUN	B
compared	O	VERB	O
with	O	ADP	O
thiopentone	B-Chemical	NOUN	B
as	O	ADP	O
an	O	DET	O
induction	O	NOUN	B
agent	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
patients	O	NOUN	B
premedicated	O	VERB	B
with	O	ADP	O
scopolamine	B-Chemical	NOUN	B
+	O	CCONJ	O
morphine	B-Chemical	NOUN	B
(+	O	NOUN	O
5	O	NUM	O
mg	O	NOUN	O
nitrazepam	B-Chemical	NOUN	B
the	O	DET	O
evening	O	NOUN	B
before	O	ADP	O
surgery	O	NOUN	B
),	O	PUNCT	O
the	O	DET	O
sleep	O	NOUN	B
-	O	PUNCT	O
inducing	O	VERB	B
effect	O	NOUN	B
of	O	ADP	O
midazolam	B-Chemical	NOUN	B
0	O	NUM	O
.	O	PUNCT	O


15	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	O
i	O	X	O
.	O	PUNCT	O


v	O	NOUN	O
.	O	PUNCT	O


was	O	AUX	O
clearly	O	ADV	O
slower	O	ADJ	O
in	O	ADP	O
onset	O	NOUN	O
than	O	ADP	O
that	O	DET	O
of	O	ADP	O
thiopentone	B-Chemical	NOUN	B
4	O	NUM	O
.	O	PUNCT	O


67	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	O
i	O	X	O
.	O	PUNCT	O


v	O	NOUN	O
.	O	PUNCT	O


Somewhat	O	ADV	O
fewer	O	ADJ	O
cardiovascular	O	ADJ	B
and	O	CCONJ	O
local	O	ADJ	B
sequelae	O	NOUN	I
were	O	AUX	O
found	O	VERB	O
in	O	ADP	O
the	O	DET	O
midazolam	B-Chemical	NOUN	B
group	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
,	O	PUNCT	O
although	O	SCONJ	O
apnoea	B-Disease	NOUN	B
occurred	O	VERB	O
less	O	ADV	O
often	O	ADV	O
in	O	ADP	O
the	O	DET	O
midazolam	B-Chemical	NOUN	B
group	O	NOUN	B
it	O	PRON	O
lasted	O	VERB	O
longer	O	ADV	O
.	O	PUNCT	O


On	O	ADP	O
the	O	DET	O
whole	O	NOUN	O
,	O	PUNCT	O
the	O	DET	O
differences	O	NOUN	O
between	O	ADP	O
midazolam	B-Chemical	NOUN	B
and	O	CCONJ	O
thiopentone	B-Chemical	NOUN	B
had	O	AUX	O
no	O	DET	O
apparent	O	ADJ	O
clinical	O	ADJ	B
consequences	O	NOUN	B
.	O	PUNCT	O


Midazolam	B-Chemical	NOUN	B


Cardiotoxic	B-Disease	ADJ	B
and	O	CCONJ	O
possible	O	ADJ	O
leukemogenic	O	ADJ	B
effects	O	NOUN	B
of	O	ADP	O
adriamycin	B-Chemical	NOUN	B
in	O	ADP	O
nonhuman	O	ADJ	B
primates	O	NOUN	I
.	O	PUNCT	O


10	O	NUM	O
monkeys	O	NOUN	B
(	O	PUNCT	O
macaques	O	NOUN	B
)	O	PUNCT	O
received	O	VERB	O
adriamycin	B-Chemical	NOUN	B
by	O	ADP	O
monthly	O	ADJ	B
intravenous	O	ADJ	B
injections	O	NOUN	I
at	O	ADP	O
12	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
m2	O	NOUN	B
(	O	PUNCT	O
1	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
).	O	PUNCT	O
8	O	NUM	O
of	O	ADP	O
the	O	DET	O
10	O	NUM	O
monkeys	O	NOUN	B
developed	O	VERB	O
congestive	B-Disease	ADJ	B
heart	I-Disease	NOUN	I
failure	I-Disease	NOUN	I
at	O	ADP	O
an	O	DET	O
average	O	ADJ	O
cumulative	O	ADJ	B
adriamycin	B-Chemical	NOUN	B
dose	O	NOUN	B
(	O	PUNCT	O
310	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
m2	O	NOUN	B
)	O	PUNCT	O
well	O	ADV	O
below	O	ADP	O
that	O	PRON	O
considered	O	VERB	O
the	O	DET	O
safe	O	ADJ	O
upper	O	ADJ	O
limit	O	NOUN	O
(	O	PUNCT	O
550	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
m2	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
man	O	NOUN	B
.	O	PUNCT	O


Histologically	O	ADV	B
,	O	PUNCT	O
the	O	DET	O
myocardial	B-Disease	ADJ	B
lesions	I-Disease	NOUN	O
resembled	O	VERB	B
those	O	DET	O
found	O	VERB	O
in	O	ADP	O
human	O	ADJ	B
anthracycline	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
cardiomyopathy	B-Disease	NOUN	B
.	O	PUNCT	O


1	O	NUM	O
of	O	ADP	O
the	O	DET	O
10	O	NUM	O
monkeys	O	NOUN	B
developed	O	VERB	O
acute	B-Disease	ADJ	B
myeloblastic	I-Disease	ADJ	I
leukemia	I-Disease	NOUN	I
after	O	ADP	O
receiving	O	VERB	O
324	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
m2	O	NOUN	B
of	O	ADP	O
adriamycin	B-Chemical	NOUN	B
;	O	PUNCT	O
the	O	DET	O
10th	O	ADJ	O
monkey	O	NOUN	B
is	O	AUX	O
alive	O	ADJ	B
and	O	CCONJ	O
well	O	ADV	O
26	O	NUM	O
months	O	NOUN	B
after	O	ADP	O
the	O	DET	O
last	O	ADJ	O
dose	O	NOUN	B
of	O	ADP	O
drug	O	NOUN	B
.	O	PUNCT	O


Our	O	PRON	O
results	O	NOUN	O
suggest	O	VERB	O
that	O	SCONJ	O
adriamycin	B-Chemical	NOUN	B
is	O	AUX	O
a	O	DET	O
more	O	ADV	O
potent	O	ADJ	O
cardiotoxin	O	NOUN	B
in	O	ADP	O
monkeys	O	NOUN	B
than	O	ADP	O
in	O	ADP	O
man	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
that	O	SCONJ	O
leukemia	B-Disease	NOUN	B


Doxorubicin	B-Chemical	NOUN	B
cardiomyopathy	B-Disease	NOUN	I
in	O	ADP	O
children	O	NOUN	B
with	O	ADP	O
left	O	ADJ	B
-	O	PUNCT	O
sided	O	ADJ	B
Wilms	B-Disease	ADJ	B
tumor	I-Disease	NOUN	I
.	O	PUNCT	O


Two	O	NUM	O
children	O	NOUN	B
with	O	ADP	O
Wilms	B-Disease	ADJ	B
tumor	I-Disease	NOUN	I
of	O	ADP	O
the	O	DET	O
left	O	ADJ	B
kidney	O	NOUN	I
experienced	O	VERB	O
severe	O	ADJ	O
anthracycline	B-Chemical	NOUN	B
cardiomyopathy	B-Disease	NOUN	I
after	O	ADP	O
irradiation	O	NOUN	B
to	O	PART	O
the	O	DET	O
tumor	B-Disease	NOUN	B
bed	O	NOUN	I
and	O	CCONJ	O
conventional	O	ADJ	B
dosage	O	NOUN	B
of	O	ADP	O
doxorubicin	B-Chemical	NOUN	B
.	O	PUNCT	O


The	O	DET	O
cardiomyopathy	B-Disease	NOUN	B
is	O	AUX	O
attributed	O	VERB	O
1	O	NUM	O
)	O	PUNCT	O
to	O	ADP	O
the	O	DET	O
fact	O	NOUN	O
that	O	SCONJ	O
radiation	O	NOUN	B
fields	O	NOUN	I
for	O	ADP	O
left	O	ADJ	B
Wilms	B-Disease	NOUN	I
tumor	I-Disease	NOUN	I
include	O	VERB	O
the	O	DET	O
lower	O	ADJ	O
portion	O	NOUN	B
of	O	ADP	O
the	O	DET	O
heart	O	NOUN	B
and	O	CCONJ	O
2	O	NUM	O
)	O	PUNCT	O
to	O	PART	O
the	O	DET	O
interaction	O	NOUN	B
of	O	ADP	O
doxorubicin	B-Chemical	NOUN	B
and	O	CCONJ	O
irradiation	O	NOUN	B
on	O	ADP	O
cardiac	O	ADJ	B
muscle	O	NOUN	I
.	O	PUNCT	O


It	O	PRON	O
is	O	AUX	O
recommended	O	VERB	O
that	O	SCONJ	O
doxorubicin	B-Chemical	NOUN	B
dosage	O	NOUN	I
be	O	AUX	O
sharply	O	ADV	O
restricted	O	ADJ	O
in	O	ADP	O
children	O	NOUN	B
with	O	ADP	O
Wilms	B-Disease	NOUN	B
tumor	I-Disease	NOUN	I


Promotional	O	ADJ	B
effects	O	NOUN	I
of	O	ADP	O
testosterone	B-Chemical	NOUN	B
and	O	CCONJ	O
dietary	O	ADJ	B
fat	O	NOUN	I
on	O	ADP	O
prostate	O	NOUN	B
carcinogenesis	B-Disease	NOUN	I
in	O	ADP	O
genetically	O	ADV	B
susceptible	O	ADJ	I
rats	O	NOUN	B
.	O	PUNCT	O


Germfree	O	PROPN	B
(	O	PUNCT	O
GF	O	NOUN	B
)	O	PUNCT	O
Lobund	O	NOUN	B
strain	O	NOUN	I
Wistar	O	PROPN	I
(	O	PUNCT	O
LW	O	PROPN	O
)	O	PUNCT	O
rats	O	NOUN	B
,	O	PUNCT	O
fed	O	VERB	B
vegetable	O	NOUN	I
diet	O	NOUN	I
L	O	PROPN	B
-	O	PUNCT	O
485	O	NUM	O
,	O	PUNCT	O
have	O	AUX	O
developed	O	VERB	O
prostate	B-Disease	NOUN	B
adenocarcinomas	I-Disease	NOUN	I
spontaneously	O	ADV	B
(	O	PUNCT	O
10	O	NUM	O
%	O	NOUN	O
incidence	O	NOUN	B
)	O	PUNCT	O
at	O	ADP	O
average	O	ADJ	B
age	O	NOUN	B
34	O	NUM	O
months	O	NOUN	B
.	O	PUNCT	O


Conventional	O	ADJ	B
LW	O	PROPN	B
rats	O	NOUN	B
,	O	PUNCT	O
implanted	O	VERB	B
with	O	ADP	O
testosterone	B-Chemical	NOUN	B
at	O	ADP	O
age	O	NOUN	B
4	O	NUM	O
months	O	NOUN	B
,	O	PUNCT	O
developed	O	VERB	O
a	O	DET	O
higher	O	ADJ	O
incidence	O	NOUN	B
of	O	ADP	O
prostate	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
after	O	ADP	O
an	O	DET	O
average	O	ADJ	B
interval	O	NOUN	I
of	O	ADP	O
14	O	NUM	O
months	O	NOUN	B
:	O	PUNCT	O
24	O	NUM	O
%	O	NOUN	O
had	O	AUX	O
developed	O	VERB	O
gross	O	ADJ	B
tumors	B-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
40	O	NUM	O
%	O	NOUN	O
when	O	SCONJ	O
it	O	PRON	O
included	O	VERB	O
microscopic	O	ADJ	B
tumors	B-Disease	NOUN	I
.	O	PUNCT	O


Preliminary	O	ADJ	B
results	O	NOUN	B
indicate	O	VERB	O
that	O	SCONJ	O
testosterone	B-Chemical	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
LW	O	NOUN	B
rats	O	NOUN	B
that	O	PRON	O
were	O	AUX	O
fed	O	VERB	B
the	O	DET	O
same	O	ADJ	O
diet	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
was	O	AUX	O
supplemented	O	VERB	O
with	O	ADP	O
corn	O	NOUN	B
oil	O	NOUN	I
up	O	ADV	O
to	O	PART	O
20	O	NUM	O
%	O	NOUN	O
fat	O	NOUN	B
,	O	PUNCT	O
developed	O	VERB	O
prostate	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
after	O	ADP	O
intervals	O	NOUN	B
of	O	ADP	O
6	O	NUM	O
-	O	PUNCT	O
12	O	NUM	O
months	O	NOUN	B
.	O	PUNCT	O


Aged	O	ADJ	B
GF	O	PROPN	B
Sprague	O	PROPN	B
-	O	PUNCT	O
Dawley	O	PROPN	B
(	O	PUNCT	O
SD	O	NOUN	B
)	O	PUNCT	O
rats	O	NOUN	B
have	O	AUX	O
not	O	PART	O
developed	O	VERB	O
prostate	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
spontaneously	O	ADV	B
.	O	PUNCT	O


Conventional	O	ADJ	B
SD	O	NOUN	I
rats	O	NOUN	B
fed	O	VERB	O
diet	O	ADJ	B
L	O	PROPN	B
-	O	PUNCT	O
485	O	NUM	O
and	O	CCONJ	O
treated	O	VERB	B
with	O	ADP	I
testosterone	B-Chemical	NOUN	B
developed	O	VERB	O
only	O	ADV	O
prostatitis	B-Disease	NOUN	B
.	O	PUNCT	O


Experimental	O	ADJ	B
designs	O	NOUN	I
should	O	AUX	O
consider	O	VERB	O
genetic	O	ADJ	B
susceptibility	O	NOUN	I
as	O	ADP	O
a	O	DET	O
basic	O	ADJ	O
prerequisite	O	NOUN	O
for	O	ADP	O
studies	O	NOUN	B
on	O	ADP	O
experimental	O	ADJ	B
prostate	B-Disease	NOUN	O
cancer	I-Disease	NOUN	O


Mitomycin	B-Chemical	NOUN	B
C	I-Chemical	NOUN	I
associated	O	VERB	O
hemolytic	B-Disease	ADJ	B
uremic	I-Disease	ADJ	I
syndrome	I-Disease	NOUN	I
.	O	PUNCT	O


Mitomycin	B-Chemical	NOUN	B
C	I-Chemical	NOUN	I
associated	O	VERB	O
Hemolytic	B-Disease	ADJ	B
Uremic	I-Disease	ADJ	I
Syndrome	I-Disease	NOUN	I
(	O	PUNCT	O
HUS	B-Disease	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
a	O	DET	O
potentially	O	ADV	O
fatal	O	ADJ	B
but	O	CCONJ	O
uncommon	O	ADJ	O
condition	O	NOUN	B
that	O	PRON	O
is	O	AUX	O
not	O	PART	O
yet	O	ADV	O
widely	O	ADV	O
recognised	O	VERB	O
.	O	PUNCT	O


It	O	PRON	O
consists	O	VERB	O
of	O	ADP	O
microangiopathic	O	ADJ	B
hemolytic	B-Disease	ADJ	B
anemia	I-Disease	NOUN	I
,	O	PUNCT	O
thrombocytopenia	B-Disease	NOUN	B
and	O	CCONJ	O
progressive	O	ADJ	B
renal	B-Disease	ADJ	B
failure	I-Disease	NOUN	I
associated	O	VERB	B
with	O	ADP	I
mitomycin	B-Chemical	NOUN	B
C	I-Chemical	NOUN	O
treatment	O	NOUN	B
and	O	CCONJ	O
affects	O	VERB	O
about	O	ADV	O
10	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
this	O	DET	O
agent	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
renal	B-Disease	ADJ	B
failure	I-Disease	NOUN	I
usually	O	ADV	O
develops	O	VERB	O
about	O	ADV	O
8	O	NUM	O
-	O	PUNCT	O
10	O	NUM	O
mth	O	NOUN	B
after	O	ADP	O
start	O	NOUN	O
of	O	ADP	O
mitomycin	B-Chemical	NOUN	B
C	I-Chemical	NOUN	O
treatment	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
mortality	O	NOUN	B
is	O	AUX	O
approximately	O	ADV	O
60	O	NUM	O
%	O	NOUN	O
from	O	ADP	O
renal	B-Disease	ADJ	B
failure	I-Disease	NOUN	I
or	O	CCONJ	O
pulmonary	B-Disease	ADJ	B
edema	I-Disease	NOUN	I
.	O	PUNCT	O


Renal	B-Disease	ADJ	B
lesions	I-Disease	NOUN	I
are	O	AUX	O
similar	O	ADJ	O
to	O	PART	O
those	O	DET	O
seen	O	VERB	O
in	O	ADP	O
idiopathic	O	ADJ	B
HUS	B-Disease	NOUN	I
and	O	CCONJ	O
include	O	VERB	O
arteriolar	O	ADJ	B
fibrin	O	NOUN	I
thrombi	B-Disease	NOUN	I
,	O	PUNCT	O
expanded	O	VERB	O
subendothelial	O	ADJ	B
zones	O	NOUN	O
in	O	ADP	O
glomerular	O	ADJ	B
capillary	O	ADJ	I
walls	O	NOUN	I
,	O	PUNCT	O
ischemic	B-Disease	ADJ	B
wrinkling	O	NOUN	I
of	O	ADP	O
glomerular	O	ADJ	B
basement	O	NOUN	I
membranes	O	NOUN	I
and	O	CCONJ	O
mesangiolysis	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
mechanism	O	NOUN	B
of	O	ADP	O
action	O	NOUN	B
is	O	AUX	O
postulated	O	VERB	O
as	O	ADP	O
mitomycin	B-Chemical	NOUN	B
C	I-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
endothelial	O	ADJ	B
cell	O	NOUN	I
damage	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
describe	O	VERB	O
the	O	DET	O
clinical	O	ADJ	B
course	O	NOUN	I
and	O	CCONJ	O
pathological	O	ADJ	B
findings	O	NOUN	B
in	O	ADP	O
a	O	DET	O
65	O	NUM	O
yr	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
man	O	NOUN	B
with	O	ADP	O
gastric	B-Disease	ADJ	B
adenocarcinoma	I-Disease	NOUN	I
who	O	PRON	O
developed	O	VERB	O
renal	B-Disease	ADJ	B
failure	I-Disease	NOUN	I
and	O	CCONJ	O
thrombocytopenia	B-Disease	NOUN	B
while	O	SCONJ	O
on	O	ADP	O
treatment	O	NOUN	B
with	O	ADP	O
mitomycin	B-Chemical	NOUN	B
C	I-Chemical	NOUN	I
and	O	CCONJ	O
died	O	VERB	B
in	O	ADP	O
pulmonary	B-Disease	ADJ	B
edema	I-Disease	NOUN	I


Continuous	O	ADJ	B
ambulatory	O	ADJ	I
ECG	O	PROPN	B
monitoring	O	NOUN	O
during	O	ADP	O
fluorouracil	B-Chemical	NOUN	B
therapy	O	NOUN	I
:	O	PUNCT	O
a	O	DET	O
prospective	O	ADJ	B
study	O	NOUN	I
.	O	PUNCT	O


Although	O	SCONJ	O
there	O	PRON	O
have	O	AUX	O
been	O	AUX	O
anecdotal	O	ADJ	B
reports	O	NOUN	I
of	O	ADP	O
cardiac	B-Disease	ADJ	B
toxicity	I-Disease	NOUN	B
associated	O	VERB	B
with	O	ADP	I
fluorouracil	B-Chemical	NOUN	B
(	O	PUNCT	O
5-FU	B-Chemical	NOUN	B
)	O	PUNCT	O
therapy	O	NOUN	B
,	O	PUNCT	O
this	O	DET	O
phenomenon	O	NOUN	B
has	O	AUX	O
not	O	PART	O
been	O	AUX	O
studied	O	VERB	O
in	O	ADP	O
a	O	DET	O
systematic	O	ADJ	B
fashion	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
prospectively	O	ADV	O
performed	O	VERB	O
continuous	O	ADJ	B
ambulatory	O	ADJ	B
ECG	O	PROPN	B
monitoring	O	NOUN	B
on	O	ADP	O
25	O	NUM	O
patients	O	NOUN	B
undergoing	O	VERB	O
5-FU	B-Chemical	NOUN	B
infusion	O	NOUN	B
for	O	ADP	O
treatment	O	NOUN	B
of	O	ADP	O
solid	O	ADJ	B
tumors	B-Disease	NOUN	I
in	O	ADP	O
order	O	NOUN	O
to	O	PART	O
assess	O	VERB	B
the	O	DET	O
incidence	O	NOUN	B
of	O	ADP	O
ischemic	B-Disease	ADJ	B
ST	O	NOUN	B
changes	O	NOUN	B
.	O	PUNCT	O


Patients	O	NOUN	B
were	O	AUX	O
monitored	O	VERB	B
for	O	ADP	O
23	O	NUM	O
+/-	O	CCONJ	O
4	O	NUM	O
hours	O	NOUN	B
before	O	ADP	O
5-FU	B-Chemical	NOUN	B
infusion	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
98	O	NUM	O
+/-	O	CCONJ	O
9	O	NUM	O
hours	O	NOUN	B
during	O	ADP	O
5-FU	B-Chemical	NOUN	B
infusion	O	NOUN	B
.	O	PUNCT	O


Anginal	B-Disease	ADJ	B
episodes	O	NOUN	I
were	O	AUX	O
rare	O	ADJ	B
:	O	PUNCT	O
only	O	ADV	O
one	O	NUM	O
patient	O	NOUN	B
had	O	AUX	O
angina	B-Disease	ADJ	B
(	O	PUNCT	O
during	O	ADP	O
5-FU	B-Chemical	NOUN	B
infusion	O	NOUN	B
).	O	PUNCT	B
However	O	ADV	O
,	O	PUNCT	O
asymptomatic	O	ADJ	B
ST	O	ADJ	B
changes	O	NOUN	B
(	O	PUNCT	O
greater	O	ADJ	O
than	O	ADP	O
or	O	CCONJ	O
equal	O	ADJ	O
to	O	PART	O
1	O	NUM	O
mm	O	X	O
ST	O	ADJ	B
deviation	O	NOUN	O
)	O	PUNCT	O
were	O	AUX	O
common	O	ADJ	O
:	O	PUNCT	O
six	O	NUM	O
of	O	ADP	O
25	O	NUM	O
patients	O	NOUN	B
(	O	PUNCT	O
24	O	NUM	O
%)	O	NOUN	O
had	O	AUX	O
ST	O	ADJ	B
changes	O	NOUN	B
before	O	ADP	O
5-FU	B-Chemical	NOUN	B
infusion	O	NOUN	B
v	O	ADP	O
17	O	NUM	O
(	O	PUNCT	O
68	O	NUM	O
%)	O	NOUN	O
during	O	ADP	O
5-FU	B-Chemical	NOUN	B
infusion	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
.	O	PUNCT	O


002	O	NUM	O
).	O	PUNCT	O
The	O	DET	O
incidence	O	NOUN	B
of	O	ADP	O
ischemic	B-Disease	ADJ	B
episodes	O	NOUN	O
per	O	ADP	O
patient	O	NOUN	B
per	O	ADP	O
hour	O	NOUN	O
was	O	AUX	O
0	O	NUM	O
.	O	PUNCT	O


05	O	NUM	O
+/-	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


02	O	NUM	O
prior	O	ADJ	O
to	O	PART	O
5-FU	B-Chemical	NOUN	B
infusion	O	NOUN	B
v	O	NOUN	O
0	O	NUM	O
.	O	PUNCT	O


13	O	NUM	O
+/-	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


03	O	NUM	O
during	O	ADP	O
5-FU	B-Chemical	NOUN	B
infusion	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
.	O	PUNCT	O


001	O	NUM	O
);	O	NOUN	O
the	O	DET	O
duration	O	NOUN	B
of	O	ADP	O
ECG	O	PROPN	B
changes	O	NOUN	B
was	O	AUX	O
0	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
+/-	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


3	O	NUM	O
minutes	O	NOUN	B
per	O	ADP	O
patient	O	NOUN	B
per	O	ADP	O
hour	O	NOUN	O
before	O	ADP	O
5-FU	B-Chemical	NOUN	B
v	O	ADP	O
1	O	NUM	O
.	O	PUNCT	O


9	O	NUM	O
+/-	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
minutes	O	NOUN	B
per	O	ADP	O
patient	O	NOUN	B
per	O	ADP	O
hour	O	NOUN	O
during	O	ADP	O
5-FU	B-Chemical	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
.	O	PUNCT	O


01	O	NUM	O
).	O	PUNCT	O
ECG	O	PROPN	B
changes	O	NOUN	B
were	O	AUX	O
more	O	ADV	O
common	O	ADJ	O
among	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
known	O	ADJ	O
coronary	B-Disease	ADJ	B
artery	I-Disease	NOUN	I
disease	I-Disease	NOUN	I
.	O	PUNCT	O


There	O	PRON	O
were	O	AUX	O
two	O	NUM	O
cases	O	NOUN	B
of	O	ADP	O
sudden	B-Disease	ADJ	B
death	I-Disease	NOUN	I
,	O	PUNCT	O
both	O	DET	O
of	O	ADP	O
which	O	DET	O
occurred	O	VERB	O
at	O	ADP	O
the	O	DET	O
end	O	NOUN	O
of	O	ADP	O
the	O	DET	O
chemotherapy	O	NOUN	B
course	O	NOUN	O
.	O	PUNCT	O


We	O	PRON	O
conclude	O	VERB	O
that	O	SCONJ	O
5-FU	B-Chemical	NOUN	B
infusion	O	NOUN	B
is	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
a	O	DET	O
significant	O	ADJ	O
increase	O	NOUN	B
in	O	ADP	O
silent	O	ADJ	B
ST	O	NOUN	B
segment	O	NOUN	O
deviation	O	NOUN	O
suggestive	O	ADJ	O
of	O	ADP	O
ischemia	B-Disease	NOUN	B
,	O	PUNCT	O
particularly	O	ADV	O
among	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
coronary	B-Disease	ADJ	B
artery	I-Disease	NOUN	I
disease	I-Disease	NOUN	I


Lethal	O	ADJ	B
anuria	B-Disease	NOUN	I
complicating	O	VERB	O
high	O	ADJ	B
dose	O	NOUN	I
ifosfamide	B-Chemical	NOUN	B
chemotherapy	O	NOUN	I
in	O	ADP	O
a	O	DET	O
breast	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
patient	O	NOUN	B
with	O	ADP	O
an	O	DET	O
impaired	B-Disease	ADJ	B
renal	I-Disease	ADJ	O
function	I-Disease	NOUN	O
.	O	PUNCT	O


A	O	DET	O
sixty	O	NUM	B
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
woman	O	NOUN	B
with	O	ADP	O
advanced	O	ADJ	B
breast	B-Disease	NOUN	I
cancer	I-Disease	NOUN	I
,	O	PUNCT	O
previously	O	ADV	O
treated	O	VERB	B
with	O	ADP	I
cisplatin	B-Chemical	NOUN	B
,	O	PUNCT	O
developed	O	VERB	O
an	O	DET	O
irreversible	O	ADJ	B
lethal	O	ADJ	B
renal	B-Disease	ADJ	I
failure	I-Disease	NOUN	I
with	O	ADP	O
anuria	B-Disease	NOUN	B
,	O	PUNCT	O
the	O	DET	O
day	O	NOUN	B
after	O	ADP	O
5	O	NUM	O
g	O	NOUN	B
/	O	SYM	O
m2	O	NOUN	B
bolus	O	NOUN	I
ifosfamide	B-Chemical	NOUN	I
.	O	PUNCT	O


Postrenal	B-Disease	ADJ	B
failure	I-Disease	NOUN	I
was	O	AUX	O
excluded	O	VERB	O
by	O	ADP	O
echography	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
prerenal	O	ADJ	B
component	O	NOUN	I
could	O	AUX	O
have	O	AUX	O
contributed	O	VERB	O
to	O	PART	O
renal	B-Disease	ADJ	B
failure	I-Disease	NOUN	I
because	O	SCONJ	O
of	O	ADP	O
a	O	DET	O
transient	O	ADJ	B
hypotension	B-Disease	NOUN	B
,	O	PUNCT	O
due	O	ADP	O
to	O	PART	O
an	O	DET	O
increasing	O	VERB	B
ascitis	O	NOUN	B
,	O	PUNCT	O
occurring	O	VERB	O
just	O	ADV	O
before	O	ADP	O
anuria	B-Disease	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
correction	O	NOUN	B
of	O	ADP	O
the	O	DET	O
hemodynamic	O	ADJ	B
parameters	O	NOUN	B
did	O	AUX	O
not	O	PART	O
improve	O	VERB	O
renal	O	ADJ	B
function	O	NOUN	I
.	O	PUNCT	O


Ifosfamide	B-Chemical	NOUN	B
is	O	AUX	O
a	O	DET	O
known	O	ADJ	O
nephrotoxic	B-Disease	ADJ	B
drug	O	NOUN	O
with	O	ADP	O
demonstrated	O	VERB	O
tubulopathies	B-Disease	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
strongly	O	ADV	O
suspect	O	VERB	O
that	O	SCONJ	O
this	O	DET	O
lethal	O	ADJ	B
anuria	B-Disease	NOUN	I
was	O	AUX	O
mainly	O	ADV	O
due	O	ADJ	O
to	O	PART	O
ifosfamide	B-Chemical	NOUN	B
,	O	PUNCT	O
occurring	O	VERB	O
in	O	ADP	O
a	O	DET	O
patient	O	NOUN	B
having	O	VERB	O
received	O	VERB	O
previous	O	ADJ	O
cisplatin	B-Chemical	NOUN	B
chemotherapy	O	NOUN	B
and	O	CCONJ	O
with	O	ADP	O
poor	O	ADJ	B
kidney	O	NOUN	I
perfusion	O	NOUN	I
due	O	ADJ	O
to	O	PART	O
transient	O	ADJ	B
hypotension	B-Disease	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
recommend	O	VERB	O
careful	O	ADJ	O
use	O	NOUN	O
of	O	ADP	O
ifosfamide	B-Chemical	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
pretreated	O	VERB	B
with	O	ADP	O
nephrotoxic	B-Disease	NOUN	B


Central	O	ADJ	B
vein	B-Disease	NOUN	I
thrombosis	I-Disease	NOUN	I
and	O	CCONJ	O
topical	O	ADJ	B
dipivalyl	B-Chemical	ADJ	I
epinephrine	I-Chemical	NOUN	B
.	O	PUNCT	O


A	O	DET	O
report	O	NOUN	B
is	O	AUX	O
given	O	VERB	O
on	O	ADP	O
an	O	DET	O
83	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
female	O	NOUN	B
who	O	PRON	O
acquired	O	VERB	O
central	O	ADJ	O
vein	B-Disease	NOUN	O
thrombosis	I-Disease	NOUN	O
in	O	ADP	O
her	O	PRON	O
seeing	O	VERB	O
eye	O	NOUN	B
one	O	NUM	O
day	O	NOUN	B
after	O	ADP	O
having	O	VERB	O
started	O	VERB	O
topical	O	ADJ	B
medication	O	NOUN	I
with	O	ADP	O
dipivalyl	B-Chemical	ADJ	B
epinephrine	I-Chemical	NOUN	B
for	O	ADP	O
advanced	O	ADJ	B
glaucoma	B-Disease	NOUN	I


Amelioration	O	NOUN	B
of	O	ADP	O
bendrofluazide	B-Chemical	ADJ	B
-	O	PUNCT	O
induced	O	VERB	B
hypokalemia	B-Disease	NOUN	B
by	O	ADP	O
timolol	B-Chemical	NOUN	B
.	O	PUNCT	O


The	O	DET	O
beta	O	NOUN	B
adrenergic	O	ADJ	I
blocking	O	NOUN	O
drug	O	NOUN	B
,	O	PUNCT	O
timolol	B-Chemical	NOUN	B
,	O	PUNCT	O
tended	O	VERB	O
to	O	PART	O
correct	O	VERB	O
the	O	DET	O
hypokalemia	B-Disease	NOUN	B
of	O	ADP	O
short	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
bendrofluazide	B-Chemical	ADJ	B
treatment	O	NOUN	B
in	O	ADP	O
6	O	NUM	O
healthy	O	ADJ	B
male	O	NOUN	B
subjects	O	NOUN	O
and	O	CCONJ	O
although	O	SCONJ	O
the	O	DET	O
effect	O	NOUN	B
was	O	AUX	O
small	O	ADJ	O
it	O	PRON	O
was	O	AUX	O
significant	O	ADJ	B
.	O	PUNCT	O


Timolol	B-Chemical	PROPN	B
also	O	ADV	O
reduced	O	VERB	B
the	O	DET	O
rise	O	NOUN	O
in	O	ADP	O
plasma	O	NOUN	B
aldosterone	B-Chemical	NOUN	O
and	O	CCONJ	O
urine	O	NOUN	B
potassium	B-Chemical	NOUN	O
excretion	O	NOUN	B
following	O	VERB	O
bendrofluazide	B-Chemical	NOUN	B
and	O	CCONJ	O
increased	O	VERB	B
the	O	DET	O
urine	O	NOUN	B
sodium	B-Chemical	NOUN	I
/	O	SYM	O
potassium	B-Chemical	NOUN	B
ratio	O	NOUN	I
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
no	O	DET	O
evidence	O	NOUN	B
of	O	ADP	O
a	O	DET	O
shift	O	NOUN	B
of	O	ADP	O
potassium	B-Chemical	NOUN	B


A	O	DET	O
cross	O	NOUN	B
-	O	PUNCT	O
sectional	O	ADJ	B
evaluation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
risperidone	B-Chemical	NOUN	B
and	O	CCONJ	O
selective	O	ADJ	O
serotonin	B-Chemical	NOUN	B
reuptake	O	NOUN	I
inhibitors	O	NOUN	I
on	O	ADP	O
bone	O	NOUN	B
mineral	O	ADJ	I
density	O	NOUN	I
in	O	ADP	O
boys	O	NOUN	B
.	O	PUNCT	O


OBJECTIVE	O	NOUN	B
:	O	PUNCT	O
The	O	DET	O
aim	O	NOUN	O
of	O	ADP	O
the	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
investigate	O	VERB	B
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
risperidone	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
hyperprolactinemia	B-Disease	NOUN	B
on	O	ADP	O
trabecular	O	NOUN	B
bone	O	NOUN	I
mineral	O	ADJ	O
density	O	NOUN	O
(	O	PUNCT	O
BMD	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
children	O	NOUN	B
and	O	CCONJ	O
adolescents	O	NOUN	B
.	O	PUNCT	O


METHOD	O	NOUN	B
:	O	PUNCT	O
Medically	O	ADV	B
healthy	O	ADJ	I
7	O	NUM	I
-	O	PUNCT	O
to	O	ADP	O
17	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
males	O	NOUN	B
chronically	O	ADV	B
treated	O	VERB	B
,	O	PUNCT	O
in	O	ADP	O
a	O	DET	O
naturalistic	O	ADJ	B
setting	O	NOUN	I
,	O	PUNCT	O
with	O	ADP	O
risperidone	B-Chemical	NOUN	B
were	O	AUX	O
recruited	O	VERB	O
for	O	ADP	O
this	O	DET	O
cross	O	NOUN	B
-	O	PUNCT	O
sectional	O	ADJ	B
study	O	NOUN	I
through	O	ADP	O
child	O	NOUN	B
psychiatry	O	NOUN	B
outpatient	O	ADJ	B
clinics	O	NOUN	I
between	O	ADP	O
November	O	PROPN	O
2005	O	NUM	O
and	O	CCONJ	O
June	O	PROPN	O
2007	O	NUM	O
.	O	PUNCT	O


Anthropometric	O	ADJ	B
measurements	O	NOUN	I
and	O	CCONJ	O
laboratory	O	ADJ	B
testing	O	NOUN	I
were	O	AUX	O
conducted	O	VERB	O
.	O	PUNCT	O


The	O	DET	O
clinical	O	ADJ	B
diagnoses	O	NOUN	I
were	O	AUX	O
based	O	VERB	O
on	O	ADP	O
chart	O	NOUN	B
review	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
developmental	O	ADJ	B
and	O	CCONJ	O
treatment	O	NOUN	B
history	O	NOUN	I
was	O	AUX	O
obtained	O	VERB	O
from	O	ADP	O
the	O	DET	O
medical	O	ADJ	B
record	O	NOUN	I
.	O	PUNCT	O


Volumetric	O	ADJ	B
BMD	O	NOUN	B
of	O	ADP	O
the	O	DET	O
ultradistal	O	ADJ	B
radius	O	NOUN	I
was	O	AUX	O
measured	O	VERB	B
using	O	VERB	O
peripheral	O	ADJ	B
quantitative	O	ADJ	I
computed	O	ADJ	I
tomography	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
areal	O	ADJ	B
BMD	O	NOUN	I
of	O	ADP	O
the	O	DET	O
lumbar	O	ADJ	B
spine	O	NOUN	I
was	O	AUX	O
estimated	O	VERB	O
using	O	VERB	O
dual	O	ADJ	B
-	O	PUNCT	O
energy	O	NOUN	B
x	O	NOUN	O
-	O	PUNCT	O
ray	O	NOUN	B
absorptiometry	O	NOUN	I
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
Hyperprolactinemia	B-Disease	NOUN	B
was	O	AUX	O
present	O	ADJ	O
in	O	ADP	O
49	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
83	O	NUM	O
boys	O	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
41	O	NUM	O
)	O	PUNCT	O
treated	O	VERB	B
with	O	ADP	I
risperidone	B-Chemical	NOUN	B
for	O	ADP	O
a	O	DET	O
mean	O	NOUN	O
of	O	ADP	O
2	O	NUM	O
.	O	PUNCT	O


9	O	NUM	O
years	O	NOUN	B
.	O	PUNCT	O


Serum	O	NOUN	B
testosterone	B-Chemical	NOUN	B
concentration	O	NOUN	B
increased	O	VERB	B
with	O	ADP	O
pubertal	O	ADJ	B
status	O	NOUN	I
but	O	CCONJ	O
was	O	AUX	O
not	O	PART	O
affected	O	VERB	O
by	O	ADP	O
hyperprolactinemia	B-Disease	NOUN	B
.	O	PUNCT	O


As	O	ADP	O
expected	O	VERB	O
,	O	PUNCT	O
bone	O	NOUN	B
mineral	O	ADJ	I
content	O	NOUN	I
and	O	CCONJ	O
BMD	O	NOUN	B
increased	O	VERB	B
with	O	ADP	O
sexual	O	ADJ	B
maturity	O	NOUN	I
.	O	PUNCT	O


After	O	ADP	O
adjusting	O	VERB	O
for	O	ADP	O
the	O	DET	O
stage	O	NOUN	B
of	O	ADP	O
sexual	O	ADJ	B
development	O	NOUN	I
and	O	CCONJ	O
height	O	NOUN	B
and	O	CCONJ	O
BMI	O	PROPN	B
z	O	PROPN	O
scores	O	NOUN	O
,	O	PUNCT	O
serum	O	NOUN	B
prolactin	O	NOUN	I
was	O	AUX	O
negatively	O	ADV	O
associated	O	VERB	B
with	O	ADP	I
trabecular	O	NOUN	B
volumetric	O	ADJ	B
BMD	O	NOUN	B
at	O	ADP	O
the	O	DET	O
ultradistal	O	ADJ	B
radius	O	NOUN	I
(	O	PUNCT	O
P	O	NOUN	O
<.	O	VERB	O
03	O	NUM	O
).	O	PUNCT	B
Controlling	O	VERB	B
for	O	ADP	O
relevant	O	ADJ	B
covariates	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
also	O	ADV	O
found	O	VERB	O
treatment	O	NOUN	B
with	O	ADP	O
selective	O	ADJ	O
serotonin	B-Chemical	NOUN	B
reuptake	O	NOUN	I
inhibitors	O	NOUN	I
(	O	PUNCT	O
SSRIs	O	NOUN	B
)	O	PUNCT	O
to	O	PART	O
be	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
lower	O	ADJ	O
trabecular	O	NOUN	B
BMD	O	NOUN	I
at	O	ADP	O
the	O	DET	O
radius	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=.	O	NOUN	O
03	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
BMD	O	NOUN	B
z	O	NOUN	I
score	O	NOUN	I
at	O	ADP	O
the	O	DET	O
lumbar	O	ADJ	B
spine	O	NOUN	I
(	O	PUNCT	O
P	O	NOUN	O
<.	O	VERB	O
05	O	NUM	O
).	O	PUNCT	O
These	O	DET	O
findings	O	NOUN	B
became	O	VERB	O
more	O	ADV	O
marked	O	ADJ	O
when	O	SCONJ	O
the	O	DET	O
analysis	O	NOUN	B
was	O	AUX	O
restricted	O	ADJ	O
to	O	PART	O
non	O	ADV	B
-	O	PUNCT	O
Hispanic	O	ADJ	B
white	O	ADJ	I
patients	O	NOUN	B
.	O	PUNCT	O


Of	O	ADP	O
13	O	NUM	O
documented	O	VERB	B
fractures	B-Disease	NOUN	B
,	O	PUNCT	O
3	O	NUM	O
occurred	O	VERB	O
after	O	ADP	O
risperidone	B-Chemical	NOUN	B
and	O	CCONJ	O
SSRIs	O	NOUN	B
were	O	AUX	O
started	O	VERB	B
,	O	PUNCT	O
and	O	CCONJ	O
none	O	NOUN	O
occurred	O	VERB	O
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
hyperprolactinemia	B-Disease	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
:	O	PUNCT	O
This	O	DET	O
is	O	AUX	O
the	O	DET	O
first	O	ADJ	O
study	O	NOUN	B
to	O	PART	O
link	O	VERB	O
risperidone	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
hyperprolactinemia	B-Disease	NOUN	B


Seizures	B-Disease	NOUN	B
associated	O	VERB	B
with	O	ADP	I
levofloxacin	B-Chemical	NOUN	B
:	O	PUNCT	O
case	O	NOUN	B
presentation	O	NOUN	I
and	O	CCONJ	O
literature	O	NOUN	B
review	O	NOUN	I
.	O	PUNCT	O


PURPOSE	O	NOUN	B
:	O	PUNCT	O
We	O	PRON	O
present	O	VERB	O
a	O	DET	O
case	O	NOUN	B
of	O	ADP	O
a	O	DET	O
patient	O	NOUN	B
who	O	PRON	O
developed	O	VERB	O
seizures	B-Disease	NOUN	B
shortly	O	ADV	O
after	O	ADP	O
initiating	O	VERB	O
treatment	O	NOUN	B
with	O	ADP	O
levofloxacin	B-Chemical	NOUN	B
and	O	CCONJ	O
to	O	PART	O
discuss	O	VERB	O
the	O	DET	O
potential	O	ADJ	B
drug	O	NOUN	B
-	O	PUNCT	O
drug	O	NOUN	B
interactions	O	NOUN	B
related	O	ADJ	O
to	O	PART	O
the	O	DET	O
inhibition	O	NOUN	B
of	O	ADP	O
cytochrome	O	NOUN	B
P450	O	NOUN	I
(	O	PUNCT	O
CYP	O	NOUN	B
)	O	PUNCT	O
1A2	O	NOUN	O
in	O	ADP	O
this	O	DET	O
case	O	NOUN	B
,	O	PUNCT	O
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
in	O	ADP	O
other	O	ADJ	O
cases	O	NOUN	B
,	O	PUNCT	O
of	O	ADP	O
levofloxacin	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
seizures	B-Disease	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
:	O	PUNCT	O
Several	O	ADJ	O
biomedical	O	ADJ	B
databases	O	NOUN	I
were	O	AUX	O
searched	O	VERB	O
including	O	VERB	O
MEDLINE	O	PROPN	B
,	O	PUNCT	O
Cochrane	O	PROPN	B
and	O	CCONJ	O
Ovid	O	PROPN	B
.	O	PUNCT	O


The	O	DET	O
main	O	ADJ	O
search	O	NOUN	B
terms	O	NOUN	O
utilized	O	VERB	O
were	O	AUX	O
case	O	NOUN	B
report	O	NOUN	I
and	O	CCONJ	O
levofloxacin	B-Chemical	NOUN	B
.	O	PUNCT	O


The	O	DET	O
search	O	NOUN	B
was	O	AUX	O
limited	O	ADJ	O
to	O	PART	O
studies	O	NOUN	B
published	O	VERB	B
in	O	ADP	O
English	O	PROPN	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
Six	O	NUM	O
cases	O	NOUN	B
of	O	ADP	O
levofloxacin	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
seizures	B-Disease	NOUN	B
have	O	AUX	O
been	O	AUX	O
reported	O	VERB	O
in	O	ADP	O
the	O	DET	O
literature	O	NOUN	B
.	O	PUNCT	O


Drug	O	NOUN	B
-	O	PUNCT	O
drug	O	NOUN	B
interactions	O	NOUN	B
related	O	ADJ	O
to	O	PART	O
the	O	DET	O
inhibition	O	NOUN	B
of	O	ADP	O
CYP1A2	O	NOUN	B
by	O	ADP	O
levofloxacin	B-Chemical	NOUN	B
are	O	AUX	O
likely	O	ADV	O
involved	O	VERB	O
in	O	ADP	O
the	O	DET	O
clinical	O	ADJ	B
outcome	O	NOUN	I
of	O	ADP	O
these	O	DET	O
cases	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
:	O	PUNCT	O
Clinicians	O	NOUN	B
are	O	AUX	O
exhorted	O	VERB	O
to	O	PART	O
pay	O	VERB	O
close	O	ADJ	O
attention	O	NOUN	B
when	O	SCONJ	O
initiating	O	VERB	O
levofloxacin	B-Chemical	NOUN	B


Mice	O	NOUN	B
lacking	O	VERB	B
mPGES	O	NOUN	B
-	O	PUNCT	O
1	O	NUM	O
are	O	AUX	O
resistant	O	ADJ	B
to	O	PART	O
lithium	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
polyuria	B-Disease	NOUN	B
.	O	PUNCT	O


Cyclooxygenase	O	NOUN	B
-	O	PUNCT	O
2	O	NUM	O
activity	O	NOUN	B
is	O	AUX	O
required	O	VERB	O
for	O	ADP	O
the	O	DET	O
development	O	NOUN	B
of	O	ADP	O
lithium	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
polyuria	B-Disease	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
involvement	O	NOUN	B
of	O	ADP	O
a	O	DET	O
specific	O	ADJ	B
,	O	PUNCT	O
terminal	O	ADJ	B
prostaglandin	B-Chemical	NOUN	B
(	O	PUNCT	O
PG	B-Chemical	NOUN	B
)	O	PUNCT	O
isomerase	O	NOUN	B
has	O	AUX	O
not	O	PART	O
been	O	AUX	O
evaluated	O	VERB	B
.	O	PUNCT	O


The	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
was	O	AUX	O
undertaken	O	VERB	O
to	O	PART	O
assess	O	VERB	B
lithium	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
polyuria	B-Disease	NOUN	B
in	O	ADP	O
mice	O	NOUN	B
deficient	O	ADJ	B
in	O	ADP	O
microsomal	O	ADJ	B
prostaglandin	B-Chemical	NOUN	I
E	I-Chemical	NOUN	I
synthase	O	NOUN	I
-	O	PUNCT	O
1	O	NUM	O
(	O	PUNCT	O
mPGES	O	NOUN	B
-	O	PUNCT	O
1	O	NUM	O
).	O	PUNCT	O
A	O	NOUN	O
2	O	NUM	O
-	O	PUNCT	O
wk	O	NOUN	O
administration	O	NOUN	B
of	O	ADP	O
LiCl	B-Chemical	NOUN	B
(	O	PUNCT	O
4	O	NUM	O
mmol	O	NOUN	O
.	O	PUNCT	O


kg	O	NOUN	O
(-	O	PUNCT	O
1	O	NUM	O
).	O	PUNCT	O
day	O	NOUN	B
(-	O	PUNCT	O
1	O	NUM	O
)	O	PUNCT	O
ip	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
mPGES	O	NOUN	B
-	O	PUNCT	O
1	O	NUM	B
+/+	O	NOUN	O
mice	O	NOUN	B
led	O	VERB	O
to	O	PART	O
a	O	DET	O
marked	O	ADJ	O
polyuria	B-Disease	NOUN	B
with	O	ADP	O
hyposmotic	O	ADJ	B
urine	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
was	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
elevated	O	ADJ	B
renal	O	ADJ	O
mPGES	O	NOUN	B
-	O	PUNCT	O
1	O	NUM	O
protein	O	NOUN	B
expression	O	NOUN	I
and	O	CCONJ	O
increased	O	VERB	B
urine	O	NOUN	B
PGE(2)	B-Chemical	NOUN	B
excretion	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
contrast	O	NOUN	O
,	O	PUNCT	O
mPGES	O	NOUN	B
-	O	PUNCT	O
1	O	NUM	B
-/-	O	ADJ	O
mice	O	NOUN	B
were	O	AUX	O
largely	O	ADV	O
resistant	O	ADJ	B
to	O	PART	O
lithium	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
polyuria	B-Disease	NOUN	B
and	O	CCONJ	O
a	O	DET	O
urine	O	NOUN	B
concentrating	O	NOUN	O
defect	O	NOUN	B
,	O	PUNCT	O
accompanied	O	VERB	O
by	O	ADP	O
nearly	O	ADV	O
complete	O	ADJ	O
blockade	O	NOUN	B
of	O	ADP	O
high	O	ADJ	O
urine	O	NOUN	B
PGE(2)	B-Chemical	NOUN	B
and	O	CCONJ	O
cAMP	O	NOUN	B
output	O	NOUN	B
.	O	PUNCT	O


Immunoblotting	O	NOUN	B
,	O	PUNCT	O
immunohistochemistry	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
quantitative	O	ADJ	B
(	O	PUNCT	O
q	O	NOUN	O
)	O	PUNCT	O
RT	O	PROPN	B
-	O	PUNCT	O
PCR	O	PROPN	B
consistently	O	ADV	O
detected	O	VERB	B
a	O	DET	O
significant	O	ADJ	O
decrease	O	NOUN	B
in	O	ADP	O
aquaporin	O	NOUN	B
-	O	PUNCT	O
2	O	NUM	B
(	O	PUNCT	O
AQP2	O	NOUN	B
)	O	PUNCT	O
protein	O	NOUN	B
expression	O	NOUN	I
in	O	ADP	O
both	O	CCONJ	O
the	O	DET	O
renal	O	ADJ	B
cortex	O	NOUN	I
and	O	CCONJ	O
medulla	O	NOUN	B
of	O	ADP	O
lithium	B-Chemical	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
+/+	O	NOUN	B
mice	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
decrease	O	NOUN	B
was	O	AUX	O
significantly	O	ADV	O
attenuated	O	VERB	B
in	O	ADP	O
the	O	DET	O
-/-	O	ADJ	O
mice	O	NOUN	B
.	O	PUNCT	O


qRT	O	NOUN	B
-	O	PUNCT	O
PCR	O	NOUN	B
detected	O	VERB	B
similar	O	ADJ	O
patterns	O	NOUN	B
of	O	ADP	O
changes	O	NOUN	B
in	O	ADP	O
AQP2	O	NOUN	B
mRNA	O	NOUN	B
in	O	ADP	O
the	O	DET	O
medulla	O	NOUN	B
but	O	CCONJ	O
not	O	PART	O
in	O	ADP	O
the	O	DET	O
cortex	O	NOUN	B
.	O	PUNCT	O


Similarly	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
total	O	ADJ	O
protein	O	NOUN	B
abundance	O	NOUN	B
of	O	ADP	O
the	O	DET	O
Na	B-Chemical	PROPN	B
-	O	PUNCT	O
K	B-Chemical	PROPN	B
-	O	PUNCT	O
2	O	NUM	B
Cl	B-Chemical	NOUN	I
cotransporter	O	NOUN	I
(	O	PUNCT	O
NKCC2	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
medulla	O	NOUN	B
but	O	CCONJ	O
not	O	PART	O
in	O	ADP	O
the	O	DET	O
cortex	O	NOUN	B
of	O	ADP	O
the	O	DET	O
+/+	O	NOUN	B
mice	O	NOUN	B
was	O	AUX	O
significantly	O	ADV	O
reduced	O	VERB	B
by	O	ADP	O
lithium	B-Chemical	NOUN	B
treatment	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
contrast	O	NOUN	O
,	O	PUNCT	O
the	O	DET	O
dowregulation	O	NOUN	B
of	O	ADP	O
renal	O	ADJ	B
medullary	O	ADJ	I
NKCC2	O	NOUN	B
expression	O	NOUN	B
was	O	AUX	O
significantly	O	ADV	O
attenuated	O	VERB	B
in	O	ADP	O
the	O	DET	O
-/-	O	ADJ	O
mice	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
conclude	O	VERB	O
that	O	SCONJ	O
mPGES	O	NOUN	B
-	O	PUNCT	O
1	O	NUM	B
-	O	PUNCT	O
derived	O	VERB	B
PGE(2)	B-Chemical	NOUN	B
mediates	O	VERB	O
lithium	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
polyuria	B-Disease	NOUN	B


Identification	O	NOUN	B
of	O	ADP	O
a	O	DET	O
simple	O	ADJ	O
and	O	CCONJ	O
sensitive	O	ADJ	B
microplate	O	NOUN	B
method	O	NOUN	I
for	O	ADP	O
the	O	DET	O
detection	O	NOUN	B
of	O	ADP	O
oversulfated	O	ADJ	B
chondroitin	B-Chemical	NOUN	I
sulfate	I-Chemical	NOUN	I
in	O	ADP	O
heparin	B-Chemical	NOUN	B
products	O	NOUN	I
.	O	PUNCT	O


Heparin	B-Chemical	NOUN	B
is	O	AUX	O
a	O	DET	O
commonly	O	ADV	O
implemented	O	VERB	B
anticoagulant	O	NOUN	B
used	O	VERB	O
to	O	PART	O
treat	O	VERB	B
critically	O	ADV	B
ill	O	ADJ	I
patients	O	NOUN	B
.	O	PUNCT	O


Recently	O	ADV	O
,	O	PUNCT	O
a	O	DET	O
number	O	NOUN	O
of	O	ADP	O
commercial	O	ADJ	B
lots	O	NOUN	B
of	O	ADP	O
heparin	B-Chemical	NOUN	B
products	O	NOUN	B
were	O	AUX	O
found	O	VERB	O
to	O	PART	O
be	O	AUX	O
contaminated	O	VERB	B
with	O	ADP	O
an	O	DET	O
oversulfated	O	ADJ	B
chondroitin	B-Chemical	NOUN	I
sulfate	I-Chemical	NOUN	I
(	O	PUNCT	O
OSCS	O	NOUN	B
)	O	PUNCT	O
derivative	O	NOUN	B
that	O	PRON	O
could	O	AUX	O
elicit	O	VERB	O
a	O	DET	O
hypotensive	B-Disease	ADJ	B
response	O	NOUN	I
in	O	ADP	O
pigs	O	NOUN	B
following	O	VERB	O
a	O	DET	O
single	O	ADJ	O
high	O	ADJ	B
-	O	PUNCT	O
dose	O	NOUN	B
infusion	O	NOUN	B
.	O	PUNCT	O


Using	O	VERB	O
both	O	DET	O
contaminated	O	VERB	B
heparin	B-Chemical	NOUN	B
products	O	NOUN	O
and	O	CCONJ	O
the	O	DET	O
synthetically	O	ADV	B
produced	O	VERB	O
derivative	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
showed	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
OSCS	O	NOUN	B
produces	O	VERB	O
dose	O	NOUN	B
-	O	PUNCT	O
dependent	O	ADJ	B
hypotension	B-Disease	NOUN	B
in	O	ADP	O
pigs	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
no	O	DET	O
observed	O	VERB	O
effect	O	NOUN	B
level	O	NOUN	O
(	O	PUNCT	O
NOEL	O	NOUN	B
)	O	PUNCT	O
for	O	ADP	O
this	O	DET	O
contaminant	O	NOUN	B
appears	O	VERB	O
to	O	PART	O
be	O	AUX	O
approximately	O	ADV	B
1mg	O	NOUN	B
/	O	SYM	O
kg	O	NOUN	B
,	O	PUNCT	O
corresponding	O	VERB	O
to	O	PART	O
a	O	DET	O
contamination	O	NOUN	B
level	O	NOUN	B
of	O	ADP	O
approximately	O	ADV	O
3	O	NUM	O
%.	O	NOUN	B
We	O	PRON	O
also	O	ADV	O
demonstrated	O	VERB	O
that	O	SCONJ	O
OSCS	O	NOUN	B
can	O	AUX	O
be	O	AUX	O
identified	O	VERB	B
in	O	ADP	O
heparin	B-Chemical	NOUN	B
products	O	NOUN	O
using	O	VERB	O
a	O	DET	O
simple	O	NOUN	O
,	O	PUNCT	O
inexpensive	O	ADJ	B
,	O	PUNCT	O
commercially	O	ADV	O
available	O	ADJ	O
heparin	B-Chemical	NOUN	B
enzyme	O	NOUN	O
immunoassay	O	NOUN	O
(	O	PUNCT	O
EIA	O	NOUN	B
)	O	PUNCT	O
kit	O	NOUN	B
that	O	PRON	O
has	O	AUX	O
a	O	DET	O
limit	O	NOUN	O
of	O	ADP	O
detection	O	NOUN	B
of	O	ADP	O
approximately	O	ADV	B
0	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
%,	O	ADV	O
well	O	ADV	O
below	O	ADP	O
the	O	DET	O
NOEL	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
kit	O	NOUN	B
may	O	AUX	O
provide	O	VERB	O
a	O	DET	O
useful	O	ADJ	O
method	O	NOUN	B
to	O	PART	O
test	O	VERB	B
heparin	B-Chemical	NOUN	B


Doxorubicin	B-Chemical	NOUN	B
cardiomyopathy	B-Disease	NOUN	I
-	O	PUNCT	O
induced	O	VERB	B
inflammation	B-Disease	NOUN	B
and	O	CCONJ	O
apoptosis	O	NOUN	B
are	O	AUX	O
attenuated	O	VERB	B
by	O	ADP	O
gene	O	NOUN	B
deletion	O	NOUN	I
of	O	ADP	O
the	O	DET	O
kinin	O	NOUN	B
B1	O	NOUN	I
receptor	O	NOUN	I
.	O	PUNCT	O


Clinical	O	ADJ	B
use	O	NOUN	I
of	O	ADP	I
the	O	DET	O
anthracycline	B-Chemical	NOUN	B
doxorubicin	B-Chemical	NOUN	I
(	O	PUNCT	O
DOX	B-Chemical	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
limited	O	VERB	O
by	O	ADP	O
its	O	PRON	O
cardiotoxic	B-Disease	ADJ	B
effects	O	NOUN	I
,	O	PUNCT	O
which	O	DET	O
are	O	AUX	O
attributed	O	VERB	O
to	O	PART	O
the	O	DET	O
induction	O	NOUN	B
of	O	ADP	O
apoptosis	O	NOUN	B
.	O	PUNCT	O


To	O	PART	O
elucidate	O	VERB	O
the	O	DET	O
possible	O	ADJ	O
role	O	NOUN	O
of	O	ADP	O
the	O	DET	O
kinin	O	NOUN	B
B1	O	NOUN	I
receptor	O	NOUN	I
(	O	PUNCT	O
B1R	O	NOUN	B
)	O	PUNCT	O
during	O	ADP	O
the	O	DET	O
development	O	NOUN	B
of	O	ADP	O
DOX	B-Chemical	NOUN	B
cardiomyopathy	B-Disease	NOUN	I
,	O	PUNCT	O
we	O	PRON	O
studied	O	VERB	O
B1R	O	NOUN	B
knockout	O	NOUN	B
mice	O	NOUN	I
(	O	PUNCT	O
B1R	O	NOUN	B
(-/-))	O	NOUN	O
by	O	ADP	O
investigating	O	VERB	B
cardiac	O	ADJ	B
inflammation	B-Disease	NOUN	I
and	O	CCONJ	O
apoptosis	O	NOUN	B
after	O	ADP	O
induction	O	NOUN	B
of	O	ADP	O
DOX	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
cardiomyopathy	B-Disease	NOUN	B
.	O	PUNCT	O


DOX	B-Chemical	NOUN	B
control	O	NOUN	O
mice	O	NOUN	B
showed	O	VERB	O
cardiac	B-Disease	ADJ	B
dysfunction	I-Disease	NOUN	I
measured	O	VERB	B
by	O	ADP	O
pressure	O	NOUN	B
-	O	PUNCT	O
volume	O	NOUN	B
loops	O	NOUN	O
in	O	X	B
vivo	O	X	I
.	O	PUNCT	O


This	O	DET	O
was	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
a	O	DET	O
reduced	O	VERB	B
activation	O	NOUN	B
state	O	NOUN	I
of	O	ADP	O
AKT	O	NOUN	B
,	O	PUNCT	O
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
an	O	DET	O
increased	O	VERB	B
bax	O	NOUN	B
/	O	SYM	O
bcl2	O	NOUN	B
ratio	O	NOUN	B
in	O	ADP	O
Western	O	NOUN	B
blots	O	NOUN	I
,	O	PUNCT	O
indicating	O	VERB	O
cardiac	B-Disease	ADJ	B
apoptosis	I-Disease	NOUN	B
.	O	PUNCT	O


Furthermore	O	ADV	O
,	O	PUNCT	O
mRNA	O	NOUN	B
levels	O	NOUN	O
of	O	ADP	O
the	O	DET	O
proinflammatory	O	ADJ	B
cytokine	O	NOUN	I
interleukin	O	NOUN	I
6	O	NUM	I
were	O	AUX	O
increased	O	VERB	B
in	O	ADP	O
the	O	DET	O
cardiac	O	ADJ	B
tissue	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
DOX	B-Chemical	NOUN	B
B1R	O	NOUN	B
(-/-)	O	NOUN	O
mice	O	NOUN	B
,	O	PUNCT	O
cardiac	B-Disease	ADJ	B
dysfunction	I-Disease	NOUN	I
was	O	AUX	O
improved	O	VERB	O
compared	O	VERB	O
to	O	PART	O
DOX	B-Chemical	NOUN	B
control	O	NOUN	O
mice	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
was	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
normalization	O	NOUN	B
of	O	ADP	O
the	O	DET	O
bax	O	NOUN	B
/	O	PUNCT	O
bcl	O	NOUN	B
-	O	PUNCT	O
2	O	NUM	O
ratio	O	NOUN	B
and	O	CCONJ	O
interleukin	O	NOUN	B
6	O	NUM	I
,	O	PUNCT	O
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
AKT	O	NOUN	B
activation	O	NOUN	B
state	O	NOUN	I
.	O	PUNCT	O


These	O	DET	O
findings	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
B1R	O	NOUN	B
is	O	AUX	O
detrimental	O	ADJ	B
in	O	ADP	O
DOX	B-Chemical	NOUN	B
cardiomyopathy	B-Disease	NOUN	I
in	O	ADP	O
that	O	SCONJ	O
it	O	PRON	O
mediates	O	VERB	O
the	O	DET	O
inflammatory	O	ADJ	B
response	O	NOUN	I
and	O	CCONJ	O
apoptosis	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
insights	O	NOUN	O
might	O	AUX	O
have	O	AUX	O
useful	O	ADJ	O
implications	O	NOUN	O
for	O	ADP	O
future	O	ADJ	O
studies	O	NOUN	B
utilizing	O	VERB	O
B1R	O	NOUN	B
antagonists	O	NOUN	I
for	O	ADP	O
treatment	O	NOUN	B
of	O	ADP	O
human	O	ADJ	B
DOX	B-Chemical	NOUN	B
cardiomyopathy	B-Disease	NOUN	I


Hepatotoxicity	B-Disease	NOUN	B
associated	O	VERB	B
with	O	ADP	I
sulfasalazine	B-Chemical	NOUN	B
in	O	ADP	O
inflammatory	O	ADJ	B
arthritis	B-Disease	NOUN	I
:	O	PUNCT	O
A	O	DET	O
case	O	NOUN	B
series	O	NOUN	I
from	O	ADP	O
a	O	DET	O
local	O	ADJ	B
surveillance	O	NOUN	B
of	O	ADP	O
serious	O	ADJ	O
adverse	O	ADJ	B
events	O	NOUN	I
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
:	O	PUNCT	O
Spontaneous	O	ADJ	B
reporting	O	NOUN	I
systems	O	NOUN	I
for	O	ADP	O
adverse	O	ADJ	B
drug	O	NOUN	I
reactions	O	NOUN	I
(	O	PUNCT	O
ADRs	O	NOUN	B
)	O	PUNCT	O
are	O	AUX	O
handicapped	O	VERB	B
by	O	ADP	O
under	O	ADP	O
-	O	PUNCT	O
reporting	O	NOUN	B
and	O	CCONJ	O
limited	O	ADJ	O
detail	O	NOUN	O
on	O	ADP	O
individual	O	ADJ	O
cases	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
an	O	DET	O
investigation	O	NOUN	B
from	O	ADP	O
a	O	DET	O
local	O	ADJ	B
surveillance	O	NOUN	B
for	O	ADP	O
serious	O	ADJ	O
adverse	O	ADJ	B
drug	O	NOUN	I
reactions	O	NOUN	I
associated	O	VERB	B
with	O	ADP	I
disease	O	NOUN	B
modifying	O	VERB	O
anti	O	ADJ	B
-	O	PUNCT	O
rheumatic	O	ADJ	B
drugs	O	NOUN	B
that	O	PRON	O
was	O	AUX	O
triggered	O	VERB	O
by	O	ADP	O
the	O	DET	O
occurrence	O	NOUN	B
of	O	ADP	O
liver	B-Disease	NOUN	B
failure	I-Disease	NOUN	I
in	O	ADP	O
two	O	NUM	O
of	O	ADP	O
our	O	PRON	O
patients	O	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
:	O	PUNCT	O
Serious	O	ADJ	B
ADR	O	NOUN	B
reports	O	NOUN	B
have	O	AUX	O
been	O	AUX	O
solicited	O	VERB	B
from	O	ADP	O
local	O	ADJ	O
clinicians	O	NOUN	B
by	O	ADP	O
regular	O	ADJ	B
postcards	O	NOUN	B
over	O	ADP	O
the	O	DET	O
past	O	ADJ	O
seven	O	NUM	O
years	O	NOUN	B
.	O	PUNCT	O


Patients	O	NOUN	B
',	O	VERB	I
who	O	PRON	O
had	O	AUX	O
hepatotoxicity	B-Disease	NOUN	B
on	O	ADP	O
sulfasalazine	B-Chemical	NOUN	B
and	O	CCONJ	O
met	O	VERB	O
a	O	DET	O
definition	O	NOUN	B
of	O	ADP	O
a	O	DET	O
serious	O	ADJ	O
ADR	O	NOUN	B
,	O	PUNCT	O
were	O	AUX	O
identified	O	VERB	B
.	O	PUNCT	O


Two	O	NUM	O
clinicians	O	NOUN	B
reviewed	O	VERB	B
structured	O	ADJ	O
case	O	NOUN	O
reports	O	NOUN	O
and	O	CCONJ	O
assessed	O	VERB	B
causality	O	NOUN	B
by	O	ADP	O
consensus	O	NOUN	B
and	O	CCONJ	O
by	O	ADP	O
using	O	VERB	O
a	O	DET	O
causality	O	NOUN	B
assessment	O	NOUN	I
instrument	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
likely	O	ADJ	O
frequency	O	NOUN	B
of	O	ADP	O
hepatotoxicity	B-Disease	NOUN	B
with	O	ADP	O
sulfasalazine	B-Chemical	NOUN	B
was	O	AUX	O
estimated	O	VERB	O
by	O	ADP	O
making	O	VERB	O
a	O	DET	O
series	O	NOUN	O
of	O	ADP	O
conservative	O	ADJ	O
assumptions	O	NOUN	O
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
Ten	O	NUM	O
cases	O	NOUN	B
were	O	AUX	O
identified	O	VERB	B
:	O	PUNCT	O
eight	O	NUM	O
occurred	O	VERB	O
during	O	ADP	O
surveillance	O	NOUN	B
.	O	PUNCT	O


Eight	O	NUM	O
patients	O	NOUN	B
were	O	AUX	O
hospitalised	O	VERB	B
,	O	PUNCT	O
two	O	NUM	O
in	O	ADP	O
hepatic	B-Disease	ADJ	B
failure	I-Disease	NOUN	I
-	O	PUNCT	O
one	O	NOUN	O
died	O	VERB	B
after	O	ADP	O
a	O	DET	O
liver	O	NOUN	B
transplant	O	NOUN	I
.	O	PUNCT	O


All	O	DET	O
but	O	CCONJ	O
one	O	NUM	O
event	O	NOUN	B
occurred	O	VERB	O
within	O	ADP	O
6	O	NUM	O
weeks	O	NOUN	B
of	O	ADP	O
treatment	O	NOUN	B
.	O	PUNCT	O


Seven	O	NUM	O
patients	O	NOUN	B
had	O	AUX	O
a	O	DET	O
skin	B-Disease	NOUN	B
rash	I-Disease	NOUN	I
,	O	PUNCT	O
three	O	NUM	O
eosinophilia	B-Disease	NOUN	B
and	O	CCONJ	O
one	O	NUM	O
interstitial	B-Disease	ADJ	B
nephritis	I-Disease	NOUN	I
.	O	PUNCT	O


Five	O	NUM	O
patients	O	NOUN	B
were	O	AUX	O
of	O	ADP	O
Black	O	ADJ	B
British	O	PROPN	I
of	O	ADP	O
African	O	ADJ	B
or	O	CCONJ	O
Caribbean	O	ADJ	B
descent	O	NOUN	I
.	O	PUNCT	O


Liver	O	NOUN	B
enzymes	O	NOUN	I
showed	O	VERB	O
a	O	DET	O
hepatocellular	O	NOUN	B
pattern	O	NOUN	I
in	O	ADP	O
four	O	NUM	O
cases	O	NOUN	B
and	O	CCONJ	O
a	O	DET	O
mixed	O	ADJ	O
pattern	O	NOUN	B
in	O	ADP	O
six	O	NUM	O
.	O	PUNCT	O


Drug	O	NOUN	B
-	O	PUNCT	O
related	O	VERB	B
hepatotoxicity	B-Disease	NOUN	B
was	O	AUX	O
judged	O	VERB	O
probable	O	ADJ	B
or	O	CCONJ	O
highly	O	ADV	O
probable	O	ADJ	O
in	O	ADP	O
8	O	NUM	O
patients	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
likely	O	ADJ	O
frequency	O	NOUN	B
of	O	ADP	O
serious	O	ADJ	O
hepatotoxicity	B-Disease	NOUN	B
with	O	ADP	O
sulfasalazine	B-Chemical	NOUN	B
was	O	AUX	O
estimated	O	VERB	B
at	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


4	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
treated	O	VERB	B
patients	O	NOUN	B
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
:	O	PUNCT	O
Serious	O	ADJ	B
hepatotoxicity	B-Disease	NOUN	B
associated	O	VERB	B
with	O	ADP	I
sulfasalazine	B-Chemical	NOUN	B


An	O	DET	O
evaluation	O	NOUN	B
of	O	ADP	O
amikacin	B-Chemical	NOUN	B
nephrotoxicity	B-Disease	NOUN	B
in	O	ADP	O
the	O	DET	O
hematology	O	NOUN	B
/	O	SYM	O
oncology	O	NOUN	B
population	O	NOUN	I
.	O	PUNCT	O


Amikacin	B-Chemical	NOUN	B
is	O	AUX	O
an	O	DET	O
aminoglycoside	B-Chemical	NOUN	B
commonly	O	ADV	O
used	O	VERB	O
to	O	PART	O
provide	O	VERB	O
empirical	O	ADJ	B
double	O	ADJ	O
gram	O	X	B
-	O	PUNCT	O
negative	O	ADJ	B
treatment	O	NOUN	B
for	O	ADP	O
febrile	B-Disease	ADJ	B
neutropenia	I-Disease	NOUN	B
and	O	CCONJ	O
other	O	ADJ	O
suspected	O	VERB	B
infections	B-Disease	NOUN	B
.	O	PUNCT	O


Strategies	O	NOUN	B
of	O	ADP	O
extended	O	VERB	B
-	O	PUNCT	O
interval	O	NOUN	B
and	O	CCONJ	O
conventional	O	ADJ	B
dosing	O	NOUN	B
have	O	AUX	O
been	O	AUX	O
utilized	O	VERB	O
extensively	O	ADV	O
in	O	ADP	O
the	O	DET	O
general	O	ADJ	B
medical	O	ADJ	I
population	O	NOUN	I
;	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
data	O	NOUN	B
are	O	AUX	O
lacking	O	VERB	O
to	O	PART	O
support	O	VERB	O
a	O	DET	O
dosing	O	ADJ	B
strategy	O	NOUN	O
in	O	ADP	O
the	O	DET	O
hematology	O	NOUN	B
/	O	SYM	O
oncology	O	NOUN	B
population	O	NOUN	I
.	O	PUNCT	O


To	O	PART	O
evaluate	O	VERB	B
amikacin	B-Chemical	NOUN	B
-	O	PUNCT	O
associated	O	VERB	B
nephrotoxicity	B-Disease	NOUN	B
in	O	ADP	O
an	O	DET	O
adult	O	ADJ	B
hematology	O	NOUN	B
/	O	SYM	O
oncology	O	NOUN	B
population	O	NOUN	I
,	O	PUNCT	O
a	O	DET	O
prospective	O	ADJ	B
,	O	PUNCT	O
randomized	O	ADJ	B
,	O	PUNCT	O
open	O	ADJ	B
-	O	PUNCT	O
label	O	NOUN	B
trial	O	NOUN	B
was	O	AUX	O
conducted	O	VERB	O
at	O	ADP	O
a	O	DET	O
university	O	NOUN	B
-	O	PUNCT	O
affiliated	O	VERB	B
medical	O	ADJ	B
center	O	NOUN	I
.	O	PUNCT	O


Forty	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
a	O	DET	O
diagnosis	O	NOUN	B
consistent	O	ADJ	B
with	O	ADP	I
a	O	DET	O
hematologic/oncologic	B-Disease	ADJ	B
disorder	I-Disease	NOUN	I
that	O	PRON	O
required	O	VERB	O
treatment	O	NOUN	B
with	O	ADP	O
an	O	DET	O
aminoglycoside	B-Chemical	NOUN	B
were	O	AUX	O
randomized	O	VERB	B
to	O	PART	O
either	O	CCONJ	O
conventional	O	ADJ	B
or	O	CCONJ	O
extended	O	VERB	B
-	O	PUNCT	O
interval	O	NOUN	B
amikacin	B-Chemical	NOUN	B
.	O	PUNCT	O


The	O	DET	O
occurrence	O	NOUN	B
of	O	ADP	O
nephrotoxicity	B-Disease	NOUN	B
by	O	ADP	O
means	O	NOUN	O
of	O	ADP	O
an	O	DET	O
increase	O	NOUN	B
in	O	ADP	O
serum	O	NOUN	B
creatinine	B-Chemical	NOUN	I
and	O	CCONJ	O
evaluation	O	NOUN	B
of	O	ADP	O
efficacy	O	NOUN	B
via	O	ADP	O
amikacin	B-Chemical	NOUN	B
serum	O	NOUN	B
concentrations	O	NOUN	B
with	O	ADP	O
respective	O	ADJ	O
pathogens	O	NOUN	B
were	O	AUX	O
assessed	O	VERB	B
.	O	PUNCT	O


The	O	DET	O
occurrence	O	NOUN	B
of	O	ADP	O
nephrotoxicity	B-Disease	NOUN	B
was	O	AUX	O
similar	O	ADJ	O
between	O	ADP	O
the	O	DET	O
conventional	O	ADJ	B
and	O	CCONJ	O
extended	O	VERB	B
-	O	PUNCT	O
interval	O	NOUN	B
groups	O	NOUN	B
,	O	PUNCT	O
at	O	ADP	O
10	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
5	O	NUM	O
%,	O	NOUN	O
respectively	O	ADV	O
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
1	O	NUM	O
.	O	PUNCT	O


00	O	NUM	O
).	O	PUNCT	O
Six	O	NUM	O
patients	O	NOUN	B
in	O	ADP	O
the	O	DET	O
conventional	O	ADJ	B
group	O	NOUN	I
had	O	AUX	O
a	O	DET	O
positive	O	ADJ	B
culture	O	NOUN	O
,	O	PUNCT	O
compared	O	VERB	B
with	O	ADP	O
none	O	NOUN	O
in	O	ADP	O
the	O	DET	O
extended	O	VERB	B
-	O	PUNCT	O
interval	O	NOUN	B
group	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


002	O	NUM	O
).	O	PUNCT	O
The	O	DET	O
occurrence	O	NOUN	B
of	O	ADP	O
nephrotoxicity	B-Disease	NOUN	B


Memory	O	NOUN	B
function	O	NOUN	I
and	O	CCONJ	O
serotonin	B-Chemical	NOUN	B
transporter	O	NOUN	I
promoter	O	NOUN	B
gene	O	NOUN	I
polymorphism	O	NOUN	B
in	O	ADP	O
ecstasy	B-Chemical	NOUN	B
(	O	PUNCT	O
MDMA	B-Chemical	NOUN	B
)	O	PUNCT	O
users	O	NOUN	B
.	O	PUNCT	O


Although	O	SCONJ	O
3,4-methylenedioxymethamphetamine	B-Chemical	NOUN	B
(	O	PUNCT	O
MDMA	B-Chemical	NOUN	B
or	O	CCONJ	O
ecstasy	B-Chemical	NOUN	B
)	O	PUNCT	O
has	O	AUX	O
been	O	AUX	O
shown	O	VERB	O
to	O	PART	O
damage	O	VERB	B
brain	O	NOUN	O
serotonin	B-Chemical	NOUN	O
(	O	PUNCT	O
5-HT	B-Chemical	NOUN	B
)	O	PUNCT	O
neurons	O	NOUN	B
in	O	ADP	O
animals	O	NOUN	B
and	O	CCONJ	O
possibly	O	ADV	O
humans	O	NOUN	B
,	O	PUNCT	O
little	O	ADJ	O
is	O	AUX	O
known	O	VERB	O
about	O	ADP	O
the	O	DET	O
long	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
consequences	O	NOUN	B
of	O	ADP	O
MDMA	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
5-HT	B-Chemical	NOUN	B
neurotoxic	B-Disease	ADJ	B
lesions	I-Disease	NOUN	I
on	O	ADP	O
functions	O	NOUN	B
in	O	ADP	O
which	O	DET	O
5-HT	B-Chemical	NOUN	B
is	O	AUX	O
involved	O	VERB	O
,	O	PUNCT	O
such	O	ADJ	O
as	O	ADP	O
cognitive	O	ADJ	B
function	O	NOUN	I
.	O	PUNCT	O


Because	O	SCONJ	O
5-HT	B-Chemical	NOUN	B
transporters	O	NOUN	B
play	O	VERB	O
a	O	DET	O
key	O	ADJ	O
element	O	NOUN	B
in	O	ADP	O
the	O	DET	O
regulation	O	NOUN	B
of	O	ADP	O
synaptic	O	ADJ	B
5-HT	B-Chemical	NOUN	I
transmission	O	NOUN	B
it	O	PRON	O
may	O	AUX	O
be	O	AUX	O
important	O	ADJ	O
to	O	PART	O
control	O	VERB	B
for	O	ADP	O
the	O	DET	O
potential	O	ADJ	B
covariance	O	NOUN	B
effect	O	NOUN	O
of	O	ADP	O
a	O	DET	O
polymorphism	O	NOUN	B
in	O	ADP	O
the	O	DET	O
5-HT	B-Chemical	NOUN	B
transporter	O	NOUN	I
promoter	O	NOUN	B
gene	O	NOUN	I
region	O	NOUN	I
(	O	PUNCT	O
5	O	NUM	O
-	O	PUNCT	O
HTTLPR	O	NOUN	B
)	O	PUNCT	O
when	O	SCONJ	O
studying	O	VERB	O
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	O
MDMA	B-Chemical	NOUN	B
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
cognitive	O	ADJ	B
functioning	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
aim	O	NOUN	O
of	O	ADP	O
the	O	DET	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
investigate	O	VERB	B
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
moderate	O	ADJ	B
and	O	CCONJ	O
heavy	O	ADJ	B
MDMA	B-Chemical	NOUN	I
use	O	NOUN	O
on	O	ADP	O
cognitive	O	ADJ	B
function	O	NOUN	I
,	O	PUNCT	O
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
long	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
abstention	O	NOUN	B
from	O	ADP	O
MDMA	B-Chemical	NOUN	B
,	O	PUNCT	O
in	O	ADP	O
subjects	O	NOUN	B
genotyped	O	VERB	B
for	O	ADP	O
5	O	NUM	O
-	O	PUNCT	O
HTTLPR	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
second	O	ADJ	O
aim	O	NOUN	O
of	O	ADP	O
the	O	DET	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
determine	O	VERB	O
whether	O	SCONJ	O
these	O	DET	O
effects	O	NOUN	B
differ	O	VERB	O
for	O	ADP	O
females	O	NOUN	B
and	O	CCONJ	O
males	O	NOUN	B
.	O	PUNCT	O


Fifteen	O	NUM	O
moderate	O	ADJ	B
MDMA	B-Chemical	NOUN	B
users	O	NOUN	B
(<	O	VERB	O
55	O	NUM	O
lifetime	O	NOUN	B
tablets	O	NOUN	B
),	O	PUNCT	O
22	O	NUM	O
heavy	O	ADJ	O
MDMA	B-Chemical	NOUN	B
+	O	CCONJ	O
users	O	NOUN	B
(>	O	VERB	O
55	O	NUM	O
lifetime	O	NOUN	B
tablets	O	NOUN	B
),	O	PUNCT	O
16	O	NUM	O
ex	O	X	B
-	O	PUNCT	O
MDMA	B-Chemical	NOUN	B
+	O	CCONJ	O
users	O	NOUN	B
(	O	PUNCT	O
last	O	ADJ	O
tablet	O	NOUN	B
>	O	NOUN	O
1	O	NUM	O
year	O	NOUN	B
ago	O	ADV	O
)	O	PUNCT	O
and	O	CCONJ	O
13	O	NUM	O
controls	O	NOUN	B
were	O	AUX	O
compared	O	VERB	B
on	O	ADP	O
a	O	DET	O
battery	O	NOUN	B
of	O	ADP	O
neuropsychological	O	ADJ	B
tests	O	NOUN	I
.	O	PUNCT	O


DNA	O	NOUN	B
from	O	ADP	O
peripheral	O	ADJ	B
nuclear	O	ADJ	B
blood	O	NOUN	I
cells	O	NOUN	I
was	O	AUX	O
genotyped	O	VERB	B
for	O	ADP	O
5	O	NUM	O
-	O	PUNCT	O
HTTLPR	O	NOUN	B
using	O	VERB	O
standard	O	ADJ	B
polymerase	O	NOUN	I
chain	O	NOUN	I
reaction	O	NOUN	I
methods	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
significant	O	ADJ	B
group	O	NOUN	B
effect	O	NOUN	O
was	O	AUX	O
observed	O	VERB	O
only	O	ADV	O
on	O	ADP	O
memory	O	NOUN	B
function	O	NOUN	I
tasks	O	NOUN	I
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


04	O	NUM	O
)	O	PUNCT	O
but	O	CCONJ	O
not	O	PART	O
on	O	ADP	O
reaction	O	NOUN	B
times	O	NOUN	O
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


61	O	NUM	O
)	O	PUNCT	O
or	O	CCONJ	O
attention	O	NOUN	B
/	O	SYM	O
executive	O	ADJ	B
functioning	O	NOUN	O
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


59	O	NUM	O
).	O	PUNCT	B
Heavy	O	ADJ	B
and	O	CCONJ	O
ex	O	ADP	B
-	O	PUNCT	O
MDMA	B-Chemical	NOUN	B
+	O	CCONJ	O
users	O	NOUN	B
performed	O	VERB	O
significantly	O	ADV	O
poorer	O	ADJ	B
on	O	ADP	O
memory	O	NOUN	B
tasks	O	NOUN	I
than	O	ADP	O
controls	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
contrast	O	NOUN	O
,	O	PUNCT	O
no	O	DET	O
evidence	O	NOUN	O
of	O	ADP	O
memory	B-Disease	NOUN	B
impairment	I-Disease	NOUN	I
was	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
moderate	O	ADJ	B
MDMA	B-Chemical	NOUN	B
users	O	NOUN	B
.	O	PUNCT	O


No	O	DET	B
significant	O	ADJ	I
effect	O	NOUN	B
of	O	ADP	O
5	O	NUM	O
-	O	PUNCT	O
HTTLPR	O	NOUN	B
or	O	CCONJ	O
gender	O	NOUN	B
was	O	AUX	O
observed	O	VERB	B
.	O	PUNCT	O


While	O	SCONJ	O
the	O	DET	O
use	O	NOUN	O
of	O	ADP	O
MDMA	B-Chemical	NOUN	B
in	O	ADP	O
quantities	O	NOUN	B
that	O	PRON	O
may	O	AUX	O
be	O	AUX	O
considered	O	VERB	O
"	O	PUNCT	O
moderate	O	ADJ	B
"	O	PUNCT	O
is	O	AUX	O
not	O	PART	O
associated	O	VERB	B
with	O	ADP	I
impaired	B-Disease	ADJ	B
memory	I-Disease	NOUN	O
functioning	I-Disease	NOUN	O
,	O	PUNCT	O
heavy	O	ADJ	B
use	O	NOUN	I
of	O	ADP	O
MDMA	B-Chemical	NOUN	B
use	O	NOUN	B
may	O	AUX	O
lead	O	VERB	O
to	O	PART	O
long	O	ADJ	O
lasting	O	VERB	O
memory	B-Disease	NOUN	B
impairments	I-Disease	NOUN	I
.	O	PUNCT	O


No	O	DET	B
effect	O	NOUN	I
of	O	ADP	O
5	O	NUM	O
-	O	PUNCT	O
HTTLPR	O	NOUN	B
or	O	CCONJ	O
gender	O	NOUN	B
on	O	ADP	O
memory	O	NOUN	B
function	O	NOUN	I
or	O	CCONJ	O
MDMA	B-Chemical	NOUN	B


Aging	O	NOUN	B
process	O	NOUN	I
of	O	ADP	O
epithelial	O	ADJ	B
cells	O	NOUN	I
of	O	ADP	O
the	O	DET	O
rat	O	NOUN	B
prostate	O	NOUN	B
lateral	O	ADJ	I
lobe	O	NOUN	I
in	O	ADP	O
experimental	O	ADJ	B
hyperprolactinemia	B-Disease	NOUN	B
induced	O	VERB	B
by	O	ADP	O
haloperidol	B-Chemical	NOUN	B
.	O	PUNCT	O


The	O	DET	O
aim	O	NOUN	O
of	O	ADP	O
the	O	DET	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
examine	O	VERB	O
the	O	DET	O
influence	O	NOUN	B
of	O	ADP	O
hyperprolactinemia	B-Disease	NOUN	B
,	O	PUNCT	O
induced	O	VERB	B
by	O	ADP	O
haloperidol	B-Chemical	NOUN	B
(	O	PUNCT	O
HAL	B-Chemical	NOUN	B
)	O	PUNCT	O
on	O	ADP	O
age	O	NOUN	B
related	O	ADJ	O
morphology	O	NOUN	B
and	O	CCONJ	O
function	O	VERB	B
changes	O	NOUN	B
of	O	ADP	O
epithelial	O	ADJ	B
cells	O	NOUN	I
in	O	ADP	O
rat	O	NOUN	B
prostate	O	NOUN	B
lateral	O	ADJ	I
lobe	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
study	O	NOUN	B
was	O	AUX	O
performed	O	VERB	O
on	O	ADP	O
sexually	O	ADV	B
mature	O	ADJ	I
male	O	NOUN	B
rats	O	NOUN	B
.	O	PUNCT	O


Serum	O	NOUN	B
concentrations	O	NOUN	B
of	O	ADP	O
prolactin	O	NOUN	B
(	O	PUNCT	O
PRL	B-Chemical	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
testosterone	B-Chemical	NOUN	B
(	O	PUNCT	O
T	B-Chemical	NOUN	B
)	O	PUNCT	O
were	O	AUX	O
measured	O	VERB	B
.	O	PUNCT	O


Tissue	O	NOUN	B
sections	O	NOUN	I
were	O	AUX	O
evaluated	O	VERB	B
with	O	ADP	O
light	O	ADJ	B
and	O	CCONJ	O
electron	O	NOUN	B
microscopy	O	NOUN	I
.	O	PUNCT	O


Immunohistochemical	O	ADJ	B
reactions	O	NOUN	I
for	O	ADP	O
Anti	O	PROPN	B
-	O	PUNCT	O
Proliferating	O	NOUN	B
Cell	O	NOUN	I
Nuclear	O	ADJ	I
Antigen	O	NOUN	I
(	O	PUNCT	O
PCNA	O	NOUN	B
)	O	PUNCT	O
were	O	AUX	O
performed	O	VERB	O
.	O	PUNCT	O


In	O	ADP	O
rats	O	NOUN	B
of	O	ADP	O
the	O	DET	O
experimental	O	ADJ	B
group	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
mean	O	ADJ	O
concentration	O	NOUN	B
of	O	ADP	O
:	O	PUNCT	O
PRL	B-Chemical	NOUN	B
was	O	AUX	O
more	O	ADJ	O
than	O	ADP	O
twice	O	ADV	O
higher	O	ADJ	B
,	O	PUNCT	O
whereas	O	SCONJ	O
T	B-Chemical	NOUN	B
concentration	O	NOUN	B
was	O	AUX	O
almost	O	ADV	O
twice	O	ADV	O
lower	O	ADJ	O
than	O	ADP	O
that	O	DET	O
in	O	ADP	O
the	O	DET	O
control	O	NOUN	B
group	O	NOUN	I
.	O	PUNCT	O


Light	O	ADJ	B
microscopy	O	NOUN	I
visualized	O	VERB	B
the	O	DET	O
following	O	NOUN	O
:	O	PUNCT	O
hypertrophy	B-Disease	NOUN	B
and	O	CCONJ	O
epithelium	O	NOUN	B
hyperplasia	B-Disease	NOUN	I


Does	O	AUX	O
supplemental	O	ADJ	B
vitamin	B-Chemical	NOUN	B
C	I-Chemical	NOUN	I
increase	O	VERB	B
cardiovascular	B-Disease	ADJ	B
disease	I-Disease	NOUN	I
risk	O	NOUN	O
in	O	ADP	O
women	O	NOUN	B
with	O	ADP	O
diabetes	B-Disease	NOUN	B
?	O	PUNCT	O
BACKGROUND	O	NOUN	B
:	O	PUNCT	O
Vitamin	B-Chemical	NOUN	B
C	I-Chemical	NOUN	I
acts	O	VERB	O
as	O	ADP	O
a	O	DET	O
potent	O	ADJ	O
antioxidant	O	NOUN	B
;	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
it	O	PRON	O
can	O	AUX	O
also	O	ADV	O
be	O	AUX	O
a	O	DET	O
prooxidant	O	ADJ	B
and	O	CCONJ	O
glycate	O	NOUN	B
protein	O	NOUN	I
under	O	ADP	O
certain	O	ADJ	O
circumstances	O	NOUN	O
in	O	X	B
vitro	O	X	I
.	O	PUNCT	O


These	O	DET	O
observations	O	NOUN	B
led	O	VERB	O
us	O	PRON	O
to	O	PART	O
hypothesize	O	VERB	O
that	O	SCONJ	O
a	O	DET	O
high	O	ADJ	O
intake	O	NOUN	B
of	O	ADP	O
vitamin	B-Chemical	NOUN	B
C	I-Chemical	NOUN	I
in	O	ADP	O
diabetic	B-Disease	ADJ	B
persons	O	NOUN	B
might	O	AUX	O
promote	O	VERB	B
atherosclerosis	B-Disease	NOUN	B
.	O	PUNCT	O


OBJECTIVE	O	NOUN	B
:	O	PUNCT	O
The	O	DET	O
objective	O	NOUN	B
was	O	AUX	O
to	O	PART	O
examine	O	VERB	O
the	O	DET	O
relation	O	NOUN	O
between	O	ADP	O
vitamin	B-Chemical	NOUN	B
C	I-Chemical	NOUN	I
intake	O	NOUN	B
and	O	CCONJ	O
mortality	O	NOUN	B
from	O	ADP	O
cardiovascular	B-Disease	ADJ	B
disease	I-Disease	NOUN	I
.	O	PUNCT	O


DESIGN	O	NOUN	O
:	O	PUNCT	O
We	O	PRON	O
studied	O	VERB	O
the	O	DET	O
relation	O	NOUN	O
between	O	ADP	O
vitamin	B-Chemical	NOUN	B
C	I-Chemical	NOUN	I
intake	O	NOUN	B
and	O	CCONJ	O
mortality	O	NOUN	B
from	O	ADP	O
total	O	ADJ	O
cardiovascular	B-Disease	ADJ	O
disease	I-Disease	NOUN	O
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
281	O	NUM	O
),	O	PUNCT	O
coronary	B-Disease	ADJ	B
artery	I-Disease	NOUN	I
disease	I-Disease	NOUN	I
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
175	O	NUM	O
),	O	PUNCT	O
and	O	CCONJ	O
stroke	B-Disease	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
57	O	NUM	O
)	O	PUNCT	O
in	O	ADP	O
1923	O	NUM	O
postmenopausal	O	ADJ	B
women	O	NOUN	B
who	O	PRON	O
reported	O	VERB	O
being	O	AUX	O
diabetic	B-Disease	ADJ	B
at	O	ADP	O
baseline	O	NOUN	B
.	O	PUNCT	O


Diet	O	NOUN	B
was	O	AUX	O
assessed	O	VERB	B
with	O	ADP	O
a	O	DET	O
food	O	NOUN	B
-	O	PUNCT	O
frequency	O	NOUN	B
questionnaire	O	NOUN	B
at	O	ADP	O
baseline	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
subjects	O	NOUN	B
initially	O	ADV	O
free	O	ADJ	B
of	O	ADP	O
coronary	B-Disease	ADJ	B
artery	I-Disease	NOUN	I
disease	I-Disease	NOUN	I
were	O	AUX	O
prospectively	O	ADV	O
followed	O	VERB	O
for	O	ADP	O
15	O	NUM	O
y	O	NOUN	O
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
After	O	ADP	O
adjustment	O	NOUN	B
for	O	ADP	O
cardiovascular	B-Disease	ADJ	B
disease	I-Disease	NOUN	I
risk	O	NOUN	B
factors	O	NOUN	I
,	O	PUNCT	O
type	O	NOUN	O
of	O	ADP	O
diabetes	B-Disease	NOUN	B
medication	O	NOUN	I
used	O	VERB	O
,	O	PUNCT	O
duration	O	NOUN	B
of	O	ADP	O
diabetes	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
intakes	O	NOUN	B
of	O	ADP	O
folate	B-Chemical	NOUN	B
,	O	PUNCT	O
vitamin	B-Chemical	NOUN	B
E	I-Chemical	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
beta-carotene	B-Chemical	NOUN	B
,	O	PUNCT	O
the	O	DET	O
adjusted	O	ADJ	O
relative	O	ADJ	O
risks	O	NOUN	B
of	O	ADP	O
total	O	ADJ	O
cardiovascular	B-Disease	ADJ	O
disease	I-Disease	NOUN	O
mortality	O	NOUN	B
were	O	AUX	O
1	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
,	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


97	O	NUM	O
,	O	PUNCT	O
1	O	NUM	O
.	O	PUNCT	O


11	O	NUM	O
,	O	PUNCT	O
1	O	NUM	O
.	O	PUNCT	O


47	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
1	O	NUM	O
.	O	PUNCT	O


84	O	NUM	O
(	O	PUNCT	O
P	O	NOUN	O
for	O	ADP	O
trend	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


01	O	NUM	O
)	O	PUNCT	O
across	O	ADP	O
quintiles	O	NOUN	B
of	O	ADP	O
total	O	ADJ	O
vitamin	B-Chemical	NOUN	B
C	I-Chemical	NOUN	I
intake	O	NOUN	B
from	O	ADP	O
food	O	NOUN	B
and	O	CCONJ	O
supplements	O	NOUN	B
.	O	PUNCT	O


Adjusted	O	VERB	B
relative	O	ADJ	O
risks	O	NOUN	B
of	O	ADP	O
coronary	B-Disease	ADJ	B
artery	I-Disease	NOUN	I
disease	I-Disease	NOUN	I
were	O	AUX	O
1	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
,	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


81	O	NUM	O
,	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


99	O	NUM	O
,	O	PUNCT	O
1	O	NUM	O
.	O	PUNCT	O


26	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
1	O	NUM	O
.	O	PUNCT	O


91	O	NUM	O
(	O	PUNCT	O
P	O	NOUN	O
for	O	ADP	O
trend	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


01	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
of	O	ADP	O
stroke	B-Disease	NOUN	B
were	O	AUX	O
1	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
,	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


52	O	NUM	O
,	O	PUNCT	O
1	O	NUM	O
.	O	PUNCT	O


23	O	NUM	O
,	O	PUNCT	O
2	O	NUM	O
.	O	PUNCT	O


22	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
2	O	NUM	O
.	O	PUNCT	O


57	O	NUM	O
(	O	PUNCT	O
P	O	NOUN	O
for	O	ADP	O
trend	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


01	O	NUM	O
).	O	PUNCT	O
When	O	SCONJ	O
dietary	O	ADJ	B
and	O	CCONJ	O
supplemental	O	ADJ	B
vitamin	B-Chemical	NOUN	B
C	I-Chemical	NOUN	I
were	O	AUX	O
analyzed	O	VERB	B
separately	O	ADV	O
,	O	PUNCT	O
only	O	ADV	O
supplemental	O	ADJ	O
vitamin	B-Chemical	NOUN	B
C	I-Chemical	NOUN	I
showed	O	VERB	O
a	O	DET	O
positive	O	ADJ	B
association	O	NOUN	B
with	O	ADP	O
mortality	O	NOUN	B
endpoints	O	NOUN	B
.	O	PUNCT	O


Vitamin	B-Chemical	NOUN	B
C	I-Chemical	NOUN	I
intake	O	NOUN	B
was	O	AUX	O
unrelated	O	ADJ	O
to	O	PART	O
mortality	O	NOUN	B
from	O	ADP	O
cardiovascular	B-Disease	ADJ	B
disease	I-Disease	NOUN	I
in	O	ADP	O
the	O	DET	O
nondiabetic	O	ADJ	B
subjects	O	NOUN	B
at	O	ADP	O
baseline	O	NOUN	B
.	O	PUNCT	O


CONCLUSION	O	NOUN	B
:	O	PUNCT	O
A	O	DET	O
high	O	ADJ	O
vitamin	B-Chemical	NOUN	B
C	I-Chemical	NOUN	I
intake	O	NOUN	B
from	O	ADP	O
supplements	O	NOUN	B
is	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
an	O	DET	O
increased	O	VERB	B
risk	O	NOUN	B
of	O	ADP	O
cardiovascular	B-Disease	ADJ	B
disease	I-Disease	NOUN	I
mortality	O	NOUN	B
in	O	ADP	O
postmenopausal	O	ADJ	B
women	O	NOUN	B
with	O	ADP	O
diabetes	B-Disease	NOUN	B


Absolute	O	ADJ	B
and	O	CCONJ	O
attributable	O	ADJ	O
risk	O	NOUN	B
of	O	ADP	O
venous	B-Disease	ADJ	B
thromboembolism	I-Disease	NOUN	I
in	O	ADP	O
women	O	NOUN	B
on	O	ADP	O
combined	O	ADJ	O
cyproterone	B-Chemical	NOUN	B
acetate	I-Chemical	NOUN	B
and	O	CCONJ	O
ethinylestradiol	B-Chemical	NOUN	B
.	O	PUNCT	O


OBJECTIVE	O	NOUN	B
:	O	PUNCT	O
To	O	PART	O
achieve	O	VERB	O
absolute	O	ADJ	B
risk	O	NOUN	O
estimates	O	NOUN	O
of	O	ADP	O
venous	B-Disease	ADJ	B
thromboembolism	I-Disease	NOUN	I
(	O	PUNCT	O
VTE	B-Disease	NOUN	B
)	O	PUNCT	O
among	O	ADP	O
women	O	NOUN	B
on	O	ADP	O
cyproterone	B-Chemical	NOUN	B
acetate	I-Chemical	NOUN	B
plus	O	CCONJ	I
ethinylestradiol	B-Chemical	NOUN	B
(	O	PUNCT	O
CPA	B-Chemical	NOUN	B
/	O	PUNCT	O
EE	B-Chemical	PROPN	B
),	O	PUNCT	O
and	O	CCONJ	O
among	O	ADP	O
women	O	NOUN	B
on	O	ADP	O
combined	B-Chemical	ADJ	O
oral	I-Chemical	ADJ	O
contraceptives	I-Chemical	NOUN	O
(	O	PUNCT	O
COCs	B-Chemical	NOUN	B
).	O	PUNCT	O
METHODS	O	NOUN	O
:	O	PUNCT	O
From	O	ADP	O
the	O	DET	O
Danish	O	PROPN	B
National	O	PROPN	I
Register	O	PROPN	I
of	O	ADP	I
Patients	O	NOUN	B
(	O	PUNCT	O
NRP	O	PROPN	B
),	O	PUNCT	O
1996	O	NUM	O
to	O	PART	O
1998	O	NUM	O
,	O	PUNCT	O
the	O	DET	O
records	O	NOUN	B
of	O	ADP	O
1	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
million	O	NUM	O
Danish	O	ADJ	B
women	O	NOUN	B
,	O	PUNCT	O
ages	O	VERB	B
15	O	NUM	O
to	O	PART	O
44	O	NUM	O
years	O	NOUN	B
,	O	PUNCT	O
were	O	AUX	O
searched	O	VERB	O
for	O	ADP	O
evidence	O	NOUN	B
of	O	ADP	O
VTE	B-Disease	NOUN	B
.	O	PUNCT	O


COC	B-Chemical	NOUN	B
use	O	NOUN	O
was	O	AUX	O
ascertained	O	VERB	O
through	O	ADP	O
mailed	O	VERB	B
questionnaires	O	NOUN	B
.	O	PUNCT	O


Sales	O	NOUN	B
statistics	O	NOUN	B
of	O	ADP	O
COCs	B-Chemical	NOUN	B
and	O	CCONJ	O
CPA	B-Chemical	PROPN	B
/	O	SYM	O
EE	B-Chemical	PROPN	B
were	O	AUX	O
provided	O	VERB	O
through	O	ADP	O
Danish	O	PROPN	B
Drug	O	PROPN	I
Statistics	O	PROPN	I
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
During	O	ADP	O
the	O	DET	O
time	O	NOUN	B
frame	O	NOUN	I
of	O	ADP	O
the	O	DET	O
study	O	NOUN	B
,	O	PUNCT	O
330	O	NUM	O
women	O	NOUN	B
were	O	AUX	O
found	O	VERB	O
to	O	PART	O
have	O	AUX	O
had	O	AUX	O
VTE	B-Disease	PROPN	B
while	O	SCONJ	O
on	O	ADP	O
COCs	B-Chemical	NOUN	B
.	O	PUNCT	O


Of	O	ADP	O
these	O	DET	O
women	O	NOUN	B
,	O	PUNCT	O
67	O	NUM	O
were	O	AUX	O
on	O	ADP	O
levonorgestrel	B-Chemical	NOUN	B
-	O	PUNCT	O
containing	O	VERB	B
COCs	B-Chemical	NOUN	B
.	O	PUNCT	O


Eleven	O	NUM	O
were	O	AUX	O
on	O	ADP	O
CPA	B-Chemical	PROPN	B
/	O	PUNCT	O
EE	B-Chemical	PROPN	B
.	O	PUNCT	O


The	O	DET	O
corresponding	O	ADJ	O
absolute	O	ADJ	B
risk	O	NOUN	B
of	O	ADP	O
VTE	B-Disease	NOUN	B
was	O	AUX	O
3	O	NUM	O
.	O	PUNCT	O


4	O	NUM	O
(	O	PUNCT	O
range	O	NOUN	B
,	O	PUNCT	O
3	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
-	O	SYM	O
3	O	NUM	O
.	O	PUNCT	O


8	O	NUM	O
)	O	PUNCT	O
per	O	ADP	O
10	O	NUM	O
000	O	NUM	O
women	O	NOUN	B
years	O	NOUN	B
among	O	ADP	O
the	O	DET	O
women	O	NOUN	B
on	O	ADP	O
COCs	B-Chemical	NOUN	B
,	O	PUNCT	O
4	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
(	O	PUNCT	O
range	O	NOUN	B
,	O	PUNCT	O
3	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
-	O	SYM	O
5	O	NUM	O
.	O	PUNCT	O


2	O	X	O
)	O	PUNCT	O
per	O	ADP	O
10	O	NUM	O
000	O	NUM	O
women	O	NOUN	B
years	O	NOUN	B
among	O	ADP	O
women	O	NOUN	B
on	O	ADP	O
levonorgestrel	B-Chemical	NOUN	B
-	O	PUNCT	O
containing	O	VERB	B
COCs	B-Chemical	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
3	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
(	O	PUNCT	O
range	O	NOUN	B
,	O	PUNCT	O
1	O	NUM	O
.	O	PUNCT	O


3	O	NUM	O
-	O	SYM	O
4	O	NUM	O
.	O	PUNCT	O


9	O	NUM	O
)	O	PUNCT	O
per	O	ADP	O
10	O	NUM	O
000	O	NUM	O
women	O	NOUN	B
years	O	NOUN	B
among	O	ADP	O
the	O	DET	O
women	O	NOUN	B
on	O	ADP	O
CPA	B-Chemical	PROPN	B
/	O	PUNCT	O
EE	B-Chemical	PROPN	B
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
:	O	PUNCT	O
Our	O	PRON	O
results	O	NOUN	B
suggest	O	VERB	O
the	O	DET	O
absolute	O	ADJ	B
risk	O	NOUN	I
of	O	ADP	O
VTE	B-Disease	NOUN	B
among	O	ADP	O
Danish	O	ADJ	B
women	O	NOUN	I
on	O	ADP	O
COCs	B-Chemical	NOUN	B
is	O	AUX	O
similar	O	ADJ	O
to	O	PART	O
that	O	DET	O
among	O	ADP	O
women	O	NOUN	B
taking	O	VERB	O
CPA	B-Chemical	PROPN	B
/	O	PUNCT	O
EE	B-Chemical	PROPN	B


Effect	O	NOUN	B
of	O	ADP	O
lindane	B-Chemical	NOUN	B
on	O	ADP	O
hepatic	O	ADJ	B
and	O	CCONJ	O
brain	O	NOUN	B
cytochrome	O	NOUN	I
P450s	O	NOUN	B
and	O	CCONJ	O
influence	O	NOUN	B
of	O	ADP	O
P450	O	NOUN	B
modulation	O	NOUN	B
in	O	ADP	O
lindane	B-Chemical	NOUN	B
induced	O	ADJ	B
neurotoxicity	B-Disease	NOUN	B
.	O	PUNCT	O


Oral	O	ADJ	B
administration	O	NOUN	I
of	O	ADP	O
lindane	B-Chemical	NOUN	B
(	O	PUNCT	O
2	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
,	O	PUNCT	O
5	O	NUM	O
,	O	PUNCT	O
10	O	NUM	O
and	O	CCONJ	O
15	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
,	O	PUNCT	O
body	O	NOUN	B
weight	O	NOUN	I
)	O	PUNCT	O
for	O	ADP	O
5	O	NUM	O
days	O	NOUN	B
was	O	AUX	O
found	O	VERB	O
to	O	PART	O
produce	O	VERB	O
a	O	DET	O
dose	O	NOUN	B
-	O	PUNCT	O
dependent	O	ADJ	B
increase	O	NOUN	B
in	O	ADP	O
the	O	DET	O
activity	O	NOUN	B
of	O	ADP	O
P450	O	NOUN	B
dependent	O	ADJ	O
7	O	NUM	O
-	O	PUNCT	O
ethoxyresorufin	O	NOUN	B
-	O	PUNCT	O
O	O	NOUN	B
-	O	PUNCT	O
deethylase	O	NOUN	B
(	O	PUNCT	O
EROD	O	NOUN	B
),	O	PUNCT	O
7	O	NUM	O
-	O	PUNCT	O
pentoxyresorufin	O	NOUN	B
-	O	PUNCT	O
O	O	NOUN	B
-	O	PUNCT	O
dealkylase	O	NOUN	B
(	O	PUNCT	O
PROD	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
N-nitrosodimethylamine	B-Chemical	NOUN	B
demethylase	O	NOUN	I
(	O	PUNCT	O
NDMA	B-Chemical	NOUN	B
-	O	PUNCT	O
d	O	NOUN	O
)	O	PUNCT	O
in	O	ADP	O
rat	O	NOUN	B
brain	O	NOUN	B
and	O	CCONJ	O
liver	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
significant	O	ADJ	O
increase	O	NOUN	B
in	O	ADP	O
the	O	DET	O
hepatic	O	ADJ	B
and	O	CCONJ	O
brain	O	NOUN	B
P450	O	NOUN	B
monooxygenases	O	NOUN	I
was	O	AUX	O
also	O	ADV	O
observed	O	VERB	O
when	O	SCONJ	O
the	O	DET	O
duration	O	NOUN	B
of	O	ADP	O
exposure	O	NOUN	B
of	O	ADP	I
low	O	ADJ	B
dose	O	NOUN	I
(	O	PUNCT	O
2	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
)	O	PUNCT	O
of	O	ADP	O
lindane	B-Chemical	NOUN	B
was	O	AUX	O
increased	O	VERB	B
from	O	ADP	O
5	O	NUM	O
days	O	NOUN	B
to	O	PART	O
15	O	NUM	O
or	O	CCONJ	O
21	O	NUM	O
days	O	NOUN	B
.	O	PUNCT	O


As	O	ADP	O
observed	O	VERB	O
with	O	ADP	O
different	O	ADJ	O
doses	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
magnitude	O	NOUN	B
of	O	ADP	O
induction	O	NOUN	B
in	O	ADP	O
the	O	DET	O
activity	O	NOUN	B
of	O	ADP	O
P450	O	NOUN	B
monooxygenases	O	NOUN	I
was	O	AUX	O
several	O	ADJ	O
fold	O	ADV	O
higher	O	ADJ	B
in	O	ADP	O
liver	O	NOUN	B
microsomes	O	NOUN	I
when	O	SCONJ	O
compared	O	VERB	B
with	O	ADP	O
the	O	DET	O
brain	O	NOUN	B
.	O	PUNCT	O


Western	O	NOUN	B
blotting	O	NOUN	I
studies	O	NOUN	I
have	O	AUX	O
indicated	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
increase	O	NOUN	B
in	O	ADP	O
the	O	DET	O
P450	O	NOUN	B
enzymes	O	NOUN	I
could	O	AUX	O
be	O	AUX	O
due	O	ADJ	O
to	O	PART	O
the	O	DET	O
increase	O	NOUN	B
in	O	ADP	O
the	O	DET	O
expression	O	NOUN	B
of	O	ADP	O
P450	O	NOUN	B
1A1	O	NOUN	I
/	O	SYM	O
1A2	O	NOUN	B
,	O	PUNCT	O
2B1	O	NOUN	B
/	O	SYM	O
2B2	O	NUM	B
and	O	CCONJ	O
2E1	O	NOUN	B
isoenzymes	O	NOUN	B
.	O	PUNCT	O


In	O	X	B
vitro	O	X	I
studies	O	NOUN	B
using	O	VERB	O
organic	O	ADJ	B
inhibitors	O	NOUN	I
specific	O	ADJ	O
for	O	ADP	O
individual	O	ADJ	B
P450	O	NOUN	B
isoenzymes	O	NOUN	B
and	O	CCONJ	O
antibody	O	NOUN	B
inhibition	O	NOUN	I
experiments	O	NOUN	I
have	O	AUX	O
further	O	ADV	O
demonstrated	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
increase	O	NOUN	B
in	O	ADP	O
the	O	DET	O
activity	O	NOUN	B
of	O	ADP	O
PROD	O	NOUN	B
,	O	PUNCT	O
EROD	O	NOUN	B
and	O	CCONJ	O
NDMA	B-Chemical	NOUN	B
-	O	PUNCT	O
d	O	NOUN	B
are	O	AUX	O
due	O	ADJ	O
to	O	PART	O
the	O	DET	O
increase	O	NOUN	B
in	O	ADP	O
the	O	DET	O
levels	O	NOUN	B
of	O	ADP	O
P450	O	NOUN	B
2B1	O	NOUN	I
/	O	SYM	O
2B2	O	PROPN	B
,	O	PUNCT	O
1A1	O	NUM	B
/	O	SYM	O
1A2	O	NOUN	B
and	O	CCONJ	O
2E1	O	NOUN	B
isoenzymes	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


Induction	O	NOUN	B
studies	O	NOUN	I
have	O	AUX	O
further	O	ADV	O
shown	O	VERB	O
that	O	SCONJ	O
while	O	SCONJ	O
pretreatment	O	NOUN	B
of	O	ADP	O
3-methylcholanthrene	B-Chemical	NOUN	B
(	O	PUNCT	O
MC	B-Chemical	NOUN	B
),	O	PUNCT	O
an	O	DET	O
inducer	O	NOUN	B
of	O	ADP	O
P4501A1	O	NOUN	B
/	O	PUNCT	O
1A2	O	NOUN	B
,	O	PUNCT	O
did	O	AUX	O
not	O	PART	O
produce	O	VERB	O
any	O	DET	O
significant	O	ADJ	O
effect	O	NOUN	B
in	O	ADP	O
the	O	DET	O
incidence	O	NOUN	B
of	O	ADP	O
lindane	B-Chemical	NOUN	B
induced	O	VERB	B
convulsions	B-Disease	NOUN	B
,	O	PUNCT	O
pretreatment	O	NOUN	B
with	O	ADP	O
phenobarbital	B-Chemical	NOUN	B
(	O	PUNCT	O
PB	O	NOUN	B
),	O	PUNCT	O
an	O	DET	O
inducer	O	NOUN	B
of	O	ADP	O
P450	O	NOUN	B
2B1	O	NOUN	I
/	O	PUNCT	O
2B2	O	NUM	B
or	O	CCONJ	O
ethanol	B-Chemical	NOUN	B
,	O	PUNCT	O
an	O	DET	O
inducer	O	NOUN	B
of	O	ADP	O
P450	O	NOUN	B
2E1	O	NOUN	I
catalysed	O	VERB	B
reactions	O	NOUN	I
,	O	PUNCT	O
significantly	O	ADV	O
increased	O	VERB	B
the	O	DET	O
incidence	O	NOUN	B
of	O	ADP	O
lindane	B-Chemical	NOUN	B
induced	O	VERB	B
convulsions	B-Disease	NOUN	B
.	O	PUNCT	O


Similarly	O	ADV	O
,	O	PUNCT	O
when	O	SCONJ	O
the	O	DET	O
P450	O	NOUN	B
-	O	PUNCT	O
mediated	O	VERB	B
metabolism	O	NOUN	B
of	O	ADP	O
lindane	B-Chemical	NOUN	B
was	O	AUX	O
blocked	O	VERB	B
by	O	ADP	O
cobalt	B-Chemical	NOUN	B
chloride	I-Chemical	NOUN	I
incidence	O	NOUN	B
of	O	ADP	O
convulsions	B-Disease	NOUN	B
was	O	AUX	O
increased	O	VERB	B
in	O	ADP	O
animals	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
lindane	B-Chemical	NOUN	B
indicating	O	VERB	O
that	O	SCONJ	O
lindane	B-Chemical	NOUN	B
per	O	X	O
se	O	X	O
or	O	CCONJ	O
its	O	PRON	O
metabolites	O	NOUN	B
formed	O	VERB	O
by	O	ADP	O
PB	O	NOUN	B
or	O	CCONJ	O
ethanol	B-Chemical	NOUN	B
inducible	O	ADJ	B
P450	O	NOUN	B
isoenzymes	O	NOUN	I
are	O	AUX	O
involved	O	VERB	O
in	O	ADP	O
its	O	PRON	O
neurobehavioral	O	ADJ	B
toxicity	B-Disease	NOUN	B


Seizure	B-Disease	NOUN	B
associated	O	VERB	B
with	O	ADP	I
sleep	B-Disease	NOUN	B
deprivation	I-Disease	NOUN	I
and	O	CCONJ	O
sustained	O	ADJ	B
-	O	PUNCT	O
release	O	NOUN	B
bupropion	B-Chemical	NOUN	B
.	O	PUNCT	O


This	O	DET	O
case	O	NOUN	B
report	O	NOUN	I
describes	O	VERB	O
a	O	DET	O
generalized	O	VERB	B
seizure	B-Disease	NOUN	I
associated	O	VERB	B
with	O	ADP	I
sustained	O	ADJ	B
-	O	PUNCT	O
release	O	NOUN	B
bupropion	B-Chemical	NOUN	B
use	O	NOUN	O
and	O	CCONJ	O
sleep	B-Disease	NOUN	B
deprivation	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
subject	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
31	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
female	O	NOUN	B
smoker	O	NOUN	O
,	O	PUNCT	O
was	O	AUX	O
participating	O	VERB	O
in	O	ADP	O
a	O	DET	O
clinical	O	ADJ	B
trial	O	NOUN	I
evaluating	O	VERB	B
an	O	DET	O
investigational	O	ADJ	B
medication	O	NOUN	B
for	O	ADP	O
smoking	O	NOUN	B
cessation	O	NOUN	I
that	O	PRON	O
used	O	VERB	O
sustained	O	ADJ	B
-	O	PUNCT	O
release	O	NOUN	B
bupropion	B-Chemical	NOUN	B
as	O	ADP	O
an	O	DET	O
active	O	ADJ	B
control	O	NOUN	I
.	O	PUNCT	O


After	O	ADP	O
5	O	NUM	O
weeks	O	NOUN	B
of	O	ADP	O
bupropion	B-Chemical	NOUN	B
use	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
subject	O	NOUN	B
experienced	O	VERB	O
a	O	DET	O
generalized	O	VERB	O
tonic	O	ADJ	O
clonic	O	ADJ	O
seizure	B-Disease	NOUN	O
after	O	ADP	O
staying	O	VERB	O
up	O	ADP	O
nearly	O	ADV	O
all	O	DET	O
night	O	NOUN	B
packing	O	VERB	I
and	O	CCONJ	O
moving	O	VERB	B
to	O	ADP	O
a	O	DET	O
new	O	ADJ	O
residence	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
patient	O	NOUN	B
had	O	AUX	O
no	O	DET	O
other	O	ADJ	O
risk	O	NOUN	B
factors	O	NOUN	I
for	O	ADP	O
seizures	B-Disease	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
suggest	O	VERB	O
that	O	SCONJ	O
sleep	B-Disease	NOUN	B
deprivation	I-Disease	NOUN	I
may	O	AUX	O
add	O	VERB	O
to	O	ADP	O
the	O	DET	O
risk	O	NOUN	B
of	O	ADP	O
bupropion	B-Chemical	NOUN	B
-	O	PUNCT	O
associated	O	VERB	B
seizures	B-Disease	NOUN	B


Nephrotoxic	B-Disease	NOUN	B
effects	O	NOUN	B
in	O	ADP	O
high	O	ADJ	B
-	O	PUNCT	O
risk	O	NOUN	B
patients	O	NOUN	B
undergoing	O	VERB	O
angiography	O	NOUN	B
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
:	O	PUNCT	O
The	O	DET	O
use	O	NOUN	O
of	O	ADP	O
iodinated	O	ADJ	B
contrast	O	NOUN	O
medium	O	NOUN	O
can	O	AUX	O
result	O	VERB	O
in	O	ADP	O
nephropathy	B-Disease	NOUN	B
.	O	PUNCT	O


Whether	O	SCONJ	O
iso	O	NOUN	B
-	O	PUNCT	O
osmolar	O	ADJ	B
contrast	O	NOUN	O
medium	O	NOUN	O
is	O	AUX	O
less	O	ADV	O
nephrotoxic	B-Disease	ADJ	B
than	O	ADP	O
low	O	ADJ	B
-	O	PUNCT	O
osmolar	O	ADJ	B
contrast	O	NOUN	O
medium	O	NOUN	O
in	O	ADP	O
high	O	ADJ	B
-	O	PUNCT	O
risk	O	NOUN	B
patients	O	NOUN	B
is	O	AUX	O
uncertain	O	ADJ	O
.	O	PUNCT	O


METHODS	O	NOUN	O
:	O	PUNCT	O
We	O	PRON	O
conducted	O	VERB	O
a	O	DET	O
randomized	O	ADJ	B
,	O	PUNCT	O
double	O	ADJ	B
-	O	PUNCT	O
blind	O	NOUN	B
,	O	PUNCT	O
prospective	O	ADJ	B
,	O	PUNCT	O
multicenter	O	NOUN	B
study	O	NOUN	I
comparing	O	VERB	O
the	O	DET	O
nephrotoxic	B-Disease	ADJ	B
effects	O	NOUN	B
of	O	ADP	O
an	O	DET	O
iso	O	NOUN	B
-	O	PUNCT	O
osmolar	O	ADJ	B
,	O	PUNCT	O
dimeric	O	ADJ	B
,	O	PUNCT	O
nonionic	O	ADJ	B
contrast	O	NOUN	I
medium	O	NOUN	I
,	O	PUNCT	O
iodixanol	B-Chemical	INTJ	B
,	O	PUNCT	O
with	O	ADP	O
those	O	DET	O
of	O	ADP	O
a	O	DET	O
low	O	ADJ	B
-	O	PUNCT	O
osmolar	O	ADJ	B
,	O	PUNCT	O
nonionic	O	ADJ	B
,	O	PUNCT	O
monomeric	O	ADJ	B
contrast	O	NOUN	I
medium	O	NOUN	I
,	O	PUNCT	O
iohexol	B-Chemical	NOUN	B
.	O	PUNCT	O


The	O	DET	O
study	O	NOUN	B
involved	O	VERB	O
129	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
diabetes	B-Disease	NOUN	B
with	O	ADP	O
serum	O	NOUN	B
creatinine	B-Chemical	NOUN	I
concentrations	O	NOUN	I
of	O	ADP	O
1	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
to	O	PART	O
3	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
mg	O	NOUN	O
per	O	ADP	O
deciliter	O	NOUN	O
who	O	PRON	O
underwent	O	VERB	O
coronary	O	ADJ	B
or	O	CCONJ	O
aortofemoral	O	ADJ	B
angiography	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
primary	O	ADJ	O
end	O	NOUN	O
point	O	NOUN	O
was	O	AUX	O
the	O	DET	O
peak	O	ADJ	O
increase	O	NOUN	B
from	O	ADP	O
base	O	NOUN	B
line	O	NOUN	I
in	O	ADP	O
the	O	DET	O
creatinine	B-Chemical	NOUN	B
concentration	O	NOUN	B
during	O	ADP	O
the	O	DET	O
three	O	NUM	O
days	O	NOUN	B
after	O	ADP	O
angiography	O	NOUN	B
.	O	PUNCT	O


Other	O	ADJ	O
end	O	NOUN	O
points	O	NOUN	O
were	O	AUX	O
an	O	DET	O
increase	O	NOUN	B
in	O	ADP	O
the	O	DET	O
creatinine	B-Chemical	NOUN	B
concentration	O	NOUN	B
of	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
mg	O	NOUN	O
per	O	ADP	O
deciliter	O	NOUN	O
or	O	CCONJ	O
more	O	ADJ	O
,	O	PUNCT	O
an	O	DET	O
increase	O	NOUN	B
of	O	ADP	O
1	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
mg	O	NOUN	O
per	O	ADP	O
deciliter	O	NOUN	O
or	O	CCONJ	O
more	O	ADJ	O
,	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
change	O	NOUN	B
in	O	ADP	O
the	O	DET	O
creatinine	B-Chemical	NOUN	B
concentration	O	NOUN	B
from	O	ADP	O
day	O	NOUN	B
0	O	NUM	O
to	O	ADP	O
day	O	NOUN	B
7	O	NUM	O
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
The	O	DET	O
creatinine	B-Chemical	NOUN	B
concentration	O	NOUN	B
increased	O	VERB	B
significantly	O	ADV	O
less	O	ADJ	O
in	O	ADP	O
patients	O	NOUN	B
who	O	PRON	O
received	O	VERB	O
iodixanol	B-Chemical	NOUN	B
.	O	PUNCT	O


From	O	ADP	O
day	O	NOUN	B
0	O	NUM	O
to	O	PART	O
day	O	NOUN	B
3	O	NUM	O
,	O	PUNCT	O
the	O	DET	O
mean	O	ADJ	O
peak	O	ADJ	O
increase	O	NOUN	B
in	O	ADP	O
creatinine	B-Chemical	NOUN	B
was	O	AUX	O
0	O	NUM	O
.	O	PUNCT	O


13	O	NUM	O
mg	O	NOUN	O
per	O	ADP	O
deciliter	O	NOUN	O
in	O	ADP	O
the	O	DET	O
iodixanol	B-Chemical	NOUN	B
group	O	NOUN	B
and	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


55	O	NUM	O
mg	O	NOUN	O
per	O	ADP	O
deciliter	O	NOUN	O
in	O	ADP	O
the	O	DET	O
iohexol	B-Chemical	ADJ	B
group	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


001	O	NUM	O
;	O	PUNCT	O
the	O	DET	O
increase	O	NOUN	B
with	O	ADP	O
iodixanol	B-Chemical	NOUN	B
minus	O	CCONJ	B
the	O	DET	O
increase	O	NOUN	B
with	O	ADP	O
iohexol	B-Chemical	NOUN	B
,-	O	VERB	O
0	O	NUM	O
.	O	PUNCT	O


42	O	NUM	O
mg	O	NOUN	O
per	O	ADP	B
deciliter	O	NOUN	I
[	O	PUNCT	O
95	O	NUM	O
percent	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
,-	O	NOUN	O
0	O	NUM	O
.	O	PUNCT	O


73	O	NUM	O
to	O	PART	O
-	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


22	O	NUM	O
]).	O	PUNCT	O
Two	O	NUM	O
of	O	ADP	O
the	O	DET	O
64	O	NUM	O
patients	O	NOUN	B
in	O	ADP	O
the	O	DET	O
iodixanol	B-Chemical	NOUN	B
group	O	NOUN	B
(	O	PUNCT	O
3	O	NUM	O
percent	O	NOUN	O
)	O	PUNCT	O
had	O	AUX	O
an	O	DET	O
increase	O	NOUN	B
in	O	ADP	O
the	O	DET	O
creatinine	B-Chemical	NOUN	B
concentration	O	NOUN	B
of	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
mg	O	NOUN	O
per	O	ADP	O
deciliter	O	NOUN	O
or	O	CCONJ	O
more	O	ADJ	O
,	O	PUNCT	O
as	O	ADP	O
compared	O	VERB	B
with	O	ADP	O
17	O	NUM	O
of	O	ADP	O
the	O	DET	O
65	O	NUM	O
patients	O	NOUN	B
in	O	ADP	O
the	O	DET	O
iohexol	B-Chemical	ADJ	B
group	O	NOUN	B
(	O	PUNCT	O
26	O	NUM	O
percent	O	NOUN	O
)(	O	NOUN	O
P	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


002	O	NUM	O
;	O	PUNCT	O
odds	O	NOUN	B
ratio	O	NOUN	I
for	O	ADP	O
such	O	DET	O
an	O	DET	O
increase	O	NOUN	B
in	O	ADP	O
the	O	DET	O
iodixanol	B-Chemical	NOUN	B
group	O	NOUN	B
,	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


09	O	NUM	O
[	O	PUNCT	O
95	O	NUM	O
percent	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
,	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


02	O	NUM	O
to	O	PART	O
0	O	NUM	O
.	O	PUNCT	O


41	O	NUM	O
]).	O	PUNCT	O
No	O	DET	O
patient	O	NOUN	B
receiving	O	VERB	O
iodixanol	B-Chemical	NOUN	B
had	O	AUX	O
an	O	DET	O
increase	O	NOUN	B
of	O	ADP	O
1	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
mg	O	NOUN	O
per	O	ADP	O
deciliter	O	NOUN	O
or	O	CCONJ	O
more	O	ADJ	O
,	O	PUNCT	O
but	O	CCONJ	O
10	O	NUM	O
patients	O	NOUN	B
in	O	ADP	O
the	O	DET	O
iohexol	B-Chemical	ADJ	B
group	O	NOUN	B
(	O	PUNCT	O
15	O	NUM	O
percent	O	NOUN	O
)	O	PUNCT	O
did	O	AUX	O
.	O	PUNCT	O


The	O	DET	O
mean	O	ADJ	O
change	O	NOUN	O
in	O	ADP	O
the	O	DET	O
creatinine	B-Chemical	NOUN	B
concentration	O	NOUN	B
from	O	ADP	O
day	O	NOUN	B
0	O	NUM	O
to	O	PART	O
day	O	NOUN	B
7	O	NUM	O
was	O	AUX	O
0	O	NUM	O
.	O	PUNCT	O


07	O	NUM	O
mg	O	NOUN	O
per	O	ADP	O
deciliter	O	NOUN	O
in	O	ADP	O
the	O	DET	O
iodixanol	B-Chemical	NOUN	B
group	O	NOUN	B
and	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


24	O	NUM	O
mg	O	NOUN	O
per	O	ADP	O
deciliter	O	NOUN	O
in	O	ADP	O
the	O	DET	O
iohexol	B-Chemical	ADJ	B
group	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


003	O	NUM	O
;	O	PUNCT	O
value	O	NOUN	O
in	O	ADP	O
the	O	DET	O
iodixanol	B-Chemical	NOUN	B
group	O	NOUN	B
minus	O	CCONJ	B
the	O	DET	O
value	O	NOUN	O
in	O	ADP	O
the	O	DET	O
iohexol	B-Chemical	ADJ	B
group	O	NOUN	B
,-	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


17	O	NUM	O
mg	O	NOUN	O
per	O	ADP	B
deciliter	O	NOUN	I
[	O	PUNCT	O
95	O	NUM	O
percent	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
,-	O	NOUN	O
0	O	NUM	O
.	O	PUNCT	O


34	O	NUM	O
to	O	PART	O
-	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


07	O	NUM	O
]).	O	PUNCT	O
CONCLUSIONS	O	NOUN	B
:	O	PUNCT	O
Nephropathy	B-Disease	NOUN	B
induced	O	VERB	B
by	O	ADP	O
contrast	O	NOUN	B
medium	O	NOUN	I
may	O	AUX	O
be	O	AUX	O
less	O	ADV	O
likely	O	ADJ	O
to	O	PART	O
develop	O	VERB	O
in	O	ADP	O
high	O	ADJ	B
-	O	PUNCT	O
risk	O	NOUN	B
patients	O	NOUN	B
when	O	SCONJ	O
iodixanol	B-Chemical	NOUN	B


Experimental	O	ADJ	B
cranial	O	ADJ	O
pain	B-Disease	NOUN	O
elicited	O	VERB	O
by	O	ADP	O
capsaicin	B-Chemical	NOUN	B
:	O	PUNCT	O
a	O	DET	O
PET	O	NOUN	B
study	O	NOUN	B
.	O	PUNCT	O


Using	O	VERB	O
a	O	DET	O
positron	O	NOUN	B
emission	O	NOUN	I
tomography	O	NOUN	I
(	O	PUNCT	O
PET	O	NOUN	B
)	O	PUNCT	O
study	O	NOUN	B
it	O	PRON	O
was	O	AUX	O
shown	O	VERB	O
recently	O	ADV	O
that	O	SCONJ	O
in	O	ADP	O
migraine	B-Disease	NOUN	B
without	O	ADP	O
aura	O	NOUN	B
certain	O	ADJ	O
areas	O	NOUN	O
in	O	ADP	O
the	O	DET	O
brain	O	NOUN	B
stem	O	NOUN	I
were	O	AUX	O
activated	O	VERB	B
during	O	ADP	O
the	O	DET	O
headache	B-Disease	NOUN	B
state	O	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
not	O	PART	O
in	O	ADP	O
the	O	DET	O
headache	B-Disease	NOUN	B
free	O	ADJ	I
interval	O	NOUN	I
.	O	PUNCT	O


It	O	PRON	O
was	O	AUX	O
suggested	O	VERB	O
that	O	SCONJ	O
this	O	DET	O
brain	O	NOUN	B
stem	O	NOUN	I
activation	O	NOUN	O
is	O	AUX	O
inherent	O	ADJ	O
to	O	PART	O
the	O	DET	O
migraine	B-Disease	NOUN	B
attack	O	NOUN	B
itself	O	PRON	O
and	O	CCONJ	O
represents	O	VERB	B
the	O	DET	O
so	O	ADV	O
called	O	VERB	O
'	O	PART	O
migraine	B-Disease	NOUN	B
generator	O	NOUN	I
'.	O	ADJ	I
To	O	PART	O
test	O	VERB	O
this	O	DET	O
hypothesis	O	NOUN	B
we	O	PRON	O
performed	O	VERB	O
an	O	DET	O
experimental	O	ADJ	B
pain	B-Disease	NOUN	I
study	O	NOUN	O
in	O	ADP	O
seven	O	NUM	O
healthy	O	ADJ	B
volunteers	O	NOUN	I
,	O	PUNCT	O
using	O	VERB	O
the	O	DET	O
same	O	ADJ	O
positioning	O	NOUN	B
in	O	ADP	O
the	O	DET	O
PET	O	PROPN	B
scanner	O	NOUN	B
as	O	ADP	O
in	O	ADP	O
the	O	DET	O
migraine	B-Disease	NOUN	B
patients	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
small	O	ADJ	O
amount	O	NOUN	O
of	O	ADP	O
capsaicin	B-Chemical	NOUN	B
was	O	AUX	O
administered	O	VERB	B
subcutaneously	O	ADV	B
in	O	ADP	O
the	O	DET	O
right	O	ADJ	B
forehead	O	NOUN	I
to	O	PART	O
evoke	O	VERB	B
a	O	DET	O
burning	O	VERB	B
painful	B-Disease	ADJ	B
sensation	O	NOUN	B
in	O	ADP	O
the	O	DET	O
first	O	ADJ	O
division	O	NOUN	B
of	O	ADP	O
the	O	DET	O
trigeminal	O	ADJ	B
nerve	O	NOUN	I
.	O	PUNCT	O


Increases	O	NOUN	B
of	O	ADP	O
regional	O	ADJ	B
cerebral	O	ADJ	B
blood	O	NOUN	I
flow	O	NOUN	I
(	O	PUNCT	O
rCBF	O	NOUN	B
)	O	PUNCT	O
were	O	AUX	O
found	O	VERB	O
bilaterally	O	ADV	B
in	O	ADP	O
the	O	DET	O
insula	O	NOUN	B
,	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
anterior	O	ADJ	B
cingulate	O	NOUN	B
cortex	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
cavernous	O	ADJ	B
sinus	O	NOUN	I
and	O	CCONJ	O
the	O	DET	O
cerebellum	O	NOUN	B
.	O	PUNCT	O


Using	O	VERB	O
the	O	DET	O
same	O	ADJ	O
stereotactic	O	ADJ	B
space	O	NOUN	I
limits	O	VERB	O
as	O	ADP	O
in	O	ADP	O
the	O	DET	O
above	O	ADJ	O
mentioned	O	VERB	O
migraine	B-Disease	NOUN	B
study	O	VERB	B
no	O	DET	O
brain	O	NOUN	B
stem	O	NOUN	I
activation	O	NOUN	O
was	O	AUX	O
found	O	VERB	O
in	O	ADP	O
the	O	DET	O
acute	O	ADJ	B
pain	B-Disease	NOUN	I
state	O	NOUN	I
compared	O	VERB	B
to	O	ADP	O
the	O	DET	O
pain	B-Disease	NOUN	B
free	O	ADJ	I
state	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
increase	O	NOUN	B
of	O	ADP	O
activation	O	NOUN	B
in	O	ADP	O
the	O	DET	O
region	O	NOUN	B
of	O	ADP	O
the	O	DET	O
cavernous	O	ADJ	B
sinus	O	NOUN	I
however	O	ADV	O
,	O	PUNCT	O
suggests	O	VERB	O
that	O	SCONJ	O
this	O	DET	O
structure	O	NOUN	B
is	O	AUX	O
more	O	ADV	O
likely	O	ADJ	O
to	O	PART	O
be	O	AUX	O
involved	O	VERB	O
in	O	ADP	O
trigeminal	O	ADJ	B
transmitted	O	VERB	I
pain	B-Disease	NOUN	I
as	O	ADP	O
such	O	ADJ	O
,	O	PUNCT	O
rather	O	ADV	O
than	O	ADP	O
in	O	ADP	O
a	O	DET	O
specific	O	ADJ	O
type	O	NOUN	O
of	O	ADP	O
headache	B-Disease	NOUN	B
as	O	ADP	O
was	O	AUX	O
suggested	O	VERB	O
for	O	ADP	O
cluster	B-Disease	NOUN	B
headache	I-Disease	NOUN	I


Neuroleptic	B-Disease	ADJ	B
malignant	I-Disease	ADJ	I
syndrome	I-Disease	NOUN	I
with	O	ADP	O
risperidone	B-Chemical	NOUN	B
.	O	PUNCT	O


Neuroleptic	B-Disease	ADJ	B
malignant	I-Disease	ADJ	I
syndrome	I-Disease	NOUN	I
is	O	AUX	O
thought	O	VERB	O
to	O	PART	O
be	O	AUX	O
a	O	DET	O
result	O	NOUN	O
of	O	ADP	O
dopamine	B-Chemical	NOUN	B
D2	O	NOUN	I
receptor	O	NOUN	I
blockade	O	NOUN	B
in	O	ADP	O
the	O	DET	O
striatum	O	NOUN	B
of	O	ADP	O
the	O	DET	O
basal	O	ADJ	B
ganglia	O	NOUN	I
.	O	PUNCT	O


Risperidone	B-Chemical	NOUN	B
,	O	PUNCT	O
a	O	DET	O
benzisoxazole	B-Chemical	ADJ	B
derivative	O	ADJ	I
antipsychotic	O	NOUN	B
,	O	PUNCT	O
has	O	AUX	O
high	O	ADJ	O
serotonin	B-Chemical	NOUN	B
5	O	NUM	I
-	O	PUNCT	O
HT2	O	NOUN	B
receptor	O	NOUN	O
blockade	O	NOUN	B
and	O	CCONJ	O
dose	O	NOUN	B
-	O	PUNCT	O
related	O	ADJ	B
D2	O	NOUN	B
receptor	O	NOUN	I
blockade	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
high	O	ADJ	O
ratio	O	NOUN	B
is	O	AUX	O
believed	O	VERB	O
to	O	PART	O
impart	O	VERB	O
the	O	DET	O
low	O	ADJ	B
frequency	O	NOUN	B
of	O	ADP	O
extrapyramidal	B-Disease	ADJ	B
symptoms	I-Disease	NOUN	I
with	O	ADP	O
risperidone	B-Chemical	NOUN	B
at	O	ADP	O
low	O	ADJ	O
dosages	O	NOUN	B
.	O	PUNCT	O


With	O	ADP	O
this	O	DET	O
low	O	ADJ	B
frequency	O	NOUN	I
of	O	ADP	O
extrapyramidal	B-Disease	ADJ	B
symptoms	I-Disease	NOUN	I
,	O	PUNCT	O
it	O	PRON	O
was	O	AUX	O
thought	O	VERB	O
the	O	DET	O
frequency	O	NOUN	B
of	O	ADP	O
neuroleptic	B-Disease	ADJ	B
malignant	I-Disease	ADJ	I
syndrome	I-Disease	NOUN	I
might	O	AUX	O
also	O	ADV	O
be	O	AUX	O
lowered	O	VERB	B
.	O	PUNCT	O


A	O	DET	O
73	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
woman	O	NOUN	B
developed	O	VERB	O
neuroleptic	B-Disease	ADJ	B
malignant	I-Disease	ADJ	I
syndrome	I-Disease	NOUN	I
after	O	ADP	O
monotherapy	O	NOUN	B
with	O	ADP	O
risperidone	B-Chemical	NOUN	B
.	O	PUNCT	O


The	O	DET	O
syndrome	O	NOUN	B
reversed	O	VERB	B
after	O	ADP	O
discontinuing	O	VERB	B
risperidone	B-Chemical	NOUN	B
and	O	CCONJ	O
starting	O	VERB	O
treatment	O	NOUN	B
with	O	ADP	O
dantrolene	B-Chemical	NOUN	B
and	O	CCONJ	O
bromocriptine	B-Chemical	NOUN	B
.	O	PUNCT	O


It	O	PRON	O
appears	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
protection	O	NOUN	B
from	O	ADP	O
extrapyramidal	O	ADJ	B
side	O	NOUN	B
effects	O	NOUN	I
observed	O	VERB	O
with	O	ADP	O
risperidone	B-Chemical	NOUN	B
does	O	AUX	O
not	O	PART	O
ensure	O	VERB	O
protection	O	NOUN	B
from	O	ADP	O
neuroleptic	B-Disease	ADJ	B
malignant	I-Disease	ADJ	I
syndrome	I-Disease	NOUN	I


Hepatic	O	ADJ	B
and	O	CCONJ	O
extrahepatic	O	ADJ	B
angiotensinogen	O	NOUN	O
gene	O	NOUN	B
expression	O	NOUN	I
in	O	ADP	O
rats	O	NOUN	B
with	O	ADP	O
acute	O	ADJ	B
nephrotic	B-Disease	ADJ	I
syndrome	I-Disease	NOUN	I
.	O	PUNCT	O


Plasma	O	NOUN	B
concentration	O	NOUN	B
and	O	CCONJ	O
urine	O	NOUN	B
excretion	O	NOUN	B
of	O	ADP	O
the	O	DET	O
renin	O	NOUN	B
-	O	PUNCT	O
angiotensin	B-Chemical	NOUN	B
system	O	NOUN	I
proteins	O	NOUN	I
are	O	AUX	O
altered	O	VERB	O
in	O	ADP	O
rats	O	NOUN	B
with	O	ADP	O
nephrotic	B-Disease	ADJ	B
syndrome	I-Disease	NOUN	I
(	O	PUNCT	O
NS	B-Disease	NOUN	B
).	O	PUNCT	O
In	O	ADP	O
this	O	DET	O
work	O	NOUN	O
the	O	DET	O
messenger	O	NOUN	B
ribonucleic	O	ADJ	I
acid	O	NOUN	I
(	O	PUNCT	O
mRNA	O	NOUN	B
)	O	PUNCT	O
levels	O	NOUN	B
of	O	ADP	O
angiotensinogen	O	NOUN	B
(	O	PUNCT	O
Ao	O	NOUN	B
)	O	PUNCT	O
were	O	AUX	O
analyzed	O	VERB	B
with	O	ADP	O
the	O	DET	O
slot	O	NOUN	B
-	O	PUNCT	O
blot	O	NOUN	B
hybridization	O	NOUN	I
technique	O	NOUN	I
in	O	ADP	O
liver	O	NOUN	B
and	O	CCONJ	O
other	O	ADJ	O
extrahepatic	O	ADJ	B
tissues	O	NOUN	I
:	O	PUNCT	O
kidney	O	NOUN	B
,	O	PUNCT	O
heart	O	NOUN	B
,	O	PUNCT	O
brain	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
adrenal	O	ADJ	B
gland	O	NOUN	I
from	O	ADP	O
control	O	NOUN	B
,	O	PUNCT	O
nephrotic	B-Disease	ADJ	B
,	O	PUNCT	O
and	O	CCONJ	O
pair	O	NOUN	B
-	O	PUNCT	O
fed	O	VERB	B
(	O	PUNCT	O
PF	O	NOUN	B
)	O	PUNCT	O
rats	O	NOUN	B
.	O	PUNCT	O


NS	B-Disease	NOUN	B
was	O	AUX	O
induced	O	VERB	B
by	O	ADP	O
a	O	DET	O
single	O	ADJ	O
injection	O	NOUN	B
of	O	ADP	O
puromycin	B-Chemical	NOUN	B
amino-nucleoside	I-Chemical	NOUN	B
(	O	PUNCT	O
PAN	B-Chemical	NOUN	B
).	O	PUNCT	O
Although	O	SCONJ	O
a	O	DET	O
great	O	ADJ	O
urinary	O	ADJ	B
excretion	O	NOUN	B
and	O	CCONJ	O
half	O	NOUN	B
-	O	PUNCT	O
normal	O	ADJ	B
plasma	O	NOUN	B
levels	O	NOUN	B
of	O	ADP	O
Ao	O	PROPN	B
were	O	AUX	O
observed	O	VERB	O
on	O	ADP	O
day	O	NOUN	B
6	O	NUM	O
after	O	ADP	O
PAN	B-Chemical	NOUN	B
injection	O	NOUN	B
,	O	PUNCT	O
when	O	SCONJ	O
NS	B-Disease	NOUN	B
was	O	AUX	O
clearly	O	ADV	O
established	O	VERB	O
,	O	PUNCT	O
hepatic	O	ADJ	B
Ao	O	ADJ	B
mRNA	O	NOUN	B
levels	O	NOUN	O
did	O	AUX	O
not	O	PART	O
change	O	VERB	O
.	O	PUNCT	O


Furthermore	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
Ao	O	ADJ	B
mRNA	O	NOUN	B
levels	O	NOUN	O
did	O	AUX	O
not	O	PART	O
change	O	VERB	O
in	O	ADP	O
any	O	DET	O
of	O	ADP	O
the	O	DET	O
extrahepatic	O	ADJ	B
tissues	O	NOUN	I
studied	O	VERB	O
on	O	ADP	O
day	O	NOUN	B
6	O	NUM	O
,	O	PUNCT	O
nor	O	CCONJ	O
did	O	AUX	O
its	O	PRON	O
hepatic	O	ADJ	B
levels	O	NOUN	I
at	O	ADP	O
days	O	NOUN	B
1	O	NUM	O
,	O	PUNCT	O
3	O	NUM	O
,	O	PUNCT	O
5	O	NUM	O
,	O	PUNCT	O
or	O	CCONJ	O
7	O	NUM	O
after	O	ADP	O
PAN	B-Chemical	NOUN	B
injection	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
data	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
hepatic	O	ADJ	B
and	O	CCONJ	O
extrahepatic	O	ADJ	B
Ao	O	ADJ	B
mRNA	O	NOUN	B
levels	O	NOUN	O
are	O	AUX	O
unaltered	O	ADJ	B
during	O	ADP	O
the	O	DET	O
development	O	NOUN	B
of	O	ADP	O
the	O	DET	O
acute	O	ADJ	B
NS	B-Disease	NOUN	I
induced	O	VERB	B
by	O	ADP	O
PAN	B-Chemical	NOUN	B


Cyclophosphamide	B-Chemical	NOUN	B
associated	O	VERB	O
bladder	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
--	O	PUNCT	O
a	O	DET	O
highly	O	ADV	O
aggressive	O	ADJ	O
disease	O	NOUN	O
:	O	PUNCT	O
analysis	O	NOUN	B
of	O	ADP	O
12	O	NUM	O
cases	O	NOUN	B
.	O	PUNCT	O


PURPOSE	O	NOUN	B
:	O	PUNCT	O
We	O	PRON	O
gained	O	VERB	O
knowledge	O	NOUN	B
of	O	ADP	O
the	O	DET	O
etiology	O	NOUN	B
,	O	PUNCT	O
treatment	O	NOUN	B
and	O	CCONJ	O
prevention	O	NOUN	B
of	O	ADP	O
cyclophosphamide	B-Chemical	NOUN	B
associated	O	ADJ	O
urothelial	B-Disease	ADJ	O
cancer	I-Disease	NOUN	O
.	O	PUNCT	O


MATERIALS	O	NOUN	O
AND	O	CCONJ	O
METHODS	O	NOUN	O
:	O	PUNCT	O
The	O	DET	O
medical	O	ADJ	B
records	O	NOUN	I
of	O	ADP	O
6	O	NUM	O
men	O	NOUN	B
and	O	CCONJ	O
6	O	NUM	O
women	O	NOUN	B
(	O	PUNCT	O
mean	O	VERB	O
age	O	NOUN	B
55	O	NUM	O
years	O	NOUN	B
)	O	PUNCT	O
with	O	ADP	O
cyclophosphamide	B-Chemical	NOUN	B
associated	O	ADJ	O
bladder	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
were	O	AUX	O
reviewed	O	VERB	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
All	O	DET	O
tumors	B-Disease	NOUN	B
were	O	AUX	O
grade	O	NOUN	O
3	O	NUM	O
or	O	CCONJ	O
4	O	NUM	O
transitional	O	ADJ	B
cell	O	NOUN	I
carcinoma	B-Disease	NOUN	I
.	O	PUNCT	O


Of	O	ADP	O
the	O	DET	O
5	O	NUM	O
patients	O	NOUN	B
initially	O	ADV	O
treated	O	VERB	B
with	O	ADP	I
endoscopic	O	ADJ	B
resection	O	NOUN	I
alone	O	ADV	O
only	O	ADV	O
1	O	NUM	O
is	O	AUX	O
alive	O	ADJ	B
without	O	ADP	O
disease	O	NOUN	B
.	O	PUNCT	O


Of	O	ADP	O
the	O	DET	O
6	O	NUM	O
patients	O	NOUN	B
who	O	PRON	O
underwent	O	VERB	O
early	O	ADJ	O
cystectomy	O	NOUN	B
4	O	NUM	O
were	O	AUX	O
alive	O	ADJ	B
at	O	ADP	O
24	O	NUM	O
to	O	PART	O
111	O	NUM	O
months	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
remaining	O	VERB	O
patient	O	NOUN	B
with	O	ADP	O
extensive	O	ADJ	O
cancer	B-Disease	NOUN	B
underwent	O	VERB	O
partial	O	ADJ	B
cystectomy	O	NOUN	I
for	O	ADP	O
palliation	O	NOUN	B
and	O	CCONJ	O
died	O	VERB	B
3	O	NUM	O
months	O	NOUN	B
later	O	ADV	O
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	B
:	O	PUNCT	O
Cyclophosphamide	B-Chemical	NOUN	B
associated	O	VERB	O
bladder	B-Disease	NOUN	B
tumor	I-Disease	NOUN	I
is	O	AUX	O
an	O	DET	O
aggressive	O	ADJ	B
disease	O	NOUN	I
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
long	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
survival	O	NOUN	B
is	O	AUX	O
possible	O	ADJ	O
when	O	SCONJ	O
radical	O	ADJ	B
cystectomy	O	NOUN	I
is	O	AUX	O
performed	O	VERB	O
for	O	ADP	O
bladder	B-Disease	NOUN	B
tumors	I-Disease	NOUN	I


Leg	B-Disease	NOUN	B
and	I-Disease	CCONJ	O
back	I-Disease	ADJ	B
pain	I-Disease	NOUN	I
after	O	ADP	O
spinal	O	ADJ	B
anaesthesia	O	NOUN	I
involving	O	VERB	O
hyperbaric	O	NOUN	B
5	O	NUM	O
%	O	NOUN	O
lignocaine	B-Chemical	NOUN	B
.	O	PUNCT	O


Fifty	O	PROPN	B
-	O	PUNCT	O
four	O	NUM	B
patients	O	NOUN	B
,	O	PUNCT	O
aged	O	ADJ	B
27	O	NUM	O
-	O	SYM	O
90	O	NUM	O
years	O	NOUN	B
,	O	PUNCT	O
who	O	PRON	O
were	O	AUX	O
given	O	VERB	O
lignocaine	B-Chemical	NOUN	B
5	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
6	O	NUM	O
.	O	PUNCT	O


8	O	NUM	O
%	O	NOUN	O
glucose	B-Chemical	NOUN	B
solution	O	NOUN	I
for	O	ADP	O
spinal	O	ADJ	B
anaesthesia	O	NOUN	I
were	O	AUX	O
studied	O	VERB	O
.	O	PUNCT	O


Thirteen	O	NUM	O
of	O	ADP	O
these	O	DET	O
patients	O	NOUN	B
experienced	O	VERB	O
pain	B-Disease	NOUN	B
in	I-Disease	ADP	O
the	I-Disease	DET	O
legs	I-Disease	NOUN	B
and/or	I-Disease	CCONJ	O
back	I-Disease	ADV	O
after	O	ADP	O
recovery	O	NOUN	B
from	O	ADP	O
anaesthesia	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
patients	O	NOUN	B
affected	O	VERB	B
were	O	AUX	O
younger	O	ADJ	B
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


05	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
site	O	NOUN	B
of	O	ADP	O
the	O	DET	O
dural	O	ADJ	B
puncture	O	NOUN	I
was	O	AUX	O
higher	O	ADJ	O
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


01	O	NUM	O
)	O	PUNCT	O
than	O	ADP	O
those	O	DET	O
individuals	O	NOUN	B
without	O	ADP	O
pain	B-Disease	NOUN	B
.	O	PUNCT	O


Five	O	NUM	O
of	O	ADP	O
the	O	DET	O
13	O	NUM	O
patients	O	NOUN	B
(	O	PUNCT	O
38	O	NUM	O
%)	O	NOUN	O
with	O	ADP	O
pain	B-Disease	NOUN	B
and	O	CCONJ	O
seven	O	NUM	O
of	O	ADP	O
the	O	DET	O
41	O	NUM	O
patients	O	NOUN	B
(	O	PUNCT	O
17	O	NUM	O
%)	O	NOUN	O
without	O	ADP	O
pain	B-Disease	NOUN	B
admitted	O	VERB	B
to	O	ADP	O
a	O	DET	O
high	O	ADJ	O
alcohol	B-Chemical	NOUN	B
intake	O	NOUN	I
,	O	PUNCT	O
which	O	DET	O
might	O	AUX	O
be	O	AUX	O
a	O	DET	O
contributing	O	VERB	O
factor	O	NOUN	B
.	O	PUNCT	O


Leg	B-Disease	NOUN	B
and/or	I-Disease	CCONJ	O
back	I-Disease	ADJ	B
pain	I-Disease	NOUN	I
is	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
the	O	DET	O
intrathecal	O	ADJ	B
use	O	NOUN	O
of	O	ADP	O
hyperbaric	O	NOUN	B
5	O	NUM	O
%	O	NOUN	O
lignocaine	B-Chemical	NOUN	B


Acute	O	ADJ	B
blood	O	NOUN	I
pressure	O	NOUN	I
elevations	O	NOUN	B
with	O	ADP	O
caffeine	B-Chemical	NOUN	B
in	O	ADP	O
men	O	NOUN	B
with	O	ADP	O
borderline	O	NOUN	B
systemic	O	ADJ	I
hypertension	B-Disease	NOUN	I
.	O	PUNCT	O


Whether	O	SCONJ	O
the	O	DET	O
vasoconstrictive	O	ADJ	B
actions	O	NOUN	I
of	O	ADP	O
caffeine	B-Chemical	NOUN	B
are	O	AUX	O
enhanced	O	VERB	B
in	O	ADP	O
hypertensive	B-Disease	ADJ	B
persons	O	NOUN	B
has	O	AUX	O
not	O	PART	O
been	O	AUX	O
demonstrated	O	VERB	O
.	O	PUNCT	O


Thus	O	ADV	O
,	O	PUNCT	O
caffeine	B-Chemical	NOUN	B
(	O	PUNCT	O
3	O	NUM	O
.	O	PUNCT	O


3	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
)	O	PUNCT	O
versus	O	CCONJ	O
placebo	O	NOUN	B
was	O	AUX	O
tested	O	VERB	B
in	O	ADP	O
48	O	NUM	O
healthy	O	ADJ	B
men	O	NOUN	B
(	O	PUNCT	O
aged	O	ADJ	B
20	O	NUM	O
to	O	PART	O
35	O	NUM	O
years	O	NOUN	B
)	O	PUNCT	O
selected	O	VERB	O
after	O	ADP	O
screening	O	VERB	B
on	O	ADP	O
2	O	NUM	O
separate	O	ADJ	O
occasions	O	NOUN	B
.	O	PUNCT	O


Borderline	O	NOUN	B
hypertensive	B-Disease	ADJ	I
men	O	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
24	O	NUM	O
)	O	PUNCT	O
were	O	AUX	O
selected	O	VERB	O
with	O	ADP	O
screening	O	VERB	B
systolic	O	ADJ	B
blood	O	NOUN	I
pressure	O	NOUN	I
(	O	PUNCT	O
BP	O	NOUN	B
)	O	PUNCT	O
of	O	ADP	O
140	O	NUM	O
to	O	PART	O
160	O	NUM	O
mm	O	X	B
Hg	O	NOUN	I
and	O	CCONJ	O
/	O	SYM	O
or	O	CCONJ	O
diastolic	O	ADJ	B
BP	O	NOUN	I
90	O	NUM	O
to	O	PART	O
99	O	NUM	O
mm	O	NOUN	B
Hg	O	NOUN	I
.	O	PUNCT	O


Low	O	ADJ	B
-	O	PUNCT	O
risk	O	NOUN	B
controls	O	NOUN	I
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
24	O	NUM	O
)	O	PUNCT	O
reported	O	VERB	O
no	O	DET	O
parental	O	ADJ	B
history	O	NOUN	I
of	O	ADP	O
hypertension	B-Disease	NOUN	B
and	O	CCONJ	O
had	O	AUX	O
screening	O	VERB	B
BP	O	NOUN	I
<	O	X	O
130	O	NUM	O
/	O	SYM	O
85	O	NUM	O
mm	O	NOUN	B
Hg	O	NOUN	I
.	O	PUNCT	O


Participants	O	NOUN	B
were	O	AUX	O
then	O	ADV	O
tested	O	VERB	B
on	O	ADP	O
2	O	NUM	O
occasions	O	NOUN	B
after	O	ADP	O
12	O	NUM	O
-	O	PUNCT	O
hour	O	NOUN	B
abstinence	O	NOUN	B
from	O	ADP	O
caffeine	B-Chemical	NOUN	B
in	O	ADP	O
each	O	DET	O
of	O	ADP	O
2	O	NUM	O
protocols	O	NOUN	B
;	O	PUNCT	O
this	O	DET	O
required	O	VERB	O
a	O	DET	O
total	O	NOUN	O
of	O	ADP	O
4	O	NUM	O
laboratory	O	NOUN	B
visits	O	NOUN	I
.	O	PUNCT	O


Caffeine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
changes	O	NOUN	B
in	O	ADP	O
diastolic	O	ADJ	B
BP	O	NOUN	I
were	O	AUX	O
2	O	NUM	O
to	O	PART	O
3	O	NUM	O
times	O	NOUN	O
larger	O	ADJ	O
in	O	ADP	O
borderline	O	NOUN	B
subjects	O	NOUN	I
than	O	ADP	O
in	O	ADP	O
controls	O	NOUN	B
(+	O	NOUN	O
8	O	NUM	O
.	O	PUNCT	O


4	O	NUM	O
vs	O	CCONJ	O
+	O	CCONJ	O
3	O	NUM	O
.	O	PUNCT	O


8	O	NUM	O
mm	O	NOUN	B
Hg	O	NOUN	I
,	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


0001	O	NUM	O
),	O	PUNCT	O
and	O	CCONJ	O
were	O	AUX	O
attributable	O	ADJ	O
to	O	PART	O
larger	O	ADJ	O
changes	O	NOUN	B
in	O	ADP	O
impedance	O	NOUN	B
-	O	PUNCT	O
derived	O	VERB	B
measures	O	NOUN	B
of	O	ADP	O
systemic	O	ADJ	B
vascular	O	ADJ	O
resistance	O	NOUN	O
(+	O	NOUN	O
135	O	NUM	O
vs	O	CCONJ	O
+	O	CCONJ	O
45	O	NUM	O
dynes	O	NOUN	B
.	O	PUNCT	O


s	O	NOUN	O
.	O	PUNCT	O


cm	O	NOUN	O
-	O	PUNCT	O
5	O	NUM	O
,	O	PUNCT	O
p	O	X	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


004	O	NUM	O
).	O	PUNCT	O
These	O	DET	O
findings	O	NOUN	B
were	O	AUX	O
consistent	O	ADJ	O
and	O	CCONJ	O
reached	O	VERB	O
significance	O	NOUN	B
in	O	ADP	O
both	O	DET	O
protocols	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
percentage	O	NOUN	B
of	O	ADP	O
borderline	O	NOUN	B
subjects	O	NOUN	I
in	O	ADP	O
whom	O	PRON	O
diastolic	O	ADJ	B
BP	O	NOUN	B
changes	O	NOUN	B
exceeded	O	VERB	O
the	O	DET	O
median	O	ADJ	O
control	O	NOUN	O
response	O	NOUN	O
was	O	AUX	O
96	O	NUM	O
%.	O	NOUN	B
Consequently	O	ADV	O
,	O	PUNCT	O
whereas	O	SCONJ	O
all	O	DET	O
participants	O	NOUN	B
exhibited	O	VERB	O
normotensive	O	ADJ	B
levels	O	NOUN	B
during	O	ADP	O
the	O	DET	O
resting	O	VERB	B
predrug	O	NOUN	I
baseline	O	NOUN	B
,	O	PUNCT	O
33	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
borderline	O	NOUN	B
subjects	O	NOUN	I
achieved	O	VERB	O
hypertensive	B-Disease	ADJ	B
BP	O	NOUN	O
levels	O	NOUN	B
after	O	ADP	O
caffeine	B-Chemical	NOUN	B
ingestion	O	NOUN	B
.	O	PUNCT	O


Thus	O	ADV	O
,	O	PUNCT	O
in	O	ADP	O
borderline	O	NOUN	B
hypertensive	B-Disease	ADJ	I
men	O	NOUN	B
,	O	PUNCT	O
exaggerated	O	ADJ	B
responses	O	NOUN	B
to	O	PART	O
caffeine	B-Chemical	NOUN	B
were	O	AUX	O
:	O	PUNCT	O
selective	O	ADJ	O
for	O	ADP	O
diastolic	O	ADJ	B
BP	O	NOUN	I
,	O	PUNCT	O
consistent	O	ADJ	B
with	O	ADP	I
greater	O	ADJ	O
vasoconstriction	O	NOUN	B
,	O	PUNCT	O
replicated	O	VERB	B
in	O	ADP	O
2	O	NUM	O
protocols	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
representative	O	NOUN	B
of	O	ADP	O
nearly	O	ADV	O
all	O	DET	O
borderline	O	NOUN	B
hypertensives	B-Disease	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
suspect	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
potential	O	NOUN	B
for	O	ADP	O
caffeine	B-Chemical	NOUN	B


Hallucinations	B-Disease	NOUN	B
and	O	CCONJ	O
ifosfamide	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
neurotoxicity	B-Disease	NOUN	B
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
:	O	PUNCT	O
Hallucinations	B-Disease	NOUN	B
as	O	ADP	O
a	O	DET	O
symptom	O	NOUN	B
of	O	ADP	O
central	O	ADJ	B
neurotoxicity	B-Disease	NOUN	I
are	O	AUX	O
a	O	DET	O
known	O	ADJ	O
but	O	CCONJ	O
poorly	O	ADV	O
described	O	VERB	O
side	O	NOUN	B
effect	O	NOUN	I
of	O	ADP	O
ifosfamide	B-Chemical	NOUN	B
.	O	PUNCT	O


Most	O	ADJ	O
cases	O	NOUN	B
of	O	ADP	O
ifosfamide	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
hallucinations	B-Disease	NOUN	B
have	O	AUX	O
been	O	AUX	O
reported	O	VERB	O
with	O	ADP	O
other	O	ADJ	O
mental	O	ADJ	B
status	O	NOUN	I
changes	O	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
:	O	PUNCT	O
The	O	DET	O
authors	O	NOUN	B
interviewed	O	VERB	B
six	O	NUM	O
persons	O	NOUN	B
with	O	ADP	O
ifosfamide	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
hallucinations	B-Disease	NOUN	B
in	O	ADP	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
a	O	DET	O
clear	O	ADJ	O
sensorium	O	NOUN	B
.	O	PUNCT	O


All	O	DET	O
patients	O	NOUN	B
were	O	AUX	O
receiving	O	VERB	O
high	O	ADJ	B
-	O	PUNCT	O
dose	O	NOUN	B
ifosfamide	B-Chemical	NOUN	B
as	O	ADP	O
part	O	NOUN	O
of	O	ADP	O
their	O	PRON	O
bone	O	NOUN	B
marrow	O	NOUN	I
transplant	O	NOUN	I
procedure	O	NOUN	I
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
Hallucinations	B-Disease	NOUN	B
occurred	O	VERB	O
only	O	ADV	O
when	O	SCONJ	O
the	O	DET	O
patient	O	NOUN	B
'	O	PART	O
s	O	NOUN	O
eyes	O	NOUN	B
were	O	AUX	O
closed	O	VERB	B
and	O	CCONJ	O
,	O	PUNCT	O
in	O	ADP	O
all	O	DET	O
but	O	CCONJ	O
one	O	NUM	O
case	O	NOUN	B
,	O	PUNCT	O
were	O	AUX	O
reported	O	VERB	O
as	O	ADP	O
disturbing	O	VERB	O
or	O	CCONJ	O
frightening	O	ADJ	B
.	O	PUNCT	O


Underreporting	O	NOUN	B
of	O	ADP	O
these	O	DET	O
hallucinations	B-Disease	NOUN	B
by	O	ADP	O
patients	O	NOUN	B
is	O	AUX	O
likely	O	ADJ	O
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
:	O	PUNCT	O
Hallucinations	B-Disease	NOUN	B
may	O	AUX	O
be	O	AUX	O
the	O	DET	O
sole	O	NOUN	B
or	O	CCONJ	O
first	O	ADJ	O
manifestation	O	NOUN	B
of	O	ADP	O
neurotoxicity	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
incidence	O	NOUN	B
may	O	AUX	O
be	O	AUX	O
dose	O	NOUN	B
and	O	CCONJ	O
infusion	O	NOUN	B
-	O	PUNCT	O
time	O	NOUN	B
related	O	VERB	O
.	O	PUNCT	O


The	O	DET	O
clinician	O	NOUN	B
should	O	AUX	O
be	O	AUX	O
alerted	O	VERB	O
for	O	ADP	O
possible	O	ADJ	O
ifosfamide	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
hallucinations	B-Disease	NOUN	B
,	O	PUNCT	O
which	O	DET	O
may	O	AUX	O
occur	O	VERB	O
without	O	ADP	O
other	O	ADJ	O
signs	O	NOUN	O
of	O	ADP	O
neurotoxicity	B-Disease	NOUN	B
."	O	PUNCT	O
Eyes	O	NOUN	B
-	O	PUNCT	O
closed	O	VERB	B
"	O	PUNCT	O
hallucinatory	B-Disease	ADJ	B
experiences	O	NOUN	B
appear	O	VERB	O
to	O	PART	O
be	O	AUX	O
an	O	DET	O
unusual	O	ADJ	O
feature	O	NOUN	O
of	O	ADP	O
this	O	DET	O
presentation	O	NOUN	B
.	O	PUNCT	O


Patients	O	NOUN	B
anxious	O	ADJ	B
about	O	ADP	O
this	O	DET	O
experience	O	NOUN	B
respond	O	VERB	O
well	O	ADV	O
to	O	PART	O
support	O	VERB	B
and	O	CCONJ	O
education	O	NOUN	B
about	O	ADP	O
this	O	DET	O
occurrence	O	NOUN	B
.	O	PUNCT	O


Optimal	O	ADJ	B
pharmacologic	O	ADJ	B
management	O	NOUN	I
of	O	ADP	O
disturbed	O	VERB	O
patients	O	NOUN	B
is	O	AUX	O
unclear	O	ADJ	B
.	O	PUNCT	O


If	O	SCONJ	O
agitation	B-Disease	NOUN	B
becomes	O	VERB	O
marked	O	ADJ	O
,	O	PUNCT	O
high	O	ADJ	B
-	O	PUNCT	O
potency	O	NOUN	B
neuroleptics	O	NOUN	B
(	O	PUNCT	O
i	O	X	O
.	O	PUNCT	O


e	O	X	O
.,	O	PUNCT	O
haloperidol	B-Chemical	NOUN	B


Chlorpropamide	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
optic	B-Disease	ADJ	B
neuropathy	I-Disease	NOUN	I
.	O	PUNCT	O


A	O	DET	O
65	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
woman	O	NOUN	B
with	O	ADP	O
adult-onset	B-Disease	ADJ	B
diabetes	I-Disease	NOUN	I
treated	O	VERB	B
with	O	ADP	I
chlorpropamide	B-Chemical	NOUN	B
(	O	PUNCT	O
Diabenese	B-Chemical	NOUN	B
)	O	PUNCT	O
had	O	AUX	O
a	O	DET	O
toxic	B-Disease	ADJ	B
optic	I-Disease	ADJ	B
neuropathy	I-Disease	NOUN	I
that	O	PRON	O
resolved	O	VERB	B
with	O	ADP	O
discontinuation	O	NOUN	B
of	O	ADP	O
chlorpropamide	B-Chemical	NOUN	B
therapy	O	NOUN	I
.	O	PUNCT	O


Visual	B-Disease	ADJ	B
loss	I-Disease	NOUN	I
occurs	O	VERB	O
in	O	ADP	O
diabetics	B-Disease	NOUN	B
for	O	ADP	O
a	O	DET	O
variety	O	NOUN	O
of	O	ADP	O
reasons	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
accurate	O	ADJ	B
diagnosis	O	NOUN	B
is	O	AUX	O
necessary	O	ADJ	O
to	O	PART	O
institute	O	VERB	B
appropriate	O	ADJ	O
therapy	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
possibility	O	NOUN	O
of	O	ADP	O
a	O	DET	O
drug	O	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
optic	B-Disease	ADJ	B
neuropathy	I-Disease	NOUN	I
should	O	AUX	O
be	O	AUX	O
considered	O	VERB	O
in	O	ADP	O
the	O	DET	O
differential	O	ADJ	B
diagnosis	O	NOUN	I
of	O	ADP	O
visual	B-Disease	ADJ	B
loss	I-Disease	NOUN	I
in	O	ADP	O
diabetics	B-Disease	NOUN	B


Levodopa	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
dyskinesia	B-Disease	NOUN	B
and	O	CCONJ	O
thalamotomy	O	NOUN	B
.	O	PUNCT	O


Levodopa	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
dyskinesia	B-Disease	NOUN	B
of	O	ADP	O
the	O	DET	O
limbs	O	NOUN	B
in	O	ADP	O
thirteen	O	NUM	O
cases	O	NOUN	B
of	O	ADP	O
Parkinsonism	B-Disease	NOUN	B
,	O	PUNCT	O
which	O	DET	O
was	O	AUX	O
choreic	O	ADJ	B
,	O	PUNCT	O
ballistic	O	ADJ	B
or	O	CCONJ	O
dystonic	B-Disease	ADJ	B
in	O	ADP	O
type	O	NOUN	B
,	O	PUNCT	O
was	O	AUX	O
alleviated	O	VERB	O
almost	O	ADV	O
completely	O	ADV	O
by	O	ADP	O
stereotaxic	O	ADJ	B
surgery	O	NOUN	I
using	O	VERB	O
a	O	DET	O
microelectrode	O	ADJ	B
technique	O	NOUN	I
for	O	ADP	O
the	O	DET	O
ventralis	O	X	B
oralis	O	X	I
anterior	O	ADJ	I
and	O	CCONJ	O
posterior	O	ADJ	B
nuclei	O	NOUN	I
of	O	ADP	O
the	O	DET	O
thalamus	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
much	O	ADV	O
less	O	ADJ	O
by	O	ADP	O
the	O	DET	O
ventralis	O	X	B
intermedius	O	X	I
nucleus	O	NOUN	I
.	O	PUNCT	O


Control	O	NOUN	B
of	O	ADP	O
levodopa	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
dyskinesias	B-Disease	NOUN	B
by	O	ADP	O
thalamic	B-Disease	ADJ	B
lesions	I-Disease	NOUN	B
in	O	ADP	O
the	O	DET	O
course	O	NOUN	B
of	O	ADP	O
routine	O	ADJ	B
treatment	O	NOUN	B
of	O	ADP	O
Parkinsonism	B-Disease	NOUN	B


Factors	O	NOUN	B
associated	O	VERB	B
with	O	ADP	I
nephrotoxicity	B-Disease	NOUN	B
and	O	CCONJ	O
clinical	O	ADJ	B
outcome	O	NOUN	I
in	O	ADP	O
patients	O	NOUN	B
receiving	O	VERB	O
amikacin	B-Chemical	NOUN	B
.	O	PUNCT	O


Data	O	NOUN	B
from	O	ADP	O
60	O	NUM	O
patients	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
amikacin	B-Chemical	NOUN	B
were	O	AUX	O
analyzed	O	VERB	B
for	O	ADP	O
factors	O	NOUN	B
associated	O	VERB	B
with	O	ADP	I
nephrotoxicity	B-Disease	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
42	O	NUM	O
of	O	ADP	O
these	O	DET	O
patients	O	NOUN	B
,	O	PUNCT	O
data	O	NOUN	B
were	O	AUX	O
examined	O	VERB	O
for	O	ADP	O
factors	O	NOUN	B
associated	O	VERB	B
with	O	ADP	I
clinical	O	ADJ	B
outcome	O	NOUN	I
.	O	PUNCT	O


Variables	O	NOUN	B
evaluated	O	VERB	B
included	O	VERB	O
patient	O	NOUN	B
weight	O	NOUN	I
,	O	PUNCT	O
age	O	NOUN	B
,	O	PUNCT	O
sex	O	NOUN	B
,	O	PUNCT	O
serum	O	NOUN	B
creatinine	B-Chemical	NOUN	I
level	O	NOUN	I
,	O	PUNCT	O
creatinine	B-Chemical	NOUN	B
clearance	O	NOUN	B
,	O	PUNCT	O
duration	O	NOUN	B
of	O	ADP	I
therapy	O	NOUN	B
,	O	PUNCT	O
total	O	ADJ	B
dose	O	NOUN	I
,	O	PUNCT	O
mean	O	VERB	O
daily	O	ADJ	O
dose	O	NOUN	O
,	O	PUNCT	O
organism	O	NOUN	B
minimum	O	NOUN	O
inhibitory	O	ADJ	O
concentration	O	NOUN	O
(	O	PUNCT	O
MIC	O	NOUN	B
),	O	PUNCT	O
mean	O	VERB	O
peak	O	NOUN	O
levels	O	NOUN	O
,	O	PUNCT	O
mean	O	VERB	O
trough	O	NOUN	O
levels	O	NOUN	O
,	O	PUNCT	O
mean	O	INTJ	B
area	O	NOUN	I
under	O	ADP	O
the	O	DET	O
serum	O	NOUN	B
concentration	O	NOUN	B
-	O	PUNCT	O
time	O	NOUN	B
curve	O	NOUN	I
(	O	PUNCT	O
AUC	O	NOUN	B
),	O	PUNCT	O
total	O	ADJ	O
AUC	O	NOUN	B
,	O	PUNCT	O
mean	O	VERB	O
AUC	O	NOUN	B
greater	O	ADJ	O
than	O	ADP	O
MIC	O	NOUN	B
,	O	PUNCT	O
total	O	ADJ	O
AUC	O	NOUN	B
greater	O	ADJ	O
than	O	ADP	O
MIC	O	NOUN	B
,	O	PUNCT	O
mean	O	VERB	O
Schumacher	O	PROPN	O
'	O	PART	O
s	O	NOUN	O
intensity	O	NOUN	B
factor	O	NOUN	I
(	O	PUNCT	O
IF	O	NOUN	B
),	O	PUNCT	O
total	O	ADJ	O
IF	O	NOUN	B
,	O	PUNCT	O
In	O	ADP	O
(	O	PUNCT	O
mean	O	ADJ	O
maximum	O	ADJ	O
concentration	O	NOUN	B
[	O	PUNCT	O
Cmax	O	NOUN	B
]/	O	PUNCT	O
MIC	O	NOUN	B
).	O	PUNCT	O
Model	O	NOUN	B
-	O	PUNCT	O
dependent	O	ADJ	B
pharmacokinetic	O	ADJ	B
parameters	O	NOUN	B
were	O	AUX	O
calculated	O	VERB	B
by	O	ADP	O
computer	O	NOUN	B
based	O	VERB	O
on	O	ADP	O
a	O	DET	O
one	O	NUM	B
-	O	PUNCT	O
compartment	O	NOUN	B
model	O	NOUN	B
.	O	PUNCT	O


When	O	SCONJ	O
the	O	DET	O
parameters	O	NOUN	B
were	O	AUX	O
examined	O	VERB	O
individually	O	ADV	O
,	O	PUNCT	O
duration	O	NOUN	B
of	O	ADP	O
therapy	O	NOUN	B
and	O	CCONJ	O
total	O	ADJ	O
AUC	O	NOUN	B
correlated	O	VERB	B
significantly	O	ADV	O
(	O	PUNCT	O
P	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
.	O	PUNCT	O


05	O	NUM	O
)	O	PUNCT	O
with	O	ADP	O
nephrotoxicity	B-Disease	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
contrast	O	NOUN	O
,	O	PUNCT	O
a	O	DET	O
stepwise	O	ADJ	O
discriminant	O	ADJ	O
function	O	NOUN	O
analysis	O	NOUN	O
identified	O	VERB	B
only	O	ADV	O
duration	O	NOUN	B
of	O	ADP	I
therapy	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
.	O	PUNCT	O


001	O	NUM	O
)	O	PUNCT	O
as	O	ADP	O
an	O	DET	O
important	O	ADJ	O
factor	O	NOUN	B
.	O	PUNCT	O


Based	O	VERB	O
on	O	ADP	O
this	O	DET	O
model	O	NOUN	B
and	O	CCONJ	O
on	O	ADP	O
Bayes	O	PROPN	B
'	O	PART	I
theorem	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
predictive	O	ADJ	B
accuracy	O	NOUN	B
of	O	ADP	O
identifying	O	VERB	B
"	O	PUNCT	O
nephrotoxic	B-Disease	NOUN	B


Cardiac	O	ADJ	B
transplantation	O	NOUN	I
:	O	PUNCT	O
improved	O	VERB	B
quality	O	NOUN	B
of	O	ADP	O
survival	O	NOUN	B
with	O	ADP	O
a	O	DET	O
modified	O	ADJ	B
immunosuppressive	O	ADJ	B
protocol	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
effects	O	NOUN	B
on	O	ADP	O
renal	O	ADJ	B
function	O	NOUN	I
on	O	ADP	O
two	O	NUM	O
different	O	ADJ	O
immunosuppressive	O	ADJ	B
protocols	O	NOUN	I
were	O	AUX	O
evaluated	O	VERB	B
retrospectively	O	ADV	B
in	O	ADP	O
two	O	NUM	O
subsequent	O	ADJ	O
groups	O	NOUN	B
of	O	ADP	O
heart	O	NOUN	B
transplant	O	NOUN	I
recipients	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
group	O	NOUN	B
I	O	NOUN	I
,	O	PUNCT	O
cyclosporine	B-Chemical	NOUN	B
was	O	AUX	O
given	O	VERB	O
before	O	ADP	O
the	O	DET	O
procedure	O	NOUN	B
at	O	ADP	O
a	O	DET	O
loading	O	NOUN	B
dose	O	NOUN	I
of	O	ADP	O
17	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
and	O	CCONJ	O
then	O	ADV	O
continued	O	VERB	O
after	O	ADP	O
the	O	DET	O
procedure	O	NOUN	B
to	O	PART	O
keep	O	VERB	O
a	O	DET	O
whole	O	ADJ	B
blood	O	NOUN	I
level	O	NOUN	O
about	O	ADP	O
1000	O	NUM	O
ng	O	NOUN	O
/	O	PUNCT	O
ml	O	NOUN	O
.	O	PUNCT	O


In	O	ADP	O
group	O	NOUN	B
II	O	NUM	I
,	O	PUNCT	O
cyclosporine	B-Chemical	NOUN	B
was	O	AUX	O
started	O	VERB	O
only	O	ADV	O
after	O	ADP	O
the	O	DET	O
procedure	O	NOUN	B
at	O	ADP	O
a	O	DET	O
lower	O	ADJ	O
dosage	O	NOUN	B
and	O	CCONJ	O
was	O	AUX	O
complemented	O	VERB	B
by	O	ADP	O
azathioprine	B-Chemical	NOUN	B
,	O	PUNCT	O
which	O	DET	O
was	O	AUX	O
used	O	VERB	O
for	O	ADP	O
the	O	DET	O
first	O	ADJ	O
postoperative	O	ADJ	B
week	O	NOUN	B
.	O	PUNCT	O


Group	O	PROPN	B
II	O	PROPN	I
showed	O	VERB	O
a	O	DET	O
better	O	ADV	O
perioperative	O	ADJ	B
renal	O	ADJ	B
function	O	NOUN	I
as	O	ADP	O
determined	O	VERB	O
by	O	ADP	O
serum	O	NOUN	B
blood	O	NOUN	I
urea	B-Chemical	NOUN	I
nitrogen	I-Chemical	NOUN	I
and	O	CCONJ	O
serum	O	NOUN	B
creatinine	B-Chemical	NOUN	I
levels	O	NOUN	I
.	O	PUNCT	O


Group	O	PROPN	B
II	O	PROPN	I
also	O	ADV	O
showed	O	VERB	O
a	O	DET	O
significant	O	ADJ	O
decrease	O	NOUN	B
of	O	ADP	O
chronic	O	ADJ	B
nephrotoxicity	B-Disease	NOUN	I
secondary	O	ADJ	B
to	O	PART	I
long	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
therapy	O	NOUN	B
with	O	ADP	O
cyclosporine	B-Chemical	NOUN	B
.	O	PUNCT	O


Despite	O	SCONJ	O
this	O	DET	O
improvement	O	NOUN	B
in	O	ADP	O
late	O	ADJ	B
renal	O	ADJ	I
function	O	NOUN	I
,	O	PUNCT	O
group	O	NOUN	B
II	O	NUM	I
still	O	ADV	O
shows	O	VERB	O
a	O	DET	O
slow	O	ADJ	B
rise	O	NOUN	O
in	O	ADP	O
serum	O	NOUN	B
creatinine	B-Chemical	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
think	O	VERB	O
that	O	SCONJ	O
even	O	ADV	O
these	O	DET	O
lower	O	ADJ	O
dosages	O	NOUN	B
of	O	ADP	O
cyclosporine	B-Chemical	NOUN	B
can	O	AUX	O
cause	O	VERB	O
chronic	O	ADJ	B
nephrotoxicity	B-Disease	NOUN	O


Reversible	O	ADJ	B
cholestasis	B-Disease	NOUN	B
with	O	ADP	O
bile	B-Disease	NOUN	B
duct	I-Disease	NOUN	I
injury	I-Disease	NOUN	I
following	O	VERB	O
azathioprine	B-Chemical	NOUN	B
therapy	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
case	O	NOUN	B
report	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
67	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
patient	O	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
primary	O	ADJ	B
polymyositis	B-Disease	NOUN	I
and	O	CCONJ	O
without	O	ADP	O
previous	O	ADJ	O
evidence	O	NOUN	B
of	O	ADP	O
liver	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
,	O	PUNCT	O
developed	O	VERB	O
clinical	O	ADJ	B
and	O	CCONJ	O
biochemical	O	ADJ	B
features	O	NOUN	B
of	O	ADP	O
severe	O	ADJ	B
cholestasis	B-Disease	NOUN	B
3	O	NUM	O
months	O	NOUN	B
after	O	ADP	O
initiation	O	NOUN	B
of	O	ADP	O
azathioprine	B-Chemical	NOUN	B
therapy	O	NOUN	I
.	O	PUNCT	O


Liver	O	NOUN	B
biopsy	O	NOUN	I
showed	O	VERB	O
cholestasis	B-Disease	NOUN	B
with	O	ADP	O
both	O	CCONJ	O
cytological	O	ADJ	B
and	O	CCONJ	O
architectural	O	ADJ	B
alterations	O	NOUN	B
of	O	ADP	O
interlobular	O	ADJ	B
bile	O	NOUN	I
ducts	O	NOUN	I
.	O	PUNCT	O


Azathioprine	B-Chemical	NOUN	B
withdrawal	O	NOUN	B
resulted	O	VERB	O
after	O	ADP	O
7	O	NUM	O
weeks	O	NOUN	B
in	O	ADP	O
the	O	DET	O
resolution	O	NOUN	B
of	O	ADP	O
clinical	O	ADJ	B
and	O	CCONJ	O
biochemical	O	ADJ	B
abnormalities	O	NOUN	I
.	O	PUNCT	O


It	O	PRON	O
is	O	AUX	O
believed	O	VERB	O
that	O	SCONJ	O
this	O	DET	O
is	O	AUX	O
the	O	DET	O
first	O	ADJ	O
reported	O	VERB	O
case	O	NOUN	B
of	O	ADP	O
reversible	O	ADJ	B
azathioprine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
cholestasis	B-Disease	NOUN	B
associated	O	VERB	B
with	O	ADP	I
histological	O	ADJ	B
evidence	O	NOUN	B
of	O	ADP	O
bile	B-Disease	NOUN	B
duct	I-Disease	NOUN	I
injury	I-Disease	NOUN	O


Renal	O	ADJ	B
function	O	NOUN	I
and	O	CCONJ	O
hemodynamics	O	NOUN	B
during	O	ADP	O
prolonged	O	ADJ	B
isoflurane	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
hypotension	B-Disease	NOUN	B
in	O	ADP	O
humans	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
isoflurane	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
hypotension	B-Disease	NOUN	B
on	O	ADP	O
glomerular	O	ADJ	B
function	O	NOUN	I
and	O	CCONJ	O
renal	O	ADJ	B
blood	O	NOUN	I
flow	O	NOUN	I
was	O	AUX	O
investigated	O	VERB	B
in	O	ADP	O
20	O	NUM	O
human	O	ADJ	B
subjects	O	NOUN	B
.	O	PUNCT	O


Glomerular	O	ADJ	B
filtration	O	NOUN	I
rate	O	NOUN	I
(	O	PUNCT	O
GFR	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
effective	O	ADJ	B
renal	O	ADJ	B
plasma	O	NOUN	I
flow	O	NOUN	I
(	O	PUNCT	O
ERPF	O	NOUN	B
)	O	PUNCT	O
were	O	AUX	O
measured	O	VERB	O
by	O	ADP	O
inulin	O	NOUN	B
and	O	CCONJ	O
para-aminohippurate	B-Chemical	NOUN	B
(	O	PUNCT	O
PAH	B-Chemical	NOUN	B
)	O	PUNCT	O
clearance	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


Anesthesia	O	NOUN	B
was	O	AUX	O
maintained	O	VERB	B
with	O	ADP	O
fentanyl	B-Chemical	NOUN	B
,	O	PUNCT	O
nitrous	B-Chemical	ADJ	B
oxide	I-Chemical	NOUN	I
,	O	PUNCT	O
oxygen	B-Chemical	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
isoflurane	B-Chemical	NOUN	B
.	O	PUNCT	O


Hypotension	B-Disease	NOUN	B
was	O	AUX	O
induced	O	VERB	B
for	O	ADP	O
236	O	NUM	O
.	O	PUNCT	O


9	O	NUM	O
+/-	O	CCONJ	O
15	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
min	O	NOUN	O
by	O	ADP	O
increasing	O	VERB	B
the	O	DET	O
isoflurane	B-Chemical	NOUN	B
inspired	O	VERB	O
concentration	O	NOUN	B
to	O	PART	O
maintain	O	VERB	O
a	O	DET	O
mean	O	ADJ	O
arterial	O	ADJ	B
pressure	O	NOUN	I
of	O	ADP	O
59	O	NUM	O
.	O	PUNCT	O


8	O	NUM	O
+/-	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


4	O	NUM	O
mmHg	O	NOUN	B
.	O	PUNCT	O


GFR	O	NOUN	B
and	O	CCONJ	O
ERPF	O	NOUN	B
decreased	O	VERB	B
with	O	ADP	O
the	O	DET	O
induction	O	NOUN	B
of	O	ADP	O
anesthesia	O	NOUN	B
but	O	CCONJ	O
not	O	PART	O
significantly	O	ADV	O
more	O	ADV	O
during	O	ADP	O
hypotension	B-Disease	NOUN	B
.	O	PUNCT	O


Postoperatively	O	ADV	B
,	O	PUNCT	O
ERPF	O	NOUN	B
returned	O	VERB	O
to	O	ADP	O
preoperative	O	ADJ	B
values	O	NOUN	B
,	O	PUNCT	O
whereas	O	SCONJ	O
GFR	O	NOUN	B
was	O	AUX	O
higher	O	ADJ	O
than	O	ADP	O
preoperative	O	ADJ	B
values	O	NOUN	B
.	O	PUNCT	O


Renal	O	ADJ	B
vascular	O	ADJ	I
resistance	O	NOUN	I
increased	O	VERB	B
during	O	ADP	O
anesthesia	O	NOUN	B
but	O	CCONJ	O
decreased	O	VERB	B
when	O	SCONJ	O
hypotension	B-Disease	NOUN	B
was	O	AUX	O
induced	O	VERB	B
,	O	PUNCT	O
allowing	O	VERB	O
the	O	DET	O
maintenance	O	NOUN	B
of	O	ADP	O
renal	O	ADJ	B
blood	O	NOUN	I
flow	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
conclude	O	VERB	O
that	O	SCONJ	O
renal	O	ADJ	B
compensatory	O	ADJ	O
mechanisms	O	NOUN	B
are	O	AUX	O
preserved	O	VERB	O
during	O	ADP	O
isoflurane	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
hypotension	B-Disease	NOUN	B


Debrisoquine	B-Chemical	NOUN	B
phenotype	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
pharmacokinetics	O	NOUN	B
and	O	CCONJ	O
beta	O	NOUN	B
-	O	PUNCT	O
2	O	NUM	B
receptor	O	NOUN	I
pharmacodynamics	O	NOUN	B
of	O	ADP	O
metoprolol	B-Chemical	NOUN	B
and	O	CCONJ	O
its	O	PRON	O
enantiomers	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
metabolism	O	NOUN	B
of	O	ADP	O
the	O	DET	O
cardioselective	O	ADJ	B
beta	O	NOUN	I
-	O	PUNCT	O
blocker	O	NOUN	B
metoprolol	B-Chemical	NOUN	B
is	O	AUX	O
under	O	ADP	O
genetic	O	ADJ	B
control	O	NOUN	I
of	O	ADP	O
the	O	DET	O
debrisoquine	B-Chemical	NOUN	B
/	O	SYM	O
sparteine	B-Chemical	NOUN	B
type	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
two	O	NUM	O
metabolic	O	ADJ	B
phenotypes	O	NOUN	B
,	O	PUNCT	O
extensive	O	ADJ	B
(	O	PUNCT	O
EM	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
poor	O	ADJ	B
metabolizers	O	NOUN	I
(	O	PUNCT	O
PM	O	PROPN	B
),	O	PUNCT	O
show	O	VERB	O
different	O	ADJ	O
stereoselective	O	ADJ	B
metabolism	O	NOUN	I
,	O	PUNCT	O
resulting	O	VERB	O
in	O	ADP	O
apparently	O	ADV	O
higher	O	ADJ	O
beta	O	NOUN	B
-	O	PUNCT	O
1	O	NUM	O
adrenoceptor	O	NOUN	B
antagonistic	O	ADJ	B
potency	O	NOUN	B
of	O	ADP	O
racemic	O	ADJ	B
metoprolol	B-Chemical	NOUN	B
in	O	ADP	O
EMs	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
investigated	O	VERB	B
if	O	SCONJ	O
the	O	DET	O
latter	O	NOUN	O
also	O	ADV	O
applies	O	VERB	O
to	O	ADP	O
the	O	DET	O
beta	O	NOUN	B
-	O	PUNCT	O
2	O	NUM	B
adrenoceptor	O	NOUN	B
antagonism	O	NOUN	B
by	O	ADP	O
metoprolol	B-Chemical	NOUN	B
.	O	PUNCT	O


The	O	DET	O
drug	O	NOUN	B
effect	O	NOUN	I
studied	O	VERB	O
was	O	AUX	O
the	O	DET	O
antagonism	O	NOUN	B
by	O	ADP	O
metoprolol	B-Chemical	NOUN	B
of	O	ADP	O
terbutaline	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
hypokalemia	B-Disease	NOUN	B
.	O	PUNCT	O


By	O	ADP	O
using	O	VERB	O
pharmacokinetic	O	ADJ	B
pharmacodynamic	O	ADJ	O
modeling	O	VERB	O
the	O	DET	O
pharmacodynamics	O	NOUN	B
of	O	ADP	O
racemic	O	ADJ	B
metoprolol	B-Chemical	NOUN	B
and	O	CCONJ	O
the	O	DET	O
active	O	ADJ	B
S	O	NOUN	B
-	O	PUNCT	O
isomer	O	NOUN	B
,	O	PUNCT	O
were	O	AUX	O
quantitated	O	VERB	B
in	O	ADP	O
EMs	O	NOUN	B
and	O	CCONJ	O
PMs	O	NOUN	B
in	O	ADP	O
terms	O	NOUN	O
of	O	ADP	O
IC50	O	NOUN	B
values	O	NOUN	B
,	O	PUNCT	O
representing	O	VERB	O
metoprolol	B-Chemical	NOUN	B
plasma	O	NOUN	B
concentrations	O	NOUN	B
resulting	O	VERB	O
in	O	ADP	O
half	O	NUM	B
-	O	PUNCT	O
maximum	O	NOUN	B
receptor	O	NOUN	B
occupancy	O	NOUN	B
.	O	PUNCT	O


Six	O	NUM	O
EMs	O	NOUN	B
received	O	VERB	O
0	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
mg	O	NOUN	O
of	O	ADP	O
terbutaline	B-Chemical	NOUN	B
s	O	NOUN	O
.	O	PUNCT	O


c	O	X	O
.	O	PUNCT	O


on	O	ADP	O
two	O	NUM	O
different	O	ADJ	O
occasions	O	NOUN	B
:	O	PUNCT	O
1	O	X	O
)	O	PUNCT	O
1	O	NUM	O
hr	O	NOUN	O
after	O	ADP	O
administration	O	NOUN	B
of	O	ADP	O
a	O	DET	O
placebo	O	NOUN	B
and	O	CCONJ	O
2	O	NUM	O
)	O	PUNCT	O
1	O	NUM	O
hr	O	NOUN	O
after	O	ADP	O
150	O	NUM	O
mg	O	NOUN	O
of	O	ADP	O
metoprolol	B-Chemical	NOUN	B
p	O	NOUN	O
.	O	PUNCT	O


o	O	X	O
.	O	PUNCT	O


Five	O	NUM	O
PMs	O	NOUN	B
were	O	AUX	O
studied	O	VERB	O
according	O	VERB	O
to	O	ADP	O
the	O	DET	O
same	O	ADJ	O
protocol	O	NOUN	B
,	O	PUNCT	O
except	O	SCONJ	O
for	O	ADP	O
a	O	DET	O
higher	O	ADJ	B
terbutaline	B-Chemical	NOUN	B
dose	O	NOUN	B
(	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


75	O	NUM	O
mg	O	NOUN	O
)	O	PUNCT	O
on	O	ADP	O
day	O	NOUN	B
2	O	NUM	O
.	O	PUNCT	O


Blood	O	NOUN	B
samples	O	NOUN	I
for	O	ADP	O
the	O	DET	O
analysis	O	NOUN	B
of	O	ADP	O
plasma	O	NOUN	B
potassium	B-Chemical	NOUN	O
,	O	PUNCT	O
terbutaline	B-Chemical	NOUN	B
,	O	PUNCT	O
metoprolol	B-Chemical	NOUN	B
(	O	PUNCT	O
racemic	O	ADJ	B
,	O	PUNCT	O
R	O	PROPN	B
-	O	PUNCT	O
and	O	CCONJ	O
S	O	NOUN	B
-	O	PUNCT	O
isomer	O	NOUN	B
),	O	PUNCT	O
and	O	CCONJ	O
alpha-hydroxymetoprolol	B-Chemical	ADJ	B
concentrations	O	NOUN	B
were	O	AUX	O
taken	O	VERB	O
at	O	ADP	O
regular	O	ADJ	O
time	O	NOUN	O
intervals	O	NOUN	O
,	O	PUNCT	O
during	O	ADP	O
8	O	NUM	O
hr	O	NOUN	O
after	O	ADP	O
metoprolol	B-Chemical	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
PMs	O	PROPN	B
,	O	PUNCT	O
metoprolol	B-Chemical	NOUN	B
increased	O	VERB	B
the	O	DET	O
terbutaline	B-Chemical	NOUN	B
area	O	NOUN	B
under	O	ADP	O
the	O	DET	O
plasma	O	NOUN	B
concentration	O	NOUN	B
vs	O	CCONJ	O
.	O	PUNCT	O


time	O	NOUN	O
curve	O	NOUN	O
(+	O	NOUN	O
67	O	NUM	O
%).	O	ADV	O
Higher	O	ADJ	O
metoprolol	B-Chemical	PROPN	B
/	O	PUNCT	O
alpha-hydroxymetoprolol	B-Chemical	ADJ	B
ratios	O	NOUN	B
in	O	ADP	O
PMs	O	NOUN	B
were	O	AUX	O
predictive	O	ADJ	B
for	O	ADP	O
higher	O	ADJ	B
R	O	NOUN	B
-/	O	NOUN	O
S	O	NOUN	B
-	O	PUNCT	O
isomer	O	NOUN	B
ratios	O	NOUN	B
of	O	ADP	O
unchanged	O	ADJ	B
drug	O	NOUN	B
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
a	O	DET	O
difference	O	NOUN	O
in	O	ADP	O
metoprolol	B-Chemical	NOUN	B
potency	O	NOUN	B
with	O	ADP	O
higher	O	ADJ	O
racemic	O	ADJ	B
metoprolol	B-Chemical	NOUN	B


Cefotetan	B-Chemical	PROPN	B
-	O	PUNCT	O
induced	O	VERB	B
immune	O	ADJ	B
hemolytic	B-Disease	ADJ	O
anemia	I-Disease	NOUN	B
.	O	PUNCT	O


Immune	O	ADJ	B
hemolytic	B-Disease	ADJ	I
anemia	I-Disease	NOUN	B
due	O	ADP	O
to	O	ADP	O
a	O	DET	O
drug	O	NOUN	B
-	O	PUNCT	O
adsorption	O	NOUN	B
mechanism	O	NOUN	B
has	O	AUX	O
been	O	AUX	O
described	O	VERB	O
primarily	O	ADV	O
in	O	ADP	O
patients	O	NOUN	B
receiving	O	VERB	O
penicillins	B-Chemical	NOUN	B
and	O	CCONJ	O
first	O	ADJ	B
-	O	PUNCT	O
generation	O	NOUN	B
cephalosporins	B-Chemical	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
describe	O	VERB	O
a	O	DET	O
patient	O	NOUN	B
who	O	PRON	O
developed	O	VERB	O
anemia	B-Disease	NOUN	B
while	O	SCONJ	O
receiving	O	VERB	O
intravenous	O	ADJ	B
cefotetan	B-Chemical	NOUN	B
.	O	PUNCT	O


Cefotetan	B-Chemical	PROPN	B
-	O	PUNCT	O
dependent	O	ADJ	B
antibodies	O	NOUN	B
were	O	AUX	O
detected	O	VERB	B
in	O	ADP	O
the	O	DET	O
patient	O	NOUN	B
'	O	PART	O
s	O	NOUN	O
serum	O	NOUN	B
and	O	CCONJ	O
in	O	ADP	O
an	O	DET	O
eluate	O	NOUN	B
prepared	O	VERB	B
from	O	ADP	O
his	O	PRON	O
red	O	ADJ	B
blood	O	NOUN	I
cells	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
eluate	O	NOUN	B
also	O	ADV	O
reacted	O	VERB	O
weakly	O	ADV	O
with	O	ADP	O
red	O	ADJ	B
blood	O	NOUN	I
cells	O	NOUN	I
in	O	ADP	O
the	O	DET	O
absence	O	NOUN	B
of	O	ADP	O
cefotetan	B-Chemical	NOUN	B
,	O	PUNCT	O
suggesting	O	VERB	O
the	O	DET	O
concomitant	O	ADJ	B
formation	O	NOUN	B
of	O	ADP	O
warm	O	ADJ	B
-	O	PUNCT	O
reactive	O	ADJ	B
autoantibodies	O	NOUN	I
.	O	PUNCT	O


These	O	DET	O
observations	O	NOUN	B
,	O	PUNCT	O
in	O	ADP	O
conjunction	O	NOUN	B
with	O	ADP	O
clinical	O	ADJ	B
and	O	CCONJ	O
laboratory	O	ADJ	B
evidence	O	NOUN	B
of	O	ADP	O
extravascular	O	ADJ	B
hemolysis	B-Disease	NOUN	I
,	O	PUNCT	O
are	O	AUX	O
consistent	O	ADJ	B
with	O	ADP	I
drug	O	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
hemolytic	B-Disease	ADJ	B
anemia	I-Disease	NOUN	B
,	O	PUNCT	O
possibly	O	ADV	O
involving	O	VERB	O
both	O	DET	O
drug	O	NOUN	B
-	O	PUNCT	O
adsorption	O	NOUN	B
and	O	CCONJ	O
autoantibody	O	NOUN	B
formation	O	NOUN	B
mechanisms	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
case	O	NOUN	B
emphasizes	O	VERB	O
the	O	DET	O
need	O	NOUN	O
for	O	ADP	O
increased	O	VERB	B
awareness	O	NOUN	B
of	O	ADP	O
hemolytic	O	ADJ	B
reactions	O	NOUN	I
to	O	ADP	O
all	O	DET	O
cephalosporins	B-Chemical	NOUN	B


Acute	B-Disease	ADJ	B
renal	I-Disease	ADJ	I
failure	I-Disease	NOUN	I
subsequent	O	ADJ	O
to	O	PART	O
the	O	DET	O
administration	O	NOUN	B
of	O	ADP	O
rifampicin	B-Chemical	NOUN	B
.	O	PUNCT	O


A	O	DET	O
follow	O	NOUN	B
-	O	PUNCT	O
up	O	ADP	O
study	O	NOUN	B
of	O	ADP	O
cases	O	NOUN	B
reported	O	VERB	O
earlier	O	ADV	O
.	O	PUNCT	O


A	O	DET	O
clinical	O	ADJ	B
presentation	O	NOUN	I
is	O	AUX	O
made	O	VERB	O
of	O	ADP	O
a	O	DET	O
2	O	NUM	O
-	O	SYM	O
3	O	NUM	O
year	O	NOUN	B
follow	O	NOUN	B
-	O	PUNCT	O
up	O	NOUN	O
of	O	ADP	O
six	O	NUM	O
cases	O	NOUN	B
of	O	ADP	O
acute	B-Disease	ADJ	B
renal	I-Disease	ADJ	I
failure	I-Disease	NOUN	I
that	O	PRON	O
have	O	AUX	O
been	O	AUX	O
reported	O	VERB	O
earlier	O	ADV	O
.	O	PUNCT	O


The	O	DET	O
patients	O	NOUN	B
had	O	AUX	O
developed	O	VERB	O
transient	O	ADJ	B
renal	B-Disease	ADJ	I
failure	I-Disease	NOUN	I
after	O	ADP	O
the	O	DET	O
intermittent	O	ADJ	B
administration	O	NOUN	B
of	O	ADP	O
rifampicin	B-Chemical	NOUN	B
.	O	PUNCT	O


The	O	DET	O
stage	O	NOUN	B
of	O	ADP	O
olig	O	NOUN	B
-	O	PUNCT	O
anuria	B-Disease	NOUN	B
lasted	O	VERB	O
for	O	ADP	O
1	O	NUM	O
-	O	PUNCT	O
3	O	NUM	O
weeks	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
five	O	NUM	O
of	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
were	O	AUX	O
treated	O	VERB	B
by	O	ADP	I
hemodialysis	O	NOUN	B
.	O	PUNCT	O


Two	O	NUM	O
of	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
died	O	VERB	B
due	O	ADJ	O
to	O	PART	O
unrelated	O	ADJ	O
causes	O	NOUN	O
during	O	ADP	O
the	O	DET	O
follow	O	NOUN	B
-	O	PUNCT	O
up	O	ADP	O
period	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
four	O	NUM	O
patients	O	NOUN	B
re	O	X	B
-	O	PUNCT	O
examined	O	VERB	B
were	O	AUX	O
clinically	O	ADV	B
cured	O	VERB	O
.	O	PUNCT	O


Pathologic	O	ADJ	B
findings	O	NOUN	B
by	O	ADP	O
light	O	ADJ	B
microscopy	O	NOUN	I
and	O	CCONJ	O
immunofluorescence	O	NOUN	B
at	O	ADP	O
biopsy	O	NOUN	B
were	O	AUX	O
scarce	O	ADJ	O
.	O	PUNCT	O


Nothing	O	PRON	B
abnormal	O	ADJ	B
was	O	AUX	O
seen	O	VERB	O
by	O	ADP	O
electron	O	NOUN	B
microscopy	O	NOUN	I
in	O	ADP	O
two	O	NUM	O
of	O	ADP	O
the	O	DET	O
cases	O	NOUN	B
studied	O	VERB	O
.	O	PUNCT	O


Renal	O	ADJ	B
function	O	NOUN	I
was	O	AUX	O
normal	O	ADJ	O
.	O	PUNCT	O


In	O	ADP	O
three	O	NUM	O
cases	O	NOUN	B
the	O	DET	O
excretion	O	NOUN	B
at	O	ADP	O
131I	O	NOUN	B
-	O	PUNCT	O
hippuran	O	NOUN	B
renography	O	NOUN	B
was	O	AUX	O
slightly	O	ADV	O
slowed	O	VERB	B
.	O	PUNCT	O


Although	O	SCONJ	O
in	O	ADP	O
the	O	DET	O
acute	O	ADJ	B
stage	O	NOUN	I
the	O	DET	O
renal	B-Disease	ADJ	B
lesions	I-Disease	NOUN	I


Type	B-Disease	NOUN	B
B	I-Disease	NOUN	I
hepatitis	I-Disease	NOUN	I
after	O	ADP	O
needle	O	NOUN	B
-	O	PUNCT	O
stick	O	NOUN	B
exposure	O	NOUN	B
:	O	PUNCT	O
prevention	O	NOUN	B
with	O	ADP	O
hepatitis	B-Disease	NOUN	B
B	I-Disease	NOUN	I
immune	O	ADJ	I
globulin	O	NOUN	I
.	O	PUNCT	O


Final	O	ADJ	O
report	O	NOUN	B
of	O	ADP	O
the	O	DET	O
Veterans	O	PROPN	B
Administration	O	PROPN	I
Cooperative	O	PROPN	I
Study	O	PROPN	I
.	O	PUNCT	O


Hepatitis	B-Disease	NOUN	B
B	I-Disease	NOUN	I
immune	O	ADJ	I
globulin	O	NOUN	I
(	O	PUNCT	O
HBIG	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
immune	O	ADJ	B
serum	O	NOUN	I
globulin	O	NOUN	I
(	O	PUNCT	O
ISG	O	NOUN	B
)	O	PUNCT	O
were	O	AUX	O
examined	O	VERB	O
in	O	ADP	O
a	O	DET	O
randomized	O	ADJ	B
,	O	PUNCT	O
double	O	ADJ	B
-	O	PUNCT	O
blind	O	ADJ	B
trial	O	NOUN	B
to	O	PART	O
assess	O	VERB	B
their	O	PRON	O
relative	O	ADJ	O
efficacies	O	NOUN	B
in	O	ADP	O
preventing	O	VERB	B
type	B-Disease	NOUN	B
B	I-Disease	NOUN	I
hepatitis	I-Disease	NOUN	I
after	O	ADP	O
needle	O	NOUN	B
-	O	PUNCT	O
stick	O	NOUN	B
exposure	O	NOUN	B
to	O	PART	I
hepatitis	B-Chemical	NOUN	B
B	I-Chemical	NOUN	I
surface	I-Chemical	NOUN	I
antigen	I-Chemical	NOUN	I
(	O	PUNCT	O
HBsAG	B-Chemical	NOUN	B
)-	O	ADJ	O
positive	O	ADJ	B
donors	O	NOUN	B
.	O	PUNCT	O


Clinical	O	ADJ	B
hepatitis	B-Disease	NOUN	I
developed	O	VERB	O
in	O	ADP	O
1	O	NUM	O
.	O	PUNCT	O


4	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
HBIG	O	NOUN	B
and	O	CCONJ	O
in	O	ADP	O
5	O	NUM	O
.	O	PUNCT	O


9	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
ISG	O	NOUN	B
recipients	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


016	O	NUM	O
),	O	PUNCT	O
and	O	CCONJ	O
seroconversion	O	NOUN	B
(	O	PUNCT	O
anti	O	ADJ	B
-	O	PUNCT	O
HBs	O	NOUN	B
)	O	PUNCT	O
occurred	O	VERB	O
in	O	ADP	O
5	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
20	O	NUM	O
.	O	PUNCT	O


7	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
them	O	PRON	O
respectively	O	ADV	O
(	O	PUNCT	O
P	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


001	O	NUM	O
).	O	PUNCT	O
Mild	O	ADJ	B
and	O	CCONJ	O
transient	O	ADJ	B
side	O	NOUN	B
-	O	PUNCT	O
effects	O	NOUN	B
were	O	AUX	O
noted	O	VERB	O
in	O	ADP	O
3	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
ISG	O	NOUN	B
and	O	CCONJ	O
in	O	ADP	O
3	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
HBIG	O	NOUN	B
recipients	O	NOUN	B
.	O	PUNCT	O


Available	O	NOUN	B
donor	O	NOUN	B
sera	O	NOUN	B
were	O	AUX	O
examined	O	VERB	O
for	O	ADP	O
DNA	O	NOUN	B
polymerase	O	NOUN	I
(	O	PUNCT	O
DNAP	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
e	O	NOUN	B
antigen	O	NOUN	I
and	O	CCONJ	O
antibody	O	NOUN	B
(	O	PUNCT	O
HBeAg	B-Chemical	NOUN	B
;	O	PUNCT	O
anti	O	ADJ	B
-	O	PUNCT	O
HBE	O	NOUN	B
).	O	PUNCT	O
Both	O	CCONJ	O
DNAP	O	NOUN	B
and	O	CCONJ	O
HBeAg	B-Chemical	NOUN	B
showed	O	VERB	O
a	O	DET	O
highly	O	ADV	O
statistically	O	ADV	B
significant	O	ADJ	I
correlation	O	NOUN	B
with	O	ADP	O
the	O	DET	O
infectivity	O	NOUN	B
of	O	ADP	O
HBsAg	B-Chemical	NOUN	B
-	O	PUNCT	O
positive	O	ADJ	B
donors	O	NOUN	B
.	O	PUNCT	O


Hepatitis	B-Disease	NOUN	B
B	I-Disease	NOUN	I
immune	O	ADJ	I
globulin	O	NOUN	I
remained	O	VERB	O
significantly	O	ADV	O
superior	O	ADJ	O
to	O	PART	O
ISG	O	NOUN	B
in	O	ADP	O
preventing	O	VERB	B
type	B-Disease	NOUN	B
B	I-Disease	NOUN	I
hepatitis	I-Disease	NOUN	I
even	O	ADV	O
when	O	SCONJ	O
the	O	DET	O
analysis	O	NOUN	B
was	O	AUX	O
confined	O	VERB	O
to	O	PART	O
these	O	DET	O
two	O	NUM	O
high	O	ADJ	B
-	O	PUNCT	O
risk	O	NOUN	B
subgroups	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
efficacy	O	NOUN	B
of	O	ADP	O
ISG	O	NOUN	B
in	O	ADP	O
preventing	O	VERB	B
type	B-Disease	NOUN	B
B	I-Disease	NOUN	I
hepatitis	I-Disease	NOUN	I


Serotonin	B-Disease	NOUN	B
syndrome	I-Disease	NOUN	I
from	O	ADP	O
venlafaxine	B-Chemical	NOUN	B
-	O	PUNCT	O
tranylcypromine	B-Chemical	NOUN	B
interaction	O	NOUN	B
.	O	PUNCT	O


Excessive	O	ADJ	B
stimulation	O	NOUN	B
of	O	ADP	O
serotonin	B-Chemical	NOUN	B
5HT1A	O	NOUN	I
receptors	O	NOUN	I
causes	O	VERB	O
a	O	DET	O
syndrome	O	NOUN	B
of	O	ADP	O
serotonin	B-Chemical	NOUN	B
excess	O	NOUN	B
that	O	PRON	O
consists	O	VERB	O
of	O	ADP	O
shivering	O	NOUN	B
,	O	PUNCT	O
muscle	B-Disease	NOUN	B
rigidity	I-Disease	NOUN	I
,	O	PUNCT	O
salivation	B-Disease	NOUN	B
,	O	PUNCT	O
confusion	B-Disease	NOUN	B
,	O	PUNCT	O
agitation	B-Disease	NOUN	B
and	O	CCONJ	O
hyperthermia	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
most	O	ADV	O
common	O	ADJ	O
cause	O	NOUN	B
of	O	ADP	O
this	O	DET	O
syndrome	O	NOUN	B
is	O	AUX	O
an	O	DET	O
interaction	O	NOUN	B
between	O	ADP	O
a	O	DET	O
monoamine	O	NOUN	B
oxidase	O	NOUN	I
inhibitor	O	NOUN	I
(	O	PUNCT	O
MAOI	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
specific	O	ADJ	O
serotonin	B-Chemical	NOUN	B
reuptake	O	NOUN	I
inhibitor	O	NOUN	I
.	O	PUNCT	O


Venlafaxine	B-Chemical	NOUN	B
is	O	AUX	O
a	O	DET	O
new	O	ADJ	O
antidepressant	O	ADJ	B
agent	O	NOUN	I
that	O	PRON	O
inhibits	O	VERB	B
the	O	DET	O
reuptake	O	NOUN	B
of	O	ADP	O
serotonin	B-Chemical	NOUN	B
and	O	CCONJ	O
norepinephrine	B-Chemical	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
a	O	DET	O
venlafaxine	B-Chemical	NOUN	B
-	O	PUNCT	O
MAOI	O	NOUN	B
interaction	O	NOUN	B
that	O	PRON	O
resulted	O	VERB	O
in	O	ADP	O
the	O	DET	O
serotonin	B-Disease	NOUN	B
syndrome	I-Disease	NOUN	I
in	O	ADP	O
a	O	DET	O
23	O	NUM	O
-	O	PUNCT	O
y	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
male	O	NOUN	B
who	O	PRON	O
was	O	AUX	O
taking	O	VERB	O
tranylcypromine	B-Chemical	NOUN	B
for	O	ADP	O
depression	B-Disease	NOUN	B
.	O	PUNCT	O


He	O	PRON	O
had	O	AUX	O
been	O	AUX	O
well	O	ADV	O
until	O	ADP	O
the	O	DET	O
morning	O	NOUN	B
of	O	ADP	O
presentation	O	NOUN	B
when	O	SCONJ	O
he	O	PRON	O
took	O	VERB	O
1	O	NUM	O
/	O	SYM	O
2	O	NUM	O
tab	O	NOUN	B
of	O	ADP	O
venlafaxine	B-Chemical	NOUN	B
.	O	PUNCT	O


Within	O	ADP	O
2	O	NUM	O
h	O	NOUN	O
he	O	PRON	O
became	O	VERB	O
confused	O	VERB	O
with	O	ADP	O
jerking	O	ADJ	B
movements	O	NOUN	B
of	O	ADP	O
his	O	PRON	O
extremities	O	NOUN	B
,	O	PUNCT	O
tremors	B-Disease	NOUN	B
and	O	CCONJ	O
rigidity	B-Disease	NOUN	B
.	O	PUNCT	O


He	O	PRON	O
was	O	AUX	O
brought	O	VERB	O
directly	O	ADV	O
to	O	ADP	O
a	O	DET	O
hospital	O	NOUN	B
where	O	SCONJ	O
he	O	PRON	O
was	O	AUX	O
found	O	VERB	O
to	O	PART	O
be	O	AUX	O
agitated	O	VERB	B
and	O	CCONJ	O
confused	O	VERB	O
with	O	ADP	O
shivering	O	NOUN	B
,	O	PUNCT	O
myoclonic	B-Disease	ADJ	B
jerks	I-Disease	NOUN	I
,	O	PUNCT	O
rigidity	B-Disease	NOUN	B
,	O	PUNCT	O
salivation	B-Disease	NOUN	B
and	O	CCONJ	O
diaphoresis	O	NOUN	B
.	O	PUNCT	O


His	O	PRON	O
pupils	O	NOUN	B
were	O	AUX	O
7	O	NUM	O
mm	O	NOUN	O
and	O	CCONJ	O
sluggishly	O	ADV	O
reactive	O	ADJ	O
to	O	PART	O
light	O	NOUN	O
.	O	PUNCT	O


Vital	O	NOUN	B
signs	O	NOUN	I
were	O	AUX	O
:	O	PUNCT	O
blood	O	NOUN	B
pressure	O	NOUN	I
120	O	NUM	O
/	O	SYM	O
67	O	NUM	O
mm	O	NOUN	B
Hg	O	NOUN	I
,	O	PUNCT	O
heart	O	NOUN	B
rate	O	NOUN	I
127	O	NUM	O
/	O	SYM	O
min	O	NOUN	B
,	O	PUNCT	O
respiratory	O	ADJ	B
rate	O	NOUN	I
28	O	NUM	O
/	O	SYM	O
min	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
temperature	O	NOUN	B
97	O	NUM	O
F	O	PROPN	B
.	O	PUNCT	O


After	O	ADP	O
180	O	NUM	O
mg	O	NOUN	O
of	O	ADP	O
diazepam	B-Chemical	NOUN	B
i	O	NUM	O
.	O	PUNCT	O


v	O	NOUN	O
.	O	PUNCT	O


he	O	PRON	O
remained	O	VERB	O
tremulous	O	ADJ	B
with	O	ADP	O
muscle	B-Disease	NOUN	B
rigidity	I-Disease	NOUN	I
and	O	CCONJ	O
clenched	O	ADJ	B
jaws	O	NOUN	I
.	O	PUNCT	O


He	O	PRON	O
was	O	AUX	O
intubated	O	VERB	B
for	O	ADP	O
airway	O	NOUN	B
protection	O	NOUN	B
and	O	CCONJ	O
because	O	SCONJ	O
of	O	ADP	O
hypoventilation	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
was	O	AUX	O
paralyzed	B-Disease	ADJ	B
to	O	PART	O
control	O	VERB	B
muscle	B-Disease	NOUN	I
rigidity	I-Disease	NOUN	O
.	O	PUNCT	O


His	O	PRON	O
subsequent	O	ADJ	O
course	O	NOUN	B
was	O	AUX	O
remarkable	O	ADJ	O
for	O	ADP	O
non	O	ADJ	B
-	O	PUNCT	O
immune	O	ADJ	B
thrombocytopenia	B-Disease	NOUN	I
which	O	DET	O
resolved	O	VERB	B
.	O	PUNCT	O


The	O	DET	O
patient	O	NOUN	B
'	O	PART	O
s	O	NOUN	O
maximal	O	ADJ	B
temperature	O	NOUN	B
was	O	AUX	O
101	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
F	O	PROPN	O
and	O	CCONJ	O
his	O	PRON	O
CPK	O	NOUN	B
remained	O	VERB	O
<	O	X	O
500	O	NUM	O
units	O	NOUN	B
/	O	SYM	O
L	O	NOUN	B
with	O	ADP	O
no	O	DET	O
other	O	ADJ	O
evidence	O	NOUN	B
of	O	ADP	O
rhabdomyolysis	B-Disease	NOUN	B
.	O	PUNCT	O


His	O	PRON	O
mental	O	ADJ	B
status	O	NOUN	I
normalized	O	VERB	B
and	O	CCONJ	O
he	O	PRON	O
was	O	AUX	O
transferred	O	VERB	B
to	O	ADP	O
a	O	DET	O
psychiatry	O	NOUN	B
ward	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
patient	O	NOUN	B
survived	O	VERB	O
without	O	ADP	O
sequelae	O	NOUN	B
due	O	ADP	O
to	O	PART	O
the	O	DET	O
aggressive	O	ADJ	B
sedation	O	NOUN	B
and	O	CCONJ	O
neuromuscular	O	ADJ	B
paralysis	B-Disease	NOUN	I


Effect	O	NOUN	B
of	O	ADP	O
nondopaminergic	O	ADJ	B
drugs	O	NOUN	I
on	O	ADP	O
L-dopa	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
dyskinesias	B-Disease	NOUN	B
in	O	ADP	O
MPTP	B-Chemical	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
monkeys	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
group	O	NOUN	B
of	O	ADP	O
four	O	NUM	O
monkeys	O	NOUN	B
was	O	AUX	O
rendered	O	VERB	O
parkinsonian	B-Disease	ADJ	B
with	O	ADP	O
the	O	DET	O
toxin	O	NOUN	B
MPTP	B-Chemical	NOUN	B
.	O	PUNCT	O


They	O	PRON	O
were	O	AUX	O
then	O	ADV	O
treated	O	VERB	B
chronically	O	ADV	B
with	O	ADP	O
L-DOPA/benserazide	B-Chemical	NOUN	B
50	O	NUM	O
/	O	SYM	O
12	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
mg	O	NOUN	O
/	O	PUNCT	O
kg	O	NOUN	O
given	O	VERB	O
orally	O	ADV	B
daily	O	ADV	O
for	O	ADP	O
2	O	NUM	O
months	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
dose	O	NOUN	B
produced	O	VERB	O
a	O	DET	O
striking	O	ADJ	O
antiparkinsonian	O	ADJ	B
effect	O	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
all	O	DET	O
animals	O	NOUN	B
manifested	O	VERB	O
dyskinesia	B-Disease	NOUN	B
.	O	PUNCT	O


A	O	DET	O
series	O	NOUN	B
of	O	ADP	O
agents	O	NOUN	B
acting	O	VERB	O
primarily	O	ADV	O
on	O	ADP	O
neurotransmitters	O	NOUN	B
other	O	ADJ	O
than	O	ADP	O
dopamine	B-Chemical	NOUN	B
were	O	AUX	O
then	O	ADV	O
tested	O	VERB	B
in	O	ADP	O
combination	O	NOUN	B
with	O	ADP	O
L-DOPA	B-Chemical	NOUN	B
to	O	PART	O
see	O	VERB	O
if	O	SCONJ	O
the	O	DET	O
dyskinetic	B-Disease	ADJ	B
movements	O	NOUN	B
would	O	AUX	O
be	O	AUX	O
modified	O	VERB	B
.	O	PUNCT	O


Several	O	ADJ	O
drugs	O	NOUN	B
,	O	PUNCT	O
including	O	VERB	O
clonidine	B-Chemical	NOUN	B
,	O	PUNCT	O
physostigmine	B-Chemical	NOUN	B
,	O	PUNCT	O
methysergide	B-Chemical	NOUN	B
,	O	PUNCT	O
5-MDOT	B-Chemical	ADV	B
,	O	PUNCT	O
propranolol	B-Chemical	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
MK-801	B-Chemical	NOUN	B
,	O	PUNCT	O
markedly	O	ADV	O
reduced	O	VERB	B
the	O	DET	O
dyskinetic	B-Disease	ADJ	B
movements	O	NOUN	B
but	O	CCONJ	O
at	O	ADP	O
the	O	DET	O
cost	O	NOUN	B
of	O	ADP	O
a	O	DET	O
return	O	NOUN	B
of	O	ADP	I
parkinsonian	B-Disease	ADJ	B
symptomatology	O	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
yohimbine	B-Chemical	NOUN	B
and	O	CCONJ	O
meperidine	B-Chemical	NOUN	B
reduced	O	VERB	B
predominantly	O	ADV	O
the	O	DET	O
dyskinetic	B-Disease	ADJ	B
movements	O	NOUN	B
.	O	PUNCT	O


Baclofen	B-Chemical	NOUN	B
was	O	AUX	O
also	O	ADV	O
useful	O	ADJ	O
in	O	ADP	O
one	O	NUM	O
monkey	O	NOUN	B
against	O	ADP	O
a	O	DET	O
more	O	ADV	O
dystonic	B-Disease	ADJ	B
form	O	NOUN	I
of	O	ADP	I
dyskinesia	B-Disease	NOUN	B
.	O	PUNCT	O


Atropine	B-Chemical	NOUN	B
converted	O	VERB	O
the	O	DET	O
dystonic	B-Disease	ADJ	B
movements	O	NOUN	B
into	O	ADP	O
chorea	B-Disease	NOUN	B


CCNU	B-Chemical	NOUN	B
(	O	PUNCT	O
lomustine	B-Chemical	NOUN	B
)	O	PUNCT	O
toxicity	B-Disease	NOUN	B
in	O	ADP	O
dogs	O	NOUN	B
:	O	PUNCT	O
a	O	DET	O
retrospective	O	ADJ	B
study	O	NOUN	I
(	O	PUNCT	O
2002	O	NUM	O
-	O	SYM	O
07	O	NUM	O
).	O	PUNCT	O
OBJECTIVE	O	NOUN	B
:	O	PUNCT	O
To	O	PART	O
describe	O	VERB	O
the	O	DET	O
incidence	O	NOUN	B
of	O	ADP	O
haematological,	B-Disease	ADJ	B
renal,	I-Disease	NOUN	O
hepatic	I-Disease	ADJ	B
and	I-Disease	CCONJ	O
gastrointestinal	I-Disease	ADJ	B
toxicities	I-Disease	NOUN	B
in	O	ADP	O
tumour	O	NOUN	B
-	O	PUNCT	O
bearing	O	VERB	O
dogs	O	NOUN	B
receiving	O	VERB	O
1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea	B-Chemical	NOUN	B
(	O	PUNCT	O
CCNU	B-Chemical	NOUN	B
).	O	PUNCT	O
DESIGN	O	NOUN	O
:	O	PUNCT	O
The	O	DET	O
medical	O	ADJ	B
records	O	NOUN	I
of	O	ADP	O
206	O	NUM	O
dogs	O	NOUN	B
that	O	PRON	O
were	O	AUX	O
treated	O	VERB	B
with	O	ADP	I
CCNU	B-Chemical	NOUN	B
at	O	ADP	O
the	O	DET	O
Melbourne	O	PROPN	B
Veterinary	O	PROPN	I
Specialist	O	PROPN	I
Centre	O	PROPN	I
between	O	ADP	O
February	O	PROPN	O
2002	O	NUM	O
and	O	CCONJ	O
December	O	PROPN	O
2007	O	NUM	O
were	O	AUX	O
retrospectively	O	ADV	B
evaluated	O	VERB	I
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
Of	O	ADP	O
the	O	DET	O
206	O	NUM	O
dogs	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
CCNU	B-Chemical	NOUN	B
,	O	PUNCT	O
185	O	NUM	O
met	O	VERB	O
the	O	DET	O
inclusion	O	NOUN	B
criteria	O	NOUN	I
for	O	ADP	O
at	O	ADP	O
least	O	ADJ	O
one	O	NUM	O
class	O	NOUN	O
of	O	ADP	O
toxicity	B-Disease	NOUN	B
.	O	PUNCT	O


CCNU	B-Chemical	NOUN	B
was	O	AUX	O
used	O	VERB	O
most	O	ADV	O
commonly	O	ADV	O
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
lymphoma	B-Disease	NOUN	B
,	O	PUNCT	O
mast	B-Disease	NOUN	B
cell	I-Disease	NOUN	I
tumour	I-Disease	NOUN	I
,	O	PUNCT	O
brain	B-Disease	NOUN	B
tumour	I-Disease	NOUN	I
,	O	PUNCT	O
histiocytic	B-Disease	ADJ	B
tumours	I-Disease	NOUN	I
and	O	CCONJ	O
epitheliotropic	B-Disease	ADJ	B
lymphoma	I-Disease	NOUN	I
.	O	PUNCT	O


Throughout	O	ADP	O
treatment	O	NOUN	B
,	O	PUNCT	O
56	O	NUM	O
.	O	PUNCT	O


9	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
dogs	O	NOUN	B
experienced	O	VERB	O
neutropenia	B-Disease	NOUN	B
,	O	PUNCT	O
34	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
%	O	NOUN	O
experienced	O	ADJ	O
anaemia	B-Disease	NOUN	B
and	O	CCONJ	O
14	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
%	O	NOUN	O
experienced	O	ADJ	O
thrombocytopenia	B-Disease	NOUN	B
.	O	PUNCT	O


Gastrointestinal	B-Disease	ADJ	B
toxicosis	I-Disease	NOUN	B
was	O	AUX	O
detected	O	VERB	B
in	O	ADP	O
37	O	NUM	O
.	O	PUNCT	O


8	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
dogs	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
most	O	ADV	O
common	O	ADJ	O
sign	O	NOUN	B
of	O	ADP	O
which	O	DET	O
was	O	AUX	O
vomiting	B-Disease	NOUN	B
(	O	PUNCT	O
24	O	NUM	O
.	O	PUNCT	O


3	O	NUM	O
%).	O	ADJ	O
Potential	O	ADJ	B
renal	O	ADJ	B
toxicity	B-Disease	NOUN	B
and	O	CCONJ	O
elevated	O	ADJ	B
alanine	B-Chemical	NOUN	O
transaminase	O	NOUN	O
(	O	PUNCT	O
ALT	O	NOUN	B
)	O	PUNCT	O
concentration	O	NOUN	B
were	O	AUX	O
reported	O	VERB	O
in	O	ADP	O
12	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
48	O	NUM	O
.	O	PUNCT	O


8	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
dogs	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


The	O	DET	O
incidence	O	NOUN	B
of	O	ADP	O
hepatic	B-Disease	ADJ	B
failure	I-Disease	NOUN	I
was	O	AUX	O
1	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
%.	O	NOUN	B
CONCLUSIONS	O	NOUN	O
:	O	PUNCT	O
CCNU	B-Chemical	NOUN	B
-	O	PUNCT	O
associated	O	VERB	B
toxicity	B-Disease	NOUN	B


Neuroactive	O	ADJ	B
steroids	B-Chemical	NOUN	I
protect	O	VERB	O
against	O	ADP	O
pilocarpine	B-Chemical	NOUN	B
-	O	PUNCT	O
and	O	CCONJ	O
kainic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
-	O	PUNCT	O
induced	O	VERB	B
limbic	O	ADJ	B
seizures	B-Disease	NOUN	B
and	O	CCONJ	O
status	B-Disease	VERB	B
epilepticus	I-Disease	NOUN	I
in	O	ADP	O
mice	O	NOUN	B
.	O	PUNCT	O


Several	O	ADJ	O
structurally	O	ADV	B
related	O	ADJ	O
metabolites	O	NOUN	B
of	O	ADP	O
progesterone	B-Chemical	NOUN	B
(	O	PUNCT	O
3	B-Chemical	NUM	O
alpha-hydroxy	I-Chemical	ADJ	O
pregnane-20-ones	I-Chemical	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
deoxycorticosterone	B-Chemical	NOUN	B
(	O	PUNCT	O
3	B-Chemical	NUM	O
alpha-hydroxy	I-Chemical	ADJ	B
pregnane-21-diol-20-ones	I-Chemical	NOUN	I
)	O	PUNCT	O
and	O	CCONJ	O
their	O	PRON	O
3	O	NUM	O
beta	O	NOUN	B
-	O	PUNCT	O
epimers	O	NOUN	B
were	O	AUX	O
evaluated	O	VERB	B
for	O	ADP	O
protective	O	ADJ	B
activity	O	NOUN	I
against	O	ADP	O
pilocarpine	B-Chemical	NOUN	B
-,	O	ADJ	O
kainic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
-	O	PUNCT	O
and	O	CCONJ	O
N-methyl-D-aspartate	B-Chemical	NOUN	B
(	O	PUNCT	O
NMDA	B-Chemical	NOUN	B
)-	O	ADJ	O
induced	O	VERB	B
seizures	B-Disease	NOUN	B
in	O	ADP	O
mice	O	NOUN	B
.	O	PUNCT	O


Steroids	B-Chemical	NOUN	B
with	O	ADP	O
the	O	DET	O
3	O	NUM	B
-	O	PUNCT	O
hydroxy	O	NOUN	B
group	O	NOUN	B
in	O	ADP	O
the	O	DET	O
alpha	O	NOUN	B
-	O	PUNCT	O
position	O	NOUN	B
and	O	CCONJ	O
5	O	NUM	O
-	O	PUNCT	O
H	O	NOUN	B
in	O	ADP	O
the	O	DET	O
alpha	O	NOUN	B
-	O	PUNCT	O
or	O	CCONJ	O
beta	O	NOUN	B
-	O	PUNCT	O
configurations	O	NOUN	B
were	O	AUX	O
highly	O	ADV	O
effective	O	ADJ	B
in	O	ADP	O
protecting	O	VERB	O
against	O	ADP	O
pilocarpine	B-Chemical	NOUN	B
(	O	PUNCT	O
416	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
,	O	PUNCT	O
s	O	NOUN	O
.	O	PUNCT	O


c	O	X	O
.)-	O	ADV	O
induced	O	VERB	B
limbic	O	ADJ	B
motor	O	NOUN	B
seizures	B-Disease	NOUN	I
and	O	CCONJ	O
status	B-Disease	NOUN	B
epilepticus	I-Disease	NOUN	I
(	O	PUNCT	O
ED50	O	NOUN	B
values	O	NOUN	B
,	O	PUNCT	O
7	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
-	O	SYM	O
18	O	NUM	O
.	O	PUNCT	O


7	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
,	O	PUNCT	O
i	O	X	O
.	O	PUNCT	O


p	O	NOUN	O
.).	O	NOUN	O
The	O	DET	O
corresponding	O	ADJ	O
epimers	O	NOUN	B
with	O	ADP	O
the	O	DET	O
3	O	NUM	B
-	O	PUNCT	O
hydroxy	O	NOUN	B
group	O	NOUN	B
in	O	ADP	O
the	O	DET	O
beta	O	NOUN	B
-	O	PUNCT	O
position	O	NOUN	B
were	O	AUX	O
also	O	ADV	O
effective	O	ADJ	B
but	O	CCONJ	O
less	O	ADV	O
potent	O	ADJ	O
(	O	PUNCT	O
ED50	O	NOUN	B
values	O	NOUN	B
,	O	PUNCT	O
33	O	NUM	O
.	O	PUNCT	O


8	O	NUM	O
-	O	SYM	O
63	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
,	O	PUNCT	O
i	O	X	O
.	O	PUNCT	O


p	O	NOUN	O
.).	O	NOUN	O
Although	O	SCONJ	O
the	O	DET	O
neuroactive	O	ADJ	B
steroids	B-Chemical	NOUN	I
were	O	AUX	O
considerably	O	ADV	O
less	O	ADV	O
potent	O	ADJ	O
than	O	ADP	O
the	O	DET	O
benzodiazepine	B-Chemical	NOUN	B
clonazepam	B-Chemical	NOUN	B
in	O	ADP	O
protecting	O	VERB	O
against	O	ADP	O
pilocarpine	B-Chemical	NOUN	B
seizures	B-Disease	NOUN	B
,	O	PUNCT	O
steroids	B-Chemical	NOUN	B
with	O	ADP	O
the	O	DET	O
5	O	NUM	O
alpha	O	NOUN	B
,	O	PUNCT	O
3	O	NUM	O
alpha	O	NOUN	B
-	O	PUNCT	O
configuration	O	NOUN	B
had	O	AUX	O
comparable	O	ADJ	O
or	O	CCONJ	O
higher	O	ADJ	O
protective	O	ADJ	B
index	O	NOUN	I
values	O	NOUN	I
(	O	PUNCT	O
TD50	O	NOUN	B
for	O	ADP	O
motor	O	NOUN	B
impairment	O	NOUN	I
divided	O	VERB	O
by	O	ADP	O
ED50	O	NOUN	B
for	O	ADP	O
seizure	B-Disease	NOUN	B
protection	O	NOUN	B
)	O	PUNCT	O
than	O	ADP	O
clonazepam	B-Chemical	NOUN	B
,	O	PUNCT	O
indicating	O	VERB	O
that	O	SCONJ	O
some	O	DET	O
neuroactive	O	ADJ	B
steroids	B-Chemical	NOUN	I
may	O	AUX	O
have	O	AUX	O
lower	O	ADJ	O
relative	O	ADJ	O
toxicity	B-Disease	NOUN	B
.	O	PUNCT	O


Steroids	B-Chemical	NOUN	B
with	O	ADP	O
the	O	DET	O
5	O	NUM	O
alpha	O	NOUN	B
,	O	PUNCT	O
3	O	NUM	O
alpha	O	NOUN	B
-	O	PUNCT	O
or	O	CCONJ	O
5	O	NUM	O
beta	O	NOUN	B
,	O	PUNCT	O
3	O	NUM	O
alpha	O	NOUN	B
-	O	PUNCT	O
configurations	O	NOUN	B
also	O	ADV	O
produced	O	VERB	O
a	O	DET	O
dose	O	NOUN	B
-	O	PUNCT	O
dependent	O	ADJ	B
delay	O	NOUN	B
in	O	ADP	O
the	O	DET	O
onset	O	NOUN	O
of	O	ADP	O
limbic	O	ADJ	B
seizures	B-Disease	NOUN	B
induced	O	VERB	B
by	O	ADP	O
kainic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
(	O	PUNCT	O
32	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
,	O	PUNCT	O
s	O	NOUN	O
.	O	PUNCT	O


c	O	X	O
.),	O	NOUN	O
but	O	CCONJ	O
did	O	AUX	O
not	O	PART	O
completely	O	ADV	O
protect	O	VERB	O
against	O	ADP	O
the	O	DET	O
seizures	B-Disease	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
when	O	SCONJ	O
a	O	DET	O
second	O	ADJ	O
dose	O	NOUN	B
of	O	ADP	O
the	O	DET	O
steroid	B-Chemical	NOUN	B
was	O	AUX	O
administered	O	VERB	B
1	O	NUM	O
hr	O	NOUN	O
after	O	ADP	O
the	O	DET	O
first	O	ADJ	O
dose	O	NOUN	B
,	O	PUNCT	O
complete	O	ADJ	O
protection	O	NOUN	B
from	O	ADP	O
the	O	DET	O
kainic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
-	O	PUNCT	O
induced	O	VERB	B
limbic	O	ADJ	B
seizures	B-Disease	NOUN	B
and	O	CCONJ	O
status	B-Disease	NOUN	B
epilepticus	I-Disease	NOUN	I
was	O	AUX	O
obtained	O	VERB	O
.	O	PUNCT	O


The	O	DET	O
steroids	B-Chemical	NOUN	B
also	O	ADV	O
caused	O	VERB	O
a	O	DET	O
dose	O	NOUN	B
-	O	PUNCT	O
dependent	O	ADJ	B
delay	O	NOUN	B
in	O	ADP	O
NMDA	B-Chemical	NOUN	B
(	O	PUNCT	O
257	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
,	O	PUNCT	O
s	O	NOUN	O
.	O	PUNCT	O


c	O	X	O
.)-	O	ADV	O
induced	O	VERB	B
lethality	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
did	O	AUX	O
not	O	PART	O
completely	O	ADV	O
protect	O	VERB	O
against	O	ADP	O
NMDA	B-Chemical	NOUN	B
seizures	B-Disease	NOUN	B
or	O	CCONJ	O
lethality	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
conclude	O	VERB	O
that	O	SCONJ	O
neuroactive	O	ADJ	B
steroids	B-Chemical	NOUN	I
are	O	AUX	O
highly	O	ADV	O
effective	O	ADJ	B
in	O	ADP	O
protecting	O	VERB	O
against	O	ADP	O
pilocarpine	B-Chemical	NOUN	B
-	O	PUNCT	O
and	O	CCONJ	O
kainic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
-	O	PUNCT	O
induced	O	VERB	B
seizures	B-Disease	NOUN	B
and	O	CCONJ	O
status	B-Disease	VERB	B
epilepticus	I-Disease	NOUN	I
in	O	ADP	O
mice	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
may	O	AUX	O
be	O	AUX	O
of	O	ADP	O
utility	O	NOUN	O
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
some	O	DET	O
forms	O	NOUN	O
of	O	ADP	O
status	B-Disease	NOUN	B
epilepticus	I-Disease	NOUN	I


The	O	DET	O
safety	O	NOUN	B
and	O	CCONJ	O
efficacy	O	NOUN	B
of	O	ADP	O
combination	O	NOUN	B
N-butyl-deoxynojirimycin	B-Chemical	NOUN	B
(	O	PUNCT	O
SC-48334	B-Chemical	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
zidovudine	B-Chemical	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
HIV-1	B-Disease	NOUN	B
infection	I-Disease	NOUN	O
and	O	CCONJ	O
200	O	NUM	O
-	O	PUNCT	O
500	O	NUM	O
CD4	O	NOUN	B
cells	O	NOUN	I
/	O	SYM	O
mm3	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
conducted	O	VERB	O
a	O	DET	O
double	O	ADJ	B
-	O	PUNCT	O
blind	O	ADJ	B
,	O	PUNCT	O
randomized	O	ADJ	B
phase	O	NOUN	I
II	O	NUM	I
study	O	NOUN	B
to	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
safety	O	NOUN	B
and	O	CCONJ	O
activity	O	NOUN	B
of	O	ADP	O
combination	O	NOUN	B
therapy	O	NOUN	I
with	O	ADP	O
N-butyl-deoxynojirimycin	B-Chemical	NOUN	B
(	O	PUNCT	O
SC-48334	B-Chemical	NOUN	B
)(	O	NOUN	O
an	O	DET	O
alpha	O	NOUN	B
-	O	PUNCT	O
glucosidase	O	NOUN	B
I	O	NUM	I
inhibitor	O	NOUN	I
)	O	PUNCT	O
and	O	CCONJ	O
zidovudine	B-Chemical	NOUN	B
versus	O	CCONJ	O
zidovudine	B-Chemical	NOUN	B
alone	O	ADV	O
.	O	PUNCT	O


Patients	O	NOUN	B
with	O	ADP	O
200	O	NUM	O
to	O	PART	O
500	O	NUM	O
CD4	O	NOUN	B
cells	O	NOUN	I
/	O	PUNCT	O
mm3	O	NOUN	B
who	O	PRON	O
tolerated	O	VERB	B
<	O	X	O
or	O	CCONJ	O
=	O	ADJ	O
12	O	NUM	O
weeks	O	NOUN	B
of	O	ADP	O
prior	O	ADJ	B
zidovudine	B-Chemical	NOUN	B
therapy	O	NOUN	I
received	O	VERB	O
SC-48334	B-Chemical	NOUN	B
(	O	PUNCT	O
1000	O	NUM	O
mg	O	NOUN	O
every	O	DET	O
8	O	NUM	O
h	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
zidovudine	B-Chemical	NOUN	B
(	O	PUNCT	O
100	O	NUM	O
mg	O	NOUN	O
every	O	DET	O
8	O	NUM	O
h	O	NOUN	O
)	O	PUNCT	O
or	O	CCONJ	O
zidovudine	B-Chemical	NOUN	B
and	O	CCONJ	O
placebo	O	NOUN	B
.	O	PUNCT	O


Sixty	O	NUM	O
patients	O	NOUN	B
received	O	VERB	O
combination	O	NOUN	B
therapy	O	NOUN	I
and	O	CCONJ	O
58	O	NUM	O
,	O	PUNCT	O
zidovudine	B-Chemical	NOUN	B
and	O	CCONJ	O
placebo	O	NOUN	B
.	O	PUNCT	O


Twenty	O	NUM	B
-	O	PUNCT	O
three	O	NUM	B
patients	O	NOUN	B
(	O	PUNCT	O
38	O	NUM	O
%)	O	NOUN	O
and	O	CCONJ	O
15	O	NUM	O
(	O	PUNCT	O
26	O	NUM	O
%),	O	ADJ	O
in	O	ADP	O
the	O	DET	O
combination	O	NOUN	B
and	O	CCONJ	O
zidovudine	B-Chemical	NOUN	B
groups	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
,	O	PUNCT	O
discontinued	O	VERB	B
therapy	O	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


15	O	NUM	O
).	O	PUNCT	O
The	O	DET	O
mean	O	ADJ	O
SC-48334	B-Chemical	ADJ	B
steady	O	ADJ	B
-	O	PUNCT	O
state	O	NOUN	B
trough	O	NOUN	O
level	O	NOUN	O
(	O	PUNCT	O
4	O	NUM	O
.	O	PUNCT	O


04	O	NUM	O
+/-	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


99	O	NUM	O
micrograms	O	NOUN	B
/	O	PUNCT	O
ml	O	NOUN	O
)	O	PUNCT	O
was	O	AUX	O
below	O	ADP	O
the	O	DET	O
in	O	X	B
vitro	O	X	I
inhibitory	O	ADJ	B
concentration	O	NOUN	B
for	O	ADP	O
human	O	ADJ	B
immunodeficiency	B-Disease	NOUN	I
virus	O	NOUN	I
(	O	PUNCT	O
HIV	O	NOUN	B
).	O	PUNCT	O
The	O	DET	O
mean	O	ADJ	O
increase	O	NOUN	B
in	O	ADP	O
CD4	O	NOUN	B
cells	O	NOUN	I
at	O	ADP	O
week	O	NOUN	B
4	O	NUM	O
was	O	AUX	O
73	O	NUM	O
.	O	PUNCT	O


8	O	NUM	O
cells	O	NOUN	B
/	O	SYM	O
mm3	O	NUM	B
and	O	CCONJ	O
52	O	NUM	O
.	O	PUNCT	O


4	O	NUM	O
cells	O	NOUN	B
/	O	SYM	O
mm3	O	NOUN	B
for	O	ADP	O
the	O	DET	O
combination	O	NOUN	B
and	O	CCONJ	O
zidovudine	B-Chemical	NOUN	B
groups	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
(	O	PUNCT	O
p	O	NOUN	O
>	O	NOUN	O
0	O	NUM	O
.	O	PUNCT	O


36	O	NUM	O
).	O	PUNCT	O
For	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
prior	O	ADJ	O
zidovudine	B-Chemical	NOUN	B
therapy	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
mean	O	ADJ	O
change	O	NOUN	O
in	O	ADP	O
CD4	O	NOUN	B
cells	O	NOUN	I
in	O	ADP	O
the	O	DET	O
combination	O	NOUN	B
and	O	CCONJ	O
zidovudine	B-Chemical	NOUN	B
groups	O	NOUN	B
was	O	AUX	O
63	O	NUM	O
.	O	PUNCT	O


7	O	NUM	O
cells	O	NOUN	B
/	O	PUNCT	O
mm3	O	NUM	B
and	O	CCONJ	O
4	O	NUM	O
.	O	PUNCT	O


9	O	NUM	O
cells	O	NOUN	B
/	O	SYM	O
mm3	O	NOUN	B
at	O	ADP	O
week	O	NOUN	B
8	O	NUM	O
and	O	CCONJ	O
6	O	NUM	O
.	O	PUNCT	O


8	O	NUM	O
cells	O	NOUN	B
/	O	SYM	O
mm3	O	NUM	B
and	O	CCONJ	O
-	O	PUNCT	O
45	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
cells	O	NOUN	B
/	O	SYM	O
mm3	O	NOUN	B
at	O	ADP	O
week	O	NOUN	B
16	O	NUM	O
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


The	O	DET	O
number	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
suppression	O	NOUN	B
of	O	ADP	O
HIV	O	NOUN	B
p24	O	NOUN	O
antigenemia	O	NOUN	B
in	O	ADP	O
the	O	DET	O
combination	O	NOUN	B
and	O	CCONJ	O
zidovudine	B-Chemical	NOUN	B
groups	O	NOUN	B
was	O	AUX	O
six	O	NUM	O
(	O	PUNCT	O
40	O	NUM	O
%)	O	NOUN	O
and	O	CCONJ	O
two	O	NUM	O
(	O	PUNCT	O
11	O	NUM	O
%)	O	NOUN	O
at	O	ADP	O
week	O	NOUN	B
4	O	NUM	O
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


10	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
five	O	NUM	O
(	O	PUNCT	O
45	O	NUM	O
%)	O	NOUN	O
and	O	CCONJ	O
two	O	NUM	O
(	O	PUNCT	O
14	O	NUM	O
%)	O	NOUN	O
at	O	ADP	O
week	O	NOUN	B
24	O	NUM	O
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


08	O	NUM	O
),	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


Diarrhea	B-Disease	NOUN	B
,	O	PUNCT	O
flatulence	B-Disease	NOUN	B
,	O	PUNCT	O
abdominal	B-Disease	ADJ	B
pain	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
weight	B-Disease	NOUN	B
loss	I-Disease	NOUN	I


Recent	O	ADJ	O
preclinical	O	ADJ	B
and	O	CCONJ	O
clinical	O	ADJ	B
studies	O	NOUN	I
with	O	ADP	O
the	O	DET	O
thymidylate	O	ADJ	B
synthase	O	NOUN	I
inhibitor	O	NOUN	I
N10-propargyl-5,8-dideazafolic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
(	O	PUNCT	O
CB	B-Chemical	NOUN	B
3717	I-Chemical	NUM	O
).	O	PUNCT	O
CB	B-Chemical	NOUN	B
3717	I-Chemical	NUM	O
,	O	PUNCT	O
N10-propargyl-5,8-dideazafolic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
,	O	PUNCT	O
is	O	AUX	O
a	O	DET	O
tight	O	ADJ	B
-	O	PUNCT	O
binding	O	VERB	B
inhibitor	O	NOUN	B
of	O	ADP	O
thymidylate	O	ADJ	B
synthase	O	NOUN	I
(	O	PUNCT	O
TS	O	NOUN	B
)	O	PUNCT	O
whose	O	DET	O
cytotoxicity	B-Disease	NOUN	B
is	O	AUX	O
mediated	O	VERB	O
solely	O	ADV	O
through	O	ADP	O
the	O	DET	O
inhibition	O	NOUN	B
of	O	ADP	O
this	O	DET	O
enzyme	O	NOUN	B
.	O	PUNCT	O


Recent	O	ADJ	O
preclinical	O	ADJ	B
studies	O	NOUN	I
have	O	AUX	O
focused	O	VERB	O
on	O	ADP	O
the	O	DET	O
intracellular	O	ADJ	B
formation	O	NOUN	B
of	O	ADP	O
CB	B-Chemical	NOUN	B
3717	I-Chemical	NUM	O
polyglutamates	O	NOUN	B
.	O	PUNCT	O


Following	O	VERB	O
a	O	DET	O
12	O	NUM	O
-	O	PUNCT	O
hour	O	NOUN	B
exposure	O	NOUN	B
of	O	ADP	O
L1210	O	ADJ	B
cells	O	NOUN	I
to	O	PART	O
50	O	NUM	O
microM	O	NOUN	O
[	O	PUNCT	O
3H	O	NOUN	B
]	O	PUNCT	O
CB	B-Chemical	NOUN	O
3717	I-Chemical	NUM	O
,	O	PUNCT	O
30	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
extractable	O	ADJ	B
radioactivity	O	NOUN	B
could	O	AUX	O
be	O	AUX	O
accounted	O	VERB	O
for	O	ADP	O
as	O	ADP	O
CB	B-Chemical	NOUN	B
3717	I-Chemical	NUM	O
tetra	O	NOUN	B
-	O	PUNCT	O
and	O	CCONJ	O
pentaglutamate	O	NOUN	B
,	O	PUNCT	O
as	O	ADP	O
determined	O	VERB	O
by	O	ADP	O
high	O	ADJ	B
-	O	PUNCT	O
pressure	O	NOUN	B
liquid	O	ADJ	I
chromatography	O	NOUN	I
(	O	PUNCT	O
HPLC	O	NOUN	B
)	O	PUNCT	O
analyses	O	NOUN	O
.	O	PUNCT	O


As	O	ADP	O
inhibitors	O	NOUN	B
of	O	ADP	O
isolated	O	VERB	B
L1210	O	ADJ	B
TS	O	NOUN	B
,	O	PUNCT	O
CB	O	NOUN	B
3717	O	NUM	O
di	O	NOUN	O
-,	O	NOUN	O
tri	O	NOUN	O
-,	O	ADJ	O
tetra	O	NOUN	B
-	O	PUNCT	O
and	O	CCONJ	O
pentaglutamate	O	NOUN	B
are	O	AUX	O
26	O	NUM	O
-,	O	NOUN	O
87	O	NUM	O
-,	O	NOUN	O
119	O	NUM	O
-	O	PUNCT	O
and	O	CCONJ	O
114	O	NUM	O
-	O	PUNCT	O
fold	O	ADJ	B
more	O	ADV	O
potent	O	ADJ	O
than	O	ADP	O
CB	B-Chemical	NOUN	B
3717	I-Chemical	NUM	O
,	O	PUNCT	O
respectively	O	ADV	O
,	O	PUNCT	O
and	O	CCONJ	O
their	O	PRON	O
formation	O	NOUN	B
may	O	AUX	O
,	O	PUNCT	O
therefore	O	ADV	O
,	O	PUNCT	O
be	O	AUX	O
an	O	DET	O
important	O	ADJ	O
determinant	O	NOUN	O
of	O	ADP	O
CB	B-Chemical	NOUN	B
3717	I-Chemical	NUM	O
cytotoxicity	B-Disease	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
early	O	ADJ	O
clinical	O	ADJ	B
studies	O	NOUN	I
with	O	ADP	O
CB	B-Chemical	NOUN	B
3717	I-Chemical	NUM	O
,	O	PUNCT	O
activity	O	NOUN	B
has	O	AUX	O
been	O	AUX	O
seen	O	VERB	O
in	O	ADP	O
breast	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
,	O	PUNCT	O
ovarian	B-Disease	ADJ	B
cancer	I-Disease	NOUN	I
,	O	PUNCT	O
hepatoma	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
mesothelioma	B-Disease	NOUN	B
.	O	PUNCT	O


Toxicities	B-Disease	NOUN	B
included	O	VERB	O
hepatotoxicity	B-Disease	NOUN	B
,	O	PUNCT	O
malaise	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
dose	O	NOUN	B
-	O	PUNCT	O
limiting	O	VERB	B
nephrotoxicity	B-Disease	NOUN	B
.	O	PUNCT	O


This	O	DET	O
latter	O	ADJ	O
effect	O	NOUN	B
is	O	AUX	O
thought	O	VERB	O
to	O	PART	O
be	O	AUX	O
due	O	ADJ	O
to	O	PART	O
drug	O	NOUN	B
precipitation	O	NOUN	I
within	O	ADP	O
the	O	DET	O
renal	O	ADJ	B
tubule	O	NOUN	I
as	O	ADP	O
a	O	DET	O
result	O	NOUN	O
of	O	ADP	O
the	O	DET	O
poor	O	ADJ	B
solubility	O	NOUN	B
of	O	ADP	O
CB	B-Chemical	NOUN	B
3717	I-Chemical	NUM	O
under	O	ADP	O
acidic	O	ADJ	B
conditions	O	NOUN	O
.	O	PUNCT	O


In	O	ADP	O
an	O	DET	O
attempt	O	NOUN	O
to	O	PART	O
overcome	O	VERB	B
this	O	DET	O
problem	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
clinical	O	ADJ	B
trial	O	NOUN	I
of	O	ADP	O
CB	B-Chemical	NOUN	B
3717	I-Chemical	NUM	O
administered	O	VERB	B
with	O	ADP	O
alkaline	O	NOUN	B
diuresis	O	NOUN	B
is	O	AUX	O
under	O	ADP	O
way	O	NOUN	O
.	O	PUNCT	O


Preliminary	O	ADJ	B
results	O	NOUN	B
at	O	ADP	O
400	O	NUM	O
and	O	CCONJ	O
500	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
m2	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
a	O	DET	O
reduction	O	NOUN	B
in	O	ADP	O
nephrotoxicity	B-Disease	NOUN	B
may	O	AUX	O
have	O	AUX	O
been	O	AUX	O
achieved	O	VERB	O
with	O	ADP	O
only	O	ADV	O
1	O	NUM	O
instance	O	NOUN	O
of	O	ADP	O
renal	B-Disease	ADJ	B
toxicity	I-Disease	NOUN	B
in	O	ADP	O
10	O	NUM	O
patients	O	NOUN	B
.	O	PUNCT	O


Hepatotoxicity	B-Disease	NOUN	B
and	O	CCONJ	O
malaise	B-Disease	NOUN	B
are	O	AUX	O
again	O	ADV	O
the	O	DET	O
most	O	ADV	O
frequent	O	ADJ	B
side	O	NOUN	B
effects	O	NOUN	I
.	O	PUNCT	O


Evidence	O	NOUN	B
of	O	ADP	O
antitumor	O	ADJ	B
activity	O	NOUN	I
has	O	AUX	O
been	O	AUX	O
seen	O	VERB	O
in	O	ADP	O
3	O	NUM	O
patients	O	NOUN	B
.	O	PUNCT	O


Pharmacokinetic	O	ADJ	B
investigations	O	NOUN	B
have	O	AUX	O
shown	O	VERB	O
that	O	SCONJ	O
alkaline	O	NOUN	B
diuresis	O	NOUN	B
does	O	AUX	O
not	O	PART	O
alter	O	VERB	O
CB	B-Chemical	NOUN	B
3717	I-Chemical	NUM	O


Ethopropazine	B-Chemical	NOUN	B
and	O	CCONJ	O
benztropine	B-Chemical	NOUN	B
in	O	ADP	O
neuroleptic	O	ADJ	B
-	O	PUNCT	O
induced	O	VERB	B
parkinsonism	B-Disease	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
a	O	DET	O
12	O	NUM	O
-	O	PUNCT	O
week	O	NOUN	B
controlled	O	VERB	B
study	O	NOUN	I
ethopropazine	B-Chemical	NOUN	B
was	O	AUX	O
compared	O	VERB	O
to	O	PART	O
benztropine	B-Chemical	NOUN	B
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
parkinsonism	B-Disease	NOUN	B
induced	O	VERB	B
by	O	ADP	O
fluphenazine	B-Chemical	NOUN	B
enanthate	I-Chemical	NOUN	B
in	O	ADP	O
60	O	NUM	O
schizophrenic	B-Disease	ADJ	B
outpatients	O	NOUN	B
.	O	PUNCT	O


Ethopropazine	B-Chemical	NOUN	B
and	O	CCONJ	O
benztropine	B-Chemical	NOUN	B
were	O	AUX	O
found	O	VERB	O
to	O	PART	O
be	O	AUX	O
equally	O	ADV	O
effective	O	ADJ	B
in	O	ADP	O
controlling	O	VERB	B
parkinsonian	B-Disease	ADJ	B
symptoms	I-Disease	NOUN	B
and	O	CCONJ	O
were	O	AUX	O
as	O	ADV	O
efficacious	O	ADJ	B
as	O	ADP	O
procyclidine	B-Chemical	NOUN	B
,	O	PUNCT	O
their	O	PRON	O
previous	O	ADJ	O
antiparkinsonian	O	ADJ	B
drug	O	NOUN	I
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
benztropine	B-Chemical	NOUN	B
treated	O	ADJ	B
patients	O	NOUN	B
had	O	AUX	O
a	O	DET	O
significant	O	ADJ	O
increase	O	NOUN	B
in	O	ADP	O
tardive	B-Disease	ADJ	B
dyskinesia	I-Disease	NOUN	I
compared	O	VERB	O
to	O	ADP	O
their	O	PRON	O
condition	O	NOUN	B
during	O	ADP	O
procyclindine	B-Chemical	NOUN	B
treatment	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
significantly	O	ADV	O
more	O	ADJ	O
anxiety	B-Disease	NOUN	B
and	O	CCONJ	O
depression	B-Disease	NOUN	B
than	O	ADP	O
ethopropazine	B-Chemical	NOUN	B
treated	O	ADJ	B
patients	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
suggests	O	VERB	O
that	O	SCONJ	O
benztropine	B-Chemical	NOUN	B
is	O	AUX	O
not	O	PART	O
the	O	DET	O
anticholinergic	O	ADJ	B
drug	O	NOUN	I
of	O	ADP	O
choice	O	NOUN	O
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
neuroleptic	O	ADJ	B
-	O	PUNCT	O
induced	O	VERB	B
parkinsonian	B-Disease	ADJ	B
symptoms	I-Disease	NOUN	B


Effect	O	NOUN	B
of	O	ADP	O
alpha-tocopherol	B-Chemical	NOUN	B
and	O	CCONJ	O
deferoxamine	B-Chemical	NOUN	B
on	O	ADP	O
methamphetamine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
neurotoxicity	B-Disease	NOUN	B
.	O	PUNCT	O


Methamphetamine	B-Chemical	NOUN	B
(	O	PUNCT	O
MA	B-Chemical	PROPN	B
)-	O	ADJ	O
induced	O	VERB	B
dopaminergic	O	ADJ	B
neurotoxicity	B-Disease	NOUN	B
is	O	AUX	O
believed	O	VERB	O
to	O	PART	O
be	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
the	O	DET	O
increased	O	VERB	B
formation	O	NOUN	B
of	O	ADP	O
free	O	ADJ	B
radicals	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
study	O	NOUN	B
examined	O	VERB	O
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
alpha-tocopherol	B-Chemical	NOUN	B
(	O	PUNCT	O
alpha-TC	B-Chemical	ADJ	B
),	O	PUNCT	O
a	O	DET	O
scavenger	O	NOUN	B
of	O	ADP	O
reactive	O	ADJ	B
oxygen	B-Chemical	NOUN	I
species	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
deferoxamine	B-Chemical	NOUN	B
(	O	PUNCT	O
DFO	B-Chemical	NOUN	B
),	O	PUNCT	O
an	O	DET	O
iron	B-Chemical	NOUN	B
chelator	O	NOUN	I
,	O	PUNCT	O
on	O	ADP	O
the	O	DET	O
MA	B-Chemical	PROPN	B
-	O	PUNCT	O
induced	O	VERB	B
neurotoxicity	B-Disease	NOUN	B
.	O	PUNCT	O


Male	O	NOUN	B
rats	O	NOUN	B
were	O	AUX	O
treated	O	VERB	B
with	O	ADP	I
MA	B-Chemical	NOUN	B
(	O	PUNCT	O
10	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
,	O	PUNCT	O
every	O	DET	O
2	O	NUM	O
h	O	NOUN	O
for	O	ADP	O
four	O	NUM	O
injections	O	NOUN	B
).	O	PUNCT	O
The	O	DET	O
rat	O	NOUN	B
received	O	VERB	O
either	O	CCONJ	O
alpha-TC	B-Chemical	ADJ	B
(	O	PUNCT	O
20	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
)	O	PUNCT	O
intraperitoneally	O	ADV	B
for	O	ADP	O
3	O	NUM	O
days	O	NOUN	B
and	O	CCONJ	O
30	O	NUM	O
min	O	NOUN	O
prior	O	ADJ	O
to	O	PART	O
MA	B-Chemical	NOUN	B
administration	O	NOUN	B
or	O	CCONJ	O
DFO	B-Chemical	NOUN	B
(	O	PUNCT	O
50	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
)	O	PUNCT	O
subcutaneously	O	ADV	O
30	O	NUM	O
min	O	NOUN	O
before	O	ADP	O
MA	B-Chemical	NOUN	B
administration	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
concentrations	O	NOUN	B
of	O	ADP	O
dopamine	B-Chemical	NOUN	B
(	O	PUNCT	O
DA	B-Chemical	NOUN	B
),	O	PUNCT	O
serotonin	B-Chemical	NOUN	B
and	O	CCONJ	O
their	O	PRON	O
metabolites	O	NOUN	B
decreased	O	VERB	B
significantly	O	ADV	O
after	O	ADP	O
MA	B-Chemical	NOUN	B
administration	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
was	O	AUX	O
inhibited	O	VERB	B
by	O	ADP	O
the	O	DET	O
alpha-TC	B-Chemical	ADJ	B
and	O	CCONJ	O
DFO	B-Chemical	NOUN	B
pretreatment	O	NOUN	B
.	O	PUNCT	O


alpha-TC	B-Chemical	ADJ	B
and	O	CCONJ	O
DFO	B-Chemical	NOUN	B
attenuated	O	VERB	B
the	O	DET	O
MA	B-Chemical	PROPN	B
-	O	PUNCT	O
induced	O	VERB	B
hyperthermia	B-Disease	NOUN	B
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
the	O	DET	O
alterations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
locomotor	O	NOUN	B
activity	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
level	O	NOUN	B
of	O	ADP	O
lipid	O	NOUN	B
peroxidation	O	NOUN	I
was	O	AUX	O
higher	O	ADJ	B
and	O	CCONJ	O
the	O	DET	O
reduced	O	VERB	B
glutathione	B-Chemical	NOUN	B
concentration	O	NOUN	B
was	O	AUX	O
lower	O	ADJ	O
in	O	ADP	O
the	O	DET	O
MA	B-Chemical	PROPN	B
-	O	PUNCT	O
treated	O	VERB	B
rats	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
changes	O	NOUN	B
were	O	AUX	O
significantly	O	ADV	O
attenuated	O	VERB	B
by	O	ADP	O
alpha-TC	B-Chemical	ADJ	B
and	O	CCONJ	O
DFO	B-Chemical	NOUN	B
.	O	PUNCT	O


This	O	DET	O
suggests	O	VERB	O
that	O	SCONJ	O
alpha-TC	B-Chemical	ADJ	B
and	O	CCONJ	O
DFO	B-Chemical	NOUN	B
ameliorate	O	VERB	B
the	O	DET	O
MA	B-Chemical	PROPN	B
-	O	PUNCT	O
induced	O	VERB	B
neuronal	B-Disease	ADJ	B
damage	I-Disease	NOUN	O


Use	O	NOUN	B
of	O	ADP	I
dexamethasone	B-Chemical	NOUN	B
with	O	ADP	O
mesna	B-Chemical	NOUN	B
for	O	ADP	O
the	O	DET	O
prevention	O	NOUN	B
of	O	ADP	O
ifosfamide	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
hemorrhagic	B-Disease	ADJ	B
cystitis	I-Disease	NOUN	I
.	O	PUNCT	O


AIM	O	NOUN	B
:	O	PUNCT	O
Hemorrhagic	B-Disease	ADJ	B
cystitis	I-Disease	NOUN	I
(	O	PUNCT	O
HC	B-Disease	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
a	O	DET	O
limiting	O	VERB	O
side	O	NOUN	B
-	O	PUNCT	O
effect	O	NOUN	B
of	O	ADP	O
chemotherapy	O	NOUN	B
with	O	ADP	O
ifosfamide	B-Chemical	NOUN	B
(	O	PUNCT	O
IFS	B-Chemical	PROPN	B
).	O	PUNCT	O
In	O	ADP	O
the	O	DET	O
study	O	NOUN	B
presented	O	VERB	O
here	O	ADV	O
,	O	PUNCT	O
we	O	PRON	O
investigated	O	VERB	B
the	O	DET	O
use	O	NOUN	O
of	O	ADP	O
dexamethasone	B-Chemical	NOUN	B
in	O	ADP	O
combination	O	NOUN	B
with	O	ADP	O
mesna	B-Chemical	NOUN	B
for	O	ADP	O
the	O	DET	O
prevention	O	NOUN	B
of	O	ADP	O
IFS	B-Chemical	PROPN	B
-	O	PUNCT	O
induced	O	VERB	B
HC	B-Disease	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
:	O	PUNCT	O
Male	O	NOUN	B
Wistar	O	PROPN	B
rats	O	NOUN	I
(	O	PUNCT	O
150	O	NUM	O
-	O	PUNCT	O
200	O	NUM	O
g	O	NOUN	O
;	O	PUNCT	O
6	O	NUM	O
rats	O	NOUN	B
per	O	ADP	O
group	O	NOUN	B
)	O	PUNCT	O
were	O	AUX	O
treated	O	VERB	B
with	O	ADP	I
saline	O	NOUN	B
or	O	CCONJ	O
mesna	B-Chemical	NOUN	B
5	O	NUM	O
min	O	NOUN	B
(	O	PUNCT	O
i	O	X	O
.	O	PUNCT	O


p	O	NOUN	O
.)	O	ADV	O
before	O	ADV	O
and	O	CCONJ	O
2	O	NUM	O
and	O	CCONJ	O
6	O	NUM	O
h	O	NOUN	O
after	O	ADP	O
(	O	PUNCT	O
v	O	NOUN	O
.	O	PUNCT	O


o	O	INTJ	O
.)	O	NUM	O
administration	O	NOUN	B
of	O	ADP	O
IFS	B-Chemical	PROPN	B
.	O	PUNCT	O


One	O	NUM	O
,	O	PUNCT	O
two	O	NUM	O
or	O	CCONJ	O
three	O	NUM	O
doses	O	NOUN	B
of	O	ADP	O
mesna	B-Chemical	NOUN	B
were	O	AUX	O
replaced	O	VERB	O
with	O	ADP	O
dexamethasone	B-Chemical	NOUN	B
alone	O	ADV	O
or	O	CCONJ	O
with	O	ADP	O
dexamethasone	B-Chemical	NOUN	B
plus	O	CCONJ	O
mesna	B-Chemical	NOUN	B
.	O	PUNCT	O


Cystitis	B-Disease	NOUN	B
was	O	AUX	O
evaluated	O	VERB	B
24	O	NUM	O
h	O	NOUN	O
after	O	ADP	O
its	O	PRON	O
induction	O	NOUN	B
by	O	ADP	O
the	O	DET	O
changes	O	NOUN	B
in	O	ADP	O
bladder	O	NOUN	B
wet	O	ADJ	I
weight	O	NOUN	I
and	O	CCONJ	O
by	O	ADP	O
macroscopic	O	ADJ	B
and	O	CCONJ	O
microscopic	O	ADJ	B
analysis	O	NOUN	I
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
The	O	DET	O
replacement	O	NOUN	B
of	O	ADP	O
the	O	DET	O
last	O	ADJ	O
dose	O	NOUN	B
or	O	CCONJ	O
the	O	DET	O
last	O	ADJ	O
two	O	NUM	O
doses	O	NOUN	B
of	O	ADP	O
mesna	B-Chemical	NOUN	B
with	O	ADP	O
dexamethasone	B-Chemical	NOUN	B
reduced	O	VERB	B
the	O	DET	O
increase	O	NOUN	B
in	O	ADP	O
bladder	O	NOUN	B
wet	O	ADJ	I
weight	O	NOUN	I
induced	O	VERB	B
by	O	ADP	O
IFS	B-Chemical	PROPN	B
by	O	ADP	O
84	O	NUM	O
.	O	PUNCT	O


79	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
89	O	NUM	O
.	O	PUNCT	O


13	O	NUM	O
%,	O	NOUN	B
respectively	O	ADV	O
.	O	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
,	O	PUNCT	O
it	O	PRON	O
almost	O	ADV	O
abolished	O	VERB	O
the	O	DET	O
macroscopic	O	ADJ	B
and	O	CCONJ	O
microscopic	O	ADJ	B
alterations	O	NOUN	B
induced	O	VERB	B
by	O	ADP	O
IFS	B-Chemical	PROPN	B
.	O	PUNCT	O


Moreover	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
addition	O	NOUN	O
of	O	ADP	O
dexamethasone	B-Chemical	NOUN	B
to	O	PART	O
the	O	DET	O
last	O	ADJ	O
two	O	NUM	O
doses	O	NOUN	B
of	O	ADP	O
mesna	B-Chemical	NOUN	B
was	O	AUX	O
more	O	ADV	O
efficient	O	ADJ	B
than	O	ADP	O
three	O	NUM	O
doses	O	NOUN	B
of	O	ADP	O
mesna	B-Chemical	NOUN	B
alone	O	ADV	O
when	O	SCONJ	O
evaluated	O	VERB	B
microscopically	O	ADV	B
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
:	O	PUNCT	O
Dexamethasone	B-Chemical	NOUN	B
in	O	ADP	O
combination	O	NOUN	B
with	O	ADP	O
mesna	B-Chemical	NOUN	B
was	O	AUX	O
efficient	O	ADJ	B
in	O	ADP	O
blocking	O	VERB	B
IFS	B-Chemical	PROPN	B
-	O	PUNCT	O
induced	O	VERB	B
HC	B-Disease	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
replacement	O	NOUN	B
of	O	ADP	O
last	O	ADJ	O
two	O	NUM	O
doses	O	NOUN	B
of	O	ADP	O
mesna	B-Chemical	NOUN	B
with	O	ADP	O
saline	O	NOUN	B
or	O	CCONJ	O
all	O	DET	O
of	O	ADP	O
the	O	DET	O
mesna	B-Chemical	NOUN	B
doses	O	NOUN	B
with	O	ADP	O
dexamethasone	B-Chemical	NOUN	B
did	O	AUX	O
not	O	PART	O
prevent	O	VERB	O
HC	B-Disease	NOUN	B


Behavioral	O	ADJ	B
effects	O	NOUN	B
of	O	ADP	O
MK-801	B-Chemical	NOUN	B
on	O	ADP	O
reserpine	B-Chemical	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
mice	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
dizocilpine	B-Chemical	NOUN	B
(	O	PUNCT	O
MK-801	B-Chemical	NOUN	B
),	O	PUNCT	O
a	O	DET	O
noncompetitive	O	ADJ	B
N-methyl-D-aspartate	B-Chemical	NOUN	I
(	O	PUNCT	O
NMDA	B-Chemical	NOUN	B
)	O	PUNCT	O
receptor	O	NOUN	O
antagonist	O	NOUN	B
,	O	PUNCT	O
were	O	AUX	O
studied	O	VERB	O
on	O	ADP	O
dopamine	B-Chemical	NOUN	B
-	O	PUNCT	O
related	O	VERB	B
behaviors	O	NOUN	B
induced	O	VERB	B
by	O	ADP	O
reserpine	B-Chemical	NOUN	B
treatments	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
study	O	NOUN	B
focuses	O	VERB	O
on	O	ADP	O
behavioral	O	ADJ	B
syndromes	O	NOUN	I
that	O	PRON	O
may	O	AUX	O
used	O	VERB	O
as	O	ADP	O
models	O	NOUN	B
for	O	ADP	O
Parkinson's	B-Disease	ADJ	B
disease	I-Disease	NOUN	I
,	O	PUNCT	O
or	O	CCONJ	O
tardive	B-Disease	ADJ	B
dyskinesia	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
its	O	PRON	O
response	O	NOUN	B
after	O	ADP	O
glutamatergic	O	ADJ	B
blockage	O	NOUN	I
.	O	PUNCT	O


Reserpine	B-Chemical	NOUN	B
(	O	PUNCT	O
1	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
),	O	PUNCT	O
administered	O	VERB	B
once	O	ADV	O
every	O	DET	O
other	O	ADJ	O
day	O	NOUN	B
for	O	ADP	O
4	O	NUM	O
days	O	NOUN	B
,	O	PUNCT	O
produced	O	VERB	O
increases	O	NOUN	B
in	O	ADP	O
orofacial	B-Disease	ADJ	B
dyskinesia	I-Disease	NOUN	I
,	O	PUNCT	O
tongue	O	NOUN	B
protrusion	O	NOUN	I
and	O	CCONJ	O
vacuous	O	ADJ	B
chewing	O	NOUN	I
in	O	ADP	O
mice	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
are	O	AUX	O
signs	O	NOUN	O
indicative	O	ADJ	B
of	O	ADP	O
tardive	B-Disease	ADJ	B
dyskinesia	I-Disease	NOUN	I
.	O	PUNCT	O


Reserpine	B-Chemical	NOUN	B
also	O	ADV	O
produced	O	VERB	O
tremor	B-Disease	NOUN	B
and	O	CCONJ	O
catalepsy	B-Disease	NOUN	B
,	O	PUNCT	O
which	O	DET	O
are	O	AUX	O
signs	O	NOUN	O
suggestive	O	ADJ	O
of	O	ADP	O
Parkinson's	B-Disease	ADJ	B
disease	I-Disease	NOUN	I
.	O	PUNCT	O


MK-801	B-Chemical	NOUN	B
(	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
),	O	PUNCT	O
administered	O	VERB	B
30	O	NUM	O
min	O	NOUN	O
before	O	ADP	O
the	O	DET	O
observation	O	NOUN	B
test	O	NOUN	I
,	O	PUNCT	O
prevented	O	VERB	B
the	O	DET	O
vacuous	O	ADJ	B
chewing	O	NOUN	I
movements	O	NOUN	B
,	O	PUNCT	O
tongue	O	NOUN	B
protrusions	O	NOUN	I
and	O	CCONJ	O
catalepsy	B-Disease	NOUN	B
induced	O	VERB	B
by	O	ADP	O
reserpine	B-Chemical	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
MK-801	B-Chemical	NOUN	B
injection	O	NOUN	B
produced	O	VERB	O
a	O	DET	O
significant	O	ADJ	O
increase	O	NOUN	B
of	O	ADP	O
tremor	B-Disease	NOUN	B
in	O	ADP	O
reserpine	B-Chemical	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
mice	O	NOUN	B
.	O	PUNCT	O


Reserpine	B-Chemical	NOUN	B
(	O	PUNCT	O
1	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
),	O	PUNCT	O
administered	O	VERB	B
90	O	NUM	O
min	O	NOUN	O
before	O	ADP	O
the	O	DET	O
test	O	NOUN	B
and	O	CCONJ	O
followed	O	VERB	O
by	O	ADP	O
apomophine	B-Chemical	NOUN	B
injection	O	NOUN	B
(	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
)	O	PUNCT	O
5	O	NUM	O
min	O	NOUN	O
before	O	ADP	O
the	O	DET	O
test	O	NOUN	B
,	O	PUNCT	O
did	O	AUX	O
not	O	PART	O
produce	O	VERB	O
oral	B-Disease	ADJ	B
dyskinesia	I-Disease	NOUN	I
in	O	ADP	O
mice	O	NOUN	B
.	O	PUNCT	O


On	O	ADP	O
the	O	DET	O
other	O	ADJ	O
hand	O	NOUN	B
,	O	PUNCT	O
reserpine	B-Chemical	NOUN	B
induced	O	VERB	B
increases	O	NOUN	B
in	O	ADP	O
tremor	B-Disease	NOUN	B
and	O	CCONJ	O
catalepsy	B-Disease	NOUN	B
compared	O	VERB	O
to	O	PART	O
control	O	NOUN	B
mice	O	NOUN	B
.	O	PUNCT	O


MK-801	B-Chemical	NOUN	B
(	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
)	O	PUNCT	O
administration	O	NOUN	B
attenuated	O	VERB	B
the	O	DET	O
catalepsy	B-Disease	NOUN	B
and	O	CCONJ	O
tremor	B-Disease	NOUN	B
induced	O	VERB	B
by	O	ADP	O
reserpine	B-Chemical	NOUN	B
.	O	PUNCT	O


Pretreatment	O	NOUN	B
with	O	ADP	O
reserpine	B-Chemical	NOUN	B
(	O	PUNCT	O
1	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
)	O	PUNCT	O
24	O	NUM	O
h	O	NOUN	O
before	O	ADP	O
the	O	DET	O
observation	O	NOUN	B
test	O	NOUN	I
produced	O	VERB	O
increases	O	NOUN	B
in	O	ADP	O
vacuous	O	ADJ	B
chewing	O	NOUN	I
movements	O	NOUN	B
and	O	CCONJ	O
tongue	O	NOUN	B
protrusion	O	NOUN	I
,	O	PUNCT	O
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
increases	O	NOUN	B
in	O	ADP	O
tremor	B-Disease	NOUN	B
and	O	CCONJ	O
catalepsy	B-Disease	NOUN	B
,	O	PUNCT	O
whereas	O	SCONJ	O
MK-801	B-Chemical	NOUN	B
(	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
)	O	PUNCT	O
injection	O	NOUN	B
90	O	NUM	O
min	O	NOUN	O
before	O	ADP	O
the	O	DET	O
test	O	NOUN	B
reversed	O	VERB	B
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	O
reserpine	B-Chemical	NOUN	B
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	B
show	O	VERB	O
that	O	SCONJ	O
reserpine	B-Chemical	NOUN	B
produces	O	VERB	O
different	O	ADJ	O
and	O	CCONJ	O
abnormal	B-Disease	ADJ	B
movements	I-Disease	NOUN	B
,	O	PUNCT	O
which	O	DET	O
are	O	AUX	O
related	O	ADJ	O
to	O	PART	O
dose	O	NOUN	B
and	O	CCONJ	O
schedule	O	NOUN	B
employed	O	VERB	B
and	O	CCONJ	O
can	O	AUX	O
be	O	AUX	O
considered	O	VERB	O
as	O	ADP	O
parkinsonian	B-Disease	ADJ	B
-	O	PUNCT	O
like	O	NOUN	B
and	O	CCONJ	O
tardive	B-Disease	ADJ	B
dsykinesia	I-Disease	NOUN	B
signs	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
glutamatergic	O	ADJ	B
blockage	O	NOUN	I
produced	O	VERB	O
by	O	ADP	O
NMDA	B-Chemical	NOUN	B
can	O	AUX	O
restore	O	VERB	O
these	O	DET	O
signs	O	NOUN	B
,	O	PUNCT	O
such	O	ADJ	O
as	O	ADP	O
vacuous	O	ADJ	B
chewing	O	NOUN	I
movements	O	NOUN	B
,	O	PUNCT	O
tongue	O	NOUN	B
protrusions	O	NOUN	I
,	O	PUNCT	O
catalepsy	B-Disease	NOUN	B
and	O	CCONJ	O
tremor	B-Disease	NOUN	B


Effect	O	NOUN	B
of	O	ADP	O
glyceryl	B-Chemical	NOUN	B
trinitrate	I-Chemical	NOUN	I
on	O	ADP	O
the	O	DET	O
sphincter	B-Disease	NOUN	B
of	I-Disease	ADP	O
Oddi	I-Disease	NOUN	B
spasm	I-Disease	NOUN	I
evoked	O	VERB	B
by	O	ADP	O
prostigmine	B-Chemical	NOUN	B
-	O	PUNCT	O
morphine	B-Chemical	NOUN	B
administration	O	NOUN	B
.	O	PUNCT	O


OBJECTIVE	O	NOUN	O
:	O	PUNCT	O
In	O	ADP	O
this	O	DET	O
study	O	NOUN	B
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
glyceryl	B-Chemical	NOUN	B
trinitrate	I-Chemical	NOUN	I
on	O	ADP	O
the	O	DET	O
prostigmine	B-Chemical	NOUN	B
-	O	PUNCT	O
morphine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
sphincter	B-Disease	NOUN	B
of	I-Disease	ADP	O
Oddi	I-Disease	NOUN	B
spasm	I-Disease	NOUN	I
was	O	AUX	O
evaluated	O	VERB	B
in	O	ADP	O
nine	O	NUM	O
female	O	ADJ	B
patients	O	NOUN	B
with	O	ADP	O
sphincter	B-Disease	NOUN	B
of	I-Disease	ADP	O
Oddi	I-Disease	NOUN	B
dyskinesia	I-Disease	NOUN	I
.	O	PUNCT	O


METHOD	O	NOUN	B
:	O	PUNCT	O
Sphincter	B-Disease	NOUN	B
of	I-Disease	ADP	O
Oddi	I-Disease	NOUN	B
spasm	I-Disease	NOUN	I
was	O	AUX	O
induced	O	VERB	B
by	O	ADP	O
prostigmine	B-Chemical	NOUN	B
-	O	PUNCT	O
morphine	B-Chemical	NOUN	B
administration	O	NOUN	B
(	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
mg	O	NOUN	O
prostigmine	B-Chemical	NOUN	B
intramuscularly	O	ADV	B
and	O	CCONJ	O
10	O	NUM	O
mg	O	NOUN	O
morphine	B-Chemical	NOUN	B
subcutaneously	O	ADV	B
)	O	PUNCT	O
and	O	CCONJ	O
visualized	O	VERB	B
by	O	ADP	O
quantitative	O	ADJ	B
hepatobiliary	O	ADJ	B
scintigraphy	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
entire	O	ADJ	O
procedure	O	NOUN	B
was	O	AUX	O
repeated	O	VERB	O
during	O	ADP	O
glyceryl	B-Chemical	NOUN	B
trinitrate	I-Chemical	NOUN	I
infusion	O	NOUN	B
(	O	PUNCT	O
Nitrolingual	B-Chemical	NOUN	B
1	O	NUM	O
microg	O	NOUN	B
/	O	SYM	O
kg	O	NOUN	B
/	O	SYM	O
min	O	NOUN	B
for	O	ADP	O
120	O	NUM	O
min	O	NOUN	O
).	O	PUNCT	O
RESULTS	O	NOUN	O
:	O	PUNCT	O
Prostigmine	B-Chemical	NOUN	B
-	O	PUNCT	O
morphine	B-Chemical	NOUN	B
provocation	O	NOUN	B
caused	O	VERB	O
significant	O	ADJ	O
increases	O	NOUN	B
in	O	ADP	O
the	O	DET	O
time	O	NOUN	O
to	O	PART	O
peak	O	NOUN	B
activity	O	NOUN	I
(	O	PUNCT	O
Tmax	O	NOUN	B
)	O	PUNCT	O
over	O	ADP	O
the	O	DET	O
hepatic	O	ADJ	B
hilum	O	NOUN	I
(	O	PUNCT	O
HH	O	PROPN	B
:	O	PUNCT	O
34	O	NUM	O
.	O	PUNCT	O


33	O	NUM	O
+/-	O	CCONJ	O
5	O	NUM	O
.	O	PUNCT	O


05	O	NUM	O
vs	O	CCONJ	O
.	O	PUNCT	O


22	O	NUM	O
.	O	PUNCT	O


77	O	NUM	O
+/-	O	CCONJ	O
3	O	NUM	O
.	O	PUNCT	O


26	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
common	O	ADJ	O
bile	O	NOUN	B
duct	O	NOUN	I
(	O	PUNCT	O
CBD	O	NOUN	B
:	O	PUNCT	O
60	O	NUM	O
.	O	PUNCT	O


44	O	NUM	O
+/-	O	CCONJ	O
5	O	NUM	O
.	O	PUNCT	O


99	O	NUM	O
vs	O	CCONJ	O
.	O	PUNCT	O


40	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
+/-	O	CCONJ	O
2	O	NUM	O
.	O	PUNCT	O


88	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
in	O	ADP	O
the	O	DET	O
half	O	NUM	B
-	O	PUNCT	O
time	O	NOUN	B
of	O	ADP	O
excretion	O	NOUN	B
(	O	PUNCT	O
T1	O	NOUN	B
/	O	SYM	O
2	O	NUM	B
)	O	PUNCT	O
over	O	ADP	O
the	O	DET	O
liver	O	NOUN	B
parenchyma	O	NOUN	I
(	O	PUNCT	O
LP	O	NOUN	B
:	O	PUNCT	O
120	O	NUM	O
.	O	PUNCT	O


04	O	NUM	O
+/-	O	CCONJ	O
16	O	NUM	O
.	O	PUNCT	O


01	O	NUM	O
vs	O	CCONJ	O
.	O	PUNCT	O


27	O	NUM	O
.	O	PUNCT	O


37	O	NUM	O
+/-	O	CCONJ	O
2	O	NUM	O
.	O	PUNCT	O


19	O	NUM	O
),	O	PUNCT	O
HH	O	NOUN	B
(	O	PUNCT	O
117	O	NUM	O
.	O	PUNCT	O


61	O	NUM	O
+/-	O	CCONJ	O
14	O	NUM	O
.	O	PUNCT	O


71	O	NUM	O
vs	O	NOUN	O
.	O	PUNCT	O


31	O	NUM	O
.	O	PUNCT	O


85	O	NUM	O
+/-	O	CCONJ	O
3	O	NUM	O
.	O	PUNCT	O


99	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
CBD	O	NOUN	B
(	O	PUNCT	O
158	O	NUM	O
.	O	PUNCT	O


11	O	NUM	O
+/-	O	CCONJ	O
9	O	NUM	O
.	O	PUNCT	O


18	O	NUM	O
vs	O	CCONJ	O
.	O	PUNCT	O


40	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
+/-	O	CCONJ	O
6	O	NUM	O
.	O	PUNCT	O


24	O	NUM	O
),	O	PUNCT	O
indicating	O	VERB	O
a	O	DET	O
complete	O	ADJ	O
spasm	B-Disease	NOUN	B
at	O	ADP	O
the	O	DET	O
level	O	NOUN	B
of	O	ADP	O
the	O	DET	O
sphincter	O	NOUN	B
of	O	ADP	O
Oddi	O	NOUN	B
.	O	PUNCT	O


Glyceryl	B-Chemical	NOUN	B
trinitrate	I-Chemical	NOUN	I
infusion	O	NOUN	B
completely	O	ADV	O
normalized	O	VERB	O
the	O	DET	O
prostigmine	B-Chemical	NOUN	B
-	O	PUNCT	O
morphine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
alterations	O	NOUN	B
in	O	ADP	O
these	O	DET	O
quantitative	O	ADJ	B
parameters	O	NOUN	B
(	O	PUNCT	O
TmaX	O	NOUN	B
over	O	ADP	O
the	O	DET	O
LP	O	NOUN	B
:	O	PUNCT	O
11	O	NUM	O
.	O	PUNCT	O


33	O	NUM	O
+/-	O	CCONJ	O
1	O	NUM	O
.	O	PUNCT	O


13	O	NUM	O
;	O	PUNCT	O
over	O	ADP	O
the	O	DET	O
HH	O	PROPN	B
:	O	PUNCT	O
18	O	NUM	O
.	O	PUNCT	O


88	O	NUM	O
+/-	O	CCONJ	O
1	O	NUM	O
.	O	PUNCT	O


48	O	NUM	O
;	O	PUNCT	O
and	O	CCONJ	O
over	O	ADP	O
the	O	DET	O
CBD	O	NOUN	B
:	O	PUNCT	O
36	O	NUM	O
.	O	PUNCT	O


22	O	NUM	O
+/-	O	CCONJ	O
1	O	NUM	O
.	O	PUNCT	O


92	O	NUM	O
;	O	PUNCT	O
and	O	CCONJ	O
T1	O	NOUN	B
/	O	SYM	O
2	O	NUM	B
over	O	ADP	O
the	O	DET	O
LP	O	NOUN	B
:	O	PUNCT	O
28	O	NUM	O
.	O	PUNCT	O


21	O	NUM	O
+/-	O	CCONJ	O
1	O	NUM	O
.	O	PUNCT	O


83	O	NUM	O
;	O	PUNCT	O
over	O	ADP	O
the	O	DET	O
HH	O	PROPN	B
:	O	PUNCT	O
33	O	NUM	O
.	O	PUNCT	O


42	O	NUM	O
+/-	O	CCONJ	O
3	O	NUM	O
.	O	PUNCT	O


10	O	NUM	O
;	O	PUNCT	O
and	O	CCONJ	O
over	O	ADP	O
the	O	DET	O
CBD	O	NOUN	B
:	O	PUNCT	O
41	O	NUM	O
.	O	PUNCT	O


66	O	NUM	O
+/-	O	CCONJ	O
6	O	NUM	O
.	O	PUNCT	O


33	O	NUM	O
),	O	PUNCT	O
suggesting	O	VERB	O
an	O	DET	O
effective	O	ADJ	B
sphincter	O	NOUN	B
-	O	PUNCT	O
relaxing	O	VERB	B
effect	O	NOUN	B
of	O	ADP	O
glyceryl	B-Chemical	NOUN	B
trinitrate	I-Chemical	NOUN	I
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
:	O	PUNCT	O
These	O	DET	O
results	O	NOUN	B
provide	O	VERB	O
the	O	DET	O
first	O	ADJ	O
evidence	O	NOUN	B
of	O	ADP	O
the	O	DET	O
effectiveness	O	NOUN	B
of	O	ADP	O
glyceryl	B-Chemical	NOUN	B
trinitrate	I-Chemical	NOUN	I
on	O	ADP	O
the	O	DET	O
morphine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
sphincter	B-Disease	NOUN	B
of	I-Disease	ADP	O
Oddi	I-Disease	NOUN	B
spasm	I-Disease	NOUN	I
in	O	ADP	O
humans	O	NOUN	B
.	O	PUNCT	O


Since	O	SCONJ	O
glyceryl	B-Chemical	NOUN	B
trinitrate	I-Chemical	NOUN	I
is	O	AUX	O
able	O	ADJ	O
to	O	PART	O
overcome	O	VERB	B
even	O	ADV	O
the	O	DET	O
drastic	O	ADJ	B
effect	O	NOUN	B
of	O	ADP	O
morphine	B-Chemical	NOUN	B
,	O	PUNCT	O
it	O	PRON	O
might	O	AUX	O
be	O	AUX	O
of	O	ADP	O
relevance	O	NOUN	B
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
sphincter	B-Disease	NOUN	B
of	I-Disease	ADP	O
Oddi	I-Disease	NOUN	B
dyskinesia	I-Disease	NOUN	I


Effects	O	NOUN	B
of	O	ADP	I
acute	O	ADJ	B
steroid	B-Chemical	NOUN	O
administration	O	NOUN	O
on	O	ADP	O
ventilatory	O	ADJ	B
and	O	CCONJ	O
peripheral	O	ADJ	B
muscles	O	NOUN	I
in	O	ADP	O
rats	O	NOUN	B
.	O	PUNCT	O


Occasional	O	ADJ	B
case	O	NOUN	O
reports	O	NOUN	O
have	O	AUX	O
shown	O	VERB	O
that	O	SCONJ	O
acute	O	ADJ	B
myopathy	B-Disease	NOUN	I
may	O	AUX	O
occur	O	VERB	O
in	O	ADP	O
patients	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
massive	O	ADJ	B
doses	O	NOUN	I
of	O	ADP	O
corticosteroids	B-Chemical	NOUN	B
.	O	PUNCT	O


The	O	DET	O
mechanism	O	NOUN	B
of	O	ADP	O
this	O	DET	O
myopathy	B-Disease	NOUN	B
is	O	AUX	O
poorly	O	ADV	O
understood	O	VERB	O
.	O	PUNCT	O


Therefore	O	ADV	O
,	O	PUNCT	O
60	O	NUM	O
male	O	NOUN	B
rats	O	NOUN	B
were	O	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
to	O	PART	O
receive	O	VERB	O
daily	O	ADJ	B
injection	O	NOUN	B
of	O	ADP	O
saline	O	NOUN	B
(	O	PUNCT	O
C	O	NOUN	B
),	O	PUNCT	O
methylprednisolone	B-Chemical	NOUN	B
(	O	PUNCT	O
M	B-Chemical	NOUN	B
),	O	PUNCT	O
or	O	CCONJ	O
triamcinolone	B-Chemical	NOUN	B
(	O	PUNCT	O
T	B-Chemical	NOUN	B
)	O	PUNCT	O
80	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
/	O	SYM	O
d	O	NOUN	O
for	O	ADP	O
5	O	NUM	O
d	O	NOUN	O
.	O	PUNCT	O


Nutritional	O	ADJ	B
intake	O	NOUN	B
,	O	PUNCT	O
measured	O	VERB	B
daily	O	ADV	B
in	O	ADP	O
15	O	NUM	O
animals	O	NOUN	B
,	O	PUNCT	O
showed	O	VERB	O
a	O	DET	O
significant	O	ADJ	O
reduction	B-Disease	NOUN	B
of	I-Disease	ADP	O
food	I-Disease	NOUN	B
intake	I-Disease	NOUN	I
in	O	ADP	O
the	O	DET	O
steroid	B-Chemical	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
groups	O	NOUN	B
(-	O	PUNCT	O
50	O	NUM	O
and	O	CCONJ	O
-	O	PUNCT	O
79	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
M	B-Chemical	NOUN	B
and	O	CCONJ	O
T	B-Chemical	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
).	O	PUNCT	O
This	O	DET	O
was	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
a	O	DET	O
similar	O	ADJ	O
loss	B-Disease	NOUN	B
in	I-Disease	ADP	O
body	I-Disease	NOUN	B
weight	I-Disease	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
45	O	NUM	O
remaining	O	VERB	O
animals	O	NOUN	B
,	O	PUNCT	O
diaphragm	O	NOUN	B
contractility	O	NOUN	I
and	O	CCONJ	O
histopathologic	O	ADJ	B
features	O	NOUN	I
of	O	ADP	O
several	O	ADJ	O
muscles	O	NOUN	B
were	O	AUX	O
studied	O	VERB	O
.	O	PUNCT	O


Weights	O	NOUN	B
of	O	ADP	O
respiratory	O	ADJ	B
and	O	CCONJ	O
peripheral	O	ADJ	B
muscles	O	NOUN	I
were	O	AUX	O
similarly	O	ADV	O
decreased	O	VERB	B
after	O	ADP	O
steroid	B-Chemical	NOUN	B
treatment	O	NOUN	B
.	O	PUNCT	O


Maximal	O	ADJ	B
twitches	O	NOUN	B
of	O	ADP	O
the	O	DET	O
diaphragm	O	NOUN	B
were	O	AUX	O
lower	O	ADJ	O
in	O	ADP	O
the	O	DET	O
C	O	NOUN	B
group	O	NOUN	I
(	O	PUNCT	O
653	O	NUM	O
+/-	O	CCONJ	O
174	O	NUM	O
g	O	NOUN	O
/	O	SYM	O
cm	O	NOUN	O
(	O	PUNCT	O
2	O	NUM	O
))	O	PUNCT	O
than	O	ADP	O
in	O	ADP	O
the	O	DET	O
M	B-Chemical	NOUN	B
group	O	NOUN	I
(	O	PUNCT	O
837	O	NUM	O
+/-	O	CCONJ	O
171	O	NUM	O
g	O	NOUN	O
/	O	SYM	O
cm	O	NOUN	O
(	O	PUNCT	O
2	O	NUM	O
);	O	ADJ	O
p	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


05	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
T	B-Chemical	NOUN	B
group	O	NOUN	I
(	O	PUNCT	O
765	O	NUM	O
+/-	O	CCONJ	O
145	O	NUM	O
g	O	NOUN	O
/	O	SYM	O
cm	O	NOUN	O
(	O	PUNCT	O
2	O	NUM	O
),	O	PUNCT	O
NS	O	NOUN	B
).	O	PUNCT	O
Half	O	ADJ	B
-	O	PUNCT	O
relaxation	O	NOUN	B
time	O	NOUN	B
was	O	AUX	O
prolonged	O	ADJ	B
in	O	ADP	O
both	O	CCONJ	O
steroid	B-Chemical	NOUN	B
groups	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
time	O	NOUN	O
to	O	PART	O
peak	O	VERB	B
tension	O	NOUN	I
was	O	AUX	O
longer	O	ADJ	O
with	O	ADP	O
M	B-Chemical	NOUN	B
,	O	PUNCT	O
whereas	O	SCONJ	O
tetanic	B-Disease	ADJ	B
tensions	O	NOUN	B
were	O	AUX	O
similar	O	ADJ	O
.	O	PUNCT	O


Steroid	B-Chemical	NOUN	B
treatment	O	NOUN	B
also	O	ADV	O
induced	O	VERB	B
a	O	DET	O
leftward	O	ADJ	O
shift	O	NOUN	B
of	O	ADP	O
the	O	DET	O
force	O	NOUN	B
-	O	PUNCT	O
frequency	O	NOUN	B
curve	O	NOUN	O
at	O	ADP	O
25	O	NUM	O
and	O	CCONJ	O
50	O	NUM	O
Hz	O	NOUN	O
when	O	SCONJ	O
compared	O	VERB	B
with	O	ADP	O
saline	O	NOUN	B
treatment	O	NOUN	I
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


05	O	NUM	O
).	O	PUNCT	O
ATPase	O	NOUN	B
staining	O	NOUN	B
of	O	ADP	O
the	O	DET	O
diaphragm	O	NOUN	B
,	O	PUNCT	O
scalenus	O	NOUN	B
medius	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
gastrocnemius	O	NOUN	B
showed	O	VERB	O
type	O	NOUN	O
IIb	O	NOUN	O
fiber	O	NOUN	O
atrophy	B-Disease	NOUN	O
in	O	ADP	O
the	O	DET	O
steroid	B-Chemical	NOUN	B
groups	O	NOUN	B
and	O	CCONJ	O
also	O	ADV	O
diaphragmatic	O	ADJ	B
type	O	NOUN	I
IIa	O	NOUN	I
atrophy	B-Disease	NOUN	I
with	O	ADP	O
T	B-Chemical	NOUN	B
,	O	PUNCT	O
whereas	O	SCONJ	O
histologic	O	ADJ	B
examinations	O	NOUN	I
revealed	O	VERB	O
a	O	DET	O
normal	O	ADJ	O
muscular	O	ADJ	B
pattern	O	NOUN	O
with	O	ADP	O
absence	O	NOUN	B
of	O	ADP	O
necrosis	B-Disease	NOUN	B
.	O	PUNCT	O


Finally	O	ADV	O
,	O	PUNCT	O
a	O	DET	O
pair	O	NOUN	B
-	O	PUNCT	O
fed	O	VERB	B
(	O	PUNCT	O
PF	O	NOUN	B
)	O	PUNCT	O
study	O	NOUN	B
,	O	PUNCT	O
performed	O	VERB	O
in	O	ADP	O
18	O	NUM	O
rats	O	NOUN	B
(	O	PUNCT	O
C	O	NOUN	B
,	O	PUNCT	O
T	B-Chemical	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
PF	O	NOUN	B
),	O	PUNCT	O
showed	O	VERB	O
that	O	SCONJ	O
muscle	B-Disease	NOUN	B
atrophy	I-Disease	NOUN	I
was	O	AUX	O
considerably	O	ADV	O
less	O	ADV	O
pronounced	O	ADJ	O
in	O	ADP	O
PF	O	NOUN	B
animals	O	NOUN	B
than	O	ADP	O
in	O	ADP	O
T	B-Chemical	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
animals	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
conclude	O	VERB	O
that	O	SCONJ	O
(	O	PUNCT	O
1	O	X	O
)	O	PUNCT	O
short	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
treatment	O	NOUN	B
with	O	ADP	O
massive	O	ADJ	B
doses	O	NOUN	I
of	O	ADP	O
steroids	B-Chemical	NOUN	B
induced	O	VERB	B
severe	O	ADJ	B
respiratory	O	ADJ	B
and	O	CCONJ	O
limb	O	NOUN	B
muscle	O	NOUN	I
wasting	O	NOUN	O
;(	O	PUNCT	O
2	O	X	O
)	O	PUNCT	O
both	O	DET	O
types	O	NOUN	O
of	O	ADP	O
steroids	B-Chemical	NOUN	B
induced	O	VERB	B
predominantly	O	ADV	O
type	O	NOUN	B
IIb	O	NOUN	I
atrophy	B-Disease	NOUN	I
,	O	PUNCT	O
resulting	O	VERB	O
in	O	ADP	O
the	O	DET	O
expected	O	VERB	O
alterations	O	NOUN	B
in	O	ADP	O
diaphragm	O	ADJ	B
contractile	O	NOUN	B
properties	O	NOUN	B
;(	O	PUNCT	O
3	O	X	O
)	O	PUNCT	O
neither	O	CCONJ	O
steroid	B-Chemical	NOUN	B
caused	O	VERB	O
muscle	O	NOUN	B
necrosis	B-Disease	NOUN	I
;(	O	PUNCT	I
4	O	NUM	I
)	O	PUNCT	O
type	O	NOUN	B
IIb	O	NOUN	I
atrophy	B-Disease	NOUN	I


Refractory	O	ADJ	B
cardiogenic	B-Disease	ADJ	B
shock	I-Disease	NOUN	I
and	O	CCONJ	O
complete	O	ADJ	B
heart	B-Disease	NOUN	B
block	I-Disease	NOUN	I
after	O	ADP	O
verapamil	B-Chemical	NOUN	B
SR	O	ADJ	B
and	O	CCONJ	O
metoprolol	B-Chemical	NOUN	B
treatment	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
case	O	NOUN	B
report	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
seventy	O	NUM	B
-	O	PUNCT	O
eight	O	NUM	B
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
woman	O	NOUN	B
presented	O	VERB	O
with	O	ADP	O
complete	O	ADJ	O
heart	B-Disease	NOUN	B
block	I-Disease	NOUN	I
and	O	CCONJ	O
refractory	O	ADJ	B
hypotension	B-Disease	NOUN	B
two	O	NUM	O
days	O	NOUN	B
after	O	ADP	O
a	O	DET	O
therapeutic	O	ADJ	B
dose	O	NOUN	I
of	O	ADP	O
sustained	O	ADJ	B
-	O	PUNCT	O
release	O	NOUN	B
verapamil	B-Chemical	NOUN	B
with	O	ADP	O
concomitant	O	ADJ	B
use	O	NOUN	O
of	O	ADP	O
metoprolol	B-Chemical	NOUN	B
.	O	PUNCT	O


The	O	DET	O
patient	O	NOUN	B
continued	O	VERB	O
to	O	PART	O
remain	O	VERB	O
hypotensive	B-Disease	ADJ	B
with	O	ADP	O
complete	O	ADJ	O
heart	B-Disease	NOUN	B
block	I-Disease	NOUN	I
,	O	PUNCT	O
even	O	ADV	O
with	O	ADP	O
multiple	O	ADJ	O
uses	O	NOUN	O
of	O	ADP	O
intravenous	O	ADJ	B
atropine	B-Chemical	NOUN	B
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
high	O	ADJ	B
doses	O	NOUN	I
of	O	ADP	O
pressor	O	NOUN	B
agents	O	NOUN	I
such	O	ADJ	O
as	O	ADP	O
dopamine	B-Chemical	NOUN	B
and	O	CCONJ	O
dobutamine	B-Chemical	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
shortly	O	ADV	O
after	O	ADP	O
the	O	DET	O
use	O	NOUN	O
of	O	ADP	O
intravenous	O	ADJ	B
calcium	B-Chemical	NOUN	O
chloride	I-Chemical	NOUN	O
,	O	PUNCT	O
the	O	DET	O
refractory	O	ADJ	B
hypotension	B-Disease	NOUN	B
and	O	CCONJ	O
complete	O	ADJ	B
heart	B-Disease	NOUN	O
block	I-Disease	NOUN	O


A	O	DET	O
phase	O	NOUN	B
I	O	NUM	I
clinical	O	ADJ	B
study	O	NOUN	I
of	O	ADP	O
the	O	DET	O
antipurine	B-Chemical	NOUN	B
antifolate	O	NOUN	B
lometrexol	B-Chemical	NOUN	I
(	O	PUNCT	O
DDATHF	B-Chemical	NOUN	B
)	O	PUNCT	O
given	O	VERB	O
with	O	ADP	O
oral	O	ADJ	B
folic	B-Chemical	ADJ	I
acid	I-Chemical	NOUN	I
.	O	PUNCT	O


Lometrexol	B-Chemical	NOUN	B
is	O	AUX	O
an	O	DET	O
antifolate	O	NOUN	B
which	O	DET	O
inhibits	O	VERB	B
glycinamide	B-Chemical	NOUN	B
ribonucleotide	I-Chemical	ADJ	I
formyltransferase	O	NOUN	I
(	O	PUNCT	O
GARFT	O	NOUN	B
),	O	PUNCT	O
an	O	DET	O
enzyme	O	NOUN	B
essential	O	ADJ	B
for	O	ADP	O
de	O	X	B
novo	O	X	I
purine	B-Chemical	NOUN	B
synthesis	O	NOUN	O
.	O	PUNCT	O


Extensive	O	ADJ	O
experimental	O	ADJ	B
and	O	CCONJ	O
limited	O	ADJ	O
clinical	O	ADJ	B
data	O	NOUN	O
have	O	AUX	O
shown	O	VERB	O
that	O	SCONJ	O
lometrexol	B-Chemical	NOUN	B
has	O	AUX	O
activity	O	NOUN	B
against	O	ADP	O
tumours	B-Disease	NOUN	B
which	O	DET	O
are	O	AUX	O
refractory	O	ADJ	B
to	O	PART	O
other	O	ADJ	O
drugs	O	NOUN	B
,	O	PUNCT	O
notably	O	ADV	O
methotrexate	B-Chemical	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
initial	O	ADJ	O
clinical	O	ADJ	B
development	O	NOUN	I
of	O	ADP	O
lometrexol	B-Chemical	NOUN	B
was	O	AUX	O
curtailed	O	VERB	B
because	O	SCONJ	O
of	O	ADP	O
severe	O	ADJ	B
and	O	CCONJ	O
cumulative	O	ADJ	B
antiproliferative	O	ADJ	B
toxicities	B-Disease	NOUN	B
.	O	PUNCT	O


Preclinical	O	ADJ	B
murine	O	ADJ	O
studies	O	NOUN	B
demonstrated	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
toxicity	B-Disease	NOUN	B
of	O	ADP	O
lometrexol	B-Chemical	NOUN	B
can	O	AUX	O
be	O	AUX	O
prevented	O	VERB	B
by	O	ADP	O
low	O	ADJ	B
dose	O	NOUN	B
folic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
administration	O	NOUN	I
,	O	PUNCT	O
i	O	X	O
.	O	PUNCT	O


e	O	X	O
.	O	PUNCT	O


for	O	ADP	O
7	O	NUM	O
days	O	NOUN	B
prior	O	ADJ	O
to	O	PART	O
and	O	CCONJ	O
7	O	NUM	O
days	O	NOUN	B
following	O	VERB	O
a	O	DET	O
single	O	ADJ	O
bolus	O	NOUN	B
dose	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
observation	O	NOUN	B
prompted	O	VERB	O
a	O	DET	O
Phase	O	NOUN	B
I	O	NUM	I
clinical	O	ADJ	B
study	O	NOUN	I
of	O	ADP	O
lometrexol	B-Chemical	NOUN	B
given	O	VERB	O
with	O	ADP	O
folic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
supplementation	O	NOUN	B
which	O	DET	O
has	O	AUX	O
confirmed	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
toxicity	B-Disease	NOUN	B
of	O	ADP	O
lometrexol	B-Chemical	NOUN	B
can	O	AUX	O
be	O	AUX	O
markedly	O	ADV	O
reduced	O	VERB	B
by	O	ADP	O
folic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
supplementation	O	NOUN	B
.	O	PUNCT	O


Thrombocytopenia	B-Disease	NOUN	B
and	O	CCONJ	O
mucositis	B-Disease	NOUN	B
were	O	AUX	O
the	O	DET	O
major	O	ADJ	O
toxicities	B-Disease	NOUN	B
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
no	O	DET	O
clear	O	ADJ	O
relationship	O	NOUN	B
between	O	ADP	O
clinical	O	ADJ	B
toxicity	B-Disease	NOUN	B
and	O	CCONJ	O
the	O	DET	O
extent	O	NOUN	O
of	O	ADP	O
plasma	O	NOUN	B
folate	B-Chemical	NOUN	O
elevation	O	NOUN	O
.	O	PUNCT	O


Associated	O	ADJ	O
studies	O	NOUN	O
demonstrated	O	VERB	O
that	O	SCONJ	O
lometrexol	B-Chemical	NOUN	B
plasma	O	NOUN	B
pharmacokinetics	O	NOUN	B
were	O	AUX	O
not	O	PART	O
altered	O	VERB	O
by	O	ADP	O
folic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
administration	O	NOUN	I
indicating	O	VERB	O
that	O	SCONJ	O
supplementation	O	NOUN	B
is	O	AUX	O
unlikely	O	ADJ	O
to	O	PART	O
reduce	O	VERB	B
toxicity	B-Disease	NOUN	B
by	O	ADP	O
enhancing	O	VERB	O
lometrexol	B-Chemical	NOUN	B
plasma	O	NOUN	B
clearance	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
work	O	NOUN	O
described	O	VERB	O
in	O	ADP	O
this	O	DET	O
report	O	NOUN	B
has	O	AUX	O
identified	O	VERB	B
for	O	ADP	O
the	O	DET	O
first	O	ADJ	O
time	O	NOUN	O
a	O	DET	O
clinically	O	ADV	B
acceptable	O	ADJ	O
schedule	O	NOUN	B
for	O	ADP	O
the	O	DET	O
administration	O	NOUN	B
of	O	ADP	O
a	O	DET	O
GARFT	O	NOUN	B
inhibitor	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
information	O	NOUN	B
will	O	AUX	O
facilitate	O	VERB	O
the	O	DET	O
future	O	ADJ	O
evaluation	O	NOUN	B
of	O	ADP	O
this	O	DET	O
class	O	NOUN	O
of	O	ADP	O
compounds	O	NOUN	B
in	O	ADP	O
cancer	B-Disease	NOUN	B


Involvement	O	NOUN	B
of	O	ADP	O
the	O	DET	O
mu	O	NOUN	B
-	O	PUNCT	O
opiate	O	ADJ	B
receptor	O	NOUN	I
in	O	ADP	O
peripheral	O	ADJ	B
analgesia	B-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
intradermal	O	ADJ	B
injection	O	NOUN	I
of	O	ADP	O
mu	O	NOUN	O
(	O	PUNCT	O
morphine	B-Chemical	NOUN	B
,	O	PUNCT	O
Tyr-D-Ala-Gly-NMe-Phe-Gly-ol	B-Chemical	NOUN	B
and	O	CCONJ	O
morphiceptin	B-Chemical	NOUN	B
),	O	PUNCT	O
kappa	O	NOUN	O
(	O	PUNCT	O
trans-3,4-dichloro-N-methyl-N[2-(1-pyrrolidinyl)	B-Chemical	NOUN	O
cyclohexyl]benzeneactemide	I-Chemical	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
delta	O	NOUN	B
(	O	PUNCT	O
[D-Pen2.5]-enkephalin	B-Chemical	NOUN	B
and	O	CCONJ	O
[D-Ser2]-[Leu]enkephalin-Thr	B-Chemical	X	O
)	O	PUNCT	O
selective	O	ADJ	O
opioid	O	NOUN	B
-	O	PUNCT	O
agonists	O	NOUN	B
,	O	PUNCT	O
by	O	ADP	O
themselves	O	PRON	O
,	O	PUNCT	O
did	O	AUX	O
not	O	PART	O
significantly	O	ADV	O
affect	O	VERB	O
the	O	DET	O
mechanical	O	ADJ	B
nociceptive	O	ADJ	I
threshold	O	NOUN	B
in	O	ADP	O
the	O	DET	O
hindpaw	O	NOUN	B
of	O	ADP	O
the	O	DET	O
rat	O	NOUN	B
.	O	PUNCT	O


Intradermal	O	ADJ	B
injection	O	NOUN	I
of	O	ADP	O
mu	O	NOUN	O
,	O	PUNCT	O
but	O	CCONJ	O
not	O	PART	O
delta	O	NOUN	O
or	O	CCONJ	O
kappa	O	NOUN	O
opioid	O	NOUN	B
-	O	PUNCT	O
agonists	O	NOUN	B
,	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
produced	O	VERB	O
dose	O	NOUN	B
-	O	PUNCT	O
dependent	O	ADJ	B
inhibition	O	NOUN	B
of	O	ADP	O
prostaglandin	B-Chemical	NOUN	B
E2	I-Chemical	NOUN	I
-	O	PUNCT	O
induced	O	VERB	B
hyperalgesia	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
analgesic	O	ADJ	B
effect	O	NOUN	I
of	O	ADP	O
the	O	DET	O
mu	O	NOUN	B
-	O	PUNCT	O
agonist	O	NOUN	B
morphine	B-Chemical	NOUN	B
was	O	AUX	O
dose	O	NOUN	B
-	O	PUNCT	O
dependently	O	ADV	B
antagonized	O	VERB	B
by	O	ADP	O
naloxone	B-Chemical	NOUN	B
and	O	CCONJ	O
prevented	O	VERB	B
by	O	ADP	O
co	O	X	B
-	O	PUNCT	O
injection	O	NOUN	B
of	O	ADP	O
pertussis	O	NOUN	B
toxin	O	NOUN	I
.	O	PUNCT	O


Morphine	B-Chemical	NOUN	B
did	O	AUX	O
not	O	PART	O
,	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
alter	O	VERB	O
the	O	DET	O
hyperalgesia	B-Disease	NOUN	B
induced	O	VERB	B
by	O	ADP	O
8-bromo	B-Chemical	NOUN	B
cyclic	I-Chemical	ADJ	B
adenosine	I-Chemical	NOUN	I
monophosphate	I-Chemical	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
conclude	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
analgesic	O	NOUN	B
action	O	NOUN	I
of	O	ADP	O
opioids	O	NOUN	B
on	O	ADP	O
the	O	DET	O
peripheral	O	ADJ	B
terminals	O	NOUN	B
of	O	ADP	O
primary	O	ADJ	B
afferents	O	NOUN	I
is	O	AUX	O
via	O	ADP	O
a	O	DET	O
binding	O	VERB	B
site	O	NOUN	I
with	O	ADP	O
characteristics	O	NOUN	B
of	O	ADP	O
the	O	DET	O
mu	O	NOUN	B
-	O	PUNCT	O
opioid	O	NOUN	B
receptor	O	NOUN	I
and	O	CCONJ	O
that	O	SCONJ	O
this	O	DET	O
action	O	NOUN	B
is	O	AUX	O
mediated	O	VERB	O
by	O	ADP	O
inhibition	O	NOUN	B
of	O	ADP	O
the	O	DET	O
cyclic	B-Chemical	ADJ	B
adenosine	I-Chemical	NOUN	I
monophosphate	I-Chemical	NOUN	I


Adequate	O	ADJ	B
timing	O	NOUN	B
of	O	ADP	O
ribavirin	B-Chemical	NOUN	B
reduction	O	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
hemolysis	B-Disease	NOUN	B
during	O	ADP	O
combination	O	NOUN	B
therapy	O	NOUN	I
of	O	ADP	O
interferon	B-Chemical	NOUN	B
and	O	CCONJ	O
ribavirin	B-Chemical	NOUN	B
for	O	ADP	O
chronic	B-Disease	ADJ	B
hepatitis	I-Disease	NOUN	I
C	I-Disease	NOUN	I
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
:	O	PUNCT	O
Hemolytic	B-Disease	ADJ	B
anemia	I-Disease	NOUN	I
is	O	AUX	O
one	O	NUM	O
of	O	ADP	O
the	O	DET	O
major	O	ADJ	O
adverse	O	ADJ	B
events	O	NOUN	I
of	O	ADP	O
the	O	DET	O
combination	O	NOUN	B
therapy	O	NOUN	I
of	O	ADP	O
interferon	B-Chemical	NOUN	B
and	O	CCONJ	O
ribavirin	B-Chemical	NOUN	B
.	O	PUNCT	O


Because	O	SCONJ	O
of	O	ADP	O
ribavirin	B-Chemical	NOUN	B
-	O	PUNCT	O
related	O	ADJ	B
hemolytic	B-Disease	ADJ	B
anemia	I-Disease	NOUN	B
,	O	PUNCT	O
dose	O	NOUN	B
reduction	O	NOUN	B
is	O	AUX	O
a	O	DET	O
common	O	ADJ	O
event	O	NOUN	B
in	O	ADP	O
this	O	DET	O
therapy	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
this	O	DET	O
clinical	O	ADJ	B
retrospective	O	ADJ	O
cohort	O	NOUN	O
study	O	NOUN	O
we	O	PRON	O
have	O	AUX	O
examined	O	VERB	O
the	O	DET	O
suitable	O	ADJ	O
timing	O	NOUN	B
of	O	ADP	O
ribavirin	B-Chemical	NOUN	B
reduction	O	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
hemolysis	B-Disease	NOUN	B
during	O	ADP	O
combination	O	NOUN	B
therapy	O	NOUN	I
.	O	PUNCT	O


METHODS	O	NOUN	O
:	O	PUNCT	O
Thirty	O	NUM	B
-	O	PUNCT	O
seven	O	NUM	B
of	O	ADP	O
160	O	NUM	O
patients	O	NOUN	B
who	O	PRON	O
had	O	AUX	O
HCV	O	NOUN	B
-	O	PUNCT	O
genotype	O	NOUN	B
1b	O	NOUN	O
,	O	PUNCT	O
had	O	AUX	O
high	O	ADJ	O
virus	O	NOUN	B
load	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
received	O	VERB	O
24	O	NUM	O
-	O	PUNCT	O
week	O	NOUN	B
combination	O	NOUN	B
therapy	O	NOUN	I
developed	O	VERB	O
anemia	B-Disease	NOUN	B
with	O	ADP	O
hemoglobin	O	NOUN	B
level	O	NOUN	I
<	O	X	O
10	O	NUM	O
g	O	NOUN	O
/	O	SYM	O
dl	O	NOUN	B
or	O	CCONJ	O
anemia	B-Disease	NOUN	B
-	O	PUNCT	O
related	O	VERB	B
signs	O	NOUN	B
during	O	ADP	O
therapy	O	NOUN	B
.	O	PUNCT	O


After	O	ADP	O
that	O	DET	O
,	O	PUNCT	O
these	O	DET	O
37	O	NUM	O
patients	O	NOUN	B
were	O	AUX	O
reduced	O	VERB	B
one	O	NUM	O
tablet	O	NOUN	B
of	O	ADP	O
ribavirin	B-Chemical	NOUN	B
(	O	PUNCT	O
200	O	NUM	O
mg	O	NOUN	O
)	O	PUNCT	O
per	O	ADP	O
day	O	NOUN	B
.	O	PUNCT	O


After	O	ADP	O
reduction	O	NOUN	B
of	O	ADP	O
ribavirin	B-Chemical	NOUN	B
,	O	PUNCT	O
27	O	NUM	O
of	O	ADP	O
37	O	NUM	O
patients	O	NOUN	B
could	O	AUX	O
continue	O	VERB	O
combination	O	NOUN	B
therapy	O	NOUN	I
for	O	ADP	O
a	O	DET	O
total	O	NOUN	O
of	O	ADP	O
24	O	NUM	O
weeks	O	NOUN	B
(	O	PUNCT	O
group	O	NOUN	B
A	O	PROPN	O
).	O	PUNCT	B
However	O	ADV	O
,	O	PUNCT	O
10	O	NUM	O
of	O	ADP	O
37	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
reduction	O	NOUN	B
of	O	ADP	O
ribavirin	B-Chemical	NOUN	B
could	O	AUX	O
not	O	PART	O
continue	O	VERB	O
combination	O	NOUN	B
therapy	O	NOUN	I
because	O	SCONJ	O
their	O	PRON	O
<	O	X	O
8	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
g	O	NOUN	B
/	O	SYM	O
dl	O	NOUN	B
hemoglobin	O	NOUN	B
values	O	NOUN	I
decreased	O	VERB	B
to	O	PART	O
or	O	CCONJ	O
anemia	B-Disease	NOUN	B
-	O	PUNCT	O
related	O	VERB	B
severe	O	ADJ	B
side	O	NOUN	B
effects	O	NOUN	I
occurred	O	VERB	O
(	O	PUNCT	O
group	O	NOUN	B
B	O	NOUN	I
).	O	PUNCT	O
We	O	PRON	O
assessed	O	VERB	B
the	O	DET	O
final	O	ADJ	O
efficacy	O	NOUN	B
and	O	CCONJ	O
safety	O	NOUN	B
after	O	ADP	O
reduction	O	NOUN	B
of	O	ADP	O
ribavirin	B-Chemical	NOUN	B
in	O	ADP	O
groups	O	NOUN	B
A	O	NOUN	O
and	O	CCONJ	O
B	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
A	O	DET	O
sustained	O	ADJ	O
virological	O	ADJ	B
response	O	NOUN	O
(	O	PUNCT	O
SVR	O	NOUN	B
)	O	PUNCT	O
was	O	AUX	O
29	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
%(	O	NOUN	O
8	O	NUM	O
/	O	SYM	O
27	O	NUM	O
)	O	PUNCT	O
in	O	ADP	O
group	O	NOUN	B
A	O	NOUN	I
and	O	CCONJ	O
10	O	NUM	O
%(	O	NOUN	O
1	O	NUM	O
/	O	SYM	O
10	O	NUM	O
)	O	PUNCT	O
in	O	ADP	O
group	O	NOUN	B
B	O	NOUN	I
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


A	O	DET	O
34	O	NUM	O
.	O	PUNCT	O


4	O	NUM	O
%(	O	NOUN	O
12	O	NUM	O
/	O	SYM	O
27	O	NUM	O
)	O	PUNCT	O
of	O	ADP	O
SVR	O	NOUN	B
+	O	CCONJ	O
biological	O	ADJ	B
response	O	NOUN	I
in	O	ADP	O
group	O	NOUN	B
A	O	NOUN	I
was	O	AUX	O
higher	O	ADJ	O
than	O	ADP	O
10	O	NUM	O
%(	O	NOUN	O
1	O	NUM	O
/	O	SYM	O
10	O	NUM	O
)	O	PUNCT	O
in	O	ADP	O
group	O	NOUN	B
B	O	NOUN	I
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


051	O	NUM	O
),	O	PUNCT	O
with	O	ADP	O
slight	O	ADJ	O
significance	O	NOUN	B
.	O	PUNCT	O


With	O	ADP	O
respect	O	NOUN	O
to	O	PART	O
hemoglobin	O	NOUN	B
level	O	NOUN	I
at	O	ADP	O
the	O	DET	O
time	O	NOUN	B
of	O	ADP	O
ribavirin	B-Chemical	NOUN	B
reduction	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
rate	O	NOUN	B
of	O	ADP	O
continuation	O	NOUN	B
of	O	ADP	O
therapy	O	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
>	O	NOUN	O
or	O	CCONJ	O
=	O	ADJ	O
10	O	NUM	O
g	O	NOUN	B
/	O	SYM	O
dl	O	NOUN	B
hemoglobin	O	NOUN	B
was	O	AUX	O
higher	O	ADJ	O
than	O	ADP	O
that	O	DET	O
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
<	O	NOUN	O
10	O	NUM	O
g	O	NOUN	O
/	O	SYM	O
dl	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


036	O	NUM	O
).	O	PUNCT	O
CONCLUSIONS	O	NOUN	O
:	O	PUNCT	O
Reduction	O	NOUN	B
of	O	ADP	O
ribavirin	B-Chemical	NOUN	B


Increased	O	VERB	B
expression	O	NOUN	B
and	O	CCONJ	O
apical	O	ADJ	B
targeting	O	NOUN	B
of	O	ADP	O
renal	O	ADJ	B
ENaC	O	NOUN	I
subunits	O	NOUN	I
in	O	ADP	O
puromycin	B-Chemical	NOUN	B
aminonucleoside	I-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
nephrotic	B-Disease	ADJ	B
syndrome	I-Disease	NOUN	I
in	O	ADP	O
rats	O	NOUN	B
.	O	PUNCT	O


Nephrotic	B-Disease	ADJ	B
syndrome	I-Disease	NOUN	I
is	O	AUX	O
often	O	ADV	O
accompanied	O	VERB	O
by	O	ADP	O
sodium	B-Chemical	NOUN	B
retention	O	NOUN	I
and	O	CCONJ	O
generalized	O	VERB	B
edema	B-Disease	NOUN	I
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
molecular	O	ADJ	B
basis	O	NOUN	I
for	O	ADP	O
the	O	DET	O
decreased	O	VERB	B
renal	O	ADJ	B
sodium	B-Chemical	NOUN	I
excretion	O	NOUN	B
remains	O	VERB	O
undefined	O	ADJ	O
.	O	PUNCT	O


We	O	PRON	O
hypothesized	O	VERB	O
that	O	SCONJ	O
epithelial	O	ADJ	B
Na	B-Chemical	NOUN	I
channel	O	NOUN	I
(	O	PUNCT	O
ENaC	O	NOUN	B
)	O	PUNCT	O
subunit	O	NOUN	B
dysregulation	O	NOUN	B
may	O	AUX	O
be	O	AUX	O
responsible	O	ADJ	O
for	O	ADP	O
the	O	DET	O
increased	O	VERB	B
sodium	B-Chemical	NOUN	B
retention	O	NOUN	I
.	O	PUNCT	O


An	O	DET	O
experimental	O	ADJ	B
group	O	NOUN	I
of	O	ADP	O
rats	O	NOUN	B
was	O	AUX	O
treated	O	VERB	B
with	O	ADP	I
puromycin	B-Chemical	NOUN	O
aminonucleoside	I-Chemical	NOUN	B
(	O	PUNCT	O
PAN	B-Chemical	NOUN	B
;	O	PUNCT	O
180	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
iv	O	NOUN	O
),	O	PUNCT	O
whereas	O	SCONJ	O
the	O	DET	O
control	O	NOUN	B
group	O	NOUN	I
received	O	VERB	O
only	O	ADV	O
vehicle	O	NOUN	B
.	O	PUNCT	O


After	O	ADP	O
7	O	NUM	O
days	O	NOUN	B
,	O	PUNCT	O
PAN	B-Chemical	NOUN	B
treatment	O	NOUN	B
induced	O	VERB	B
significant	O	ADJ	O
proteinuria	B-Disease	NOUN	B
,	O	PUNCT	O
hypoalbuminemia	B-Disease	NOUN	B
,	O	PUNCT	O
decreased	O	VERB	B
urinary	O	ADJ	B
sodium	B-Chemical	NOUN	I
excretion	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
extensive	O	ADJ	B
ascites	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
protein	O	NOUN	B
abundance	O	NOUN	B
of	O	ADP	O
alpha	O	NOUN	B
-	O	PUNCT	O
ENaC	O	NOUN	B
and	O	CCONJ	O
beta	O	NOUN	B
-	O	PUNCT	O
ENaC	O	NOUN	B
was	O	AUX	O
increased	O	VERB	B
in	O	ADP	O
the	O	DET	O
inner	O	ADJ	B
stripe	O	NOUN	I
of	O	ADP	O
the	O	DET	O
outer	O	ADJ	B
medulla	O	NOUN	I
(	O	PUNCT	O
ISOM	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
in	O	ADP	O
the	O	DET	O
inner	O	ADJ	B
medulla	O	NOUN	I
(	O	PUNCT	O
IM	O	NOUN	B
)	O	PUNCT	O
but	O	CCONJ	O
was	O	AUX	O
not	O	PART	O
altered	O	VERB	O
in	O	ADP	O
the	O	DET	O
cortex	O	NOUN	B
.	O	PUNCT	O


gamma	O	NOUN	B
-	O	PUNCT	O
ENaC	O	NOUN	B
abundance	O	NOUN	B
was	O	AUX	O
increased	O	VERB	B
in	O	ADP	O
the	O	DET	O
cortex	O	NOUN	B
,	O	PUNCT	O
ISOM	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
IM	O	NOUN	B
.	O	PUNCT	O


Immunoperoxidase	O	NOUN	B
brightfield	O	NOUN	I
-	O	PUNCT	O
and	O	CCONJ	O
laser	O	NOUN	B
-	O	PUNCT	O
scanning	O	VERB	B
confocal	O	ADJ	B
fluorescence	O	NOUN	I
microscopy	O	NOUN	I
demonstrated	O	VERB	O
increased	O	VERB	B
targeting	O	NOUN	B
of	O	ADP	O
alpha	O	NOUN	B
-	O	PUNCT	O
ENaC	O	NOUN	B
,	O	PUNCT	O
beta	O	NOUN	B
-	O	PUNCT	O
ENaC	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
gamma	O	NOUN	B
-	O	PUNCT	O
ENaC	O	NOUN	B
subunits	O	NOUN	B
to	O	PART	O
the	O	DET	O
apical	O	ADJ	B
plasma	O	NOUN	O
membrane	O	NOUN	O
in	O	ADP	O
the	O	DET	O
distal	O	ADJ	B
convoluted	O	ADJ	I
tubule	O	NOUN	I
(	O	PUNCT	O
DCT2	O	ADJ	B
),	O	PUNCT	O
connecting	O	VERB	O
tubule	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
cortical	O	ADJ	B
and	O	CCONJ	O
medullary	O	ADJ	B
collecting	O	VERB	O
duct	O	NOUN	B
segments	O	NOUN	B
.	O	PUNCT	O


Immunoelectron	O	NOUN	B
microscopy	O	NOUN	I
further	O	ADV	O
revealed	O	VERB	O
an	O	DET	O
increased	O	VERB	B
labeling	O	NOUN	B
of	O	ADP	O
alpha	O	NOUN	B
-	O	PUNCT	O
ENaC	O	NOUN	B
in	O	ADP	O
the	O	DET	O
apical	O	ADJ	B
plasma	O	NOUN	O
membrane	O	NOUN	O
of	O	ADP	O
cortical	O	ADJ	B
collecting	O	VERB	I
duct	O	NOUN	B
principal	O	ADJ	I
cells	O	NOUN	I
of	O	ADP	O
PAN	B-Chemical	PROPN	B
-	O	PUNCT	O
treated	O	VERB	B
rats	O	NOUN	B
,	O	PUNCT	O
indicating	O	VERB	O
enhanced	O	VERB	B
apical	O	ADJ	B
targeting	O	NOUN	B
of	O	ADP	O
alpha	O	NOUN	B
-	O	PUNCT	O
ENaC	O	NOUN	B
subunits	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
contrast	O	NOUN	O
,	O	PUNCT	O
the	O	DET	O
protein	O	NOUN	B
abundances	O	NOUN	I
of	O	ADP	O
Na	B-Chemical	NOUN	B
(+)/	O	NOUN	I
H	B-Chemical	NOUN	I
(+)	O	ADJ	I
exchanger	O	NOUN	I
type	O	NOUN	I
3	O	NUM	I
(	O	PUNCT	O
NHE3	O	NOUN	B
),	O	PUNCT	O
Na	B-Chemical	NOUN	B
(+)-	O	NOUN	B
K	B-Chemical	NOUN	B
(+)-	O	NOUN	I
2	O	NUM	I
Cl	B-Chemical	NOUN	B
(-)	O	ADJ	I
cotransporter	O	NOUN	I
(	O	PUNCT	O
BSC	O	PROPN	B
-	O	PUNCT	O
1	O	NUM	O
),	O	PUNCT	O
and	O	CCONJ	O
thiazide	B-Chemical	NOUN	B
-	O	PUNCT	O
sensitive	O	ADJ	B
Na	B-Chemical	NOUN	B
(+)-	O	NOUN	B
Cl	B-Chemical	NOUN	B
(-)	O	ADJ	I
cotransporter	O	NOUN	I
(	O	PUNCT	O
TSC	O	NOUN	B
)	O	PUNCT	O
were	O	AUX	O
decreased	O	VERB	B
.	O	PUNCT	O


Moreover	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
abundance	O	NOUN	B
of	O	ADP	O
the	O	DET	O
alpha	O	NOUN	B
(	O	PUNCT	O
1	O	NUM	O
)-	O	ADJ	O
subunit	O	NOUN	B
of	O	ADP	O
the	O	DET	O
Na	B-Chemical	PROPN	B
-	O	PUNCT	O
K	B-Chemical	PROPN	B
-	O	PUNCT	O
ATPase	O	NOUN	B
was	O	AUX	O
decreased	O	VERB	B
in	O	ADP	O
the	O	DET	O
cortex	O	NOUN	B
and	O	CCONJ	O
ISOM	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
it	O	PRON	O
remained	O	VERB	O
unchanged	O	ADJ	B
in	O	ADP	O
the	O	DET	O
IM	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
conclusion	O	NOUN	O
,	O	PUNCT	O
the	O	DET	O
increased	O	VERB	B
or	O	CCONJ	O
sustained	O	ADJ	B
expression	O	NOUN	B
of	O	ADP	O
ENaC	O	NOUN	B
subunits	O	NOUN	I
combined	O	VERB	O
with	O	ADP	O
increased	O	VERB	B
apical	O	ADJ	B
targeting	O	NOUN	B
in	O	ADP	O
the	O	DET	O
DCT2	O	NOUN	B
,	O	PUNCT	O
connecting	O	VERB	O
tubule	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
collecting	O	VERB	O
duct	O	NOUN	B
are	O	AUX	O
likely	O	ADJ	O
to	O	PART	O
play	O	VERB	O
a	O	DET	O
role	O	NOUN	O
in	O	ADP	O
the	O	DET	O
sodium	B-Chemical	NOUN	B
retention	O	NOUN	I
associated	O	VERB	B
with	O	ADP	I
PAN	B-Chemical	PROPN	B
-	O	PUNCT	O
induced	O	VERB	B
nephrotic	B-Disease	ADJ	B
syndrome	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
decreased	O	VERB	B
abundance	O	NOUN	B
of	O	ADP	O
NHE3	O	NOUN	B
,	O	PUNCT	O
BSC	O	PROPN	B
-	O	PUNCT	O
1	O	NUM	B
,	O	PUNCT	O
TSC	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
Na	B-Chemical	PROPN	B
-	O	PUNCT	O
K	B-Chemical	PROPN	B
-	O	PUNCT	O
ATPase	O	NOUN	B
may	O	AUX	O
play	O	VERB	O
a	O	DET	O
compensatory	O	ADJ	B
role	O	NOUN	O
to	O	PART	O
promote	O	VERB	B
sodium	B-Chemical	NOUN	B


Does	O	AUX	O
hormone	O	NOUN	B
therapy	O	NOUN	I
for	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
breast	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
have	O	AUX	O
a	O	DET	O
detrimental	B-Disease	ADJ	B
effect	I-Disease	NOUN	I
on	I-Disease	ADP	O
memory	I-Disease	NOUN	B
and	I-Disease	CCONJ	O
cognition	I-Disease	NOUN	B
?	O	PUNCT	O
A	O	DET	O
pilot	O	NOUN	B
study	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
pilot	O	NOUN	B
study	O	NOUN	I
examines	O	VERB	O
whether	O	SCONJ	O
hormone	O	NOUN	B
therapy	O	NOUN	I
for	O	ADP	O
breast	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
affects	O	VERB	B
cognition	O	NOUN	B
.	O	PUNCT	O


Patients	O	NOUN	B
participating	O	VERB	B
in	O	ADP	O
a	O	DET	O
randomised	O	ADJ	B
trial	O	NOUN	I
of	O	ADP	O
anastrozole	B-Chemical	NOUN	B
,	O	PUNCT	O
tamoxifen	B-Chemical	NOUN	B
alone	O	ADV	O
or	O	CCONJ	O
combined	O	ADJ	B
(	O	PUNCT	O
ATAC	O	NOUN	B
)(	O	NOUN	O
n	O	NOUN	O
=	O	ADJ	O
94	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
group	O	NOUN	B
of	O	ADP	O
women	O	NOUN	B
without	O	ADP	O
breast	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
35	O	NUM	O
)	O	PUNCT	O
completed	O	VERB	O
a	O	DET	O
battery	O	NOUN	B
of	O	ADP	O
neuropsychological	O	ADJ	B
measures	O	NOUN	I
.	O	PUNCT	O


Compared	O	VERB	B
with	O	ADP	O
the	O	DET	O
control	O	NOUN	B
group	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
patients	O	NOUN	B
were	O	AUX	O
impaired	O	ADJ	B
on	O	ADP	O
a	O	DET	O
processing	O	NOUN	B
speed	O	NOUN	B
task	O	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


032	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
on	O	ADP	O
a	O	DET	O
measure	O	NOUN	B
of	O	ADP	O
immediate	O	ADJ	B
verbal	O	ADJ	B
memory	O	NOUN	I
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


026	O	NUM	O
)	O	PUNCT	O
after	O	ADP	O
controlling	O	VERB	B
for	O	ADP	O
the	O	DET	O
use	O	NOUN	O
of	O	ADP	O
hormone	O	NOUN	B
replacement	O	NOUN	I
therapy	O	NOUN	I
in	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
.	O	PUNCT	O


Patient	O	ADJ	B
group	O	NOUN	I
performance	O	NOUN	B
was	O	AUX	O
not	O	PART	O
significantly	O	ADV	O
related	O	ADJ	O
to	O	PART	O
length	O	NOUN	B
of	O	ADP	I
treatment	O	NOUN	B
or	O	CCONJ	O
measures	O	NOUN	B
of	O	ADP	O
psychological	O	ADJ	B
morbidity	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
results	O	NOUN	B
showed	O	VERB	O
specific	O	ADJ	O
impairments	O	NOUN	B
in	O	ADP	O
processing	O	VERB	B
speed	O	NOUN	B
and	O	CCONJ	O
verbal	O	ADJ	B
memory	O	NOUN	I
in	O	ADP	O
women	O	NOUN	B
receiving	O	VERB	O
hormonal	O	ADJ	B
therapy	O	NOUN	I
for	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
breast	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
.	O	PUNCT	O


Verbal	O	ADJ	B
memory	O	NOUN	I
may	O	AUX	O
be	O	AUX	O
especially	O	ADV	O
sensitive	O	ADJ	B
to	O	PART	O
changes	O	NOUN	B
in	O	ADP	O
oestrogen	B-Chemical	NOUN	B


Association	O	NOUN	B
of	O	ADP	O
nitric	B-Chemical	ADJ	B
oxide	I-Chemical	NOUN	I
production	O	NOUN	B
and	O	CCONJ	O
apoptosis	O	NOUN	B
in	O	ADP	O
a	O	DET	O
model	O	NOUN	B
of	O	ADP	O
experimental	O	ADJ	B
nephropathy	B-Disease	NOUN	I
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
:	O	PUNCT	O
In	O	ADP	O
recent	O	ADJ	O
studies	O	NOUN	B
increased	O	VERB	B
amounts	O	NOUN	O
of	O	ADP	O
nitric	B-Chemical	ADJ	B
oxide	I-Chemical	NOUN	I
(	O	PUNCT	O
NO	B-Chemical	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
apoptosis	O	NOUN	B
have	O	AUX	O
been	O	AUX	O
implicated	O	VERB	O
in	O	ADP	O
various	O	ADJ	O
pathological	O	ADJ	B
conditions	O	NOUN	O
in	O	ADP	O
the	O	DET	O
kidney	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
studied	O	VERB	O
the	O	DET	O
role	O	NOUN	O
of	O	ADP	O
NO	B-Chemical	NOUN	B
and	O	CCONJ	O
its	O	PRON	O
association	O	NOUN	B
with	O	ADP	O
apoptosis	O	NOUN	B
in	O	ADP	O
an	O	DET	O
experimental	O	ADJ	B
model	O	NOUN	I
of	O	ADP	O
nephrotic	B-Disease	ADJ	B
syndrome	I-Disease	NOUN	I
induced	O	VERB	B
by	O	ADP	O
a	O	DET	O
single	O	ADJ	O
injection	O	NOUN	B
of	O	ADP	O
adriamycin	B-Chemical	NOUN	B
(	O	PUNCT	O
ADR	B-Chemical	NOUN	B
).	O	PUNCT	O
METHODS	O	NOUN	O
:	O	PUNCT	O
The	O	DET	O
alteration	O	NOUN	B
in	O	ADP	O
the	O	DET	O
NO	B-Chemical	NOUN	B
pathway	O	NOUN	I
was	O	AUX	O
assessed	O	VERB	B
by	O	ADP	O
measuring	O	VERB	B
nitrite	B-Chemical	NOUN	B
levels	O	NOUN	O
in	O	ADP	O
serum	O	NOUN	B
/	O	PUNCT	O
urine	O	NOUN	B
and	O	CCONJ	O
by	O	ADP	O
evaluating	O	VERB	B
the	O	DET	O
changes	O	NOUN	B
in	O	ADP	O
vascular	O	ADJ	B
reactivity	O	NOUN	I
of	O	ADP	O
the	O	DET	O
isolated	O	VERB	B
perfused	O	ADJ	B
rat	O	NOUN	I
kidney	O	NOUN	I
(	O	PUNCT	O
IPRK	O	NOUN	B
)	O	PUNCT	O
system	O	NOUN	O
.	O	PUNCT	O


Rats	O	NOUN	B
were	O	AUX	O
stratified	O	VERB	B
into	O	ADP	O
control	O	ADJ	B
groups	O	NOUN	I
and	O	CCONJ	O
ADR	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
nephropathy	B-Disease	NOUN	B
groups	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
two	O	NUM	O
groups	O	NOUN	B
were	O	AUX	O
then	O	ADV	O
divided	O	VERB	O
into	O	ADP	O
:	O	PUNCT	O
group	O	NOUN	B
1	O	NUM	I
,	O	PUNCT	O
animals	O	NOUN	B
receiving	O	VERB	O
saline	O	NOUN	B
;	O	PUNCT	O
and	O	CCONJ	O
group	O	NOUN	B
2	O	NUM	I
,	O	PUNCT	O
animals	O	NOUN	B
receiving	O	VERB	O
aminoguanidine	B-Chemical	NOUN	B
(	O	PUNCT	O
AG	B-Chemical	PROPN	B
)	O	PUNCT	O
which	O	DET	O
is	O	AUX	O
a	O	DET	O
specific	O	ADJ	O
inhibitor	O	NOUN	B
of	O	ADP	O
inducible	O	ADJ	B
-	O	PUNCT	O
NO	B-Chemical	NOUN	B
synthase	O	NOUN	I
.	O	PUNCT	O


On	O	ADP	O
day	O	NOUN	B
21	O	NUM	O
,	O	PUNCT	O
rats	O	NOUN	B
were	O	AUX	O
sacrificed	O	VERB	B
after	O	ADP	O
obtaining	O	VERB	O
material	O	NOUN	B
for	O	ADP	O
biochemical	O	ADJ	B
analysis	O	NOUN	I
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
Histopathological	O	ADJ	B
examination	O	NOUN	B
of	O	ADP	O
the	O	DET	O
kidneys	O	NOUN	B
of	O	ADP	O
rats	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
ADR	B-Chemical	NOUN	B
revealed	O	VERB	O
focal	O	ADJ	B
areas	O	NOUN	I
of	O	ADP	O
mesangial	B-Disease	ADJ	B
proliferation	I-Disease	NOUN	I
and	O	CCONJ	O
mild	O	ADJ	B
tubulointerstitial	B-Disease	ADJ	B
inflammation	I-Disease	NOUN	I
.	O	PUNCT	O


They	O	PRON	O
also	O	ADV	O
had	O	AUX	O
significantly	O	ADV	O
higher	O	ADJ	O
levels	O	NOUN	B
of	O	ADP	O
proteinuria	B-Disease	NOUN	B
compared	O	VERB	O
with	O	ADP	O
control	O	NOUN	B
and	O	CCONJ	O
treatment	O	NOUN	B
groups	O	NOUN	I
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


05	O	NUM	O
).	O	PUNCT	B
Urine	O	NOUN	B
nitrite	B-Chemical	NOUN	O
levels	O	NOUN	B
were	O	AUX	O
significantly	O	ADV	O
increased	O	VERB	B
in	O	ADP	O
the	O	DET	O
ADR	B-Chemical	NOUN	B
-	O	PUNCT	O
nephropathy	B-Disease	NOUN	B
group	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


05	O	NUM	O
).	O	PUNCT	O
In	O	ADP	O
the	O	DET	O
IPRK	O	NOUN	B
phenylephrine	B-Chemical	NOUN	B
and	O	CCONJ	O
acetylcholine	B-Chemical	NOUN	B
related	O	ADJ	O
responses	O	NOUN	B
were	O	AUX	O
significantly	O	ADV	O
impaired	O	ADJ	B
in	O	ADP	O
the	O	DET	O
ADR	B-Chemical	NOUN	B
-	O	PUNCT	O
nephropathy	B-Disease	NOUN	B
group	O	NOUN	B
.	O	PUNCT	O


Apoptosis	O	NOUN	B
was	O	AUX	O
not	O	PART	O
detected	O	VERB	B
in	O	ADP	O
controls	O	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
ADR	B-Chemical	NOUN	B
-	O	PUNCT	O
nephropathy	B-Disease	NOUN	B
group	O	NOUN	B
,	O	PUNCT	O
numerous	O	ADJ	O
apoptotic	O	ADJ	B
cells	O	NOUN	I
were	O	AUX	O
identified	O	VERB	B
in	O	ADP	O
the	O	DET	O
tubulointerstitial	O	ADJ	B
areas	O	NOUN	O
.	O	PUNCT	O


Double	O	ADJ	B
staining	O	NOUN	I
revealed	O	VERB	O
numerous	O	ADJ	O
interstitial	O	ADJ	B
apoptotic	O	ADJ	O
cells	O	NOUN	O
to	O	PART	O
stain	O	VERB	B
for	O	ADP	O
ED1	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
marker	O	NOUN	B
for	O	ADP	O
monocytes	O	NOUN	B
/	O	PUNCT	O
macrophages	O	NOUN	B
.	O	PUNCT	O


Treatment	O	NOUN	B
with	O	ADP	O
AG	B-Chemical	PROPN	B
prevented	O	VERB	B
the	O	DET	O
impairment	O	NOUN	B
of	O	ADP	O
renal	O	ADJ	B
vascular	O	ADJ	I
bed	O	NOUN	I
responses	O	NOUN	I
and	O	CCONJ	O
reduced	O	VERB	B
both	O	CCONJ	O
urine	O	NOUN	B
nitrite	B-Chemical	NOUN	B
levels	O	NOUN	B
and	O	CCONJ	O
apoptosis	O	NOUN	B
to	O	PART	O
control	O	NOUN	O
levels	O	NOUN	O
.	O	PUNCT	O


CONCLUSION	O	NOUN	B
:	O	PUNCT	O
We	O	PRON	O
suggest	O	VERB	O
that	O	SCONJ	O
interactions	O	NOUN	B
between	O	ADP	O
NO	B-Chemical	NOUN	B
and	O	CCONJ	O
apoptosis	O	NOUN	B
are	O	AUX	O
important	O	ADJ	O
in	O	ADP	O
the	O	DET	O
pathogenesis	O	NOUN	B
of	O	ADP	O
the	O	DET	O
ADR	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
nephrosis	B-Disease	NOUN	B


The	O	DET	O
attenuating	O	ADJ	B
effect	O	NOUN	B
of	O	ADP	O
carteolol	B-Chemical	ADJ	B
hydrochloride	I-Chemical	NOUN	B
,	O	PUNCT	O
a	O	DET	O
beta	O	NOUN	B
-	O	PUNCT	O
adrenoceptor	O	NOUN	B
antagonist	O	NOUN	B
,	O	PUNCT	O
on	O	ADP	O
neuroleptic	O	ADJ	B
-	O	PUNCT	O
induced	O	VERB	B
catalepsy	B-Disease	NOUN	B
in	O	ADP	O
rats	O	NOUN	B
.	O	PUNCT	O


It	O	PRON	O
is	O	AUX	O
known	O	VERB	O
that	O	SCONJ	O
beta	O	NOUN	B
-	O	PUNCT	O
adrenoceptor	O	NOUN	B
antagonists	O	NOUN	B
are	O	AUX	O
effective	O	ADJ	B
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
akathisia	B-Disease	NOUN	B
,	O	PUNCT	O
one	O	NUM	O
of	O	ADP	O
the	O	DET	O
extrapyramidal	O	ADJ	B
side	O	NOUN	O
effects	O	NOUN	O
that	O	PRON	O
occur	O	VERB	O
during	O	ADP	O
neuroleptic	O	ADJ	B
treatment	O	NOUN	B
.	O	PUNCT	O


Neuroleptic	O	ADJ	B
-	O	PUNCT	O
induced	O	VERB	B
catalepsy	B-Disease	NOUN	B
,	O	PUNCT	O
a	O	DET	O
model	O	NOUN	B
of	O	ADP	O
neuroleptic	O	ADJ	B
-	O	PUNCT	O
induced	O	VERB	B
extrapyramidal	O	ADJ	B
side	O	NOUN	I
effects	O	NOUN	I
,	O	PUNCT	O
was	O	AUX	O
considered	O	VERB	O
suitable	O	ADJ	O
as	O	ADP	O
a	O	DET	O
model	O	NOUN	B
for	O	ADP	O
predicting	O	VERB	B
neuroleptic	O	ADJ	B
-	O	PUNCT	O
induced	O	VERB	B
akathisia	B-Disease	NOUN	B
in	O	ADP	O
humans	O	NOUN	B
,	O	PUNCT	O
although	O	SCONJ	O
neuroleptic	O	ADJ	B
-	O	PUNCT	O
induced	O	VERB	B
catalepsy	B-Disease	NOUN	B
was	O	AUX	O
not	O	PART	O
considered	O	VERB	O
a	O	DET	O
specific	O	ADJ	O
test	O	NOUN	B
for	O	ADP	O
neuroleptic	O	ADJ	B
-	O	PUNCT	O
induced	O	VERB	B
akathisia	B-Disease	NOUN	B
.	O	PUNCT	O


Therefore	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
carteolol	B-Chemical	NOUN	B
,	O	PUNCT	O
a	O	DET	O
beta	O	NOUN	B
-	O	PUNCT	O
adrenoceptor	O	NOUN	B
antagonist	O	NOUN	B
,	O	PUNCT	O
on	O	ADP	O
haloperidol	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
catalepsy	B-Disease	NOUN	B
in	O	ADP	O
rats	O	NOUN	B
were	O	AUX	O
behaviorally	O	ADV	B
studied	O	VERB	I
and	O	CCONJ	O
compared	O	VERB	B
with	O	ADP	O
those	O	DET	O
of	O	ADP	O
propranolol	B-Chemical	NOUN	B
and	O	CCONJ	O
biperiden	B-Chemical	NOUN	B
,	O	PUNCT	O
a	O	DET	O
muscarinic	O	ADJ	B
receptor	O	NOUN	I
antagonist	O	NOUN	I
.	O	PUNCT	O


Carteolol	B-Chemical	NOUN	B
,	O	PUNCT	O
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
propranolol	B-Chemical	NOUN	B
and	O	CCONJ	O
biperiden	B-Chemical	NOUN	B
,	O	PUNCT	O
inhibited	O	VERB	B
the	O	DET	O
haloperidol	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
catalepsy	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
inhibitory	O	ADJ	B
effect	O	NOUN	O
of	O	ADP	O
carteolol	B-Chemical	NOUN	B
was	O	AUX	O
almost	O	ADV	O
comparable	O	ADJ	O
to	O	PART	O
that	O	DET	O
of	O	ADP	O
propranolol	B-Chemical	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
was	O	AUX	O
weaker	O	ADJ	O
than	O	ADP	O
that	O	DET	O
of	O	ADP	O
biperiden	B-Chemical	NOUN	B
.	O	PUNCT	O


Carteolol	B-Chemical	PROPN	B
did	O	AUX	O
not	O	PART	O
evoke	O	VERB	O
postsynaptic	O	ADJ	B
dopamine	B-Chemical	NOUN	I
receptor	O	NOUN	I
-	O	PUNCT	O
stimulating	O	VERB	B
behavioral	O	ADJ	B
signs	O	NOUN	B
such	O	ADJ	O
as	O	ADP	O
stereotypy	O	NOUN	B
and	O	CCONJ	O
hyperlocomotion	B-Disease	NOUN	B
in	O	ADP	O
rats	O	NOUN	B
.	O	PUNCT	O


Carteolol	B-Chemical	PROPN	B
did	O	AUX	O
not	O	PART	O
antagonize	O	VERB	B
the	O	DET	O
inhibitory	O	ADJ	B
effects	O	NOUN	B
of	O	ADP	O
haloperidol	B-Chemical	NOUN	B
on	O	ADP	O
apomorphine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
stereotypy	O	NOUN	B
and	O	CCONJ	O
locomotor	O	NOUN	B
activity	O	NOUN	I
in	O	ADP	O
rats	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
,	O	PUNCT	O
carteolol	B-Chemical	NOUN	B
did	O	AUX	O
not	O	PART	O
evoke	O	VERB	O
5	O	NUM	O
-	O	PUNCT	O
HT1A	O	NOUN	B
receptor	O	NOUN	I
-	O	PUNCT	O
stimulating	O	VERB	B
behavioral	O	ADJ	B
signs	O	NOUN	B
such	O	ADJ	O
as	O	ADP	O
flat	O	ADJ	B
body	O	NOUN	I
posture	O	NOUN	I
and	O	CCONJ	O
forepaw	O	VERB	B
treading	O	NOUN	B
and	O	CCONJ	O
did	O	AUX	O
not	O	PART	O
inhibit	O	VERB	B
5-hydroxytryptophan	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
head	O	NOUN	B
twitch	O	NOUN	I
in	O	ADP	O
rats	O	NOUN	B
.	O	PUNCT	O


Finally	O	ADV	O
,	O	PUNCT	O
carteolol	B-Chemical	NOUN	B
did	O	AUX	O
not	O	PART	O
inhibit	O	VERB	B
physostigmine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
lethality	O	NOUN	B
in	O	ADP	O
rats	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	B
strongly	O	ADV	O
suggest	O	VERB	O
that	O	SCONJ	O
carteolol	B-Chemical	NOUN	B
improves	O	VERB	O
haloperidol	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
catalepsy	B-Disease	NOUN	B
via	O	ADP	O
its	O	PRON	O
beta	O	NOUN	B
-	O	PUNCT	O
adrenoceptor	O	NOUN	B
antagonistic	O	ADJ	B
activity	O	NOUN	I
and	O	CCONJ	O
is	O	AUX	O
expected	O	VERB	O
to	O	PART	O
be	O	AUX	O
effective	O	ADJ	B
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
akathisia	B-Disease	NOUN	B
without	O	ADP	O
attenuating	O	VERB	B
neuroleptic	O	ADJ	B
-	O	PUNCT	O
induced	O	VERB	B
antipsychotic	O	ADJ	B
effects	O	NOUN	O
due	O	ADJ	O
to	O	PART	O
its	O	PRON	O
postsynaptic	O	ADJ	B
dopamine	B-Chemical	NOUN	I


Penicillamine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
rapidly	O	ADV	O
progressive	O	ADJ	B
glomerulonephritis	B-Disease	NOUN	B
in	O	ADP	O
a	O	DET	O
patient	O	NOUN	B
with	O	ADP	O
rheumatoid	B-Disease	ADJ	B
arthritis	I-Disease	NOUN	I
.	O	PUNCT	O


A	O	DET	O
67	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
woman	O	NOUN	B
with	O	ADP	O
rheumatoid	B-Disease	ADJ	B
arthritis	I-Disease	NOUN	I
presented	O	VERB	O
rapidly	O	ADV	O
progressive	O	ADJ	B
glomerulonephritis	B-Disease	NOUN	O
(	O	PUNCT	O
RPGN	B-Disease	NOUN	B
)	O	PUNCT	O
after	O	ADP	O
5	O	NUM	O
months	O	NOUN	B
of	O	ADP	O
D-penicillamine	B-Chemical	NOUN	B
(	O	PUNCT	O
250	O	NUM	O
mg	O	NOUN	O
/	O	PUNCT	O
day	O	NOUN	B
)	O	PUNCT	O
treatment	O	NOUN	B
.	O	PUNCT	O


Light	O	ADJ	B
microscopy	O	ADJ	I
study	O	NOUN	B
showed	O	VERB	O
severe	O	ADJ	B
glomerulonephritis	B-Disease	NOUN	B
with	O	ADP	O
crescent	O	ADJ	B
formation	O	NOUN	B
in	O	ADP	O
60	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
glomeruli	O	NOUN	B
and	O	CCONJ	O
infiltration	O	NOUN	B
of	O	ADP	O
inflammatory	O	ADJ	B
cells	O	NOUN	I
in	O	ADP	O
the	O	DET	O
wall	O	NOUN	B
of	O	ADP	O
an	O	DET	O
arteriole	O	NOUN	B
.	O	PUNCT	O


Immunofluorescence	O	NOUN	B
revealed	O	VERB	O
scanty	O	ADJ	B
granular	O	ADJ	B
IgG	O	NOUN	B
,	O	PUNCT	O
IgA	O	NOUN	B
and	O	CCONJ	O
C3	O	NOUN	B
deposits	O	NOUN	I
along	O	ADP	O
the	O	DET	O
capillary	O	ADJ	B
walls	O	NOUN	I
and	O	CCONJ	O
mesangium	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
patient	O	NOUN	B
was	O	AUX	O
treated	O	VERB	B
with	O	ADP	I
steroid	B-Chemical	NOUN	B
pulse	O	NOUN	O
,	O	PUNCT	O
plasmapheresis	O	NOUN	B
,	O	PUNCT	O
cyclophosphamide	B-Chemical	NOUN	B
and	O	CCONJ	O
antiplatelet	B-Chemical	NOUN	B
agents	I-Chemical	NOUN	I
.	O	PUNCT	O


A	O	DET	O
complete	O	ADJ	B
recovery	O	NOUN	B
of	O	ADP	O
renal	O	ADJ	B
function	O	NOUN	I
was	O	AUX	O
achieved	O	VERB	O
in	O	ADP	O
a	O	DET	O
few	O	ADJ	O
weeks	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
new	O	ADJ	O
case	O	NOUN	B
of	O	ADP	O
RPGN	B-Disease	NOUN	B
in	O	ADP	O
the	O	DET	O
course	O	NOUN	B
of	O	ADP	O
D-penicillamine	B-Chemical	NOUN	B
treatment	O	NOUN	B
emphasizes	O	VERB	O
the	O	DET	O
need	O	NOUN	O
for	O	ADP	O
frequent	O	ADJ	B
monitoring	O	NOUN	B
of	O	ADP	O
renal	O	ADJ	B
function	O	NOUN	I
and	O	CCONJ	O
evaluation	O	NOUN	B
of	O	ADP	O
urinary	O	ADJ	B
sediment	O	NOUN	I
and	O	CCONJ	O
proteinuria	B-Disease	NOUN	B
in	O	ADP	O
these	O	DET	O
patients	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
prompt	O	ADJ	O
discontinuation	O	NOUN	B
of	O	ADP	O
D-penicillamine	B-Chemical	NOUN	B


Nature	O	NOUN	B
,	O	PUNCT	O
time	O	NOUN	B
course	O	NOUN	I
and	O	CCONJ	O
dose	O	NOUN	B
dependence	O	NOUN	O
of	O	ADP	O
zidovudine	B-Chemical	NOUN	B
-	O	PUNCT	O
related	O	VERB	B
side	O	NOUN	B
effects	O	NOUN	I
:	O	PUNCT	O
results	O	NOUN	B
from	O	ADP	O
the	O	DET	O
Multicenter	O	PROPN	B
Canadian	O	PROPN	I
Azidothymidine	B-Chemical	PROPN	I
Trial	O	PROPN	I
.	O	PUNCT	O


To	O	PART	O
characterize	O	VERB	O
the	O	DET	O
nature	O	NOUN	B
,	O	PUNCT	O
time	O	NOUN	B
course	O	NOUN	I
and	O	CCONJ	O
dose	O	NOUN	B
dependency	O	NOUN	B
of	O	ADP	O
zidovudine	B-Chemical	NOUN	B
-	O	PUNCT	O
related	O	VERB	B
side	O	NOUN	B
effects	O	NOUN	I
,	O	PUNCT	O
we	O	PRON	O
undertook	O	VERB	O
a	O	DET	O
multicenter	O	NOUN	B
,	O	PUNCT	O
prospective	O	ADJ	B
,	O	PUNCT	O
dose	O	NOUN	B
-	O	PUNCT	O
range	O	NOUN	B
finding	O	NOUN	O
study	O	NOUN	O
.	O	PUNCT	O


Our	O	PRON	O
study	O	NOUN	B
group	O	NOUN	I
consisted	O	VERB	O
of	O	ADP	O
74	O	NUM	O
HIV	O	NOUN	B
-	O	PUNCT	O
positive	O	ADJ	B
homosexual	O	ADJ	B
men	O	NOUN	B
belonging	O	VERB	O
to	O	ADP	O
groups	O	NOUN	B
II	O	NUM	O
B	O	NOUN	O
,	O	PUNCT	O
III	O	NUM	O
and	O	CCONJ	O
IV	O	NUM	O
C2	O	NOUN	O
from	O	ADP	O
the	O	DET	O
Centers	O	PROPN	B
for	O	ADP	I
Disease	O	PROPN	I
Control	O	PROPN	I
(	O	PUNCT	I
CDC	O	PROPN	B
)	O	PUNCT	O
classification	O	NOUN	B
of	O	ADP	O
HIV	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
.	O	PUNCT	O


Following	O	VERB	O
a	O	DET	O
3	O	NUM	O
-	O	PUNCT	O
week	O	NOUN	B
observation	O	NOUN	B
period	O	NOUN	B
,	O	PUNCT	O
volunteers	O	NOUN	B
were	O	AUX	O
treated	O	VERB	B
with	O	ADP	I
zidovudine	B-Chemical	NOUN	B
600	O	NUM	O
mg	O	NOUN	O
/	O	PUNCT	O
day	O	NOUN	B
for	O	ADP	O
18	O	NUM	O
weeks	O	NOUN	B
,	O	PUNCT	O
900	O	NUM	O
mg	O	NOUN	O
/	O	PUNCT	O
day	O	NOUN	B
for	O	ADP	O
9	O	NUM	O
weeks	O	NOUN	B
and	O	CCONJ	O
1200	O	NUM	O
mg	O	NOUN	O
/	O	PUNCT	O
day	O	NOUN	B
for	O	ADP	O
9	O	NUM	O
weeks	O	NOUN	B
,	O	PUNCT	O
followed	O	VERB	O
by	O	ADP	O
a	O	DET	O
washout	O	ADJ	O
period	O	NOUN	B
of	O	ADP	O
6	O	NUM	O
weeks	O	NOUN	B
after	O	ADP	O
which	O	DET	O
they	O	PRON	O
were	O	AUX	O
re	O	ADP	B
-	O	PUNCT	O
started	O	VERB	B
on	O	ADP	O
1200	O	NUM	O
mg	O	NOUN	O
/	O	PUNCT	O
day	O	NOUN	B
or	O	CCONJ	O
the	O	DET	O
highest	O	ADV	O
tolerated	O	VERB	B
dose	O	NOUN	B
at	O	ADP	O
8	O	NUM	O
-	O	PUNCT	O
hourly	O	ADJ	B
intervals	O	NOUN	B
.	O	PUNCT	O


Subjects	O	NOUN	B
were	O	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
to	O	PART	O
4	O	NUM	O
-	O	PUNCT	O
hourly	O	ADJ	B
or	O	CCONJ	O
8	O	NUM	O
-	O	PUNCT	O
hourly	O	ADJ	B
regimens	O	NOUN	B
within	O	ADP	O
CDC	O	PROPN	B
groups	O	NOUN	B
while	O	SCONJ	O
taking	O	VERB	O
600	O	NUM	O
and	O	CCONJ	O
1200	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
day	O	NOUN	B
.	O	PUNCT	O


Clinical	O	ADJ	B
and	O	CCONJ	O
laboratory	O	NOUN	B
evaluations	O	NOUN	I
were	O	AUX	O
performed	O	VERB	O
at	O	ADP	O
3	O	NUM	O
-	O	PUNCT	O
week	O	NOUN	B
intervals	O	NOUN	B
.	O	PUNCT	O


Symptomatic	O	ADJ	B
adverse	O	ADJ	B
effects	O	NOUN	I
were	O	AUX	O
present	O	ADJ	O
in	O	ADP	O
96	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
subjects	O	NOUN	B
,	O	PUNCT	O
most	O	ADV	O
commonly	O	ADV	O
nausea	B-Disease	NOUN	B
(	O	PUNCT	O
64	O	NUM	O
%),	O	ADJ	O
fatigue	B-Disease	NOUN	B
(	O	PUNCT	O
55	O	NUM	O
%)	O	NOUN	O
and	O	CCONJ	O
headache	B-Disease	NOUN	B
(	O	PUNCT	O
49	O	NUM	O
%).	O	NOUN	O
These	O	DET	O
were	O	AUX	O
generally	O	ADV	O
self	O	NOUN	B
-	O	PUNCT	O
limited	O	ADJ	B
,	O	PUNCT	O
reappearing	O	VERB	O
briefly	O	ADV	O
at	O	ADP	O
each	O	DET	O
dose	O	NOUN	B
increment	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
decrease	O	NOUN	B
in	O	ADP	O
hemoglobin	O	NOUN	B
occurred	O	VERB	O
shortly	O	ADV	O
after	O	ADP	O
initiation	O	NOUN	B
of	O	ADP	O
therapy	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
was	O	AUX	O
not	O	PART	O
dose	O	NOUN	B
dependent	O	ADJ	O
and	O	CCONJ	O
reversed	O	VERB	O
rapidly	O	ADV	O
upon	O	SCONJ	O
discontinuation	O	NOUN	B
of	O	ADP	O
treatment	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
red	O	ADJ	B
blood	O	NOUN	I
cell	O	NOUN	I
count	O	NOUN	O
decrease	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
mean	O	ADJ	O
cell	O	NOUN	B
volume	O	NOUN	I
increase	O	NOUN	B
and	O	CCONJ	O
a	O	DET	O
granulocyte	O	NOUN	B
count	O	NOUN	O
decrease	O	NOUN	B
developed	O	VERB	O
early	O	ADV	B
in	O	ADP	O
a	O	DET	O
dose	O	NOUN	B
-	O	PUNCT	O
independent	O	ADJ	B
fashion	O	NOUN	B
,	O	PUNCT	O
reverting	O	VERB	O
at	O	ADP	O
least	O	ADV	O
partially	O	ADV	O
during	O	ADP	O
the	O	DET	O
washout	O	NOUN	B
phase	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
decrease	O	NOUN	B
in	O	ADP	O
reticulocyte	O	NOUN	B
count	O	NOUN	O
was	O	AUX	O
dose	O	NOUN	B
related	O	ADJ	O
between	O	ADP	O
600	O	NUM	O
and	O	CCONJ	O
900	O	NUM	O
mg	O	NOUN	O
/	O	PUNCT	O
day	O	NOUN	B
with	O	ADP	O
no	O	DET	O
further	O	ADJ	O
change	O	NOUN	O
when	O	SCONJ	O
the	O	DET	O
dose	O	NOUN	B
was	O	AUX	O
escalated	O	VERB	O
to	O	PART	O
1200	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
day	O	NOUN	B
.	O	PUNCT	O


Bone	O	NOUN	B
marrow	O	NOUN	I
changes	O	NOUN	O
occurred	O	VERB	O
rapidly	O	ADV	O
as	O	ADP	O
demonstrated	O	VERB	O
by	O	ADP	O
megaloblastosis	B-Disease	NOUN	B


Bilateral	B-Disease	ADJ	B
optic	I-Disease	ADJ	B
neuropathy	I-Disease	NOUN	I
due	O	ADJ	O
to	O	PART	O
combined	O	ADJ	O
ethambutol	B-Chemical	NOUN	B
and	O	CCONJ	O
isoniazid	B-Chemical	NOUN	B
treatment	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
case	O	NOUN	B
of	O	ADP	O
a	O	DET	O
40	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
patient	O	NOUN	B
who	O	PRON	O
underwent	O	VERB	O
an	O	DET	O
unsuccessful	O	ADJ	O
cadaver	O	NOUN	B
kidney	O	NOUN	I
transplantation	O	NOUN	I
and	O	CCONJ	O
was	O	AUX	O
treated	O	VERB	B
with	O	ADP	I
ethambutol	B-Chemical	NOUN	B
and	O	CCONJ	O
isoniazid	B-Chemical	NOUN	B
is	O	AUX	O
reported	O	VERB	O
.	O	PUNCT	O


A	O	DET	O
bilateral	B-Disease	ADJ	B
retrobulbar	I-Disease	NOUN	O
neuropathy	I-Disease	NOUN	O
with	O	ADP	O
an	O	DET	O
unusual	O	ADJ	B
central	O	ADJ	B
bitemporal	O	ADJ	I
hemianopic	O	ADJ	I
scotoma	B-Disease	NOUN	B
was	O	AUX	O
found	O	VERB	O
.	O	PUNCT	O


Ethambutol	B-Chemical	NOUN	B
was	O	AUX	O
stopped	O	VERB	B
and	O	CCONJ	O
only	O	ADV	O
small	O	ADJ	O
improvement	O	NOUN	B
of	O	ADP	O
the	O	DET	O
visual	O	ADJ	B
acuity	O	NOUN	I
followed	O	VERB	O
.	O	PUNCT	O


Isoniazid	B-Chemical	NOUN	B
was	O	AUX	O
discontinued	O	VERB	B
later	O	ADV	O
,	O	PUNCT	O
followed	O	VERB	O
by	O	ADP	O
a	O	DET	O
dramatic	O	ADJ	O
improvement	O	NOUN	B
in	O	ADP	O
the	O	DET	O
visual	O	ADJ	B
acuity	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
hazards	O	NOUN	B
of	O	ADP	O
optic	O	ADJ	B
nerve	O	NOUN	I
toxicity	B-Disease	NOUN	B
due	O	ADJ	O
to	O	PART	O
ethambutol	B-Chemical	NOUN	B
are	O	AUX	O
known	O	VERB	O
.	O	PUNCT	O


We	O	PRON	O
emphasize	O	VERB	O
the	O	DET	O
potential	O	ADJ	B
danger	O	NOUN	B
in	O	ADP	O
the	O	DET	O
use	O	NOUN	O
of	O	ADP	O
ethambutol	B-Chemical	NOUN	B
and	O	CCONJ	O
isoniazid	B-Chemical	NOUN	B


Progestational	O	ADJ	B
agents	O	NOUN	I
and	O	CCONJ	O
blood	B-Disease	NOUN	B
coagulation	I-Disease	NOUN	I
.	O	PUNCT	O


VII	O	NOUN	B
.	O	PUNCT	O


Thromboembolic	B-Disease	ADJ	B
and	O	CCONJ	O
other	O	ADJ	O
complications	O	NOUN	B
of	O	ADP	O
oral	B-Chemical	ADJ	B
contraceptive	I-Chemical	ADJ	I
therapy	O	NOUN	I
in	O	ADP	O
relationship	O	NOUN	B
to	O	PART	O
pretreatment	O	NOUN	B
levels	O	NOUN	B
of	O	ADP	O
blood	B-Disease	NOUN	B
coagulation	I-Disease	NOUN	I
factors	O	NOUN	I
:	O	PUNCT	O
summary	O	ADJ	O
report	O	NOUN	O
of	O	ADP	O
a	O	DET	O
ten	O	NUM	B
-	O	PUNCT	O
year	O	NOUN	B
study	O	NOUN	B
.	O	PUNCT	O


During	O	ADP	O
a	O	DET	O
ten	O	NUM	B
-	O	PUNCT	O
year	O	NOUN	B
period	O	NOUN	B
,	O	PUNCT	O
348	O	NUM	O
women	O	NOUN	B
were	O	AUX	O
studied	O	VERB	O
for	O	ADP	O
a	O	DET	O
total	O	NOUN	O
of	O	ADP	O
5	O	NUM	O
,	O	PUNCT	O
877	O	NUM	O
patient	O	NOUN	B
months	O	NOUN	B
in	O	ADP	O
four	O	NUM	O
separate	O	ADJ	O
studies	O	NOUN	B
relating	O	VERB	O
oral	B-Chemical	ADJ	B
contraceptives	I-Chemical	NOUN	I
to	O	PART	O
changes	O	NOUN	B
in	O	ADP	O
hematologic	O	ADJ	B
parameters	O	NOUN	B
.	O	PUNCT	O


Significant	O	ADJ	B
increases	O	NOUN	B
in	O	ADP	O
certain	O	ADJ	O
factors	O	NOUN	B
of	O	ADP	O
the	O	DET	O
blood	B-Disease	NOUN	B
coagulation	I-Disease	NOUN	I
and	O	CCONJ	O
fibrinolysin	O	NOUN	B
systems	O	NOUN	I
(	O	PUNCT	O
factors	O	NOUN	B
I	O	NUM	I
,	O	PUNCT	O
II	O	NUM	B
,	O	PUNCT	O
VII	O	PROPN	B
,	O	PUNCT	O
VIII	O	NOUN	B
,	O	PUNCT	O
IX	O	NUM	B
,	O	PUNCT	O
and	O	CCONJ	O
X	O	NOUN	B
and	O	CCONJ	O
plasminogen	O	NOUN	B
)	O	PUNCT	O
were	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
the	O	DET	O
treated	O	VERB	B
groups	O	NOUN	B
.	O	PUNCT	O


Severe	O	ADJ	B
complications	O	NOUN	B
developed	O	VERB	O
in	O	ADP	O
four	O	NUM	O
patients	O	NOUN	B
.	O	PUNCT	O


All	O	DET	O
four	O	NUM	O
had	O	AUX	O
an	O	DET	O
abnormal	O	ADJ	B
blood	B-Disease	NOUN	B
coagulation	I-Disease	NOUN	I
profile	O	NOUN	I
,	O	PUNCT	O
suggesting	O	VERB	O
"	O	PUNCT	O
hypercoagulability	B-Disease	NOUN	B
"	O	PUNCT	O
before	O	ADP	O
initiation	O	NOUN	B
of	O	ADP	O
therapy	O	NOUN	B
.	O	PUNCT	O


Some	O	DET	O
of	O	ADP	O
these	O	DET	O
findings	O	NOUN	B
represented	O	VERB	O
the	O	DET	O
most	O	ADV	O
extreme	O	ADJ	O
abnormalities	O	NOUN	B
seen	O	VERB	O
in	O	ADP	O
the	O	DET	O
entire	O	ADJ	O
group	O	NOUN	B
of	O	ADP	O
patients	O	NOUN	B
;	O	PUNCT	O
some	O	DET	O
increased	O	VERB	B
further	O	ADV	O
during	O	ADP	O
therapy	O	NOUN	B
.	O	PUNCT	O


One	O	NUM	O
of	O	ADP	O
these	O	DET	O
patients	O	NOUN	B
developed	O	VERB	O
a	O	DET	O
myocardial	B-Disease	ADJ	B
infarction	I-Disease	NOUN	I
before	O	ADP	O
receiving	O	VERB	O
any	O	DET	O
medication	O	NOUN	B
,	O	PUNCT	O
shortly	O	ADV	O
after	O	ADP	O
the	O	DET	O
base	O	NOUN	B
-	O	PUNCT	O
line	O	NOUN	B
values	O	NOUN	B
were	O	AUX	O
obtained	O	VERB	O
.	O	PUNCT	O


One	O	NUM	O
patient	O	NOUN	B
developed	O	VERB	O
retinopathy	B-Disease	NOUN	B
19	O	NUM	O
months	O	NOUN	B
after	O	ADP	O
she	O	PRON	O
began	O	VERB	O
therapy	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
another	O	DET	O
developed	O	VERB	O
thrombophlebitis	B-Disease	NOUN	B
after	O	ADP	O
27	O	NUM	O
months	O	NOUN	B
of	O	ADP	O
therapy	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
fourth	O	ADJ	O
patient	O	NOUN	B
developed	O	VERB	O
thrombophlebitis	B-Disease	NOUN	B
14	O	NUM	O
days	O	NOUN	B
after	O	ADP	O
initiation	O	NOUN	B
of	O	ADP	O
contraceptive	O	ADJ	B
therapy	O	NOUN	I
.	O	PUNCT	O


All	O	DET	O
four	O	NUM	O
patients	O	NOUN	B
were	O	AUX	O
of	O	ADP	O
the	O	DET	O
A	O	NOUN	B
or	O	CCONJ	O
AB	O	NOUN	B
blood	O	NOUN	I
group	O	NOUN	I
.	O	PUNCT	O


Previous	O	ADJ	O
studies	O	NOUN	B
suggested	O	VERB	O
the	O	DET	O
possiblility	O	NOUN	B
of	O	ADP	O
increased	O	VERB	B
propensity	O	NOUN	B
for	O	ADP	O
thromboembolic	B-Disease	NOUN	B
episodes	I-Disease	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
possessing	O	VERB	O
the	O	DET	O
A	O	NOUN	B
antigen	O	NOUN	I
.	O	PUNCT	O


It	O	PRON	O
appears	O	VERB	O
from	O	ADP	O
these	O	DET	O
data	O	NOUN	B
that	O	SCONJ	O
hematologic	O	ADJ	B
work	O	NOUN	I
-	O	PUNCT	O
ups	O	NOUN	B
may	O	AUX	O
be	O	AUX	O
useful	O	ADJ	O
in	O	ADP	O
women	O	NOUN	B
who	O	PRON	O
are	O	AUX	O
about	O	ADJ	O
to	O	PART	O
start	O	VERB	O
long	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
oral	B-Chemical	ADJ	B
contraceptive	I-Chemical	NOUN	O


Cardiac	B-Disease	ADJ	B
arrest	I-Disease	NOUN	I
in	O	ADP	O
a	O	DET	O
child	O	NOUN	B
with	O	ADP	O
cerebral	B-Disease	ADJ	B
palsy	I-Disease	NOUN	I
undergoing	O	VERB	O
sevoflurane	B-Chemical	NOUN	B
induction	O	NOUN	I
of	O	ADP	O
anesthesia	O	NOUN	B
after	O	ADP	O
preoperative	O	ADJ	B
clonidine	B-Chemical	NOUN	B
.	O	PUNCT	O


Clonidine	B-Chemical	NOUN	B
is	O	AUX	O
a	O	DET	O
frequently	O	ADV	O
administered	O	VERB	B
alpha2	O	NOUN	B
-	O	PUNCT	O
adrenergic	O	ADJ	B
agonist	O	NOUN	B
which	O	DET	O
can	O	AUX	O
decrease	O	VERB	B
heart	O	NOUN	B
rate	O	NOUN	I
and	O	CCONJ	O
blood	O	NOUN	B
pressure	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
present	O	VERB	O
a	O	DET	O
case	O	NOUN	B
of	O	ADP	O
a	O	DET	O
5	O	NUM	B
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
child	O	NOUN	B
with	O	ADP	O
cerebral	B-Disease	ADJ	B
palsy	I-Disease	NOUN	I
and	O	CCONJ	O
seizure	B-Disease	ADJ	B
disorder	I-Disease	NOUN	I
,	O	PUNCT	O
receiving	O	VERB	O
clonidine	B-Chemical	NOUN	B
for	O	ADP	O
restlessness	B-Disease	NOUN	B
,	O	PUNCT	O
who	O	PRON	O
presented	O	VERB	O
for	O	ADP	O
placement	O	NOUN	B
of	O	ADP	O
a	O	DET	O
baclofen	B-Chemical	NOUN	B
pump	O	NOUN	I
.	O	PUNCT	O


Without	O	ADP	O
the	O	DET	O
knowledge	O	NOUN	B
of	O	ADP	O
the	O	DET	O
medical	O	ADJ	B
personnel	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
patient	O	NOUN	B
'	O	PART	O
s	O	NOUN	O
mother	O	NOUN	B
administered	O	VERB	B
three	O	NUM	O
doses	O	NOUN	B
of	O	ADP	O
clonidine	B-Chemical	NOUN	B
during	O	ADP	O
the	O	DET	O
evening	O	NOUN	B
before	O	ADP	B
and	O	CCONJ	O
morning	O	NOUN	B
of	O	ADP	O
surgery	O	NOUN	B
to	O	PART	O
reduce	O	VERB	B
anxiety	B-Disease	NOUN	B
.	O	PUNCT	O


During	O	ADP	O
induction	O	NOUN	B
of	O	ADP	O
anesthesia	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
patient	O	NOUN	B
developed	O	VERB	O
bradycardia	B-Disease	NOUN	B
and	O	CCONJ	O
hypotension	B-Disease	NOUN	B
requiring	O	VERB	O
cardiac	O	ADJ	B
resuscitation	O	NOUN	I
.	O	PUNCT	O


There	O	PRON	O
are	O	AUX	O
no	O	DET	O
previous	O	ADJ	O
reports	O	NOUN	B
of	O	ADP	O
clonidine	B-Chemical	NOUN	B
-	O	PUNCT	O
associated	O	VERB	B
cardiac	B-Disease	ADJ	B
arrest	I-Disease	NOUN	I


Effects	O	NOUN	B
of	O	ADP	O
UMB24	B-Chemical	NOUN	B
and	O	CCONJ	O
(+/-)-	O	NOUN	B
SM	B-Chemical	NOUN	B
21	I-Chemical	NUM	O
,	O	PUNCT	O
putative	O	ADJ	B
sigma2	O	NOUN	I
-	O	PUNCT	O
preferring	O	VERB	B
antagonists	O	NOUN	B
,	O	PUNCT	O
on	O	ADP	O
behavioral	O	ADJ	B
toxic	O	ADJ	B
and	O	CCONJ	O
stimulant	O	ADJ	B
effects	O	NOUN	B
of	O	ADP	O
cocaine	B-Chemical	NOUN	B
in	O	ADP	O
mice	O	NOUN	B
.	O	PUNCT	O


Earlier	O	ADJ	O
studies	O	NOUN	B
have	O	AUX	O
demonstrated	O	VERB	O
that	O	SCONJ	O
antagonism	O	NOUN	B
of	O	ADP	O
sigma1	O	NOUN	B
receptors	O	NOUN	I
attenuates	O	VERB	B
the	O	DET	O
convulsive	B-Disease	ADJ	B
,	O	PUNCT	O
lethal	O	ADJ	B
,	O	PUNCT	O
locomotor	O	NOUN	B
stimulatory	O	ADJ	I
and	O	CCONJ	O
rewarding	O	ADJ	O
actions	O	NOUN	B
of	O	ADP	O
cocaine	B-Chemical	NOUN	B
in	O	ADP	O
mice	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
contrast	O	NOUN	O
,	O	PUNCT	O
the	O	DET	O
contribution	O	NOUN	B
of	O	ADP	O
sigma2	O	NOUN	B
receptors	O	NOUN	I
is	O	AUX	O
unclear	O	ADJ	B
because	O	SCONJ	O
experimental	O	ADJ	B
tools	O	NOUN	O
to	O	PART	O
selectively	O	ADV	O
target	O	VERB	B
this	O	DET	O
subtype	O	NOUN	B
are	O	AUX	O
unavailable	O	ADJ	O
.	O	PUNCT	O


To	O	PART	O
begin	O	VERB	O
addressing	O	VERB	O
this	O	DET	O
need	O	NOUN	O
,	O	PUNCT	O
we	O	PRON	O
characterized	O	VERB	B
UMB24	B-Chemical	NOUN	B
(	O	PUNCT	O
1-(2-phenethyl)-4-(2-pyridyl)-piperazine	B-Chemical	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
(+/-)-	O	NOUN	O
SM	B-Chemical	NOUN	B
21	I-Chemical	NUM	O
(	O	PUNCT	O
3alpha-tropanyl-2-(4-chorophenoxy)butyrate	B-Chemical	NOUN	O
)	O	PUNCT	O
in	O	ADP	O
receptor	O	NOUN	B
binding	O	NOUN	I
and	O	CCONJ	O
behavioral	O	ADJ	B
studies	O	NOUN	I
.	O	PUNCT	O


Receptor	O	NOUN	B
binding	O	NOUN	I
studies	O	NOUN	I
confirmed	O	VERB	O
that	O	SCONJ	O
UMB24	B-Chemical	NOUN	B
and	O	CCONJ	O
(+/-)-	O	NOUN	B
SM	B-Chemical	NOUN	B
21	I-Chemical	NUM	O
display	O	VERB	O
preferential	O	ADJ	O
affinity	O	NOUN	B
for	O	ADP	O
sigma2	O	NOUN	B
over	O	ADP	O
sigma1	O	NOUN	B
receptors	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
behavioral	O	ADJ	B
studies	O	NOUN	I
,	O	PUNCT	O
pretreatment	O	NOUN	B
of	O	ADP	O
Swiss	O	ADJ	B
Webster	O	PROPN	I
mice	O	NOUN	I
with	O	ADP	O
UMB24	B-Chemical	NOUN	B
or	O	CCONJ	O
(+/-)-	O	NOUN	O
SM	B-Chemical	NOUN	B
21	I-Chemical	NUM	O
significantly	O	ADV	O
attenuated	O	VERB	B
cocaine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
convulsions	B-Disease	NOUN	B
and	O	CCONJ	O
locomotor	O	NOUN	B
activity	O	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
not	O	PART	O
lethality	O	NOUN	B
.	O	PUNCT	O


When	O	SCONJ	O
administered	O	VERB	B
alone	O	ADV	O
,(+/-)-	O	ADJ	B
SM	B-Chemical	NOUN	B
21	I-Chemical	NUM	O
produced	O	VERB	O
no	O	DET	O
significant	O	ADJ	O
effects	O	NOUN	B
compared	O	VERB	O
to	O	PART	O
control	O	ADJ	B
injections	O	NOUN	I
of	O	ADP	O
saline	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
UMB24	B-Chemical	NOUN	B
had	O	AUX	O
locomotor	O	NOUN	B
depressant	O	ADJ	B
actions	O	NOUN	I
.	O	PUNCT	O


Together	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
data	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
sigma2	O	NOUN	B
receptor	O	NOUN	I
antagonists	O	NOUN	I
have	O	AUX	O
the	O	DET	O
potential	O	NOUN	B
to	O	PART	O
attenuate	O	VERB	B
some	O	DET	O
of	O	ADP	O
the	O	DET	O
behavioral	O	ADJ	B
effects	O	NOUN	B
of	O	ADP	O
cocaine	B-Chemical	NOUN	B


Methimazole	B-Chemical	PROPN	B
-	O	PUNCT	O
induced	O	VERB	B
cholestatic	B-Disease	ADJ	B
jaundice	I-Disease	NOUN	I
.	O	PUNCT	O


Methimazole	B-Chemical	NOUN	B
is	O	AUX	O
a	O	DET	O
widely	O	ADV	O
used	O	VERB	O
and	O	CCONJ	O
generally	O	ADV	O
well	O	ADV	B
-	O	PUNCT	O
tolerated	O	VERB	B
antithyroid	O	NOUN	B
agent	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
43	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
woman	O	NOUN	B
had	O	AUX	O
severe	O	ADJ	B
jaundice	B-Disease	NOUN	B
and	O	CCONJ	O
itching	B-Disease	VERB	B
1	O	NUM	O
month	O	NOUN	B
after	O	ADP	O
receiving	O	VERB	O
methimazole	B-Chemical	NOUN	B
(	O	PUNCT	O
10	O	NUM	O
mg	O	NOUN	O
tid	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
propranolol	B-Chemical	NOUN	B
(	O	PUNCT	O
20	O	NUM	O
mg	O	NOUN	O
tid	O	NOUN	B
)	O	PUNCT	O
for	O	ADP	O
treatment	O	NOUN	B
of	O	ADP	O
hyperthyroidism	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
patient	O	NOUN	B
continued	O	VERB	O
treatment	O	NOUN	B
for	O	ADP	O
another	O	DET	O
4	O	NUM	O
days	O	NOUN	B
after	O	ADP	O
the	O	DET	O
appearance	O	NOUN	B
of	O	ADP	O
jaundice	B-Disease	NOUN	B
until	O	ADP	O
she	O	PRON	O
finished	O	VERB	O
both	O	DET	O
medications	O	NOUN	B
.	O	PUNCT	O


When	O	SCONJ	O
seen	O	VERB	O
at	O	ADP	O
the	O	DET	O
emergency	O	NOUN	B
department	O	NOUN	I
2	O	NUM	O
weeks	O	NOUN	B
later	O	ADV	O
,	O	PUNCT	O
she	O	PRON	O
still	O	ADV	O
had	O	AUX	O
severe	O	ADJ	B
icterus	B-Disease	NOUN	B
,	O	PUNCT	O
pruritus	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
hyperbilirubinemia	B-Disease	NOUN	B
,	O	PUNCT	O
formed	O	VERB	O
mainly	O	ADV	O
of	O	ADP	O
the	O	DET	O
conjugated	O	VERB	B
fraction	O	NOUN	B
.	O	PUNCT	O


Methimazole	B-Chemical	PROPN	B
-	O	PUNCT	O
induced	O	VERB	B
cholestasis	B-Disease	NOUN	B
was	O	AUX	O
diagnosed	O	VERB	B
,	O	PUNCT	O
and	O	CCONJ	O
propranolol	B-Chemical	NOUN	B
therapy	O	NOUN	I
was	O	AUX	O
resumed	O	VERB	O
.	O	PUNCT	O


Over	O	ADP	O
the	O	DET	O
following	O	VERB	O
9	O	NUM	O
days	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
symptoms	O	NOUN	B
improved	O	VERB	B
and	O	CCONJ	O
plasma	O	NOUN	B
bilirubin	B-Chemical	NOUN	O
levels	O	NOUN	O
were	O	AUX	O
normal	O	ADJ	O
after	O	ADP	O
12	O	NUM	O
weeks	O	NOUN	B
without	O	ADP	O
methimazole	B-Chemical	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
rare	O	ADJ	B
cases	O	NOUN	B
within	O	ADP	O
the	O	DET	O
first	O	ADJ	O
few	O	ADJ	O
weeks	O	NOUN	B
of	O	ADP	O
therapy	O	NOUN	B
,	O	PUNCT	O
this	O	DET	O
drug	O	NOUN	B
can	O	AUX	O
cause	O	VERB	O
severe	O	ADJ	B
and	O	CCONJ	O
reversible	O	ADJ	B
cholestatic	B-Disease	ADJ	B
jaundice	I-Disease	NOUN	I
.	O	PUNCT	O


Physicians	O	NOUN	B
and	O	CCONJ	O
patients	O	NOUN	B
should	O	AUX	O
be	O	AUX	O
aware	O	ADJ	O
of	O	ADP	O
this	O	DET	O
adverse	O	ADJ	B
effect	O	NOUN	I
so	O	SCONJ	O
that	O	DET	O
,	O	PUNCT	O
upon	O	SCONJ	O
occurrence	O	NOUN	B
,	O	PUNCT	O
they	O	PRON	O
can	O	AUX	O
discontinue	O	VERB	O
methimazole	B-Chemical	NOUN	B


Ciprofloxacin	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
acute	O	ADJ	B
interstitial	B-Disease	ADJ	I
nephritis	I-Disease	NOUN	I
and	O	CCONJ	O
autoimmune	B-Disease	ADJ	B
hemolytic	I-Disease	ADJ	I
anemia	I-Disease	NOUN	I
.	O	PUNCT	O


Ciprofloxacin	B-Chemical	NOUN	B
has	O	AUX	O
been	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
several	O	ADJ	O
side	O	NOUN	B
effects	O	NOUN	I
including	O	VERB	O
interstitial	B-Disease	ADJ	B
nephritis	I-Disease	NOUN	I
and	O	CCONJ	O
hemolytic	B-Disease	ADJ	B
anemia	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
combination	O	NOUN	B
of	O	ADP	O
both	O	DET	O
side	O	NOUN	B
effects	O	NOUN	I
is	O	AUX	O
extremely	O	ADV	O
rare	O	ADJ	B
.	O	PUNCT	O


In	O	ADP	O
this	O	DET	O
report	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
describe	O	VERB	O
a	O	DET	O
case	O	NOUN	B
of	O	ADP	O
ciprofloxacin	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
interstitial	B-Disease	ADJ	B
nephritis	I-Disease	NOUN	I
and	O	CCONJ	O
autoimmune	B-Disease	ADJ	B
hemolytic	I-Disease	ADJ	I
anemia	I-Disease	NOUN	I
.	O	PUNCT	O


Hemolytic	B-Disease	ADJ	B
anemia	I-Disease	NOUN	I
improved	O	VERB	B
after	O	ADP	O
stopping	O	VERB	B
the	O	DET	O
drug	O	NOUN	B
and	O	CCONJ	O
initiation	O	NOUN	B
of	O	ADP	O
steroid	B-Chemical	NOUN	B
therapy	O	NOUN	I
.	O	PUNCT	O


Unfortunately	O	ADV	O
,	O	PUNCT	O
acute	O	ADJ	B
interstitial	B-Disease	ADJ	I
nephritis	I-Disease	NOUN	I
was	O	AUX	O
irreversible	O	ADJ	B
and	O	CCONJ	O
the	O	DET	O
patient	O	NOUN	B
developed	O	VERB	O
end-stage	B-Disease	ADJ	B
renal	I-Disease	ADJ	I
disease	I-Disease	NOUN	I


Contribution	O	NOUN	B
of	O	ADP	O
sodium	B-Chemical	NOUN	B
valproate	I-Chemical	NOUN	I
to	O	PART	O
the	O	DET	O
syndrome	B-Disease	NOUN	B
of	I-Disease	ADP	O
inappropriate	I-Disease	ADJ	O
secretion	I-Disease	NOUN	B
of	I-Disease	ADP	O
antidiuretic	I-Disease	ADJ	B
hormone	I-Disease	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
the	O	DET	O
case	O	NOUN	B
of	O	ADP	O
a	O	DET	O
62	O	NUM	B
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
man	O	NOUN	B
who	O	PRON	O
was	O	AUX	O
administered	O	VERB	B
sodium	B-Chemical	NOUN	B
valproate	I-Chemical	NOUN	I
(	O	PUNCT	O
VPA	B-Chemical	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
who	O	PRON	O
subsequently	O	ADV	O
developed	O	VERB	O
the	O	DET	O
syndrome	B-Disease	NOUN	B
of	I-Disease	ADP	O
inappropriate	I-Disease	ADJ	O
secretion	I-Disease	NOUN	B
of	I-Disease	ADP	O
antidiuretic	I-Disease	ADJ	B
hormone	I-Disease	NOUN	I
(	O	PUNCT	O
SIADH	B-Disease	NOUN	B
).	O	PUNCT	O
He	O	PRON	O
had	O	AUX	O
been	O	AUX	O
taking	O	VERB	O
VPA	B-Chemical	NOUN	B
for	O	ADP	O
treatment	O	NOUN	B
of	O	ADP	O
idiopathic	O	ADJ	B
generalized	O	ADJ	I
tonic-clonic	B-Disease	ADJ	I
convulsions	I-Disease	NOUN	I
since	O	SCONJ	O
he	O	PRON	O
was	O	AUX	O
56	O	NUM	O
years	O	NOUN	B
old	O	ADJ	O
.	O	PUNCT	O


After	O	ADP	O
substituting	O	VERB	O
VPA	B-Chemical	NOUN	B
with	O	ADP	O
zonisamide	B-Chemical	NOUN	B
,	O	PUNCT	O
the	O	DET	O
serum	O	NOUN	B
sodium	B-Chemical	NOUN	I
level	O	NOUN	I
returned	O	VERB	O
to	O	ADP	O
normal	O	ADJ	B
.	O	PUNCT	O


We	O	PRON	O
consider	O	VERB	O
this	O	DET	O
episode	O	NOUN	B
of	O	ADP	O
SIADH	B-Disease	NOUN	B
to	O	PART	O
be	O	AUX	O
the	O	DET	O
result	O	NOUN	O
of	O	ADP	O
a	O	DET	O
combination	O	NOUN	B
of	O	ADP	O
factors	O	NOUN	B
including	O	VERB	O
a	O	DET	O
weakness	B-Disease	NOUN	B
of	I-Disease	ADP	O
the	I-Disease	DET	O
central	I-Disease	ADJ	B
nervous	I-Disease	ADJ	I
system	I-Disease	NOUN	I
and	O	CCONJ	O
the	O	DET	O
long	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
administration	O	NOUN	B
of	O	ADP	O
VPA	B-Chemical	NOUN	B


Vasopressin	B-Chemical	NOUN	B
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
milrinone	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
hypotension	B-Disease	NOUN	B
in	O	ADP	O
severe	O	ADJ	B
heart	B-Disease	NOUN	B
failure	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
use	O	NOUN	O
of	O	ADP	O
phosphodiesterase	O	NOUN	B
inhibitors	O	NOUN	I
such	O	ADJ	O
as	O	ADP	O
milrinone	B-Chemical	NOUN	B
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
severe	O	ADJ	B
heart	B-Disease	NOUN	B
failure	I-Disease	NOUN	I
is	O	AUX	O
frequently	O	ADV	O
restricted	O	ADJ	B
because	O	SCONJ	O
they	O	PRON	O
cause	O	VERB	O
vasodilation	O	NOUN	B
and	O	CCONJ	O
hypotension	B-Disease	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
decompensated	O	ADJ	B
heart	B-Disease	NOUN	I
failure	I-Disease	NOUN	I
with	O	ADP	O
hypotension	B-Disease	NOUN	B
after	O	ADP	O
treatment	O	NOUN	B
with	O	ADP	O
milrinone	B-Chemical	NOUN	B
,	O	PUNCT	O
low	O	ADJ	B
doses	O	NOUN	I
of	O	ADP	O
vasopressin	B-Chemical	NOUN	B
restored	O	VERB	O
blood	O	NOUN	B
pressure	O	NOUN	I
without	O	ADP	O
inhibiting	O	VERB	B
the	O	DET	O
inotropic	O	ADJ	B
effect	O	NOUN	I
of	O	ADP	O
milrinone	B-Chemical	NOUN	B


Halogenated	O	ADJ	B
anesthetics	O	NOUN	I
form	O	VERB	O
liver	O	NOUN	B
adducts	O	NOUN	I
and	O	CCONJ	O
antigens	O	NOUN	B
that	O	PRON	O
cross	O	VERB	B
-	O	PUNCT	O
react	O	VERB	B
with	O	ADP	O
halothane	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
antibodies	O	NOUN	B
.	O	PUNCT	O


Two	O	NUM	O
halogenated	O	ADJ	B
anesthetics	O	NOUN	I
,	O	PUNCT	O
enflurane	B-Chemical	NOUN	B
and	O	CCONJ	O
isoflurane	B-Chemical	NOUN	B
,	O	PUNCT	O
have	O	AUX	O
been	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
an	O	DET	O
allergic	O	ADJ	B
-	O	PUNCT	O
type	O	NOUN	B
hepatic	B-Disease	ADJ	B
injury	I-Disease	NOUN	I
both	O	CCONJ	O
alone	O	ADV	O
and	O	CCONJ	O
following	O	VERB	O
previous	O	ADJ	O
exposure	O	NOUN	B
to	O	PART	I
halothane	B-Chemical	NOUN	B
.	O	PUNCT	O


Halothane	B-Chemical	NOUN	B
hepatitis	B-Disease	NOUN	I
appears	O	VERB	O
to	O	PART	O
involve	O	VERB	O
an	O	DET	O
aberrant	O	ADJ	B
immune	O	ADJ	B
response	O	NOUN	I
.	O	PUNCT	O


An	O	DET	O
antibody	O	NOUN	B
response	O	NOUN	I
to	O	PART	O
a	O	DET	O
protein	O	NOUN	B
-	O	PUNCT	O
bound	O	VERB	B
biotransformation	O	NOUN	B
product	O	NOUN	B
(	O	PUNCT	O
trifluoroacetyl	B-Chemical	NOUN	B
adduct	O	NOUN	I
)	O	PUNCT	O
has	O	AUX	O
been	O	AUX	O
detected	O	VERB	B
on	O	ADP	O
halothane	B-Chemical	NOUN	B
hepatitis	B-Disease	NOUN	B
patients	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
study	O	NOUN	B
was	O	AUX	O
performed	O	VERB	O
to	O	PART	O
determine	O	VERB	O
cross	O	NOUN	B
-	O	PUNCT	O
reactivity	O	NOUN	B
between	O	ADP	O
enflurane	B-Chemical	NOUN	B
and	O	CCONJ	O
isoflurane	B-Chemical	NOUN	B
with	O	ADP	O
the	O	DET	O
hypersensitivity	B-Disease	NOUN	B
induced	O	VERB	B
by	O	ADP	O
halothane	B-Chemical	NOUN	B
.	O	PUNCT	O


The	O	DET	O
subcellular	O	ADJ	B
and	O	CCONJ	O
lobular	O	ADJ	B
production	O	NOUN	B
of	O	ADP	O
hepatic	O	ADJ	B
neoantigens	O	NOUN	I
recognized	O	VERB	O
by	O	ADP	O
halothane	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
antibodies	O	NOUN	B
following	O	VERB	O
enflurane	B-Chemical	NOUN	B
and	O	CCONJ	O
isoflurane	B-Chemical	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
biochemical	O	ADJ	B
nature	O	NOUN	B
of	O	ADP	O
these	O	DET	O
neoantigens	O	NOUN	B
was	O	AUX	O
investigated	O	VERB	B
in	O	ADP	O
two	O	NUM	O
animal	O	NOUN	B
models	O	NOUN	I
.	O	PUNCT	O


Enflurane	B-Chemical	NOUN	B
administration	O	NOUN	B
resulted	O	VERB	O
in	O	ADP	O
neoantigens	O	NOUN	B
detected	O	VERB	B
in	O	ADP	O
both	O	CCONJ	O
the	O	DET	O
microsomal	O	ADJ	B
and	O	CCONJ	O
cytosolic	O	ADJ	B
fraction	O	NOUN	I
of	O	ADP	O
liver	O	NOUN	B
homogenates	O	NOUN	I
and	O	CCONJ	O
in	O	ADP	O
the	O	DET	O
centrilobular	O	ADJ	B
region	O	NOUN	I
of	O	ADP	O
the	O	DET	O
liver	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
same	O	ADJ	O
liver	O	NOUN	B
,	O	PUNCT	O
biochemical	O	ADJ	B
analysis	O	NOUN	I
detected	O	VERB	O
fluorinated	O	ADJ	B
liver	O	NOUN	I
adducts	O	NOUN	I
that	O	PRON	O
were	O	AUX	O
up	O	ADP	O
to	O	PART	O
20	O	NUM	O
-	O	PUNCT	O
fold	O	NOUN	B
greater	O	ADJ	B
in	O	ADP	O
guinea	O	NOUN	B
pigs	O	NOUN	B
than	O	ADP	O
in	O	ADP	O
rats	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
supports	O	NOUN	B
and	O	CCONJ	O
extends	O	VERB	O
previous	O	ADJ	O
evidence	O	NOUN	B
for	O	ADP	O
a	O	DET	O
mechanism	O	NOUN	B
by	O	ADP	O
which	O	DET	O
enflurane	B-Chemical	NOUN	B
and	O	CCONJ	O
/	O	SYM	O
or	O	CCONJ	O
isoflurane	B-Chemical	NOUN	B
could	O	AUX	O
produce	O	VERB	O
a	O	DET	O
hypersensitivity	B-Disease	NOUN	B
condition	O	NOUN	B
similar	O	ADJ	O
to	O	PART	O
that	O	DET	O
of	O	ADP	O
halothane	B-Chemical	NOUN	B
hepatitis	B-Disease	NOUN	I
either	O	CCONJ	O
alone	O	ADV	O
or	O	CCONJ	O
subsequent	O	ADJ	O
to	O	PART	O
halothane	B-Chemical	NOUN	B


Induction	O	NOUN	B
by	O	ADP	O
paracetamol	B-Chemical	NOUN	B
of	O	ADP	O
bladder	B-Disease	NOUN	B
and	I-Disease	CCONJ	O
liver	I-Disease	NOUN	B
tumours	I-Disease	NOUN	I
in	O	ADP	O
the	O	DET	O
rat	O	NOUN	B
.	O	PUNCT	O


Effects	O	NOUN	B
on	O	ADP	O
hepatocyte	O	NOUN	B
fine	O	ADJ	O
structure	O	NOUN	O
.	O	PUNCT	O


Groups	O	NOUN	B
of	O	ADP	O
male	O	NOUN	B
and	O	CCONJ	O
female	O	ADJ	B
inbred	O	ADJ	O
Leeds	O	ADJ	O
strain	O	NOUN	O
rats	O	NOUN	B
were	O	AUX	O
fed	O	VERB	O
diets	O	NOUN	B
containing	O	VERB	O
either	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
%	O	NOUN	O
or	O	CCONJ	O
1	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
%	O	NOUN	O
paracetamol	B-Chemical	NOUN	B
by	O	ADP	O
weight	O	NOUN	B
for	O	ADP	O
up	O	ADV	O
to	O	PART	O
18	O	NUM	O
months	O	NOUN	B
.	O	PUNCT	O


At	O	ADP	O
the	O	DET	O
1	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
%	O	NOUN	O
dosage	O	NOUN	B
level	O	NOUN	B
,	O	PUNCT	O
20	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
rats	O	NOUN	B
of	O	ADP	O
both	O	DET	O
sexes	O	NOUN	B
developed	O	VERB	O
neoplastic	O	ADJ	B
nodules	O	NOUN	I
of	O	ADP	O
the	O	DET	O
liver	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
statistically	O	ADV	B
significant	O	ADJ	I
incidence	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
rats	O	NOUN	B
also	O	ADV	O
showed	O	VERB	O
gross	O	ADJ	B
enlargement	O	NOUN	I
of	O	ADP	O
their	O	PRON	O
livers	O	NOUN	B
and	O	CCONJ	O
an	O	DET	O
increase	O	NOUN	B
in	O	ADP	O
foci	O	NOUN	B
of	O	ADP	O
cellular	O	ADJ	B
alteration	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
latter	O	NOUN	O
also	O	ADV	O
being	O	AUX	O
observed	O	VERB	B
in	O	ADP	O
the	O	DET	O
low	O	ADJ	B
dosage	O	NOUN	B
male	O	NOUN	B
rats	O	NOUN	B
.	O	PUNCT	O


Papillomas	B-Disease	NOUN	B
of	O	ADP	O
the	O	DET	O
transitional	O	ADJ	B
epithelium	O	NOUN	B
of	O	ADP	O
the	O	DET	O
bladder	O	NOUN	B
developed	O	VERB	O
in	O	ADP	O
all	O	DET	O
paracetamol	B-Chemical	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
groups	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
three	O	NUM	O
rats	O	NOUN	B
bore	O	VERB	O
bladder	B-Disease	NOUN	B
carcinomas	I-Disease	NOUN	I
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
significant	O	ADJ	B
yields	O	NOUN	O
of	O	ADP	O
bladder	B-Disease	NOUN	B
tumours	I-Disease	NOUN	I
were	O	AUX	O
only	O	ADV	O
obtained	O	VERB	O
from	O	ADP	O
low	O	ADJ	B
dosage	O	NOUN	B
females	O	NOUN	B
and	O	CCONJ	O
high	O	ADJ	O
dosage	O	NOUN	B
males	O	NOUN	B
.	O	PUNCT	O


Additionally	O	ADV	O
,	O	PUNCT	O
20	O	NUM	O
to	O	PART	O
25	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
paracetamol	B-Chemical	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
rats	O	NOUN	B
developed	O	VERB	O
hyperplasia	B-Disease	NOUN	B
of	O	ADP	O
the	O	DET	O
bladder	O	NOUN	B
epithelium	O	NOUN	I
,	O	PUNCT	O
which	O	DET	O
was	O	AUX	O
not	O	PART	O
coincident	O	ADJ	B
with	O	ADP	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
bladder	B-Disease	NOUN	B
calculi	I-Disease	NOUN	I
.	O	PUNCT	O


A	O	DET	O
low	O	ADJ	O
yield	O	NOUN	O
of	O	ADP	O
tumours	B-Disease	NOUN	B
at	O	ADP	O
various	O	ADJ	O
other	O	ADJ	O
sites	O	NOUN	B
also	O	ADV	O
arose	O	VERB	O
following	O	VERB	O
paracetamol	B-Chemical	NOUN	B
feeding	O	NOUN	B
.	O	PUNCT	O


An	O	DET	O
electron	O	NOUN	B
microscope	O	NOUN	I
study	O	NOUN	O
of	O	ADP	O
the	O	DET	O
livers	O	NOUN	B
of	O	ADP	O
paracetamol	B-Chemical	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
rats	O	NOUN	B
revealed	O	VERB	O
ultrastructural	O	ADJ	B
changes	O	NOUN	B
in	O	ADP	O
the	O	DET	O
hepatocytes	O	NOUN	B
that	O	PRON	O
resemble	O	VERB	O
those	O	DET	O
that	O	PRON	O
result	O	VERB	O
from	O	ADP	O
exposure	O	NOUN	B
to	O	PART	I
a	O	DET	O
variety	O	NOUN	O
of	O	ADP	O
known	O	VERB	O
hepatocarcinogens	B-Disease	NOUN	B


Rat	O	NOUN	B
extraocular	O	ADJ	I
muscle	O	NOUN	O
regeneration	O	NOUN	O
.	O	PUNCT	O


Repair	O	NOUN	B
of	O	ADP	O
local	O	ADJ	B
anesthetic	O	ADJ	B
-	O	PUNCT	O
induced	O	VERB	B
damage	O	NOUN	B
.	O	PUNCT	O


Local	O	ADJ	B
anesthetics	O	NOUN	O
that	O	PRON	O
are	O	AUX	O
commonly	O	ADV	O
used	O	VERB	O
in	O	ADP	O
ophthalmic	O	ADJ	B
surgery	O	NOUN	I
(	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


75	O	NUM	O
%	O	NOUN	O
bupivacaine	B-Chemical	NOUN	B
hydrochloride	I-Chemical	NOUN	I
,	O	PUNCT	O
2	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
%	O	NOUN	O
mepivacaine	B-Chemical	NOUN	B
hydrochloride	I-Chemical	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
2	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
%	O	NOUN	O
lidocaine	B-Chemical	NOUN	B
hydrochloride	I-Chemical	NOUN	O
plus	O	CCONJ	O
1	O	NUM	O
:	O	PUNCT	O
100	O	NUM	O
,	O	PUNCT	O
000	O	NUM	O
epinephrine	B-Chemical	NOUN	B
)	O	PUNCT	O
were	O	AUX	O
injected	O	VERB	B
into	O	ADP	O
the	O	DET	O
retrobulbar	O	NOUN	B
area	O	NOUN	I
of	O	ADP	O
rat	O	NOUN	B
eyes	O	NOUN	B
.	O	PUNCT	O


Controls	O	NOUN	B
were	O	AUX	O
injected	O	VERB	B
with	O	ADP	O
physiological	O	ADJ	B
saline	O	NOUN	I
.	O	PUNCT	O


All	O	DET	O
three	O	NUM	O
anesthetics	O	NOUN	B
produced	O	VERB	O
massive	O	ADJ	B
degeneration	O	NOUN	I
of	O	ADP	O
the	O	DET	O
extraocular	O	ADJ	B
muscles	O	NOUN	I
.	O	PUNCT	O


Muscle	B-Disease	NOUN	B
degeneration	I-Disease	NOUN	I
is	O	AUX	O
followed	O	VERB	O
by	O	ADP	O
regeneration	O	NOUN	B
of	O	ADP	O
the	O	DET	O
damaged	O	VERB	B
muscle	O	NOUN	B
fibers	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
to	O	PART	O
muscle	B-Disease	NOUN	B
damage	I-Disease	NOUN	I
,	O	PUNCT	O
severe	O	ADJ	B
damage	O	NOUN	B
was	O	AUX	O
also	O	ADV	O
seen	O	VERB	O
in	O	ADP	O
harderian	O	ADJ	B
glands	O	NOUN	I
,	O	PUNCT	O
especially	O	ADV	O
after	O	ADP	O
exposure	O	NOUN	B
to	O	PART	I
mepivacaine	B-Chemical	NOUN	B
and	O	CCONJ	O
lidocaine	B-Chemical	NOUN	B
plus	O	CCONJ	O
epinephrine	B-Chemical	NOUN	B
.	O	PUNCT	O


With	O	ADP	O
these	O	DET	O
findings	O	NOUN	B
in	O	ADP	O
rats	O	NOUN	B
,	O	PUNCT	O
it	O	PRON	O
is	O	AUX	O
hypothesized	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
temporary	O	ADJ	B
diplopia	B-Disease	NOUN	B


Reversal	O	ADJ	B
of	O	ADP	O
neuroleptic	O	ADJ	B
-	O	PUNCT	O
induced	O	VERB	B
catalepsy	B-Disease	NOUN	B
by	O	ADP	O
novel	O	ADJ	O
aryl-piperazine	B-Chemical	ADJ	B
anxiolytic	O	ADJ	I
drugs	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
novel	O	ADJ	O
anxiolytic	O	ADJ	B
drug	O	NOUN	I
,	O	PUNCT	O
buspirone	B-Chemical	NOUN	B
,	O	PUNCT	O
reverses	O	VERB	B
catalepsy	B-Disease	NOUN	B
induced	O	VERB	B
by	O	ADP	O
haloperidol	B-Chemical	NOUN	B
.	O	PUNCT	O


A	O	DET	O
series	O	NOUN	B
of	O	ADP	O
aryl-piperazine	B-Chemical	ADJ	B
analogues	O	NOUN	I
of	O	ADP	O
buspirone	B-Chemical	NOUN	B
and	O	CCONJ	O
other	O	ADJ	O
5-hydroxytryptaminergic	B-Chemical	ADJ	B
agonists	I-Chemical	NOUN	B
were	O	AUX	O
tested	O	VERB	B
for	O	ADP	O
their	O	PRON	O
ability	O	NOUN	O
to	O	PART	O
reverse	O	VERB	B
haloperidol	B-Chemical	NOUN	I
induced	O	ADJ	B
catalepsy	B-Disease	NOUN	B
.	O	PUNCT	O


Those	O	DET	O
drugs	O	NOUN	B
with	O	ADP	O
strong	O	ADJ	B
affinity	O	NOUN	B
for	O	ADP	O
5-hydroxytryptamine	B-Chemical	NOUN	B
1a	O	NOUN	I
receptors	O	NOUN	I
were	O	AUX	O
able	O	ADJ	O
to	O	PART	O
reverse	O	VERB	B
catalepsy	B-Disease	NOUN	I
.	O	PUNCT	O


Drugs	O	NOUN	B
with	O	ADP	O
affinity	O	NOUN	B
for	O	ADP	O
other	O	ADJ	O
5-HT	B-Chemical	NOUN	B
receptors	O	NOUN	I
or	O	CCONJ	O
weak	O	ADJ	B
affinity	O	NOUN	B
were	O	AUX	O
ineffective	O	ADJ	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
inhibition	O	NOUN	B
of	O	ADP	O
postsynaptic	O	ADJ	B
5-HT	B-Chemical	NOUN	I
receptors	O	NOUN	I
neither	O	CCONJ	O
inhibited	O	VERB	B
nor	O	CCONJ	O
potentiated	O	ADJ	B
reversal	O	NOUN	B
of	O	ADP	O
catalepsy	B-Disease	NOUN	B


Diazepam	B-Chemical	NOUN	B
facilitates	O	VERB	O
reflex	O	ADJ	B
bradycardia	B-Disease	NOUN	I
in	O	ADP	O
conscious	O	ADJ	B
rats	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
effects	O	NOUN	B
of	O	ADP	O
diazepam	B-Chemical	NOUN	B
on	O	ADP	O
cardiovascular	O	ADJ	B
function	O	NOUN	I
were	O	AUX	O
assessed	O	VERB	B
in	O	ADP	O
conscious	O	ADJ	B
rats	O	NOUN	B
.	O	PUNCT	O


Intravenous	O	ADJ	B
administration	O	NOUN	I
of	O	ADP	O
diazepam	B-Chemical	NOUN	B
(	O	PUNCT	O
1	O	NUM	O
-	O	SYM	O
30	O	NUM	O
mg	O	NOUN	O
kg	O	NOUN	O
-	O	PUNCT	O
1	O	NUM	O
)	O	PUNCT	O
produced	O	VERB	O
a	O	DET	O
dose	O	NOUN	B
-	O	PUNCT	O
dependent	O	ADJ	B
decrease	O	NOUN	B
in	O	ADP	O
both	O	CCONJ	O
the	O	DET	O
mean	O	ADJ	O
arterial	O	ADJ	B
pressure	O	NOUN	I
and	O	CCONJ	O
the	O	DET	O
heart	O	NOUN	B
rate	O	NOUN	I
.	O	PUNCT	O


Also	O	ADV	O
,	O	PUNCT	O
reflex	O	ADJ	B
bradycardia	B-Disease	NOUN	I
was	O	AUX	O
produced	O	VERB	O
in	O	ADP	O
rats	O	NOUN	B
by	O	ADP	O
intravenous	O	ADJ	B
infusion	O	NOUN	B
of	O	ADP	O
adrenaline	B-Chemical	NOUN	B
(	O	PUNCT	O
1	O	NUM	O
.	O	PUNCT	O


25	O	NUM	O
-	O	SYM	O
2	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
micrograms	O	NOUN	B
kg	O	NOUN	O
-	O	PUNCT	O
1	O	NUM	O
).	O	PUNCT	O
Intravenous	O	ADJ	B
pretreatment	O	NOUN	B
of	O	ADP	O
the	O	DET	O
rats	O	NOUN	B
with	O	ADP	O
diazepam	B-Chemical	NOUN	B
,	O	PUNCT	O
although	O	SCONJ	O
causing	O	VERB	O
no	O	DET	O
change	O	NOUN	O
in	O	ADP	O
the	O	DET	O
adrenaline	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
pressor	O	NOUN	B
effect	O	NOUN	O
,	O	PUNCT	O
did	O	AUX	O
enhance	O	VERB	O
the	O	DET	O
adrenaline	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
reflex	O	ADJ	B
bradycardia	B-Disease	NOUN	I
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
diazepam	B-Chemical	NOUN	B
enhancement	O	NOUN	B
of	O	ADP	O
adrenaline	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
reflex	O	ADJ	B
bradycardia	B-Disease	NOUN	O
was	O	AUX	O
antagonized	O	VERB	B
by	O	ADP	O
pretreatment	O	NOUN	B
of	O	ADP	O
rats	O	NOUN	B
with	O	ADP	O
an	O	DET	O
intravenous	O	ADJ	B
dose	O	NOUN	I
of	O	ADP	O
picrotoxin	B-Chemical	NOUN	B
(	O	PUNCT	O
an	O	DET	O
agent	O	NOUN	B
blocks	O	VERB	B
chloride	B-Chemical	NOUN	B
channels	O	NOUN	I
by	O	ADP	O
binding	O	VERB	B
to	O	PART	O
sites	O	NOUN	O
associated	O	VERB	B
with	O	ADP	I
the	O	DET	O
benzodiazepine	B-Chemical	NOUN	B
-	O	PUNCT	O
GABA	B-Chemical	PROPN	B
-	O	PUNCT	O
chloride	B-Chemical	NOUN	B
channel	O	NOUN	I
macromolecular	O	ADJ	I
complex	O	NOUN	I
).	O	PUNCT	O
The	O	DET	O
data	O	NOUN	B
indicate	O	VERB	O
that	O	SCONJ	O
diazepam	B-Chemical	NOUN	B
acts	O	VERB	O
through	O	ADP	O
the	O	DET	O
benzodiazepine	B-Chemical	NOUN	B
-	O	PUNCT	O
GABA	B-Chemical	PROPN	B
-	O	PUNCT	O
chloride	B-Chemical	NOUN	B
channel	O	NOUN	I
macromolecular	O	ADJ	I
complex	O	NOUN	I
within	O	ADP	O
the	O	DET	O
central	O	ADJ	B
nervous	O	ADJ	I
system	O	NOUN	I
to	O	PART	O
facilitate	O	VERB	O
reflex	O	ADJ	B
bradycardia	B-Disease	NOUN	O


Chronic	O	ADJ	B
carbamazepine	B-Chemical	NOUN	I
inhibits	O	VERB	B
the	O	DET	O
development	O	NOUN	B
of	O	ADP	O
local	O	ADJ	B
anesthetic	O	ADJ	B
seizures	B-Disease	NOUN	I
kindled	O	VERB	B
by	O	ADP	O
cocaine	B-Chemical	NOUN	B
and	O	CCONJ	O
lidocaine	B-Chemical	NOUN	B
.	O	PUNCT	O


The	O	DET	O
effects	O	NOUN	B
of	O	ADP	O
carbamazepine	B-Chemical	NOUN	B
(	O	PUNCT	O
CBZ	B-Chemical	NOUN	B
)	O	PUNCT	O
treatment	O	NOUN	B
on	O	ADP	O
local	O	ADJ	B
anesthetic	O	ADJ	B
-	O	PUNCT	O
kindled	O	VERB	B
seizures	B-Disease	NOUN	B
and	O	CCONJ	O
lethality	O	NOUN	B
were	O	AUX	O
evaluated	O	VERB	B
in	O	ADP	O
different	O	ADJ	O
stages	O	NOUN	B
of	O	ADP	O
the	O	DET	O
kindling	O	NOUN	B
process	O	NOUN	I
and	O	CCONJ	O
under	O	ADP	O
different	O	ADJ	O
methods	O	NOUN	B
of	O	ADP	O
CBZ	B-Chemical	NOUN	B
administration	O	NOUN	B
.	O	PUNCT	O


Chronic	O	ADJ	B
oral	O	ADJ	I
CBZ	B-Chemical	NOUN	B
inhibited	O	VERB	B
the	O	DET	O
development	O	NOUN	B
of	O	ADP	O
both	O	CCONJ	O
lidocaine	B-Chemical	NOUN	B
-	O	PUNCT	O
and	O	CCONJ	O
cocaine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
seizures	B-Disease	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
had	O	AUX	O
little	O	ADJ	O
effect	O	NOUN	B
on	O	ADP	O
the	O	DET	O
fully	O	ADV	O
developed	O	VERB	O
local	O	ADJ	O
anesthetic	O	ADJ	B
seizures	B-Disease	NOUN	I
.	O	PUNCT	O


Chronic	O	ADJ	B
CBZ	B-Chemical	NOUN	B
also	O	ADV	O
decreased	O	VERB	B
the	O	DET	O
incidence	O	NOUN	B
of	O	ADP	O
seizure	B-Disease	NOUN	B
-	O	PUNCT	O
related	O	VERB	B
mortality	O	NOUN	B
in	O	ADP	O
the	O	DET	O
cocaine	B-Chemical	NOUN	B
-	O	PUNCT	O
injected	O	VERB	B
rats	O	NOUN	B
.	O	PUNCT	O


Acute	O	ADJ	B
CBZ	B-Chemical	NOUN	B
over	O	ADP	O
a	O	DET	O
range	O	NOUN	O
of	O	ADP	O
doses	O	NOUN	B
(	O	PUNCT	O
15	O	NUM	O
-	O	SYM	O
50	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
)	O	PUNCT	O
had	O	AUX	O
no	O	DET	B
effect	O	NOUN	I
on	O	ADP	O
completed	O	VERB	O
lidocaine	B-Chemical	NOUN	B
-	O	PUNCT	O
kindled	O	VERB	B
or	O	CCONJ	O
acute	O	ADJ	B
cocaine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
seizures	B-Disease	NOUN	B
.	O	PUNCT	O


Repeated	O	VERB	O
i	O	X	O
.	O	PUNCT	O


p	O	NOUN	O
.	O	PUNCT	O


injection	O	NOUN	B
of	O	ADP	O
CBZ	B-Chemical	NOUN	B
(	O	PUNCT	O
15	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
)	O	PUNCT	O
also	O	ADV	O
was	O	AUX	O
without	O	ADP	O
effect	O	NOUN	B
on	O	ADP	O
the	O	DET	O
development	O	NOUN	B
of	O	ADP	O
lidocaine	B-Chemical	NOUN	B
-	O	PUNCT	O
or	O	CCONJ	O
cocaine	B-Chemical	NOUN	B
-	O	PUNCT	O
kindled	O	VERB	B
seizures	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
differential	O	ADJ	B
effects	O	NOUN	O
of	O	ADP	O
CBZ	B-Chemical	NOUN	B
depending	O	VERB	O
upon	O	SCONJ	O
stage	O	NOUN	B
of	O	ADP	O
seizure	B-Disease	NOUN	B
development	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
distinct	O	ADJ	O
mechanisms	O	NOUN	B
underlie	O	VERB	O
the	O	DET	O
development	O	NOUN	B
versus	O	CCONJ	O
maintenance	O	NOUN	B
of	O	ADP	O
local	O	ADJ	B
anesthetic	O	ADJ	B
-	O	PUNCT	O
kindled	O	VERB	B
seizures	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
effectiveness	O	NOUN	B
of	O	ADP	O
chronic	O	ADJ	B
but	O	CCONJ	O
not	O	PART	O
repeated	O	VERB	O
,	O	PUNCT	O
intermittent	O	ADJ	B
injections	O	NOUN	B
of	O	ADP	O
CBZ	B-Chemical	NOUN	B
suggests	O	VERB	O
that	O	SCONJ	O
different	O	ADJ	O
biochemical	O	ADJ	B
consequences	O	NOUN	B
result	O	VERB	O
from	O	ADP	O
the	O	DET	O
different	O	ADJ	O
treatment	O	NOUN	B
regimens	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
possible	O	ADJ	O
utility	O	NOUN	O
of	O	ADP	O
chronic	O	ADJ	B
CBZ	B-Chemical	NOUN	B
in	O	ADP	O
preventing	O	VERB	B
the	O	DET	O
development	O	NOUN	B
of	O	ADP	O
toxic	O	ADJ	B
side	O	NOUN	B
effects	O	NOUN	I
in	O	ADP	O
human	O	ADJ	B
cocaine	B-Chemical	NOUN	B


D-penicillamine	B-Chemical	NOUN	B
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
localized	B-Disease	ADJ	B
scleroderma	I-Disease	NOUN	I
.	O	PUNCT	O


Localized	B-Disease	ADJ	B
scleroderma	I-Disease	NOUN	I
has	O	AUX	O
no	O	DET	O
recognized	O	VERB	O
internal	O	ADJ	B
organ	O	NOUN	I
involvement	O	NOUN	B
but	O	CCONJ	O
may	O	AUX	O
be	O	AUX	O
disfiguring	O	ADJ	B
and	O	CCONJ	O
disabling	O	VERB	B
when	O	SCONJ	O
the	O	DET	O
cutaneous	O	ADJ	B
lesions	O	NOUN	I
are	O	AUX	O
extensive	O	ADJ	B
or	O	CCONJ	O
affect	O	VERB	O
children	O	NOUN	B
.	O	PUNCT	O


There	O	PRON	O
is	O	AUX	O
no	O	DET	O
accepted	O	VERB	O
or	O	CCONJ	O
proven	O	VERB	O
treatment	O	NOUN	B
for	O	ADP	O
localized	B-Disease	ADJ	B
scleroderma	I-Disease	NOUN	I
.	O	PUNCT	O


Case	O	NOUN	B
reports	O	NOUN	I
of	O	ADP	O
11	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
severe	O	ADJ	B
,	O	PUNCT	O
extensive	O	ADJ	O
localized	B-Disease	ADJ	B
scleroderma	I-Disease	NOUN	I
who	O	PRON	O
were	O	AUX	O
treated	O	VERB	B
with	O	ADP	I
D-penicillamine	B-Chemical	NOUN	B
are	O	AUX	O
summarized	O	VERB	O
in	O	ADP	O
this	O	DET	O
article	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
drug	O	NOUN	B
was	O	AUX	O
judged	O	VERB	O
to	O	PART	O
have	O	AUX	O
a	O	DET	O
favorable	O	ADJ	B
effect	O	NOUN	I
on	O	ADP	O
the	O	DET	O
disease	O	NOUN	B
course	O	NOUN	O
in	O	ADP	O
7	O	NUM	O
(	O	PUNCT	O
64	O	NUM	O
%)	O	NOUN	O
of	O	ADP	O
11	O	NUM	O
patients	O	NOUN	B
.	O	PUNCT	O


Improvement	O	NOUN	B
began	O	VERB	O
within	O	ADP	O
3	O	NUM	O
to	O	PART	O
6	O	NUM	O
months	O	NOUN	B
and	O	CCONJ	O
consisted	O	VERB	O
of	O	ADP	O
cessation	O	NOUN	B
of	O	ADP	O
active	O	ADJ	B
cutaneous	O	ADJ	I
lesions	O	NOUN	O
in	O	ADP	O
all	O	DET	O
7	O	NUM	O
patients	O	NOUN	B
,	O	PUNCT	O
skin	O	NOUN	B
softening	O	NOUN	I
in	O	ADP	O
5	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
more	O	ADV	O
normal	O	ADJ	O
growth	O	NOUN	O
of	O	ADP	O
the	O	DET	O
affected	O	VERB	B
limb	O	NOUN	B
in	O	ADP	O
2	O	NUM	O
of	O	ADP	O
3	O	NUM	O
children	O	NOUN	B
.	O	PUNCT	O


Joint	O	ADJ	B
stiffness	O	NOUN	I
and	O	CCONJ	O
contractures	B-Disease	NOUN	B
also	O	ADV	O
improved	O	VERB	B
.	O	PUNCT	O


The	O	DET	O
dose	O	NOUN	B
of	O	ADP	O
D-penicillamine	B-Chemical	NOUN	B
associated	O	VERB	B
with	O	ADP	I
a	O	DET	O
favorable	O	ADJ	B
response	O	NOUN	I
was	O	AUX	O
as	O	ADV	O
low	O	ADJ	O
as	O	ADP	O
2	O	NUM	O
to	O	PART	O
5	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
per	O	ADP	O
day	O	NOUN	B
given	O	VERB	O
over	O	ADP	O
a	O	DET	O
period	O	NOUN	B
ranging	O	VERB	O
from	O	ADP	O
15	O	NUM	O
to	O	PART	O
53	O	NUM	O
months	O	NOUN	B
.	O	PUNCT	O


D-Penicillamine	B-Chemical	NOUN	B
caused	O	VERB	O
nephrotic	B-Disease	ADJ	B
syndrome	I-Disease	NOUN	I
in	O	ADP	O
1	O	NUM	O
patient	O	NOUN	B
and	O	CCONJ	O
milder	O	ADJ	O
reversible	O	ADJ	B
proteinuria	B-Disease	NOUN	B
in	O	ADP	O
3	O	NUM	O
other	O	ADJ	O
patients	O	NOUN	B
;	O	PUNCT	O
none	O	NOUN	O
developed	O	VERB	O
renal	B-Disease	ADJ	B
insufficiency	I-Disease	NOUN	I
.	O	PUNCT	O


These	O	DET	O
data	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
D-penicillamine	B-Chemical	NOUN	B
may	O	AUX	O
be	O	AUX	O
effective	O	ADJ	B
in	O	ADP	O
severe	O	ADJ	B
cases	O	NOUN	B
of	O	ADP	O
localized	B-Disease	ADJ	B
scleroderma	I-Disease	NOUN	I


Preservation	O	NOUN	B
of	O	ADP	O
renal	O	ADJ	B
blood	O	NOUN	I
flow	O	NOUN	I
during	O	ADP	O
hypotension	B-Disease	NOUN	B
induced	O	VERB	B
with	O	ADP	O
fenoldopam	B-Chemical	NOUN	B
in	O	ADP	O
dogs	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
introduction	O	NOUN	B
of	O	ADP	O
drugs	O	NOUN	B
that	O	PRON	O
could	O	AUX	O
induce	O	VERB	B
hypotension	B-Disease	NOUN	B
with	O	ADP	O
different	O	ADJ	O
pharmacological	O	ADJ	B
actions	O	NOUN	O
would	O	AUX	O
be	O	AUX	O
advantageous	O	ADJ	O
because	O	SCONJ	O
side	O	NOUN	B
effects	O	NOUN	I
unique	O	ADJ	B
to	O	PART	O
a	O	DET	O
specific	O	ADJ	O
drug	O	NOUN	B
could	O	AUX	O
be	O	AUX	O
minimized	O	VERB	O
by	O	ADP	O
selecting	O	VERB	O
appropriate	O	ADJ	O
therapy	O	NOUN	B
.	O	PUNCT	O


Specific	O	ADJ	O
dopamine	B-Chemical	NOUN	B
-	O	PUNCT	O
1	O	NUM	O
,(	O	PUNCT	O
DA	B-Chemical	NOUN	B
1	O	NUM	I
)	O	PUNCT	O
and	O	CCONJ	O
dopamine	B-Chemical	NOUN	B
-	O	PUNCT	O
2	O	NUM	B
(	O	PUNCT	O
DA	B-Chemical	NOUN	B
2	O	NUM	I
)	O	PUNCT	O
receptor	O	NOUN	B
agonists	O	NOUN	I
are	O	AUX	O
now	O	ADV	O
under	O	ADP	O
clinical	O	ADJ	B
investigation	O	NOUN	B
.	O	PUNCT	O


Fenoldopam	B-Chemical	NOUN	B
mesylate	I-Chemical	NOUN	B
is	O	AUX	O
a	O	DET	O
specific	O	ADJ	O
DA1	O	NOUN	B
receptor	O	NOUN	I
agonist	O	NOUN	B
that	O	PRON	O
lowers	O	VERB	O
blood	O	NOUN	B
pressure	O	NOUN	I
by	O	ADP	O
vasodilatation	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
hypothesis	O	NOUN	B
that	O	SCONJ	O
fenoldopam	B-Chemical	NOUN	B
could	O	AUX	O
be	O	AUX	O
used	O	VERB	O
to	O	PART	O
induce	O	VERB	B
hypotension	B-Disease	NOUN	B
and	O	CCONJ	O
preserve	O	VERB	O
blood	O	NOUN	B
flow	O	NOUN	I
to	O	PART	O
the	O	DET	O
kidney	O	NOUN	B
was	O	AUX	O
tested	O	VERB	B
.	O	PUNCT	O


Systemic	O	ADJ	B
aortic	O	ADJ	I
blood	O	NOUN	I
pressure	O	NOUN	I
and	O	CCONJ	O
renal	O	ADJ	B
blood	O	NOUN	I
flow	O	NOUN	I
were	O	AUX	O
measured	O	VERB	O
continuously	O	ADV	O
with	O	ADP	O
a	O	DET	O
carotid	O	NOUN	B
arterial	O	ADJ	I
catheter	O	NOUN	I
and	O	CCONJ	O
an	O	DET	O
electromagnetic	O	ADJ	B
flow	O	NOUN	I
probe	O	NOUN	I
respectively	O	ADV	O
,	O	PUNCT	O
in	O	ADP	O
order	O	NOUN	O
to	O	PART	O
compare	O	VERB	B
the	O	DET	O
cardiovascular	O	ADJ	B
and	O	CCONJ	O
renal	O	ADJ	B
vascular	O	ADJ	I
effects	O	NOUN	I
of	O	ADP	O
fenoldopam	B-Chemical	NOUN	B
and	O	CCONJ	O
sodium	B-Chemical	NOUN	B
nitroprusside	B-Chemical	NOUN	I
in	O	ADP	O
ten	O	NUM	O
dogs	O	NOUN	B
under	O	ADP	O
halothane	B-Chemical	NOUN	B
general	O	ADJ	B
anaesthesia	O	NOUN	I
.	O	PUNCT	O


Mean	O	VERB	O
arterial	O	ADJ	B
pressure	O	NOUN	I
was	O	AUX	O
decreased	O	VERB	B
30	O	NUM	O
+/-	O	CCONJ	O
8	O	NUM	O
per	O	ADP	O
cent	O	NOUN	O
from	O	ADP	O
control	O	NOUN	B
with	O	ADP	O
infusion	O	NOUN	B
of	O	ADP	O
fenoldopam	B-Chemical	NOUN	B
(	O	PUNCT	O
3	O	NUM	O
.	O	PUNCT	O


4	O	NUM	O
+/-	O	CCONJ	O
2	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
micrograms	O	NOUN	B
.	O	PUNCT	O


kg	O	NOUN	O
-	O	PUNCT	O
1	O	NUM	O
.	O	PUNCT	O


min	O	NOUN	B
-	O	PUNCT	O
1	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
34	O	NUM	O
+/-	O	CCONJ	O
4	O	NUM	O
per	O	ADP	O
cent	O	NOUN	O
with	O	ADP	O
infusion	O	NOUN	B
of	O	ADP	O
sodium	B-Chemical	NOUN	B
nitroprusside	B-Chemical	NOUN	I
(	O	PUNCT	O
5	O	NUM	O
.	O	PUNCT	O


9	O	NUM	O
micrograms	O	NOUN	B
.	O	PUNCT	O


kg	O	NOUN	O
-	O	PUNCT	O
1	O	NUM	O
.	O	PUNCT	O


min	O	NOUN	B
-	O	PUNCT	O
1	O	NUM	O
)(	O	NOUN	O
NS	O	NOUN	B
).	O	PUNCT	O
Renal	O	ADJ	B
blood	O	NOUN	I
flow	O	NOUN	I
(	O	PUNCT	O
RBF	O	NOUN	B
)	O	PUNCT	O
increased	O	VERB	B
during	O	ADP	O
fenoldopam	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
hypotension	B-Disease	NOUN	B
11	O	NUM	O
+/-	O	CCONJ	O
7	O	NUM	O
per	O	ADP	O
cent	O	NOUN	O
and	O	CCONJ	O
decreased	O	VERB	B
21	O	NUM	O
+/-	O	CCONJ	O
8	O	NUM	O
per	O	ADP	O
cent	O	NOUN	O
during	O	ADP	O
sodium	B-Chemical	NOUN	B
nitroprusside	B-Chemical	NOUN	I
-	O	PUNCT	O
induced	O	VERB	B
hypotension	B-Disease	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


01	O	NUM	O
).	O	PUNCT	O
Sodium	O	NOUN	B
nitroprusside	B-Chemical	NOUN	I
is	O	AUX	O
a	O	DET	O
non	O	ADJ	B
-	O	PUNCT	O
selective	O	ADJ	B
arteriolar	O	ADJ	B
and	O	CCONJ	O
venous	O	ADJ	B
vasodilator	O	NOUN	I
that	O	PRON	O
can	O	AUX	O
produce	O	VERB	O
redistribution	O	NOUN	B
of	O	ADP	O
blood	O	NOUN	B
flow	O	NOUN	I
away	O	ADV	O
from	O	ADP	O
the	O	DET	O
kidney	O	NOUN	B
during	O	ADP	O
induced	O	VERB	B
hypotension	B-Disease	NOUN	B
.	O	PUNCT	O


Fenoldopam	O	NOUN	B
is	O	AUX	O
a	O	DET	O
selective	O	ADJ	O
dopamine	B-Chemical	NOUN	B
-	O	PUNCT	O
1	O	NUM	O
(	O	PUNCT	O
DA1	O	NOUN	B
)	O	PUNCT	O
receptor	O	NOUN	O
agonist	O	NOUN	B
that	O	PRON	O
causes	O	VERB	O
vasodilatation	O	NOUN	B
to	O	PART	O
the	O	DET	O
kidney	O	NOUN	B
and	O	CCONJ	O
other	O	ADJ	O
organs	O	NOUN	B
with	O	ADP	O
DA1	O	NOUN	B
receptors	O	NOUN	I
and	O	CCONJ	O
preserves	O	VERB	O
blood	O	NOUN	B
flow	O	NOUN	I
to	O	PART	O
the	O	DET	O
kidney	O	NOUN	B
during	O	ADP	O
induced	O	VERB	B
hypotension	B-Disease	NOUN	B


Antiarrhythmic	O	ADJ	B
effects	O	NOUN	I
of	O	ADP	O
optical	O	ADJ	B
isomers	O	NOUN	I
of	O	ADP	O
cibenzoline	B-Chemical	NOUN	B
on	O	ADP	O
canine	O	ADJ	B
ventricular	B-Disease	ADJ	B
arrhythmias	I-Disease	NOUN	I
.	O	PUNCT	O


Antiarrhythmic	O	ADJ	B
effects	O	NOUN	I
of	O	ADP	O
(+)-	O	NOUN	B
cibenzoline	B-Chemical	NOUN	B
and	O	CCONJ	O
(-)-	O	NOUN	B
cibenzoline	B-Chemical	NOUN	I
were	O	AUX	O
examined	O	VERB	O
using	O	VERB	O
two	O	NUM	O
canine	O	ADJ	B
ventricular	B-Disease	ADJ	B
arrhythmia	I-Disease	NOUN	I
models	O	NOUN	O
.	O	PUNCT	O


Digitalis	B-Chemical	NOUN	B
arrhythmia	B-Disease	NOUN	B
,	O	PUNCT	O
which	O	DET	O
is	O	AUX	O
suppressed	O	VERB	B
by	O	ADP	O
Na	B-Chemical	NOUN	B
channel	O	NOUN	I
blockers	O	NOUN	I
,	O	PUNCT	O
was	O	AUX	O
induced	O	VERB	B
by	O	ADP	O
intermittent	O	ADJ	B
intravenous	O	ADJ	I
(	O	PUNCT	O
i	O	X	O
.	O	PUNCT	O


v	O	DET	O
.)	O	ADJ	O
injection	O	NOUN	B
of	O	ADP	O
ouabain	B-Chemical	NOUN	B
in	O	ADP	O
pentobarbital	B-Chemical	ADJ	B
-	O	PUNCT	O
anesthetized	O	VERB	B
dogs	O	NOUN	B
.	O	PUNCT	O


Adrenaline	B-Disease	NOUN	B
arrhythmia	I-Disease	NOUN	I
,	O	PUNCT	O
which	O	DET	O
is	O	AUX	O
suppressed	O	VERB	B
by	O	ADP	O
Ca	B-Chemical	NOUN	B
channel	O	NOUN	I
blockers	O	NOUN	I
,	O	PUNCT	O
was	O	AUX	O
induced	O	VERB	B
by	O	ADP	O
adrenaline	B-Chemical	NOUN	B
infusion	O	NOUN	B
in	O	ADP	O
halothane	B-Chemical	NOUN	B
-	O	PUNCT	O
anesthetized	O	VERB	B
dogs	O	NOUN	B
.	O	PUNCT	O


Ten	O	NUM	O
and	O	CCONJ	O
5	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	O
i	O	X	O
.	O	PUNCT	O


v	O	ADP	O
.(+)-	O	PUNCT	O
cibenzoline	B-Chemical	NOUN	B
suppressed	O	VERB	B
digitalis	B-Chemical	NOUN	B
-	O	PUNCT	O
and	O	CCONJ	O
adrenaline	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
arrhythmias	B-Disease	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


The	O	DET	O
minimum	O	ADJ	B
effective	O	ADJ	B
plasma	O	NOUN	B
concentrations	O	NOUN	B
of	O	ADP	O
(+)-	O	NOUN	B
cibenzoline	B-Chemical	NOUN	B
for	O	ADP	O
digitalis	B-Chemical	NOUN	B
-	O	PUNCT	O
and	O	CCONJ	O
adrenaline	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
arrhythmias	B-Disease	NOUN	B
were	O	AUX	O
1	O	NUM	O
.	O	PUNCT	O


4	O	NUM	O
+/-	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


4	O	NUM	O
and	O	CCONJ	O
2	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
+/-	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
micrograms	O	NOUN	B
/	O	SYM	O
ml	O	NOUN	O
,	O	PUNCT	O
respectively	O	ADV	O
(	O	PUNCT	O
mean	O	NOUN	O
+/-	O	CCONJ	O
SD	O	NOUN	B
,	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
6	O	NUM	O
).	O	PUNCT	O
A	O	DET	O
lower	O	ADJ	B
dose	O	NOUN	I
of	O	ADP	O
1	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	O
i	O	X	O
.	O	PUNCT	O


v	O	NOUN	O
.	O	PUNCT	O


of	O	ADP	O
(-)-	O	NOUN	B
cibenzoline	B-Chemical	NOUN	I
suppressed	O	VERB	B
the	O	DET	O
digitalis	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
arrhythmia	B-Disease	NOUN	B
,	O	PUNCT	O
whereas	O	SCONJ	O
5	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	O
i	O	X	O
.	O	PUNCT	O


v	O	NOUN	O
.	O	PUNCT	O


was	O	AUX	O
needed	O	VERB	O
to	O	PART	O
suppress	O	VERB	B
adrenaline	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
arrhythmias	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
minimum	O	ADJ	B
effective	O	ADJ	B
plasma	O	NOUN	B
concentrations	O	NOUN	B
of	O	ADP	O
(-)-	O	NOUN	B
cibenzoline	B-Chemical	NOUN	I
for	O	ADP	O
digitalis	B-Chemical	NOUN	B
-	O	PUNCT	O
and	O	CCONJ	O
adrenaline	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
arrhythmia	B-Disease	NOUN	B
were	O	AUX	O
0	O	NUM	O
.	O	PUNCT	O


06	O	NUM	O
+/-	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


04	O	NUM	O
and	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


7	O	NUM	O
+/-	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
micrograms	O	NOUN	B
/	O	SYM	O
ml	O	NOUN	O
,	O	PUNCT	O
respectively	O	ADV	O
(	O	PUNCT	O
mean	O	NOUN	O
+/-	O	CCONJ	O
SD	O	NOUN	B
,	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
6	O	NUM	O
).	O	PUNCT	O
The	O	DET	O
stronger	O	ADJ	O
antiarrhythmic	O	ADJ	B
effect	O	NOUN	I
of	O	ADP	O
(-)-	O	NOUN	B
cibenzoline	B-Chemical	NOUN	I
indicates	O	VERB	O
that	O	SCONJ	O
(-)-	O	NOUN	B
isomer	O	NOUN	I
may	O	AUX	O
have	O	AUX	O
an	O	DET	O
effect	O	NOUN	B
nearly	O	ADV	O
5	O	NUM	O
-	O	SYM	O
20	O	NUM	O
times	O	NOUN	O
stronger	O	ADJ	B
in	O	ADP	O
suppressing	O	VERB	B
Na	B-Chemical	NOUN	B
channels	O	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
effects	O	NOUN	B
of	O	ADP	I
both	O	DET	O
drugs	O	NOUN	B
on	O	ADP	O
Ca	B-Chemical	NOUN	B


Effect	O	NOUN	B
of	O	ADP	O
Hibiscus	B-Chemical	X	B
rosa	I-Chemical	X	I
sinensis	I-Chemical	NOUN	I
on	O	ADP	O
reserpine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
neurobehavioral	O	ADJ	B
and	O	CCONJ	O
biochemical	O	ADJ	B
alterations	O	NOUN	B
in	O	ADP	O
rats	O	NOUN	B
.	O	PUNCT	O


Effect	O	NOUN	B
of	O	ADP	O
methanolic	O	ADJ	B
extract	O	NOUN	I
of	O	ADP	O
Hibiscus	B-Chemical	X	B
rosa	I-Chemical	X	I
sinensis	I-Chemical	NOUN	I
(	O	PUNCT	O
100	O	NUM	O
-	O	PUNCT	O
300	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
)	O	PUNCT	O
was	O	AUX	O
studied	O	VERB	O
on	O	ADP	O
reserpine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
orofacial	O	ADJ	B
dyskinesia	B-Disease	NOUN	I
and	O	CCONJ	O
neurochemical	O	ADJ	B
alterations	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
rats	O	NOUN	B
were	O	AUX	O
treated	O	VERB	B
with	O	ADP	I
intraperitoneal	O	ADJ	B
reserpine	B-Chemical	NOUN	B
(	O	PUNCT	O
1	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
,	O	PUNCT	O
ip	O	NOUN	B
)	O	PUNCT	O
for	O	ADP	O
3	O	NUM	O
days	O	NOUN	B
every	O	DET	O
other	O	ADJ	O
day	O	NOUN	B
.	O	PUNCT	O


On	O	ADP	O
day	O	NOUN	B
5	O	NUM	O
,	O	PUNCT	O
vacuous	O	ADJ	B
chewing	O	NOUN	I
movements	O	NOUN	B
and	O	CCONJ	O
tongue	O	NOUN	B
protrusions	O	NOUN	I
were	O	AUX	O
counted	O	VERB	B
for	O	ADP	O
5	O	NUM	O
min	O	NOUN	O
.	O	PUNCT	O


Reserpine	B-Chemical	NOUN	B
treated	O	ADJ	B
rats	O	NOUN	B
significantly	O	ADV	O
developed	O	VERB	O
vacuous	O	ADJ	B
chewing	O	NOUN	I
movements	O	NOUN	B
and	O	CCONJ	O
tongue	O	NOUN	B
protrusions	O	NOUN	B
however	O	ADV	O
,	O	PUNCT	O
coadministration	O	NOUN	B
of	O	ADP	O
Hibiscus	B-Chemical	X	B
rosa	I-Chemical	X	I
sinensis	I-Chemical	NOUN	O
roots	O	NOUN	B
extract	O	NOUN	O
(	O	PUNCT	O
100	O	NUM	O
,	O	PUNCT	O
200	O	NUM	O
and	O	CCONJ	O
300	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
,	O	PUNCT	O
per	O	ADP	O
orally	O	ADV	B
)	O	PUNCT	O
attenuated	O	VERB	B
the	O	DET	O
effects	O	NOUN	B
.	O	PUNCT	O


Biochemical	O	ADJ	B
analysis	O	NOUN	I
of	O	ADP	O
brain	O	NOUN	B
revealed	O	VERB	B
that	O	SCONJ	O
the	O	DET	O
reserpine	B-Chemical	NOUN	B
treatment	O	NOUN	B
significantly	O	ADV	O
increased	O	VERB	B
lipid	O	NOUN	B
peroxidation	O	NOUN	I
and	O	CCONJ	O
decreased	O	VERB	B
levels	O	NOUN	B
of	O	ADP	O
superoxide	B-Chemical	NOUN	B
dismutase	O	NOUN	I
(	O	PUNCT	O
SOD	O	NOUN	B
),	O	PUNCT	O
catalase	O	NOUN	B
(	O	PUNCT	O
CAT	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
glutathione	B-Chemical	NOUN	B
reductase	O	NOUN	I
(	O	PUNCT	O
GSH	O	NOUN	B
),	O	PUNCT	O
an	O	DET	O
index	O	NOUN	O
of	O	ADP	O
oxidative	O	ADJ	B
stress	O	NOUN	I
process	O	NOUN	I
.	O	PUNCT	O


Coadministration	O	NOUN	B
of	O	ADP	O
extract	O	NOUN	B
significantly	O	ADV	O
reduced	O	VERB	B
the	O	DET	O
lipid	O	NOUN	B
peroxidation	O	NOUN	I
and	O	CCONJ	O
reversed	O	VERB	B
the	O	DET	O
decrease	O	NOUN	B
in	O	ADP	O
brain	O	NOUN	B
SOD	O	NOUN	B
,	O	PUNCT	O
CAT	O	NOUN	B
and	O	CCONJ	O
GSH	O	NOUN	B
levels	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
results	O	NOUN	B
of	O	ADP	O
the	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
suggested	O	VERB	O
that	O	SCONJ	O
Hibiscus	B-Chemical	PROPN	B
rosa	I-Chemical	X	I
sinensis	I-Chemical	NOUN	I
had	O	AUX	O
a	O	DET	O
protective	O	ADJ	O
role	O	NOUN	O
against	O	ADP	O
reserpine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
orofacial	O	ADJ	B
dyskinesia	B-Disease	NOUN	I


Comparison	O	NOUN	B
of	O	ADP	O
aqueous	O	ADJ	B
and	O	CCONJ	O
gellan	O	NOUN	B
ophthalmic	O	ADJ	O
timolol	B-Chemical	NOUN	B
with	O	ADP	O
placebo	O	NOUN	B
on	O	ADP	O
the	O	DET	O
24	O	NUM	O
-	O	PUNCT	O
hour	O	NOUN	B
heart	O	NOUN	B
rate	O	NOUN	I
response	O	NOUN	I
in	O	ADP	O
patients	O	NOUN	B
on	O	ADP	O
treatment	O	NOUN	B
for	O	ADP	O
glaucoma	B-Disease	NOUN	B
.	O	PUNCT	O


PURPOSE	O	NOUN	B
:	O	PUNCT	O
Topical	O	ADJ	B
beta	O	NOUN	I
-	O	PUNCT	O
blocker	O	NOUN	B
treatment	O	NOUN	B
is	O	AUX	O
routine	O	ADJ	O
therapy	O	NOUN	B
in	O	ADP	O
the	O	DET	O
management	O	NOUN	B
of	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
glaucoma	B-Disease	NOUN	B
.	O	PUNCT	O


Therapy	O	NOUN	B
results	O	VERB	B
in	O	ADP	O
systemic	O	ADJ	B
absorption	O	NOUN	I
,	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
degree	O	NOUN	B
of	O	ADP	O
reduction	O	NOUN	B
of	O	ADP	O
resting	O	VERB	B
and	O	CCONJ	O
peak	O	ADJ	B
heart	O	NOUN	I
rate	O	NOUN	I
has	O	AUX	O
not	O	PART	O
been	O	AUX	O
quantified	O	VERB	B
.	O	PUNCT	O


DESIGN	O	NOUN	O
:	O	PUNCT	O
This	O	DET	O
trial	O	NOUN	B
evaluated	O	VERB	B
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
placebo	O	NOUN	B
,	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
%	O	NOUN	O
aqueous	O	ADJ	B
timolol	B-Chemical	NOUN	B
(	O	PUNCT	O
timolol	B-Chemical	NOUN	B
solution	O	NOUN	I
)	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
0	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
%	O	NOUN	O
timolol	B-Chemical	NOUN	B
suspension	O	NOUN	B
that	O	PRON	O
forms	O	VERB	O
a	O	DET	O
gel	O	NOUN	B
on	O	ADP	O
application	O	NOUN	O
to	O	ADP	O
the	O	DET	O
conjunctiva	O	NOUN	B
(	O	PUNCT	O
timolol	B-Chemical	NOUN	B
gellan	O	NOUN	B
)	O	PUNCT	O
on	O	ADP	O
the	O	DET	O
24	O	NUM	O
-	O	PUNCT	O
hour	O	NOUN	B
heart	O	NOUN	B
rate	O	NOUN	I
in	O	ADP	O
patients	O	NOUN	B
currently	O	ADV	O
being	O	AUX	O
treated	O	VERB	B
for	O	ADP	O
glaucoma	B-Disease	NOUN	B
to	O	PART	O
quantify	O	VERB	B
the	O	DET	O
reduction	O	NOUN	B
in	O	ADP	O
mean	O	ADJ	O
heart	O	NOUN	O
rate	O	NOUN	O
.	O	PUNCT	O


METHODS	O	NOUN	O
:	O	PUNCT	O
Forty	O	NUM	B
-	O	PUNCT	O
three	O	NUM	O
Caucasian	O	ADJ	B
patients	O	NOUN	B
with	O	ADP	O
primary	O	ADJ	B
open-angle	B-Disease	ADJ	I
glaucoma	I-Disease	NOUN	I
or	O	CCONJ	O
ocular	B-Disease	ADJ	B
hypertension	I-Disease	NOUN	I
with	O	ADP	O
a	O	DET	O
mean	O	NOUN	O
(+/-	O	PUNCT	O
SD	O	NOUN	B
)	O	PUNCT	O
age	O	NOUN	B
of	O	ADP	O
63	O	NUM	O
(+/-	O	PUNCT	O
8	O	NUM	O
)	O	PUNCT	O
years	O	NOUN	B
were	O	AUX	O
randomized	O	VERB	B
and	O	CCONJ	O
crossed	O	VERB	O
over	O	ADP	O
in	O	ADP	O
a	O	DET	O
double	O	ADV	B
-	O	PUNCT	O
masked	O	VERB	B
manner	O	NOUN	O
to	O	PART	O
14	O	NUM	O
days	O	NOUN	B
of	O	ADP	O
treatment	O	NOUN	B
with	O	ADP	O
placebo	O	NOUN	B
(	O	PUNCT	O
morning	O	NOUN	B
and	O	CCONJ	O
evening	O	NOUN	B
in	O	ADP	O
both	O	DET	O
eyes	O	NOUN	B
),	O	PUNCT	O
timolol	B-Chemical	NOUN	B
solution	O	NOUN	O
(	O	PUNCT	O
morning	O	NOUN	B
and	O	CCONJ	O
evening	O	NOUN	B
in	O	ADP	O
both	O	DET	O
eyes	O	NOUN	B
),	O	PUNCT	O
or	O	CCONJ	O
timolol	B-Chemical	NOUN	B
gellan	O	NOUN	B
(	O	PUNCT	O
morning	O	NOUN	B
in	O	ADP	O
both	O	DET	O
eyes	O	NOUN	B
with	O	ADP	O
placebo	O	NOUN	B
in	O	ADP	O
the	O	DET	O
evening	O	NOUN	B
).	O	PUNCT	B
On	O	ADP	O
the	O	DET	O
13th	O	ADJ	O
day	O	NOUN	B
of	O	ADP	O
each	O	DET	O
period	O	NOUN	B
,	O	PUNCT	O
heart	O	NOUN	B
rate	O	NOUN	I
was	O	AUX	O
recorded	O	VERB	O
continuously	O	ADV	O
during	O	ADP	O
a	O	DET	O
typical	O	ADJ	B
,	O	PUNCT	O
ambulant	O	ADJ	B
24	O	NUM	O
-	O	PUNCT	O
hour	O	NOUN	B
period	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
Both	O	CCONJ	O
timolol	B-Chemical	VERB	B
solution	O	NOUN	B
and	O	CCONJ	O
timolol	B-Chemical	NOUN	B
gellan	O	NOUN	B
reduced	O	VERB	B
the	O	DET	O
mean	O	ADJ	O
24	O	NUM	O
-	O	PUNCT	O
hour	O	NOUN	B
heart	O	NOUN	B
rate	O	NOUN	I
compared	O	VERB	B
with	O	ADP	O
placebo	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
or	O	CCONJ	O
=.	O	NOUN	O
001	O	NUM	O
),	O	PUNCT	O
and	O	CCONJ	O
this	O	DET	O
reduction	O	NOUN	B
was	O	AUX	O
most	O	ADV	O
pronounced	O	ADJ	O
during	O	ADP	O
the	O	DET	O
daytime	O	NOUN	B
(-	O	PUNCT	O
7	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
%	O	NOUN	O
change	O	NOUN	B
in	O	ADP	O
mean	O	ADJ	O
heart	O	NOUN	O
rate	O	NOUN	O
,-	O	PUNCT	O
5	O	NUM	O
.	O	PUNCT	O


7	O	NUM	O
beats	O	NOUN	B
/	O	SYM	O
min	O	NOUN	B
).	O	PUNCT	O
Timolol	B-Chemical	PROPN	B
gellan	O	NOUN	B
showed	O	VERB	O
a	O	DET	O
numerically	O	ADV	B
but	O	CCONJ	O
not	O	PART	O
significantly	O	ADV	O
smaller	O	ADJ	O
reduction	O	NOUN	B
in	O	ADP	O
24	O	NUM	O
-	O	PUNCT	O
hour	O	NOUN	B
heart	O	NOUN	B
rate	O	NOUN	I
,	O	PUNCT	O
compared	O	VERB	B
with	O	ADP	O
timolol	B-Chemical	NOUN	B
solution	O	NOUN	B
.	O	PUNCT	O


During	O	ADP	O
the	O	DET	O
night	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
mean	O	NOUN	O
12	O	NUM	O
-	O	PUNCT	O
hour	O	NOUN	B
heart	O	NOUN	B
rate	O	NOUN	I
on	O	ADP	O
placebo	O	NOUN	B
and	O	CCONJ	O
timolol	B-Chemical	NOUN	B
gellan	O	NOUN	B
were	O	AUX	O
both	O	CCONJ	O
significantly	O	ADV	O
less	O	ADJ	O
than	O	ADP	O
on	O	ADP	O
timolol	B-Chemical	NOUN	B
solution	O	NOUN	B
;	O	PUNCT	O
the	O	DET	O
difference	O	NOUN	O
between	O	ADP	O
solution	O	NOUN	B
and	O	CCONJ	O
gellan	O	NOUN	B
treatments	O	NOUN	B
was	O	AUX	O
statistically	O	ADV	B
significant	O	ADJ	I
(	O	PUNCT	O
P	O	NOUN	O
=.	O	NOUN	O
01	O	NUM	O
).	O	PUNCT	O
CONCLUSIONS	O	NOUN	O
:	O	PUNCT	O
Both	O	CCONJ	O
timolol	B-Chemical	VERB	B
solution	O	NOUN	B
and	O	CCONJ	O
timolol	B-Chemical	NOUN	B
gellan	O	NOUN	B
decrease	O	VERB	B
the	O	DET	O
mean	O	ADJ	O
24	O	NUM	O
-	O	PUNCT	O
hour	O	NOUN	B
heart	O	NOUN	B
rate	O	NOUN	I
compared	O	VERB	B
with	O	ADP	O
placebo	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
response	O	NOUN	B
was	O	AUX	O
most	O	ADV	O
pronounced	O	ADJ	O
during	O	ADP	O
the	O	DET	O
active	O	ADJ	B
daytime	O	NOUN	I
period	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
data	O	NOUN	B
quantify	O	VERB	I
the	O	DET	O
modest	O	ADJ	O
bradycardia	B-Disease	NOUN	B
associated	O	VERB	B
with	O	ADP	I
ophthalmic	O	ADJ	B
beta	O	NOUN	B
-	O	PUNCT	O
blocker	O	NOUN	B
therapy	O	NOUN	B
in	O	ADP	O
a	O	DET	O
typical	O	ADJ	O
patient	O	NOUN	B
population	O	NOUN	I
on	O	ADP	O
therapy	O	NOUN	B
for	O	ADP	O
glaucoma	B-Disease	NOUN	B


5	B-Chemical	NUM	O
flourouracil	I-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
apical	B-Disease	ADJ	B
ballooning	I-Disease	NOUN	I
syndrome	I-Disease	NOUN	I
:	O	PUNCT	O
a	O	DET	O
case	O	NOUN	B
report	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
apical	B-Disease	ADJ	B
ballooning	I-Disease	NOUN	I
syndrome	I-Disease	NOUN	I
(	O	PUNCT	O
ABS	B-Disease	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
a	O	DET	O
recently	O	ADV	O
described	O	VERB	O
stress	O	NOUN	B
-	O	PUNCT	O
mediated	O	VERB	B
acute	B-Disease	ADJ	B
cardiac	I-Disease	ADJ	I
syndrome	I-Disease	NOUN	I
characterized	O	VERB	B
by	O	ADP	O
transient	O	ADJ	B
wall	O	NOUN	I
-	O	PUNCT	O
motion	O	NOUN	B
abnormalities	O	NOUN	O
involving	O	VERB	O
the	O	DET	O
apex	O	NOUN	B
and	O	CCONJ	O
midventricle	O	NOUN	B
with	O	ADP	O
hyperkinesis	B-Disease	NOUN	B
of	O	ADP	O
the	O	DET	O
basal	O	ADJ	B
left	O	ADJ	I
ventricular	O	ADJ	I
(	O	PUNCT	I
LV	O	NOUN	O
)	O	PUNCT	O
segments	O	NOUN	B
without	O	ADP	O
obstructive	O	ADJ	B
epicardial	B-Disease	ADJ	O
coronary	I-Disease	ADJ	O
disease	I-Disease	NOUN	O
.	O	PUNCT	O


Cardiotoxicity	B-Disease	NOUN	B
is	O	AUX	O
not	O	PART	O
an	O	DET	O
uncommon	O	ADJ	B
adverse	O	ADJ	B
effect	O	NOUN	I
of	O	ADP	O
chemotherapeutic	O	ADJ	B
agents	O	NOUN	I
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
there	O	PRON	O
are	O	AUX	O
no	O	DET	O
reports	O	NOUN	O
of	O	ADP	O
ABS	B-Disease	NOUN	B
secondary	O	ADJ	B
to	O	PART	I
chemotherapeutic	O	ADJ	B
agents	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
describe	O	VERB	O
the	O	DET	O
case	O	NOUN	B
of	O	ADP	O
a	O	DET	O
woman	O	NOUN	B
who	O	PRON	O
developed	O	VERB	O
the	O	DET	O
syndrome	O	NOUN	B
after	O	ADP	O
chemotherapy	O	NOUN	B
for	O	ADP	O
metastatic	O	ADJ	B
cancer	B-Disease	NOUN	I
.	O	PUNCT	O


A	O	DET	O
79	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
woman	O	NOUN	B
presented	O	VERB	O
with	O	ADP	O
typical	O	ADJ	O
ischemic	B-Disease	ADJ	B
chest	B-Disease	ADJ	I
pain	I-Disease	NOUN	I
,	O	PUNCT	O
elevated	O	ADJ	B
cardiac	O	ADJ	O
enzymes	O	NOUN	O
with	O	ADP	O
significant	O	ADJ	O
ST	O	PROPN	B
-	O	PUNCT	O
segment	O	NOUN	B
abnormalities	O	NOUN	B
on	O	ADP	O
her	O	PRON	O
electrocardiogram	O	NOUN	B
.	O	PUNCT	O


She	O	PRON	O
underwent	O	VERB	O
recent	O	ADJ	O
chemotherapy	O	NOUN	B
with	O	ADP	O
fluorouracil	B-Chemical	NOUN	B
for	O	ADP	O
metastatic	O	ADJ	B
colorectal	B-Disease	NOUN	I
cancer	I-Disease	NOUN	I
.	O	PUNCT	O


Echocardiography	O	NOUN	B
revealed	O	VERB	O
a	O	DET	O
wall	O	NOUN	B
-	O	PUNCT	O
motion	O	NOUN	B
abnormality	O	NOUN	B
involving	O	VERB	O
the	O	DET	O
apical	O	ADJ	B
and	O	CCONJ	O
periapical	O	ADJ	B
segments	O	NOUN	O
which	O	DET	O
appeared	O	VERB	O
akinetic	B-Disease	ADJ	B
.	O	PUNCT	O


Coronary	O	ADJ	B
angiography	O	NOUN	I
revealed	O	VERB	O
no	O	DET	O
obstructive	O	ADJ	O
coronary	O	ADJ	B
lesions	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
patient	O	NOUN	B
was	O	AUX	O
stabilized	O	VERB	B
with	O	ADP	O
medical	O	ADJ	B
therapy	O	NOUN	I
.	O	PUNCT	O


Four	O	NUM	O
weeks	O	NOUN	B
later	O	ADV	O
she	O	PRON	O
remained	O	VERB	O
completely	O	ADV	O
asymptomatic	O	ADJ	B
.	O	PUNCT	O


Echocardiogram	O	NOUN	B
revealed	O	VERB	O
a	O	DET	O
normal	O	ADJ	O
ejection	O	NOUN	O
fraction	O	NOUN	O
and	O	CCONJ	O
a	O	DET	O
resolution	O	NOUN	B
of	O	ADP	O
the	O	DET	O
apical	O	ADJ	B
akinesis	B-Disease	NOUN	I
.	O	PUNCT	O


Pathogenetic	O	ADJ	B
mechanisms	O	NOUN	O
of	O	ADP	O
cardiac	B-Disease	ADJ	B
complications	I-Disease	NOUN	I
in	O	ADP	O
cancer	B-Disease	NOUN	B
patients	O	NOUN	B
undergoing	O	VERB	O
chemotherapy	O	NOUN	B
include	O	VERB	O
coronary	B-Disease	ADJ	B
vasospasm	I-Disease	NOUN	I
,	O	PUNCT	O
endothelial	O	ADJ	B
damage	O	NOUN	I
and	O	CCONJ	O
consequent	O	ADJ	O
thrombus	B-Disease	NOUN	B
formation	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
our	O	PRON	O
patient	O	NOUN	B
,	O	PUNCT	O
both	O	CCONJ	O
supraphysiologic	O	ADJ	B
levels	O	NOUN	B
of	O	ADP	O
plasma	O	NOUN	B
catecholamines	B-Chemical	NOUN	O
and	O	CCONJ	O
stress	O	NOUN	B
related	O	ADJ	O
neuropeptides	O	NOUN	B
caused	O	VERB	O
by	O	ADP	O
cancer	B-Disease	NOUN	B
diagnosis	O	NOUN	I
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
chemotherapy	O	NOUN	B
may	O	AUX	O
have	O	AUX	O
contributed	O	VERB	O
the	O	DET	O
development	O	NOUN	B
of	O	ADP	O
ABS	B-Disease	PROPN	B


Reduction	O	NOUN	B
of	O	ADP	O
pain	B-Disease	NOUN	B
during	O	ADP	O
induction	O	NOUN	B
with	O	ADP	O
target	O	NOUN	B
-	O	PUNCT	O
controlled	O	VERB	B
propofol	B-Chemical	NOUN	B
and	O	CCONJ	O
remifentanil	B-Chemical	NOUN	B
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
:	O	PUNCT	O
Pain	B-Disease	ADV	B
on	O	ADP	O
injection	O	NOUN	B
of	O	ADP	O
propofol	B-Chemical	NOUN	B
is	O	AUX	O
unpleasant	O	ADJ	B
.	O	PUNCT	O


We	O	PRON	O
hypothesized	O	VERB	O
that	O	SCONJ	O
propofol	B-Chemical	NOUN	B
infusion	O	NOUN	B
pain	B-Disease	NOUN	I
might	O	AUX	O
be	O	AUX	O
prevented	O	VERB	B
by	O	ADP	O
infusing	O	VERB	B
remifentanil	B-Chemical	NOUN	B
before	O	ADP	O
starting	O	VERB	O
the	O	DET	O
propofol	B-Chemical	NOUN	B
infusion	O	NOUN	B
in	O	ADP	O
a	O	DET	O
clinical	O	ADJ	B
setting	O	NOUN	I
where	O	SCONJ	O
target	O	NOUN	B
-	O	PUNCT	O
controlled	O	VERB	B
infusions	O	NOUN	B
(	O	PUNCT	O
TCI	O	NOUN	B
)	O	PUNCT	O
of	O	ADP	O
both	O	DET	O
drugs	O	NOUN	B
were	O	AUX	O
used	O	VERB	O
.	O	PUNCT	O


A	O	DET	O
prospective	O	ADJ	B
,	O	PUNCT	O
randomized	O	ADJ	B
,	O	PUNCT	O
double	O	ADJ	B
-	O	PUNCT	O
blind	O	ADJ	B
,	O	PUNCT	O
placebo	O	NOUN	B
-	O	PUNCT	O
controlled	O	VERB	B
trial	O	NOUN	I
was	O	AUX	O
performed	O	VERB	O
to	O	PART	O
determine	O	VERB	O
the	O	DET	O
effect	O	NOUN	B
-	O	PUNCT	O
site	O	NOUN	B
concentration	O	NOUN	B
(	O	PUNCT	O
Ce	O	NOUN	B
)	O	PUNCT	O
of	O	ADP	O
remifentanil	B-Chemical	NOUN	B
to	O	PART	O
prevent	O	VERB	B
the	O	DET	O
pain	B-Disease	NOUN	B
without	O	ADP	O
producing	O	VERB	O
complications	O	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
:	O	PUNCT	O
A	O	DET	O
total	O	NOUN	O
of	O	ADP	O
128	O	NUM	O
patients	O	NOUN	B
undergoing	O	VERB	O
general	O	ADJ	B
surgery	O	NOUN	I
were	O	AUX	O
randomly	O	ADV	O
allocated	O	VERB	O
to	O	PART	O
receive	O	VERB	O
normal	O	ADJ	B
saline	O	NOUN	I
(	O	PUNCT	O
control	O	NOUN	B
)	O	PUNCT	O
or	O	CCONJ	O
remifentanil	B-Chemical	NOUN	B
to	O	PART	O
a	O	DET	O
target	O	NOUN	B
Ce	O	NOUN	B
of	O	ADP	O
2	O	NUM	O
ng	O	NOUN	O
ml	O	NOUN	O
(-	O	PUNCT	O
1	O	NUM	O
)(	O	NOUN	O
R2	O	NOUN	O
),	O	PUNCT	O
4	O	NUM	O
ng	O	NOUN	O
ml	O	NOUN	O
(-	O	PUNCT	O
1	O	NUM	O
)(	O	NOUN	O
R4	O	NOUN	O
),	O	PUNCT	O
or	O	CCONJ	O
6	O	NUM	O
ng	O	NOUN	O
ml	O	NOUN	O
(-	O	PUNCT	O
1	O	NUM	O
)(	O	NOUN	O
R6	O	NOUN	O
)	O	PUNCT	O
administered	O	VERB	B
via	O	ADP	O
TCI	O	PROPN	B
.	O	PUNCT	O


After	O	ADP	O
the	O	DET	O
target	O	NOUN	B
Ce	O	NOUN	B
was	O	AUX	O
achieved	O	VERB	O
,	O	PUNCT	O
the	O	DET	O
infusion	O	NOUN	B
of	O	ADP	O
propofol	B-Chemical	NOUN	B
was	O	AUX	O
started	O	VERB	B
.	O	PUNCT	O


Remifentanil	B-Chemical	NOUN	B
-	O	PUNCT	O
related	O	VERB	B
complications	O	NOUN	B
were	O	AUX	O
assessed	O	VERB	B
during	O	ADP	O
the	O	DET	O
remifentanil	B-Chemical	NOUN	B
infusion	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
pain	B-Disease	NOUN	B
caused	O	VERB	O
by	O	ADP	O
propofol	B-Chemical	NOUN	B
was	O	AUX	O
evaluated	O	VERB	B
using	O	VERB	O
a	O	DET	O
four	O	NUM	B
-	O	PUNCT	O
point	O	NOUN	B
scale	O	NOUN	I
during	O	ADP	O
the	O	DET	O
propofol	B-Chemical	NOUN	B
infusion	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
The	O	DET	O
incidence	O	NOUN	B
of	O	ADP	O
pain	B-Disease	NOUN	B
was	O	AUX	O
significantly	O	ADV	O
lower	O	ADJ	O
in	O	ADP	O
Groups	O	NOUN	B
R4	O	NOUN	I
and	O	CCONJ	O
R6	O	NOUN	O
than	O	ADP	O
in	O	ADP	O
the	O	DET	O
control	O	NOUN	B
and	O	CCONJ	O
R2	O	NOUN	O
groups	O	NOUN	B
(	O	PUNCT	O
12	O	NUM	O
/	O	SYM	O
32	O	NUM	O
and	O	CCONJ	O
6	O	NUM	O
/	O	SYM	O
31	O	NUM	O
vs	O	CCONJ	O
26	O	NUM	O
/	O	SYM	O
31	O	NUM	O
and	O	CCONJ	O
25	O	NUM	O
/	O	SYM	O
32	O	NUM	O
,	O	PUNCT	O
respectively	O	ADV	O
,	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


001	O	NUM	O
).	O	PUNCT	B
Pain	B-Disease	NOUN	I
was	O	AUX	O
less	O	ADV	O
severe	O	ADJ	B
in	O	ADP	O
Groups	O	NOUN	B
R4	O	NOUN	I
and	O	CCONJ	O
R6	O	NOUN	O
than	O	ADP	O
in	O	ADP	O
the	O	DET	O
control	O	NOUN	B
and	O	CCONJ	O
R2	O	NOUN	O
groups	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


001	O	NUM	O
).	O	PUNCT	O
However	O	ADV	O
,	O	PUNCT	O
both	O	DET	O
incidence	O	NOUN	B
and	O	CCONJ	O
severity	O	NOUN	B
of	O	ADP	O
pain	B-Disease	NOUN	B
were	O	AUX	O
not	O	PART	O
different	O	ADJ	O
between	O	ADP	O
Groups	O	NOUN	B
R4	O	NOUN	O
and	O	CCONJ	O
R6	O	NOUN	B
.	O	PUNCT	O


No	O	DET	B
significant	O	ADJ	I
complications	O	NOUN	B
were	O	AUX	O
observed	O	VERB	O
during	O	ADP	O
the	O	DET	O
study	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
:	O	PUNCT	O
During	O	ADP	O
induction	O	NOUN	B
of	O	ADP	O
anaesthesia	O	NOUN	O
with	O	ADP	O
TCI	O	NOUN	B
of	O	ADP	O
propofol	B-Chemical	NOUN	B
and	O	CCONJ	O
remifentanil	B-Chemical	NOUN	B
,	O	PUNCT	O
a	O	DET	O
significant	O	ADJ	O
reduction	O	NOUN	B
in	O	ADP	O
propofol	B-Chemical	NOUN	B
infusion	O	NOUN	B
pain	B-Disease	NOUN	O
was	O	AUX	O
achieved	O	VERB	O
without	O	ADP	O
significant	O	ADJ	O
complications	O	NOUN	B
by	O	ADP	O
prior	O	ADJ	O
administration	O	NOUN	B
of	O	ADP	O
remifentanil	B-Chemical	NOUN	B


Prenatal	O	ADJ	B
exposure	O	NOUN	O
to	O	PART	O
fluoxetine	B-Chemical	NOUN	B
induces	O	VERB	O
fetal	B-Disease	ADJ	B
pulmonary	I-Disease	ADJ	I
hypertension	I-Disease	NOUN	I
in	O	ADP	O
the	O	DET	O
rat	O	NOUN	B
.	O	PUNCT	O


RATIONALE	O	NOUN	B
:	O	PUNCT	O
Fluoxetine	B-Chemical	NOUN	B
is	O	AUX	O
a	O	DET	O
selective	O	ADJ	O
serotonin	B-Chemical	NOUN	B
reuptake	O	NOUN	I
inhibitor	O	NOUN	I
antidepressant	O	NOUN	B
widely	O	ADV	O
used	O	VERB	O
by	O	ADP	O
pregnant	O	ADJ	B
women	O	NOUN	I
.	O	PUNCT	O


Epidemiological	O	ADJ	B
data	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
fluoxetine	B-Chemical	NOUN	B
exposure	O	NOUN	B
prenatally	O	ADV	B
increases	O	VERB	B
the	O	DET	O
prevalence	O	NOUN	B
of	O	ADP	O
persistent	O	ADJ	B
pulmonary	B-Disease	ADJ	B
hypertension	I-Disease	NOUN	I
syndrome	I-Disease	NOUN	I
of	O	ADP	O
the	O	DET	O
newborn	O	ADJ	B
.	O	PUNCT	O


The	O	DET	O
mechanism	O	NOUN	B
responsible	O	ADJ	O
for	O	ADP	O
this	O	DET	O
effect	O	NOUN	B
is	O	AUX	O
unclear	O	ADJ	B
and	O	CCONJ	O
paradoxical	O	ADJ	B
,	O	PUNCT	O
considering	O	VERB	O
the	O	DET	O
current	O	ADJ	O
evidence	O	NOUN	B
of	O	ADP	O
a	O	DET	O
pulmonary	B-Disease	ADJ	B
hypertension	I-Disease	NOUN	I
protective	O	ADJ	O
fluoxetine	B-Chemical	NOUN	B
effect	O	NOUN	B
in	O	ADP	O
adult	O	ADJ	B
rodents	O	NOUN	B
.	O	PUNCT	O


OBJECTIVES	O	NOUN	O
:	O	PUNCT	O
To	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
fluoxetine	B-Chemical	NOUN	B
effect	O	NOUN	B
on	O	ADP	O
fetal	O	ADJ	B
rat	O	NOUN	I
pulmonary	O	ADJ	B
vascular	O	ADJ	B
smooth	O	ADJ	I
muscle	O	NOUN	I
mechanical	O	ADJ	B
properties	O	NOUN	I
and	O	CCONJ	O
cell	O	NOUN	B
proliferation	O	NOUN	I
rate	O	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
:	O	PUNCT	O
Pregnant	O	ADJ	B
rats	O	NOUN	I
were	O	AUX	O
treated	O	VERB	B
with	O	ADP	I
fluoxetine	B-Chemical	NOUN	B
(	O	PUNCT	O
10	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
)	O	PUNCT	O
from	O	ADP	O
Day	O	PROPN	B
11	O	NUM	O
through	O	ADP	O
Day	O	PROPN	B
21	O	NUM	O
of	O	ADP	O
gestation	O	NOUN	B
.	O	PUNCT	O


MEASUREMENTS	O	NOUN	O
AND	O	CCONJ	O
MAIN	O	NOUN	O
RESULTS	O	NOUN	O
:	O	PUNCT	O
Fetuses	O	NOUN	B
were	O	AUX	O
delivered	O	VERB	O
by	O	ADP	O
cesarean	O	NOUN	B
section	O	NOUN	I
.	O	PUNCT	O


As	O	ADP	O
compared	O	VERB	B
with	O	ADP	O
controls	O	NOUN	B
,	O	PUNCT	O
fluoxetine	B-Chemical	NOUN	B
exposure	O	NOUN	B
resulted	O	VERB	O
in	O	ADP	O
fetal	B-Disease	ADJ	B
pulmonary	I-Disease	ADJ	I
hypertension	I-Disease	NOUN	I
as	O	ADP	O
evidenced	O	VERB	O
by	O	ADP	O
an	O	DET	O
increase	O	NOUN	B
in	O	ADP	O
the	O	DET	O
weight	O	NOUN	B
ratio	O	NOUN	I
of	O	ADP	O
the	O	DET	O
right	O	ADJ	B
ventricle	O	NOUN	I
to	O	ADP	O
the	O	DET	O
left	O	ADJ	B
ventricle	O	NOUN	I
plus	O	CCONJ	I
septum	O	NOUN	I
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


02	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
by	O	ADP	O
an	O	DET	O
increase	O	NOUN	B
in	O	ADP	O
pulmonary	O	ADJ	B
arterial	O	ADJ	I
medial	O	ADJ	I
thickness	O	NOUN	I
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


01	O	NUM	O
).	O	PUNCT	O
Postnatal	O	NOUN	B
mortality	O	NOUN	B
was	O	AUX	O
increased	O	VERB	B
among	O	ADP	O
experimental	O	ADJ	B
animals	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
arterial	O	ADJ	B
oxygen	B-Chemical	NOUN	I
saturation	O	NOUN	I
was	O	AUX	O
96	O	NUM	O
+/-	O	CCONJ	O
1	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
1	O	NUM	O
-	O	PUNCT	O
day	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
control	O	NOUN	I
animals	O	NOUN	I
and	O	CCONJ	O
significantly	O	ADV	O
lower	O	ADJ	O
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


01	O	NUM	O
)	O	PUNCT	O
in	O	ADP	O
fluoxetine	B-Chemical	NOUN	B
-	O	PUNCT	O
exposed	O	VERB	B
pups	O	NOUN	B
(	O	PUNCT	O
79	O	NUM	O
+/-	O	CCONJ	O
2	O	NUM	O
%).	O	NOUN	B
In	O	X	B
vitro	O	X	I
,	O	PUNCT	O
fluoxetine	B-Chemical	NOUN	B
induced	O	VERB	B
pulmonary	O	ADJ	B
arterial	O	ADJ	I
muscle	O	NOUN	I
contraction	O	NOUN	I
in	O	ADP	O
fetal	O	ADJ	B
,	O	PUNCT	O
but	O	CCONJ	O
not	O	PART	O
adult	O	ADJ	B
,	O	PUNCT	O
animals	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


01	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
reduced	O	VERB	B
serotonin	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
contraction	O	NOUN	B
at	O	ADP	O
both	O	DET	O
ages	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


01	O	NUM	O
).	O	PUNCT	O
After	O	ADP	O
in	O	ADP	O
utero	O	ADJ	B
exposure	O	NOUN	B
to	O	PART	O
a	O	DET	O
low	O	ADJ	B
fluoxetine	B-Chemical	NOUN	B
concentration	O	NOUN	B
the	O	DET	O
pulmonary	O	ADJ	B
arterial	O	ADJ	I
smooth	O	ADJ	I
muscle	O	NOUN	I
cell	O	NOUN	I
proliferation	O	NOUN	I
rate	O	NOUN	B
was	O	AUX	O
significantly	O	ADV	O
increased	O	VERB	B
in	O	ADP	O
fetal	O	ADJ	B
,	O	PUNCT	O
but	O	CCONJ	O
not	O	PART	O
adult	O	ADJ	B
,	O	PUNCT	O
cells	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


01	O	NUM	O
).	O	PUNCT	O
CONCLUSIONS	O	NOUN	O
:	O	PUNCT	O
In	O	ADP	O
contrast	O	NOUN	O
to	O	PART	O
the	O	DET	O
adult	O	NOUN	B
,	O	PUNCT	O
fluoxetine	B-Chemical	NOUN	B
exposure	O	NOUN	B
in	O	ADP	O
utero	O	NOUN	B
induces	O	VERB	O
pulmonary	B-Disease	ADJ	B
hypertension	I-Disease	NOUN	I


Syncope	B-Disease	NOUN	B
and	O	CCONJ	O
QT	B-Disease	NOUN	B
prolongation	I-Disease	NOUN	O
among	O	ADP	O
patients	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
methadone	B-Chemical	NOUN	B
for	O	ADP	O
heroin	B-Chemical	NOUN	B
dependence	O	NOUN	B
in	O	ADP	O
the	O	DET	O
city	O	NOUN	B
of	O	ADP	O
Copenhagen	O	PROPN	B
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
:	O	PUNCT	O
Methadone	B-Chemical	NOUN	B
is	O	AUX	O
prescribed	O	VERB	B
to	O	PART	O
heroin	B-Chemical	NOUN	B
addicts	O	NOUN	B
to	O	PART	O
decrease	O	VERB	B
illicit	O	NOUN	B
opioid	O	NOUN	I
use	O	NOUN	I
.	O	PUNCT	O


Prolongation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
QT	O	NOUN	B
interval	O	NOUN	I
in	O	ADP	O
the	O	DET	O
ECG	O	PROPN	B
of	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
torsade	B-Disease	NOUN	B
de	I-Disease	X	I
pointes	I-Disease	X	I
(	O	PUNCT	O
TdP	B-Disease	NOUN	B
)	O	PUNCT	O
has	O	AUX	O
been	O	AUX	O
reported	O	VERB	O
in	O	ADP	O
methadone	B-Chemical	NOUN	B
users	O	NOUN	B
.	O	PUNCT	O


As	O	ADP	O
heroin	B-Chemical	NOUN	B
addicts	O	NOUN	B
sometimes	O	ADV	O
faint	O	ADJ	O
while	O	SCONJ	O
using	O	VERB	O
illicit	O	ADJ	B
drugs	O	NOUN	I
,	O	PUNCT	O
doctors	O	NOUN	B
might	O	AUX	O
attribute	O	VERB	O
too	O	ADV	O
many	O	ADJ	O
episodes	O	NOUN	B
of	O	ADP	O
syncope	B-Disease	NOUN	B
to	O	ADP	O
illicit	O	NOUN	B
drug	O	NOUN	I
use	O	NOUN	I
and	O	CCONJ	O
thereby	O	ADV	O
underestimate	O	VERB	O
the	O	DET	O
incidence	O	NOUN	B
of	O	ADP	O
TdP	B-Disease	NOUN	B
in	O	ADP	O
this	O	DET	O
special	O	ADJ	O
population	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
high	O	ADJ	B
mortality	O	NOUN	B
in	O	ADP	O
this	O	DET	O
population	O	NOUN	B
may	O	AUX	O
,	O	PUNCT	O
in	O	ADP	O
part	O	NOUN	O
,	O	PUNCT	O
be	O	AUX	O
caused	O	VERB	O
by	O	ADP	O
the	O	DET	O
proarrhythmic	O	ADJ	B
effect	O	NOUN	I
of	O	ADP	O
methadone	B-Chemical	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
:	O	PUNCT	O
In	O	ADP	O
this	O	DET	O
cross	O	NOUN	B
-	O	PUNCT	O
sectional	O	ADJ	B
study	O	NOUN	I
interview	O	NOUN	B
,	O	PUNCT	O
ECGs	O	NOUN	B
and	O	CCONJ	O
blood	O	NOUN	B
samples	O	NOUN	I
were	O	AUX	O
collected	O	VERB	O
in	O	ADP	O
a	O	DET	O
population	O	NOUN	B
of	O	ADP	O
adult	O	ADJ	B
heroin	B-Chemical	NOUN	B
addicts	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
methadone	B-Chemical	NOUN	B
or	O	CCONJ	O
buprenorphine	B-Chemical	NOUN	B
on	O	ADP	O
a	O	DET	O
daily	O	ADJ	O
basis	O	NOUN	O
.	O	PUNCT	O


Of	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
at	O	ADP	O
the	O	DET	O
Drug	O	PROPN	B
Addiction	O	PROPN	I
Service	O	PROPN	I
in	O	ADP	O
the	O	DET	O
municipal	O	NOUN	B
of	O	ADP	O
Copenhagen	O	PROPN	B
,	O	PUNCT	O
450	O	NUM	O
(	O	PUNCT	O
approximately	O	ADV	O
52	O	NUM	O
%)	O	NOUN	O
were	O	AUX	O
included	O	VERB	O
.	O	PUNCT	O


The	O	DET	O
QT	O	NOUN	B
interval	O	NOUN	I
was	O	AUX	O
estimated	O	VERB	O
from	O	ADP	O
12	O	NUM	O
lead	O	NOUN	B
ECGs	O	NOUN	I
.	O	PUNCT	O


All	O	DET	O
participants	O	NOUN	B
were	O	AUX	O
interviewed	O	VERB	B
about	O	ADP	O
any	O	DET	O
experience	O	NOUN	B
of	O	ADP	O
syncope	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
association	O	NOUN	B
between	O	ADP	O
opioid	O	NOUN	B
dose	O	NOUN	B
and	O	CCONJ	O
QT	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
methadone	B-Chemical	NOUN	B
dose	O	NOUN	B
and	O	CCONJ	O
reporting	O	NOUN	B
of	O	ADP	O
syncope	B-Disease	NOUN	B
was	O	AUX	O
assessed	O	VERB	B
using	O	VERB	O
multivariate	O	ADJ	B
linear	O	ADJ	I
regression	O	NOUN	I
and	O	CCONJ	O
logistic	O	ADJ	B
regression	O	NOUN	I
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
Methadone	B-Chemical	NOUN	B
dose	O	NOUN	B
was	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
longer	O	ADJ	O
QT	O	NOUN	B
interval	O	NOUN	I
of	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


140	O	NUM	O
ms	O	NOUN	O
/	O	SYM	O
mg	O	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


002	O	NUM	O
).	O	PUNCT	O
No	O	DET	O
association	O	NOUN	B
between	O	ADP	O
buprenorphine	B-Chemical	NOUN	B
and	O	CCONJ	O
QTc	O	NOUN	B
was	O	AUX	O
found	O	VERB	O
.	O	PUNCT	O


Among	O	ADP	O
the	O	DET	O
subjects	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
methadone	B-Chemical	NOUN	B
,	O	PUNCT	O
28	O	NUM	O
%	O	NOUN	O
men	O	NOUN	B
and	O	CCONJ	O
32	O	NUM	O
%	O	NOUN	O
women	O	NOUN	B
had	O	AUX	O
prolonged	B-Disease	ADJ	B
QTc	I-Disease	NOUN	B
interval	I-Disease	NOUN	I
.	O	PUNCT	O


of	O	ADP	O
the	O	DET	O
subjects	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
buprenorphine	B-Chemical	NOUN	B
had	O	AUX	O
QTc	O	NOUN	B
interval	O	NOUN	I
>	O	NOUN	O
0	O	NUM	O
.	O	PUNCT	O


440	O	NUM	O
s	O	NOUN	O
((	O	NOUN	O
1	O	NUM	O
/	O	SYM	O
2	O	NUM	B
)).	O	NOUN	O
A	O	NOUN	O
50	O	NUM	O
mg	O	NOUN	O
higher	O	ADJ	O
methadone	B-Chemical	NOUN	B
dose	O	NOUN	B
was	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
a	O	DET	O
1	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
1	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
to	O	PART	O
1	O	NUM	O
.	O	PUNCT	O


4	O	X	O
)	O	PUNCT	O
times	O	NOUN	O
higher	O	ADJ	O
odds	O	NOUN	B
for	O	ADP	O
syncope	B-Disease	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
:	O	PUNCT	O
Methadone	B-Chemical	NOUN	B
is	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
QT	B-Disease	NOUN	B
prolongation	I-Disease	NOUN	O
and	O	CCONJ	O
higher	O	ADJ	O
reporting	O	NOUN	B
of	O	ADP	O
syncope	B-Disease	NOUN	B
in	O	ADP	O
a	O	DET	O
population	O	NOUN	B
of	O	ADP	O
heroin	B-Chemical	NOUN	B


Peripheral	B-Disease	ADJ	B
neuropathy	I-Disease	NOUN	I
caused	O	VERB	O
by	O	ADP	O
high	O	ADJ	B
-	O	PUNCT	O
dose	O	NOUN	B
cytosine	B-Chemical	NOUN	B
arabinoside	I-Chemical	NOUN	I
treatment	O	NOUN	B
in	O	ADP	O
a	O	DET	O
patient	O	NOUN	B
with	O	ADP	O
acute	B-Disease	ADJ	B
myeloid	I-Disease	ADJ	I
leukemia	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
central	O	ADJ	B
nervous	O	ADJ	I
system	O	NOUN	I
toxicity	B-Disease	NOUN	B
of	O	ADP	O
high	O	ADJ	B
-	O	PUNCT	O
dose	O	NOUN	B
cytosine	B-Chemical	NOUN	B
arabinoside	I-Chemical	NOUN	I
is	O	AUX	O
well	O	ADV	O
recognized	O	VERB	O
,	O	PUNCT	O
but	O	CCONJ	O
the	O	DET	O
toxicity	B-Disease	NOUN	B
of	O	ADP	O
cytosine	B-Chemical	NOUN	B
arabinoside	I-Chemical	NOUN	I
in	O	ADP	O
the	O	DET	O
peripheral	O	ADJ	B
nervous	O	ADJ	I
system	O	NOUN	I
has	O	AUX	O
been	O	AUX	O
infrequently	O	ADV	O
reported	O	VERB	O
.	O	PUNCT	O


A	O	DET	O
49	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
Japanese	O	ADJ	B
man	O	NOUN	B
was	O	AUX	O
diagnosed	O	VERB	B
with	O	ADP	O
acute	B-Disease	ADJ	B
myeloid	I-Disease	ADJ	I
leukemia	I-Disease	NOUN	I
.	O	PUNCT	O


After	O	ADP	O
he	O	PRON	O
achieved	O	VERB	O
complete	O	ADJ	O
remission	O	NOUN	B
,	O	PUNCT	O
he	O	PRON	O
received	O	VERB	O
high	O	ADJ	B
-	O	PUNCT	O
dose	O	NOUN	B
cytosine	B-Chemical	NOUN	B
arabinoside	I-Chemical	NOUN	I
treatment	O	NOUN	B
(	O	PUNCT	O
2	O	NUM	O
g	O	NOUN	O
/	O	SYM	O
m2	O	NOUN	B
twice	O	ADV	O
a	O	DET	O
day	O	NOUN	B
for	O	ADP	O
5	O	NUM	O
days	O	NOUN	B
;	O	PUNCT	O
total	O	NOUN	O
,	O	PUNCT	O
20	O	NUM	O
g	O	NOUN	B
/	O	SYM	O
m2	O	NOUN	B
)	O	PUNCT	O
as	O	ADP	O
consolidation	O	NOUN	B
therapy	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
first	O	ADJ	O
course	O	NOUN	B
of	O	ADP	O
high	O	ADJ	B
-	O	PUNCT	O
dose	O	NOUN	B
cytosine	B-Chemical	NOUN	B
arabinoside	I-Chemical	NOUN	I
resulted	O	VERB	O
in	O	ADP	O
no	O	DET	O
unusual	O	ADJ	O
symptoms	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
on	O	ADP	O
day	O	NOUN	B
21	O	NUM	O
of	O	ADP	O
the	O	DET	O
second	O	ADJ	O
course	O	NOUN	B
of	O	ADP	O
treatment	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
patient	O	NOUN	B
complained	O	VERB	O
of	O	ADP	O
numbness	B-Disease	NOUN	B
in	O	ADP	O
his	O	PRON	O
right	O	ADJ	B
foot	O	NOUN	I
.	O	PUNCT	O


Electromyogram	O	NOUN	B
and	O	CCONJ	O
nerve	O	NOUN	B
-	O	PUNCT	O
conduction	O	NOUN	B
studies	O	NOUN	O
showed	O	VERB	O
peripheral	B-Disease	ADJ	B
neuropathy	I-Disease	NOUN	I
in	O	ADP	O
both	O	DET	O
peroneal	O	ADJ	B
nerves	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
neuropathy	B-Disease	NOUN	B
was	O	AUX	O
gradually	O	ADV	O
resolving	O	VERB	O
;	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
after	O	ADP	O
the	O	DET	O
patient	O	NOUN	B
received	O	VERB	O
allogeneic	O	ADJ	B
bone	O	NOUN	I
marrow	O	NOUN	I
transplantation	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
symptoms	O	NOUN	B
worsened	O	VERB	B
,	O	PUNCT	O
with	O	ADP	O
the	O	DET	O
development	O	NOUN	B
of	O	ADP	O
graft-versus-host	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
symptoms	O	NOUN	B
subsequently	O	ADV	O
responded	O	VERB	O
to	O	ADP	O
methylprednisolone	B-Chemical	NOUN	B
.	O	PUNCT	O


Although	O	SCONJ	O
the	O	DET	O
mechanisms	O	NOUN	B
of	O	ADP	O
peripheral	B-Disease	ADJ	B
neuropathy	I-Disease	NOUN	I
are	O	AUX	O
still	O	ADV	O
unclear	O	ADJ	B
,	O	PUNCT	O
high	O	ADJ	B
-	O	PUNCT	O
dose	O	NOUN	B
cytosine	B-Chemical	NOUN	B
arabinoside	I-Chemical	NOUN	I


Atorvastatin	B-Chemical	NOUN	B
prevented	O	VERB	B
and	O	CCONJ	O
reversed	O	VERB	O
dexamethasone	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
hypertension	B-Disease	NOUN	B
in	O	ADP	O
the	O	DET	O
rat	O	NOUN	B
.	O	PUNCT	O


To	O	PART	O
assess	O	VERB	O
the	O	DET	O
antioxidant	O	ADJ	B
effects	O	NOUN	O
of	O	ADP	O
atorvastatin	B-Chemical	NOUN	B
(	O	PUNCT	O
atorva	B-Chemical	NOUN	B
)	O	PUNCT	O
on	O	ADP	O
dexamethasone	B-Chemical	NOUN	B
(	O	PUNCT	O
dex	B-Chemical	NOUN	B
)-	O	ADJ	O
induced	O	VERB	B
hypertension	B-Disease	NOUN	B
,	O	PUNCT	O
60	O	NUM	O
male	O	NOUN	B
Sprague	O	PROPN	B
-	O	PUNCT	O
Dawley	O	NOUN	B
rats	O	NOUN	B
were	O	AUX	O
treated	O	VERB	B
with	O	ADP	I
atorva	B-Chemical	NOUN	B
30	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
/	O	PUNCT	O
day	O	NOUN	B
or	O	CCONJ	O
tap	O	NOUN	B
water	O	NOUN	I
for	O	ADP	O
15	O	NUM	O
days	O	NOUN	B
.	O	PUNCT	O


Dex	B-Chemical	NOUN	B
increased	O	VERB	B
systolic	O	NOUN	B
blood	O	NOUN	I
pressure	O	NOUN	I
(	O	PUNCT	O
SBP	O	NOUN	B
)	O	PUNCT	O
from	O	ADP	O
109	O	NUM	O
+/-	O	CCONJ	O
1	O	NUM	O
.	O	PUNCT	O


8	O	NUM	O
to	O	PART	O
135	O	NUM	O
+/-	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
mmHg	O	NOUN	B
and	O	CCONJ	O
plasma	O	NOUN	B
superoxide	B-Chemical	NOUN	I
(	O	PUNCT	O
5711	O	NUM	O
+/-	O	CCONJ	O
284	O	NUM	O
.	O	PUNCT	O


9	O	NUM	O
saline	O	NOUN	B
,	O	PUNCT	O
7931	O	NUM	O
+/-	O	CCONJ	O
392	O	NUM	O
.	O	PUNCT	O


8	O	NUM	O
U	O	NOUN	B
/	O	PUNCT	O
ml	O	NOUN	O
dex	B-Chemical	NOUN	B
,	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


001	O	NUM	O
).	O	PUNCT	O
In	O	ADP	O
this	O	DET	O
prevention	O	NOUN	B
study	O	NOUN	I
,	O	PUNCT	O
SBP	O	NOUN	B
in	O	ADP	O
the	O	DET	O
atorva	B-Chemical	NOUN	B
+	O	CCONJ	O
dex	B-Chemical	NOUN	B
group	O	NOUN	B
was	O	AUX	O
increased	O	VERB	B
from	O	ADP	O
115	O	NUM	O
+/-	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


4	O	NUM	O
to	O	PART	O
124	O	NUM	O
+/-	O	CCONJ	O
1	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
mmHg	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
this	O	DET	O
was	O	AUX	O
significantly	O	ADV	O
lower	O	ADJ	O
than	O	ADP	O
in	O	ADP	O
the	O	DET	O
dex	B-Chemical	NOUN	B
-	O	PUNCT	O
only	O	ADJ	O
group	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
'<	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


05	O	NUM	O
).	O	PUNCT	O
Atorva	B-Chemical	PROPN	B
reversed	O	VERB	O
dex	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
hypertension	B-Disease	NOUN	B
(	O	PUNCT	O
129	O	NUM	O
+/-	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
mmHg	O	NOUN	B
,	O	PUNCT	O
vs	O	CCONJ	O
.	O	PUNCT	O


135	O	NUM	O
+/-	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
mmHg	O	NOUN	B
P	O	NOUN	O
'<	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


05	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
decreased	O	VERB	B
plasma	O	NOUN	B
superoxide	B-Chemical	NOUN	O
(	O	PUNCT	O
7931	O	NUM	O
+/-	O	CCONJ	O
392	O	NUM	O
.	O	PUNCT	O


8	O	NUM	O
dex	B-Chemical	NOUN	B
,	O	PUNCT	O
1187	O	NUM	O
+/-	O	CCONJ	O
441	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
atorva	B-Chemical	NOUN	B
+	O	CCONJ	O
dex	B-Chemical	NOUN	B
,	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


0001	O	NUM	O
).	O	PUNCT	O
Plasma	O	NOUN	B
nitrate	B-Chemical	NOUN	B
/	O	SYM	O
nitrite	B-Chemical	NOUN	B
(	O	PUNCT	O
NOx	O	NOUN	B
)	O	PUNCT	O
was	O	AUX	O
decreased	O	VERB	B
in	O	ADP	O
dex	B-Chemical	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
rats	O	NOUN	B
compared	O	VERB	B
to	O	PART	O
saline	O	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
rats	O	NOUN	B
(	O	PUNCT	O
11	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
+/-	O	CCONJ	O
1	O	NUM	O
.	O	PUNCT	O


08	O	NUM	O
microm	O	NOUN	B
,	O	PUNCT	O
15	O	NUM	O
.	O	PUNCT	O


3	O	NUM	O
+/-	O	CCONJ	O
1	O	NUM	O
.	O	PUNCT	O


17	O	NUM	O
microm	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
,	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


05	O	NUM	O
).	O	PROPN	O
Atorva	B-Chemical	PROPN	B
affected	O	VERB	O
neither	O	CCONJ	O
plasma	O	NOUN	B
NOx	O	NOUN	B
nor	O	CCONJ	O
thymus	O	NOUN	B
weight	O	NOUN	B
.	O	PUNCT	O


Thus	O	ADV	O
,	O	PUNCT	O
atorvastatin	B-Chemical	NOUN	B
prevented	O	VERB	B
and	O	CCONJ	O
reversed	O	VERB	O
dexamethasone	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
hypertension	B-Disease	NOUN	B


Two	O	NUM	O
prodrugs	O	NOUN	B
of	O	ADP	O
potent	O	ADJ	O
and	O	CCONJ	O
selective	O	ADJ	O
GluR5	O	NOUN	B
kainate	B-Chemical	NOUN	B
receptor	O	NOUN	I
antagonists	O	NOUN	B
actives	O	VERB	O
in	O	ADP	O
three	O	NUM	O
animal	O	NOUN	B
models	O	NOUN	I
of	O	ADP	O
pain	B-Disease	NOUN	B
.	O	PUNCT	O


Amino	O	NOUN	B
acids	O	NOUN	I
5	O	NUM	I
and	O	CCONJ	O
7	O	NUM	O
,	O	PUNCT	O
two	O	NUM	O
potent	O	ADJ	O
and	O	CCONJ	O
selective	O	ADJ	O
competitive	O	ADJ	B
GluR5	O	NOUN	B
KA	B-Chemical	NOUN	I
receptor	O	NOUN	I
antagonists	O	NOUN	B
,	O	PUNCT	O
exhibited	O	VERB	O
high	O	ADJ	O
GluR5	O	NOUN	B
receptor	O	NOUN	I
affinity	O	NOUN	B
over	O	ADP	O
other	O	ADJ	O
glutamate	B-Chemical	NOUN	B
receptors	O	NOUN	I
.	O	PUNCT	O


Their	O	PRON	O
ester	O	NOUN	B
prodrugs	O	NOUN	I
6	O	NUM	O
and	O	CCONJ	O
8	O	NUM	O
were	O	AUX	O
orally	O	ADV	B
active	O	ADJ	O
in	O	ADP	O
three	O	NUM	O
models	O	NOUN	B
of	O	ADP	O
pain	B-Disease	NOUN	B
:	O	PUNCT	O
reversal	O	NOUN	B
of	O	ADP	O
formalin	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
paw	O	NOUN	B
licking	O	NOUN	O
,	O	PUNCT	O
carrageenan	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
thermal	B-Disease	ADJ	B
hyperalgesia	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
capsaicin	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
mechanical	B-Disease	ADJ	B
hyperalgesia	I-Disease	NOUN	I


Sirolimus	B-Chemical	NOUN	B
and	O	CCONJ	O
mycophenolate	B-Chemical	NOUN	B
mofetil	I-Chemical	NOUN	I
for	O	ADP	O
calcineurin	O	NOUN	B
-	O	PUNCT	O
free	O	ADJ	B
immunosuppression	O	NOUN	B
in	O	ADP	O
renal	O	ADJ	B
transplant	O	NOUN	I
recipients	O	NOUN	B
.	O	PUNCT	O


Calcineurin	O	NOUN	B
inhibitors	O	NOUN	B
,	O	PUNCT	O
such	O	ADJ	O
as	O	ADP	O
cyclosporine	B-Chemical	NOUN	B
and	O	CCONJ	O
tacrolimus	B-Chemical	NOUN	B
,	O	PUNCT	O
have	O	AUX	O
been	O	AUX	O
available	O	ADJ	O
for	O	ADP	O
almost	O	ADV	O
20	O	NUM	O
years	O	NOUN	B
.	O	PUNCT	O


Although	O	SCONJ	O
these	O	DET	O
drugs	O	NOUN	B
are	O	AUX	O
highly	O	ADV	O
effective	O	ADJ	B
and	O	CCONJ	O
represent	O	VERB	O
the	O	DET	O
mainstay	O	ADJ	O
of	O	ADP	O
transplant	O	ADJ	B
immunosuppression	O	NOUN	B
,	O	PUNCT	O
they	O	PRON	O
are	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
acute	O	ADJ	B
and	O	CCONJ	O
chronic	O	ADJ	B
nephrotoxicity	B-Disease	NOUN	O
.	O	PUNCT	O


Acute	O	ADJ	B
nephrotoxicity	B-Disease	NOUN	B
,	O	PUNCT	O
which	O	DET	O
occurs	O	VERB	O
in	O	ADP	O
the	O	DET	O
early	O	ADJ	B
period	O	NOUN	O
after	O	ADP	O
transplantation	O	NOUN	B
,	O	PUNCT	O
leads	O	VERB	O
to	O	PART	O
a	O	DET	O
higher	O	ADJ	O
rate	O	NOUN	B
of	O	ADP	O
dialysis	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
chronic	O	ADJ	B
nephrotoxicity	B-Disease	NOUN	B
may	O	AUX	O
eventually	O	ADV	O
result	O	VERB	O
in	O	ADP	O
graft	O	NOUN	B
loss	O	NOUN	I
.	O	PUNCT	O


Acute	O	ADJ	B
and	O	CCONJ	O
chronic	O	ADJ	B
nephrotoxicity	B-Disease	NOUN	B
is	O	AUX	O
becoming	O	VERB	O
more	O	ADV	O
common	O	ADJ	O
as	O	ADP	O
the	O	DET	O
use	O	NOUN	O
of	O	ADP	O
marginal	O	ADJ	B
kidneys	O	NOUN	B
for	O	ADP	O
transplantation	O	NOUN	B
increases	O	VERB	B
.	O	PUNCT	O


Two	O	NUM	O
recently	O	ADV	O
available	O	ADJ	O
immunosuppressive	O	ADJ	B
agents	O	NOUN	I
,	O	PUNCT	O
mycophenolate	B-Chemical	ADJ	B
mofetil	I-Chemical	NOUN	I
and	O	CCONJ	O
sirolimus	B-Chemical	NOUN	B
(	O	PUNCT	O
rapamycin	B-Chemical	NOUN	B
),	O	PUNCT	O
have	O	AUX	O
no	O	DET	O
nephrotoxicity	B-Disease	NOUN	B


Erythropoietin	O	NOUN	B
restores	O	VERB	B
the	O	DET	O
anemia	B-Disease	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
reduction	O	NOUN	B
in	O	ADP	O
cyclophosphamide	B-Chemical	NOUN	B
cytotoxicity	B-Disease	NOUN	B
in	O	ADP	O
rat	O	NOUN	B
tumors	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
aim	O	NOUN	O
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
examine	O	VERB	O
the	O	DET	O
impact	O	NOUN	B
of	O	ADP	O
anemia	B-Disease	NOUN	B
prevention	O	NOUN	B
by	O	ADP	O
recombinant	O	ADJ	B
human	O	ADJ	O
erythropoietin	O	NOUN	O
(	O	PUNCT	O
rHuEPO	O	NOUN	B
)	O	PUNCT	O
treatment	O	NOUN	B
on	O	ADP	O
the	O	DET	O
cytotoxicity	B-Disease	NOUN	B
of	O	ADP	O
cyclophosphamide	B-Chemical	NOUN	B
in	O	ADP	O
solid	O	ADJ	B
experimental	O	ADJ	I
tumors	B-Disease	NOUN	I
.	O	PUNCT	O


Anemia	B-Disease	NOUN	B
was	O	AUX	O
induced	O	VERB	B
using	O	VERB	O
a	O	DET	O
single	O	ADJ	B
dose	O	NOUN	I
of	O	ADP	O
carboplatin	B-Chemical	NOUN	B
(	O	PUNCT	O
50	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	O
i	O	X	O
.	O	PUNCT	O


v	O	ADP	O
.)	O	NOUN	O
resulting	O	VERB	O
in	O	ADP	O
a	O	DET	O
long	O	ADV	B
-	O	PUNCT	O
lasting	O	VERB	B
reduction	O	NOUN	B
(	O	PUNCT	O
30	O	NUM	O
%)	O	NOUN	O
of	O	ADP	O
the	O	DET	O
hemoglobin	O	NOUN	B
concentration	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
a	O	DET	O
second	O	ADJ	O
group	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
development	O	NOUN	B
of	O	ADP	O
anemia	B-Disease	NOUN	B
was	O	AUX	O
prevented	O	VERB	B
by	O	ADP	O
rHuEPO	O	NOUN	B
(	O	PUNCT	O
1000	O	NUM	O
IU	O	PROPN	B
/	O	SYM	O
kg	O	NOUN	B
)	O	PUNCT	O
administered	O	VERB	B
s	O	NOUN	O
.	O	PUNCT	O


c	O	X	O
.	O	PUNCT	O


three	O	NUM	O
times	O	NOUN	B
/	O	PUNCT	O
week	O	NOUN	B
starting	O	VERB	O
7	O	NUM	O
days	O	NOUN	B
before	O	ADP	O
carboplatin	B-Chemical	NOUN	B
application	O	NOUN	B
.	O	PUNCT	O


Four	O	NUM	O
days	O	NOUN	B
after	O	ADP	O
carboplatin	B-Chemical	NOUN	B
treatment	O	NOUN	B
,	O	PUNCT	O
tumors	B-Disease	NOUN	B
(	O	PUNCT	O
DS	O	NOUN	B
-	O	PUNCT	O
sarcoma	B-Disease	NOUN	B
of	O	ADP	O
the	O	DET	O
rat	O	NOUN	B
)	O	PUNCT	O
were	O	AUX	O
implanted	O	VERB	B
s	O	NOUN	O
.	O	PUNCT	O


c	O	X	O
.	O	PUNCT	O


onto	O	ADP	O
the	O	DET	O
hind	O	NOUN	B
food	O	NOUN	I
dorsum	O	NOUN	I
.	O	PUNCT	O


Neither	O	CCONJ	O
carboplatin	B-Chemical	NOUN	O
nor	O	CCONJ	O
rHuEPO	O	ADJ	B
treatment	O	NOUN	B
influenced	O	VERB	O
tumor	B-Disease	NOUN	B
growth	O	NOUN	I
rate	O	NOUN	O
per	O	X	O
se	O	X	O
.	O	PUNCT	O


When	O	SCONJ	O
tumors	B-Disease	NOUN	B
were	O	AUX	O
treated	O	VERB	B
with	O	ADP	I
a	O	DET	O
single	O	ADJ	B
dose	O	NOUN	I
of	O	ADP	O
cyclophosphamide	B-Chemical	NOUN	B
(	O	PUNCT	O
60	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	O
i	O	X	O
.	O	PUNCT	O


p	O	NOUN	O
.)	O	SYM	O
5	O	NUM	O
days	O	NOUN	B
after	O	ADP	O
implantation	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
growth	O	NOUN	B
delay	O	NOUN	I
with	O	ADP	O
a	O	DET	O
subsequent	O	ADJ	O
regrowth	O	NOUN	B
of	O	ADP	O
the	O	DET	O
tumors	B-Disease	NOUN	B
was	O	AUX	O
observed	O	VERB	O
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
anemia	B-Disease	NOUN	B
group	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
growth	O	NOUN	B
delay	O	NOUN	I
was	O	AUX	O
significantly	O	ADV	O
shorter	O	ADJ	O
compared	O	VERB	B
with	O	ADP	O
nonanemic	O	ADJ	B
controls	O	NOUN	I
(	O	PUNCT	O
13	O	NUM	O
.	O	PUNCT	O


3	O	NUM	O
days	O	NOUN	B
versus	O	CCONJ	O
8	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
days	O	NOUN	B
).	O	PUNCT	O
In	O	ADP	O
the	O	DET	O
group	O	NOUN	B
where	O	SCONJ	O
anemia	B-Disease	NOUN	B
was	O	AUX	O
prevented	O	VERB	B
by	O	ADP	O
rHuEPO	O	NOUN	B
treatment	O	NOUN	B
,	O	PUNCT	O
growth	O	NOUN	B
delay	O	NOUN	I
was	O	AUX	O
comparable	O	ADJ	O
with	O	ADP	O
that	O	DET	O
of	O	ADP	O
nonanemic	O	ADJ	B
controls	O	NOUN	I
(	O	PUNCT	O
13	O	NUM	O
.	O	PUNCT	O


3	O	NUM	O
days	O	NOUN	B
).	O	PUNCT	O
These	O	DET	O
results	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
chemotherapy	O	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
anemia	B-Disease	NOUN	B
reduces	O	VERB	O
cytotoxicity	B-Disease	NOUN	B
of	O	ADP	O
cyclophosphamide	B-Chemical	NOUN	B
in	O	ADP	O
tumors	B-Disease	NOUN	B
,	O	PUNCT	O
whereas	O	SCONJ	O
correction	O	NOUN	B
of	O	ADP	O
anemia	B-Disease	NOUN	B
by	O	ADP	O
rHuEPO	O	NOUN	B
treatment	O	NOUN	B
(	O	PUNCT	O
epoetin	O	NOUN	B
alpha	O	NOUN	I
)	O	PUNCT	O
increases	O	VERB	B
the	O	DET	O
sensitivity	O	NOUN	B
,	O	PUNCT	O
probably	O	ADV	O
as	O	ADP	O
a	O	DET	O
result	O	NOUN	O
of	O	ADP	O
an	O	DET	O
improved	O	VERB	B
oxygen	B-Chemical	NOUN	B
supply	O	NOUN	I
to	O	ADP	O
tumor	B-Disease	NOUN	B


The	O	DET	O
role	O	NOUN	O
of	O	ADP	O
nitrergic	O	ADJ	B
system	O	NOUN	I
in	O	ADP	O
lidocaine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
convulsion	B-Disease	NOUN	B
in	O	ADP	O
the	O	DET	O
mouse	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
effects	O	NOUN	B
of	O	ADP	O
N-nitro-L-arginine-methyl	B-Chemical	NOUN	B
ester	I-Chemical	NOUN	I
(	O	PUNCT	O
L-NAME	B-Chemical	NOUN	B
)	O	PUNCT	O
a	O	DET	O
nitric	B-Chemical	ADJ	B
oxide	I-Chemical	NOUN	I
(	O	PUNCT	O
NO	B-Chemical	NOUN	B
)	O	PUNCT	O
synthase	O	NOUN	O
inhibitor	O	NOUN	O
and	O	CCONJ	O
L-arginine	B-Chemical	NOUN	B
,	O	PUNCT	O
a	O	DET	O
NO	B-Chemical	NOUN	B
precursor	O	NOUN	B
,	O	PUNCT	O
were	O	AUX	O
investigated	O	VERB	B
on	O	ADP	O
lidocaine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
convulsions	B-Disease	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
first	O	ADJ	O
experiment	O	NOUN	B
,	O	PUNCT	O
four	O	NUM	O
groups	O	NOUN	B
of	O	ADP	O
mice	O	NOUN	B
received	O	VERB	O
physiological	O	ADJ	B
saline	O	NOUN	I
(	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


9	O	NUM	O
%),	O	ADJ	O
L-arginine	B-Chemical	NOUN	B
(	O	PUNCT	O
300	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
,	O	PUNCT	O
i	O	X	O
.	O	PUNCT	O


p	O	X	O
.),	O	PUNCT	O
L-NAME	B-Chemical	NOUN	B
(	O	PUNCT	O
100	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
,	O	PUNCT	O
i	O	X	O
.	O	PUNCT	O


p	O	NOUN	O
.)	O	NOUN	O
and	O	CCONJ	O
diazepam	B-Chemical	NOUN	B
(	O	PUNCT	O
2	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
),	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


Thirty	O	NUM	O
minutes	O	NOUN	B
after	O	ADP	O
these	O	DET	O
injections	O	NOUN	B
,	O	PUNCT	O
all	O	DET	O
mice	O	NOUN	B
received	O	VERB	O
lidocaine	B-Chemical	NOUN	B
(	O	PUNCT	O
50	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
,	O	PUNCT	O
i	O	X	O
.	O	PUNCT	O


p	O	NOUN	O
.).	O	NOUN	O
In	O	ADP	O
the	O	DET	O
second	O	ADJ	O
experiment	O	NOUN	B
,	O	PUNCT	O
four	O	NUM	O
groups	O	NOUN	B
of	O	ADP	O
mice	O	NOUN	B
received	O	VERB	O
similar	O	ADJ	O
treatment	O	NOUN	B
in	O	ADP	O
the	O	DET	O
first	O	ADJ	O
experiment	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
30	O	NUM	O
min	O	NOUN	O
after	O	ADP	O
these	O	DET	O
injections	O	NOUN	B
,	O	PUNCT	O
all	O	DET	O
mice	O	NOUN	B
received	O	VERB	O
a	O	DET	O
higher	O	ADJ	B
dose	O	NOUN	B
of	O	ADP	O
lidocaine	B-Chemical	NOUN	B
(	O	PUNCT	O
80	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
).	O	PUNCT	O
L-NAME	B-Chemical	NOUN	B
(	O	PUNCT	O
100	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
,	O	PUNCT	O
i	O	X	O
.	O	PUNCT	O


p	O	NOUN	O
.)	O	NOUN	O
and	O	CCONJ	O
diazepam	B-Chemical	NOUN	B
(	O	PUNCT	O
2	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
)	O	PUNCT	O
significantly	O	ADV	O
decreased	O	VERB	B
the	O	DET	O
incidence	O	NOUN	B
of	O	ADP	O
lidocaine	B-Chemical	NOUN	B
(	O	PUNCT	O
50	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
)-	O	ADJ	O
induced	O	VERB	B
convulsions	B-Disease	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
contrast	O	NOUN	O
,	O	PUNCT	O
the	O	DET	O
L-arginine	B-Chemical	NOUN	B
treatment	O	NOUN	B
increased	O	VERB	B
the	O	DET	O
incidence	O	NOUN	B
of	O	ADP	O
lidocaine	B-Chemical	NOUN	B
(	O	PUNCT	O
80	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
,	O	PUNCT	O
i	O	X	O
.	O	PUNCT	O


p	O	NOUN	O
.)-	O	PUNCT	O
induced	O	VERB	B
convulsions	B-Disease	NOUN	B
significantly	O	ADV	B
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	B
may	O	AUX	O
suggest	O	VERB	O
that	O	SCONJ	O
NO	B-Chemical	NOUN	B
is	O	AUX	O
a	O	DET	O
proconvulsant	O	ADJ	B
mediator	O	NOUN	O
in	O	ADP	O
lidocaine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
convulsions	B-Disease	NOUN	B


Effect	O	NOUN	B
of	O	ADP	O
intravenous	O	ADJ	B
metoprolol	B-Chemical	NOUN	B
or	O	CCONJ	O
intravenous	O	ADJ	B
metoprolol	B-Chemical	NOUN	B
plus	O	CCONJ	O
glucagon	O	NOUN	B
on	O	ADP	O
dobutamine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
myocardial	B-Disease	ADJ	B
ischemia	I-Disease	NOUN	I
.	O	PUNCT	O


STUDY	O	NOUN	O
OBJECTIVE	O	NOUN	O
:	O	PUNCT	O
To	O	PART	O
determine	O	VERB	O
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
metoprolol	B-Chemical	NOUN	B
on	O	ADP	O
dobutamine	B-Chemical	NOUN	B
stress	O	NOUN	O
testing	O	NOUN	O
with	O	ADP	O
technetium-99m	B-Chemical	NOUN	B
sestamibi	I-Chemical	NOUN	I
single	O	ADJ	I
-	O	PUNCT	O
photon	O	NOUN	B
emission	O	NOUN	O
computed	O	VERB	O
tomography	O	NOUN	O
imaging	O	NOUN	O
and	O	CCONJ	O
ST	O	ADJ	B
-	O	PUNCT	O
segment	O	NOUN	B
monitoring	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
to	O	PART	O
assess	O	VERB	B
the	O	DET	O
impact	O	NOUN	B
of	O	ADP	O
intravenous	O	ADJ	B
glucagon	O	NOUN	B
on	O	ADP	O
metoprolol	B-Chemical	NOUN	B
'	O	PART	O
s	O	NOUN	O
effects	O	NOUN	B
.	O	PUNCT	O


DESIGN	O	NOUN	B
:	O	PUNCT	O
Randomized	O	ADJ	B
,	O	PUNCT	O
double	O	ADJ	B
-	O	PUNCT	O
blind	O	ADJ	B
,	O	PUNCT	O
placebo	O	NOUN	B
-	O	PUNCT	O
controlled	O	VERB	B
trial	O	NOUN	I
.	O	PUNCT	O


SETTING	O	NOUN	O
:	O	PUNCT	O
Community	O	PROPN	B
hospital	O	NOUN	I
.	O	PUNCT	O


PATIENTS	O	NOUN	B
:	O	PUNCT	O
Twenty	O	NUM	B
-	O	PUNCT	O
two	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
known	O	ADJ	O
reversible	O	ADJ	B
perfusion	O	NOUN	B
defects	O	NOUN	B
.	O	PUNCT	O


INTERVENTION	O	NOUN	B
:	O	PUNCT	O
Patients	O	NOUN	B
underwent	O	VERB	O
dobutamine	B-Chemical	NOUN	B
stress	O	NOUN	I
tests	O	NOUN	I
per	O	ADP	O
standard	O	ADJ	B
protocol	O	NOUN	I
.	O	PUNCT	O


Before	O	ADP	O
dobutamine	B-Chemical	NOUN	B
was	O	AUX	O
begun	O	VERB	O
,	O	PUNCT	O
no	O	DET	O
therapy	O	NOUN	O
was	O	AUX	O
given	O	VERB	O
during	O	ADP	O
the	O	DET	O
first	O	ADJ	O
visit	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
patients	O	NOUN	B
were	O	AUX	O
randomized	O	VERB	B
on	O	ADP	O
subsequent	O	ADJ	O
visits	O	NOUN	B
to	O	PART	O
receive	O	VERB	O
metoprolol	B-Chemical	NOUN	B
or	O	CCONJ	O
metoprolol	B-Chemical	NOUN	B
plus	O	CCONJ	O
glucagon	O	NOUN	B
1	O	NUM	O
mg	O	NOUN	O
.	O	PUNCT	O


Metoprolol	B-Chemical	PROPN	B
was	O	AUX	O
dosed	O	VERB	B
to	O	PART	O
achieve	O	VERB	O
a	O	DET	O
resting	O	VERB	O
predobutamine	B-Chemical	NOUN	B
heart	O	NOUN	I
rate	O	NOUN	I
below	O	ADP	O
65	O	NUM	O
beats	O	NOUN	B
/	O	SYM	O
minute	O	NOUN	B
or	O	CCONJ	O
a	O	DET	O
total	O	ADJ	O
intravenous	O	ADJ	B
dose	O	NOUN	I
of	O	ADP	O
20	O	NUM	O
mg	O	NOUN	O
.	O	PUNCT	O


MEASUREMENTS	O	NOUN	O
AND	O	CCONJ	O
MAIN	O	NOUN	O
RESULTS	O	NOUN	O
:	O	PUNCT	O
Metoprolol	B-Chemical	NOUN	B
reduced	O	VERB	B
maximum	O	ADJ	O
heart	O	NOUN	O
rate	O	NOUN	O
31	O	NUM	O
%,	O	NOUN	B
summed	O	VERB	O
stress	O	NOUN	B
scores	O	NOUN	I
29	O	NUM	O
%,	O	NOUN	B
and	O	CCONJ	O
summed	O	VERB	O
difference	O	NOUN	O
scores	O	NOUN	B
43	O	NUM	O
%	O	NOUN	O
versus	O	ADP	O
control	O	NOUN	B
.	O	PUNCT	O


Metoprolol	B-Chemical	NOUN	B
plus	O	CCONJ	O
glucagon	O	NOUN	B
also	O	ADV	O
reduced	O	VERB	B
the	O	DET	O
maximum	O	ADJ	B
heart	O	NOUN	O
rate	O	NOUN	O
29	O	NUM	O
%	O	NOUN	O
versus	O	ADP	O
control	O	NOUN	B
.	O	PUNCT	O


Summed	O	VERB	B
stress	O	NOUN	B
and	O	CCONJ	O
summed	O	VERB	O
difference	O	NOUN	O
scores	O	NOUN	B
were	O	AUX	O
not	O	PART	O
significantly	O	ADV	O
reduced	O	VERB	B
,	O	PUNCT	O
although	O	SCONJ	O
they	O	PRON	O
were	O	AUX	O
18	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
30	O	NUM	O
%	O	NOUN	O
lower	O	ADJ	B
,	O	PUNCT	O
respectively	O	ADV	O
,	O	PUNCT	O
than	O	ADP	O
control	O	NOUN	B
.	O	PUNCT	O


No	O	DET	B
significant	O	ADJ	I
differences	O	NOUN	O
were	O	AUX	O
found	O	VERB	O
in	O	ADP	O
any	O	DET	O
parameter	O	NOUN	B
between	O	ADP	O
metoprolol	B-Chemical	NOUN	B
and	O	CCONJ	O
metoprolol	B-Chemical	NOUN	B
-	O	PUNCT	O
glucagon	O	NOUN	B
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
:	O	PUNCT	O
During	O	ADP	O
dobutamine	B-Chemical	NOUN	B
stress	O	NOUN	O
testing	O	NOUN	O
,	O	PUNCT	O
metoprolol	B-Chemical	NOUN	B
attenuates	O	VERB	B
or	O	CCONJ	O
eliminates	O	VERB	O
evidence	O	NOUN	B
of	O	ADP	O
myocardial	B-Disease	ADJ	B
ischemia	I-Disease	NOUN	I


Prednisolone	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
muscle	B-Disease	NOUN	B
dysfunction	I-Disease	NOUN	I
is	O	AUX	O
caused	O	VERB	O
more	O	ADV	O
by	O	ADP	O
atrophy	B-Disease	NOUN	B
than	O	ADP	O
by	O	ADP	O
altered	O	ADJ	O
acetylcholine	B-Chemical	NOUN	B
receptor	O	NOUN	I
expression	O	NOUN	B
.	O	PUNCT	O


Large	O	ADJ	O
doses	O	NOUN	B
of	O	ADP	O
glucocorticoids	O	NOUN	B
can	O	AUX	O
alter	O	VERB	O
muscle	O	NOUN	B
physiology	O	NOUN	B
and	O	CCONJ	O
susceptibility	O	NOUN	B
to	O	PART	O
neuromuscular	O	ADJ	B
blocking	O	VERB	I
drugs	O	NOUN	I
by	O	ADP	O
mechanisms	O	NOUN	B
not	O	PART	O
clearly	O	ADV	O
understood	O	VERB	O
.	O	PUNCT	O


We	O	PRON	O
investigated	O	VERB	B
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
moderate	O	ADJ	B
and	O	CCONJ	O
large	O	ADJ	O
doses	O	NOUN	B
of	O	ADP	O
prednisolone	B-Chemical	NOUN	B
on	O	ADP	O
muscle	O	NOUN	B
function	O	NOUN	I
and	O	CCONJ	O
pharmacology	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
their	O	PRON	O
relationship	O	NOUN	B
to	O	PART	O
changes	O	NOUN	B
in	O	ADP	O
muscle	O	NOUN	B
size	O	NOUN	I
and	O	CCONJ	O
acetylcholine	B-Chemical	NOUN	B
receptor	O	NOUN	I
(	O	PUNCT	O
AChR	O	NOUN	B
)	O	PUNCT	O
expression	O	NOUN	B
.	O	PUNCT	O


With	O	ADP	O
institutional	O	ADJ	B
approval	O	NOUN	I
,	O	PUNCT	O
35	O	NUM	O
Sprague	O	PROPN	B
-	O	PUNCT	O
Dawley	O	NOUN	B
rats	O	NOUN	B
were	O	AUX	O
randomly	O	ADV	O
allocated	O	VERB	O
to	O	PART	O
receive	O	VERB	O
daily	O	ADJ	B
subcutaneous	O	ADJ	B
doses	O	NOUN	I
of	O	ADP	O
10	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
prednisolone	B-Chemical	NOUN	B
(	O	PUNCT	O
P10	O	NOUN	O
group	O	NOUN	B
),	O	PUNCT	O
100	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
prednisolone	B-Chemical	NOUN	B
(	O	PUNCT	O
P100	O	NOUN	B
group	O	NOUN	I
),	O	PUNCT	O
or	O	CCONJ	O
an	O	DET	O
equal	O	ADJ	O
volume	O	NOUN	B
of	O	ADP	O
saline	O	NOUN	B
(	O	PUNCT	O
S	O	NOUN	B
group	O	NOUN	I
)	O	PUNCT	O
for	O	ADP	O
7	O	NUM	O
days	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
fourth	O	ADJ	O
group	O	NOUN	B
of	O	ADP	O
rats	O	NOUN	B
was	O	AUX	O
pair	O	NOUN	B
fed	O	VERB	I
(	O	PUNCT	O
food	O	NOUN	B
restricted	O	ADJ	I
)	O	PUNCT	O
with	O	ADP	O
the	O	DET	O
P100	O	NOUN	B
rats	O	NOUN	B
for	O	ADP	O
7	O	NUM	O
days	O	NOUN	B
(	O	PUNCT	O
FR	O	NOUN	B
group	O	NOUN	B
).	O	PUNCT	B
On	O	ADP	O
Day	O	PROPN	O
8	O	NUM	O
,	O	PUNCT	O
the	O	DET	O
nerve	O	NOUN	B
-	O	PUNCT	O
evoked	O	VERB	B
peak	O	ADJ	O
twitch	O	NOUN	B
tensions	O	NOUN	B
,	O	PUNCT	O
tetanic	B-Disease	ADJ	B
tensions	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
fatigability	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
dose	O	NOUN	B
-	O	PUNCT	O
response	O	NOUN	B
curves	O	NOUN	I
of	O	ADP	O
d-tubocurarine	B-Chemical	NOUN	B
in	O	ADP	O
the	O	DET	O
tibialis	O	NOUN	B
cranialis	O	NOUN	I
muscle	O	NOUN	I
were	O	AUX	O
measured	O	VERB	O
in	O	X	B
vivo	O	X	I
and	O	CCONJ	O
related	O	ADJ	O
to	O	PART	O
muscle	O	NOUN	B
mass	O	NOUN	I
or	O	CCONJ	O
expression	O	NOUN	B
of	O	ADP	O
AChRs	O	NOUN	B
.	O	PUNCT	O


Rate	O	NOUN	B
of	O	ADP	O
body	O	NOUN	B
weight	O	NOUN	I
gain	O	NOUN	O
was	O	AUX	O
depressed	O	ADJ	B
in	O	ADP	O
the	O	DET	O
P100	O	NOUN	B
,	O	PUNCT	O
FR	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
P10	O	NOUN	B
groups	O	NOUN	B
compared	O	VERB	B
with	O	ADP	O
the	O	DET	O
S	O	NOUN	B
group	O	NOUN	I
.	O	PUNCT	O


Tibialis	O	NOUN	B
muscle	O	NOUN	I
mass	O	NOUN	O
was	O	AUX	O
smaller	O	ADJ	O
in	O	ADP	O
the	O	DET	O
P100	O	NOUN	B
group	O	NOUN	B
than	O	ADP	O
in	O	ADP	O
the	O	DET	O
P10	O	NOUN	B
or	O	CCONJ	O
S	O	NOUN	B
groups	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
evoked	O	VERB	B
peak	O	ADJ	I
twitch	O	NOUN	I
and	O	CCONJ	O
tetanic	B-Disease	ADJ	B
tensions	O	NOUN	B
were	O	AUX	O
less	O	ADJ	O
in	O	ADP	O
the	O	DET	O
P100	O	NOUN	B
group	O	NOUN	B
than	O	ADP	O
in	O	ADP	O
the	O	DET	O
P10	O	NOUN	B
or	O	CCONJ	O
S	O	NOUN	B
groups	O	NOUN	I
,	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
tension	O	NOUN	B
per	O	ADP	O
milligram	O	NOUN	O
of	O	ADP	O
muscle	O	NOUN	B
mass	O	NOUN	I
was	O	AUX	O
greater	O	ADJ	O
in	O	ADP	O
the	O	DET	O
P100	O	NOUN	B
group	O	NOUN	B
than	O	ADP	O
in	O	ADP	O
the	O	DET	O
S	O	NOUN	B
group	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
50	O	NUM	O
%	O	NOUN	O
effective	O	ADJ	B
dose	O	NOUN	B
of	O	ADP	O
d-tubocurarine	B-Chemical	NOUN	B
(	O	PUNCT	O
microg	O	NOUN	B
/	O	SYM	O
kg	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
tibialis	O	NOUN	B
muscle	O	NOUN	I
was	O	AUX	O
smaller	O	ADJ	O
in	O	ADP	O
the	O	DET	O
P10	O	NOUN	B
(	O	PUNCT	O
33	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
+/-	O	CCONJ	O
5	O	NUM	O
.	O	PUNCT	O


4	O	X	O
)	O	PUNCT	O
than	O	ADP	O
in	O	ADP	O
the	O	DET	O
S	O	NOUN	B
(	O	PUNCT	O
61	O	NUM	O
.	O	PUNCT	O


9	O	NUM	O
+/-	O	CCONJ	O
5	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
)	O	PUNCT	O
or	O	CCONJ	O
the	O	DET	O
P100	O	NOUN	B
(	O	PUNCT	O
71	O	NUM	O
.	O	PUNCT	O


3	O	NUM	O
+/-	O	CCONJ	O
9	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
)	O	PUNCT	O
groups	O	NOUN	B
.	O	PUNCT	O


AChR	O	NOUN	B
expression	O	NOUN	B
was	O	AUX	O
less	O	ADJ	O
in	O	ADP	O
the	O	DET	O
P10	O	NOUN	B
group	O	NOUN	B
than	O	ADP	O
in	O	ADP	O
the	O	DET	O
S	O	NOUN	B
group	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
evoked	O	VERB	B
tensions	O	NOUN	B
correlated	O	VERB	B
with	O	ADP	O
muscle	O	NOUN	B
mass	O	NOUN	I
(	O	PUNCT	O
r	O	NOUN	O
(	O	PUNCT	O
2	O	NUM	O
)=	O	SYM	O
0	O	NUM	O
.	O	PUNCT	O


32	O	NUM	O
,	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


001	O	NUM	O
),	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
not	O	PART	O
with	O	ADP	O
expression	O	NOUN	B
of	O	ADP	O
AChR	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
50	O	NUM	O
%	O	NOUN	O
effective	O	ADJ	B
dose	O	NOUN	B
of	O	ADP	O
d-tubocurarine	B-Chemical	NOUN	B
did	O	AUX	O
not	O	PART	O
correlate	O	VERB	O
with	O	ADP	O
muscle	O	NOUN	B
mass	O	NOUN	I
or	O	CCONJ	O
AChR	O	NOUN	B
expression	O	NOUN	B
.	O	PUNCT	O


Our	O	PRON	O
results	O	NOUN	O
suggest	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
neuromuscular	B-Disease	ADJ	B
dysfunction	I-Disease	NOUN	I
after	O	ADP	O
prednisolone	B-Chemical	NOUN	B
is	O	AUX	O
dose	O	NOUN	B
-	O	PUNCT	O
dependent	O	ADJ	B
,	O	PUNCT	O
and	O	CCONJ	O
derives	O	VERB	O
primarily	O	ADV	O
from	O	ADP	O
muscle	B-Disease	NOUN	B
atrophy	I-Disease	NOUN	I
and	O	CCONJ	O
derives	O	VERB	O
less	O	ADV	O
so	O	ADV	O
from	O	ADP	O
changes	O	NOUN	B
in	O	ADP	O
AChR	O	NOUN	B
expression	O	NOUN	B
.	O	PUNCT	O


IMPLICATIONS	O	NOUN	B
:	O	PUNCT	O
The	O	DET	O
mechanisms	O	NOUN	B
by	O	ADP	O
which	O	DET	O
chronic	O	ADJ	B
glucocorticoid	O	NOUN	I
therapy	O	NOUN	I
alters	O	VERB	O
neuromuscular	O	ADJ	B
physiology	O	NOUN	I
and	O	CCONJ	O
pharmacology	O	NOUN	B
are	O	AUX	O
unclear	O	ADJ	B
.	O	PUNCT	O


We	O	PRON	O
suggest	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
observed	O	VERB	B
effects	O	NOUN	B
are	O	AUX	O
dose	O	NOUN	B
-	O	PUNCT	O
dependent	O	ADJ	B
and	O	CCONJ	O
derive	O	VERB	O
primarily	O	ADV	O
from	O	ADP	O
muscle	B-Disease	NOUN	B
atrophy	I-Disease	NOUN	I
and	O	CCONJ	O
derive	O	VERB	O
less	O	ADJ	O
from	O	ADP	O
changes	O	NOUN	B
in	O	ADP	O
acetylcholine	B-Chemical	NOUN	B


Rapid	O	ADJ	O
reversal	O	NOUN	B
of	O	ADP	I
life	O	NOUN	I
-	O	PUNCT	O
threatening	O	VERB	B
diltiazem	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
tetany	B-Disease	NOUN	B
with	O	ADP	O
calcium	B-Chemical	NOUN	B
chloride	I-Chemical	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
describe	O	VERB	O
a	O	DET	O
patient	O	NOUN	B
who	O	PRON	O
developed	O	VERB	O
tetany	B-Disease	NOUN	B
with	O	ADP	O
sudden	O	ADJ	B
respiratory	B-Disease	ADJ	I
arrest	I-Disease	NOUN	I
after	O	ADP	O
the	O	DET	O
infusion	O	NOUN	B
of	O	ADP	O
intravenous	O	ADJ	B
diltiazem	B-Chemical	NOUN	B
.	O	PUNCT	O


The	O	DET	O
administration	O	NOUN	B
of	O	ADP	O
calcium	B-Chemical	NOUN	B
chloride	I-Chemical	NOUN	I
rapidly	O	ADV	O
resolved	O	VERB	B
the	O	DET	O
patient	O	NOUN	B
'	O	PART	O
s	O	NOUN	O
tetany	B-Disease	NOUN	B
with	O	ADP	O
prompt	O	ADJ	O
recovery	O	NOUN	B
of	O	ADP	O
respiratory	O	ADJ	B
function	O	NOUN	I
,	O	PUNCT	O
averting	O	VERB	O
the	O	DET	O
need	O	NOUN	O
for	O	ADP	O
more	O	ADV	O
aggressive	O	ADJ	B
airway	O	NOUN	B
management	O	NOUN	O
and	O	CCONJ	O
ventilatory	O	ADJ	B
support	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
emergency	O	NOUN	B
physician	O	NOUN	I
should	O	AUX	O
be	O	AUX	O
aware	O	ADJ	O
that	O	SCONJ	O
life	O	NOUN	B
-	O	PUNCT	O
threatening	O	VERB	B
tetany	B-Disease	NOUN	B
may	O	AUX	O
accompany	O	VERB	O
the	O	DET	O
administration	O	NOUN	B
of	O	ADP	O
intravenous	O	ADJ	B
diltiazem	B-Chemical	NOUN	B
and	O	CCONJ	O
that	O	SCONJ	O
calcium	B-Chemical	NOUN	B
chloride	I-Chemical	NOUN	I


Effects	O	NOUN	B
of	O	ADP	I
nonsteroidal	O	ADJ	B
anti	O	ADJ	I
-	O	PUNCT	O
inflammatory	O	ADJ	B
drugs	O	NOUN	B
on	O	ADP	O
hemostasis	O	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
aneurysmal	B-Disease	ADJ	B
subarachnoid	I-Disease	ADJ	B
hemorrhage	I-Disease	NOUN	B
.	O	PUNCT	O


Platelet	O	NOUN	B
function	O	NOUN	I
is	O	AUX	O
impaired	O	VERB	B
by	O	ADP	O
nonsteroidal	O	ADJ	B
anti	O	ADJ	I
-	O	PUNCT	O
inflammatory	O	ADJ	B
drugs	O	NOUN	I
(	O	PUNCT	O
NSAIDs	O	NOUN	B
)	O	PUNCT	O
with	O	ADP	O
prominent	O	ADJ	O
anti	O	ADJ	B
-	O	PUNCT	O
inflammatory	O	ADJ	B
properties	O	NOUN	B
.	O	PUNCT	O


Their	O	PRON	O
safety	O	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
undergoing	O	VERB	O
intracranial	O	ADJ	B
surgery	O	NOUN	I
is	O	AUX	O
under	O	ADP	O
debate	O	NOUN	O
.	O	PUNCT	O


Patients	O	NOUN	B
with	O	ADP	O
aneurysmal	B-Disease	ADJ	B
subarachnoid	I-Disease	ADJ	O
hemorrhage	I-Disease	NOUN	O
(	O	PUNCT	O
SAH	B-Disease	NOUN	B
)	O	PUNCT	O
were	O	AUX	O
randomized	O	VERB	B
to	O	PART	O
receive	O	VERB	O
either	O	CCONJ	O
ketoprofen	B-Chemical	NOUN	B
,	O	PUNCT	O
100	O	NUM	O
mg	O	NOUN	O
,	O	PUNCT	O
three	O	NUM	O
times	O	NOUN	O
a	O	DET	O
day	O	NOUN	B
(	O	PUNCT	O
ketoprofen	B-Chemical	NOUN	B
group	O	NOUN	B
,	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
9	O	NUM	O
)	O	PUNCT	O
or	O	CCONJ	O
a	O	DET	O
weak	O	ADJ	B
NSAID	O	NOUN	B
,	O	PUNCT	O
acetaminophen	B-Chemical	NOUN	B
,	O	PUNCT	O
1	O	NUM	O
g	O	NOUN	O
,	O	PUNCT	O
three	O	NUM	O
times	O	NOUN	O
a	O	DET	O
day	O	NOUN	B
(	O	PUNCT	O
acetaminophen	B-Chemical	NOUN	B
group	O	NOUN	I
,	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
9	O	NUM	O
)	O	PUNCT	O
starting	O	VERB	O
immediately	O	ADV	O
after	O	ADP	O
the	O	DET	O
diagnosis	O	NOUN	B
of	O	ADP	O
aneurysmal	B-Disease	ADJ	B
SAH	B-Disease	NOUN	B
.	O	PUNCT	O


Treatment	O	NOUN	B
was	O	AUX	O
continued	O	VERB	O
for	O	ADP	O
3	O	NUM	O
days	O	NOUN	B
postoperatively	O	ADV	B
.	O	PUNCT	O


Test	O	NOUN	B
blood	O	NOUN	I
samples	O	NOUN	I
were	O	AUX	O
taken	O	VERB	O
before	O	ADP	O
treatment	O	NOUN	B
and	O	CCONJ	O
surgery	O	NOUN	B
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
on	O	ADP	O
the	O	DET	O
first	O	ADJ	O
,	O	PUNCT	O
third	O	ADJ	O
,	O	PUNCT	O
and	O	CCONJ	O
fifth	O	ADJ	O
postoperative	O	ADJ	B
mornings	O	NOUN	B
.	O	PUNCT	O


Maximal	O	ADJ	B
platelet	B-Disease	NOUN	O
aggregation	I-Disease	NOUN	O
induced	O	VERB	B
by	O	ADP	O
6	O	NUM	O
microM	O	NOUN	O
of	O	ADP	O
adenosine	B-Chemical	NOUN	B
diphosphate	I-Chemical	NOUN	I
decreased	O	VERB	B
after	O	ADP	O
administration	O	NOUN	B
of	O	ADP	O
ketoprofen	B-Chemical	NOUN	B
.	O	PUNCT	O


Aggregation	O	NOUN	B
was	O	AUX	O
lower	O	ADJ	O
(	O	PUNCT	O
P	O	NOUN	O
<.	O	ADJ	O
05	O	NUM	O
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
ketoprofen	B-Chemical	NOUN	B
group	O	NOUN	B
than	O	ADP	O
in	O	ADP	O
the	O	DET	O
acetaminophen	B-Chemical	NOUN	B
group	O	NOUN	O
just	O	ADV	O
before	O	ADP	O
surgery	O	NOUN	B
and	O	CCONJ	O
on	O	ADP	O
the	O	DET	O
third	O	ADJ	O
postoperative	O	ADJ	B
day	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
contrast	O	NOUN	O
,	O	PUNCT	O
maximal	O	ADJ	B
platelet	B-Disease	NOUN	O
aggregation	I-Disease	NOUN	O
increased	O	VERB	B
in	O	ADP	O
the	O	DET	O
acetaminophen	B-Chemical	NOUN	B
group	O	NOUN	O
on	O	ADP	O
the	O	DET	O
third	O	ADJ	O
postoperative	O	ADJ	B
day	O	NOUN	B
as	O	ADP	O
compared	O	VERB	B
with	O	ADP	O
the	O	DET	O
pretreatment	O	NOUN	B
platelet	B-Disease	NOUN	B
aggregation	I-Disease	NOUN	I
results	O	VERB	B
(	O	PUNCT	O
P	O	NOUN	O
<.	O	VERB	O
05	O	NUM	O
).	O	PUNCT	O
One	O	NUM	O
patient	O	NOUN	B
in	O	ADP	O
the	O	DET	O
ketoprofen	B-Chemical	NOUN	B
group	O	NOUN	B
developed	O	VERB	O
a	O	DET	O
postoperative	O	ADJ	B
intracranial	O	ADJ	B
hematoma	B-Disease	NOUN	I
.	O	PUNCT	O


Coagulation	O	NOUN	B
(	O	PUNCT	O
prothrombin	O	NOUN	B
time	O	NOUN	I
[	O	PUNCT	O
PT	O	PROPN	B
],	O	PUNCT	O
activated	O	VERB	B
partial	O	ADJ	I
thromboplastin	O	NOUN	I
time	O	NOUN	I
[	O	PUNCT	O
APPT	O	NOUN	O
],	O	NOUN	O
fibrinogen	O	NOUN	O
concentration	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
antithrombin	O	NOUN	B
III	O	NUM	I
[	O	PUNCT	I
AT	O	PROPN	O
III	O	NUM	O
])	O	PUNCT	O
was	O	AUX	O
comparable	O	ADJ	O
between	O	ADP	O
the	O	DET	O
two	O	NUM	O
groups	O	NOUN	B
.	O	PUNCT	O


Ketoprofen	B-Chemical	NOUN	B
but	O	CCONJ	O
not	O	PART	O
acetaminophen	B-Chemical	VERB	B
impaired	O	ADJ	B
platelet	O	NOUN	B
function	O	NOUN	I
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
SAH	B-Disease	NOUN	B
.	O	PUNCT	O


If	O	SCONJ	O
ketoprofen	B-Chemical	NOUN	B
is	O	AUX	O
used	O	VERB	O
before	O	ADP	O
surgery	O	NOUN	B
on	O	ADP	O
cerebral	O	ADJ	B
artery	B-Disease	NOUN	I
aneurysms	I-Disease	NOUN	I
,	O	PUNCT	O
it	O	PRON	O
may	O	AUX	O
pose	O	VERB	O
an	O	DET	O
additional	O	ADJ	O
risk	O	NOUN	B
factor	O	NOUN	I
for	O	ADP	O
hemorrhage	B-Disease	NOUN	B


Value	O	NOUN	B
of	O	ADP	O
methylprednisolone	B-Chemical	NOUN	B
in	O	ADP	O
prevention	O	NOUN	B
of	O	ADP	O
the	O	DET	O
arthralgia	B-Disease	NOUN	B
-	O	PUNCT	O
myalgia	B-Disease	NOUN	B
syndrome	O	NOUN	I
associated	O	VERB	B
with	O	ADP	I
the	O	DET	O
total	O	ADJ	B
dose	O	NOUN	I
infusion	O	NOUN	B
of	O	ADP	O
iron	B-Chemical	NOUN	B
dextran	I-Chemical	NOUN	I
:	O	PUNCT	O
a	O	DET	O
double	O	ADJ	O
blind	O	ADJ	O
randomized	O	ADJ	B
trial	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
safety	O	NOUN	B
and	O	CCONJ	O
efficacy	O	NOUN	B
of	O	ADP	O
total	O	ADJ	B
dose	O	NOUN	I
infusion	O	NOUN	I
(	O	PUNCT	O
TDI	O	NOUN	B
)	O	PUNCT	O
of	O	ADP	O
iron	B-Chemical	NOUN	B
dextran	I-Chemical	NOUN	I
has	O	AUX	O
been	O	AUX	O
well	O	ADV	O
documented	O	VERB	B
.	O	PUNCT	O


In	O	ADP	O
40	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
treated	O	VERB	B
patients	O	NOUN	B
,	O	PUNCT	O
an	O	DET	O
arthralgia	B-Disease	NOUN	B
-	O	PUNCT	O
myalgia	B-Disease	NOUN	B
syndrome	O	NOUN	I
develops	O	VERB	B
.	O	PUNCT	O


The	O	DET	O
purpose	O	NOUN	O
of	O	ADP	O
this	O	DET	O
randomized	O	ADJ	B
,	O	PUNCT	O
double	O	ADJ	B
-	O	PUNCT	O
blind	O	ADJ	B
,	O	PUNCT	O
prospective	O	ADJ	B
study	O	NOUN	I
was	O	AUX	O
to	O	PART	O
investigate	O	VERB	B
whether	O	SCONJ	O
intravenous	O	ADJ	B
(	O	PUNCT	O
i	O	X	O
.	O	PUNCT	O


v	O	ADP	O
.)	O	ADJ	O
administration	O	NOUN	B
of	O	ADP	O
methylprednisolone	B-Chemical	NOUN	B
(	O	PUNCT	O
MP	B-Chemical	NOUN	B
)	O	PUNCT	O
prevents	O	VERB	B
this	O	DET	O
complication	O	NOUN	B
.	O	PUNCT	O


Sixty	O	NUM	B
-	O	PUNCT	O
five	O	NUM	B
patients	O	NOUN	B
,	O	PUNCT	O
34	O	NUM	O
women	O	NOUN	B
and	O	CCONJ	O
31	O	NUM	O
men	O	NOUN	B
,	O	PUNCT	O
ages	O	VERB	B
36	O	NUM	O
to	O	PART	O
80	O	NUM	O
years	O	NOUN	B
,	O	PUNCT	O
received	O	VERB	O
either	O	CCONJ	O
normal	O	ADJ	B
saline	O	NOUN	I
before	O	ADP	O
and	O	CCONJ	O
after	O	ADP	O
TDI	O	PROPN	B
(	O	PUNCT	O
group	O	NOUN	B
1	O	NUM	O
),	O	PUNCT	O
125	O	NUM	O
mg	O	NOUN	O
i	O	NUM	O
.	O	PUNCT	O


v	O	NOUN	O
.	O	PUNCT	O


MP	B-Chemical	NOUN	B
before	O	ADP	O
and	O	CCONJ	O
saline	O	NOUN	B
after	O	ADP	O
TDI	O	NOUN	B
(	O	PUNCT	O
group	O	NOUN	B
2	O	NUM	O
),	O	PUNCT	O
or	O	CCONJ	O
125	O	NUM	O
mg	O	NOUN	O
i	O	NUM	O
.	O	PUNCT	O


v	O	NOUN	O
.	O	PUNCT	O


MP	B-Chemical	NOUN	B
before	O	ADP	O
and	O	CCONJ	O
after	O	ADP	O
TDI	O	PROPN	B
(	O	PUNCT	O
group	O	NOUN	B
3	O	NUM	O
).	O	PUNCT	B
Patients	O	NOUN	B
were	O	AUX	O
observed	O	VERB	O
for	O	ADP	O
72	O	NUM	O
hours	O	NOUN	B
and	O	CCONJ	O
reactions	O	NOUN	B
were	O	AUX	O
recorded	O	VERB	O
and	O	CCONJ	O
graded	O	VERB	B
according	O	VERB	O
to	O	ADP	O
severity	O	NOUN	B
.	O	PUNCT	O


Fifty	O	NUM	B
-	O	PUNCT	O
eight	O	NUM	O
percent	O	NOUN	O
of	O	ADP	O
group	O	NOUN	B
1	O	NUM	O
patients	O	NOUN	B
,	O	PUNCT	O
33	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
group	O	NOUN	B
2	O	NUM	I
,	O	PUNCT	O
and	O	CCONJ	O
26	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
group	O	NOUN	B
3	O	NUM	O
had	O	AUX	O
reactions	O	NOUN	B
to	O	ADP	O
TDI	O	PROPN	B
.	O	PUNCT	O


The	O	DET	O
severity	O	NOUN	B
of	O	ADP	O
reactions	O	NOUN	O
(	O	PUNCT	O
minimal	O	ADJ	B
,	O	PUNCT	O
mild	O	ADJ	B
,	O	PUNCT	O
and	O	CCONJ	O
moderate	O	ADJ	B
,	O	PUNCT	O
respectively	O	ADV	O
)	O	PUNCT	O
was	O	AUX	O
as	O	ADP	O
follows	O	VERB	O
:	O	PUNCT	O
group	O	NOUN	B
1	O	NUM	O
--	O	PUNCT	O
6	O	NUM	O
,	O	PUNCT	O
6	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
2	O	NUM	O
;	O	PUNCT	O
group	O	NOUN	B
2	O	NUM	O
--	O	PUNCT	O
1	O	NUM	O
,	O	PUNCT	O
5	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
0	O	NUM	O
;	O	PUNCT	O
group	O	NOUN	B
3	O	NUM	O
--	O	PUNCT	O
5	O	NUM	O
,	O	PUNCT	O
1	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


Data	O	NOUN	B
were	O	AUX	O
analyzed	O	VERB	B
by	O	ADP	O
the	O	DET	O
two	O	NUM	O
-	O	PUNCT	O
sided	O	ADJ	B
Fisher	O	PROPN	B
'	O	PART	I
s	O	NOUN	I
exact	O	ADJ	I
test	O	NOUN	I
using	O	VERB	O
95	O	NUM	O
%	O	NOUN	O
confidence	O	NOUN	B
intervals	O	NOUN	I
with	O	ADP	O
the	O	DET	O
approximation	O	NOUN	B
of	O	ADP	O
Woolf	O	PROPN	B
.	O	PUNCT	O


These	O	DET	O
data	O	NOUN	B
demonstrate	O	VERB	O
that	O	SCONJ	O
administration	O	NOUN	B
of	O	ADP	O
MP	B-Chemical	NOUN	B
before	O	ADP	O
and	O	CCONJ	O
after	O	ADP	O
TDI	O	PROPN	B
reduces	O	VERB	B
the	O	DET	O
frequency	O	NOUN	B
and	O	CCONJ	O
severity	O	NOUN	B
of	O	ADP	O
the	O	DET	O
arthralgia	B-Disease	NOUN	B
-	O	PUNCT	O
myalgia	B-Disease	NOUN	B
syndrome	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
conclude	O	VERB	O
that	O	SCONJ	O
125	O	NUM	O
mg	O	NOUN	O
i	O	NUM	O
.	O	PUNCT	O


v	O	NOUN	O
.	O	PUNCT	O


MP	B-Chemical	NOUN	B
should	O	AUX	O
be	O	AUX	O
given	O	VERB	O
routinely	O	ADV	O
before	O	ADV	B
and	O	CCONJ	O
after	O	ADP	O
TDI	O	PROPN	B
of	O	ADP	O
iron	B-Chemical	NOUN	B
dextran	I-Chemical	NOUN	I


Long	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
effects	O	NOUN	B
of	O	ADP	O
vincristine	B-Chemical	NOUN	B
on	O	ADP	O
the	O	DET	O
peripheral	O	ADJ	B
nervous	O	ADJ	I
system	O	NOUN	I
.	O	PUNCT	O


Forty	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
Non-Hodgkin's	B-Disease	NOUN	B
Lymphoma	I-Disease	NOUN	I
treated	O	VERB	B
with	O	ADP	I
vincristine	B-Chemical	NOUN	B
between	O	ADP	O
1984	O	NUM	O
and	O	CCONJ	O
1990	O	NUM	O
(	O	PUNCT	O
cumulative	O	ADJ	B
dose	O	NOUN	B
12	O	NUM	O
mg	O	NOUN	O
in	O	ADP	O
18	O	NUM	O
-	O	PUNCT	O
24	O	NUM	O
weeks	O	NOUN	B
)	O	PUNCT	O
were	O	AUX	O
investigated	O	VERB	B
in	O	ADP	O
order	O	NOUN	O
to	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
long	O	ADJ	B
term	O	NOUN	I
effects	O	NOUN	B
of	O	ADP	O
vincristine	B-Chemical	NOUN	B
on	O	ADP	O
the	O	DET	O
peripheral	O	ADJ	B
nervous	O	ADJ	I
system	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
patients	O	NOUN	B
were	O	AUX	O
interviewed	O	VERB	B
with	O	ADP	O
emphasis	O	NOUN	O
on	O	ADP	O
neuropathic	B-Disease	ADJ	B
symptoms	I-Disease	NOUN	I
.	O	PUNCT	O


Physical	O	ADJ	B
and	O	CCONJ	O
quantitative	O	ADJ	B
sensory	O	ADJ	O
examination	O	NOUN	O
with	O	ADP	O
determination	O	NOUN	B
of	O	ADP	O
vibratory	O	ADJ	B
perception	O	NOUN	I
and	O	CCONJ	O
thermal	O	ADJ	B
discrimination	O	NOUN	I
thresholds	O	NOUN	B
were	O	AUX	O
performed	O	VERB	O
,	O	PUNCT	O
four	O	NUM	O
to	O	PART	O
77	O	NUM	O
months	O	NOUN	B
(	O	PUNCT	O
median	O	ADJ	B
34	O	NUM	O
months	O	NOUN	B
)	O	PUNCT	O
after	O	ADP	O
vincristine	B-Chemical	NOUN	B
treatment	O	NOUN	B
.	O	PUNCT	O


Twenty	O	NUM	B
-	O	PUNCT	O
seven	O	NUM	B
patients	O	NOUN	B
reported	O	VERB	O
neuropathic	B-Disease	ADJ	B
symptoms	I-Disease	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
13	O	NUM	O
of	O	ADP	O
these	O	DET	O
27	O	NUM	O
patients	O	NOUN	B
symptoms	O	NOUN	B
were	O	AUX	O
still	O	ADV	O
present	O	ADJ	O
at	O	ADP	O
the	O	DET	O
time	O	NOUN	B
of	O	ADP	O
examination	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
these	O	DET	O
patients	O	NOUN	B
sensory	O	ADJ	B
signs	O	NOUN	I
and	O	CCONJ	O
symptoms	O	NOUN	B
predominated	O	VERB	O
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
other	O	ADJ	O
14	O	NUM	O
patients	O	NOUN	B
symptoms	O	NOUN	B
had	O	AUX	O
been	O	AUX	O
present	O	ADJ	O
in	O	ADP	O
the	O	DET	O
past	O	NOUN	O
.	O	PUNCT	O


Symptoms	O	NOUN	B
persisted	O	VERB	O
maximally	O	ADV	O
40	O	NUM	O
months	O	NOUN	B
since	O	SCONJ	O
cessation	O	NOUN	B
of	O	ADP	O
therapy	O	NOUN	B
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
no	O	DET	O
age	O	NOUN	O
difference	O	NOUN	O
between	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
and	O	CCONJ	O
without	O	ADP	O
complaints	O	NOUN	B
at	O	ADP	O
the	O	DET	O
time	O	NOUN	O
of	O	ADP	O
examination	O	NOUN	B
.	O	PUNCT	O


Normal	O	ADJ	B
reflexes	O	NOUN	I
were	O	AUX	O
found	O	VERB	O
in	O	ADP	O
two	O	NUM	O
third	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
.	O	PUNCT	O


Neuropathic	O	ADJ	B
complaints	O	NOUN	I
were	O	AUX	O
not	O	PART	O
very	O	ADV	O
troublesome	O	ADJ	O
on	O	ADP	O
the	O	DET	O
long	O	ADJ	B
term	O	NOUN	I
.	O	PUNCT	O


It	O	PRON	O
is	O	AUX	O
concluded	O	VERB	O
that	O	SCONJ	O
with	O	ADP	O
the	O	DET	O
above	O	ADJ	O
mentioned	O	VERB	O
vincristine	B-Chemical	NOUN	B
dose	O	NOUN	O
schedule	O	NOUN	B
signs	O	NOUN	B
and	O	CCONJ	O
symptoms	O	NOUN	B
of	O	ADP	O
vincristine	B-Chemical	NOUN	B
neuropathy	B-Disease	NOUN	I


A	O	DET	O
case	O	NOUN	B
of	O	ADP	O
polymyositis	B-Disease	NOUN	B
in	O	ADP	O
a	O	DET	O
patient	O	NOUN	B
with	O	ADP	O
primary	B-Disease	ADJ	B
biliary	I-Disease	ADJ	I
cirrhosis	I-Disease	NOUN	I
treated	O	VERB	B
with	O	ADP	I
D-penicillamine	B-Chemical	NOUN	B
.	O	PUNCT	O


Although	O	SCONJ	O
D-penicillamine	B-Chemical	NOUN	B
has	O	AUX	O
been	O	AUX	O
used	O	VERB	O
for	O	ADP	O
many	O	ADJ	O
rheumatologic	B-Disease	ADJ	B
diseases	I-Disease	NOUN	I
,	O	PUNCT	O
toxicity	B-Disease	NOUN	B
limits	O	VERB	B
its	O	PRON	O
usefulness	O	NOUN	B
in	O	ADP	O
many	O	ADJ	O
patients	O	NOUN	B
.	O	PUNCT	O


Polymyositis	B-Disease	NOUN	B
/	O	PUNCT	O
dermatomyositis	B-Disease	NOUN	B
can	O	AUX	O
develop	O	VERB	O
as	O	ADP	O
one	O	NUM	O
of	O	ADP	O
the	O	DET	O
autoimmune	O	ADJ	B
complications	O	NOUN	O
of	O	ADP	O
D-penicillamine	B-Chemical	NOUN	B
treatment	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
its	O	PRON	O
exact	O	ADJ	O
pathogenesis	O	NOUN	B
remains	O	VERB	O
unclear	O	ADJ	B
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
a	O	DET	O
patient	O	NOUN	B
with	O	ADP	O
primary	B-Disease	ADJ	B
biliary	I-Disease	ADJ	I
cirrhosis	I-Disease	NOUN	I
,	O	PUNCT	O
who	O	PRON	O
developed	O	VERB	O
polymyositis	B-Disease	NOUN	B
while	O	SCONJ	O
receiving	O	VERB	O
D-penicillamine	B-Chemical	NOUN	B
therapy	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
described	O	VERB	O
the	O	DET	O
special	O	ADJ	O
clinical	O	ADJ	B
course	O	NOUN	I
of	O	ADP	O
the	O	DET	O
patient	O	NOUN	B
.	O	PUNCT	O


Patients	O	NOUN	B
receiving	O	VERB	O
D-penicillamine	B-Chemical	NOUN	B
therapy	O	NOUN	I
should	O	AUX	O
be	O	AUX	O
followed	O	VERB	O
carefully	O	ADV	O
for	O	ADP	O
the	O	DET	O
development	O	NOUN	B
of	O	ADP	O
autoimmune	O	ADJ	B
complications	O	NOUN	I
like	O	ADP	O
polymyositis	B-Disease	NOUN	B
/	O	SYM	O
dermatomyositis	B-Disease	NOUN	B


Photodistributed	O	ADJ	B
nifedipine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
facial	O	ADJ	B
telangiectasia	B-Disease	NOUN	I
.	O	PUNCT	O


Five	O	NUM	O
months	O	NOUN	B
after	O	ADP	O
starting	O	VERB	O
nifedipine	B-Chemical	NOUN	B
(	O	PUNCT	O
Adalat	B-Chemical	PROPN	B
),	O	PUNCT	O
two	O	NUM	O
patients	O	NOUN	B
developed	O	VERB	O
photodistributed	O	ADJ	B
facial	O	ADJ	B
telangiectasia	B-Disease	NOUN	I
,	O	PUNCT	O
which	O	DET	O
became	O	VERB	O
more	O	ADV	O
noticeable	O	ADJ	O
with	O	ADP	O
time	O	NOUN	B
.	O	PUNCT	O


Neither	O	DET	B
patient	O	NOUN	B
complained	O	VERB	O
of	O	ADP	O
photosensitivity	O	NOUN	B
or	O	CCONJ	O
flushing	B-Disease	NOUN	B
.	O	PUNCT	O


Both	O	DET	O
patients	O	NOUN	B
reported	O	VERB	O
a	O	DET	O
significant	O	ADJ	O
cosmetic	O	ADJ	B
improvement	O	NOUN	I
after	O	ADP	O
discontinuing	O	VERB	B
the	O	DET	O
drug	O	NOUN	B
.	O	PUNCT	O


One	O	NUM	O
commenced	O	VERB	O
the	O	DET	O
closely	O	ADV	O
related	O	ADJ	O
drug	O	NOUN	B
amlodipine	B-Chemical	NOUN	I
3	O	NUM	O
years	O	NOUN	B
later	O	ADV	O
,	O	PUNCT	O
with	O	ADP	O
recurrence	O	NOUN	B
of	O	ADP	O
telangiectasia	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
photodistribution	O	NOUN	B
of	O	ADP	O
the	O	DET	O
telangiectasia	B-Disease	NOUN	B


Nephrotoxicity	B-Disease	NOUN	B
of	O	ADP	O
cyclosporin	B-Chemical	NOUN	B
A	I-Chemical	NOUN	I
and	O	CCONJ	O
FK506	B-Chemical	NOUN	B
:	O	PUNCT	O
inhibition	O	NOUN	B
of	O	ADP	O
calcineurin	O	NOUN	B
phosphatase	O	NOUN	I
.	O	PUNCT	O


Cyclosporin	B-Chemical	NOUN	B
A	I-Chemical	NOUN	I
(	O	PUNCT	O
CsA	B-Chemical	NOUN	B
;	O	PUNCT	O
50	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
Fujimycine	B-Chemical	PROPN	B
(	O	PUNCT	O
FK506	B-Chemical	NOUN	B
;	O	PUNCT	O
5	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
),	O	PUNCT	O
but	O	CCONJ	O
not	O	PART	O
the	O	DET	O
related	O	ADJ	O
macrolide	B-Chemical	NOUN	B
immunosuppressant	O	ADJ	B
rapamycin	B-Chemical	NOUN	I
(	O	PUNCT	O
5	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
),	O	PUNCT	O
caused	O	VERB	O
a	O	DET	O
reduction	O	NOUN	B
of	O	ADP	O
glomerular	O	ADJ	B
filtration	O	NOUN	I
rate	O	NOUN	I
,	O	PUNCT	O
degenerative	O	ADJ	B
changes	O	NOUN	B
of	O	ADP	O
proximal	O	ADJ	B
tubular	O	ADJ	B
epithelium	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
hypertrophy	B-Disease	NOUN	B
of	O	ADP	O
the	O	DET	O
juxtaglomerular	O	ADJ	B
apparatus	O	NOUN	I
in	O	ADP	O
male	O	NOUN	B
Wistar	O	NOUN	B
rats	O	NOUN	I
when	O	SCONJ	O
given	O	VERB	O
for	O	ADP	O
10	O	NUM	O
days	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
molecular	O	ADJ	B
mechanisms	O	NOUN	I
of	O	ADP	O
CsA	B-Chemical	NOUN	B
and	O	CCONJ	O
FK506	B-Chemical	NOUN	B
toxicity	B-Disease	NOUN	B
were	O	AUX	O
investigated	O	VERB	B
.	O	PUNCT	O


Cyclophilin	O	NOUN	B
A	O	NOUN	I
and	O	CCONJ	O
FK506	B-Chemical	NOUN	B
-	O	PUNCT	O
binding	O	VERB	B
protein	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
main	O	ADJ	O
intracytoplasmic	O	ADJ	B
receptors	O	NOUN	I
for	O	ADP	O
CsA	B-Chemical	NOUN	B
and	O	CCONJ	O
FK506	B-Chemical	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
,	O	PUNCT	O
were	O	AUX	O
each	O	DET	O
detected	O	VERB	B
in	O	ADP	O
renal	O	ADJ	B
tissue	O	NOUN	I
extract	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
kidney	O	NOUN	B
,	O	PUNCT	O
high	O	ADJ	O
levels	O	NOUN	B
of	O	ADP	O
immunoreactive	O	ADJ	B
and	O	CCONJ	O
enzymatically	O	ADV	B
active	O	ADJ	I
calcineurin	O	NOUN	B
were	O	AUX	O
found	O	VERB	O
which	O	DET	O
were	O	AUX	O
inhibited	O	VERB	B
by	O	ADP	O
the	O	DET	O
immunosuppressants	O	NOUN	B
CsA	B-Chemical	NOUN	B
and	O	CCONJ	O
FK506	B-Chemical	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
not	O	PART	O
by	O	ADP	O
rapamycin	B-Chemical	NOUN	B
.	O	PUNCT	O


Finally	O	ADV	O
,	O	PUNCT	O
specific	O	ADJ	O
immunophilin	O	NOUN	B
-	O	PUNCT	O
drug	O	NOUN	B
-	O	PUNCT	O
calcineurin	O	NOUN	B
complexes	O	NOUN	B
formed	O	VERB	O
only	O	ADV	O
in	O	ADP	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
CsA	B-Chemical	NOUN	B
and	O	CCONJ	O
FK506	B-Chemical	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
not	O	PART	O
rapamycin	B-Chemical	NOUN	B
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
nephrotoxic	B-Disease	ADJ	B
effects	O	NOUN	B
of	O	ADP	O
CsA	B-Chemical	NOUN	B
and	O	CCONJ	O
FK506	B-Chemical	NOUN	B


Massive	O	ADJ	B
cerebral	B-Disease	ADJ	I
edema	I-Disease	NOUN	I
associated	O	VERB	B
with	O	ADP	I
fulminant	O	ADJ	B
hepatic	B-Disease	ADJ	B
failure	I-Disease	NOUN	I
in	O	ADP	O
acetaminophen	B-Chemical	NOUN	B
overdose	B-Disease	NOUN	I
:	O	PUNCT	O
possible	O	ADJ	O
role	O	NOUN	O
of	O	ADP	O
cranial	O	ADJ	B
decompression	O	NOUN	I
.	O	PUNCT	O


Cerebral	B-Disease	ADJ	B
edema	I-Disease	NOUN	I
may	O	AUX	O
complicate	O	VERB	B
the	O	DET	O
course	O	NOUN	B
of	O	ADP	O
fulminant	B-Disease	ADJ	B
hepatic	I-Disease	ADJ	B
failure	I-Disease	NOUN	I
.	O	PUNCT	O


Response	O	NOUN	B
to	O	PART	O
conventional	O	ADJ	B
therapy	O	NOUN	I
has	O	AUX	O
been	O	AUX	O
disappointing	O	ADJ	O
.	O	PUNCT	O


We	O	PRON	O
present	O	VERB	O
a	O	DET	O
patient	O	NOUN	B
with	O	ADP	O
fatal	O	ADJ	B
acetaminophen	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
fulminant	B-Disease	ADJ	B
hepatic	I-Disease	ADJ	B
failure	I-Disease	NOUN	I
,	O	PUNCT	O
with	O	ADP	O
signs	O	NOUN	B
and	O	CCONJ	I
symptoms	O	NOUN	B
of	O	ADP	O
cerebral	B-Disease	ADJ	B
edema	I-Disease	NOUN	I


Gentamicin	B-Chemical	NOUN	B
nephropathy	B-Disease	NOUN	I
in	O	ADP	O
a	O	DET	O
neonate	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
clinical	O	ADJ	B
and	O	CCONJ	O
autopsy	O	NOUN	B
findings	O	NOUN	B
in	O	ADP	O
a	O	DET	O
premature	O	ADJ	B
baby	O	NOUN	I
who	O	PRON	O
died	O	VERB	B
of	O	ADP	O
acute	B-Disease	ADJ	B
renal	I-Disease	ADJ	I
failure	I-Disease	NOUN	I
after	O	ADP	O
therapy	O	NOUN	B
with	O	ADP	O
gentamicin	B-Chemical	NOUN	B
(	O	PUNCT	O
5	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
/	O	PUNCT	O
day	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
penicillin	B-Chemical	NOUN	B
are	O	AUX	O
presented	O	VERB	O
.	O	PUNCT	O


The	O	DET	O
serum	O	NOUN	B
gentamicin	B-Chemical	NOUN	B
concentration	O	NOUN	B
had	O	AUX	O
reached	O	VERB	O
toxic	O	ADJ	B
levels	O	NOUN	O
when	O	SCONJ	O
anuria	B-Disease	NOUN	B
developed	O	VERB	O
.	O	PUNCT	O


Numerous	O	ADJ	O
periodic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
Schiff	O	NOUN	I
(	O	PUNCT	O
PAS	O	NOUN	B
)	O	PUNCT	O
positive	O	ADJ	B
,	O	PUNCT	O
diastase	O	NOUN	B
resistant	O	ADJ	I
cytoplasmic	O	ADJ	B
inclusion	O	NOUN	O
bodies	O	NOUN	O
which	O	DET	O
appeared	O	VERB	O
as	O	ADP	O
myelin	O	NOUN	B
figures	O	NOUN	O
in	O	ADP	O
cytosegresomes	O	NOUN	B
under	O	ADP	O
the	O	DET	O
electron	O	NOUN	B
microscope	O	NOUN	I
were	O	AUX	O
identified	O	VERB	B
in	O	ADP	O
the	O	DET	O
proximal	O	ADJ	B
convoluted	O	ADJ	O
tubules	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
pathological	O	ADJ	B
changes	O	NOUN	B
induced	O	VERB	B
by	O	ADP	O
gentamicin	B-Chemical	NOUN	B


Anti	O	PROPN	B
-	O	PUNCT	O
carcinogenic	B-Disease	ADJ	B
action	O	NOUN	B
of	O	ADP	O
phenobarbital	B-Chemical	NOUN	B
given	O	VERB	O
simultaneously	O	ADV	B
with	O	ADP	O
diethylnitrosamine	B-Chemical	NOUN	B
in	O	ADP	O
the	O	DET	O
rat	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
present	O	ADJ	O
work	O	NOUN	O
has	O	AUX	O
been	O	AUX	O
planned	O	VERB	B
in	O	ADP	O
order	O	NOUN	O
to	O	PART	O
elucidate	O	VERB	O
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
phenobarbital	B-Chemical	NOUN	B
(	O	PUNCT	O
PB	B-Chemical	NOUN	B
:	O	PUNCT	O
15	O	NUM	O
mg	O	NOUN	O
per	O	ADP	O
rat	O	NOUN	B
of	O	ADP	O
ingested	O	VERB	B
dose	O	NOUN	I
)	O	PUNCT	O
on	O	ADP	O
carcinogenesis	B-Disease	NOUN	B
when	O	SCONJ	O
it	O	PRON	O
is	O	AUX	O
administered	O	VERB	B
simultaneously	O	ADV	B
with	O	ADP	O
diethylnitrosamine	B-Chemical	NOUN	B
(	O	PUNCT	O
DEN	B-Chemical	NOUN	B
:	O	PUNCT	O
10	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
/	O	PUNCT	O
day	O	NOUN	B
).	O	PUNCT	O
Wistar	O	PROPN	B
rats	O	NOUN	I
(	O	PUNCT	O
180	O	NUM	O
g	O	NOUN	O
)	O	PUNCT	O
were	O	AUX	O
treated	O	VERB	B
by	O	ADP	O
DEN	B-Chemical	NOUN	B
alone	O	ADV	O
or	O	CCONJ	O
by	O	ADP	O
DEN	B-Chemical	NOUN	B
+	O	CCONJ	O
PB	B-Chemical	NOUN	B
during	O	ADP	O
2	O	NUM	O
,	O	PUNCT	O
4	O	NUM	O
and	O	CCONJ	O
6	O	NUM	O
weeks	O	NOUN	B
according	O	VERB	O
to	O	ADP	O
our	O	PRON	O
schedule	O	NOUN	B
for	O	ADP	O
hepatocarcinogenesis	B-Disease	NOUN	B
.	O	PUNCT	O


After	O	ADP	O
the	O	DET	O
end	O	NOUN	O
of	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
number	O	NOUN	O
and	O	CCONJ	O
the	O	DET	O
size	O	NOUN	B
of	O	ADP	O
induced	O	VERB	B
PAS	O	NOUN	B
positive	O	ADJ	B
preneoplastic	B-Disease	ADJ	B
foci	I-Disease	NOUN	O
was	O	AUX	O
significantly	O	ADV	O
reduced	O	VERB	B
when	O	SCONJ	O
PB	B-Chemical	NOUN	B
was	O	AUX	O
given	O	VERB	O
simultaneously	O	ADV	B
with	O	ADP	O
DEN	B-Chemical	NOUN	B
for	O	ADP	O
4	O	NUM	O
and	O	CCONJ	O
6	O	NUM	O
weeks	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
mitotic	O	ADJ	B
inhibition	O	NOUN	I
and	O	CCONJ	O
the	O	DET	O
production	O	NOUN	B
of	O	ADP	O
micronuclei	O	NOUN	B
normally	O	ADV	O
observed	O	VERB	O
after	O	ADP	O
partial	O	ADJ	B
hepatectomy	O	NOUN	B
in	O	ADP	O
DEN	B-Chemical	NOUN	B
treated	O	ADJ	B
rats	O	NOUN	B
were	O	AUX	O
also	O	ADV	O
significantly	O	ADV	O
decreased	O	VERB	B
in	O	ADP	O
DEN	B-Chemical	NOUN	B
+	O	CCONJ	O
PB	B-Chemical	NOUN	B
treated	O	ADJ	B
rats	O	NOUN	B
.	O	PUNCT	O


When	O	SCONJ	O
the	O	DET	O
treatment	O	NOUN	B
last	O	ADJ	O
only	O	ADV	O
2	O	NUM	O
weeks	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
PB	B-Chemical	NOUN	B
did	O	AUX	O
not	O	PART	O
change	O	VERB	O
significantly	O	ADV	O
the	O	DET	O
last	O	ADJ	O
parameters	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
DEN	B-Chemical	NOUN	B
+	O	CCONJ	O
PB	B-Chemical	NOUN	B
treated	O	ADJ	B
rats	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
survival	O	NOUN	B
was	O	AUX	O
prolonged	O	ADJ	B
and	O	CCONJ	O
the	O	DET	O
tumor	B-Disease	NOUN	B
incidence	O	NOUN	B
decreased	O	VERB	B
as	O	ADP	O
compared	O	VERB	B
with	O	ADP	O
the	O	DET	O
results	O	NOUN	B
obtained	O	VERB	O
by	O	ADP	O
DEN	B-Chemical	NOUN	B
alone	O	ADV	O
.	O	PUNCT	O


It	O	PRON	O
is	O	AUX	O
concluded	O	VERB	O
that	O	SCONJ	O
PB	B-Chemical	NOUN	B
,	O	PUNCT	O
which	O	DET	O
promotes	O	VERB	B
carcinogenesis	B-Disease	NOUN	B
when	O	SCONJ	O
administered	O	VERB	B
after	O	ADP	O
the	O	DET	O
DEN	B-Chemical	NOUN	B
treatment	O	NOUN	B
,	O	PUNCT	O
reduces	O	VERB	O
the	O	DET	O
carcinogen	O	NOUN	B
effect	O	NOUN	B
when	O	SCONJ	O
given	O	VERB	O
simultaneously	O	ADV	B
with	O	ADP	O
DEN	B-Chemical	NOUN	B
.	O	PUNCT	O


This	O	DET	O
'	O	PUNCT	O
anti	O	ADJ	B
-	O	PUNCT	O
carcinogen	O	NOUN	B
'	O	PART	O
effect	O	NOUN	B
acts	O	VERB	O
on	O	ADP	O
the	O	DET	O
initiation	O	NOUN	B
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
on	O	ADP	O
the	O	DET	O
promotion	O	NOUN	B
of	O	ADP	O
the	O	DET	O
precancerous	B-Disease	ADJ	B
lesions	I-Disease	NOUN	B
.	O	PUNCT	O


Biochemical	O	ADJ	B
investigations	O	NOUN	B
are	O	AUX	O
in	O	ADP	O
progress	O	NOUN	B
to	O	PART	O
obtain	O	VERB	O
more	O	ADJ	O
information	O	NOUN	B
about	O	ADP	O
this	O	DET	O
'	O	PUNCT	O
paradoxical	O	ADJ	B
'	O	PUNCT	O
PB	B-Chemical	NOUN	B


Post	O	NOUN	B
-	O	PUNCT	O
operative	O	ADJ	B
rigidity	B-Disease	NOUN	B
after	O	ADP	O
fentanyl	B-Chemical	NOUN	B
administration	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
case	O	NOUN	B
of	O	ADP	O
thoraco	O	ADJ	B
-	O	PUNCT	O
abdominal	O	ADJ	B
rigidity	B-Disease	NOUN	B
leading	O	VERB	O
to	O	PART	O
respiratory	B-Disease	ADJ	B
failure	I-Disease	NOUN	I
is	O	AUX	O
described	O	VERB	O
in	O	ADP	O
the	O	DET	O
post	O	NOUN	B
-	O	PUNCT	O
operative	O	ADJ	B
period	O	NOUN	B
in	O	ADP	O
an	O	DET	O
elderly	O	ADJ	B
patient	O	NOUN	I
who	O	PRON	O
received	O	VERB	O
a	O	DET	O
moderate	O	ADJ	B
dose	O	NOUN	B
of	O	ADP	O
fentanyl	B-Chemical	NOUN	B
.	O	PUNCT	O


This	O	DET	O
was	O	AUX	O
successfully	O	ADV	O
reversed	O	VERB	O
by	O	ADP	O
naloxone	B-Chemical	NOUN	B


Postpartum	O	NOUN	B
psychosis	B-Disease	NOUN	I
induced	O	VERB	B
by	O	ADP	O
bromocriptine	B-Chemical	NOUN	B
.	O	PUNCT	O


Two	O	NUM	O
multigravida	O	NOUN	B
patients	O	NOUN	B
with	O	ADP	O
no	O	DET	O
prior	O	ADJ	O
psychiatric	B-Disease	ADJ	B
history	O	NOUN	I
were	O	AUX	O
seen	O	VERB	O
with	O	ADP	O
postpartum	O	NOUN	B
psychosis	B-Disease	NOUN	I
,	O	PUNCT	O
having	O	VERB	O
received	O	VERB	O
bromocriptine	B-Chemical	NOUN	B
for	O	ADP	O
inhibition	B-Disease	NOUN	B
of	I-Disease	ADP	O
lactation	I-Disease	NOUN	B
.	O	PUNCT	O


Bromocriptine	B-Chemical	NOUN	B
given	O	VERB	O
in	O	ADP	O
high	O	ADJ	B
doses	O	NOUN	I
has	O	AUX	O
been	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
psychosis	B-Disease	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
receiving	O	VERB	O
the	O	DET	O
drug	O	NOUN	B
for	O	ADP	O
Parkinson's	B-Disease	ADJ	O
disease	I-Disease	NOUN	O
.	O	PUNCT	O


These	O	DET	O
cases	O	NOUN	B
demonstrate	O	VERB	O
that	O	SCONJ	O
bromocriptine	B-Chemical	NOUN	B
may	O	AUX	O
cause	O	VERB	O
psychosis	B-Disease	NOUN	B


A	O	DET	O
prospective	O	ADJ	B
study	O	NOUN	I
on	O	ADP	O
the	O	DET	O
dose	O	NOUN	B
dependency	O	NOUN	B
of	O	ADP	O
cardiotoxicity	B-Disease	NOUN	B
induced	O	VERB	B
by	O	ADP	O
mitomycin	B-Chemical	NOUN	B
C	I-Chemical	NOUN	O
.	O	PUNCT	O


Since	O	SCONJ	O
1975	O	NUM	O
mitomycin	B-Chemical	NOUN	B
C	I-Chemical	NOUN	I
(	O	PUNCT	O
MMC	B-Chemical	NOUN	B
)	O	PUNCT	O
has	O	AUX	O
been	O	AUX	O
suggested	O	VERB	O
to	O	PART	O
be	O	AUX	O
cardiotoxic	B-Disease	ADJ	B
,	O	PUNCT	O
especially	O	ADV	O
when	O	SCONJ	O
combined	O	VERB	B
with	O	ADP	O
or	O	CCONJ	O
given	O	VERB	O
following	O	VERB	O
doxorubicin	B-Chemical	NOUN	B
.	O	PUNCT	O


Data	O	NOUN	B
on	O	ADP	O
dose	O	NOUN	B
dependency	O	NOUN	B
or	O	CCONJ	O
incidence	O	NOUN	B
concerning	O	VERB	O
this	O	DET	O
side	O	NOUN	B
effect	O	NOUN	I
were	O	AUX	O
not	O	PART	O
known	O	VERB	O
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
initiated	O	VERB	O
a	O	DET	O
prospective	O	ADJ	B
study	O	NOUN	I
to	O	PART	O
obtain	O	VERB	O
some	O	DET	O
more	O	ADJ	O
data	O	NOUN	B
on	O	ADP	O
these	O	DET	O
subjects	O	NOUN	B
.	O	PUNCT	O


Forty	O	NUM	B
-	O	PUNCT	O
four	O	NUM	B
MMC	B-Chemical	PROPN	B
-	O	PUNCT	O
treated	O	VERB	B
patients	O	NOUN	B
were	O	AUX	O
studied	O	VERB	O
,	O	PUNCT	O
37	O	NUM	O
of	O	ADP	O
them	O	PRON	O
could	O	AUX	O
be	O	AUX	O
evaluated	O	VERB	B
.	O	PUNCT	O


All	O	DET	O
patients	O	NOUN	B
were	O	AUX	O
studied	O	VERB	O
by	O	ADP	O
repeated	O	VERB	O
physical	O	ADJ	B
examinations	O	NOUN	I
,	O	PUNCT	O
chest	O	ADJ	B
X	O	NOUN	I
-	O	PUNCT	O
rays	O	NOUN	B
,	O	PUNCT	O
electro	O	NOUN	B
-	O	PUNCT	O
and	O	CCONJ	O
echocardiography	O	NOUN	B
and	O	CCONJ	O
radionuclide	O	NOUN	B
left	O	VERB	I
ventricular	O	ADJ	I
ejection	O	NOUN	I
fraction	O	NOUN	I
(	O	PUNCT	O
EF	O	NOUN	B
)	O	PUNCT	O
determinations	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
results	O	NOUN	B
were	O	AUX	O
evaluated	O	VERB	B
per	O	ADP	O
cumulative	O	ADJ	B
dose	O	NOUN	B
level	O	NOUN	B
.	O	PUNCT	O


One	O	NUM	O
of	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
developed	O	VERB	O
cardiac	B-Disease	ADJ	B
failure	I-Disease	NOUN	I
after	O	ADP	O
30	O	NUM	O
mg	O	NOUN	O
m	O	NOUN	O
-	O	SYM	O
2	O	NUM	B
MMC	B-Chemical	PROPN	B
and	O	CCONJ	O
only	O	ADV	O
150	O	NUM	O
mg	O	NOUN	O
m	O	NOUN	O
-	O	SYM	O
2	O	NUM	B
doxorubicin	B-Chemical	NOUN	B
.	O	PUNCT	O


The	O	DET	O
cardiac	B-Disease	ADJ	B
failure	I-Disease	NOUN	I
was	O	AUX	O
predicted	O	VERB	O
by	O	ADP	O
a	O	DET	O
drop	O	NOUN	B
in	O	ADP	O
EF	O	PROPN	B
determined	O	VERB	O
during	O	ADP	O
a	O	DET	O
cold	O	ADJ	B
pressor	O	NOUN	I
test	O	NOUN	I
.	O	PUNCT	O


of	O	ADP	O
the	O	DET	O
other	O	ADJ	O
patients	O	NOUN	B
developed	O	VERB	O
clinical	O	ADJ	B
cardiotoxicity	B-Disease	NOUN	B
,	O	PUNCT	O
nor	O	CCONJ	O
did	O	AUX	O
the	O	DET	O
studied	O	VERB	O
parameters	O	NOUN	B
change	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
literature	O	NOUN	B
on	O	ADP	O
this	O	DET	O
subject	O	NOUN	B
was	O	AUX	O
also	O	ADV	O
reviewed	O	VERB	B
.	O	PUNCT	O


Based	O	VERB	O
on	O	ADP	O
the	O	DET	O
combined	O	ADJ	B
data	O	NOUN	B
from	O	ADP	O
the	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
literature	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
suggest	O	VERB	O
that	O	SCONJ	O
MMC	B-Chemical	PROPN	B
-	O	PUNCT	O
related	O	VERB	B
cardiotoxicity	B-Disease	NOUN	B
is	O	AUX	O
dose	O	NOUN	B
dependent	O	ADJ	I
,	O	PUNCT	O
occurring	O	VERB	O
at	O	ADP	O
cumulative	O	ADJ	B
dose	O	NOUN	B
levels	O	NOUN	B
of	O	ADP	O
30	O	NUM	O
mg	O	NOUN	O
m	O	NOUN	O
-	O	SYM	O
2	O	NUM	O
or	O	CCONJ	O
more	O	ADJ	O
,	O	PUNCT	O
mainly	O	ADV	O
in	O	ADP	O
patients	O	NOUN	B
also	O	ADV	O
(	O	PUNCT	O
previously	O	ADV	O
or	O	CCONJ	O
simultaneously	O	ADV	B
)	O	PUNCT	O
treated	O	VERB	B
with	O	ADP	I
doxorubicin	B-Chemical	NOUN	B


Phlorizin	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
glycosuria	B-Disease	NOUN	B
does	O	AUX	O
not	O	PART	O
prevent	O	VERB	O
gentamicin	B-Chemical	NOUN	B
nephrotoxicity	B-Disease	NOUN	B
in	O	ADP	O
rats	O	NOUN	B
.	O	PUNCT	O


Because	O	SCONJ	O
rats	O	NOUN	B
with	O	ADP	O
streptozotocin	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
diabetes	B-Disease	NOUN	B
mellitus	I-Disease	NOUN	I
(	O	PUNCT	O
DM	B-Disease	NOUN	B
)	O	PUNCT	O
have	O	AUX	O
a	O	DET	O
high	O	ADJ	O
solute	O	NOUN	O
diuresis	O	NOUN	O
(	O	PUNCT	O
glycosuria	B-Disease	NOUN	B
of	O	ADP	O
10	O	NUM	O
to	O	PART	O
12	O	NUM	O
g	O	NOUN	B
/	O	PUNCT	O
day	O	NOUN	B
),	O	PUNCT	O
we	O	PRON	O
have	O	AUX	O
suggested	O	VERB	O
that	O	SCONJ	O
this	O	DET	O
may	O	AUX	O
in	O	ADP	O
part	O	NOUN	O
be	O	AUX	O
responsible	O	ADJ	O
for	O	ADP	O
their	O	PRON	O
resistance	O	NOUN	B
to	O	PART	O
gentamicin	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
acute	B-Disease	ADJ	B
renal	I-Disease	ADJ	I
failure	I-Disease	NOUN	I
(	O	PUNCT	O
ARF	B-Disease	NOUN	B
).	O	PUNCT	O
The	O	DET	O
protection	O	NOUN	B
from	O	ADP	O
gentamicin	B-Chemical	NOUN	B
nephrotoxicity	B-Disease	NOUN	B
was	O	AUX	O
studied	O	VERB	O
in	O	ADP	O
non	O	ADJ	B
-	O	PUNCT	O
diabetic	B-Disease	ADJ	B
rats	O	NOUN	B
with	O	ADP	O
chronic	O	ADJ	B
solute	O	NOUN	I
diuresis	O	NOUN	I
induced	O	VERB	B
by	O	ADP	O
blockage	O	NOUN	B
of	O	ADP	O
tubular	O	ADJ	B
glucose	B-Chemical	NOUN	I
reabsorption	O	NOUN	I
with	O	ADP	O
phlorizin	B-Chemical	NOUN	B
(	O	PUNCT	O
P	B-Chemical	NOUN	O
).	O	PUNCT	O
DM	B-Disease	NOUN	B
rats	O	NOUN	B
with	O	ADP	O
mild	O	ADJ	B
glycosuria	B-Disease	NOUN	B
(	O	PUNCT	O
similar	O	ADJ	O
in	O	ADP	O
degree	O	NOUN	B
to	O	PART	O
that	O	DET	O
of	O	ADP	O
the	O	DET	O
P	B-Chemical	NOUN	O
treated	O	ADJ	B
animals	O	NOUN	B
)	O	PUNCT	O
were	O	AUX	O
also	O	ADV	O
studied	O	VERB	O
.	O	PUNCT	O


Unanesthetized	O	ADJ	B
adult	O	ADJ	I
female	O	NOUN	B
,	O	PUNCT	O
Sprague	O	PROPN	B
-	O	PUNCT	O
Dawley	O	NOUN	B
rats	O	NOUN	B
were	O	AUX	O
divided	O	VERB	O
in	O	ADP	O
four	O	NUM	O
groups	O	NOUN	B
and	O	CCONJ	O
studied	O	VERB	O
for	O	ADP	O
15	O	NUM	O
days	O	NOUN	B
.	O	PUNCT	O


Group	O	NOUN	B
1	O	NUM	O
(	O	PUNCT	O
P	B-Chemical	NOUN	O
alone	O	ADV	O
)	O	PUNCT	O
received	O	VERB	O
P	B-Chemical	NOUN	O
,	O	PUNCT	O
360	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
day	O	NOUN	B
,	O	PUNCT	O
for	O	ADP	O
15	O	NUM	O
days	O	NOUN	B
;	O	PUNCT	O
Group	O	PROPN	B
II	O	NUM	I
(	O	PUNCT	O
P	B-Chemical	NOUN	O
+	O	CCONJ	O
gentamicin	B-Chemical	NOUN	B
);	O	ADJ	O
Group	O	PROPN	O
III	O	NUM	O
(	O	PUNCT	O
gentamicin	B-Chemical	NOUN	B
alone	O	ADV	O
)	O	PUNCT	O
and	O	CCONJ	O
Group	O	PROPN	B
IV	O	NUM	I
(	O	PUNCT	O
mild	O	ADJ	B
DM	B-Disease	NOUN	I
+	O	CCONJ	O
gentamicin	B-Chemical	NOUN	B
).	O	PUNCT	O
Nephrotoxic	B-Disease	NOUN	B
doses	O	NOUN	O
(	O	PUNCT	O
40	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
body	O	NOUN	I
wt	O	PROPN	O
/	O	PUNCT	O
day	O	NOUN	B
)	O	PUNCT	O
of	O	ADP	O
gentamicin	B-Chemical	NOUN	B
were	O	AUX	O
injected	O	VERB	B
during	O	ADP	O
the	O	DET	O
last	O	ADJ	O
nine	O	NUM	O
days	O	NOUN	B
of	O	ADP	O
study	O	NOUN	B
to	O	ADP	O
the	O	DET	O
animals	O	NOUN	B
of	O	ADP	O
groups	O	NOUN	B
II	O	NUM	I
to	O	PART	O
IV	O	NUM	B
.	O	PUNCT	O


In	O	ADP	O
Group	O	PROPN	B
I	O	PROPN	I
,	O	PUNCT	O
P	B-Chemical	NOUN	O
induced	O	VERB	B
a	O	DET	O
moderate	O	ADJ	B
and	O	CCONJ	O
stable	O	ADJ	B
glycosuria	B-Disease	NOUN	B
(	O	PUNCT	O
3	O	NUM	O
.	O	PUNCT	O


9	O	NUM	O
+/-	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
g	O	NOUN	B
/	O	PUNCT	O
day	O	NOUN	B
,	O	PUNCT	O
SE	O	NOUN	B
),	O	PUNCT	O
and	O	CCONJ	O
no	O	DET	O
functional	O	ADJ	O
or	O	CCONJ	O
morphologic	O	ADJ	B
evidence	O	NOUN	B
of	O	ADP	O
renal	B-Disease	ADJ	B
dysfunction	I-Disease	NOUN	I
(	O	PUNCT	O
baseline	O	NOUN	B
CCr	O	NOUN	B
2	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
+/-	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
ml	O	NOUN	O
/	O	SYM	O
min	O	NOUN	B
,	O	PUNCT	O
undetectable	O	ADJ	B
lysozymuria	O	NOUN	B
)	O	PUNCT	O
or	O	CCONJ	O
damage	O	NOUN	B
(	O	PUNCT	O
tubular	B-Disease	ADJ	B
necrosis	I-Disease	NOUN	I
score	O	NOUN	I
[	O	PUNCT	O
maximum	O	NOUN	B
4	O	NUM	O
],	O	PUNCT	O
zero	O	NUM	O
).	O	PUNCT	B
In	O	ADP	O
Group	O	PROPN	B
II	O	PROPN	I
,	O	PUNCT	O
P	B-Chemical	NOUN	O
did	O	AUX	O
not	O	PART	O
prevent	O	VERB	O
gentamicin	B-Chemical	NOUN	B
-	O	PUNCT	O
ARF	B-Disease	NOUN	B
(	O	PUNCT	O
maximal	O	ADJ	B
decrease	O	NOUN	B
in	O	ADP	O
CCr	O	NOUN	B
at	O	ADP	O
day	O	NOUN	B
9	O	NUM	O
.	O	PUNCT	O


89	O	NUM	O
%,	O	NOUN	O
P	B-Chemical	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


001	O	NUM	O
;	O	PUNCT	O
peak	O	NOUN	B
lysozymuria	O	NOUN	I
,	O	PUNCT	O
1863	O	NUM	O
+/-	O	CCONJ	O
321	O	NUM	O
micrograms	O	NOUN	B
/	O	PUNCT	O
day	O	NOUN	B
;	O	PUNCT	O
and	O	CCONJ	O
tubular	B-Disease	ADJ	B
necrosis	I-Disease	NOUN	I
score	O	NOUN	I
,	O	PUNCT	O
3	O	NUM	O
.	O	PUNCT	O


9	O	NUM	O
+/-	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
).	O	PUNCT	O
These	O	DET	O
values	O	NOUN	B
were	O	AUX	O
not	O	PART	O
different	O	ADJ	O
from	O	ADP	O
those	O	DET	O
of	O	ADP	O
Group	O	PROPN	B
III	O	NUM	O
:	O	PUNCT	O
maximal	O	ADJ	B
decrease	O	NOUN	B
in	O	ADP	O
CCr	O	NOUN	B
73	O	NUM	O
%(	O	NOUN	O
P	B-Chemical	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


001	O	NUM	O
);	O	ADJ	B
lysozymuria	O	NOUN	I
,	O	PUNCT	O
2147	O	NUM	O
+/-	O	CCONJ	O
701	O	NUM	O
micrograms	O	NOUN	B
/	O	PUNCT	O
day	O	NOUN	B
;	O	PUNCT	O
tubular	B-Disease	ADJ	B
necrosis	I-Disease	NOUN	I


Tiapride	B-Chemical	NOUN	B
in	O	ADP	O
levodopa	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
involuntary	B-Disease	ADJ	B
movements	I-Disease	NOUN	B
.	O	PUNCT	O


Tiapride	B-Chemical	NOUN	B
,	O	PUNCT	O
a	O	DET	O
substituted	O	VERB	B
benzamide	B-Chemical	NOUN	I
derivative	O	NOUN	I
closely	O	ADV	O
related	O	ADJ	O
to	O	PART	O
metoclopramide	B-Chemical	NOUN	B
,	O	PUNCT	O
reduced	O	VERB	B
levodopa	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
peak	O	NOUN	B
dose	O	NOUN	I
involuntary	B-Disease	ADJ	B
movements	I-Disease	NOUN	B
in	O	ADP	O
16	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
idiopathic	B-Disease	ADJ	B
Parkinson's	I-Disease	ADJ	I
disease	I-Disease	NOUN	I
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
an	O	DET	O
unacceptable	O	ADJ	O
increase	O	NOUN	B
in	O	ADP	O
disability	O	NOUN	B
from	O	ADP	O
Parkinsonism	B-Disease	NOUN	B
with	O	ADP	O
aggravation	O	NOUN	B
of	O	ADP	O
end	O	NOUN	B
-	O	PUNCT	O
of	O	ADP	B
-	O	PUNCT	O
dose	O	NOUN	B
akinesia	B-Disease	NOUN	B
led	O	VERB	O
to	O	ADP	O
its	O	PRON	O
cessation	O	NOUN	B
in	O	ADP	O
14	O	NUM	O
patients	O	NOUN	B
.	O	PUNCT	O


Tiapride	B-Chemical	NOUN	B
had	O	AUX	O
no	O	DET	B
effect	O	NOUN	I
on	O	ADP	O
levodopa	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
early	O	ADJ	B
morning	O	NOUN	O
of	O	ADP	O
"	O	PUNCT	O
off	O	ADJ	B
-	O	PUNCT	O
period	O	NOUN	B
"	O	PUNCT	O
segmental	O	ADJ	B
dystonia	B-Disease	NOUN	I
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	B
fail	O	VERB	O
to	O	PART	O
support	O	VERB	O
the	O	DET	O
notion	O	NOUN	O
that	O	SCONJ	O
levodopa	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
dyskinesias	B-Disease	NOUN	B
are	O	AUX	O
caused	O	VERB	O
by	O	ADP	O
overstimulation	O	NOUN	B
of	O	ADP	O
a	O	DET	O
separate	O	ADJ	O
group	O	NOUN	B
of	O	ADP	O
dopamine	B-Chemical	NOUN	B


Effects	O	NOUN	B
of	O	ADP	I
the	O	DET	O
hippocampal	O	NOUN	B
deep	O	ADJ	B
brain	O	NOUN	I
stimulation	O	NOUN	I
on	O	ADP	O
cortical	O	ADJ	B
epileptic	B-Disease	ADJ	I
discharges	O	NOUN	I
in	O	ADP	O
penicillin	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
epilepsy	B-Disease	NOUN	B
model	O	NOUN	B
in	O	ADP	O
rats	O	NOUN	B
.	O	PUNCT	O


AIM	O	NOUN	B
:	O	PUNCT	O
Experimental	O	ADJ	B
and	O	CCONJ	O
clinical	O	ADJ	B
studies	O	NOUN	I
have	O	AUX	O
revealed	O	VERB	O
that	O	SCONJ	O
hippocampal	O	NOUN	B
DBS	O	PROPN	B
can	O	AUX	O
control	O	VERB	O
epileptic	B-Disease	ADJ	B
activity	O	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
the	O	DET	O
mechanism	O	NOUN	B
of	O	ADP	O
action	O	NOUN	B
is	O	AUX	O
obscure	O	ADJ	B
and	O	CCONJ	O
optimal	O	ADJ	B
stimulation	O	NOUN	B
parameters	O	NOUN	B
are	O	AUX	O
not	O	PART	O
clearly	O	ADV	O
defined	O	VERB	O
.	O	PUNCT	O


The	O	DET	O
aim	O	NOUN	O
was	O	AUX	O
to	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
high	O	ADJ	B
frequency	O	NOUN	I
hippocampal	O	NOUN	B
stimulation	O	NOUN	B
on	O	ADP	O
cortical	O	ADJ	B
epileptic	B-Disease	ADJ	I
activity	O	NOUN	I
in	O	ADP	O
penicillin	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
epilepsy	B-Disease	NOUN	B
model	O	NOUN	B
.	O	PUNCT	O


MATERIAL	O	NOUN	B
AND	O	CCONJ	O
METHODS	O	NOUN	O
:	O	PUNCT	O
Twenty	O	NUM	B
-	O	PUNCT	O
five	O	NUM	B
Sprague	O	PROPN	B
-	O	PUNCT	O
Dawley	O	NOUN	B
rats	O	NOUN	B
were	O	AUX	O
implanted	O	VERB	B
DBS	O	NOUN	B
electrodes	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
group	O	NOUN	B
-	O	PUNCT	O
1	O	NUM	O
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
10	O	NUM	O
)	O	PUNCT	O
hippocampal	O	NOUN	B
DBS	O	NOUN	B
was	O	AUX	O
off	O	ADP	O
and	O	CCONJ	O
in	O	ADP	O
the	O	DET	O
group	O	NOUN	B
-	O	PUNCT	O
2	O	NUM	O
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
10	O	NUM	O
)	O	PUNCT	O
hippocampal	O	NOUN	B
DBS	O	NOUN	B
was	O	AUX	O
on	O	ADP	O
(	O	PUNCT	O
185	O	NUM	O
Hz	O	NOUN	O
,	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


5V	O	NOUN	O
,	O	PUNCT	O
1V	O	PROPN	B
,	O	PUNCT	O
2V	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
5V	O	NOUN	O
for	O	ADP	O
60	O	NUM	O
sec	O	NOUN	O
)	O	PUNCT	O
following	O	VERB	O
penicillin	B-Chemical	NOUN	B
G	I-Chemical	NOUN	I
injection	O	NOUN	B
intracortically	O	ADV	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
control	O	ADJ	B
group	O	NOUN	I
hippocampal	O	NOUN	B
DBS	O	PROPN	B
was	O	AUX	O
on	O	ADP	O
following	O	VERB	O
8	O	NUM	O
l	O	NOUN	O
saline	O	NOUN	B
injection	O	NOUN	B
intracortically	O	ADV	B
.	O	PUNCT	O


EEG	O	NOUN	B
recordings	O	NOUN	B
were	O	AUX	O
obtained	O	VERB	O
before	O	ADP	O
and	O	CCONJ	O
15	O	NUM	O
minutes	O	NOUN	B
following	O	VERB	O
penicillin-G	B-Chemical	ADJ	B
injection	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
at	O	ADP	O
10th	O	ADJ	O
minutes	O	NOUN	B
following	O	VERB	O
each	O	DET	O
stimulus	O	NOUN	B
for	O	ADP	O
analysis	O	NOUN	B
in	O	ADP	O
terms	O	NOUN	O
of	O	ADP	O
frequency	O	NOUN	B
,	O	PUNCT	O
amplitude	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
power	O	NOUN	B
spectrum	O	NOUN	I
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
High	O	ADJ	B
frequency	O	NOUN	I
hippocampal	O	NOUN	B
DBS	O	NOUN	B
suppressed	O	VERB	B
the	O	DET	O
acute	O	ADJ	B
penicillin	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
cortical	O	ADJ	B
epileptic	B-Disease	ADJ	O
activity	O	NOUN	O
independent	O	ADJ	O
from	O	ADP	O
stimulus	O	NOUN	B
intensity	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
control	O	NOUN	B
group	O	NOUN	I
,	O	PUNCT	O
hippocampal	O	ADJ	B
stimulation	O	NOUN	B
alone	O	ADV	O
lead	O	VERB	O
only	O	ADV	O
to	O	PART	O
diffuse	O	NOUN	O
slowing	O	NOUN	O
of	O	ADP	O
cerebral	O	ADJ	B
bioelectrical	O	ADJ	I
activity	O	NOUN	I
at	O	ADP	O
5V	O	NOUN	B
stimulation	O	NOUN	I
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
:	O	PUNCT	O
Our	O	PRON	O
results	O	NOUN	B
revealed	O	VERB	O
that	O	SCONJ	O
continuous	O	ADJ	B
high	O	ADJ	B
frequency	O	NOUN	I
stimulation	O	NOUN	O
of	O	ADP	O
the	O	DET	O
hippocampus	O	NOUN	B
suppressed	O	VERB	B
acute	O	ADJ	B
cortical	O	ADJ	I
epileptic	B-Disease	ADJ	I
activity	O	NOUN	I
effectively	O	ADV	O
without	O	ADP	O
causing	O	VERB	O
secondary	O	ADJ	O
epileptic	B-Disease	ADJ	B
discharges	O	NOUN	I
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	B
are	O	AUX	O
important	O	ADJ	O
in	O	ADP	O
terms	O	NOUN	O
of	O	ADP	O
defining	O	VERB	O
the	O	DET	O
optimal	O	ADJ	B
parameters	O	NOUN	B
of	O	ADP	O
hippocampal	O	ADJ	B
DBS	O	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
epilepsy	B-Disease	NOUN	B


Neural	O	ADJ	B
correlates	O	NOUN	B
of	O	ADP	O
S-ketamine	B-Chemical	NOUN	B
induced	O	ADJ	B
psychosis	B-Disease	NOUN	B
during	O	ADP	O
overt	O	ADJ	B
continuous	O	ADJ	B
verbal	O	ADJ	B
fluency	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
glutamatergic	O	ADJ	B
N-methyl-D-aspartate	B-Chemical	NOUN	I
(	O	PUNCT	O
NMDA	B-Chemical	NOUN	B
)	O	PUNCT	O
receptor	O	NOUN	O
has	O	AUX	O
been	O	AUX	O
implicated	O	VERB	O
in	O	ADP	O
the	O	DET	O
pathophysiology	O	NOUN	B
of	O	ADP	O
schizophrenia	B-Disease	NOUN	B
.	O	PUNCT	O


Administered	O	VERB	B
to	O	PART	O
healthy	O	ADJ	B
volunteers	O	NOUN	I
,	O	PUNCT	O
a	O	DET	O
subanesthetic	O	ADJ	B
dose	O	NOUN	O
of	O	ADP	O
the	O	DET	O
non	O	ADJ	B
-	O	PUNCT	O
competitive	O	ADJ	B
NMDA	B-Chemical	NOUN	B
receptor	O	NOUN	I
antagonist	O	NOUN	B
ketamine	B-Chemical	NOUN	B
leads	O	VERB	O
to	O	PART	O
psychopathological	O	ADJ	B
symptoms	O	NOUN	B
similar	O	ADJ	O
to	O	PART	O
those	O	DET	O
observed	O	VERB	O
in	O	ADP	O
schizophrenia	B-Disease	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
schizophrenia	B-Disease	NOUN	B
,	O	PUNCT	O
ketamine	B-Chemical	NOUN	B
exacerbates	O	VERB	B
the	O	DET	O
core	O	NOUN	B
symptoms	O	NOUN	I
of	O	ADP	O
illness	O	NOUN	B
,	O	PUNCT	O
supporting	O	VERB	O
the	O	DET	O
hypothesis	O	NOUN	B
of	O	ADP	O
a	O	DET	O
glutamatergic	B-Disease	ADJ	B
dysfunction	I-Disease	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
a	O	DET	O
counterbalanced	O	ADJ	B
,	O	PUNCT	O
placebo	O	NOUN	B
-	O	PUNCT	O
controlled	O	VERB	B
,	O	PUNCT	O
double	O	ADJ	B
-	O	PUNCT	O
blind	O	ADJ	B
study	O	NOUN	B
design	O	NOUN	I
,	O	PUNCT	O
healthy	O	ADJ	B
subjects	O	NOUN	I
were	O	AUX	O
administered	O	VERB	B
a	O	DET	O
continuous	O	ADJ	B
subanesthetic	O	ADJ	B
S-ketamine	B-Chemical	NOUN	B
infusion	O	NOUN	B
while	O	SCONJ	O
differences	O	NOUN	B
in	O	ADP	O
BOLD	O	NOUN	B
responses	O	NOUN	B
measured	O	VERB	B
with	O	ADP	O
fMRI	O	NOUN	B
were	O	AUX	O
detected	O	VERB	B
.	O	PUNCT	O


During	O	ADP	O
the	O	DET	O
scanning	O	NOUN	B
period	O	NOUN	B
,	O	PUNCT	O
subjects	O	NOUN	B
performed	O	VERB	O
continuous	O	ADJ	O
overt	O	ADJ	B
verbal	O	ADJ	B
fluency	O	NOUN	I
tasks	O	NOUN	I
(	O	PUNCT	O
phonological	O	ADJ	B
,	O	PUNCT	O
lexical	O	ADJ	B
and	O	CCONJ	O
semantic	O	ADJ	B
).	O	PUNCT	B
Ketamine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
psychopathological	O	ADJ	B
symptoms	O	NOUN	B
were	O	AUX	O
assessed	O	VERB	B
with	O	ADP	O
the	O	DET	O
Positive	O	ADJ	B
and	O	CCONJ	I
Negative	O	ADJ	O
Syndrome	O	NOUN	O
Scale	O	NOUN	O
(	O	PUNCT	O
PANSS	O	VERB	B
).	O	PUNCT	O
Ketamine	B-Chemical	NOUN	B
elicited	O	VERB	O
psychosis	B-Disease	NOUN	B
like	O	ADP	O
psychopathology	O	NOUN	B
.	O	PUNCT	O


Post	O	NOUN	B
-	O	PUNCT	O
hoc	O	NOUN	B
t	O	NOUN	O
-	O	PUNCT	O
tests	O	NOUN	B
revealed	O	VERB	O
significant	O	ADJ	O
differences	O	NOUN	O
between	O	ADP	O
placebo	O	NOUN	B
and	O	CCONJ	O
ketamine	B-Chemical	NOUN	B
for	O	ADP	O
the	O	DET	O
amounts	O	NOUN	B
of	O	ADP	O
words	O	NOUN	B
generated	O	VERB	O
during	O	ADP	O
lexical	O	ADJ	B
and	O	CCONJ	O
semantic	O	ADJ	B
verbal	O	ADJ	O
fluency	O	NOUN	O
,	O	PUNCT	O
while	O	SCONJ	O
the	O	DET	O
phonological	O	ADJ	B
domain	O	NOUN	I
remained	O	VERB	O
unaffected	O	ADJ	B
.	O	PUNCT	O


Ketamine	B-Chemical	NOUN	B
led	O	VERB	O
to	O	PART	O
enhanced	O	VERB	B
cortical	O	ADJ	B
activations	O	NOUN	I
in	O	ADP	O
supramarginal	O	ADJ	B
and	O	CCONJ	O
frontal	O	ADJ	B
brain	O	NOUN	I
regions	O	NOUN	I
for	O	ADP	O
phonological	O	ADJ	B
and	O	CCONJ	O
lexical	O	ADJ	B
verbal	O	ADJ	B
fluency	O	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
not	O	PART	O
for	O	ADP	O
semantic	O	ADJ	B
verbal	O	ADJ	B
fluency	O	NOUN	I
.	O	PUNCT	O


Ketamine	B-Chemical	NOUN	B
induces	O	VERB	O
activation	O	NOUN	B
changes	O	NOUN	B
in	O	ADP	O
healthy	O	ADJ	B
subjects	O	NOUN	I
similar	O	ADJ	O
to	O	PART	O
those	O	DET	O
observed	O	VERB	O
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
schizophrenia	B-Disease	NOUN	B
,	O	PUNCT	O
particularly	O	ADV	O
in	O	ADP	O
frontal	O	ADJ	B
and	O	CCONJ	O
temporal	O	ADJ	B
brain	O	NOUN	O
regions	O	NOUN	O
.	O	PUNCT	O


Our	O	PRON	O
results	O	NOUN	B
provide	O	VERB	O
further	O	ADJ	O
support	O	NOUN	O
for	O	ADP	O
the	O	DET	O
hypothesis	O	NOUN	B
of	O	ADP	O
an	O	DET	O
NMDA	B-Chemical	NOUN	B
receptor	O	NOUN	I
dysfunction	O	NOUN	B
in	O	ADP	O
the	O	DET	O
pathophysiology	O	NOUN	B
of	O	ADP	O
schizophrenia	B-Disease	NOUN	B


Dopamine	B-Chemical	NOUN	B
is	O	AUX	O
not	O	PART	O
essential	O	ADJ	O
for	O	ADP	O
the	O	DET	O
development	O	NOUN	B
of	O	ADP	O
methamphetamine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
neurotoxicity	B-Disease	NOUN	B
.	O	PUNCT	O


It	O	PRON	O
is	O	AUX	O
widely	O	ADV	O
believed	O	VERB	O
that	O	SCONJ	O
dopamine	B-Chemical	NOUN	B
(	O	PUNCT	O
DA	B-Chemical	NOUN	B
)	O	PUNCT	O
mediates	O	VERB	O
methamphetamine	B-Chemical	NOUN	B
(	O	PUNCT	O
METH	B-Chemical	NOUN	B
)-	O	ADJ	O
induced	O	VERB	B
toxicity	B-Disease	NOUN	B
to	O	PART	O
brain	O	NOUN	B
dopaminergic	O	ADJ	B
neurons	O	NOUN	B
,	O	PUNCT	O
because	O	SCONJ	O
drugs	O	NOUN	B
that	O	PRON	O
interfere	O	VERB	B
with	O	ADP	I
DA	B-Chemical	NOUN	B
neurotransmission	O	NOUN	I
decrease	O	VERB	B
toxicity	B-Disease	NOUN	B
,	O	PUNCT	O
whereas	O	SCONJ	O
drugs	O	NOUN	B
that	O	PRON	O
increase	O	VERB	B
DA	B-Chemical	NOUN	B
neurotransmission	O	NOUN	I
enhance	O	VERB	O
toxicity	B-Disease	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
temperature	O	NOUN	B
effects	O	NOUN	B
of	O	ADP	O
drugs	O	NOUN	B
that	O	PRON	O
have	O	AUX	O
been	O	AUX	O
used	O	VERB	O
to	O	PART	O
manipulate	O	VERB	O
brain	O	NOUN	B
DA	B-Chemical	NOUN	B
neurotransmission	O	NOUN	I
confound	O	VERB	O
interpretation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
data	O	NOUN	B
.	O	PUNCT	O


Here	O	ADV	O
we	O	PRON	O
show	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
recently	O	ADV	O
reported	O	VERB	O
ability	O	NOUN	O
of	O	ADP	O
L-dihydroxyphenylalanine	B-Chemical	NOUN	B
to	O	PART	O
reverse	O	VERB	O
the	O	DET	O
protective	O	ADJ	B
effect	O	NOUN	I
of	O	ADP	O
alpha-methyl-para-tyrosine	B-Chemical	NOUN	B
on	O	ADP	O
METH	B-Chemical	PROPN	B
-	O	PUNCT	O
induced	O	VERB	B
DA	B-Chemical	NOUN	B
neurotoxicity	B-Disease	NOUN	I
is	O	AUX	O
also	O	ADV	O
confounded	O	VERB	O
by	O	ADP	O
drug	O	NOUN	B
effects	O	NOUN	I
on	O	ADP	O
body	O	NOUN	B
temperature	O	NOUN	I
.	O	PUNCT	O


Further	O	ADV	O
,	O	PUNCT	O
we	O	PRON	O
show	O	VERB	O
that	O	SCONJ	O
mice	O	NOUN	B
genetically	O	ADV	B
engineered	O	VERB	B
to	O	PART	O
be	O	AUX	O
deficient	O	ADJ	B
in	O	ADP	O
brain	O	NOUN	B
DA	B-Chemical	NOUN	I
develop	O	VERB	O
METH	B-Chemical	NOUN	B
neurotoxicity	B-Disease	NOUN	B
,	O	PUNCT	O
as	O	ADV	O
long	O	ADV	O
as	O	ADP	O
the	O	DET	O
thermic	O	ADJ	B
effects	O	NOUN	I
of	O	ADP	O
METH	B-Chemical	NOUN	B
are	O	AUX	O
preserved	O	VERB	O
.	O	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
,	O	PUNCT	O
we	O	PRON	O
demonstrate	O	VERB	O
that	O	SCONJ	O
mice	O	NOUN	B
genetically	O	ADV	B
engineered	O	VERB	B
to	O	PART	O
have	O	AUX	O
unilateral	O	ADJ	B
brain	O	NOUN	B
DA	B-Chemical	NOUN	B
deficits	O	NOUN	I
develop	O	VERB	O
METH	B-Chemical	PROPN	B
-	O	PUNCT	O
induced	O	VERB	B
dopaminergic	B-Disease	ADJ	B
deficits	I-Disease	NOUN	I
that	O	PRON	O
are	O	AUX	O
of	O	ADP	O
comparable	O	ADJ	O
magnitude	O	NOUN	B
on	O	ADP	O
both	O	DET	O
sides	O	NOUN	O
of	O	ADP	O
the	O	DET	O
brain	O	NOUN	B
.	O	PUNCT	O


Taken	O	VERB	O
together	O	ADV	O
,	O	PUNCT	O
these	O	DET	O
findings	O	NOUN	B
demonstrate	O	VERB	O
that	O	SCONJ	O
DA	B-Chemical	NOUN	B
is	O	AUX	O
not	O	PART	O
essential	O	ADJ	O
for	O	ADP	O
the	O	DET	O
development	O	NOUN	B
of	O	ADP	O
METH	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
dopaminergic	O	ADJ	B
neurotoxicity	B-Disease	NOUN	B
and	O	CCONJ	O
suggest	O	VERB	O
that	O	SCONJ	O
mechanisms	O	NOUN	B
independent	O	ADJ	B
of	O	ADP	O
DA	B-Chemical	NOUN	B


Brainstem	B-Disease	NOUN	B
dysgenesis	I-Disease	NOUN	I
in	O	ADP	O
an	O	DET	O
infant	O	NOUN	B
prenatally	O	ADV	B
exposed	O	VERB	B
to	O	PART	O
cocaine	B-Chemical	NOUN	B
.	O	PUNCT	O


Many	O	ADJ	O
authors	O	NOUN	B
described	O	VERB	O
the	O	DET	O
effects	O	NOUN	B
on	O	ADP	O
the	O	DET	O
fetus	O	NOUN	B
of	O	ADP	O
maternal	O	ADJ	B
cocaine	B-Disease	NOUN	B
abuse	I-Disease	NOUN	I
during	O	ADP	O
pregnancy	O	NOUN	B
.	O	PUNCT	O


Vasoconstriction	O	NOUN	B
appears	O	VERB	O
to	O	PART	O
be	O	AUX	O
the	O	DET	O
common	O	ADJ	O
mechanism	O	NOUN	B
of	O	ADP	O
action	O	NOUN	B
leading	O	VERB	O
to	O	PART	O
a	O	DET	O
wide	O	ADJ	O
range	O	NOUN	O
of	O	ADP	O
fetal	B-Disease	ADJ	B
anomalies	I-Disease	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
on	O	ADP	O
an	O	DET	O
infant	O	NOUN	B
with	O	ADP	O
multiple	B-Disease	ADJ	B
cranial-nerve	I-Disease	ADJ	I
involvement	I-Disease	NOUN	B
attributable	O	ADJ	O
to	O	PART	O
brainstem	B-Disease	NOUN	B
dysgenesis	I-Disease	NOUN	I
,	O	PUNCT	O
born	O	VERB	B
to	O	PART	O
a	O	DET	O
cocaine-addicted	B-Disease	ADJ	B


The	O	DET	O
protective	O	ADJ	O
role	O	NOUN	O
of	O	ADP	O
Nrf2	O	NOUN	B
in	O	ADP	O
streptozotocin	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
diabetic	B-Disease	ADJ	B
nephropathy	I-Disease	NOUN	I
.	O	PUNCT	O


OBJECTIVE	O	NOUN	B
:	O	PUNCT	O
Diabetic	B-Disease	ADJ	B
nephropathy	I-Disease	NOUN	I
is	O	AUX	O
one	O	NUM	O
of	O	ADP	O
the	O	DET	O
major	O	ADJ	O
causes	O	NOUN	O
of	O	ADP	O
renal	B-Disease	ADJ	B
failure	I-Disease	NOUN	I
,	O	PUNCT	O
which	O	DET	O
is	O	AUX	O
accompanied	O	VERB	O
by	O	ADP	O
the	O	DET	O
production	O	NOUN	B
of	O	ADP	O
reactive	O	ADJ	B
oxygen	B-Chemical	NOUN	I
species	O	NOUN	I
(	O	PUNCT	O
ROS	O	NOUN	B
).	O	PUNCT	O
Nrf2	O	NOUN	B
is	O	AUX	O
the	O	DET	O
primary	O	ADJ	B
transcription	O	NOUN	I
factor	O	NOUN	I
that	O	PRON	O
controls	O	VERB	B
the	O	DET	O
antioxidant	O	ADJ	B
response	O	NOUN	I
essential	O	ADJ	O
for	O	ADP	O
maintaining	O	VERB	O
cellular	O	ADJ	B
redox	O	NOUN	O
homeostasis	O	NOUN	O
.	O	PUNCT	O


Here	O	ADV	O
,	O	PUNCT	O
we	O	PRON	O
report	O	VERB	O
our	O	PRON	O
findings	O	NOUN	B
demonstrating	O	VERB	O
a	O	DET	O
protective	O	ADJ	O
role	O	NOUN	O
of	O	ADP	O
Nrf2	O	NOUN	B
against	O	ADP	O
diabetic	B-Disease	ADJ	B
nephropathy	I-Disease	NOUN	I
.	O	PUNCT	O


RESEARCH	O	NOUN	O
DESIGN	O	NOUN	O
AND	O	CCONJ	O
METHODS	O	NOUN	O
:	O	PUNCT	O
We	O	PRON	O
explore	O	VERB	O
the	O	DET	O
protective	O	ADJ	O
role	O	NOUN	O
of	O	ADP	O
Nrf2	O	NOUN	B
against	O	ADP	O
diabetic	B-Disease	ADJ	B
nephropathy	I-Disease	NOUN	I
using	O	VERB	O
human	O	ADJ	B
kidney	O	NOUN	I
biopsy	O	NOUN	I
tissues	O	NOUN	O
from	O	ADP	O
diabetic	B-Disease	ADJ	B
nephropathy	I-Disease	NOUN	I
patients	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
streptozotocin	B-Chemical	PROPN	B
-	O	PUNCT	O
induced	O	VERB	B
diabetic	B-Disease	ADJ	B
nephropathy	I-Disease	NOUN	I
model	O	NOUN	B
in	O	ADP	O
Nrf2	O	NOUN	B
(-/-)	O	NOUN	O
mice	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
cultured	O	VERB	B
human	O	ADJ	B
mesangial	O	ADJ	B
cells	O	NOUN	I
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
The	O	DET	O
glomeruli	O	NOUN	B
of	O	ADP	O
human	O	ADJ	B
diabetic	B-Disease	ADJ	I
nephropathy	I-Disease	NOUN	I
patients	O	NOUN	B
were	O	AUX	O
under	O	ADP	O
oxidative	O	ADJ	B
stress	O	NOUN	I
and	O	CCONJ	O
had	O	AUX	O
elevated	O	ADJ	B
Nrf2	O	NOUN	B
levels	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
animal	O	NOUN	B
study	O	NOUN	I
,	O	PUNCT	O
Nrf2	O	NOUN	B
was	O	AUX	O
demonstrated	O	VERB	O
to	O	PART	O
be	O	AUX	O
crucial	O	ADJ	O
in	O	ADP	O
ameliorating	O	VERB	B
streptozotocin	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
renal	B-Disease	ADJ	B
damage	I-Disease	NOUN	I
.	O	PUNCT	O


This	O	DET	O
is	O	AUX	O
evident	O	ADJ	O
by	O	ADP	O
Nrf2	O	NOUN	B
(-/-)	O	NOUN	O
mice	O	NOUN	B
having	O	VERB	O
higher	O	ADJ	O
ROS	O	NOUN	B
production	O	NOUN	B
and	O	CCONJ	O
suffering	O	NOUN	B
from	O	ADP	O
greater	O	ADJ	O
oxidative	O	ADJ	B
DNA	O	NOUN	O
damage	O	NOUN	O
and	O	CCONJ	O
renal	B-Disease	ADJ	B
injury	I-Disease	NOUN	I
compared	O	VERB	O
with	O	ADP	O
Nrf2	O	NOUN	B
(+/+)	O	NOUN	B
mice	O	NOUN	I
.	O	PUNCT	O


Mechanistic	O	ADJ	B
studies	O	NOUN	I
in	O	ADP	O
both	O	CCONJ	O
in	O	X	B
vivo	O	X	I
and	O	CCONJ	O
in	O	X	B
vitro	O	X	I
systems	O	NOUN	I
showed	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
Nrf2	O	NOUN	B
-	O	PUNCT	O
mediated	O	VERB	B
protection	O	NOUN	B
against	O	ADP	O
diabetic	B-Disease	ADJ	B
nephropathy	I-Disease	NOUN	I
is	O	AUX	O
,	O	PUNCT	O
at	O	ADP	O
least	O	ADJ	O
,	O	PUNCT	O
partially	O	ADV	B
through	O	ADP	O
inhibition	O	NOUN	B
of	O	ADP	O
transforming	O	VERB	B
growth	O	NOUN	I
factor	O	NOUN	I
-	O	PUNCT	O
beta1	O	NOUN	B
(	O	PUNCT	O
TGF	O	NOUN	B
-	O	PUNCT	O
beta1	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
reduction	O	NOUN	B
of	O	ADP	O
extracellular	O	ADJ	B
matrix	O	NOUN	I
production	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
human	O	ADJ	B
renal	O	ADJ	O
mesangial	O	ADJ	O
cells	O	NOUN	O
,	O	PUNCT	O
high	O	ADJ	B
glucose	B-Chemical	NOUN	I
induced	O	VERB	B
ROS	O	NOUN	B
production	O	NOUN	B
and	O	CCONJ	O
activated	O	VERB	B
expression	O	NOUN	B
of	O	ADP	O
Nrf2	O	NOUN	B
and	O	CCONJ	O
its	O	PRON	O
downstream	O	ADJ	B
genes	O	NOUN	I
.	O	PUNCT	O


Furthermore	O	ADV	O
,	O	PUNCT	O
activation	O	NOUN	B
or	O	CCONJ	O
overexpression	O	NOUN	B
of	O	ADP	O
Nrf2	O	NOUN	B
inhibited	O	VERB	B
the	O	DET	O
promoter	O	NOUN	B
activity	O	NOUN	I
of	O	ADP	O
TGF	O	NOUN	B
-	O	PUNCT	O
beta1	O	NOUN	B
in	O	ADP	O
a	O	DET	O
dose	O	NOUN	B
-	O	PUNCT	O
dependent	O	ADJ	B
manner	O	NOUN	O
,	O	PUNCT	O
whereas	O	SCONJ	O
knockdown	O	NOUN	B
of	O	ADP	O
Nrf2	O	NOUN	B
by	O	ADP	O
siRNA	O	NOUN	B
enhanced	O	VERB	B
TGF	O	NOUN	B
-	O	PUNCT	O
beta1	O	NOUN	B
transcription	O	NOUN	B
and	O	CCONJ	O
fibronectin	O	NOUN	B
production	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
:	O	PUNCT	O
This	O	DET	O
work	O	NOUN	O
clearly	O	ADV	O
indicates	O	VERB	O
a	O	DET	O
protective	O	ADJ	O
role	O	NOUN	O
of	O	ADP	O
Nrf2	O	NOUN	B
in	O	ADP	O
diabetic	B-Disease	ADJ	B
nephropathy	I-Disease	NOUN	I
,	O	PUNCT	O
suggesting	O	VERB	O
that	O	SCONJ	O
dietary	O	ADJ	B
or	O	CCONJ	O
therapeutic	O	ADJ	B
activation	O	NOUN	I
of	O	ADP	O
Nrf2	O	NOUN	B
could	O	AUX	O
be	O	AUX	O
used	O	VERB	O
as	O	ADP	O
a	O	DET	O
strategy	O	NOUN	O
to	O	PART	O
prevent	O	VERB	B
or	O	CCONJ	O
slow	O	VERB	B
down	O	ADP	I
the	O	DET	O
progression	O	NOUN	B
of	O	ADP	O
diabetic	B-Disease	ADJ	B
nephropathy	I-Disease	NOUN	I


High	O	ADJ	B
-	O	PUNCT	O
dose	O	NOUN	B
tranexamic	B-Chemical	ADJ	B
Acid	I-Chemical	PROPN	I
is	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
nonischemic	O	ADJ	B
clinical	O	ADJ	B
seizures	B-Disease	NOUN	I
in	O	ADP	O
cardiac	O	ADJ	B
surgical	O	ADJ	I
patients	O	NOUN	B
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
:	O	PUNCT	O
In	O	ADP	O
2	O	NUM	O
separate	O	ADJ	O
centers	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
observed	O	VERB	O
a	O	DET	O
notable	O	ADJ	O
increase	O	NOUN	B
in	O	ADP	O
the	O	DET	O
incidence	O	NOUN	B
of	O	ADP	O
postoperative	O	ADJ	B
convulsive	B-Disease	ADJ	B
seizures	B-Disease	NOUN	I
from	O	ADP	O
1	O	NUM	O
.	O	PUNCT	O


3	O	NUM	O
%	O	NOUN	O
to	O	PART	O
3	O	NUM	O
.	O	PUNCT	O


8	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
patients	O	NOUN	B
having	O	VERB	O
undergone	O	VERB	O
major	O	ADJ	O
cardiac	O	ADJ	B
surgical	O	ADJ	I
procedures	O	NOUN	I
.	O	PUNCT	O


These	O	DET	O
events	O	NOUN	B
were	O	AUX	O
temporally	O	ADV	O
coincident	O	ADJ	B
with	O	ADP	O
the	O	DET	O
initial	O	ADJ	O
use	O	NOUN	O
of	O	ADP	O
high	O	ADJ	B
-	O	PUNCT	O
dose	O	NOUN	B
tranexamic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
(	O	PUNCT	O
TXA	B-Chemical	NOUN	B
)	O	PUNCT	O
therapy	O	NOUN	B
after	O	ADP	O
withdrawal	O	NOUN	O
of	O	ADP	O
aprotinin	O	NOUN	B
from	O	ADP	O
general	O	ADJ	O
clinical	O	ADJ	B
usage	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
purpose	O	NOUN	O
of	O	ADP	O
this	O	DET	O
review	O	NOUN	B
was	O	AUX	O
to	O	PART	O
perform	O	VERB	O
a	O	DET	O
retrospective	O	ADJ	B
analysis	O	NOUN	I
to	O	PART	O
examine	O	VERB	O
whether	O	SCONJ	O
there	O	PRON	O
was	O	AUX	O
a	O	DET	O
relation	O	NOUN	O
between	O	ADP	O
TXA	B-Chemical	NOUN	B
usage	O	NOUN	B
and	O	CCONJ	O
seizures	B-Disease	NOUN	B
after	O	ADP	O
cardiac	O	ADJ	B
surgery	O	NOUN	I
.	O	PUNCT	O


METHODS	O	NOUN	O
:	O	PUNCT	O
An	O	DET	O
in	O	ADP	O
-	O	PUNCT	O
depth	O	NOUN	B
chart	O	NOUN	O
review	O	NOUN	O
was	O	AUX	O
undertaken	O	VERB	O
in	O	ADP	O
all	O	DET	O
24	O	NUM	O
patients	O	NOUN	B
who	O	PRON	O
developed	O	VERB	O
perioperative	O	ADJ	B
seizures	B-Disease	NOUN	B
.	O	PUNCT	O


Electroencephalographic	O	ADJ	B
activity	O	NOUN	I
was	O	AUX	O
recorded	O	VERB	O
in	O	ADP	O
11	O	NUM	O
of	O	ADP	O
these	O	DET	O
patients	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
all	O	DET	O
patients	O	NOUN	B
had	O	AUX	O
a	O	DET	O
formal	O	ADJ	O
neurological	O	ADJ	B
evaluation	O	NOUN	B
and	O	CCONJ	O
brain	O	NOUN	B
imaging	O	NOUN	I
studies	O	NOUN	O
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
Twenty	O	NUM	B
-	O	PUNCT	O
one	O	NUM	O
of	O	ADP	O
the	O	DET	O
24	O	NUM	O
patients	O	NOUN	B
did	O	AUX	O
not	O	PART	O
have	O	AUX	O
evidence	O	NOUN	B
of	O	ADP	O
new	O	ADJ	O
cerebral	B-Disease	ADJ	B
ischemic	I-Disease	ADJ	I
injury	I-Disease	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
seizures	B-Disease	NOUN	B
were	O	AUX	O
likely	O	ADJ	O
due	O	ADJ	O
to	O	PART	O
ischemic	B-Disease	ADJ	B
brain	I-Disease	NOUN	B
injury	I-Disease	NOUN	I
in	O	ADP	O
3	O	NUM	O
patients	O	NOUN	B
.	O	PUNCT	O


All	O	DET	O
patients	O	NOUN	B
with	O	ADP	O
seizures	B-Disease	NOUN	B
did	O	AUX	O
not	O	PART	O
have	O	AUX	O
permanent	O	ADJ	B
neurological	B-Disease	ADJ	B
abnormalities	I-Disease	NOUN	I
.	O	PUNCT	O


All	O	DET	O
24	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
seizures	B-Disease	NOUN	B
received	O	VERB	O
high	O	ADJ	B
doses	O	NOUN	I
of	O	ADP	O
TXA	B-Chemical	NOUN	B
intraoperatively	O	ADV	B
ranging	O	VERB	O
from	O	ADP	O
61	O	NUM	O
to	O	PART	O
259	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
,	O	PUNCT	O
had	O	AUX	O
a	O	DET	O
mean	O	ADJ	O
age	O	NOUN	B
of	O	ADP	O
69	O	NUM	O
.	O	PUNCT	O


9	O	NUM	O
years	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
21	O	NUM	O
of	O	ADP	O
24	O	NUM	O
had	O	AUX	O
undergone	O	VERB	O
open	O	ADJ	B
chamber	O	NOUN	I
rather	O	ADV	O
than	O	ADP	O
coronary	O	ADJ	B
bypass	O	NOUN	I
procedures	O	NOUN	I
.	O	PUNCT	O


All	O	DET	O
but	O	CCONJ	O
one	O	NUM	O
patient	O	NOUN	B
were	O	AUX	O
managed	O	VERB	O
using	O	VERB	O
cardiopulmonary	O	ADJ	B
bypass	O	NOUN	I
.	O	PUNCT	O


No	O	DET	O
evidence	O	NOUN	O
of	O	ADP	O
brain	B-Disease	NOUN	B
ischemic	I-Disease	ADJ	I
,	O	PUNCT	O
metabolic	O	ADJ	B
,	O	PUNCT	O
or	O	CCONJ	O
hyperthermia	B-Disease	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
causes	O	NOUN	O
for	O	ADP	O
their	O	PRON	O
seizures	B-Disease	NOUN	B
was	O	AUX	O
apparent	O	ADJ	B
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
:	O	PUNCT	O
Our	O	PRON	O
results	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
use	O	NOUN	O
of	O	ADP	O
high	O	ADJ	B
-	O	PUNCT	O
dose	O	NOUN	B
TXA	B-Chemical	NOUN	B
in	O	ADP	O
older	O	ADJ	B
patients	O	NOUN	I
in	O	ADP	O
conjunction	O	NOUN	B
with	O	ADP	O
cardiopulmonary	O	ADJ	B
bypass	O	NOUN	I
and	O	CCONJ	O
open	O	ADJ	B
-	O	PUNCT	O
chamber	O	NOUN	B
cardiac	O	ADJ	B
surgery	O	NOUN	I
is	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
clinical	O	ADJ	B
seizures	B-Disease	NOUN	I


Recurrent	O	ADJ	B
dysosmia	B-Disease	NOUN	I
induced	O	VERB	B
by	O	ADP	O
pyrazinamide	B-Chemical	NOUN	B
.	O	PUNCT	O


Pyrazinamide	B-Chemical	NOUN	B
can	O	AUX	O
have	O	AUX	O
adverse	O	ADJ	B
effects	O	NOUN	I
such	O	ADJ	O
as	O	ADP	O
hepatic	B-Disease	ADJ	B
toxicity	I-Disease	NOUN	B
,	O	PUNCT	O
hyperuricemia	B-Disease	NOUN	B
or	O	CCONJ	O
digestive	O	ADJ	B
disorders	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
rare	O	ADJ	B
cases	O	NOUN	B
,	O	PUNCT	O
alterations	O	NOUN	B
in	O	ADP	O
taste	O	NOUN	B
and	O	CCONJ	O
smell	O	NOUN	B
function	O	NOUN	I
have	O	AUX	O
been	O	AUX	O
reported	O	VERB	O
for	O	ADP	O
pyrazinamide	B-Chemical	NOUN	B
when	O	SCONJ	O
combined	O	VERB	B
with	O	ADP	O
other	O	ADJ	O
drugs	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
a	O	DET	O
case	O	NOUN	B
of	O	ADP	O
reversible	O	ADJ	B
olfactory	B-Disease	ADJ	B
disorder	I-Disease	NOUN	I
related	O	ADJ	O
to	O	PART	O
pyrazinamide	B-Chemical	NOUN	B
in	O	ADP	O
a	O	DET	O
woman	O	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
a	O	DET	O
positive	O	ADJ	B
rechallenge	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
patient	O	NOUN	B
presented	O	VERB	O
every	O	DET	O
day	O	NOUN	B
a	O	DET	O
sensation	O	NOUN	B
of	O	ADP	O
smelling	O	VERB	B
something	O	PRON	I
burning	O	VERB	B
15	O	NUM	O
min	O	NOUN	O
after	O	ADP	O
drug	O	NOUN	B
intake	O	NOUN	I
.	O	PUNCT	O


Dysosmia	B-Disease	PROPN	B
disappeared	O	VERB	O
completely	O	ADV	O
after	O	ADP	O
pyrazinamide	B-Chemical	NOUN	B


Longitudinal	O	ADJ	B
assessment	O	NOUN	I
of	O	ADP	O
air	O	NOUN	B
conduction	O	NOUN	I
audiograms	O	NOUN	B
in	O	ADP	O
a	O	DET	O
phase	O	NOUN	B
III	O	NUM	I
clinical	O	ADJ	I
trial	O	NOUN	I
of	O	ADP	O
difluoromethylornithine	B-Chemical	NOUN	B
and	O	CCONJ	O
sulindac	B-Chemical	NOUN	B
for	O	ADP	O
prevention	O	NOUN	B
of	O	ADP	O
sporadic	O	ADJ	B
colorectal	B-Disease	ADJ	B
adenomas	I-Disease	NOUN	I
.	O	PUNCT	O


A	O	DET	O
phase	O	NOUN	B
III	O	NUM	I
clinical	O	ADJ	I
trial	O	NOUN	I
assessed	O	VERB	B
the	O	DET	O
recurrence	O	NOUN	B
of	O	ADP	O
adenomatous	B-Disease	ADJ	B
polyps	I-Disease	NOUN	I
after	O	ADP	O
treatment	O	NOUN	B
for	O	ADP	O
36	O	NUM	O
months	O	NOUN	B
with	O	ADP	O
difluoromethylornithine	B-Chemical	NOUN	B
(	O	PUNCT	O
DFMO	B-Chemical	NOUN	B
)	O	PUNCT	O
plus	O	CCONJ	O
sulindac	B-Chemical	NOUN	B
or	O	CCONJ	O
matched	O	VERB	B
placebos	O	NOUN	B
.	O	PUNCT	O


Temporary	O	ADJ	B
hearing	B-Disease	NOUN	O
loss	I-Disease	NOUN	O
is	O	AUX	O
a	O	DET	O
known	O	ADJ	O
toxicity	B-Disease	NOUN	B
of	O	ADP	O
treatment	O	NOUN	B
with	O	ADP	O
DFMO	B-Chemical	NOUN	B
,	O	PUNCT	O
thus	O	ADV	O
a	O	DET	O
comprehensive	O	ADJ	B
approach	O	NOUN	O
was	O	AUX	O
developed	O	VERB	O
to	O	PART	O
analyze	O	VERB	O
serial	O	ADJ	B
air	O	NOUN	B
conduction	O	NOUN	I
audiograms	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
generalized	O	VERB	B
estimating	O	VERB	I
equation	O	NOUN	I
method	O	NOUN	I
estimated	O	VERB	B
the	O	DET	O
mean	O	ADJ	O
difference	O	NOUN	O
between	O	ADP	O
treatment	O	NOUN	B
arms	O	NOUN	O
with	O	ADP	O
regard	O	NOUN	O
to	O	PART	O
change	O	VERB	O
in	O	ADP	O
air	O	NOUN	B
conduction	O	NOUN	I
pure	O	ADJ	O
tone	O	NOUN	B
thresholds	O	NOUN	B
while	O	SCONJ	O
accounting	O	VERB	O
for	O	ADP	O
within	O	ADP	B
-	O	PUNCT	O
subject	O	ADJ	B
correlation	O	NOUN	B
due	O	ADJ	O
to	O	PART	O
repeated	O	VERB	O
measurements	O	NOUN	B
at	O	ADP	O
frequencies	O	NOUN	B
.	O	PUNCT	O


Based	O	VERB	O
on	O	ADP	O
290	O	NUM	O
subjects	O	NOUN	B
,	O	PUNCT	O
there	O	PRON	O
was	O	AUX	O
an	O	DET	O
average	O	ADJ	O
difference	O	NOUN	O
of	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


50	O	NUM	O
dB	O	NOUN	O
between	O	ADP	O
subjects	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
DFMO	B-Chemical	NOUN	B
plus	O	CCONJ	O
sulindac	B-Chemical	NOUN	B
compared	O	VERB	B
with	O	ADP	O
those	O	DET	O
treated	O	VERB	B
with	O	ADP	I
placebo	O	NOUN	B
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
,-	O	NOUN	O
0	O	NUM	O
.	O	PUNCT	O


64	O	NUM	O
to	O	PART	O
1	O	NUM	O
.	O	PUNCT	O


63	O	NUM	O
dB	O	NOUN	O
;	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


39	O	NUM	O
),	O	PUNCT	O
adjusted	O	VERB	O
for	O	ADP	O
baseline	O	NOUN	B
values	O	NOUN	O
,	O	PUNCT	O
age	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
frequencies	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
normal	O	ADJ	B
speech	O	NOUN	I
range	O	NOUN	I
of	O	ADP	O
500	O	NUM	O
to	O	PART	O
3	O	NUM	O
,	O	PUNCT	O
000	O	NUM	O
Hz	O	NOUN	O
,	O	PUNCT	O
an	O	DET	O
estimated	O	ADJ	O
difference	O	NOUN	O
of	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


99	O	NUM	O
dB	O	NOUN	O
(-	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


17	O	NUM	O
to	O	PART	O
2	O	NUM	O
.	O	PUNCT	O


14	O	NUM	O
dB	O	NOUN	O
;	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


09	O	NUM	O
)	O	PUNCT	O
was	O	AUX	O
detected	O	VERB	B
.	O	PUNCT	O


Dose	O	NOUN	B
intensity	O	NOUN	I
did	O	AUX	O
not	O	PART	O
add	O	VERB	O
information	O	NOUN	B
to	O	ADP	O
models	O	NOUN	B
.	O	PUNCT	O


There	O	PRON	O
were	O	AUX	O
14	O	NUM	O
of	O	ADP	O
151	O	NUM	O
(	O	PUNCT	O
9	O	NUM	O
.	O	PUNCT	O


3	O	NUM	O
%)	O	NOUN	O
in	O	ADP	O
the	O	DET	O
DFMO	B-Chemical	NOUN	B
plus	O	CCONJ	O
sulindac	B-Chemical	NOUN	B
group	O	NOUN	B
and	O	CCONJ	O
4	O	NUM	O
of	O	ADP	O
139	O	NUM	O
(	O	PUNCT	O
2	O	NUM	O
.	O	PUNCT	O


9	O	NUM	O
%)	O	NOUN	O
in	O	ADP	O
the	O	DET	O
placebo	O	ADJ	B
group	O	NOUN	O
who	O	PRON	O
experienced	O	VERB	O
at	O	ADP	O
least	O	ADV	O
15	O	NUM	O
dB	O	NOUN	O
hearing	O	NOUN	B
reduction	O	NOUN	B
from	O	ADP	O
baseline	O	NOUN	B
in	O	ADP	O
2	O	NUM	O
or	O	CCONJ	O
more	O	ADV	O
consecutive	O	ADJ	B
frequencies	O	NOUN	B
across	O	ADP	O
the	O	DET	O
entire	O	ADJ	O
range	O	NOUN	O
tested	O	VERB	B
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


02	O	NUM	O
).	O	PUNCT	O
Follow	O	PROPN	B
-	O	PUNCT	O
up	O	ADP	B
air	O	NOUN	B
conduction	O	NOUN	I
done	O	VERB	O
at	O	ADP	O
least	O	ADJ	O
6	O	NUM	O
months	O	NOUN	B
after	O	ADP	O
end	O	NOUN	O
of	O	ADP	O
treatment	O	NOUN	B
showed	O	VERB	O
an	O	DET	O
adjusted	O	VERB	O
mean	O	NOUN	O
difference	O	NOUN	O
in	O	ADP	O
hearing	O	NOUN	B
thresholds	O	NOUN	I
of	O	ADP	O
1	O	NUM	O
.	O	PUNCT	O


08	O	NUM	O
dB	O	NOUN	O
(-	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


81	O	NUM	O
to	O	PART	O
2	O	NUM	O
.	O	PUNCT	O


96	O	NUM	O
dB	O	NOUN	O
;	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


26	O	NUM	O
)	O	PUNCT	O
between	O	ADP	O
treatment	O	NOUN	B
arms	O	NOUN	O
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
no	O	DET	B
significant	O	ADJ	I
difference	O	NOUN	O
in	O	ADP	O
the	O	DET	O
proportion	O	NOUN	B
of	O	ADP	O
subjects	O	NOUN	B
in	O	ADP	O
the	O	DET	O
DFMO	B-Chemical	NOUN	B
plus	O	CCONJ	O
sulindac	B-Chemical	NOUN	B
group	O	NOUN	B
who	O	PRON	O
experienced	O	VERB	O
clinically	O	ADV	B
significant	O	ADJ	I
hearing	B-Disease	NOUN	B
loss	I-Disease	NOUN	I
compared	O	VERB	B
with	O	ADP	O
the	O	DET	O
placebo	O	ADJ	B
group	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
estimated	O	VERB	B
attributable	O	ADJ	O
risk	O	NOUN	B
of	O	ADP	O
ototoxicity	B-Disease	NOUN	B
from	O	ADP	O
exposure	O	NOUN	B
to	O	PART	I
the	O	DET	O
drug	O	NOUN	B
is	O	AUX	O
8	O	NUM	O
.	O	PUNCT	O


4	O	NUM	O
%(	O	NOUN	O
95	O	NUM	O
%	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
,-	O	PUNCT	O
2	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
%	O	NOUN	O
to	O	ADP	O
18	O	NUM	O
.	O	PUNCT	O


8	O	NUM	O
%;	O	X	O
P	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


12	O	NUM	O
).	O	PUNCT	O
There	O	PRON	O
is	O	AUX	O
a	O	DET	O
<	O	X	O
2	O	NUM	O
dB	O	NOUN	O
difference	O	NOUN	O
in	O	ADP	O
mean	O	ADJ	O
threshold	O	NOUN	B
for	O	ADP	O
patients	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
DFMO	B-Chemical	NOUN	B
plus	O	CCONJ	O
sulindac	B-Chemical	NOUN	B


Increased	O	VERB	B
mental	B-Disease	ADJ	B
slowing	I-Disease	NOUN	I
associated	O	VERB	B
with	O	ADP	I
the	O	DET	O
APOE	O	NOUN	B
epsilon4	O	NOUN	B
allele	O	NOUN	B
after	O	ADP	O
trihexyphenidyl	B-Chemical	NOUN	B
oral	O	ADJ	O
anticholinergic	O	ADJ	B
challenge	O	NOUN	O
in	O	ADP	O
healthy	O	ADJ	B
elderly	O	ADV	B
.	O	PUNCT	O


OBJECTIVES	O	NOUN	O
:	O	PUNCT	O
The	O	DET	O
objectives	O	NOUN	O
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
were	O	AUX	O
to	O	PART	O
examine	O	VERB	O
the	O	DET	O
relationship	O	NOUN	B
between	O	ADP	O
APOE	O	NOUN	B
epsilon4	O	NOUN	B
and	O	CCONJ	O
subjective	O	ADJ	B
effects	O	NOUN	I
of	O	ADP	O
trihexyphenidyl	B-Chemical	NOUN	B
on	O	ADP	O
measures	O	NOUN	B
reflecting	O	VERB	O
sedation	O	NOUN	B
and	O	CCONJ	O
confusion	B-Disease	NOUN	B
and	O	CCONJ	O
to	O	PART	O
investigate	O	VERB	B
the	O	DET	O
relationship	O	NOUN	B
between	O	ADP	O
trihexyphenidyl	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
subjective	O	ADJ	B
effects	O	NOUN	I
and	O	CCONJ	O
objective	O	ADJ	B
memory	O	NOUN	B
performance	O	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
:	O	PUNCT	O
This	O	DET	O
study	O	NOUN	B
comprised	O	VERB	O
24	O	NUM	O
cognitively	O	ADV	B
intact	O	ADJ	B
,	O	PUNCT	O
health	O	NOUN	B
elderly	O	ADJ	I
adults	O	NOUN	I
(	O	PUNCT	O
12	O	NUM	O
APOE	O	NOUN	B
epsilon4	O	PROPN	B
carriers	O	NOUN	B
)	O	PUNCT	O
at	O	ADP	O
an	O	DET	O
outpatient	O	ADJ	B
geriatric	O	ADJ	B
psychiatry	O	NOUN	O
research	O	NOUN	O
clinic	O	NOUN	O
.	O	PUNCT	O


This	O	DET	O
was	O	AUX	O
a	O	DET	O
randomized	O	ADJ	B
,	O	PUNCT	O
double	O	ADJ	O
blind	O	ADJ	B
,	O	PUNCT	O
placebo	O	NOUN	B
-	O	PUNCT	O
controlled	O	VERB	B
,	O	PUNCT	O
three	O	NUM	O
-	O	PUNCT	O
way	O	NOUN	B
,	O	PUNCT	O
crossover	O	NOUN	B
experimental	O	ADJ	I
design	O	NOUN	I
.	O	PUNCT	O


All	O	DET	O
participants	O	NOUN	B
received	O	VERB	O
1	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
mg	O	NOUN	O
or	O	CCONJ	O
2	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
mg	O	NOUN	O
trihexyphenidyl	B-Chemical	NOUN	B
or	O	CCONJ	O
placebo	O	NOUN	B
administered	O	VERB	B
in	O	ADP	O
counterbalanced	O	VERB	O
sequences	O	NOUN	B
over	O	ADP	O
a	O	DET	O
period	O	NOUN	B
of	O	ADP	O
three	O	NUM	O
consecutive	O	ADJ	B
weeks	O	NOUN	B
.	O	PUNCT	O


Bond	O	NOUN	B
and	O	CCONJ	O
Lader	O	PROPN	B
'	O	PART	O
s	O	NOUN	O
visual	O	ADJ	B
analog	O	NOUN	I
scales	O	NOUN	I
and	O	CCONJ	O
alternate	O	ADJ	B
versions	O	NOUN	I
of	O	ADP	O
the	O	DET	O
Buschke	O	PROPN	B
Selective	O	ADJ	I
Reminding	O	PROPN	I
Test	O	PROPN	I
were	O	AUX	O
administered	O	VERB	B
in	O	ADP	O
a	O	DET	O
repeated	O	VERB	O
measures	O	NOUN	B
design	O	NOUN	B
at	O	ADP	O
baseline	O	NOUN	B
,	O	PUNCT	O
1	O	NUM	O
,	O	PUNCT	O
2	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
5	O	NUM	O
hours	O	NOUN	B
postdrug	O	NOUN	B
administration	O	NOUN	I
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
A	O	DET	O
2	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
-	O	PUNCT	O
mg	O	NOUN	O
oral	O	ADJ	B
dose	O	NOUN	I
of	O	ADP	O
trihexyphenidyl	B-Chemical	NOUN	B
resulted	O	VERB	O
in	O	ADP	O
increased	O	VERB	B
subjective	O	ADJ	O
ratings	O	NOUN	B
of	O	ADP	O
mental	B-Disease	ADJ	B
slowness	I-Disease	NOUN	I
in	O	ADP	O
carriers	O	NOUN	B
of	O	ADP	O
the	O	DET	O
APOE	O	NOUN	B
epsilon4	O	NOUN	B
allele	O	NOUN	B
only	O	ADV	O
.	O	PUNCT	O


Drug	O	NOUN	B
effects	O	NOUN	I
as	O	ADP	O
determined	O	VERB	O
by	O	ADP	O
difference	O	NOUN	O
scores	O	NOUN	B
between	O	ADP	O
2	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
mg	O	NOUN	O
trihexyphenidyl	B-Chemical	NOUN	B
and	O	CCONJ	O
placebo	O	NOUN	B
on	O	ADP	O
ratings	O	NOUN	B
of	O	ADP	O
mental	B-Disease	ADJ	B
slowness	I-Disease	NOUN	I
significantly	O	ADV	O
correlated	O	VERB	B
with	O	ADP	O
total	O	NOUN	O
and	O	CCONJ	O
delayed	O	VERB	B
recall	O	NOUN	I
on	O	ADP	O
the	O	DET	O
Buschke	O	PROPN	B
Selective	O	ADJ	I
Reminding	O	PROPN	I
Test	O	NOUN	I
in	O	ADP	O
carriers	O	NOUN	B
of	O	ADP	O
the	O	DET	O
APOE	O	NOUN	B
epsilon4	O	NOUN	B
allele	O	NOUN	B
only	O	ADV	O
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
no	O	DET	O
significant	O	ADJ	O
effects	O	NOUN	B
were	O	AUX	O
found	O	VERB	O
with	O	ADP	O
other	O	ADJ	O
visual	O	ADJ	B
analog	O	NOUN	I
scales	O	NOUN	I
reflecting	O	VERB	O
subjective	O	ADJ	O
sedation	O	NOUN	B
and	O	CCONJ	O
clear	O	ADJ	B
-	O	PUNCT	O
headedness	O	NOUN	B
.	O	PUNCT	O


CONCLUSION	O	NOUN	B
:	O	PUNCT	O
The	O	DET	O
epsilon4	O	NOUN	B
allele	O	NOUN	B
in	O	ADP	O
healthy	O	ADJ	B
elderly	O	ADJ	B
was	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
increased	O	VERB	B
subjective	O	ADJ	O
mental	B-Disease	ADJ	B
slowing	I-Disease	NOUN	I
after	O	ADP	O
trihexyphenidyl	B-Chemical	NOUN	B


Behavioral	O	ADJ	B
effects	O	NOUN	B
of	O	ADP	O
pubertal	O	ADJ	B
anabolic	O	ADJ	B
androgenic	O	ADJ	B
steroid	B-Chemical	NOUN	I
exposure	O	NOUN	B
in	O	ADP	O
male	O	NOUN	B
rats	O	NOUN	B
with	O	ADP	O
low	O	ADJ	B
serotonin	B-Chemical	NOUN	B
.	O	PUNCT	O


The	O	DET	O
goal	O	NOUN	B
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
assess	O	VERB	B
the	O	DET	O
interactive	O	ADJ	B
effects	O	NOUN	B
of	O	ADP	O
chronic	O	ADJ	B
anabolic	O	ADJ	O
androgenic	O	ADJ	O
steroid	B-Chemical	NOUN	O
(	O	PUNCT	O
AAS	O	NOUN	B
)	O	PUNCT	O
exposure	O	NOUN	B
and	O	CCONJ	O
brain	O	NOUN	B
serotonin	B-Chemical	NOUN	I
(	O	PUNCT	O
5-hydroxytryptamine	B-Chemical	NOUN	B
,	O	PUNCT	O
5-HT	B-Chemical	NOUN	B
)	O	PUNCT	O
depletion	O	NOUN	B
on	O	ADP	O
behavior	O	NOUN	B
of	O	ADP	O
pubertal	O	ADJ	B
male	O	NOUN	B
rats	O	NOUN	B
.	O	PUNCT	O


Serotonin	B-Chemical	NOUN	B
was	O	AUX	O
depleted	O	VERB	B
beginning	O	VERB	O
on	O	ADP	O
postnatal	O	ADJ	B
day	O	NOUN	B
26	O	NUM	O
with	O	ADP	O
parachlorophenylalanine	B-Chemical	NOUN	B
(	O	PUNCT	O
PCPA	B-Chemical	NOUN	B
100	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
,	O	PUNCT	O
every	O	DET	O
other	O	ADJ	O
day	O	NOUN	B
);	O	ADJ	O
controls	O	NOUN	O
received	O	VERB	O
saline	O	NOUN	B
.	O	PUNCT	O


At	O	ADP	O
puberty	O	NOUN	B
(	O	PUNCT	O
P40	O	NOUN	B
),	O	PUNCT	O
half	O	DET	O
the	O	DET	O
PCPA	B-Chemical	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
rats	O	NOUN	B
and	O	CCONJ	O
half	O	DET	B
the	O	DET	O
saline	O	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
rats	O	NOUN	B
began	O	VERB	O
treatment	O	NOUN	B
with	O	ADP	O
testosterone	B-Chemical	NOUN	B
(	O	PUNCT	O
T	B-Chemical	NOUN	B
,	O	PUNCT	O
5	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
,	O	PUNCT	O
5	O	NUM	O
days	O	NOUN	B
/	O	SYM	O
week	O	NOUN	B
).	O	PUNCT	O
Behavioral	O	ADJ	B
measures	O	NOUN	B
included	O	VERB	O
locomotion	O	NOUN	B
,	O	PUNCT	O
irritability	B-Disease	NOUN	B
,	O	PUNCT	O
copulation	O	NOUN	B
,	O	PUNCT	O
partner	O	NOUN	B
preference	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
aggression	B-Disease	NOUN	B
.	O	PUNCT	O


Animals	O	NOUN	B
were	O	AUX	O
tested	O	VERB	B
for	O	ADP	O
aggression	B-Disease	NOUN	B
in	O	ADP	O
their	O	PRON	O
home	O	NOUN	B
cage	O	NOUN	I
,	O	PUNCT	O
both	O	CCONJ	O
with	O	ADP	O
and	O	CCONJ	O
without	O	ADP	O
physical	O	ADJ	B
provocation	O	NOUN	I
(	O	PUNCT	O
mild	O	ADJ	B
tail	O	NOUN	I
pinch	O	NOUN	I
).	O	PUNCT	O
Brain	O	PROPN	B
levels	O	NOUN	O
of	O	ADP	O
5-HT	B-Chemical	NOUN	B
and	O	CCONJ	O
its	O	PRON	O
metabolite	O	NOUN	B
,	O	PUNCT	O
5-hydroxyindoleacetic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
(	O	PUNCT	O
5-HIAA	B-Chemical	ADJ	B
),	O	PUNCT	O
were	O	AUX	O
determined	O	VERB	O
using	O	VERB	O
HPLC	O	NOUN	B
.	O	PUNCT	O


PCPA	B-Chemical	NOUN	B
significantly	O	ADV	B
and	O	CCONJ	O
substantially	O	ADV	O
depleted	O	VERB	B
5-HT	B-Chemical	NOUN	B
and	O	CCONJ	O
5-HIAA	B-Chemical	ADV	B
in	O	ADP	O
all	O	DET	O
brain	O	NOUN	B
regions	O	NOUN	I
examined	O	VERB	B
.	O	PUNCT	O


Chronic	O	ADJ	B
T	B-Chemical	NOUN	I
treatment	O	NOUN	B
significantly	O	ADV	O
decreased	O	VERB	B
5-HT	B-Chemical	NOUN	B
and	O	CCONJ	O
5-HIAA	B-Chemical	ADV	B
in	O	ADP	O
certain	O	ADJ	O
brain	O	NOUN	B
areas	O	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
to	O	ADP	O
a	O	DET	O
much	O	ADV	O
lesser	O	ADJ	B
extent	O	NOUN	O
than	O	ADP	O
PCPA	B-Chemical	NOUN	B
.	O	PUNCT	O


Chronic	O	ADJ	B
exposure	O	NOUN	O
to	O	ADP	O
PCPA	B-Chemical	NOUN	B
alone	O	ADV	O
significantly	O	ADV	O
decreased	O	VERB	B
locomotor	O	NOUN	B
activity	O	NOUN	I
and	O	CCONJ	O
increased	O	VERB	B
irritability	B-Disease	NOUN	B
but	O	CCONJ	O
had	O	AUX	O
no	O	DET	B
effect	O	NOUN	I
on	O	ADP	O
sexual	O	ADJ	B
behavior	O	NOUN	I
,	O	PUNCT	O
partner	O	NOUN	B
preference	O	NOUN	I
,	O	PUNCT	O
or	O	CCONJ	O
aggression	B-Disease	NOUN	B
.	O	PUNCT	O


T	B-Chemical	NOUN	B
alone	O	ADV	O
had	O	AUX	O
no	O	DET	B
effect	O	NOUN	I
on	O	ADP	O
locomotion	O	NOUN	B
,	O	PUNCT	O
irritability	B-Disease	NOUN	B
,	O	PUNCT	O
or	O	CCONJ	O
sexual	O	ADJ	B
behavior	O	NOUN	I
but	O	CCONJ	O
increased	O	VERB	B
partner	O	NOUN	B
preference	O	NOUN	I
and	O	CCONJ	O
aggression	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
most	O	ADV	O
striking	O	ADJ	O
effect	O	NOUN	B
of	O	ADP	O
combining	O	VERB	O
T	B-Chemical	NOUN	B
+	O	CCONJ	O
PCPA	B-Chemical	NOUN	B
was	O	AUX	O
a	O	DET	O
significant	O	ADJ	O
increase	O	NOUN	B
in	O	ADP	O
attack	O	NOUN	B
frequency	O	NOUN	I
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
a	O	DET	O
significant	O	ADJ	O
decrease	O	NOUN	B
in	O	ADP	O
the	O	DET	O
latency	O	NOUN	B
to	O	PART	O
attack	O	VERB	B
,	O	PUNCT	O
particularly	O	ADV	O
following	O	VERB	O
physical	O	ADJ	B
provocation	O	NOUN	I
.	O	PUNCT	O


Based	O	VERB	O
on	O	ADP	O
these	O	DET	O
data	O	NOUN	B
,	O	PUNCT	O
it	O	PRON	O
can	O	AUX	O
be	O	AUX	O
speculated	O	VERB	O
that	O	SCONJ	O
pubertal	O	ADJ	B
AAS	O	NOUN	B
users	O	NOUN	B
with	O	ADP	O
low	O	ADJ	B
central	O	ADJ	O
5-HT	B-Chemical	NOUN	O
may	O	AUX	O
be	O	AUX	O
especially	O	ADV	O
prone	O	ADJ	O
to	O	PART	O
exhibit	O	VERB	O
aggressive	B-Disease	ADJ	B
behavior	I-Disease	NOUN	I


Intracavitary	O	ADJ	B
chemotherapy	O	NOUN	I
(	O	PUNCT	O
paclitaxel	B-Chemical	NOUN	B
/	O	SYM	O
carboplatin	B-Chemical	NOUN	B
liquid	O	ADJ	B
crystalline	O	ADJ	I
cubic	O	ADJ	I
phases	O	NOUN	O
)	O	PUNCT	O
for	O	ADP	O
recurrent	O	ADJ	B
glioblastoma	B-Disease	NOUN	B
--	O	PUNCT	O
clinical	O	ADJ	B
observations	O	NOUN	B
.	O	PUNCT	O


Human	O	ADJ	B
malignant	O	ADJ	B
brain	B-Disease	NOUN	O
tumors	I-Disease	NOUN	O
have	O	AUX	O
a	O	DET	O
poor	O	ADJ	B
prognosis	O	NOUN	I
in	O	ADP	O
spite	O	NOUN	O
of	O	ADP	O
surgery	O	NOUN	B
and	O	CCONJ	O
radiation	O	NOUN	B
therapy	O	NOUN	I
.	O	PUNCT	O


Cubic	O	ADJ	B
phases	O	NOUN	I
consist	O	VERB	O
of	O	ADP	O
curved	O	ADJ	O
biocontinuous	O	ADJ	B
lipid	O	NOUN	B
bilayers	O	NOUN	I
,	O	PUNCT	O
separating	O	VERB	O
two	O	NUM	O
congruent	O	ADJ	B
networks	O	NOUN	B
of	O	ADP	O
water	O	NOUN	B
channels	O	NOUN	I
.	O	PUNCT	O


Used	O	VERB	O
as	O	ADP	O
a	O	DET	O
host	O	NOUN	B
for	O	ADP	O
cytotoxic	O	ADJ	B
drugs	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
gel	O	NOUN	B
-	O	PUNCT	O
like	O	ADJ	B
matrix	O	NOUN	B
can	O	AUX	O
easily	O	ADV	O
be	O	AUX	O
applied	O	VERB	O
to	O	ADP	O
the	O	DET	O
walls	O	NOUN	B
of	O	ADP	O
a	O	DET	O
surgical	O	ADJ	B
resection	O	NOUN	I
cavity	O	NOUN	I
.	O	PUNCT	O


For	O	ADP	O
human	O	ADJ	B
glioblastoma	B-Disease	NOUN	B
recurrences	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
feasibility	O	NOUN	B
,	O	PUNCT	O
safety	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
short	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
effects	O	NOUN	B
of	O	ADP	O
a	O	DET	O
surgical	O	ADJ	B
intracavitary	O	ADJ	B
application	O	NOUN	B
of	O	ADP	O
paclitaxel	B-Chemical	NOUN	B
and	O	CCONJ	O
carboplatin	B-Chemical	NOUN	B
encapsulated	O	VERB	B
by	O	ADP	O
liquid	O	ADJ	B
crystalline	O	ADJ	I
cubic	O	ADJ	I
phases	O	NOUN	B
are	O	AUX	O
examined	O	VERB	O
in	O	ADP	O
a	O	DET	O
pilot	O	NOUN	B
study	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
total	O	NOUN	O
of	O	ADP	O
12	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
a	O	DET	O
recurrence	O	NOUN	B
of	O	ADP	O
a	O	DET	O
glioblastoma	B-Disease	NOUN	B
multiforme	O	NOUN	B
underwent	O	VERB	O
re	O	NOUN	B
-	O	PUNCT	O
resection	O	NOUN	B
and	O	CCONJ	O
received	O	VERB	O
an	O	DET	O
intracavitary	O	ADJ	B
application	O	NOUN	B
of	O	ADP	O
paclitaxel	B-Chemical	NOUN	B
and	O	CCONJ	O
carboplatin	B-Chemical	NOUN	B
cubic	O	ADJ	B
phases	O	NOUN	O
in	O	ADP	O
different	O	ADJ	O
dosages	O	NOUN	B
.	O	PUNCT	O


Six	O	NUM	O
of	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
received	O	VERB	O
more	O	ADJ	O
than	O	ADP	O
15	O	NUM	O
mg	O	NOUN	O
paclitaxel	B-Chemical	NOUN	B
and	O	CCONJ	O
suffered	O	VERB	O
from	O	ADP	O
moderate	O	ADJ	B
to	O	PART	O
severe	O	ADJ	O
brain	B-Disease	NOUN	B
edema	I-Disease	NOUN	I
,	O	PUNCT	O
while	O	SCONJ	O
the	O	DET	O
remaining	O	VERB	O
patients	O	NOUN	B
received	O	VERB	O
only	O	ADV	O
a	O	DET	O
total	O	NOUN	O
of	O	ADP	O
15	O	NUM	O
mg	O	NOUN	O
paclitaxel	B-Chemical	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
latter	O	ADJ	O
group	O	NOUN	B
,	O	PUNCT	O
brain	B-Disease	NOUN	B
edema	I-Disease	NOUN	I
was	O	AUX	O
markedly	O	ADV	O
reduced	O	VERB	B
and	O	CCONJ	O
dealt	O	VERB	O
medically	O	ADV	O
.	O	PUNCT	O


Intracavitary	O	ADJ	B
chemotherapy	O	NOUN	I
in	O	ADP	O
recurrent	O	ADJ	B
glioblastoma	B-Disease	NOUN	B


Methylphenidate	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
obsessive-compulsive	B-Disease	ADJ	B
symptoms	I-Disease	NOUN	O
in	O	ADP	O
an	O	DET	O
elderly	O	ADJ	B
man	O	NOUN	I
.	O	PUNCT	O


An	O	DET	O
82	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
man	O	NOUN	B
with	O	ADP	O
treatment-resistant	B-Disease	ADJ	B
depression	I-Disease	NOUN	I
and	O	CCONJ	O
early	O	ADJ	B
Alzheimer's	B-Disease	ADJ	O
disease	I-Disease	NOUN	B
was	O	AUX	O
started	O	VERB	O
on	O	ADP	O
methylphenidate	B-Chemical	NOUN	B
.	O	PUNCT	O


Significant	O	ADJ	B
obsessive-compulsive	B-Disease	ADJ	B
behavior	I-Disease	NOUN	I
ensued	O	VERB	B
but	O	CCONJ	O
diminished	O	VERB	B
over	O	ADP	O
several	O	ADJ	O
weeks	O	NOUN	B
when	O	SCONJ	O
methylphenidate	B-Chemical	NOUN	B
was	O	AUX	O
replaced	O	VERB	O
by	O	ADP	O
fluvoxamine	B-Chemical	NOUN	B
.	O	PUNCT	O


The	O	DET	O
patient	O	NOUN	B
had	O	AUX	O
no	O	DET	O
prior	O	ADJ	O
psychiatric	B-Disease	ADJ	B
history	O	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
he	O	PRON	O
had	O	AUX	O
a	O	DET	O
sister	O	NOUN	O
with	O	ADP	O
obsessive-compulsive	B-Disease	ADJ	B
disorder	I-Disease	NOUN	I
.	O	PUNCT	O


It	O	PRON	O
appears	O	VERB	O
that	O	SCONJ	O
methylphenidate	B-Chemical	NOUN	B


Cardiac	B-Disease	ADJ	B
arrest	I-Disease	NOUN	I
after	O	ADP	O
intravenous	O	ADJ	B
metoclopramide	B-Chemical	NOUN	B
-	O	PUNCT	O
a	O	DET	O
case	O	NOUN	B
of	O	ADP	O
five	O	NUM	O
repeated	O	ADJ	O
injections	O	NOUN	B
of	O	ADP	O
metoclopramide	B-Chemical	NOUN	B
causing	O	VERB	O
five	O	NUM	O
episodes	O	NOUN	B
of	O	ADP	O
cardiac	B-Disease	ADJ	B
arrest	I-Disease	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
describe	O	VERB	O
a	O	DET	O
patient	O	NOUN	B
where	O	SCONJ	O
intravenous	O	ADJ	B
injection	O	NOUN	I
of	O	ADP	O
metoclopramide	B-Chemical	NOUN	B
was	O	AUX	O
immediately	O	ADV	O
followed	O	VERB	O
by	O	ADP	O
asystole	B-Disease	NOUN	B
repeatedly	O	ADV	O
.	O	PUNCT	O


The	O	DET	O
patient	O	NOUN	B
received	O	VERB	O
metoclopramide	B-Chemical	NOUN	B
10	O	NUM	O
mg	O	NOUN	O
i	O	NUM	O
.	O	PUNCT	O


v	O	NOUN	O
.	O	PUNCT	O


five	O	NUM	O
times	O	NOUN	O
during	O	ADP	O
48	O	NUM	O
h	O	NOUN	O
.	O	PUNCT	O


After	O	ADP	O
interviewing	O	VERB	B
the	O	DET	O
attending	O	VERB	B
nurses	O	NOUN	B
and	O	CCONJ	O
reviewing	O	VERB	B
the	O	DET	O
written	O	VERB	B
documentation	O	NOUN	I
,	O	PUNCT	O
it	O	PRON	O
is	O	AUX	O
clear	O	ADJ	O
that	O	SCONJ	O
every	O	DET	O
administration	O	NOUN	B
of	O	ADP	O
metoclopramide	B-Chemical	NOUN	B
was	O	AUX	O
immediately	O	ADV	O
(	O	PUNCT	O
within	O	ADP	O
s	O	NOUN	O
)	O	PUNCT	O
followed	O	VERB	O
by	O	ADP	O
asystole	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
asystole	B-Disease	NOUN	B
lasted	O	VERB	O
15	O	NUM	O
-	O	SYM	O
30	O	NUM	O
s	O	NOUN	O
on	O	ADP	O
four	O	NUM	O
occasions	O	NOUN	B
,	O	PUNCT	O
on	O	ADP	O
one	O	NUM	O
occasion	O	NOUN	O
it	O	PRON	O
lasted	O	VERB	O
2	O	NUM	O
min	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
patient	O	NOUN	B
received	O	VERB	O
atropine	B-Chemical	NOUN	B
0	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
-	O	SYM	O
1	O	NUM	O
mg	O	NOUN	O
and	O	CCONJ	O
chest	O	ADJ	B
compressions	O	NOUN	I
,	O	PUNCT	O
before	O	ADP	O
sinus	O	NOUN	B
rhythm	O	NOUN	O
again	O	ADV	O
took	O	VERB	O
over	O	ADP	O
.	O	PUNCT	O


We	O	PRON	O
interpret	O	VERB	O
this	O	DET	O
as	O	ADP	O
episodes	O	NOUN	B
of	O	ADP	O
cardiac	B-Disease	ADJ	B
arrest	I-Disease	NOUN	I
caused	O	VERB	O
by	O	ADP	O
metoclopramide	B-Chemical	NOUN	B
.	O	PUNCT	O


The	O	DET	O
rapid	O	ADJ	O
injection	O	NOUN	B
via	O	ADP	O
the	O	DET	O
central	O	ADJ	B
venous	O	ADJ	I
route	O	NOUN	I
and	O	CCONJ	O
the	O	DET	O
concomitant	O	ADJ	B
tapering	O	NOUN	B
of	O	ADP	O
dopamine	B-Chemical	NOUN	B


Severe	O	ADJ	B
immune	O	ADJ	B
hemolytic	B-Disease	ADJ	I
anemia	I-Disease	NOUN	I
associated	O	VERB	B
with	O	ADP	I
prophylactic	O	ADJ	B
use	O	NOUN	O
of	O	ADP	O
cefotetan	B-Chemical	NOUN	B
in	O	ADP	O
obstetric	O	ADJ	B
and	O	CCONJ	O
gynecologic	O	ADJ	B
procedures	O	NOUN	I
.	O	PUNCT	O


Second	O	ADV	B
-	O	PUNCT	O
and	O	CCONJ	O
third	O	ADJ	B
-	O	PUNCT	O
generation	O	NOUN	B
cephalosporins	B-Chemical	NOUN	B
,	O	PUNCT	O
especially	O	ADV	O
cefotetan	B-Chemical	NOUN	B
,	O	PUNCT	O
are	O	AUX	O
increasingly	O	ADV	O
associated	O	VERB	B
with	O	ADP	I
severe	O	ADJ	B
,	O	PUNCT	O
sometimes	O	ADV	O
fatal	O	ADJ	B
immune	O	ADJ	B
hemolytic	B-Disease	ADJ	I
anemia	I-Disease	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
noticed	O	VERB	O
that	O	SCONJ	O
10	O	NUM	O
of	O	ADP	O
our	O	PRON	O
35	O	NUM	O
cases	O	NOUN	B
of	O	ADP	O
cefotetan	B-Chemical	ADJ	B
-	O	PUNCT	O
induced	O	VERB	B
hemolytic	B-Disease	ADJ	B
anemias	I-Disease	NOUN	I
were	O	AUX	O
in	O	ADP	O
patients	O	NOUN	B
who	O	PRON	O
had	O	AUX	O
received	O	VERB	O
cefotetan	B-Chemical	ADJ	B
prophylactically	O	ADV	B
for	O	ADP	O
obstetric	O	ADJ	B
and	O	CCONJ	O
gynecologic	O	ADJ	B
procedures	O	NOUN	I
.	O	PUNCT	O


Eight	O	NUM	O
of	O	ADP	O
these	O	DET	O
cases	O	NOUN	B
of	O	ADP	O
severe	O	ADJ	B
immune	O	ADJ	B
hemolytic	B-Disease	ADJ	I
anemia	I-Disease	NOUN	I


Cauda	B-Disease	ADJ	B
equina	I-Disease	NOUN	I
syndrome	I-Disease	NOUN	I
after	O	ADP	O
spinal	O	ADJ	B
anaesthesia	O	NOUN	I
with	O	ADP	O
hyperbaric	O	NOUN	B
5	O	NUM	O
%	O	NOUN	O
lignocaine	B-Chemical	NOUN	B
:	O	PUNCT	O
a	O	DET	O
review	O	NOUN	B
of	O	ADP	O
six	O	NUM	O
cases	O	NOUN	B
of	O	ADP	O
cauda	B-Disease	ADJ	B
equina	I-Disease	NOUN	B
syndrome	I-Disease	NOUN	I
reported	O	VERB	O
to	O	ADP	O
the	O	DET	O
Swedish	O	PROPN	B
Pharmaceutical	O	PROPN	O
Insurance	O	PROPN	O
1993	O	NUM	O
-	O	SYM	O
1997	O	NUM	O
.	O	PUNCT	O


Six	O	NUM	O
cases	O	NOUN	B
of	O	ADP	O
cauda	B-Disease	ADJ	B
equina	I-Disease	NOUN	I
syndrome	I-Disease	NOUN	I
with	O	ADP	O
varying	O	VERB	O
severity	O	NOUN	B
were	O	AUX	O
reported	O	VERB	O
to	O	ADP	O
the	O	DET	O
Swedish	O	PROPN	B
Pharmaceutical	O	PROPN	B
Insurance	O	PROPN	I
during	O	ADP	O
the	O	DET	O
period	O	NOUN	B
1993	O	NUM	O
-	O	SYM	O
1997	O	NUM	O
.	O	PUNCT	O


All	O	DET	O
were	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
spinal	O	ADJ	B
anaesthesia	O	NOUN	I
using	O	VERB	O
hyperbaric	O	NOUN	B
5	O	NUM	O
%	O	NOUN	O
lignocaine	B-Chemical	NOUN	B
.	O	PUNCT	O


Five	O	NUM	O
cases	O	NOUN	B
had	O	AUX	O
single	O	ADJ	B
-	O	PUNCT	O
shot	O	VERB	B
spinal	O	ADJ	B
anaesthesia	O	NOUN	I
and	O	CCONJ	O
one	O	PRON	O
had	O	AUX	O
a	O	DET	O
repeat	O	NOUN	O
spinal	O	ADJ	B
anaesthetic	O	ADJ	O
due	O	ADJ	O
to	O	ADP	O
inadequate	O	ADJ	O
block	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
dose	O	NOUN	B
of	O	ADP	O
hyperbaric	O	NOUN	B
5	O	NUM	O
%	O	NOUN	O
lignocaine	B-Chemical	NOUN	B
administered	O	VERB	B
ranged	O	VERB	O
from	O	ADP	O
60	O	NUM	O
to	O	PART	O
120	O	NUM	O
mg	O	NOUN	O
.	O	PUNCT	O


Three	O	NUM	O
of	O	ADP	O
the	O	DET	O
cases	O	NOUN	B
were	O	AUX	O
most	O	ADV	O
likely	O	ADV	O
caused	O	VERB	O
by	O	ADP	O
direct	O	ADJ	O
neurotoxicity	B-Disease	NOUN	B
of	O	ADP	O
hyperbaric	O	NOUN	B
5	O	NUM	O
%	O	NOUN	O
lignocaine	B-Chemical	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
other	O	ADJ	O
3	O	NUM	O
cases	O	NOUN	B
,	O	PUNCT	O
direct	O	ADJ	O
neurotoxicity	B-Disease	NOUN	B
was	O	AUX	O
also	O	ADV	O
probable	O	ADJ	O
,	O	PUNCT	O
but	O	CCONJ	O
unfortunately	O	ADV	O
radiological	O	ADJ	B
investigations	O	NOUN	I
were	O	AUX	O
not	O	PART	O
done	O	VERB	O
to	O	PART	O
definitely	O	ADV	O
exclude	O	VERB	O
a	O	DET	O
compressive	O	ADJ	B
aetiology	O	NOUN	I
.	O	PUNCT	O


All	O	DET	O
cases	O	NOUN	B
sustained	O	VERB	O
permanent	O	ADJ	B
neurological	B-Disease	ADJ	B
deficits	I-Disease	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
recommend	O	VERB	O
that	O	SCONJ	O
hyperbaric	O	ADJ	B
lignocaine	B-Chemical	NOUN	B


Cortical	O	ADJ	B
motor	O	NOUN	O
overactivation	O	NOUN	B
in	O	ADP	O
parkinsonian	B-Disease	ADJ	B
patients	O	NOUN	B
with	O	ADP	O
L-dopa	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
peak	O	NOUN	B
-	O	PUNCT	O
dose	O	NOUN	B
dyskinesia	B-Disease	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
studied	O	VERB	O
the	O	DET	O
regional	O	ADJ	B
cerebral	O	ADJ	B
blood	O	NOUN	I
flow	O	NOUN	I
(	O	PUNCT	O
rCBF	O	NOUN	B
)	O	PUNCT	O
changes	O	NOUN	B
induced	O	VERB	B
by	O	ADP	O
the	O	DET	O
execution	O	NOUN	B
of	O	ADP	O
a	O	DET	O
finger	O	NOUN	B
-	O	PUNCT	O
to	O	ADP	O
-	O	PUNCT	O
thumb	O	NOUN	B
opposition	O	NOUN	O
motor	O	NOUN	O
task	O	NOUN	O
in	O	ADP	O
the	O	DET	O
supplementary	O	ADJ	O
and	O	CCONJ	O
primary	O	ADJ	B
motor	O	NOUN	B
cortex	O	NOUN	I
of	O	ADP	O
two	O	NUM	O
groups	O	NOUN	B
of	O	ADP	O
parkinsonian	B-Disease	ADJ	B
patients	O	NOUN	B
on	O	ADP	O
L-dopa	B-Chemical	ADJ	B
medication	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
first	O	ADJ	O
one	O	NOUN	O
without	O	ADP	O
L-dopa	B-Chemical	ADJ	B
induced	O	ADJ	B
dyskinesia	B-Disease	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
23	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
other	O	ADJ	O
with	O	ADP	O
moderate	O	ADJ	B
peak	O	NOUN	B
-	O	PUNCT	O
dose	O	NOUN	B
dyskinesia	B-Disease	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
15	O	NUM	O
),	O	PUNCT	O
and	O	CCONJ	O
of	O	ADP	O
a	O	DET	O
group	O	NOUN	B
of	O	ADP	O
14	O	NUM	O
normal	O	ADJ	B
subjects	O	NOUN	I
.	O	PUNCT	O


Single	O	ADJ	B
photon	O	ADJ	I
emission	O	NOUN	I
tomography	O	NOUN	I
with	O	ADP	O
i	O	PRON	O
.	O	PUNCT	O


v	O	NOUN	O
.	O	PUNCT	O


133Xe	O	NUM	O
was	O	AUX	O
used	O	VERB	O
to	O	PART	O
measure	O	VERB	B
the	O	DET	O
rCBF	O	NOUN	B
changes	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
dyskinetic	B-Disease	ADJ	B
parkinsonian	B-Disease	ADJ	B
patients	O	NOUN	B
exhibited	O	VERB	O
a	O	DET	O
pattern	O	NOUN	B
of	O	ADP	O
response	O	NOUN	B
which	O	DET	O
was	O	AUX	O
markedly	O	ADV	O
different	O	ADJ	O
from	O	ADP	O
those	O	DET	O
of	O	ADP	O
the	O	DET	O
normal	O	ADJ	B
subjects	O	NOUN	I
and	O	CCONJ	O
non	O	ADJ	B
-	O	PUNCT	O
dyskinetic	B-Disease	ADJ	B
parkinsonian	B-Disease	ADJ	B
patients	O	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
a	O	DET	O
significant	O	ADJ	O
overactivation	O	NOUN	B
in	O	ADP	O
the	O	DET	O
supplementary	O	ADJ	O
motor	O	NOUN	B
area	O	NOUN	I
and	O	CCONJ	O
the	O	DET	O
ipsi	O	NOUN	B
-	O	PUNCT	O
and	O	CCONJ	O
contralateral	O	ADJ	B
primary	O	ADJ	O
motor	O	NOUN	O
areas	O	NOUN	O
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	B
are	O	AUX	O
compatible	O	ADJ	O
with	O	ADP	O
the	O	DET	O
hypothesis	O	NOUN	B
that	O	SCONJ	O
an	O	DET	O
hyperkinetic	B-Disease	ADJ	B
abnormal	B-Disease	ADJ	B
involuntary	I-Disease	ADJ	B
movement	I-Disease	NOUN	B
,	O	PUNCT	O
like	O	ADP	O
L-dopa	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
peak	O	NOUN	B
dose	O	NOUN	I
dyskinesia	B-Disease	NOUN	I


Dexamethasone	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
ocular	B-Disease	ADJ	B
hypertension	I-Disease	NOUN	I
in	O	ADP	O
perfusion	O	NOUN	B
-	O	PUNCT	O
cultured	O	VERB	B
human	O	ADJ	B
eyes	O	NOUN	B
.	O	PUNCT	O


PURPOSE	O	NOUN	B
:	O	PUNCT	O
Glucocorticoid	O	NOUN	B
administration	O	NOUN	I
can	O	AUX	O
lead	O	VERB	O
to	O	PART	O
the	O	DET	O
development	O	NOUN	B
of	O	ADP	O
ocular	B-Disease	ADJ	B
hypertension	I-Disease	NOUN	I
and	O	CCONJ	O
corticosteroid	B-Disease	NOUN	B
glaucoma	I-Disease	NOUN	I
in	O	ADP	O
a	O	DET	O
subset	O	NOUN	O
of	O	ADP	O
the	O	DET	O
population	O	NOUN	B
through	O	ADP	O
a	O	DET	O
decrease	O	NOUN	B
in	O	ADP	O
the	O	DET	O
aqueous	O	ADJ	B
humor	O	NOUN	B
outflow	O	NOUN	B
facility	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
purpose	O	NOUN	O
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
determine	O	VERB	O
whether	O	SCONJ	O
glucocorticoid	O	NOUN	B
treatment	O	NOUN	O
can	O	AUX	O
directly	O	ADV	O
affect	O	VERB	O
the	O	DET	O
outflow	O	NOUN	B
facility	O	NOUN	I
of	O	ADP	O
isolated	O	VERB	B
,	O	PUNCT	O
perfusion	O	NOUN	B
-	O	PUNCT	O
cultured	O	VERB	B
human	O	ADJ	B
eyes	O	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
:	O	PUNCT	O
The	O	DET	O
anterior	O	ADJ	B
segments	O	NOUN	B
of	O	ADP	O
human	O	ADJ	B
donor	O	NOUN	O
eyes	O	NOUN	O
from	O	ADP	O
regional	O	ADJ	B
eye	O	NOUN	I
banks	O	NOUN	I
were	O	AUX	O
placed	O	VERB	O
in	O	ADP	O
a	O	DET	O
constant	O	ADJ	B
flow	O	NOUN	I
,	O	PUNCT	O
variable	O	ADJ	B
pressure	O	NOUN	I
perfusion	O	NOUN	I
culture	O	NOUN	I
system	O	NOUN	I
.	O	PUNCT	O


Paired	O	ADJ	B
eyes	O	NOUN	I
were	O	AUX	O
perfused	O	VERB	B
in	O	ADP	O
serum	O	NOUN	B
-	O	PUNCT	O
free	O	ADJ	B
media	O	NOUN	O
with	O	ADP	O
or	O	CCONJ	O
without	O	ADP	O
10	O	NUM	O
(-	O	PUNCT	O
7	O	NUM	O
)	O	PUNCT	O
M	O	NOUN	O
dexamethasone	B-Chemical	NOUN	B
for	O	ADP	O
12	O	NUM	O
days	O	NOUN	B
.	O	PUNCT	O


Intraocular	O	ADJ	B
pressure	O	NOUN	I
was	O	AUX	O
monitored	O	VERB	O
daily	O	ADV	B
.	O	PUNCT	O


After	O	ADP	O
incubation	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
eyes	O	NOUN	B
were	O	AUX	O
morphologically	O	ADV	B
characterized	O	VERB	B
by	O	ADP	O
light	O	ADJ	B
microscopy	O	NOUN	I
,	O	PUNCT	O
transmission	O	NOUN	B
and	O	CCONJ	O
scanning	O	NOUN	B
electron	O	NOUN	I
microscopy	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
scanning	O	VERB	B
laser	O	NOUN	I
confocal	O	ADJ	I
microscopy	O	NOUN	I
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
A	O	DET	O
significant	O	ADJ	O
increase	O	NOUN	B
in	O	ADP	O
intraocular	O	ADJ	B
pressure	O	NOUN	I
developed	O	VERB	O
in	O	ADP	O
13	O	NUM	O
of	O	ADP	O
the	O	DET	O
44	O	NUM	O
pairs	O	NOUN	B
of	O	ADP	O
eyes	O	NOUN	B
perfused	O	VERB	B
with	O	ADP	O
dexamethasone	B-Chemical	NOUN	B
with	O	ADP	O
an	O	DET	O
average	O	ADJ	B
pressure	O	NOUN	B
rise	O	NOUN	O
of	O	ADP	O
17	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
+/-	O	CCONJ	O
3	O	NUM	O
.	O	PUNCT	O


8	O	NUM	O
mm	O	NOUN	B
Hg	O	NOUN	I
after	O	ADP	O
12	O	NUM	O
days	O	NOUN	B
of	O	ADP	O
dexamethasone	B-Chemical	NOUN	B
exposure	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
contralateral	O	ADJ	B
control	O	NOUN	O
eyes	O	NOUN	O
,	O	PUNCT	O
which	O	DET	O
did	O	AUX	O
not	O	PART	O
receive	O	VERB	O
dexamethasone	B-Chemical	NOUN	B
,	O	PUNCT	O
maintained	O	VERB	B
a	O	DET	O
stable	O	ADJ	B
intraocular	O	ADJ	B
pressure	O	NOUN	I
during	O	ADP	O
the	O	DET	O
same	O	ADJ	O
period	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
outflow	O	NOUN	B
pathway	O	NOUN	I
of	O	ADP	O
the	O	DET	O
untreated	O	ADJ	B
eyes	O	NOUN	I
appeared	O	VERB	O
morphologically	O	ADV	B
normal	O	ADJ	O
.	O	PUNCT	O


In	O	ADP	O
contrast	O	NOUN	O
,	O	PUNCT	O
the	O	DET	O
dexamethasone	B-Chemical	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
hypertensive	B-Disease	ADJ	B
eyes	I-Disease	NOUN	O
had	O	AUX	O
thickened	O	ADJ	B
trabecular	O	NOUN	B
beams	O	NOUN	I
,	O	PUNCT	O
decreased	O	VERB	B
intertrabecular	O	ADJ	B
spaces	O	NOUN	B
,	O	PUNCT	O
thickened	O	ADJ	B
juxtacanalicular	O	ADJ	B
tissue	O	NOUN	I
,	O	PUNCT	O
activated	O	VERB	B
trabecular	O	NOUN	O
meshwork	O	NOUN	O
cells	O	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
increased	O	VERB	B
amounts	O	NOUN	O
of	O	ADP	O
amorphogranular	O	ADJ	B
extracellular	O	ADJ	I
material	O	NOUN	I
,	O	PUNCT	O
especially	O	ADV	O
in	O	ADP	O
the	O	DET	O
juxtacanalicular	O	ADJ	B
tissue	O	NOUN	I
and	O	CCONJ	O
beneath	O	ADP	O
the	O	DET	O
endothelial	O	ADJ	B
lining	O	NOUN	I
of	O	ADP	O
the	O	DET	O
canal	O	NOUN	B
of	O	ADP	O
Schlemm	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
dexamethasone	B-Chemical	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
nonresponder	O	ADJ	B
eyes	O	NOUN	B
appeared	O	VERB	O
to	O	PART	O
be	O	AUX	O
morphologically	O	ADV	B
similar	O	ADJ	O
to	O	PART	O
the	O	DET	O
untreated	O	ADJ	B
eyes	O	NOUN	B
,	O	PUNCT	O
although	O	SCONJ	O
several	O	ADJ	O
subtle	O	ADJ	O
dexamethasone	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
morphologic	O	ADJ	B
changes	O	NOUN	I
were	O	AUX	O
evident	O	ADJ	O
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
:	O	PUNCT	O
Dexamethasone	B-Chemical	NOUN	B
treatment	O	NOUN	B
of	O	ADP	O
isolated	O	VERB	B
,	O	PUNCT	O
perfusion	O	NOUN	B
-	O	PUNCT	O
cultured	O	VERB	B
human	O	ADJ	B
eyes	O	NOUN	B
led	O	VERB	O
to	O	PART	O
the	O	DET	O
generation	O	NOUN	B
of	O	ADP	O
ocular	B-Disease	ADJ	B
hypertension	I-Disease	NOUN	I
in	O	ADP	O
approximately	O	ADV	O
30	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
dexamethasone	B-Chemical	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
eyes	O	NOUN	B
.	O	PUNCT	O


Steroid	B-Chemical	NOUN	B
treatment	O	NOUN	B
resulted	O	VERB	O
in	O	ADP	O
morphologic	O	ADJ	B
changes	O	NOUN	B
in	O	ADP	O
the	O	DET	O
trabecular	O	NOUN	B
meshwork	O	NOUN	I
similar	O	ADJ	O
to	O	PART	O
those	O	DET	O
reported	O	VERB	O
for	O	ADP	O
corticosteroid	B-Disease	NOUN	B
glaucoma	I-Disease	NOUN	I
and	O	CCONJ	O
open	B-Disease	ADJ	B
angle	I-Disease	NOUN	I
glaucoma	I-Disease	NOUN	I
.	O	PUNCT	O


This	O	DET	O
system	O	NOUN	B
may	O	AUX	O
provide	O	VERB	O
an	O	DET	O
acute	O	ADJ	B
model	O	NOUN	I
in	O	ADP	O
which	O	DET	O
to	O	PART	O
study	O	VERB	B
the	O	DET	O
pathogenic	O	ADJ	B
mechanisms	O	NOUN	B
involved	O	VERB	O
in	O	ADP	O
steroid	B-Disease	NOUN	B
glaucoma	I-Disease	NOUN	I
and	O	CCONJ	O
primary	B-Disease	ADJ	B
open	I-Disease	ADJ	I
angle	I-Disease	NOUN	I
glaucoma	I-Disease	NOUN	I


Cognitive	B-Disease	ADJ	B
deterioration	I-Disease	NOUN	I
from	O	ADP	O
long	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
abuse	O	NOUN	B
of	O	ADP	O
dextromethorphan	B-Chemical	NOUN	B
:	O	PUNCT	O
a	O	DET	O
case	O	NOUN	B
report	O	NOUN	I
.	O	PUNCT	O


Dextromethorphan	B-Chemical	NOUN	B
(	O	PUNCT	O
DM	B-Chemical	NOUN	B
),	O	PUNCT	O
the	O	DET	O
dextrorotatory	O	ADJ	B
isomer	O	NOUN	B
of	O	ADP	O
3-hydroxy-N-methylmorphinan	B-Chemical	NOUN	B
,	O	PUNCT	O
is	O	AUX	O
the	O	DET	O
main	O	ADJ	O
ingredient	O	NOUN	B
in	O	ADP	O
a	O	DET	O
number	O	NOUN	O
of	O	ADP	O
widely	O	ADV	O
available	O	ADJ	O
,	O	PUNCT	O
over	O	ADP	B
-	O	PUNCT	O
the	O	DET	O
-	O	PUNCT	O
counter	O	NOUN	B
antitussives	O	NOUN	I
.	O	PUNCT	O


Initial	O	ADJ	O
studies	O	NOUN	B
(	O	PUNCT	O
Bornstein	O	PROPN	O
1968	O	NUM	O
)	O	PUNCT	O
showed	O	VERB	O
that	O	SCONJ	O
it	O	PRON	O
possessed	O	VERB	O
no	O	DET	O
respiratory	O	ADJ	B
suppressant	O	NOUN	I
effects	O	NOUN	O
and	O	CCONJ	O
no	O	DET	O
addiction	O	NOUN	B
liability	O	NOUN	I
.	O	PUNCT	O


Subsequently	O	ADV	O
,	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
several	O	ADJ	O
articles	O	NOUN	B
reporting	O	VERB	O
abuse	O	NOUN	B
of	O	ADP	O
this	O	DET	O
drug	O	NOUN	B
have	O	AUX	O
appeared	O	VERB	O
in	O	ADP	O
the	O	DET	O
literature	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
drug	O	NOUN	B
is	O	AUX	O
known	O	VERB	O
to	O	PART	O
cause	O	VERB	O
a	O	DET	O
variety	O	NOUN	O
of	O	ADP	O
acute	O	ADJ	B
toxic	O	ADJ	O
effects	O	NOUN	O
,	O	PUNCT	O
ranging	O	VERB	O
from	O	ADP	O
nausea	B-Disease	NOUN	B
,	O	PUNCT	O
restlessness	B-Disease	NOUN	B
,	O	PUNCT	O
insomnia	B-Disease	NOUN	B
,	O	PUNCT	O
ataxia	B-Disease	NOUN	B
,	O	PUNCT	O
slurred	O	ADJ	B
speech	O	NOUN	I
and	O	CCONJ	O
nystagmus	B-Disease	NOUN	B
to	O	PART	O
mood	O	NOUN	B
changes	O	NOUN	I
,	O	PUNCT	O
perceptual	O	ADJ	B
alterations	O	NOUN	B
,	O	PUNCT	O
inattention	O	NOUN	B
,	O	PUNCT	O
disorientation	O	NOUN	B
and	O	CCONJ	O
aggressive	B-Disease	ADJ	B
behavior	I-Disease	NOUN	I
(	O	PUNCT	O
Rammer	O	PROPN	B
et	O	X	O
al	O	X	O
1988	O	NUM	O
;	O	PUNCT	O
Katona	O	PROPN	B
and	O	CCONJ	O
Watson	O	PROPN	O
1986	O	NUM	O
;	O	PUNCT	O
Isbell	O	PROPN	B
and	O	CCONJ	O
Fraser	O	PROPN	O
1953	O	NUM	O
;	O	PUNCT	O
Devlin	O	PROPN	O
et	O	X	O
al	O	X	O
1985	O	NUM	O
;	O	PUNCT	O
McCarthy	O	PROPN	B
1971	O	NUM	I
;	O	PUNCT	O
Dodds	O	PROPN	B
and	O	CCONJ	O
Revai	O	PROPN	O
1967	O	NUM	O
;	O	PUNCT	O
Degkwitz	O	PROPN	O
1964	O	NUM	O
;	O	PUNCT	O
Hildebrand	O	PROPN	O
et	O	X	O
al	O	X	O
1989	O	NUM	O
).	O	PUNCT	O
There	O	PRON	O
have	O	AUX	O
also	O	ADV	O
been	O	AUX	O
two	O	NUM	O
reported	O	VERB	O
fatalities	O	NOUN	B
from	O	ADP	O
DM	B-Chemical	NOUN	B
overdoses	O	NOUN	I
(	O	PUNCT	O
Fleming	O	NOUN	O
1986	O	NUM	O
).	O	PUNCT	O
However	O	ADV	O
,	O	PUNCT	O
there	O	PRON	O
are	O	AUX	O
no	O	DET	O
reports	O	NOUN	O
describing	O	VERB	O
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
chronic	O	ADJ	B
abuse	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
report	O	NOUN	B
describes	O	VERB	O
a	O	DET	O
case	O	NOUN	B
of	O	ADP	O
cognitive	B-Disease	ADJ	B
deterioration	I-Disease	NOUN	I
resulting	O	VERB	O
from	O	ADP	O
prolonged	O	ADJ	B
use	O	NOUN	O
of	O	ADP	O
DM	B-Chemical	NOUN	B


Long	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
lithium	B-Chemical	NOUN	B
treatment	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
kidney	O	NOUN	B
.	O	PUNCT	O


Interim	O	ADJ	B
report	O	NOUN	O
on	O	ADP	O
fifty	O	NUM	O
patients	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
is	O	AUX	O
a	O	DET	O
report	O	NOUN	B
on	O	ADP	O
the	O	DET	O
first	O	ADJ	O
part	O	NOUN	O
of	O	ADP	O
our	O	PRON	O
study	O	NOUN	B
of	O	ADP	O
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
long	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
lithium	B-Chemical	NOUN	B
treatment	O	NOUN	B
on	O	ADP	O
the	O	DET	O
kidney	O	NOUN	B
.	O	PUNCT	O


Creatinine	B-Chemical	NOUN	B
clearance	O	NOUN	B
,	O	PUNCT	O
maximum	O	ADJ	B
urinary	O	ADJ	B
osmolality	O	NOUN	I
and	O	CCONJ	O
24	O	NUM	O
hour	O	NOUN	B
urine	O	NOUN	B
volume	O	NOUN	I
have	O	AUX	O
been	O	AUX	O
tested	O	VERB	B
in	O	ADP	O
50	O	NUM	O
affectively	O	ADV	B
ill	O	ADJ	I
patients	O	NOUN	B
who	O	PRON	O
have	O	AUX	O
been	O	AUX	O
on	O	ADP	O
long	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
lithium	B-Chemical	NOUN	B
for	O	ADP	O
more	O	ADJ	O
than	O	ADP	O
one	O	NUM	O
year	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
findings	O	NOUN	B
have	O	AUX	O
been	O	AUX	O
compared	O	VERB	B
with	O	ADP	O
norms	O	NOUN	B
and	O	CCONJ	O
with	O	ADP	O
values	O	NOUN	B
of	O	ADP	O
the	O	DET	O
same	O	ADJ	O
tests	O	NOUN	B
from	O	ADP	O
screening	O	VERB	B
prior	O	ADV	O
to	O	PART	O
lithium	B-Chemical	NOUN	B
,	O	PUNCT	O
available	O	ADJ	O
for	O	ADP	O
most	O	ADJ	O
of	O	ADP	O
our	O	PRON	O
patients	O	NOUN	B
.	O	PUNCT	O


No	O	DET	B
evidence	O	NOUN	I
was	O	AUX	O
found	O	VERB	O
for	O	ADP	O
any	O	DET	O
reduction	O	NOUN	B
of	O	ADP	O
glomerular	O	ADJ	B
filtration	O	NOUN	I
during	O	ADP	O
lithium	B-Chemical	NOUN	B
treatment	O	NOUN	B
.	O	PUNCT	O


Low	O	ADJ	B
clearance	O	NOUN	B
values	O	NOUN	I
found	O	VERB	O
in	O	ADP	O
several	O	ADJ	O
patients	O	NOUN	B
could	O	AUX	O
be	O	AUX	O
accounted	O	VERB	O
for	O	ADP	O
by	O	ADP	O
their	O	PRON	O
age	O	NOUN	B
and	O	CCONJ	O
their	O	PRON	O
pre	O	ADJ	B
-	O	PUNCT	O
lithium	B-Chemical	NOUN	B
values	O	NOUN	B
.	O	PUNCT	O


Urinary	O	ADJ	B
concentration	O	NOUN	O
defect	O	NOUN	O
appeared	O	VERB	O
frequent	O	ADJ	B
but	O	CCONJ	O
the	O	DET	O
extent	O	NOUN	O
of	O	ADP	O
the	O	DET	O
impairment	O	NOUN	B
is	O	AUX	O
difficult	O	ADJ	O
to	O	PART	O
assess	O	VERB	B
because	O	SCONJ	O
of	O	ADP	O
the	O	DET	O
uncertainty	O	NOUN	B
about	O	ADP	O
the	O	DET	O
norms	O	NOUN	B
applicable	O	ADJ	O
to	O	ADP	O
this	O	DET	O
group	O	NOUN	B
of	O	ADP	O
patients	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
concentration	O	NOUN	B
defect	O	NOUN	B
appeared	O	VERB	O
reversible	O	ADJ	B
,	O	PUNCT	O
at	O	ADP	O
least	O	ADJ	O
in	O	ADP	O
part	O	NOUN	O
.	O	PUNCT	O


Polyuria	B-Disease	NOUN	B


Complete	O	ADJ	B
heart	B-Disease	NOUN	O
block	I-Disease	NOUN	O
following	O	VERB	O
a	O	DET	O
single	O	ADJ	B
dose	O	NOUN	I
of	O	ADP	O
trazodone	B-Chemical	NOUN	B
.	O	PUNCT	O


Forty	O	NUM	O
minutes	O	NOUN	B
after	O	ADP	O
receiving	O	VERB	O
a	O	DET	O
single	O	ADJ	O
starting	O	NOUN	O
dose	O	NOUN	B
of	O	ADP	O
trazodone	B-Chemical	NOUN	B
,	O	PUNCT	O
a	O	DET	O
patient	O	NOUN	B
developed	O	VERB	O
complete	O	ADJ	O
heart	B-Disease	NOUN	B
block	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
case	O	NOUN	B
illustrates	O	VERB	O
that	O	SCONJ	O
,	O	PUNCT	O
despite	O	SCONJ	O
the	O	DET	O
results	O	NOUN	B
of	O	ADP	O
earlier	O	ADJ	O
studies	O	NOUN	B
,	O	PUNCT	O
trazodone	B-Chemical	NOUN	B


Quinidine	B-Chemical	NOUN	B
phenylethylbarbiturate	I-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
fulminant	O	ADJ	B
hepatitis	B-Disease	NOUN	B
in	O	ADP	O
a	O	DET	O
pregnant	O	ADJ	B
woman	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
case	O	NOUN	B
report	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
the	O	DET	O
case	O	NOUN	B
of	O	ADP	O
a	O	DET	O
19	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
Laotian	O	ADJ	B
patient	O	NOUN	B
affected	O	VERB	B
by	O	ADP	O
fulminant	O	ADJ	B
hepatitis	B-Disease	NOUN	B
during	O	ADP	O
the	O	DET	O
third	O	ADJ	B
trimester	O	NOUN	I
of	O	ADP	O
her	O	PRON	O
pregnancy	O	NOUN	B
after	O	ADP	O
a	O	DET	O
1	O	NUM	O
-	O	PUNCT	O
month	O	NOUN	B
administration	O	NOUN	B
of	O	ADP	O
quinidine	B-Chemical	NOUN	B
phenylethylbarbiturate	I-Chemical	NOUN	B
.	O	PUNCT	O


After	O	ADP	O
delivery	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
patient	O	NOUN	B
underwent	O	VERB	O
orthotopic	O	ADJ	B
liver	O	NOUN	I
transplantation	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
patient	O	NOUN	B
was	O	AUX	O
in	O	ADP	O
good	O	ADJ	O
condition	O	NOUN	B
16	O	NUM	O
months	O	NOUN	B
after	O	ADP	O
liver	O	NOUN	B
transplantation	O	NOUN	I
.	O	PUNCT	O


Quinidine	B-Chemical	NOUN	B
itself	O	PRON	O
or	O	CCONJ	O
phenylethylbarbiturate	B-Chemical	NOUN	B
may	O	AUX	O
be	O	AUX	O
responsible	O	ADJ	O
for	O	ADP	O
fulminant	O	ADJ	B
hepatitis	B-Disease	NOUN	B


The	O	DET	O
epidemiology	O	NOUN	B
of	O	ADP	O
the	O	DET	O
acute	O	ADJ	B
flank	B-Disease	ADJ	I
pain	I-Disease	NOUN	I
syndrome	O	NOUN	I
from	O	ADP	O
suprofen	B-Chemical	NOUN	B
.	O	PUNCT	O


Suprofen	B-Chemical	NOUN	B
,	O	PUNCT	O
a	O	DET	O
new	O	ADJ	O
nonsteroidal	O	ADJ	B
anti	O	ADJ	I
-	O	PUNCT	O
inflammatory	O	ADJ	B
drug	O	NOUN	O
,	O	PUNCT	O
was	O	AUX	O
marketed	O	VERB	B
in	O	ADP	O
early	O	ADJ	O
1986	O	NUM	O
as	O	ADP	O
an	O	DET	O
analgesic	O	NOUN	B
agent	O	NOUN	I
.	O	PUNCT	O


Until	O	ADP	O
physicians	O	NOUN	B
began	O	VERB	O
reporting	O	VERB	B
an	O	DET	O
unusual	O	ADJ	B
acute	O	ADJ	B
flank	B-Disease	ADJ	I
pain	I-Disease	NOUN	I
syndrome	O	NOUN	I
to	O	PART	O
the	O	DET	O
spontaneous	O	ADJ	B
reporting	O	NOUN	O
system	O	NOUN	O
,	O	PUNCT	O
700	O	NUM	O
,	O	PUNCT	O
000	O	NUM	O
persons	O	NOUN	B
used	O	VERB	O
the	O	DET	O
drug	O	NOUN	B
in	O	ADP	O
the	O	DET	O
United	O	PROPN	B
States	O	PROPN	I
.	O	PUNCT	O


Through	O	ADP	O
August	O	PROPN	O
1986	O	NUM	O
,	O	PUNCT	O
a	O	DET	O
total	O	NOUN	O
of	O	ADP	O
163	O	NUM	O
cases	O	NOUN	B
of	O	ADP	O
this	O	DET	O
syndrome	O	NOUN	B
were	O	AUX	O
reported	O	VERB	O
.	O	PUNCT	O


To	O	PART	O
elucidate	O	VERB	O
the	O	DET	O
epidemiology	O	NOUN	B
of	O	ADP	O
the	O	DET	O
syndrome	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
case	O	NOUN	B
-	O	PUNCT	O
control	O	NOUN	B
study	O	NOUN	I
was	O	AUX	O
performed	O	VERB	O
,	O	PUNCT	O
comparing	O	VERB	B
62	O	NUM	O
of	O	ADP	O
the	O	DET	O
case	O	NOUN	B
patients	O	NOUN	I
who	O	PRON	O
had	O	AUX	O
been	O	AUX	O
reported	O	VERB	O
to	O	PART	O
the	O	DET	O
spontaneous	O	ADJ	B
reporting	O	NOUN	O
system	O	NOUN	O
to	O	ADP	O
185	O	NUM	O
suprofen	B-Chemical	NOUN	B
-	O	PUNCT	O
exposed	O	VERB	B
control	O	NOUN	O
subjects	O	NOUN	O
who	O	PRON	O
did	O	AUX	O
not	O	PART	O
have	O	AUX	O
the	O	DET	O
syndrome	O	NOUN	B
.	O	PUNCT	O


Case	O	NOUN	B
patients	O	NOUN	I
were	O	AUX	O
more	O	ADV	O
likely	O	ADJ	O
to	O	PART	O
be	O	AUX	O
men	O	NOUN	B
(	O	PUNCT	O
odds	O	NOUN	B
ratio	O	NOUN	I
,	O	PUNCT	O
3	O	NUM	O
.	O	PUNCT	O


8	O	NUM	O
;	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
,	O	PUNCT	O
1	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
-	O	SYM	O
12	O	NUM	O
.	O	PUNCT	O


1	O	X	O
),	O	PUNCT	O
suffer	O	VERB	O
from	O	ADP	O
hay	B-Disease	NOUN	B
fever	I-Disease	NOUN	I
and	O	CCONJ	O
asthma	B-Disease	NOUN	B
(	O	PUNCT	O
odds	O	NOUN	B
ratio	O	NOUN	I
,	O	PUNCT	O
3	O	NUM	O
.	O	PUNCT	O


4	O	NUM	O
;	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
,	O	PUNCT	O
1	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
-	O	SYM	O
11	O	NUM	O
.	O	PUNCT	O


9	O	NUM	O
);	O	ADJ	O
to	O	PART	O
participate	O	VERB	B
in	O	ADP	O
regular	O	ADJ	B
exercise	O	NOUN	I
(	O	PUNCT	O
odds	O	NOUN	B
ratio	O	NOUN	I
,	O	PUNCT	O
5	O	NUM	O
.	O	PUNCT	O


9	O	NUM	O
;	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
,	O	PUNCT	O
1	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
-	O	SYM	O
30	O	NUM	O
.	O	PUNCT	O


7	O	NUM	O
),	O	PUNCT	O
especially	O	ADV	O
in	O	ADP	O
the	O	DET	O
use	O	NOUN	O
of	O	ADP	O
Nautilus	O	PROPN	B
equipment	O	NOUN	I
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


02	O	NUM	O
);	O	NOUN	B
and	O	CCONJ	O
to	O	PART	O
use	O	VERB	O
alcohol	B-Chemical	NOUN	O
(	O	PUNCT	O
odds	O	NOUN	B
ratio	O	NOUN	I
,	O	PUNCT	O
4	O	NUM	O
.	O	PUNCT	O


4	O	NUM	O
;	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
,	O	PUNCT	O
1	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
-	O	SYM	O
17	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
).	O	PUNCT	O
Possible	O	ADJ	O
risk	O	NOUN	B
factors	O	NOUN	I
included	O	VERB	O
young	O	ADJ	B
age	O	NOUN	I
,	O	PUNCT	O
concurrent	O	ADJ	B
use	O	NOUN	O
of	O	ADP	O
other	O	ADJ	O
analgesic	O	NOUN	B
agents	O	NOUN	I
(	O	PUNCT	O
especially	O	ADV	O
ibuprofen	B-Chemical	NOUN	B
),	O	PUNCT	O
preexisting	O	VERB	O
renal	B-Disease	ADJ	B
disease	I-Disease	NOUN	I
,	O	PUNCT	O
a	O	DET	O
history	O	NOUN	B
of	O	ADP	O
kidney	B-Disease	NOUN	B
stones	I-Disease	NOUN	I
,	O	PUNCT	O
a	O	DET	O
history	O	NOUN	B
of	O	ADP	O
gout	B-Disease	NOUN	B
,	O	PUNCT	O
a	O	DET	O
recent	O	ADJ	O
increase	O	NOUN	B
in	O	ADP	O
activity	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
recent	O	ADJ	O
increase	O	NOUN	B
in	O	ADP	O
sun	O	NOUN	B
exposure	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
residence	O	NOUN	B
in	O	ADP	O
the	O	DET	O
Sunbelt	O	PROPN	B
.	O	PUNCT	O


These	O	DET	O
were	O	AUX	O
findings	O	NOUN	B
that	O	PRON	O
were	O	AUX	O
suggestive	O	ADJ	O
but	O	CCONJ	O
did	O	AUX	O
not	O	PART	O
reach	O	VERB	O
conventional	O	ADJ	B
statistical	O	ADJ	B
significance	O	NOUN	I
.	O	PUNCT	O


These	O	DET	O
findings	O	NOUN	B
are	O	AUX	O
consistent	O	ADJ	B
with	O	ADP	I
the	O	DET	O
postulated	O	VERB	O
mechanism	O	NOUN	B
for	O	ADP	O
this	O	DET	O
unusual	O	ADJ	O
syndrome	O	NOUN	B
:	O	PUNCT	O
acute	O	ADJ	B
diffuse	O	ADJ	I
crystallization	O	NOUN	I
of	O	ADP	O
uric	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I


Hemolytic-uremic	B-Disease	ADJ	B
syndrome	I-Disease	NOUN	I
associated	O	VERB	B
with	O	ADP	I
ingestion	O	NOUN	B
of	O	ADP	O
quinine	B-Chemical	NOUN	B
.	O	PUNCT	O


Hemolytic-uremic	B-Disease	ADJ	B
syndrome	I-Disease	NOUN	I
following	O	VERB	O
quinine	B-Chemical	NOUN	B
ingestion	O	NOUN	B
is	O	AUX	O
a	O	DET	O
newly	O	ADV	O
described	O	VERB	O
phenomenon	O	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
just	O	ADV	O
two	O	NUM	O
previous	O	ADJ	O
descriptions	O	NOUN	B
of	O	ADP	O
4	O	NUM	O
cases	O	NOUN	B
in	O	ADP	O
the	O	DET	O
literature	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
describe	O	VERB	O
a	O	DET	O
5th	O	ADJ	O
case	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
reaction	O	NOUN	B
may	O	AUX	O
be	O	AUX	O
mediated	O	VERB	O
by	O	ADP	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
antibodies	O	NOUN	B
reactive	O	ADJ	B
against	O	ADP	O
platelets	O	NOUN	B
in	O	ADP	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
quinine	B-Chemical	NOUN	B
.	O	PUNCT	O


Treatment	O	NOUN	B
has	O	AUX	O
included	O	VERB	O
use	O	NOUN	O
of	O	ADP	O
plasma	O	NOUN	B
exchange	O	NOUN	O
,	O	PUNCT	O
prednisone	B-Chemical	NOUN	B
,	O	PUNCT	O
aspirin	B-Chemical	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
dipyridamole	B-Chemical	NOUN	B
.	O	PUNCT	O


The	O	DET	O
patients	O	NOUN	B
have	O	AUX	O
all	O	DET	O
regained	O	VERB	B
some	O	DET	O
degree	O	NOUN	B
of	O	ADP	O
renal	O	ADJ	B
function	O	NOUN	I
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
it	O	PRON	O
is	O	AUX	O
unclear	O	ADJ	O
whether	O	SCONJ	O
pharmacological	O	ADJ	B
treatment	O	NOUN	I
or	O	CCONJ	O
spontaneous	O	ADJ	B
resolution	O	NOUN	B
is	O	AUX	O
responsible	O	ADJ	O
for	O	ADP	O
the	O	DET	O
improvement	O	NOUN	B
.	O	PUNCT	O


Quinine	B-Chemical	NOUN	B
-	O	PUNCT	O
associated	O	VERB	B
hemolytic-uremic	B-Disease	ADJ	B
syndrome	I-Disease	NOUN	I
probably	O	ADV	O
occurs	O	VERB	O
more	O	ADV	O
often	O	ADV	O
than	O	ADP	O
is	O	AUX	O
recognized	O	VERB	O
.	O	PUNCT	O


It	O	PRON	O
is	O	AUX	O
important	O	ADJ	O
to	O	PART	O
recognize	O	VERB	O
this	O	DET	O
reaction	O	NOUN	B
when	O	SCONJ	O
it	O	PRON	O
occurs	O	VERB	B
and	O	CCONJ	O
to	O	PART	O
avoid	O	VERB	O
further	O	ADJ	O
quinine	B-Chemical	NOUN	B


Pyeloureteral	O	ADJ	B
filling	O	NOUN	I
defects	O	NOUN	I
associated	O	VERB	B
with	O	ADP	I
systemic	O	ADJ	B
anticoagulation	O	NOUN	I
:	O	PUNCT	O
a	O	DET	O
case	O	NOUN	B
report	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
etiology	O	NOUN	B
of	O	ADP	O
pyeloureteritis	B-Disease	NOUN	B
cystica	I-Disease	NOUN	I
has	O	AUX	O
long	O	ADV	O
been	O	AUX	O
attributed	O	VERB	O
to	O	PART	O
chronic	O	ADJ	B
infection	B-Disease	NOUN	I
and	O	CCONJ	O
inflammation	B-Disease	NOUN	B
.	O	PUNCT	O


A	O	DET	O
case	O	NOUN	B
is	O	AUX	O
presented	O	VERB	O
that	O	PRON	O
is	O	AUX	O
unique	O	ADJ	B
in	O	ADP	O
that	O	SCONJ	O
the	O	DET	O
acute	O	ADJ	B
onset	O	NOUN	I
and	O	CCONJ	O
the	O	DET	O
rapid	O	ADJ	O
resolution	O	NOUN	B
of	O	ADP	O
pyeloureteral	O	ADJ	B
filling	O	NOUN	I
defects	O	NOUN	I
in	O	ADP	O
this	O	DET	O
patient	O	NOUN	B
were	O	AUX	O
documented	O	VERB	B
by	O	ADP	O
radiography	O	NOUN	B
.	O	PUNCT	O


There	O	PRON	O
is	O	AUX	O
no	O	DET	O
evidence	O	NOUN	O
of	O	ADP	O
antecedent	O	ADJ	B
or	O	CCONJ	O
concurrent	O	ADJ	B
infection	B-Disease	NOUN	B
in	O	ADP	O
this	O	DET	O
patient	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
disease	O	NOUN	B
occurred	O	VERB	O
subsequent	O	ADJ	O
to	O	PART	O
the	O	DET	O
initiation	O	NOUN	B
of	O	ADP	O
heparin	B-Chemical	NOUN	B
therapy	O	NOUN	I
for	O	ADP	O
suspected	O	ADJ	B
pelvic	O	ADJ	B
thrombophlebitis	B-Disease	NOUN	I
and	O	CCONJ	O
cleared	O	VERB	B
rapidly	O	ADV	O
subsequent	O	ADJ	O
to	O	PART	O
its	O	PRON	O
discontinuation	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
rate	O	NOUN	B
of	O	ADP	O
resolution	O	NOUN	B
of	O	ADP	O
the	O	DET	O
radiographic	O	ADJ	B
findings	O	NOUN	B
may	O	AUX	O
be	O	AUX	O
helpful	O	ADJ	O
in	O	ADP	O
distinguishing	O	VERB	O
between	O	ADP	O
true	O	ADJ	O
pyeloureteritis	B-Disease	NOUN	B
cystica	I-Disease	NOUN	I
and	O	CCONJ	O
submucosal	B-Disease	ADJ	B
hemorrhage	I-Disease	NOUN	I


Changes	O	NOUN	B
in	O	ADP	O
peroxisomes	O	NOUN	B
in	O	ADP	O
preneoplastic	O	ADJ	B
liver	O	NOUN	B
and	O	CCONJ	O
hepatoma	B-Disease	NOUN	B
of	O	ADP	O
mice	O	NOUN	B
induced	O	VERB	B
by	O	ADP	O
alpha-benzene	B-Chemical	ADJ	B
hexachloride	I-Chemical	NOUN	I
.	O	PUNCT	O


Peroxisomes	O	NOUN	B
in	O	ADP	O
hepatomas	B-Disease	NOUN	B
and	O	CCONJ	O
hyperplastic	O	ADJ	B
preneoplastic	O	ADJ	B
liver	B-Disease	NOUN	B
lesions	I-Disease	NOUN	I
induced	O	VERB	B
in	O	ADP	O
mice	O	NOUN	B
by	O	ADP	O
500	O	NUM	O
ppm	O	NOUN	O
alpha-benzene	B-Chemical	NOUN	B
hexachloride	I-Chemical	NOUN	I
were	O	AUX	O
examined	O	VERB	O
histochemically	O	ADV	B
and	O	CCONJ	O
electron	O	NOUN	B
microscopically	O	ADV	I
.	O	PUNCT	O


Although	O	SCONJ	O
most	O	ADJ	O
of	O	ADP	O
the	O	DET	O
hepatomas	B-Disease	NOUN	B
were	O	AUX	O
well	O	ADV	B
-	O	PUNCT	O
differentiated	O	VERB	B
tumors	B-Disease	NOUN	B
and	O	CCONJ	O
contained	O	VERB	O
a	O	DET	O
considerable	O	ADJ	O
number	O	NOUN	O
of	O	ADP	O
peroxisomes	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
tumor	B-Disease	NOUN	B
cells	O	NOUN	I
did	O	AUX	O
not	O	PART	O
respond	O	VERB	O
to	O	PART	O
ethyl-alpha-p-chlorophenoxyisobutyrate	B-Chemical	NOUN	B
with	O	ADP	O
proliferation	O	NOUN	B
of	O	ADP	O
peroxisomes	O	NOUN	B
.	O	PUNCT	O


At	O	ADP	O
the	O	DET	O
16th	O	ADJ	O
week	O	NOUN	B
of	O	ADP	O
carcinogen	O	NOUN	B
feeding	O	NOUN	B
,	O	PUNCT	O
hyperplastic	O	ADJ	B
nodules	O	NOUN	I
appeared	O	VERB	O
and	O	CCONJ	O
advanced	O	VERB	B
to	O	PART	O
further	O	ADJ	O
stages	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
majority	O	NOUN	O
of	O	ADP	O
the	O	DET	O
nodules	O	NOUN	B
showed	O	VERB	O
a	O	DET	O
considerable	O	ADJ	O
number	O	NOUN	O
of	O	ADP	O
peroxisomes	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
inductive	O	ADJ	B
proliferation	O	NOUN	I
of	O	ADP	O
peroxisomes	O	NOUN	B
.	O	PUNCT	O


Within	O	ADP	O
the	O	DET	O
nodules	O	NOUN	B
,	O	PUNCT	O
foci	O	NOUN	B
of	O	ADP	O
proliferation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
cells	O	NOUN	B
that	O	PRON	O
showed	O	VERB	O
no	O	DET	O
inducibility	O	NOUN	B
of	O	ADP	O
proliferation	O	NOUN	B
of	O	ADP	O
peroxisomes	O	NOUN	B
appeared	O	VERB	O
.	O	PUNCT	O


These	O	DET	O
cells	O	NOUN	B
proliferated	O	VERB	O
further	O	ADV	O
,	O	PUNCT	O
replacing	O	VERB	O
the	O	DET	O
most	O	ADJ	O
part	O	NOUN	O
of	O	ADP	O
the	O	DET	O
nodules	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
with	O	ADP	O
this	O	DET	O
process	O	NOUN	B
hepatomas	B-Disease	NOUN	B
appeared	O	VERB	O
to	O	PART	O
have	O	AUX	O
been	O	AUX	O
formed	O	VERB	O
.	O	PUNCT	O


No	O	DET	O
abnormal	O	ADJ	B
matrical	O	ADJ	B
inclusions	O	NOUN	B
of	O	ADP	O
peroxisomes	O	NOUN	B
were	O	AUX	O
formed	O	VERB	O
in	O	ADP	O
the	O	DET	O
cells	O	NOUN	B
of	O	ADP	O
hyperplastic	O	ADJ	B
nodules	O	NOUN	I
by	O	ADP	O
ethyl-alpha-p-chlorophenoxyisobutyrate	B-Chemical	NOUN	B


Quinidine	B-Chemical	NOUN	B
hepatitis	B-Disease	NOUN	I
.	O	PUNCT	O


Long	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
administration	O	NOUN	B
of	O	ADP	O
quinidine	B-Chemical	NOUN	B
was	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
persistent	O	ADJ	B
elevation	O	NOUN	B
of	O	ADP	O
serum	O	NOUN	B
concentrations	O	NOUN	B
of	O	ADP	O
SGOT	O	NOUN	B
,	O	PUNCT	O
lactic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
dehydrogenase	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
alkaline	O	NOUN	B
phosphatase	O	NOUN	I
.	O	PUNCT	O


Liver	O	NOUN	B
biopsy	O	NOUN	I
showed	O	VERB	O
active	O	ADJ	B
hepatitis	B-Disease	NOUN	I
.	O	PUNCT	O


Discontinuance	O	NOUN	B
of	O	ADP	O
quinidine	B-Chemical	NOUN	B
therapy	O	NOUN	O
led	O	VERB	O
to	O	PART	O
normalization	O	NOUN	B
of	O	ADP	O
liver	O	NOUN	B
function	O	NOUN	I
tests	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
challenge	O	NOUN	B
dose	O	NOUN	I
of	O	ADP	O
quinidine	B-Chemical	NOUN	B
caused	O	VERB	O
clinical	O	ADJ	B
symptoms	O	NOUN	I
and	O	CCONJ	O
abrupt	O	ADJ	B
elevation	O	NOUN	B
of	O	ADP	O
SGOT	O	NOUN	B
,	O	PUNCT	O
alkaline	O	NOUN	B
phosphatase	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
lactic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
dehydrogenase	O	NOUN	I
values	O	NOUN	O
.	O	PUNCT	O


We	O	PRON	O
concluded	O	VERB	O
that	O	SCONJ	O
this	O	DET	O
patient	O	NOUN	B
had	O	AUX	O
quinidine	B-Chemical	NOUN	B
hepatotoxicity	B-Disease	NOUN	B
and	O	CCONJ	O
believe	O	VERB	O
that	O	SCONJ	O
this	O	DET	O
is	O	AUX	O
the	O	DET	O
first	O	ADJ	O
case	O	NOUN	B
reported	O	VERB	O
with	O	ADP	O
liver	O	NOUN	B
biopsy	O	NOUN	I
documentation	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
report	O	NOUN	B
also	O	ADV	O
suggests	O	VERB	O
that	O	SCONJ	O
,	O	PUNCT	O
even	O	ADV	O
after	O	ADP	O
long	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
administration	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
hepatic	B-Disease	ADJ	B
toxicity	I-Disease	NOUN	B


Cholesteryl	B-Chemical	NOUN	B
hemisuccinate	I-Chemical	NOUN	I
treatment	O	NOUN	B
protects	O	VERB	B
rodents	O	NOUN	B
from	O	ADP	O
the	O	DET	O
toxic	O	ADJ	B
effects	O	NOUN	O
of	O	ADP	O
acetaminophen	B-Chemical	NOUN	B
,	O	PUNCT	O
adriamycin	B-Chemical	NOUN	B
,	O	PUNCT	O
carbon	B-Chemical	NOUN	B
tetrachloride	I-Chemical	NOUN	I
,	O	PUNCT	O
chloroform	B-Chemical	NOUN	B
and	O	CCONJ	O
galactosamine	B-Chemical	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
to	O	PART	O
its	O	PRON	O
use	O	NOUN	O
as	O	ADP	O
a	O	DET	O
stabilizer	O	NOUN	B
/	O	SYM	O
rigidifier	O	NOUN	B
of	O	ADP	I
membranes	O	NOUN	I
,	O	PUNCT	O
cholesteryl	B-Chemical	NOUN	B
hemisuccinate	I-Chemical	NOUN	I
,	O	PUNCT	O
tris	B-Chemical	ADJ	B
salt	I-Chemical	NOUN	I
(	O	PUNCT	O
CS	B-Chemical	ADJ	B
)	O	PUNCT	O
administration	O	NOUN	B
has	O	AUX	O
also	O	ADV	O
been	O	AUX	O
shown	O	VERB	O
to	O	PART	O
protect	O	VERB	O
rats	O	NOUN	B
from	O	ADP	O
the	O	DET	O
hepatotoxic	B-Disease	ADJ	B
effects	O	NOUN	B
of	O	ADP	O
carbon	B-Chemical	NOUN	B
tetrachloride	I-Chemical	NOUN	I
(	O	PUNCT	O
CCl4	B-Chemical	NOUN	B
).	O	PUNCT	O
To	O	PART	O
further	O	VERB	O
our	O	PRON	O
understanding	O	NOUN	O
of	O	ADP	O
the	O	DET	O
mechanism	O	NOUN	B
of	O	ADP	O
CS	B-Chemical	ADJ	B
cytoprotection	O	NOUN	I
,	O	PUNCT	O
we	O	PRON	O
examined	O	VERB	O
in	O	ADP	O
rats	O	NOUN	B
and	O	CCONJ	O
mice	O	NOUN	B
the	O	DET	O
protective	O	ADJ	B
abilities	O	NOUN	I
of	O	ADP	O
CS	B-Chemical	NOUN	B
and	O	CCONJ	O
the	O	DET	O
non	O	ADJ	B
-	O	PUNCT	O
hydrolyzable	O	ADJ	B
ether	O	NOUN	O
form	O	NOUN	O
of	O	ADP	O
CS	B-Chemical	ADJ	B
,	O	PUNCT	O
gamma-cholesteryloxybutyric	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
,	O	PUNCT	O
tris	B-Chemical	ADJ	B
salt	I-Chemical	NOUN	I
(	O	PUNCT	O
CSE	B-Chemical	PROPN	B
)	O	PUNCT	O
against	O	ADP	O
acetaminophen	B-Chemical	NOUN	B
-,	O	ADJ	O
adriamycin	B-Chemical	NOUN	B
-,	O	NOUN	O
carbon	B-Chemical	NOUN	B
tetrachloride	I-Chemical	NOUN	I
-,	O	NOUN	O
chloroform	B-Chemical	NOUN	B
-	O	PUNCT	O
and	O	CCONJ	O
galactosamine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
toxicity	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
results	O	NOUN	B
of	O	ADP	O
these	O	DET	O
studies	O	NOUN	B
demonstrated	O	VERB	O
that	O	SCONJ	O
CS	B-Chemical	PROPN	B
-	O	PUNCT	O
mediated	O	VERB	B
protection	O	NOUN	B
is	O	AUX	O
not	O	PART	O
selective	O	ADJ	O
for	O	ADP	O
a	O	DET	O
particular	O	ADJ	O
species	O	NOUN	B
,	O	PUNCT	O
organ	O	NOUN	B
system	O	NOUN	I
or	O	CCONJ	O
toxic	O	ADJ	B
chemical	O	NOUN	O
.	O	PUNCT	O


A	O	DET	O
24	O	NUM	O
-	O	PUNCT	O
h	O	NOUN	B
pretreatment	O	NOUN	B
of	O	ADP	O
both	O	DET	O
rats	O	NOUN	B
and	O	CCONJ	O
mice	O	NOUN	B
with	O	ADP	O
a	O	DET	O
single	O	ADJ	B
dose	O	NOUN	I
of	O	ADP	O
CS	B-Chemical	NOUN	B
(	O	PUNCT	O
100mg	O	ADJ	B
/	O	SYM	O
kg	O	NOUN	B
,	O	PUNCT	O
i	O	X	O
.	O	PUNCT	O


p	O	NOUN	O
.),	O	NUM	O
resulted	O	VERB	O
in	O	ADP	O
significant	O	ADJ	O
protection	O	NOUN	B
against	O	ADP	O
the	O	DET	O
hepatotoxic	B-Disease	ADJ	B
effects	O	NOUN	B
of	O	ADP	O
CCl4	B-Chemical	NOUN	B
,	O	PUNCT	O
CHCl3	B-Chemical	NOUN	B
,	O	PUNCT	O
acetaminophen	B-Chemical	NOUN	B
and	O	CCONJ	O
galactosamine	B-Chemical	NOUN	B
and	O	CCONJ	O
against	O	ADP	O
the	O	DET	O
lethal	O	ADJ	B
(	O	PUNCT	O
and	O	CCONJ	O
presumably	O	ADV	O
cardiotoxic	B-Disease	ADJ	B
)	O	PUNCT	O
effect	O	NOUN	B
of	O	ADP	O
adriamycin	B-Chemical	NOUN	B
administration	O	NOUN	B
.	O	PUNCT	O


Maximal	O	ADJ	B
CS	B-Chemical	PROPN	B
-	O	PUNCT	O
mediated	O	VERB	B
protection	O	NOUN	B
was	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
experimental	O	ADJ	B
animals	O	NOUN	I
pretreated	O	VERB	B
24	O	NUM	O
h	O	NOUN	O
prior	O	ADJ	O
to	O	PART	O
the	O	DET	O
toxic	O	ADJ	B
insult	O	NOUN	I
.	O	PUNCT	O


These	O	DET	O
data	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
CS	B-Chemical	NOUN	B
intervenes	O	VERB	O
in	O	ADP	O
a	O	DET	O
critical	O	ADJ	O
cellular	O	ADJ	B
event	O	NOUN	I
that	O	PRON	O
is	O	AUX	O
an	O	DET	O
important	O	ADJ	O
common	O	ADJ	O
pathway	O	NOUN	B
to	O	PART	O
toxic	O	ADJ	B
cell	O	NOUN	O
death	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
mechanism	O	NOUN	B
of	O	ADP	O
CS	B-Chemical	ADJ	B
protection	O	NOUN	B
does	O	AUX	O
not	O	PART	O
appear	O	VERB	O
to	O	PART	O
be	O	AUX	O
dependent	O	ADJ	B
on	O	ADP	O
the	O	DET	O
inhibition	O	NOUN	B
of	O	ADP	O
chemical	O	ADJ	B
bioactivation	O	NOUN	I
to	O	PART	O
a	O	DET	O
toxic	O	ADJ	B
reactive	O	ADJ	O
intermediate	O	NOUN	O
(	O	PUNCT	O
in	O	ADP	O
light	O	NOUN	O
of	O	ADP	O
the	O	DET	O
protection	O	NOUN	B
observed	O	VERB	O
against	O	ADP	O
galactosamine	B-Chemical	NOUN	B
hepatotoxicity	B-Disease	NOUN	B
).	O	PUNCT	B
However	O	ADV	O
,	O	PUNCT	O
based	O	VERB	O
on	O	ADP	O
the	O	DET	O
data	O	NOUN	B
presented	O	VERB	O
,	O	PUNCT	O
we	O	PRON	O
can	O	AUX	O
not	O	PART	O
exclude	O	VERB	O
the	O	DET	O
possibility	O	NOUN	O
that	O	SCONJ	O
CS	B-Chemical	ADJ	B
administration	O	NOUN	O
inhibits	O	VERB	B
chemical	O	NOUN	B
bioactivation	O	NOUN	I
.	O	PUNCT	O


Our	O	PRON	O
findings	O	NOUN	B
do	O	AUX	O
suggest	O	VERB	O
that	O	SCONJ	O
CS	B-Chemical	PROPN	B
-	O	PUNCT	O
mediated	O	VERB	B
protection	O	NOUN	B
is	O	AUX	O
dependent	O	ADJ	B
on	O	ADP	O
the	O	DET	O
action	O	NOUN	B
of	O	ADP	O
the	O	DET	O
intact	O	ADJ	B
anionic	O	ADJ	B
CS	B-Chemical	ADJ	I
molecule	O	NOUN	I
(	O	PUNCT	O
non	O	ADJ	B
-	O	PUNCT	O
hydrolyzable	O	ADJ	B
CSE	B-Chemical	PROPN	B
was	O	AUX	O
as	O	ADV	O
protective	O	ADJ	O
as	O	ADP	O
CS	B-Chemical	ADJ	B


DSMM	O	NOUN	B
XI	O	NOUN	I
study	O	NOUN	B
:	O	PUNCT	O
dose	O	NOUN	B
definition	O	NOUN	B
for	O	ADP	O
intravenous	O	ADJ	B
cyclophosphamide	B-Chemical	NOUN	I
in	O	ADP	O
combination	O	NOUN	B
with	O	ADP	O
bortezomib	B-Chemical	NOUN	B
/	O	PUNCT	O
dexamethasone	B-Chemical	NOUN	B
for	O	ADP	O
remission	O	NOUN	B
induction	O	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
newly	O	ADV	B
diagnosed	O	VERB	I
myeloma	B-Disease	NOUN	B
.	O	PUNCT	O


A	O	DET	O
clinical	O	ADJ	B
trial	O	NOUN	I
was	O	AUX	O
initiated	O	VERB	O
to	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
recommended	O	VERB	B
dose	O	NOUN	I
of	O	ADP	O
cyclophosphamide	B-Chemical	NOUN	B
in	O	ADP	O
combination	O	NOUN	B
with	O	ADP	O
bortezomib	B-Chemical	NOUN	B
and	O	CCONJ	O
dexamethasone	B-Chemical	NOUN	B
as	O	ADP	O
induction	O	NOUN	B
treatment	O	NOUN	B
before	O	ADP	O
stem	O	NOUN	B
cell	O	NOUN	I
transplantation	O	NOUN	I
for	O	ADP	O
younger	O	ADJ	B
patients	O	NOUN	B
with	O	ADP	O
newly	O	ADV	B
diagnosed	O	VERB	I
multiple	B-Disease	ADJ	B
myeloma	I-Disease	NOUN	I
(	O	PUNCT	O
MM	B-Disease	NOUN	B
).	O	PUNCT	O
Thirty	O	NUM	O
patients	O	NOUN	B
were	O	AUX	O
treated	O	VERB	B
with	O	ADP	I
three	O	NUM	O
21	O	NUM	O
-	O	PUNCT	O
day	O	NOUN	B
cycles	O	NOUN	B
of	O	ADP	O
bortezomib	B-Chemical	NOUN	B
1	O	NUM	I
.	O	PUNCT	O


3	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
m	O	NOUN	B
(	O	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
on	O	ADP	O
days	O	NOUN	B
1	O	NUM	O
,	O	PUNCT	O
4	O	NUM	O
,	O	PUNCT	O
8	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
11	O	NUM	O
plus	O	CCONJ	B
dexamethasone	B-Chemical	NOUN	B
40	O	NUM	O
mg	O	NOUN	O
on	O	ADP	O
the	O	DET	O
day	O	NOUN	B
of	O	ADP	O
bortezomib	B-Chemical	NOUN	B
injection	O	NOUN	I
and	O	CCONJ	O
the	O	DET	O
day	O	NOUN	B
after	O	ADP	O
plus	O	CCONJ	O
cyclophosphamide	B-Chemical	NOUN	B
at	O	ADP	O
900	O	NUM	O
,	O	PUNCT	O
1	O	NUM	O
,	O	PUNCT	O
200	O	NUM	O
,	O	PUNCT	O
or	O	CCONJ	O
1	O	NUM	O
,	O	PUNCT	O
500	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
m	O	NOUN	B
(	O	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
on	O	ADP	O
day	O	NOUN	B
1	O	NUM	O
.	O	PUNCT	O


The	O	DET	O
maximum	O	NOUN	B
tolerated	O	ADJ	B
dose	O	NOUN	O
of	O	ADP	O
cyclophosphamide	B-Chemical	NOUN	B
was	O	AUX	O
defined	O	VERB	O
as	O	ADP	O
900	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
m	O	NOUN	B
(	O	PUNCT	O
2	O	NUM	O
).	O	PUNCT	O
At	O	ADP	O
this	O	DET	O
dose	O	NOUN	B
level	O	NOUN	B
,	O	PUNCT	O
92	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
achieved	O	VERB	O
at	O	ADP	O
least	O	ADJ	O
a	O	DET	O
partial	O	ADJ	B
response	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
overall	O	ADJ	O
response	O	NOUN	B
rate	O	NOUN	I
[	O	PUNCT	O
complete	O	ADJ	B
response	O	NOUN	I
(	O	PUNCT	O
CR	O	NOUN	B
)	O	PUNCT	O
plus	O	CCONJ	O
partial	O	ADJ	O
response	O	NOUN	O
(	O	PUNCT	O
PR	O	NOUN	B
)]	O	PUNCT	O
across	O	ADP	O
all	O	DET	O
dose	O	NOUN	B
levels	O	NOUN	B
was	O	AUX	O
77	O	NUM	O
%,	O	NOUN	O
with	O	ADP	O
a	O	DET	O
10	O	NUM	O
%	O	NOUN	O
CR	O	ADJ	B
rate	O	NOUN	B
.	O	PUNCT	O


No	O	DET	O
patient	O	NOUN	B
experienced	O	VERB	O
progressive	O	ADJ	B
disease	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
most	O	ADV	O
frequent	O	ADJ	B
adverse	O	ADJ	B
events	O	NOUN	I
were	O	AUX	O
hematological	B-Disease	ADJ	B
and	I-Disease	CCONJ	O
gastrointestinal	I-Disease	ADJ	B
toxicities	I-Disease	NOUN	B
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
neuropathy	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
results	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
bortezomib	B-Chemical	NOUN	B
in	O	ADP	O
combination	O	NOUN	B
with	O	ADP	O
cyclophosphamide	B-Chemical	NOUN	B
at	O	ADP	O
900	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
m	O	NOUN	B
(	O	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
dexamethasone	B-Chemical	NOUN	B
is	O	AUX	O
an	O	DET	O
effective	O	ADJ	B
induction	O	NOUN	B
treatment	O	NOUN	B
for	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
newly	O	ADV	O
diagnosed	O	VERB	B
MM	B-Disease	NOUN	B


Results	O	NOUN	B
of	O	ADP	O
a	O	DET	O
comparative	O	ADJ	B
,	O	PUNCT	O
phase	O	NOUN	B
III	O	NUM	I
,	O	PUNCT	O
12	O	NUM	O
-	O	PUNCT	O
week	O	NOUN	B
,	O	PUNCT	O
multicenter	O	NOUN	B
,	O	PUNCT	O
prospective	O	ADJ	B
,	O	PUNCT	O
randomized	O	ADJ	B
,	O	PUNCT	O
double	O	ADJ	B
-	O	PUNCT	O
blind	O	NOUN	B
assessment	O	NOUN	B
of	O	ADP	O
the	O	DET	O
efficacy	O	NOUN	B
and	O	CCONJ	O
tolerability	O	NOUN	B
of	O	ADP	O
a	O	DET	O
fixed	O	VERB	B
-	O	PUNCT	O
dose	O	NOUN	B
combination	O	NOUN	B
of	O	ADP	O
telmisartan	B-Chemical	ADJ	B
and	O	CCONJ	O
amlodipine	B-Chemical	NOUN	B
versus	O	CCONJ	O
amlodipine	B-Chemical	NOUN	B
monotherapy	O	NOUN	B
in	O	ADP	O
Indian	O	ADJ	B
adults	O	NOUN	B
with	O	ADP	O
stage	O	NOUN	B
II	O	NUM	I
hypertension	B-Disease	NOUN	I
.	O	PUNCT	O


OBJECTIVE	O	NOUN	B
:	O	PUNCT	O
The	O	DET	O
aim	O	NOUN	O
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
efficacy	O	NOUN	B
and	O	CCONJ	O
tolerability	O	NOUN	B
of	O	ADP	O
a	O	DET	O
new	O	ADJ	O
fixed	O	VERB	B
-	O	PUNCT	O
dose	O	NOUN	B
combination	O	NOUN	B
(	O	PUNCT	O
FDC	O	NOUN	B
)	O	PUNCT	O
of	O	ADP	O
telmisartan	B-Chemical	NOUN	B
40	O	NUM	O
mg	O	NOUN	O
+	O	CCONJ	O
amlodipine	B-Chemical	NOUN	B
5	O	NUM	O
mg	O	NOUN	O
(	O	PUNCT	O
T	O	NOUN	O
+	O	CCONJ	O
A	O	NOUN	O
)	O	PUNCT	O
compared	O	VERB	B
with	O	ADP	O
amlodipine	B-Chemical	NOUN	B
5	O	NUM	O
-	O	PUNCT	O
mg	O	NOUN	O
monotherapy	O	NOUN	B
(	O	PUNCT	O
A	O	NOUN	O
)	O	PUNCT	O
in	O	ADP	O
adult	O	ADJ	B
Indian	O	ADJ	B
patients	O	NOUN	B
with	O	ADP	O
stage	O	NOUN	B
II	O	NUM	I
hypertension	B-Disease	NOUN	I
.	O	PUNCT	O


METHODS	O	NOUN	O
:	O	PUNCT	O
This	O	DET	O
comparative	O	NOUN	B
,	O	PUNCT	O
Phase	O	NOUN	B
III	O	NUM	I
,	O	PUNCT	O
12	O	NUM	O
-	O	PUNCT	O
week	O	NOUN	B
,	O	PUNCT	O
multicenter	O	NOUN	B
,	O	PUNCT	O
prospective	O	ADJ	B
,	O	PUNCT	O
randomized	O	ADJ	B
,	O	PUNCT	O
double	O	ADJ	B
-	O	PUNCT	O
blind	O	ADJ	B
study	O	NOUN	B
was	O	AUX	O
conducted	O	VERB	O
in	O	ADP	O
Indian	O	ADJ	B
patients	O	NOUN	B
aged	O	ADJ	B
18	O	NUM	O
to	O	PART	O
65	O	NUM	O
years	O	NOUN	B
with	O	ADP	O
established	O	ADJ	O
stage	O	NOUN	B
II	O	NUM	I
hypertension	B-Disease	NOUN	I
.	O	PUNCT	O


Patients	O	NOUN	B
were	O	AUX	O
treated	O	VERB	B
with	O	ADP	I
oral	O	ADJ	B
FDC	O	NOUN	B
of	O	ADP	O
T	O	NOUN	B
+	O	CCONJ	O
A	O	NOUN	O
or	O	CCONJ	O
A	O	NOUN	O
QD	O	NOUN	B
before	O	ADP	O
breakfast	O	NOUN	B
for	O	ADP	O
12	O	NUM	O
weeks	O	NOUN	B
;	O	PUNCT	O
blood	O	NOUN	B
pressure	O	NOUN	I
(	O	PUNCT	O
BP	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
heart	O	NOUN	B
rate	O	NOUN	I
were	O	AUX	O
measured	O	VERB	B
in	O	ADP	O
the	O	DET	O
sitting	O	NOUN	B
position	O	NOUN	O
.	O	PUNCT	O


Primary	O	ADJ	B
efficacy	O	NOUN	I
end	O	NOUN	O
points	O	NOUN	O
were	O	AUX	O
reduction	O	NOUN	B
in	O	ADP	O
clinical	O	ADJ	B
systolic	O	NOUN	I
BP	O	NOUN	I
(	O	PUNCT	O
SBP	O	NOUN	B
)/	O	NOUN	O
diastolic	O	ADJ	O
BP	O	NOUN	O
(	O	PUNCT	O
DBP	O	NOUN	B
)	O	PUNCT	O
from	O	ADP	O
baseline	O	NOUN	B
to	O	PART	O
study	O	NOUN	B
end	O	NOUN	O
and	O	CCONJ	O
number	O	NOUN	O
of	O	ADP	O
responders	O	NOUN	B
(	O	PUNCT	O
ie	O	X	O
,	O	PUNCT	O
patients	O	NOUN	B
who	O	PRON	O
achieved	O	VERB	O
target	O	NOUN	B
SBP	O	NOUN	B
/	O	PUNCT	O
DBP	O	NOUN	B
<	O	NOUN	O
130	O	NUM	O
/<	O	PUNCT	O
80	O	NUM	O
mm	O	NOUN	B
Hg	O	NOUN	I
)	O	PUNCT	O
at	O	ADP	O
end	O	NOUN	O
of	O	ADP	O
study	O	NOUN	B
.	O	PUNCT	O


Tolerability	O	NOUN	B
was	O	AUX	O
assessed	O	VERB	B
by	O	ADP	O
treatment	O	NOUN	B
-	O	PUNCT	O
emergent	O	ADJ	B
adverse	O	ADJ	B
events	O	NOUN	I
,	O	PUNCT	O
identified	O	VERB	B
using	O	VERB	O
physical	O	ADJ	B
examination	O	NOUN	I
,	O	PUNCT	O
laboratory	O	NOUN	B
analysis	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
electrocardiography	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
A	O	DET	O
total	O	NOUN	O
of	O	ADP	O
210	O	NUM	O
patients	O	NOUN	B
were	O	AUX	O
enrolled	O	VERB	O
in	O	ADP	O
the	O	DET	O
study	O	NOUN	B
;	O	PUNCT	O
203	O	NUM	O
patients	O	NOUN	B
(	O	PUNCT	O
143	O	NUM	O
men	O	NOUN	B
,	O	PUNCT	O
60	O	NUM	O
women	O	NOUN	B
)	O	PUNCT	O
completed	O	VERB	O
the	O	DET	O
study	O	NOUN	B
while	O	SCONJ	O
7	O	NUM	O
were	O	AUX	O
lost	O	VERB	B
to	O	PART	O
follow	O	VERB	B
-	O	PUNCT	O
up	O	NOUN	O
(	O	PUNCT	O
4	O	NUM	O
patients	O	NOUN	B
in	O	ADP	O
the	O	DET	O
T	O	NOUN	B
+	O	CCONJ	O
A	O	NOUN	O
group	O	NOUN	B
and	O	CCONJ	O
3	O	NUM	O
in	O	ADP	O
the	O	DET	O
A	O	NOUN	O
group	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
considered	O	VERB	O
with	O	ADP	O
-	O	PUNCT	O
drawn	O	VERB	B
.	O	PUNCT	O


At	O	ADP	O
study	O	NOUN	B
end	O	NOUN	O
,	O	PUNCT	O
statistically	O	ADV	B
significant	O	ADJ	I
percentage	O	NOUN	B
reductions	O	NOUN	B
from	O	ADP	O
baseline	O	NOUN	B
within	O	ADP	O
groups	O	NOUN	B
and	O	CCONJ	O
between	O	ADP	O
groups	O	NOUN	B
were	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
SBP	O	NOUN	B
(	O	PUNCT	O
T	O	NOUN	B
+	O	CCONJ	O
A	O	DET	O
[-	O	X	O
27	O	NUM	O
.	O	PUNCT	O


4	O	NUM	O
%];	O	NOUN	O
A	O	DET	O
[-	O	X	O
16	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
%])	O	NOUN	B
and	O	CCONJ	O
DBP	O	NOUN	B
(	O	PUNCT	O
T	O	NOUN	B
+	O	CCONJ	O
A	O	DET	O
[-	O	X	O
20	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
%];	O	NOUN	O
A	O	DET	O
[-	O	X	O
13	O	NUM	O
.	O	PUNCT	O


3	O	NUM	O
%])(	O	NOUN	O
all	O	DET	O
,	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


05	O	NUM	O
).	O	ADJ	O
Response	O	NOUN	B
rates	O	NOUN	I
were	O	AUX	O
87	O	NUM	O
.	O	PUNCT	O


3	O	NUM	O
%(	O	NOUN	O
89	O	NUM	O
/	O	SYM	O
102	O	NUM	O
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
T	O	NOUN	B
+	O	CCONJ	O
A	O	NOUN	O
group	O	NOUN	B
and	O	CCONJ	O
69	O	NUM	O
.	O	PUNCT	O


3	O	NUM	O
%(	O	NOUN	O
70	O	NUM	O
/	O	SYM	O
101	O	NUM	O
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
A	O	NOUN	O
group	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


05	O	NUM	O
).	O	PUNCT	O
The	O	DET	O
prevalences	O	NOUN	B
of	O	ADP	O
adverse	O	ADJ	B
events	O	NOUN	I
were	O	AUX	O
not	O	PART	O
significantly	O	ADV	O
different	O	ADJ	O
between	O	ADP	O
the	O	DET	O
2	O	NUM	O
treatment	O	NOUN	B
groups	O	NOUN	I
(	O	PUNCT	O
T	O	NOUN	B
+	O	CCONJ	O
A	O	NOUN	O
,	O	PUNCT	O
16	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
%[	O	NOUN	O
17	O	NUM	O
/	O	SYM	O
106	O	NUM	O
];	O	NOUN	B
A	O	NOUN	O
,	O	PUNCT	O
15	O	NUM	O
.	O	PUNCT	O


4	O	NUM	O
%[	O	NOUN	O
16	O	NUM	O
/	O	SYM	O
104	O	NUM	O
]).	O	ADJ	O
Peripheral	O	ADJ	B
edema	B-Disease	NOUN	I
was	O	AUX	O
reported	O	VERB	O
in	O	ADP	O
8	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
%	O	NOUN	O
patients	O	NOUN	B
(	O	PUNCT	O
9	O	NUM	O
/	O	SYM	O
106	O	NUM	O
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
T	O	NOUN	B
+	O	CCONJ	O
A	O	NOUN	O
group	O	NOUN	B
compared	O	VERB	B
with	O	ADP	O
13	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
%(	O	NOUN	O
14	O	NUM	O
/	O	SYM	O
104	O	NUM	O
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
A	O	NOUN	O
group	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
cough	B-Disease	NOUN	B
was	O	AUX	O
reported	O	VERB	O
in	O	ADP	O
3	O	NUM	O
.	O	PUNCT	O


8	O	NUM	O
%	O	NOUN	O
patients	O	NOUN	B
(	O	PUNCT	O
4	O	NUM	O
/	O	SYM	O
106	O	NUM	O
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
T	O	NOUN	B
+	O	CCONJ	O
A	O	NOUN	O
group	O	NOUN	B
and	O	CCONJ	O
1	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
%(	O	NOUN	O
1	O	NUM	O
/	O	SYM	O
104	O	NUM	O
)	O	PUNCT	O
patients	O	NOUN	B
in	O	ADP	O
the	O	DET	O
A	O	NOUN	O
group	O	NOUN	B
;	O	PUNCT	O
these	O	DET	O
differences	O	NOUN	B
did	O	AUX	O
not	O	PART	O
reach	O	VERB	O
statistical	O	ADJ	B
significance	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
incidences	O	NOUN	B
of	O	ADP	O
headache	B-Disease	NOUN	B
,	O	PUNCT	O
dizziness	B-Disease	ADJ	B
,	O	PUNCT	O
and	O	CCONJ	O
diarrhea	B-Disease	NOUN	B
were	O	AUX	O
similar	O	ADJ	O
between	O	ADP	O
the	O	DET	O
2	O	NUM	O
groups	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
:	O	PUNCT	O
Among	O	ADP	O
these	O	DET	O
Indian	O	ADJ	B
patients	O	NOUN	B
with	O	ADP	O
stage	O	NOUN	B
II	O	NUM	I
hypertension	B-Disease	NOUN	I


Cutaneous	B-Disease	ADJ	B
leucocytoclastic	I-Disease	ADJ	I
vasculitis	I-Disease	NOUN	I
associated	O	VERB	B
with	O	ADP	I
oxacillin	B-Chemical	NOUN	B
.	O	PUNCT	O


A	O	DET	O
67	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
man	O	NOUN	B
who	O	PRON	O
was	O	AUX	O
treated	O	VERB	B
with	O	ADP	I
oxacillin	B-Chemical	NOUN	B
for	O	ADP	O
one	O	NUM	O
week	O	NOUN	B
because	O	SCONJ	O
of	O	ADP	O
Staphylococcus	B-Disease	X	B
aureus	I-Disease	X	I
bacteremia	I-Disease	NOUN	B
,	O	PUNCT	O
developed	O	VERB	O
renal	B-Disease	ADJ	B
failure	I-Disease	NOUN	I
and	O	CCONJ	O
diffuse	O	NOUN	B
,	O	PUNCT	O
symmetric	O	ADJ	B
,	O	PUNCT	O
palpable	O	ADJ	B
purpuric	B-Disease	ADJ	B
lesions	I-Disease	NOUN	B
on	O	ADP	O
his	O	PRON	O
feet	O	NOUN	B
.	O	PUNCT	O


Necrotic	B-Disease	ADJ	B
blisters	I-Disease	NOUN	I
were	O	AUX	O
noted	O	VERB	O
on	O	ADP	O
his	O	PRON	O
fingers	O	NOUN	B
.	O	PUNCT	O


Skin	O	NOUN	B
biopsies	O	NOUN	I
showed	O	VERB	O
findings	O	NOUN	B
diagnostic	O	ADJ	B
of	O	ADP	O
leucocytoclastic	B-Disease	ADJ	B
vasculitis	I-Disease	NOUN	I
.	O	PUNCT	O


Oxacillin	B-Chemical	NOUN	B
was	O	AUX	O
discontinued	O	VERB	B
and	O	CCONJ	O
patient	O	NOUN	B
was	O	AUX	O
treated	O	VERB	B
with	O	ADP	I
corticosteroids	B-Chemical	NOUN	B
.	O	PUNCT	O


The	O	DET	O
rash	B-Disease	NOUN	B
disappeared	O	VERB	O
after	O	ADP	O
three	O	NUM	O
weeks	O	NOUN	B
and	O	CCONJ	O
renal	O	ADJ	B
function	O	NOUN	I
returned	O	VERB	O
to	O	ADP	O
normal	O	ADJ	B
.	O	PUNCT	O


Leucocytoclastic	B-Disease	ADJ	B
vasculitis	I-Disease	NOUN	I
presents	O	VERB	O
as	O	ADP	O
palpable	O	ADJ	B
purpura	B-Disease	NOUN	I
of	O	ADP	O
the	O	DET	O
lower	O	ADJ	B
extremities	O	NOUN	I
often	O	ADV	O
accompanied	O	VERB	O
by	O	ADP	O
abdominal	B-Disease	ADJ	B
pain	I-Disease	NOUN	I
,	O	PUNCT	O
arthralgia	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
renal	B-Disease	ADJ	B
involvement	I-Disease	NOUN	B
.	O	PUNCT	O


Etiologic	O	ADJ	B
factors	O	NOUN	I
or	O	CCONJ	O
associated	O	VERB	B
disorders	O	NOUN	I
include	O	VERB	O
infections	B-Disease	NOUN	B
,	O	PUNCT	O
medications	O	NOUN	B
,	O	PUNCT	O
collagen	B-Disease	NOUN	B
vascular	I-Disease	ADJ	I
disease	I-Disease	NOUN	I
and	O	CCONJ	O
neoplasia	B-Disease	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
in	O	ADP	O
half	O	NOUN	O
of	O	ADP	O
the	O	DET	O
cases	O	NOUN	B
no	O	DET	O
etiologic	O	ADJ	B
factor	O	NOUN	I
is	O	AUX	O
identified	O	VERB	B
.	O	PUNCT	O


Usually	O	ADV	O
it	O	PRON	O
is	O	AUX	O
a	O	DET	O
self	O	NOUN	B
-	O	PUNCT	O
limited	O	ADJ	B
disorder	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
corticosteroid	B-Chemical	NOUN	B
therapy	O	NOUN	I
may	O	AUX	O
be	O	AUX	O
needed	O	VERB	O
in	O	ADP	O
life	O	NOUN	B
-	O	PUNCT	O
threatening	O	VERB	B
cases	O	NOUN	B
since	O	SCONJ	O
early	O	ADJ	B
treatment	O	NOUN	I
with	O	ADP	O
corticosteroids	B-Chemical	NOUN	B
in	O	ADP	O
severe	O	ADJ	B
cases	O	NOUN	B
can	O	AUX	O
prevent	O	VERB	B
complications	O	NOUN	B
.	O	PUNCT	O


Oxacillin	B-Chemical	NOUN	B
should	O	AUX	O
be	O	AUX	O
included	O	VERB	O
among	O	ADP	O
the	O	DET	O
drugs	O	NOUN	B
that	O	PRON	O
can	O	AUX	O
cause	O	VERB	O
leucocytoclastic	B-Disease	ADJ	B
vasculitis	I-Disease	NOUN	I


Naloxazone	B-Chemical	NOUN	B
pretreatment	O	NOUN	B
modifies	O	VERB	B
cardiorespiratory	O	NOUN	B
,	O	PUNCT	O
temperature	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
behavioral	O	ADJ	B
effects	O	NOUN	B
of	O	ADP	O
morphine	B-Chemical	NOUN	B
.	O	PUNCT	O


Behavioral	O	ADJ	B
and	O	CCONJ	O
cardiorespiratory	O	ADJ	B
responses	O	NOUN	I
to	O	PART	O
a	O	DET	O
lethal	O	ADJ	B
dose	O	NOUN	I
of	O	ADP	O
morphine	B-Chemical	NOUN	B
were	O	AUX	O
evaluated	O	VERB	B
in	O	ADP	O
rats	O	NOUN	B
pretreated	O	VERB	B
with	O	ADP	O
saline	O	NOUN	B
or	O	CCONJ	O
naloxazone	B-Chemical	NOUN	B
,	O	PUNCT	O
an	O	DET	O
antagonist	O	NOUN	B
of	O	ADP	O
high	O	ADJ	B
-	O	PUNCT	O
affinity	O	NOUN	B
mu	O	NOUN	O
1	O	NUM	O
opioid	O	NOUN	B
receptors	O	NOUN	I
.	O	PUNCT	O


Pretreatment	O	NOUN	B
with	O	ADP	O
naloxazone	B-Chemical	NOUN	B
significantly	O	ADV	O
blocked	O	VERB	B
morphine	B-Chemical	NOUN	B
analgesia	B-Disease	NOUN	B
,	O	PUNCT	O
catalepsy	B-Disease	NOUN	B
and	O	CCONJ	O
hypothermia	B-Disease	NOUN	B
at	O	ADP	O
a	O	DET	O
dose	O	NOUN	B
which	O	DET	O
completely	O	ADV	O
eliminated	O	VERB	O
high	O	ADJ	B
-	O	PUNCT	O
affinity	O	NOUN	B
binding	O	NOUN	O
in	O	ADP	O
brain	O	NOUN	B
membranes	O	NOUN	I
.	O	PUNCT	O


Moreover	O	ADV	O
,	O	PUNCT	O
naloxazone	B-Chemical	NOUN	B
significantly	O	ADV	O
attenuated	O	VERB	B
the	O	DET	O
morphine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
hypotension	B-Disease	NOUN	B
and	O	CCONJ	O
respiratory	B-Disease	ADJ	B
depression	I-Disease	NOUN	I
,	O	PUNCT	O
whereas	O	SCONJ	O
morphine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
bradycardia	B-Disease	NOUN	B
was	O	AUX	O
less	O	ADV	O
affected	O	VERB	B
.	O	PUNCT	O


Results	O	NOUN	B
indicate	O	VERB	O
that	O	SCONJ	O
subpopulations	O	NOUN	B
of	O	ADP	O
mu	O	NOUN	B
receptors	O	NOUN	I
may	O	AUX	O
mediate	O	VERB	O
selective	O	ADJ	O
behavioral	O	ADJ	B
and	O	CCONJ	O
cardiorespiratory	O	ADJ	B
responses	O	NOUN	I
to	O	PART	O
morphine	B-Chemical	NOUN	B


Dexrazoxane	B-Chemical	NOUN	B
protects	O	VERB	B
against	O	ADP	O
myelosuppression	B-Disease	NOUN	B
from	O	ADP	O
the	O	DET	O
DNA	O	NOUN	B
cleavage	O	NOUN	I
-	O	PUNCT	O
enhancing	O	VERB	B
drugs	O	NOUN	B
etoposide	B-Chemical	NOUN	B
and	O	CCONJ	O
daunorubicin	B-Chemical	NOUN	B
but	O	CCONJ	O
not	O	PART	O
doxorubicin	B-Chemical	NOUN	B
.	O	PUNCT	O


PURPOSE	O	NOUN	B
:	O	PUNCT	O
The	O	DET	O
anthracyclines	B-Chemical	NOUN	B
daunorubicin	B-Chemical	NOUN	B
and	O	CCONJ	O
doxorubicin	B-Chemical	NOUN	B
and	O	CCONJ	O
the	O	DET	O
epipodophyllotoxin	B-Chemical	NOUN	B
etoposide	B-Chemical	NOUN	I
are	O	AUX	O
potent	O	ADJ	O
DNA	O	NOUN	B
cleavage	O	NOUN	I
-	O	PUNCT	O
enhancing	O	VERB	B
drugs	O	NOUN	B
that	O	PRON	O
are	O	AUX	O
widely	O	ADV	O
used	O	VERB	O
in	O	ADP	O
clinical	O	ADJ	B
oncology	O	NOUN	I
;	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
myelosuppression	B-Disease	NOUN	B
and	O	CCONJ	O
cardiac	B-Disease	ADJ	B
toxicity	I-Disease	NOUN	B
limit	O	VERB	O
their	O	PRON	O
use	O	NOUN	O
.	O	PUNCT	O


Dexrazoxane	B-Chemical	NOUN	B
(	O	PUNCT	O
ICRF-187	B-Chemical	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
recommended	O	VERB	B
for	O	ADP	O
protection	O	NOUN	B
against	O	ADP	O
anthracycline	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
cardiotoxicity	B-Disease	NOUN	B
.	O	PUNCT	O


EXPERIMENTAL	O	NOUN	B
DESIGN	O	NOUN	O
:	O	PUNCT	O
Because	O	SCONJ	O
of	O	ADP	O
their	O	PRON	O
widespread	O	ADJ	B
use	O	NOUN	O
,	O	PUNCT	O
the	O	DET	O
hematologic	B-Disease	ADJ	B
toxicity	I-Disease	NOUN	B
following	O	VERB	O
coadministration	O	NOUN	B
of	O	ADP	O
dexrazoxane	B-Chemical	NOUN	B
and	O	CCONJ	O
these	O	DET	O
three	O	NUM	O
structurally	O	ADV	B
different	O	ADJ	O
DNA	O	NOUN	B
cleavage	O	NOUN	I
enhancers	O	NOUN	B
was	O	AUX	O
investigated	O	VERB	B
:	O	PUNCT	O
Sensitivity	O	NOUN	B
of	O	ADP	O
human	O	ADJ	B
and	O	CCONJ	O
murine	O	ADJ	B
blood	O	NOUN	B
progenitor	O	NOUN	I
cells	O	NOUN	I
to	O	PART	O
etoposide	B-Chemical	NOUN	B
,	O	PUNCT	O
daunorubicin	B-Chemical	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
doxorubicin	B-Chemical	NOUN	B
+/-	O	CCONJ	O
dexrazoxane	B-Chemical	NOUN	B
was	O	AUX	O
determined	O	VERB	O
in	O	ADP	O
granulocyte	O	NOUN	B
-	O	PUNCT	O
macrophage	O	NOUN	B
colony	O	NOUN	B
forming	O	NOUN	I
assays	O	NOUN	I
.	O	PUNCT	O


Likewise	O	ADV	O
,	O	PUNCT	O
in	O	X	B
vivo	O	X	I
,	O	PUNCT	O
B6D2F1	O	NOUN	B
mice	O	NOUN	I
were	O	AUX	O
treated	O	VERB	B
with	O	ADP	I
etoposide	B-Chemical	NOUN	B
,	O	PUNCT	O
daunorubicin	B-Chemical	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
doxorubicin	B-Chemical	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
or	O	CCONJ	O
without	O	ADP	O
dexrazoxane	B-Chemical	NOUN	B
over	O	ADP	O
a	O	DET	O
wide	O	ADJ	O
range	O	NOUN	O
of	O	ADP	O
doses	O	NOUN	B
:	O	PUNCT	O
posttreatment	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
full	O	ADJ	O
hematologic	O	ADJ	B
evaluation	O	NOUN	B
was	O	AUX	O
done	O	VERB	O
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
Nontoxic	O	ADJ	B
doses	O	NOUN	I
of	O	ADP	O
dexrazoxane	B-Chemical	NOUN	B
reduced	O	VERB	B
myelosuppression	B-Disease	NOUN	B
and	O	CCONJ	O
weight	B-Disease	NOUN	B
loss	I-Disease	NOUN	I
from	O	ADP	O
daunorubicin	B-Chemical	NOUN	B
and	O	CCONJ	O
etoposide	B-Chemical	NOUN	B
in	O	ADP	O
mice	O	NOUN	B
and	O	CCONJ	O
antagonized	O	VERB	B
their	O	PRON	O
antiproliferative	O	ADJ	B
effects	O	NOUN	I
in	O	ADP	O
the	O	DET	O
colony	O	NOUN	B
assay	O	NOUN	O
;	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
dexrazoxane	B-Chemical	NOUN	B
neither	O	CCONJ	O
reduced	O	VERB	B
myelosuppression	B-Disease	NOUN	B
,	O	PUNCT	O
weight	B-Disease	NOUN	B
loss	I-Disease	NOUN	I
,	O	PUNCT	O
nor	O	CCONJ	O
the	O	DET	O
in	O	X	B
vitro	O	X	I
cytotoxicity	B-Disease	NOUN	B
from	O	ADP	O
doxorubicin	B-Chemical	NOUN	B
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
:	O	PUNCT	O
Although	O	SCONJ	O
our	O	PRON	O
findings	O	NOUN	B
support	O	VERB	O
the	O	DET	O
observation	O	NOUN	B
that	O	SCONJ	O
dexrazoxane	B-Chemical	NOUN	B
reduces	O	VERB	B
neither	O	CCONJ	O
hematologic	O	ADJ	B
activity	O	NOUN	I
nor	O	CCONJ	O
antitumor	O	ADJ	B
activity	O	NOUN	I
from	O	ADP	O
doxorubicin	B-Chemical	NOUN	B
clinically	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
potent	O	ADJ	O
antagonism	O	NOUN	B
of	O	ADP	O
daunorubicin	B-Chemical	NOUN	B
activity	O	NOUN	B
raises	O	VERB	O
concern	O	NOUN	O
;	O	PUNCT	O
a	O	DET	O
possible	O	ADJ	O
interference	O	NOUN	B
with	O	ADP	O
anticancer	O	NOUN	B
efficacy	O	NOUN	I
certainly	O	ADV	O
would	O	AUX	O
call	O	VERB	O
for	O	ADP	O
renewed	O	VERB	O
attention	O	NOUN	B
.	O	PUNCT	O


Our	O	PRON	O
data	O	NOUN	B
also	O	ADV	O
suggest	O	VERB	O
that	O	SCONJ	O
significant	O	ADJ	O
etoposide	B-Chemical	NOUN	B
dose	O	NOUN	O
escalation	O	NOUN	B
is	O	AUX	O
perhaps	O	ADV	O
possible	O	ADJ	O
by	O	ADP	O
the	O	DET	O
use	O	NOUN	O
of	O	ADP	O
dexrazoxane	B-Chemical	NOUN	B
.	O	PUNCT	O


Clinical	O	ADJ	B
trials	O	NOUN	I
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
brain	O	NOUN	B
metastases	B-Disease	NOUN	I
combining	O	VERB	O
dexrazoxane	B-Chemical	NOUN	B
and	O	CCONJ	O
high	O	ADJ	B
doses	O	NOUN	I
of	O	ADP	O
etoposide	B-Chemical	NOUN	B
is	O	AUX	O
ongoing	O	ADJ	O
with	O	ADP	O
the	O	DET	O
aim	O	NOUN	O
of	O	ADP	O
improving	O	VERB	B
efficacy	O	NOUN	B
without	O	ADP	O
aggravating	O	VERB	B
hematologic	B-Disease	ADJ	B
toxicity	I-Disease	NOUN	B


Effects	O	NOUN	B
of	O	ADP	I
the	O	DET	O
novel	O	ADJ	B
compound	O	NOUN	B
aniracetam	B-Chemical	NOUN	B
(	O	PUNCT	O
Ro	B-Chemical	NOUN	B
13-5057	I-Chemical	NUM	I
)	O	PUNCT	O
upon	O	SCONJ	O
impaired	B-Disease	ADJ	B
learning	I-Disease	NOUN	B
and	I-Disease	CCONJ	O
memory	I-Disease	NOUN	B
in	O	ADP	O
rodents	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
aniracetam	B-Chemical	NOUN	B
(	O	PUNCT	O
Ro	B-Chemical	NOUN	B
13-5057	I-Chemical	NUM	O
,	O	PUNCT	O
1-anisoyl-2-pyrrolidinone	B-Chemical	ADJ	O
)	O	PUNCT	O
was	O	AUX	O
studied	O	VERB	O
on	O	ADP	O
various	O	ADJ	O
forms	O	NOUN	O
of	O	ADP	O
experimentally	O	ADV	B
impaired	B-Disease	ADJ	B
cognitive	I-Disease	ADJ	B
functions	I-Disease	NOUN	I
(	O	PUNCT	O
learning	O	NOUN	B
and	O	CCONJ	O
memory	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
rodents	O	NOUN	B
and	O	CCONJ	O
produced	O	VERB	O
the	O	DET	O
following	O	VERB	O
effects	O	NOUN	B
:(	O	PUNCT	O
1	O	X	O
)	O	PUNCT	O
almost	O	ADV	O
complete	O	ADJ	O
prevention	O	NOUN	B
of	O	ADP	O
the	O	DET	O
incapacity	O	NOUN	B
to	O	PART	O
learn	O	VERB	O
a	O	DET	O
discrete	O	ADJ	O
escape	O	NOUN	B
response	O	NOUN	I
in	O	ADP	O
rats	O	NOUN	B
exposed	O	VERB	B
to	O	PART	O
sublethal	O	ADJ	B
hypercapnia	B-Disease	NOUN	B
immediately	O	ADV	O
before	O	ADP	O
the	O	DET	O
acquisition	O	NOUN	B
session	O	NOUN	B
;(	O	PUNCT	O
2	O	X	O
)	O	PUNCT	O
partial	O	ADJ	B
(	O	PUNCT	O
rats	O	NOUN	B
)	O	PUNCT	O
or	O	CCONJ	O
complete	O	ADJ	B
(	O	PUNCT	O
mice	O	NOUN	B
)	O	PUNCT	O
prevention	O	NOUN	B
of	O	ADP	O
the	O	DET	O
scopolamine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
short	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
amnesia	B-Disease	NOUN	B
for	O	ADP	O
a	O	DET	O
passive	O	ADJ	B
avoidance	O	NOUN	O
task	O	NOUN	O
;(	O	PUNCT	O
3	O	X	O
)	O	PUNCT	O
complete	O	ADJ	O
protection	O	NOUN	B
against	O	ADP	O
amnesia	B-Disease	NOUN	B
for	O	ADP	O
a	O	DET	O
passive	O	ADJ	B
avoidance	O	NOUN	O
task	O	NOUN	B
in	O	ADP	O
rats	O	NOUN	B
submitted	O	VERB	O
to	O	PART	O
electroconvulsive	O	ADJ	B
shock	O	NOUN	I
immediately	O	ADV	O
after	O	ADP	O
avoidance	O	NOUN	B
acquisition	O	NOUN	B
;(	O	PUNCT	O
4	O	X	O
)	O	PUNCT	O
prevention	O	NOUN	B
of	O	ADP	O
the	O	DET	O
long	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
retention	O	NOUN	B
-	O	PUNCT	O
or	O	CCONJ	O
retrieval	O	NOUN	B
-	O	PUNCT	O
deficit	O	NOUN	B
for	O	ADP	O
a	O	DET	O
passive	O	ADJ	B
avoidance	O	NOUN	O
task	O	NOUN	B
induced	O	VERB	B
in	O	ADP	O
rats	O	NOUN	B
and	O	CCONJ	O
mice	O	NOUN	B
by	O	ADP	O
chloramphenicol	B-Chemical	NOUN	B
or	O	CCONJ	O
cycloheximide	B-Chemical	NOUN	B
administered	O	VERB	B
immediately	O	ADV	O
after	O	ADP	O
acquisition	O	NOUN	B
;(	O	PUNCT	O
5	O	NUM	O
)	O	PUNCT	O
reversal	O	NOUN	B
,	O	PUNCT	O
when	O	SCONJ	O
administered	O	VERB	B
as	O	ADV	O
late	O	ADV	O
as	O	ADP	O
1	O	NUM	O
h	O	NOUN	O
before	O	ADP	O
the	O	DET	O
retention	O	NOUN	B
test	O	NOUN	I
,	O	PUNCT	O
of	O	ADP	O
the	O	DET	O
deficit	O	NOUN	B
in	O	ADP	O
retention	O	NOUN	B
or	O	CCONJ	O
retrieval	O	NOUN	B
of	O	ADP	O
a	O	DET	O
passive	O	ADJ	B
avoidance	O	NOUN	O
task	O	NOUN	B
induced	O	VERB	B
by	O	ADP	O
cycloheximide	B-Chemical	NOUN	B
injected	O	VERB	O
2	O	NUM	O
days	O	NOUN	B
previously	O	ADV	O
;(	O	PUNCT	O
6	O	NUM	O
)	O	PUNCT	O
prevention	O	NOUN	B
of	O	ADP	O
the	O	DET	O
deficit	O	NOUN	B
in	O	ADP	O
the	O	DET	O
retrieval	O	NOUN	B
of	O	ADP	O
an	O	DET	O
active	O	ADJ	B
avoidance	O	NOUN	I
task	O	NOUN	B
induced	O	VERB	B
in	O	ADP	O
mice	O	NOUN	B
by	O	ADP	O
subconvulsant	O	ADJ	B
electroshock	O	NOUN	I
or	O	CCONJ	O
hypercapnia	B-Disease	NOUN	B
applied	O	VERB	O
immediately	O	ADV	O
before	O	ADP	O
retrieval	O	NOUN	B
testing	O	NOUN	I
(	O	PUNCT	O
24	O	NUM	O
h	O	NOUN	O
after	O	ADP	O
acquisition	O	NOUN	B
).	O	VERB	O
These	O	DET	O
improvements	O	NOUN	B
or	O	CCONJ	O
normalizations	O	NOUN	B
of	O	ADP	O
impaired	B-Disease	ADJ	B
cognitive	I-Disease	ADJ	B
functions	I-Disease	NOUN	I
were	O	AUX	O
seen	O	VERB	O
at	O	ADP	O
oral	O	ADJ	B
aniracetam	B-Chemical	NOUN	B
doses	O	NOUN	B
of	O	ADP	O
10	O	NUM	O
-	O	SYM	O
100	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
.	O	PUNCT	O


Generally	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
dose	O	NOUN	B
-	O	PUNCT	O
response	O	NOUN	B
curves	O	NOUN	I
were	O	AUX	O
bell	O	ADV	B
-	O	PUNCT	O
shaped	O	VERB	B
.	O	PUNCT	O


The	O	DET	O
mechanisms	O	NOUN	B
underlying	O	VERB	O
the	O	DET	O
activity	O	NOUN	B
of	O	ADP	O
aniracetam	B-Chemical	NOUN	B
and	O	CCONJ	O
its	O	PRON	O
'	O	PUNCT	O
therapeutic	O	ADJ	B
window	O	NOUN	I
'	O	PUNCT	O
are	O	AUX	O
unknown	O	ADJ	O
.	O	PUNCT	O


Piracetam	B-Chemical	NOUN	B
,	O	PUNCT	O
another	O	DET	O
pyrrolidinone	B-Chemical	NOUN	B
derivative	O	NOUN	I
was	O	AUX	O
used	O	VERB	O
for	O	ADP	O
comparison	O	NOUN	B
.	O	PUNCT	O


It	O	PRON	O
was	O	AUX	O
active	O	ADJ	B
only	O	ADV	O
in	O	ADP	O
six	O	NUM	O
of	O	ADP	O
nine	O	NUM	O
tests	O	NOUN	B
and	O	CCONJ	O
had	O	AUX	O
about	O	ADP	O
one	O	NUM	O
-	O	PUNCT	O
tenth	O	NOUN	B
the	O	DET	O
potency	O	NOUN	B
of	O	ADP	O
aniracetam	B-Chemical	NOUN	B
.	O	PUNCT	O


The	O	DET	O
results	O	NOUN	B
indicate	O	VERB	O
that	O	SCONJ	O
aniracetam	B-Chemical	NOUN	B


Nicotine	B-Chemical	NOUN	B
potentiation	O	NOUN	B
of	O	ADP	O
morphine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
catalepsy	B-Disease	NOUN	B
in	O	ADP	O
mice	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
,	O	PUNCT	O
effects	O	NOUN	B
of	O	ADP	I
nicotine	B-Chemical	NOUN	B
on	O	ADP	O
catalepsy	B-Disease	NOUN	B
induced	O	VERB	B
by	O	ADP	O
morphine	B-Chemical	NOUN	B
in	O	ADP	O
mice	O	NOUN	B
have	O	AUX	O
been	O	AUX	O
investigated	O	VERB	B
.	O	PUNCT	O


Morphine	B-Chemical	NOUN	B
but	O	CCONJ	O
not	O	PART	O
nicotine	B-Chemical	NOUN	B
induced	O	VERB	B
a	O	DET	O
dose	O	NOUN	B
-	O	PUNCT	O
dependent	O	ADJ	B
catalepsy	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
response	O	NOUN	B
of	O	ADP	O
morphine	B-Chemical	NOUN	B
was	O	AUX	O
potentiated	O	VERB	B
by	O	ADP	O
nicotine	B-Chemical	NOUN	B
.	O	PUNCT	O


Intraperitoneal	O	NOUN	B
administration	O	NOUN	B
of	O	ADP	O
atropine	B-Chemical	NOUN	B
,	O	PUNCT	O
naloxone	B-Chemical	NOUN	B
,	O	PUNCT	O
mecamylamine	B-Chemical	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
hexamethonium	B-Chemical	NOUN	B
to	O	PART	O
mice	O	NOUN	B
reduced	O	VERB	B
catalepsy	B-Disease	NOUN	B
induced	O	VERB	B
by	O	ADP	O
a	O	DET	O
combination	O	NOUN	B
of	O	ADP	O
morphine	B-Chemical	NOUN	B
with	O	ADP	O
nicotine	B-Chemical	NOUN	B
.	O	PUNCT	O


Intracerebroventricular	O	NOUN	B
injection	O	NOUN	B
of	O	ADP	O
atropine	B-Chemical	NOUN	B
,	O	PUNCT	O
hexamethonium	B-Chemical	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
naloxone	B-Chemical	NOUN	B
also	O	ADV	O
decreased	O	VERB	B
catalepsy	B-Disease	NOUN	B
induced	O	VERB	B
by	O	ADP	O
morphine	B-Chemical	NOUN	B
plus	O	CCONJ	O
nicotine	B-Chemical	NOUN	B
.	O	PUNCT	O


Intraperitoneal	O	NOUN	B
administration	O	NOUN	B
of	O	ADP	O
atropine	B-Chemical	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
not	O	PART	O
intraperitoneal	O	ADJ	B
or	O	CCONJ	O
intracerebroventricular	O	ADJ	B
injection	O	NOUN	B
of	O	ADP	O
hexamethonium	B-Chemical	NOUN	B
,	O	PUNCT	O
decreased	O	VERB	B
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
a	O	DET	O
single	O	ADJ	B
dose	O	NOUN	I
of	O	ADP	O
morphine	B-Chemical	NOUN	B
.	O	PUNCT	O


It	O	PRON	O
was	O	AUX	O
concluded	O	VERB	O
that	O	SCONJ	O
morphine	B-Chemical	NOUN	B
catalepsy	B-Disease	NOUN	B
can	O	AUX	O
be	O	AUX	O
elicited	O	VERB	O
by	O	ADP	O
opioid	O	NOUN	B
and	O	CCONJ	O
cholinergic	O	ADJ	B
receptors	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
potentiation	O	NOUN	B
of	O	ADP	O
morphine	B-Chemical	NOUN	B
induced	O	VERB	B
by	O	ADP	O
nicotine	B-Chemical	NOUN	B


Reduced	O	VERB	B
cardiotoxicity	B-Disease	NOUN	B
and	O	CCONJ	O
preserved	O	VERB	O
antitumor	O	ADJ	B
efficacy	O	NOUN	B
of	O	ADP	O
liposome	O	NOUN	B
-	O	PUNCT	O
encapsulated	O	VERB	B
doxorubicin	B-Chemical	NOUN	B
and	O	CCONJ	O
cyclophosphamide	B-Chemical	NOUN	B
compared	O	VERB	B
with	O	ADP	O
conventional	O	ADJ	B
doxorubicin	B-Chemical	NOUN	B
and	O	CCONJ	O
cyclophosphamide	B-Chemical	NOUN	B
in	O	ADP	O
a	O	DET	O
randomized	O	ADJ	B
,	O	PUNCT	O
multicenter	O	ADJ	B
trial	O	NOUN	I
of	O	ADP	O
metastatic	O	ADJ	B
breast	B-Disease	NOUN	I
cancer	I-Disease	NOUN	I
.	O	PUNCT	O


PURPOSE	O	NOUN	B
:	O	PUNCT	O
To	O	PART	O
determine	O	VERB	O
whether	O	SCONJ	O
Myocet	B-Chemical	PROPN	B
(	O	PUNCT	O
liposome	O	NOUN	B
-	O	PUNCT	O
encapsulated	O	VERB	B
doxorubicin	B-Chemical	NOUN	B
;	O	PUNCT	O
The	O	DET	O
Liposome	O	PROPN	B
Company	O	PROPN	I
,	O	PUNCT	O
Elan	O	PROPN	B
Corporation	O	PROPN	I
,	O	PUNCT	O
Princeton	O	PROPN	B
,	O	PUNCT	O
NJ	O	PROPN	B
)	O	PUNCT	O
in	O	ADP	O
combination	O	NOUN	B
with	O	ADP	O
cyclophosphamide	B-Chemical	NOUN	B
significantly	O	ADV	O
reduces	O	VERB	O
doxorubicin	B-Chemical	NOUN	B
cardiotoxicity	B-Disease	NOUN	B
while	O	SCONJ	O
providing	O	VERB	O
comparable	O	ADJ	O
antitumor	O	NOUN	B
efficacy	O	NOUN	B
in	O	ADP	O
first	O	ADJ	B
-	O	PUNCT	O
line	O	NOUN	B
treatment	O	NOUN	B
of	O	ADP	O
metastatic	O	ADJ	B
breast	B-Disease	NOUN	I
cancer	I-Disease	NOUN	I
(	O	PUNCT	O
MBC	B-Disease	NOUN	B
).	O	PUNCT	O
PATIENTS	O	NOUN	B
AND	O	CCONJ	O
METHODS	O	NOUN	O
:	O	PUNCT	O
Two	O	NUM	O
hundred	O	NUM	O
ninety	O	NUM	B
-	O	PUNCT	O
seven	O	NUM	B
patients	O	NOUN	B
with	O	ADP	O
MBC	B-Disease	NOUN	B
and	O	CCONJ	O
no	O	DET	O
prior	O	ADJ	O
chemotherapy	O	NOUN	B
for	O	ADP	O
metastatic	O	ADJ	B
disease	O	NOUN	I
were	O	AUX	O
randomized	O	VERB	B
to	O	PART	O
receive	O	VERB	O
either	O	CCONJ	O
60	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
m	O	NOUN	B
(	O	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
of	O	ADP	O
Myocet	B-Chemical	PROPN	B
(	O	PUNCT	O
M	O	NOUN	B
)	O	PUNCT	O
or	O	CCONJ	O
conventional	O	ADJ	B
doxorubicin	B-Chemical	NOUN	B
(	O	PUNCT	O
A	O	NOUN	O
),	O	PUNCT	O
in	O	ADP	O
combination	O	NOUN	B
with	O	ADP	O
600	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
m	O	NOUN	B
(	O	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
of	O	ADP	O
cyclophosphamide	B-Chemical	NOUN	B
(	O	PUNCT	O
C	O	NOUN	B
),	O	PUNCT	O
every	O	DET	O
3	O	NUM	O
weeks	O	NOUN	B
until	O	ADP	O
disease	O	NOUN	B
progression	O	NOUN	I
or	O	CCONJ	O
unacceptable	O	ADJ	O
toxicity	B-Disease	NOUN	B
.	O	PUNCT	O


Cardiotoxicity	B-Disease	NOUN	B
was	O	AUX	O
defined	O	VERB	O
by	O	ADP	O
reductions	O	NOUN	B
in	O	ADP	O
left	O	VERB	B
-	O	PUNCT	O
ventricular	O	ADJ	B
ejection	O	NOUN	I
fraction	O	NOUN	I
,	O	PUNCT	O
assessed	O	VERB	B
by	O	ADP	O
serial	O	ADJ	O
multigated	O	VERB	B
radionuclide	O	NOUN	I
angiography	O	NOUN	I
scans	O	NOUN	I
,	O	PUNCT	O
or	O	CCONJ	O
congestive	B-Disease	ADJ	B
heart	I-Disease	NOUN	I
failure	I-Disease	NOUN	I
(	O	PUNCT	O
CHF	B-Disease	NOUN	B
).	O	PUNCT	O
Antitumor	O	NOUN	B
efficacy	O	NOUN	B
was	O	AUX	O
assessed	O	VERB	B
by	O	ADP	O
objective	O	ADJ	O
tumor	B-Disease	NOUN	B
response	O	NOUN	I
rates	O	NOUN	I
(	O	PUNCT	O
World	O	PROPN	B
Health	O	PROPN	I
Organization	O	PROPN	I
criteria	O	NOUN	I
),	O	PUNCT	O
time	O	NOUN	O
to	O	PART	O
progression	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
survival	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
Six	O	NUM	O
percent	O	NOUN	O
of	O	ADP	O
MC	O	NOUN	B
patients	O	NOUN	B
versus	O	CCONJ	O
21	O	NUM	O
%(	O	NOUN	O
including	O	VERB	O
five	O	NUM	O
cases	O	NOUN	B
of	O	ADP	O
CHF	B-Disease	NOUN	B
)	O	PUNCT	O
of	O	ADP	O
AC	O	NOUN	B
patients	O	NOUN	B
developed	O	VERB	O
cardiotoxicity	B-Disease	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=.	O	NOUN	O
0002	O	NUM	O
).	O	PUNCT	O
Median	O	ADJ	B
cumulative	O	ADJ	B
doxorubicin	B-Chemical	NOUN	B
dose	O	NOUN	I
at	O	ADP	O
onset	O	NOUN	O
was	O	AUX	O
more	O	ADJ	O
than	O	ADP	O
2	O	NUM	O
,	O	PUNCT	O
220	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
m	O	NOUN	B
(	O	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
for	O	ADP	O
MC	O	NOUN	B
versus	O	CCONJ	O
480	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
m	O	NOUN	B
(	O	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
for	O	ADP	O
AC	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=.	O	NOUN	O
0001	O	NUM	O
,	O	PUNCT	O
hazard	O	NOUN	B
ratio	O	NOUN	I
,	O	PUNCT	O
5	O	NUM	O
.	O	PUNCT	O


04	O	NUM	O
).	O	PUNCT	O
MC	O	NOUN	B
patients	O	NOUN	B
also	O	ADV	O
experienced	O	VERB	O
less	O	ADJ	O
grade	O	NOUN	O
4	O	NUM	O
neutropenia	B-Disease	NOUN	B
.	O	PUNCT	O


Antitumor	O	NOUN	B
efficacy	O	NOUN	B
of	O	ADP	O
MC	O	NOUN	B
versus	O	CCONJ	O
AC	O	PROPN	B
was	O	AUX	O
comparable	O	ADJ	O
:	O	PUNCT	O
objective	O	ADJ	O
response	O	NOUN	B
rates	O	NOUN	I
,	O	PUNCT	O
43	O	NUM	O
%	O	NOUN	O
versus	O	CCONJ	O
43	O	NUM	O
%;	O	NOUN	O
median	O	ADJ	B
time	O	NOUN	O
to	O	PART	O
progression	O	NOUN	B
,	O	PUNCT	O
5	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
%	O	NOUN	O
versus	O	CCONJ	O
5	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
months	O	NOUN	B
;	O	PUNCT	O
median	O	ADJ	B
time	O	NOUN	O
to	O	PART	O
treatment	O	NOUN	B
failure	O	NOUN	I
,	O	PUNCT	O
4	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
versus	O	CCONJ	O
4	O	NUM	O
.	O	PUNCT	O


4	O	NUM	O
months	O	NOUN	B
;	O	PUNCT	O
and	O	CCONJ	O
median	O	ADJ	B
survival	O	NOUN	I
,	O	PUNCT	O
19	O	NUM	O
versus	O	CCONJ	O
16	O	NUM	O
months	O	NOUN	B
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
:	O	PUNCT	O
Myocet	B-Chemical	PROPN	B
improves	O	VERB	B
the	O	DET	O
therapeutic	O	ADJ	B
index	O	NOUN	I
of	O	ADP	O
doxorubicin	B-Chemical	NOUN	B
by	O	ADP	O
significantly	O	ADV	O
reducing	O	VERB	O
cardiotoxicity	B-Disease	NOUN	B
and	O	CCONJ	O
grade	O	NOUN	B
4	O	NUM	I
neutropenia	B-Disease	NOUN	B
and	O	CCONJ	O
provides	O	VERB	O
comparable	O	ADJ	O
antitumor	O	NOUN	B
efficacy	O	NOUN	B
,	O	PUNCT	O
when	O	SCONJ	O
used	O	VERB	O
in	O	ADP	O
combination	O	NOUN	B
with	O	ADP	O
cyclophosphamide	B-Chemical	NOUN	B
as	O	ADP	O
first	O	ADJ	B
-	O	PUNCT	O
line	O	NOUN	B
therapy	O	NOUN	I
for	O	ADP	O
MBC	B-Disease	NOUN	B


Protective	O	ADJ	B
effect	O	NOUN	I
of	O	ADP	O
a	O	DET	O
specific	O	ADJ	O
platelet	O	NOUN	B
-	O	PUNCT	O
activating	O	VERB	B
factor	O	NOUN	O
antagonist	O	NOUN	O
,	O	PUNCT	O
BN	B-Chemical	NOUN	B
52021	I-Chemical	NUM	O
,	O	PUNCT	O
on	O	ADP	O
bupivacaine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
cardiovascular	B-Disease	ADJ	B
impairments	I-Disease	NOUN	O
in	O	ADP	O
rats	O	NOUN	B
.	O	PUNCT	O


Administration	O	NOUN	B
of	O	ADP	O
the	O	DET	O
local	O	ADJ	B
anaesthetic	O	ADJ	O
bupivacaine	B-Chemical	NOUN	O
(	O	PUNCT	O
1	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
or	O	CCONJ	O
2	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
,	O	PUNCT	O
i	O	X	O
.	O	PUNCT	O


v	O	ADP	O
.)	O	NOUN	O
to	O	PART	O
rats	O	NOUN	B
elicited	O	VERB	O
a	O	DET	O
marked	O	ADJ	O
decrease	B-Disease	NOUN	B
of	I-Disease	ADP	O
mean	I-Disease	ADJ	O
arterial	I-Disease	ADJ	B
blood	I-Disease	NOUN	I
pressure	I-Disease	NOUN	I
(MBP)	I-Disease	PROPN	I
and	I-Disease	CCONJ	O
heart	I-Disease	NOUN	B
rate	I-Disease	NOUN	I
(HR)	I-Disease	NOUN	O
leading	O	VERB	O
to	O	ADP	O
death	O	NOUN	B
(	O	PUNCT	O
in	O	ADP	O
67	O	NUM	O
%	O	NOUN	O
or	O	CCONJ	O
90	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
animals	O	NOUN	B
respectively	O	ADV	O
).	O	PUNCT	O
Intravenous	O	ADJ	B
injection	O	NOUN	I
of	O	ADP	O
the	O	DET	O
specific	O	ADJ	O
platelet	O	NOUN	B
-	O	PUNCT	O
activating	O	VERB	B
factor	O	NOUN	O
(	O	PUNCT	O
PAF	O	NOUN	B
)	O	PUNCT	O
antagonist	O	NOUN	B
BN	B-Chemical	NOUN	B
52021	I-Chemical	NOUN	O
(	O	PUNCT	O
10	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
),	O	PUNCT	O
30	O	NUM	O
min	O	NOUN	O
before	O	ADP	O
bupivacaine	B-Chemical	NOUN	B
administration	O	NOUN	B
(	O	PUNCT	O
2	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	O
i	O	X	O
.	O	PUNCT	O


v	O	ADP	O
.)	O	NOUN	O
suppressed	O	VERB	B
both	O	CCONJ	O
the	O	DET	O
decrease	B-Disease	NOUN	B
of	I-Disease	ADP	O
MBP	I-Disease	NOUN	B
and	I-Disease	CCONJ	O
HR	I-Disease	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
contrast	O	NOUN	O
,	O	PUNCT	O
doses	O	NOUN	B
of	O	ADP	O
1	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
BN	B-Chemical	NOUN	B
52021	I-Chemical	NOUN	O
given	O	VERB	O
30	O	NUM	O
min	O	NOUN	O
before	O	ADP	O
or	O	CCONJ	O
10	O	NUM	O
mg	O	NOUN	O
/	O	PUNCT	O
kg	O	NOUN	B
administered	O	VERB	B
5	O	NUM	O
min	O	NOUN	O
before	O	ADP	O
i	O	PRON	O
.	O	PUNCT	O


v	O	NOUN	O
.	O	PUNCT	O


injection	O	NOUN	B
of	O	ADP	O
bupivacaine	B-Chemical	NOUN	B
were	O	AUX	O
ineffective	O	ADJ	B
.	O	PUNCT	O


When	O	SCONJ	O
BN	B-Chemical	NOUN	B
52021	I-Chemical	NOUN	O
(	O	PUNCT	O
20	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	O
i	O	X	O
.	O	PUNCT	O


v	O	X	O
.)	O	NOUN	O
was	O	AUX	O
injected	O	VERB	B
immediately	O	ADV	O
after	O	ADP	O
bupivacaine	B-Chemical	NOUN	B
(	O	PUNCT	O
2	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
),	O	PUNCT	O
a	O	DET	O
partial	O	ADJ	B
reversion	O	NOUN	B
of	O	ADP	O
the	O	DET	O
decrease	B-Disease	NOUN	B
of	I-Disease	ADP	O
MBP	I-Disease	NOUN	B
and	I-Disease	CCONJ	O
HR	I-Disease	NOUN	B
was	O	AUX	O
observed	O	VERB	B
,	O	PUNCT	O
whereas	O	SCONJ	O
the	O	DET	O
dose	O	NOUN	B
of	O	ADP	O
10	O	NUM	O
mg	O	NOUN	O
/	O	PUNCT	O
kg	O	NOUN	B
was	O	AUX	O
ineffective	O	ADJ	B
.	O	PUNCT	O


A	O	DET	O
partial	O	ADJ	B
recovery	O	NOUN	B
of	O	ADP	O
bupivacaine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
ECG	O	PROPN	B
alterations	O	NOUN	B
was	O	AUX	O
observed	O	VERB	O
after	O	ADP	O
pretreatment	O	NOUN	B
of	O	ADP	O
the	O	DET	O
rats	O	NOUN	B
with	O	ADP	O
BN	B-Chemical	NOUN	B
52021	I-Chemical	NOUN	O
.	O	PUNCT	O


Since	O	SCONJ	O
the	O	DET	O
administration	O	NOUN	B
of	O	ADP	O
BN	B-Chemical	NOUN	B
52021	I-Chemical	NUM	O
,	O	PUNCT	O
at	O	ADP	O
all	O	DET	O
doses	O	NOUN	B
studied	O	VERB	O
,	O	PUNCT	O
did	O	AUX	O
not	O	PART	O
alter	O	VERB	O
MBP	O	NOUN	B
and	O	CCONJ	O
HR	O	NOUN	B
at	O	ADP	O
the	O	DET	O
doses	O	NOUN	B
used	O	VERB	O
,	O	PUNCT	O
the	O	DET	O
bulk	O	NOUN	O
of	O	ADP	O
these	O	DET	O
results	O	NOUN	B
clearly	O	ADV	O
demonstrate	O	VERB	O
a	O	DET	O
protective	O	ADJ	B
action	O	NOUN	I
of	O	ADP	O
BN	B-Chemical	NOUN	B
52021	I-Chemical	NOUN	O
,	O	PUNCT	O
a	O	DET	O
specific	O	ADJ	O
antagonist	O	NOUN	B
of	O	ADP	O
PAF	O	NOUN	B
,	O	PUNCT	O
against	O	ADP	O
bupivacaine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
cardiovascular	B-Disease	ADJ	B
toxicity	I-Disease	NOUN	B
.	O	PUNCT	O


Thus	O	ADV	O
,	O	PUNCT	O
consistent	O	ADJ	B
with	O	ADP	I
its	O	PRON	O
direct	O	ADJ	O
effect	O	NOUN	O
on	O	ADP	O
heart	O	NOUN	B
,	O	PUNCT	O
PAF	O	NOUN	B
appears	O	VERB	O
to	O	PART	O
be	O	AUX	O
implicated	O	VERB	O
in	O	ADP	O
bupivacaine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
cardiovascular	B-Disease	ADJ	B
alterations	I-Disease	NOUN	B


Benzylacyclouridine	B-Chemical	NOUN	B
reverses	O	VERB	B
azidothymidine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
marrow	B-Disease	NOUN	B
suppression	I-Disease	NOUN	I
without	O	ADP	O
impairment	O	NOUN	B
of	O	ADP	O
anti	O	ADJ	B
-	O	PUNCT	O
human	O	ADJ	B
immunodeficiency	B-Disease	NOUN	I
virus	O	NOUN	I
activity	O	NOUN	B
.	O	PUNCT	O


Increased	O	VERB	B
extracellular	O	ADJ	B
concentrations	O	NOUN	B
of	O	ADP	O
uridine	B-Chemical	NOUN	B
(	O	PUNCT	O
Urd	B-Chemical	NOUN	B
)	O	PUNCT	O
have	O	AUX	O
been	O	AUX	O
reported	O	VERB	O
to	O	PART	O
reduce	O	VERB	B
,	O	PUNCT	O
in	O	X	B
vitro	O	X	I
,	O	PUNCT	O
azidothymidine	B-Chemical	NOUN	B
(	O	PUNCT	O
AZT	B-Chemical	NOUN	B
)-	O	ADJ	O
induced	O	VERB	B
inhibition	O	NOUN	B
of	O	ADP	O
human	O	ADJ	B
granulocyte	O	NOUN	B
-	O	PUNCT	O
macrophage	O	NOUN	B
progenitor	O	NOUN	B
cells	O	NOUN	I
without	O	ADP	O
impairment	O	NOUN	B
of	O	ADP	O
its	O	PRON	O
antihuman	O	ADJ	B
immunodeficiency	B-Disease	NOUN	I
virus	O	NOUN	I
(	O	PUNCT	O
HIV	O	NOUN	B
)	O	PUNCT	O
activity	O	NOUN	B
.	O	PUNCT	O


Because	O	SCONJ	O
of	O	ADP	O
the	O	DET	O
clinical	O	ADJ	B
toxicities	B-Disease	NOUN	B
associated	O	VERB	B
with	O	ADP	I
chronic	O	ADJ	B
Urd	B-Chemical	NOUN	O
administration	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
ability	O	NOUN	O
of	O	ADP	O
benzylacyclouridine	B-Chemical	NOUN	B
(	O	PUNCT	O
BAU	B-Chemical	NOUN	B
)	O	PUNCT	O
to	O	PART	O
effect	O	VERB	B
,	O	PUNCT	O
in	O	X	B
vivo	O	X	I
,	O	PUNCT	O
AZT	B-Chemical	PROPN	B
-	O	PUNCT	O
induced	O	VERB	B
anemia	B-Disease	NOUN	B
and	O	CCONJ	O
leukopenia	B-Disease	NOUN	B
was	O	AUX	O
assessed	O	VERB	B
.	O	PUNCT	O


This	O	DET	O
agent	O	NOUN	B
inhibits	O	VERB	B
Urd	B-Chemical	NOUN	B
catabolism	O	NOUN	B
and	O	CCONJ	O
,	O	PUNCT	O
in	O	X	B
vivo	O	X	I
,	O	PUNCT	O
increases	O	VERB	B
the	O	DET	O
plasma	O	NOUN	B
concentration	O	NOUN	B
of	O	ADP	O
Urd	B-Chemical	NOUN	B
in	O	ADP	O
a	O	DET	O
dose	O	NOUN	B
-	O	PUNCT	O
dependent	O	ADJ	B
manner	O	NOUN	O
,	O	PUNCT	O
without	O	ADP	O
Urd	B-Chemical	NOUN	B
-	O	PUNCT	O
related	O	VERB	B
toxicity	B-Disease	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
mice	O	NOUN	B
rendered	O	VERB	O
anemic	B-Disease	ADJ	B
and	O	CCONJ	O
leukopenic	B-Disease	ADJ	B
by	O	ADP	O
the	O	DET	O
administration	O	NOUN	B
of	O	ADP	O
AZT	B-Chemical	NOUN	B
for	O	ADP	O
28	O	NUM	O
days	O	NOUN	B
in	O	ADP	O
drinking	O	NOUN	B
water	O	NOUN	I
(	O	PUNCT	O
1	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
mL	O	NOUN	B
),	O	PUNCT	O
the	O	DET	O
continued	O	ADJ	O
administration	O	NOUN	B
of	O	ADP	O
AZT	B-Chemical	NOUN	B
plus	O	CCONJ	O
daily	O	ADJ	B
BAU	B-Chemical	PROPN	B
(	O	PUNCT	O
300	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
,	O	PUNCT	O
orally	O	ADV	B
)	O	PUNCT	O
partially	O	ADV	O
reversed	O	VERB	O
AZT	B-Chemical	PROPN	B
-	O	PUNCT	O
induced	O	VERB	B
anemia	B-Disease	NOUN	B
and	O	CCONJ	O
leukopenia	B-Disease	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
.	O	PUNCT	O


05	O	NUM	O
),	O	PUNCT	O
increased	O	VERB	B
peripheral	O	ADJ	B
reticulocytes	O	NOUN	O
(	O	PUNCT	O
to	O	PART	O
4	O	NUM	O
.	O	PUNCT	O


9	O	NUM	O
%,	O	NOUN	O
P	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
.	O	PUNCT	O


01	O	NUM	O
),	O	PUNCT	O
increased	O	VERB	B
cellularity	O	NOUN	B
in	O	ADP	O
the	O	DET	O
marrow	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
improved	O	VERB	B
megaloblastosis	B-Disease	NOUN	B
.	O	PUNCT	O


When	O	SCONJ	O
coadministered	O	VERB	B
with	O	ADP	O
AZT	B-Chemical	NOUN	B
from	O	ADP	O
the	O	DET	O
onset	O	NOUN	O
of	O	ADP	O
drug	O	NOUN	B
administration	O	NOUN	I
,	O	PUNCT	O
BAU	B-Chemical	PROPN	B
reduced	O	VERB	O
AZT	B-Chemical	PROPN	B
-	O	PUNCT	O
induced	O	VERB	B
marrow	B-Disease	NOUN	B
toxicity	I-Disease	NOUN	B
.	O	PUNCT	O


In	O	X	B
vitro	O	X	I
,	O	PUNCT	O
at	O	ADP	O
a	O	DET	O
concentration	O	NOUN	B
of	O	ADP	O
100	O	NUM	O
mumol	O	NOUN	B
/	O	SYM	O
L	O	PROPN	B
,	O	PUNCT	O
BAU	B-Chemical	PROPN	B
possesses	O	VERB	O
minimal	O	ADJ	O
anti	O	ADJ	B
-	O	PUNCT	O
HIV	O	NOUN	B
activity	O	NOUN	B
and	O	CCONJ	O
has	O	AUX	O
no	O	DET	O
effect	O	NOUN	O
on	O	ADP	O
the	O	DET	O
ability	O	NOUN	O
of	O	ADP	O
AZT	B-Chemical	NOUN	B


Cyclophosphamide	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
cystitis	B-Disease	NOUN	B
in	O	ADP	O
freely	O	ADV	B
-	O	PUNCT	O
moving	O	VERB	B
conscious	O	ADJ	B
rats	O	NOUN	B
:	O	PUNCT	O
behavioral	O	ADJ	B
approach	O	NOUN	I
to	O	ADP	O
a	O	DET	O
new	O	ADJ	O
model	O	NOUN	B
of	O	ADP	O
visceral	B-Disease	ADJ	B
pain	I-Disease	NOUN	I
.	O	PUNCT	O


PURPOSE	O	NOUN	B
:	O	PUNCT	O
To	O	PART	O
develop	O	VERB	O
a	O	DET	O
model	O	NOUN	B
of	O	ADP	O
visceral	B-Disease	ADJ	B
pain	I-Disease	NOUN	I
in	O	ADP	O
rats	O	NOUN	B
using	O	VERB	O
a	O	DET	O
behavioral	O	ADJ	B
approach	O	NOUN	I
.	O	PUNCT	O


Cyclophosphamide	B-Chemical	NOUN	B
(	O	PUNCT	O
CP	B-Chemical	NOUN	B
),	O	PUNCT	O
an	O	DET	O
antitumoral	O	ADJ	B
agent	O	NOUN	I
known	O	VERB	O
to	O	PART	O
produce	O	VERB	O
toxic	O	ADJ	B
effects	O	NOUN	O
on	O	ADP	O
the	O	DET	O
bladder	O	NOUN	B
wall	O	NOUN	I
through	O	ADP	O
its	O	PRON	O
main	O	ADJ	O
toxic	O	ADJ	B
metabolite	O	NOUN	B
acrolein	B-Chemical	NOUN	B
,	O	PUNCT	O
was	O	AUX	O
used	O	VERB	O
to	O	PART	O
induce	O	VERB	B
cystitis	B-Disease	NOUN	B
.	O	PUNCT	O


MATERIALS	O	NOUN	O
AND	O	CCONJ	O
METHODS	O	NOUN	O
:	O	PUNCT	O
CP	B-Chemical	NOUN	B
was	O	AUX	O
administered	O	VERB	B
at	O	ADP	O
doses	O	NOUN	B
of	O	ADP	O
50	O	NUM	O
,	O	PUNCT	O
100	O	NUM	O
and	O	CCONJ	O
200	O	NUM	O
mg	O	NOUN	O
./	O	NOUN	O
kg	O	NOUN	O
.	O	PUNCT	O


i	O	X	O
.	O	PUNCT	O


p	O	NOUN	O
.	O	PUNCT	O


to	O	PART	O
male	O	NOUN	B
rats	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
their	O	PRON	O
behavior	O	NOUN	B
observed	O	VERB	B
and	O	CCONJ	O
scored	O	VERB	B
.	O	PUNCT	O


The	O	DET	O
effects	O	NOUN	B
of	O	ADP	O
morphine	B-Chemical	NOUN	B
(	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
to	O	PART	O
4	O	NUM	O
mg	O	NOUN	O
./	O	NOUN	O
kg	O	NOUN	O
.	O	PUNCT	O


i	O	X	O
.	O	PUNCT	O


v	O	ADP	O
.)	O	NOUN	O
on	O	ADP	O
CP	B-Chemical	PROPN	B
-	O	PUNCT	O
induced	O	VERB	B
behavioral	O	ADJ	B
modifications	O	NOUN	B
were	O	AUX	O
tested	O	VERB	B
administered	O	VERB	B
alone	O	ADV	O
and	O	CCONJ	O
after	O	ADP	O
naloxone	B-Chemical	NOUN	B
(	O	PUNCT	O
1	O	NUM	O
mg	O	NOUN	O
./	O	NOUN	O
kg	O	NOUN	O
.	O	PUNCT	O


s	O	NOUN	O
.	O	PUNCT	O


c	O	X	O
.).	O	NOUN	O
In	O	ADP	O
addition	O	NOUN	O
,	O	PUNCT	O
90	O	NUM	O
minutes	O	NOUN	B
after	O	ADP	O
CP	B-Chemical	NOUN	B
injection	O	NOUN	B
,	O	PUNCT	O
that	O	ADV	O
is	O	ADV	O
,	O	PUNCT	O
at	O	ADP	O
the	O	DET	O
time	O	NOUN	O
of	O	ADP	O
administration	O	NOUN	B
of	O	ADP	O
morphine	B-Chemical	NOUN	B
,	O	PUNCT	O
the	O	DET	O
bladder	O	NOUN	B
was	O	AUX	O
removed	O	VERB	O
in	O	ADP	O
some	O	DET	O
rats	O	NOUN	B
for	O	ADP	O
histological	O	ADJ	B
examination	O	NOUN	I
.	O	PUNCT	O


Finally	O	ADV	O
,	O	PUNCT	O
to	O	PART	O
show	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
bladder	O	NOUN	B
is	O	AUX	O
essential	O	ADJ	O
for	O	ADP	O
the	O	DET	O
CP	B-Chemical	PROPN	B
-	O	PUNCT	O
induced	O	VERB	B
behavioral	O	ADJ	B
modifications	O	NOUN	B
,	O	PUNCT	O
female	O	ADJ	B
rats	O	NOUN	B
also	O	ADV	O
received	O	VERB	O
CP	B-Chemical	NOUN	B
at	O	ADP	O
doses	O	NOUN	B
of	O	ADP	O
200	O	NUM	O
mg	O	NOUN	O
./	O	NOUN	O
kg	O	NOUN	O
.	O	PUNCT	O


i	O	X	O
.	O	PUNCT	O


p	O	NOUN	O
.	O	PUNCT	O


and	O	CCONJ	O
of	O	ADP	O
20	O	NUM	O
mg	O	NOUN	O
.	O	PUNCT	O


by	O	ADP	O
the	O	DET	O
intravesical	O	ADJ	B
route	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
acrolein	B-Chemical	NOUN	B
at	O	ADP	O
doses	O	NOUN	B
of	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
mg	O	NOUN	O
.	O	PUNCT	O


by	O	ADP	O
the	O	DET	O
intravesical	O	ADJ	B
route	O	NOUN	I
and	O	CCONJ	O
of	O	ADP	O
5	O	NUM	O
mg	O	NOUN	O
./	O	NOUN	O
kg	O	NOUN	O
.	O	PUNCT	O


i	O	X	O
.	O	PUNCT	O


v	O	NOUN	O
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
CP	B-Chemical	NOUN	B
dose	O	NOUN	B
-	O	PUNCT	O
relatedly	O	NOUN	B
induced	O	VERB	B
marked	O	ADJ	O
behavioral	O	ADJ	B
modifications	O	NOUN	B
in	O	ADP	O
male	O	NOUN	B
rats	O	NOUN	B
:	O	PUNCT	O
breathing	O	NOUN	B
rate	O	NOUN	I
decrease	O	NOUN	B
,	O	PUNCT	O
closing	O	NOUN	B
of	O	ADP	O
the	O	DET	O
eyes	O	NOUN	B
and	O	CCONJ	O
occurrence	O	NOUN	B
of	O	ADP	O
specific	O	ADJ	B
postures	O	NOUN	B
.	O	PUNCT	O


Morphine	B-Chemical	NOUN	B
dose	O	NOUN	B
-	O	PUNCT	O
dependently	O	ADV	B
reversed	O	VERB	B
these	O	DET	O
behavioral	B-Disease	ADJ	B
disorders	I-Disease	NOUN	I
.	O	PUNCT	O


A	O	DET	O
dose	O	NOUN	B
of	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
mg	O	NOUN	O
./	O	NOUN	O
kg	O	NOUN	O
.	O	PUNCT	O


produced	O	VERB	O
a	O	DET	O
reduction	O	NOUN	B
of	O	ADP	O
almost	O	ADV	O
50	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
behavioral	O	ADJ	B
score	O	NOUN	I
induced	O	VERB	B
by	O	ADP	O
CP	B-Chemical	NOUN	B
200	O	NUM	O
mg	O	NOUN	O
./	O	NOUN	O
kg	O	NOUN	O
.	O	PUNCT	O


This	O	DET	O
effect	O	NOUN	B
was	O	AUX	O
completely	O	ADV	O
prevented	O	VERB	B
by	O	ADP	O
pretreatment	O	NOUN	B
with	O	ADP	O
naloxone	B-Chemical	NOUN	B
.	O	PUNCT	O


At	O	ADP	O
the	O	DET	O
time	O	NOUN	O
of	O	ADP	O
administration	O	NOUN	B
of	O	ADP	O
morphine	B-Chemical	NOUN	B
,	O	PUNCT	O
histological	O	ADJ	B
modifications	O	NOUN	B
of	O	ADP	O
the	O	DET	O
bladder	O	NOUN	B
wall	O	NOUN	I
,	O	PUNCT	O
such	O	ADJ	O
as	O	ADP	O
chorionic	O	ADJ	B
and	O	CCONJ	O
muscle	O	NOUN	B
layer	O	NOUN	I
edema	B-Disease	NOUN	I
,	O	PUNCT	O
were	O	AUX	O
observed	O	VERB	O
.	O	PUNCT	O


In	O	ADP	O
female	O	ADJ	B
rats	O	NOUN	B
,	O	PUNCT	O
CP	B-Chemical	NOUN	B
200	O	NUM	O
mg	O	NOUN	O
./	O	NOUN	O
kg	O	NOUN	O
.	O	PUNCT	O


i	O	X	O
.	O	PUNCT	O


p	O	NOUN	O
.	O	PUNCT	O


produced	O	VERB	O
the	O	DET	O
same	O	ADJ	O
marked	O	ADJ	O
behavioral	O	ADJ	B
modifications	O	NOUN	B
as	O	ADP	O
those	O	DET	O
observed	O	VERB	O
in	O	ADP	O
male	O	NOUN	B
rats	O	NOUN	B
.	O	PUNCT	O


Administered	O	VERB	B
at	O	ADP	O
the	O	DET	O
dose	O	NOUN	B
of	O	ADP	O
20	O	NUM	O
mg	O	NOUN	O
.	O	PUNCT	O


intravesically	O	ADV	B
,	O	PUNCT	O
CP	B-Chemical	NOUN	B
did	O	AUX	O
not	O	PART	O
produce	O	VERB	O
any	O	DET	O
behavioral	O	ADJ	B
effects	O	NOUN	O
,	O	PUNCT	O
whereas	O	SCONJ	O
acrolein	B-Chemical	NOUN	B
at	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
mg	O	NOUN	O
.	O	PUNCT	O


intravesically	O	ADV	B
induced	O	VERB	B
behavioral	O	ADJ	B
modifications	O	NOUN	B
identical	O	ADJ	B
to	O	PART	O
those	O	DET	O
under	O	ADP	O
CP	B-Chemical	NOUN	B
200	O	NUM	O
mg	O	NOUN	O
./	O	NOUN	O
kg	O	NOUN	O
.	O	PUNCT	O


i	O	X	O
.	O	PUNCT	O


p	O	X	O
.,	O	NOUN	O
with	O	ADP	O
the	O	DET	O
same	O	ADJ	O
maximal	O	ADJ	B
levels	O	NOUN	B
.	O	PUNCT	O


Conversely	O	ADV	O
,	O	PUNCT	O
acrolein	B-Chemical	NOUN	B
5	O	NUM	I
mg	O	NOUN	I
./	O	NOUN	I
kg	O	NOUN	I
.	O	PUNCT	O


i	O	X	O
.	O	PUNCT	O


v	O	NOUN	O
.	O	PUNCT	O


did	O	AUX	O
not	O	PART	O
produce	O	VERB	O
any	O	DET	O
behavioral	O	ADJ	B
effects	O	NOUN	B
at	O	ADV	O
all	O	ADV	O
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
:	O	PUNCT	O
Overall	O	ADV	O
,	O	PUNCT	O
these	O	DET	O
results	O	NOUN	B
indicate	O	VERB	O
that	O	SCONJ	O
this	O	DET	O
experimental	O	ADJ	B
model	O	NOUN	I
of	O	ADP	O
CP	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
cystitis	B-Disease	NOUN	B
may	O	AUX	O
be	O	AUX	O
an	O	DET	O
interesting	O	ADJ	O
new	O	ADJ	O
behavioral	O	ADJ	B
model	O	NOUN	O
of	O	ADP	O
inflammatory	O	ADJ	B
visceral	B-Disease	ADJ	I
pain	I-Disease	NOUN	I
,	O	PUNCT	O
allowing	O	VERB	O
a	O	DET	O
better	O	ADJ	O
understanding	O	NOUN	O
of	O	ADP	O
these	O	DET	O
painful	B-Disease	ADJ	B
syndromes	I-Disease	NOUN	I


Hyperalgesia	B-Disease	NOUN	B
and	O	CCONJ	O
myoclonus	B-Disease	NOUN	B
in	O	ADP	O
terminal	O	ADJ	B
cancer	B-Disease	NOUN	O
patients	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
continuous	O	ADJ	O
intravenous	O	ADJ	B
morphine	B-Chemical	NOUN	B
.	O	PUNCT	O


Eight	O	NUM	O
cancer	B-Disease	NOUN	B
patients	O	NOUN	B
in	O	ADP	O
the	O	DET	O
terminal	O	ADJ	B
stages	O	NOUN	I
of	O	ADP	O
the	O	DET	O
disease	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
high	O	ADJ	O
doses	O	NOUN	B
of	O	ADP	O
intravenous	O	ADJ	B
morphine	B-Chemical	NOUN	B
developed	O	VERB	O
hyperalgesia	B-Disease	NOUN	B
.	O	PUNCT	O


All	O	DET	O
cases	O	NOUN	B
were	O	AUX	O
retrospectively	O	ADV	B
sampled	O	VERB	B
from	O	ADP	O
three	O	NUM	O
different	O	ADJ	O
hospitals	O	NOUN	B
in	O	ADP	O
Copenhagen	O	PROPN	B
.	O	PUNCT	O


Five	O	NUM	O
patients	O	NOUN	B
developed	O	VERB	O
universal	O	ADJ	O
hyperalgesia	B-Disease	NOUN	B
and	O	CCONJ	O
hyperesthesia	B-Disease	NOUN	B
which	O	DET	O
in	O	ADP	O
2	O	NUM	O
cases	O	NOUN	B
were	O	AUX	O
accompanied	O	VERB	O
by	O	ADP	O
myoclonus	B-Disease	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
3	O	NUM	O
patients	O	NOUN	B
a	O	DET	O
pre	O	ADV	B
-	O	PUNCT	O
existing	O	VERB	B
neuralgia	B-Disease	NOUN	B
increased	O	VERB	B
to	O	PART	O
excruciating	O	ADJ	B
intensity	O	NOUN	I
and	O	CCONJ	O
in	O	ADP	O
2	O	NUM	O
of	O	ADP	O
these	O	DET	O
cases	O	NOUN	B
myoclonus	B-Disease	NOUN	B
occurred	O	VERB	O
simultaneously	O	ADV	B
.	O	PUNCT	O


Although	O	SCONJ	O
only	O	ADV	O
few	O	ADJ	O
clinical	O	ADJ	B
descriptions	O	NOUN	B
of	O	ADP	O
the	O	DET	O
relationship	O	NOUN	B
between	O	ADP	O
hyperalgesia	B-Disease	NOUN	B
/	O	SYM	O
myoclonus	B-Disease	NOUN	B
and	O	CCONJ	O
high	O	ADJ	B
doses	O	NOUN	I
of	O	ADP	O
morphine	B-Chemical	NOUN	B
are	O	AUX	O
available	O	ADJ	O
,	O	PUNCT	O
experimental	O	ADJ	B
support	O	NOUN	O
from	O	ADP	O
animal	O	NOUN	B
studies	O	NOUN	I
indicates	O	VERB	O
that	O	SCONJ	O
morphine	B-Chemical	NOUN	B


A	O	DET	O
prospective	O	ADJ	B
study	O	NOUN	I
of	O	ADP	O
adverse	O	ADJ	B
reactions	O	NOUN	I
associated	O	VERB	B
with	O	ADP	I
vancomycin	B-Chemical	NOUN	B
therapy	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
prospective	O	ADJ	O
evaluation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
efficacy	O	NOUN	B
and	O	CCONJ	O
safety	O	NOUN	B
of	O	ADP	O
vancomycin	B-Chemical	NOUN	B
was	O	AUX	O
conducted	O	VERB	O
in	O	ADP	O
54	O	NUM	O
consecutive	O	ADJ	B
patients	O	NOUN	B
over	O	ADP	O
a	O	DET	O
16	O	NUM	O
-	O	PUNCT	O
month	O	NOUN	B
period	O	NOUN	B
.	O	PUNCT	O


Vancomycin	B-Chemical	NOUN	B
was	O	AUX	O
curative	O	ADJ	B
in	O	ADP	O
95	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
43	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
proven	O	VERB	O
infection	B-Disease	NOUN	B
.	O	PUNCT	O


Drugs	O	NOUN	B
were	O	AUX	O
ceased	O	VERB	B
in	O	ADP	O
six	O	NUM	O
patients	O	NOUN	B
because	O	SCONJ	O
of	O	ADP	O
adverse	O	ADJ	B
reactions	O	NOUN	I
;	O	PUNCT	O
in	O	ADP	O
three	O	NUM	O
of	O	ADP	O
these	O	DET	O
vancomycin	B-Chemical	NOUN	B
was	O	AUX	O
considered	O	VERB	O
the	O	DET	O
likely	O	ADJ	O
cause	O	NOUN	B
.	O	PUNCT	O


Reactions	O	NOUN	B
included	O	VERB	O
thrombophlebitis	B-Disease	NOUN	B
(	O	PUNCT	O
20	O	NUM	O
of	O	ADP	O
54	O	NUM	O
patients	O	NOUN	B
),	O	PUNCT	O
rash	B-Disease	NOUN	B
(	O	PUNCT	O
4	O	NUM	O
of	O	ADP	O
54	O	NUM	O
),	O	PUNCT	O
nephrotoxicity	B-Disease	NOUN	B
(	O	PUNCT	O
4	O	NUM	O
of	O	ADP	O
50	O	NUM	O
),	O	PUNCT	O
proteinuria	B-Disease	NOUN	B
(	O	PUNCT	O
1	O	NUM	O
of	O	ADP	O
50	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
ototoxicity	B-Disease	NOUN	B
(	O	PUNCT	O
1	O	NUM	O
of	O	ADP	O
11	O	NUM	O
patients	O	NOUN	B
tested	O	VERB	B
by	O	ADP	O
audiometry	O	NOUN	B
).	O	PUNCT	O
Thrombophlebitis	B-Disease	NOUN	B
occurred	O	VERB	O
only	O	ADV	O
with	O	ADP	O
infusion	O	NOUN	B
through	O	ADP	O
peripheral	O	ADJ	B
cannulae	O	NOUN	I
;	O	PUNCT	O
nephrotoxicity	B-Disease	NOUN	B
and	O	CCONJ	O
ototoxicity	B-Disease	NOUN	B
were	O	AUX	O
confined	O	VERB	O
to	O	PART	O
patients	O	NOUN	B
receiving	O	VERB	O
an	O	DET	O
aminoglycoside	B-Chemical	NOUN	B
plus	O	CCONJ	O
vancomycin	B-Chemical	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
conclude	O	VERB	O
that	O	SCONJ	O
vancomycin	B-Chemical	NOUN	B
,	O	PUNCT	O
administered	O	VERB	B
appropriately	O	ADV	O
,	O	PUNCT	O
constitutes	O	VERB	O
safe	O	ADJ	O
,	O	PUNCT	O
effective	O	ADJ	B
therapy	O	NOUN	B
for	O	ADP	O
infections	B-Disease	NOUN	B


Blockade	O	NOUN	B
of	O	ADP	O
both	O	CCONJ	O
D	O	NOUN	B
-	O	PUNCT	O
1	O	NUM	B
and	O	CCONJ	O
D	O	NOUN	B
-	O	PUNCT	O
2	O	NUM	O
dopamine	B-Chemical	NOUN	B
receptors	O	NOUN	I
may	O	AUX	O
induce	O	VERB	B
catalepsy	B-Disease	NOUN	B
in	O	ADP	O
mice	O	NOUN	B
.	O	PUNCT	O


1	O	X	O
.	O	PUNCT	O


The	O	DET	O
catalepsy	B-Disease	NOUN	B
induced	O	VERB	B
by	O	ADP	O
dopamine	B-Chemical	NOUN	B
antagonists	O	NOUN	B
has	O	AUX	O
been	O	AUX	O
tested	O	VERB	B
and	O	CCONJ	O
the	O	DET	O
possible	O	ADJ	O
dopamine	B-Chemical	NOUN	B
subtypes	O	NOUN	B
involved	O	VERB	O
in	O	ADP	O
catalepsy	B-Disease	NOUN	B
was	O	AUX	O
determined	O	VERB	O
.	O	PUNCT	O


2	O	X	O
.	O	PUNCT	O


Dopamine	B-Chemical	NOUN	B
antagonist	O	NOUN	I
fluphenazine	B-Chemical	NOUN	B
,	O	PUNCT	O
D	O	NOUN	B
-	O	PUNCT	O
1	O	NUM	O
antagonist	O	NOUN	B
SCH	B-Chemical	NOUN	B
23390	I-Chemical	NUM	O
or	O	CCONJ	O
D	O	NOUN	B
-	O	PUNCT	O
2	O	NUM	O
antagonist	O	NOUN	B
sulpiride	B-Chemical	NOUN	B
induced	O	VERB	B
catalepsy	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
fluphenazine	B-Chemical	NOUN	B
and	O	CCONJ	O
sulpiride	B-Chemical	NOUN	B
was	O	AUX	O
dose	O	NOUN	B
-	O	PUNCT	O
dependent	O	ADJ	B
.	O	PUNCT	O


Combination	O	NOUN	B
of	O	ADP	O
SCH	B-Chemical	NOUN	B
23390	I-Chemical	NUM	I
with	O	ADP	O
sulpiride	B-Chemical	NOUN	B
did	O	AUX	O
not	O	PART	O
induce	O	VERB	O
catalepsy	B-Disease	NOUN	B
potentiation	O	NOUN	B
.	O	PUNCT	O


3	O	X	O
.	O	PUNCT	O


D	O	NOUN	B
-	O	PUNCT	O
1	O	NUM	O
agonist	O	NOUN	B
SKF	B-Chemical	NOUN	B
38393	I-Chemical	NUM	O
or	O	CCONJ	O
D	O	NOUN	B
-	O	PUNCT	O
2	O	NUM	O
agonist	O	NOUN	B
quinpirole	B-Chemical	NOUN	B
decreased	O	VERB	B
the	O	DET	O
catalepsy	B-Disease	NOUN	B
induced	O	VERB	B
by	O	ADP	O
fluphenazine	B-Chemical	NOUN	B
,	O	PUNCT	O
SCH	B-Chemical	NOUN	B
23390	I-Chemical	NUM	I
or	O	CCONJ	O
sulpiride	B-Chemical	NOUN	B
.	O	PUNCT	O


4	O	X	O
.	O	PUNCT	O


Combination	O	NOUN	B
of	O	ADP	O
SKF	B-Chemical	NOUN	B
38393	I-Chemical	NUM	I
with	O	ADP	O
quinpirole	B-Chemical	NOUN	B
did	O	AUX	O
not	O	PART	O
cause	O	VERB	O
potentiated	O	VERB	B
inhibitory	O	ADJ	B
effect	O	NOUN	O
on	O	ADP	O
catalepsy	B-Disease	NOUN	B
induced	O	VERB	B
by	O	ADP	O
dopamine	B-Chemical	NOUN	B
antagonists	O	NOUN	B
.	O	PUNCT	O


5	O	NUM	O
.	O	PUNCT	O


The	O	DET	O
data	O	NOUN	B
may	O	AUX	O
indicate	O	VERB	O
that	O	SCONJ	O
although	O	SCONJ	O
D	O	NOUN	B
-	O	PUNCT	O
2	O	NUM	B
receptor	O	NOUN	I
blockade	O	NOUN	B
is	O	AUX	O
involved	O	VERB	O
in	O	ADP	O
catalepsy	B-Disease	NOUN	B


Dextran	B-Chemical	NOUN	B
-	O	PUNCT	O
etodolac	B-Chemical	NOUN	B
conjugates	O	NOUN	B
:	O	PUNCT	O
synthesis	O	NOUN	B
,	O	PUNCT	O
in	O	X	B
vitro	O	X	I
and	O	CCONJ	O
in	O	X	B
vivo	O	X	I
evaluation	O	NOUN	B
.	O	PUNCT	O


Etodolac	B-Chemical	NOUN	B
(	O	PUNCT	O
E	B-Chemical	NOUN	B
),	O	PUNCT	O
is	O	AUX	O
a	O	DET	O
non	O	ADV	B
-	O	PUNCT	O
narcotic	O	ADJ	B
analgesic	O	NOUN	O
and	O	CCONJ	O
antiinflammatory	O	ADJ	B
drug	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
biodegradable	O	ADJ	B
polymer	O	NOUN	B
dextran	B-Chemical	NOUN	B
has	O	AUX	O
been	O	AUX	O
utilized	O	VERB	O
as	O	ADP	O
a	O	DET	O
carrier	O	NOUN	B
for	O	ADP	O
synthesis	O	NOUN	B
of	O	ADP	O
etodolac	B-Chemical	NOUN	B
-	O	PUNCT	O
dextran	B-Chemical	NOUN	B
conjugates	O	NOUN	B
(	O	PUNCT	O
ED	O	NOUN	B
)	O	PUNCT	O
to	O	PART	O
improve	O	VERB	B
its	O	PRON	O
aqueous	O	ADJ	B
solubility	O	NOUN	B
and	O	CCONJ	O
reduce	O	VERB	B
gastrointestinal	O	ADJ	B
side	O	NOUN	O
effects	O	NOUN	O
.	O	PUNCT	O


An	O	DET	O
activated	O	VERB	B
moiety	O	NOUN	O
,	O	PUNCT	O
i	O	X	O
.	O	PUNCT	O


e	O	X	O
.	O	PUNCT	O


N-acylimidazole	B-Chemical	NOUN	B
derivative	O	NOUN	I
of	O	ADP	O
etodolac	B-Chemical	NOUN	B
(	O	PUNCT	O
EAI	B-Chemical	NOUN	B
),	O	PUNCT	O
was	O	AUX	O
condensed	O	VERB	B
with	O	ADP	O
the	O	DET	O
polysaccharide	O	NOUN	B
polymer	O	NOUN	B
dextran	B-Chemical	NOUN	B
of	O	ADP	O
different	O	ADJ	O
molecular	O	ADJ	B
weights	O	NOUN	I
(	O	PUNCT	O
40000	O	NUM	O
,	O	PUNCT	O
60000	O	NUM	O
,	O	PUNCT	O
110000	O	NUM	O
and	O	CCONJ	O
200000	O	NUM	O
).	O	ADJ	O
IR	O	NOUN	B
spectral	O	ADJ	O
data	O	NOUN	B
confirmed	O	VERB	O
formation	O	NOUN	B
of	O	ADP	O
ester	O	NOUN	B
bonding	O	NOUN	I
in	O	ADP	O
the	O	DET	O
conjugates	O	NOUN	B
.	O	PUNCT	O


Etodolac	B-Chemical	NOUN	B
contents	O	NOUN	B
were	O	AUX	O
evaluated	O	VERB	B
by	O	ADP	O
UV	O	NOUN	B
-	O	PUNCT	O
spectrophotometric	O	ADJ	B
analysis	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
molecular	O	ADJ	B
weights	O	NOUN	I
were	O	AUX	O
determined	O	VERB	O
by	O	ADP	O
measuring	O	VERB	B
viscosity	O	NOUN	B
using	O	VERB	O
the	O	DET	O
Mark	O	PROPN	B
-	O	PUNCT	O
Howink	O	PROPN	B
-	O	PUNCT	O
Sakurada	O	PROPN	B
equation	O	NOUN	I
.	O	PUNCT	O


In	O	X	B
vitro	O	X	I
hydrolysis	O	NOUN	B
of	O	ADP	O
ED	O	PROPN	B
was	O	AUX	O
done	O	VERB	O
in	O	ADP	O
aqueous	O	ADJ	B
buffers	O	NOUN	I
(	O	PUNCT	O
pH	O	NOUN	B
1	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
,	O	PUNCT	O
7	O	NUM	O
.	O	PUNCT	O


4	O	NUM	O
,	O	PUNCT	O
9	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
in	O	ADP	O
80	O	NUM	O
%(	O	NOUN	O
v	O	X	O
/	O	SYM	O
v	O	X	O
)	O	PUNCT	O
human	O	ADJ	B
plasma	O	NOUN	B
(	O	PUNCT	O
pH	O	NOUN	B
7	O	NUM	O
.	O	PUNCT	O


4	O	NUM	O
).	O	PUNCT	O
At	O	ADP	O
pH	O	NOUN	B
9	O	NUM	O
,	O	PUNCT	O
a	O	DET	O
higher	O	ADJ	O
rate	O	NOUN	B
of	O	ADP	O
etodolac	B-Chemical	NOUN	B
release	O	NOUN	B
from	O	ADP	O
ED	O	PROPN	B
was	O	AUX	O
observed	O	VERB	O
as	O	ADP	O
compared	O	VERB	O
to	O	PART	O
aqueous	O	ADJ	B
buffer	O	NOUN	I
of	O	ADP	O
pH	O	NOUN	B
7	O	NUM	O
.	O	PUNCT	O


4	O	NUM	O
and	O	CCONJ	O
80	O	NUM	O
%	O	NOUN	O
human	O	ADJ	B
plasma	O	NOUN	B
(	O	PUNCT	O
pH	O	NOUN	B
7	O	NUM	O
.	O	PUNCT	O


4	O	NUM	O
),	O	PUNCT	O
following	O	VERB	O
first	O	ADJ	B
-	O	PUNCT	O
order	O	NOUN	B
kinetics	O	NOUN	B
.	O	PUNCT	O


In	O	X	B
vivo	O	X	I
investigations	O	NOUN	B
were	O	AUX	O
performed	O	VERB	O
in	O	ADP	O
animals	O	NOUN	B
.	O	PUNCT	O


Acute	O	ADJ	B
analgesic	O	NOUN	I
and	O	CCONJ	O
antiinflammatory	O	ADJ	B
activities	O	NOUN	I
were	O	AUX	O
ascertained	O	VERB	O
using	O	VERB	O
acetic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
induced	O	VERB	B
writhing	B-Disease	NOUN	B
model	O	NOUN	I
(	O	PUNCT	O
mice	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
carrageenan	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
rat	O	NOUN	B
paw	O	NOUN	O
edema	B-Disease	NOUN	O
model	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


In	O	ADP	O
comparison	O	NOUN	B
to	O	PART	O
control	O	NOUN	B
,	O	PUNCT	O
E	B-Chemical	NOUN	B
and	O	CCONJ	O
ED1	O	NOUN	B
-	O	PUNCT	O
ED4	O	NOUN	B
showed	O	VERB	O
highly	O	ADV	O
significant	O	ADJ	O
analgesic	O	NOUN	B
and	O	CCONJ	O
antiinflammatory	O	ADJ	B
activities	O	NOUN	I
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


001	O	NUM	O
).	O	PUNCT	O
Biological	O	ADJ	B
evaluation	O	NOUN	B
suggested	O	VERB	O
that	O	SCONJ	O
conjugates	O	NOUN	B
(	O	PUNCT	O
ED1	O	NOUN	B
-	O	PUNCT	O
ED4	O	NOUN	B
)	O	PUNCT	O
retained	O	VERB	O
comparable	O	ADJ	O
analgesic	O	NOUN	B
and	O	CCONJ	O
antiinflammatory	O	ADJ	B
activities	O	NOUN	I
with	O	ADP	O
remarkably	O	ADV	O
reduced	O	VERB	B
ulcerogenicity	O	NOUN	B
as	O	ADP	O
compared	O	VERB	O
to	O	PART	O
their	O	PRON	O
parent	O	NOUN	B
drug	O	NOUN	B
--	O	PUNCT	O
etodolac	B-Chemical	NOUN	B


Hypersensitivity	B-Disease	NOUN	B
myocarditis	B-Disease	NOUN	I
complicating	O	VERB	O
hypertrophic	B-Disease	ADJ	B
cardiomyopathy	I-Disease	NOUN	I
heart	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
present	O	ADJ	O
report	O	NOUN	B
describes	O	VERB	O
a	O	DET	O
case	O	NOUN	B
of	O	ADP	O
eosinophilic	B-Disease	ADJ	B
myocarditis	I-Disease	NOUN	I
complicating	O	VERB	O
hypertrophic	B-Disease	ADJ	B
cardiomyopathy	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
47	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
female	O	ADJ	B
patient	O	NOUN	B
,	O	PUNCT	O
known	O	VERB	O
to	O	PART	O
have	O	AUX	O
hypertrophic	B-Disease	ADJ	B
cardiomyopathy	I-Disease	NOUN	I
,	O	PUNCT	O
was	O	AUX	O
admitted	O	VERB	B
with	O	ADP	I
biventricular	B-Disease	ADJ	B
failure	I-Disease	NOUN	I
and	O	CCONJ	O
managed	O	VERB	O
aggressively	O	ADV	O
with	O	ADP	O
dobutamine	B-Chemical	NOUN	B
infusion	O	NOUN	B
and	O	CCONJ	O
other	O	ADJ	O
drugs	O	NOUN	B
while	O	SCONJ	O
being	O	AUX	O
assessed	O	VERB	B
for	O	ADP	O
heart	O	NOUN	B
transplantation	O	NOUN	I
.	O	PUNCT	O


On	O	ADP	O
transthoracic	O	NOUN	B
echocardiogram	O	NOUN	I
,	O	PUNCT	O
she	O	PRON	O
had	O	AUX	O
moderate	O	ADJ	B
left	B-Disease	ADJ	B
ventricular	I-Disease	ADJ	I
dysfunction	I-Disease	NOUN	I
with	O	ADP	O
regional	O	ADJ	B
variability	O	NOUN	B
and	O	CCONJ	O
moderate	O	ADJ	B
mitral	B-Disease	ADJ	B
regurgitation	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
recipient	O	NOUN	B
'	O	PART	O
s	O	NOUN	O
heart	O	NOUN	B
showed	O	VERB	O
the	O	DET	O
features	O	NOUN	B
of	O	ADP	O
apical	O	ADJ	B
hypertrophic	B-Disease	ADJ	I
cardiomyopathy	I-Disease	NOUN	I
and	O	CCONJ	O
myocarditis	B-Disease	NOUN	B
with	O	ADP	O
abundant	O	ADJ	B
eosinophils	O	NOUN	B
.	O	PUNCT	O


Myocarditis	B-Disease	NOUN	B
is	O	AUX	O
rare	O	ADJ	B
and	O	CCONJ	O
eosinophilic	B-Disease	ADJ	B
myocarditis	I-Disease	NOUN	I
is	O	AUX	O
rarer	O	ADJ	B
.	O	PUNCT	O


It	O	PRON	O
is	O	AUX	O
likely	O	ADJ	O
that	O	SCONJ	O
the	O	DET	O
hypersensitivity	B-Disease	NOUN	B
(	O	PUNCT	O
eosinophilic	B-Disease	ADJ	B
)	O	PUNCT	O
myocarditis	B-Disease	NOUN	B
was	O	AUX	O
related	O	ADJ	O
to	O	PART	O
dobutamine	B-Chemical	NOUN	B
infusion	O	NOUN	B
therapy	O	NOUN	O
.	O	PUNCT	O


Eosinophilic	B-Disease	ADJ	B
myocarditis	I-Disease	NOUN	I


All-	B-Chemical	NOUN	O
trans-retinoic	I-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
-	O	PUNCT	O
induced	O	VERB	B
erythema	B-Disease	NOUN	B
nodosum	I-Disease	NOUN	I
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
acute	B-Disease	ADJ	B
promyelocytic	I-Disease	ADJ	I
leukemia	I-Disease	NOUN	I
.	O	PUNCT	O


Erythema	B-Disease	NOUN	B
nodosum	I-Disease	NOUN	I
associated	O	VERB	B
with	O	ADP	I
all-	B-Chemical	ADJ	O
trans-retinoic	I-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
(	O	PUNCT	O
ATRA	B-Chemical	NOUN	B
)	O	PUNCT	O
for	O	ADP	O
acute	B-Disease	ADJ	B
promyelocytic	I-Disease	ADJ	I
leukemia	I-Disease	NOUN	I
(	O	PUNCT	O
APL	B-Disease	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
very	O	ADV	O
rare	O	ADJ	O
.	O	PUNCT	O


We	O	PRON	O
describe	O	VERB	O
four	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
classic	O	ADJ	O
APL	B-Disease	NOUN	B
who	O	PRON	O
developed	O	VERB	O
erythema	B-Disease	NOUN	B
nodosum	I-Disease	NOUN	I
during	O	ADP	O
ATRA	B-Chemical	NOUN	B
therapy	O	NOUN	B
.	O	PUNCT	O


Fever	B-Disease	NOUN	B
and	O	CCONJ	O
subsequent	O	ADJ	O
multiple	O	ADJ	B
painful	B-Disease	ADJ	B
erythematous	B-Disease	ADJ	B
nodules	I-Disease	NOUN	I
over	O	ADP	O
extremities	O	NOUN	B
developed	O	VERB	O
on	O	ADP	O
D11	O	NOUN	B
,	O	PUNCT	O
D16	O	NOUN	B
,	O	PUNCT	O
D17	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
D19	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
,	O	PUNCT	O
after	O	ADP	O
ATRA	B-Chemical	NOUN	B
therapy	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
skin	O	NOUN	B
biopsy	O	NOUN	I
taken	O	VERB	O
from	O	ADP	O
each	O	DET	O
patient	O	NOUN	B
was	O	AUX	O
consistent	O	ADJ	B
with	O	ADP	I
erythema	B-Disease	NOUN	B
nodosum	I-Disease	NOUN	I
.	O	PUNCT	O


All	O	DET	O
patients	O	NOUN	B
received	O	VERB	O
short	O	ADJ	B
course	O	NOUN	I
of	O	ADP	O
steroids	B-Chemical	NOUN	B
.	O	PUNCT	O


Fever	B-Disease	NOUN	B
subsided	O	VERB	B
rapidly	O	ADV	O
and	O	CCONJ	O
the	O	DET	O
skin	O	NOUN	B
lesions	O	NOUN	I
regressed	O	VERB	O
completely	O	ADV	O
.	O	PUNCT	O


All	O	DET	O
patients	O	NOUN	B
achieved	O	VERB	O
complete	O	ADJ	O
remission	O	NOUN	B
without	O	ADP	O
withdrawal	O	NOUN	B
of	O	ADP	O
ATRA	B-Chemical	NOUN	B
.	O	PUNCT	O


ATRA	B-Chemical	NOUN	B
seemed	O	VERB	O
to	O	PART	O
be	O	AUX	O
the	O	DET	O
most	O	ADV	O
possible	O	ADJ	O
etiology	O	NOUN	B
of	O	ADP	O
erythema	B-Disease	NOUN	B
nodosum	I-Disease	NOUN	I
in	O	ADP	O
our	O	PRON	O
patients	O	NOUN	B
.	O	PUNCT	O


Short	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
use	O	NOUN	O
of	O	ADP	O
steroid	B-Chemical	NOUN	B
is	O	AUX	O
very	O	ADV	O
effective	O	ADJ	B
in	O	ADP	O
ATRA	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
erythema	B-Disease	NOUN	B
nodosum	I-Disease	NOUN	I


Delayed	O	VERB	B
-	O	PUNCT	O
onset	O	NOUN	B
heparin	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
thrombocytopenia	B-Disease	NOUN	B
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
:	O	PUNCT	O
Heparin	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
thrombocytopenia	B-Disease	NOUN	B
presents	O	VERB	O
5	O	NUM	O
to	O	PART	O
12	O	NUM	O
days	O	NOUN	B
after	O	ADP	O
heparin	B-Chemical	NOUN	B
exposure	O	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
or	O	CCONJ	O
without	O	ADP	O
arterial	B-Disease	ADJ	B
or	I-Disease	CCONJ	O
venous	I-Disease	ADJ	B
thromboemboli	I-Disease	NOUN	I
.	O	PUNCT	O


Delayed	O	VERB	B
recognition	O	NOUN	I
and	O	CCONJ	O
treatment	O	NOUN	B
of	O	ADP	O
heparin	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
thrombocytopenia	B-Disease	NOUN	B
contribute	O	VERB	O
to	O	ADP	O
poor	O	ADJ	B
patient	O	NOUN	B
outcomes	O	NOUN	B
.	O	PUNCT	O


OBJECTIVE	O	NOUN	B
:	O	PUNCT	O
To	O	PART	O
describe	O	VERB	O
and	O	CCONJ	O
increase	O	VERB	B
awareness	O	NOUN	B
of	O	ADP	O
a	O	DET	O
clinical	O	ADJ	B
scenario	O	NOUN	I
in	O	ADP	O
which	O	DET	O
the	O	DET	O
onset	O	NOUN	O
or	O	CCONJ	O
manifestations	O	NOUN	B
of	O	ADP	O
heparin	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
thrombocytopenia	B-Disease	NOUN	B
are	O	AUX	O
delayed	O	VERB	B
.	O	PUNCT	O


DESIGN	O	NOUN	O
:	O	PUNCT	O
Retrospective	O	ADJ	B
case	O	NOUN	I
series	O	NOUN	I
.	O	PUNCT	O


SETTING	O	NOUN	O
:	O	PUNCT	O
Three	O	NUM	O
large	O	ADJ	O
urban	O	ADJ	B
hospitals	O	NOUN	B
(	O	PUNCT	O
with	O	ADP	O
active	O	ADJ	O
cardiovascular	O	ADJ	B
surgery	O	NOUN	I
programs	O	NOUN	O
).	O	PUNCT	O
PATIENTS	O	NOUN	B
:	O	PUNCT	O
14	O	NUM	O
patients	O	NOUN	B
seen	O	VERB	O
over	O	ADP	O
a	O	DET	O
3	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
period	O	NOUN	B
in	O	ADP	O
whom	O	PRON	O
heparin	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
thrombocytopenia	B-Disease	NOUN	B
became	O	VERB	O
apparent	O	ADJ	B
on	O	ADP	O
delayed	O	VERB	B
presentation	O	NOUN	I
with	O	ADP	O
thromboembolic	B-Disease	ADJ	B
complications	O	NOUN	B
.	O	PUNCT	O


MEASUREMENTS	O	NOUN	B
:	O	PUNCT	O
Platelet	O	NOUN	B
counts	O	NOUN	I
,	O	PUNCT	O
onset	O	NOUN	O
of	O	ADP	O
objectively	O	ADV	B
determined	O	VERB	O
thromboembolism	B-Disease	NOUN	B
,	O	PUNCT	O
results	O	NOUN	B
of	O	ADP	O
heparin	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
platelet	O	NOUN	B
factor	O	NOUN	I
4	O	NUM	I
antibody	O	NOUN	I
tests	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
outcomes	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
Patients	O	NOUN	B
went	O	VERB	O
home	O	ADV	B
after	O	ADP	O
hospitalizations	O	NOUN	B
that	O	PRON	O
had	O	AUX	O
included	O	VERB	O
heparin	B-Chemical	NOUN	B
exposure	O	NOUN	B
--	O	PUNCT	O
in	O	ADP	O
most	O	ADJ	O
cases	O	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
no	O	DET	O
thrombocytopenia	B-Disease	NOUN	O
recognized	O	VERB	B
--	O	PUNCT	O
only	O	ADV	O
to	O	PART	O
return	O	VERB	B
to	O	ADP	I
the	O	DET	I
hospital	O	NOUN	I
(	O	PUNCT	O
median	O	NOUN	B
,	O	PUNCT	O
day	O	NOUN	B
14	O	NUM	O
)	O	PUNCT	O
with	O	ADP	O
thromboembolic	B-Disease	ADJ	B
complications	O	NOUN	B
.	O	PUNCT	O


Thromboemboli	B-Disease	NOUN	B
were	O	AUX	O
venous	O	ADJ	B
(	O	PUNCT	O
12	O	NUM	O
patients	O	NOUN	B
,	O	PUNCT	O
7	O	NUM	O
with	O	ADP	O
pulmonary	B-Disease	ADJ	B
emboli	I-Disease	NOUN	I
)	O	PUNCT	O
or	O	CCONJ	O
arterial	O	ADJ	B
(	O	PUNCT	O
4	O	NUM	O
patients	O	NOUN	B
)	O	PUNCT	O
or	O	CCONJ	O
both	O	DET	O
.	O	PUNCT	O


Platelet	O	NOUN	B
counts	O	NOUN	I
were	O	AUX	O
mildly	O	ADV	B
decreased	O	VERB	B
in	O	ADP	O
all	O	DET	O
but	O	CCONJ	O
2	O	NUM	O
patients	O	NOUN	B
on	O	ADP	O
second	O	ADJ	O
presentation	O	NOUN	B
.	O	PUNCT	O


On	O	ADP	O
readmission	O	NOUN	B
,	O	PUNCT	O
11	O	NUM	O
patients	O	NOUN	B
received	O	VERB	O
therapeutic	O	ADJ	B
heparin	B-Chemical	NOUN	B
,	O	PUNCT	O
which	O	DET	O
worsened	O	VERB	B
the	O	DET	O
patients	O	NOUN	B
'	O	PART	O
clinical	O	ADJ	B
condition	O	NOUN	I
and	O	CCONJ	O
,	O	PUNCT	O
in	O	ADP	O
all	O	DET	O
11	O	NUM	O
cases	O	NOUN	B
,	O	PUNCT	O
decreased	O	VERB	B
the	O	DET	O
platelet	O	NOUN	B
count	O	NOUN	I
(	O	PUNCT	O
mean	O	NOUN	O
at	O	ADP	O
readmission	O	NOUN	B
,	O	PUNCT	O
143	O	NUM	O
x	O	CCONJ	O
10	O	NUM	O
(	O	PUNCT	O
9	O	NUM	O
)	O	PUNCT	O
cells	O	NOUN	B
/	O	SYM	O
L	O	NOUN	B
;	O	PUNCT	O
mean	O	ADJ	O
nadir	O	NOUN	O
after	O	ADP	O
heparin	B-Chemical	NOUN	B
re	O	X	B
-	O	PUNCT	O
exposure	O	NOUN	B
,	O	PUNCT	O
39	O	NUM	O
x	O	NOUN	O
10	O	NUM	O
(	O	PUNCT	O
9	O	NUM	O
)	O	PUNCT	O
cells	O	NOUN	B
/	O	SYM	O
L	O	NOUN	B
).	O	PUNCT	B
Results	O	NOUN	I
of	O	ADP	O
serologic	O	ADJ	B
tests	O	NOUN	I
for	O	ADP	O
heparin	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
antibodies	O	NOUN	B
were	O	AUX	O
positive	O	ADJ	B
in	O	ADP	O
all	O	DET	O
patients	O	NOUN	B
.	O	PUNCT	O


Subsequent	O	ADJ	O
treatments	O	NOUN	B
included	O	VERB	O
alternative	O	ADJ	B
anticoagulants	O	NOUN	I
(	O	PUNCT	O
11	O	NUM	O
patients	O	NOUN	B
),	O	PUNCT	O
thrombolytic	O	ADJ	B
drugs	O	NOUN	I
(	O	PUNCT	O
3	O	NUM	O
patients	O	NOUN	B
),	O	PUNCT	O
inferior	O	ADJ	B
vena	O	NOUN	I
cava	O	NOUN	I
filters	O	NOUN	I
(	O	PUNCT	O
3	O	NUM	O
patients	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
,	O	PUNCT	O
eventually	O	ADV	O
,	O	PUNCT	O
warfarin	B-Chemical	NOUN	B
(	O	PUNCT	O
11	O	NUM	O
patients	O	NOUN	B
).	O	PUNCT	O
Three	O	NUM	O
patients	O	NOUN	B
died	O	VERB	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
:	O	PUNCT	O
Delayed	O	VERB	B
-	O	PUNCT	O
onset	O	NOUN	B
heparin	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
thrombocytopenia	B-Disease	NOUN	B
is	O	AUX	O
increasingly	O	ADV	O
being	O	AUX	O
recognized	O	VERB	O
.	O	PUNCT	O


To	O	PART	O
avoid	O	VERB	O
disastrous	O	ADJ	O
outcomes	O	NOUN	B
,	O	PUNCT	O
physicians	O	NOUN	B
must	O	AUX	O
consider	O	VERB	O
heparin	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
thrombocytopenia	B-Disease	NOUN	B
whenever	O	SCONJ	O
a	O	DET	O
recently	O	ADV	O
hospitalized	O	VERB	B
patient	O	NOUN	B
returns	O	NOUN	O
with	O	ADP	O
thromboembolism	B-Disease	NOUN	B
;	O	PUNCT	O
therapy	O	NOUN	B
with	O	ADP	O
alternative	O	ADJ	B
anticoagulants	O	NOUN	I
,	O	PUNCT	O
not	O	PART	O
heparin	B-Chemical	NOUN	B


Valsartan	B-Chemical	PROPN	B
,	O	PUNCT	O
a	O	DET	O
new	O	ADJ	O
angiotensin	B-Chemical	NOUN	B
II	I-Chemical	NUM	I
antagonist	O	NOUN	I
for	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
essential	O	ADJ	B
hypertension	B-Disease	NOUN	I
:	O	PUNCT	O
a	O	DET	O
comparative	O	ADJ	B
study	O	NOUN	I
of	O	ADP	O
the	O	DET	O
efficacy	O	NOUN	B
and	O	CCONJ	O
safety	O	NOUN	B
against	O	ADP	O
amlodipine	B-Chemical	NOUN	B
.	O	PUNCT	O


OBJECTIVE	O	NOUN	O
:	O	PUNCT	O
To	O	PART	O
compare	O	VERB	B
the	O	DET	O
antihypertensive	O	ADJ	B
efficacy	O	NOUN	B
of	O	ADP	O
a	O	DET	O
new	O	ADJ	O
angiotensin	B-Chemical	NOUN	B
II	I-Chemical	NUM	I
antagonist	O	NOUN	I
,	O	PUNCT	O
valsartan	B-Chemical	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
a	O	DET	O
reference	O	NOUN	B
therapy	O	NOUN	I
,	O	PUNCT	O
amlodipine	B-Chemical	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
:	O	PUNCT	O
One	O	NUM	O
hundred	O	NUM	O
sixty	O	NUM	B
-	O	PUNCT	O
eight	O	NUM	O
adult	O	ADJ	B
outpatients	O	NOUN	B
with	O	ADP	O
mild	O	ADJ	B
to	O	PART	O
moderate	O	ADJ	B
hypertension	B-Disease	NOUN	B
were	O	AUX	O
randomly	O	ADV	O
allocated	O	VERB	O
in	O	ADP	O
double	O	ADJ	B
-	O	PUNCT	O
blind	O	ADJ	B
fashion	O	NOUN	B
and	O	CCONJ	O
equal	O	ADJ	O
number	O	NOUN	O
to	O	PART	O
receive	O	VERB	O
80	O	NUM	O
mg	O	NOUN	O
valsartan	B-Chemical	NOUN	B
or	O	CCONJ	O
5	O	NUM	O
mg	O	NOUN	O
amlodipine	B-Chemical	NOUN	B
for	O	ADP	O
12	O	NUM	O
weeks	O	NOUN	B
.	O	PUNCT	O


After	O	ADP	O
8	O	NUM	O
weeks	O	NOUN	B
of	O	ADP	O
therapy	O	NOUN	B
,	O	PUNCT	O
in	O	ADP	O
patients	O	NOUN	B
whose	O	DET	O
blood	O	NOUN	B
pressure	O	NOUN	I
remained	O	VERB	O
uncontrolled	O	ADJ	B
,	O	PUNCT	O
5	O	NUM	O
mg	O	NOUN	O
amlodipine	B-Chemical	NOUN	B
was	O	AUX	O
added	O	VERB	O
to	O	PART	O
the	O	DET	O
initial	O	ADJ	O
therapy	O	NOUN	B
.	O	PUNCT	O


Patients	O	NOUN	B
were	O	AUX	O
assessed	O	VERB	B
at	O	ADP	O
4	O	NUM	O
,	O	PUNCT	O
8	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
12	O	NUM	O
weeks	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
primary	O	ADJ	O
efficacy	O	NOUN	B
variable	O	NOUN	B
was	O	AUX	O
change	O	NOUN	O
from	O	ADP	O
baseline	O	NOUN	B
in	O	ADP	O
mean	O	ADJ	B
sitting	O	VERB	I
diastolic	O	ADJ	I
blood	O	NOUN	I
pressure	O	NOUN	I
at	O	ADP	O
8	O	NUM	O
weeks	O	NOUN	B
.	O	PUNCT	O


Secondary	O	ADJ	B
variables	O	NOUN	I
included	O	VERB	O
change	O	NOUN	O
in	O	ADP	O
sitting	O	VERB	B
systolic	O	ADJ	B
blood	O	NOUN	I
pressure	O	NOUN	I
and	O	CCONJ	O
responder	O	NOUN	B
rates	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
Both	O	CCONJ	O
valsartan	B-Chemical	NOUN	B
and	O	CCONJ	O
amlodipine	B-Chemical	NOUN	B
were	O	AUX	O
effective	O	ADJ	B
at	O	ADP	O
lowering	O	VERB	B
blood	O	NOUN	B
pressure	O	NOUN	I
at	O	ADP	O
4	O	NUM	O
,	O	PUNCT	O
8	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
12	O	NUM	O
weeks	O	NOUN	B
.	O	PUNCT	O


Similar	O	ADJ	O
decreases	O	NOUN	B
were	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
no	O	DET	O
statistically	O	ADV	B
significant	O	ADJ	I
differences	O	NOUN	O
between	O	ADP	O
the	O	DET	O
groups	O	NOUN	B
for	O	ADP	O
any	O	DET	O
variable	O	ADJ	B
analyzed	O	VERB	B
.	O	PUNCT	O


For	O	ADP	O
the	O	DET	O
primary	O	ADJ	B
variable	O	ADJ	B
the	O	DET	O
difference	O	NOUN	B
was	O	AUX	O
0	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
mm	O	NOUN	O
Hg	O	NOUN	O
in	O	ADP	O
favor	O	NOUN	O
of	O	ADP	O
valsartan	B-Chemical	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


68	O	NUM	O
;	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
,-	O	PUNCT	O
2	O	NUM	O
.	O	PUNCT	O


7	O	NUM	O
to	O	PART	O
1	O	NUM	O
.	O	PUNCT	O


7	O	NUM	O
).	O	PUNCT	O
Responder	O	NOUN	B
rates	O	NOUN	B
at	O	ADP	O
8	O	NUM	O
weeks	O	NOUN	B
were	O	AUX	O
66	O	NUM	O
.	O	PUNCT	O


7	O	NUM	O
%	O	NOUN	O
for	O	ADP	O
valsartan	B-Chemical	NOUN	B
and	O	CCONJ	O
60	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
%	O	NOUN	O
for	O	ADP	O
amlodipine	B-Chemical	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


39	O	NUM	O
).	O	PUNCT	O
Both	O	DET	O
treatments	O	NOUN	B
were	O	AUX	O
well	O	ADV	O
tolerated	O	VERB	B
.	O	PUNCT	O


The	O	DET	O
incidence	O	NOUN	B
of	O	ADP	O
drug	O	NOUN	B
-	O	PUNCT	O
related	O	VERB	B
dependent	O	ADJ	B
edema	B-Disease	NOUN	B
was	O	AUX	O
somewhat	O	ADV	O
higher	O	ADJ	O
in	O	ADP	O
the	O	DET	O
amlodipine	B-Chemical	ADJ	B
group	O	NOUN	B
,	O	PUNCT	O
particularly	O	ADV	O
at	O	ADP	O
a	O	DET	O
dose	O	NOUN	B
of	O	ADP	O
10	O	NUM	O
mg	O	NOUN	O
per	O	ADP	O
day	O	NOUN	B
(	O	PUNCT	O
2	O	NUM	O
.	O	PUNCT	O


4	O	NUM	O
%	O	NOUN	O
for	O	ADP	O
80	O	NUM	O
mg	O	NOUN	O
valsartan	B-Chemical	NOUN	B
;	O	PUNCT	O
3	O	X	O
.	O	PUNCT	O


6	O	NUM	O
%	O	NOUN	O
for	O	ADP	O
5	O	NUM	O
mg	O	NOUN	O
amlodipine	B-Chemical	NOUN	B
;	O	PUNCT	O
0	O	NUM	O
%	O	NOUN	O
for	O	ADP	O
valsartan	B-Chemical	NOUN	B
plus	O	CCONJ	O
5	O	NUM	O
mg	O	NOUN	O
amlodipine	B-Chemical	NOUN	B
;	O	PUNCT	O
14	O	NUM	O
.	O	PUNCT	O


3	O	NUM	O
%	O	NOUN	O
for	O	ADP	O
10	O	NUM	O
mg	O	NOUN	O
amlodipine	B-Chemical	ADJ	B
).	O	PUNCT	O
CONCLUSIONS	O	NOUN	O
:	O	PUNCT	O
The	O	DET	O
data	O	NOUN	B
show	O	VERB	O
that	O	SCONJ	O
valsartan	B-Chemical	NOUN	B
is	O	AUX	O
at	O	ADV	O
least	O	ADV	O
as	O	ADV	O
effective	O	ADJ	B
as	O	ADP	O
amlodipine	B-Chemical	NOUN	B
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
mild	O	ADJ	B
to	O	PART	O
moderate	O	ADJ	B
hypertension	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
results	O	NOUN	B
also	O	ADV	O
show	O	VERB	O
valsartan	B-Chemical	NOUN	B
to	O	PART	O
be	O	AUX	O
well	O	ADV	O
tolerated	O	VERB	B
and	O	CCONJ	O
suggest	O	VERB	O
that	O	SCONJ	O
it	O	PRON	O
is	O	AUX	O
not	O	PART	O
associated	O	VERB	B
with	O	ADP	I
side	O	NOUN	B
effects	O	NOUN	I
characteristic	O	ADJ	O
of	O	ADP	O
this	O	DET	O
comparator	O	NOUN	B
class	O	NOUN	I
,	O	PUNCT	O
dihydropyridine	B-Chemical	NOUN	B
calcium	B-Chemical	NOUN	I


KF17837	B-Chemical	NOUN	B
:	O	PUNCT	O
a	O	DET	O
novel	O	ADJ	O
selective	O	ADJ	O
adenosine	B-Chemical	NOUN	O
A2A	O	NOUN	O
receptor	O	NOUN	O
antagonist	O	NOUN	B
with	O	ADP	O
anticataleptic	O	ADJ	B
activity	O	NOUN	I
.	O	PUNCT	O


KF17837	B-Chemical	NOUN	B
is	O	AUX	O
a	O	DET	O
novel	O	ADJ	O
selective	O	ADJ	O
adenosine	B-Chemical	NOUN	O
A2A	O	NOUN	O
receptor	O	NOUN	O
antagonist	O	NOUN	B
.	O	PUNCT	O


Oral	O	ADJ	B
administration	O	NOUN	I
of	O	ADP	O
KF17837	B-Chemical	NOUN	B
(	O	PUNCT	O
2	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
,	O	PUNCT	O
10	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
and	O	CCONJ	O
30	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
)	O	PUNCT	O
significantly	O	ADV	O
ameliorated	O	VERB	B
the	O	DET	O
cataleptic	B-Disease	ADJ	B
responses	O	NOUN	O
induced	O	VERB	B
by	O	ADP	O
intracerebroventricular	O	ADJ	B
administration	O	NOUN	B
of	O	ADP	O
an	O	DET	O
adenosine	B-Chemical	NOUN	B
A2A	O	NOUN	I
receptor	O	NOUN	I
agonist	O	NOUN	B
,	O	PUNCT	O
CGS	B-Chemical	NOUN	B
21680	I-Chemical	NUM	O
(	O	PUNCT	O
10	O	NUM	O
micrograms	O	NOUN	O
),	O	PUNCT	O
in	O	ADP	O
a	O	DET	O
dose	O	NOUN	B
-	O	PUNCT	O
dependent	O	ADJ	B
manner	O	NOUN	O
.	O	PUNCT	O


KF17837	B-Chemical	NOUN	B
also	O	ADV	O
reduced	O	VERB	B
the	O	DET	O
catalepsy	B-Disease	NOUN	B
induced	O	VERB	B
by	O	ADP	O
haloperidol	B-Chemical	NOUN	B
(	O	PUNCT	O
1	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	O
i	O	X	O
.	O	PUNCT	O


p	O	NOUN	O
.)	O	NOUN	O
and	O	CCONJ	O
by	O	ADP	O
reserpine	B-Chemical	NOUN	B
(	O	PUNCT	O
5	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	O
i	O	X	O
.	O	PUNCT	O


p	O	NOUN	O
.).	O	NOUN	O
These	O	DET	O
anticataleptic	O	ADJ	B
effects	O	NOUN	O
were	O	AUX	O
exhibited	O	VERB	O
dose	O	NOUN	B
dependently	O	ADV	B
at	O	ADP	O
doses	O	NOUN	B
from	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


625	O	NUM	O
and	O	CCONJ	O
2	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	O
p	O	NOUN	O
.	O	PUNCT	O


o	O	X	O
.,	O	NOUN	O
respectively	O	ADV	O
.	O	PUNCT	O


Moreover	O	ADV	O
,	O	PUNCT	O
KF17837	B-Chemical	NOUN	B
(	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


625	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	O
p	O	NOUN	O
.	O	PUNCT	O


o	O	INTJ	O
.)	O	NOUN	O
potentiated	O	VERB	B
the	O	DET	O
anticataleptic	O	ADJ	B
effects	O	NOUN	B
of	O	ADP	O
a	O	DET	O
subthreshold	O	ADJ	B
dose	O	NOUN	B
of	O	ADP	O
L-3,4-dihydroxyphenylalanine	B-Chemical	NOUN	B
(	O	PUNCT	O
L-DOPA	B-Chemical	NOUN	B
;	O	PUNCT	O
25	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	O
i	O	X	O
.	O	PUNCT	O


p	O	NOUN	O
.)	O	NUM	O
plus	O	CCONJ	O
benserazide	B-Chemical	NOUN	B
(	O	PUNCT	O
6	O	NUM	O
.	O	PUNCT	O


25	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	O
i	O	X	O
.	O	PUNCT	O


p	O	NOUN	O
.).	O	NOUN	O
These	O	DET	O
results	O	NOUN	B
suggested	O	VERB	O
that	O	SCONJ	O
KF17837	B-Chemical	NOUN	B
is	O	AUX	O
a	O	DET	O
centrally	O	ADV	O
active	O	ADJ	O
adenosine	B-Chemical	NOUN	B
A2A	O	NOUN	I
receptor	O	NOUN	I
antagonist	O	NOUN	B
and	O	CCONJ	O
that	O	SCONJ	O
the	O	DET	O
dopaminergic	O	ADJ	B
function	O	NOUN	I
of	O	ADP	O
the	O	DET	O
nigrostriatal	O	NOUN	B
pathway	O	NOUN	I
is	O	AUX	O
potentiated	O	VERB	B
by	O	ADP	O
adenosine	B-Chemical	NOUN	B
A2A	O	NOUN	I
receptor	O	NOUN	I
antagonists	O	NOUN	B
.	O	PUNCT	O


Furthermore	O	ADV	O
,	O	PUNCT	O
KF17837	B-Chemical	NOUN	B
may	O	AUX	O
be	O	AUX	O
a	O	DET	O
useful	O	ADJ	O
drug	O	NOUN	B
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
parkinsonism	B-Disease	NOUN	B


Some	O	DET	O
central	O	ADJ	B
effects	O	NOUN	I
of	O	ADP	O
repeated	O	VERB	B
treatment	O	NOUN	B
with	O	ADP	O
fluvoxamine	B-Chemical	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
investigated	O	VERB	B
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
repeated	O	VERB	B
treatment	O	NOUN	B
with	O	ADP	O
fluvoxamine	B-Chemical	NOUN	B
,	O	PUNCT	O
a	O	DET	O
selective	O	ADJ	O
serotonin	B-Chemical	NOUN	B
uptake	O	NOUN	O
inhibitor	O	NOUN	B
,	O	PUNCT	O
on	O	ADP	O
behavioral	O	ADJ	B
effects	O	NOUN	B
of	O	ADP	O
dopaminomimetics	O	NOUN	B
and	O	CCONJ	O
methoxamine	B-Chemical	NOUN	B
and	O	CCONJ	O
on	O	ADP	O
the	O	DET	O
animal	O	NOUN	B
behavior	O	NOUN	I
in	O	ADP	O
the	O	DET	O
"	O	PUNCT	O
behavioral	O	ADJ	B
despair	O	NOUN	O
"	O	PUNCT	O
test	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
repeated	O	ADJ	O
treatment	O	NOUN	B
with	O	ADP	O
fluvoxamine	B-Chemical	NOUN	B
(	O	PUNCT	O
twice	O	ADV	O
daily	O	ADV	O
for	O	ADP	O
14	O	NUM	O
days	O	NOUN	B
)	O	PUNCT	O
potentiated	O	VERB	B
in	O	ADP	O
mice	O	NOUN	B
and	O	CCONJ	O
in	O	ADP	O
rats	O	NOUN	B
(	O	PUNCT	O
weaker	O	ADJ	O
)	O	PUNCT	O
the	O	DET	O
amphetamine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
hyperactivity	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
hyperactivity	B-Disease	NOUN	B
induced	O	VERB	B
by	O	ADP	O
nomifensine	B-Chemical	NOUN	B
in	O	ADP	O
mice	O	NOUN	B
remained	O	VERB	O
unaffected	O	ADJ	O
by	O	ADP	O
fluvoxamine	B-Chemical	NOUN	B
.	O	PUNCT	O


The	O	DET	O
stimulation	O	NOUN	B
of	O	ADP	O
locomotor	O	NOUN	B
activity	O	NOUN	I
by	O	ADP	O
intracerebroventricularly	O	ADV	B
administered	O	VERB	B
methoxamine	B-Chemical	NOUN	B
was	O	AUX	O
not	O	PART	O
affected	O	VERB	B
by	O	ADP	O
repeated	O	VERB	O
treatment	O	NOUN	B
with	O	ADP	O
fluvoxamine	B-Chemical	NOUN	B
.	O	PUNCT	O


Given	O	VERB	O
three	O	NUM	O
times	O	NOUN	O
fluvoxamine	B-Chemical	NOUN	B
had	O	AUX	O
no	O	DET	B
effect	O	NOUN	I
on	O	ADP	O
the	O	DET	O
immobilization	O	NOUN	B
time	O	NOUN	I
in	O	ADP	O
the	O	DET	O
"	O	PUNCT	O
behavioral	O	ADJ	B
despair	O	NOUN	O
"	O	PUNCT	O
test	O	NOUN	B
in	O	ADP	O
rats	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
results	O	NOUN	B
indicate	O	VERB	O
that	O	SCONJ	O
fluvoxamine	B-Chemical	NOUN	B
given	O	VERB	O
repeatedly	O	ADV	O
acts	O	VERB	O
differently	O	ADV	O
than	O	ADP	O
citalopram	B-Chemical	NOUN	B
,	O	PUNCT	O
another	O	DET	O
selective	O	ADJ	O
serotonin	B-Chemical	NOUN	B


Severe	O	ADJ	B
congestive	B-Disease	ADJ	B
heart	I-Disease	NOUN	I
failure	I-Disease	NOUN	I
patient	O	NOUN	B
on	O	ADP	O
amiodarone	B-Chemical	NOUN	B
presenting	O	NOUN	O
with	O	ADP	O
myxedemic	B-Disease	ADJ	B
coma	I-Disease	NOUN	I
:	O	PUNCT	O
a	O	DET	O
case	O	NOUN	B
report	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
is	O	AUX	O
a	O	DET	O
case	O	NOUN	B
report	O	NOUN	I
of	O	ADP	O
myxedema	B-Disease	ADJ	B
coma	I-Disease	NOUN	I
secondary	O	ADJ	B
to	O	PART	I
amiodarone	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
hypothyroidism	B-Disease	NOUN	B
in	O	ADP	O
a	O	DET	O
patient	O	NOUN	B
with	O	ADP	O
severe	O	ADJ	B
congestive	B-Disease	ADJ	B
heart	I-Disease	NOUN	I
failure	I-Disease	NOUN	I
(	O	PUNCT	O
CHF	B-Disease	NOUN	B
).	O	PUNCT	O
To	O	PART	O
our	O	PRON	O
knowledge	O	NOUN	B
and	O	CCONJ	O
after	O	ADP	O
reviewing	O	VERB	B
the	O	DET	O
literature	O	NOUN	B
there	O	PRON	O
is	O	AUX	O
one	O	NUM	O
case	O	NOUN	B
report	O	NOUN	I
of	O	ADP	O
myxedema	B-Disease	ADJ	B
coma	I-Disease	NOUN	I
during	O	ADP	O
long	O	ADJ	B
term	O	NOUN	I
amiodarone	B-Chemical	NOUN	B
therapy	O	NOUN	I
.	O	PUNCT	O


Myxedema	B-Disease	NOUN	B
coma	I-Disease	NOUN	I
is	O	AUX	O
a	O	DET	O
life	O	NOUN	B
threatening	O	ADJ	I
condition	O	NOUN	B
that	O	PRON	O
carries	O	VERB	O
a	O	DET	O
mortality	O	NOUN	B
reaching	O	VERB	O
as	O	ADV	O
high	O	ADJ	O
as	O	ADP	O
20	O	NUM	O
%	O	NOUN	O
with	O	ADP	O
treatment	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
condition	O	NOUN	B
is	O	AUX	O
treated	O	VERB	B
with	O	ADP	I
intravenous	O	ADJ	B
thyroxine	B-Chemical	NOUN	I
(	O	PUNCT	O
T4	B-Chemical	NOUN	B
)	O	PUNCT	O
or	O	CCONJ	O
intravenous	O	ADJ	B
tri-iodo-thyronine	B-Chemical	NOUN	I
(	O	PUNCT	O
T3	B-Chemical	NOUN	B
).	O	PUNCT	O
Patients	O	NOUN	B
with	O	ADP	O
CHF	B-Disease	NOUN	B
on	O	ADP	O
amiodarone	B-Chemical	NOUN	B
may	O	AUX	O
suffer	O	VERB	O
serious	O	ADJ	O
morbidity	O	NOUN	B
and	O	CCONJ	O
mortality	O	NOUN	B
from	O	ADP	O
hypothyroidism	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
thus	O	ADV	O
may	O	AUX	O
deserve	O	VERB	O
closer	O	ADJ	O
follow	O	VERB	B
up	O	ADP	I
for	O	ADP	O
thyroid	O	NOUN	B
stimulating	O	NOUN	I
hormone	O	NOUN	I
(	O	PUNCT	O
TSH	O	NOUN	B
)	O	PUNCT	O
levels	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
case	O	NOUN	B
report	O	NOUN	I
carries	O	VERB	O
an	O	DET	O
important	O	ADJ	O
clinical	O	ADJ	B
application	O	NOUN	O
given	O	VERB	O
the	O	DET	O
frequent	O	ADJ	B
usage	O	NOUN	B
of	O	ADP	O
amiodarone	B-Chemical	NOUN	B
among	O	ADP	O
CHF	B-Disease	NOUN	B
patients	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
myriad	O	ADJ	B
clinical	O	ADJ	I
presentation	O	NOUN	I
of	O	ADP	O
myxedema	B-Disease	ADJ	B
coma	I-Disease	NOUN	I
and	O	CCONJ	O
its	O	PRON	O
serious	O	ADJ	O
morbidity	O	NOUN	B
and	O	CCONJ	O
mortality	O	NOUN	B
stresses	O	VERB	I
the	O	DET	O
need	O	NOUN	O
to	O	PART	O
suspect	O	VERB	O
this	O	DET	O
clinical	O	ADJ	B
syndrome	O	NOUN	I
among	O	ADP	O
CHF	B-Disease	NOUN	B
patients	O	NOUN	B
presenting	O	VERB	O
with	O	ADP	O
hypotension	B-Disease	NOUN	B
,	O	PUNCT	O
weakness	B-Disease	NOUN	B


Fear	O	NOUN	B
-	O	PUNCT	O
potentiated	O	VERB	B
startle	B-Disease	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
not	O	PART	O
light	O	ADJ	B
-	O	PUNCT	O
enhanced	O	VERB	B
startle	B-Disease	NOUN	B
,	O	PUNCT	O
is	O	AUX	O
enhanced	O	VERB	O
by	O	ADP	O
anxiogenic	O	ADJ	B
drugs	O	NOUN	I
.	O	PUNCT	O


RATIONALE	O	NOUN	B
AND	O	CCONJ	O
OBJECTIVES	O	NOUN	O
:	O	PUNCT	O
The	O	DET	O
light	O	ADJ	B
-	O	PUNCT	O
enhanced	O	VERB	B
startle	B-Disease	NOUN	B
paradigm	O	NOUN	O
(	O	PUNCT	O
LES	O	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
suggested	O	VERB	O
to	O	PART	O
model	O	VERB	B
anxiety	B-Disease	NOUN	B
,	O	PUNCT	O
because	O	SCONJ	O
of	O	ADP	O
the	O	DET	O
non	O	ADJ	B
-	O	PUNCT	O
specific	O	ADJ	B
cue	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
long	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
effect	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
contrast	O	NOUN	O
,	O	PUNCT	O
the	O	DET	O
fear	O	NOUN	B
-	O	PUNCT	O
potentiated	O	VERB	B
startle	B-Disease	NOUN	B
(	O	PUNCT	O
FPS	O	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
suggested	O	VERB	O
to	O	PART	O
model	O	VERB	B
conditioned	O	ADJ	B
fear	O	NOUN	I
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
pharmacological	O	ADJ	B
profiles	O	NOUN	I
of	O	ADP	O
these	O	DET	O
two	O	NUM	O
paradigms	O	NOUN	B
are	O	AUX	O
very	O	ADV	O
similar	O	ADJ	O
.	O	PUNCT	O


The	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
investigated	O	VERB	B
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
putative	O	ADJ	B
anxiogenic	O	ADJ	I
drugs	O	NOUN	I
on	O	ADP	O
LES	O	NOUN	B
and	O	CCONJ	O
FPS	O	PROPN	B
and	O	CCONJ	O
aimed	O	VERB	O
at	O	ADP	O
determining	O	VERB	O
the	O	DET	O
sensitivity	O	NOUN	B
of	O	ADP	O
LES	O	NOUN	B
for	O	ADP	O
anxiogenic	O	ADJ	B
drugs	O	NOUN	I
and	O	CCONJ	O
to	O	PART	O
potentially	O	ADV	O
showing	O	VERB	O
a	O	DET	O
pharmacological	O	ADJ	B
differentiation	O	NOUN	I
between	O	ADP	O
these	O	DET	O
two	O	NUM	O
paradigms	O	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
:	O	PUNCT	O
Male	O	NOUN	B
Wistar	O	PROPN	B
rats	O	NOUN	I
received	O	VERB	O
each	O	DET	O
dose	O	NOUN	B
of	O	ADP	O
the	O	DET	O
alpha	O	NOUN	B
(	O	PUNCT	O
2	O	NUM	O
)-	O	ADJ	O
adrenoceptor	O	NOUN	B
antagonist	O	NOUN	I
yohimbine	B-Chemical	NOUN	B
(	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


25	O	NUM	O
-	O	SYM	O
1	O	NUM	O
.	O	PUNCT	O


0mg	O	ADJ	B
/	O	SYM	O
kg	O	NOUN	B
),	O	PUNCT	O
the	O	DET	O
5-HT	B-Chemical	NOUN	B
(	O	PUNCT	O
2C	O	NOUN	B
)	O	PUNCT	O
receptor	O	NOUN	O
agonist	O	NOUN	O
m-chlorophenylpiperazine	B-Chemical	NOUN	B
(	O	PUNCT	O
mCPP	B-Chemical	NOUN	B
,	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
-	O	SYM	O
2	O	NUM	O
.	O	PUNCT	O


0mg	O	ADJ	B
/	O	SYM	O
kg	O	NOUN	B
)	O	PUNCT	O
or	O	CCONJ	O
the	O	DET	O
GABA	B-Chemical	NOUN	B
(	O	PUNCT	O
A	O	NOUN	O
)	O	PUNCT	O
inverse	O	ADJ	B
receptor	O	NOUN	I
agonist	O	NOUN	I
pentylenetetrazole	B-Chemical	NOUN	B
(	O	PUNCT	O
PTZ	B-Chemical	NOUN	B
,	O	PUNCT	O
3	O	NUM	O
-	O	PUNCT	O
30mg	O	ADJ	B
/	O	SYM	O
kg	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
were	O	AUX	O
subsequently	O	ADV	O
tested	O	VERB	B
in	O	ADP	O
either	O	CCONJ	O
LES	O	NOUN	B
or	O	CCONJ	O
FPS	O	PROPN	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
of	O	ADP	O
the	O	DET	O
drugs	O	NOUN	B
enhanced	O	VERB	B
LES	O	NOUN	B
,	O	PUNCT	O
whereas	O	SCONJ	O
mCPP	B-Chemical	NOUN	B
increased	O	VERB	B
percentage	O	NOUN	B
FPS	O	PROPN	B
and	O	CCONJ	O
yohimbine	B-Chemical	NOUN	B
increased	O	VERB	B
absolute	O	ADJ	B
FPS	O	NOUN	B
values	O	NOUN	B
.	O	PUNCT	O


Furthermore	O	ADV	O
,	O	PUNCT	O
yohimbine	B-Chemical	NOUN	B
increased	O	VERB	B
baseline	O	NOUN	B
startle	B-Disease	NOUN	B
amplitude	O	NOUN	B
in	O	ADP	O
the	O	DET	O
LES	O	NOUN	B
,	O	PUNCT	O
while	O	SCONJ	O
mCPP	B-Chemical	NOUN	B
suppressed	O	VERB	B
baseline	O	NOUN	B
startle	B-Disease	NOUN	B
in	O	ADP	O
both	O	CCONJ	O
the	O	DET	O
LES	O	NOUN	B
and	O	CCONJ	O
FPS	O	PROPN	B
and	O	CCONJ	O
PTZ	B-Chemical	NOUN	B
suppressed	O	VERB	B
baseline	O	NOUN	B
startle	B-Disease	NOUN	B


Proteinase	O	NOUN	B
3	O	NUM	I
-	O	PUNCT	O
antineutrophil	O	NOUN	B
cytoplasmic	O	ADJ	O
antibody	O	NOUN	O
-(	O	NOUN	O
PR3	O	NOUN	B
-	O	PUNCT	O
ANCA	O	NOUN	B
)	O	PUNCT	O
positive	O	ADJ	B
necrotizing	O	NOUN	B
glomerulonephritis	B-Disease	NOUN	I
after	O	ADP	O
restarting	O	VERB	B
sulphasalazine	B-Chemical	NOUN	B
treatment	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
59	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
woman	O	NOUN	B
with	O	ADP	O
ulcerative	B-Disease	ADJ	B
colitis	I-Disease	NOUN	I
developed	O	VERB	O
red	B-Disease	ADJ	B
eyes	I-Disease	NOUN	I
,	O	PUNCT	O
pleural	B-Disease	ADJ	B
effusion	I-Disease	NOUN	I
,	O	PUNCT	O
eosinophilia	B-Disease	NOUN	B
and	O	CCONJ	O
urinary	B-Disease	ADJ	B
abnormalities	I-Disease	NOUN	I
after	O	ADP	O
restarting	O	NOUN	B
of	O	ADP	O
sulphasalazine	B-Chemical	NOUN	B
treatment	O	NOUN	B
.	O	PUNCT	O


Light	O	ADJ	B
microscopy	O	NOUN	I
of	O	ADP	O
a	O	DET	O
kidney	O	NOUN	B
biopsy	O	NOUN	I
revealed	O	VERB	O
segmental	B-Disease	ADJ	B
necrotizing	I-Disease	NOUN	I
glomerulonephritis	I-Disease	NOUN	I
without	O	ADP	O
deposition	O	NOUN	B
of	O	ADP	O
immunoglobulin	O	NOUN	B
or	O	CCONJ	O
complement	O	NOUN	B
.	O	PUNCT	O


Proteinase	O	NOUN	B
3	O	NUM	I
-	O	PUNCT	O
antineutrophil	O	NOUN	B
cytoplasmic	O	ADJ	O
antibody	O	NOUN	O
(	O	PUNCT	O
PR3	O	NOUN	B
-	O	PUNCT	O
ANCA	O	NOUN	B
)	O	PUNCT	O
titer	O	NOUN	B
was	O	AUX	O
elevated	O	VERB	B
at	O	ADP	O
183	O	NUM	O
ELISA	O	NOUN	B
units	O	NOUN	O
(	O	PUNCT	O
EU	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
sera	O	NOUN	B
(	O	PUNCT	O
normal	O	ADJ	O
range	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
10	O	NUM	O
EU	O	NOUN	B
),	O	PUNCT	O
myeloperoxidase	O	NOUN	B
-	O	PUNCT	O
ANCA	O	NOUN	B
was	O	AUX	O
negative	O	ADJ	B
.	O	PUNCT	O


PR3	O	NOUN	B
-	O	PUNCT	O
ANCA	O	NOUN	B
titer	O	NOUN	B
was	O	AUX	O
250	O	NUM	O
and	O	CCONJ	O
1	O	NUM	O
,	O	PUNCT	O
070	O	NUM	O
EU	O	NOUN	B
in	O	ADP	O
pleural	B-Disease	ADJ	B
effusions	I-Disease	NOUN	I
on	O	ADP	O
right	O	ADJ	B
and	O	CCONJ	O
left	O	VERB	B
side	O	NOUN	I
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


Although	O	SCONJ	O
cessation	O	NOUN	B
of	O	ADP	O
sulphasalazine	B-Chemical	NOUN	B
treatment	O	NOUN	B
resulted	O	VERB	O
in	O	ADP	O
improvements	O	NOUN	B
in	O	ADP	O
fever	B-Disease	NOUN	B
,	O	PUNCT	O
red	B-Disease	ADJ	B
eyes	I-Disease	NOUN	I
,	O	PUNCT	O
chest	B-Disease	ADJ	B
pain	I-Disease	NOUN	I
,	O	PUNCT	O
titer	O	NOUN	B
of	O	ADP	O
C	O	NOUN	B
-	O	PUNCT	O
reactive	O	ADJ	B
protein	O	NOUN	I
and	O	CCONJ	O
volume	O	NOUN	B
of	O	ADP	O
the	O	DET	O
pleural	B-Disease	ADJ	B
effusions	I-Disease	NOUN	I
,	O	PUNCT	O
we	O	PRON	O
initiated	O	VERB	O
steroid	B-Chemical	NOUN	B
therapy	O	NOUN	I
,	O	PUNCT	O
because	O	SCONJ	O
PR3	O	NOUN	B
-	O	PUNCT	O
ANCA	O	NOUN	B
titer	O	NOUN	B
rose	O	VERB	O
to	O	ADP	O
320	O	NUM	O
EU	O	PROPN	B
,	O	PUNCT	O
eosinophil	O	NOUN	B
count	O	NOUN	O
increased	O	VERB	B
to	O	PART	O
1	O	NUM	O
,	O	PUNCT	O
100	O	NUM	O
cells	O	NOUN	B
/	O	SYM	O
microl	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
pleural	B-Disease	ADJ	B
effusion	I-Disease	NOUN	I
remained	O	VERB	O
.	O	PUNCT	O


One	O	NUM	O
month	O	NOUN	B
after	O	ADP	O
steroid	B-Chemical	NOUN	B
therapy	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
pleural	B-Disease	ADJ	B
effusion	I-Disease	NOUN	I
disappeared	O	VERB	O
,	O	PUNCT	O
and	O	CCONJ	O
PR3	O	NOUN	B
-	O	PUNCT	O
ANCA	O	NOUN	B
titer	O	NOUN	B
normalized	O	VERB	O
3	O	NUM	O
months	O	NOUN	B
later	O	ADV	O
.	O	PUNCT	O


This	O	DET	O
case	O	NOUN	B
suggests	O	VERB	O
that	O	SCONJ	O
sulphasalazine	B-Chemical	NOUN	B
can	O	AUX	O
induce	O	VERB	B
PR3	O	NOUN	B
-	O	PUNCT	O
ANCA	O	NOUN	B
-	O	PUNCT	O
positive	O	ADJ	B
necrotizing	O	NOUN	B
glomerulonephritis	B-Disease	NOUN	I


Is	O	AUX	O
phenytoin	B-Chemical	NOUN	B
administration	O	NOUN	B
safe	O	ADJ	O
in	O	ADP	O
a	O	DET	O
hypothermic	B-Disease	ADJ	B
child	O	NOUN	B
?	O	PUNCT	O
A	O	DET	O
male	O	NOUN	B
neonate	O	NOUN	B
with	O	ADP	O
a	O	DET	O
Chiari	B-Disease	NOUN	B
malformation	I-Disease	NOUN	I
and	O	CCONJ	O
a	O	DET	O
leaking	O	VERB	B
myelomeningocoele	O	NOUN	B
underwent	O	VERB	O
ventriculoperitoneal	O	NOUN	B
shunt	O	NOUN	I
insertion	O	NOUN	B
followed	O	VERB	O
by	O	ADP	O
repair	O	NOUN	B
of	O	ADP	O
myelomeningocoele	O	NOUN	B
.	O	PUNCT	O


During	O	ADP	O
anaesthesia	O	NOUN	B
and	O	CCONJ	O
surgery	O	NOUN	B
,	O	PUNCT	O
he	O	PRON	O
inadvertently	O	ADV	O
became	O	VERB	O
moderately	O	ADV	B
hypothermic	B-Disease	ADJ	B
.	O	PUNCT	O


Intravenous	O	ADJ	B
phenytoin	B-Chemical	NOUN	O
was	O	AUX	O
administered	O	VERB	B
during	O	ADP	O
the	O	DET	O
later	O	ADJ	O
part	O	NOUN	O
of	O	ADP	O
the	O	DET	O
surgery	O	NOUN	B
for	O	ADP	O
seizure	B-Disease	NOUN	B
prophylaxis	O	NOUN	B
.	O	PUNCT	O


Following	O	VERB	O
phenytoin	B-Chemical	NOUN	B
administration	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
patient	O	NOUN	B
developed	O	VERB	O
acute	O	ADJ	B
severe	O	ADJ	I
bradycardia	B-Disease	NOUN	I
,	O	PUNCT	O
refractory	O	ADJ	B
to	O	PART	O
atropine	B-Chemical	NOUN	B
and	O	CCONJ	O
adrenaline	B-Chemical	NOUN	B
.	O	PUNCT	O


The	O	DET	O
cardiac	O	ADJ	B
depressant	O	ADJ	O
actions	O	NOUN	O
of	O	ADP	O
phenytoin	B-Chemical	NOUN	B
and	O	CCONJ	O
hypothermia	B-Disease	NOUN	B
can	O	AUX	O
be	O	AUX	O
additive	O	ADJ	B
.	O	PUNCT	O


Administration	O	NOUN	B
of	O	ADP	O
phenytoin	B-Chemical	NOUN	B
in	O	ADP	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
hypothermia	B-Disease	NOUN	B
may	O	AUX	O
lead	O	VERB	O
to	O	PART	O
an	O	DET	O
adverse	O	ADJ	B
cardiac	O	ADJ	I
event	O	NOUN	I
in	O	ADP	O
children	O	NOUN	B
.	O	PUNCT	O


As	O	ADP	O
phenytoin	B-Chemical	NOUN	B


Amisulpride	B-Chemical	NOUN	B
related	O	VERB	O
tic-like	B-Disease	ADJ	B
symptoms	I-Disease	NOUN	I
in	O	ADP	O
an	O	DET	O
adolescent	O	ADJ	B
schizophrenic	B-Disease	NOUN	B
.	O	PUNCT	O


Tic	B-Disease	ADJ	B
disorders	I-Disease	NOUN	I
can	O	AUX	O
be	O	AUX	O
effectively	O	ADV	O
treated	O	VERB	B
by	O	ADP	O
atypical	O	ADJ	B
antipsychotics	O	NOUN	B
such	O	ADJ	O
as	O	ADP	O
risperidone	B-Chemical	NOUN	B
,	O	PUNCT	O
olanzapine	B-Chemical	NOUN	B
and	O	CCONJ	O
ziprasidone	B-Chemical	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
there	O	PRON	O
are	O	AUX	O
two	O	NUM	O
case	O	NOUN	B
reports	O	NOUN	I
that	O	PRON	O
show	O	VERB	O
tic-like	B-Disease	ADJ	B
symptoms	I-Disease	NOUN	I
,	O	PUNCT	O
including	O	VERB	O
motor	O	NOUN	B
and	O	CCONJ	O
phonic	O	ADJ	B
variants	O	NOUN	B
,	O	PUNCT	O
occurring	O	VERB	O
during	O	ADP	O
treatment	O	NOUN	B
with	O	ADP	O
quetiapine	B-Chemical	NOUN	B
or	O	CCONJ	O
clozapine	B-Chemical	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
present	O	VERB	O
a	O	DET	O
15	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
girl	O	NOUN	I
schizophrenic	B-Disease	ADJ	B
who	O	PRON	O
developed	O	VERB	O
frequent	O	ADJ	B
involuntary	B-Disease	ADJ	B
eye-blinking	I-Disease	ADJ	B
movements	I-Disease	NOUN	I
after	O	ADP	O
5	O	NUM	O
months	O	NOUN	B
of	O	ADP	O
amisulpride	B-Chemical	NOUN	B
treatment	O	NOUN	B
(	O	PUNCT	O
1000	O	NUM	O
mg	O	NOUN	O
per	O	ADP	O
day	O	NOUN	B
).	O	PUNCT	O
The	O	DET	O
tic-like	B-Disease	ADJ	B
symptoms	I-Disease	NOUN	I
resolved	O	VERB	B
completely	O	ADV	O
after	O	ADP	O
we	O	PRON	O
reduced	O	VERB	B
the	O	DET	O
dose	O	NOUN	B
of	O	ADP	O
amisulpride	B-Chemical	NOUN	B
down	O	ADV	O
to	O	PART	O
800	O	NUM	O
mg	O	NOUN	O
per	O	ADP	O
day	O	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
her	O	PRON	O
psychosis	B-Disease	NOUN	B
recurred	O	VERB	B
after	O	ADP	O
the	O	DET	O
dose	O	NOUN	B
reduction	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
then	O	ADV	O
placed	O	VERB	O
her	O	PRON	O
on	O	ADP	O
an	O	DET	O
additional	O	ADJ	O
100	O	NUM	O
mg	O	NOUN	O
per	O	ADP	O
day	O	NOUN	B
of	O	ADP	O
quetiapine	B-Chemical	NOUN	B
.	O	PUNCT	O


She	O	PRON	O
has	O	AUX	O
been	O	AUX	O
in	O	ADP	O
complete	O	ADJ	O
remission	O	NOUN	B
under	O	ADP	O
the	O	DET	O
combined	O	ADJ	O
medications	O	NOUN	B
for	O	ADP	O
more	O	ADJ	O
than	O	ADP	O
one	O	NUM	O
year	O	NOUN	B
and	O	CCONJ	O
maintains	O	VERB	B
a	O	DET	O
fair	O	ADJ	O
role	O	NOUN	O
function	O	NOUN	O
.	O	PUNCT	O


No	O	ADV	O
more	O	ADV	O
tic-like	B-Disease	ADJ	B
symptoms	I-Disease	NOUN	I
or	O	CCONJ	O
other	O	ADJ	O
side	O	NOUN	B
effects	O	NOUN	I
have	O	AUX	O
been	O	AUX	O
reported	O	VERB	O
.	O	PUNCT	O


Together	O	ADV	O
with	O	ADP	O
previously	O	ADV	O
reported	O	VERB	O
cases	O	NOUN	B
,	O	PUNCT	O
our	O	PRON	O
patient	O	NOUN	B
suggests	O	VERB	O
that	O	SCONJ	O
tic-like	B-Disease	ADJ	B
symptoms	I-Disease	NOUN	I
might	O	AUX	O
occur	O	VERB	O
in	O	ADP	O
certain	O	ADJ	O
vulnerable	O	ADJ	B
individuals	O	NOUN	B
during	O	ADP	O
treatment	O	NOUN	B
with	O	ADP	O
atypical	O	ADJ	B
antipsychotics	O	NOUN	B
such	O	ADJ	O
as	O	ADP	O
quetiapine	B-Chemical	NOUN	B
,	O	PUNCT	O
clozapine	B-Chemical	NOUN	B
,	O	PUNCT	O
or	O	CCONJ	O
amisulpride	B-Chemical	NOUN	B


Comparison	O	NOUN	B
of	O	ADP	O
developmental	O	ADJ	B
toxicology	O	NOUN	B
of	O	ADP	O
aspirin	B-Chemical	NOUN	B
(	O	PUNCT	O
acetylsalicylic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
)	O	PUNCT	O
in	O	ADP	O
rats	O	NOUN	B
using	O	VERB	O
selected	O	VERB	O
dosing	O	NOUN	B
paradigms	O	NOUN	B
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
:	O	PUNCT	O
Analysis	O	NOUN	B
of	O	ADP	O
the	O	DET	O
literature	O	NOUN	B
for	O	ADP	O
nonsteroidal	O	ADJ	B
anti	O	ADJ	I
-	O	PUNCT	O
inflammatory	O	ADJ	B
drugs	O	NOUN	I
(	O	PUNCT	O
NSAIDs	O	NOUN	B
)	O	PUNCT	O
suggests	O	VERB	O
that	O	SCONJ	O
a	O	DET	O
low	O	ADJ	B
incidence	O	NOUN	B
of	O	ADP	O
developmental	B-Disease	ADJ	B
anomalies	I-Disease	NOUN	B
occurs	O	VERB	O
in	O	ADP	O
rats	O	NOUN	B
given	O	VERB	O
NSAIDs	O	NOUN	B
on	O	ADP	O
specific	O	ADJ	O
days	O	NOUN	B
during	O	ADP	O
organogenesis	O	NOUN	B
.	O	PUNCT	O


Aspirin	B-Chemical	NOUN	B
(	O	PUNCT	O
acetylsalicylic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
[	O	PUNCT	O
ASA	B-Chemical	PROPN	B
]),	O	NOUN	O
an	O	DET	O
irreversible	O	ADJ	B
cyclooxygenase	O	NOUN	O
1	O	NUM	O
and	O	CCONJ	O
2	O	NUM	O
inhibitor	O	NOUN	B
,	O	PUNCT	O
induces	O	VERB	O
developmental	B-Disease	ADJ	B
anomalies	I-Disease	NOUN	B
when	O	SCONJ	O
administered	O	VERB	B
to	O	PART	O
Wistar	O	ADJ	B
rats	O	NOUN	I
on	O	ADP	O
gestational	O	ADJ	B
day	O	NOUN	I
(	O	PUNCT	O
GD	O	NOUN	B
)	O	PUNCT	O
9	O	NUM	O
,	O	PUNCT	O
10	O	NUM	O
,	O	PUNCT	O
or	O	CCONJ	O
11	O	NUM	O
(	O	PUNCT	O
Kimmel	O	PROPN	B
CA	O	PROPN	I
,	O	PUNCT	O
Wilson	O	PROPN	B
JG	O	PROPN	I
,	O	PUNCT	O
Schumacher	O	PROPN	O
HJ	O	PROPN	B
.	O	PUNCT	O


Teratology	O	NOUN	O
4	O	NUM	O
:	O	PUNCT	O
15	O	NUM	O
-	O	SYM	O
24	O	NUM	O
,	O	PUNCT	O
1971	O	NUM	O
).	O	PUNCT	O
There	O	PRON	O
are	O	AUX	O
no	O	DET	O
published	O	VERB	B
ASA	B-Chemical	NOUN	O
studies	O	NOUN	B
using	O	VERB	O
the	O	DET	O
multiple	O	ADJ	B
dosing	O	NOUN	B
paradigm	O	NOUN	B
of	O	ADP	O
GDs	O	NOUN	B
6	O	NUM	O
to	O	PART	O
17	O	NUM	O
.	O	PUNCT	O


Objectives	O	NOUN	O
of	O	ADP	O
the	O	DET	O
current	O	ADJ	O
study	O	NOUN	B
were	O	AUX	O
to	O	PART	O
compare	O	VERB	B
results	O	NOUN	B
between	O	ADP	O
Sprague	O	PROPN	B
-	O	PUNCT	O
Dawley	O	PROPN	B
(	O	PUNCT	O
SD	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
Wistar	O	PROPN	B
strains	O	NOUN	I
when	O	SCONJ	O
ASA	B-Chemical	NOUN	B
is	O	AUX	O
administered	O	VERB	B
on	O	ADP	O
GD	O	NOUN	B
9	O	NUM	O
,	O	PUNCT	O
10	O	NUM	O
,	O	PUNCT	O
or	O	CCONJ	O
11	O	NUM	O
;	O	PUNCT	O
to	O	PART	O
compare	O	VERB	B
the	O	DET	O
malformation	O	NOUN	B
patterns	O	NOUN	B
following	O	VERB	O
single	O	ADJ	O
and	O	CCONJ	O
multiple	O	ADJ	B
dosings	O	NOUN	B
during	O	ADP	O
organogenesis	O	NOUN	B
in	O	ADP	O
SD	O	NOUN	B
rats	O	NOUN	B
;	O	PUNCT	O
and	O	CCONJ	O
to	O	PART	O
test	O	VERB	O
the	O	DET	O
hypothesis	O	NOUN	B
that	O	SCONJ	O
maternal	O	ADJ	B
gastrointestinal	B-Disease	ADJ	B
toxicity	I-Disease	NOUN	B
confounds	O	VERB	B
the	O	DET	O
detection	O	NOUN	B
of	O	ADP	O
low	O	ADJ	B
incidence	O	NOUN	O
malformations	B-Disease	NOUN	O
with	O	ADP	O
ASA	B-Chemical	NOUN	B
when	O	SCONJ	O
a	O	DET	O
multiple	O	ADJ	B
dosing	O	NOUN	B
paradigm	O	NOUN	B
is	O	AUX	O
used	O	VERB	O
.	O	PUNCT	O


METHODS	O	NOUN	O
:	O	PUNCT	O
ASA	B-Chemical	NOUN	B
was	O	AUX	O
administered	O	VERB	B
as	O	ADP	O
a	O	DET	O
single	O	ADJ	B
dose	O	NOUN	I
on	O	ADP	O
GD	O	NOUN	B
9	O	NUM	O
(	O	PUNCT	O
0	O	NUM	O
,	O	PUNCT	O
250	O	NUM	O
,	O	PUNCT	O
500	O	NUM	O
,	O	PUNCT	O
or	O	CCONJ	O
625	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
),	O	PUNCT	O
10	O	NUM	O
(	O	PUNCT	O
0	O	NUM	O
,	O	PUNCT	O
500	O	NUM	O
,	O	PUNCT	O
625	O	NUM	O
,	O	PUNCT	O
or	O	CCONJ	O
750	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
),	O	PUNCT	O
or	O	CCONJ	O
11	O	NUM	O
(	O	PUNCT	O
0	O	NUM	O
,	O	PUNCT	O
500	O	NUM	O
,	O	PUNCT	O
750	O	NUM	O
,	O	PUNCT	O
or	O	CCONJ	O
1000	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
from	O	ADP	O
GD	O	NOUN	B
6	O	NUM	O
to	O	PART	O
GD	O	NOUN	B
17	O	NUM	O
(	O	PUNCT	O
0	O	NUM	O
,	O	PUNCT	O
50	O	NUM	O
,	O	PUNCT	O
125	O	NUM	O
,	O	PUNCT	O
or	O	CCONJ	O
250	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	O
a	O	DET	O
day	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
multiple	O	ADJ	B
dose	O	NOUN	I
study	O	NOUN	I
to	O	PART	O
SD	O	NOUN	B
rats	O	NOUN	B
.	O	PUNCT	O


Animals	O	NOUN	B
were	O	AUX	O
killed	O	VERB	B
on	O	ADP	O
GD	O	NOUN	B
21	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
fetuses	O	NOUN	B
were	O	AUX	O
examined	O	VERB	O
viscerally	O	ADV	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
The	O	DET	O
literature	O	NOUN	B
evaluation	O	NOUN	B
suggested	O	VERB	O
that	O	SCONJ	O
NSAIDs	O	NOUN	B
induce	O	VERB	O
ventricular	B-Disease	ADJ	B
septal	I-Disease	ADJ	I
defects	I-Disease	NOUN	I
(	O	PUNCT	O
VSDs	B-Disease	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
midline	B-Disease	NOUN	B
defects	I-Disease	NOUN	I
(	O	PUNCT	O
MDs	B-Disease	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
rats	O	NOUN	B
and	O	CCONJ	O
diaphragmatic	B-Disease	ADJ	B
hernia	I-Disease	NOUN	I
(	O	PUNCT	O
DH	B-Disease	NOUN	B
),	O	PUNCT	O
MDs	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
VSDs	B-Disease	NOUN	B
in	O	ADP	O
rabbits	O	NOUN	B
(	O	PUNCT	O
Cook	O	PROPN	B
JC	O	PROPN	I
et	O	X	O
al	O	X	O
.,	O	NOUN	O
2003	O	NUM	O
);	O	ADJ	B
hence	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
focused	O	VERB	O
on	O	ADP	O
these	O	DET	O
malformations	B-Disease	NOUN	B
,	O	PUNCT	O
even	O	ADV	O
though	O	SCONJ	O
ASA	B-Chemical	NOUN	B
induces	O	VERB	B
several	O	ADJ	O
other	O	ADJ	O
low	O	ADJ	B
-	O	PUNCT	O
incidence	O	NOUN	B
malformations	B-Disease	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
single	O	ADJ	B
dose	O	NOUN	I
studies	O	NOUN	I
,	O	PUNCT	O
DH	B-Disease	NOUN	B
,	O	PUNCT	O
MD	B-Disease	PROPN	B
,	O	PUNCT	O
and	O	CCONJ	O
VSD	B-Disease	PROPN	B
were	O	AUX	O
induced	O	VERB	B
on	O	ADP	O
GDs	O	NOUN	B
9	O	NUM	O
and	O	CCONJ	O
10	O	NUM	O
.	O	PUNCT	O


VSD	B-Disease	PROPN	B
also	O	ADV	O
was	O	AUX	O
noted	O	VERB	O
following	O	VERB	O
treatment	O	NOUN	B
on	O	ADP	O
GD	O	NOUN	B
11	O	NUM	O
.	O	PUNCT	O


In	O	ADP	O
contrast	O	NOUN	O
,	O	PUNCT	O
DH	B-Disease	NOUN	B
and	O	CCONJ	O
MD	B-Disease	PROPN	B
were	O	AUX	O
noted	O	VERB	O
in	O	ADP	O
the	O	DET	O
multiple	O	ADJ	B
dose	O	NOUN	I
study	O	NOUN	I
design	O	NOUN	B
only	O	ADV	O
in	O	ADP	O
the	O	DET	O
high	O	ADJ	B
-	O	PUNCT	O
dose	O	NOUN	B
group	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
VSD	B-Disease	PROPN	B
was	O	AUX	O
noted	O	VERB	O
across	O	ADP	O
all	O	DET	O
dose	O	NOUN	B
groups	O	NOUN	I
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
:	O	PUNCT	O
High	O	ADJ	O
concordance	O	NOUN	B
in	O	ADP	O
major	O	ADJ	O
developmental	B-Disease	ADJ	B
anomalies	I-Disease	NOUN	B
between	O	ADP	O
Wistar	O	PROPN	B
and	O	CCONJ	O
SD	O	NOUN	B
rats	O	NOUN	B
were	O	AUX	O
noted	O	VERB	O
with	O	ADP	O
the	O	DET	O
exception	O	NOUN	O
of	O	ADP	O
VSD	B-Disease	PROPN	B
in	O	ADP	O
the	O	DET	O
SD	O	NOUN	B
rats	O	NOUN	B
and	O	CCONJ	O
hydrocephalus	B-Disease	NOUN	B
in	O	ADP	O
the	O	DET	O
Wistar	O	PROPN	B
rats	O	NOUN	I
.	O	PUNCT	O


Variations	O	NOUN	B
and	O	CCONJ	O
malformations	B-Disease	NOUN	B
were	O	AUX	O
similar	O	ADJ	O
when	O	SCONJ	O
ASA	B-Chemical	NOUN	B
was	O	AUX	O
administered	O	VERB	B
as	O	ADP	O
a	O	DET	O
single	O	ADJ	B
dose	O	NOUN	I
or	O	CCONJ	O
during	O	ADP	O
the	O	DET	O
period	O	NOUN	B
of	O	ADP	O
organogenesis	O	NOUN	B
(	O	PUNCT	O
GDs	O	NOUN	B
6	O	NUM	O
to	O	PART	O
17	O	NUM	O
).	O	PUNCT	O
It	O	PRON	O
was	O	AUX	O
also	O	ADV	O
evident	O	ADJ	O
that	O	SCONJ	O
,	O	PUNCT	O
by	O	ADP	O
titrating	O	VERB	O
the	O	DET	O
dose	O	NOUN	B
to	O	PART	O
achieve	O	VERB	O
a	O	DET	O
maximum	O	NOUN	O
tolerated	O	ADJ	O
dose	O	NOUN	O
,	O	PUNCT	O
malformations	B-Disease	NOUN	B
that	O	PRON	O
normally	O	ADV	O
occur	O	VERB	O
at	O	ADP	O
low	O	ADJ	B
incidence	O	NOUN	B
,	O	PUNCT	O
as	O	ADP	O
reported	O	VERB	O
from	O	ADP	O
previous	O	ADJ	O
single	O	ADJ	B
dose	O	NOUN	I
studies	O	NOUN	I
,	O	PUNCT	O
could	O	AUX	O
also	O	ADV	O
be	O	AUX	O
induced	O	VERB	B
with	O	ADP	O
ASA	B-Chemical	NOUN	B


Torsade	B-Disease	NOUN	B
de	I-Disease	X	I
pointes	I-Disease	X	I
induced	O	VERB	B
by	O	ADP	O
metoclopramide	B-Chemical	NOUN	B
in	O	ADP	O
an	O	DET	O
elderly	O	ADJ	B
woman	O	NOUN	I
with	O	ADP	O
preexisting	O	VERB	O
complete	O	ADJ	O
left	B-Disease	ADJ	B
bundle	I-Disease	NOUN	I
branch	I-Disease	NOUN	I
block	I-Disease	NOUN	I
.	O	PUNCT	O


There	O	PRON	O
is	O	AUX	O
a	O	DET	O
growing	O	VERB	O
list	O	NOUN	O
of	O	ADP	O
drugs	O	NOUN	B
implicated	O	VERB	O
in	O	ADP	O
acquired	O	VERB	O
long	B-Disease	ADJ	B
QT	I-Disease	NOUN	I
syndrome	I-Disease	NOUN	I
and	O	CCONJ	O
torsade	B-Disease	NOUN	B
de	I-Disease	X	I
pointes	I-Disease	NOUN	I
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
torsadogenic	O	ADJ	B
potential	O	NOUN	B
of	O	ADP	O
metoclopramide	B-Chemical	NOUN	B
,	O	PUNCT	O
a	O	DET	O
commonly	O	ADV	O
used	O	VERB	O
antiemetic	O	ADJ	B
and	O	CCONJ	O
prokinetic	O	ADJ	B
drug	O	NOUN	I
,	O	PUNCT	O
has	O	AUX	O
not	O	PART	O
been	O	AUX	O
reported	O	VERB	O
in	O	ADP	O
the	O	DET	O
literature	O	NOUN	B
,	O	PUNCT	O
despite	O	SCONJ	O
its	O	PRON	O
chemical	O	NOUN	B
similarity	O	NOUN	I
to	O	PART	O
procainamide	B-Chemical	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
on	O	ADP	O
a	O	DET	O
92	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
woman	O	NOUN	B
with	O	ADP	O
preexisting	O	VERB	O
complete	O	ADJ	O
left	B-Disease	ADJ	B
bundle	I-Disease	NOUN	I
branch	I-Disease	NOUN	I
block	I-Disease	NOUN	I
who	O	PRON	O
developed	O	VERB	O
torsade	B-Disease	NOUN	B
de	I-Disease	X	I
pointes	I-Disease	NOUN	I
after	O	ADP	O
intravenous	O	ADJ	B
and	O	CCONJ	O
oral	O	ADJ	B
administration	O	NOUN	I
of	O	ADP	O
metoclopramide	B-Chemical	NOUN	B
.	O	PUNCT	O


This	O	DET	O
patient	O	NOUN	B
also	O	ADV	O
developed	O	VERB	O
torsade	B-Disease	NOUN	B
de	I-Disease	X	I
pointes	I-Disease	NOUN	I
when	O	SCONJ	O
cisapride	B-Chemical	NOUN	B
and	O	CCONJ	O
erythromycin	B-Chemical	NOUN	B
were	O	AUX	O
given	O	VERB	O
simultaneously	O	ADV	B
.	O	PUNCT	O


These	O	DET	O
two	O	NUM	O
episodes	O	NOUN	B
were	O	AUX	O
suppressed	O	VERB	B
successfully	O	ADV	O
after	O	ADP	O
discontinuing	O	VERB	B
the	O	DET	O
offending	O	NOUN	B
drugs	O	NOUN	I
and	O	CCONJ	O
administering	O	VERB	B
class	O	NOUN	B
IB	O	NOUN	I
drugs	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
is	O	AUX	O
the	O	DET	O
first	O	ADJ	O
documentation	O	NOUN	B
that	O	SCONJ	O
metoclopramide	B-Chemical	NOUN	B
provokes	O	VERB	O
torsade	B-Disease	NOUN	B
de	I-Disease	X	I
pointes	I-Disease	X	I
clinically	O	ADV	B
.	O	PUNCT	O


Metoclopramide	B-Chemical	NOUN	B
should	O	AUX	O
be	O	AUX	O
used	O	VERB	O
cautiously	O	ADV	O
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
a	O	DET	O
risk	O	NOUN	B
of	O	ADP	O
torsade	B-Disease	X	B
de	I-Disease	X	I
pointes	I-Disease	X	I


Apomorphine	B-Chemical	NOUN	B
:	O	PUNCT	O
an	O	DET	O
underutilized	O	ADJ	O
therapy	O	NOUN	B
for	O	ADP	O
Parkinson's	B-Disease	ADJ	B
disease	I-Disease	NOUN	I
.	O	PUNCT	O


Apomorphine	B-Chemical	NOUN	B
was	O	AUX	O
the	O	DET	O
first	O	ADJ	O
dopaminergic	O	ADJ	B
drug	O	NOUN	O
ever	O	ADV	O
used	O	VERB	O
to	O	PART	O
treat	O	VERB	B
symptoms	O	NOUN	B
of	O	ADP	O
Parkinson's	B-Disease	ADJ	B
disease	I-Disease	NOUN	I
.	O	PUNCT	O


While	O	SCONJ	O
powerful	O	ADJ	O
antiparkinsonian	O	ADJ	B
effects	O	NOUN	O
had	O	AUX	O
been	O	AUX	O
observed	O	VERB	O
as	O	ADV	O
early	O	ADV	O
as	O	ADP	O
1951	O	NUM	O
,	O	PUNCT	O
the	O	DET	O
potential	O	NOUN	B
of	O	ADP	O
treating	O	VERB	B
fluctuating	O	VERB	B
Parkinson's	B-Disease	ADJ	O
disease	I-Disease	NOUN	B
by	O	ADP	O
subcutaneous	O	ADJ	B
administration	O	NOUN	I
of	O	ADP	O
apomorphine	B-Chemical	NOUN	B
has	O	AUX	O
only	O	ADV	O
recently	O	ADV	O
become	O	VERB	O
the	O	DET	O
subject	O	NOUN	B
of	O	ADP	O
systematic	O	ADJ	B
study	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
number	O	NOUN	O
of	O	ADP	O
small	O	ADJ	O
scale	O	NOUN	O
clinical	O	ADJ	O
trials	O	NOUN	O
have	O	AUX	O
unequivocally	O	ADV	O
shown	O	VERB	O
that	O	SCONJ	O
intermittent	O	ADJ	B
subcutaneous	O	ADJ	B
apomorphine	B-Chemical	NOUN	I
injections	O	NOUN	I
produce	O	VERB	O
antiparkinsonian	O	ADJ	B
benefit	O	NOUN	B
close	O	NOUN	O
if	O	SCONJ	O
not	O	PART	O
identical	O	ADJ	O
to	O	PART	O
that	O	DET	O
seen	O	VERB	O
with	O	ADP	O
levodopa	B-Chemical	NOUN	B
and	O	CCONJ	O
that	O	SCONJ	O
apomorphine	B-Chemical	NOUN	B
rescue	O	NOUN	I
injections	O	NOUN	B
can	O	AUX	O
reliably	O	ADV	O
revert	O	VERB	O
off	O	ADP	B
-	O	PUNCT	O
periods	O	NOUN	B
even	O	ADV	O
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
complex	O	NOUN	B
on	O	ADP	O
-	O	PUNCT	O
off	O	ADP	B
motor	O	NOUN	B
swings	O	NOUN	I
.	O	PUNCT	O


Continuous	O	ADJ	B
subcutaneous	O	ADJ	B
apomorphine	B-Chemical	NOUN	O
infusions	O	NOUN	B
can	O	AUX	O
reduce	O	VERB	O
daily	O	ADV	B
off	O	ADJ	B
-	O	PUNCT	O
time	O	NOUN	B
by	O	ADP	O
more	O	ADJ	O
than	O	ADP	O
50	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
this	O	DET	O
group	O	NOUN	B
of	O	ADP	O
patients	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
appears	O	VERB	O
to	O	PART	O
be	O	AUX	O
a	O	DET	O
stronger	O	ADJ	O
effect	O	NOUN	B
than	O	ADP	O
that	O	DET	O
generally	O	ADV	O
seen	O	VERB	O
with	O	ADP	O
add	O	VERB	O
-	O	PUNCT	O
on	O	ADP	O
therapy	O	NOUN	B
with	O	ADP	O
oral	O	ADJ	B
dopamine	B-Chemical	NOUN	O
agonists	O	NOUN	O
or	O	CCONJ	O
COMT	O	NOUN	B
inhibitors	O	NOUN	B
.	O	PUNCT	O


Extended	O	VERB	O
follow	O	VERB	B
-	O	PUNCT	O
up	O	ADP	O
studies	O	NOUN	B
of	O	ADP	O
up	O	ADV	O
to	O	PART	O
8	O	NUM	O
years	O	NOUN	B
have	O	AUX	O
demonstrated	O	VERB	O
long	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
persistence	O	NOUN	B
of	O	ADP	O
apomorphine	B-Chemical	NOUN	B
efficacy	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
,	O	PUNCT	O
there	O	PRON	O
is	O	AUX	O
convincing	O	VERB	O
clinical	O	ADJ	B
evidence	O	NOUN	I
that	O	SCONJ	O
monotherapy	O	NOUN	B
with	O	ADP	O
continuous	O	ADJ	B
subcutaneous	O	ADJ	B
apomorphine	B-Chemical	NOUN	O
infusions	O	NOUN	B
is	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
marked	O	ADJ	O
reductions	O	NOUN	B
of	O	ADP	O
preexisting	O	VERB	O
levodopa	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
dyskinesias	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
main	O	ADJ	O
side	O	NOUN	B
effects	O	NOUN	I
of	O	ADP	O
subcutaneous	O	ADJ	B
apomorphine	B-Chemical	NOUN	O
treatment	O	NOUN	O
are	O	AUX	O
related	O	ADJ	O
to	O	PART	O
cutaneous	O	ADJ	B
tolerability	O	NOUN	B
problems	O	NOUN	O
,	O	PUNCT	O
whereas	O	SCONJ	O
sedation	O	NOUN	B
and	O	CCONJ	O
psychiatric	B-Disease	ADJ	B
complications	O	NOUN	I
play	O	VERB	O
a	O	DET	O
lesser	O	ADJ	O
role	O	NOUN	O
.	O	PUNCT	O


Given	O	VERB	O
the	O	DET	O
marked	O	ADJ	O
degree	O	NOUN	B
of	O	ADP	O
efficacy	O	NOUN	B
of	O	ADP	O
subcutaneous	O	ADJ	B
apomorphine	B-Chemical	NOUN	O
treatment	O	NOUN	O
in	O	ADP	O
fluctuating	O	VERB	B
Parkinson's	B-Disease	ADJ	O
disease	I-Disease	NOUN	B


Fatal	O	ADJ	B
excited	O	ADJ	B
delirium	B-Disease	NOUN	I
following	O	VERB	O
cocaine	B-Chemical	NOUN	B
use	O	NOUN	I
:	O	PUNCT	O
epidemiologic	O	ADJ	B
findings	O	NOUN	I
provide	O	VERB	O
new	O	ADJ	O
evidence	O	NOUN	B
for	O	ADP	O
mechanisms	O	NOUN	B
of	O	ADP	O
cocaine	B-Chemical	NOUN	B
toxicity	B-Disease	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
describe	O	VERB	O
an	O	DET	O
outbreak	O	NOUN	B
of	O	ADP	O
deaths	O	NOUN	B
from	O	ADP	O
cocaine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
excited	O	ADJ	B
delirium	B-Disease	NOUN	I
(	O	PUNCT	O
EDDs	B-Disease	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
Dade	O	PROPN	B
County	O	PROPN	I
,	O	PUNCT	O
Florida	O	PROPN	B
between	O	ADP	O
1979	O	NUM	O
and	O	CCONJ	O
1990	O	NUM	O
.	O	PUNCT	O


From	O	ADP	O
a	O	DET	O
registry	O	NOUN	B
of	O	ADP	O
all	O	DET	O
cocaine	B-Chemical	NOUN	B
-	O	PUNCT	O
related	O	VERB	B
deaths	O	NOUN	B
in	O	ADP	O
Dade	O	PROPN	B
County	O	PROPN	I
,	O	PUNCT	O
Florida	O	PROPN	B
,	O	PUNCT	O
from	O	ADP	O
1969	O	NUM	O
-	O	PUNCT	O
1990	O	NUM	O
,	O	PUNCT	O
58	O	NUM	O
EDDs	B-Disease	NOUN	B
were	O	AUX	O
compared	O	VERB	B
with	O	ADP	O
125	O	NUM	O
victims	O	NOUN	B
of	O	ADP	O
accidental	O	ADJ	B
cocaine	B-Chemical	NOUN	I
overdose	B-Disease	NOUN	B
without	O	ADP	O
excited	O	ADJ	B
delirium	B-Disease	NOUN	I
.	O	PUNCT	O


Compared	O	VERB	B
with	O	ADP	O
controls	O	NOUN	B
,	O	PUNCT	O
EDDs	B-Disease	NOUN	B
were	O	AUX	O
more	O	ADV	O
frequently	O	ADV	O
black	O	ADJ	B
,	O	PUNCT	O
male	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
younger	O	ADJ	B
.	O	PUNCT	O


They	O	PRON	O
were	O	AUX	O
less	O	ADV	O
likely	O	ADJ	O
to	O	PART	O
have	O	AUX	O
a	O	DET	O
low	O	ADJ	B
body	O	NOUN	B
mass	O	NOUN	I
index	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
more	O	ADV	O
likely	O	ADJ	O
to	O	PART	O
have	O	AUX	O
died	O	VERB	B
in	O	ADP	O
police	O	NOUN	B
custody	O	NOUN	B
,	O	PUNCT	O
to	O	PART	O
have	O	AUX	O
received	O	VERB	O
medical	O	ADJ	B
treatment	O	NOUN	I
immediately	O	ADV	O
before	O	ADP	O
death	O	NOUN	B
,	O	PUNCT	O
to	O	PART	O
have	O	AUX	O
survived	O	VERB	O
for	O	ADP	O
a	O	DET	O
longer	O	ADJ	O
period	O	NOUN	B
,	O	PUNCT	O
to	O	PART	O
have	O	AUX	O
developed	O	VERB	O
hyperthermia	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
to	O	PART	O
have	O	AUX	O
died	O	VERB	B
in	O	ADP	O
summer	O	NOUN	B
months	O	NOUN	B
.	O	PUNCT	O


EDDs	B-Disease	NOUN	B
had	O	AUX	O
concentrations	O	NOUN	B
of	O	ADP	O
cocaine	B-Chemical	NOUN	B
and	O	CCONJ	O
benzoylecgonine	B-Chemical	NOUN	B
in	O	ADP	O
autopsy	O	ADJ	B
blood	O	NOUN	B
that	O	PRON	O
were	O	AUX	O
similar	O	ADJ	O
to	O	PART	O
those	O	DET	O
for	O	ADP	O
controls	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
epidemiologic	O	ADJ	B
findings	O	NOUN	B
are	O	AUX	O
most	O	ADV	O
consistent	O	ADJ	B
with	O	ADP	I
the	O	DET	O
hypothesis	O	NOUN	B
that	O	SCONJ	O
chronic	O	ADJ	B
cocaine	B-Chemical	NOUN	I
use	O	NOUN	O
disrupts	O	VERB	O
dopaminergic	O	ADJ	B
function	O	NOUN	I
and	O	CCONJ	O
,	O	PUNCT	O
when	O	SCONJ	O
coupled	O	VERB	B
with	O	ADP	O
recent	O	ADJ	O
cocaine	B-Chemical	NOUN	B
use	O	NOUN	O
,	O	PUNCT	O
may	O	AUX	O
precipitate	O	VERB	B
agitation	B-Disease	NOUN	B
,	O	PUNCT	O
delirium	B-Disease	NOUN	B
,	O	PUNCT	O
aberrant	O	ADJ	B
thermoregulation	O	NOUN	B
,	O	PUNCT	O
rhabdomyolysis	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
sudden	B-Disease	ADJ	B
death	I-Disease	NOUN	I


Heparin	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
thrombocytopenia	B-Disease	NOUN	B
,	O	PUNCT	O
thrombosis	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
hemorrhage	B-Disease	NOUN	B
.	O	PUNCT	O


Sixty	O	PROPN	B
-	O	PUNCT	O
two	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
a	O	DET	O
heparin	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
thrombocytopenia	B-Disease	NOUN	B
are	O	AUX	O
reported	O	VERB	O
.	O	PUNCT	O


Clinical	O	ADJ	B
manifestations	O	NOUN	O
of	O	ADP	O
this	O	DET	O
disorder	O	NOUN	B
include	O	VERB	O
hemorrhage	B-Disease	NOUN	B
or	O	CCONJ	O
,	O	PUNCT	O
more	O	ADV	O
frequently	O	ADV	O
,	O	PUNCT	O
thromboembolic	B-Disease	ADJ	B
events	O	NOUN	O
in	O	ADP	O
patients	O	NOUN	B
receiving	O	VERB	O
heparin	B-Chemical	NOUN	B
.	O	PUNCT	O


Laboratory	O	NOUN	B
testing	O	NOUN	I
has	O	AUX	O
revealed	O	VERB	B
a	B-Disease	DET	O
falling	I-Disease	VERB	B
platelet	I-Disease	NOUN	B
count	I-Disease	NOUN	I
,	O	PUNCT	O
increased	O	VERB	B
resistance	O	NOUN	B
to	O	PART	O
heparin	B-Chemical	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
aggregation	O	NOUN	B
of	O	ADP	O
platelets	O	NOUN	B
by	O	ADP	O
the	O	DET	O
patient	O	NOUN	B
'	O	PART	O
s	O	NOUN	O
plasma	O	NOUN	B
when	O	SCONJ	O
heparin	B-Chemical	NOUN	B
is	O	AUX	O
added	O	VERB	O
.	O	PUNCT	O


Immunologic	O	ADJ	B
testing	O	NOUN	I
has	O	AUX	O
demonstrated	O	VERB	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
a	O	DET	O
heparin	B-Chemical	NOUN	B
-	O	PUNCT	O
dependent	O	ADJ	B
platelet	O	NOUN	B
membrane	O	NOUN	I
antibody	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
20	O	NUM	O
deaths	O	NOUN	B
,	O	PUNCT	O
52	O	NUM	O
hemorrhagic	B-Disease	ADJ	B
and	I-Disease	CCONJ	O
thromboembolic	I-Disease	ADJ	B
complications	I-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
21	O	NUM	O
surgical	O	ADJ	B
procedures	O	NOUN	I
to	O	PART	O
manage	O	VERB	O
the	O	DET	O
complications	O	NOUN	B
confirm	O	VERB	B
the	O	DET	O
seriousness	O	NOUN	B
of	O	ADP	O
the	O	DET	O
disorder	O	NOUN	B
.	O	PUNCT	O


Specific	O	ADJ	O
risk	O	NOUN	B
factors	O	NOUN	I
have	O	AUX	O
not	O	PART	O
been	O	AUX	O
identified	O	VERB	B
;	O	PUNCT	O
therefore	O	ADV	O
,	O	PUNCT	O
all	O	DET	O
patients	O	NOUN	B
receiving	O	VERB	O
heparin	B-Chemical	NOUN	B
should	O	AUX	O
be	O	AUX	O
monitored	O	VERB	B
.	O	PUNCT	O


If	O	SCONJ	O
the	O	DET	O
platelet	O	NOUN	B
count	O	NOUN	I
falls	O	VERB	I
to	O	ADP	O
less	O	ADJ	O
than	O	ADP	O
100	O	NUM	O
,	O	PUNCT	O
000	O	NUM	O
/	O	SYM	O
mm3	O	NOUN	B
,	O	PUNCT	O
while	O	SCONJ	O
the	O	DET	O
patient	O	NOUN	B
is	O	AUX	O
receiving	O	VERB	O
heparin	B-Chemical	NOUN	B
,	O	PUNCT	O
platelet	B-Disease	NOUN	B
aggregation	I-Disease	NOUN	I
testing	O	NOUN	I
,	O	PUNCT	O
using	O	VERB	O
the	O	DET	O
patient	O	NOUN	B
'	O	PART	O
s	O	NOUN	O
plasma	O	NOUN	B
,	O	PUNCT	O
is	O	AUX	O
indicated	O	VERB	O
.	O	PUNCT	O


Management	O	NOUN	B
consists	O	VERB	O
of	O	ADP	O
cessation	O	NOUN	B
of	O	ADP	O
heparin	B-Chemical	NOUN	B


Cardiac	B-Disease	ADJ	B
toxicity	I-Disease	NOUN	B
of	O	ADP	O
5-fluorouracil	B-Chemical	NOUN	B
.	O	PUNCT	O


Report	O	NOUN	B
of	O	ADP	O
a	O	DET	O
case	O	NOUN	B
of	O	ADP	O
spontaneous	O	ADJ	B
angina	B-Disease	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
a	O	DET	O
case	O	NOUN	B
of	O	ADP	O
a	O	DET	O
patient	O	NOUN	B
with	O	ADP	O
colon	B-Disease	NOUN	B
carcinoma	I-Disease	NOUN	I
and	O	CCONJ	O
liver	O	NOUN	B
metastasis	B-Disease	NOUN	I
who	O	PRON	O
presented	O	VERB	O
chest	B-Disease	ADJ	B
pain	I-Disease	NOUN	I
after	O	ADP	O
5-fluorouracil	B-Chemical	NOUN	B
(	O	PUNCT	O
5-FU	B-Chemical	NOUN	B
)	O	PUNCT	O
administration	O	NOUN	B
.	O	PUNCT	O


Clinical	O	ADJ	B
electrocardiographic	O	ADJ	O
evolution	O	NOUN	O
was	O	AUX	O
similar	O	ADJ	O
to	O	PART	O
that	O	DET	O
observed	O	VERB	B
in	O	ADP	O
Prinzmetal's	B-Disease	NOUN	B
angina	I-Disease	ADJ	I
,	O	PUNCT	O
and	O	CCONJ	O
chest	B-Disease	ADJ	B
pain	I-Disease	NOUN	I
promptly	O	ADV	O
resolved	O	VERB	B
with	O	ADP	O
nifedipine	B-Chemical	NOUN	B
.	O	PUNCT	O


These	O	DET	O
data	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
coronary	B-Disease	ADJ	B
spasm	I-Disease	NOUN	I
may	O	AUX	O
be	O	AUX	O
the	O	DET	O
cause	O	NOUN	O
of	O	ADP	O
cardiotoxicity	B-Disease	NOUN	B
due	O	ADJ	O
to	O	PART	O
5-FU	B-Chemical	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
that	O	SCONJ	O
calcium	B-Chemical	NOUN	B
antagonists	O	NOUN	I
may	O	AUX	O
probably	O	ADV	O
be	O	AUX	O
used	O	VERB	O
in	O	ADP	O
the	O	DET	O
prevention	O	NOUN	B
or	O	CCONJ	O
treatment	O	NOUN	B
of	O	ADP	O
5-FU	B-Chemical	NOUN	B
cardiotoxicity	B-Disease	NOUN	B


Toxicity	B-Disease	NOUN	B
due	O	ADP	O
to	O	PART	O
remission	O	NOUN	B
inducing	O	VERB	O
drugs	O	NOUN	B
in	O	ADP	O
rheumatoid	B-Disease	ADJ	B
arthritis	I-Disease	NOUN	I
.	O	PUNCT	O


Association	O	NOUN	B
with	O	ADP	O
HLA	O	NOUN	B
-	O	PUNCT	O
B35	O	NOUN	B
and	O	CCONJ	O
Cw4	O	NOUN	B
antigens	O	NOUN	B
.	O	PUNCT	O


Twenty	O	NUM	B
-	O	PUNCT	O
five	O	NUM	B
patients	O	NOUN	B
with	O	ADP	O
rheumatoid	B-Disease	ADJ	B
arthritis	I-Disease	NOUN	I
(	O	PUNCT	O
RA	B-Disease	NOUN	B
)	O	PUNCT	O
who	O	PRON	O
developed	O	VERB	O
toxicity	B-Disease	NOUN	B
while	O	SCONJ	O
taking	O	VERB	O
remission	O	NOUN	B
inducing	O	VERB	O
drugs	O	NOUN	B
and	O	CCONJ	O
30	O	NUM	O
without	O	ADP	O
toxicity	B-Disease	NOUN	B
were	O	AUX	O
studied	O	VERB	O
for	O	ADP	O
possible	O	ADJ	O
associations	O	NOUN	B
with	O	ADP	O
class	O	NOUN	B
I	O	NUM	I
and	O	CCONJ	O
II	O	NUM	O
HLA	O	NOUN	B
antigens	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
strong	O	ADJ	O
association	O	NOUN	B
has	O	AUX	O
been	O	AUX	O
found	O	VERB	O
between	O	ADP	O
nephritis	B-Disease	NOUN	B
and	O	CCONJ	O
dermatitis	B-Disease	NOUN	B
due	O	ADP	O
to	O	ADP	O
Tiopronin	B-Chemical	PROPN	B
(	O	PUNCT	O
a	O	DET	O
D-Penicillamine	B-Chemical	NOUN	B
like	O	ADP	O
compound	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
class	O	NOUN	B
I	O	NUM	I
antigens	O	NOUN	I
B35	O	NOUN	I
-	O	PUNCT	O
Cw4	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
between	O	ADP	O
dermatitis	B-Disease	NOUN	B
due	O	ADP	O
to	O	PART	O
gold	B-Chemical	ADJ	B
thiosulphate	B-Chemical	NOUN	B
and	O	CCONJ	O
B35	O	NOUN	B
.	O	PUNCT	O


Compared	O	VERB	O
to	O	PART	O
healthy	O	ADJ	B
controls	O	NOUN	I
a	O	DET	O
lower	O	ADJ	O
DR5	O	NOUN	B
frequency	O	NOUN	B
was	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
RA	B-Disease	NOUN	B
except	O	SCONJ	O
for	O	ADP	O
the	O	DET	O
Tiopronin	B-Chemical	NOUN	B
related	O	ADJ	O
nephritis	B-Disease	NOUN	B


Transient	O	ADJ	B
hemiparesis	B-Disease	NOUN	I
:	O	PUNCT	O
a	O	DET	O
rare	O	ADJ	B
manifestation	O	NOUN	B
of	O	ADP	O
diphenylhydantoin	B-Chemical	NOUN	B
toxicity	B-Disease	NOUN	B
.	O	PUNCT	O


Report	O	NOUN	B
of	O	ADP	O
two	O	NUM	O
cases	O	NOUN	B
.	O	PUNCT	O


Among	O	ADP	O
the	O	DET	O
common	O	ADJ	O
side	O	NOUN	B
effects	O	NOUN	I
of	O	ADP	O
diphenylhydantoin	B-Chemical	NOUN	B
(	O	PUNCT	O
DPH	B-Chemical	NOUN	B
)	O	PUNCT	O
overdose	B-Disease	NOUN	B
,	O	PUNCT	O
the	O	DET	O
most	O	ADV	O
frequently	O	ADV	O
encountered	O	VERB	O
neurological	O	ADJ	B
signs	O	NOUN	I
are	O	AUX	O
those	O	DET	O
of	O	ADP	O
cerebellar	B-Disease	ADJ	B
dysfunction	I-Disease	NOUN	I
.	O	PUNCT	O


Very	O	ADV	O
rarely	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
toxic	O	ADJ	B
neurological	O	ADJ	B
manifestations	O	NOUN	O
of	O	ADP	O
this	O	DET	O
drug	O	NOUN	B
are	O	AUX	O
of	O	ADP	O
cerebral	O	ADJ	B
origin	O	NOUN	I
.	O	PUNCT	O


Two	O	NUM	O
patients	O	NOUN	B
are	O	AUX	O
presented	O	VERB	O
who	O	PRON	O
suffered	O	VERB	O
progressive	O	ADJ	B
hemiparesis	B-Disease	NOUN	B
due	O	ADJ	O
to	O	ADP	O
DPH	B-Chemical	NOUN	B
overdose	B-Disease	NOUN	B
.	O	PUNCT	O


Both	O	DET	O
had	O	AUX	O
brain	O	NOUN	B
surgery	O	NOUN	I
before	O	ADP	O
DPH	B-Chemical	NOUN	B
treatment	O	NOUN	B
.	O	PUNCT	O


It	O	PRON	O
is	O	AUX	O
assumed	O	VERB	O
that	O	SCONJ	O
patients	O	NOUN	B
with	O	ADP	O
some	O	DET	O
cerebral	B-Disease	ADJ	B
damage	I-Disease	NOUN	I
are	O	AUX	O
liable	O	ADJ	O
to	O	PART	O
manifest	O	VERB	B
DPH	B-Chemical	NOUN	B
toxicity	B-Disease	NOUN	B


Nerve	O	NOUN	B
growth	O	NOUN	I
factor	O	NOUN	I
and	O	CCONJ	O
prostaglandins	B-Chemical	NOUN	B
in	O	ADP	O
the	O	DET	O
urine	O	NOUN	B
of	O	ADP	O
female	O	ADJ	B
patients	O	NOUN	B
with	O	ADP	O
overactive	B-Disease	ADJ	B
bladder	I-Disease	NOUN	I
.	O	PUNCT	O


PURPOSE	O	NOUN	B
:	O	PUNCT	O
NGF	O	NOUN	B
and	O	CCONJ	O
PGs	B-Chemical	NOUN	B
in	O	ADP	O
the	O	DET	O
bladder	O	NOUN	B
can	O	AUX	O
be	O	AUX	O
affected	O	VERB	B
by	O	ADP	O
pathological	O	ADJ	B
changes	O	NOUN	B
in	O	ADP	O
the	O	DET	O
bladder	O	NOUN	B
and	O	CCONJ	O
these	O	DET	O
changes	O	NOUN	B
can	O	AUX	O
be	O	AUX	O
detected	O	VERB	B
in	O	ADP	O
urine	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
investigated	O	VERB	B
changes	O	NOUN	B
in	O	ADP	O
urinary	O	ADJ	B
NGF	O	NOUN	B
and	O	CCONJ	O
PGs	B-Chemical	NOUN	B
in	O	ADP	O
women	O	NOUN	B
with	O	ADP	O
OAB	B-Disease	NOUN	B
.	O	PUNCT	O


MATERIALS	O	NOUN	O
AND	O	CCONJ	O
METHODS	O	NOUN	O
:	O	PUNCT	O
The	O	DET	O
study	O	NOUN	B
groups	O	NOUN	I
included	O	VERB	O
65	O	NUM	O
women	O	NOUN	B
with	O	ADP	O
OAB	B-Disease	NOUN	B
and	O	CCONJ	O
20	O	NUM	O
without	O	ADP	O
bladder	O	NOUN	B
symptoms	O	NOUN	B
who	O	PRON	O
served	O	VERB	O
as	O	ADP	O
controls	O	NOUN	B
.	O	PUNCT	O


Evaluation	O	NOUN	B
included	O	VERB	O
patient	O	NOUN	B
history	O	NOUN	I
,	O	PUNCT	O
urinalysis	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
voiding	O	ADJ	B
diary	O	NOUN	I
and	O	CCONJ	O
urodynamic	O	ADJ	B
studies	O	NOUN	I
.	O	PUNCT	O


Urine	O	NOUN	B
samples	O	NOUN	I
were	O	AUX	O
collected	O	VERB	O
.	O	PUNCT	O


NGF	O	NOUN	B
,	O	PUNCT	O
PGE2	B-Chemical	NOUN	B
,	O	PUNCT	O
PGF2alpha	B-Chemical	NOUN	B
and	O	CCONJ	O
PGI2	B-Chemical	NOUN	B
were	O	AUX	O
measured	O	VERB	B
using	O	VERB	O
enzyme	O	NOUN	B
-	O	PUNCT	O
linked	O	VERB	B
immunosorbent	O	ADJ	B
assay	O	NOUN	B
and	O	CCONJ	O
compared	O	VERB	B
between	O	ADP	O
the	O	DET	O
groups	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
,	O	PUNCT	O
correlations	O	NOUN	B
between	O	ADP	O
urinary	O	ADJ	B
NGF	O	NOUN	B
and	O	CCONJ	O
PG	B-Chemical	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
urodynamic	O	ADJ	B
parameters	O	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
OAB	B-Disease	NOUN	B
were	O	AUX	O
examined	O	VERB	O
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
Urinary	O	ADJ	B
NGF	O	NOUN	B
,	O	PUNCT	O
PGE2	B-Chemical	NOUN	B
and	O	CCONJ	O
PGF2alpha	B-Chemical	NOUN	B
were	O	AUX	O
significantly	O	ADV	O
increased	O	VERB	B
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
OAB	B-Disease	NOUN	B
compared	O	VERB	B
with	O	ADP	O
controls	O	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


05	O	NUM	O
).	O	PUNCT	O
However	O	ADV	O
,	O	PUNCT	O
urinary	O	ADJ	B
PGI2	B-Chemical	NOUN	B
was	O	AUX	O
not	O	PART	O
different	O	ADJ	O
between	O	ADP	O
controls	O	NOUN	B
and	O	CCONJ	O
patients	O	NOUN	B
with	O	ADP	O
OAB	B-Disease	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
OAB	B-Disease	NOUN	B
urinary	O	ADJ	B
PGE2	B-Chemical	NOUN	B
positively	O	ADV	B
correlated	O	VERB	B
with	O	ADP	O
volume	O	NOUN	B
at	O	ADP	O
first	O	ADJ	O
desire	O	NOUN	O
to	O	PART	O
void	O	VERB	B
and	O	CCONJ	O
maximum	O	VERB	B
cystometric	O	ADJ	B
capacity	O	NOUN	O
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


05	O	NUM	O
).	O	PUNCT	O
Urinary	O	ADJ	B
NGF	O	NOUN	B
,	O	PUNCT	O
PGF2alpha	B-Chemical	NOUN	B
and	O	CCONJ	O
PGI2	B-Chemical	NOUN	B
did	O	AUX	O
not	O	PART	O
correlate	O	VERB	O
with	O	ADP	O
urodynamic	O	ADJ	B
parameters	O	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
OAB	B-Disease	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
:	O	PUNCT	O
NGF	O	NOUN	B
and	O	CCONJ	O
PGs	B-Chemical	NOUN	B
have	O	AUX	O
important	O	ADJ	O
roles	O	NOUN	O
in	O	ADP	O
the	O	DET	O
development	O	NOUN	B
of	O	ADP	O
OAB	B-Disease	NOUN	B
symptoms	O	NOUN	B
in	O	ADP	O
female	O	ADJ	B
patients	O	NOUN	B
.	O	PUNCT	O


Urinary	O	ADJ	B
levels	O	NOUN	O
of	O	ADP	O
these	O	DET	O
factors	O	NOUN	B
may	O	AUX	O
be	O	AUX	O
used	O	VERB	O
as	O	ADP	O
markers	O	NOUN	B
to	O	PART	O
evaluate	O	VERB	B
OAB	B-Disease	NOUN	B


Acute	O	ADV	B
low	B-Disease	ADV	I
back	I-Disease	ADJ	I
pain	I-Disease	NOUN	I
during	O	ADP	O
intravenous	O	ADJ	B
administration	O	NOUN	I
of	O	ADP	O
amiodarone	B-Chemical	NOUN	B
:	O	PUNCT	O
a	O	DET	O
report	O	NOUN	B
of	O	ADP	O
two	O	NUM	O
cases	O	NOUN	B
.	O	PUNCT	O


Amiodarone	B-Chemical	NOUN	B
represents	O	VERB	O
an	O	DET	O
effective	O	ADJ	B
antiarrhythmic	O	ADJ	B
drug	O	NOUN	I
for	O	ADP	O
cardioversion	O	NOUN	B
of	O	ADP	O
recent	O	ADJ	B
-	O	PUNCT	O
onset	O	NOUN	B
atrial	B-Disease	ADJ	B
fibrillation	I-Disease	NOUN	I
(	O	PUNCT	O
AF	B-Disease	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
maintenance	O	NOUN	B
of	O	ADP	O
sinus	O	NOUN	B
rhythm	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
briefly	O	ADV	O
describe	O	VERB	O
two	O	NUM	O
patients	O	NOUN	B
suffering	O	VERB	B
from	O	ADP	O
recent	O	ADJ	B
-	O	PUNCT	O
onset	O	NOUN	B
atrial	B-Disease	ADJ	B
fibrillation	I-Disease	NOUN	I
,	O	PUNCT	O
who	O	PRON	O
experienced	O	VERB	O
an	O	DET	O
acute	O	ADJ	B
devastating	O	ADJ	O
low	B-Disease	ADV	O
back	I-Disease	ADV	O
pain	I-Disease	NOUN	O
a	O	DET	O
few	O	ADJ	O
minutes	O	NOUN	O
after	O	ADP	O
initiation	O	NOUN	B
of	O	ADP	O
intravenous	O	ADJ	B
amiodarone	B-Chemical	NOUN	O


Postoperative	B-Disease	ADJ	B
myalgia	I-Disease	NOUN	I
after	O	ADP	O
succinylcholine	B-Chemical	NOUN	B
:	O	PUNCT	O
no	O	DET	O
evidence	O	NOUN	O
for	O	ADP	O
an	O	DET	O
inflammatory	O	ADJ	B
origin	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
common	O	ADJ	O
side	O	NOUN	B
effect	O	NOUN	I
associated	O	VERB	B
with	O	ADP	I
succinylcholine	B-Chemical	NOUN	B
is	O	AUX	O
postoperative	B-Disease	ADJ	B
myalgia	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
pathogenesis	O	NOUN	B
of	O	ADP	O
this	O	DET	O
myalgia	B-Disease	NOUN	B
is	O	AUX	O
still	O	ADV	O
unclear	O	ADJ	O
;	O	PUNCT	O
inflammation	B-Disease	NOUN	B
has	O	AUX	O
been	O	AUX	O
suggested	O	VERB	O
but	O	CCONJ	O
without	O	ADP	O
convincing	O	ADJ	O
evidence	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
designed	O	VERB	O
the	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
to	O	PART	O
investigate	O	VERB	B
whether	O	SCONJ	O
an	O	DET	O
inflammatory	O	ADJ	B
reaction	O	NOUN	I
contributes	O	VERB	O
to	O	PART	O
this	O	DET	O
myalgia	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
incidence	O	NOUN	B
and	O	CCONJ	O
severity	O	NOUN	B
of	O	ADP	O
succinylcholine	B-Chemical	NOUN	B
-	O	PUNCT	O
associated	O	VERB	B
myalgia	B-Disease	NOUN	B
was	O	AUX	O
determined	O	VERB	O
in	O	ADP	O
64	O	NUM	O
patients	O	NOUN	B
pretreated	O	VERB	B
with	O	ADP	O
saline	O	NOUN	B
or	O	CCONJ	O
dexamethasone	B-Chemical	NOUN	B
before	O	ADP	O
succinylcholine	B-Chemical	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
32	O	NUM	O
for	O	ADP	O
each	O	DET	O
).	O	PUNCT	B
Incidence	O	NOUN	B
and	O	CCONJ	O
severity	O	NOUN	B
of	O	ADP	O
myalgia	B-Disease	NOUN	B
did	O	AUX	O
not	O	PART	O
differ	O	VERB	O
significantly	O	ADV	O
between	O	ADP	O
the	O	DET	O
two	O	NUM	O
groups	O	NOUN	B
:	O	PUNCT	O
15	O	NUM	O
patients	O	NOUN	B
in	O	ADP	O
the	O	DET	O
dexamethasone	B-Chemical	NOUN	B
group	O	NOUN	B
complained	O	VERB	B
of	O	ADP	O
myalgia	B-Disease	NOUN	B
compared	O	VERB	B
with	O	ADP	O
18	O	NUM	O
patients	O	NOUN	B
in	O	ADP	O
the	O	DET	O
saline	O	NOUN	B
group	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
severe	O	ADJ	B
myalgia	B-Disease	NOUN	B
was	O	AUX	O
reported	O	VERB	O
by	O	ADP	O
five	O	NUM	O
patients	O	NOUN	B
and	O	CCONJ	O
three	O	NUM	O
patients	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
(	O	PUNCT	O
not	O	PART	O
significant	O	ADJ	O
).	O	PUNCT	B
At	O	ADP	O
48	O	NUM	O
h	O	NOUN	O
after	O	ADP	O
surgery	O	NOUN	B
,	O	PUNCT	O
12	O	NUM	O
patients	O	NOUN	B
in	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
still	O	ADV	O
suffered	O	VERB	O
from	O	ADP	O
myalgia	B-Disease	NOUN	B
(	O	PUNCT	O
not	O	PART	O
significant	O	ADJ	O
).	O	PUNCT	B
In	O	ADP	O
addition	O	NOUN	O
,	O	PUNCT	O
interleukin	O	NOUN	B
-	O	PUNCT	O
6	O	NUM	O
(	O	PUNCT	O
IL	O	NOUN	B
-	O	PUNCT	O
6	O	NUM	O
)	O	PUNCT	O
as	O	ADP	O
an	O	DET	O
early	O	ADJ	O
marker	O	NOUN	B
of	O	ADP	O
inflammation	B-Disease	NOUN	B
was	O	AUX	O
assessed	O	VERB	B
in	O	ADP	O
a	O	DET	O
subgroup	O	NOUN	B
of	O	ADP	O
10	O	NUM	O
patients	O	NOUN	B
pretreated	O	VERB	B
with	O	ADP	O
saline	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
found	O	VERB	O
an	O	DET	O
increase	O	NOUN	B
of	O	ADP	O
IL	O	NOUN	B
-	O	PUNCT	O
6	O	NUM	O
for	O	ADP	O
only	O	ADV	O
three	O	NUM	O
patients	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
only	O	ADV	O
one	O	NUM	O
patient	O	NOUN	B
reported	O	VERB	O
myalgia	B-Disease	NOUN	B
;	O	PUNCT	O
no	O	DET	O
relationship	O	NOUN	B
between	O	ADP	O
myalgia	B-Disease	NOUN	B
and	O	CCONJ	O
the	O	DET	O
increase	O	NOUN	B
of	O	ADP	O
IL	O	NOUN	B
-	O	PUNCT	O
6	O	NUM	O
was	O	AUX	O
found	O	VERB	O
.	O	PUNCT	O


In	O	ADP	O
conclusion	O	NOUN	O
,	O	PUNCT	O
there	O	PRON	O
is	O	AUX	O
no	O	DET	O
evidence	O	NOUN	O
for	O	ADP	O
an	O	DET	O
inflammatory	O	ADJ	B
origin	O	NOUN	B
of	O	ADP	O
succinylcholine	B-Chemical	NOUN	B
-	O	PUNCT	O
associated	O	VERB	B
myalgia	B-Disease	NOUN	B
.	O	PUNCT	O


IMPLICATIONS	O	NOUN	B
:	O	PUNCT	O
Administration	O	NOUN	B
of	O	ADP	O
dexamethasone	B-Chemical	NOUN	B
before	O	ADP	O
succinylcholine	B-Chemical	NOUN	B
was	O	AUX	O
not	O	PART	O
effective	O	ADJ	B
in	O	ADP	O
decreasing	O	VERB	B
the	O	DET	O
incidence	O	NOUN	B
or	O	CCONJ	O
the	O	DET	O
severity	O	NOUN	B
of	O	ADP	O
succinylcholine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
postoperative	B-Disease	ADJ	B
myalgia	I-Disease	NOUN	I
.	O	PUNCT	O


Furthermore	O	ADV	O
,	O	PUNCT	O
there	O	PRON	O
was	O	AUX	O
no	O	DET	O
significant	O	ADJ	O
relationship	O	NOUN	B
between	O	ADP	O
postoperative	B-Disease	ADJ	B
myalgia	I-Disease	NOUN	I
and	O	CCONJ	O
time	O	NOUN	B
course	O	NOUN	I
of	O	ADP	O
interleukin	O	NOUN	B
-	O	PUNCT	O
6	O	NUM	O
concentrations	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
marker	O	NOUN	B
of	O	ADP	O
inflammation	B-Disease	NOUN	B
.	O	PUNCT	O


Pretreatment	O	NOUN	B
with	O	ADP	O
dexamethasone	B-Chemical	NOUN	B
is	O	AUX	O
not	O	PART	O
justified	O	ADJ	O
to	O	PART	O
prevent	O	VERB	B
postoperative	B-Disease	ADJ	B
myalgia	I-Disease	NOUN	I
after	O	ADP	O
succinylcholine	B-Chemical	NOUN	B


Levodopa	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
oromandibular	O	ADJ	B
dystonia	B-Disease	NOUN	I
in	O	ADP	O
progressive	B-Disease	ADJ	B
supranuclear	I-Disease	ADJ	B
palsy	I-Disease	NOUN	I
.	O	PUNCT	O


Levodopa	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
dyskinesias	B-Disease	NOUN	B
have	O	AUX	O
been	O	AUX	O
reported	O	VERB	O
in	O	ADP	O
Parkinson's	B-Disease	ADJ	O
disease	I-Disease	NOUN	B
and	O	CCONJ	O
multiple	B-Disease	ADJ	B
system	I-Disease	NOUN	I
atrophy	I-Disease	NOUN	I
.	O	PUNCT	O


Cranial	O	ADJ	B
dystonias	B-Disease	NOUN	I
are	O	AUX	O
rare	O	ADJ	B
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
progressive	B-Disease	ADJ	B
supranuclear	I-Disease	ADJ	B
palsy	I-Disease	NOUN	I
(	O	PUNCT	O
PSP	B-Disease	PROPN	B
).	O	PUNCT	O
In	O	ADP	O
this	O	DET	O
report	O	NOUN	O
we	O	PRON	O
describe	O	VERB	O
an	O	DET	O
unusual	O	ADJ	B
case	O	NOUN	B
of	O	ADP	O
reversible	O	ADJ	B
levodopa	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
Oromandibular	B-Disease	ADJ	B
dystonia	I-Disease	NOUN	I
(	O	PUNCT	O
OMD	B-Disease	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
a	O	DET	O
PSP	B-Disease	NOUN	B
patient	O	NOUN	B
to	O	PART	O
highlight	O	VERB	O
the	O	DET	O
importance	O	NOUN	O
of	O	ADP	O
recognizing	O	VERB	O
this	O	DET	O
drug	O	NOUN	B
related	O	ADJ	O
complication	O	NOUN	B
in	O	ADP	O
the	O	DET	O
management	O	NOUN	B
of	O	ADP	O
PSP	B-Disease	PROPN	B


Protective	O	ADJ	B
effect	O	NOUN	I
of	O	ADP	O
edaravone	B-Chemical	NOUN	B
against	O	ADP	O
streptomycin	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
vestibulotoxicity	B-Disease	NOUN	B
in	O	ADP	O
the	O	DET	O
guinea	O	NOUN	B
pig	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
study	O	NOUN	B
investigated	O	VERB	B
alleviation	O	NOUN	B
of	O	ADP	O
streptomycin	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
vestibulotoxicity	B-Disease	NOUN	B
by	O	ADP	O
edaravone	B-Chemical	NOUN	B
in	O	ADP	O
guinea	O	NOUN	B
pigs	O	NOUN	B
.	O	PUNCT	O


Edaravone	B-Chemical	NOUN	B
,	O	PUNCT	O
a	O	DET	O
free	O	ADJ	B
radical	O	NOUN	I
scavenger	O	NOUN	I
,	O	PUNCT	O
has	O	AUX	O
potent	O	ADJ	O
free	O	ADJ	B
radical	O	NOUN	I
quenching	O	NOUN	I
action	O	NOUN	I
and	O	CCONJ	O
is	O	AUX	O
used	O	VERB	O
in	O	ADP	O
clinical	O	ADJ	B
practice	O	NOUN	I
to	O	PART	O
treat	O	VERB	B
cerebral	B-Disease	ADJ	B
infarction	I-Disease	NOUN	I
.	O	PUNCT	O


Streptomycin	B-Chemical	NOUN	B
was	O	AUX	O
administered	O	VERB	B
to	O	PART	O
the	O	DET	O
inner	O	ADJ	B
ear	O	NOUN	I
by	O	ADP	O
osmotic	O	ADJ	B
pump	O	NOUN	I
for	O	ADP	O
24	O	NUM	O
h	O	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
edaravone	B-Chemical	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
8	O	NUM	O
)	O	PUNCT	O
or	O	CCONJ	O
saline	O	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
6	O	NUM	O
)	O	PUNCT	O
was	O	AUX	O
intraperitoneally	O	ADV	B
injected	O	VERB	I
once	O	ADV	O
a	O	DET	O
day	O	NOUN	B
for	O	ADP	O
7	O	NUM	O
days	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
observed	O	VERB	O
horizontal	O	ADJ	B
vestibulo	O	NOUN	B
-	O	PUNCT	O
ocular	O	ADJ	B
reflex	O	NOUN	I
as	O	ADP	O
a	O	DET	O
marker	O	NOUN	B
of	O	ADP	O
postoperative	O	ADJ	B
vestibular	O	ADJ	B
function	O	NOUN	I
.	O	PUNCT	O


Animals	O	NOUN	B
injected	O	VERB	B
with	O	ADP	O
saline	O	NOUN	B
showed	O	VERB	O
statistically	O	ADV	O
smaller	O	ADJ	O
gains	O	NOUN	B
than	O	ADP	O
those	O	DET	O
injected	O	VERB	B
with	O	ADP	O
edaravone	B-Chemical	NOUN	B
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
edaravone	B-Chemical	NOUN	B
suppresses	O	VERB	B
streptomycin	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
vestibulotoxicity	B-Disease	NOUN	B


Ketamine	B-Chemical	NOUN	B
in	O	ADP	O
war	O	NOUN	B
/	O	SYM	O
tropical	O	ADJ	B
surgery	O	NOUN	I
(	O	PUNCT	O
a	O	DET	O
final	O	ADJ	O
tribute	O	NOUN	O
to	O	ADP	O
the	O	DET	O
racemic	O	ADJ	B
mixture	O	NOUN	O
).	O	PUNCT	O
A	O	NOUN	O
technique	O	NOUN	B
of	O	ADP	O
continuous	O	ADJ	B
intravenous	O	ADJ	B
anaesthesia	O	NOUN	I
with	O	ADP	O
ketamine	B-Chemical	NOUN	B
was	O	AUX	O
used	O	VERB	O
successfully	O	ADV	O
during	O	ADP	O
the	O	DET	O
Somalia	O	PROPN	B
civil	O	ADJ	B
war	O	NOUN	O
in	O	ADP	O
1994	O	NUM	O
and	O	CCONJ	O
in	O	ADP	O
north	O	NOUN	B
Uganda	O	PROPN	I
in	O	ADP	O
1999	O	NUM	O
for	O	ADP	O
64	O	NUM	O
operations	O	NOUN	B
in	O	ADP	O
62	O	NUM	O
patients	O	NOUN	B
,	O	PUNCT	O
aged	O	ADJ	B
from	O	ADP	O
6	O	NUM	O
weeks	O	NOUN	B
to	O	ADP	O
70	O	NUM	O
years	O	NOUN	B
,	O	PUNCT	O
undergoing	O	VERB	O
limb	O	NOUN	B
and	O	CCONJ	O
abdominal	O	ADJ	B
surgery	O	NOUN	I
including	O	VERB	O
caesarian	O	ADJ	B
sections	O	NOUN	I
and	O	CCONJ	O
interventions	O	NOUN	B
in	O	ADP	O
neonates	O	NOUN	B
.	O	PUNCT	O


Operations	O	NOUN	B
lasting	O	VERB	O
up	O	ADP	O
to	O	ADP	O
2h	O	NOUN	O
could	O	AUX	O
be	O	AUX	O
performed	O	VERB	O
in	O	ADP	O
the	O	DET	O
absence	O	NOUN	B
of	O	ADP	O
sophisticated	O	ADJ	B
equipment	O	NOUN	I
such	O	ADJ	O
as	O	ADP	O
pulse	O	NOUN	B
oximeters	O	NOUN	I
or	O	CCONJ	O
ventilators	O	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
on	O	ADP	O
spontaneous	O	ADJ	B
ventilation	O	NOUN	I
breathing	O	NOUN	I
air	O	NOUN	I
/	O	SYM	O
oxygen	B-Chemical	NOUN	B
only	O	ADV	O
.	O	PUNCT	O


After	O	ADP	O
premedication	O	NOUN	B
with	O	ADP	O
diazepam	B-Chemical	NOUN	B
,	O	PUNCT	O
glycopyrrolate	B-Chemical	NOUN	B
and	O	CCONJ	O
local	O	ADJ	B
anaesthesia	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
induction	O	NOUN	B
with	O	ADP	O
standard	O	ADJ	B
doses	O	NOUN	I
of	O	ADP	O
ketamine	B-Chemical	NOUN	B
,	O	PUNCT	O
a	O	DET	O
maintenance	O	NOUN	B
dose	O	NOUN	B
of	O	ADP	O
10	O	NUM	O
-	O	PUNCT	O
20	O	NUM	O
microg	O	NOUN	B
/	O	SYM	O
kg	O	NOUN	B
/	O	PUNCT	O
min	O	NOUN	B
of	O	ADP	O
ketamine	B-Chemical	NOUN	B
proved	O	VERB	O
safe	O	ADJ	O
and	O	CCONJ	O
effective	O	ADJ	B
.	O	PUNCT	O


Emphasis	O	NOUN	O
was	O	AUX	O
placed	O	VERB	O
on	O	ADP	O
bedside	O	NOUN	B
clinical	O	ADJ	B
monitoring	O	NOUN	O
,	O	PUNCT	O
relying	O	VERB	O
heavily	O	ADV	O
on	O	ADP	O
the	O	DET	O
heart	O	NOUN	B
rate	O	NOUN	I
.	O	PUNCT	O


Diazepam	B-Chemical	NOUN	B
,	O	PUNCT	O
unless	O	SCONJ	O
contraindicated	O	VERB	B
or	O	CCONJ	O
risky	O	ADJ	B
,	O	PUNCT	O
remains	O	VERB	O
the	O	DET	O
only	O	ADV	O
necessary	O	ADJ	O
complementary	O	ADJ	O
drug	O	NOUN	O
to	O	PART	O
ketamine	B-Chemical	NOUN	B
as	O	ADP	O
it	O	PRON	O
buffers	O	VERB	B
its	O	PRON	O
cardiovascular	O	ADJ	B
response	O	NOUN	I
and	O	CCONJ	O
decreases	O	VERB	B
the	O	DET	O
duration	O	NOUN	B
and	O	CCONJ	O
intensity	O	NOUN	B
of	O	ADP	O
operative	O	ADJ	B
and	O	CCONJ	O
postoperative	O	ADJ	B
hallucinations	B-Disease	NOUN	O
.	O	PUNCT	O


Local	O	ADJ	B
anaesthetic	O	ADJ	B
blocks	O	NOUN	I
were	O	AUX	O
useful	O	ADJ	O
in	O	ADP	O
decreasing	O	VERB	B
the	O	DET	O
requirement	O	NOUN	B
for	O	ADP	O
postoperative	O	ADJ	B
analgesia	B-Disease	NOUN	I
.	O	PUNCT	O


An	O	DET	O
antisialogue	O	NOUN	B
was	O	AUX	O
usually	O	ADV	O
unnecessary	O	ADJ	O
in	O	ADP	O
operations	O	NOUN	B
lasting	O	VERB	O
up	O	ADV	O
to	O	PART	O
2	O	NUM	O
h	O	NOUN	O
,	O	PUNCT	O
glycopyrrolate	B-Chemical	NOUN	B


Steroid	B-Chemical	NOUN	B
structure	O	NOUN	I
and	O	CCONJ	O
pharmacological	O	ADJ	B
properties	O	NOUN	B
determine	O	VERB	O
the	O	DET	O
anti	O	ADJ	B
-	O	PUNCT	O
amnesic	B-Disease	ADJ	B
effects	O	NOUN	B
of	O	ADP	O
pregnenolone	B-Chemical	NOUN	B
sulphate	I-Chemical	NOUN	B
in	O	ADP	O
the	O	DET	O
passive	O	ADJ	B
avoidance	O	NOUN	I
task	O	NOUN	I
in	O	ADP	O
rats	O	NOUN	B
.	O	PUNCT	O


Pregnenolone	B-Chemical	NOUN	B
sulphate	I-Chemical	NOUN	O
(	O	PUNCT	O
PREGS	B-Chemical	NOUN	B
)	O	PUNCT	O
has	O	AUX	O
generated	O	VERB	O
interest	O	NOUN	O
as	O	ADP	O
one	O	NUM	O
of	O	ADP	O
the	O	DET	O
most	O	ADV	O
potent	O	ADJ	O
memory	O	NOUN	B
-	O	PUNCT	O
enhancing	O	VERB	B
neurosteroids	O	NOUN	B
to	O	PART	O
be	O	AUX	O
examined	O	VERB	O
in	O	ADP	O
rodent	O	ADJ	B
learning	O	NOUN	O
studies	O	NOUN	O
,	O	PUNCT	O
with	O	ADP	O
particular	O	ADJ	O
importance	O	NOUN	O
in	O	ADP	O
the	O	DET	O
ageing	O	NOUN	B
process	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
mechanism	O	NOUN	B
by	O	ADP	O
which	O	DET	O
this	O	DET	O
endogenous	O	ADJ	B
steroid	B-Chemical	NOUN	B
enhances	O	VERB	B
memory	O	NOUN	B
formation	O	NOUN	I
is	O	AUX	O
hypothesized	O	VERB	O
to	O	PART	O
involve	O	VERB	O
actions	O	NOUN	B
on	O	ADP	O
glutamatergic	O	ADJ	B
and	O	CCONJ	O
GABAergic	O	ADJ	B
systems	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
hypothesis	O	NOUN	B
stems	O	VERB	B
from	O	ADP	O
findings	O	NOUN	B
that	O	SCONJ	O
PREGS	B-Chemical	NOUN	B
is	O	AUX	O
a	O	DET	O
potent	O	ADJ	O
positive	O	ADJ	B
modulator	O	NOUN	O
of	O	ADP	O
N-methyl-d-aspartate	B-Chemical	NOUN	B
receptors	O	NOUN	I
(	O	PUNCT	O
NMDARs	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
negative	O	ADJ	B
modulator	O	NOUN	O
of	O	ADP	O
gamma-aminobutyric	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
(	O	PUNCT	O
A	O	NOUN	O
)	O	PUNCT	O
receptors	O	NOUN	O
(	O	PUNCT	O
GABA	B-Chemical	NOUN	B
(	O	PUNCT	O
A	O	NOUN	O
)	O	PUNCT	O
Rs	O	NOUN	B
).	O	PUNCT	O
Moreover	O	ADV	O
,	O	PUNCT	O
PREGS	B-Chemical	NOUN	B
is	O	AUX	O
able	O	ADJ	O
to	O	PART	O
reverse	O	VERB	B
the	O	DET	O
amnesic	B-Disease	ADJ	B
-	O	PUNCT	O
like	O	ADJ	B
effects	O	NOUN	B
of	O	ADP	O
NMDAR	O	NOUN	B
and	O	CCONJ	O
GABA	B-Chemical	NOUN	B
(	O	PUNCT	O
A	O	NOUN	O
)	O	PUNCT	O
R	O	NOUN	O
ligands	O	NOUN	B
.	O	PUNCT	O


To	O	PART	O
investigate	O	VERB	B
this	O	DET	O
hypothesis	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
in	O	ADP	O
rats	O	NOUN	B
examined	O	VERB	B
the	O	DET	O
memory	O	NOUN	B
-	O	PUNCT	O
altering	O	VERB	B
abilities	O	NOUN	B
of	O	ADP	O
structural	O	ADJ	B
analogs	O	NOUN	B
of	O	ADP	O
PREGS	B-Chemical	NOUN	B
,	O	PUNCT	O
which	O	DET	O
differ	O	VERB	O
in	O	ADP	O
their	O	PRON	O
modulation	O	NOUN	B
of	O	ADP	O
NMDAR	O	NOUN	B
and	O	CCONJ	O
/	O	SYM	O
or	O	CCONJ	O
GABA	B-Chemical	NOUN	B
(	O	PUNCT	O
A	O	NOUN	O
)	O	PUNCT	O
R	O	NOUN	O
function	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
analogs	O	NOUN	B
tested	O	VERB	B
were	O	AUX	O
:	O	PUNCT	O
11-ketopregnenolone	B-Chemical	ADJ	O
sulphate	I-Chemical	NOUN	B
(	O	PUNCT	O
an	O	DET	O
agent	O	NOUN	B
that	O	PRON	O
is	O	AUX	O
inactive	O	ADJ	B
at	O	ADP	O
GABA	B-Chemical	NOUN	B
(	O	PUNCT	O
A	O	NOUN	O
)	O	PUNCT	O
Rs	O	NOUN	B
and	O	CCONJ	O
NMDARs	O	NOUN	B
),	O	PUNCT	O
epipregnanolone	B-Chemical	NOUN	B
([3beta-hydroxy-5beta-pregnan-20-one]	I-Chemical	NOUN	O
sulphate	I-Chemical	NOUN	B
,	O	PUNCT	O
an	O	DET	O
inhibitor	O	NOUN	B
of	O	ADP	O
both	O	CCONJ	O
GABA	B-Chemical	NOUN	B
(	O	PUNCT	O
A	O	NOUN	O
)	O	PUNCT	O
Rs	O	NOUN	B
and	O	CCONJ	O
NMDARs	O	NOUN	B
),	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
newly	O	ADV	O
synthesized	O	VERB	B
(-)	O	ADJ	B
PREGS	B-Chemical	NOUN	I
enantiomer	O	NOUN	I
(	O	PUNCT	O
which	O	DET	O
is	O	AUX	O
identical	O	ADJ	O
to	O	PART	O
PREGS	B-Chemical	NOUN	B
in	O	ADP	O
effects	O	NOUN	B
on	O	ADP	O
GABA	B-Chemical	NOUN	B
(	O	PUNCT	O
A	O	NOUN	O
)	O	PUNCT	O
Rs	O	NOUN	B
and	O	CCONJ	O
NMDARs	O	NOUN	B
).	O	PUNCT	O
The	O	DET	O
memory	O	NOUN	B
-	O	PUNCT	O
enhancing	O	VERB	B
effects	O	NOUN	B
of	O	ADP	O
PREGS	B-Chemical	NOUN	B
and	O	CCONJ	O
its	O	PRON	O
analogs	O	NOUN	B
were	O	AUX	O
tested	O	VERB	B
in	O	ADP	O
the	O	DET	O
passive	O	ADJ	B
avoidance	O	NOUN	I
task	O	NOUN	I
using	O	VERB	O
the	O	DET	O
model	O	NOUN	B
of	O	ADP	O
scopolamine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
amnesia	B-Disease	NOUN	B
.	O	PUNCT	O


Both	O	DET	O
PREGS	B-Chemical	NOUN	B
and	O	CCONJ	O
its	O	PRON	O
(-)	O	ADJ	B
enantiomer	O	NOUN	I
blocked	O	VERB	B
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
scopolamine	B-Chemical	NOUN	B
.	O	PUNCT	O


The	O	DET	O
results	O	NOUN	B
show	O	VERB	O
that	O	SCONJ	O
,	O	PUNCT	O
unlike	O	ADP	O
PREGS	B-Chemical	NOUN	B
,	O	PUNCT	O
11-ketopregnenolone	B-Chemical	ADJ	O
sulphate	I-Chemical	NOUN	B
and	O	CCONJ	O
epipregnanolone	B-Chemical	NOUN	B
sulphate	I-Chemical	NOUN	I
failed	O	VERB	B
to	O	PART	O
block	O	VERB	B
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
scopolamine	B-Chemical	NOUN	B
,	O	PUNCT	O
suggesting	O	VERB	O
that	O	SCONJ	O
altering	O	VERB	B
the	O	DET	O
modulation	O	NOUN	B
of	O	ADP	O
NMDA	B-Chemical	NOUN	B
receptors	O	NOUN	I
diminishes	O	VERB	O
the	O	DET	O
memory	O	NOUN	B
-	O	PUNCT	O
enhancing	O	VERB	B
effects	O	NOUN	B
of	O	ADP	O
PREGS	B-Chemical	NOUN	B
.	O	PUNCT	O


Moreover	O	ADV	O
,	O	PUNCT	O
enantioselectivity	O	NOUN	B
was	O	AUX	O
demonstrated	O	VERB	O
by	O	ADP	O
the	O	DET	O
ability	O	NOUN	B
of	O	ADP	O
natural	O	ADJ	B
PREGS	B-Chemical	NOUN	B
to	O	PART	O
be	O	AUX	O
an	O	DET	O
order	O	NOUN	O
of	O	ADP	O
magnitude	O	NOUN	B
more	O	ADV	O
effective	O	ADJ	B
than	O	ADP	O
its	O	PRON	O
synthetic	O	ADJ	B
enantiomer	O	NOUN	B
in	O	ADP	O
reversing	O	VERB	O
scopolamine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
amnesia	B-Disease	NOUN	B
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	B
identify	O	VERB	O
a	O	DET	O
novel	O	ADJ	O
neuropharmacological	O	ADJ	B
site	O	NOUN	I
for	O	ADP	O
the	O	DET	O
modulation	O	NOUN	B
of	O	ADP	O
memory	O	NOUN	B
processes	O	NOUN	I
by	O	ADP	O
neuroactive	O	ADJ	B
steroids	B-Chemical	NOUN	I


Preliminary	O	ADJ	B
efficacy	O	NOUN	B
assessment	O	NOUN	B
of	O	ADP	O
intrathecal	O	ADJ	B
injection	O	NOUN	I
of	O	ADP	O
an	O	DET	O
American	O	ADJ	B
formulation	O	NOUN	B
of	O	ADP	O
adenosine	B-Chemical	NOUN	B
in	O	ADP	O
humans	O	NOUN	B
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
:	O	PUNCT	O
Preclinical	O	ADJ	B
studies	O	NOUN	I
of	O	ADP	O
intrathecal	O	ADJ	B
adenosine	B-Chemical	NOUN	I
suggest	O	VERB	O
it	O	PRON	O
may	O	AUX	O
be	O	AUX	O
effective	O	ADJ	B
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
acute	B-Disease	ADJ	B
and	I-Disease	CCONJ	O
chronic	I-Disease	ADJ	B
pain	I-Disease	NOUN	I
in	O	ADP	O
humans	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
preliminary	O	ADJ	O
studies	O	NOUN	B
in	O	ADP	O
volunteers	O	NOUN	B
and	O	CCONJ	O
patients	O	NOUN	B
with	O	ADP	O
a	O	DET	O
Swedish	O	ADJ	B
formulation	O	NOUN	B
of	O	ADP	O
adenosine	B-Chemical	NOUN	B
suggests	O	VERB	O
it	O	PRON	O
may	O	AUX	O
be	O	AUX	O
effective	O	ADJ	B
in	O	ADP	O
hypersensitivity	B-Disease	NOUN	B
states	O	NOUN	B
but	O	CCONJ	O
not	O	PART	O
with	O	ADP	O
acute	O	ADJ	B
noxious	O	ADJ	O
stimulation	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
purpose	O	NOUN	O
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
screen	O	VERB	B
for	O	ADP	O
efficacy	O	NOUN	B
of	O	ADP	O
a	O	DET	O
different	O	ADJ	O
formulation	O	NOUN	B
of	O	ADP	O
adenosine	B-Chemical	NOUN	B
marketed	O	VERB	B
in	O	ADP	O
the	O	DET	O
US	O	PROPN	B
,	O	PUNCT	O
using	O	VERB	O
both	O	CCONJ	O
acute	O	ADJ	B
noxious	O	ADJ	B
stimulation	O	NOUN	I
and	O	CCONJ	O
capsaicin	B-Chemical	NOUN	B
-	O	PUNCT	O
evoked	O	VERB	B
mechanical	O	ADJ	B
hypersensitivity	B-Disease	NOUN	I
.	O	PUNCT	O


METHODS	O	NOUN	O
:	O	PUNCT	O
Following	O	VERB	O
Food	O	PROPN	B
and	O	CCONJ	I
Drug	O	PROPN	I
Administration	O	PROPN	I
and	O	CCONJ	O
institutional	O	ADJ	B
review	O	NOUN	I
board	O	NOUN	I
approval	O	NOUN	I
and	O	CCONJ	O
written	O	VERB	B
informed	O	ADJ	I
consent	O	NOUN	I
,	O	PUNCT	O
65	O	NUM	O
volunteers	O	NOUN	B
were	O	AUX	O
studied	O	VERB	O
in	O	ADP	O
two	O	NUM	O
trials	O	NOUN	B
:	O	PUNCT	O
an	O	DET	O
open	O	ADJ	B
-	O	PUNCT	O
label	O	NOUN	B
,	O	PUNCT	O
dose	O	NOUN	B
-	O	PUNCT	O
escalating	O	VERB	B
trial	O	NOUN	B
with	O	ADP	O
intrathecal	O	ADJ	B
adenosine	B-Chemical	NOUN	I
doses	O	NOUN	I
of	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


25	O	NUM	O
-	O	SYM	O
2	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
mg	O	NOUN	O
and	O	CCONJ	O
a	O	DET	O
double	O	ADJ	B
-	O	PUNCT	O
blind	O	ADJ	B
,	O	PUNCT	O
placebo	O	NOUN	B
-	O	PUNCT	O
controlled	O	VERB	B
trial	O	NOUN	I
of	O	ADP	O
adenosine	B-Chemical	NOUN	B
,	O	PUNCT	O
2	O	NUM	O
mg	O	NOUN	O
.	O	PUNCT	O


Cerebrospinal	O	ADJ	B
fluid	O	NOUN	I
was	O	AUX	O
obtained	O	VERB	O
for	O	ADP	O
pharmacokinetic	O	ADJ	B
analysis	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
pain	B-Disease	NOUN	B
ratings	O	NOUN	I
in	O	ADP	O
response	O	NOUN	B
to	O	PART	O
acute	O	ADJ	B
heat	O	NOUN	O
stimuli	O	NOUN	O
and	O	CCONJ	O
areas	O	NOUN	B
of	O	ADP	O
mechanical	B-Disease	ADJ	B
hyperalgesia	I-Disease	NOUN	I
and	O	CCONJ	O
allodynia	B-Disease	NOUN	B
after	O	ADP	O
intradermal	O	ADJ	B
capsaicin	B-Chemical	NOUN	B
injection	O	NOUN	B
were	O	AUX	O
determined	O	VERB	O
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
Adenosine	B-Chemical	NOUN	B
produced	O	VERB	O
no	O	DET	O
effect	O	NOUN	O
on	O	ADP	O
pain	B-Disease	NOUN	B
report	O	NOUN	I
to	O	ADP	O
acute	O	ADJ	B
noxious	O	ADJ	B
thermal	O	ADJ	I
or	O	CCONJ	O
chemical	O	NOUN	B
stimulation	O	NOUN	I
but	O	CCONJ	O
reduced	O	VERB	B
mechanical	B-Disease	ADJ	B
hyperalgesia	I-Disease	NOUN	I
and	O	CCONJ	O
allodynia	B-Disease	NOUN	B
from	O	ADP	O
intradermal	O	ADJ	B
capsaicin	B-Chemical	NOUN	B
injection	O	NOUN	B
for	O	ADP	O
at	O	ADP	O
least	O	ADJ	O
24	O	NUM	O
h	O	NOUN	O
.	O	PUNCT	O


In	O	ADP	O
contrast	O	NOUN	O
,	O	PUNCT	O
residence	O	NOUN	B
time	O	NOUN	I
of	O	ADP	O
adenosine	B-Chemical	NOUN	B
in	O	ADP	O
cerebrospinal	O	ADJ	B
fluid	O	NOUN	I
was	O	AUX	O
short	O	ADJ	O
(<	O	NOUN	O
4	O	NUM	O
h	O	NOUN	O
).	O	PUNCT	O
CONCLUSIONS	O	NOUN	O
:	O	PUNCT	O
These	O	DET	O
results	O	NOUN	B
show	O	VERB	O
selective	O	ADJ	O
inhibition	O	NOUN	B
by	O	ADP	O
intrathecal	O	ADJ	B
adenosine	B-Chemical	NOUN	I
of	O	ADP	I
hypersensitivity	B-Disease	NOUN	B
,	O	PUNCT	O
presumed	O	VERB	O
to	O	PART	O
reflect	O	VERB	O
central	O	ADJ	B
sensitization	O	NOUN	I
in	O	ADP	O
humans	O	NOUN	B
after	O	ADP	O
peripheral	O	ADJ	B
capsaicin	B-Chemical	NOUN	B
injection	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
long	O	ADV	B
-	O	PUNCT	O
lasting	O	VERB	B
effect	O	NOUN	B
is	O	AUX	O
consistent	O	ADJ	B
with	O	ADP	I
that	O	DET	O
observed	O	VERB	B
in	O	ADP	O
preliminary	O	ADJ	B
reports	O	NOUN	B
of	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
chronic	O	ADJ	B
neuropathic	B-Disease	ADJ	I
pain	I-Disease	NOUN	I
and	O	CCONJ	O
is	O	AUX	O
not	O	PART	O
due	O	ADJ	O
to	O	PART	O
prolonged	O	ADJ	B
residence	O	NOUN	B
of	O	ADP	O
adenosine	B-Chemical	NOUN	B


Effect	O	NOUN	B
of	O	ADP	O
lithium	B-Chemical	NOUN	B
maintenance	O	NOUN	O
therapy	O	NOUN	O
on	O	ADP	O
thyroid	O	NOUN	B
and	O	CCONJ	O
parathyroid	O	ADJ	B
function	O	NOUN	I
.	O	PUNCT	O


OBJECTIVES	O	NOUN	O
:	O	PUNCT	O
To	O	PART	O
assess	O	VERB	O
changes	O	NOUN	B
induced	O	VERB	B
by	O	ADP	O
lithium	B-Chemical	NOUN	B
maintenance	O	NOUN	O
therapy	O	NOUN	O
on	O	ADP	O
the	O	DET	O
incidence	O	NOUN	B
of	O	ADP	O
thyroid	O	NOUN	B
,	O	PUNCT	O
parathyroid	O	ADJ	B
and	O	CCONJ	O
ion	O	NOUN	B
alterations	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
were	O	AUX	O
evaluated	O	VERB	B
with	O	ADP	O
respect	O	NOUN	O
to	O	PART	O
the	O	DET	O
duration	O	NOUN	B
of	O	ADP	O
lithium	B-Chemical	NOUN	B
therapy	O	NOUN	I
,	O	PUNCT	O
age	O	NOUN	B
,	O	PUNCT	O
sex	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
family	O	NOUN	B
history	O	NOUN	I
(	O	PUNCT	O
whether	O	SCONJ	O
or	O	CCONJ	O
not	O	PART	O
the	O	DET	O
patient	O	NOUN	B
had	O	AUX	O
a	O	DET	O
first	O	ADJ	B
-	O	PUNCT	O
degree	O	NOUN	B
relative	O	ADJ	B
with	O	ADP	O
thyroid	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
).	O	PUNCT	O
DESIGN	O	NOUN	O
:	O	PUNCT	O
Prospective	O	ADJ	B
study	O	NOUN	I
.	O	PUNCT	O


SETTING	O	NOUN	B
:	O	PUNCT	O
Affective	O	ADJ	B
Disorders	O	PROPN	I
Clinic	O	PROPN	I
at	O	ADP	O
St	O	PROPN	B
.	O	PUNCT	O


Mary	O	PROPN	B
'	O	PART	I
s	O	PROPN	I
Hospital	O	PROPN	B
,	O	PUNCT	O
Montreal	O	PROPN	B
.	O	PUNCT	O


PATIENTS	O	NOUN	B
:	O	PUNCT	O
One	O	NUM	O
hundred	O	NUM	O
and	O	CCONJ	O
one	O	NUM	O
patients	O	NOUN	B
(	O	PUNCT	O
28	O	NUM	O
men	O	NOUN	B
and	O	CCONJ	O
73	O	NUM	O
women	O	NOUN	B
)	O	PUNCT	O
with	O	ADP	O
bipolar	B-Disease	ADJ	B
disorder	I-Disease	NOUN	I
receiving	O	VERB	O
lithium	B-Chemical	NOUN	B
maintenance	O	NOUN	O
therapy	O	NOUN	O
ranging	O	VERB	O
from	O	ADP	O
1	O	NUM	O
year	O	NOUN	B
'	O	PART	O
s	O	NOUN	O
to	O	ADP	O
32	O	NUM	O
years	O	NOUN	B
'	O	PART	O
duration	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
control	O	ADJ	B
group	O	NOUN	I
consisted	O	VERB	O
of	O	ADP	O
82	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
no	O	DET	O
psychiatric	B-Disease	ADJ	B
or	O	CCONJ	O
endocrinological	O	ADJ	B
diagnoses	O	NOUN	I
from	O	ADP	O
the	O	DET	O
hospital	O	NOUN	B
'	O	PART	O
s	O	NOUN	O
out	O	ADJ	B
-	O	PUNCT	O
patient	O	NOUN	B
clinics	O	NOUN	B
.	O	PUNCT	O


OUTCOME	O	NOUN	B
MEASURES	O	NOUN	I
:	O	PUNCT	O
Laboratory	O	NOUN	B
analyses	O	NOUN	I
of	O	ADP	O
calcium	B-Chemical	NOUN	B
,	O	PUNCT	O
magnesium	B-Chemical	NOUN	B
and	O	CCONJ	O
thyroid	O	NOUN	B
-	O	PUNCT	O
stimulating	O	VERB	B
hormone	O	NOUN	B
levels	O	NOUN	B
performed	O	VERB	O
before	O	ADP	O
beginning	O	VERB	O
lithium	B-Chemical	NOUN	B
therapy	O	NOUN	I
and	O	CCONJ	O
at	O	ADP	O
biannual	O	ADJ	B
follow	O	NOUN	B
-	O	PUNCT	O
up	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
Hypothyroidism	B-Disease	NOUN	B
developed	O	VERB	O
in	O	ADP	O
40	O	NUM	O
patients	O	NOUN	B
,	O	PUNCT	O
excluding	O	VERB	O
8	O	NUM	O
patients	O	NOUN	B
who	O	PRON	O
were	O	AUX	O
hypothyroid	B-Disease	ADJ	B
at	O	ADP	O
baseline	O	NOUN	B
.	O	PUNCT	O


All	O	DET	O
patients	O	NOUN	B
having	O	VERB	O
first	O	ADJ	B
-	O	PUNCT	O
degree	O	NOUN	B
relatives	O	NOUN	O
affected	O	VERB	B
by	O	ADP	O
thyroid	B-Disease	NOUN	B
illness	I-Disease	NOUN	I
had	O	AUX	O
accelerated	O	VERB	B
onset	O	NOUN	O
of	O	ADP	O
hypothyroidism	B-Disease	NOUN	B
(	O	PUNCT	O
3	O	NUM	O
.	O	PUNCT	O


7	O	NUM	O
years	O	NOUN	B
after	O	ADP	O
onset	O	NOUN	O
of	O	ADP	O
lithium	B-Chemical	NOUN	B
therapy	O	NOUN	I
)	O	PUNCT	O
compared	O	VERB	O
with	O	ADP	O
patients	O	NOUN	B
without	O	ADP	O
a	O	DET	O
family	O	NOUN	B
history	O	NOUN	I
(	O	PUNCT	O
8	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
years	O	NOUN	B
after	O	ADP	O
onset	O	NOUN	O
of	O	ADP	O
lithium	B-Chemical	NOUN	B
therapy	O	NOUN	I
).	O	PUNCT	B
Women	O	NOUN	B
over	O	ADP	O
60	O	NUM	O
years	O	NOUN	B
of	O	ADP	O
age	O	NOUN	B
were	O	AUX	O
more	O	ADV	O
often	O	ADV	O
affected	O	VERB	B
by	O	ADP	O
hypothyroidism	B-Disease	NOUN	B
than	O	ADP	O
women	O	NOUN	B
under	O	ADP	O
60	O	NUM	O
years	O	NOUN	B
of	O	ADP	O
age	O	NOUN	B
(	O	PUNCT	O
34	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
%	O	NOUN	O
versus	O	CCONJ	O
31	O	NUM	O
.	O	PUNCT	O


9	O	NUM	O
%).	O	ADJ	B
Magnesium	B-Chemical	NOUN	B
levels	O	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
on	O	ADP	O
lithium	B-Chemical	NOUN	B
treatment	O	NOUN	B
were	O	AUX	O
unchanged	O	ADJ	B
from	O	ADP	O
baseline	O	NOUN	B
levels	O	NOUN	B
.	O	PUNCT	O


After	O	ADP	O
lithium	B-Chemical	NOUN	B
treatment	O	NOUN	B
,	O	PUNCT	O
calcium	B-Chemical	NOUN	B
levels	O	NOUN	I
were	O	AUX	O
higher	O	ADJ	O
than	O	ADP	O
either	O	CCONJ	O
baseline	O	NOUN	B
levels	O	NOUN	B
or	O	CCONJ	O
control	O	NOUN	B
levels	O	NOUN	I
.	O	PUNCT	O


Thus	O	ADV	O
,	O	PUNCT	O
lithium	B-Chemical	NOUN	B
treatment	O	NOUN	B
counteracted	O	VERB	B
the	O	DET	O
decrease	O	NOUN	B
in	O	ADP	O
plasma	O	NOUN	B
calcium	B-Chemical	NOUN	O
levels	O	NOUN	O
associated	O	VERB	B
with	O	ADP	I
aging	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
:	O	PUNCT	O
Familial	O	ADJ	B
thyroid	B-Disease	NOUN	I
illness	I-Disease	NOUN	I
is	O	AUX	O
a	O	DET	O
risk	O	NOUN	B
factor	O	NOUN	I
for	O	ADP	O
hypothyroidism	B-Disease	NOUN	B
and	O	CCONJ	O
hypercalcemia	B-Disease	NOUN	B
during	O	ADP	O
lithium	B-Chemical	NOUN	B


Systemic	O	ADJ	B
toxicity	B-Disease	NOUN	B
following	O	VERB	O
administration	O	NOUN	B
of	O	ADP	O
sirolimus	B-Chemical	NOUN	B
(	O	PUNCT	O
formerly	O	ADV	O
rapamycin	B-Chemical	NOUN	B
)	O	PUNCT	O
for	O	ADP	O
psoriasis	B-Disease	NOUN	B
:	O	PUNCT	O
association	O	NOUN	B
of	O	ADP	O
capillary	B-Disease	ADJ	B
leak	I-Disease	NOUN	I
syndrome	I-Disease	NOUN	I
with	O	ADP	O
apoptosis	O	NOUN	B
of	O	ADP	O
lesional	O	ADJ	B
lymphocytes	O	NOUN	I
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
:	O	PUNCT	O
Sirolimus	B-Chemical	NOUN	B
(	O	PUNCT	O
formerly	O	ADV	O
rapamycin	B-Chemical	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
an	O	DET	O
immunosuppressive	O	ADJ	B
agent	O	NOUN	I
that	O	PRON	O
interferes	O	VERB	B
with	O	ADP	I
T	O	NOUN	B
-	O	PUNCT	O
cell	O	NOUN	B
activation	O	NOUN	B
.	O	PUNCT	O


After	O	ADP	O
2	O	NUM	O
individuals	O	NOUN	B
with	O	ADP	O
psoriasis	B-Disease	NOUN	B
developed	O	VERB	O
a	O	DET	O
capillary	B-Disease	ADJ	B
leak	I-Disease	NOUN	I
syndrome	I-Disease	NOUN	I
following	O	VERB	O
treatment	O	NOUN	B
with	O	ADP	O
oral	O	ADJ	B
sirolimus	B-Chemical	NOUN	I
lesional	O	ADJ	I
skin	O	NOUN	I
cells	O	NOUN	I
and	O	CCONJ	O
activated	O	VERB	B
peripheral	O	ADJ	O
blood	O	NOUN	O
cells	O	NOUN	O
were	O	AUX	O
analyzed	O	VERB	B
for	O	ADP	O
induction	O	NOUN	B
of	O	ADP	O
apoptosis	O	NOUN	B
.	O	PUNCT	O


OBSERVATIONS	O	NOUN	B
:	O	PUNCT	O
A	O	DET	O
keratome	O	ADJ	B
skin	O	NOUN	I
specimen	O	NOUN	I
from	O	ADP	O
1	O	NUM	O
patient	O	NOUN	B
with	O	ADP	O
sirolimus	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
capillary	B-Disease	ADJ	B
leak	I-Disease	NOUN	I
syndrome	I-Disease	NOUN	I
had	O	AUX	O
a	O	DET	O
2	O	NUM	O
.	O	PUNCT	O


3	O	NUM	O
-	O	PUNCT	O
fold	O	ADJ	B
increase	O	NOUN	B
in	O	ADP	O
percentage	O	NOUN	B
of	O	ADP	O
apoptotic	O	ADJ	B
cells	O	NOUN	I
(	O	PUNCT	O
to	O	PART	O
48	O	NUM	O
%)	O	NOUN	O
compared	O	VERB	B
with	O	ADP	O
an	O	DET	O
unaffected	O	ADJ	O
sirolimus	B-Chemical	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
patient	O	NOUN	B
with	O	ADP	O
psoriasis	B-Disease	NOUN	B
(	O	PUNCT	O
21	O	NUM	O
%).	O	NOUN	O
Activated	O	VERB	B
peripheral	O	ADJ	B
blood	O	NOUN	I
T	O	NOUN	I
cells	O	NOUN	I
from	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
psoriasis	B-Disease	NOUN	B
tended	O	VERB	O
to	O	PART	O
exhibit	O	VERB	O
greater	O	ADJ	O
spontaneous	O	ADJ	B
or	O	CCONJ	O
dexamethasone	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
apoptosis	O	NOUN	B
than	O	ADP	O
did	O	AUX	O
normal	O	ADJ	O
T	O	NOUN	B
cells	O	NOUN	I
,	O	PUNCT	O
particularly	O	ADV	O
in	O	ADP	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
sirolimus	B-Chemical	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
:	O	PUNCT	O
Severe	O	ADJ	B
adverse	O	ADJ	B
effects	O	NOUN	I
of	O	ADP	O
sirolimus	B-Chemical	NOUN	B
include	O	VERB	O
fever	B-Disease	NOUN	B
,	O	PUNCT	O
anemia	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
capillary	B-Disease	ADJ	B
leak	I-Disease	NOUN	I
syndrome	I-Disease	NOUN	I
.	O	PUNCT	O


These	O	DET	O
symptoms	O	NOUN	B
may	O	AUX	O
be	O	AUX	O
the	O	DET	O
result	O	NOUN	B
of	O	ADP	O
drug	O	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
apoptosis	O	NOUN	B
of	O	ADP	O
lesional	O	ADJ	B
leukocytes	O	NOUN	B
,	O	PUNCT	O
especially	O	ADV	O
activated	O	VERB	B
T	O	NOUN	B
lymphocytes	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
possibly	O	ADV	O
release	O	NOUN	O
of	O	ADP	O
inflammatory	O	ADJ	B
mediators	O	NOUN	I
.	O	PUNCT	O


Because	O	SCONJ	O
patients	O	NOUN	B
with	O	ADP	O
severe	O	ADJ	B
psoriasis	B-Disease	NOUN	B
may	O	AUX	O
develop	O	VERB	O
capillary	B-Disease	ADJ	B
leak	I-Disease	NOUN	I
from	O	ADP	O
various	O	ADJ	O
systemic	O	ADJ	B
therapies	O	NOUN	I
,	O	PUNCT	O
clinical	O	ADJ	B
monitoring	O	NOUN	I
is	O	AUX	O
advisable	O	ADJ	O
for	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
inflammatory	B-Disease	ADJ	B
diseases	I-Disease	NOUN	I


Contribution	O	NOUN	B
of	O	ADP	O
the	O	DET	O
glycine	B-Chemical	NOUN	B
site	O	NOUN	I
of	O	ADP	O
NMDA	B-Chemical	NOUN	B
receptors	O	NOUN	I
in	O	ADP	O
rostral	O	ADJ	B
and	O	CCONJ	O
intermediate	O	ADJ	B
-	O	PUNCT	O
caudal	O	ADJ	B
parts	O	NOUN	B
of	O	ADP	O
the	O	DET	O
striatum	O	NOUN	B
to	O	PART	O
the	O	DET	O
regulation	O	NOUN	B
of	O	ADP	O
muscle	O	NOUN	B
tone	O	NOUN	I
in	O	ADP	O
rats	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
aim	O	NOUN	O
of	O	ADP	O
the	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
assess	O	VERB	B
the	O	DET	O
contribution	O	NOUN	B
of	O	ADP	O
the	O	DET	O
glycine	B-Chemical	NOUN	B
site	O	NOUN	I
of	O	ADP	O
NMDA	B-Chemical	NOUN	B
receptors	O	NOUN	I
in	O	ADP	O
the	O	DET	O
striatum	O	NOUN	B
to	O	PART	O
the	O	DET	O
regulation	O	NOUN	B
of	O	ADP	O
muscle	O	NOUN	B
tone	O	NOUN	I
.	O	PUNCT	O


Muscle	O	PROPN	B
tone	O	NOUN	I
was	O	AUX	O
examined	O	VERB	O
using	O	VERB	O
a	O	DET	O
combined	O	ADJ	B
mechanoand	O	NOUN	O
electromyographic	O	ADJ	O
method	O	NOUN	O
,	O	PUNCT	O
which	O	DET	O
measured	O	VERB	B
simultaneously	O	ADV	B
the	O	DET	O
muscle	O	NOUN	B
resistance	O	NOUN	I
(	O	PUNCT	O
MMG	O	NOUN	B
)	O	PUNCT	O
of	O	ADP	O
the	O	DET	O
rat	O	NOUN	B
'	O	PART	O
s	O	NOUN	O
hind	O	ADJ	B
foot	O	NOUN	O
to	O	PART	O
passive	O	ADJ	O
extension	O	NOUN	B
and	O	CCONJ	O
flexion	O	NOUN	B
in	O	ADP	O
the	O	DET	O
ankle	O	NOUN	B
joint	O	NOUN	I
and	O	CCONJ	O
the	O	DET	O
electromyographic	O	ADJ	B
activity	O	NOUN	I
(	O	PUNCT	O
EMG	O	NOUN	B
)	O	PUNCT	O
of	O	ADP	O
the	O	DET	O
antagonistic	O	ADJ	B
muscles	O	NOUN	I
of	O	ADP	O
that	O	DET	O
joint	O	NOUN	B
:	O	PUNCT	O
gastrocnemius	O	NOUN	B
and	O	CCONJ	O
tibialis	O	NOUN	B
anterior	O	NOUN	I
.	O	PUNCT	O


Muscle	B-Disease	NOUN	B
rigidity	I-Disease	NOUN	I
was	O	AUX	O
induced	O	VERB	B
by	O	ADP	O
haloperidol	B-Chemical	NOUN	B
(	O	PUNCT	O
2	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	O
i	O	X	O
.	O	PUNCT	O


p	O	NOUN	O
.).	O	NOUN	O
5,7-dichlorokynurenic	B-Chemical	ADJ	O
acid	I-Chemical	NOUN	O
(	O	PUNCT	O
5,7-DCKA	B-Chemical	NOUN	O
),	O	PUNCT	O
a	O	DET	O
selective	O	ADJ	O
glycine	B-Chemical	NOUN	B
site	O	NOUN	I
antagonist	O	NOUN	B
,	O	PUNCT	O
injected	O	VERB	B
in	O	ADP	O
doses	O	NOUN	B
of	O	ADP	O
2	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
and	O	CCONJ	O
4	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
microg	O	NOUN	B
/	O	SYM	O
0	O	NUM	B
.	O	PUNCT	O


5	O	NUM	O
microl	O	NOUN	B
bilaterally	O	ADV	B
,	O	PUNCT	O
into	O	ADP	O
the	O	DET	O
rostral	O	ADJ	B
region	O	NOUN	I
of	O	ADP	O
the	O	DET	O
striatum	O	NOUN	B
,	O	PUNCT	O
decreased	O	VERB	B
both	O	CCONJ	O
the	O	DET	O
haloperidol	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
muscle	B-Disease	NOUN	B
rigidity	I-Disease	NOUN	I
(	O	PUNCT	O
MMG	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
enhanced	O	VERB	B
electromyographic	O	ADJ	B
activity	O	NOUN	I
(	O	PUNCT	O
EMG	O	NOUN	B
).	O	PUNCT	O
5,7-DCKA	B-Chemical	NOUN	O
injected	O	VERB	B
bilaterally	O	ADV	B
in	O	ADP	O
a	O	DET	O
dose	O	NOUN	B
of	O	ADP	O
4	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
microg	O	NOUN	B
/	O	SYM	O
0	O	NUM	B
.	O	PUNCT	O


5	O	NUM	O
microl	O	NOUN	B
into	O	ADP	O
the	O	DET	O
intermediate	O	ADJ	B
-	O	PUNCT	O
caudal	O	ADJ	B
region	O	NOUN	B
of	O	ADP	O
the	O	DET	O
striatum	O	NOUN	B
of	O	ADP	O
rats	O	NOUN	B
not	O	PART	O
pretreated	O	VERB	O
with	O	ADP	O
haloperidol	B-Chemical	NOUN	B
had	O	AUX	O
no	O	DET	B
effect	O	NOUN	I
on	O	ADP	O
the	O	DET	O
muscle	O	NOUN	B
tone	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
present	O	ADJ	O
results	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
blockade	O	NOUN	B
of	O	ADP	O
the	O	DET	O
glycine	B-Chemical	NOUN	B
site	O	NOUN	I
of	O	ADP	O
NMDA	B-Chemical	NOUN	B


Efficacy	O	NOUN	B
and	O	CCONJ	O
tolerability	O	NOUN	B
of	O	ADP	O
lovastatin	B-Chemical	NOUN	B
in	O	ADP	O
3390	O	NUM	O
women	O	NOUN	B
with	O	ADP	O
moderate	O	ADJ	B
hypercholesterolemia	B-Disease	NOUN	B
.	O	PUNCT	O


OBJECTIVE	O	NOUN	B
:	O	PUNCT	O
To	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
efficacy	O	NOUN	B
and	O	CCONJ	O
safety	O	NOUN	B
of	O	ADP	O
lovastatin	B-Chemical	NOUN	B
in	O	ADP	O
women	O	NOUN	B
with	O	ADP	O
moderate	O	ADJ	B
hypercholesterolemia	B-Disease	NOUN	B
.	O	PUNCT	O


DESIGN	O	NOUN	O
:	O	PUNCT	O
The	O	DET	O
Expanded	O	ADJ	B
Clinical	O	PROPN	I
Evaluation	O	NOUN	I
of	O	ADP	O
Lovastatin	B-Chemical	NOUN	B
(	O	PUNCT	O
EXCEL	O	NOUN	B
)	O	PUNCT	O
Study	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
multicenter	O	NOUN	B
,	O	PUNCT	O
double	O	ADJ	B
-	O	PUNCT	O
blind	O	ADJ	B
,	O	PUNCT	O
diet	O	NOUN	B
-	O	PUNCT	O
and	O	CCONJ	O
placebo	O	NOUN	B
-	O	PUNCT	O
controlled	O	VERB	B
trial	O	NOUN	I
,	O	PUNCT	O
in	O	ADP	O
which	O	DET	O
participants	O	NOUN	B
were	O	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
to	O	PART	O
receive	O	VERB	O
placebo	O	NOUN	B
or	O	CCONJ	O
lovastatin	B-Chemical	NOUN	B
at	O	ADP	O
doses	O	NOUN	B
of	O	ADP	O
20	O	NUM	O
or	O	CCONJ	O
40	O	NUM	O
mg	O	NOUN	O
once	O	ADV	B
daily	O	ADV	I
,	O	PUNCT	O
or	O	CCONJ	O
20	O	NUM	O
or	O	CCONJ	O
40	O	NUM	O
mg	O	NOUN	O
twice	O	ADV	O
daily	O	ADV	B
for	O	ADP	O
48	O	NUM	O
weeks	O	NOUN	B
.	O	PUNCT	O


SETTING	O	NOUN	B
:	O	PUNCT	O
Ambulatory	O	ADJ	B
patients	O	NOUN	B
recruited	O	VERB	O
by	O	ADP	O
362	O	NUM	O
participating	O	VERB	O
centers	O	NOUN	B
throughout	O	ADP	O
the	O	DET	O
United	O	PROPN	B
States	O	PROPN	I
.	O	PUNCT	O


PATIENTS	O	NOUN	B
:	O	PUNCT	O
Women	O	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
3390	O	NUM	O
)	O	PUNCT	O
from	O	ADP	O
the	O	DET	O
total	O	ADJ	O
cohort	O	NOUN	B
of	O	ADP	O
8245	O	NUM	O
volunteers	O	NOUN	B
.	O	PUNCT	O


MEASUREMENTS	O	NOUN	B
:	O	PUNCT	O
Plasma	O	NOUN	B
total	O	NOUN	O
,	O	PUNCT	O
low	O	ADJ	B
-	O	PUNCT	O
density	O	NOUN	B
lipoprotein	O	NOUN	I
(	O	PUNCT	O
LDL	O	NOUN	B
),	O	PUNCT	O
and	O	CCONJ	O
high	O	ADJ	B
-	O	PUNCT	O
density	O	NOUN	B
lipoprotein	O	NOUN	I
(	O	PUNCT	I
HDL	O	NOUN	O
)	O	PUNCT	O
cholesterol	B-Chemical	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
triglycerides	B-Chemical	NOUN	B
;	O	PUNCT	O
and	O	CCONJ	O
laboratory	O	ADJ	B
and	O	CCONJ	O
clinical	O	ADJ	B
evidence	O	NOUN	I
of	O	ADP	O
adverse	O	ADJ	B
events	O	NOUN	I
monitored	O	VERB	O
periodically	O	ADV	O
throughout	O	ADP	O
the	O	DET	O
study	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
Among	O	ADP	O
women	O	NOUN	B
,	O	PUNCT	O
lovastatin	B-Chemical	NOUN	B
(	O	PUNCT	O
20	O	NUM	O
to	O	PART	O
80	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
d	O	NOUN	O
)	O	PUNCT	O
produced	O	VERB	O
sustained	O	ADJ	B
(	O	PUNCT	O
12	O	NUM	O
-	O	PUNCT	O
to	O	ADP	O
48	O	NUM	O
-	O	PUNCT	O
week	O	NOUN	B
),	O	PUNCT	O
dose	O	NOUN	B
-	O	PUNCT	O
related	O	VERB	B
changes	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


001	O	NUM	O
):	O	PUNCT	O
decreases	O	VERB	B
in	O	ADP	O
LDL	O	NOUN	B
cholesterol	B-Chemical	NOUN	I
(	O	PUNCT	O
24	O	NUM	O
%	O	NOUN	O
to	O	PART	O
40	O	NUM	O
%)	O	NOUN	O
and	O	CCONJ	O
triglycerides	B-Chemical	NOUN	B
(	O	PUNCT	O
9	O	NUM	O
%	O	NOUN	O
to	O	PART	O
18	O	NUM	O
%),	O	NOUN	B
and	O	CCONJ	O
increases	O	NOUN	B
in	O	ADP	O
HDL	O	NOUN	B
cholesterol	B-Chemical	NOUN	I
(	O	PUNCT	O
6	O	NUM	O
.	O	PUNCT	O


7	O	NUM	O
%	O	NOUN	O
to	O	PART	O
8	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
%).	O	NOUN	B
Depending	O	VERB	O
on	O	ADP	O
the	O	DET	O
dose	O	NOUN	B
,	O	PUNCT	O
from	O	ADP	O
82	O	NUM	O
%	O	NOUN	O
to	O	PART	O
95	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
lovastatin	B-Chemical	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
women	O	NOUN	B
achieved	O	VERB	O
the	O	DET	O
National	O	PROPN	B
Cholesterol	B-Chemical	PROPN	I
Education	O	PROPN	I
Program	O	PROPN	I
goal	O	NOUN	O
of	O	ADP	O
LDL	O	NOUN	B
cholesterol	B-Chemical	NOUN	I
levels	O	NOUN	I
less	O	ADJ	O
than	O	ADP	O
4	O	NUM	O
.	O	PUNCT	O


14	O	NUM	O
mmol	O	NOUN	B
/	O	SYM	O
L	O	NOUN	B
(	O	PUNCT	O
160	O	NUM	O
mg	O	NOUN	O
/	O	PUNCT	O
dL	O	NOUN	B
),	O	PUNCT	O
and	O	CCONJ	O
40	O	NUM	O
%	O	NOUN	O
to	O	PART	O
87	O	NUM	O
%	O	NOUN	O
achieved	O	VERB	O
the	O	DET	O
goal	O	NOUN	B
of	O	ADP	O
3	O	NUM	O
.	O	PUNCT	O


36	O	NUM	O
mmol	O	NOUN	B
/	O	SYM	O
L	O	NOUN	B
(	O	PUNCT	O
130	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
dL	O	NOUN	B
).	O	PUNCT	O
Successive	O	ADJ	B
transaminase	O	NOUN	B
elevations	O	NOUN	B
greater	O	ADJ	O
than	O	ADP	O
three	O	NUM	O
times	O	NOUN	O
the	O	DET	O
upper	O	ADJ	O
limit	O	NOUN	O
of	O	ADP	O
normal	O	ADJ	O
occurred	O	VERB	O
in	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
women	O	NOUN	B
and	O	CCONJ	O
were	O	AUX	O
dose	O	NOUN	B
dependent	O	ADJ	O
above	O	ADP	O
the	O	DET	O
20	O	NUM	O
-	O	PUNCT	O
mg	O	NOUN	O
dose	O	NOUN	B
.	O	PUNCT	O


Myopathy	B-Disease	NOUN	B
,	O	PUNCT	O
defined	O	VERB	O
as	O	ADP	O
muscle	O	NOUN	B
symptoms	O	NOUN	I
with	O	ADP	O
creatine	B-Chemical	NOUN	B
kinase	O	NOUN	I
elevations	O	NOUN	B
greater	O	ADJ	O
than	O	ADP	O
10	O	NUM	O
times	O	NOUN	O
the	O	DET	O
upper	O	ADJ	O
limit	O	NOUN	O
of	O	ADP	O
normal	O	ADJ	B
,	O	PUNCT	O
was	O	AUX	O
rare	O	ADJ	B
and	O	CCONJ	O
associated	O	VERB	B
with	O	ADP	I
the	O	DET	O
highest	O	ADV	B
recommended	O	VERB	O
daily	O	ADJ	O
dose	O	NOUN	O
of	O	ADP	O
lovastatin	B-Chemical	NOUN	B
(	O	PUNCT	O
80	O	NUM	O
mg	O	NOUN	O
).	O	PUNCT	O
Estrogen	O	NOUN	B
-	O	PUNCT	O
replacement	O	NOUN	B
therapy	O	NOUN	I
appeared	O	VERB	O
to	O	PART	O
have	O	AUX	O
no	O	DET	O
effect	O	NOUN	O
on	O	ADP	O
either	O	CCONJ	O
the	O	DET	O
efficacy	O	NOUN	B
or	O	CCONJ	O
safety	O	NOUN	B
profile	O	NOUN	I
of	O	ADP	O
lovastatin	B-Chemical	NOUN	B
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
:	O	PUNCT	O
Lovastatin	B-Chemical	NOUN	B
is	O	AUX	O
highly	O	ADV	O
effective	O	ADJ	B
and	O	CCONJ	O
generally	O	ADV	O
well	O	ADV	O
tolerated	O	VERB	B
as	O	ADP	O
therapy	O	NOUN	B
for	O	ADP	O
primary	O	ADJ	B
hypercholesterolemia	B-Disease	NOUN	B


REM	B-Disease	NOUN	B
sleep	I-Disease	NOUN	I
deprivation	I-Disease	NOUN	I
changes	O	VERB	O
behavioral	O	ADJ	B
response	O	NOUN	O
to	O	PART	O
catecholaminergic	O	ADJ	B
and	O	CCONJ	O
serotonergic	O	ADJ	B
receptor	O	NOUN	I
activation	O	NOUN	B
in	O	ADP	O
rats	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
REM	B-Disease	NOUN	B
sleep	I-Disease	NOUN	I
deprivation	I-Disease	NOUN	I
(	O	PUNCT	O
REMD	B-Disease	NOUN	B
)	O	PUNCT	O
on	O	ADP	O
apomorphine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
aggressiveness	B-Disease	NOUN	B
and	O	CCONJ	O
quipazine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
head	B-Disease	NOUN	B
twitches	I-Disease	NOUN	I
in	O	ADP	O
rats	O	NOUN	B
were	O	AUX	O
determined	O	VERB	O
.	O	PUNCT	O


Forty	O	NUM	B
-	O	PUNCT	O
eight	O	NUM	O
hr	O	NOUN	O
of	O	ADP	O
REMD	B-Disease	NOUN	B
increased	O	VERB	B
apomorphine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
aggressiveness	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
reduced	O	VERB	B
(	O	PUNCT	O
immediately	O	ADV	O
after	O	ADP	O
completing	O	VERB	O
of	O	ADP	O
REMD	B-Disease	NOUN	B
)	O	PUNCT	O
or	O	CCONJ	O
increased	O	VERB	B
(	O	PUNCT	O
96	O	NUM	O
hr	O	NOUN	O
after	O	ADP	O
completing	O	VERB	O
of	O	ADP	O
REMD	B-Disease	NOUN	B
)	O	PUNCT	O
quipazine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
head	B-Disease	NOUN	B
twitches	I-Disease	NOUN	I


Extrapyramidal	O	ADJ	B
side	O	NOUN	B
effects	O	NOUN	I
and	O	CCONJ	O
oral	O	ADJ	B
haloperidol	B-Chemical	NOUN	I
:	O	PUNCT	O
an	O	DET	O
analysis	O	NOUN	B
of	O	ADP	O
explanatory	O	ADJ	B
patient	O	NOUN	B
and	O	CCONJ	O
treatment	O	NOUN	B
characteristics	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
incidence	O	NOUN	B
of	O	ADP	O
extrapyramidal	O	ADJ	B
side	O	NOUN	I
effects	O	NOUN	I
(	O	PUNCT	O
EPS	O	NOUN	B
)	O	PUNCT	O
was	O	AUX	O
evaluated	O	VERB	B
in	O	ADP	O
98	O	NUM	O
patients	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
haloperidol	B-Chemical	NOUN	B
.	O	PUNCT	O


The	O	DET	O
incidence	O	NOUN	B
of	O	ADP	O
parkinsonism	B-Disease	NOUN	B
was	O	AUX	O
higher	O	ADJ	B
at	O	ADP	O
higher	O	ADJ	B
doses	O	NOUN	B
of	O	ADP	O
haloperidol	B-Chemical	NOUN	B
and	O	CCONJ	O
in	O	ADP	O
younger	O	ADJ	B
patients	O	NOUN	B
.	O	PUNCT	O


Prophylactic	O	ADJ	B
antiparkinsonian	O	ADJ	I
medication	O	NOUN	I
was	O	AUX	O
effective	O	ADJ	B
in	O	ADP	O
younger	O	ADJ	B
but	O	CCONJ	O
not	O	PART	O
in	O	ADP	O
older	O	ADJ	B
patients	O	NOUN	I
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
these	O	DET	O
medications	O	NOUN	B
were	O	AUX	O
more	O	ADV	O
effective	O	ADJ	B
in	O	ADP	O
both	O	CCONJ	O
young	O	ADJ	B
and	O	CCONJ	O
old	O	ADJ	O
patients	O	NOUN	B
when	O	SCONJ	O
given	O	VERB	O
after	O	ADP	O
parkinsonism	B-Disease	NOUN	B
developed	O	VERB	O
.	O	PUNCT	O


Akathisia	B-Disease	PROPN	B
was	O	AUX	O
controlled	O	VERB	B
by	O	ADP	O
the	O	DET	O
benzodiazepine	B-Chemical	NOUN	B
lorazepam	B-Chemical	NOUN	B
in	O	ADP	O
14	O	NUM	O
out	O	ADP	O
of	O	ADP	O
16	O	NUM	O
patients	O	NOUN	B
,	O	PUNCT	O
while	O	SCONJ	O
prophylactic	O	ADJ	B
antiparkinsonians	O	NOUN	I
were	O	AUX	O
ineffective	O	ADJ	B
.	O	PUNCT	O


The	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
points	O	VERB	O
to	O	PART	O
patient	O	NOUN	B
characteristics	O	NOUN	B
that	O	PRON	O
may	O	AUX	O
be	O	AUX	O
of	O	ADP	O
significance	O	NOUN	B
in	O	ADP	O
the	O	DET	O
development	O	NOUN	B
of	O	ADP	O
EPS	O	NOUN	B
due	O	ADJ	O
to	O	PART	O
haloperidol	B-Chemical	NOUN	B


Hepatic	B-Disease	ADJ	B
veno-occlusive	I-Disease	ADJ	I
disease	I-Disease	NOUN	I
caused	O	VERB	O
by	O	ADP	O
6-thioguanine	B-Chemical	NOUN	B
.	O	PUNCT	O


Clinically	O	ADV	O
reversible	O	ADJ	O
veno-occlusive	B-Disease	ADJ	B
disease	I-Disease	NOUN	I
of	I-Disease	ADP	O
the	I-Disease	DET	O
liver	I-Disease	NOUN	B
developed	O	VERB	O
in	O	ADP	O
a	O	DET	O
23	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
man	O	NOUN	B
with	O	ADP	O
acute	B-Disease	ADJ	B
lymphocytic	I-Disease	ADJ	I
leukemia	I-Disease	NOUN	I
after	O	ADP	O
10	O	NUM	O
months	O	NOUN	B
of	O	ADP	O
maintenance	O	NOUN	B
therapy	O	NOUN	I
with	O	ADP	O
6-thioguanine	B-Chemical	NOUN	B
.	O	PUNCT	O


Serial	O	ADJ	B
liver	O	NOUN	B
biopsies	O	NOUN	I
showed	O	VERB	O
the	O	DET	O
development	O	NOUN	B
and	O	CCONJ	O
resolution	O	NOUN	B
of	O	ADP	O
intense	O	ADJ	B
sinusoidal	O	ADJ	B
engorgement	O	NOUN	O
.	O	PUNCT	O


Although	O	SCONJ	O
this	O	DET	O
disease	O	NOUN	B
was	O	AUX	O
clinically	O	ADV	O
reversible	O	ADJ	O
,	O	PUNCT	O
some	O	DET	O
subintimal	O	ADJ	B
fibrosis	B-Disease	NOUN	I
about	O	ADP	O
the	O	DET	O
terminal	O	ADJ	B
hepatic	O	ADJ	B
veins	O	NOUN	I
persisted	O	VERB	O
.	O	PUNCT	O


This	O	DET	O
case	O	NOUN	B
presented	O	VERB	O
a	O	DET	O
unique	O	ADJ	O
opportunity	O	NOUN	O
to	O	PART	O
observe	O	VERB	O
the	O	DET	O
histologic	O	ADJ	B
features	O	NOUN	B
of	O	ADP	O
clinically	O	ADV	B
reversible	O	ADJ	O
hepatic	B-Disease	ADJ	B
veno-occlusive	I-Disease	ADJ	I
disease	I-Disease	NOUN	I
over	O	ADP	O
time	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
may	O	AUX	O
be	O	AUX	O
the	O	DET	O
first	O	ADJ	O
case	O	NOUN	B
of	O	ADP	O
veno	O	NOUN	B
-	O	PUNCT	O
occlusive	O	ADJ	B
related	O	ADJ	O
solely	O	ADV	O
to	O	PART	O
6-thioguanine	B-Chemical	NOUN	B


Treatment	O	NOUN	B
of	O	ADP	O
ifosfamide	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
urothelial	B-Disease	ADJ	B
toxicity	I-Disease	NOUN	B
by	O	ADP	O
oral	O	ADJ	B
administration	O	NOUN	I
of	O	ADP	O
sodium	B-Chemical	NOUN	B
2-mercaptoethane	I-Chemical	ADJ	I
sulphonate	I-Chemical	NOUN	I
(	O	PUNCT	O
MESNA	B-Chemical	NOUN	B
)	O	PUNCT	O
to	O	PART	O
patients	O	NOUN	B
with	O	ADP	O
inoperable	O	ADJ	B
lung	B-Disease	NOUN	I
cancer	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
protective	O	ADJ	B
effect	O	NOUN	I
of	O	ADP	O
oral	O	ADJ	B
administration	O	NOUN	I
of	O	ADP	O
the	O	DET	O
thiol	B-Chemical	NOUN	B
compound	O	NOUN	I
sodium	B-Chemical	NOUN	I
2-mercaptoethane	I-Chemical	ADJ	I
sulphonate	I-Chemical	NOUN	I
(	O	PUNCT	O
MESNA	B-Chemical	NOUN	B
)	O	PUNCT	O
against	O	ADP	O
urothelial	B-Disease	ADJ	B
toxicity	I-Disease	NOUN	B
induced	O	VERB	B
by	O	ADP	O
ifosfamide	B-Chemical	NOUN	B
(	O	PUNCT	O
IF	B-Chemical	NOUN	B
)	O	PUNCT	O
was	O	AUX	O
tested	O	VERB	B
in	O	ADP	O
a	O	DET	O
group	O	NOUN	B
of	O	ADP	O
45	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
inoperable	O	ADJ	B
lung	B-Disease	NOUN	I
cancer	I-Disease	NOUN	I
under	O	ADP	O
treatment	O	NOUN	B
with	O	ADP	O
IF	B-Chemical	NOUN	B
(	O	PUNCT	O
2250	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
m2	O	NOUN	B
on	O	ADP	O
days	O	NOUN	B
2	O	NUM	O
-	O	SYM	O
5	O	NUM	O
)	O	PUNCT	O
as	O	ADP	O
part	O	NOUN	O
of	O	ADP	O
a	O	DET	O
polychemotherapy	O	NOUN	B
regimen	O	NOUN	B
repeated	O	VERB	O
in	O	ADP	O
a	O	DET	O
4	O	NUM	B
-	O	PUNCT	O
week	O	NOUN	B
cycle	O	NOUN	B
.	O	PUNCT	O


MESNA	B-Chemical	NOUN	B
was	O	AUX	O
given	O	VERB	O
orally	O	ADV	B
on	O	ADP	O
the	O	DET	O
days	O	NOUN	B
of	O	ADP	O
treatment	O	NOUN	B
with	O	ADP	O
IF	B-Chemical	NOUN	B
in	O	ADP	O
3	O	NUM	O
doses	O	NOUN	B
of	O	ADP	O
840	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
m2	O	NOUN	B
,	O	PUNCT	O
each	O	DET	O
administered	O	VERB	B
at	O	ADP	O
0	O	NUM	O
hr	O	NOUN	O
(=	O	NOUN	O
injection	O	NOUN	B
of	O	ADP	O
IF	B-Chemical	NOUN	B
),	O	PUNCT	O
4	O	NUM	O
hr	O	NOUN	O
and	O	CCONJ	O
8	O	NUM	O
hr	O	NOUN	O
p	O	NOUN	O
.	O	PUNCT	O


i	O	X	O
.	O	PUNCT	O


Out	O	ADP	O
of	O	ADP	O
a	O	DET	O
total	O	NOUN	O
of	O	ADP	O
88	O	NUM	O
courses	O	NOUN	B
of	O	ADP	O
this	O	DET	O
treatment	O	NOUN	B
we	O	PRON	O
observed	O	VERB	O
10	O	NUM	O
episodes	O	NOUN	B
of	O	ADP	O
asymptomatic	O	ADJ	B
microscopic	O	ADJ	B
haematuria	B-Disease	NOUN	I
and	O	CCONJ	O
no	O	DET	O
episodes	O	NOUN	B
of	O	ADP	O
gross	O	ADJ	B
haematuria	B-Disease	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
this	O	DET	O
group	O	NOUN	B
of	O	ADP	O
45	O	NUM	O
patients	O	NOUN	B
under	O	ADP	O
protection	O	NOUN	B
with	O	ADP	O
MESNA	B-Chemical	NOUN	B
there	O	PRON	O
were	O	AUX	O
5	O	NUM	O
complete	O	ADJ	O
remissions	O	NOUN	B
and	O	CCONJ	O
9	O	NUM	O
partial	O	ADJ	B
remissions	O	NOUN	B
(	O	PUNCT	O
total	O	NOUN	O
31	O	NUM	O
%).	O	VERB	B
A	O	DET	O
further	O	ADJ	O
group	O	NOUN	B
of	O	ADP	O
25	O	NUM	O
patients	O	NOUN	B
under	O	ADP	O
polychemotherapy	O	NOUN	B
with	O	ADP	O
IF	B-Chemical	NOUN	B
were	O	AUX	O
treated	O	VERB	B
by	O	ADP	O
conventional	O	ADJ	O
prophylactic	O	ADJ	B
measures	O	NOUN	I
(	O	PUNCT	O
raised	O	VERB	B
fluid	O	ADJ	B
intake	O	NOUN	B
and	O	CCONJ	O
forced	O	VERB	B
diuresis	O	NOUN	I
).	O	PUNCT	B
In	O	ADP	O
this	O	DET	O
group	O	NOUN	B
there	O	PRON	O
were	O	AUX	O
1	O	NUM	O
complete	O	ADJ	B
and	O	CCONJ	O
5	O	NUM	O
partial	O	ADJ	B
remissions	O	NOUN	B
(	O	PUNCT	O
total	O	NOUN	O
24	O	NUM	O
%),	O	NOUN	O
but	O	CCONJ	O
nearly	O	ADV	O
all	O	DET	O
patients	O	NOUN	B
developed	O	VERB	O
either	O	CCONJ	O
gross	O	ADJ	B
haematuria	B-Disease	NOUN	I
and	O	CCONJ	O
/	O	SYM	O
or	O	CCONJ	O
symptoms	O	NOUN	B
of	O	ADP	O
bladder	B-Disease	ADJ	B
irritation	I-Disease	NOUN	I
(	O	PUNCT	O
cystitis	B-Disease	NOUN	B
and	O	CCONJ	O
pollakisuria	B-Disease	NOUN	B
).	O	PUNCT	B
There	O	PRON	O
were	O	AUX	O
no	O	DET	O
appreciable	O	ADJ	O
differences	O	NOUN	O
between	O	ADP	O
the	O	DET	O
MESNA	B-Chemical	NOUN	B
series	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
conventional	O	ADJ	B
prophylaxis	O	NOUN	B
series	O	NOUN	O
with	O	ADP	O
respect	O	NOUN	O
to	O	PART	O
either	O	CCONJ	O
haematological	O	ADJ	B
or	O	CCONJ	O
systemic	O	ADJ	B
toxicity	B-Disease	NOUN	B
of	O	ADP	O
the	O	DET	O
cytostatic	O	ADJ	B
treatment	O	NOUN	I
.	O	PUNCT	O


Our	O	PRON	O
results	O	NOUN	B
support	O	VERB	O
the	O	DET	O
view	O	NOUN	O
that	O	SCONJ	O
MESNA	B-Chemical	NOUN	B
,	O	PUNCT	O
given	O	VERB	O
orally	O	ADV	B
in	O	ADP	O
conjunction	O	NOUN	B
with	O	ADP	O
combined	O	ADJ	O
cytostatic	O	ADJ	B
regimens	O	NOUN	I
which	O	DET	O
include	O	VERB	O
IF	B-Chemical	NOUN	B
,	O	PUNCT	O
simplifies	O	VERB	O
the	O	DET	O
treatment	O	NOUN	B
and	O	CCONJ	O
provides	O	VERB	O
optimum	O	ADJ	B
protection	O	NOUN	B
for	O	ADP	O
the	O	DET	O
urinary	O	ADJ	B
epithelium	O	NOUN	I
.	O	PUNCT	O


Protection	O	NOUN	B
with	O	ADP	O
oral	O	ADJ	B
MESNA	B-Chemical	NOUN	B


Time	O	NOUN	B
course	O	NOUN	I
alterations	O	NOUN	B
of	O	ADP	O
QTC	O	PROPN	B
interval	O	NOUN	O
due	O	ADJ	O
to	O	PART	O
hypaque	B-Chemical	NOUN	B
76	I-Chemical	NUM	O
.	O	PUNCT	O


Sequential	O	ADJ	B
measurement	O	NOUN	B
of	O	ADP	O
QT	O	NOUN	B
interval	O	NOUN	I
during	O	ADP	O
left	O	ADJ	B
ventricular	O	ADJ	I
angiography	O	NOUN	I
was	O	AUX	O
made	O	VERB	O
30	O	NUM	O
seconds	O	NOUN	O
and	O	CCONJ	O
one	O	NUM	O
,	O	PUNCT	O
three	O	NUM	O
,	O	PUNCT	O
five	O	NUM	O
and	O	CCONJ	O
ten	O	NUM	O
minutes	O	NOUN	O
after	O	ADP	O
injection	O	NOUN	B
of	O	ADP	O
hypaque	B-Chemical	NOUN	B
76	I-Chemical	NUM	O
.	O	PUNCT	O


The	O	DET	O
subjects	O	NOUN	B
were	O	AUX	O
ten	O	NUM	O
patients	O	NOUN	B
found	O	VERB	O
to	O	PART	O
have	O	AUX	O
normal	O	ADJ	O
left	O	ADJ	O
ventricles	O	NOUN	O
and	O	CCONJ	O
coronary	O	ADJ	B
arteries	O	NOUN	I
.	O	PUNCT	O


Significant	O	ADJ	B
QTC	B-Disease	PROPN	B
prolongation	I-Disease	NOUN	B
occurred	O	VERB	O
in	O	ADP	O
30	O	NUM	O
seconds	O	NOUN	O
to	O	ADP	O
one	O	NUM	O
minute	O	NOUN	O
in	O	ADP	O
association	O	NOUN	B
with	O	ADP	I
marked	O	ADJ	O
hypotension	B-Disease	NOUN	B


Production	O	NOUN	B
of	O	ADP	O
autochthonous	O	ADJ	B
prostate	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
in	O	ADP	O
Lobund	O	PROPN	B
-	O	PUNCT	O
Wistar	O	PROPN	B
rats	O	NOUN	B
by	O	ADP	O
treatments	O	NOUN	B
with	O	ADP	O
N-nitroso-N-methylurea	B-Chemical	NOUN	B
and	O	CCONJ	O
testosterone	B-Chemical	NOUN	B
.	O	PUNCT	O


More	O	ADJ	O
than	O	ADP	O
50	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
Lobund	O	PROPN	B
-	O	PUNCT	O
Wistar	O	PROPN	B
(	O	PUNCT	O
L	O	PROPN	B
-	O	PUNCT	O
W	O	PROPN	B
)	O	PUNCT	O
strain	O	NOUN	B
rats	O	NOUN	I
developed	O	VERB	O
large	O	ADJ	O
,	O	PUNCT	O
palpable	O	ADJ	B
prostate	B-Disease	NOUN	O
adenocarcinomas	I-Disease	NOUN	O
(	O	PUNCT	O
PAs	B-Disease	NOUN	B
)	O	PUNCT	O
following	O	VERB	O
treatments	O	NOUN	B
with	O	ADP	O
N-nitroso-N-methylurea	B-Chemical	NOUN	B
(	O	PUNCT	O
CAS	O	NOUN	B
:	O	PUNCT	O
684	O	NUM	O
-	O	SYM	O
93	O	NUM	O
-	O	PUNCT	O
5	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
testosterone	B-Chemical	NOUN	B
propionate	I-Chemical	NOUN	B
[(	O	X	O
TP	B-Chemical	NOUN	B
)	O	PUNCT	O
CAS	O	PROPN	B
:	O	PUNCT	O
57	O	NUM	O
-	O	PUNCT	O
85	O	NUM	O
-	O	SYM	O
2	O	NUM	O
],	O	PUNCT	O
and	O	CCONJ	O
most	O	ADJ	O
of	O	ADP	O
the	O	DET	O
tumor	B-Disease	NOUN	B
-	O	PUNCT	O
bearing	O	VERB	O
rats	O	NOUN	B
manifested	O	VERB	O
metastatic	O	ADJ	B
lesions	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
incubation	O	NOUN	B
periods	O	NOUN	B
averaged	O	VERB	O
10	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
months	O	NOUN	B
.	O	PUNCT	O


Within	O	ADP	O
the	O	DET	O
same	O	ADJ	O
timeframe	O	NOUN	B
,	O	PUNCT	O
no	O	DET	O
L	O	PROPN	B
-	O	PUNCT	O
W	O	PROPN	B
rat	O	NOUN	B
developed	O	VERB	O
a	O	DET	O
similar	O	ADJ	O
palpable	O	ADJ	B
PA	B-Disease	PROPN	I
when	O	SCONJ	O
treated	O	VERB	B
only	O	ADV	O
with	O	ADP	O
TP	B-Chemical	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
L	O	PROPN	B
-	O	PUNCT	O
W	O	NOUN	B
rats	O	NOUN	B
,	O	PUNCT	O
TP	B-Chemical	NOUN	B
acted	O	VERB	O
as	O	ADP	O
a	O	DET	O
tumor	B-Disease	NOUN	B
enhancement	O	NOUN	I
agent	O	NOUN	I
,	O	PUNCT	O
with	O	ADP	O
primary	O	ADJ	O
emphasis	O	NOUN	O
on	O	ADP	O
the	O	DET	O
development	O	NOUN	B
of	O	ADP	O
prostate	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I


A	O	DET	O
dystonia	B-Disease	NOUN	B
-	O	PUNCT	O
like	O	ADJ	B
syndrome	O	NOUN	I
after	O	ADP	O
neuropeptide	O	NOUN	B
(	O	PUNCT	O
MSH	B-Chemical	PROPN	B
/	O	SYM	O
ACTH	B-Chemical	NOUN	B
)	O	PUNCT	O
stimulation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
rat	O	NOUN	B
locus	O	NOUN	B
ceruleus	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
movement	B-Disease	NOUN	B
disorder	I-Disease	NOUN	I
investigated	O	VERB	B
in	O	ADP	O
these	O	DET	O
studies	O	NOUN	B
has	O	AUX	O
some	O	DET	O
features	O	NOUN	B
in	O	ADP	O
common	O	ADJ	O
with	O	ADP	O
human	O	ADJ	B
idiopathic	O	ADJ	B
dystonia	B-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
information	O	NOUN	B
obtained	O	VERB	O
in	O	ADP	O
these	O	DET	O
studies	O	NOUN	B
may	O	AUX	O
be	O	AUX	O
of	O	ADP	O
potential	O	ADJ	B
clinical	O	ADJ	B
benefit	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
present	O	ADJ	O
experimental	O	ADJ	B
results	O	NOUN	I
indicated	O	VERB	O
that	O	SCONJ	O
peptidergic	O	ADJ	B
stimulation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
LC	O	NOUN	B
resulted	O	VERB	O
in	O	ADP	O
a	O	DET	O
NE	O	PROPN	B
-	O	PUNCT	O
mediated	O	VERB	B
inhibition	O	NOUN	B
of	O	ADP	O
cerebellar	O	ADJ	B
Purkinje	O	NOUN	B
cells	O	NOUN	I
located	O	ADJ	O
at	O	ADP	O
terminals	O	NOUN	B
of	O	ADP	O
the	O	DET	O
ceruleo	O	NOUN	B
-	O	PUNCT	O
cerebellar	O	ADJ	B
pathway	O	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
it	O	PRON	O
is	O	AUX	O
not	O	PART	O
certain	O	ADJ	O
as	O	ADP	O
to	O	ADP	O
the	O	DET	O
following	O	NOUN	O
:(	O	PUNCT	O
a	O	X	O
)	O	PUNCT	O
what	O	DET	O
receptors	O	NOUN	B
were	O	AUX	O
stimulated	O	VERB	B
by	O	ADP	O
the	O	DET	O
ACTH	B-Chemical	NOUN	B
N	O	NOUN	B
-	O	PUNCT	O
terminal	O	ADJ	B
fragments	O	NOUN	B
at	O	ADP	O
the	O	DET	O
LC	O	NOUN	B
that	O	PRON	O
resulted	O	VERB	O
in	O	ADP	O
this	O	DET	O
disorder	O	NOUN	B
;(	O	PUNCT	O
b	O	X	O
)	O	PUNCT	O
whether	O	SCONJ	O
NE	O	NOUN	B
,	O	PUNCT	O
released	O	VERB	O
onto	O	ADP	O
Purkinje	O	NOUN	B
cell	O	NOUN	I
synapses	O	NOUN	B
located	O	ADJ	O
at	O	ADP	O
terminals	O	NOUN	B
of	O	ADP	O
the	O	DET	O
ceruleo	O	NOUN	B
-	O	PUNCT	O
cerebellar	O	ADJ	B
pathway	O	NOUN	B
,	O	PUNCT	O
did	O	AUX	O
indeed	O	ADV	O
cause	O	VERB	O
the	O	DET	O
long	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
depression	B-Disease	NOUN	B
at	O	ADP	O
Purkinje	O	NOUN	B
cell	O	NOUN	I
synapses	O	NOUN	O
(	O	PUNCT	O
previously	O	ADV	O
described	O	VERB	O
by	O	ADP	O
others	O	NOUN	O
)	O	PUNCT	O
that	O	PRON	O
resulted	O	VERB	O
in	O	ADP	O
the	O	DET	O
long	O	ADJ	B
duration	O	NOUN	I
of	O	ADP	O
the	O	DET	O
movement	B-Disease	NOUN	B
disorder	I-Disease	NOUN	I


Dexmedetomidine	B-Chemical	NOUN	B
,	O	PUNCT	O
acting	O	VERB	O
through	O	ADP	O
central	O	ADJ	B
alpha	O	NOUN	I
-	O	PUNCT	O
2	O	NUM	B
adrenoceptors	O	NOUN	B
,	O	PUNCT	O
prevents	O	VERB	B
opiate	O	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
muscle	B-Disease	NOUN	B
rigidity	I-Disease	NOUN	I
in	O	ADP	O
the	O	DET	O
rat	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
highly	O	ADV	B
-	O	PUNCT	O
selective	O	ADJ	B
alpha	O	NOUN	I
-	O	PUNCT	O
2	O	NUM	B
adrenergic	O	ADJ	B
agonist	O	NOUN	I
dexmedetomidine	B-Chemical	NOUN	B
(	O	PUNCT	O
D-MED	B-Chemical	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
capable	O	ADJ	O
of	O	ADP	O
inducing	O	VERB	B
muscle	B-Disease	NOUN	B
flaccidity	I-Disease	NOUN	I
and	O	CCONJ	O
anesthesia	O	NOUN	B
in	O	ADP	O
rats	O	NOUN	B
and	O	CCONJ	O
dogs	O	NOUN	B
.	O	PUNCT	O


Intense	O	ADJ	B
generalized	O	VERB	O
muscle	B-Disease	NOUN	O
rigidity	I-Disease	NOUN	O
is	O	AUX	O
an	O	DET	O
undesirable	O	ADJ	O
side	O	NOUN	B
effect	O	NOUN	I
of	O	ADP	O
potent	O	ADJ	O
opiate	O	ADJ	B
agonists	O	NOUN	I
.	O	PUNCT	O


Although	O	SCONJ	O
the	O	DET	O
neurochemistry	O	NOUN	B
of	O	ADP	O
opiate	O	ADJ	B
-	O	PUNCT	O
induced	O	VERB	B
rigidity	B-Disease	NOUN	B
has	O	AUX	O
yet	O	ADV	O
to	O	PART	O
be	O	AUX	O
fully	O	ADV	O
elucidated	O	VERB	O
,	O	PUNCT	O
recent	O	ADJ	O
work	O	NOUN	O
suggests	O	VERB	O
a	O	DET	O
role	O	NOUN	O
for	O	ADP	O
a	O	DET	O
central	O	ADJ	B
adrenergic	O	ADJ	I
mechanism	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
authors	O	NOUN	B
determined	O	VERB	O
if	O	SCONJ	O
treatment	O	NOUN	B
with	O	ADP	O
D-MED	B-Chemical	NOUN	B
prevents	O	VERB	B
the	O	DET	O
muscle	B-Disease	NOUN	B
rigidity	I-Disease	NOUN	I
caused	O	VERB	O
by	O	ADP	O
high	O	ADJ	B
-	O	PUNCT	O
dose	O	NOUN	B
alfentanil	B-Chemical	ADJ	B
anesthesia	O	NOUN	I
in	O	ADP	O
the	O	DET	O
rat	O	NOUN	B
.	O	PUNCT	O


Animals	O	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
42	O	NUM	O
)	O	PUNCT	O
were	O	AUX	O
treated	O	VERB	B
intraperitoneally	O	ADV	B
with	O	ADP	O
one	O	NUM	O
of	O	ADP	O
the	O	DET	O
following	O	VERB	O
six	O	NUM	O
regimens	O	NOUN	B
:	O	PUNCT	O
1	O	X	O
)	O	PUNCT	O
L	O	NOUN	B
-	O	PUNCT	O
MED	O	PROPN	B
(	O	PUNCT	O
the	O	DET	O
inactive	O	ADJ	B
L	O	NOUN	B
-	O	PUNCT	O
isomer	O	NOUN	B
of	O	ADP	O
medetomidine	B-Chemical	NOUN	B
),	O	PUNCT	O
30	O	NUM	O
micrograms	O	NOUN	B
/	O	SYM	O
kg	O	NOUN	B
;	O	PUNCT	O
2	O	X	O
)	O	PUNCT	O
D-MED	B-Chemical	NOUN	B
,	O	PUNCT	O
10	O	NUM	O
micrograms	O	NOUN	B
/	O	SYM	O
kg	O	NOUN	B
;	O	PUNCT	O
3	O	X	O
)	O	PUNCT	O
D-MED	B-Chemical	NOUN	B
,	O	PUNCT	O
30	O	NUM	O
micrograms	O	NOUN	B
/	O	SYM	O
kg	O	NOUN	B
;	O	PUNCT	O
4	O	X	O
)	O	PUNCT	O
D-MED	B-Chemical	NOUN	B
[	O	PUNCT	O
30	O	NUM	O
micrograms	O	NOUN	B
/	O	SYM	O
kg	O	NOUN	B
]	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
central	O	ADJ	B
-	O	PUNCT	O
acting	O	VERB	B
alpha	O	NOUN	B
-	O	PUNCT	O
2	O	NUM	O
antagonist	O	NOUN	B
,	O	PUNCT	O
idazoxan	B-Chemical	NOUN	B
[	O	PUNCT	O
10	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	O
];	O	NOUN	O
5	O	NUM	O
)	O	PUNCT	O
D-MED	B-Chemical	NOUN	B
[	O	PUNCT	O
30	O	NUM	O
micrograms	O	NOUN	B
/	O	SYM	O
kg	O	NOUN	B
]	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
peripheral	O	ADJ	B
-	O	PUNCT	O
acting	O	VERB	B
alpha	O	NOUN	B
-	O	PUNCT	O
2	O	NUM	O
antagonist	O	NOUN	B
DG-5128	B-Chemical	NOUN	B
[	O	PUNCT	O
10	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
],	O	PUNCT	O
or	O	CCONJ	O
;	O	PUNCT	O
6	O	NUM	O
)	O	PUNCT	O
saline	O	NOUN	B
.	O	PUNCT	O


Baseline	O	NOUN	B
electromyographic	O	ADJ	B
activity	O	NOUN	I
was	O	AUX	O
recorded	O	VERB	O
from	O	ADP	O
the	O	DET	O
gastrocnemius	O	NOUN	B
muscle	O	NOUN	I
before	O	ADP	O
and	O	CCONJ	O
after	O	ADP	O
drug	O	NOUN	B
treatment	O	NOUN	I
.	O	PUNCT	O


Each	O	DET	O
rat	O	NOUN	B
was	O	AUX	O
then	O	ADV	O
injected	O	VERB	B
with	O	ADP	O
alfentanil	B-Chemical	NOUN	B
(	O	PUNCT	O
ALF	B-Chemical	NOUN	B
,	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
sc	O	NOUN	B
).	O	PUNCT	B
ALF	B-Chemical	NOUN	B
injection	O	NOUN	B
resulted	O	VERB	O
in	O	ADP	O
a	O	DET	O
marked	O	ADJ	O
increase	O	NOUN	B
in	O	ADP	O
hindlimb	O	ADJ	B
EMG	O	NOUN	B
activity	O	NOUN	B
in	O	ADP	O
the	O	DET	O
L	O	PROPN	B
-	O	PUNCT	O
MED	O	PROPN	B
treatment	O	NOUN	B
group	O	NOUN	I
which	O	DET	O
was	O	AUX	O
indistinguishable	O	ADJ	B
from	O	ADP	O
that	O	DET	O
seen	O	VERB	O
in	O	ADP	O
animals	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
saline	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
contrast	O	NOUN	O
,	O	PUNCT	O
D-MED	B-Chemical	NOUN	B
prevented	O	VERB	O
alfentanil	B-Chemical	ADJ	B
-	O	PUNCT	O
induced	O	VERB	B
muscle	B-Disease	NOUN	B
rigidity	I-Disease	NOUN	I
in	O	ADP	O
a	O	DET	O
dose	O	NOUN	B
-	O	PUNCT	O
dependent	O	ADJ	B
fashion	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
small	O	ADJ	O
EMG	O	NOUN	B
values	O	NOUN	O
obtained	O	VERB	O
in	O	ADP	O
the	O	DET	O
high	O	ADJ	B
-	O	PUNCT	O
dose	O	NOUN	B
D-MED	B-Chemical	NOUN	B
group	O	NOUN	B
were	O	AUX	O
comparable	O	ADJ	O
with	O	ADP	O
those	O	DET	O
recorded	O	VERB	O
in	O	ADP	O
earlier	O	ADJ	O
studies	O	NOUN	B
from	O	ADP	O
control	O	ADJ	B
animals	O	NOUN	I
not	O	PART	O
given	O	VERB	O
any	O	DET	O
opiate	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
high	O	ADJ	B
-	O	PUNCT	O
dose	O	NOUN	B
D-MED	B-Chemical	NOUN	B
animals	O	NOUN	B
were	O	AUX	O
flaccid	O	ADJ	B
,	O	PUNCT	O
akinetic	B-Disease	ADJ	B
,	O	PUNCT	O
and	O	CCONJ	O
lacked	O	VERB	O
a	O	DET	O
startle	B-Disease	NOUN	B


Seizure	B-Disease	NOUN	B
activity	O	NOUN	B
with	O	ADP	O
imipenem	B-Chemical	NOUN	B
therapy	O	NOUN	I
:	O	PUNCT	O
incidence	O	NOUN	B
and	O	CCONJ	O
risk	O	NOUN	B
factors	O	NOUN	I
.	O	PUNCT	O


Two	O	NUM	O
elderly	O	ADJ	B
patients	O	NOUN	B
with	O	ADP	O
a	O	DET	O
history	O	NOUN	B
of	O	ADP	O
either	O	CCONJ	O
cerebral	B-Disease	ADJ	B
vascular	I-Disease	ADJ	I
accident	I-Disease	NOUN	I
(	O	PUNCT	O
CVA	B-Disease	NOUN	B
)	O	PUNCT	O
or	O	CCONJ	O
head	B-Disease	NOUN	B
trauma	I-Disease	NOUN	I
and	O	CCONJ	O
no	O	DET	O
evidence	O	NOUN	O
of	O	ADP	O
renal	B-Disease	ADJ	B
disease	I-Disease	NOUN	I
developed	O	VERB	O
seizures	B-Disease	NOUN	B
while	O	SCONJ	O
receiving	O	VERB	O
maximum	O	ADJ	B
doses	O	NOUN	B
of	O	ADP	O
imipenem/cilastatin	B-Chemical	NOUN	B
.	O	PUNCT	O


Neither	O	DET	B
patient	O	NOUN	B
had	O	AUX	O
reported	O	VERB	O
previous	O	ADJ	O
seizures	B-Disease	NOUN	B
or	O	CCONJ	O
seizure	B-Disease	NOUN	B
-	O	PUNCT	O
like	O	ADJ	B
activity	O	NOUN	B
nor	O	CCONJ	O
was	O	AUX	O
receiving	O	VERB	O
anticonvulsant	O	ADJ	B
agents	O	NOUN	I
.	O	PUNCT	O


All	O	DET	O
seizures	B-Disease	NOUN	B
were	O	AUX	O
controlled	O	VERB	B
with	O	ADP	O
therapeutic	O	ADJ	B
doses	O	NOUN	I
of	O	ADP	O
phenytoin	B-Chemical	NOUN	B
.	O	PUNCT	O


Both	O	DET	O
patients	O	NOUN	B
had	O	AUX	O
received	O	VERB	O
maximum	O	ADJ	B
doses	O	NOUN	B
of	O	ADP	O
other	O	ADJ	O
beta-lactam	B-Chemical	ADJ	B
antibiotics	O	NOUN	I
without	O	ADP	O
evidence	O	NOUN	B
of	O	ADP	O
seizure	B-Disease	NOUN	B


The	O	DET	O
ability	O	NOUN	O
of	O	ADP	O
insulin	O	NOUN	B
treatment	O	NOUN	B
to	O	PART	O
reverse	O	VERB	B
or	O	CCONJ	O
prevent	O	VERB	B
the	O	DET	O
changes	O	NOUN	B
in	O	ADP	O
urinary	O	ADJ	B
bladder	O	NOUN	I
function	O	NOUN	I
caused	O	VERB	O
by	O	ADP	O
streptozotocin	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
diabetes	B-Disease	NOUN	B
mellitus	I-Disease	NOUN	I
.	O	PUNCT	O


1	O	X	O
.	O	PUNCT	O


The	O	DET	O
effects	O	NOUN	B
of	O	ADP	O
insulin	O	NOUN	B
treatment	O	NOUN	B
on	O	ADP	O
in	O	X	B
vivo	O	X	I
and	O	CCONJ	O
in	O	X	B
vitro	O	X	I
urinary	O	ADJ	B
bladder	O	NOUN	O
function	O	NOUN	O
in	O	ADP	O
streptozotocin	B-Chemical	NOUN	B
-	O	PUNCT	O
diabetic	B-Disease	ADJ	B
rats	O	NOUN	B
were	O	AUX	O
investigated	O	VERB	B
.	O	PUNCT	O


2	O	X	O
.	O	PUNCT	O


Diabetes	B-Disease	NOUN	B
of	O	ADP	O
2	O	NUM	O
months	O	NOUN	B
duration	O	NOUN	B
resulted	O	VERB	O
in	O	ADP	O
decreases	O	NOUN	B
in	O	ADP	O
body	O	NOUN	B
weight	O	NOUN	I
and	O	CCONJ	O
increases	O	NOUN	B
in	O	ADP	O
fluid	O	ADJ	B
consumption	O	NOUN	B
,	O	PUNCT	O
urine	O	NOUN	B
volume	O	NOUN	I
,	O	PUNCT	O
frequency	O	NOUN	B
of	O	ADP	O
micturition	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
average	O	ADJ	B
volume	O	NOUN	I
per	O	ADP	O
micturition	O	NOUN	B
;	O	PUNCT	O
effects	O	NOUN	B
which	O	DET	O
were	O	AUX	O
prevented	O	VERB	B
by	O	ADP	O
insulin	O	NOUN	B
treatment	O	NOUN	B
.	O	PUNCT	O


3	O	X	O
.	O	PUNCT	O


Insulin	O	NOUN	B
treatment	O	NOUN	B
also	O	ADV	O
prevented	O	VERB	B
the	O	DET	O
increases	O	NOUN	B
in	O	ADP	O
contractile	O	NOUN	B
responses	O	NOUN	I
of	O	ADP	O
bladder	O	NOUN	B
body	O	NOUN	B
strips	O	NOUN	I
from	O	ADP	O
diabetic	B-Disease	ADJ	B
rats	O	NOUN	B
to	O	PART	O
nerve	O	NOUN	B
stimulation	O	NOUN	I
,	O	PUNCT	O
ATP	B-Chemical	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
bethanechol	B-Chemical	NOUN	B
.	O	PUNCT	O


4	O	X	O
.	O	PUNCT	O


Diabetes	B-Disease	NOUN	B
of	O	ADP	O
4	O	NUM	O
months	O	NOUN	B
duration	O	NOUN	B
also	O	ADV	O
resulted	O	VERB	O
in	O	ADP	O
decreases	O	NOUN	B
in	O	ADP	O
body	O	NOUN	B
weight	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
increases	O	VERB	B
in	O	ADP	O
fluid	O	ADJ	B
consumption	O	NOUN	B
,	O	PUNCT	O
urine	O	NOUN	B
volume	O	NOUN	I
,	O	PUNCT	O
frequency	O	NOUN	B
of	O	ADP	O
micturition	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
average	O	ADJ	B
volume	O	NOUN	I
per	O	ADP	O
micturition	O	NOUN	B
,	O	PUNCT	O
effects	O	NOUN	B
which	O	DET	O
were	O	AUX	O
reversed	O	VERB	O
by	O	ADP	O
insulin	O	NOUN	B
treatment	O	NOUN	B
for	O	ADP	O
the	O	DET	O
final	O	ADJ	O
2	O	NUM	O
months	O	NOUN	B
of	O	ADP	O
the	O	DET	O
study	O	NOUN	B
.	O	PUNCT	O


5	O	NUM	O
.	O	PUNCT	O


Insulin	O	NOUN	B
treatment	O	NOUN	B
reversed	O	VERB	B
the	O	DET	O
increases	O	NOUN	B
in	O	ADP	O
contractile	O	NOUN	B
responses	O	NOUN	I
of	O	ADP	O
bladder	O	NOUN	B
body	O	NOUN	B
strips	O	NOUN	I
from	O	ADP	O
diabetic	B-Disease	ADJ	B
rats	O	NOUN	B
to	O	PART	O
nerve	O	NOUN	B
stimulation	O	NOUN	I
,	O	PUNCT	O
ATP	B-Chemical	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
bethanechol	B-Chemical	NOUN	B
.	O	PUNCT	O


6	O	NUM	O
.	O	PUNCT	O


The	O	DET	O
data	O	NOUN	B
indicate	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	O
streptozotocin	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
diabetes	B-Disease	NOUN	B


Delayed	O	VERB	B
institution	O	NOUN	I
of	O	ADP	O
hypertension	B-Disease	NOUN	B
during	O	ADP	O
focal	O	ADJ	B
cerebral	B-Disease	ADJ	I
ischemia	I-Disease	NOUN	I
:	O	PUNCT	O
effect	O	NOUN	B
on	O	ADP	O
brain	B-Disease	NOUN	B
edema	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
induced	O	VERB	B
hypertension	B-Disease	NOUN	B
instituted	O	VERB	B
after	O	ADP	O
a	O	DET	O
2	O	NUM	O
-	O	PUNCT	O
h	O	NOUN	B
delay	O	NOUN	B
following	O	VERB	O
middle	B-Disease	ADJ	B
cerebral	I-Disease	ADJ	I
artery	I-Disease	NOUN	I
occlusion	I-Disease	NOUN	I
(	O	PUNCT	O
MCAO	B-Disease	NOUN	B
)	O	PUNCT	O
on	O	ADP	O
brain	B-Disease	NOUN	B
edema	I-Disease	NOUN	I
formation	O	NOUN	B
and	O	CCONJ	O
histochemical	O	ADJ	B
injury	O	NOUN	I
was	O	AUX	O
studied	O	VERB	O
.	O	PUNCT	O


Under	O	ADP	O
isoflurane	B-Chemical	NOUN	B
anesthesia	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
MCA	O	PROPN	B
of	O	ADP	O
14	O	NUM	O
spontaneously	O	ADV	B
hypertensive	B-Disease	ADJ	B
rats	O	NOUN	B
was	O	AUX	O
occluded	O	VERB	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
control	O	ADJ	B
group	O	NOUN	I
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
7	O	NUM	O
),	O	PUNCT	O
the	O	DET	O
mean	O	ADJ	O
arterial	O	ADJ	O
pressure	O	NOUN	O
(	O	PUNCT	O
MAP	O	NOUN	B
)	O	PUNCT	O
was	O	AUX	O
not	O	PART	O
manipulated	O	VERB	O
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
hypertensive	B-Disease	ADJ	B
group	O	NOUN	O
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
7	O	NUM	O
),	O	PUNCT	O
the	O	DET	O
MAP	O	NOUN	B
was	O	AUX	O
elevated	O	VERB	B
by	O	ADP	O
25	O	NUM	O
-	O	SYM	O
30	O	NUM	O
mm	O	NOUN	B
Hg	O	NOUN	I
beginning	O	VERB	O
2	O	NUM	O
h	O	NOUN	O
after	O	ADP	O
MCAO	B-Disease	NOUN	B
.	O	PUNCT	O


Four	O	NUM	O
hours	O	NOUN	O
after	O	ADP	O
MCAO	B-Disease	NOUN	B
,	O	PUNCT	O
the	O	DET	O
rats	O	NOUN	B
were	O	AUX	O
killed	O	VERB	B
and	O	CCONJ	O
the	O	DET	O
brains	O	NOUN	B
harvested	O	VERB	B
.	O	PUNCT	O


The	O	DET	O
brains	O	NOUN	B
were	O	AUX	O
sectioned	O	VERB	B
along	O	ADP	O
coronal	O	ADJ	B
planes	O	NOUN	I
spanning	O	VERB	O
the	O	DET	O
distribution	O	NOUN	B
of	O	ADP	O
ischemia	B-Disease	NOUN	B
produced	O	VERB	O
by	O	ADP	O
MCAO	B-Disease	NOUN	B
.	O	PUNCT	O


Specific	O	ADJ	O
gravity	O	NOUN	O
(	O	PUNCT	O
SG	O	NOUN	B
)	O	PUNCT	O
was	O	AUX	O
determined	O	VERB	O
in	O	ADP	O
the	O	DET	O
subcortex	O	NOUN	B
and	O	CCONJ	O
in	O	ADP	O
two	O	NUM	O
sites	O	NOUN	B
in	O	ADP	O
the	O	DET	O
cortex	O	NOUN	B
(	O	PUNCT	O
core	O	NOUN	B
and	O	CCONJ	O
periphery	O	NOUN	B
of	O	ADP	O
the	O	DET	O
ischemic	B-Disease	ADJ	B
territory	O	NOUN	I
).	O	PUNCT	B
The	O	DET	O
extent	O	NOUN	O
of	O	ADP	O
neuronal	B-Disease	ADJ	B
injury	I-Disease	NOUN	I
was	O	AUX	O
determined	O	VERB	O
by	O	ADP	O
2,3,5-triphenyltetrazolium	B-Chemical	NOUN	B
staining	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
ischemic	B-Disease	ADJ	B
core	O	NOUN	O
,	O	PUNCT	O
there	O	PRON	O
was	O	AUX	O
no	O	DET	O
difference	O	NOUN	O
in	O	ADP	O
SG	O	NOUN	B
in	O	ADP	O
the	O	DET	O
subcortex	O	NOUN	B
and	O	CCONJ	O
cortex	O	NOUN	B
in	O	ADP	O
the	O	DET	O
two	O	NUM	O
groups	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
periphery	O	NOUN	B
of	O	ADP	O
the	O	DET	O
ischemic	B-Disease	ADJ	B
territory	O	NOUN	I
,	O	PUNCT	O
SG	O	NOUN	B
in	O	ADP	O
the	O	DET	O
cortex	O	NOUN	B
was	O	AUX	O
greater	O	ADJ	O
(	O	PUNCT	O
less	O	ADJ	O
edema	B-Disease	NOUN	B
accumulation	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
hypertensive	B-Disease	ADJ	B
group	O	NOUN	O
(	O	PUNCT	O
1	O	NUM	O
.	O	PUNCT	O


041	O	NUM	O
+/-	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


001	O	NUM	O
vs	O	CCONJ	O
1	O	NUM	O
.	O	PUNCT	O


039	O	NUM	O
+/-	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


001	O	NUM	O
,	O	PUNCT	O
P	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


05	O	NUM	O
).	O	PUNCT	O
The	O	DET	O
area	O	NOUN	B
of	O	ADP	O
histochemical	O	ADJ	B
injury	O	NOUN	I
(	O	PUNCT	O
as	O	ADP	O
a	O	DET	O
percent	O	NOUN	O
of	O	ADP	O
the	O	DET	O
cross	O	NOUN	B
-	O	PUNCT	O
sectional	O	ADJ	B
area	O	NOUN	I
of	O	ADP	O
the	O	DET	O
hemisphere	O	NOUN	B
)	O	PUNCT	O
was	O	AUX	O
less	O	ADJ	O
in	O	ADP	O
the	O	DET	O
hypertensive	B-Disease	ADJ	B
group	O	NOUN	O
(	O	PUNCT	O
33	O	NUM	O
+/-	O	CCONJ	O
3	O	NUM	O
%	O	NOUN	O
vs	O	CCONJ	O
21	O	NUM	O
+/-	O	CCONJ	O
2	O	NUM	O
%,	O	NOUN	O
P	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


05	O	NUM	O
).	O	PUNCT	O
The	O	DET	O
data	O	NOUN	B
indicate	O	VERB	O
that	O	SCONJ	O
phenylephrine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
hypertension	B-Disease	NOUN	B
instituted	O	VERB	O
2	O	NUM	O
h	O	NOUN	O
after	O	ADP	O
MCAO	B-Disease	NOUN	B
does	O	AUX	O
not	O	PART	O
aggravate	O	VERB	B
edema	B-Disease	NOUN	B
in	O	ADP	O
the	O	DET	O
ischemic	B-Disease	ADJ	B
core	O	NOUN	O
,	O	PUNCT	O
that	O	SCONJ	O
it	O	PRON	O
improves	O	VERB	O
edema	B-Disease	NOUN	B
in	O	ADP	O
the	O	DET	O
periphery	O	NOUN	B
of	O	ADP	O
the	O	DET	O
ischemic	B-Disease	ADJ	B
territory	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
that	O	SCONJ	O
it	O	PRON	O
reduces	O	VERB	B
the	O	DET	O
area	O	NOUN	B
of	O	ADP	O
histochemical	O	ADJ	B
neuronal	B-Disease	ADJ	I
dysfunction	I-Disease	NOUN	I


Amiodarone	B-Chemical	NOUN	B
pulmonary	B-Disease	ADJ	B
toxicity	I-Disease	NOUN	B
.	O	PUNCT	O


Amiodarone	B-Chemical	NOUN	B
is	O	AUX	O
an	O	DET	O
effective	O	ADJ	B
antiarrhythmic	O	ADJ	B
agent	O	NOUN	I
whose	O	DET	O
utility	O	NOUN	O
is	O	AUX	O
limited	O	VERB	O
by	O	ADP	O
many	O	ADJ	O
side	O	NOUN	B
-	O	PUNCT	O
effects	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
most	O	ADV	O
problematic	O	ADJ	O
being	O	AUX	O
pneumonitis	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
pulmonary	B-Disease	ADJ	B
toxicity	I-Disease	NOUN	B
of	O	ADP	O
amiodarone	B-Chemical	NOUN	B
is	O	AUX	O
thought	O	VERB	O
to	O	PART	O
result	O	VERB	O
from	O	ADP	O
direct	O	ADJ	O
injury	O	NOUN	B
related	O	ADJ	O
to	O	PART	O
the	O	DET	O
intracellular	O	ADJ	B
accumulation	O	NOUN	B
of	O	ADP	O
phospholipid	O	NOUN	B
and	O	CCONJ	O
T	O	NOUN	B
cell	O	NOUN	I
-	O	PUNCT	O
mediated	O	VERB	B
hypersensitivity	B-Disease	NOUN	I
pneumonitis	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
clinical	O	ADJ	B
and	O	CCONJ	O
radiographic	O	ADJ	B
features	O	NOUN	B
of	O	ADP	O
amiodarone	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
pulmonary	B-Disease	ADJ	B
toxicity	I-Disease	NOUN	B
are	O	AUX	O
characteristic	O	ADJ	B
but	O	CCONJ	O
nonspecific	O	ADJ	B
.	O	PUNCT	O


The	O	DET	O
diagnosis	O	NOUN	B
depends	O	VERB	O
on	O	ADP	O
exclusion	O	NOUN	B
of	O	ADP	O
other	O	ADJ	O
entities	O	NOUN	B
,	O	PUNCT	O
such	O	ADJ	O
as	O	ADP	O
heart	B-Disease	NOUN	B
failure	I-Disease	NOUN	I
,	O	PUNCT	O
infection	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
malignancy	B-Disease	NOUN	B
.	O	PUNCT	O


While	O	SCONJ	O
withdrawal	O	NOUN	B
of	O	ADP	I
amiodarone	B-Chemical	NOUN	B
leads	O	VERB	O
to	O	PART	O
clinical	O	ADJ	B
improvement	O	NOUN	I
in	O	ADP	O
majority	O	NOUN	O
of	O	ADP	O
cases	O	NOUN	B
,	O	PUNCT	O
this	O	DET	O
is	O	AUX	O
not	O	PART	O
always	O	ADV	O
possible	O	ADJ	O
or	O	CCONJ	O
advisable	O	ADJ	O
.	O	PUNCT	O


Dose	O	NOUN	B
reduction	O	NOUN	B
or	O	CCONJ	O
concomitant	O	ADJ	B
steroid	B-Chemical	NOUN	B


Light	O	ADJ	B
chain	O	NOUN	I
proteinuria	B-Disease	NOUN	I
and	O	CCONJ	O
cellular	O	ADJ	B
mediated	O	ADJ	O
immunity	O	NOUN	B
in	O	ADP	O
rifampin	B-Chemical	NOUN	B
treated	O	VERB	B
patients	O	NOUN	B
with	O	ADP	O
tuberculosis	B-Disease	NOUN	B
.	O	PUNCT	O


Light	O	ADJ	B
chain	O	NOUN	I
proteinuria	B-Disease	NOUN	I
was	O	AUX	O
found	O	VERB	O
in	O	ADP	O
9	O	NUM	O
of	O	ADP	O
17	O	NUM	O
tuberculosis	B-Disease	NOUN	B
patients	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
rifampin	B-Chemical	NOUN	B
.	O	PUNCT	O


Concomitant	O	ADJ	B
assay	O	NOUN	B
of	O	ADP	O
cellular	O	ADJ	B
mediated	O	ADJ	O
immunity	O	NOUN	B
in	O	ADP	O
these	O	DET	O
patients	O	NOUN	B
using	O	VERB	O
skin	O	NOUN	B
test	O	NOUN	I
antigen	O	NOUN	I
and	O	CCONJ	O
a	O	DET	O
lymphokine	O	NOUN	B
in	O	X	B
vitro	O	X	I
test	O	NOUN	I
provided	O	VERB	O
results	O	NOUN	B
that	O	PRON	O
were	O	AUX	O
different	O	ADJ	O
.	O	PUNCT	O


Response	O	NOUN	B
to	O	PART	O
Varidase	O	NOUN	B
skin	O	NOUN	O
test	O	NOUN	O
antigen	O	NOUN	O
was	O	AUX	O
negative	O	ADJ	B
for	O	ADP	O
all	O	DET	O
eight	O	NUM	O
tuberculosis	B-Disease	NOUN	B
patients	O	NOUN	B
tested	O	VERB	B
,	O	PUNCT	O
but	O	CCONJ	O
there	O	PRON	O
occurred	O	VERB	O
a	O	DET	O
hyper	O	ADJ	B
-	O	PUNCT	O
responsiveness	O	NOUN	B
of	O	ADP	O
the	O	DET	O
lymphocytes	O	NOUN	B
of	O	ADP	O
these	O	DET	O
eight	O	NUM	O
patients	O	NOUN	B
to	O	PART	O
phytomitogen	O	NOUN	B
(	O	PUNCT	O
PHA	O	NOUN	B
-	O	PUNCT	O
P	O	NOUN	B
).	O	PUNCT	O
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
of	O	ADP	O
those	O	DET	O
of	O	ADP	O
seven	O	NUM	O
other	O	ADJ	O
tuberculous	B-Disease	ADJ	B
patients	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
last	O	ADJ	O
finding	O	NOUN	B
may	O	AUX	O
be	O	AUX	O
related	O	ADJ	O
to	O	ADP	O
time	O	NOUN	O
of	O	ADP	O
testing	O	NOUN	B
and	O	CCONJ	O
/	O	SYM	O
or	O	CCONJ	O
endogenous	O	ADJ	B
serum	O	NOUN	B
binding	O	NOUN	I
of	O	ADP	O
rifampin	B-Chemical	NOUN	B


Initial	O	ADJ	B
potassium	B-Chemical	NOUN	B
loss	O	NOUN	I
and	O	CCONJ	O
hypokalaemia	B-Disease	NOUN	B
during	O	ADP	O
chlorthalidone	B-Chemical	NOUN	B
administration	O	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
essential	O	ADJ	B
hypertension	B-Disease	NOUN	I
:	O	PUNCT	O
the	O	DET	O
influence	O	NOUN	B
of	O	ADP	O
dietary	O	ADJ	B
sodium	B-Chemical	NOUN	I
restriction	O	NOUN	I
.	O	PUNCT	O


To	O	PART	O
investigate	O	VERB	B
the	O	DET	O
initial	O	ADJ	O
potassium	B-Chemical	NOUN	B
loss	O	NOUN	I
and	O	CCONJ	O
development	O	NOUN	B
of	O	ADP	O
hypokalaemia	B-Disease	NOUN	B
during	O	ADP	O
the	O	DET	O
administration	O	NOUN	B
of	O	ADP	O
an	O	DET	O
oral	O	ADJ	B
diuretic	O	ADJ	I
,	O	PUNCT	O
metabolic	O	ADJ	B
balance	O	NOUN	O
studies	O	NOUN	O
were	O	AUX	O
performed	O	VERB	O
in	O	ADP	O
ten	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
essential	O	ADJ	B
hypertension	B-Disease	NOUN	I
who	O	PRON	O
had	O	AUX	O
shown	O	VERB	O
hypokalaemia	B-Disease	NOUN	B
under	O	ADP	O
prior	O	ADJ	B
oral	O	ADJ	B
diuretic	O	ADJ	B
treatment	O	NOUN	I
.	O	PUNCT	O


Chlorthalidone	B-Chemical	NOUN	B
(	O	PUNCT	O
50	O	NUM	O
mg	O	NOUN	O
daily	O	ADV	B
)	O	PUNCT	O
was	O	AUX	O
given	O	VERB	O
for	O	ADP	O
14	O	NUM	O
days	O	NOUN	B
.	O	PUNCT	O


Six	O	NUM	O
patients	O	NOUN	B
received	O	VERB	O
a	O	DET	O
normal	O	ADJ	B
-	O	PUNCT	O
sodium	B-Chemical	NOUN	B
diet	O	NOUN	I
and	O	CCONJ	O
four	O	NUM	O
a	O	DET	O
low	O	ADJ	B
-	O	PUNCT	O
sodium	B-Chemical	NOUN	B
(	O	PUNCT	O
17	O	NUM	O
mmol	O	NOUN	O
/	O	PUNCT	O
day	O	NOUN	B
)	O	PUNCT	O
diet	O	NOUN	B
.	O	PUNCT	O


All	O	DET	O
patients	O	NOUN	B
had	O	AUX	O
a	O	DET	O
normal	O	ADJ	O
initial	O	ADJ	O
total	O	ADJ	B
body	O	NOUN	I
potassium	B-Chemical	NOUN	I
(	O	PUNCT	O
40K	O	NOUN	O
).	O	PUNCT	O
The	O	DET	O
electrolyte	O	NOUN	B
balances	O	NOUN	B
,	O	PUNCT	O
weight	O	NOUN	B
,	O	PUNCT	O
bromide	O	NOUN	B
space	O	NOUN	I
,	O	PUNCT	O
plasma	O	NOUN	B
renin	O	NOUN	B
activity	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
aldosterone	B-Chemical	NOUN	B
secretion	O	NOUN	I
rate	O	NOUN	B
were	O	AUX	O
measured	O	VERB	B
.	O	PUNCT	O


In	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
a	O	DET	O
potassium	B-Chemical	NOUN	B
deficit	O	NOUN	I
developed	O	VERB	O
,	O	PUNCT	O
with	O	ADP	O
proportionally	O	ADV	O
larger	O	ADJ	O
losses	O	NOUN	B
from	O	ADP	O
the	O	DET	O
extracellular	O	NOUN	B
than	O	ADP	O
from	O	ADP	O
the	O	DET	O
intracellular	O	ADJ	B
compartment	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
normal	O	ADJ	B
-	O	PUNCT	O
sodium	B-Chemical	NOUN	B
group	O	NOUN	B
the	O	DET	O
highest	O	ADJ	O
mean	O	NOUN	O
potassium	B-Chemical	NOUN	B
deficit	O	NOUN	I
was	O	AUX	O
176	O	NUM	O
mmol	O	NOUN	O
on	O	ADP	O
day	O	NOUN	B
9	O	NUM	O
,	O	PUNCT	O
after	O	ADP	O
which	O	DET	O
some	O	DET	O
potassium	B-Chemical	NOUN	B
was	O	AUX	O
regained	O	VERB	B
;	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
low	O	ADJ	B
-	O	PUNCT	O
sodium	B-Chemical	NOUN	B
group	O	NOUN	B
the	O	DET	O
highest	O	ADJ	B
deficit	O	NOUN	B
was	O	AUX	O
276	O	NUM	O
mmol	O	NOUN	O
on	O	ADP	O
day	O	NOUN	B
13	O	NUM	O
.	O	PUNCT	O


The	O	DET	O
normal	O	ADJ	B
-	O	PUNCT	O
sodium	B-Chemical	NOUN	B
group	O	NOUN	O
showed	O	VERB	O
an	O	DET	O
immediate	O	ADJ	B
but	O	CCONJ	O
temporary	O	ADJ	B
rise	O	NOUN	O
of	O	ADP	O
the	O	DET	O
renin	O	NOUN	B
and	O	CCONJ	O
aldosterone	B-Chemical	NOUN	B
levels	O	NOUN	B
;	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
low	O	ADJ	B
-	O	PUNCT	O
sodium	B-Chemical	NOUN	B
group	O	NOUN	B
renin	O	NOUN	B
and	O	CCONJ	O
aldosterone	B-Chemical	NOUN	B
increased	O	VERB	B
more	O	ADV	O
slowly	O	ADV	O
but	O	CCONJ	O
remained	O	VERB	O
elevated	O	ADJ	B
.	O	PUNCT	O


It	O	PRON	O
is	O	AUX	O
concluded	O	VERB	O
that	O	SCONJ	O
dietary	O	ADJ	B
sodium	B-Chemical	NOUN	B
restriction	O	NOUN	I
increases	O	VERB	B
diuretic	O	ADJ	B
-	O	PUNCT	O
induced	O	VERB	B
potassium	B-Chemical	NOUN	B
loss	O	NOUN	I
,	O	PUNCT	O
presumably	O	ADV	O
by	O	ADP	O
an	O	DET	O
increased	O	VERB	B
activity	O	NOUN	B
of	O	ADP	O
the	O	DET	O
renin	O	NOUN	B
-	O	PUNCT	O
angiotensin	B-Chemical	NOUN	B
-	O	PUNCT	O
aldosterone	B-Chemical	NOUN	B
system	O	NOUN	O
,	O	PUNCT	O
while	O	SCONJ	O
sodium	B-Chemical	NOUN	B
delivery	O	NOUN	I
to	O	PART	O
the	O	DET	O
distal	O	ADJ	B
renal	O	ADJ	I
tubules	O	NOUN	I
remains	O	VERB	O
sufficiently	O	ADV	O
high	O	ADJ	O
to	O	PART	O
allow	O	VERB	O
increased	O	VERB	B
potassium	B-Chemical	NOUN	B


Dynamic	O	ADJ	B
response	O	NOUN	I
of	O	ADP	O
blood	O	NOUN	B
vessel	O	NOUN	I
in	O	ADP	O
acute	B-Disease	ADJ	B
renal	I-Disease	ADJ	I
failure	I-Disease	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
this	O	DET	O
study	O	NOUN	B
we	O	PRON	O
postulated	O	VERB	O
that	O	SCONJ	O
during	O	ADP	O
acute	B-Disease	ADJ	B
renal	I-Disease	ADJ	I
failure	I-Disease	NOUN	I
induced	O	VERB	B
by	O	ADP	O
gentamicin	B-Chemical	NOUN	B
the	O	DET	O
transient	O	ADJ	B
or	O	CCONJ	O
dynamic	O	ADJ	B
response	O	NOUN	I
of	O	ADP	O
blood	O	NOUN	B
vessels	O	NOUN	I
could	O	AUX	O
be	O	AUX	O
affected	O	VERB	B
,	O	PUNCT	O
and	O	CCONJ	O
that	O	SCONJ	O
antioxidants	O	NOUN	B
can	O	AUX	O
prevent	O	VERB	B
the	O	DET	O
changes	O	NOUN	B
in	O	ADP	O
dynamic	O	ADJ	B
responses	O	NOUN	I
of	O	ADP	O
blood	O	NOUN	B
vessels	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
new	O	ADJ	O
approach	O	NOUN	O
to	O	PART	O
ex	O	X	B
vivo	O	X	I
blood	O	NOUN	B
vessel	O	NOUN	I
experiments	O	NOUN	B
in	O	ADP	O
which	O	DET	O
not	O	PART	O
only	O	ADV	O
the	O	DET	O
end	O	NOUN	O
points	O	NOUN	O
of	O	ADP	O
vessels	O	NOUN	B
response	O	NOUN	B
within	O	ADP	O
the	O	DET	O
time	O	NOUN	B
interval	O	NOUN	I
is	O	AUX	O
considered	O	VERB	O
,	O	PUNCT	O
but	O	CCONJ	O
also	O	ADV	O
dynamics	O	NOUN	B
of	O	ADP	O
this	O	DET	O
response	O	NOUN	B
,	O	PUNCT	O
was	O	AUX	O
used	O	VERB	O
in	O	ADP	O
this	O	DET	O
paper	O	NOUN	O
.	O	PUNCT	O


Our	O	PRON	O
results	O	NOUN	O
confirm	O	VERB	O
the	O	DET	O
alteration	O	NOUN	B
in	O	ADP	O
dynamic	O	ADJ	B
response	O	NOUN	I
of	O	ADP	O
blood	O	NOUN	B
vessels	O	NOUN	I
during	O	ADP	O
the	O	DET	O
change	O	NOUN	B
of	O	ADP	O
pressure	O	NOUN	B
in	O	ADP	O
gentamicin	B-Chemical	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
animals	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
beneficial	O	ADJ	O
effects	O	NOUN	B
of	O	ADP	O
vitamin	B-Chemical	NOUN	B
C	I-Chemical	NOUN	I
administration	O	NOUN	B
to	O	PART	O
gentamicin	B-Chemical	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
animals	O	NOUN	B
are	O	AUX	O
also	O	ADV	O
confirmed	O	VERB	O
through	O	ADP	O
:	O	PUNCT	O
lower	O	ADJ	B
level	O	NOUN	B
of	O	ADP	O
blood	O	NOUN	B
urea	B-Chemical	NOUN	I
and	O	CCONJ	O
creatinine	B-Chemical	NOUN	B
and	O	CCONJ	O
higher	O	ADJ	B
level	O	NOUN	B
of	O	ADP	O
potassium	B-Chemical	NOUN	B
.	O	PUNCT	O


The	O	DET	O
pressure	O	NOUN	B
dynamic	O	ADJ	O
responses	O	NOUN	O
of	O	ADP	O
isolated	O	VERB	B
blood	O	NOUN	O
vessels	O	NOUN	O
show	O	VERB	O
a	O	DET	O
faster	O	ADJ	O
pressure	O	NOUN	B
change	O	NOUN	O
in	O	ADP	O
gentamicin	B-Chemical	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
animals	O	NOUN	B
(	O	PUNCT	O
8	O	NUM	O
.	O	PUNCT	O


07	O	NUM	O
+/-	O	CCONJ	O
1	O	NUM	O
.	O	PUNCT	O


7	O	NUM	O
s	O	NOUN	O
vs	O	ADV	O
.	O	PUNCT	O


5	O	NUM	O
.	O	PUNCT	O


64	O	NUM	O
+/-	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


18	O	NUM	O
s	O	NOUN	O
).	O	PUNCT	B
Vitamin	B-Chemical	NOUN	B
C	I-Chemical	NOUN	I
administration	O	NOUN	B
induced	O	VERB	B
slowdown	O	NOUN	B
of	O	ADP	O
pressure	O	NOUN	B
change	O	NOUN	I
back	O	ADV	O
to	O	ADP	O
the	O	DET	O
control	O	NOUN	B
values	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
pressure	O	NOUN	B
dynamic	O	ADJ	B
properties	O	NOUN	O
,	O	PUNCT	O
quantitatively	O	ADV	B
defined	O	VERB	O
by	O	ADP	O
comparative	O	ADJ	B
pressure	O	NOUN	I
dynamic	O	ADJ	I
and	O	CCONJ	O
total	O	ADJ	B
pressure	O	NOUN	I
dynamic	O	ADJ	I
,	O	PUNCT	O
confirm	O	VERB	O
the	O	DET	O
alteration	O	NOUN	B
in	O	ADP	O
dynamic	O	ADJ	B
response	O	NOUN	I
of	O	ADP	O
blood	O	NOUN	B
vessels	O	NOUN	I
during	O	ADP	O
the	O	DET	O
change	O	NOUN	B
of	O	ADP	O
pressure	O	NOUN	B
in	O	ADP	O
gentamicin	B-Chemical	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
animals	O	NOUN	B
and	O	CCONJ	O
beneficial	O	ADJ	B
effects	O	NOUN	B
of	O	ADP	O
vitamin	B-Chemical	NOUN	B
C	I-Chemical	NOUN	I


The	O	DET	O
hemodynamics	O	NOUN	B
of	O	ADP	O
oxytocin	B-Chemical	NOUN	B
and	O	CCONJ	O
other	O	ADJ	O
vasoactive	O	ADJ	B
agents	O	NOUN	I
during	O	ADP	O
neuraxial	O	ADJ	B
anesthesia	O	NOUN	I
for	O	ADP	O
cesarean	O	NOUN	B
delivery	O	NOUN	I
:	O	PUNCT	O
findings	O	NOUN	B
in	O	ADP	O
six	O	NUM	O
cases	O	NOUN	B
.	O	PUNCT	O


Oxytocin	B-Chemical	NOUN	B
is	O	AUX	O
a	O	DET	O
commonly	O	ADV	O
used	O	VERB	O
uterotonic	O	ADJ	B
that	O	PRON	O
can	O	AUX	O
cause	O	VERB	O
significant	O	ADJ	B
and	O	CCONJ	O
even	O	ADV	O
fatal	O	ADJ	B
hypotension	B-Disease	NOUN	B
,	O	PUNCT	O
particularly	O	ADV	O
when	O	SCONJ	O
given	O	VERB	O
as	O	ADP	O
a	O	DET	O
bolus	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
resulting	O	VERB	O
hypotension	B-Disease	NOUN	B
can	O	AUX	O
be	O	AUX	O
produced	O	VERB	O
by	O	ADP	O
a	O	DET	O
decrease	O	NOUN	B
in	O	ADP	O
systemic	O	ADJ	B
vascular	O	ADJ	B
resistance	O	NOUN	I
or	O	CCONJ	O
cardiac	O	ADJ	B
output	O	NOUN	I
through	O	ADP	O
a	O	DET	O
decrease	O	NOUN	B
in	O	ADP	O
venous	O	ADJ	B
return	O	NOUN	I
.	O	PUNCT	O


Parturients	O	NOUN	B
with	O	ADP	O
normal	O	ADJ	B
volume	O	NOUN	I
status	O	NOUN	I
,	O	PUNCT	O
heart	O	NOUN	B
valves	O	NOUN	I
and	O	CCONJ	O
pulmonary	O	ADJ	B
vasculature	O	NOUN	I
most	O	ADV	O
often	O	ADV	O
respond	O	VERB	O
to	O	PART	O
this	O	DET	O
hypotension	B-Disease	NOUN	B
with	O	ADP	O
a	O	DET	O
compensatory	O	ADJ	B
increase	O	NOUN	B
in	O	ADP	O
heart	O	NOUN	B
rate	O	NOUN	I
and	O	CCONJ	O
stroke	B-Disease	NOUN	B
volume	O	NOUN	B
.	O	PUNCT	O


Oxytocin	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
hypotension	B-Disease	NOUN	B
at	O	ADP	O
cesarean	O	NOUN	B
delivery	O	NOUN	I
may	O	AUX	O
be	O	AUX	O
incorrectly	O	ADV	O
attributed	O	VERB	O
to	O	PART	O
blood	B-Disease	NOUN	B
loss	I-Disease	NOUN	I
.	O	PUNCT	O


Pulse	O	NOUN	B
power	O	NOUN	I
analysis	O	NOUN	I
(	O	PUNCT	O
also	O	ADV	O
called	O	VERB	O
"	O	PUNCT	O
pulse	O	NOUN	B
contour	O	NOUN	I
analysis	O	NOUN	I
")	O	PUNCT	O
of	O	ADP	O
an	O	DET	O
arterial	O	ADJ	B
pressure	O	NOUN	I
wave	O	NOUN	I
form	O	NOUN	I
allows	O	VERB	O
continuous	O	ADJ	O
evaluation	O	NOUN	B
of	O	ADP	O
systemic	O	ADJ	B
vascular	O	ADJ	B
resistance	O	NOUN	I
and	O	CCONJ	O
cardiac	O	ADJ	B
output	O	NOUN	I
in	O	ADP	O
real	O	ADJ	B
time	O	NOUN	I
,	O	PUNCT	O
thereby	O	ADV	O
elucidating	O	VERB	O
the	O	DET	O
causative	O	ADJ	B
factors	O	NOUN	I
behind	O	ADP	O
changes	O	NOUN	B
in	O	ADP	O
blood	O	NOUN	B
pressure	O	NOUN	I
.	O	PUNCT	O


Pulse	O	NOUN	B
power	O	NOUN	I
analysis	O	NOUN	I
was	O	AUX	O
conducted	O	VERB	O
in	O	ADP	O
six	O	NUM	O
cases	O	NOUN	B
of	O	ADP	O
cesarean	O	NOUN	B
delivery	O	NOUN	I
performed	O	VERB	O
under	O	ADP	O
neuraxial	O	ADJ	B
anesthesia	O	NOUN	I
.	O	PUNCT	O


Hypotension	B-Disease	NOUN	B
in	O	ADP	O
response	O	NOUN	B
to	O	PART	O
oxytocin	B-Chemical	NOUN	B
was	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
a	O	DET	O
decrease	O	NOUN	B
in	O	ADP	O
systemic	O	ADJ	B
vascular	O	ADJ	B
resistance	O	NOUN	I
and	O	CCONJ	O
a	O	DET	O
compensatory	O	ADJ	B
increase	O	NOUN	B
in	O	ADP	O
stroke	B-Disease	NOUN	B
volume	O	NOUN	B
,	O	PUNCT	O
heart	O	NOUN	B
rate	O	NOUN	I
and	O	CCONJ	O
cardiac	O	ADJ	B
output	O	NOUN	I
.	O	PUNCT	O


Pulse	O	NOUN	B
power	O	NOUN	I
analysis	O	NOUN	I
may	O	AUX	O
be	O	AUX	O
helpful	O	ADJ	O
in	O	ADP	O
determining	O	VERB	O
the	O	DET	O
etiology	O	NOUN	B
of	O	ADP	O
and	O	CCONJ	O
treating	O	VERB	B
hypotension	B-Disease	NOUN	B


Exaggerated	O	ADJ	B
expression	O	NOUN	B
of	O	ADP	O
inflammatory	O	ADJ	B
mediators	O	NOUN	I
in	O	ADP	O
vasoactive	O	ADJ	B
intestinal	O	ADJ	I
polypeptide	O	NOUN	I
knockout	O	NOUN	I
(	O	PUNCT	O
VIP	O	NOUN	B
-/-)	O	NOUN	O
mice	O	NOUN	B
with	O	ADP	O
cyclophosphamide	B-Chemical	NOUN	B
(	O	PUNCT	O
CYP	B-Chemical	NOUN	B
)-	O	ADJ	O
induced	O	VERB	B
cystitis	B-Disease	NOUN	B
.	O	PUNCT	O


Vasoactive	O	ADJ	B
intestinal	O	ADJ	I
polypeptide	O	NOUN	I
(	O	PUNCT	O
VIP	O	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
an	O	DET	O
immunomodulatory	O	ADJ	B
neuropeptide	O	NOUN	I
distributed	O	VERB	B
in	O	ADP	O
micturition	O	NOUN	B
pathways	O	NOUN	I
.	O	PUNCT	O


VIP	O	NOUN	B
(-/-)	O	NOUN	O
mice	O	NOUN	B
exhibit	O	VERB	O
altered	O	ADJ	O
bladder	O	NOUN	B
function	O	NOUN	I
and	O	CCONJ	O
neurochemical	O	ADJ	B
properties	O	NOUN	I
in	O	ADP	O
micturition	O	NOUN	B
pathways	O	NOUN	I
after	O	ADP	O
cyclophosphamide	B-Chemical	NOUN	B
(	O	PUNCT	O
CYP	B-Chemical	NOUN	B
)-	O	ADJ	O
induced	O	VERB	B
cystitis	B-Disease	NOUN	B
.	O	PUNCT	O


Given	O	ADP	O
VIP	O	NOUN	B
'	O	PART	O
s	O	NOUN	O
role	O	NOUN	O
as	O	ADP	O
an	O	DET	O
anti	O	ADJ	B
-	O	PUNCT	O
inflammatory	O	ADJ	B
mediator	O	NOUN	O
,	O	PUNCT	O
we	O	PRON	O
hypothesized	O	VERB	O
that	O	SCONJ	O
VIP	O	NOUN	B
(-/-)	O	NOUN	O
mice	O	NOUN	B
would	O	AUX	O
exhibit	O	VERB	O
enhanced	O	VERB	O
inflammatory	O	ADJ	B
mediator	O	NOUN	O
expression	O	NOUN	B
after	O	ADP	O
cystitis	B-Disease	NOUN	B
.	O	PUNCT	O


A	O	DET	O
mouse	O	NOUN	B
inflammatory	O	ADJ	B
cytokine	O	NOUN	O
and	O	CCONJ	O
receptor	O	NOUN	B
RT2	O	NOUN	I
profiler	O	NOUN	I
array	O	NOUN	O
was	O	AUX	O
used	O	VERB	O
to	O	PART	O
determine	O	VERB	O
regulated	O	VERB	O
transcripts	O	NOUN	B
in	O	ADP	O
the	O	DET	O
urinary	O	ADJ	B
bladder	O	NOUN	I
of	O	ADP	O
wild	O	ADJ	B
type	O	NOUN	I
(	O	PUNCT	O
WT	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
VIP	O	NOUN	B
(-/-)	O	NOUN	O
mice	O	NOUN	B
with	O	ADP	O
or	O	CCONJ	O
without	O	ADP	O
CYP	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
cystitis	B-Disease	NOUN	B
(	O	PUNCT	O
150	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	O
;	O	PUNCT	O
i	O	X	O
.	O	PUNCT	O


p	O	NOUN	O
.;	O	NUM	O
48	O	NUM	O
h	O	NOUN	O
).	O	PUNCT	O
Four	O	NUM	O
binary	O	ADJ	B
comparisons	O	NOUN	I
were	O	AUX	O
made	O	VERB	O
:	O	PUNCT	O
WT	O	NOUN	B
control	O	NOUN	I
versus	O	CCONJ	O
CYP	B-Chemical	NOUN	B
treatment	O	NOUN	B
(	O	PUNCT	O
48	O	NUM	O
h	O	NOUN	O
),	O	PUNCT	O
VIP	O	NOUN	B
(-/-)	O	NOUN	O
control	O	NOUN	O
versus	O	CCONJ	O
CYP	B-Chemical	NOUN	B
treatment	O	NOUN	B
(	O	PUNCT	O
48	O	NUM	O
h	O	NOUN	O
),	O	PUNCT	O
WT	O	NOUN	B
control	O	NOUN	I
versus	O	CCONJ	O
VIP	O	NOUN	B
(-/-)	O	NOUN	O
control	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
WT	O	NOUN	B
with	O	ADP	O
CYP	B-Chemical	NOUN	B
treatment	O	NOUN	B
(	O	PUNCT	O
48	O	NUM	O
h	O	NOUN	O
)	O	PUNCT	O
versus	O	CCONJ	O
VIP	O	NOUN	B
(-/-)	O	NOUN	O
with	O	ADP	O
CYP	B-Chemical	NOUN	B
treatment	O	NOUN	B
(	O	PUNCT	O
48	O	NUM	O
h	O	NOUN	O
).	O	PUNCT	O
The	O	DET	O
genes	O	NOUN	B
presented	O	VERB	O
represent	O	VERB	O
(	O	PUNCT	O
1	O	X	O
)	O	PUNCT	O
greater	O	ADJ	O
than	O	ADP	O
1	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
-	O	PUNCT	O
fold	O	ADJ	B
change	O	NOUN	B
in	O	ADP	O
either	O	DET	O
direction	O	NOUN	B
and	O	CCONJ	O
(	O	PUNCT	O
2	O	X	O
)	O	PUNCT	O
the	O	DET	O
p	O	NOUN	B
value	O	NOUN	I
is	O	AUX	O
less	O	ADJ	O
than	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


05	O	NUM	O
for	O	ADP	O
the	O	DET	O
comparison	O	NOUN	B
being	O	AUX	O
made	O	VERB	O
.	O	PUNCT	O


Several	O	ADJ	O
regulated	O	VERB	O
genes	O	NOUN	O
were	O	AUX	O
validated	O	VERB	O
using	O	VERB	O
enzyme	O	NOUN	B
-	O	PUNCT	O
linked	O	VERB	B
immunoassays	O	NOUN	B
including	O	VERB	O
IL	O	NOUN	B
-	O	PUNCT	O
1beta	O	NOUN	B
and	O	CCONJ	O
CXCL1	O	NOUN	B
.	O	PUNCT	O


CYP	B-Chemical	NOUN	B
treatment	O	NOUN	B
significantly	O	ADV	O
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
or	O	CCONJ	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


001	O	NUM	O
)	O	PUNCT	O
increased	O	VERB	B
expression	O	NOUN	B
of	O	ADP	O
CXCL1	O	NOUN	B
and	O	CCONJ	O
IL	O	NOUN	B
-	O	PUNCT	O
1beta	O	NOUN	B
in	O	ADP	O
the	O	DET	O
urinary	O	ADJ	B
bladder	O	NOUN	I
of	O	ADP	O
WT	O	NOUN	B
and	O	CCONJ	O
VIP	O	NOUN	B
(-/-)	O	NOUN	O
mice	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
expression	O	NOUN	B
in	O	ADP	O
VIP	O	NOUN	B
(-/-)	O	NOUN	O
mice	O	NOUN	B
with	O	ADP	O
CYP	B-Chemical	NOUN	B
treatment	O	NOUN	B
was	O	AUX	O
significantly	O	ADV	O
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
or	O	CCONJ	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


001	O	NUM	O
)	O	PUNCT	O
greater	O	ADJ	O
(	O	PUNCT	O
4	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
-	O	PUNCT	O
to	O	ADP	O
13	O	NUM	O
-	O	PUNCT	O
fold	O	ADJ	B
increase	O	NOUN	B
)	O	PUNCT	O
than	O	ADP	O
that	O	DET	O
observed	O	VERB	B
in	O	ADP	O
WT	O	NOUN	B
urinary	O	ADJ	O
bladder	O	NOUN	O
(	O	PUNCT	O
3	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
-	O	PUNCT	O
to	O	PART	O
5	O	NUM	O
-	O	PUNCT	O
fold	O	ADJ	B
increase	O	NOUN	B
).	O	PUNCT	B
The	O	DET	O
data	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
in	O	ADP	O
VIP	O	NOUN	B
(-/-)	O	NOUN	O
mice	O	NOUN	B
with	O	ADP	O
bladder	B-Disease	NOUN	B
inflammation	I-Disease	NOUN	B
,	O	PUNCT	O
inflammatory	O	ADJ	B
mediators	O	NOUN	I
are	O	AUX	O
increased	O	VERB	B
above	O	ADP	O
that	O	DET	O
observed	O	VERB	B
in	O	ADP	O
WT	O	NOUN	B
with	O	ADP	O
CYP	B-Chemical	NOUN	B
.	O	PUNCT	O


This	O	DET	O
shift	O	NOUN	B
in	O	ADP	O
balance	O	NOUN	B
may	O	AUX	O
contribute	O	VERB	O
to	O	PART	O
increased	O	VERB	B
bladder	B-Disease	NOUN	B
dysfunction	I-Disease	NOUN	I
in	O	ADP	O
VIP	O	NOUN	B
(-/-)	O	NOUN	O
mice	O	NOUN	B
with	O	ADP	O
bladder	B-Disease	NOUN	B
inflammation	I-Disease	NOUN	I


Intraocular	O	ADJ	B
pressure	O	NOUN	I
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
uveitis	B-Disease	NOUN	B
treated	O	VERB	B
with	O	ADP	I
fluocinolone	B-Chemical	NOUN	B
acetonide	I-Chemical	NOUN	B
implants	O	NOUN	B
.	O	PUNCT	O


OBJECTIVE	O	NOUN	O
:	O	PUNCT	O
To	O	PART	O
report	O	VERB	O
the	O	DET	O
incidence	O	NOUN	B
and	O	CCONJ	O
management	O	NOUN	B
of	O	ADP	O
elevated	B-Disease	ADJ	B
intraocular	I-Disease	ADJ	I
pressure	I-Disease	NOUN	I
(	O	PUNCT	O
IOP	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
uveitis	B-Disease	NOUN	B
treated	O	VERB	B
with	O	ADP	I
the	O	DET	O
fluocinolone	B-Chemical	NOUN	B
acetonide	I-Chemical	NOUN	I
(	O	PUNCT	O
FA	B-Chemical	NOUN	B
)	O	PUNCT	O
intravitreal	O	NOUN	B
implant	O	NOUN	I
.	O	PUNCT	O


DESIGN	O	NOUN	O
:	O	PUNCT	O
Pooled	O	VERB	B
data	O	NOUN	B
from	O	ADP	O
3	O	NUM	O
multicenter	O	NOUN	B
,	O	PUNCT	O
double	O	ADV	B
-	O	PUNCT	O
masked	O	VERB	B
,	O	PUNCT	O
randomized	O	ADJ	B
,	O	PUNCT	O
controlled	O	VERB	B
,	O	PUNCT	O
phase	O	NOUN	B
2b	O	NOUN	I
/	O	SYM	O
3	O	NUM	O
clinical	O	ADJ	B
trials	O	NOUN	I
evaluating	O	VERB	B
the	O	DET	O
safety	O	NOUN	B
and	O	CCONJ	O
efficacy	O	NOUN	B
of	O	ADP	O
the	O	DET	O
0	O	NUM	O
.	O	PUNCT	O


59	O	NUM	O
-	O	PUNCT	O
mg	O	NOUN	O
or	O	CCONJ	O
2	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
-	O	PUNCT	O
mg	O	NOUN	O
FA	B-Chemical	NOUN	B
intravitreal	O	NOUN	B
implant	O	NOUN	I
or	O	CCONJ	O
standard	O	ADJ	B
therapy	O	NOUN	I
were	O	AUX	O
analyzed	O	VERB	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
During	O	ADP	O
the	O	DET	O
3	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
follow	O	NOUN	B
-	O	PUNCT	O
up	O	ADP	O
,	O	PUNCT	O
71	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
implanted	O	VERB	B
eyes	O	NOUN	I
had	O	AUX	O
an	O	DET	O
IOP	O	NOUN	B
increase	O	NOUN	B
of	O	ADP	O
10	O	NUM	O
mm	O	X	B
Hg	O	NOUN	I
or	O	CCONJ	O
more	O	ADJ	O
than	O	ADP	O
baseline	O	NOUN	B
and	O	CCONJ	O
55	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
%,	O	NOUN	O
24	O	NUM	O
.	O	PUNCT	O


7	O	NUM	O
%,	O	NOUN	B
and	O	CCONJ	O
6	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
eyes	O	NOUN	B
reached	O	VERB	O
an	O	DET	O
IOP	O	NOUN	B
of	O	ADP	O
30	O	NUM	O
mm	O	X	B
Hg	O	NOUN	I
or	O	CCONJ	O
more	O	ADJ	O
,	O	PUNCT	O
40	O	NUM	O
mm	O	NOUN	B
Hg	O	NOUN	I
or	O	CCONJ	O
more	O	ADJ	O
,	O	PUNCT	O
and	O	CCONJ	O
50	O	NUM	O
mm	O	X	B
Hg	O	NOUN	I
or	O	CCONJ	O
more	O	ADJ	O
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


Topical	O	ADJ	B
IOP	O	NOUN	B
-	O	PUNCT	O
lowering	O	VERB	B
medication	O	NOUN	B
was	O	AUX	O
administered	O	VERB	B
in	O	ADP	O
74	O	NUM	O
.	O	PUNCT	O


8	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
implanted	O	VERB	B
eyes	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
IOP	O	NOUN	B
-	O	PUNCT	O
lowering	O	VERB	B
surgeries	O	NOUN	B
,	O	PUNCT	O
most	O	ADJ	O
of	O	ADP	O
which	O	DET	O
were	O	AUX	O
trabeculectomies	O	NOUN	B
(	O	PUNCT	O
76	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
%),	O	NOUN	O
were	O	AUX	O
performed	O	VERB	O
on	O	ADP	O
36	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
implanted	O	VERB	B
eyes	O	NOUN	I
.	O	PUNCT	O


Intraocular	O	ADJ	B
pressure	O	NOUN	I
-	O	PUNCT	O
lowering	O	VERB	B
surgeries	O	NOUN	B
were	O	AUX	O
considered	O	VERB	O
a	O	DET	O
success	O	NOUN	B
(	O	PUNCT	O
postoperative	O	ADJ	B
IOP	O	NOUN	B
of	O	ADP	O
6	O	NUM	O
-	O	SYM	O
21	O	NUM	O
mm	O	X	B
Hg	O	NOUN	I
with	O	ADP	I
or	O	CCONJ	O
without	O	ADP	O
additional	O	ADJ	O
IOP	O	NOUN	B
-	O	PUNCT	O
lowering	O	VERB	B
medication	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
85	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
eyes	O	NOUN	B
at	O	ADP	O
1	O	NUM	O
year	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
rate	O	NOUN	B
of	O	ADP	O
hypotony	B-Disease	NOUN	B


Pallidal	O	ADJ	B
stimulation	O	NOUN	B
:	O	PUNCT	O
an	O	DET	O
alternative	O	NOUN	B
to	O	PART	O
pallidotomy	O	NOUN	B
?	O	PUNCT	O
A	O	DET	O
resurgence	O	NOUN	B
of	O	ADP	O
interest	O	NOUN	O
in	O	ADP	O
the	O	DET	O
surgical	O	ADJ	B
treatment	O	NOUN	I
of	O	ADP	O
Parkinson's	B-Disease	ADJ	B
disease	I-Disease	NOUN	I
(	O	PUNCT	O
PD	B-Disease	NOUN	B
)	O	PUNCT	O
came	O	VERB	O
with	O	ADP	O
the	O	DET	O
rediscovery	O	NOUN	B
of	O	ADP	O
posteroventral	O	ADJ	B
pallidotomy	O	NOUN	I
by	O	ADP	O
Laitinen	O	PROPN	B
in	O	ADP	O
1985	O	NUM	O
.	O	PUNCT	O


Laitinen	O	PROPN	B
'	O	PART	O
s	O	NOUN	O
procedure	O	NOUN	B
improved	O	VERB	B
most	O	ADJ	O
symptoms	O	NOUN	B
in	O	ADP	O
drug	O	NOUN	B
-	O	PUNCT	O
resistant	O	ADJ	B
PD	B-Disease	NOUN	B
,	O	PUNCT	O
which	O	DET	O
engendered	O	VERB	O
wide	O	ADJ	O
interest	O	NOUN	O
in	O	ADP	O
the	O	DET	O
neurosurgical	O	ADJ	B
community	O	NOUN	I
.	O	PUNCT	O


Another	O	DET	O
lesioning	O	ADJ	B
procedure	O	NOUN	B
,	O	PUNCT	O
ventrolateral	O	ADJ	B
thalamotomy	O	NOUN	B
,	O	PUNCT	O
has	O	AUX	O
become	O	VERB	O
a	O	DET	O
powerful	O	ADJ	O
alternative	O	NOUN	O
to	O	PART	O
stimulate	O	VERB	B
the	O	DET	O
nucleus	O	NOUN	B
ventralis	O	NOUN	I
intermedius	O	NOUN	I
,	O	PUNCT	O
producing	O	VERB	O
high	O	ADJ	O
long	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
success	O	NOUN	B
rates	O	NOUN	I
and	O	CCONJ	O
low	O	ADJ	B
morbidity	O	NOUN	B
rates	O	NOUN	O
.	O	PUNCT	O


Pallidal	O	ADJ	B
stimulation	O	NOUN	B
has	O	AUX	O
not	O	PART	O
met	O	VERB	O
with	O	ADP	O
the	O	DET	O
same	O	ADJ	O
success	O	NOUN	B
.	O	PUNCT	O


According	O	VERB	O
to	O	ADP	O
the	O	DET	O
literature	O	NOUN	B
pallidotomy	O	NOUN	I
improves	O	VERB	B
the	O	DET	O
"	O	PUNCT	O
on	O	ADP	O
"	O	PUNCT	O
symptoms	O	NOUN	B
of	O	ADP	O
PD	B-Disease	NOUN	B
,	O	PUNCT	O
such	O	ADJ	O
as	O	ADP	O
dyskinesias	B-Disease	NOUN	B
,	O	PUNCT	O
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
the	O	DET	O
"	O	PUNCT	O
off	O	ADP	O
"	O	PUNCT	O
symptoms	O	NOUN	B
,	O	PUNCT	O
such	O	ADJ	O
as	O	ADP	O
rigidity	B-Disease	NOUN	B
,	O	PUNCT	O
bradykinesia	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
on	O	ADP	B
-	O	PUNCT	O
off	O	ADP	B
fluctuations	O	NOUN	B
.	O	PUNCT	O


Pallidal	O	ADJ	B
stimulation	O	NOUN	I
improves	O	VERB	B
bradykinesia	B-Disease	NOUN	B
and	O	CCONJ	O
rigidity	B-Disease	NOUN	B
to	O	PART	O
a	O	DET	O
minor	O	ADJ	B
extent	O	NOUN	B
;	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
its	O	PRON	O
strength	O	NOUN	B
seems	O	VERB	O
to	O	PART	O
be	O	AUX	O
in	O	ADP	O
improving	O	VERB	B
levodopa	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
dyskinesias	B-Disease	NOUN	B
.	O	PUNCT	O


Stimulation	O	NOUN	B
often	O	ADV	O
produces	O	VERB	O
an	O	DET	O
improvement	O	NOUN	B
in	O	ADP	O
the	O	DET	O
hyper-	B-Disease	ADJ	B
or	I-Disease	CCONJ	O
dyskinetic	I-Disease	ADJ	B


Case	O	NOUN	B
report	O	NOUN	I
:	O	PUNCT	O
Dexatrim	B-Chemical	PROPN	B
(	O	PUNCT	O
Phenylpropanolamine	B-Chemical	PROPN	B
)	O	PUNCT	O
as	O	ADP	O
a	O	DET	O
cause	O	NOUN	O
of	O	ADP	O
myocardial	B-Disease	ADJ	B
infarction	I-Disease	NOUN	I
.	O	PUNCT	O


Phenylpropanolamine	B-Chemical	NOUN	B
(	O	PUNCT	O
PPA	B-Chemical	PROPN	B
)	O	PUNCT	O
is	O	AUX	O
a	O	DET	O
sympathetic	O	ADJ	B
amine	B-Chemical	NOUN	I
used	O	VERB	O
in	O	ADP	O
over	O	ADP	O
-	O	PUNCT	O
the	O	DET	O
-	O	PUNCT	O
counter	O	NOUN	B
cold	O	ADJ	B
remedies	O	NOUN	I
and	O	CCONJ	O
weight	O	NOUN	B
-	O	PUNCT	O
control	O	NOUN	B
preparations	O	NOUN	B
worldwide	O	ADV	O
.	O	PUNCT	O


Its	O	PRON	O
use	O	NOUN	O
has	O	AUX	O
been	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
hypertensive	B-Disease	ADJ	B
episodes	O	NOUN	I
and	O	CCONJ	O
hemorrhagic	B-Disease	ADJ	B
strokes	I-Disease	NOUN	B
in	O	ADP	O
younger	O	ADJ	B
women	O	NOUN	B
.	O	PUNCT	O


Several	O	ADJ	O
reports	O	NOUN	B
have	O	AUX	O
linked	O	VERB	O
the	O	DET	O
abuse	O	NOUN	B
of	O	ADP	O
PPA	B-Chemical	PROPN	B
with	O	ADP	O
myocardial	B-Disease	ADJ	B
injury	I-Disease	NOUN	I
,	O	PUNCT	O
especially	O	ADV	O
when	O	SCONJ	O
overdose	B-Disease	NOUN	B
is	O	AUX	O
involved	O	VERB	O
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
here	O	ADV	O
the	O	DET	O
first	O	ADJ	O
case	O	NOUN	B
of	O	ADP	O
Dexatrim	B-Chemical	PROPN	B
(	O	PUNCT	O
PPA	B-Chemical	PROPN	B
)-	O	ADJ	O
induced	O	VERB	B
myocardial	B-Disease	ADJ	B
injury	I-Disease	NOUN	I
in	O	ADP	O
a	O	DET	O
young	O	ADJ	B
woman	O	NOUN	B
who	O	PRON	O
was	O	AUX	O
using	O	VERB	O
it	O	PRON	O
at	O	ADP	O
recommended	O	VERB	B
doses	O	NOUN	I
for	O	ADP	O
weight	O	NOUN	B
control	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
,	O	PUNCT	O
we	O	PRON	O
review	O	VERB	B
the	O	DET	O
7	O	NUM	O
other	O	ADJ	O
cases	O	NOUN	B
of	O	ADP	O
PPA	B-Chemical	PROPN	B
related	O	VERB	O
myocardial	B-Disease	ADJ	B
injury	I-Disease	NOUN	I
that	O	PRON	O
have	O	AUX	O
been	O	AUX	O
reported	O	VERB	O
so	O	ADV	O
far	O	ADV	O
.	O	PUNCT	O


Physicians	O	NOUN	B
and	O	CCONJ	O
patients	O	NOUN	B
should	O	AUX	O
be	O	AUX	O
alert	O	ADJ	O
to	O	PART	O
the	O	DET	O
potential	O	ADJ	B
cardiac	O	ADJ	B
risk	O	NOUN	I
associated	O	VERB	B
with	O	ADP	I
the	O	DET	O
use	O	NOUN	O
of	O	ADP	O
PPA	B-Chemical	PROPN	B


Risperidone	B-Chemical	NOUN	B
-	O	PUNCT	O
associated	O	VERB	B
,	O	PUNCT	O
benign	O	ADJ	B
transient	O	ADJ	O
visual	B-Disease	ADJ	O
disturbances	I-Disease	NOUN	O
in	O	ADP	O
schizophrenic	B-Disease	ADJ	B
patients	O	NOUN	B
with	O	ADP	O
a	O	DET	O
past	O	ADJ	O
history	O	NOUN	O
of	O	ADP	O
LSD	B-Chemical	NOUN	B
abuse	O	NOUN	I
.	O	PUNCT	O


Two	O	NUM	O
schizophrenic	B-Disease	ADJ	B
patients	O	NOUN	B
,	O	PUNCT	O
who	O	PRON	O
had	O	AUX	O
a	O	DET	O
prior	O	ADJ	O
history	O	NOUN	B
of	O	ADP	O
LSD	B-Chemical	NOUN	B
abuse	O	NOUN	I
and	O	CCONJ	O
who	O	PRON	O
had	O	AUX	O
previously	O	ADV	O
developed	O	VERB	O
EPS	B-Disease	PROPN	B
with	O	ADP	O
classic	O	ADJ	O
antipsychotics	O	NOUN	B
,	O	PUNCT	O
were	O	AUX	O
successfully	O	ADV	O
treated	O	VERB	B
with	O	ADP	I
risperidone	B-Chemical	NOUN	B
.	O	PUNCT	O


They	O	PRON	O
both	O	DET	O
reported	O	VERB	O
short	O	ADJ	B
episodes	O	NOUN	I
of	O	ADP	O
transient	O	ADJ	B
visual	B-Disease	ADJ	O
disturbances	I-Disease	NOUN	O
,	O	PUNCT	O
which	O	DET	O
appeared	O	VERB	O
immediately	O	ADV	O
after	O	ADP	O
starting	O	VERB	O
treatment	O	NOUN	B
with	O	ADP	O
risperidone	B-Chemical	NOUN	B
.	O	PUNCT	O


This	O	DET	O
imagery	O	NOUN	B
resembled	O	VERB	O
visual	B-Disease	ADJ	B
disturbances	I-Disease	NOUN	I
previously	O	ADV	O
experienced	O	VERB	O
as	O	ADP	O
"	O	PUNCT	O
flashbacks	O	NOUN	B
"	O	PUNCT	O
related	O	ADJ	O
to	O	PART	O
prior	O	ADJ	O
LSD	B-Chemical	NOUN	B
consumption	O	NOUN	B
.	O	PUNCT	O


Risperidone	B-Chemical	NOUN	B
administration	O	NOUN	B
was	O	AUX	O
continued	O	VERB	O
and	O	CCONJ	O
the	O	DET	O
visual	B-Disease	ADJ	B
disturbances	I-Disease	NOUN	B
gradually	O	ADV	O
wore	O	VERB	O
off	O	ADP	O
.	O	PUNCT	O


During	O	ADP	O
a	O	DET	O
six	O	NUM	B
-	O	PUNCT	O
month	O	NOUN	B
follow	O	NOUN	B
-	O	PUNCT	O
up	O	ADP	O
period	O	NOUN	B
,	O	PUNCT	O
there	O	PRON	O
was	O	AUX	O
no	O	DET	O
recurrence	O	NOUN	B
of	O	ADP	O
visual	B-Disease	ADJ	B
disturbances	I-Disease	NOUN	I
.	O	PUNCT	O


This	O	DET	O
phenomenon	O	NOUN	B
may	O	AUX	O
be	O	AUX	O
interpreted	O	VERB	O
as	O	ADP	O
a	O	DET	O
benign	O	ADJ	B
,	O	PUNCT	O
short	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
and	O	CCONJ	O
self	O	NOUN	B
-	O	PUNCT	O
limiting	O	VERB	B
side	O	NOUN	B
effect	O	NOUN	I
which	O	DET	O
does	O	AUX	O
not	O	PART	O
contraindicate	O	VERB	O
the	O	DET	O
use	O	NOUN	O
of	O	ADP	O
risperidone	B-Chemical	NOUN	B


Activation	O	NOUN	B
of	O	ADP	O
poly(ADP-ribose)	B-Chemical	ADJ	B
polymerase	O	NOUN	I
contributes	O	VERB	O
to	O	PART	O
development	O	NOUN	B
of	O	ADP	O
doxorubicin	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
heart	B-Disease	NOUN	B
failure	I-Disease	NOUN	I
.	O	PUNCT	O


Activation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
nuclear	O	ADJ	B
enzyme	O	NOUN	I
poly(ADP-ribose)	B-Chemical	ADJ	I
polymerase	O	NOUN	I
(	O	PUNCT	O
PARP	O	NOUN	B
)	O	PUNCT	O
by	O	ADP	O
oxidant	O	ADJ	B
-	O	PUNCT	O
mediated	O	VERB	B
DNA	O	NOUN	B
damage	O	NOUN	I
is	O	AUX	O
an	O	DET	O
important	O	ADJ	O
pathway	O	NOUN	B
of	O	ADP	O
cell	O	NOUN	B
dysfunction	O	NOUN	I
and	O	CCONJ	O
tissue	O	NOUN	B
injury	O	NOUN	I
in	O	ADP	O
conditions	O	NOUN	B
associated	O	VERB	B
with	O	ADP	I
oxidative	O	ADJ	B
stress	O	NOUN	I
.	O	PUNCT	O


Increased	O	VERB	B
oxidative	O	ADJ	B
stress	O	NOUN	I
is	O	AUX	O
a	O	DET	O
major	O	ADJ	O
factor	O	NOUN	B
implicated	O	VERB	O
in	O	ADP	O
the	O	DET	O
cardiotoxicity	B-Disease	NOUN	B
of	O	ADP	O
doxorubicin	B-Chemical	NOUN	B
(	O	PUNCT	O
DOX	B-Chemical	NOUN	B
),	O	PUNCT	O
a	O	DET	O
widely	O	ADV	O
used	O	VERB	O
antitumor	O	ADJ	B
anthracycline	B-Chemical	NOUN	B
antibiotic	O	NOUN	B
.	O	PUNCT	O


Thus	O	ADV	O
,	O	PUNCT	O
we	O	PRON	O
hypothesized	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
activation	O	NOUN	B
of	O	ADP	O
PARP	O	NOUN	B
may	O	AUX	O
contribute	O	VERB	O
to	O	PART	O
the	O	DET	O
DOX	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
cardiotoxicity	B-Disease	NOUN	B
.	O	PUNCT	O


Using	O	VERB	O
a	O	DET	O
dual	O	ADJ	O
approach	O	NOUN	O
of	O	ADP	O
PARP	O	NOUN	B
-	O	PUNCT	O
1	O	NUM	B
suppression	O	NOUN	B
,	O	PUNCT	O
by	O	ADP	O
genetic	O	ADJ	B
deletion	O	NOUN	I
or	O	CCONJ	O
pharmacological	O	ADJ	B
inhibition	O	NOUN	I
with	O	ADP	O
the	O	DET	O
phenanthridinone	O	NOUN	B
PARP	O	NOUN	O
inhibitor	O	NOUN	O
PJ34	B-Chemical	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
now	O	ADV	O
demonstrate	O	VERB	O
the	O	DET	O
role	O	NOUN	O
of	O	ADP	O
PARP	O	NOUN	B
in	O	ADP	O
the	O	DET	O
development	O	NOUN	B
of	O	ADP	O
cardiac	B-Disease	ADJ	B
dysfunction	I-Disease	NOUN	I
induced	O	VERB	B
by	O	ADP	O
DOX	B-Chemical	NOUN	B
.	O	PUNCT	O


PARP	O	NOUN	B
-	O	PUNCT	O
1	O	NUM	B
+/+	O	NOUN	B
and	O	CCONJ	O
PARP	O	NOUN	B
-	O	PUNCT	O
1	O	NUM	B
-/-	O	ADJ	O
mice	O	NOUN	B
received	O	VERB	O
a	O	DET	O
single	O	ADJ	O
injection	O	NOUN	B
of	O	ADP	O
DOX	B-Chemical	NOUN	B
(	O	PUNCT	O
25	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	O
i	O	X	O
.	O	PUNCT	O


p	O	X	O
).	O	PUNCT	O
Five	O	NUM	O
days	O	NOUN	B
after	O	ADP	O
DOX	B-Chemical	NOUN	B
administration	O	NOUN	B
,	O	PUNCT	O
left	O	VERB	B
ventricular	O	ADJ	I
performance	O	NOUN	I
was	O	AUX	O
significantly	O	ADV	O
depressed	O	ADJ	O
in	O	ADP	O
PARP	O	NOUN	B
-	O	PUNCT	O
1	O	NUM	B
+/+	O	NOUN	O
mice	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
only	O	ADV	O
to	O	PART	O
a	O	DET	O
smaller	O	ADJ	O
extent	O	NOUN	O
in	O	ADP	O
PARP	O	NOUN	B
-	O	PUNCT	O
1	O	NUM	O
-/-	O	ADJ	O
ones	O	NOUN	O
.	O	PUNCT	O


Similar	O	ADJ	O
experiments	O	NOUN	B
were	O	AUX	O
conducted	O	VERB	O
in	O	ADP	O
BALB	O	NOUN	B
/	O	SYM	O
c	O	NOUN	B
mice	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
PJ34	B-Chemical	NOUN	B
or	O	CCONJ	O
vehicle	O	NOUN	B
.	O	PUNCT	O


Treatment	O	NOUN	B
with	O	ADP	O
a	O	DET	O
PJ34	B-Chemical	NOUN	B
significantly	O	ADV	O
improved	O	VERB	O
cardiac	B-Disease	ADJ	B
dysfunction	I-Disease	NOUN	I
and	O	CCONJ	O
increased	O	VERB	B
the	O	DET	O
survival	O	NOUN	B
of	O	ADP	O
the	O	DET	O
animals	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
PJ34	B-Chemical	NOUN	B
significantly	O	ADV	O
reduced	O	VERB	O
the	O	DET	O
DOX	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
increase	O	NOUN	B
in	O	ADP	O
the	O	DET	O
serum	O	NOUN	B
lactate	B-Chemical	NOUN	I
dehydrogenase	O	NOUN	I
and	O	CCONJ	O
creatine	B-Chemical	NOUN	B
kinase	O	NOUN	I
activities	O	NOUN	I
but	O	CCONJ	O
not	O	PART	O
metalloproteinase	O	NOUN	B
activation	O	NOUN	I
in	O	ADP	O
the	O	DET	O
heart	O	NOUN	B
.	O	PUNCT	O


Thus	O	ADV	O
,	O	PUNCT	O
PARP	O	NOUN	B
activation	O	NOUN	B
contributes	O	VERB	O
to	O	PART	O
the	O	DET	O
cardiotoxicity	B-Disease	NOUN	B
of	O	ADP	O
DOX	B-Chemical	NOUN	B
.	O	PUNCT	O


PARP	O	NOUN	B
inhibitors	O	NOUN	B
may	O	AUX	O
exert	O	VERB	O
protective	O	ADJ	B
effects	O	NOUN	I
against	O	ADP	O
the	O	DET	O
development	O	NOUN	B
of	O	ADP	O
severe	O	ADJ	B
cardiac	B-Disease	ADJ	B
complications	I-Disease	NOUN	I
associated	O	VERB	B
with	O	ADP	I
the	O	DET	O
DOX	B-Chemical	NOUN	B


Fluconazole	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
torsade	B-Disease	NOUN	B
de	I-Disease	X	I
pointes	I-Disease	NOUN	I
.	O	PUNCT	O


OBJECTIVE	O	NOUN	O
:	O	PUNCT	O
To	O	PART	O
present	O	VERB	O
a	O	DET	O
case	O	NOUN	B
of	O	ADP	O
fluconazole	B-Chemical	NOUN	B
-	O	PUNCT	O
associated	O	VERB	B
torsade	B-Disease	NOUN	O
de	I-Disease	X	O
pointes	I-Disease	X	O
(	O	PUNCT	O
TDP	B-Disease	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
discuss	O	VERB	O
fluconazole	B-Chemical	NOUN	B
'	O	PART	O
s	O	NOUN	O
role	O	NOUN	O
in	O	ADP	O
causing	O	VERB	O
TDP	B-Disease	NOUN	B
.	O	PUNCT	O


CASE	O	ADJ	B
SUMMARY	O	NOUN	I
:	O	PUNCT	O
A	O	DET	O
68	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
white	O	ADJ	B
woman	O	NOUN	I
with	O	ADP	O
Candida	O	NOUN	B
glabrata	O	NOUN	I
isolated	O	VERB	B
from	O	ADP	O
a	O	DET	O
presacral	O	ADJ	B
abscess	O	NOUN	I
developed	O	VERB	O
TDP	B-Disease	NOUN	B
eight	O	NUM	O
days	O	NOUN	B
after	O	ADP	O
commencing	O	VERB	B
oral	O	ADJ	B
fluconazole	B-Chemical	NOUN	I
The	O	DET	O
patient	O	NOUN	B
had	O	AUX	O
no	O	DET	O
other	O	ADJ	O
risk	O	NOUN	B
factors	O	NOUN	I
for	O	ADP	O
TDP	B-Disease	NOUN	B
,	O	PUNCT	O
including	O	VERB	O
coronary	B-Disease	ADJ	B
artery	I-Disease	NOUN	I
disease	I-Disease	NOUN	I
,	O	PUNCT	O
cardiomyopathy	B-Disease	NOUN	B
,	O	PUNCT	O
congestive	B-Disease	ADJ	B
heart	I-Disease	NOUN	I
failure	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
electrolyte	O	NOUN	B
abnormalities	O	NOUN	I
There	O	PRON	O
was	O	AUX	O
a	O	DET	O
temporal	O	ADJ	B
association	O	NOUN	B
between	O	ADP	O
the	O	DET	O
initiation	O	NOUN	B
of	O	ADP	O
fluconazole	B-Chemical	NOUN	B
and	O	CCONJ	O
TDP	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
TDP	B-Disease	PROPN	B
resolved	O	VERB	B
when	O	SCONJ	O
fluconazole	B-Chemical	NOUN	B
was	O	AUX	O
discontinued	O	VERB	B
;	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
patient	O	NOUN	B
continued	O	VERB	O
to	O	PART	O
have	O	AUX	O
premature	B-Disease	ADJ	B
ventricular	I-Disease	ADJ	B
contractions	I-Disease	NOUN	I
and	O	CCONJ	O
nonsustained	O	ADJ	B
ventricular	B-Disease	ADJ	I
tachycardia	I-Disease	NOUN	I
(	O	PUNCT	O
NSVT	B-Disease	NOUN	B
)	O	PUNCT	O
until	O	ADP	O
six	O	NUM	O
days	O	NOUN	B
after	O	ADP	O
drug	O	NOUN	B
cessation	O	NOUN	I
DISCUSSION	O	NOUN	O
:	O	PUNCT	O
Use	O	PROPN	O
of	O	ADP	O
the	O	DET	O
Naranjo	O	PROPN	B
probability	O	NOUN	I
scale	O	NOUN	I
indicates	O	VERB	O
a	O	DET	O
probable	O	ADJ	O
relationship	O	NOUN	B
between	O	ADP	O
the	O	DET	O
use	O	NOUN	O
of	O	ADP	O
fluconazole	B-Chemical	NOUN	B
and	O	CCONJ	O
the	O	DET	O
development	O	NOUN	B
of	O	ADP	O
TDP	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
possible	O	ADJ	O
mechanism	O	NOUN	B
is	O	AUX	O
depression	B-Disease	NOUN	B
of	O	ADP	O
rapidly	O	ADV	O
activating	O	VERB	B
delayed	O	VERB	B
rectifier	O	NOUN	B
potassium	B-Chemical	NOUN	I
currents	O	NOUN	O
.	O	PUNCT	O


In	O	ADP	O
our	O	PRON	O
patient	O	NOUN	B
,	O	PUNCT	O
there	O	PRON	O
was	O	AUX	O
no	O	DET	O
other	O	ADJ	O
etiology	O	NOUN	B
identified	O	VERB	B
that	O	PRON	O
could	O	AUX	O
explain	O	VERB	O
QT	B-Disease	NOUN	B
prolongation	I-Disease	NOUN	O
or	O	CCONJ	O
TDP	B-Disease	NOUN	B
The	O	DET	O
complete	O	ADJ	O
disappearance	O	NOUN	B
of	O	ADP	O
NSVT	B-Disease	NOUN	B
and	O	CCONJ	O
premature	B-Disease	ADJ	B
ventricular	I-Disease	ADJ	I
contractions	I-Disease	NOUN	I
followed	O	VERB	O
by	O	ADP	O
normalization	O	NOUN	B
of	O	ADP	O
QT	O	NOUN	B
interval	O	NOUN	I
after	O	ADP	O
the	O	DET	O
drug	O	NOUN	B
was	O	AUX	O
stopped	O	VERB	O
strongly	O	ADV	O
suggests	O	VERB	O
fluconazole	B-Chemical	NOUN	B
as	O	ADP	O
the	O	DET	O
etiology	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
:	O	PUNCT	O
Clinicians	O	NOUN	B
should	O	AUX	O
be	O	AUX	O
aware	O	ADJ	O
that	O	SCONJ	O
fluconazole	B-Chemical	NOUN	B
,	O	PUNCT	O
even	O	ADV	O
at	O	ADP	O
low	O	ADJ	B
doses	O	NOUN	I
,	O	PUNCT	O
may	O	AUX	O
cause	O	VERB	O
prolongation	B-Disease	NOUN	B
of	I-Disease	ADP	O
the	I-Disease	DET	O
QT	I-Disease	NOUN	B
interval	I-Disease	NOUN	I
,	O	PUNCT	O
leading	O	VERB	O
to	O	PART	O
TDP	B-Disease	NOUN	B
.	O	PUNCT	O


Serial	O	ADJ	O
electrocardiographic	O	ADJ	B
monitoring	O	NOUN	I
may	O	AUX	O
be	O	AUX	O
considered	O	VERB	O
when	O	SCONJ	O
fluconazole	B-Chemical	NOUN	B
is	O	AUX	O
administered	O	VERB	B
in	O	ADP	O
patients	O	NOUN	B
who	O	PRON	O
are	O	AUX	O
at	O	ADP	O
risk	O	NOUN	B
for	O	ADP	O
ventricular	B-Disease	ADJ	B
arrhythmias	I-Disease	NOUN	I


High	O	ADJ	B
-	O	PUNCT	O
dose	O	NOUN	B
methylprednisolone	B-Chemical	NOUN	B
may	O	AUX	O
do	O	AUX	O
more	O	ADJ	O
harm	O	NOUN	O
for	O	ADP	O
spinal	B-Disease	ADJ	B
cord	I-Disease	NOUN	I
injury	I-Disease	NOUN	I
.	O	PUNCT	O


Because	O	SCONJ	O
of	O	ADP	O
the	O	DET	O
National	O	PROPN	B
Acute	O	PROPN	I
Spinal	B-Disease	PROPN	I
Cord	I-Disease	PROPN	I
Injury	I-Disease	PROPN	I
Studies	O	PROPN	I
(	O	PUNCT	O
NASCIS	O	NOUN	B
),	O	PUNCT	O
high	O	ADJ	B
-	O	PUNCT	O
dose	O	NOUN	B
methylprednisolone	B-Chemical	NOUN	B
became	O	VERB	O
the	O	DET	O
standard	O	NOUN	B
of	O	ADP	I
care	O	NOUN	I
for	O	ADP	O
the	O	DET	O
acute	O	ADJ	B
spinal	B-Disease	ADJ	I
cord	I-Disease	NOUN	I
injury	I-Disease	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
NASCIS	O	NOUN	B
,	O	PUNCT	O
there	O	PRON	O
was	O	AUX	O
no	O	DET	O
mention	O	NOUN	O
regarding	O	VERB	O
the	O	DET	O
possibility	O	NOUN	O
of	O	ADP	O
acute	O	ADJ	B
corticosteroid	B-Chemical	NOUN	I
myopathy	B-Disease	NOUN	I
that	O	SCONJ	O
high	O	ADJ	B
-	O	PUNCT	O
dose	O	NOUN	B
methylprednisolone	B-Chemical	NOUN	B
may	O	AUX	O
cause	O	VERB	O
.	O	PUNCT	O


The	O	DET	O
dosage	O	NOUN	B
of	O	ADP	O
methylprednisolone	B-Chemical	NOUN	B
recommended	O	VERB	B
by	O	ADP	O
the	O	DET	O
NASCIS	O	NOUN	B
3	O	NUM	I
is	O	AUX	O
the	O	DET	O
highest	O	ADJ	B
dose	O	NOUN	B
of	O	ADP	O
steroids	B-Chemical	NOUN	B
ever	O	ADV	O
being	O	AUX	O
used	O	VERB	O
during	O	ADP	O
a	O	DET	O
2	O	NUM	B
-	O	PUNCT	O
day	O	NOUN	B
period	O	NOUN	B
for	O	ADP	O
any	O	DET	O
clinical	O	ADJ	B
condition	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
hypothesize	O	VERB	O
that	O	SCONJ	O
it	O	PRON	O
may	O	AUX	O
cause	O	VERB	O
some	O	DET	O
damage	B-Disease	NOUN	B
to	I-Disease	ADP	O
the	I-Disease	DET	O
muscle	I-Disease	NOUN	B
of	O	ADP	O
spinal	B-Disease	ADJ	B
cord	I-Disease	NOUN	I
injury	I-Disease	NOUN	I
patients	O	NOUN	B
.	O	PUNCT	O


Further	O	ADV	O
,	O	PUNCT	O
steroid	B-Chemical	NOUN	B
myopathy	B-Disease	NOUN	I
recovers	O	VERB	O
naturally	O	ADV	B
and	O	CCONJ	O
the	O	DET	O
neurological	O	ADJ	B
improvement	O	NOUN	B
shown	O	VERB	O
in	O	ADP	O
the	O	DET	O
NASCIS	O	NOUN	B
may	O	AUX	O
be	O	AUX	O
just	O	ADV	O
a	O	DET	O
recording	O	NOUN	O
of	O	ADP	O
this	O	DET	O
natural	O	ADJ	B
motor	O	NOUN	O
recovery	O	NOUN	O
from	O	ADP	O
the	O	DET	O
steroid	B-Chemical	NOUN	B
myopathy	B-Disease	NOUN	I
,	O	PUNCT	O
instead	O	ADV	O
of	O	ADP	O
any	O	DET	O
protection	O	NOUN	B
that	O	PRON	O
methylprednisolone	B-Chemical	NOUN	B
offers	O	VERB	O
to	O	ADP	O
the	O	DET	O
spinal	B-Disease	ADJ	B
cord	I-Disease	NOUN	I
injury	I-Disease	NOUN	I
.	O	PUNCT	O


To	O	ADP	O
our	O	PRON	O
knowledge	O	NOUN	B
,	O	PUNCT	O
this	O	DET	O
is	O	AUX	O
the	O	DET	O
first	O	ADJ	O
discussion	O	NOUN	B
considering	O	VERB	O
the	O	DET	O
possibility	O	NOUN	O
that	O	SCONJ	O
the	O	DET	O
methylprednisolone	B-Chemical	NOUN	B
recommended	O	VERB	B
by	O	ADP	O
NASCIS	O	NOUN	B
may	O	AUX	O
cause	O	VERB	O
acute	O	ADJ	B
corticosteroid	B-Chemical	NOUN	I
myopathy	B-Disease	NOUN	I


Probing	O	VERB	B
peripheral	O	ADJ	B
and	O	CCONJ	O
central	O	ADJ	B
cholinergic	O	ADJ	I
system	O	NOUN	I
responses	O	NOUN	I
.	O	PUNCT	O


OBJECTIVE	O	NOUN	B
:	O	PUNCT	O
The	O	DET	O
pharmacological	O	ADJ	B
response	O	NOUN	I
to	O	ADP	O
drugs	O	NOUN	B
that	O	PRON	O
act	O	VERB	O
on	O	ADP	O
the	O	DET	O
cholinergic	O	ADJ	B
system	O	NOUN	O
of	O	ADP	O
the	O	DET	O
iris	O	NOUN	B
has	O	AUX	O
been	O	AUX	O
used	O	VERB	O
to	O	PART	O
predict	O	VERB	O
deficits	O	NOUN	B
in	O	ADP	O
central	O	ADJ	B
cholinergic	O	ADJ	I
functioning	O	NOUN	B
due	O	ADP	O
to	O	ADP	O
diseases	O	NOUN	B
such	O	ADJ	O
as	O	ADP	O
Alzheimer's	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
,	O	PUNCT	O
yet	O	CCONJ	O
correlations	O	NOUN	B
between	O	ADP	O
central	O	ADJ	B
and	O	CCONJ	O
peripheral	O	ADJ	B
responses	O	NOUN	I
have	O	AUX	O
not	O	PART	O
been	O	AUX	O
properly	O	ADV	O
studied	O	VERB	O
.	O	PUNCT	O


This	O	DET	O
study	O	NOUN	B
assessed	O	VERB	B
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
normal	O	ADJ	B
aging	O	NOUN	B
on	O	ADP	O
(	O	PUNCT	O
1	O	X	O
)	O	PUNCT	O
the	O	DET	O
tropicamide	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
increase	O	NOUN	B
in	O	ADP	O
pupil	O	NOUN	B
diameter	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
(	O	PUNCT	O
2	O	X	O
)	O	PUNCT	O
the	O	DET	O
reversal	O	NOUN	B
of	O	ADP	O
this	O	DET	O
effect	O	NOUN	B
with	O	ADP	O
pilocarpine	B-Chemical	NOUN	B
.	O	PUNCT	O


Scopolamine	B-Chemical	NOUN	B
was	O	AUX	O
used	O	VERB	O
as	O	ADP	O
a	O	DET	O
positive	O	ADJ	B
control	O	NOUN	O
to	O	PART	O
detect	O	VERB	B
age	O	NOUN	B
-	O	PUNCT	O
dependent	O	ADJ	B
changes	O	NOUN	B
in	O	ADP	O
central	O	ADJ	B
cholinergic	O	ADJ	I
functioning	O	NOUN	B
in	O	ADP	O
the	O	DET	O
elderly	O	ADJ	B
.	O	PUNCT	O


DESIGN	O	NOUN	O
:	O	PUNCT	O
Randomized	O	ADJ	B
double	O	ADJ	B
-	O	PUNCT	O
blind	O	NOUN	B
controlled	O	VERB	B
trial	O	NOUN	I
.	O	PUNCT	O


PARTICIPANTS	O	NOUN	B
:	O	PUNCT	O
Ten	O	NUM	O
healthy	O	ADJ	B
elderly	O	ADJ	B
(	O	PUNCT	O
mean	O	ADJ	O
age	O	NOUN	B
70	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
9	O	NUM	O
young	O	ADJ	B
(	O	PUNCT	O
mean	O	ADJ	O
age	O	NOUN	B
33	O	NUM	O
)	O	PUNCT	O
volunteers	O	NOUN	B
.	O	PUNCT	O


INTERVENTIONS	O	NOUN	B
:	O	PUNCT	O
Pupil	O	ADJ	B
diameter	O	NOUN	B
was	O	AUX	O
monitored	O	VERB	B
using	O	VERB	O
a	O	DET	O
computerized	O	VERB	B
infrared	O	NOUN	I
pupillometer	O	NOUN	I
over	O	ADP	O
4	O	NUM	O
hours	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
study	O	NOUN	B
involved	O	VERB	O
4	O	NUM	O
sessions	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
1	O	NUM	O
session	O	NOUN	B
,	O	PUNCT	O
tropicamide	B-Chemical	NOUN	B
(	O	PUNCT	O
20	O	NUM	O
microL	O	NOUN	B
,	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


01	O	NUM	O
%)	O	NOUN	O
was	O	AUX	O
administered	O	VERB	B
to	O	ADP	O
one	O	NUM	O
eye	O	NOUN	B
and	O	CCONJ	O
placebo	O	NOUN	B
to	O	ADP	O
the	O	DET	O
other	O	ADJ	O
.	O	PUNCT	O


In	O	ADP	O
another	O	DET	O
session	O	NOUN	B
,	O	PUNCT	O
tropicamide	B-Chemical	NOUN	B
(	O	PUNCT	O
20	O	NUM	O
microL	O	NOUN	B
,	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


01	O	NUM	O
%)	O	NOUN	O
was	O	AUX	O
administered	O	VERB	B
to	O	ADP	O
both	O	DET	O
eyes	O	NOUN	B
,	O	PUNCT	O
followed	O	VERB	O
23	O	NUM	O
minutes	O	NOUN	B
later	O	ADV	O
by	O	ADP	O
the	O	DET	O
application	O	NOUN	B
of	O	ADP	O
pilocarpine	B-Chemical	NOUN	B
(	O	PUNCT	O
20	O	NUM	O
microL	O	NOUN	B
,	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
%)	O	NOUN	O
to	O	ADP	O
one	O	NUM	O
eye	O	NOUN	B
and	O	CCONJ	O
placebo	O	NOUN	B
to	O	ADP	O
the	O	DET	O
other	O	ADJ	O
.	O	PUNCT	O


All	O	DET	O
eye	O	NOUN	B
drops	O	NOUN	I
were	O	AUX	O
given	O	VERB	O
in	O	ADP	O
a	O	DET	O
randomized	O	ADJ	B
order	O	NOUN	O
.	O	PUNCT	O


In	O	ADP	O
2	O	NUM	O
separate	O	ADJ	O
sessions	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
single	O	ADJ	O
dose	O	NOUN	B
of	O	ADP	O
scopolamine	B-Chemical	NOUN	B
(	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
mg	O	NOUN	O
,	O	PUNCT	O
intravenously	O	ADV	B
)	O	PUNCT	O
or	O	CCONJ	O
placebo	O	NOUN	B
was	O	AUX	O
administered	O	VERB	B
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
effects	O	NOUN	B
on	O	ADP	O
word	O	NOUN	B
recall	O	NOUN	I
were	O	AUX	O
measured	O	VERB	B
using	O	VERB	O
the	O	DET	O
Buschke	O	PROPN	B
Selective	O	ADJ	I
Reminding	O	PROPN	I
Test	O	PROPN	I
over	O	ADP	O
2	O	NUM	O
hours	O	NOUN	B
.	O	PUNCT	O


OUTCOME	O	NOUN	B
MEASURES	O	NOUN	I
:	O	PUNCT	O
Pupil	O	ADJ	B
size	O	NOUN	I
at	O	ADP	O
time	O	NOUN	B
points	O	NOUN	I
after	O	ADP	O
administration	O	NOUN	B
of	O	ADP	O
tropicamide	B-Chemical	NOUN	B
and	O	CCONJ	O
pilocarpine	B-Chemical	NOUN	B
;	O	PUNCT	O
scopolamine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
impairment	B-Disease	NOUN	B
in	I-Disease	ADP	O
word	I-Disease	NOUN	B
recall	I-Disease	NOUN	I
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
There	O	PRON	O
was	O	AUX	O
no	O	DET	B
significant	O	ADJ	I
difference	O	NOUN	O
between	O	ADP	O
elderly	O	ADJ	B
and	O	CCONJ	O
young	O	ADJ	B
volunteers	O	NOUN	I
in	O	ADP	O
pupillary	O	ADJ	B
response	O	NOUN	I
to	O	PART	O
tropicamide	B-Chemical	NOUN	B
at	O	ADP	O
any	O	DET	O
time	O	NOUN	B
point	O	NOUN	I
(	O	PUNCT	O
p	O	NOUN	O
>	O	NOUN	O
0	O	NUM	O
.	O	PUNCT	O


05	O	NUM	O
).	O	PUNCT	O
The	O	DET	O
elderly	O	ADJ	B
group	O	NOUN	I
had	O	AUX	O
a	O	DET	O
significantly	O	ADV	O
greater	O	ADJ	O
pilocarpine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
net	O	ADJ	B
decrease	O	NOUN	B
in	O	ADP	O
pupil	O	NOUN	B
size	O	NOUN	I
85	O	NUM	O
,	O	PUNCT	O
125	O	NUM	O
,	O	PUNCT	O
165	O	NUM	O
and	O	CCONJ	O
215	O	NUM	O
minutes	O	NOUN	B
after	O	ADP	O
administration	O	NOUN	B
,	O	PUNCT	O
compared	O	VERB	B
with	O	ADP	O
the	O	DET	O
young	O	ADJ	B
group	O	NOUN	I
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


05	O	NUM	O
).	O	PUNCT	B
Compared	O	VERB	B
with	O	ADP	O
the	O	DET	O
young	O	ADJ	B
group	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
elderly	O	ADJ	B
group	O	NOUN	I
had	O	AUX	O
greater	O	ADJ	O
scopolamine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
impairment	B-Disease	NOUN	B
in	I-Disease	ADP	O
word	I-Disease	NOUN	B
recall	I-Disease	VERB	I
60	O	NUM	O
,	O	PUNCT	O
90	O	NUM	O
and	O	CCONJ	O
120	O	NUM	O
minutes	O	NOUN	B
after	O	ADP	O
administration	O	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


05	O	NUM	O
).	O	PUNCT	O
CONCLUSION	O	NOUN	O
:	O	PUNCT	O
There	O	PRON	O
is	O	AUX	O
an	O	DET	O
age	O	NOUN	B
-	O	PUNCT	O
related	O	VERB	B
pupillary	O	ADJ	B
response	O	NOUN	I
to	O	PART	O
pilocarpine	B-Chemical	NOUN	B
that	O	PRON	O
is	O	AUX	O
not	O	PART	O
found	O	VERB	O
with	O	ADP	O
tropicamide	B-Chemical	NOUN	B
.	O	PUNCT	O


Thus	O	ADV	O
,	O	PUNCT	O
pilocarpine	B-Chemical	NOUN	B


Acetazolamide	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
Gerstmann	B-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
.	O	PUNCT	O


Acute	O	ADJ	B
confusion	B-Disease	NOUN	B
induced	O	VERB	B
by	O	ADP	O
acetazolamide	B-Chemical	NOUN	B
is	O	AUX	O
a	O	DET	O
well	O	ADV	O
known	O	ADJ	O
adverse	O	ADJ	B
drug	O	NOUN	I
reaction	O	NOUN	I
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
renal	B-Disease	ADJ	B
impairment	I-Disease	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
a	O	DET	O
case	O	NOUN	B
of	O	ADP	O
acetazolamide	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
Gerstmann	B-Disease	PROPN	B
syndrome	I-Disease	NOUN	I


Hypomania	B-Disease	NOUN	B
-	O	PUNCT	O
like	O	ADJ	B
syndrome	O	NOUN	B
induced	O	VERB	B
by	O	ADP	O
olanzapine	B-Chemical	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
a	O	DET	O
female	O	ADJ	B
patient	O	NOUN	B
with	O	ADP	O
a	O	DET	O
diagnosis	O	NOUN	B
of	O	ADP	O
a	O	DET	O
not	O	PART	O
otherwise	O	ADV	O
specified	O	VERB	O
psychotic	B-Disease	ADJ	B
disorder	I-Disease	NOUN	I
(	O	PUNCT	O
DSM	O	PROPN	B
-	O	PUNCT	O
IV	O	PROPN	B
)	O	PUNCT	O
who	O	PRON	O
developed	O	VERB	O
hypomania	B-Disease	NOUN	B
shortly	O	ADV	O
after	O	ADP	O
the	O	DET	O
introduction	O	NOUN	B
of	O	ADP	O
olanzapine	B-Chemical	NOUN	B


Neutrophil	O	NOUN	B
superoxide	B-Chemical	NOUN	I
and	O	CCONJ	O
hydrogen	B-Chemical	NOUN	B
peroxide	I-Chemical	NOUN	I
production	O	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
acute	B-Disease	ADJ	B
liver	I-Disease	NOUN	I
failure	I-Disease	NOUN	I
.	O	PUNCT	O


Defects	O	NOUN	B
in	O	ADP	O
superoxide	B-Chemical	NOUN	B
and	O	CCONJ	O
hydrogen	B-Chemical	NOUN	B
peroxide	I-Chemical	NOUN	I
production	O	NOUN	B
may	O	AUX	O
be	O	AUX	O
implicated	O	VERB	O
in	O	ADP	O
the	O	DET	O
high	O	ADJ	O
incidence	O	NOUN	B
of	O	ADP	O
bacterial	B-Disease	ADJ	B
infections	I-Disease	NOUN	I
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
acute	B-Disease	ADJ	B
liver	I-Disease	NOUN	I
failure	I-Disease	NOUN	I
(	O	PUNCT	O
ALF	B-Disease	NOUN	B
).	O	PUNCT	B
In	O	ADP	O
the	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
,	O	PUNCT	O
oxygen	B-Chemical	NOUN	B
radical	O	ADJ	I
production	O	NOUN	I
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
ALF	B-Disease	NOUN	B
due	O	ADP	O
to	O	PART	O
paracetamol	B-Chemical	NOUN	B
overdose	B-Disease	NOUN	I
was	O	AUX	O
compared	O	VERB	B
with	O	ADP	O
that	O	DET	O
of	O	ADP	O
healthy	O	ADJ	B
volunteers	O	NOUN	I
.	O	PUNCT	O


Neutrophils	O	NOUN	B
from	O	ADP	O
14	O	NUM	O
ALF	B-Disease	NOUN	B
patients	O	NOUN	B
were	O	AUX	O
stimulated	O	VERB	B
via	O	ADP	O
the	O	DET	O
complement	O	NOUN	B
receptors	O	NOUN	I
using	O	VERB	O
zymosan	O	ADJ	B
opsonized	O	VERB	I
with	O	ADP	O
ALF	B-Disease	NOUN	B
or	O	CCONJ	O
control	O	NOUN	B
serum	O	NOUN	I
.	O	PUNCT	O


Superoxide	B-Chemical	NOUN	B
and	O	CCONJ	O
hydrogen	B-Chemical	NOUN	B
peroxide	I-Chemical	NOUN	I
production	O	NOUN	B
by	O	ADP	O
ALF	B-Disease	NOUN	B
neutrophils	O	NOUN	B
stimulated	O	VERB	B
with	O	ADP	O
zymosan	O	NOUN	B
opsonized	O	VERB	B
with	O	ADP	O
ALF	B-Disease	NOUN	B
serum	O	NOUN	B
was	O	AUX	O
significantly	O	ADV	O
reduced	O	VERB	B
compared	O	VERB	B
with	O	ADP	O
the	O	DET	O
control	O	ADJ	B
subjects	O	NOUN	I
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


01	O	NUM	O
).	O	PUNCT	O
This	O	DET	O
defect	O	NOUN	B
persisted	O	VERB	O
when	O	SCONJ	O
zymosan	O	NOUN	B
opsonized	O	VERB	B
by	O	ADP	O
control	O	ADJ	B
serum	O	NOUN	B
was	O	AUX	O
used	O	VERB	O
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


05	O	NUM	O
).	O	PUNCT	B
Superoxide	B-Chemical	NOUN	B
and	O	CCONJ	O
hydrogen	B-Chemical	NOUN	B
peroxide	I-Chemical	NOUN	I
production	O	NOUN	B
in	O	ADP	O
neutrophils	O	NOUN	B
stimulated	O	VERB	B
with	O	ADP	O
formyl-methionyl-leucyl-phenylalanine	B-Chemical	NOUN	B
(	O	PUNCT	O
fMLP	B-Chemical	NOUN	B
)	O	PUNCT	O
from	O	ADP	O
a	O	DET	O
further	O	ADV	O
18	O	NUM	O
ALF	B-Disease	NOUN	B
patients	O	NOUN	B
was	O	AUX	O
unaffected	O	ADJ	O
compared	O	VERB	B
with	O	ADP	O
control	O	ADJ	B
neutrophils	O	NOUN	B
.	O	PUNCT	O


Serum	O	NOUN	B
C3	O	NOUN	I
complement	O	NOUN	I
levels	O	NOUN	O
were	O	AUX	O
significantly	O	ADV	O
reduced	O	VERB	O
in	O	ADP	O
ALF	B-Disease	NOUN	B
patients	O	NOUN	B
compared	O	VERB	O
with	O	ADP	O
control	O	ADJ	B
subjects	O	NOUN	I
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


0005	O	NUM	O
).	O	PUNCT	O
These	O	DET	O
results	O	NOUN	B
demonstrate	O	VERB	O
a	O	DET	O
neutrophil	O	NOUN	B
defect	O	NOUN	O
in	O	ADP	O
ALF	B-Disease	NOUN	B
due	O	ADP	O
to	O	PART	O
paracetamol	B-Chemical	NOUN	B
overdose	B-Disease	NOUN	I


Absence	O	NOUN	B
of	O	ADP	O
effect	O	NOUN	B
of	O	ADP	O
sertraline	B-Chemical	NOUN	B
on	O	ADP	O
time	O	NOUN	B
-	O	PUNCT	O
based	O	VERB	B
sensitization	O	NOUN	B
of	O	ADP	O
cognitive	B-Disease	ADJ	B
impairment	I-Disease	NOUN	I
with	O	ADP	O
haloperidol	B-Chemical	NOUN	B
.	O	PUNCT	O


This	O	DET	O
double	O	ADV	B
-	O	PUNCT	O
blind	O	ADJ	B
,	O	PUNCT	O
randomized	O	ADJ	B
,	O	PUNCT	O
placebo	O	NOUN	B
-	O	PUNCT	O
controlled	O	VERB	B
study	O	NOUN	I
evaluated	O	VERB	B
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	O
haloperidol	B-Chemical	NOUN	B
alone	O	ADV	O
and	O	CCONJ	O
haloperidol	B-Chemical	NOUN	B
plus	O	CCONJ	O
sertraline	B-Chemical	NOUN	B
on	O	ADP	O
cognitive	O	ADJ	B
and	O	CCONJ	O
psychomotor	O	NOUN	B
function	O	NOUN	I
in	O	ADP	O
24	O	NUM	O
healthy	O	ADJ	B
male	O	NOUN	B
subjects	O	NOUN	O
.	O	PUNCT	O


METHOD	O	NOUN	B
:	O	PUNCT	O
All	O	DET	O
subjects	O	NOUN	B
received	O	VERB	O
placebo	O	NOUN	B
on	O	ADP	O
Day	O	PROPN	B
1	O	NUM	I
and	O	CCONJ	O
haloperidol	B-Chemical	NOUN	B
2	O	NUM	O
mg	O	NOUN	O
on	O	ADP	O
Days	O	NOUN	O
2	O	NUM	O
and	O	CCONJ	O
25	O	NUM	O
.	O	PUNCT	O


From	O	ADP	O
Days	O	NOUN	O
9	O	NUM	O
to	O	PART	O
25	O	NUM	O
,	O	PUNCT	O
subjects	O	NOUN	B
were	O	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
to	O	PART	O
either	O	CCONJ	O
sertraline	B-Chemical	NOUN	B
(	O	PUNCT	O
12	O	NUM	O
subjects	O	NOUN	B
)	O	PUNCT	O
or	O	CCONJ	O
placebo	O	NOUN	B
(	O	PUNCT	O
12	O	NUM	O
subjects	O	NOUN	B
);	O	ADJ	O
the	O	DET	O
sertraline	B-Chemical	NOUN	B
dose	O	NOUN	B
was	O	AUX	O
titrated	O	VERB	B
from	O	ADP	O
50	O	NUM	O
to	O	PART	O
200	O	NUM	O
mg	O	NOUN	O
/	O	PUNCT	O
day	O	NOUN	B
from	O	ADP	O
Days	O	NOUN	B
9	O	NUM	O
to	O	PART	O
16	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
remained	O	VERB	O
at	O	ADP	O
200	O	NUM	O
mg	O	NOUN	O
/	O	PUNCT	O
day	O	NOUN	B
for	O	ADP	O
the	O	DET	O
final	O	ADJ	O
10	O	NUM	O
days	O	NOUN	B
of	O	ADP	O
the	O	DET	O
drug	O	NOUN	B
administration	O	NOUN	I
period	O	NOUN	B
.	O	PUNCT	O


Cognitive	O	ADJ	B
function	O	NOUN	I
testing	O	NOUN	I
was	O	AUX	O
performed	O	VERB	O
before	O	ADP	O
dosing	O	NOUN	B
and	O	CCONJ	O
over	O	ADP	O
a	O	DET	O
24	O	NUM	O
-	O	PUNCT	O
hour	O	NOUN	B
period	O	NOUN	B
after	O	ADP	O
dosing	O	VERB	B
on	O	ADP	O
Days	O	NOUN	B
1	O	NUM	I
,	O	PUNCT	O
2	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
25	O	NUM	O
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
Impairment	B-Disease	ADJ	B
of	I-Disease	ADP	O
cognitive	I-Disease	ADJ	B
function	I-Disease	NOUN	I
was	O	AUX	O
observed	O	VERB	O
6	O	NUM	O
to	O	PART	O
8	O	NUM	O
hours	O	NOUN	B
after	O	ADP	O
administration	O	NOUN	B
of	O	ADP	O
haloperidol	B-Chemical	NOUN	B
on	O	ADP	O
Day	O	PROPN	B
2	O	NUM	I
but	O	CCONJ	O
was	O	AUX	O
not	O	PART	O
evident	O	ADJ	O
23	O	NUM	O
hours	O	NOUN	B
after	O	ADP	O
dosing	O	NOUN	B
.	O	PUNCT	O


When	O	SCONJ	O
single	O	ADJ	B
-	O	PUNCT	O
dose	O	NOUN	B
haloperidol	B-Chemical	NOUN	B
was	O	AUX	O
given	O	VERB	O
again	O	ADV	O
25	O	NUM	O
days	O	NOUN	B
later	O	ADV	O
,	O	PUNCT	O
greater	O	ADJ	O
impairment	O	NOUN	B
with	O	ADP	O
earlier	O	ADJ	O
onset	O	NOUN	O
was	O	AUX	O
noted	O	VERB	O
in	O	ADP	O
several	O	ADJ	O
tests	O	NOUN	B
in	O	ADP	O
both	O	CCONJ	O
treatment	O	NOUN	B
groups	O	NOUN	I
,	O	PUNCT	O
suggesting	O	VERB	O
enhancement	O	NOUN	B
of	O	ADP	O
this	O	DET	O
effect	O	NOUN	B
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
no	O	DET	O
indication	O	NOUN	B
that	O	SCONJ	O
sertraline	B-Chemical	NOUN	B
exacerbated	O	VERB	B
the	O	DET	O
impairment	O	NOUN	B
produced	O	VERB	O
by	O	ADP	O
haloperidol	B-Chemical	NOUN	B
since	O	SCONJ	O
an	O	DET	O
equivalent	O	ADJ	O
effect	O	NOUN	B
also	O	ADV	O
occurred	O	VERB	O
in	O	ADP	O
the	O	DET	O
placebo	O	ADJ	B
group	O	NOUN	B
.	O	PUNCT	O


Three	O	NUM	O
subjects	O	NOUN	B
(	O	PUNCT	O
2	O	NUM	O
on	O	ADP	O
sertraline	B-Chemical	NOUN	B
and	O	CCONJ	O
1	O	NUM	O
on	O	ADP	O
placebo	O	NOUN	B
)	O	PUNCT	O
withdrew	O	VERB	O
from	O	ADP	O
the	O	DET	O
study	O	NOUN	B
because	O	SCONJ	O
of	O	ADP	O
side	O	NOUN	B
effects	O	NOUN	I
.	O	PUNCT	O


Ten	O	NUM	O
subjects	O	NOUN	B
in	O	ADP	O
each	O	DET	O
group	O	NOUN	B
reported	O	VERB	O
side	O	NOUN	B
effects	O	NOUN	I
related	O	ADJ	O
to	O	PART	O
treatment	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
side	O	NOUN	B
effect	O	NOUN	I
profiles	O	NOUN	O
of	O	ADP	O
sertraline	B-Chemical	NOUN	B
and	O	CCONJ	O
of	O	ADP	O
placebo	O	NOUN	B
were	O	AUX	O
similar	O	ADJ	O
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
:	O	PUNCT	O
Haloperidol	B-Chemical	NOUN	B
produced	O	VERB	O
a	O	DET	O
clear	O	ADJ	O
profile	O	NOUN	O
of	O	ADP	O
cognitive	B-Disease	ADJ	B
impairment	I-Disease	NOUN	I
that	O	PRON	O
was	O	AUX	O
not	O	PART	O
worsened	O	VERB	B
by	O	ADP	O
concomitant	O	ADJ	B
sertraline	B-Chemical	NOUN	B


Ciprofloxacin	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
nephrotoxicity	B-Disease	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
cancer	B-Disease	NOUN	B
.	O	PUNCT	O


Nephrotoxicity	B-Disease	NOUN	B
associated	O	VERB	B
with	O	ADP	I
ciprofloxacin	B-Chemical	NOUN	B
is	O	AUX	O
uncommon	O	ADJ	O
.	O	PUNCT	O


Five	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
cancer	B-Disease	NOUN	B
who	O	PRON	O
developed	O	VERB	O
acute	B-Disease	ADJ	B
renal	I-Disease	ADJ	I
failure	I-Disease	NOUN	I
that	O	PRON	O
followed	O	VERB	O
treatment	O	NOUN	B
with	O	ADP	O
ciprofloxacin	B-Chemical	NOUN	B
are	O	AUX	O
described	O	VERB	O
and	O	CCONJ	O
an	O	DET	O
additional	O	ADJ	O
15	O	NUM	O
cases	O	NOUN	B
reported	O	VERB	O
in	O	ADP	O
the	O	DET	O
literature	O	NOUN	B
are	O	AUX	O
reviewed	O	VERB	B
.	O	PUNCT	O


Other	O	ADJ	O
than	O	ADP	O
elevation	O	NOUN	B
of	O	ADP	O
serum	O	NOUN	B
creatinine	B-Chemical	NOUN	I
levels	O	NOUN	I
,	O	PUNCT	O
characteristic	O	ADJ	O
clinical	O	ADJ	B
manifestations	O	NOUN	O
and	O	CCONJ	O
abnormal	O	ADJ	B
laboratory	O	NOUN	B
findings	O	NOUN	I
are	O	AUX	O
not	O	PART	O
frequently	O	ADV	O
present	O	ADJ	O
.	O	PUNCT	O


Allergic	O	ADJ	B
interstitial	B-Disease	ADJ	I
nephritis	I-Disease	NOUN	I
is	O	AUX	O
believed	O	VERB	O
to	O	PART	O
be	O	AUX	O
the	O	DET	O
underlying	O	ADJ	O
pathological	O	ADJ	B
-	O	PUNCT	O
process	O	NOUN	B
.	O	PUNCT	O


Definitive	O	ADJ	B
diagnosis	O	NOUN	I
requires	O	VERB	O
performance	O	NOUN	B
of	O	ADP	O
renal	O	ADJ	B
biopsy	O	NOUN	I
,	O	PUNCT	O
although	O	SCONJ	O
this	O	DET	O
is	O	AUX	O
not	O	PART	O
always	O	ADV	O
feasible	O	ADJ	O
.	O	PUNCT	O


An	O	DET	O
improvement	O	NOUN	B
in	O	ADP	O
renal	O	ADJ	B
function	O	NOUN	I
that	O	PRON	O
followed	O	VERB	O
the	O	DET	O
discontinuation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
offending	O	NOUN	B
antibiotic	O	ADJ	B
supports	O	VERB	O
the	O	DET	O
presumptive	O	ADJ	B
diagnosis	O	NOUN	I
of	O	ADP	O
ciprofloxacin	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
acute	B-Disease	ADJ	B
renal	I-Disease	ADJ	I
failure	I-Disease	NOUN	I


Case	O	NOUN	B
report	O	NOUN	I
:	O	PUNCT	O
pentamidine	B-Chemical	NOUN	B
and	O	CCONJ	O
polymorphic	O	ADJ	B
ventricular	B-Disease	ADJ	I
tachycardia	I-Disease	NOUN	I
revisited	O	VERB	O
.	O	PUNCT	O


Pentamidine	B-Chemical	NOUN	B
isethionate	I-Chemical	NOUN	B
has	O	AUX	O
been	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
ventricular	B-Disease	ADJ	B
tachyarrhythmias	I-Disease	NOUN	I
,	O	PUNCT	O
including	O	VERB	O
torsade	B-Disease	NOUN	B
de	I-Disease	X	I
pointes	I-Disease	NOUN	I
.	O	PUNCT	O


This	O	DET	O
article	O	NOUN	O
reports	O	VERB	B
two	O	NUM	O
cases	O	NOUN	B
of	O	ADP	O
this	O	DET	O
complication	O	NOUN	B
and	O	CCONJ	O
reviews	O	VERB	B
all	O	DET	O
reported	O	VERB	O
cases	O	NOUN	B
to	O	ADP	O
date	O	NOUN	O
.	O	PUNCT	O


Pentamidine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
torsade	B-Disease	NOUN	B
de	I-Disease	X	I
pointes	I-Disease	NOUN	I
may	O	AUX	O
be	O	AUX	O
related	O	ADJ	O
to	O	PART	O
serum	O	NOUN	B
magnesium	B-Chemical	NOUN	B
levels	O	NOUN	I
and	O	CCONJ	O
hypomagnesemia	B-Disease	NOUN	B
may	O	AUX	O
synergistically	O	ADV	B
induce	O	VERB	B
torsade	O	NOUN	B
.	O	PUNCT	O


Torsade	B-Disease	NOUN	B
de	I-Disease	X	I
pointes	I-Disease	X	I
occurred	O	VERB	O
after	O	ADP	O
an	O	DET	O
average	O	NOUN	B
of	O	ADP	O
10	O	NUM	O
days	O	NOUN	B
of	O	ADP	O
treatment	O	NOUN	B
with	O	ADP	O
pentamidine	B-Chemical	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
these	O	DET	O
patients	O	NOUN	B
,	O	PUNCT	O
no	O	DET	O
other	O	ADJ	O
acute	O	ADJ	B
side	O	NOUN	B
effects	O	NOUN	I
of	O	ADP	O
pentamidine	B-Chemical	NOUN	B
were	O	AUX	O
observed	O	VERB	B
.	O	PUNCT	O


Torsade	B-Disease	NOUN	B
de	I-Disease	X	I
pointes	I-Disease	PROPN	I
can	O	AUX	O
be	O	AUX	O
treated	O	VERB	B
when	O	SCONJ	O
recognized	O	VERB	O
early	O	ADV	B
,	O	PUNCT	O
possibly	O	ADV	O
without	O	ADP	O
discontinuation	O	NOUN	B
of	O	ADP	O
pentamidine	B-Chemical	NOUN	B
.	O	PUNCT	O


When	O	SCONJ	O
QTc	B-Disease	NOUN	B
interval	I-Disease	NOUN	I
prolongation	I-Disease	NOUN	B
is	O	AUX	O
observed	O	VERB	B
,	O	PUNCT	O
early	O	ADJ	O
magnesium	B-Chemical	NOUN	B


Time	O	NOUN	B
dependence	O	NOUN	I
of	O	ADP	O
plasma	O	NOUN	B
malondialdehyde	B-Chemical	NOUN	B
,	O	PUNCT	O
oxypurines	B-Chemical	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
nucleosides	B-Chemical	NOUN	B
during	O	ADP	O
incomplete	O	ADJ	B
cerebral	B-Disease	ADJ	B
ischemia	I-Disease	NOUN	I
in	O	ADP	O
the	O	DET	O
rat	O	NOUN	B
.	O	PUNCT	O


Incomplete	O	ADJ	B
cerebral	B-Disease	ADJ	B
ischemia	I-Disease	NOUN	I
(	O	PUNCT	O
30	O	NUM	O
min	O	NOUN	O
)	O	PUNCT	O
was	O	AUX	O
induced	O	VERB	B
in	O	ADP	O
the	O	DET	O
rat	O	NOUN	B
by	O	ADP	O
bilaterally	O	ADV	B
clamping	O	VERB	I
the	O	DET	O
common	O	ADJ	O
carotid	O	NOUN	B
arteries	O	NOUN	I
.	O	PUNCT	O


Peripheral	O	ADJ	B
venous	O	ADJ	B
blood	O	NOUN	I
samples	O	NOUN	I
were	O	AUX	O
withdrawn	O	VERB	O
from	O	ADP	O
the	O	DET	O
femoral	O	ADJ	B
vein	O	NOUN	I
four	O	NUM	O
times	O	NOUN	O
(	O	PUNCT	O
once	O	ADV	O
every	O	DET	O
5	O	NUM	O
min	O	NOUN	O
)	O	PUNCT	O
before	O	ADP	O
ischemia	B-Disease	NOUN	B
(	O	PUNCT	O
0	O	NUM	O
time	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
5	O	NUM	O
,	O	PUNCT	O
15	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
30	O	NUM	O
min	O	NOUN	O
after	O	ADP	O
ischemia	B-Disease	NOUN	B
.	O	PUNCT	O


Plasma	O	NOUN	B
extracts	O	NOUN	B
were	O	AUX	O
analyzed	O	VERB	B
by	O	ADP	O
a	O	DET	O
highly	O	ADV	O
sensitive	O	ADJ	B
high	O	ADJ	B
-	O	PUNCT	O
performance	O	NOUN	B
liquid	O	ADJ	B
chromatographic	O	ADJ	I
method	O	NOUN	I
for	O	ADP	O
the	O	DET	O
direct	O	ADJ	O
determination	O	NOUN	B
of	O	ADP	O
malondialdehyde	B-Chemical	NOUN	B
,	O	PUNCT	O
oxypurines	B-Chemical	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
nucleosides	B-Chemical	NOUN	B
.	O	PUNCT	O


During	O	ADP	O
ischemia	B-Disease	NOUN	B
,	O	PUNCT	O
a	O	DET	O
time	O	NOUN	B
-	O	PUNCT	O
dependent	O	ADJ	B
increase	O	NOUN	B
of	O	ADP	O
plasma	O	NOUN	B
oxypurines	B-Chemical	NOUN	B
and	O	CCONJ	O
nucleosides	B-Chemical	NOUN	B
was	O	AUX	O
observed	O	VERB	O
.	O	PUNCT	O


Plasma	O	NOUN	B
malondialdehyde	B-Chemical	NOUN	B
,	O	PUNCT	O
which	O	DET	O
was	O	AUX	O
present	O	ADJ	O
in	O	ADP	O
minimal	O	ADJ	B
amount	O	NOUN	B
at	O	ADP	O
zero	O	NUM	O
time	O	NOUN	O
(	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


058	O	NUM	O
mumol	O	NOUN	B
/	O	SYM	O
liter	O	NOUN	B
plasma	O	NOUN	B
;	O	PUNCT	O
SD	O	NOUN	B
0	O	NUM	O
.	O	PUNCT	O


015	O	NUM	O
),	O	PUNCT	O
increased	O	VERB	B
after	O	ADP	O
5	O	NUM	O
min	O	NOUN	O
of	O	ADP	O
ischemia	B-Disease	NOUN	B
,	O	PUNCT	O
resulting	O	VERB	O
in	O	ADP	O
a	O	DET	O
fivefold	O	ADJ	O
increase	O	NOUN	B
after	O	ADP	O
30	O	NUM	O
min	O	NOUN	O
of	O	ADP	O
carotid	O	NOUN	B
occlusion	O	NOUN	I
(	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


298	O	NUM	O
mumol	O	NOUN	B
/	O	SYM	O
liter	O	NOUN	B
plasma	O	NOUN	B
;	O	PUNCT	O
SD	O	NOUN	B
0	O	NUM	O
.	O	PUNCT	O


078	O	NUM	O
).	O	PUNCT	B
Increased	O	VERB	B
plasma	O	NOUN	B
malondialdehyde	B-Chemical	NOUN	B
was	O	AUX	O
also	O	ADV	O
recorded	O	VERB	O
in	O	ADP	O
two	O	NUM	O
other	O	ADJ	O
groups	O	NOUN	B
of	O	ADP	O
animals	O	NOUN	B
subjected	O	VERB	O
to	O	PART	O
the	O	DET	O
same	O	ADJ	O
experimental	O	ADJ	B
model	O	NOUN	I
,	O	PUNCT	O
one	O	NUM	O
receiving	O	VERB	O
20	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	O
b	O	NOUN	O
.	O	PUNCT	O


w	O	X	O
.	O	PUNCT	O


of	O	ADP	O
the	O	DET	O
cyclooxygenase	O	NOUN	B
inhibitor	O	NOUN	I
acetylsalicylate	B-Chemical	NOUN	B
intravenously	O	ADV	B
immediately	O	ADV	O
before	O	ADP	O
ischemia	B-Disease	NOUN	B
,	O	PUNCT	O
the	O	DET	O
other	O	ADJ	O
receiving	O	VERB	O
650	O	NUM	O
micrograms	O	NOUN	B
/	O	PUNCT	O
kg	O	NOUN	B
b	O	NOUN	O
.	O	PUNCT	O


w	O	X	O
.	O	PUNCT	O


of	O	ADP	O
the	O	DET	O
hypotensive	B-Disease	ADJ	B
drug	O	NOUN	I
nitroprusside	B-Chemical	NOUN	I
at	O	ADP	O
a	O	DET	O
flow	O	NOUN	B
rate	O	NOUN	I
of	O	ADP	O
103	O	NUM	O
microliters	O	NOUN	B
/	O	PUNCT	O
min	O	NOUN	B
intravenously	O	ADV	B
during	O	ADP	O
ischemia	B-Disease	NOUN	B
,	O	PUNCT	O
although	O	SCONJ	O
in	O	ADP	O
this	O	DET	O
latter	O	ADJ	O
group	O	NOUN	B
malondialdehyde	B-Chemical	NOUN	B
was	O	AUX	O
significantly	O	ADV	O
higher	O	ADJ	O
.	O	PUNCT	O


The	O	DET	O
present	O	ADJ	O
data	O	NOUN	B
indicate	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
determination	O	NOUN	B
of	O	ADP	O
malondialdehyde	B-Chemical	NOUN	B
,	O	PUNCT	O
oxypurines	B-Chemical	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
nucleosides	B-Chemical	NOUN	B
in	O	ADP	O
peripheral	O	ADJ	B
blood	O	NOUN	I
,	O	PUNCT	O
may	O	AUX	O
be	O	AUX	O
used	O	VERB	O
to	O	PART	O
monitor	O	VERB	B
the	O	DET	O
metabolic	O	ADJ	B
alterations	O	NOUN	B
of	O	ADP	O
tissues	O	NOUN	B
occurring	O	VERB	O
during	O	ADP	O
ischemic	B-Disease	ADJ	B


Cholinergic	O	ADJ	B
toxicity	B-Disease	NOUN	B
resulting	O	VERB	O
from	O	ADP	O
ocular	O	ADJ	B
instillation	O	NOUN	B
of	O	ADP	O
echothiophate	B-Chemical	ADJ	B
iodide	I-Chemical	NOUN	B
eye	O	NOUN	I
drops	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
patient	O	NOUN	B
developed	O	VERB	O
a	O	DET	O
severe	O	ADJ	O
cholinergic	O	ADJ	B
syndrome	O	NOUN	I
from	O	ADP	O
the	O	DET	O
use	O	NOUN	O
of	O	ADP	O
echothiophate	B-Chemical	ADJ	B
iodide	I-Chemical	NOUN	O
ophthalmic	O	ADJ	O
drops	O	NOUN	O
,	O	PUNCT	O
presented	O	VERB	O
with	O	ADP	O
profound	O	ADJ	O
muscle	B-Disease	NOUN	B
weakness	I-Disease	NOUN	I
and	O	CCONJ	O
was	O	AUX	O
initially	O	ADV	O
given	O	VERB	O
the	O	DET	O
diagnosis	O	NOUN	B
of	O	ADP	O
myasthenia	B-Disease	NOUN	B
gravis	I-Disease	NOUN	I


Acute	B-Disease	ADJ	B
renal	I-Disease	ADJ	I
failure	I-Disease	NOUN	I
in	O	ADP	O
high	O	ADJ	B
dose	O	NOUN	I
carboplatin	B-Chemical	NOUN	O
chemotherapy	O	NOUN	B
.	O	PUNCT	O


Carboplatin	B-Chemical	NOUN	B
has	O	AUX	O
been	O	AUX	O
reported	O	VERB	O
to	O	PART	O
cause	O	VERB	O
acute	B-Disease	ADJ	B
renal	I-Disease	ADJ	I
failure	I-Disease	NOUN	I
when	O	SCONJ	O
administered	O	VERB	B
in	O	ADP	O
high	O	ADJ	B
doses	O	NOUN	I
to	O	PART	O
adult	O	ADJ	B
patients	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
a	O	DET	O
4	O	NUM	O
1	O	NUM	O
/	O	SYM	O
2	O	NUM	B
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
girl	O	NOUN	I
who	O	PRON	O
was	O	AUX	O
treated	O	VERB	B
with	O	ADP	I
high	O	ADJ	B
-	O	PUNCT	O
dose	O	NOUN	B
carboplatin	B-Chemical	NOUN	B
for	O	ADP	O
metastatic	O	ADJ	B
parameningeal	O	NOUN	I
embryonal	B-Disease	ADJ	I
rhabdomyosarcoma	I-Disease	NOUN	I
.	O	PUNCT	O


Acute	B-Disease	ADJ	B
renal	I-Disease	ADJ	I
failure	I-Disease	NOUN	I


Endometrial	B-Disease	ADJ	B
carcinoma	I-Disease	NOUN	I
after	O	ADP	O
Hodgkin	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
in	O	ADP	O
childhood	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
34	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
patient	O	NOUN	B
developed	O	VERB	O
metastic	O	ADJ	B
endometrial	B-Disease	ADJ	I
carcinoma	I-Disease	NOUN	I
after	O	ADP	O
Hodgkin	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
in	O	ADP	O
childhood	O	NOUN	B
.	O	PUNCT	O


She	O	PRON	O
had	O	AUX	O
ovarian	B-Disease	ADJ	B
failure	I-Disease	NOUN	I
after	O	ADP	O
abdominal	O	ADJ	B
irradiation	O	NOUN	I
and	O	CCONJ	O
chemotherapy	O	NOUN	B
for	O	ADP	O
Hodgkin	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
received	O	VERB	O
exogenous	O	ADJ	B
estrogens	B-Chemical	NOUN	B
,	O	PUNCT	O
a	O	DET	O
treatment	O	NOUN	B
implicated	O	VERB	O
in	O	ADP	O
the	O	DET	O
development	O	NOUN	B
of	O	ADP	O
endometrial	B-Disease	ADJ	B
cancer	I-Disease	NOUN	I
in	O	ADP	O
menopausal	O	ADJ	B
women	O	NOUN	B
.	O	PUNCT	O


Young	O	ADJ	B
women	O	NOUN	B
on	O	ADP	O
replacement	O	NOUN	B
estrogens	B-Chemical	NOUN	B
for	O	ADP	O
ovarian	B-Disease	ADJ	B
failure	I-Disease	NOUN	I
after	O	ADP	O
cancer	B-Disease	NOUN	B
therapy	O	NOUN	I
may	O	AUX	O
also	O	ADV	O
have	O	AUX	O
increased	O	VERB	B
risk	O	NOUN	B
of	O	ADP	O
endometrial	B-Disease	ADJ	B
carcinoma	I-Disease	NOUN	I


Induction	O	NOUN	B
of	O	ADP	O
the	O	DET	O
obstructive	B-Disease	ADJ	B
sleep	I-Disease	NOUN	I
apnea	I-Disease	NOUN	I
syndrome	I-Disease	NOUN	I
in	O	ADP	O
a	O	DET	O
woman	O	NOUN	B
by	O	ADP	O
exogenous	O	ADJ	B
androgen	B-Chemical	NOUN	B
administration	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
documented	O	VERB	B
airway	O	NOUN	B
occlusion	O	NOUN	I
during	O	ADP	O
sleep	O	NOUN	B
and	O	CCONJ	O
an	O	DET	O
abnormally	O	ADV	B
high	O	ADJ	O
supraglottic	O	ADJ	B
resistance	O	NOUN	I
while	O	SCONJ	O
awake	O	ADJ	B
in	O	ADP	O
a	O	DET	O
54	O	NUM	O
-	O	PUNCT	O
yr	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
woman	O	NOUN	B
who	O	PRON	O
had	O	AUX	O
developed	O	VERB	O
physical	O	ADJ	B
changes	O	NOUN	I
and	O	CCONJ	O
the	O	DET	O
syndrome	B-Disease	NOUN	B
of	I-Disease	ADP	O
obstructive	I-Disease	ADJ	B
sleep	I-Disease	NOUN	I
apnea	I-Disease	NOUN	I
while	O	SCONJ	O
being	O	AUX	O
administered	O	VERB	B
exogenous	O	ADJ	B
androgens	B-Chemical	NOUN	B
.	O	PUNCT	O


When	O	SCONJ	O
the	O	DET	O
androgens	B-Chemical	NOUN	B
were	O	AUX	O
withdrawn	O	VERB	O
,	O	PUNCT	O
the	O	DET	O
patient	O	NOUN	B
'	O	PART	O
s	O	NOUN	O
physical	O	ADJ	B
changes	O	NOUN	I
,	O	PUNCT	O
symptoms	O	NOUN	B
,	O	PUNCT	O
sleep	O	NOUN	B
study	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
supraglottic	O	ADJ	B
resistance	O	NOUN	I
all	O	DET	O
returned	O	VERB	O
to	O	ADP	O
normal	O	ADJ	B
.	O	PUNCT	O


A	O	DET	O
rechallenge	O	NOUN	B
with	O	ADP	I
androgen	B-Chemical	NOUN	B
produced	O	VERB	O
symptoms	O	NOUN	B
of	O	ADP	O
obstructive	B-Disease	ADJ	B
sleep	I-Disease	NOUN	I
apnea	I-Disease	NOUN	I
that	O	PRON	O
abated	O	VERB	O
upon	O	SCONJ	O
withdrawal	O	NOUN	B
of	O	ADP	I
the	O	DET	I
hormone	O	NOUN	B
.	O	PUNCT	O


Previous	O	ADJ	O
reports	O	NOUN	B
have	O	AUX	O
favored	O	VERB	O
a	O	DET	O
role	O	NOUN	O
of	O	ADP	O
androgens	B-Chemical	NOUN	B
in	O	ADP	O
the	O	DET	O
pathogenesis	O	NOUN	B
of	O	ADP	O
sleep	B-Disease	NOUN	B
apnea	I-Disease	NOUN	I
.	O	PUNCT	O


Our	O	PRON	O
report	O	NOUN	B
provides	O	VERB	O
direct	O	ADJ	O
evidence	O	NOUN	B
for	O	ADP	O
this	O	DET	O
role	O	NOUN	O
.	O	PUNCT	O


Structural	O	ADJ	B
and	O	CCONJ	O
functional	O	ADJ	B
measurements	O	NOUN	I
indicate	O	VERB	O
that	O	SCONJ	O
androgens	B-Chemical	NOUN	B
exert	O	VERB	O
a	O	DET	O
permissive	O	ADJ	B
or	O	CCONJ	O
necessary	O	ADJ	O
action	O	NOUN	B
on	O	ADP	O
the	O	DET	O
structural	O	ADJ	B
configuration	O	NOUN	I
of	O	ADP	O
the	O	DET	O
oropharynx	O	NOUN	B
that	O	PRON	O
predisposes	O	VERB	O
to	O	ADP	O
obstruction	O	NOUN	B
during	O	ADP	O
sleep	O	NOUN	B
.	O	PUNCT	O


Development	O	NOUN	B
of	O	ADP	O
the	O	DET	O
obstructive	B-Disease	ADJ	B
sleep	I-Disease	NOUN	I
apnea	I-Disease	NOUN	I
syndrome	I-Disease	NOUN	I
must	O	AUX	O
be	O	AUX	O
considered	O	VERB	O
a	O	DET	O
possible	O	ADJ	O
side	O	NOUN	B
effect	O	NOUN	I
of	O	ADP	O
androgen	B-Chemical	NOUN	B


Effect	O	NOUN	B
of	O	ADP	O
captopril	B-Chemical	NOUN	B
on	O	ADP	O
pre	O	NOUN	B
-	O	PUNCT	O
existing	O	VERB	B
and	O	CCONJ	O
aminonucleoside	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
proteinuria	B-Disease	NOUN	B
in	O	ADP	O
spontaneously	O	ADV	B
hypertensive	B-Disease	ADJ	I
rats	O	NOUN	B
.	O	PUNCT	O


Proteinuria	B-Disease	NOUN	B
is	O	AUX	O
a	O	DET	O
side	O	ADJ	B
effect	O	NOUN	I
of	O	ADP	O
captopril	B-Chemical	NOUN	B
treatment	O	NOUN	B
in	O	ADP	O
hypertensive	B-Disease	ADJ	B
patients	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
possibility	O	NOUN	O
of	O	ADP	O
reproducing	O	VERB	B
the	O	DET	O
same	O	ADJ	O
renal	B-Disease	ADJ	B
abnormality	I-Disease	NOUN	I
with	O	ADP	O
captopril	B-Chemical	NOUN	B
was	O	AUX	O
examined	O	VERB	O
in	O	ADP	O
SHR	O	NOUN	B
.	O	PUNCT	O


Oral	O	ADJ	B
administration	O	NOUN	I
of	O	ADP	O
captopril	B-Chemical	NOUN	B
at	O	ADP	O
100	O	NUM	O
mg	O	NOUN	O
/	O	PUNCT	O
kg	O	NOUN	O
for	O	ADP	O
14	O	NUM	O
days	O	NOUN	B
failed	O	VERB	B
to	O	PART	O
aggravate	O	VERB	B
proteinuria	B-Disease	NOUN	B
pre	O	NOUN	B
-	O	PUNCT	O
existing	O	VERB	B
in	O	ADP	O
SHR	O	NOUN	B
.	O	PUNCT	O


Also	O	ADV	O
,	O	PUNCT	O
captopril	B-Chemical	NOUN	B
treatment	O	NOUN	B
failed	O	VERB	B
to	O	PART	O
potentiate	O	VERB	B
or	O	CCONJ	O
facilitate	O	VERB	O
development	O	NOUN	B
of	O	ADP	O
massive	O	ADJ	B
proteinuria	B-Disease	NOUN	B
invoked	O	VERB	O
by	O	ADP	O
puromycin	B-Chemical	NOUN	B
aminonucleoside	I-Chemical	NOUN	B
in	O	ADP	O
SHR	O	NOUN	B
.	O	PUNCT	O


Captopril	B-Chemical	NOUN	B
had	O	AUX	O
little	O	ADJ	O
or	O	CCONJ	O
no	O	DET	O
demonstrable	O	ADJ	O
effects	O	NOUN	B
on	O	ADP	O
serum	O	NOUN	B
electrolyte	O	NOUN	B
concentrations	O	NOUN	B
,	O	PUNCT	O
excretion	O	NOUN	B
of	O	ADP	O
urine	O	NOUN	B
,	O	PUNCT	O
sodium	B-Chemical	NOUN	B
and	O	CCONJ	O
potassium	B-Chemical	NOUN	B
,	O	PUNCT	O
endogenous	O	ADJ	B
creatinine	B-Chemical	NOUN	B
clearance	O	NOUN	B
,	O	PUNCT	O
body	O	NOUN	B
weight	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
food	O	NOUN	B
and	O	CCONJ	O
water	O	NOUN	B
consumption	O	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
ketone	B-Chemical	NOUN	B
bodies	O	NOUN	I
were	O	AUX	O
consistently	O	ADV	O
present	O	ADJ	O
in	O	ADP	O
urine	O	NOUN	B
and	O	CCONJ	O
several	O	ADJ	O
lethalities	O	NOUN	B
occurred	O	VERB	O
during	O	ADP	O
multiple	O	ADJ	B
dosing	O	NOUN	B
of	O	ADP	O
captopril	B-Chemical	NOUN	B


Epileptogenic	O	ADJ	B
properties	O	NOUN	B
of	O	ADP	O
enflurane	B-Chemical	NOUN	B
and	O	CCONJ	O
their	O	PRON	O
clinical	O	ADJ	B
interpretation	O	NOUN	I
.	O	PUNCT	O


Three	O	NUM	O
cases	O	NOUN	B
of	O	ADP	O
EEG	O	NOUN	B
changes	O	NOUN	B
induced	O	VERB	B
by	O	ADP	O
single	O	ADJ	O
exposure	O	NOUN	B
to	O	PART	I
enflurane	B-Chemical	NOUN	B
anesthesia	O	NOUN	I
are	O	AUX	O
reported	O	VERB	O
.	O	PUNCT	O


In	O	ADP	O
one	O	NUM	O
patient	O	NOUN	B
,	O	PUNCT	O
enflurane	B-Chemical	NOUN	B
administered	O	VERB	B
during	O	ADP	O
a	O	DET	O
donor	O	NOUN	B
nephrectomy	O	NOUN	I
resulted	O	VERB	O
in	O	ADP	O
unexpected	O	ADJ	O
partial	O	ADJ	B
motor	O	NOUN	B
seizures	B-Disease	NOUN	I
.	O	PUNCT	O


Until	O	ADP	O
the	O	DET	O
cause	O	NOUN	O
of	O	ADP	O
the	O	DET	O
seizures	B-Disease	NOUN	B
was	O	AUX	O
correctly	O	ADV	O
identified	O	VERB	B
,	O	PUNCT	O
the	O	DET	O
patient	O	NOUN	B
was	O	AUX	O
inappropriately	O	ADV	O
treated	O	VERB	B
with	O	ADP	I
anticonvulsants	O	NOUN	B
.	O	PUNCT	O


Two	O	NUM	O
other	O	ADJ	O
patients	O	NOUN	B
suffered	O	VERB	O
from	O	ADP	O
partial	O	ADJ	B
,	O	PUNCT	O
complex	O	ADJ	B
and	O	CCONJ	O
generalized	O	VERB	B
seizures	B-Disease	NOUN	I
uncontrolled	O	ADJ	B
by	O	ADP	O
medication	O	NOUN	B
.	O	PUNCT	O


Epileptic	B-Disease	ADJ	B
foci	O	NOUN	I
delineated	O	VERB	B
and	O	CCONJ	O
activated	O	VERB	B
by	O	ADP	O
enflurane	B-Chemical	NOUN	B
were	O	AUX	O
surgically	O	ADV	B
ablated	O	VERB	B
and	O	CCONJ	O
the	O	DET	O
patients	O	NOUN	B
are	O	AUX	O
now	O	ADV	O
seizure	B-Disease	NOUN	B
-	O	PUNCT	O
free	O	ADJ	B
.	O	PUNCT	O


Previous	O	ADJ	O
exposures	O	NOUN	B
to	O	PART	O
enflurane	B-Chemical	NOUN	B
have	O	AUX	O
to	O	PART	O
be	O	AUX	O
disclosed	O	VERB	O
to	O	PART	O
avoid	O	VERB	O
mistakes	O	NOUN	B
in	O	ADP	O
clinical	O	ADJ	B
interpretation	O	NOUN	I
of	O	ADP	O
the	O	DET	O
EEG	O	PROPN	B
.	O	PUNCT	O


On	O	ADP	O
the	O	DET	O
other	O	ADJ	O
hand	O	NOUN	B
,	O	PUNCT	O
enflurane	B-Chemical	NOUN	B
may	O	AUX	O
prove	O	VERB	O
to	O	PART	O
be	O	AUX	O
a	O	DET	O
safe	O	ADJ	O
fast	O	ADJ	O
acting	O	VERB	O
activator	O	NOUN	B
of	O	ADP	O
epileptic	B-Disease	ADJ	B


Reversible	O	ADJ	B
cerebral	B-Disease	ADJ	B
lesions	I-Disease	NOUN	I
associated	O	VERB	B
with	O	ADP	I
tiazofurin	B-Chemical	NOUN	B
usage	O	NOUN	B
:	O	PUNCT	O
MR	O	NOUN	B
demonstration	O	NOUN	B
.	O	PUNCT	O


Tiazofurin	B-Chemical	NOUN	B
is	O	AUX	O
an	O	DET	O
experimental	O	ADJ	B
chemotherapeutic	O	ADJ	B
agent	O	NOUN	I
currently	O	ADV	O
undergoing	O	VERB	O
clinical	O	ADJ	B
evaluation	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
our	O	PRON	O
results	O	NOUN	B
with	O	ADP	O
magnetic	O	ADJ	B
resonance	O	NOUN	I
(	O	PUNCT	O
MR	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
demonstrating	O	VERB	O
reversible	O	ADJ	O
cerebral	B-Disease	ADJ	B
abnormalities	I-Disease	NOUN	I


Antagonism	O	NOUN	B
of	O	ADP	O
diazepam	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
sedative	O	ADJ	B
effects	O	NOUN	I
by	O	ADP	O
Ro15-1788	B-Chemical	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
after	O	ADP	O
surgery	O	NOUN	B
under	O	ADP	O
lumbar	O	ADJ	B
epidural	O	ADJ	I
block	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
double	O	ADJ	B
-	O	PUNCT	O
blind	O	ADJ	B
placebo	O	NOUN	B
-	O	PUNCT	O
controlled	O	VERB	B
investigation	O	NOUN	B
of	O	ADP	O
efficacy	O	NOUN	B
and	O	CCONJ	O
safety	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
aim	O	NOUN	O
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
assess	O	VERB	B
the	O	DET	O
efficacy	O	NOUN	B
of	O	ADP	O
Ro15-1788	B-Chemical	NOUN	B
and	O	CCONJ	O
a	O	DET	O
placebo	O	NOUN	B
in	O	ADP	O
reversing	O	VERB	B
diazepam	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
effects	O	NOUN	B
after	O	ADP	O
surgery	O	NOUN	B
under	O	ADP	O
epidural	O	ADJ	B
block	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
to	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
local	O	ADJ	B
tolerance	O	NOUN	I
and	O	CCONJ	O
general	O	ADJ	O
safety	O	NOUN	B
of	O	ADP	O
Ro15-1788	B-Chemical	NOUN	B
.	O	PUNCT	O


Fifty	O	NUM	B
-	O	PUNCT	O
seven	O	NUM	B
patients	O	NOUN	B
were	O	AUX	O
sedated	O	VERB	B
with	O	ADP	O
diazepam	B-Chemical	NOUN	B
for	O	ADP	O
surgery	O	NOUN	B
under	O	ADP	O
epidural	O	ADJ	B
anaesthesia	O	NOUN	I
.	O	PUNCT	O


Antagonism	O	NOUN	B
of	O	ADP	O
diazepam	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
effects	O	NOUN	B
by	O	ADP	O
Ro15-1788	B-Chemical	NOUN	B
was	O	AUX	O
investigated	O	VERB	B
postoperatively	O	ADV	B
in	O	ADP	O
a	O	DET	O
double	O	ADJ	B
-	O	PUNCT	O
blind	O	ADJ	B
placebo	O	NOUN	B
-	O	PUNCT	O
controlled	O	VERB	B
trial	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
patient	O	NOUN	B
'	O	PART	O
s	O	NOUN	O
subjective	O	ADJ	O
assessment	O	NOUN	B
of	O	ADP	O
mood	O	NOUN	B
rating	O	NOUN	I
,	O	PUNCT	O
an	O	DET	O
objective	O	ADJ	O
test	O	NOUN	O
of	O	ADP	O
performance	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
test	O	NOUN	B
for	O	ADP	O
amnesia	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
vital	O	ADJ	B
signs	O	NOUN	I
were	O	AUX	O
recorded	O	VERB	O
for	O	ADP	O
up	O	ADV	O
to	O	PART	O
300	O	NUM	O
min	O	NOUN	O
after	O	ADP	O
administration	O	NOUN	B
of	O	ADP	O
the	O	DET	O
trial	O	NOUN	B
drug	O	NOUN	I
.	O	PUNCT	O


No	O	DET	B
significant	O	ADJ	I
differences	O	NOUN	O
between	O	ADP	O
the	O	DET	O
two	O	NUM	O
groups	O	NOUN	B
were	O	AUX	O
observed	O	VERB	O
for	O	ADP	O
mood	O	NOUN	B
rating	O	NOUN	I
,	O	PUNCT	O
amnesia	B-Disease	NOUN	B
,	O	PUNCT	O
or	O	CCONJ	O
vital	O	ADJ	B
signs	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
Ro15-1788	B-Chemical	NOUN	B


Enhanced	O	VERB	B
stimulus	O	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
neurotransmitter	O	NOUN	B
overflow	O	NOUN	B
in	O	ADP	O
epinephrine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
hypertensive	B-Disease	ADJ	B
rats	O	NOUN	B
is	O	AUX	O
not	O	PART	O
mediated	O	VERB	O
by	O	ADP	O
prejunctional	O	ADJ	B
beta	O	NOUN	B
-	O	PUNCT	O
adrenoceptor	O	NOUN	B
activation	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
examines	O	VERB	O
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
6	O	NUM	O
-	O	PUNCT	O
day	O	NOUN	B
epinephrine	B-Chemical	NOUN	B
treatment	O	NOUN	B
(	O	PUNCT	O
100	O	NUM	O
micrograms	O	NOUN	B
/	O	PUNCT	O
kg	O	NOUN	B
per	O	ADP	O
h	O	NOUN	O
,	O	PUNCT	O
s	O	NOUN	O
.	O	PUNCT	O


c	O	X	O
.)	O	NOUN	O
on	O	ADP	O
stimulus	O	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
(	O	PUNCT	O
1	O	NUM	O
Hz	O	NOUN	O
)	O	PUNCT	O
endogenous	O	ADJ	B
neurotransmitter	O	NOUN	B
overflow	O	NOUN	B
from	O	ADP	O
the	O	DET	O
isolated	O	VERB	B
perfused	O	ADJ	B
kidney	O	NOUN	I
of	O	ADP	O
vehicle	O	NOUN	B
-	O	PUNCT	O
and	O	CCONJ	O
epinephrine	B-Chemical	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
rats	O	NOUN	B
.	O	PUNCT	O


Renal	O	ADJ	B
catecholamine	B-Chemical	NOUN	O
stores	O	NOUN	O
and	O	CCONJ	O
stimulus	O	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
overflow	O	NOUN	B
in	O	ADP	O
the	O	DET	O
vehicle	O	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
group	O	NOUN	B
consisted	O	VERB	O
of	O	ADP	O
norepinephrine	B-Chemical	NOUN	B
only	O	ADV	O
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
epinephrine	B-Chemical	NOUN	B
treatment	O	NOUN	B
resulted	O	VERB	O
in	O	ADP	O
the	O	DET	O
incorporation	O	NOUN	B
of	O	ADP	O
epinephrine	B-Chemical	NOUN	B
into	O	ADP	O
renal	O	ADJ	B
catecholamine	B-Chemical	NOUN	B
stores	O	NOUN	I
such	O	ADJ	O
that	O	DET	O
approximately	O	ADV	O
40	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
catecholamine	B-Chemical	NOUN	B
present	O	ADJ	O
was	O	AUX	O
epinephrine	B-Chemical	NOUN	B
while	O	SCONJ	O
the	O	DET	O
norepinephrine	B-Chemical	NOUN	B
content	O	NOUN	B
was	O	AUX	O
reduced	O	VERB	B
by	O	ADP	O
a	O	DET	O
similar	O	ADJ	O
degree	O	NOUN	B
.	O	PUNCT	O


Total	O	ADJ	B
tissue	O	NOUN	B
catecholamine	B-Chemical	NOUN	B
content	O	NOUN	B
of	O	ADP	O
the	O	DET	O
kidney	O	NOUN	B
on	O	ADP	O
a	O	DET	O
molar	O	ADJ	B
basis	O	NOUN	O
was	O	AUX	O
unchanged	O	ADJ	B
.	O	PUNCT	O


Stimulus	O	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
fractional	O	ADJ	B
overflow	O	NOUN	I
of	O	ADP	O
neurotransmitter	O	NOUN	B
from	O	ADP	O
the	O	DET	O
epinephrine	B-Chemical	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
kidneys	O	NOUN	B
was	O	AUX	O
approximately	O	ADV	O
twice	O	ADV	O
normal	O	ADJ	B
and	O	CCONJ	O
consisted	O	VERB	O
of	O	ADP	O
both	O	CCONJ	O
norepinephrine	B-Chemical	NOUN	B
and	O	CCONJ	O
epinephrine	B-Chemical	NOUN	B
in	O	ADP	O
proportions	O	NOUN	B
similar	O	ADJ	O
to	O	PART	O
those	O	DET	O
found	O	VERB	O
in	O	ADP	O
the	O	DET	O
kidney	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
difference	O	NOUN	O
in	O	ADP	O
fractional	O	ADJ	B
overflow	O	NOUN	I
between	O	ADP	O
groups	O	NOUN	B
was	O	AUX	O
not	O	PART	O
affected	O	VERB	O
by	O	ADP	O
neuronal	O	ADJ	B
and	O	CCONJ	O
extraneuronal	O	ADJ	B
uptake	O	NOUN	O
blockade	O	NOUN	B
.	O	PUNCT	O


Propranolol	B-Chemical	NOUN	B
had	O	AUX	O
no	O	DET	B
effect	O	NOUN	I
on	O	ADP	O
stimulus	O	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
overflow	O	NOUN	B
in	O	ADP	O
either	O	DET	O
group	O	NOUN	B
.	O	PUNCT	O


Phentolamine	B-Chemical	NOUN	B
increased	O	VERB	B
stimulus	O	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
overflow	O	NOUN	B
in	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
although	O	SCONJ	O
the	O	DET	O
increment	O	NOUN	B
in	O	ADP	O
overflow	O	NOUN	B
was	O	AUX	O
greater	O	ADJ	O
in	O	ADP	O
the	O	DET	O
epinephrine	B-Chemical	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
group	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
conclusion	O	NOUN	O
,	O	PUNCT	O
chronic	O	ADJ	B
epinephrine	B-Chemical	NOUN	B
treatment	O	NOUN	B
results	O	VERB	B
in	O	ADP	O
enhanced	O	VERB	B
fractional	O	ADJ	O
neurotransmitter	O	NOUN	B
overflow	O	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
neither	O	CCONJ	O
alterations	O	NOUN	B
in	O	ADP	O
prejunctional	O	ADJ	B
beta	O	NOUN	B
-	O	PUNCT	O
adrenoceptor	O	NOUN	B
influences	O	NOUN	B
nor	O	CCONJ	O
alterations	O	NOUN	B
in	O	ADP	O
neuronal	O	ADJ	B
and	O	CCONJ	O
extraneuronal	O	ADJ	B
uptake	O	NOUN	O
mechanisms	O	NOUN	B
appear	O	VERB	O
to	O	PART	O
be	O	AUX	O
responsible	O	ADJ	O
for	O	ADP	O
this	O	DET	O
alteration	O	NOUN	B
.	O	PUNCT	O


Furthermore	O	ADV	O
,	O	PUNCT	O
data	O	NOUN	B
obtained	O	VERB	O
with	O	ADP	O
phentolamine	B-Chemical	NOUN	B
alone	O	ADV	O
do	O	AUX	O
not	O	PART	O
suggest	O	VERB	O
alpha	O	NOUN	B
-	O	PUNCT	O
adrenoceptor	O	NOUN	B
desensitization	O	NOUN	B
as	O	ADP	O
the	O	DET	O
cause	O	NOUN	O
of	O	ADP	O
the	O	DET	O
enhanced	O	VERB	B
neurotransmitter	O	NOUN	B
overflow	O	NOUN	B
after	O	ADP	O
epinephrine	B-Chemical	NOUN	B


Ocular	O	ADJ	B
manifestations	O	NOUN	B
of	O	ADP	O
juvenile	B-Disease	ADJ	B
rheumatoid	I-Disease	ADJ	I
arthritis	I-Disease	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
followed	O	VERB	O
210	O	NUM	O
cases	O	NOUN	B
of	O	ADP	O
juvenile	B-Disease	ADJ	B
rheumatoid	I-Disease	ADJ	I
arthritis	I-Disease	NOUN	I
closely	O	ADV	O
for	O	ADP	O
eleven	O	NUM	O
years	O	NOUN	B
.	O	PUNCT	O


Thirty	O	NUM	B
-	O	PUNCT	O
six	O	NUM	O
of	O	ADP	O
the	O	DET	O
210	O	NUM	O
patients	O	NOUN	B
(	O	PUNCT	O
17	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
%)	O	NOUN	O
developed	O	VERB	O
iridocyclitis	B-Disease	NOUN	B
.	O	PUNCT	O


Iridocyclitis	B-Disease	NOUN	B
was	O	AUX	O
seen	O	VERB	O
most	O	ADV	O
frequently	O	ADV	O
in	O	ADP	O
young	O	ADJ	B
female	O	ADJ	B
patients	O	NOUN	B
(	O	PUNCT	O
0	O	NUM	O
to	O	PART	O
4	O	NUM	O
years	O	NOUN	B
)	O	PUNCT	O
with	O	ADP	O
the	O	DET	O
monoarticular	O	ADJ	B
or	O	CCONJ	O
pauciatricular	O	ADJ	B
form	O	NOUN	O
of	O	ADP	O
the	O	DET	O
arthritis	B-Disease	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
30	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
developed	O	VERB	O
uveitis	B-Disease	NOUN	B
after	O	ADP	O
16	O	NUM	O
years	O	NOUN	B
of	O	ADP	O
age	O	NOUN	B
.	O	PUNCT	O


Although	O	SCONJ	O
61	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
had	O	AUX	O
a	O	DET	O
noncontributory	O	ADJ	B
ocular	O	ADJ	B
history	O	NOUN	I
on	O	ADP	O
entry	O	NOUN	B
,	O	PUNCT	O
42	O	NUM	O
%	O	NOUN	O
had	O	AUX	O
active	O	ADJ	B
uveitis	B-Disease	NOUN	I
on	O	ADP	O
entry	O	NOUN	B
.	O	PUNCT	O


Our	O	PRON	O
approach	O	NOUN	O
was	O	AUX	O
effective	O	ADJ	B
in	O	ADP	O
detecting	O	VERB	B
uveitis	B-Disease	NOUN	B
in	O	ADP	O
new	O	ADJ	O
cases	O	NOUN	B
and	O	CCONJ	O
exacerbations	O	NOUN	B
of	O	ADP	O
uveitis	B-Disease	NOUN	B
in	O	ADP	O
established	O	ADJ	O
cases	O	NOUN	B
.	O	PUNCT	O


Forty	O	NUM	B
-	O	PUNCT	O
four	O	NUM	O
percent	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
uveitis	B-Disease	NOUN	B
had	O	AUX	O
one	O	NUM	O
or	O	CCONJ	O
more	O	ADV	O
identifiable	O	ADJ	O
signs	O	NOUN	B
or	O	CCONJ	O
symptoms	O	NOUN	B
,	O	PUNCT	O
such	O	ADJ	O
as	O	ADP	O
red	O	ADJ	B
eye	O	NOUN	I
,	O	PUNCT	O
ocular	B-Disease	ADJ	B
pain	I-Disease	NOUN	I
,	O	PUNCT	O
decreased	B-Disease	VERB	B
visual	I-Disease	ADJ	B
acuity	I-Disease	NOUN	I
,	O	PUNCT	O
or	O	CCONJ	O
photophobia	B-Disease	NOUN	B
,	O	PUNCT	O
in	O	ADP	O
order	O	NOUN	O
of	O	ADP	O
decreasing	O	VERB	B
frequency	O	NOUN	B
.	O	PUNCT	O


Even	O	ADV	O
after	O	ADP	O
early	O	ADJ	B
detection	O	NOUN	B
and	O	CCONJ	O
prompt	O	ADJ	B
treatment	O	NOUN	B
,	O	PUNCT	O
41	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
cases	O	NOUN	B
of	O	ADP	O
uveitis	B-Disease	NOUN	B
did	O	AUX	O
not	O	PART	O
respond	O	VERB	O
to	O	ADP	O
more	O	ADJ	O
than	O	ADP	O
six	O	NUM	O
months	O	NOUN	B
of	O	ADP	O
intensive	O	ADJ	B
topical	O	ADJ	B
treatment	O	NOUN	O
with	O	ADP	O
corticosteroids	B-Chemical	NOUN	B
and	O	CCONJ	O
mydriatics	O	NOUN	B
.	O	PUNCT	O


Despite	O	SCONJ	O
this	O	DET	O
,	O	PUNCT	O
there	O	PRON	O
was	O	AUX	O
a	O	DET	O
dramatic	O	ADJ	O
decrease	O	NOUN	B
in	O	ADP	O
the	O	DET	O
50	O	NUM	O
%	O	NOUN	O
incidence	O	NOUN	B
of	O	ADP	O
blinding	O	VERB	B
complications	O	NOUN	B
of	O	ADP	O
uveitis	B-Disease	NOUN	B
cited	O	VERB	O
in	O	ADP	O
earlier	O	ADJ	O
studies	O	NOUN	B
.	O	PUNCT	O


Cataract	B-Disease	NOUN	B
and	O	CCONJ	O
band	B-Disease	NOUN	B
keratopathy	I-Disease	NOUN	I
occurred	O	VERB	O
in	O	ADP	O
only	O	ADV	O
22	O	NUM	O
and	O	CCONJ	O
13	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
our	O	PRON	O
group	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


We	O	PRON	O
used	O	VERB	O
chloroquine	B-Chemical	NOUN	B
or	O	CCONJ	O
hydroxychloroquine	B-Chemical	NOUN	B
in	O	ADP	O
173	O	NUM	O
of	O	ADP	O
210	O	NUM	O
cases	O	NOUN	B
and	O	CCONJ	O
found	O	VERB	O
only	O	ADV	O
one	O	NUM	O
case	O	NOUN	B
of	O	ADP	O
chorioretinopathy	B-Disease	NOUN	B
attributable	O	ADJ	O
to	O	PART	O
these	O	DET	O
drugs	O	NOUN	B
.	O	PUNCT	O


Systemically	O	ADV	B
administered	O	VERB	I
corticosteroids	B-Chemical	NOUN	B
were	O	AUX	O
used	O	VERB	O
in	O	ADP	O
75	O	NUM	O
of	O	ADP	O
210	O	NUM	O
cases	O	NOUN	B
;	O	PUNCT	O
a	O	DET	O
significant	O	ADJ	O
number	O	NOUN	O
of	O	ADP	O
posterior	O	ADJ	B
subcapsular	O	ADJ	I
cataracts	B-Disease	NOUN	I
was	O	AUX	O
found	O	VERB	O
.	O	PUNCT	O


Typical	O	ADJ	B
keratoconjunctivitis	B-Disease	NOUN	B
sicca	O	NOUN	B
developed	O	VERB	O
in	O	ADP	O
three	O	NUM	O
of	O	ADP	O
the	O	DET	O
uveitis	B-Disease	NOUN	B
cases	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
association	O	NOUN	B
with	O	ADP	O
uveitis	B-Disease	NOUN	B
and	O	CCONJ	O
JRA	O	NOUN	B
was	O	AUX	O
not	O	PART	O
noted	O	VERB	O
previously	O	ADV	O
.	O	PUNCT	O


Surgical	O	ADJ	B
treatment	O	NOUN	I
of	O	ADP	O
cataracts	B-Disease	NOUN	B
,	O	PUNCT	O
band	B-Disease	NOUN	B
keratopathy	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
glaucoma	B-Disease	NOUN	B


Water	B-Disease	NOUN	B
intoxication	I-Disease	NOUN	B
associated	O	VERB	B
with	O	ADP	I
oxytocin	B-Chemical	NOUN	B
administration	O	NOUN	B
during	O	ADP	O
saline	O	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
abortion	B-Disease	NOUN	B
.	O	PUNCT	O


Four	O	NUM	O
cases	O	NOUN	B
of	O	ADP	O
water	B-Disease	NOUN	B
intoxication	I-Disease	NOUN	B
in	O	ADP	O
connection	O	NOUN	B
with	O	ADP	O
oxytocin	B-Chemical	NOUN	B
administration	O	NOUN	B
during	O	ADP	O
saline	O	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
abortions	B-Disease	NOUN	B
are	O	AUX	O
described	O	VERB	O
.	O	PUNCT	O


The	O	DET	O
mechanism	O	NOUN	B
of	O	ADP	O
water	B-Disease	NOUN	B
intoxication	I-Disease	NOUN	B
is	O	AUX	O
discussed	O	VERB	O
in	O	ADP	O
regard	O	NOUN	O
to	O	ADP	O
these	O	DET	O
cases	O	NOUN	B
.	O	PUNCT	O


Oxytocin	B-Chemical	NOUN	B
administration	O	NOUN	B
during	O	ADP	O
midtrimester	O	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
abortions	B-Disease	NOUN	B
is	O	AUX	O
advocated	O	VERB	O
only	O	ADV	O
if	O	SCONJ	O
it	O	PRON	O
can	O	AUX	O
be	O	AUX	O
carried	O	VERB	O
out	O	ADP	O
under	O	ADP	O
careful	O	ADJ	O
observations	O	NOUN	B
of	O	ADP	O
an	O	DET	O
alert	O	ADJ	B
nursing	O	NOUN	B
staff	O	NOUN	I
,	O	PUNCT	O
aware	O	ADJ	O
of	O	ADP	O
the	O	DET	O
symptoms	O	NOUN	B
of	O	ADP	O
water	B-Disease	NOUN	B
intoxication	I-Disease	NOUN	B
and	O	CCONJ	O
instructed	O	VERB	B
to	O	PART	O
watch	O	VERB	O
the	O	DET	O
diuresis	O	NOUN	B
and	O	CCONJ	O
report	O	VERB	B
such	O	ADJ	O
early	O	ADJ	O
signs	O	NOUN	O
of	O	ADP	O
the	O	DET	O
syndrome	O	NOUN	B
as	O	ADP	O
asthenia	B-Disease	NOUN	B
,	O	PUNCT	O
muscular	O	ADJ	B
irritability	B-Disease	NOUN	I
,	O	PUNCT	O
or	O	CCONJ	O
headaches	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
oxytocin	B-Chemical	NOUN	B
should	O	AUX	O
be	O	AUX	O
given	O	VERB	O
only	O	ADV	O
in	O	ADP	O
Ringers	O	NOUN	B
lactate	B-Chemical	NOUN	I
or	O	CCONJ	O
,	O	PUNCT	O
alternately	O	ADV	B
,	O	PUNCT	O
in	O	ADP	O
Ringers	O	NOUN	B
lactate	B-Chemical	NOUN	I
and	O	CCONJ	O
a	O	DET	O
5	O	NUM	O
per	O	ADP	O
cent	O	NOUN	O
dextrose	B-Chemical	NOUN	B
and	O	CCONJ	O
water	O	NOUN	B
solutions	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
urinary	O	ADJ	B
output	O	NOUN	I
should	O	AUX	O
be	O	AUX	O
monitored	O	VERB	B
and	O	CCONJ	O
the	O	DET	O
oxytocin	B-Chemical	NOUN	B
administration	O	NOUN	B
discontinued	O	VERB	B
and	O	CCONJ	O
the	O	DET	O
serum	O	NOUN	B
electrolytes	O	NOUN	O
checked	O	VERB	O
if	O	SCONJ	O
the	O	DET	O
urinary	O	ADJ	B
output	O	NOUN	I
decreases	O	VERB	B
.	O	PUNCT	O


The	O	DET	O
oxytocin	B-Chemical	NOUN	B
should	O	AUX	O
not	O	PART	O
be	O	AUX	O
administered	O	VERB	B
in	O	ADP	O
excess	O	NOUN	B
of	O	ADP	O
36	O	NUM	O
hours	O	NOUN	B
.	O	PUNCT	O


If	O	SCONJ	O
the	O	DET	O
patient	O	NOUN	B
has	O	AUX	O
not	O	PART	O
aborted	O	VERB	B
by	O	ADP	O
then	O	ADV	O
the	O	DET	O
oxytocin	B-Chemical	NOUN	B


